vorinostat profile

Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	5311
CHEMBL ID	98
CHEBI ID	45716
SCHEMBL ID	9018
MeSH ID	M0288128

Synonym
AC-1923
HY-10221
VORINOSTAT,CAS:149647-78-9
zolinza; saha
AB00375377-08
AB00375377-09
nsc-701852
vorinostat
zolinza
vorinostat msd
mk-0683
suberanilohydroxamic acid
sw-064652
suberoylanilide hydroxamic acid
c14h20n2o3
zolinza (tn)
149647-78-9
vorinostat (jan/usan)
D06320
octanedioic acid hydroxyamide phenylamide
SHH ,
saha
DB02546
1ZZ1
EC-000.2057
nsc701852
n-hyrdroxy-n'-phenyloctanediamide
8-(hydroxyamino)-8-oxo-n-phenyl-octanamide
ccris 8456
mk0683
saha, suberoylanilide hydroxamic acid
win64652
ski390
zolinza (tn) (merck)
n-hydroxy-n'-phenyl-octane-1,8-diotic acid diamide
octanediamide, n-hydroxy-n'-phenyl-
NCGC00168085-02
n-hydroxy-n'-phenyloctanediamide
saha cpd
vorinostat [usan]
chembl98 ,
bdbm19149
cid_5311
n-hydroxy-n''-phenyloctanediamide
n1-hydroxy-n8-phenyloctanediamide
MLS001065855
smr000486344
BRD-K81418486-001-10-3
BRD-K81418486-001-17-8
chebi:45716 ,
nsc-748799
nsc-759852
FT-0650593
n'-hydroxy-n-phenyloctanediamide
BRD-K81418486-001-12-9
NCGC00168085-01
n1-hydroxy-n8-phenyl-octanediamide
A808935
sk1390
octanediamide, n1-hydroxy-n8-phenyl
nsc748799
BRD-K81418486-001-01-2
NCGC00168085-03
NCGC00168085-04
HMS3264D20
unii-58ifb293ji
mk 0683
nsc 701852
nsc 759852
vorinostat [usan:inn]
hsdb 7930
58ifb293ji ,
nsc 748799
SUBEROYLANILIDE HYDROXAMIC ACID (SAHA)
cas-149647-78-9
dtxsid6041133 ,
tox21_112605
tox21_113623
dtxcid4021133
nsc759852
pharmakon1600-01502267
H1388
suberoylanilidehydroxamic acid
vorinostat (saha, mk0683)
HMS2219L20
VORINOSTAT - SAHA
AKOS015966648
vorinostatum
BCPP000018
vorinostat,saha,zolinza,mk-0683
octanediamide, n1-hydroxy-n8-phenyl-
AM20030018
vorinostat [mi]
vorinostat [vandf]
vorinostat [jan]
vorinostat [mart.]
vorinostat [orange book]
vorinostat [inn]
vorinostat [who-dd]
1T69
4LXZ
CS-0589
S1047
gtpl6852
HMS3327C12
BP-30216
CCG-208659
SCHEMBL9018
NCGC00168085-05
tox21_112605_1
DG-0025
vorinostat, saha, suberoylanilide hydroxamic acid
AB00375377-07
MLS006011941
W-201327
HB1396
HMS3650D09
AB01644613_25
mfcd00945317
sr-05000000373
SR-05000000373-6
HMS3654G11
SR-05000000373-2
saha, >=98% (hplc)
HMS3715E22
NCGC00168085-13
SW199536-4
EX-A2745
vorinostat (saha) ,
n-hydroxy-n inverted exclamation mark -phenyloctanediamide
SY009383
1227736-21-1
SR-05000000373-8
suberanilohydroxaminic acid
BCP01858
Q905901
BRD-K81418486-001-13-7
BRD-K81418486-001-18-6
vorinostat (saha; mk0683)
SB17319
HMS3426G03
HMS3745M03
BP-25652
vorinostat(saha)
BV164560
EN300-120641
Z1530532755

Excerpt	Reference	Relevance
"Vorinostat (SAHA) is an epigenetic modulator actively used in clinical oncology."	( Histone Methyltransferases as a New Target for Epigenetic Action of Vorinostat. Belitsky, G; Kirsanov, K; Maksimova, V; Makus, J; Popova, V; Prus, A; Trapeznikova, E; Usalka, O; Yakubovskaya, M; Zhidkova, E, 2023)	1.87
"Vorinostat is a pan histone deacetylase inhibitor (HDACi) that has been investigated in MPN."	( Methylation age as a correlate for allele burden, disease status, and clinical response in myeloproliferative neoplasm patients treated with vorinostat. Andersen, C; Greenfield, G; Grinfeld, J; Hasselbalch, HC; McMullin, MF; McPherson, S; Mills, KI; Nangalia, J, 2019)	1.44
"Vorinostat is a histone deacetylase inhibitor approved for cancer treatment, but it could attenuate its anticancer activity by activating the mTOR pathway."	( Fluvastatin potentiates anticancer activity of vorinostat in renal cancer cells. Asano, T; Isono, M; Miyai, K; Okubo, K; Sato, A, 2020)	1.54
"Vorinostat is a drug used to treat cutaneous T cell lymphoma whose action mechanism is based on Histone Deacetylase inhibition. "	( Vorinostat as potential antiparasitic drug. Ariza-Ortega, JA; Flores-García, Y; Herrera-Martínez, M; López-Contreras, L; Montaño, S; Orozco-Samperio, E, 2020)	3.44
"As vorinostat is an oral agent and not a P-glycoprotein substrate it may have advantages in such combination therapy."	( Vorinostat and fenretinide synergize in preclinical models of T-cell lymphoid malignancies. Chen, WH; Hindle, A; Kang, MH; Koneru, B; Makena, MR; Nguyen, TH; Reynolds, CP; Verlekar, DU, 2021)	2.58
"Vorinostat is an oral histone deacetylase (HDAC) inhibitor and has been used for the treatment of T-cell lymphoma."	( Vorinostat ameliorates IL-1α-induced reduction of type II collagen by inhibiting the expression of ELF3 in chondrocytes. Cao, L; Miao, X; Wang, P; Wu, Y; Yu, X; Zhang, Q; Zhou, C, 2021)	2.79
"Vorinostat is a histone deacetylase inhibitor (HDACi) that was demonstrated in our previous study to inhibit the proliferation, migration, and invasion of cervical cancer cells by regulating the PI3K/Akt signaling pathway. "	( Vorinostat targets UBE2C to reverse epithelial-mesenchymal transition and control cervical cancer growth through the ubiquitination pathway. Cai, Y; Hsiao, WLW; Liang, H; Liu, C; Luo, D; Pan, B; Peng, F; Su, J; Xia, C; Yin, S, 2021)	3.51
"Vorinostat is a histone deacetylase inhibitor (HDACi). "	( A phase 2 study of vorinostat in locally advanced, recurrent, or metastatic adenoid cystic carcinoma. Barrett, MT; Boerner, SA; Casetta, L; Chao, J; Chen, A; Goncalves, PH; Hansen, AR; Heilbrun, LK; Kummar, S; Lenkiewicz, E; LoRusso, PM; Malasi, S; Piekarz, RL; Pilat, MJ; Siu, LL; Smith, DW; Sukari, AW, 2017)	2.23
"Vorinostat is a histone deacetylase inhibitor that has demonstrated preclinical activity in numerous cancer models. "	( Clinical pharmacology profile of vorinostat, a histone deacetylase inhibitor. Agrawal, NG; Friedman, EJ; Iwamoto, M; Rubin, EH; Sandhu, P; Wagner, JA, 2013)	2.11
"Vorinostat is a small molecule inhibitor of class I and II histone deacetylase enzymes which alters the expression of target genes including the cell cycle gene p21, leading to cell cycle arrest and apoptosis."	( Vorinostat in combination with bortezomib in patients with advanced malignancies directly alters transcription of target genes. Alberti, D; Bailey, HH; Espinoza-Delgado, I; Hoang, T; Holen, KD; Kim, K; Kolesar, JM; Schelman, WR; Seo, S; Traynor, AM; Wilding, G; Wright, JJ, 2013)	3.28
"Vorinostat is an inhibitor of histone deacetylases and was shown to attenuate GVHD in preclinical models."	( Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1/2 trial. Beumer, JH; Braun, T; Chang, L; Choi, SW; Couriel, DR; Dinarello, CA; DiPersio, JF; Ferrara, JL; Goldstein, S; Hou, G; Kitko, C; Krijanovski, OI; Lehmann, MH; Levine, JE; Magenau, JM; Mapara, MY; Paczesny, S; Pawarode, A; Reddy, P; Stockerl-Goldstein, K; Sun, Y; Tawara, I; Yanik, GA, 2014)	2.57
"Vorinostat is a small molecule inhibitor of class I and II histone deacetylases with preclinical activity in melanoma."	( Phase II trial of vorinostat in advanced melanoma. Adams, PD; Alpaugh, RK; Haas, NB; Hotte, S; Litwin, S; Martin, LP; McBryan, T; McWhirter, E; Oza, A; Polintan, R; Quirt, I; vonMehren, M; Wang, L; Zweibel, J, 2014)	2.18
"Vorinostat is a panHDAC inhibitor that sensitizes breast cancer cells to taxanes and trastuzumab by suppressing HDAC6 and Hsp90 client proteins."	( A phase I-II study of the histone deacetylase inhibitor vorinostat plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in locally advanced breast cancer. Alpaugh, RK; Andreopoulou, E; Bhalla, K; Fehn, K; Fineberg, S; Fiskus, W; Hershman, DL; Huang, M; Kalinsky, K; Makower, D; Montgomery, LL; Negassa, A; Pellegrino, CM; Sparano, JA; Tu, Y; Wiechmann, LS, 2014)	1.37
"Vorinostat, which is an extensively studied inhibitor against histone deacetylase (HDAC), shows limited clinical activity to solid tumors. "	( A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I. Chao, SW; Guh, JH; Hsu, JL; Huang, WJ; Li, TK; Liu, SP; Pan, SL; Yang, YC; Yu, CC, 2014)	2.13
"Vorinostat is an anticancer agent structurally similar to PBA."	( Comparative effects of 4-phenyl-3-butenoic acid and vorinostat on cell growth and signaling. Ali, A; Burns, TJ; Matesic, DF, 2015)	1.39
"Vorinostat is a histone deacetylase inhibitor that has radiosensitizing properties."	( Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma. Chen, E; Cohn, SL; Courtier, J; Czarnecki, S; DuBois, SG; Geier, E; Giacomini, K; Goodarzian, F; Granger, MM; Groshen, S; Haas-Kogan, DA; Hawkins, R; Jackson, H; Marachelian, A; Matthay, KK; Park, JR; Shimada, H; Tsao-Wei, D; Villablanca, JG; Weiss, B; Yang, X; Yanik, GA, 2015)	1.48
"Vorinostat is a histone deacetylase inhibitor that changes gene expression and protein activity. "	( Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial. Baas, P; Buikhuisen, WA; Calvert, H; Chu, Q; Eberhardt, WE; Fennell, D; Fukuoka, K; Gaafar, RM; Hillerdal, G; Kindler, HL; Krug, LM; Lafitte, JJ; Lubiniecki, GM; Manegold, C; Öhman, R; Plummer, R; Smith, M; Sun, X; Tsao, AS, 2015)	3.3
"Vorinostat is an FDA-approved histone deacetylase inhibitor (HDACi) that has proven clinical success in some patients; however, it remains unclear why certain patients remain unresponsive to this agent and other HDACis. "	( A genome scale RNAi screen identifies GLI1 as a novel gene regulating vorinostat sensitivity. Falkenberg, KJ; Gould, CM; Johnstone, RW; Luu, J; Matthews, GM; Newbold, A; Simpson, KJ; Trapani, JA, 2016)	2.11
"Vorinostat-XP is a feasible first-line chemotherapy for patients with advanced GC. "	( Vorinostat in combination with capecitabine plus cisplatin as a first-line chemotherapy for patients with metastatic or unresectable gastric cancer: phase II study and biomarker analysis. Kang, YK; Lee, CW; Na, YS; Ryoo, BY; Ryu, MH; Yoo, C, 2016)	3.32
"Vorinostat (SAHA) is a canonical US Food and Drug Administration-approved histone deacetylase (HDAC) inhibitor for the treatment of cutaneous T-cell lymphoma."	( A facile route to form self-carried redox-responsive vorinostat nanodrug for effective solid tumor therapy. Fang, H; Han, L; Wang, T; Wu, J; Yin, X; Zhang, N, )	1.1
"Vorinostat is a potent histone deacetylase inhibitor that blocks the catalytic site of these enzymes. "	( Development of vorinostat: current applications and future perspectives for cancer therapy. Garcia-Vargas, J; Hardwick, JS; Richon, VM, 2009)	2.15
"Vorinostat is a small molecule inhibitor of histone deacetylase, and has shown preclinical activity in non-small cell lung cancer (NSCLC)."	( Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: a Wisconsin Oncology Network phase II study. Dubey, S; Eickhoff, JC; Espinoza-Delgado, I; Groteluschen, DL; Hallahan, CM; Huie, MS; Kolesar, JM; Marcotte, SM; Schell, K; Schiller, JH; Traynor, AM; Weeks, HR; Wilding, G, 2009)	3.24
"Vorinostat is a novel histone deacetylase (HDAC) inhibitor approved for the treatment of advanced CTCL. "	( Vorinostat: A novel therapy for the treatment of cutaneous T-cell lymphoma. Kavanaugh, SA; Kavanaugh, SM; Kolesar, JM; White, LA, 2010)	3.25
"Vorinostat is an inhibitor of histone deacetylase 6, which acetylates tubulin and stabilizes microtubules. "	( Phase I study of vorinostat (suberoylanilide hydroxamic acid, NSC 701852) in combination with docetaxel in patients with advanced and relapsed solid malignancies. Bradley, D; Daignault, S; Dunn, R; Egorin, MJ; Hussain, M; Kalemkerian, GP; Schneider, BJ; Smith, DC, 2012)	2.16
"Vorinostat is an epigenetic targeted drug belonging to the histone deacetylase (HDAC) inhibitors family."	( Vorinostat in acute myeloid leukemia and myelodysplastic syndromes. Prebet, T; Vey, N, 2011)	2.53
"Oral vorinostat is a promising agent in FL and MZL, with an acceptable safety profile. "	( Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma. Delioukina, M; Espinoza-Delgado, I; Forman, SJ; Frankel, P; Gandara, D; Kirschbaum, M; Matsuoka, D; Nademanee, A; Newman, E; Popplewell, L; Pullarkat, V; Pulone, B; Rotter, AJ; Zain, J, 2011)	1.22
"Vorinostat is a histone deacetylase inhibitor (HDACi) that has been approved for the treatment of cutaneous T-cell lymphoma."	( Vorinostat-induced apoptosis in mantle cell lymphoma is mediated by acetylation of proapoptotic BH3-only gene promoters. Campo, E; Colomer, D; López-Guerra, M; Rosich, L; Roué, G; Saborit-Villarroya, I; Xargay-Torrent, S, 2011)	2.53
"Vorinostat is a histone deacetylase inhibitor that effectively suppresses cancer-cell proliferation by inducing cell-cycle arrest and/or apoptosis. "	( Requirement of p38 MAPK for a cell-death pathway triggered by vorinostat in MDA-MB-231 human breast cancer cells. Kanematsu, S; Miki, H; Tsubura, A; Uehara, N; Yoshizawa, K, 2012)	2.06
"Vorinostat is a histone deacetylase inhibitor that blocks cancer cell proliferation through the regulation of cyclin-dependent kinase inhibitors. "	( Vorinostat enhances protein stability of p27 and p21 through negative regulation of Skp2 and Cks1 in human breast cancer cells. Tsubura, A; Uehara, N; Yoshizawa, K, 2012)	3.26
"Vorinostat is a histone deacetylase inhibitor used in the treatment of recurrent or persistent cases of cutaneous T-cell lymphoma (CTCL). "	( QT interval prolongation and torsades de pointes in a patient undergoing treatment with vorinostat: a case report and review of the literature. Lynch, DR; Newby, LK; Washam, JB, 2012)	2.04
"Vorinostat is a potent HDAC inhibitor and has shown potential to inhibit growth of human xenograft tumors."	( Vorinostat, an HDAC inhibitor attenuates epidermoid squamous cell carcinoma growth by dampening mTOR signaling pathway in a human xenograft murine model. Athar, M; Ballestas, ME; Chaudhary, SC; Elmets, CA; Kopelovich, L; Kurundkar, D; Srivastava, RK, 2013)	2.55
"Vorinostat is a HDACi which has produced responses in these disorders."	( Vorinostat induces apoptosis and differentiation in myeloid malignancies: genetic and molecular mechanisms. Almeida, AM; Belo, H; Cardoso, BA; Silva, G, 2013)	2.55
"Vorinostat (Zolinza) is a histone deacetylase inhibitor that has demonstrated activity in patients with advanced solid tumors in phase I trials. "	( Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer. Chen, C; Dumez, H; Randolph, SS; Ricker, JL; Schöffski, P; Van Cutsem, E; Vansteenkiste, J, 2008)	2.08
"Vorinostat is a histone deacetylase inhibitor that induces differentiation, growth arrest, and/or apoptosis of malignant cells both in vitro and in vivo and has shown clinical responses in approximately 30% of patients with advanced mycosis fungoides and Sézary syndrome cutaneous T-cell lymphoma (CTCL). "	( Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma. Fantin, VR; Frankel, SR; Gooden, F; Harrington, EA; Hendrickson, RC; Hou, XS; Kadin, ME; Korenchuk, S; Li, L; Loboda, A; Paweletz, CP; Pierce, JW; Randolph, S; Reilly, JF; Richon, VM; Roth, JA; Ware, CM, 2008)	2.01

Excerpt	Reference	Relevance
"Vorinostat has good therapeutic efficacy against primary cutaneous T-cell lymphoma in the refractory stage. "	( Vorinostat upregulates MICA via the PI3K/Akt pathway to enhance the ability of natural killer cells to kill tumor cells. Cai, Y; He, Z; Liang, S; Xia, C, 2020)	3.44
"Vorinostat has been efficient in vitro and, in some cases, in vivo, against parasites that cause parasitic diseases, such as malaria, leishmaniasis, cryptosporidiosis, amoebiasis, and schistosomiasis."	( Vorinostat as potential antiparasitic drug. Ariza-Ortega, JA; Flores-García, Y; Herrera-Martínez, M; López-Contreras, L; Montaño, S; Orozco-Samperio, E, 2020)	3.44
"Vorinostat (VST) has been reported to have antioxidant and anti-inflammatory effects in bothin-vitro and in vivo models."	( Protective Effects of Low Dose Vorinostat on Cisplatin-Induced Nephrotoxicity in Rats. Ali, AS; Ali, SS; Bashraf, OMO; Eweis, HSA, 2021)	1.63
"Vorinostat (VOR) has been reported to enhance the cytotoxic effects of doxorubicin (DOX) with fewer side effects because of the lower DOX dosage in breast cancer cells. "	( Transactivation of bad by vorinostat-induced acetylated p53 enhances doxorubicin-induced cytotoxicity in cervical cancer cells. Hoe, KL; Hwang, SO; Kim, DU; Kim, JH; Lee, SJ; Nam, JH; Nam, M; Noh, EJ, 2014)	2.15
"Vorinostat has been shown to overcome resistance to gefitinib. "	( Phase I/II study of gefitinib (Iressa(®)) and vorinostat (IVORI) in previously treated patients with advanced non-small cell lung cancer. Han, JY; Hwang, KH; Kim, HT; Kim, JY; Lee, GK; Lee, SH; Lee, YJ; Yun, T, 2015)	2.12
"Oral vorinostat has the remarkable curative effect on aggravated and recurrent cutaneous T-cell lymphoma (CTCL), but is accompanied by serious adverse effects. "	( Preparation of a mixed-matrix hydrogel of vorinostat for topical administration on the rats as experimental model. Dai, W; Li, Y; Sun, F; Teng, L; Wang, C; Yao, J; Yu, C, 2015)	1.2
"Vorinostat has shown promising clinical activity against hematologic and solid tumors at doses that have been well tolerated by patients."	( Development of vorinostat: current applications and future perspectives for cancer therapy. Garcia-Vargas, J; Hardwick, JS; Richon, VM, 2009)	1.43
"Vorinostat has demonstrated significant anticancer activity against hematologic and solid tumors at doses well tolerated by patients and has been approved for the treatment of patients with cutaneous T-cell lymphoma."	( Molecular sequelae of histone deacetylase inhibition in human retinoblastoma cell lines: clinical implications. Kotoula, V; Marks, PA; McMullan, C; Miller, JW; Mitsiades, CS; Mitsiades, N; Negri, J; Poulaki, V, 2009)	1.07
"Vorinostat has the capacity to elicit CRT exposure, suggesting its usefulness as immunogenic antitumour agent."	( The histone deacetylase inhibitor vorinostat induces calreticulin exposure in childhood brain tumour cells in vitro. Beck, JF; Becker, S; Gressmann, S; Schmudde, M; Sonnemann, J; Wittig, S, 2010)	2.08
"vorinostat has shown an acceptable toxicity profile with mainly gastrointestinal and constitutional side effects. "	( Vorinostat in acute myeloid leukemia and myelodysplastic syndromes. Prebet, T; Vey, N, 2011)	3.25
"Oral vorinostat has limited single-agent activity in relapsed/refractory HL."	( A phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma: Southwest Oncology Group Study S0517. Cook, JR; Fisher, RI; Forman, SJ; Goldman, BH; Kirschbaum, MH; Rimsza, LM; Zain, JM, 2012)	1.16
"Vorinostat has demonstrated activity in refractory cutaneous T-cell lymphoma. "	( Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma. Cheson, BD; Coiffier, B; Crump, M; Frankel, SR; Jacobsen, ED; Randolph, SS; Ricker, JL; Sun, L; Xie, H, 2008)	2.1

Excerpt	Reference	Relevance
"Vorinostat was found to inhibit KCs proliferation and to induce their differentiation and apoptosis. "	( Vorinostat, a histone deacetylase inhibitor, as a potential novel treatment for psoriasis. Bochner, R; Fuchs-Telem, D; Gilhar, A; Keren, A; Magal, L; Malovitski, K; Nousbeck, J; Sagiv, N; Samuelov, L; Sarig, O; Sprecher, E, 2022)	3.61
"Vorinostat does not enhance viral fusion with cells but rather enhances the kinetics and efficiency of postentry viral events, including reverse transcription, nuclear import, and integration, and enhances viral production in a spreading-infection assay."	( The histone deacetylase inhibitor vorinostat (SAHA) increases the susceptibility of uninfected CD4+ T cells to HIV by increasing the kinetics and efficiency of postentry viral events. Dobrowolski, C; Haqqani, AA; Karn, J; Lucera, MB; Mao, H; Tabler, CO; Tilton, CA; Tilton, JC, 2014)	1.4

Excerpt	Reference	Relevance
"Vorinostat treatment affects the reversal of drug resistance in SK-N-Be(2)C cells and may be associated with downregulation of stemness gene expression."	( Differential effect of long-term drug selection with doxorubicin and vorinostat on neuroblastoma cells with cancer stem cell characteristics. Chu, F; Clark, S; Czurylo, M; Jafari, N; Jie, C; Lautz, T; Madonna, MB; Naiditch, J; Qiu, Y; Zheng, X, 2013)	1.35
"Vorinostat treatment increased the frequency of functional regulatory T-cell subsets and their transcription factors Gata3 and FoxP3 in parallel to a decrease in inflammatory dendritic cell subsets and their cytokines IL-6, IL-12, and TNF-α."	( Lysine deacetylase inhibition prevents diabetes by chromatin-independent immunoregulation and β-cell protection. Aikin, RA; Billestrup, N; Birkbak, N; Blaabjerg, L; Christensen, DP; Dahllöf, MS; Dinarello, CA; Fossati, G; Grunnet, LG; Gysemans, C; Lundh, M; Mandrup, S; Mandrup-Poulsen, T; Mascagni, P; Mathieu, C; Monzani, V; Noesgaard, D; Paraskevas, S; Piemonti, L; Schmidt, SF; Workman, CT, 2014)	1.12
"With vorinostat treatment, the best response was partial remission in 5 patients (33%) and stabilization in 4 patients (27%)."	( Vorinostat for refractory or relapsing epidermotropic T-cell lymphoma: a retrospective cohort study of 15 patients. Brocard, A; Dréno, B; Knol, AC; Kogge, A; Peuvrel, L; Quéreux, G; Renaut, JJ; Saint-Jean, M; Volteau, C, 2015)	2.31
"Vorinostat treatment increased histone acetylation in peripheral blood mononuclear cells (PBMCs) from treated patients, confirming target HDAC inhibition."	( Histone deacetylase inhibition regulates inflammation and enhances Tregs after allogeneic hematopoietic cell transplantation in humans. Choi, SW; Dinarello, CA; Gatza, E; Hou, G; Oravecz-Wilson, K; Reddy, P; Song, Y; Sun, Y; Tawara, I; Whitfield, J, 2015)	1.14
"Vorinostat treatment also caused a significant increase in acetylhistone H3 and acetylhistone H4."	( Role of 5'TG3'-interacting factors (TGIFs) in Vorinostat (HDAC inhibitor)-mediated Corneal Fibrosis Inhibition. Mohan, RR; Sharma, A; Siddiqui, S; Sinha, NR, 2015)	1.4
"Vorinostat treatment led to GRP78 acetylation, dissociation, and subsequent activation of its client protein double-stranded RNA-activated protein-like endoplasmic reticulum kinase (PERK)."	( Activation of the unfolded protein response contributes toward the antitumor activity of vorinostat. Chinnaiyan, P; Fang, B; Kahali, S; Koomen, JM; Sarcar, B; Tofilon, PJ; Williams, ES, 2010)	1.3
"Vorinostat treatment induced CRT exposure in PFSK and DAOY cells, but not in caspase-8-deficient CADO-ES-1 cells. "	( The histone deacetylase inhibitor vorinostat induces calreticulin exposure in childhood brain tumour cells in vitro. Beck, JF; Becker, S; Gressmann, S; Schmudde, M; Sonnemann, J; Wittig, S, 2010)	2.08
"Vorinostat-treated and control mice without tumors were also examined."	( The histone deacetylase inhibitor, vorinostat, reduces tumor growth at the metastatic bone site and associated osteolysis, but promotes normal bone loss. Akech, J; Bedard, K; Dhillon, RJ; Hussain, S; Li, X; Lian, JB; McGee-Lawrence, ME; Pratap, J; Stein, GS; Stein, JL; Szabo, G; van Wijnen, AJ; Westendorf, JJ; Wixted, JJ, 2010)	1.36
"Vorinostat treatment had no effect on albuminuria, glomerular collagen IV concentration, or mesangiolysis in diabetic mice genetically deficient in eNOS."	( Long-term administration of the histone deacetylase inhibitor vorinostat attenuates renal injury in experimental diabetes through an endothelial nitric oxide synthase-dependent mechanism. Advani, A; Advani, SL; Connelly, KA; Gilbert, RE; Huang, Q; Kelly, DJ; Marsden, PA; Thai, K; White, KE; Yuen, DA, 2011)	1.33
"Vorinostat treatment resulted in increased p21 levels in all glioma cells tested in a p53 independent manner."	( Vorinostat modulates cell cycle regulatory proteins in glioma cells and human glioma slice cultures. Fuller, GN; Lang, FF; Liu, Y; Prabhu, S; Puduvalli, VK; Rao, G; Sampath, D; Xu, J, 2011)	2.53
"Vorinostat treatment also decreased the mutant allele burden in mice."	( Efficacy of vorinostat in a murine model of polycythemia vera. Akada, H; Akada, S; Bair, A; Gajra, A; Graziano, S; Hutchison, RE; Mohi, G, 2012)	1.48
"Vorinostat treatment resulted in hyperacetylation of histones H3 and H4 in peripheral mononuclear cells."	( Phase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas: North American Brain Tumor Consortium Study 04-03. Ames, MM; Chang, SM; Cloughesy, TF; Desideri, S; Drappatz, J; Espinoza-Delgado, I; Gilbert, MR; Kuhn, JG; Lamborn, KR; Lassman, AB; Lee, EQ; Lieberman, FS; McGovern, RM; Prados, MD; Puduvalli, VK; Reid, JM; Robins, HI; Wen, PY; Xu, J; Ye, X; Yung, WK, 2012)	1.44
"Treatment with vorinostat resulted in a younger MA in PV patients and older MA in ET patients, in both cases a trend towards the normal chronological age."	( Methylation age as a correlate for allele burden, disease status, and clinical response in myeloproliferative neoplasm patients treated with vorinostat. Andersen, C; Greenfield, G; Grinfeld, J; Hasselbalch, HC; McMullin, MF; McPherson, S; Mills, KI; Nangalia, J, 2019)	1.06
"Treatment of vorinostat upregulates PLD1 through PKCζ-Sp1 axis."	( Phospholipase D1 is upregulated by vorinostat and confers resistance to vorinostat in glioblastoma. Hwang, WC; Jang, Y; Kang, DW; Kang, Y; Kim, JA; Min, DS; Noh, YN, 2021)	1.25
"Treatment with vorinostat reduced the IL-1α-induced production of mitochondrial reactive oxygen species (ROS) in T/C-28a2 cells."	( Vorinostat ameliorates IL-1α-induced reduction of type II collagen by inhibiting the expression of ELF3 in chondrocytes. Cao, L; Miao, X; Wang, P; Wu, Y; Yu, X; Zhang, Q; Zhou, C, 2021)	2.4
"Treatment with Vorinostat/JQ1 inhibited glycolysis/MTOR signaling, activated the clock, and upregulated the UPR and autophagy via inhibition of YAP1/NF-κB."	( YAP1 enhances NF-κB-dependent and independent effects on clock-mediated unfolded protein responses and autophagy in sarcoma. Babichev, Y; C Brady, D; Chor, S; E Ciotti, G; E Marino, G; Egolf, S; Eisinger-Mathason, TSK; Gladdy, R; Koumenis, C; Leli, NM; Liu, Y; Mancuso, A; Pak, K; Park, PMC; Posimo, JM; Qi, J; Rivera-Reyes, A; Sostre-Colón, J; Tameire, F; Weber, K; Ye, S, 2018)	0.82
"Also treatment with vorinostat ameliorates the altered expression of p-Akt, NF-B, iNOS and caspase by the western blot assay in the neuronal tissue of TBI mice and mRNA level of HO-1 and NQO-1 significantly enhanced in vorinostat compared to the negative control group."	( Vorinostat: a histone deacetylases (HDAC) inhibitor ameliorates traumatic brain injury by inducing iNOS/Nrf2/ARE pathway. Shi, J; Xu, J; Zhang, J; Zhang, Y, 2018)	2.24
"Treatment with vorinostat, a histone deacetylase inhibitor (HDACi) resulted in an objective response, yet she died in less than one year from initial diagnosis."	( Histone deacetylase inhibitor for NUT midline carcinoma. Bell, D; Christensen, AM; Maher, OM; Tarek, N; Yedururi, S, 2015)	0.76
"Treatment with vorinostat activated IGF-1R signaling in vorinostat-resistant but not vorinostat-sensitive NSCLC cells."	( Activation of insulin-like growth factor receptor signaling mediates resistance to histone deacetylase inhibitors. Choi, SP; Hyun, SY; Kim, JS; Kim, WY; Kwon, SJ; Lee, HJ; Lee, HY; Lee, SC; Min, HY; Park, KH, 2015)	0.76
"Treatment of vorinostat-resistant cells with the GLI1 small-molecule inhibitor, GANT61, phenocopied the effect of GLI1 knockdown."	( A genome scale RNAi screen identifies GLI1 as a novel gene regulating vorinostat sensitivity. Falkenberg, KJ; Gould, CM; Johnstone, RW; Luu, J; Matthews, GM; Newbold, A; Simpson, KJ; Trapani, JA, 2016)	1.02
"Pretreatment with vorinostat led to radiosensitisation of the intrinsically radioresistant DU 145 cells, but not the radiosensitive PC-3 and 22Rv1 cells, and was independent of hypoxia status. "	( Hypoxia-independent gene expression signature associated with radiosensitisation of prostate cancer cell lines by histone deacetylase inhibition. Clancy, T; Flatmark, K; Frikstad, KM; Jonsson, M; Julin, CH; Lyng, H; Matias-Guiu, X; Ragnum, HB; Ree, AH; Seierstad, T; Stokke, T; Yeramian, A, 2016)	0.77
"Treatment with vorinostat induced hsp90 acetylation and inhibited its chaperone association with AKs, leading to depletion of AKs and Survivin."	( Co-treatment with vorinostat synergistically enhances activity of Aurora kinase inhibitor against human breast cancer cells. Balusu, R; Bhalla, KN; Fiskus, W; Hembruff, SL; Peiper, SC; Peth, K; Rao, R; Sharma, P; Smith, JE; Venkannagari, S, 2012)	1.05

Excerpt	Reference	Relevance
" Rat vorinostat-related adverse findings are decreased food consumption, weight loss, and hematologic changes; a no observed adverse effects level is not established."	( Nonclinical safety assessment of the histone deacetylase inhibitor vorinostat. Andrews, PA; Armstrong, M; Galloway, S; Kerr, JS; Lagrutta, A; Miller, T; Richon, VM, )	0.88
"In early-phase studies with targeted therapeutics and radiotherapy, it may be difficult to decide whether an adverse event should be considered a dose-limiting toxicity (DLT) of the investigational systemic agent, as acute normal tissue toxicity is frequently encountered with radiation alone."	( Gastrointestinal toxicity of vorinostat: reanalysis of phase 1 study results with emphasis on dose-volume effects of pelvic radiotherapy. Bratland, A; Dueland, S; Flatmark, K; Hollywood, D; Ree, AH, 2011)	0.66
"Of 14 eligible patients, three individuals experienced Common Terminology Criteria of Adverse Events grade 3 gastrointestinal and related toxicities, representing a toxicity profile vorinostat has in common with radiotherapy to pelvic target volumes."	( Gastrointestinal toxicity of vorinostat: reanalysis of phase 1 study results with emphasis on dose-volume effects of pelvic radiotherapy. Bratland, A; Dueland, S; Flatmark, K; Hollywood, D; Ree, AH, 2011)	0.85
" The most common drug-related adverse events were anorexia, nausea, fatigue, and hyperglycemia."	( Evaluation of safety, pharmacokinetics, and efficacy of vorinostat, a histone deacetylase inhibitor, in the treatment of gastrointestinal (GI) cancer in a phase I clinical trial. Chin, K; Doi, T; Hamaguchi, T; Hatake, K; Mehta, A; Noguchi, K; Ohtsu, A; Otsuki, T; Shirao, K, 2013)	0.64
" Treatment-related adverse events (AE) included grade 1 to 2 nausea, diarrhea, fatigue, weight loss, anemia, and elevated creatinine."	( Combined autophagy and HDAC inhibition: a phase I safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the HDAC inhibitor vorinostat in patients with advanced solid tumors. Amaravadi, RK; Carew, JS; Curiel, TJ; Davis, LE; Espitia, CM; Giles, FJ; Mahalingam, D; Mita, AC; Mita, M; Nawrocki, ST; Sarantopoulos, J; Wood, L, 2014)	0.59
" The disease is characterized by the accumulation of toxic misfolded protein species that present as perinuclear aggregates known as aggresomes."	( Tubulin hyperacetylation is adaptive in cardiac proteotoxicity by promoting autophagy. Bhuiyan, MS; Ferguson, BS; James, J; McKinsey, TA; McLendon, PM; Osinska, H; Robbins, J, 2014)	0.4
" In this Pelvic Radiation and Vorinostat (PRAVO) study, we investigated mechanisms of adverse effects in response to the histone deacetylase (HDAC) inhibitor vorinostat (suberoylanilide hydroxamic acid, SAHA) when administered as a potential radiosensitiser."	( Induction of Apoptosis in Intestinal Toxicity to a Histone Deacetylase Inhibitor in a Phase I Study with Pelvic Radiotherapy. Andersen, SN; Barua, IS; Dueland, S; Flatmark, K; Kalanxhi, E; Lindvall, JM; Pettersen, SJ; Redalen, KR; Ree, AH; Risberg, K; Waagene, S, 2017)	0.74
" To the best of our knowledge, this is the first report deciphering mechanisms of normal tissue adverse effects in response to an HDAC inhibitor within a combined-modality treatment regimen."	( Induction of Apoptosis in Intestinal Toxicity to a Histone Deacetylase Inhibitor in a Phase I Study with Pelvic Radiotherapy. Andersen, SN; Barua, IS; Dueland, S; Flatmark, K; Kalanxhi, E; Lindvall, JM; Pettersen, SJ; Redalen, KR; Ree, AH; Risberg, K; Waagene, S, 2017)	0.46
" formulations and can be suggested as a promising stable and safe nanoparticulate delivery system with prolonged release and potentiated cytotoxicity."	( Enhanced in vitro cytotoxicity and anti-tumor activity of vorinostat-loaded pluronic micelles with prolonged release and reduced hepatic and renal toxicities. Abu Hashim, II; Badria, FAE; Mohamed, EA; Shaaban, AAA; Suddek, GM; Yusif, RM, 2017)	0.7
"We recorded a total of 31 adverse events (26 grade 1 and five grade 2) in all study participants (n = 20)."	( No adverse safety or virological changes 2 years following vorinostat in HIV-infected individuals on antiretroviral therapy. Dantanarayana, A; Elliott, JH; Hagenauer, M; Hoy, JF; Lewin, SR; McMahon, J; Mota, TM; Prince, HM; Purcell, DFJ; Rasmussen, TA; Rhodes, A; Roney, J; Spelman, T; Tennakoon, S; Wightman, F, 2017)	0.7
" The existing side effect prediction methods mainly focus on the chemical and biological properties of drugs."	( Prediction of Side Effects Using Comprehensive Similarity Measures. Kim, MH; Lee, T; Seo, S; Yoon, Y, 2020)	0.56
" Suberanilohydroxamic acid (SAHA) however has been proposed to prevent corneal haze without any adverse effects."	( Safety and efficacy of combination of suberoylamilide hydroxyamic acid and mitomycin C in reducing pro-fibrotic changes in human corneal epithelial cells. Dadachanji, ZV; Das, D; Ghosh, A; Khamar, P; Krishna, L; Kumar, NR; Matalia, H; Mohan, RR; Murugeswari, P; Shetty, R; Subramani, M, 2021)	0.62
"The combination of prolonged high-dose disulfiram and vorinostat was not safe in PWH on ART and should not be pursued despite evidence of latency reversal."	( Neurotoxicity with high-dose disulfiram and vorinostat used for HIV latency reversal. Blennow, K; Bumpus, N; Burger, D; Chang, J; Dantanarayana, A; Evans, VA; Fisher, K; Gisslen, M; Hagenauer, M; Heck, CJS; Howell, BJ; Lau, JSY; Lee, S; Lewin, SR; McMahon, JH; Palmer, S; Rasmussen, TA; Solomon, A; Symons, J; Tennakoon, S; Wu, G; Zerbato, JM; Zetterberg, HH; Zuck, P, 2022)	1.23

Excerpt	Reference	Relevance
"Patients (n = 23) received single doses of 400 mg vorinostat on day 1 (fasted) and day 5 (fed) with 48 hours of pharmacokinetic sampling on both days."	( A study to determine the effects of food and multiple dosing on the pharmacokinetics of vorinostat given orally to patients with advanced cancer. Agrawal, NG; Du, L; Frankel, SR; Friedman, EJ; Gottesdiener, KM; Iwamoto, M; Mazina, KE; Ricker, JL; Rubin, EH; Scott, P; Sun, L; Wagner, JA, 2006)	0.81
" Vorinostat area under the concentration versus time curve and half-life increased when vorinostat was coadministered with carboplatin and paclitaxel, but vorinostat did not alter paclitaxel pharmacokinetics."	( Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies. Argiris, AE; Belani, CP; Egorin, MJ; Lagattuta, TF; Musguire, LA; Parise, RA; Potter, DM; Ramalingam, SS; Ramananthan, RK; Ramanathan, RK; Stoller, RG; Zwiebel, JA, 2007)	1.52
"The aim of this work was to use phosphorus magnetic resonance spectroscopy ((31)P MRS) to investigate the pharmacodynamic effects of LAQ824, a histone deacetylase (HDAC) inhibitor."	( Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of a novel histone deacetylase inhibitor, LAQ824, in human colon carcinoma cells and xenografts. Aherne, W; Atadja, P; Beloueche-Babari, M; Chung, YL; Griffiths, JR; Jackson, LE; Judson, IR; Kristeleit, R; Leach, MO; Troy, H; Workman, P, 2008)	0.35
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."	( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Lombardo, F; Obach, RS; Waters, NJ, 2008)	0.35
"Elimination half-life was higher than that of SAHA (5."	( Pharmacokinetics and tissue distribution of Kendine 91, a novel histone deacetylase inhibitor, in mice. Cossío, FP; Otaegui, D; Pedraz, JL; Rodríguez-Gascón, A; Zubia, A, 2009)	0.35
"This preliminary pharmacokinetic evaluation prompts us to believe that it is worth pursuing further development of Kendine 91 as an anticancer drug."	( Pharmacokinetics and tissue distribution of Kendine 91, a novel histone deacetylase inhibitor, in mice. Cossío, FP; Otaegui, D; Pedraz, JL; Rodríguez-Gascón, A; Zubia, A, 2009)	0.35
" The median C(max) of FU at each dose level increased significantly with increasing doses of vorinostat, suggesting a pharmacokinetic interaction between FU and vorinostat."	( A phase I, pharmacokinetic and pharmacodynamic study on vorinostat in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with refractory colorectal cancer. Egorin, MJ; Espinoza-Delgado, I; Fakih, MG; Fetterly, G; Holleran, JL; Litwin, A; Pendyala, L; Ross, ME; Rustum, YM; Toth, K; Zwiebel, JA, 2009)	0.82
" It possesses optimized pharmacokinetic properties in preclinical species, has a clean off-target profile, and is negative in a microbial mutagenicity (Ames) test."	( Discovery of a potent class I selective ketone histone deacetylase inhibitor with antitumor activity in vivo and optimized pharmacokinetic properties. Fiore, F; Fonsi, M; Gonzalez Paz, O; Jones, P; Kinzel, O; Llauger-Bufi, L; Monteagudo, E; Pescatore, G; Rowley, M; Schultz-Fademrecht, C; Steinkühler, C, 2009)	0.35
" In the 100-500 mg dose range, vorinostat area under the concentration-time curve increased in proportion to dose with a pharmacokinetic profile similar to that established in non-Japanese patients."	( Phase I and pharmacokinetic study of vorinostat (suberoylanilide hydroxamic acid) in Japanese patients with solid tumors. Fujiwara, Y; Hardwick, JS; Iwasa, T; Kanazu, S; Otsuki, T; Tamura, T; Yamada, K; Yamada, Y; Yamamoto, N, 2009)	0.91
" No pharmacokinetic interactions were noted between vorinostat and FU."	( A phase I, pharmacokinetic, and pharmacodynamic study of two schedules of vorinostat in combination with 5-fluorouracil and leucovorin in patients with refractory solid tumors. Diasio, RB; Egorin, MJ; Espinoza-Delgado, I; Fakih, MG; Fetterly, G; Holleran, JL; Litwin, A; Muindi, JR; Wang, K; Zwiebel, JA, 2010)	0.84
" Pharmacokinetic studies were performed with the initial dose."	( Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report. Adamson, PC; Ames, MM; Blaney, SM; Fouladi, M; Gilbertson, RJ; Ingle, AM; Park, JR; Reid, JM; Schaiquevich, P; Speights, R; Stewart, CF; Sun, J; Zwiebel, J, 2010)	0.61
" Pharmacokinetic parameters were assessed for the first treatment cycle."	( Evaluation of safety, pharmacokinetics, and efficacy of vorinostat, a histone deacetylase inhibitor, in the treatment of gastrointestinal (GI) cancer in a phase I clinical trial. Chin, K; Doi, T; Hamaguchi, T; Hatake, K; Mehta, A; Noguchi, K; Ohtsu, A; Otsuki, T; Shirao, K, 2013)	0.64
"Herein, we describe the pharmacokinetic optimization of a series of class-selective histone deacetylase (HDAC) inhibitors and the subsequent identification of candidate predictive biomarkers of hepatocellular carcinoma (HCC) tumor response for our clinical lead using patient-derived HCC tumor xenograft models."	( Pharmacokinetic optimization of class-selective histone deacetylase inhibitors and identification of associated candidate predictive biomarkers of hepatocellular carcinoma tumor response. Cai, J; Chen, D; Chen, J; Chen, L; Chen, T; Feng, L; Guo, L; He, Y; Ji, Y; Jin, TG; Li, S; Liang, C; Lin, X; Liu, Y; Lu, X; Mei, J; Ning, Z; Pan, D; Pan, S; Peng, Z; Ren, S; Ren, Y; Rong, Y; Shan, S; She, J; Tang, G; Wang, Z; Wong, JC; Wu, X; Xu, C; Zhang, C; Zhang, M; Zhang, N; Zhang, W; Zhang, X; Zhang, Z; Zhao, R; Zhao, W; Zhou, M, 2012)	0.38
" The pharmacodynamic effect of an increase in acetylated histone proteins in blood was detected after both routes of administration."	( Pharmacokinetics and pharmacodynamics of suberoylanilide hydroxamic acid in cats. McDonnel, SJ; Murphy, BG; Tell, LA, 2014)	0.4
" The cytotoxicity of the optimized formulation was evaluated in cancer cell lines (MCF-7, A549, and MDA-MB-231), and pharmacokinetic parameters were examined following oral and intravenous (IV) administration to rats."	( Development of vorinostat-loaded solid lipid nanoparticles to enhance pharmacokinetics and efficacy against multidrug-resistant cancer cells. Choi, HG; Kim, JO; Ramasamy, T; Shin, BS; Tran, TH; Truong, DH; Yong, CS, 2014)	0.76
" Pharmacokinetic studies clearly demonstrated that VOR-SLNs markedly improved VOR plasma circulation time and decreased its elimination rate constant."	( Development of vorinostat-loaded solid lipid nanoparticles to enhance pharmacokinetics and efficacy against multidrug-resistant cancer cells. Choi, HG; Kim, JO; Ramasamy, T; Shin, BS; Tran, TH; Truong, DH; Yong, CS, 2014)	0.76
" Furthermore, compared with SAHA, MPT0G009 exhibited longer half-life (9."	( Preclinical anti-arthritic study and pharmacokinetic properties of a potent histone deacetylase inhibitor MPT0G009. Hsieh, IN; Lai, MJ; Lee, HY; Li, YH; Liou, JP; Yang, CR, 2014)	0.4
" This study investigated the effects of complexing iron (Fe3+) to the HDACi suberoylanilide hydroxamic acid (SAHA) and LAQ824 (LAQ) prior to their encapsulation into PEGylated liposomes, and investigated whether this technique could improve drug solubility, in vitro release and in vivo pharmacokinetic (PK) properties."	( Iron complexation to histone deacetylase inhibitors SAHA and LAQ824 in PEGylated liposomes can considerably improve pharmacokinetics in rats. Steffen, D; Tu, S; Wang, Y; Xiong, M, 2014)	0.4
" This study examines pharmacokinetic interactions in simultaneous oral administration of SAHA and lapatinib to rats."	( Pharmacokinetic interaction study combining lapatinib with vorinostat in rats. Geng, P; Lin, F; Wang, S; Wu, C; Zhang, Q; Zhang, X; Zhou, Y; Zou, H, 2015)	0.66
"Statistically significant pharmacokinetic differences appeared for lapatinib levels between the lapatinib and the coadministration group."	( Pharmacokinetic interaction study combining lapatinib with vorinostat in rats. Geng, P; Lin, F; Wang, S; Wu, C; Zhang, Q; Zhang, X; Zhou, Y; Zou, H, 2015)	0.66
"The resulting data indicate that, when administered together, lapatinib does not influence the pharmacokinetic profile of SAHA in rats, while, in contrast, SAHA influences the pharmacokinetic profile of lapatinib."	( Pharmacokinetic interaction study combining lapatinib with vorinostat in rats. Geng, P; Lin, F; Wang, S; Wu, C; Zhang, Q; Zhang, X; Zhou, Y; Zou, H, 2015)	0.66
" This model may be used as a mechanistic bridge to link vorinostat exposure to molecular events and pharmacodynamic (PD) outcomes."	( Cell Signaling Model Connects Vorinostat Pharmacokinetics and Tumor Growth Response in Multiple Myeloma Xenografts. Mager, DE; Nanavati, C; Ruszaj, D, 2017)	0.99
" In pharmacokinetics assay, 23g showed a significant improvement of pharmacokinetic profile for oral administration."	( Design, synthesis and biological evaluation of novel HDAC inhibitors with improved pharmacokinetic profile in breast cancer. He, Z; Huang, J; Jiang, J; Li, C; Wang, J; Yao, D; Zhang, J, 2020)	0.56
" Simulations revealed that the greatest magnitude of pharmacodynamic drug interactions between bortezomib and vorinostat occurred at caspase-9, AKT, and Bcl-2."	( Cluster Gauss-Newton and CellNOpt Parameter Estimation in a Small Protein Signaling Network of Vorinostat and Bortezomib Pharmacodynamics. Chen, T; Ghasemi, M; Mager, DE; Nguyen, VA; Niu, J, 2021)	1.05

Excerpt	Reference	Relevance
"The primary objective of this study was to determine the recommended phase II doses of the novel histone deacetylase inhibitor vorinostat when administered in combination with carboplatin and paclitaxel."	( Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies. Argiris, AE; Belani, CP; Egorin, MJ; Lagattuta, TF; Musguire, LA; Parise, RA; Potter, DM; Ramalingam, SS; Ramananthan, RK; Ramanathan, RK; Stoller, RG; Zwiebel, JA, 2007)	0.82
"Both schedules of vorinostat (400 mg oral qd x 14 days or 300 mg bd x 7 days) were tolerated well in combination with carboplatin (area under the concentration versus time curve = 6 mg/mL x min) and paclitaxel (200 mg/m(2))."	( Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies. Argiris, AE; Belani, CP; Egorin, MJ; Lagattuta, TF; Musguire, LA; Parise, RA; Potter, DM; Ramalingam, SS; Ramananthan, RK; Ramanathan, RK; Stoller, RG; Zwiebel, JA, 2007)	0.95
" These results demonstrate that compound 2 and its combination with SAHA are potentially useful agents that warrant further preclinical development for treatment of prostate cancer."	( Improved synthesis of histone deacetylase inhibitors (HDIs) (MS-275 and CI-994) and inhibitory effects of HDIs alone or in combination with RAMBAs or retinoids on growth of human LNCaP prostate cancer cells and tumor xenografts. Belosay, A; Gediya, LK; Khandelwal, A; Njar, VC; Purushottamachar, P, 2008)	0.35
" ABT-737 was ineffective against Emu-myc/Mcl-1 and Emu-myc/A1 cells either as a single agent or in combination with HDACi."	( Defining the target specificity of ABT-737 and synergistic antitumor activities in combination with histone deacetylase inhibitors. Alsop, AE; Banks, KM; Cluse, LA; Coomans, C; Johnstone, RW; Lindemann, RK; Newbold, A; Peart, MJ; Whitecross, KF; Wiegmans, A, 2009)	0.35
" Etoposide combined with vorinostat was additive to synergistic, and the synergism became more pronounced when etoposide was given after vorinostat."	( Preclinical studies of vorinostat (suberoylanilide hydroxamic acid) combined with cytosine arabinoside and etoposide for treatment of acute leukemias. Carlton, D; Edelman, MJ; Fang, HB; Gojo, I; Nakanishi, T; Ross, DD; Sausville, EA; Shiozawa, K; Tan, M; Wang, WC, 2009)	0.97
"These findings using two independent methods to assess drug combination effects provide a preclinical rationale for phase I trials of the sequential combination of vorinostat followed by ara-C and etoposide in patients with advanced or refractory leukemias."	( Preclinical studies of vorinostat (suberoylanilide hydroxamic acid) combined with cytosine arabinoside and etoposide for treatment of acute leukemias. Carlton, D; Edelman, MJ; Fang, HB; Gojo, I; Nakanishi, T; Ross, DD; Sausville, EA; Shiozawa, K; Tan, M; Wang, WC, 2009)	0.86
" Moreover, in combination with 5-fluorouracil modulated by folinic acid (5FU-FA) or with Raltitrexed (RTX), both commonly used in the treatment of this disease, it showed a clear schedule-dependent synergistic antiproliferative interaction as demonstrated by calculating combination indexes."	( Modulation of thymidilate synthase and p53 expression by HDAC inhibitor vorinostat resulted in synergistic antitumor effect in combination with 5FU or raltitrexed. Avallone, A; Bruzzese, F; Budillon, A; Delrio, P; Di Gennaro, E; Leone, A; Pepe, S; Subbarayan, PR, 2009)	0.59
"We conducted a phase I study to determine the maximum tolerated dose of vorinostat in combination with fixed doses of 5-fluorouracil (FU), leucovorin, and oxaliplatin (FOLFOX)."	( A phase I, pharmacokinetic and pharmacodynamic study on vorinostat in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with refractory colorectal cancer. Egorin, MJ; Espinoza-Delgado, I; Fakih, MG; Fetterly, G; Holleran, JL; Litwin, A; Pendyala, L; Ross, ME; Rustum, YM; Toth, K; Zwiebel, JA, 2009)	0.83
"The maximum tolerated dose of vorinostat in combination with FOLFOX is 300 mg orally twice daily x 1 week every 2 weeks."	( A phase I, pharmacokinetic and pharmacodynamic study on vorinostat in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with refractory colorectal cancer. Egorin, MJ; Espinoza-Delgado, I; Fakih, MG; Fetterly, G; Holleran, JL; Litwin, A; Pendyala, L; Ross, ME; Rustum, YM; Toth, K; Zwiebel, JA, 2009)	0.89
" This phase II randomized, double-blinded, placebo-controlled study evaluated the efficacy of vorinostat in combination with carboplatin and paclitaxel in patients with advanced-stage NSCLC."	( Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. Argiris, AE; Belani, CP; Espinoza-Delgado, I; Frankel, P; Gandara, DR; Gitlitz, B; Koczywas, M; Maitland, ML; Ramalingam, SS; Thomas, S; Vokes, EE, 2010)	0.83
" In this study, we determined if vorinostat alone or in combination with EGCG imparts anti-proliferative effects against human melanoma cells."	( Anti-melanoma effects of vorinostat in combination with polyphenolic antioxidant (-)-epigallocatechin-3-gallate (EGCG). Nihal, M; Roelke, CT; Wood, GS, 2010)	0.95
" This phase 1 study assessed the use of vorinostat combined with pelvic palliative radiotherapy for gastrointestinal carcinoma."	( Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study. Abrahamsen, TW; Dueland, S; Flatmark, K; Folkvord, S; Hole, KH; Johansen, M; Ree, AH; Seierstad, T, 2010)	2.07
" The maximum-tolerated dose of vorinostat in combination with palliative radiotherapy was thus determined to be 300 mg once daily."	( Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study. Abrahamsen, TW; Dueland, S; Flatmark, K; Folkvord, S; Hole, KH; Johansen, M; Ree, AH; Seierstad, T, 2010)	2.09
"Vorinostat can be safely combined with short-term pelvic palliative radiotherapy."	( Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study. Abrahamsen, TW; Dueland, S; Flatmark, K; Folkvord, S; Hole, KH; Johansen, M; Ree, AH; Seierstad, T, 2010)	3.25
" HDACi have single-agent clinical activity in haematological malignancies and have synergistic anti-leukaemia activity when combined with anthracyclines in vitro."	( A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia. Egorin, MJ; Espinoza-Delgado, I; Ferrajoli, A; Garcia-Manero, G; Holleran, JL; Kadia, TM; Kantarjian, HM; Madden, TL; Maddipotti, S; Newsome, W; Ravandi, F; Sanchez-Gonzalez, B; Schroeder, C; Thomas, DA; Yang, H; Zwiebel, JA, 2010)	0.69
"We conducted a phase I clinical trial to determine the maximum tolerated dose (MTD) of daily or twice daily vorinostat x 3 days when combined with fixed doses of 5-fluorouracil (FU) and leucovorin every 2 weeks."	( A phase I, pharmacokinetic, and pharmacodynamic study of two schedules of vorinostat in combination with 5-fluorouracil and leucovorin in patients with refractory solid tumors. Diasio, RB; Egorin, MJ; Espinoza-Delgado, I; Fakih, MG; Fetterly, G; Holleran, JL; Litwin, A; Muindi, JR; Wang, K; Zwiebel, JA, 2010)	0.8
"The MTD of vorinostat in combination with sLV5FU2 is 1,700 mg orally once daily x 3 or 600 mg orally twice daily x 3 days every 2 weeks."	( A phase I, pharmacokinetic, and pharmacodynamic study of two schedules of vorinostat in combination with 5-fluorouracil and leucovorin in patients with refractory solid tumors. Diasio, RB; Egorin, MJ; Espinoza-Delgado, I; Fakih, MG; Fetterly, G; Holleran, JL; Litwin, A; Muindi, JR; Wang, K; Zwiebel, JA, 2010)	0.98
" Vorinostat and docetaxel pharmacokinetics were comparable to previous reports in the literature, without obvious drug-drug interactions."	( Phase I study of vorinostat (suberoylanilide hydroxamic acid, NSC 701852) in combination with docetaxel in patients with advanced and relapsed solid malignancies. Bradley, D; Daignault, S; Dunn, R; Egorin, MJ; Hussain, M; Kalemkerian, GP; Schneider, BJ; Smith, DC, 2012)	1.63
"To clarify the source of deviations of drug combination effects evaluated with different drug interaction mathematical models, the cytotoxicity of SAHA and arsenic trioxide and their combinations were observed in a series of human cancer cell lines and a normal cell line."	( [Three different drug interaction mathematical models used to evaluate the cytotoxicity of SAHA and arsenic trioxide in combination]. Liu, ZJ; Lu, N; Wang, N; Yan, Z, 2010)	0.36
" The objective of this study was to investigate the effects of 1,25(OH)(2)D(3) and the superagonistic analog CD578 in anaplastic thyroid cancer, alone or in combination with paclitaxel, a taxane, and suberoylanilide hydroxamic acid (SAHA), a potent histone deacetylase inhibitor with promising effects in undifferentiated thyroid cancer."	( 1,25-dihydroxyvitamin D3 and a superagonistic analog in combination with paclitaxel or suberoylanilide hydroxamic acid have potent antiproliferative effects on anaplastic thyroid cancer. Bouillon, R; Clinckspoor, I; Decallonne, B; Korch, C; Mathieu, C; Overbergh, L; Verlinden, L; Verstuyf, A, 2011)	0.37
" Herein, we demonstrate that HDACi can be combined with immune-activating antibodies designed to promote the function of antigen-presenting cells (APCs) and enhance proliferation and survival of cytotoxic T cells (CTL) to stimulate a host antitumor immune response resulting in eradication of established solid tumors."	( Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies. Banks, KM; Christiansen, AJ; Haynes, NM; Johnstone, RW; Smyth, MJ; Teng, MW; West, A, 2011)	0.37
" We aim to evaluate the activity of vorinostat in combination with interferon (IFN) alpha and extracorporeal photopheresis (ECP) with persistent, progressive advanced stage MF and Sezary syndrome (SS)."	( The efficacy of vorinostat in combination with interferon alpha and extracorporeal photopheresis in late stage mycosis fungoides and Sezary syndrome. Akay, BN; Akyol, A; Anadolu, R; Ozcan, M; Sanli, H; Saral, S, 2011)	0.99
"Our experience in this case series is suggestive of the synergistic effect of vorinostat in combination with IFN and ECP and supports the efficacy of vorinostat in inducing prolonged responses in patients with progressive disease and/or stable disease in otherwise progressive and treatment refractory late stage MF/SS."	( The efficacy of vorinostat in combination with interferon alpha and extracorporeal photopheresis in late stage mycosis fungoides and Sezary syndrome. Akay, BN; Akyol, A; Anadolu, R; Ozcan, M; Sanli, H; Saral, S, 2011)	0.94
" Mechanistically, SAHA combined with bortezomib enhanced protein ubiquitination synergistically and enhanced histone acetylation by inhibiting the expression of HDACs."	( Suberoylanilide hydroxamic acid (SAHA) combined with bortezomib inhibits renal cancer growth by enhancing histone acetylation and protein ubiquitination synergistically. Asano, T; Ito, K; Sato, A; Sumitomo, M, 2012)	0.38
"SAHA combined with bortezomib inhibits the proliferation of renal cancer cells in vitro and in vivo, and the effectiveness of the combination is due to its synergistic enhancement of histone acetylation and protein ubiquitination."	( Suberoylanilide hydroxamic acid (SAHA) combined with bortezomib inhibits renal cancer growth by enhancing histone acetylation and protein ubiquitination synergistically. Asano, T; Ito, K; Sato, A; Sumitomo, M, 2012)	0.38
" Vorinostat was combined with bevacizumab and CPT-11 and was escalated using a standard 3 + 3 design."	( Phase I trial of vorinostat combined with bevacizumab and CPT-11 in recurrent glioblastoma. Brem, S; Chinnaiyan, P; Chowdhary, S; Kahali, S; Murtagh, R; Pan, E; Potthast, L; Prabhu, A; Rojiani, A; Sarcar, B; Tsai, YY; Yu, HM, 2012)	1.63
" Primary objective was to determine maximum tolerated dose (MTD) of vorinostat, a competitive inhibitor of histone deacetylase (HDAC), in combination with vinorelbine."	( Unexpected high levels of vorinostat when combined with vinorelbine in patients with advanced cancer. Arellano, C; Campone, M; Chalret du Rieu, Q; Chatelut, E; Delord, JP; Filleron, T; Gandia, P; Hennebelle, I; Lochon, I; Pierga, JY; Poublanc, M, 2011)	0.9
"Starting dose of once daily oral vorinostat was 200 mg for 7 days every 21 days in combination with a 20-min intraveinous weekly infusion of vinorelbine 25 mg/m2, starting 4 hours after the first vorinostat dose."	( Unexpected high levels of vorinostat when combined with vinorelbine in patients with advanced cancer. Arellano, C; Campone, M; Chalret du Rieu, Q; Chatelut, E; Delord, JP; Filleron, T; Gandia, P; Hennebelle, I; Lochon, I; Pierga, JY; Poublanc, M, 2011)	0.95
" Mean vorinostat plasma AUC was higher than reported previously at a similar dose when used as single agent or in combination with other cytotoxics."	( Unexpected high levels of vorinostat when combined with vinorelbine in patients with advanced cancer. Arellano, C; Campone, M; Chalret du Rieu, Q; Chatelut, E; Delord, JP; Filleron, T; Gandia, P; Hennebelle, I; Lochon, I; Pierga, JY; Poublanc, M, 2011)	1.15
"MDT of the combination was 200 mg oral vorinostat for 7 days in combination with 25 mg/m2 weekly vinorelbine."	( Unexpected high levels of vorinostat when combined with vinorelbine in patients with advanced cancer. Arellano, C; Campone, M; Chalret du Rieu, Q; Chatelut, E; Delord, JP; Filleron, T; Gandia, P; Hennebelle, I; Lochon, I; Pierga, JY; Poublanc, M, 2011)	0.94
" We therefore conducted a phase II trial to evaluate the efficacy of vorinostat in combination with the proteasome inhibitor bortezomib in patients with recurrent GBM."	( Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study. Anderson, SK; Buckner, J; Friday, BB; Galanis, E; Geoffroy, F; Giannini, C; Gross, H; Jaeckle, K; Mazurczak, M; Pajon, E; Schwerkoske, J; Yu, C, 2012)	0.95
"Potential radiosensitization by SAHA was assessed in MRT xenografts by analysis of tumor growth delay, necrosis (HE), apoptosis (TUNEL), proliferation (ki-67) and γH2AX expression as well as dynamic 18F-Fluorodeoxyglucose Positron Emission Tomography (18F-FDG -PET) after treatment with either SAHA alone, single-dose (10 Gy) or fractionated XRT (3 × 3Gy) solely as well as in combination with SAHA compared to controls."	( In vivo efficacy of the histone deacetylase inhibitor suberoylanilide hydroxamic acid in combination with radiotherapy in a malignant rhabdoid tumor mouse model. Battmann, C; Bischof, M; Debus, J; Ehemann, V; Haberkorn, U; Huber, PE; Kulozik, AE; Oertel, S; Perez, RL; Stenzinger, A; Thiemann, M; Weber, KJ; Weichert, W, 2012)	0.38
"A phase I, dose-finding study of vorinostat in combination with temozolomide (TMZ) was conducted to determine the maximum tolerated dose (MTD), safety, and pharmacokinetics in patients with high-grade glioma (HGG)."	( Phase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas: North American Brain Tumor Consortium Study 04-03. Ames, MM; Chang, SM; Cloughesy, TF; Desideri, S; Drappatz, J; Espinoza-Delgado, I; Gilbert, MR; Kuhn, JG; Lamborn, KR; Lassman, AB; Lee, EQ; Lieberman, FS; McGovern, RM; Prados, MD; Puduvalli, VK; Reid, JM; Robins, HI; Wen, PY; Xu, J; Ye, X; Yung, WK, 2012)	1
" Part 1 was a dose-escalation study of vorinostat in combination with TMZ 150 mg/m(2)/day for 5 days every 28 days."	( Phase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas: North American Brain Tumor Consortium Study 04-03. Ames, MM; Chang, SM; Cloughesy, TF; Desideri, S; Drappatz, J; Espinoza-Delgado, I; Gilbert, MR; Kuhn, JG; Lamborn, KR; Lassman, AB; Lee, EQ; Lieberman, FS; McGovern, RM; Prados, MD; Puduvalli, VK; Reid, JM; Robins, HI; Wen, PY; Xu, J; Ye, X; Yung, WK, 2012)	0.99
"In part 1, the MTD of vorinostat administered on days 1 to 7 and 15 to 21 of every 28-day cycle, in combination with TMZ, was 500 mg daily."	( Phase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas: North American Brain Tumor Consortium Study 04-03. Ames, MM; Chang, SM; Cloughesy, TF; Desideri, S; Drappatz, J; Espinoza-Delgado, I; Gilbert, MR; Kuhn, JG; Lamborn, KR; Lassman, AB; Lee, EQ; Lieberman, FS; McGovern, RM; Prados, MD; Puduvalli, VK; Reid, JM; Robins, HI; Wen, PY; Xu, J; Ye, X; Yung, WK, 2012)	1.03
"Vorinostat in combination with temozolomide is well tolerated in patients with HGG."	( Phase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas: North American Brain Tumor Consortium Study 04-03. Ames, MM; Chang, SM; Cloughesy, TF; Desideri, S; Drappatz, J; Espinoza-Delgado, I; Gilbert, MR; Kuhn, JG; Lamborn, KR; Lassman, AB; Lee, EQ; Lieberman, FS; McGovern, RM; Prados, MD; Puduvalli, VK; Reid, JM; Robins, HI; Wen, PY; Xu, J; Ye, X; Yung, WK, 2012)	2.16
" We examined this drug combination in advanced relapsing and/or refractory MM patients (n = 34)."	( Phase I trial of vorinostat combined with bortezomib for the treatment of relapsing and/or refractory multiple myeloma. Graef, T; Hardwick, JS; Hussein, M; Jagannath, S; Lupinacci, L; Schiller, GJ; Sobecks, RM; Weber, DM, 2012)	0.72
" Vorinostat combined with bortezomib has demonstrated synergistic antiproliferative and proapoptotic activity in preclinical models of MM."	( Phase I trial of vorinostat combined with bortezomib for the treatment of relapsing and/or refractory multiple myeloma. Graef, T; Hardwick, JS; Hussein, M; Jagannath, S; Lupinacci, L; Schiller, GJ; Sobecks, RM; Weber, DM, 2012)	1.63
" In xenograft models, while gefitinib induced marked regression via apoptosis of tumors without the BIM polymorphism, its combination with vorinostat was needed to induce marked regression of tumors with the BIM polymorphism in the same manner."	( EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition. Ebi, H; Hasegawa, Y; Ishikawa, D; Nakagawa, T; Nanjo, S; Sano, T; Sato, M; Sekido, Y; Takeuchi, S; Yamada, T; Yano, S, 2013)	0.59
"To determine the maximum-tolerated dose (MTD) of the histone deacetylase inhibitor vorinostat combined with fixed doses of cytarabine (ara-C or cytosine arabinoside) and etoposide in patients with poor-risk or advanced acute leukemia, to obtain preliminary efficacy data, describe pharmacokinetics, and in vivo pharmacodynamic effects of vorinostat in leukemia blasts."	( Translational phase I trial of vorinostat (suberoylanilide hydroxamic acid) combined with cytarabine and etoposide in patients with relapsed, refractory, or high-risk acute myeloid leukemia. Anyang, BN; Baer, MR; Beumer, JH; Carrier, F; Espinoza-Delgado, I; Fang, HB; Gojo, I; Lapidus, R; Ross, DD; Sadowska, M; Srivastava, RK; Tan, M, 2013)	0.9
"A phase I trial of first-line vorinostat, an orally bio-available histone deacetylase inhibitor, in combination with capecitabine plus cisplatin (XP) was performed to assess recommend phase II trial dose in patients with advanced gastric cancer."	( Phase I and pharmacodynamic study of vorinostat combined with capecitabine and cisplatin as first-line chemotherapy in advanced gastric cancer. Kang, YK; Kim, SY; Koo, DH; Lee, CW; Maeng, J; Na, YS; Park, I; Ryoo, BY; Ryu, MH; Yoo, C, 2014)	0.96
" Therefore, we studied the effect of polo-like kinase 1 (Plk1) inhibitors on prostate cancer cells as a single agent and in combination with histone deacetylase (HDAC) inhibitors valproic acid and vorinostat."	( Targeting prostate cancer cell lines with polo-like kinase 1 inhibitors as a single agent and in combination with histone deacetylase inhibitors. Carducci, MA; Gonzalez, M; Hammers, H; Kachhap, SK; Kaelber, NS; Kim, E; Kortenhorst, MS; Mendonca, J; van Diest, PJ; Wissing, MD, 2013)	0.58
"We aimed to assess efficacy and tolerability of vorinostat in combination with bortezomib for treatment of patients with relapsed or refractory multiple myeloma."	( Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study. Anderson, KC; Blacklock, H; Dimopoulos, M; Eid, JE; Facon, T; Goldschmidt, H; Graef, T; Hajek, R; Houp, J; Hungria, V; Lonial, S; Palumbo, A; Qi, J; Rosinol, L; Siegel, DS; Spencer, A; Sun, L; Vuocolo, S; Williams, C, 2013)	2.09
" We randomly allocated patients (1:1) using an interactive voice response system to receive 21 day cycles of bortezomib (1·3 mg/m(2) intravenously on days 1, 4, 8, and 11) in combination with oral vorinostat (400 mg) or matching placebo once-daily on days 1-14."	( Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study. Anderson, KC; Blacklock, H; Dimopoulos, M; Eid, JE; Facon, T; Goldschmidt, H; Graef, T; Hajek, R; Houp, J; Hungria, V; Lonial, S; Palumbo, A; Qi, J; Rosinol, L; Siegel, DS; Spencer, A; Sun, L; Vuocolo, S; Williams, C, 2013)	2.02
"A phase I study to assess the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), pharmacokinetics (PK) and antitumor activity of vorinostat in combination with bortezomib in patients with advanced solid tumors."	( A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies. Alberti, D; Ames, MM; Attia, S; Bailey, HH; Eickhoff, J; Espinoza-Delgado, I; Hoang, T; Holen, KD; Jiang, Z; Kolesar, JM; Marnocha, R; McGovern, RM; Reid, JM; Schelman, WR; Traynor, AM; Wilding, G; Wright, JJ, 2013)	0.92
" We previously examined a once-daily continuous dosing schedule of vorinostat in combination with bortezomib which was well tolerated in cycles 1 and 2; however, there was concern regarding the tolerability through multiple cycles."	( A Phase I study of intermittently dosed vorinostat in combination with bortezomib in patients with advanced solid tumors. Alberti, D; Ames, MM; Bailey, HH; Deming, DA; Eickhoff, J; Espinoza-Delgado, I; Kolesar, JM; Marnocha, R; McGovern, RM; Ninan, J; Reid, JM; Schelman, WR; Wilding, G; Wright, J, 2014)	0.91
" In conclusion, the poor results obtained with lenalidomide in combination with vorinostat and dexamethasone provide no arguments that could justify further investigation of this drug combination for the treatment of relapsed PTCL."	( Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed/refractory peripheral T cell lymphoma (PTCL): report of a phase I/II trial. Egle, A; Greil, R; Hopfinger, G; Lang, A; Linkesch, W; Melchardt, T; Nösslinger, T; Weiss, L, 2014)	0.91
" Patients were treated orally with escalating doses of HCQ daily (QD) (d 2 to 21 of a 21-d cycle) in combination with 400 mg VOR QD (d one to 21)."	( Combined autophagy and HDAC inhibition: a phase I safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the HDAC inhibitor vorinostat in patients with advanced solid tumors. Amaravadi, RK; Carew, JS; Curiel, TJ; Davis, LE; Espitia, CM; Giles, FJ; Mahalingam, D; Mita, AC; Mita, M; Nawrocki, ST; Sarantopoulos, J; Wood, L, 2014)	0.59
" The aim of the study presented here was to analyze the effects of a pharmacological inhibition of EZH2 alone and in combination with other anticancer drugs on RTs cells in vitro."	( Analysis of the antiproliferative effects of 3-deazaneoplanocin A in combination with standard anticancer agents in rhabdoid tumor cell lines. Borchardt, C; Clemens, D; Dirksen, U; Frühwald, MC; Kool, M; Unland, R, 2015)	0.42
" We investigated the efficacy of the histone deacetylase (HDAC) inhibitor vorinostat combined with one of several B-cell receptor (BCR) signaling inhibitors on MCL cell death and the underlying mechanisms, using MCL cell lines."	( The synergistic effect of BCR signaling inhibitors combined with an HDAC inhibitor on cell death in a mantle cell lymphoma cell line. Hagiwara, K; Iida, H; Kunishima, S; Miyata, Y; Nagai, H; Naoe, T, 2015)	0.65
" In this study, we analysed the effects of the pan-aurora kinases inhibitor AMG 900 alone or in combination with the iHDAC SaHa (Vorinostat) on paediatric MB cell lines (UW402, UW473 and ONS-76)."	( Antitumour activity of AMG 900 alone or in combination with histone deacetylase inhibitor SaHa on medulloblastoma cell lines. Andrade, AF; Borges, KS; Geron, L; Scrideli, CA; Suazo, VK; Tone, LG, 2015)	0.62
" Drug combination analyses were made based on Chou-Talalay method."	( Antitumour activity of AMG 900 alone or in combination with histone deacetylase inhibitor SaHa on medulloblastoma cell lines. Andrade, AF; Borges, KS; Geron, L; Scrideli, CA; Suazo, VK; Tone, LG, 2015)	0.42
"These results indicate that AMG 900 may be a promising drug for the adjuvant treatment of MB, mainly when combined with iHDAC."	( Antitumour activity of AMG 900 alone or in combination with histone deacetylase inhibitor SaHa on medulloblastoma cell lines. Andrade, AF; Borges, KS; Geron, L; Scrideli, CA; Suazo, VK; Tone, LG, 2015)	0.42
" We performed an open-label, multi-center, phase II study to investigate the effect and quality of life (QoL) of treatment with vorinostat in combination with fludarabine, mitoxantrone and dexamethasone (V-FND) for relapsed or refractory MCL."	( Results of a phase II study of vorinostat in combination with intravenous fludarabine, mitoxantrone, and dexamethasone in patients with relapsed or refractory mantle cell lymphoma: an interim analysis. Kim, BS; Kim, HJ; Kim, JA; Kim, SJ; Kim, WS; Kong, JH; Park, SK; Park, Y; Shin, DY; Won, JH; Yoon, DH, 2016)	0.93
"The present global, open-label, single-arm, multicenter, phase IIb study was designed to determine the efficacy and tolerability of oral vorinostat combined with standard doses of bortezomib in patients with multiple myeloma considered refractory to novel myeloma agents."	( VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma. Anderson, KC; Dimopoulos, M; Durrant, S; Eid, JE; Gause, C; Goldschmidt, H; Graef, T; Houp, J; Jagannath, S; Kaufman, JL; Leleu, X; Nagler, A; Offner, F; Siegel, DS; Vuocolo, S, 2016)	0.88
"Vorinostat, a histone deacetylase (HDAC) inhibitor, was investigated in combination with capecitabine plus cisplatin (XP) as a first-line chemotherapy for patients with unresectable or metastatic gastric cancer (GC)."	( Vorinostat in combination with capecitabine plus cisplatin as a first-line chemotherapy for patients with metastatic or unresectable gastric cancer: phase II study and biomarker analysis. Kang, YK; Lee, CW; Na, YS; Ryoo, BY; Ryu, MH; Yoo, C, 2016)	3.32
" Here, we report in vivo data for OTX015 in combination with the histone deacetylase inhibitor vorinostat, the Bruton's tyrosine kinase inhibitor ibrutinib, the anti-CD20 monoclonal antibody rituximab, and the mTOR inhibitor everolimus in a diffuse large B cell lymphoma model."	( Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong in vivo antitumor activity in lymphoma. Bernasconi, E; Bertoni, F; Cascione, L; Cvitkovic, E; Gaudio, E; Odore, E; Ponzoni, M; Rezai, K; Rinaldi, A; Riveiro, E; Stathis, A; Tarantelli, C; Zucca, E, 2016)	0.65
"Clinical trials of vorinostat, a Class I/II histone deacetylase inhibitor, in combination with proteasome inhibitors and immunomodulatory agents have shown activity in relapsed/refractory multiple myeloma."	( A phase IIb trial of vorinostat in combination with lenalidomide and dexamethasone in patients with multiple myeloma refractory to previous lenalidomide-containing regimens. Anand, P; Bilotti, E; Biran, N; Ivanovski, K; McBride, L; Richter, JR; Sanchez, L; Siegel, DS; Vesole, DH, 2017)	1.1
"In patients with HER2-positive metastatic breast cancer who had relapsed or progressed during trastuzumab therapy, we observed no DLTs with SAHA 200 mg twice daily combined with trastuzumab; however, there was insufficient statistical evidence that adding SAHA reversed trastuzumab resistance in these patients."	( A Phase I/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab (Herceptin) in patients with advanced metastatic and/or local chest wall recurrent HER2-amplified breast cancer: a trial of the ECOG-ACRIN Cancer Research Group ( Bhalla, KN; Falkson, CI; Goldstein, LJ; Katherine Alpaugh, R; Klein, P; Meropol, NJ; Pellegrino, CM; Sledge, GW; Sparano, JA; Swaby, RF; Wang, M; Zhao, F, 2017)	0.46
" Consistent additive to synergistic interactions were observed in HCT116 cells when PENT was combined with SAHA at all drug tested concentrations."	( Enhanced anticancer efficacy of histone deacetyl inhibitor, suberoylanilide hydroxamic acid, in combination with a phosphodiesterase inhibitor, pentoxifylline, in human cancer cell lines and in-vivo tumor xenografts. Chandrasekhar, KB; Karthikeyan, K; Khan, FR; Kulkarni, NM; Narayanan, S; Nidhyanandan, S; Raghul, J; Reddy, ND; Thippeswamy, BS; Vijaykanth, G, 2017)	0.46
" This open-label, single-arm trial evaluated the maximum tolerated dose (MTD; phase I) and efficacy (phase II) of vorinostat combined with standard chemoradiation in newly diagnosed glioblastoma."	( Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02. Ahluwalia, MS; Anderson, SK; Ballman, KV; Buckner, JC; Cerhan, J; Galanis, E; Gerstner, ER; Giannini, C; Grossman, SA; Jaeckle, K; Lee, EQ; Lesser, GJ; Ligon, KL; Loboda, A; Miller, CR; Moore, DF; Nebozhyn, M; Prados, M; Sarkaria, JN; Schiff, D; Wen, PY, 2018)	1.01
"Vorinostat combined with standard chemoradiation had acceptable tolerability in newly diagnosed glioblastoma."	( Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02. Ahluwalia, MS; Anderson, SK; Ballman, KV; Buckner, JC; Cerhan, J; Galanis, E; Gerstner, ER; Giannini, C; Grossman, SA; Jaeckle, K; Lee, EQ; Lesser, GJ; Ligon, KL; Loboda, A; Miller, CR; Moore, DF; Nebozhyn, M; Prados, M; Sarkaria, JN; Schiff, D; Wen, PY, 2018)	2.25
" S0806 was a single arm phase I/II trial of vorinostat given at 400 mg po daily on days 1-9 (subsequently amended to days 1-5 due to toxicity), combined with R-CHOP given on day 3 of a 21-day cycle for 8 cycles, with primary phase II endpoint of 2-year progression free survival (PFS)."	( A phase I/II trial of vorinostat (SAHA) in combination with rituximab-CHOP in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0806. Bane, CL; Barr, PM; Fisher, RI; Friedberg, JW; LeBlanc, M; Li, H; Persky, DO; Popplewell, LL; Rimsza, LM; Smith, SM; Von Gehr, A, 2018)	1.06
" The primary objective of this Phase I study was to determine the maximally tolerated dose (MTD) and safety of Vorinostat in combination with standard chemoradiation therapy treatment in HNSCC."	( A phase 1 trial of Vorinostat in combination with concurrent chemoradiation therapy in the treatment of advanced staged head and neck squamous cell carcinoma. Agrawal, A; Baiocchi, R; Blakaj, D; Carrau, R; Diavolitsis, V; Grecula, J; Kang, S; Kumar, B; Kumar, P; Old, MO; Ozer, E; Palettas, M; Pan, Q; Rocco, J; Savvides, P; Teknos, TN; Wei, L, 2019)	1.05
" However, the efficacy and underlying toxicity of these hybrids in combination with other agents remain unclear."	( Novel SAHA‑bendamustine hybrid NL‑101 in combination with daunorubicin synergistically suppresses acute myeloid leukemia. Guo, W; Huang, J; Huang, S; Huang, X; Jin, J; Li, F; Li, X; Ling, Q; Pan, J; Ye, W, 2020)	0.56
"This study was conducted to identify novel therapeutic targets that can be combined with HDACis for treating CTCL."	( Kinome profiling analysis identified Src pathway as a novel therapeutic target in combination with histone deacetylase inhibitors for cutaneous T-cell lymphoma. Fujii, K; Jimura, N; Kanekura, T; Kondo, T; Qiao, Z; Tsuchiya, R; Yoshimatsu, Y, 2021)	0.62
" Vorinostat combined with brigatinib significantly improved EGFR-TKI sensitivity to EGFR C797S by inducing EGFR-dependent cell death and may be a promising therapy in treating C797S-resistant lung adenocarcinomas."	( Vorinostat combined with brigatinib overcomes acquired resistance in EGFR-C797S-mutated lung cancer. Chang, YH; Chang, YL; Chung, WC; Ho, CC; Huang, KY; Kao, SH; Lin, CA; Lin, CY; Lin, YC; Shih, CC; Shih, JY; Yang, PC; Yang, SC, 2021)	2.97
" Here we explored the impact of the histone deacetylase (HDAC) inhibitor suberoylanilide hydroxamic acid (SAHA) on somatic hyperalgesia induced by stress or stress combined with orofacial inflammation, which mimicked the comorbidity of FMS and TMD in rats."	( SAHA Inhibits Somatic Hyperalgesia Induced by Stress Combined with Orofacial Inflammation Through Targeting Different Spinal 5-HT Receptor Subtypes. Bai, G; Cao, DY; Li, JF; Qiu, XY; Tao, ZY; Wei, SQ, 2022)	0.72
" Platinum-based drugs have been used in multiple clinical trials as monotherapy or in combination with other chemotherapeutic agents for the treatment of CRPC."	( Combination with vorinostat enhances the antitumor activity of cisplatin in castration-resistant prostate cancer by inhibiting DNA damage repair pathway and detoxification of GSH. Chang, T; Lian, Z; Liang, Z; Liu, R; Ma, S; Ma, X; Wang, Y; Wen, X, 2023)	1.25
" The efficacy and safety of SAHA combined with CDDP in the treatment of CRPC were further verified through animal experiments."	( Combination with vorinostat enhances the antitumor activity of cisplatin in castration-resistant prostate cancer by inhibiting DNA damage repair pathway and detoxification of GSH. Chang, T; Lian, Z; Liang, Z; Liu, R; Ma, S; Ma, X; Wang, Y; Wen, X, 2023)	1.25
" We evaluated the potential drug combinations that interact the most with hub genes and hence have the most potential to reverse the disease process."	( Drug repurposing based on differentially expressed genes suggests drug combinations with possible synergistic effects in treatment of lung adenocarcinoma. Teimourian, S; Yesharim, L, 2023)	0.91

Excerpt	Reference	Relevance
"(S)-HDAC-42 is a potent orally bioavailable inhibitor of HDAC, as well as targets regulating multiple aspects of cancer cell survival, which might have clinical value in prostate cancer chemotherapy and warrants further investigation in this regard."	( Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer. Chen, CS; Chen, CY; Kulp, SK; Wang, DS, 2006)	0.33
" A high-fat meal increased the extent and modestly decreased the rate of absorption of vorinostat; this effect is not anticipated to be clinically meaningful."	( A study to determine the effects of food and multiple dosing on the pharmacokinetics of vorinostat given orally to patients with advanced cancer. Agrawal, NG; Du, L; Frankel, SR; Friedman, EJ; Gottesdiener, KM; Iwamoto, M; Mazina, KE; Ricker, JL; Rubin, EH; Scott, P; Sun, L; Wagner, JA, 2006)	0.78
"In vitro liver microsomal stability, permeability, pharmacokinetics (PK) and oral bioavailability of SB639, a novel HDACi (Histone Deacetylase inhibitor), were determined."	( In vitro phase I cytochrome P450 metabolism, permeability and pharmacokinetics of SB639, a novel histone deacetylase inhibitor in preclinical species. Goh, E; Kantharaj, E; New, LS; Pasha, MK; Sangthongpitag, K; Venkatesh, PR; Xin, L; Yeo, P; Zeng, P, 2007)	0.34
"OSU-HDAC42 is a potent, orally bioavailable inhibitor of HDAC with a broad spectrum of antitumor activity that includes targets regulating multiple aspects of cancer cell survival."	( Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma. Chen, CS; Chen, TJ; Cheng, AL; Hung, JH; Kashida, Y; Kulp, SK; Lin, ZZ; Lu, YS; Tang, M; Wang, D; Wang, YC, 2007)	0.34
"The present investigation was undertaken to characterize the pharmacokinetics and oral bioavailability of Kendine 91 in mice and to compare it with other HDAC (histone deacetylases) inhibitors."	( Pharmacokinetics and tissue distribution of Kendine 91, a novel histone deacetylase inhibitor, in mice. Cossío, FP; Otaegui, D; Pedraz, JL; Rodríguez-Gascón, A; Zubia, A, 2009)	0.35
" Absolute oral bioavailability was found to be 18%."	( Pharmacokinetics and tissue distribution of Kendine 91, a novel histone deacetylase inhibitor, in mice. Cossío, FP; Otaegui, D; Pedraz, JL; Rodríguez-Gascón, A; Zubia, A, 2009)	0.35
" Vorinostat possessed high serum clearance, a short elimination half-life and low oral bioavailability in both species."	( Disposition of vorinostat, a novel histone deacetylase inhibitor and anticancer agent, in preclinical species. Andrews, PA; Baillie, TA; Baker, MP; Koeplinger, KA; Miller, T; Sandhu, P; Soli, ED, 2007)	1.6
"A novel series of HDAC inhibitors demonstrating class I subtype selectivity and good oral bioavailability is described."	( Discovery of 2-(6-{[(6-fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a class I selective orally active histone deacetylase inhibitor. Aherne, W; Bawden, L; Belfield, A; Bone, E; Box, G; Brotherton, D; Clark, V; Day, F; Donald, A; Eccles, S; Hardcastle, A; Moffat, D; Mortenson, P; Owen, J; Patel, S; Raynaud, F; Rowlands, M; Stimson, L; van Meurs, S; Wibawa, J, 2010)	0.36
" This work resulted in the discovery of spirocycle 30d that shows good oral bioavailability and tumor growth inhibition in an HCT-116 murine xenograft model."	( Discovery, synthesis, and pharmacological evaluation of spiropiperidine hydroxamic acid based derivatives as structurally novel histone deacetylase (HDAC) inhibitors. Abate, A; Bigogno, C; Boggio, R; Carenzi, G; Cataudella, T; Dal Zuffo, R; Dondio, G; Fulco, MC; Mai, A; Mercurio, C; Minucci, S; Rozio, MG; Thaler, F; Varasi, M, 2011)	0.37
" No differences were noted in the pharmacokinetics of vorinostat at the 800- or 1,400-mg dose-levels, suggesting bioavailability saturation."	( A randomized phase II study of two doses of vorinostat in combination with 5-FU/LV in patients with refractory colorectal cancer. Fakih, MG; Groman, A; McMahon, J; Muindi, JR; Wilding, G, 2012)	0.89
" The pharmaceutical properties (LogD, solubility, liver micrsomal stability (t1/2), plasma stability (t1/2), and apparent permeability) strongly suggested that NK-HDAC-1 might be superior to SAHA in bioavailability and in vivo half-life."	( Discovery and extensive in vitro evaluations of NK-HDAC-1: a chiral histone deacetylase inhibitor as a promising lead. Fang, Q; Feng, C; Gu, G; Guo, W; Hou, J; Li, Z; Lin, J; Liu, P; Liu, R; Shen, J; Shi, YK; Tian, Y; Wang, H; Wang, PG; Yin, Z; Zhang, H, 2012)	0.38
" pharmacokinetics and bioavailability of vorinostat, which warrants further investigation."	( Vorinostat with sustained exposure and high solubility in poly(ethylene glycol)-b-poly(DL-lactic acid) micelle nanocarriers: characterization and effects on pharmacokinetics in rat serum and urine. Borg, TM; Davies, NM; Foda, AM; Forrest, ML; Martinez, SE; Meshali, MM; Mohamed, EA; Remsberg, CM; Sayre, CL; Takemoto, JK; Zhao, Y, 2012)	2.09
" Through a combination of conformational constraint and scaffold hopping, we lowered the in vivo clearance (CL) and significantly improved the bioavailability (F) and exposure (AUC) of our HDAC inhibitors while maintaining selectivity toward the class I HDAC family with particular potency against HDAC1, resulting in clinical lead 5 (HDAC1 IC₅₀ = 60 nM, mouse CL = 39 mL/min/kg, mouse F = 100%, mouse AUC after single oral dose at 10 mg/kg = 6316 h·ng/mL)."	( Pharmacokinetic optimization of class-selective histone deacetylase inhibitors and identification of associated candidate predictive biomarkers of hepatocellular carcinoma tumor response. Cai, J; Chen, D; Chen, J; Chen, L; Chen, T; Feng, L; Guo, L; He, Y; Ji, Y; Jin, TG; Li, S; Liang, C; Lin, X; Liu, Y; Lu, X; Mei, J; Ning, Z; Pan, D; Pan, S; Peng, Z; Ren, S; Ren, Y; Rong, Y; Shan, S; She, J; Tang, G; Wang, Z; Wong, JC; Wu, X; Xu, C; Zhang, C; Zhang, M; Zhang, N; Zhang, W; Zhang, X; Zhang, Z; Zhao, R; Zhao, W; Zhou, M, 2012)	0.38
" Two representative examples exhibited a good pharmacokinetic profile with an oral bioavailability equal or higher than 35% and one of them studied in an HCT116 murine xenograft model showing a robust tumour growth inhibition."	( Synthesis and biological characterization of spiro[2H-(1,3)-benzoxazine-2,4'-piperidine] based histone deacetylase inhibitors. Abate, A; Bigogno, C; Boggio, R; Carenzi, G; Colombo, A; Dondio, G; Gagliardi, S; Mercurio, C; Minucci, S; Rapetti, D; Regalia, N; Resconi, A; Thaler, F; Varasi, M; Vultaggio, S; Zuffo, RD, 2013)	0.39
"To investigate whether delivery of a histone deacetylase inhibitor, vorinostat (VOR), by using solid lipid nanoparticles (SLNs) enhanced its bioavailability and effects on multidrug-resistant cancer cells."	( Development of vorinostat-loaded solid lipid nanoparticles to enhance pharmacokinetics and efficacy against multidrug-resistant cancer cells. Choi, HG; Kim, JO; Ramasamy, T; Shin, BS; Tran, TH; Truong, DH; Yong, CS, 2014)	0.99
" These in vivo results clearly highlighted the remarkable potential of SLNs to augment the bioavailability of VOR."	( Development of vorinostat-loaded solid lipid nanoparticles to enhance pharmacokinetics and efficacy against multidrug-resistant cancer cells. Choi, HG; Kim, JO; Ramasamy, T; Shin, BS; Tran, TH; Truong, DH; Yong, CS, 2014)	0.76
" There are several potential mechanisms by which histone deacetylase inhibition may alter dapsone metabolism including changes in hepatic acetylation or N-glucuronidation leading to an increase in the bioavailability of dapsone's hematotoxic metabolites."	( Hemolytic anemia in two patients with glioblastoma multiforme: A possible interaction between vorinostat and dapsone. Harmon, M; Lesser, GJ; Lewis, JA; Owen, J; Peacock, JE; Petty, WJ; Pirmohamed, M; Valente, K, 2015)	0.64
"53 h for oral administration) and higher oral bioavailability (13%) in rats."	( Preclinical anti-arthritic study and pharmacokinetic properties of a potent histone deacetylase inhibitor MPT0G009. Hsieh, IN; Lai, MJ; Lee, HY; Li, YH; Liou, JP; Yang, CR, 2014)	0.4
" It has a good pharmacokinetic profile with oral bioavailability of 33%."	( Azaindolylsulfonamides, with a more selective inhibitory effect on histone deacetylase 6 activity, exhibit antitumor activity in colorectal cancer HCT116 cells. Chang, CY; Chang, JY; Chen, MC; Cheng, YC; Kuo, CC; Lee, HY; Liou, JP; Liu, JF; Liu, YM; Pan, SL; Shen, PJ; Tsai, AC; Wang, JC; Yeh, TK, 2014)	0.4
" Carfilzomib and its orally bioavailable structural analog oprozomib are second-generation, highly-selective, proteasome inhibitors."	( Carfilzomib and oprozomib synergize with histone deacetylase inhibitors in head and neck squamous cell carcinoma models of acquired resistance to proteasome inhibitors. Johnson, DE; Kirk, CJ; Zang, Y, 2014)	0.4
"These results suggest the potential of NLCs as an oral delivery system for enhancement of cellular uptake, in vitro cytotoxicity in cancer cell lines and the oral bioavailability of VRS."	( Development of lipid nanoparticles for a histone deacetylases inhibitor as a promising anticancer therapeutic. Chu, DT; Hoang, VL; Jeong, JH; Kim, JO; Tak, JW; Tran, TH; Truong, DH; Yong, CS, 2016)	0.43
" Notably, one of these new derivatives, (E)-N-hydroxy-3-(2-oxo-1-(quinolin-2-ylmethyl)-1,2-dihydropyridin-3-yl)acrylamide (4l), significantly restored RUNX3 in a dose-dependent manner and showed high metabolic stability, a good pharmacokinetic profile with high oral bioavailability and long half-life, and strong antitumor activity."	( Discovery of Orally Available Runt-Related Transcription Factor 3 (RUNX3) Modulators for Anticancer Chemotherapy by Epigenetic Activation and Protein Stabilization. Cho, M; Choi, S; Han, G; Jeong, JH; Kang, JS; Kim, H; Kim, HJ; Kim, JH; Lee, C; Oh, SJ; Yang, JS, 2015)	0.42
" It indicated that a higher relative bioavailability for hydrogel was achieved compared with oral vorinostat."	( Preparation of a mixed-matrix hydrogel of vorinostat for topical administration on the rats as experimental model. Dai, W; Li, Y; Sun, F; Teng, L; Wang, C; Yao, J; Yu, C, 2015)	0.9
" 23bb has a good pharmacokinetic profile with oral bioavailability of 47."	( Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer. Cao, D; Chen, L; Chen, X; Liu, Z; Long, C; Ma, L; Niu, T; Tang, M; Wang, F; Wang, T; Wang, X; Xiang, W; Yang, Z; Yi, Y; You, J, 2016)	0.43
"To improve the bioavailability and anticancer potential of suberoylanilide hydroxamic acid (SAHA) by developing a drug-loaded polymeric nanomicellar system."	( Polymeric micelles of suberoylanilide hydroxamic acid to enhance the anticancer potential in vitro and in vivo. Biswas, S; Ghanta, P; Ghosh, B; Kiran Rompicharla, SV; Kumari, P; Trivedi, P, 2017)	0.46
"Cell membrane permeability is an important determinant for oral absorption and bioavailability of a drug molecule."	( Highly predictive and interpretable models for PAMPA permeability. Jadhav, A; Kerns, E; Nguyen, K; Shah, P; Sun, H; Xu, X; Yan, Z; Yu, KR, 2017)	0.46
" What's more, 6d possessed desirable pharmacokinetic profiles with the oral bioavailability of 72% in SD rats and considerable in vivo antitumor efficacy in a human colorectal adenocarcinoma (HT-29) xenograft model."	( Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously. Chou, CJ; Huang, Y; Jia, Y; Li, X; Liang, X; Xu, W; Zang, J; Zhang, Y, 2018)	0.48
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51
" In this study, a novel combination strategy was applied by combining curcumin with Suberoylanilide Hydroxamic Acid (SAHA) to increase both bioavailability of curcumin and the efficiency of SAHA, which have limited efficiency when used alone."	( Synergistic Combination of Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid and Natural Flavonoid Curcumin Exhibits Anticancer and Antibacterial Activity. Altundağ, EM; Güran, M; Kerküklü, NR; Özbilenler, C; Şanlıtürk, G; Toprak, K; Yalçın, AS; Yılmaz, AM, 2021)	0.62
" In the present study, we hypothesize that a combination of an epigenetic modulator, vorinostat, along with rosiglitazone can impart improved gene expression of neurotrophic factors and attenuate biochemical and cellular alteration associated with AD mainly by loading these drugs in a surface modified nanocarrier system for enhanced bioavailability and enhanced therapeutic efficacy."	( Neuroprotective Efficacy of Co-Encapsulated Rosiglitazone and Vorinostat Nanoparticle on Streptozotocin Induced Mice Model of Alzheimer Disease. Chitkara, D; Dubey, SK; K C, S; Kakoty, V; Krishna, KV; Taliyan, R, 2021)	1.09
" However, the solely clinically used SERD fulvestrant, is low orally bioavailable and requires intravenous injection, which severely limits its clinical application."	( Novel hybrid conjugates with dual estrogen receptor α degradation and histone deacetylase inhibitory activities for breast cancer therapy. Hu, Z; Huang, J; Li, C; Ning, W; Tang, C; Xin, L; Zhao, C; Zhou, HB, 2021)	0.62

Excerpt	Relevance	Reference
" TSA also prevented, in a dose-response relationship, the sprouting of capillaries from rat aortic rings."	( Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Blacher, S; Bonjean, K; Castronovo, V; Clausse, N; Colige, A; Deroanne, CF; Devy, L; Foidart, JM; Nusgens, BV; Servotte, S; Verdin, E, 2002)	0.31
" Four compounds having an MTD > or = 100 mg/kg were selected for dose-response studies in the HCT116 xenograft model."	( N-hydroxy-3-phenyl-2-propenamides as novel inhibitors of human histone deacetylase with in vivo antitumor activity: discovery of (2E)-N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide (NVP-LAQ824). Atadja, P; Bair, KW; Bontempo, J; Cesarz, D; Chandramouli, N; Chen, R; Cheung, M; Cornell-Kennon, S; Dean, K; Diamantidis, G; France, D; Green, MA; Howell, KL; Kashi, R; Kwon, P; Lassota, P; Martin, MS; Mou, Y; Perez, LB; Remiszewski, SW; Sambucetti, LC; Sharma, S; Smith, T; Sorensen, E; Taplin, F; Trogani, N; Versace, R; Walker, H; Weltchek-Engler, S; Wood, A; Wu, A, 2003)	0.32
"To determine the safety, dosing schedules, pharmacokinetic profile, and biologic effect of orally administered histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) in patients with advanced cancer."	( Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. Chiao, JH; Chu, E; Curley, T; Heaney, M; Kelly, WK; Krug, LM; MacGregore-Cortelli, B; Marks, PA; O'Connor, OA; Olgac, S; Richardson, S; Richon, VM; Scher, H; Schwartz, L; Secrist, JP; Tong, W, 2005)	0.33
" The maximum tolerated dose was 400 mg qd and 200 mg bid for continuous daily dosing and 300 mg bid for 3 consecutive days per week dosing."	( Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. Chiao, JH; Chu, E; Curley, T; Heaney, M; Kelly, WK; Krug, LM; MacGregore-Cortelli, B; Marks, PA; O'Connor, OA; Olgac, S; Richardson, S; Richon, VM; Scher, H; Schwartz, L; Secrist, JP; Tong, W, 2005)	0.33
"Animals were dosed on Gestation Days 6-20 or 7-20, respectively, with litter/fetal parameters evaluated on GD 21 and 28, respectively."	( Assessment of developmental toxicity of vorinostat, a histone deacetylase inhibitor, in Sprague-Dawley rats and Dutch Belted rabbits. Kerr, JS; Turner, KJ; Wise, LD, 2007)	0.61
" In this paper, we develop statistical methods for experimental design and data analysis of combination studies of drugs that have log-linear dose-response curves."	( Experimental design and interaction analysis of combination studies of drugs with log-linear dose responses. Fang, HB; Ross, DD; Sausville, E; Tan, M, 2008)	0.35
" Alternative vorinostat dosing schedules may be needed for optimal down-regulation of TS expression."	( A phase I, pharmacokinetic and pharmacodynamic study on vorinostat in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with refractory colorectal cancer. Egorin, MJ; Espinoza-Delgado, I; Fakih, MG; Fetterly, G; Holleran, JL; Litwin, A; Pendyala, L; Ross, ME; Rustum, YM; Toth, K; Zwiebel, JA, 2009)	0.97
" Once-daily dosing was tested at 400 and 500 mg."	( Phase I and pharmacokinetic study of vorinostat (suberoylanilide hydroxamic acid) in Japanese patients with solid tumors. Fujiwara, Y; Hardwick, JS; Iwasa, T; Kanazu, S; Otsuki, T; Tamura, T; Yamada, K; Yamada, Y; Yamamoto, N, 2009)	0.63
"In total, 32 patients were treated; vorinostat was dosed at 400, 600, 800, or 1000 mg day(-1) on days 1-3, followed by doxorubicin (20 mg m(-2)) on day 3 for 3 of 4 weeks."	( Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker. Chiappori, A; Daud, A; Egorin, M; Lee, JH; Marchion, D; Minton, S; Munster, PN; Simon, G; Springett, G; Sullivan, D; Thomas, S, 2009)	0.97
" Vorinostat is orally dosed daily in rats (controls, 20, 50, or 150 mg/kg/d) and dogs (controls, 60, 80, or 100/125/160 mg/kg/d) for 26 weeks with a 4-week recovery."	( Nonclinical safety assessment of the histone deacetylase inhibitor vorinostat. Andrews, PA; Armstrong, M; Galloway, S; Kerr, JS; Lagrutta, A; Miller, T; Richon, VM, )	1.28
" Daily histone deacetylase (HDAC) inhibitor infusions in the shell of the nucleus accumbens (NAc) caused an upward shift in the dose-response curve under fixed-ratio schedule and increased the break point under progressive-ratio schedule, indicating enhanced motivation for self-administered drug."	( Chronic cocaine-induced H3 acetylation and transcriptional activation of CaMKIIalpha in the nucleus accumbens is critical for motivation for drug reinforcement. Hu, Z; Hui, B; Lv, Z; Ma, L; Sheng, J; Sun, J; Wang, L, 2010)	0.36
"Vorinostat efficiently suppressed MES-SA cell growth at a low dosage (3 microM) already after 24 hours treatment."	( Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo. Denk, H; Hrzenjak, A; Kremser, ML; Moinfar, F; Petru, E; Strohmeier, B; Zatloukal, K, 2010)	2.09
" V concentrations higher than previously reported with oral dosing were achieved."	( A phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumors. Ames, MM; Cane, LM; Carvajal, RD; Dials, HJ; Dickson, MA; Gonen, M; Grant, S; Lefkowitz, RA; McGovern, RM; Rathkopf, DE; Reid, JM; Roberts, JD; Schwartz, GK, 2011)	0.63
"The pharmacology, pharmacokinetics, clinical efficacy, safety, adverse effects, dosage and administration, and role in therapy of vorinostat in the treatment of cutaneous T-cell lymphoma (CTCL) are reviewed."	( Vorinostat: A novel therapy for the treatment of cutaneous T-cell lymphoma. Kavanaugh, SA; Kavanaugh, SM; Kolesar, JM; White, LA, 2010)	2.01
" The present results show the applicability of our novel statistical methodology for quantitatively assessing drug synergy across a wide range of doses of agents with complex dose-response profiles, a methodology with great potential for advancing the development of chemopreventive combinations."	( Validation of a novel statistical model for assessing the synergy of combined-agent cancer chemoprevention. Fujimoto, J; Hong, WK; Kong, M; Lee, JJ; Lotan, R, 2010)	0.36
" One week later, daily vorinostat dosing was begun and continued until toxicity or disease progression occurred."	( Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study. Belani, CP; Beumer, JH; Egorin, MJ; Harvey, RD; Holleran, J; Ivy, SP; Kummar, S; Lin, Y; LoRusso, P; Ramalingam, SS; Sarantopoulos, J; Shibata, S; Yerk, M, 2010)	1.01
" We demonstrated that when dose-response curves were fitted with the same method, similar evaluated results for drug combinations would be derived with different models."	( [Three different drug interaction mathematical models used to evaluate the cytotoxicity of SAHA and arsenic trioxide in combination]. Liu, ZJ; Lu, N; Wang, N; Yan, Z, 2010)	0.36
" Here we evaluated the dosage effects of HDAC inhibitors suberoylanilide hydroxamic acid (SAHA) and valproic acid (VPA) in a series of human leukaemia cell lines."	( Epigenetic modulation of gene expression of human leukemia cell lines - induction of cell death and senescence. Elknerova, K; Lacinova, Z; Marinov, I; Myslivcova, D; Stöckbauer, P; Uherkova, L, 2011)	0.37
" However, the sequential schedule of decitabine 10 mg/m(2)/day on days 1 to 5 and vorinostat 200 mg twice a day on days 6 to 12 was more deliverable than both MTDs with fewer delays on repeated dosing and it represents the recommended phase II (RP2D) dose of this combination."	( Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas. Chen, EX; Egorin, MJ; Espinoza-Delgado, I; Hirte, HW; Holleran, JL; Hotte, SJ; Laughlin, A; McGill, S; Moretto, P; Oza, AM; Siu, LL; Stathis, A; Stayner, LA; Wang, L; Webster, S; Zhang, WJ, 2011)	0.85
" Control and streptozotocin-diabetic wild-type and eNOS(-/-) mice were treated with vorinostat by daily oral dosing for 18 weeks."	( Long-term administration of the histone deacetylase inhibitor vorinostat attenuates renal injury in experimental diabetes through an endothelial nitric oxide synthase-dependent mechanism. Advani, A; Advani, SL; Connelly, KA; Gilbert, RE; Huang, Q; Kelly, DJ; Marsden, PA; Thai, K; White, KE; Yuen, DA, 2011)	0.83
" When orally dosed to tumor-bearing mice, 3 is enriched in tumor tissue which may contribute to its potent antitumor activity and prolonged duration of action."	( Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile. Bonday, Z; Chang, JW; Chen, D; Deng, W; Dymock, BW; Fang, L; Goh, KC; Goh, KL; Goh, SK; Hu, C; Kantharaj, E; Khng, HH; Khoo, ML; Lee, KC; Liu, X; Lu, T; Lye, PL; Ng, MC; Poulsen, A; Sangthongpitag, K; Sun, ET; Wang, H; Wang, X; Wood, JM; Wu, X; Yeo, P; Yu, N, 2011)	0.37
" In this study, we evaluated the safety, pharmacokinetics, and efficacy of two dosing regimens of vorinostat, an oral HDACi, in patients with GI tumors."	( Evaluation of safety, pharmacokinetics, and efficacy of vorinostat, a histone deacetylase inhibitor, in the treatment of gastrointestinal (GI) cancer in a phase I clinical trial. Chin, K; Doi, T; Hamaguchi, T; Hatake, K; Mehta, A; Noguchi, K; Ohtsu, A; Otsuki, T; Shirao, K, 2013)	0.85
" No DLTs were encountered, but vorinostat dosing could not be escalated further due to thrombocytopenia."	( Phase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas: North American Brain Tumor Consortium Study 04-03. Ames, MM; Chang, SM; Cloughesy, TF; Desideri, S; Drappatz, J; Espinoza-Delgado, I; Gilbert, MR; Kuhn, JG; Lamborn, KR; Lassman, AB; Lee, EQ; Lieberman, FS; McGovern, RM; Prados, MD; Puduvalli, VK; Reid, JM; Robins, HI; Wen, PY; Xu, J; Ye, X; Yung, WK, 2012)	1
" Dose-response of different concentrations of bortezomib and SAHA on inhibition of cell proliferation of NPC was determined."	( Bortezomib and SAHA synergistically induce ROS-driven caspase-dependent apoptosis of nasopharyngeal carcinoma and block replication of Epstein-Barr virus. Chiang, AK; Ho, DN; Hui, KF; Lam, BH; Tsao, SW, 2013)	0.39
" There was no clear relationship between vorinostat dosage and drug exposure over the dose range studied."	( A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a Children's Oncology Group phase 1 consortium study. Ahern, C; Ames, MM; Blaney, SM; Fouladi, M; Gilbertson, RJ; Horton, T; Hummel, TR; Ingle, AM; McGovern, RM; Reid, JM; Wagner, L; Weigel, B, 2013)	0.95
" Blood samples were obtained on days 1 and 9 of cycle 1 prior to dosing and 2 and 6 h post-dosing in all 60 subjects."	( Vorinostat in combination with bortezomib in patients with advanced malignancies directly alters transcription of target genes. Alberti, D; Bailey, HH; Espinoza-Delgado, I; Hoang, T; Holen, KD; Kim, K; Kolesar, JM; Schelman, WR; Seo, S; Traynor, AM; Wilding, G; Wright, JJ, 2013)	1.83
" Bortezomib dosing was increased using a standard phase I dose-escalation schema."	( A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies. Alberti, D; Ames, MM; Attia, S; Bailey, HH; Eickhoff, J; Espinoza-Delgado, I; Hoang, T; Holen, KD; Jiang, Z; Kolesar, JM; Marnocha, R; McGovern, RM; Reid, JM; Schelman, WR; Traynor, AM; Wilding, G; Wright, JJ, 2013)	0.72
" We previously examined a once-daily continuous dosing schedule of vorinostat in combination with bortezomib which was well tolerated in cycles 1 and 2; however, there was concern regarding the tolerability through multiple cycles."	( A Phase I study of intermittently dosed vorinostat in combination with bortezomib in patients with advanced solid tumors. Alberti, D; Ames, MM; Bailey, HH; Deming, DA; Eickhoff, J; Espinoza-Delgado, I; Kolesar, JM; Marnocha, R; McGovern, RM; Ninan, J; Reid, JM; Schelman, WR; Wilding, G; Wright, J, 2014)	0.91
" DLTs in the intermittent dosing scheduled included thrombocytopenia and fatigue."	( A Phase I study of intermittently dosed vorinostat in combination with bortezomib in patients with advanced solid tumors. Alberti, D; Ames, MM; Bailey, HH; Deming, DA; Eickhoff, J; Espinoza-Delgado, I; Kolesar, JM; Marnocha, R; McGovern, RM; Ninan, J; Reid, JM; Schelman, WR; Wilding, G; Wright, J, 2014)	0.67
" Tolerability was not improved with the intermittent dosing schedule of vorinostat when compared to continuous dosing."	( A Phase I study of intermittently dosed vorinostat in combination with bortezomib in patients with advanced solid tumors. Alberti, D; Ames, MM; Bailey, HH; Deming, DA; Eickhoff, J; Espinoza-Delgado, I; Kolesar, JM; Marnocha, R; McGovern, RM; Ninan, J; Reid, JM; Schelman, WR; Wilding, G; Wright, J, 2014)	0.9
" Delayed dosing did not reduce adhesions."	( Histone deacetylase inhibitors decrease intra-abdominal adhesions with one intraoperative dose by reducing peritoneal fibrin deposition pathways. Cassidy, MR; Gainsbury, ML; Heydrick, S; Sheldon, HK; Sherburne, AC; Stucchi, AF, 2014)	0.4
" A single, intraoperative intervention provides an ideal dosing strategy and indicates an exciting new role for HDACIs in adhesion prevention."	( Histone deacetylase inhibitors decrease intra-abdominal adhesions with one intraoperative dose by reducing peritoneal fibrin deposition pathways. Cassidy, MR; Gainsbury, ML; Heydrick, S; Sheldon, HK; Sherburne, AC; Stucchi, AF, 2014)	0.4
"Vorinostat (VOR) has been reported to enhance the cytotoxic effects of doxorubicin (DOX) with fewer side effects because of the lower DOX dosage in breast cancer cells."	( Transactivation of bad by vorinostat-induced acetylated p53 enhances doxorubicin-induced cytotoxicity in cervical cancer cells. Hoe, KL; Hwang, SO; Kim, DU; Kim, JH; Lee, SJ; Nam, JH; Nam, M; Noh, EJ, 2014)	2.15
" In an HCT-116 nude mice xenograft model, compound 1o displayed significant antitumor activity in both continuous and intermittent dosing schedules."	( Design, synthesis and evaluation of novel HDAC inhibitors as potential antitumor agents. Cheng, J; Guo, S; Qin, J; Qiu, H; Zhong, Y, 2014)	0.4
"In vivo histone deacetylase (HDAC) inhibition by vorinostat under clinically acceptable dosing is limited by its poor pharmacokinetics properties."	( Vorinostat-polymer conjugate nanoparticles for Acid-responsive delivery and passive tumor targeting. Bertrand, P; Blanquart, C; Collette, F; Delatouche, R; Denis, I; El Bahhaj, F; Grégoire, M; Gueugnon, F; Héroguez, V; Pichavant, L; Pouliquen, D, 2014)	2.1
"The recommended phase II dosage was oral pazopanib at 600 mg daily plus oral vorinostat at 300 mg daily."	( Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation. Araujo, D; Fu, S; Hess, K; Hong, D; Hou, MM; Hwu, P; Janku, F; Karp, D; Kee, B; Kurzrock, R; Meric-Bernstam, F; Naing, A; Piha-Paul, S; Subbiah, V; Tsimberidou, A; Wheler, J; Wolff, R; Zinner, R, 2015)	0.93
" Busulfan dosing targeted 4000 μM-minute/day (days -8 to -5)."	( Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas. Ahmed, S; Alousi, A; Anderlini, P; Andersson, BS; Bashir, Q; Champlin, R; Dabaja, B; Fanale, M; Gulbis, A; Hagemeister, F; Hosing, C; Jones, RB; Liu, Y; Nieto, Y; Oki, Y; Pinnix, C; Popat, U; Qazilbash, M; Shah, N; Shpall, EJ; Thall, PF; Valdez, BC, 2015)	1.86
" Dosing was limited by thrombocytopenia."	( Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumors. Corrigan, A; Denlinger, CS; Devarajan, K; Malizzia, L; Olszanski, AJ; Plimack, ER; Roethke, SK; Tetzlaff, CH; Wong, YN; Zibelman, M, 2015)	0.65
" The first dose level (DL A) tested vorinostat as daily oral dosing from days 1 to 14."	( Phase I study of combination of vorinostat, carboplatin, and gemcitabine in women with recurrent, platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer. Berlin, S; Campos, S; Horowitz, N; Krasner, C; Lee, H; Liu, J; Matulonis, U; Obermayer, E; Penson, R; Whalen, C, 2015)	0.98
" We hypothesized that HDACi-modulated genes would be best identified with a dose-response analysis."	( Dose-responsive gene expression in suberoylanilide hydroxamic acid-treated resting CD4+ T cells. Beliakova-Bethell, N; Margolis, DM; Reardon, B; Richman, DR; Singhania, A; Spina, CA; Woelk, CH, 2015)	0.42
" Additional in vivo SAHA dosing studies with larger sample size are warranted."	( Development of a novel in vivo corneal fibrosis model in the dog. Bunyak, F; Giuliano, EA; Gronkiewicz, KM; Hamm, CW; Kuroki, K; Mohan, RR; Sharma, A; Teixeira, LB, 2016)	0.43
" Dose-response curves revealed dose-dependent profiles with greater potency of HDACis over CyA (IC50 values of 82."	( Inhibition of Histone Deacetylase 6 Reveals a Potent Immunosuppressant Effect in Models of Transplantation. Cobbold, M; Drayson, MT; Ellis, JD; Hampson, P; Inston, NG; Jenkinson, E; Neil, DA; Ready, AR; Shuttleworth, SJ, 2016)	0.43
" The N-hydroxyl group of this motif is highly subject to sulfation/glucoronidation-based inactivation in humans; compounds containing this motif require much higher dosing in clinic to achieve therapeutic concentrations."	( Development of Allosteric Hydrazide-Containing Class I Histone Deacetylase Inhibitors for Use in Acute Myeloid Leukemia. Chou, CJ; Inks, ES; Li, J; McClure, JJ; Peterson, YK; Zhang, C, 2016)	0.43
" Thus, genotype-directed dosing could improve pharmacotherapy by reducing the risk of toxicities or preventing suboptimal treatment."	( Pharmacogenomics and histone deacetylase inhibitors. Figg, WD; Goey, AK; Peer, CJ; Sissung, TM, 2016)	0.43
" Triple combinations with a low dosage of cisplatin demonstrate similar therapeutic effects."	( Vorinostat enhances the cisplatin-mediated anticancer effects in small cell lung cancer cells. Chang, YF; Ko, JC; Lee, MS; Liang, MC; Liang, SK; Pan, CH; Wen, BC, 2016)	1.88
"SAHA and TSA could inhibit total HDAC activity and placental HDAC1/2/3 expression both in Bewo and JAR, but displayed a transient induction of HDAC mRNA or protein level after being treated at low dosage or prolonged exposure to drugs."	( The effect of histone deacetylase inhibition on the expression of P-glycoprotein in human placental trophoblast cell lines. Duan, H; Hua, Y; Li, Q; Li, Y; Qiu, D; Wang, C; Wang, T; Zhang, Y; Zhou, K, 2017)	0.46
" Increased p21 and cleaved PARP expression can potentially explain mechanisms of their enhanced effects, which require further PK/PD systems analysis to suggest an optimal dosing regimen."	( Sequential Exposure of Bortezomib and Vorinostat is Synergistic in Multiple Myeloma Cells. Mager, DE; Nanavati, C, 2017)	0.73
" We sought to identify the optimal dosing of VOR for effective serial reversal of HIV latency."	( Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency. Allard, B; Archin, NM; Clutton, G; Eron, J; Gay, CL; Goonetilleke, N; Kashuba, AD; Kirchherr, JL; Kuruc, JD; Margolis, DM; Sholtis, K; Stuelke, E; Sung, JA; Xu, Y, 2017)	0.72
"This study aimed at recommending pediatric dosages of the histone deacetylase (HDAC) inhibitor vorinostat and potentially more effective adult dosing regimens than the approved standard dosing regimen of 400 mg/day, using a comprehensive physiologically based pharmacokinetic/pharmacodynamic (PBPK/PD) modeling approach."	( A physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model of the histone deacetylase (HDAC) inhibitor vorinostat for pediatric and adult patients and its application for dose specification. Britz, H; Burhenne, J; Egerer, G; Haefeli, WE; Lehr, T; Moj, D; Stewart, CF, 2017)	0.88
"Thoroughly developed PBPK models enable dosage recommendations in pediatric patients and integrated PBPK/PD models, considering PD biomarkers (e."	( A physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model of the histone deacetylase (HDAC) inhibitor vorinostat for pediatric and adult patients and its application for dose specification. Britz, H; Burhenne, J; Egerer, G; Haefeli, WE; Lehr, T; Moj, D; Stewart, CF, 2017)	0.66
" Furthermore, SAHA dosing did not compromise corneal endothelial phenotype, density, or function in rabbit eyes, whereas MMC application did (P < ."	( Efficacy and Safety Comparison Between Suberoylanilide Hydroxamic Acid and Mitomycin C in Reducing the Risk of Corneal Haze After PRK Treatment In Vivo. Anumanthan, G; Gupta, S; Hamm, CW; Hesemann, NP; Mohan, RR; Sharma, A; Waggoner, M, 2017)	0.46
" At the end of dosing schedule, neurobehavioral tests were conducted; followed by mechanistic evaluation through biochemical analysis, RTPCR and western blot in serum and hippocampus."	( Antidepressant activity of vorinostat is associated with amelioration of oxidative stress and inflammation in a corticosterone-induced chronic stress model in mice. Js, IC; Kv, A; Lahkar, M; Madhana, RM; Naidu, VGM; Sinha, S, 2018)	0.78
"Inhibition of more than one pathway in a cancer cell with a single molecule could result in better therapies with less complex dosing regimens."	( Merging of ruxolitinib and vorinostat leads to highly potent inhibitors of JAK2 and histone deacetylase 6 (HDAC6). Dymock, BW; Ohlson, S; Poulsen, A; Ramanujulu, PM; Yao, L, 2018)	0.78
" Vorinostat was administered at the assigned dosage level (100-400 mg, three times weekly) in a standard 3 + 3 dose escalation design."	( A phase 1 trial of Vorinostat in combination with concurrent chemoradiation therapy in the treatment of advanced staged head and neck squamous cell carcinoma. Agrawal, A; Baiocchi, R; Blakaj, D; Carrau, R; Diavolitsis, V; Grecula, J; Kang, S; Kumar, B; Kumar, P; Old, MO; Ozer, E; Palettas, M; Pan, Q; Rocco, J; Savvides, P; Teknos, TN; Wei, L, 2019)	1.75
" Behavioral tests such as Morris water maze test, novel object recognition test, and object in place test were performed at the end of the dosing schedule to assess cognition."	( Cognitive Improvement by Vorinostat through Modulation of Endoplasmic Reticulum Stress in a Corticosterone-Induced Chronic Stress Model in Mice. Bais, AK; K V, A; Kumar, P; Lahkar, M; Madhana, RM; Malik, A; Samudrala, PK; Singh, VB; Sinha, S, 2020)	0.86
" As the VOR treatment-related adverse changes are mostly found reversible, further optimization of the therapeutic strategies with respect to dose, dosage regimen, and formulations of VOR could propel its clinical prospects."	( Repurposing Vorinostat for the Treatment of Disorders Affecting Brain. Athira, KV; Chakravarty, S; Sadanandan, P, 2021)	1
" The model can be potentially applied to evaluate their combination regimens and explore in vivo dosing regimens."	( Network-Based Systems Analysis Explains Sequence-Dependent Synergism of Bortezomib and Vorinostat in Multiple Myeloma. Mager, DE; Nanavati, C, 2021)	0.84

Role	Description
EC 3.5.1.98 (histone deacetylase) inhibitor	An EC 3.5.1.* (non-peptide linear amide C-N hydrolase) inhibitor that interferes with the function of histone deacetylase (EC 3.5.1.98).
apoptosis inducer	Any substance that induces the process of apoptosis (programmed cell death) in multi-celled organisms.
antineoplastic agent	A substance that inhibits or prevents the proliferation of neoplasms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
hydroxamic acid	A compound, RkE(=O)lNHOH, derived from an oxoacid RkE(=O)l(OH) (l =/= 0) by replacing -OH with -NHOH, and derivatives thereof. Specific examples of hydroxamic acids are preferably named as N-hydroxy amides.
dicarboxylic acid diamide
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Nrf2	Homo sapiens (human)	Potency	3.3889	0.0920	8.2222	23.1093	AID624171; AID651593
RAR-related orphan receptor gamma	Mus musculus (house mouse)	Potency	1.2909	0.0060	38.0041	19,952.5996	AID1159521; AID1159523
PPM1D protein	Homo sapiens (human)	Potency	1.4740	0.0052	9.4661	32.9993	AID1347411
TDP1 protein	Homo sapiens (human)	Potency	0.5087	0.0008	11.3822	44.6684	AID686978; AID686979
GLI family zinc finger 3	Homo sapiens (human)	Potency	0.1239	0.0007	14.5928	83.7951	AID1259369; AID1259392
AR protein	Homo sapiens (human)	Potency	2.0669	0.0002	21.2231	8,912.5098	AID1259243; AID1259247; AID743035; AID743040; AID743042; AID743053; AID743054; AID743063
Smad3	Homo sapiens (human)	Potency	3.1623	0.0052	7.8098	29.0929	AID588855
caspase 7, apoptosis-related cysteine protease	Homo sapiens (human)	Potency	4.2163	0.0133	26.9810	70.7614	AID1346978
estrogen receptor 2 (ER beta)	Homo sapiens (human)	Potency	5.6278	0.0006	57.9133	22,387.1992	AID1259377; AID1259378
nuclear receptor subfamily 1, group I, member 3	Homo sapiens (human)	Potency	3.6190	0.0010	22.6508	76.6163	AID1224838; AID1224893
progesterone receptor	Homo sapiens (human)	Potency	0.9439	0.0004	17.9460	75.1148	AID1346795
EWS/FLI fusion protein	Homo sapiens (human)	Potency	2.6525	0.0013	10.1577	42.8575	AID1259252; AID1259253; AID1259255; AID1259256
glucocorticoid receptor [Homo sapiens]	Homo sapiens (human)	Potency	0.9003	0.0002	14.3764	60.0339	AID720692
retinoic acid nuclear receptor alpha variant 1	Homo sapiens (human)	Potency	1.0576	0.0030	41.6115	22,387.1992	AID1159552; AID1159553; AID1159555
estrogen-related nuclear receptor alpha	Homo sapiens (human)	Potency	1.0951	0.0015	30.6073	15,848.9004	AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptor	Homo sapiens (human)	Potency	2.1130	0.3758	27.4851	61.6524	AID743217
pregnane X nuclear receptor	Homo sapiens (human)	Potency	7.4978	0.0054	28.0263	1,258.9301	AID1346982
estrogen nuclear receptor alpha	Homo sapiens (human)	Potency	4.7548	0.0002	29.3054	16,493.5996	AID1259244; AID1259248; AID743069; AID743075; AID743078; AID743079; AID743080; AID743091
cytochrome P450 2D6	Homo sapiens (human)	Potency	4.8975	0.0010	8.3798	61.1304	AID1645840
caspase-3	Homo sapiens (human)	Potency	4.2163	0.0133	26.9810	70.7614	AID1346978
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a	Homo sapiens (human)	Potency	6.7267	0.0017	23.8393	78.1014	AID743083
Caspase-7	Cricetulus griseus (Chinese hamster)	Potency	14.9601	0.0067	23.4960	68.5896	AID1346980
caspase-3	Cricetulus griseus (Chinese hamster)	Potency	14.9601	0.0067	23.4960	68.5896	AID1346980
thyroid hormone receptor beta isoform 2	Rattus norvegicus (Norway rat)	Potency	2.3177	0.0003	23.4451	159.6830	AID743065; AID743067
histone deacetylase 9 isoform 3	Homo sapiens (human)	Potency	0.3261	0.0376	17.0823	61.1927	AID1259364; AID1259388
nuclear factor erythroid 2-related factor 2 isoform 1	Homo sapiens (human)	Potency	5.2134	0.0006	27.2152	1,122.0200	AID743202; AID743219
DNA polymerase iota isoform a (long)	Homo sapiens (human)	Potency	0.8913	0.0501	27.0736	89.1251	AID588590
urokinase-type plasminogen activator precursor	Mus musculus (house mouse)	Potency	0.0631	0.1585	5.2879	12.5893	AID540303
plasminogen precursor	Mus musculus (house mouse)	Potency	0.0631	0.1585	5.2879	12.5893	AID540303
urokinase plasminogen activator surface receptor precursor	Mus musculus (house mouse)	Potency	0.0631	0.1585	5.2879	12.5893	AID540303
geminin	Homo sapiens (human)	Potency	6.5213	0.0046	11.3741	33.4983	AID624296; AID624297
peripheral myelin protein 22	Rattus norvegicus (Norway rat)	Potency	1.6276	0.0056	12.3677	36.1254	AID624032; AID624044
DNA dC->dU-editing enzyme APOBEC-3F isoform a	Homo sapiens (human)	Potency	7.0795	0.0259	11.2398	31.6228	AID602313
Voltage-dependent calcium channel gamma-2 subunit	Mus musculus (house mouse)	Potency	3.3491	0.0015	57.7890	15,848.9004	AID1259244
Interferon beta	Homo sapiens (human)	Potency	2.1534	0.0033	9.1582	39.8107	AID1347407; AID1347411
Cellular tumor antigen p53	Homo sapiens (human)	Potency	0.7542	0.0023	19.5956	74.0614	AID651631; AID720552
Glutamate receptor 2	Rattus norvegicus (Norway rat)	Potency	3.3491	0.0015	51.7393	15,848.9004	AID1259244
Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus	Potency	39.8107	0.0096	10.5250	35.4813	AID1479145
ATPase family AAA domain-containing protein 5	Homo sapiens (human)	Potency	1.9938	0.0119	17.9420	71.5630	AID651632; AID720516
Ataxin-2	Homo sapiens (human)	Potency	1.8959	0.0119	12.2221	68.7989	AID651632
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, Histone deacetylase-like amidohydrolase	Alcaligenaceae bacterium FB188	IC50 (µMol)	0.9500	0.9500	0.9500	0.9500	AID977608
Chain A, Histone deacetylase-like amidohydrolase	Alcaligenaceae bacterium FB188	IC50 (µMol)	0.9500	0.9500	0.9500	0.9500	AID977608
Histone deacetylase 8	Schistosoma mansoni	IC50 (µMol)	1.3147	0.3034	1.3350	3.6200	AID1296346; AID1446915; AID1784185
Histone deacetylase	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.1650	0.0028	0.3517	3.5120	AID90522
Lysine-specific demethylase 4E	Homo sapiens (human)	IC50 (µMol)	277.0000	0.2000	1.9569	6.3096	AID1798635; AID1885254; AID604081; AID604082
Gli1	Mus musculus (house mouse)	IC50 (µMol)	2.2300	0.0270	4.2939	11.4000	AID602464
nuclear receptor subfamily 0 group B member 1	Homo sapiens (human)	IC50 (µMol)	45.3437	0.1343	0.8646	2.1450	AID588797; AID687017
cystic fibrosis transmembrane conductance regulator	Homo sapiens (human)	IC50 (µMol)	1.5500	0.1400	16.6250	50.0000	AID1224863
steroidogenic factor 1	Homo sapiens (human)	IC50 (µMol)	67.4740	1.8730	2.9295	3.9860	AID687018
protein Wnt-3a precursor	Mus musculus (house mouse)	IC50 (µMol)	50.0000	0.4410	4.9952	14.8000	AID651570
Histone deacetylase 1	Mus musculus (house mouse)	IC50 (µMol)	0.1120	0.0014	0.7230	8.1000	AID273173; AID316880; AID90675; AID90680; AID90681
Histone deacetylase 1	Mus musculus (house mouse)	Ki	0.0676	0.0011	0.0343	0.0676	AID90677
Histone deacetylase 3	Homo sapiens (human)	IC50 (µMol)	1.5944	0.0004	0.6196	10.0000	AID1061953; AID1063058; AID1063059; AID1065634; AID1126958; AID1126961; AID1127324; AID1128556; AID1129005; AID1139706; AID1141243; AID1141761; AID1164026; AID1164782; AID1164908; AID1166497; AID1173501; AID1174680; AID1174694; AID1177044; AID1178597; AID1201642; AID1205625; AID1206764; AID1225983; AID1227031; AID1234889; AID1239049; AID1246509; AID1250642; AID1256443; AID1263144; AID1266094; AID1266808; AID1273866; AID1273871; AID1274873; AID1275076; AID1275247; AID1275592; AID1275632; AID1275636; AID1280307; AID1281848; AID1282239; AID1293553; AID1293565; AID1303686; AID1308511; AID1312867; AID1321702; AID1339569; AID1340594; AID1341595; AID1341621; AID1341623; AID1348917; AID1349715; AID1361633; AID1380938; AID1384208; AID1390009; AID1390012; AID1390020; AID1394888; AID1398800; AID1399543; AID1401341; AID1401374; AID1403153; AID1409640; AID1409641; AID1409642; AID1415637; AID1418667; AID1439349; AID1449216; AID1451831; AID1482099; AID1487001; AID1487094; AID1493593; AID1511130; AID1525779; AID1541444; AID1541452; AID1541453; AID1541563; AID1541565; AID1542181; AID1543943; AID1545756; AID1545761; AID1547269; AID1548247; AID1548256; AID1548728; AID1549163; AID1550094; AID1563942; AID1566039; AID1566804; AID1578147; AID1578156; AID1578475; AID1578887; AID1587865; AID1597974; AID1600657; AID1600732; AID1600735; AID1614128; AID1622907; AID1622908; AID1622913; AID1622931; AID1622954; AID1622962; AID1622977; AID1623525; AID1639362; AID1650413; AID1650415; AID1655789; AID1659646; AID1659649; AID1677516; AID1688025; AID1690106; AID1690833; AID1690844; AID1697196; AID1702062; AID1720096; AID1722282; AID1727740; AID1742179; AID1753839; AID1754753; AID1758467; AID1759720; AID1759721; AID1759727; AID1759728; AID1762488; AID1762497; AID1764247; AID1764248; AID1764288; AID1764292; AID1765326; AID1771467; AID1775547; AID1775565; AID1784987; AID1785334; AID1798419; AID1798524; AID1798526; AID1800141; AID1801572; AID1802356; AID1802398; AID1808546; AID1812439; AID1812444; AID1816187; AID1819502; AID1821272; AID1821957; AID1821959; AID1825925; AID1832670; AID1832687; AID1832805; AID1846147; AID1848558; AID1848559; AID1848585; AID1861251; AID1861259; AID1861655; AID1863173; AID1863435; AID1864216; AID1864240; AID1865258; AID1865263; AID1873383; AID1873409; AID1873410; AID1873411; AID1873412; AID1873413; AID1876341; AID1882466; AID1886185; AID1888420; AID1890310; AID1890512; AID1893824; AID1899585; AID1901148; AID1901153; AID1901761; AID1915571; AID1915585; AID240505; AID240810; AID258011; AID269668; AID288446; AID292436; AID294382; AID297470; AID300832; AID303347; AID304373; AID310180; AID313731; AID316872; AID316875; AID316877; AID316878; AID316931; AID324949; AID328795; AID331898; AID331899; AID343689; AID343690; AID348798; AID350715; AID352517; AID352748; AID353356; AID366642; AID373073; AID373076; AID374818; AID382342; AID408882; AID420326; AID456795; AID459821; AID461250; AID463865; AID465151; AID473030; AID473175; AID487873; AID488238; AID488275; AID499799; AID511065; AID525002; AID527317; AID539709; AID541646; AID545854; AID546545; AID546549; AID591330; AID593548; AID594123; AID603542; AID605298; AID605394; AID608776; AID609506; AID615998; AID622254; AID622256; AID626565; AID628440; AID631668; AID652747; AID652762; AID663331; AID669756; AID670514; AID670971; AID673992; AID675299; AID708770; AID717824; AID717827; AID723467; AID723468; AID723469; AID723470; AID723471; AID723472; AID723479; AID723726; AID725668; AID729522; AID732145; AID732875; AID732878; AID744378; AID748112; AID748985; AID749389; AID749705; AID750109; AID753149; AID753167; AID755627; AID760510; AID761584; AID764219; AID764647; AID772639; AID780575; AID780587; AID781051; AID80353; AID90195; AID90211; AID90340; AID90342; AID90350; AID90351; AID90352; AID90353; AID90529
Histone deacetylase 3	Homo sapiens (human)	Ki	0.3218	0.0002	0.4237	8.1900	AID1170742; AID1740130; AID331899; AID447579; AID482943; AID496803; AID619048; AID765391
ATP-binding cassette sub-family C member 3	Homo sapiens (human)	IC50 (µMol)	133.0000	0.6315	4.4531	9.3000	AID1473740
Multidrug resistance-associated protein 4	Homo sapiens (human)	IC50 (µMol)	133.0000	0.2000	5.6774	10.0000	AID1473741
Transient receptor potential cation channel subfamily V member 1	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.0010	0.0004	0.2147	4.0000	AID348801; AID348802
Lysine-specific histone demethylase 1A	Homo sapiens (human)	IC50 (µMol)	100.0000	0.0031	2.1602	9.6000	AID1502982; AID1816685
Tyrosine-protein kinase JAK2	Homo sapiens (human)	IC50 (µMol)	10.0000	0.0001	0.3722	10.0000	AID1201644
Bromodomain-containing protein 4	Homo sapiens (human)	IC50 (µMol)	4.1586	0.0004	0.4032	9.0500	AID1454051; AID1462230; AID1727731; AID1727732; AID1845320
Nuclear receptor corepressor 1	Homo sapiens (human)	IC50 (µMol)	0.0382	0.0098	0.0741	0.2340	AID1349715; AID1451831; AID1742179
Nuclear receptor corepressor 1	Homo sapiens (human)	Ki	0.0120	0.0002	0.0124	0.0250	AID765391
Bile salt export pump	Homo sapiens (human)	IC50 (µMol)	133.0000	0.1100	7.1903	10.0000	AID1473738
Tyrosine-protein kinase ABL1	Homo sapiens (human)	IC50 (µMol)	100.0000	0.0001	0.7128	10.0000	AID414721
Epidermal growth factor receptor	Homo sapiens (human)	IC50 (µMol)	0.4560	0.0000	0.5369	10.0000	AID1720112; AID1915572
Tubulin alpha-1A chain	Sus scrofa (pig)	IC50 (µMol)	1.5000	0.0067	2.1603	10.0000	AID711157
Tubulin beta chain	Sus scrofa (pig)	IC50 (µMol)	1.5000	0.0067	2.1374	10.0000	AID711157
Albumin	Homo sapiens (human)	IC50 (µMol)	0.1072	0.0013	1.6217	3.5000	AID373082
3-hydroxy-3-methylglutaryl-coenzyme A reductase	Homo sapiens (human)	IC50 (µMol)	10.0000	0.0000	0.7949	8.9000	AID737918
Amyloid-beta precursor protein	Homo sapiens (human)	IC50 (µMol)	20.0000	0.0005	3.8895	10.0000	AID1690839
Heat shock protein HSP 90-alpha	Homo sapiens (human)	IC50 (µMol)	167.3333	0.0004	0.6950	10.0000	AID1394887; AID1578157; AID1690105
Cytochrome P450 3A4	Homo sapiens (human)	IC50 (µMol)	11.0000	0.0001	1.7536	10.0000	AID274013; AID609494
Leukotriene A-4 hydrolase	Homo sapiens (human)	IC50 (µMol)	4.6600	0.0005	1.2854	7.6500	AID1441630; AID1441631
Cytochrome P450 2C8	Homo sapiens (human)	IC50 (µMol)	0.0903	0.0008	1.8848	7.9000	AID1067347; AID1437239
Cytochrome P450 2D6	Homo sapiens (human)	IC50 (µMol)	0.0110	0.0000	2.0151	10.0000	AID1437239
Cytochrome P450 2C9	Homo sapiens (human)	IC50 (µMol)	0.2400	0.0000	2.8005	10.0000	AID1200971
Aminopeptidase N	Sus scrofa (pig)	IC50 (µMol)	100.0000	0.0005	3.5354	8.9000	AID1802060
Androgen receptor	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.1582	0.0010	1.9794	14.1600	AID1166497
Alpha-1B adrenergic receptor	Rattus norvegicus (Norway rat)	IC50 (µMol)	2.8000	0.0002	1.8742	10.0000	AID759303
5-hydroxytryptamine receptor 1A	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.0530	0.0003	1.3833	8.4000	AID764219
Cannabinoid receptor 1	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.1160	0.0002	0.6609	10.0000	AID1200971; AID1200972
Amine oxidase [flavin-containing] A	Homo sapiens (human)	IC50 (µMol)	100.0000	0.0000	2.3789	9.7700	AID1502983
Alpha-1D adrenergic receptor	Rattus norvegicus (Norway rat)	IC50 (µMol)	2.8000	0.0002	1.2704	10.0000	AID759303
Leukotriene A-4 hydrolase	Mus musculus (house mouse)	IC50 (µMol)	6.1500	0.7900	3.4700	6.1500	AID1441702
DNA (cytosine-5)-methyltransferase 1	Homo sapiens (human)	IC50 (µMol)	10.0000	0.0186	1.6488	6.0000	AID1775568
Amine oxidase [flavin-containing] B	Homo sapiens (human)	IC50 (µMol)	100.0000	0.0000	1.8914	9.5700	AID1502984
Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)	IC50 (µMol)	10.0000	0.0000	0.6832	10.0000	AID1312848
Proteasome subunit beta type-5	Homo sapiens (human)	IC50 (µMol)	25.0000	0.0005	0.9394	10.0000	AID1363797; AID1363798; AID1363799
Cytochrome P450 2C19	Homo sapiens (human)	IC50 (µMol)	0.0420	0.0000	2.3983	10.0000	AID1200972; AID1401904
Prostaglandin G/H synthase 2	Homo sapiens (human)	IC50 (µMol)	0.1300	0.0001	0.9950	10.0000	AID1067347
Vascular endothelial growth factor receptor 2	Homo sapiens (human)	IC50 (µMol)	10.0000	0.0000	0.4830	8.8000	AID1256442; AID1275245; AID1915578
Receptor-type tyrosine-protein kinase FLT3	Homo sapiens (human)	IC50 (µMol)	10.0000	0.0001	0.3275	9.5480	AID1201643
Delta-type opioid receptor	Homo sapiens (human)	IC50 (µMol)	7.2000	0.0002	0.7521	8.0140	AID80353
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)	IC50 (µMol)	10.0000	0.0000	0.7340	10.0000	AID1312848
Alpha-1A adrenergic receptor	Rattus norvegicus (Norway rat)	IC50 (µMol)	2.8000	0.0000	1.8194	10.0000	AID759303
Histamine H2 receptor	Cavia porcellus (domestic guinea pig)	IC50 (µMol)	7.2000	0.0040	2.1555	7.2000	AID80353
Histone deacetylase 4	Homo sapiens (human)	IC50 (µMol)	7.1129	0.0006	1.0526	10.0000	AID1063059; AID1065630; AID1065631; AID1065638; AID1126958; AID1127325; AID1128557; AID1129006; AID1139706; AID1141243; AID1141761; AID1164186; AID1164909; AID1174680; AID1178599; AID1181304; AID1201642; AID1205625; AID1206765; AID1246514; AID1250644; AID1256443; AID1266808; AID1273866; AID1275076; AID1275247; AID1275632; AID1275638; AID1281849; AID1282240; AID1293553; AID1293564; AID1308511; AID1312867; AID1340594; AID1341595; AID1341621; AID1341623; AID1348919; AID1349725; AID1352482; AID1380938; AID1390009; AID1390020; AID1394888; AID1401341; AID1409640; AID1409641; AID1409642; AID1415637; AID1451832; AID1466062; AID1482101; AID1511134; AID1541452; AID1541453; AID1541456; AID1542182; AID1545761; AID1547268; AID1548248; AID1549163; AID1550094; AID1566806; AID1578147; AID1578156; AID1597974; AID1600732; AID1600735; AID1614133; AID1622907; AID1622908; AID1622932; AID1622954; AID1622973; AID1623527; AID1639362; AID1650413; AID1650415; AID1652191; AID1655790; AID1659646; AID1677516; AID1690106; AID1690835; AID1697196; AID1720096; AID1727741; AID1742181; AID1754754; AID1762488; AID1762489; AID1764247; AID1764248; AID1764252; AID1764288; AID1764292; AID1771467; AID1785335; AID1794854; AID1798524; AID1798526; AID1801045; AID1801572; AID1802239; AID1802356; AID1802398; AID1811364; AID1812439; AID1816189; AID1819502; AID1821957; AID1832670; AID1832688; AID1846147; AID1848558; AID1848559; AID1848587; AID1861251; AID1861260; AID1863436; AID1864216; AID1864226; AID1864240; AID1865258; AID1873384; AID1888420; AID1893824; AID1901148; AID1901156; AID1915571; AID1915596; AID240505; AID240810; AID258011; AID269668; AID288446; AID292436; AID294382; AID297470; AID300832; AID303347; AID304373; AID310180; AID313732; AID316872; AID316875; AID316877; AID316878; AID324950; AID328796; AID328797; AID331898; AID343689; AID343690; AID348800; AID350715; AID352749; AID353356; AID373073; AID373077; AID382342; AID420326; AID440821; AID456795; AID459821; AID461250; AID463865; AID473175; AID487873; AID492804; AID499799; AID525000; AID527317; AID539709; AID541648; AID545854; AID546545; AID591330; AID593549; AID603542; AID605298; AID608776; AID615998; AID616004; AID622254; AID626565; AID663331; AID669756; AID670514; AID675299; AID708770; AID711156; AID717827; AID723464; AID723467; AID723468; AID723469; AID723470; AID723471; AID723472; AID723479; AID723726; AID732153; AID732878; AID748111; AID749705; AID750109; AID753167; AID755627; AID760509; AID761584; AID764219; AID780575; AID781051; AID80353; AID90195; AID90211; AID90340; AID90342; AID90350; AID90351; AID90352; AID90353; AID90529
Histone deacetylase 4	Homo sapiens (human)	Ki	12.5010	0.0002	1.6255	9.1242	AID1439780; AID1600730; AID1650411; AID447579; AID482944; AID619049
Glutamate receptor ionotropic, NMDA 2B	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.0860	0.0006	1.5257	10.0000	AID1279124; AID1279125
E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)	Ki	20.0000	0.0009	0.1981	1.2400	AID1361628
Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)	IC50 (µMol)	22.5805	0.0009	1.9014	10.0000	AID1464879; AID1742739; AID609493; AID613341
Platelet-activating factor acetylhydrolase	Homo sapiens (human)	IC50 (µMol)	0.1000	0.0000	0.3837	3.9000	AID1293554
Histone deacetylase 1	Homo sapiens (human)	IC50 (µMol)	1.4481	0.0001	0.5543	9.9000	AID1061955; AID1063056; AID1063059; AID1065629; AID1065971; AID1067347; AID1126958; AID1126959; AID1127323; AID1128544; AID1128978; AID1139706; AID1141243; AID1141761; AID1141786; AID1162484; AID1164024; AID1164185; AID1164780; AID1164906; AID1166496; AID1168913; AID1173499; AID1174680; AID1174692; AID1177042; AID1178595; AID1181303; AID1200971; AID1201642; AID1202583; AID1203889; AID1205625; AID1206736; AID1206762; AID1225985; AID1227029; AID1231807; AID1233250; AID1234887; AID1234888; AID1235108; AID1235256; AID1239048; AID1240548; AID1246507; AID1248356; AID1250640; AID1251316; AID1256443; AID1260653; AID1266092; AID1266808; AID1266818; AID1273866; AID1274871; AID1275076; AID1275077; AID1275247; AID1275590; AID1275632; AID1275633; AID1276240; AID1279124; AID1280259; AID1280306; AID1281847; AID1282229; AID1293553; AID1293563; AID1296348; AID1303685; AID1308511; AID1312847; AID1312867; AID1321619; AID1321700; AID1326509; AID1330926; AID1337195; AID1339567; AID1340594; AID1341595; AID1341621; AID1341623; AID1348915; AID1349719; AID1352480; AID1355688; AID1361627; AID1365022; AID1379287; AID1380938; AID1383985; AID1384206; AID1384210; AID1384215; AID1390009; AID1390010; AID1390020; AID1390962; AID1393285; AID1394888; AID1396985; AID1399542; AID1401341; AID1401372; AID1401902; AID1403152; AID1409640; AID1409641; AID1409642; AID1410323; AID1415637; AID1421602; AID1421911; AID1437240; AID1437552; AID1439348; AID1449214; AID1449326; AID1451821; AID1452273; AID1459953; AID1462221; AID1464870; AID1466061; AID1469380; AID1476119; AID1478590; AID1478591; AID1482097; AID1486293; AID1486677; AID1486999; AID1487092; AID1493590; AID1502986; AID1503840; AID1511132; AID1511967; AID1514595; AID1515840; AID1518781; AID1525777; AID1535339; AID1537554; AID1541446; AID1541452; AID1541453; AID1541563; AID1541565; AID1542179; AID1543929; AID1545755; AID1545761; AID1547270; AID1548244; AID1548245; AID1548256; AID1548726; AID1549163; AID1549164; AID1550094; AID1558002; AID1563940; AID1566037; AID1566802; AID1572341; AID1576449; AID1578147; AID1578149; AID1578156; AID1578886; AID1587863; AID1589336; AID1591715; AID1597931; AID1597974; AID1600659; AID1600732; AID1600735; AID1614126; AID1622904; AID1622905; AID1622907; AID1622908; AID1622909; AID1622912; AID1622929; AID1622954; AID1622960; AID1622972; AID1622975; AID1623523; AID1633653; AID1639362; AID1650413; AID1650415; AID1652190; AID1655787; AID1658889; AID1659234; AID1659646; AID1659647; AID1667066; AID1677512; AID1677516; AID1688023; AID1690106; AID1690833; AID1690842; AID1697196; AID1698862; AID1699972; AID1702055; AID1702060; AID1704066; AID1707507; AID1720096; AID1722281; AID1723742; AID1727729; AID1730857; AID1731759; AID1737133; AID1742177; AID1751984; AID1752936; AID1753636; AID1753835; AID1754751; AID1758461; AID1759721; AID1759727; AID1759728; AID1762488; AID1762495; AID1764247; AID1764248; AID1764288; AID1764292; AID1764800; AID1764815; AID1765324; AID1769648; AID1771467; AID1775545; AID1775563; AID1777021; AID1783108; AID1784189; AID1784985; AID1785332; AID1794854; AID1797826; AID1798419; AID1798524; AID1798526; AID1798784; AID1800141; AID1801045; AID1801572; AID1802239; AID1802356; AID1802398; AID1802920; AID1808545; AID1810051; AID1811363; AID1812439; AID1812442; AID1816186; AID1816687; AID1819502; AID1819503; AID1821270; AID1821957; AID1821958; AID1825923; AID1826595; AID1832670; AID1832671; AID1832801; AID1845307; AID1845459; AID1846130; AID1846147; AID1847777; AID1848558; AID1848559; AID1848582; AID1849157; AID1855242; AID1855243; AID1856988; AID1861251; AID1861653; AID1863172; AID1863433; AID1864216; AID1864224; AID1864240; AID1865258; AID1865261; AID1873381; AID1873399; AID1873400; AID1873401; AID1873402; AID1873403; AID1876461; AID1882089; AID1882456; AID1886183; AID1888420; AID1888466; AID1888581; AID1890307; AID1890510; AID1893824; AID1897365; AID1897805; AID1899585; AID1901054; AID1901148; AID1901152; AID1907399; AID1915523; AID1915537; AID1915562; AID1915571; AID1915574; AID1917530; AID240505; AID240810; AID258011; AID269668; AID274015; AID274062; AID274110; AID288446; AID292436; AID294382; AID297470; AID297471; AID300832; AID303347; AID303348; AID304373; AID308049; AID310180; AID313729; AID316872; AID316875; AID316877; AID316878; AID316892; AID316896; AID324948; AID328793; AID331898; AID343687; AID343689; AID343690; AID344920; AID347808; AID348792; AID350715; AID350716; AID352516; AID353356; AID366640; AID373073; AID373074; AID374811; AID382342; AID392398; AID392406; AID395022; AID408880; AID411253; AID414717; AID420324; AID420326; AID438216; AID440819; AID449260; AID456795; AID459821; AID461250; AID463865; AID465149; AID473029; AID473175; AID482939; AID482940; AID487873; AID488273; AID492803; AID499799; AID511063; AID525003; AID527317; AID538408; AID539709; AID541644; AID545854; AID546545; AID546547; AID591330; AID593547; AID603542; AID605298; AID605392; AID608776; AID609489; AID609505; AID615998; AID616002; AID619041; AID621737; AID622254; AID622255; AID623020; AID626565; AID628437; AID631666; AID655470; AID655476; AID659492; AID659493; AID663331; AID669756; AID669761; AID670013; AID670514; AID670970; AID672021; AID672022; AID673990; AID675299; AID683274; AID708770; AID711159; AID717826; AID717827; AID723466; AID723467; AID723468; AID723469; AID723470; AID723471; AID723472; AID723479; AID723726; AID725670; AID729522; AID732146; AID732877; AID732878; AID734736; AID737917; AID744378; AID747252; AID748114; AID748983; AID749390; AID749704; AID749705; AID750109; AID753167; AID755627; AID759305; AID760512; AID761583; AID761584; AID764219; AID764647; AID772655; AID780575; AID780588; AID781051; AID80353; AID90195; AID90211; AID90212; AID90214; AID90340; AID90342; AID90347; AID90350; AID90351; AID90352; AID90353; AID90529; AID90663; AID90665
Histone deacetylase 1	Homo sapiens (human)	Ki	0.3652	0.0000	0.4988	8.1900	AID1170740; AID1389960; AID1399812; AID1740129; AID1798196; AID385229; AID447579; AID482939; AID496801; AID619046; AID765393
Histone deacetylase 1	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.1650	0.0028	0.3451	3.5120	AID90522
Histone deacetylase	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.1650	0.0028	0.3517	3.5120	AID90522
Sigma non-opioid intracellular receptor 1	Cavia porcellus (domestic guinea pig)	IC50 (µMol)	0.0700	0.0020	2.1233	10.0000	AID1063058
Renin	Macaca fascicularis (crab-eating macaque)	IC50 (µMol)	0.0670	0.0670	0.7685	1.4700	AID748985
Histone deacetylase 3	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.1650	0.0028	0.3517	3.5120	AID90522
Histone deacetylase-like amidohydrolase	Alcaligenaceae bacterium FB188	IC50 (µMol)	1.0000	1.0000	1.1000	1.2000	AID420318
Histone deacetylase-like amidohydrolase	Alcaligenaceae bacterium FB188	Ki	1.1500	0.7000	3.0500	9.2000	AID420317; AID420320
Histone deacetylase	Plasmodium falciparum 3D7	IC50 (µMol)	0.1000	0.1000	0.1000	0.1000	AID544400
Histone deacetylase 7	Homo sapiens (human)	IC50 (µMol)	6.5889	0.0007	1.0260	9.9000	AID1063059; AID1065636; AID1126958; AID1127328; AID1128560; AID1129009; AID1139706; AID1141243; AID1141761; AID1164030; AID1164912; AID1174680; AID1201642; AID1205625; AID1246516; AID1250646; AID1256443; AID1266808; AID1273866; AID1275076; AID1275247; AID1275632; AID1282242; AID1293553; AID1293568; AID1308511; AID1312867; AID1340594; AID1341595; AID1341621; AID1341623; AID1348921; AID1380938; AID1390009; AID1390020; AID1394888; AID1401341; AID1409640; AID1409641; AID1409642; AID1415637; AID1511136; AID1541452; AID1541453; AID1542185; AID1545761; AID1547271; AID1549163; AID1550094; AID1566808; AID1578147; AID1578156; AID1597974; AID1600732; AID1600735; AID1614135; AID1622907; AID1622908; AID1622935; AID1622954; AID1623529; AID1639362; AID1650413; AID1650415; AID1659646; AID1659651; AID1677516; AID1690106; AID1690834; AID1697196; AID1720096; AID1731758; AID1742183; AID1754756; AID1762488; AID1762490; AID1764247; AID1764248; AID1764288; AID1764292; AID1771467; AID1785338; AID1798524; AID1801572; AID1802356; AID1802398; AID1812439; AID1816190; AID1819502; AID1821957; AID1832670; AID1832691; AID1846147; AID1848558; AID1848559; AID1861251; AID1863168; AID1864216; AID1864240; AID1865258; AID1865266; AID1873387; AID1888420; AID1893824; AID1901148; AID1915571; AID240505; AID240810; AID258011; AID269668; AID288446; AID292436; AID294382; AID297470; AID300832; AID303347; AID304373; AID310180; AID313735; AID316872; AID316875; AID316877; AID316878; AID328800; AID331898; AID343689; AID343690; AID348802; AID350715; AID353356; AID373073; AID373080; AID374821; AID382342; AID420326; AID440823; AID456795; AID459821; AID461250; AID463865; AID473175; AID487873; AID499799; AID524997; AID527317; AID539709; AID541650; AID545854; AID546545; AID591330; AID593552; AID603542; AID605298; AID608776; AID615998; AID622254; AID626565; AID652751; AID663331; AID669756; AID670514; AID675299; AID708770; AID717827; AID723467; AID723468; AID723469; AID723470; AID723471; AID723472; AID723479; AID723726; AID732143; AID732878; AID747268; AID748108; AID749705; AID750109; AID753167; AID755627; AID760506; AID761584; AID764219; AID780575; AID781051; AID80353; AID90195; AID90211; AID90340; AID90342; AID90350; AID90351; AID90352; AID90353; AID90529
Histone deacetylase 7	Homo sapiens (human)	Ki	1.2995	0.0002	2.0005	9.5000	AID447579; AID619052
Histone deacetylase 2	Homo sapiens (human)	IC50 (µMol)	1.9998	0.0001	0.7221	9.9700	AID1055355; AID1061954; AID1063057; AID1063059; AID1065628; AID1067347; AID1126958; AID1126960; AID1127318; AID1128555; AID1129004; AID1139706; AID1141243; AID1141761; AID1141787; AID1164025; AID1164781; AID1164907; AID1168913; AID1173500; AID1174680; AID1174693; AID1177043; AID1178596; AID1201642; AID1203890; AID1205625; AID1206736; AID1206763; AID1225984; AID1227030; AID1231808; AID1234887; AID1235108; AID1235256; AID1240548; AID1246508; AID1248356; AID1250641; AID1251315; AID1256443; AID1266093; AID1266808; AID1273866; AID1273870; AID1274872; AID1275076; AID1275247; AID1275591; AID1275632; AID1275635; AID1276240; AID1279124; AID1279125; AID1282238; AID1293553; AID1293554; AID1308511; AID1312867; AID1321619; AID1321701; AID1326520; AID1339568; AID1340594; AID1341595; AID1341621; AID1341623; AID1348916; AID1349724; AID1352481; AID1361632; AID1365023; AID1380938; AID1380953; AID1383985; AID1383986; AID1384207; AID1390009; AID1390011; AID1390020; AID1393286; AID1394888; AID1401341; AID1401373; AID1401903; AID1409640; AID1409641; AID1409642; AID1415637; AID1449217; AID1451829; AID1459954; AID1466055; AID1478590; AID1482098; AID1486678; AID1487000; AID1487093; AID1493592; AID1502987; AID1511131; AID1525778; AID1541445; AID1541452; AID1541453; AID1541563; AID1541565; AID1542180; AID1545761; AID1547273; AID1548244; AID1548246; AID1548256; AID1548727; AID1549163; AID1550094; AID1550100; AID1563941; AID1566038; AID1566803; AID1578147; AID1578156; AID1587864; AID1597974; AID1600658; AID1600732; AID1600735; AID1614127; AID1622907; AID1622908; AID1622912; AID1622930; AID1622954; AID1622961; AID1622976; AID1622984; AID1623524; AID1639362; AID1650413; AID1650415; AID1655788; AID1659646; AID1659648; AID1677511; AID1677516; AID1688024; AID1690106; AID1690833; AID1690843; AID1697196; AID1697200; AID1702061; AID1720096; AID1730854; AID1737134; AID1742178; AID1753838; AID1754752; AID1758466; AID1759721; AID1759727; AID1759728; AID1762488; AID1762496; AID1764247; AID1764248; AID1764251; AID1764288; AID1764292; AID1765325; AID1769649; AID1771467; AID1775546; AID1775564; AID1783109; AID1784986; AID1785333; AID1798419; AID1798524; AID1800141; AID1801572; AID1802356; AID1802398; AID1802589; AID1802920; AID1808547; AID1812439; AID1812443; AID1816710; AID1819502; AID1819504; AID1821271; AID1821957; AID1825921; AID1832670; AID1832686; AID1832804; AID1846147; AID1848558; AID1848559; AID1848583; AID1855242; AID1861251; AID1861258; AID1861654; AID1863434; AID1864216; AID1864240; AID1865258; AID1865262; AID1873382; AID1873404; AID1873405; AID1873406; AID1873407; AID1873408; AID1882457; AID1886184; AID1888420; AID1890309; AID1890511; AID1893824; AID1897373; AID1899585; AID1901055; AID1901148; AID1915563; AID1915571; AID1915594; AID240505; AID240810; AID258011; AID269668; AID288446; AID292436; AID294382; AID297470; AID300832; AID303347; AID304373; AID310123; AID310180; AID313730; AID316872; AID316875; AID316877; AID316878; AID328794; AID331898; AID343689; AID343690; AID348797; AID350715; AID350717; AID352519; AID352747; AID353356; AID366641; AID373073; AID373075; AID374817; AID382342; AID408881; AID411253; AID420326; AID420502; AID438216; AID440820; AID449260; AID456795; AID459821; AID461250; AID463865; AID465150; AID473175; AID480067; AID480068; AID487873; AID488237; AID488274; AID499799; AID511064; AID525001; AID527317; AID539709; AID541645; AID545854; AID546545; AID591330; AID593546; AID594124; AID603542; AID605298; AID605393; AID608776; AID615998; AID622254; AID626565; AID628436; AID631667; AID655477; AID659492; AID663331; AID669756; AID669762; AID670514; AID672023; AID672025; AID673991; AID675299; AID708770; AID711158; AID717827; AID723465; AID723467; AID723468; AID723469; AID723470; AID723471; AID723472; AID723479; AID723726; AID725669; AID732154; AID732876; AID732878; AID737916; AID748113; AID748984; AID749705; AID750109; AID753148; AID753167; AID755627; AID760511; AID761584; AID764219; AID775843; AID780575; AID781051; AID80353; AID90195; AID90211; AID90212; AID90214; AID90340; AID90342; AID90347; AID90350; AID90351; AID90352; AID90353; AID90529; AID90685
Histone deacetylase 2	Homo sapiens (human)	Ki	0.3447	0.0000	0.4709	8.1900	AID1170741; AID1600731; AID1650412; AID447579; AID482942; AID496802; AID619047; AID765392
Canalicular multispecific organic anion transporter 1	Homo sapiens (human)	IC50 (µMol)	133.0000	2.4100	6.3433	10.0000	AID1473739
HD2 type histone deacetylase HDA106	Zea mays	IC50 (µMol)	0.2227	0.0030	0.1737	2.0000	AID241474; AID255813; AID273166; AID90197; AID90359; AID90682; AID90687; AID90689; AID90690; AID90691; AID90696
HD2 type histone deacetylase HDA106	Zea mays	Ki	0.1318	0.0044	0.0681	0.1318	AID90199; AID90693
Polyamine deacetylase HDAC10	Homo sapiens (human)	IC50 (µMol)	1.5771	0.0005	0.7245	9.9000	AID1061951; AID1063036; AID1063059; AID1126958; AID1127331; AID1128562; AID1129012; AID1139706; AID1141243; AID1141761; AID1164033; AID1164785; AID1164915; AID1173506; AID1174680; AID1177047; AID1201642; AID1205625; AID1246512; AID1250649; AID1256443; AID1266808; AID1273866; AID1274880; AID1275076; AID1275247; AID1275632; AID1282244; AID1293553; AID1293571; AID1308511; AID1312867; AID1340594; AID1341595; AID1341621; AID1341623; AID1380938; AID1390009; AID1390020; AID1394888; AID1401341; AID1409640; AID1409641; AID1409642; AID1415637; AID1482104; AID1511139; AID1541452; AID1541453; AID1542188; AID1545761; AID1547264; AID1549163; AID1550094; AID1566811; AID1578147; AID1578156; AID1587859; AID1587860; AID1597974; AID1600732; AID1600735; AID1614131; AID1622907; AID1622908; AID1622938; AID1622954; AID1622964; AID1623532; AID1639362; AID1650413; AID1650415; AID1659646; AID1677516; AID1690106; AID1697196; AID1702069; AID1720096; AID1742185; AID1758470; AID1762488; AID1764247; AID1764248; AID1764288; AID1764292; AID1771467; AID1798419; AID1802398; AID1812439; AID1816191; AID1819502; AID1821957; AID1832670; AID1846147; AID1848558; AID1848559; AID1861251; AID1864216; AID1864240; AID1865258; AID1865268; AID1873390; AID1888420; AID1893824; AID1901148; AID1915571; AID240505; AID240810; AID258011; AID269668; AID288446; AID292436; AID294382; AID297470; AID300832; AID303347; AID304373; AID310180; AID316872; AID316875; AID316877; AID316878; AID331898; AID343689; AID343690; AID350715; AID352520; AID353356; AID366645; AID373073; AID382342; AID420326; AID456795; AID459821; AID461250; AID463865; AID465153; AID473175; AID487873; AID499799; AID511067; AID524995; AID527317; AID539709; AID541653; AID545854; AID546545; AID591330; AID593555; AID603542; AID605298; AID608776; AID615998; AID622254; AID626565; AID652754; AID663331; AID669756; AID670514; AID675299; AID708770; AID717827; AID723467; AID723468; AID723469; AID723470; AID723471; AID723472; AID723479; AID723726; AID732878; AID749705; AID750109; AID753167; AID755627; AID760503; AID761584; AID764219; AID780575; AID781051; AID80353; AID90195; AID90211; AID90340; AID90342; AID90350; AID90351; AID90352; AID90353; AID90529
Polyamine deacetylase HDAC10	Homo sapiens (human)	Ki	0.6550	0.0000	0.7687	8.1900	AID1170745; AID447579; AID482949; AID619055
Histone deacetylase 11	Homo sapiens (human)	IC50 (µMol)	3.3867	0.0003	0.9298	9.9000	AID1061949; AID1063035; AID1063059; AID1126958; AID1127332; AID1128563; AID1129013; AID1139706; AID1141243; AID1141761; AID1164034; AID1164786; AID1164916; AID1174680; AID1177048; AID1201642; AID1205625; AID1206768; AID1246513; AID1250650; AID1256443; AID1266808; AID1273866; AID1275076; AID1275247; AID1275632; AID1275639; AID1282245; AID1293553; AID1293572; AID1294805; AID1308511; AID1312867; AID1340594; AID1341595; AID1341621; AID1341623; AID1380938; AID1390009; AID1390020; AID1394888; AID1401341; AID1409640; AID1409641; AID1409642; AID1415637; AID1467234; AID1482105; AID1511140; AID1541452; AID1541453; AID1542189; AID1545761; AID1547263; AID1549163; AID1550094; AID1566812; AID1578147; AID1578156; AID1578478; AID1597974; AID1600732; AID1600735; AID1614137; AID1622907; AID1622908; AID1622939; AID1622954; AID1623533; AID1639362; AID1650413; AID1650415; AID1659646; AID1677516; AID1690106; AID1697196; AID1720096; AID1727743; AID1742186; AID1751997; AID1762488; AID1764247; AID1764248; AID1764288; AID1764292; AID1771467; AID1785341; AID1794854; AID1802239; AID1808542; AID1812439; AID1816712; AID1819502; AID1821957; AID1832670; AID1846147; AID1848558; AID1848559; AID1861251; AID1864216; AID1864240; AID1865239; AID1865258; AID1873391; AID1876344; AID1888420; AID1893824; AID1901148; AID1901764; AID1915571; AID1915597; AID1917542; AID240505; AID240810; AID258011; AID269668; AID288446; AID292436; AID294382; AID297470; AID300832; AID303347; AID304373; AID310180; AID316872; AID316875; AID316877; AID316878; AID331898; AID343689; AID343690; AID350715; AID353356; AID373073; AID382342; AID420326; AID456795; AID459821; AID461250; AID463865; AID473175; AID487873; AID499799; AID527317; AID539709; AID541654; AID545854; AID546545; AID591330; AID593556; AID603542; AID605298; AID608776; AID615998; AID622254; AID626565; AID652755; AID663331; AID669756; AID670514; AID675299; AID708770; AID717827; AID723460; AID723467; AID723468; AID723469; AID723470; AID723471; AID723472; AID723479; AID723726; AID732878; AID749705; AID750109; AID753167; AID755627; AID760502; AID761584; AID764219; AID780575; AID781051; AID80353; AID90195; AID90211; AID90340; AID90342; AID90350; AID90351; AID90352; AID90353; AID90529
Histone deacetylase 11	Homo sapiens (human)	Ki	0.5126	0.0001	1.2147	8.1900	AID1170746; AID447579; AID482950; AID619056; AID765383
Carboxypeptidase B2	Homo sapiens (human)	IC50 (µMol)	0.3620	0.0015	0.5429	1.8000	AID1129013
Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)	IC50 (µMol)	10.0000	0.0025	1.1480	9.2000	AID1775567
Histone deacetylase 7	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.1650	0.0028	0.3517	3.5120	AID90522
Histone deacetylase 6	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.1650	0.0028	0.3517	3.5120	AID90522
Histone deacetylase 4	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.1650	0.0028	0.3517	3.5120	AID90522
Histone deacetylase 8	Homo sapiens (human)	IC50 (µMol)	2.2348	0.0007	0.9947	9.9000	AID1061950; AID1063055; AID1063059; AID1065632; AID1065967; AID1126958; AID1127329; AID1128561; AID1129010; AID1139706; AID1141243; AID1141761; AID1164027; AID1164784; AID1164913; AID1173505; AID1174680; AID1177046; AID1178598; AID1200973; AID1201642; AID1202585; AID1203891; AID1205625; AID1206767; AID1225981; AID1227033; AID1231809; AID1246510; AID1250643; AID1256443; AID1266808; AID1266820; AID1273866; AID1274878; AID1275076; AID1275247; AID1275632; AID1275637; AID1279129; AID1280261; AID1280309; AID1282231; AID1293553; AID1293569; AID1296347; AID1308511; AID1312867; AID1322159; AID1326522; AID1339571; AID1340594; AID1341595; AID1341621; AID1341623; AID1348918; AID1349726; AID1361635; AID1380938; AID1380956; AID1383988; AID1390009; AID1390014; AID1390020; AID1394888; AID1401341; AID1401376; AID1403155; AID1409640; AID1409641; AID1409642; AID1415637; AID1449218; AID1449328; AID1451833; AID1464872; AID1466064; AID1478593; AID1482100; AID1487003; AID1487095; AID1511137; AID1525780; AID1533327; AID1541452; AID1541453; AID1541457; AID1541563; AID1541565; AID1543945; AID1545761; AID1547266; AID1548250; AID1548256; AID1549163; AID1550094; AID1550102; AID1563944; AID1566041; AID1566805; AID1572344; AID1578147; AID1578156; AID1578477; AID1578889; AID1587866; AID1597927; AID1597974; AID1600732; AID1600735; AID1614129; AID1622907; AID1622908; AID1622936; AID1622954; AID1622963; AID1622974; AID1622978; AID1622986; AID1631200; AID1639362; AID1649884; AID1650413; AID1650415; AID1652193; AID1655793; AID1659646; AID1659652; AID1667068; AID1677510; AID1677516; AID1690106; AID1690833; AID1697196; AID1699974; AID1720096; AID1727742; AID1737135; AID1742180; AID1751996; AID1753840; AID1758469; AID1759721; AID1759727; AID1759728; AID1762488; AID1763821; AID1764247; AID1764248; AID1764254; AID1764288; AID1764292; AID1764801; AID1765328; AID1771467; AID1783110; AID1784187; AID1784988; AID1785339; AID1794854; AID1794865; AID1798419; AID1798524; AID1798784; AID1801572; AID1802059; AID1802239; AID1802356; AID1802398; AID1812439; AID1816188; AID1816711; AID1819502; AID1819506; AID1821274; AID1821957; AID1821961; AID1825927; AID1832670; AID1832692; AID1846147; AID1848558; AID1848559; AID1848586; AID1855245; AID1861251; AID1861262; AID1861657; AID1863440; AID1864216; AID1864225; AID1864240; AID1865258; AID1865264; AID1873388; AID1876343; AID1882467; AID1886187; AID1888420; AID1890311; AID1890514; AID1893824; AID1897374; AID1899585; AID1901148; AID1901154; AID1901763; AID1915571; AID1915595; AID1917541; AID240505; AID240810; AID258011; AID269668; AID288446; AID292436; AID294382; AID297470; AID300832; AID303347; AID304373; AID310180; AID313736; AID316872; AID316875; AID316877; AID316878; AID316893; AID316910; AID328801; AID331898; AID343689; AID343690; AID348803; AID350715; AID350718; AID352751; AID353356; AID366643; AID373073; AID373081; AID374822; AID382342; AID408883; AID411254; AID420326; AID438217; AID441872; AID456795; AID459821; AID461250; AID462789; AID463865; AID465152; AID473175; AID482941; AID487873; AID488277; AID489911; AID499799; AID499800; AID524996; AID527317; AID539709; AID541647; AID545854; AID546545; AID546550; AID591330; AID593553; AID594125; AID603542; AID605298; AID608776; AID615998; AID616003; AID622254; AID623021; AID626565; AID628439; AID652752; AID652764; AID659495; AID663331; AID669756; AID670514; AID675299; AID689653; AID704015; AID708770; AID711157; AID717827; AID723461; AID723467; AID723468; AID723469; AID723470; AID723471; AID723472; AID723479; AID723726; AID729522; AID732151; AID732878; AID734738; AID744378; AID748106; AID748978; AID749702; AID749705; AID750109; AID753167; AID755627; AID759303; AID760505; AID761584; AID764219; AID764647; AID780575; AID781051; AID80353; AID90195; AID90211; AID90340; AID90342; AID90350; AID90351; AID90352; AID90353; AID90529; AID90839
Histone deacetylase 8	Homo sapiens (human)	Ki	2.0845	0.0002	0.7525	8.1900	AID1170743; AID1503585; AID1600728; AID1650409; AID1798196; AID441872; AID447579; AID482941; AID496808; AID619053; AID760388; AID765390
NAD-dependent protein deacylase sirtuin-5, mitochondrial	Homo sapiens (human)	IC50 (µMol)	100.0000	0.1000	3.3800	6.6000	AID699752
REST corepressor 3	Homo sapiens (human)	Ki	0.0030	0.0030	0.0030	0.0030	AID1389960
Histone deacetylase 6	Homo sapiens (human)	IC50 (µMol)	1.2867	0.0000	0.5376	9.9000	AID1055353; AID1061952; AID1063037; AID1063059; AID1065633; AID1065968; AID1126958; AID1126962; AID1127327; AID1128559; AID1129008; AID1139706; AID1141243; AID1141761; AID1141788; AID1164032; AID1164187; AID1164783; AID1164911; AID1165117; AID1166498; AID1173495; AID1174680; AID1174695; AID1177045; AID1178601; AID1181305; AID1200972; AID1201642; AID1202584; AID1205625; AID1206766; AID1225982; AID1227032; AID1233269; AID1234890; AID1239050; AID1246511; AID1250648; AID1251317; AID1256443; AID1263145; AID1266095; AID1266808; AID1266819; AID1273866; AID1273872; AID1274876; AID1275076; AID1275078; AID1275247; AID1275632; AID1275634; AID1280260; AID1280308; AID1281850; AID1282230; AID1293553; AID1293567; AID1296349; AID1308511; AID1312867; AID1321703; AID1326521; AID1330927; AID1337196; AID1339570; AID1340594; AID1341595; AID1341621; AID1341623; AID1348923; AID1349716; AID1352483; AID1361634; AID1365024; AID1373246; AID1380938; AID1380955; AID1383987; AID1384209; AID1390009; AID1390013; AID1390020; AID1390963; AID1394888; AID1396986; AID1398799; AID1399544; AID1401341; AID1401375; AID1401904; AID1403154; AID1409640; AID1409641; AID1409642; AID1415637; AID1418666; AID1421603; AID1421912; AID1437239; AID1439350; AID1449215; AID1449327; AID1451830; AID1452274; AID1459955; AID1464871; AID1466063; AID1476121; AID1478592; AID1486294; AID1487002; AID1487096; AID1493591; AID1503841; AID1511133; AID1511968; AID1518780; AID1525776; AID1533326; AID1535340; AID1537555; AID1541443; AID1541452; AID1541453; AID1543944; AID1545761; AID1547272; AID1548249; AID1548729; AID1549163; AID1549165; AID1550094; AID1550101; AID1558003; AID1563943; AID1566040; AID1566810; AID1572342; AID1578147; AID1578156; AID1578476; AID1578888; AID1591716; AID1597932; AID1597974; AID1600656; AID1600732; AID1600735; AID1614130; AID1622906; AID1622907; AID1622908; AID1622910; AID1622914; AID1622934; AID1622954; AID1622965; AID1622985; AID1623531; AID1633654; AID1639362; AID1650413; AID1650415; AID1652192; AID1655792; AID1658891; AID1659236; AID1659646; AID1659650; AID1667067; AID1677516; AID1688026; AID1690106; AID1690838; AID1697196; AID1697202; AID1699973; AID1702065; AID1707508; AID1720096; AID1722283; AID1723743; AID1727730; AID1742175; AID1751995; AID1752944; AID1753635; AID1753834; AID1758468; AID1762488; AID1762492; AID1763822; AID1764247; AID1764248; AID1764253; AID1764288; AID1764292; AID1764799; AID1764816; AID1765327; AID1769650; AID1771467; AID1775548; AID1775566; AID1777022; AID1783107; AID1784193; AID1784989; AID1785337; AID1794854; AID1798419; AID1798524; AID1798526; AID1800141; AID1801572; AID1802239; AID1802356; AID1802398; AID1810052; AID1811362; AID1812439; AID1812445; AID1816184; AID1816689; AID1819502; AID1819505; AID1819859; AID1821273; AID1821957; AID1821960; AID1825926; AID1832670; AID1832690; AID1832800; AID1845460; AID1846147; AID1847778; AID1848280; AID1848558; AID1848559; AID1848584; AID1849158; AID1855244; AID1856989; AID1861251; AID1861261; AID1861656; AID1863169; AID1863438; AID1864216; AID1864227; AID1864240; AID1865258; AID1865267; AID1873386; AID1876342; AID1876462; AID1882462; AID1886186; AID1888420; AID1888582; AID1890308; AID1890513; AID1893824; AID1895827; AID1897366; AID1897806; AID1901057; AID1901148; AID1901155; AID1901762; AID1915524; AID1915538; AID1915564; AID1915571; AID1917529; AID240505; AID240810; AID258011; AID269668; AID288446; AID292436; AID294382; AID297470; AID300832; AID303347; AID303349; AID304373; AID310180; AID313734; AID316872; AID316875; AID316877; AID316878; AID316899; AID324956; AID328799; AID331898; AID331900; AID343688; AID343689; AID343690; AID348799; AID350715; AID350719; AID352518; AID352750; AID353356; AID366644; AID373073; AID373079; AID374820; AID382342; AID392399; AID408885; AID411256; AID414718; AID420326; AID438219; AID456795; AID459821; AID461250; AID463865; AID465154; AID473175; AID487873; AID488239; AID488276; AID499799; AID499802; AID511066; AID524999; AID527317; AID538409; AID539709; AID541652; AID545854; AID546545; AID546548; AID591330; AID593551; AID603542; AID603543; AID605298; AID605396; AID608776; AID609507; AID615998; AID616005; AID622254; AID622257; AID626565; AID631669; AID652750; AID652763; AID659494; AID663331; AID669756; AID669763; AID670012; AID670514; AID670972; AID673993; AID675299; AID708770; AID711155; AID717825; AID717827; AID723462; AID723467; AID723468; AID723469; AID723470; AID723471; AID723472; AID723479; AID723726; AID732152; AID732874; AID732878; AID734740; AID737915; AID748109; AID748981; AID749388; AID749703; AID749705; AID750109; AID753146; AID753167; AID755627; AID759304; AID760507; AID761582; AID761584; AID764219; AID780575; AID780586; AID781051; AID80353; AID90195; AID90211; AID90340; AID90342; AID90350; AID90351; AID90352; AID90353; AID90529; AID90702
Histone deacetylase 6	Homo sapiens (human)	Ki	0.3047	0.0001	0.4156	8.1900	AID1170744; AID1578479; AID1600729; AID1650410; AID1798196; AID1802011; AID331900; AID385230; AID447579; AID482946; AID482947; AID496806; AID619051; AID765385
Histone deacetylase 9	Homo sapiens (human)	IC50 (µMol)	6.1691	0.0005	0.9413	9.9000	AID1063059; AID1065635; AID1126958; AID1127330; AID1129011; AID1139706; AID1141243; AID1141761; AID1164031; AID1164914; AID1174680; AID1178600; AID1201642; AID1205625; AID1246517; AID1250647; AID1256443; AID1266808; AID1273866; AID1275076; AID1275247; AID1275632; AID1282243; AID1293553; AID1293570; AID1308511; AID1312867; AID1340594; AID1341595; AID1341621; AID1341623; AID1348922; AID1380938; AID1390009; AID1390020; AID1394888; AID1401341; AID1409640; AID1409641; AID1409642; AID1415637; AID1482103; AID1511138; AID1541452; AID1541453; AID1545761; AID1547265; AID1549163; AID1550094; AID1566809; AID1578147; AID1578156; AID1597974; AID1600732; AID1600735; AID1614136; AID1622907; AID1622908; AID1622937; AID1622954; AID1623530; AID1639362; AID1650413; AID1650415; AID1659646; AID1677516; AID1690106; AID1690837; AID1697196; AID1720096; AID1742184; AID1754757; AID1762488; AID1762491; AID1764247; AID1764248; AID1764288; AID1764292; AID1771467; AID1785340; AID1801572; AID1802398; AID1812439; AID1819502; AID1821957; AID1832670; AID1832693; AID1846147; AID1848558; AID1848559; AID1861251; AID1863441; AID1864216; AID1864240; AID1865258; AID1873389; AID1888420; AID1893824; AID1901148; AID1915571; AID240505; AID240810; AID258011; AID269668; AID288446; AID292436; AID294382; AID297470; AID300832; AID303347; AID304373; AID310180; AID316872; AID316875; AID316877; AID316878; AID331898; AID343689; AID343690; AID350715; AID353356; AID373073; AID373082; AID382342; AID420326; AID456795; AID459821; AID461250; AID463865; AID473175; AID487873; AID499799; AID524994; AID527317; AID539709; AID541651; AID545854; AID546545; AID591330; AID593554; AID603542; AID605298; AID608776; AID615998; AID622254; AID626565; AID663331; AID669756; AID670514; AID675299; AID708770; AID717827; AID723467; AID723468; AID723469; AID723470; AID723471; AID723472; AID723479; AID723726; AID725667; AID732142; AID732878; AID748107; AID749705; AID750109; AID753167; AID755627; AID760504; AID761584; AID764219; AID780575; AID781051; AID80353; AID90195; AID90211; AID90340; AID90342; AID90350; AID90351; AID90352; AID90353; AID90529
Histone deacetylase 9	Homo sapiens (human)	Ki	1.1460	0.0002	1.8520	9.0000	AID385231; AID447579; AID482948; AID619054
Histone deacetylase 5	Homo sapiens (human)	IC50 (µMol)	4.0941	0.0007	0.9610	10.0000	AID1063059; AID1065637; AID1126958; AID1127326; AID1128558; AID1129007; AID1139706; AID1141243; AID1141761; AID1164029; AID1164910; AID1174680; AID1201642; AID1205625; AID1246515; AID1250645; AID1256443; AID1266808; AID1273866; AID1274875; AID1275076; AID1275247; AID1275632; AID1282241; AID1293553; AID1293566; AID1308511; AID1312867; AID1340594; AID1341595; AID1341621; AID1341623; AID1348920; AID1380938; AID1390009; AID1390020; AID1394888; AID1401341; AID1409640; AID1409641; AID1409642; AID1415637; AID1482102; AID1511135; AID1541452; AID1541453; AID1545761; AID1547267; AID1549163; AID1550094; AID1566807; AID1578147; AID1578156; AID1597974; AID1600732; AID1600735; AID1614134; AID1622907; AID1622908; AID1622933; AID1622954; AID1623528; AID1639362; AID1650413; AID1650415; AID1655791; AID1659646; AID1677516; AID1690106; AID1690836; AID1697196; AID1720096; AID1742182; AID1754755; AID1762488; AID1764247; AID1764248; AID1764288; AID1764292; AID1771467; AID1785336; AID1798524; AID1801572; AID1802356; AID1802398; AID1812439; AID1819502; AID1821957; AID1832670; AID1832689; AID1846147; AID1848558; AID1848559; AID1861251; AID1864216; AID1864240; AID1865258; AID1865265; AID1873385; AID1888420; AID1893824; AID1901148; AID1915571; AID1915598; AID240505; AID240810; AID258011; AID269668; AID288446; AID292436; AID294382; AID297470; AID300832; AID303347; AID304373; AID310180; AID313733; AID316872; AID316875; AID316877; AID316878; AID331898; AID343689; AID343690; AID348801; AID350715; AID353356; AID373073; AID373078; AID374819; AID382342; AID420326; AID440822; AID456795; AID459821; AID461250; AID463865; AID473175; AID487873; AID499799; AID524998; AID527317; AID539709; AID541649; AID545854; AID546545; AID591330; AID593550; AID603542; AID605298; AID605395; AID608776; AID615998; AID622254; AID626565; AID652749; AID663331; AID669756; AID670514; AID675299; AID708770; AID717827; AID723463; AID723467; AID723468; AID723469; AID723470; AID723471; AID723472; AID723479; AID723726; AID729522; AID732144; AID732878; AID744378; AID748110; AID749705; AID750109; AID753167; AID755627; AID760508; AID761584; AID764219; AID764647; AID780575; AID781051; AID80353; AID90195; AID90211; AID90340; AID90342; AID90350; AID90351; AID90352; AID90353; AID90529
Histone deacetylase 5	Homo sapiens (human)	Ki	3.6278	0.0002	1.2993	9.5000	AID1439781; AID447579; AID482945; AID496805; AID619050
Histone deacetylase	Plasmodium falciparum (malaria parasite P. falciparum)	IC50 (µMol)	0.0945	0.0006	0.1688	0.9400	AID414980; AID499814
Nuclear receptor corepressor 2	Homo sapiens (human)	IC50 (µMol)	0.0905	0.0017	0.5952	8.0000	AID1061953; AID1128556; AID1129005; AID1225983; AID1293565; AID1348917; AID1390012; AID1398800; AID1449216; AID1541444; AID1548728; AID1566039; AID1566804; AID1587865; AID1600657; AID1622931; AID1622977; AID1688025; AID1690844; AID1702062; AID1754753; AID1775565; AID1785334; AID1808546; AID1832687; AID331899; AID594123; AID628440; AID652747; AID652762; AID673992
Nuclear receptor corepressor 2	Homo sapiens (human)	Ki	0.0020	0.0003	0.3325	3.2000	AID331899
Histone deacetylase 6	Mus musculus (house mouse)	IC50 (µMol)	0.3742	0.0006	0.2066	0.7870	AID1797826; AID1801045
Histone deacetylase	Zea mays	IC50 (µMol)	0.0290	0.0004	0.0133	0.0300	AID273168; AID384316
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Histone deacetylase 3	Homo sapiens (human)	EC50 (µMol)	2.8197	0.0300	1.8512	6.7000	AID1312869; AID1404339; AID1599722; AID1664945; AID297472; AID343694; AID371221; AID414719
Nuclear receptor subfamily 1 group I member 2	Homo sapiens (human)	EC50 (µMol)	30.3000	0.0020	3.5196	10.0000	AID1215086; AID1215094
Protein Tat	HIV-1 M:B_HXB2R	EC50 (µMol)	2.3000	0.1300	3.5100	8.1000	AID1598103
Histone deacetylase 4	Homo sapiens (human)	EC50 (µMol)	3.4300	0.0300	2.3523	6.7000	AID1404339; AID1599722; AID297472; AID343694; AID371221; AID414719
Histone deacetylase 1	Homo sapiens (human)	EC50 (µMol)	2.8197	0.0300	1.9877	6.7000	AID1312869; AID1404339; AID1599722; AID1664945; AID297472; AID343694; AID371221; AID414719
Histone deacetylase 1	Homo sapiens (human)	Kd	0.1283	0.0121	0.1049	0.2820	AID1802399; AID637888
Histone deacetylase-like amidohydrolase	Alcaligenaceae bacterium FB188	Kd	0.3000	0.3000	0.3000	0.3000	AID637887
Histone deacetylase 7	Homo sapiens (human)	EC50 (µMol)	3.4300	0.0300	2.3211	6.7000	AID1404339; AID1599722; AID297472; AID343694; AID371221; AID414719
Histone deacetylase 2	Homo sapiens (human)	EC50 (µMol)	2.8197	0.0300	1.8575	6.7000	AID1312869; AID1404339; AID1599722; AID1664945; AID297472; AID343694; AID371221; AID414719
Histone deacetylase 2	Homo sapiens (human)	Kd	0.1725	0.0121	0.1130	0.2820	AID1802399
Polyamine deacetylase HDAC10	Homo sapiens (human)	EC50 (µMol)	3.4300	0.0300	2.5465	6.7000	AID1404339; AID1599722; AID297472; AID343694; AID371221; AID414719
Histone deacetylase 11	Homo sapiens (human)	EC50 (µMol)	3.4300	0.0300	2.5465	6.7000	AID1404339; AID1599722; AID297472; AID343694; AID371221; AID414719
Histone deacetylase 8	Homo sapiens (human)	EC50 (µMol)	3.1686	0.0300	2.2734	6.7000	AID1404339; AID1599722; AID1664945; AID297472; AID343694; AID371221; AID414719
Histone deacetylase 8	Homo sapiens (human)	Kd	2.8700	0.0031	2.5926	9.1600	AID1260656; AID1800408; AID1800409; AID637891
Nuclear receptor subfamily 1 group I member 2	Rattus norvegicus (Norway rat)	EC50 (µMol)	2.5000	0.0100	4.1394	10.0000	AID1215090
Histone deacetylase 6	Homo sapiens (human)	EC50 (µMol)	2.1328	0.0052	1.5998	6.7000	AID1164902; AID1200970; AID1266100; AID1312868; AID1404339; AID1599722; AID1702141; AID297472; AID343694; AID371221; AID414719
Histone deacetylase 6	Homo sapiens (human)	Kd	0.3000	0.3000	0.3000	0.3000	AID637889
Histone deacetylase 9	Homo sapiens (human)	EC50 (µMol)	3.4300	0.0300	2.3266	6.7000	AID1404339; AID1599722; AID297472; AID343694; AID371221; AID414719
Histone deacetylase 5	Homo sapiens (human)	EC50 (µMol)	3.4300	0.0300	2.5465	6.7000	AID1404339; AID1599722; AID297472; AID343694; AID371221; AID414719
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
PAX8	Homo sapiens (human)	AC50	4.5800	0.0488	5.4354	69.1700	AID687027
cystic fibrosis transmembrane conductance regulator ATP-binding cassette sub-family C member 7	Homo sapiens (human)	AC50	0.9330	0.0398	15.0025	50.0000	AID743267
Histone deacetylase 3	Homo sapiens (human)	AC50	3.1000	0.0100	2.7020	7.9000	AID90344
Histone deacetylase 3	Homo sapiens (human)	INH	0.1885	0.0244	0.2434	0.5720	AID1622899; AID603218
Histone deacetylase 3	Homo sapiens (human)	Inhibition	0.0800	0.0035	0.0417	0.0800	AID243634
Cytochrome P450 3A4	Homo sapiens (human)	INH	24.8000	1.7000	2.8500	4.0000	AID663472
Histone deacetylase 4	Homo sapiens (human)	AC50	3.1000	0.0100	2.7020	7.9000	AID90344
Histone deacetylase 4	Homo sapiens (human)	INH	0.1885	0.0244	0.2434	0.5720	AID1622899; AID603218
Histone deacetylase 4	Homo sapiens (human)	Inhibition	0.0800	0.0035	0.0417	0.0800	AID243634
Histone deacetylase 1	Homo sapiens (human)	AC50	3.1000	0.0100	2.7020	7.9000	AID90344
Histone deacetylase 1	Homo sapiens (human)	INH	0.1885	0.0244	0.2434	0.5720	AID1622899; AID603218
Histone deacetylase 1	Homo sapiens (human)	Inhibition	0.0800	0.0035	0.0417	0.0800	AID243634
Histone deacetylase 7	Homo sapiens (human)	AC50	3.1000	0.0100	2.7020	7.9000	AID90344
Histone deacetylase 7	Homo sapiens (human)	INH	0.1885	0.0244	0.2434	0.5720	AID1622899; AID603218
Histone deacetylase 7	Homo sapiens (human)	Inhibition	0.0800	0.0035	0.0417	0.0800	AID243634
Histone deacetylase 2	Homo sapiens (human)	AC50	3.1000	0.0100	2.7020	7.9000	AID90344
Histone deacetylase 2	Homo sapiens (human)	INH	0.1885	0.0244	0.2434	0.5720	AID1622899; AID603218
Histone deacetylase 2	Homo sapiens (human)	Inhibition	0.0800	0.0035	0.0417	0.0800	AID243634
Polyamine deacetylase HDAC10	Homo sapiens (human)	AC50	3.1000	0.0100	2.7020	7.9000	AID90344
Polyamine deacetylase HDAC10	Homo sapiens (human)	INH	0.1885	0.0244	0.2434	0.5720	AID1622899; AID603218
Polyamine deacetylase HDAC10	Homo sapiens (human)	Inhibition	0.0800	0.0035	0.0417	0.0800	AID243634
Histone deacetylase 11	Homo sapiens (human)	AC50	3.1000	0.0100	2.7020	7.9000	AID90344
Histone deacetylase 11	Homo sapiens (human)	INH	0.1885	0.0244	0.2434	0.5720	AID1622899; AID603218
Histone deacetylase 11	Homo sapiens (human)	Inhibition	0.0800	0.0035	0.0417	0.0800	AID243634
Histone deacetylase 8	Homo sapiens (human)	AC50	3.1000	0.0100	2.7020	7.9000	AID90344
Histone deacetylase 8	Homo sapiens (human)	INH	0.1885	0.0244	0.2434	0.5720	AID1622899; AID603218
Histone deacetylase 8	Homo sapiens (human)	Inhibition	0.0800	0.0035	0.0417	0.0800	AID243634
Histone deacetylase 6	Homo sapiens (human)	AC50	3.1000	0.0100	2.7020	7.9000	AID90344
Histone deacetylase 6	Homo sapiens (human)	INH	0.1885	0.0244	0.2434	0.5720	AID1622899; AID603218
Histone deacetylase 6	Homo sapiens (human)	Inhibition	0.0800	0.0035	0.0417	0.0800	AID243634
Histone deacetylase 9	Homo sapiens (human)	AC50	3.1000	0.0100	2.7020	7.9000	AID90344
Histone deacetylase 9	Homo sapiens (human)	INH	0.1885	0.0244	0.2434	0.5720	AID1622899; AID603218
Histone deacetylase 9	Homo sapiens (human)	Inhibition	0.0800	0.0035	0.0417	0.0800	AID243634
Histone deacetylase 5	Homo sapiens (human)	AC50	3.1000	0.0100	2.7020	7.9000	AID90344
Histone deacetylase 5	Homo sapiens (human)	INH	0.1885	0.0244	0.2434	0.5720	AID1622899; AID603218
Histone deacetylase 5	Homo sapiens (human)	Inhibition	0.0800	0.0035	0.0417	0.0800	AID243634
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
regulation of gene expression	Lysine-specific demethylase 4E	Homo sapiens (human)
chromatin remodeling	Lysine-specific demethylase 4E	Homo sapiens (human)
negative regulation of myotube differentiation	Histone deacetylase 3	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Histone deacetylase 3	Homo sapiens (human)
establishment of mitotic spindle orientation	Histone deacetylase 3	Homo sapiens (human)
in utero embryonic development	Histone deacetylase 3	Homo sapiens (human)
positive regulation of protein phosphorylation	Histone deacetylase 3	Homo sapiens (human)
chromatin organization	Histone deacetylase 3	Homo sapiens (human)
transcription by RNA polymerase II	Histone deacetylase 3	Homo sapiens (human)
protein deacetylation	Histone deacetylase 3	Homo sapiens (human)
regulation of mitotic cell cycle	Histone deacetylase 3	Homo sapiens (human)
positive regulation of protein ubiquitination	Histone deacetylase 3	Homo sapiens (human)
regulation of protein stability	Histone deacetylase 3	Homo sapiens (human)
positive regulation of TOR signaling	Histone deacetylase 3	Homo sapiens (human)
circadian regulation of gene expression	Histone deacetylase 3	Homo sapiens (human)
regulation of multicellular organism growth	Histone deacetylase 3	Homo sapiens (human)
positive regulation of protein import into nucleus	Histone deacetylase 3	Homo sapiens (human)
regulation of circadian rhythm	Histone deacetylase 3	Homo sapiens (human)
negative regulation of apoptotic process	Histone deacetylase 3	Homo sapiens (human)
negative regulation of DNA-templated transcription	Histone deacetylase 3	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Histone deacetylase 3	Homo sapiens (human)
negative regulation of JNK cascade	Histone deacetylase 3	Homo sapiens (human)
spindle assembly	Histone deacetylase 3	Homo sapiens (human)
establishment of skin barrier	Histone deacetylase 3	Homo sapiens (human)
cellular response to fluid shear stress	Histone deacetylase 3	Homo sapiens (human)
positive regulation of cold-induced thermogenesis	Histone deacetylase 3	Homo sapiens (human)
DNA repair-dependent chromatin remodeling	Histone deacetylase 3	Homo sapiens (human)
cornified envelope assembly	Histone deacetylase 3	Homo sapiens (human)
negative regulation of cardiac muscle cell differentiation	Histone deacetylase 3	Homo sapiens (human)
epigenetic regulation of gene expression	Histone deacetylase 3	Homo sapiens (human)
xenobiotic metabolic process	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
bile acid and bile salt transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
leukotriene transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
monoatomic anion transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transport across blood-brain barrier	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
prostaglandin secretion	Multidrug resistance-associated protein 4	Homo sapiens (human)
cilium assembly	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet degranulation	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic metabolic process	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
bile acid and bile salt transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
cAMP transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
leukotriene transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
monoatomic anion transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
export across plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
transport across blood-brain barrier	Multidrug resistance-associated protein 4	Homo sapiens (human)
guanine nucleotide transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
regulation of double-strand break repair via homologous recombination	Lysine-specific histone demethylase 1A	Homo sapiens (human)
positive regulation of protein ubiquitination	Lysine-specific histone demethylase 1A	Homo sapiens (human)
regulation of protein localization	Lysine-specific histone demethylase 1A	Homo sapiens (human)
cellular response to UV	Lysine-specific histone demethylase 1A	Homo sapiens (human)
cellular response to gamma radiation	Lysine-specific histone demethylase 1A	Homo sapiens (human)
DNA repair-dependent chromatin remodeling	Lysine-specific histone demethylase 1A	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Lysine-specific histone demethylase 1A	Homo sapiens (human)
positive regulation of neuroblast proliferation	Lysine-specific histone demethylase 1A	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Lysine-specific histone demethylase 1A	Homo sapiens (human)
protein demethylation	Lysine-specific histone demethylase 1A	Homo sapiens (human)
positive regulation of epithelial to mesenchymal transition	Lysine-specific histone demethylase 1A	Homo sapiens (human)
positive regulation of neuron projection development	Lysine-specific histone demethylase 1A	Homo sapiens (human)
cerebral cortex development	Lysine-specific histone demethylase 1A	Homo sapiens (human)
negative regulation of protein binding	Lysine-specific histone demethylase 1A	Homo sapiens (human)
neuron maturation	Lysine-specific histone demethylase 1A	Homo sapiens (human)
negative regulation of DNA binding	Lysine-specific histone demethylase 1A	Homo sapiens (human)
negative regulation of DNA-binding transcription factor activity	Lysine-specific histone demethylase 1A	Homo sapiens (human)
negative regulation of DNA damage response, signal transduction by p53 class mediator	Lysine-specific histone demethylase 1A	Homo sapiens (human)
positive regulation of cell size	Lysine-specific histone demethylase 1A	Homo sapiens (human)
negative regulation of DNA-templated transcription	Lysine-specific histone demethylase 1A	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Lysine-specific histone demethylase 1A	Homo sapiens (human)
guanine metabolic process	Lysine-specific histone demethylase 1A	Homo sapiens (human)
muscle cell development	Lysine-specific histone demethylase 1A	Homo sapiens (human)
regulation of androgen receptor signaling pathway	Lysine-specific histone demethylase 1A	Homo sapiens (human)
response to fungicide	Lysine-specific histone demethylase 1A	Homo sapiens (human)
cellular response to cAMP	Lysine-specific histone demethylase 1A	Homo sapiens (human)
regulation of DNA methylation-dependent heterochromatin formation	Lysine-specific histone demethylase 1A	Homo sapiens (human)
positive regulation of cold-induced thermogenesis	Lysine-specific histone demethylase 1A	Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Lysine-specific histone demethylase 1A	Homo sapiens (human)
positive regulation of neural precursor cell proliferation	Lysine-specific histone demethylase 1A	Homo sapiens (human)
positive regulation of stem cell proliferation	Lysine-specific histone demethylase 1A	Homo sapiens (human)
chromatin remodeling	Lysine-specific histone demethylase 1A	Homo sapiens (human)
positive regulation of platelet aggregation	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of platelet activation	Tyrosine-protein kinase JAK2	Homo sapiens (human)
response to antibiotic	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of SMAD protein signal transduction	Tyrosine-protein kinase JAK2	Homo sapiens (human)
microglial cell activation	Tyrosine-protein kinase JAK2	Homo sapiens (human)
adaptive immune response	Tyrosine-protein kinase JAK2	Homo sapiens (human)
chromatin remodeling	Tyrosine-protein kinase JAK2	Homo sapiens (human)
transcription by RNA polymerase II	Tyrosine-protein kinase JAK2	Homo sapiens (human)
protein phosphorylation	Tyrosine-protein kinase JAK2	Homo sapiens (human)
apoptotic process	Tyrosine-protein kinase JAK2	Homo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic process	Tyrosine-protein kinase JAK2	Homo sapiens (human)
immune response	Tyrosine-protein kinase JAK2	Homo sapiens (human)
signal transduction	Tyrosine-protein kinase JAK2	Homo sapiens (human)
enzyme-linked receptor protein signaling pathway	Tyrosine-protein kinase JAK2	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of cytosolic calcium ion concentration	Tyrosine-protein kinase JAK2	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Tyrosine-protein kinase JAK2	Homo sapiens (human)
tyrosine phosphorylation of STAT protein	Tyrosine-protein kinase JAK2	Homo sapiens (human)
mesoderm development	Tyrosine-protein kinase JAK2	Homo sapiens (human)
negative regulation of cell population proliferation	Tyrosine-protein kinase JAK2	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to oxidative stress	Tyrosine-protein kinase JAK2	Homo sapiens (human)
negative regulation of cardiac muscle cell apoptotic process	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of cell-substrate adhesion	Tyrosine-protein kinase JAK2	Homo sapiens (human)
response to amine	Tyrosine-protein kinase JAK2	Homo sapiens (human)
peptidyl-tyrosine phosphorylation	Tyrosine-protein kinase JAK2	Homo sapiens (human)
cytokine-mediated signaling pathway	Tyrosine-protein kinase JAK2	Homo sapiens (human)
negative regulation of cell-cell adhesion	Tyrosine-protein kinase JAK2	Homo sapiens (human)
actin filament polymerization	Tyrosine-protein kinase JAK2	Homo sapiens (human)
cell differentiation	Tyrosine-protein kinase JAK2	Homo sapiens (human)
erythrocyte differentiation	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of cell migration	Tyrosine-protein kinase JAK2	Homo sapiens (human)
axon regeneration	Tyrosine-protein kinase JAK2	Homo sapiens (human)
intracellular mineralocorticoid receptor signaling pathway	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of insulin secretion	Tyrosine-protein kinase JAK2	Homo sapiens (human)
response to lipopolysaccharide	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of type II interferon production	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of interleukin-1 beta production	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of interleukin-17 production	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of tumor necrosis factor production	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of natural killer cell proliferation	Tyrosine-protein kinase JAK2	Homo sapiens (human)
response to hydroperoxide	Tyrosine-protein kinase JAK2	Homo sapiens (human)
tumor necrosis factor-mediated signaling pathway	Tyrosine-protein kinase JAK2	Homo sapiens (human)
symbiont-induced defense-related programmed cell death	Tyrosine-protein kinase JAK2	Homo sapiens (human)
response to tumor necrosis factor	Tyrosine-protein kinase JAK2	Homo sapiens (human)
post-embryonic hemopoiesis	Tyrosine-protein kinase JAK2	Homo sapiens (human)
intracellular signal transduction	Tyrosine-protein kinase JAK2	Homo sapiens (human)
interleukin-12-mediated signaling pathway	Tyrosine-protein kinase JAK2	Homo sapiens (human)
cellular response to interleukin-3	Tyrosine-protein kinase JAK2	Homo sapiens (human)
interleukin-5-mediated signaling pathway	Tyrosine-protein kinase JAK2	Homo sapiens (human)
collagen-activated signaling pathway	Tyrosine-protein kinase JAK2	Homo sapiens (human)
interleukin-3-mediated signaling pathway	Tyrosine-protein kinase JAK2	Homo sapiens (human)
granulocyte-macrophage colony-stimulating factor signaling pathway	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of T cell proliferation	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of protein import into nucleus	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of tyrosine phosphorylation of STAT protein	Tyrosine-protein kinase JAK2	Homo sapiens (human)
activation of Janus kinase activity	Tyrosine-protein kinase JAK2	Homo sapiens (human)
negative regulation of DNA binding	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of MAPK cascade	Tyrosine-protein kinase JAK2	Homo sapiens (human)
negative regulation of neuron apoptotic process	Tyrosine-protein kinase JAK2	Homo sapiens (human)
post-translational protein modification	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of MHC class II biosynthetic process	Tyrosine-protein kinase JAK2	Homo sapiens (human)
regulation of nitric oxide biosynthetic process	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of nitric oxide biosynthetic process	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of cell differentiation	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Tyrosine-protein kinase JAK2	Homo sapiens (human)
regulation of receptor signaling pathway via JAK-STAT	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of receptor signaling pathway via JAK-STAT	Tyrosine-protein kinase JAK2	Homo sapiens (human)
protein autophosphorylation	Tyrosine-protein kinase JAK2	Homo sapiens (human)
platelet-derived growth factor receptor signaling pathway	Tyrosine-protein kinase JAK2	Homo sapiens (human)
regulation of inflammatory response	Tyrosine-protein kinase JAK2	Homo sapiens (human)
modulation of chemical synaptic transmission	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of NK T cell proliferation	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of nitric-oxide synthase biosynthetic process	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	Tyrosine-protein kinase JAK2	Homo sapiens (human)
type II interferon-mediated signaling pathway	Tyrosine-protein kinase JAK2	Homo sapiens (human)
growth hormone receptor signaling pathway	Tyrosine-protein kinase JAK2	Homo sapiens (human)
growth hormone receptor signaling pathway via JAK-STAT	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of growth hormone receptor signaling pathway	Tyrosine-protein kinase JAK2	Homo sapiens (human)
mammary gland epithelium development	Tyrosine-protein kinase JAK2	Homo sapiens (human)
interleukin-6-mediated signaling pathway	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of leukocyte proliferation	Tyrosine-protein kinase JAK2	Homo sapiens (human)
response to interleukin-12	Tyrosine-protein kinase JAK2	Homo sapiens (human)
interleukin-35-mediated signaling pathway	Tyrosine-protein kinase JAK2	Homo sapiens (human)
cellular response to lipopolysaccharide	Tyrosine-protein kinase JAK2	Homo sapiens (human)
cellular response to dexamethasone stimulus	Tyrosine-protein kinase JAK2	Homo sapiens (human)
extrinsic apoptotic signaling pathway	Tyrosine-protein kinase JAK2	Homo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway	Tyrosine-protein kinase JAK2	Homo sapiens (human)
cellular response to virus	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of cold-induced thermogenesis	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of growth factor dependent skeletal muscle satellite cell proliferation	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of epithelial cell apoptotic process	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferation	Tyrosine-protein kinase JAK2	Homo sapiens (human)
regulation of postsynapse to nucleus signaling pathway	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of signaling receptor activity	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of T-helper 17 type immune response	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of apoptotic signaling pathway	Tyrosine-protein kinase JAK2	Homo sapiens (human)
regulation of apoptotic process	Tyrosine-protein kinase JAK2	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Bromodomain-containing protein 4	Homo sapiens (human)
positive regulation of G2/M transition of mitotic cell cycle	Bromodomain-containing protein 4	Homo sapiens (human)
positive regulation of transcription elongation by RNA polymerase II	Bromodomain-containing protein 4	Homo sapiens (human)
chromatin organization	Bromodomain-containing protein 4	Homo sapiens (human)
DNA damage response	Bromodomain-containing protein 4	Homo sapiens (human)
positive regulation of transcription elongation by RNA polymerase II	Bromodomain-containing protein 4	Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transduction	Bromodomain-containing protein 4	Homo sapiens (human)
positive regulation of DNA-templated transcription	Bromodomain-containing protein 4	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Bromodomain-containing protein 4	Homo sapiens (human)
regulation of inflammatory response	Bromodomain-containing protein 4	Homo sapiens (human)
positive regulation of T-helper 17 cell lineage commitment	Bromodomain-containing protein 4	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Nuclear receptor corepressor 1	Homo sapiens (human)
chromatin organization	Nuclear receptor corepressor 1	Homo sapiens (human)
locomotor rhythm	Nuclear receptor corepressor 1	Homo sapiens (human)
negative regulation of glycolytic process	Nuclear receptor corepressor 1	Homo sapiens (human)
negative regulation of DNA-templated transcription	Nuclear receptor corepressor 1	Homo sapiens (human)
negative regulation of fatty acid metabolic process	Nuclear receptor corepressor 1	Homo sapiens (human)
negative regulation of JNK cascade	Nuclear receptor corepressor 1	Homo sapiens (human)
spindle assembly	Nuclear receptor corepressor 1	Homo sapiens (human)
negative regulation of androgen receptor signaling pathway	Nuclear receptor corepressor 1	Homo sapiens (human)
negative regulation of miRNA transcription	Nuclear receptor corepressor 1	Homo sapiens (human)
negative regulation of DNA-templated transcription	Nuclear receptor subfamily 1 group I member 2	Homo sapiens (human)
regulation of DNA-templated transcription	Nuclear receptor subfamily 1 group I member 2	Homo sapiens (human)
xenobiotic metabolic process	Nuclear receptor subfamily 1 group I member 2	Homo sapiens (human)
signal transduction	Nuclear receptor subfamily 1 group I member 2	Homo sapiens (human)
steroid metabolic process	Nuclear receptor subfamily 1 group I member 2	Homo sapiens (human)
positive regulation of gene expression	Nuclear receptor subfamily 1 group I member 2	Homo sapiens (human)
intracellular receptor signaling pathway	Nuclear receptor subfamily 1 group I member 2	Homo sapiens (human)
xenobiotic catabolic process	Nuclear receptor subfamily 1 group I member 2	Homo sapiens (human)
xenobiotic transport	Nuclear receptor subfamily 1 group I member 2	Homo sapiens (human)
positive regulation of DNA-templated transcription	Nuclear receptor subfamily 1 group I member 2	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Nuclear receptor subfamily 1 group I member 2	Homo sapiens (human)
cell differentiation	Nuclear receptor subfamily 1 group I member 2	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Nuclear receptor subfamily 1 group I member 2	Homo sapiens (human)
fatty acid metabolic process	Bile salt export pump	Homo sapiens (human)
bile acid biosynthetic process	Bile salt export pump	Homo sapiens (human)
xenobiotic metabolic process	Bile salt export pump	Homo sapiens (human)
xenobiotic transmembrane transport	Bile salt export pump	Homo sapiens (human)
response to oxidative stress	Bile salt export pump	Homo sapiens (human)
bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
response to organic cyclic compound	Bile salt export pump	Homo sapiens (human)
bile acid and bile salt transport	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transport	Bile salt export pump	Homo sapiens (human)
protein ubiquitination	Bile salt export pump	Homo sapiens (human)
regulation of fatty acid beta-oxidation	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transport	Bile salt export pump	Homo sapiens (human)
bile acid signaling pathway	Bile salt export pump	Homo sapiens (human)
cholesterol homeostasis	Bile salt export pump	Homo sapiens (human)
response to estrogen	Bile salt export pump	Homo sapiens (human)
response to ethanol	Bile salt export pump	Homo sapiens (human)
xenobiotic export from cell	Bile salt export pump	Homo sapiens (human)
lipid homeostasis	Bile salt export pump	Homo sapiens (human)
phospholipid homeostasis	Bile salt export pump	Homo sapiens (human)
positive regulation of bile acid secretion	Bile salt export pump	Homo sapiens (human)
regulation of bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
transmembrane transport	Bile salt export pump	Homo sapiens (human)
response to oxidative stress	Tyrosine-protein kinase ABL1	Homo sapiens (human)
positive regulation of cytosolic calcium ion concentration	Tyrosine-protein kinase ABL1	Homo sapiens (human)
negative regulation of ubiquitin-protein transferase activity	Tyrosine-protein kinase ABL1	Homo sapiens (human)
negative regulation of phospholipase C activity	Tyrosine-protein kinase ABL1	Homo sapiens (human)
mitotic cell cycle	Tyrosine-protein kinase ABL1	Homo sapiens (human)
neural tube closure	Tyrosine-protein kinase ABL1	Homo sapiens (human)
B-1 B cell homeostasis	Tyrosine-protein kinase ABL1	Homo sapiens (human)
positive regulation of protein phosphorylation	Tyrosine-protein kinase ABL1	Homo sapiens (human)
B cell proliferation involved in immune response	Tyrosine-protein kinase ABL1	Homo sapiens (human)
transitional one stage B cell differentiation	Tyrosine-protein kinase ABL1	Homo sapiens (human)
mismatch repair	Tyrosine-protein kinase ABL1	Homo sapiens (human)
regulation of DNA-templated transcription	Tyrosine-protein kinase ABL1	Homo sapiens (human)
autophagy	Tyrosine-protein kinase ABL1	Homo sapiens (human)
DNA damage response	Tyrosine-protein kinase ABL1	Homo sapiens (human)
integrin-mediated signaling pathway	Tyrosine-protein kinase ABL1	Homo sapiens (human)
canonical NF-kappaB signal transduction	Tyrosine-protein kinase ABL1	Homo sapiens (human)
associative learning	Tyrosine-protein kinase ABL1	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage	Tyrosine-protein kinase ABL1	Homo sapiens (human)
response to xenobiotic stimulus	Tyrosine-protein kinase ABL1	Homo sapiens (human)
post-embryonic development	Tyrosine-protein kinase ABL1	Homo sapiens (human)
regulation of autophagy	Tyrosine-protein kinase ABL1	Homo sapiens (human)
positive regulation of endothelial cell migration	Tyrosine-protein kinase ABL1	Homo sapiens (human)
peptidyl-tyrosine phosphorylation	Tyrosine-protein kinase ABL1	Homo sapiens (human)
cerebellum morphogenesis	Tyrosine-protein kinase ABL1	Homo sapiens (human)
negative regulation of cell-cell adhesion	Tyrosine-protein kinase ABL1	Homo sapiens (human)
microspike assembly	Tyrosine-protein kinase ABL1	Homo sapiens (human)
actin cytoskeleton organization	Tyrosine-protein kinase ABL1	Homo sapiens (human)
actin filament polymerization	Tyrosine-protein kinase ABL1	Homo sapiens (human)
regulation of endocytosis	Tyrosine-protein kinase ABL1	Homo sapiens (human)
regulation of cell adhesion	Tyrosine-protein kinase ABL1	Homo sapiens (human)
neuron differentiation	Tyrosine-protein kinase ABL1	Homo sapiens (human)
BMP signaling pathway	Tyrosine-protein kinase ABL1	Homo sapiens (human)
negative regulation of BMP signaling pathway	Tyrosine-protein kinase ABL1	Homo sapiens (human)
regulation of axon extension	Tyrosine-protein kinase ABL1	Homo sapiens (human)
regulation of microtubule polymerization	Tyrosine-protein kinase ABL1	Homo sapiens (human)
regulation of Cdc42 protein signal transduction	Tyrosine-protein kinase ABL1	Homo sapiens (human)
positive regulation of type II interferon production	Tyrosine-protein kinase ABL1	Homo sapiens (human)
positive regulation of interleukin-2 production	Tyrosine-protein kinase ABL1	Homo sapiens (human)
regulation of actin cytoskeleton organization	Tyrosine-protein kinase ABL1	Homo sapiens (human)
positive regulation of osteoblast proliferation	Tyrosine-protein kinase ABL1	Homo sapiens (human)
substrate adhesion-dependent cell spreading	Tyrosine-protein kinase ABL1	Homo sapiens (human)
cellular response to oxidative stress	Tyrosine-protein kinase ABL1	Homo sapiens (human)
response to endoplasmic reticulum stress	Tyrosine-protein kinase ABL1	Homo sapiens (human)
platelet-derived growth factor receptor-beta signaling pathway	Tyrosine-protein kinase ABL1	Homo sapiens (human)
protein modification process	Tyrosine-protein kinase ABL1	Homo sapiens (human)
peptidyl-tyrosine autophosphorylation	Tyrosine-protein kinase ABL1	Homo sapiens (human)
Fc-gamma receptor signaling pathway involved in phagocytosis	Tyrosine-protein kinase ABL1	Homo sapiens (human)
neuropilin signaling pathway	Tyrosine-protein kinase ABL1	Homo sapiens (human)
signal transduction in response to DNA damage	Tyrosine-protein kinase ABL1	Homo sapiens (human)
positive regulation of apoptotic process	Tyrosine-protein kinase ABL1	Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transduction	Tyrosine-protein kinase ABL1	Homo sapiens (human)
positive regulation of neuron apoptotic process	Tyrosine-protein kinase ABL1	Homo sapiens (human)
endothelial cell migration	Tyrosine-protein kinase ABL1	Homo sapiens (human)
regulation of T cell differentiation	Tyrosine-protein kinase ABL1	Homo sapiens (human)
positive regulation of vasoconstriction	Tyrosine-protein kinase ABL1	Homo sapiens (human)
negative regulation of mitotic cell cycle	Tyrosine-protein kinase ABL1	Homo sapiens (human)
positive regulation of mitotic cell cycle	Tyrosine-protein kinase ABL1	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Tyrosine-protein kinase ABL1	Homo sapiens (human)
alpha-beta T cell differentiation	Tyrosine-protein kinase ABL1	Homo sapiens (human)
protein autophosphorylation	Tyrosine-protein kinase ABL1	Homo sapiens (human)
positive regulation of fibroblast proliferation	Tyrosine-protein kinase ABL1	Homo sapiens (human)
spleen development	Tyrosine-protein kinase ABL1	Homo sapiens (human)
thymus development	Tyrosine-protein kinase ABL1	Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation	Tyrosine-protein kinase ABL1	Homo sapiens (human)
activated T cell proliferation	Tyrosine-protein kinase ABL1	Homo sapiens (human)
T cell receptor signaling pathway	Tyrosine-protein kinase ABL1	Homo sapiens (human)
B cell receptor signaling pathway	Tyrosine-protein kinase ABL1	Homo sapiens (human)
neuromuscular process controlling balance	Tyrosine-protein kinase ABL1	Homo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosol	Tyrosine-protein kinase ABL1	Homo sapiens (human)
positive regulation of oxidoreductase activity	Tyrosine-protein kinase ABL1	Homo sapiens (human)
neuron apoptotic process	Tyrosine-protein kinase ABL1	Homo sapiens (human)
negative regulation of ubiquitin-protein transferase activity	Tyrosine-protein kinase ABL1	Homo sapiens (human)
myoblast proliferation	Tyrosine-protein kinase ABL1	Homo sapiens (human)
positive regulation of stress fiber assembly	Tyrosine-protein kinase ABL1	Homo sapiens (human)
establishment of localization in cell	Tyrosine-protein kinase ABL1	Homo sapiens (human)
regulation of cell cycle	Tyrosine-protein kinase ABL1	Homo sapiens (human)
mitochondrial depolarization	Tyrosine-protein kinase ABL1	Homo sapiens (human)
positive regulation of focal adhesion assembly	Tyrosine-protein kinase ABL1	Homo sapiens (human)
Bergmann glial cell differentiation	Tyrosine-protein kinase ABL1	Homo sapiens (human)
cardiac muscle cell proliferation	Tyrosine-protein kinase ABL1	Homo sapiens (human)
neuroepithelial cell differentiation	Tyrosine-protein kinase ABL1	Homo sapiens (human)
cellular response to hydrogen peroxide	Tyrosine-protein kinase ABL1	Homo sapiens (human)
ERK1 and ERK2 cascade	Tyrosine-protein kinase ABL1	Homo sapiens (human)
negative regulation of ERK1 and ERK2 cascade	Tyrosine-protein kinase ABL1	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	Tyrosine-protein kinase ABL1	Homo sapiens (human)
DNA conformation change	Tyrosine-protein kinase ABL1	Homo sapiens (human)
cellular response to lipopolysaccharide	Tyrosine-protein kinase ABL1	Homo sapiens (human)
cellular response to transforming growth factor beta stimulus	Tyrosine-protein kinase ABL1	Homo sapiens (human)
response to epinephrine	Tyrosine-protein kinase ABL1	Homo sapiens (human)
negative regulation of protein serine/threonine kinase activity	Tyrosine-protein kinase ABL1	Homo sapiens (human)
positive regulation of cell migration involved in sprouting angiogenesis	Tyrosine-protein kinase ABL1	Homo sapiens (human)
cellular senescence	Tyrosine-protein kinase ABL1	Homo sapiens (human)
cell-cell adhesion	Tyrosine-protein kinase ABL1	Homo sapiens (human)
positive regulation of dendrite development	Tyrosine-protein kinase ABL1	Homo sapiens (human)
positive regulation of substrate adhesion-dependent cell spreading	Tyrosine-protein kinase ABL1	Homo sapiens (human)
negative regulation of long-term synaptic potentiation	Tyrosine-protein kinase ABL1	Homo sapiens (human)
regulation of hematopoietic stem cell differentiation	Tyrosine-protein kinase ABL1	Homo sapiens (human)
positive regulation of extracellular matrix organization	Tyrosine-protein kinase ABL1	Homo sapiens (human)
podocyte apoptotic process	Tyrosine-protein kinase ABL1	Homo sapiens (human)
cellular response to dopamine	Tyrosine-protein kinase ABL1	Homo sapiens (human)
positive regulation of establishment of T cell polarity	Tyrosine-protein kinase ABL1	Homo sapiens (human)
DN4 thymocyte differentiation	Tyrosine-protein kinase ABL1	Homo sapiens (human)
protein localization to cytoplasmic microtubule plus-end	Tyrosine-protein kinase ABL1	Homo sapiens (human)
positive regulation of microtubule binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
positive regulation of actin filament binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
regulation of modification of synaptic structure	Tyrosine-protein kinase ABL1	Homo sapiens (human)
positive regulation of blood vessel branching	Tyrosine-protein kinase ABL1	Homo sapiens (human)
activation of protein kinase C activity	Tyrosine-protein kinase ABL1	Homo sapiens (human)
negative regulation of double-strand break repair via homologous recombination	Tyrosine-protein kinase ABL1	Homo sapiens (human)
positive regulation of Wnt signaling pathway, planar cell polarity pathway	Tyrosine-protein kinase ABL1	Homo sapiens (human)
regulation of cell motility	Tyrosine-protein kinase ABL1	Homo sapiens (human)
negative regulation of endothelial cell apoptotic process	Tyrosine-protein kinase ABL1	Homo sapiens (human)
positive regulation of T cell migration	Tyrosine-protein kinase ABL1	Homo sapiens (human)
negative regulation of cellular senescence	Tyrosine-protein kinase ABL1	Homo sapiens (human)
epidermal growth factor receptor signaling pathway	Tyrosine-protein kinase ABL1	Homo sapiens (human)
protein phosphorylation	Tyrosine-protein kinase ABL1	Homo sapiens (human)
cell surface receptor signaling pathway	Epidermal growth factor receptor	Homo sapiens (human)
epidermal growth factor receptor signaling pathway	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of cell population proliferation	Epidermal growth factor receptor	Homo sapiens (human)
MAPK cascade	Epidermal growth factor receptor	Homo sapiens (human)
ossification	Epidermal growth factor receptor	Homo sapiens (human)
embryonic placenta development	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of protein phosphorylation	Epidermal growth factor receptor	Homo sapiens (human)
hair follicle development	Epidermal growth factor receptor	Homo sapiens (human)
translation	Epidermal growth factor receptor	Homo sapiens (human)
signal transduction	Epidermal growth factor receptor	Homo sapiens (human)
epidermal growth factor receptor signaling pathway	Epidermal growth factor receptor	Homo sapiens (human)
activation of phospholipase C activity	Epidermal growth factor receptor	Homo sapiens (human)
salivary gland morphogenesis	Epidermal growth factor receptor	Homo sapiens (human)
midgut development	Epidermal growth factor receptor	Homo sapiens (human)
learning or memory	Epidermal growth factor receptor	Homo sapiens (human)
circadian rhythm	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of cell population proliferation	Epidermal growth factor receptor	Homo sapiens (human)
diterpenoid metabolic process	Epidermal growth factor receptor	Homo sapiens (human)
peptidyl-tyrosine phosphorylation	Epidermal growth factor receptor	Homo sapiens (human)
cerebral cortex cell migration	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of cell growth	Epidermal growth factor receptor	Homo sapiens (human)
lung development	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of cell migration	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of superoxide anion generation	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation	Epidermal growth factor receptor	Homo sapiens (human)
response to cobalamin	Epidermal growth factor receptor	Homo sapiens (human)
response to hydroxyisoflavone	Epidermal growth factor receptor	Homo sapiens (human)
cellular response to reactive oxygen species	Epidermal growth factor receptor	Homo sapiens (human)
peptidyl-tyrosine autophosphorylation	Epidermal growth factor receptor	Homo sapiens (human)
ERBB2-EGFR signaling pathway	Epidermal growth factor receptor	Homo sapiens (human)
negative regulation of epidermal growth factor receptor signaling pathway	Epidermal growth factor receptor	Homo sapiens (human)
negative regulation of protein catabolic process	Epidermal growth factor receptor	Homo sapiens (human)
vasodilation	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of phosphorylation	Epidermal growth factor receptor	Homo sapiens (human)
ovulation cycle	Epidermal growth factor receptor	Homo sapiens (human)
hydrogen peroxide metabolic process	Epidermal growth factor receptor	Homo sapiens (human)
negative regulation of apoptotic process	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of MAP kinase activity	Epidermal growth factor receptor	Homo sapiens (human)
tongue development	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of cyclin-dependent protein serine/threonine kinase activity	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of DNA repair	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of DNA replication	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of bone resorption	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of DNA-templated transcription	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of vasoconstriction	Epidermal growth factor receptor	Homo sapiens (human)
negative regulation of mitotic cell cycle	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Epidermal growth factor receptor	Homo sapiens (human)
regulation of JNK cascade	Epidermal growth factor receptor	Homo sapiens (human)
symbiont entry into host cell	Epidermal growth factor receptor	Homo sapiens (human)
protein autophosphorylation	Epidermal growth factor receptor	Homo sapiens (human)
astrocyte activation	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of fibroblast proliferation	Epidermal growth factor receptor	Homo sapiens (human)
digestive tract morphogenesis	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of smooth muscle cell proliferation	Epidermal growth factor receptor	Homo sapiens (human)
neuron projection morphogenesis	Epidermal growth factor receptor	Homo sapiens (human)
epithelial cell proliferation	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of epithelial cell proliferation	Epidermal growth factor receptor	Homo sapiens (human)
regulation of peptidyl-tyrosine phosphorylation	Epidermal growth factor receptor	Homo sapiens (human)
protein insertion into membrane	Epidermal growth factor receptor	Homo sapiens (human)
response to calcium ion	Epidermal growth factor receptor	Homo sapiens (human)
regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of synaptic transmission, glutamatergic	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of glial cell proliferation	Epidermal growth factor receptor	Homo sapiens (human)
morphogenesis of an epithelial fold	Epidermal growth factor receptor	Homo sapiens (human)
eyelid development in camera-type eye	Epidermal growth factor receptor	Homo sapiens (human)
response to UV-A	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of mucus secretion	Epidermal growth factor receptor	Homo sapiens (human)
regulation of ERK1 and ERK2 cascade	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	Epidermal growth factor receptor	Homo sapiens (human)
cellular response to amino acid stimulus	Epidermal growth factor receptor	Homo sapiens (human)
cellular response to mechanical stimulus	Epidermal growth factor receptor	Homo sapiens (human)
cellular response to cadmium ion	Epidermal growth factor receptor	Homo sapiens (human)
cellular response to epidermal growth factor stimulus	Epidermal growth factor receptor	Homo sapiens (human)
cellular response to estradiol stimulus	Epidermal growth factor receptor	Homo sapiens (human)
cellular response to xenobiotic stimulus	Epidermal growth factor receptor	Homo sapiens (human)
cellular response to dexamethasone stimulus	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of canonical Wnt signaling pathway	Epidermal growth factor receptor	Homo sapiens (human)
liver regeneration	Epidermal growth factor receptor	Homo sapiens (human)
cell-cell adhesion	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of protein kinase C activity	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycle	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transduction	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of prolactin secretion	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of miRNA transcription	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of protein localization to plasma membrane	Epidermal growth factor receptor	Homo sapiens (human)
negative regulation of cardiocyte differentiation	Epidermal growth factor receptor	Homo sapiens (human)
neurogenesis	Epidermal growth factor receptor	Homo sapiens (human)
multicellular organism development	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of kinase activity	Epidermal growth factor receptor	Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathway	Epidermal growth factor receptor	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell activation involved in immune response	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to virus	Interferon beta	Homo sapiens (human)
positive regulation of autophagy	Interferon beta	Homo sapiens (human)
cytokine-mediated signaling pathway	Interferon beta	Homo sapiens (human)
natural killer cell activation	Interferon beta	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT protein	Interferon beta	Homo sapiens (human)
cellular response to interferon-beta	Interferon beta	Homo sapiens (human)
B cell proliferation	Interferon beta	Homo sapiens (human)
negative regulation of viral genome replication	Interferon beta	Homo sapiens (human)
innate immune response	Interferon beta	Homo sapiens (human)
positive regulation of innate immune response	Interferon beta	Homo sapiens (human)
regulation of MHC class I biosynthetic process	Interferon beta	Homo sapiens (human)
negative regulation of T cell differentiation	Interferon beta	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Interferon beta	Homo sapiens (human)
defense response to virus	Interferon beta	Homo sapiens (human)
type I interferon-mediated signaling pathway	Interferon beta	Homo sapiens (human)
neuron cellular homeostasis	Interferon beta	Homo sapiens (human)
cellular response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
cellular response to virus	Interferon beta	Homo sapiens (human)
negative regulation of Lewy body formation	Interferon beta	Homo sapiens (human)
negative regulation of T-helper 2 cell cytokine production	Interferon beta	Homo sapiens (human)
positive regulation of apoptotic signaling pathway	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell differentiation	Interferon beta	Homo sapiens (human)
natural killer cell activation involved in immune response	Interferon beta	Homo sapiens (human)
adaptive immune response	Interferon beta	Homo sapiens (human)
T cell activation involved in immune response	Interferon beta	Homo sapiens (human)
humoral immune response	Interferon beta	Homo sapiens (human)
cellular response to starvation	Albumin	Homo sapiens (human)
negative regulation of mitochondrial depolarization	Albumin	Homo sapiens (human)
cellular response to calcium ion starvation	Albumin	Homo sapiens (human)
cellular oxidant detoxification	Albumin	Homo sapiens (human)
transport	Albumin	Homo sapiens (human)
cholesterol biosynthetic process	3-hydroxy-3-methylglutaryl-coenzyme A reductase	Homo sapiens (human)
visual learning	3-hydroxy-3-methylglutaryl-coenzyme A reductase	Homo sapiens (human)
coenzyme A metabolic process	3-hydroxy-3-methylglutaryl-coenzyme A reductase	Homo sapiens (human)
negative regulation of protein catabolic process	3-hydroxy-3-methylglutaryl-coenzyme A reductase	Homo sapiens (human)
negative regulation of protein secretion	3-hydroxy-3-methylglutaryl-coenzyme A reductase	Homo sapiens (human)
long-term synaptic potentiation	3-hydroxy-3-methylglutaryl-coenzyme A reductase	Homo sapiens (human)
regulation of ERK1 and ERK2 cascade	3-hydroxy-3-methylglutaryl-coenzyme A reductase	Homo sapiens (human)
negative regulation of amyloid-beta clearance	3-hydroxy-3-methylglutaryl-coenzyme A reductase	Homo sapiens (human)
isoprenoid biosynthetic process	3-hydroxy-3-methylglutaryl-coenzyme A reductase	Homo sapiens (human)
sterol biosynthetic process	3-hydroxy-3-methylglutaryl-coenzyme A reductase	Homo sapiens (human)
negative regulation of cell population proliferation	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle G2/M phase transition	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response	Cellular tumor antigen p53	Homo sapiens (human)
ER overload response	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to glucose starvation	Cellular tumor antigen p53	Homo sapiens (human)

Process	via Protein(s)	Taxonomy
metal ion binding	Lysine-specific demethylase 4E	Homo sapiens (human)
histone H3K9me2/H3K9me3 demethylase activity	Lysine-specific demethylase 4E	Homo sapiens (human)
histone H3K9 demethylase activity	Lysine-specific demethylase 4E	Homo sapiens (human)
histone deacetylase activity	Histone deacetylase 1	Mus musculus (house mouse)
transcription corepressor binding	Histone deacetylase 3	Homo sapiens (human)
chromatin binding	Histone deacetylase 3	Homo sapiens (human)
transcription corepressor activity	Histone deacetylase 3	Homo sapiens (human)
histone deacetylase activity	Histone deacetylase 3	Homo sapiens (human)
protein binding	Histone deacetylase 3	Homo sapiens (human)
enzyme binding	Histone deacetylase 3	Homo sapiens (human)
cyclin binding	Histone deacetylase 3	Homo sapiens (human)
chromatin DNA binding	Histone deacetylase 3	Homo sapiens (human)
protein lysine deacetylase activity	Histone deacetylase 3	Homo sapiens (human)
histone deacetylase binding	Histone deacetylase 3	Homo sapiens (human)
NF-kappaB binding	Histone deacetylase 3	Homo sapiens (human)
DNA-binding transcription factor binding	Histone deacetylase 3	Homo sapiens (human)
protein decrotonylase activity	Histone deacetylase 3	Homo sapiens (human)
histone decrotonylase activity	Histone deacetylase 3	Homo sapiens (human)
protein de-2-hydroxyisobutyrylase activity	Histone deacetylase 3	Homo sapiens (human)
ATP binding	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type xenobiotic transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type bile acid transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATP hydrolysis activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
icosanoid transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
guanine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
purine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type bile acid transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
efflux transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP hydrolysis activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
telomeric DNA binding	Lysine-specific histone demethylase 1A	Homo sapiens (human)
p53 binding	Lysine-specific histone demethylase 1A	Homo sapiens (human)
chromatin binding	Lysine-specific histone demethylase 1A	Homo sapiens (human)
transcription coactivator activity	Lysine-specific histone demethylase 1A	Homo sapiens (human)
protein binding	Lysine-specific histone demethylase 1A	Homo sapiens (human)
oxidoreductase activity	Lysine-specific histone demethylase 1A	Homo sapiens (human)
enzyme binding	Lysine-specific histone demethylase 1A	Homo sapiens (human)
nuclear receptor coactivator activity	Lysine-specific histone demethylase 1A	Homo sapiens (human)
demethylase activity	Lysine-specific histone demethylase 1A	Homo sapiens (human)
histone demethylase activity	Lysine-specific histone demethylase 1A	Homo sapiens (human)
histone H3K4 demethylase activity	Lysine-specific histone demethylase 1A	Homo sapiens (human)
histone H3K9 demethylase activity	Lysine-specific histone demethylase 1A	Homo sapiens (human)
identical protein binding	Lysine-specific histone demethylase 1A	Homo sapiens (human)
MRF binding	Lysine-specific histone demethylase 1A	Homo sapiens (human)
flavin adenine dinucleotide binding	Lysine-specific histone demethylase 1A	Homo sapiens (human)
nuclear androgen receptor binding	Lysine-specific histone demethylase 1A	Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor binding	Lysine-specific histone demethylase 1A	Homo sapiens (human)
telomeric repeat-containing RNA binding	Lysine-specific histone demethylase 1A	Homo sapiens (human)
DNA-binding transcription factor binding	Lysine-specific histone demethylase 1A	Homo sapiens (human)
FAD-dependent H3K4me/H3K4me3 demethylase activity	Lysine-specific histone demethylase 1A	Homo sapiens (human)
promoter-specific chromatin binding	Lysine-specific histone demethylase 1A	Homo sapiens (human)
transcription factor binding	Lysine-specific histone demethylase 1A	Homo sapiens (human)
protein kinase activity	Tyrosine-protein kinase JAK2	Homo sapiens (human)
protein tyrosine kinase activity	Tyrosine-protein kinase JAK2	Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activity	Tyrosine-protein kinase JAK2	Homo sapiens (human)
signaling receptor binding	Tyrosine-protein kinase JAK2	Homo sapiens (human)
growth hormone receptor binding	Tyrosine-protein kinase JAK2	Homo sapiens (human)
interleukin-12 receptor binding	Tyrosine-protein kinase JAK2	Homo sapiens (human)
protein binding	Tyrosine-protein kinase JAK2	Homo sapiens (human)
ATP binding	Tyrosine-protein kinase JAK2	Homo sapiens (human)
protein kinase binding	Tyrosine-protein kinase JAK2	Homo sapiens (human)
heme binding	Tyrosine-protein kinase JAK2	Homo sapiens (human)
type 1 angiotensin receptor binding	Tyrosine-protein kinase JAK2	Homo sapiens (human)
acetylcholine receptor binding	Tyrosine-protein kinase JAK2	Homo sapiens (human)
histone H3Y41 kinase activity	Tyrosine-protein kinase JAK2	Homo sapiens (human)
SH2 domain binding	Tyrosine-protein kinase JAK2	Homo sapiens (human)
histone binding	Tyrosine-protein kinase JAK2	Homo sapiens (human)
identical protein binding	Tyrosine-protein kinase JAK2	Homo sapiens (human)
phosphatidylinositol 3-kinase binding	Tyrosine-protein kinase JAK2	Homo sapiens (human)
insulin receptor substrate binding	Tyrosine-protein kinase JAK2	Homo sapiens (human)
metal ion binding	Tyrosine-protein kinase JAK2	Homo sapiens (human)
peptide hormone receptor binding	Tyrosine-protein kinase JAK2	Homo sapiens (human)
transcription cis-regulatory region binding	Bromodomain-containing protein 4	Homo sapiens (human)
p53 binding	Bromodomain-containing protein 4	Homo sapiens (human)
chromatin binding	Bromodomain-containing protein 4	Homo sapiens (human)
transcription coregulator activity	Bromodomain-containing protein 4	Homo sapiens (human)
transcription coactivator activity	Bromodomain-containing protein 4	Homo sapiens (human)
protein binding	Bromodomain-containing protein 4	Homo sapiens (human)
RNA polymerase II CTD heptapeptide repeat kinase activity	Bromodomain-containing protein 4	Homo sapiens (human)
enzyme binding	Bromodomain-containing protein 4	Homo sapiens (human)
lysine-acetylated histone binding	Bromodomain-containing protein 4	Homo sapiens (human)
RNA polymerase II C-terminal domain binding	Bromodomain-containing protein 4	Homo sapiens (human)
P-TEFb complex binding	Bromodomain-containing protein 4	Homo sapiens (human)
histone reader activity	Bromodomain-containing protein 4	Homo sapiens (human)
transcription cis-regulatory region binding	Nuclear receptor corepressor 1	Homo sapiens (human)
transcription corepressor activity	Nuclear receptor corepressor 1	Homo sapiens (human)
protein binding	Nuclear receptor corepressor 1	Homo sapiens (human)
nuclear receptor binding	Nuclear receptor corepressor 1	Homo sapiens (human)
histone deacetylase binding	Nuclear receptor corepressor 1	Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor binding	Nuclear receptor corepressor 1	Homo sapiens (human)
nuclear thyroid hormone receptor binding	Nuclear receptor corepressor 1	Homo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA binding	Nuclear receptor subfamily 1 group I member 2	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Nuclear receptor subfamily 1 group I member 2	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Nuclear receptor subfamily 1 group I member 2	Homo sapiens (human)
nuclear receptor activity	Nuclear receptor subfamily 1 group I member 2	Homo sapiens (human)
protein binding	Nuclear receptor subfamily 1 group I member 2	Homo sapiens (human)
zinc ion binding	Nuclear receptor subfamily 1 group I member 2	Homo sapiens (human)
nuclear receptor binding	Nuclear receptor subfamily 1 group I member 2	Homo sapiens (human)
sequence-specific double-stranded DNA binding	Nuclear receptor subfamily 1 group I member 2	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Nuclear receptor subfamily 1 group I member 2	Homo sapiens (human)
protein binding	Bile salt export pump	Homo sapiens (human)
ATP binding	Bile salt export pump	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Bile salt export pump	Homo sapiens (human)
bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
ABC-type bile acid transporter activity	Bile salt export pump	Homo sapiens (human)
ATP hydrolysis activity	Bile salt export pump	Homo sapiens (human)
supercoiled DNA binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
magnesium ion binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
four-way junction DNA binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
bubble DNA binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
phosphotyrosine residue binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
DNA binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
transcription coactivator activity	Tyrosine-protein kinase ABL1	Homo sapiens (human)
actin monomer binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
nicotinate-nucleotide adenylyltransferase activity	Tyrosine-protein kinase ABL1	Homo sapiens (human)
protein kinase activity	Tyrosine-protein kinase ABL1	Homo sapiens (human)
protein tyrosine kinase activity	Tyrosine-protein kinase ABL1	Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activity	Tyrosine-protein kinase ABL1	Homo sapiens (human)
protein kinase C binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
protein binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
ATP binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
kinase activity	Tyrosine-protein kinase ABL1	Homo sapiens (human)
SH3 domain binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
syntaxin binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
manganese ion binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
neuropilin binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
SH2 domain binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
ephrin receptor binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
actin filament binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
mitogen-activated protein kinase binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
proline-rich region binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
delta-catenin binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
sequence-specific double-stranded DNA binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
epidermal growth factor receptor activity	Epidermal growth factor receptor	Homo sapiens (human)
virus receptor activity	Epidermal growth factor receptor	Homo sapiens (human)
chromatin binding	Epidermal growth factor receptor	Homo sapiens (human)
double-stranded DNA binding	Epidermal growth factor receptor	Homo sapiens (human)
MAP kinase kinase kinase activity	Epidermal growth factor receptor	Homo sapiens (human)
protein tyrosine kinase activity	Epidermal growth factor receptor	Homo sapiens (human)
transmembrane receptor protein tyrosine kinase activity	Epidermal growth factor receptor	Homo sapiens (human)
transmembrane signaling receptor activity	Epidermal growth factor receptor	Homo sapiens (human)
epidermal growth factor receptor activity	Epidermal growth factor receptor	Homo sapiens (human)
integrin binding	Epidermal growth factor receptor	Homo sapiens (human)
protein binding	Epidermal growth factor receptor	Homo sapiens (human)
calmodulin binding	Epidermal growth factor receptor	Homo sapiens (human)
ATP binding	Epidermal growth factor receptor	Homo sapiens (human)
enzyme binding	Epidermal growth factor receptor	Homo sapiens (human)
kinase binding	Epidermal growth factor receptor	Homo sapiens (human)
protein kinase binding	Epidermal growth factor receptor	Homo sapiens (human)
protein phosphatase binding	Epidermal growth factor receptor	Homo sapiens (human)
protein tyrosine kinase activator activity	Epidermal growth factor receptor	Homo sapiens (human)
transmembrane receptor protein tyrosine kinase activator activity	Epidermal growth factor receptor	Homo sapiens (human)
ubiquitin protein ligase binding	Epidermal growth factor receptor	Homo sapiens (human)
identical protein binding	Epidermal growth factor receptor	Homo sapiens (human)
cadherin binding	Epidermal growth factor receptor	Homo sapiens (human)
actin filament binding	Epidermal growth factor receptor	Homo sapiens (human)
ATPase binding	Epidermal growth factor receptor	Homo sapiens (human)
epidermal growth factor binding	Epidermal growth factor receptor	Homo sapiens (human)
cytokine activity	Interferon beta	Homo sapiens (human)
cytokine receptor binding	Interferon beta	Homo sapiens (human)
type I interferon receptor binding	Interferon beta	Homo sapiens (human)
protein binding	Interferon beta	Homo sapiens (human)
chloramphenicol O-acetyltransferase activity	Interferon beta	Homo sapiens (human)
oxygen binding	Albumin	Homo sapiens (human)
DNA binding	Albumin	Homo sapiens (human)
fatty acid binding	Albumin	Homo sapiens (human)
copper ion binding	Albumin	Homo sapiens (human)
protein binding	Albumin	Homo sapiens (human)
toxic substance binding	Albumin	Homo sapiens (human)
antioxidant activity	Albumin	Homo sapiens (human)
pyridoxal phosphate binding	Albumin	Homo sapiens (human)
identical protein binding	Albumin	Homo sapiens (human)
protein-folding chaperone binding	Albumin	Homo sapiens (human)
exogenous protein binding	Albumin	Homo sapiens (human)
enterobactin binding	Albumin	Homo sapiens (human)
hydroxymethylglutaryl-CoA reductase (NADPH) activity	3-hydroxy-3-methylglutaryl-coenzyme A reductase	Homo sapiens (human)
protein binding	3-hydroxy-3-methylglutaryl-coenzyme A reductase	Homo sapiens (human)
GTPase regulator activity	3-hydroxy-3-methylglutaryl-coenzyme A reductase	Homo sapiens (human)
NADPH binding	3-hydroxy-3-methylglutaryl-coenzyme A reductase	Homo sapiens (human)
coenzyme A binding	3-hydroxy-3-methylglutaryl-coenzyme A reductase	Homo sapiens (human)
transcription cis-regulatory region binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
cis-regulatory region sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
core promoter sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
TFIID-class transcription factor complex binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
protease binding	Cellular tumor antigen p53	Homo sapiens (human)
p53 binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
chromatin binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription factor activity	Cellular tumor antigen p53	Homo sapiens (human)
mRNA 3'-UTR binding	Cellular tumor antigen p53	Homo sapiens (human)
copper ion binding	Cellular tumor antigen p53	Homo sapiens (human)
protein binding	Cellular tumor antigen p53	Homo sapiens (human)
zinc ion binding	Cellular tumor antigen p53	Homo sapiens (human)
enzyme binding	Cellular tumor antigen p53	Homo sapiens (human)
receptor tyrosine kinase binding	Cellular tumor antigen p53	Homo sapiens (human)
ubiquitin protein ligase binding	Cellular tumor antigen p53	Homo sapiens (human)
histone deacetylase regulator activity	Cellular tumor antigen p53	Homo sapiens (human)
ATP-dependent DNA/DNA annealing activity	Cellular tumor antigen p53	Homo sapiens (human)
identical protein binding	Cellular tumor antigen p53	Homo sapiens (human)
histone deacetylase binding	Cellular tumor antigen p53	Homo sapiens (human)
protein heterodimerization activity	Cellular tumor antigen p53	Homo sapiens (human)
protein-folding chaperone binding	Cellular tumor antigen p53	Homo sapiens (human)
protein phosphatase 2A binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor binding	Cellular tumor antigen p53	Homo sapiens (human)
14-3-3 protein binding	Cellular tumor antigen p53	Homo sapiens (human)
MDM2/MDM4 family protein binding	Cellular tumor antigen p53	Homo sapiens (human)
disordered domain specific binding	Cellular tumor antigen p53	Homo sapiens (human)
general transcription initiation factor binding	Cellular tumor antigen p53	Homo sapiens (human)
molecular function activator activity	Cellular tumor antigen p53	Homo sapiens (human)
promoter-specific chromatin binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Amyloid-beta precursor protein	Homo sapiens (human)
DNA binding	Amyloid-beta precursor protein	Homo sapiens (human)
serine-type endopeptidase inhibitor activity	Amyloid-beta precursor protein	Homo sapiens (human)
signaling receptor binding	Amyloid-beta precursor protein	Homo sapiens (human)
protein binding	Amyloid-beta precursor protein	Homo sapiens (human)
heparin binding	Amyloid-beta precursor protein	Homo sapiens (human)
enzyme binding	Amyloid-beta precursor protein	Homo sapiens (human)
identical protein binding	Amyloid-beta precursor protein	Homo sapiens (human)
transition metal ion binding	Amyloid-beta precursor protein	Homo sapiens (human)
receptor ligand activity	Amyloid-beta precursor protein	Homo sapiens (human)
PTB domain binding	Amyloid-beta precursor protein	Homo sapiens (human)
protein serine/threonine kinase binding	Amyloid-beta precursor protein	Homo sapiens (human)
signaling receptor activator activity	Amyloid-beta precursor protein	Homo sapiens (human)
UTP binding	Heat shock protein HSP 90-alpha	Homo sapiens (human)
CTP binding	Heat shock protein HSP 90-alpha	Homo sapiens (human)
RNA binding	Heat shock protein HSP 90-alpha	Homo sapiens (human)
mRNA binding	Heat shock protein HSP 90-alpha	Homo sapiens (human)
protein binding	Heat shock protein HSP 90-alpha	Homo sapiens (human)
ATP binding	Heat shock protein HSP 90-alpha	Homo sapiens (human)
GTP binding	Heat shock protein HSP 90-alpha	Homo sapiens (human)
ATP hydrolysis activity	Heat shock protein HSP 90-alpha	Homo sapiens (human)
sulfonylurea receptor binding	Heat shock protein HSP 90-alpha	Homo sapiens (human)
protein phosphatase binding	Heat shock protein HSP 90-alpha	Homo sapiens (human)
MHC class II protein complex binding	Heat shock protein HSP 90-alpha	Homo sapiens (human)
nitric-oxide synthase regulator activity	Heat shock protein HSP 90-alpha	Homo sapiens (human)
TPR domain binding	Heat shock protein HSP 90-alpha	Homo sapiens (human)
ubiquitin protein ligase binding	Heat shock protein HSP 90-alpha	Homo sapiens (human)
dATP binding	Heat shock protein HSP 90-alpha	Homo sapiens (human)
identical protein binding	Heat shock protein HSP 90-alpha	Homo sapiens (human)
protein homodimerization activity	Heat shock protein HSP 90-alpha	Homo sapiens (human)
histone deacetylase binding	Heat shock protein HSP 90-alpha	Homo sapiens (human)
transmembrane transporter binding	Heat shock protein HSP 90-alpha	Homo sapiens (human)
tau protein binding	Heat shock protein HSP 90-alpha	Homo sapiens (human)
GTPase binding	Heat shock protein HSP 90-alpha	Homo sapiens (human)
Rho GDP-dissociation inhibitor binding	Heat shock protein HSP 90-alpha	Homo sapiens (human)
DNA polymerase binding	Heat shock protein HSP 90-alpha	Homo sapiens (human)
scaffold protein binding	Heat shock protein HSP 90-alpha	Homo sapiens (human)
disordered domain specific binding	Heat shock protein HSP 90-alpha	Homo sapiens (human)
ATP-dependent protein folding chaperone	Heat shock protein HSP 90-alpha	Homo sapiens (human)
protein tyrosine kinase binding	Heat shock protein HSP 90-alpha	Homo sapiens (human)
unfolded protein binding	Heat shock protein HSP 90-alpha	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
steroid binding	Cytochrome P450 3A4	Homo sapiens (human)
iron ion binding	Cytochrome P450 3A4	Homo sapiens (human)
protein binding	Cytochrome P450 3A4	Homo sapiens (human)
steroid hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
retinoic acid 4-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 3A4	Homo sapiens (human)
oxygen binding	Cytochrome P450 3A4	Homo sapiens (human)
enzyme binding	Cytochrome P450 3A4	Homo sapiens (human)
heme binding	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D3 25-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
caffeine oxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
quinine 3-monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
testosterone 6-beta-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 8,9 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 11,12 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 14,15 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
aromatase activity	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D 24-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
estrogen 16-alpha-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
estrogen 2-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
arachidonate 5-lipoxygenase activity	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
arachidonate 12(S)-lipoxygenase activity	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
iron ion binding	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
protein binding	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
hydrolase activity	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
arachidonate 8(S)-lipoxygenase activity	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
RNA binding	Leukotriene A-4 hydrolase	Homo sapiens (human)
aminopeptidase activity	Leukotriene A-4 hydrolase	Homo sapiens (human)
epoxide hydrolase activity	Leukotriene A-4 hydrolase	Homo sapiens (human)
leukotriene-A4 hydrolase activity	Leukotriene A-4 hydrolase	Homo sapiens (human)
protein binding	Leukotriene A-4 hydrolase	Homo sapiens (human)
peptidase activity	Leukotriene A-4 hydrolase	Homo sapiens (human)
zinc ion binding	Leukotriene A-4 hydrolase	Homo sapiens (human)
tripeptide aminopeptidase activity	Leukotriene A-4 hydrolase	Homo sapiens (human)
metalloaminopeptidase activity	Leukotriene A-4 hydrolase	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 2C8	Homo sapiens (human)
iron ion binding	Cytochrome P450 2C8	Homo sapiens (human)
protein binding	Cytochrome P450 2C8	Homo sapiens (human)
arachidonic acid epoxygenase activity	Cytochrome P450 2C8	Homo sapiens (human)
retinoic acid 4-hydroxylase activity	Cytochrome P450 2C8	Homo sapiens (human)
caffeine oxidase activity	Cytochrome P450 2C8	Homo sapiens (human)
aromatase activity	Cytochrome P450 2C8	Homo sapiens (human)
estrogen 16-alpha-hydroxylase activity	Cytochrome P450 2C8	Homo sapiens (human)
heme binding	Cytochrome P450 2C8	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2C8	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 2D6	Homo sapiens (human)
iron ion binding	Cytochrome P450 2D6	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 2D6	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2D6	Homo sapiens (human)
heme binding	Cytochrome P450 2D6	Homo sapiens (human)
anandamide 8,9 epoxidase activity	Cytochrome P450 2D6	Homo sapiens (human)
anandamide 11,12 epoxidase activity	Cytochrome P450 2D6	Homo sapiens (human)
anandamide 14,15 epoxidase activity	Cytochrome P450 2D6	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
iron ion binding	Cytochrome P450 2C9	Homo sapiens (human)
arachidonic acid epoxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
steroid hydroxylase activity	Cytochrome P450 2C9	Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 2C9	Homo sapiens (human)
(S)-limonene 6-monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
(S)-limonene 7-monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
caffeine oxidase activity	Cytochrome P450 2C9	Homo sapiens (human)
(R)-limonene 6-monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
aromatase activity	Cytochrome P450 2C9	Homo sapiens (human)
heme binding	Cytochrome P450 2C9	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2C9	Homo sapiens (human)
arachidonate 12(S)-lipoxygenase activity	Polyunsaturated fatty acid lipoxygenase ALOX15	Homo sapiens (human)
iron ion binding	Polyunsaturated fatty acid lipoxygenase ALOX15	Homo sapiens (human)
protein binding	Polyunsaturated fatty acid lipoxygenase ALOX15	Homo sapiens (human)
phosphatidylinositol-4,5-bisphosphate binding	Polyunsaturated fatty acid lipoxygenase ALOX15	Homo sapiens (human)
linoleate 13S-lipoxygenase activity	Polyunsaturated fatty acid lipoxygenase ALOX15	Homo sapiens (human)
arachidonate 15-lipoxygenase activity	Polyunsaturated fatty acid lipoxygenase ALOX15	Homo sapiens (human)
arachidonate 12(S)-lipoxygenase activity	Polyunsaturated fatty acid lipoxygenase ALOX12	Homo sapiens (human)
iron ion binding	Polyunsaturated fatty acid lipoxygenase ALOX12	Homo sapiens (human)
protein binding	Polyunsaturated fatty acid lipoxygenase ALOX12	Homo sapiens (human)
linoleate 13S-lipoxygenase activity	Polyunsaturated fatty acid lipoxygenase ALOX12	Homo sapiens (human)
hepoxilin-epoxide hydrolase activity	Polyunsaturated fatty acid lipoxygenase ALOX12	Homo sapiens (human)
arachidonate 15-lipoxygenase activity	Polyunsaturated fatty acid lipoxygenase ALOX12	Homo sapiens (human)
protein binding	Amine oxidase [flavin-containing] A	Homo sapiens (human)
primary amine oxidase activity	Amine oxidase [flavin-containing] A	Homo sapiens (human)
aliphatic amine oxidase activity	Amine oxidase [flavin-containing] A	Homo sapiens (human)
monoamine oxidase activity	Amine oxidase [flavin-containing] A	Homo sapiens (human)
flavin adenine dinucleotide binding	Amine oxidase [flavin-containing] A	Homo sapiens (human)
DNA binding	DNA (cytosine-5)-methyltransferase 1	Homo sapiens (human)
RNA binding	DNA (cytosine-5)-methyltransferase 1	Homo sapiens (human)
DNA (cytosine-5-)-methyltransferase activity	DNA (cytosine-5)-methyltransferase 1	Homo sapiens (human)
protein binding	DNA (cytosine-5)-methyltransferase 1	Homo sapiens (human)
zinc ion binding	DNA (cytosine-5)-methyltransferase 1	Homo sapiens (human)
methyl-CpG binding	DNA (cytosine-5)-methyltransferase 1	Homo sapiens (human)
DNA-methyltransferase activity	DNA (cytosine-5)-methyltransferase 1	Homo sapiens (human)
promoter-specific chromatin binding	DNA (cytosine-5)-methyltransferase 1	Homo sapiens (human)
protein binding	Amine oxidase [flavin-containing] B	Homo sapiens (human)
primary amine oxidase activity	Amine oxidase [flavin-containing] B	Homo sapiens (human)
electron transfer activity	Amine oxidase [flavin-containing] B	Homo sapiens (human)
identical protein binding	Amine oxidase [flavin-containing] B	Homo sapiens (human)
aliphatic amine oxidase activity	Amine oxidase [flavin-containing] B	Homo sapiens (human)
monoamine oxidase activity	Amine oxidase [flavin-containing] B	Homo sapiens (human)
flavin adenine dinucleotide binding	Amine oxidase [flavin-containing] B	Homo sapiens (human)
phosphotyrosine residue binding	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
transmembrane receptor protein tyrosine kinase adaptor activity	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
insulin receptor binding	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
insulin-like growth factor receptor binding	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
neurotrophin TRKA receptor binding	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
protein binding	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
kinase activator activity	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
protein phosphatase binding	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
phosphatidylinositol 3-kinase regulator activity	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
phosphatidylinositol 3-kinase regulatory subunit binding	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
ErbB-3 class receptor binding	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
phosphatidylinositol 3-kinase binding	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
insulin binding	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
insulin receptor substrate binding	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
protein heterodimerization activity	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
phosphatidylinositol kinase activity	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
enzyme-substrate adaptor activity	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
phosphatidylinositol 3-kinase activator activity	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
1-phosphatidylinositol-3-kinase regulator activity	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
threonine-type endopeptidase activity	Proteasome subunit beta type-5	Homo sapiens (human)
protein binding	Proteasome subunit beta type-5	Homo sapiens (human)
peptidase activity	Proteasome subunit beta type-5	Homo sapiens (human)
endopeptidase activity	Proteasome subunit beta type-5	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
iron ion binding	Cytochrome P450 2C19	Homo sapiens (human)
steroid hydroxylase activity	Cytochrome P450 2C19	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 2C19	Homo sapiens (human)
(S)-limonene 6-monooxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
(S)-limonene 7-monooxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
oxygen binding	Cytochrome P450 2C19	Homo sapiens (human)
enzyme binding	Cytochrome P450 2C19	Homo sapiens (human)
heme binding	Cytochrome P450 2C19	Homo sapiens (human)
(R)-limonene 6-monooxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
aromatase activity	Cytochrome P450 2C19	Homo sapiens (human)
long-chain fatty acid omega-1 hydroxylase activity	Cytochrome P450 2C19	Homo sapiens (human)
arachidonic acid epoxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2C19	Homo sapiens (human)
peroxidase activity	Prostaglandin G/H synthase 2	Homo sapiens (human)
prostaglandin-endoperoxide synthase activity	Prostaglandin G/H synthase 2	Homo sapiens (human)
protein binding	Prostaglandin G/H synthase 2	Homo sapiens (human)
enzyme binding	Prostaglandin G/H synthase 2	Homo sapiens (human)
heme binding	Prostaglandin G/H synthase 2	Homo sapiens (human)
protein homodimerization activity	Prostaglandin G/H synthase 2	Homo sapiens (human)
metal ion binding	Prostaglandin G/H synthase 2	Homo sapiens (human)
oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygen	Prostaglandin G/H synthase 2	Homo sapiens (human)
protein tyrosine kinase activity	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
transmembrane receptor protein tyrosine kinase activity	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
vascular endothelial growth factor receptor activity	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
integrin binding	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
protein binding	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
ATP binding	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
coreceptor activity	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
growth factor binding	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
vascular endothelial growth factor binding	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
identical protein binding	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
cadherin binding	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
Hsp90 protein binding	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
protein tyrosine kinase activity	Receptor-type tyrosine-protein kinase FLT3	Homo sapiens (human)
transmembrane receptor protein tyrosine kinase activity	Receptor-type tyrosine-protein kinase FLT3	Homo sapiens (human)
cytokine receptor activity	Receptor-type tyrosine-protein kinase FLT3	Homo sapiens (human)
vascular endothelial growth factor receptor activity	Receptor-type tyrosine-protein kinase FLT3	Homo sapiens (human)
protein binding	Receptor-type tyrosine-protein kinase FLT3	Homo sapiens (human)
ATP binding	Receptor-type tyrosine-protein kinase FLT3	Homo sapiens (human)
nuclear glucocorticoid receptor binding	Receptor-type tyrosine-protein kinase FLT3	Homo sapiens (human)
protein-containing complex binding	Receptor-type tyrosine-protein kinase FLT3	Homo sapiens (human)
phosphatidylinositol 3-kinase activator activity	Receptor-type tyrosine-protein kinase FLT3	Homo sapiens (human)
growth factor binding	Receptor-type tyrosine-protein kinase FLT3	Homo sapiens (human)
G protein-coupled opioid receptor activity	Delta-type opioid receptor	Homo sapiens (human)
protein binding	Delta-type opioid receptor	Homo sapiens (human)
receptor serine/threonine kinase binding	Delta-type opioid receptor	Homo sapiens (human)
G protein-coupled enkephalin receptor activity	Delta-type opioid receptor	Homo sapiens (human)
neuropeptide binding	Delta-type opioid receptor	Homo sapiens (human)
protein serine/threonine kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
protein binding	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
ATP binding	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
1-phosphatidylinositol-3-kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
protein kinase activator activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
insulin receptor substrate binding	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
1-phosphatidylinositol-4,5-bisphosphate 3-kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
protein serine kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
1-phosphatidylinositol-4-phosphate 3-kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
transcription cis-regulatory region binding	Histone deacetylase 4	Homo sapiens (human)
histone binding	Histone deacetylase 4	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Histone deacetylase 4	Homo sapiens (human)
histone deacetylase activity	Histone deacetylase 4	Homo sapiens (human)
protein binding	Histone deacetylase 4	Homo sapiens (human)
zinc ion binding	Histone deacetylase 4	Homo sapiens (human)
SUMO transferase activity	Histone deacetylase 4	Homo sapiens (human)
potassium ion binding	Histone deacetylase 4	Homo sapiens (human)
protein lysine deacetylase activity	Histone deacetylase 4	Homo sapiens (human)
identical protein binding	Histone deacetylase 4	Homo sapiens (human)
histone deacetylase binding	Histone deacetylase 4	Homo sapiens (human)
molecular adaptor activity	Histone deacetylase 4	Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor binding	Histone deacetylase 4	Homo sapiens (human)
DNA-binding transcription factor binding	Histone deacetylase 4	Homo sapiens (human)
p53 binding	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
ubiquitin-protein transferase activity	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
protein binding	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
5S rRNA binding	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
zinc ion binding	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
ligase activity	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
SUMO transferase activity	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
enzyme binding	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
protein domain specific binding	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
ubiquitin protein ligase binding	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
receptor serine/threonine kinase binding	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
identical protein binding	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
peroxisome proliferator activated receptor binding	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
ribonucleoprotein complex binding	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
ubiquitin binding	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
ubiquitin protein ligase activity	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
NEDD8 ligase activity	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
disordered domain specific binding	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
protein binding	Apoptosis regulator BAX	Homo sapiens (human)
lipid binding	Apoptosis regulator BAX	Homo sapiens (human)
channel activity	Apoptosis regulator BAX	Homo sapiens (human)
Hsp70 protein binding	Apoptosis regulator BAX	Homo sapiens (human)
identical protein binding	Apoptosis regulator BAX	Homo sapiens (human)
protein homodimerization activity	Apoptosis regulator BAX	Homo sapiens (human)
protein heterodimerization activity	Apoptosis regulator BAX	Homo sapiens (human)
BH3 domain binding	Apoptosis regulator BAX	Homo sapiens (human)
BH domain binding	Apoptosis regulator BAX	Homo sapiens (human)
transcription cis-regulatory region binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)

Process	via Protein(s)	Taxonomy
nucleus	Lysine-specific demethylase 4E	Homo sapiens (human)
nucleoplasm	Lysine-specific demethylase 4E	Homo sapiens (human)
chromatin	Lysine-specific demethylase 4E	Homo sapiens (human)
nucleus	Lysine-specific demethylase 4E	Homo sapiens (human)
nucleoplasm	Histone deacetylase 1	Mus musculus (house mouse)
nucleus	Histone deacetylase 3	Homo sapiens (human)
nucleoplasm	Histone deacetylase 3	Homo sapiens (human)
cytoplasm	Histone deacetylase 3	Homo sapiens (human)
Golgi apparatus	Histone deacetylase 3	Homo sapiens (human)
cytosol	Histone deacetylase 3	Homo sapiens (human)
plasma membrane	Histone deacetylase 3	Homo sapiens (human)
mitotic spindle	Histone deacetylase 3	Homo sapiens (human)
histone deacetylase complex	Histone deacetylase 3	Homo sapiens (human)
transcription repressor complex	Histone deacetylase 3	Homo sapiens (human)
nucleus	Histone deacetylase 3	Homo sapiens (human)
plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basal plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basolateral plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
nucleolus	Multidrug resistance-associated protein 4	Homo sapiens (human)
Golgi apparatus	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet dense granule membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
external side of apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
chromatin	Lysine-specific histone demethylase 1A	Homo sapiens (human)
nucleus	Lysine-specific histone demethylase 1A	Homo sapiens (human)
chromosome, telomeric region	Lysine-specific histone demethylase 1A	Homo sapiens (human)
nucleus	Lysine-specific histone demethylase 1A	Homo sapiens (human)
nucleoplasm	Lysine-specific histone demethylase 1A	Homo sapiens (human)
transcription regulator complex	Lysine-specific histone demethylase 1A	Homo sapiens (human)
protein-containing complex	Lysine-specific histone demethylase 1A	Homo sapiens (human)
DNA repair complex	Lysine-specific histone demethylase 1A	Homo sapiens (human)
extrinsic component of plasma membrane	Tyrosine-protein kinase JAK2	Homo sapiens (human)
extrinsic component of cytoplasmic side of plasma membrane	Tyrosine-protein kinase JAK2	Homo sapiens (human)
nucleus	Tyrosine-protein kinase JAK2	Homo sapiens (human)
nucleoplasm	Tyrosine-protein kinase JAK2	Homo sapiens (human)
cytoplasm	Tyrosine-protein kinase JAK2	Homo sapiens (human)
cytosol	Tyrosine-protein kinase JAK2	Homo sapiens (human)
cytoskeleton	Tyrosine-protein kinase JAK2	Homo sapiens (human)
plasma membrane	Tyrosine-protein kinase JAK2	Homo sapiens (human)
caveola	Tyrosine-protein kinase JAK2	Homo sapiens (human)
focal adhesion	Tyrosine-protein kinase JAK2	Homo sapiens (human)
granulocyte macrophage colony-stimulating factor receptor complex	Tyrosine-protein kinase JAK2	Homo sapiens (human)
endosome lumen	Tyrosine-protein kinase JAK2	Homo sapiens (human)
interleukin-12 receptor complex	Tyrosine-protein kinase JAK2	Homo sapiens (human)
membrane raft	Tyrosine-protein kinase JAK2	Homo sapiens (human)
interleukin-23 receptor complex	Tyrosine-protein kinase JAK2	Homo sapiens (human)
postsynapse	Tyrosine-protein kinase JAK2	Homo sapiens (human)
glutamatergic synapse	Tyrosine-protein kinase JAK2	Homo sapiens (human)
euchromatin	Tyrosine-protein kinase JAK2	Homo sapiens (human)
cytosol	Tyrosine-protein kinase JAK2	Homo sapiens (human)
condensed nuclear chromosome	Bromodomain-containing protein 4	Homo sapiens (human)
nucleus	Bromodomain-containing protein 4	Homo sapiens (human)
nucleoplasm	Bromodomain-containing protein 4	Homo sapiens (human)
nucleus	Nuclear receptor corepressor 1	Homo sapiens (human)
nucleoplasm	Nuclear receptor corepressor 1	Homo sapiens (human)
cytosol	Nuclear receptor corepressor 1	Homo sapiens (human)
membrane	Nuclear receptor corepressor 1	Homo sapiens (human)
mitotic spindle	Nuclear receptor corepressor 1	Homo sapiens (human)
histone deacetylase complex	Nuclear receptor corepressor 1	Homo sapiens (human)
chromatin	Nuclear receptor corepressor 1	Homo sapiens (human)
transcription repressor complex	Nuclear receptor corepressor 1	Homo sapiens (human)
nucleoplasm	Nuclear receptor subfamily 1 group I member 2	Homo sapiens (human)
transcription regulator complex	Nuclear receptor subfamily 1 group I member 2	Homo sapiens (human)
nuclear body	Nuclear receptor subfamily 1 group I member 2	Homo sapiens (human)
intermediate filament cytoskeleton	Nuclear receptor subfamily 1 group I member 2	Homo sapiens (human)
chromatin	Nuclear receptor subfamily 1 group I member 2	Homo sapiens (human)
nucleus	Nuclear receptor subfamily 1 group I member 2	Homo sapiens (human)
basolateral plasma membrane	Bile salt export pump	Homo sapiens (human)
Golgi membrane	Bile salt export pump	Homo sapiens (human)
endosome	Bile salt export pump	Homo sapiens (human)
plasma membrane	Bile salt export pump	Homo sapiens (human)
cell surface	Bile salt export pump	Homo sapiens (human)
apical plasma membrane	Bile salt export pump	Homo sapiens (human)
intercellular canaliculus	Bile salt export pump	Homo sapiens (human)
intracellular canaliculus	Bile salt export pump	Homo sapiens (human)
recycling endosome	Bile salt export pump	Homo sapiens (human)
recycling endosome membrane	Bile salt export pump	Homo sapiens (human)
extracellular exosome	Bile salt export pump	Homo sapiens (human)
membrane	Bile salt export pump	Homo sapiens (human)
ruffle	Tyrosine-protein kinase ABL1	Homo sapiens (human)
nucleus	Tyrosine-protein kinase ABL1	Homo sapiens (human)
nucleoplasm	Tyrosine-protein kinase ABL1	Homo sapiens (human)
nucleolus	Tyrosine-protein kinase ABL1	Homo sapiens (human)
cytoplasm	Tyrosine-protein kinase ABL1	Homo sapiens (human)
mitochondrion	Tyrosine-protein kinase ABL1	Homo sapiens (human)
cytosol	Tyrosine-protein kinase ABL1	Homo sapiens (human)
actin cytoskeleton	Tyrosine-protein kinase ABL1	Homo sapiens (human)
nuclear body	Tyrosine-protein kinase ABL1	Homo sapiens (human)
dendrite	Tyrosine-protein kinase ABL1	Homo sapiens (human)
growth cone	Tyrosine-protein kinase ABL1	Homo sapiens (human)
nuclear membrane	Tyrosine-protein kinase ABL1	Homo sapiens (human)
neuronal cell body	Tyrosine-protein kinase ABL1	Homo sapiens (human)
perinuclear region of cytoplasm	Tyrosine-protein kinase ABL1	Homo sapiens (human)
postsynapse	Tyrosine-protein kinase ABL1	Homo sapiens (human)
protein-containing complex	Tyrosine-protein kinase ABL1	Homo sapiens (human)
plasma membrane	Tyrosine-protein kinase ABL1	Homo sapiens (human)
endosome	Epidermal growth factor receptor	Homo sapiens (human)
plasma membrane	Epidermal growth factor receptor	Homo sapiens (human)
ruffle membrane	Epidermal growth factor receptor	Homo sapiens (human)
Golgi membrane	Epidermal growth factor receptor	Homo sapiens (human)
extracellular space	Epidermal growth factor receptor	Homo sapiens (human)
nucleus	Epidermal growth factor receptor	Homo sapiens (human)
cytoplasm	Epidermal growth factor receptor	Homo sapiens (human)
endosome	Epidermal growth factor receptor	Homo sapiens (human)
endoplasmic reticulum membrane	Epidermal growth factor receptor	Homo sapiens (human)
plasma membrane	Epidermal growth factor receptor	Homo sapiens (human)
focal adhesion	Epidermal growth factor receptor	Homo sapiens (human)
cell surface	Epidermal growth factor receptor	Homo sapiens (human)
endosome membrane	Epidermal growth factor receptor	Homo sapiens (human)
membrane	Epidermal growth factor receptor	Homo sapiens (human)
basolateral plasma membrane	Epidermal growth factor receptor	Homo sapiens (human)
apical plasma membrane	Epidermal growth factor receptor	Homo sapiens (human)
cell junction	Epidermal growth factor receptor	Homo sapiens (human)
clathrin-coated endocytic vesicle membrane	Epidermal growth factor receptor	Homo sapiens (human)
early endosome membrane	Epidermal growth factor receptor	Homo sapiens (human)
nuclear membrane	Epidermal growth factor receptor	Homo sapiens (human)
membrane raft	Epidermal growth factor receptor	Homo sapiens (human)
perinuclear region of cytoplasm	Epidermal growth factor receptor	Homo sapiens (human)
multivesicular body, internal vesicle lumen	Epidermal growth factor receptor	Homo sapiens (human)
intracellular vesicle	Epidermal growth factor receptor	Homo sapiens (human)
protein-containing complex	Epidermal growth factor receptor	Homo sapiens (human)
receptor complex	Epidermal growth factor receptor	Homo sapiens (human)
Shc-EGFR complex	Epidermal growth factor receptor	Homo sapiens (human)
basal plasma membrane	Epidermal growth factor receptor	Homo sapiens (human)
extracellular space	Interferon beta	Homo sapiens (human)
extracellular region	Interferon beta	Homo sapiens (human)
extracellular region	Albumin	Homo sapiens (human)
extracellular space	Albumin	Homo sapiens (human)
nucleus	Albumin	Homo sapiens (human)
endoplasmic reticulum	Albumin	Homo sapiens (human)
endoplasmic reticulum lumen	Albumin	Homo sapiens (human)
Golgi apparatus	Albumin	Homo sapiens (human)
platelet alpha granule lumen	Albumin	Homo sapiens (human)
extracellular exosome	Albumin	Homo sapiens (human)
blood microparticle	Albumin	Homo sapiens (human)
protein-containing complex	Albumin	Homo sapiens (human)
cytoplasm	Albumin	Homo sapiens (human)
peroxisomal membrane	3-hydroxy-3-methylglutaryl-coenzyme A reductase	Homo sapiens (human)
endoplasmic reticulum	3-hydroxy-3-methylglutaryl-coenzyme A reductase	Homo sapiens (human)
endoplasmic reticulum membrane	3-hydroxy-3-methylglutaryl-coenzyme A reductase	Homo sapiens (human)
endoplasmic reticulum membrane	3-hydroxy-3-methylglutaryl-coenzyme A reductase	Homo sapiens (human)
peroxisomal membrane	3-hydroxy-3-methylglutaryl-coenzyme A reductase	Homo sapiens (human)
nuclear body	Cellular tumor antigen p53	Homo sapiens (human)
nucleus	Cellular tumor antigen p53	Homo sapiens (human)
nucleoplasm	Cellular tumor antigen p53	Homo sapiens (human)
replication fork	Cellular tumor antigen p53	Homo sapiens (human)
nucleolus	Cellular tumor antigen p53	Homo sapiens (human)
cytoplasm	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrion	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrial matrix	Cellular tumor antigen p53	Homo sapiens (human)
endoplasmic reticulum	Cellular tumor antigen p53	Homo sapiens (human)
centrosome	Cellular tumor antigen p53	Homo sapiens (human)
cytosol	Cellular tumor antigen p53	Homo sapiens (human)
nuclear matrix	Cellular tumor antigen p53	Homo sapiens (human)
PML body	Cellular tumor antigen p53	Homo sapiens (human)
transcription repressor complex	Cellular tumor antigen p53	Homo sapiens (human)
site of double-strand break	Cellular tumor antigen p53	Homo sapiens (human)
germ cell nucleus	Cellular tumor antigen p53	Homo sapiens (human)
chromatin	Cellular tumor antigen p53	Homo sapiens (human)
transcription regulator complex	Cellular tumor antigen p53	Homo sapiens (human)
protein-containing complex	Cellular tumor antigen p53	Homo sapiens (human)
extracellular space	Amyloid-beta precursor protein	Homo sapiens (human)
dendrite	Amyloid-beta precursor protein	Homo sapiens (human)
extracellular region	Amyloid-beta precursor protein	Homo sapiens (human)
extracellular space	Amyloid-beta precursor protein	Homo sapiens (human)
nuclear envelope lumen	Amyloid-beta precursor protein	Homo sapiens (human)
cytoplasm	Amyloid-beta precursor protein	Homo sapiens (human)
mitochondrial inner membrane	Amyloid-beta precursor protein	Homo sapiens (human)
endosome	Amyloid-beta precursor protein	Homo sapiens (human)
early endosome	Amyloid-beta precursor protein	Homo sapiens (human)
endoplasmic reticulum	Amyloid-beta precursor protein	Homo sapiens (human)
endoplasmic reticulum lumen	Amyloid-beta precursor protein	Homo sapiens (human)
smooth endoplasmic reticulum	Amyloid-beta precursor protein	Homo sapiens (human)
Golgi apparatus	Amyloid-beta precursor protein	Homo sapiens (human)
Golgi lumen	Amyloid-beta precursor protein	Homo sapiens (human)
Golgi-associated vesicle	Amyloid-beta precursor protein	Homo sapiens (human)
cytosol	Amyloid-beta precursor protein	Homo sapiens (human)
plasma membrane	Amyloid-beta precursor protein	Homo sapiens (human)
clathrin-coated pit	Amyloid-beta precursor protein	Homo sapiens (human)
cell-cell junction	Amyloid-beta precursor protein	Homo sapiens (human)
synaptic vesicle	Amyloid-beta precursor protein	Homo sapiens (human)
cell surface	Amyloid-beta precursor protein	Homo sapiens (human)
membrane	Amyloid-beta precursor protein	Homo sapiens (human)
COPII-coated ER to Golgi transport vesicle	Amyloid-beta precursor protein	Homo sapiens (human)
axon	Amyloid-beta precursor protein	Homo sapiens (human)
growth cone	Amyloid-beta precursor protein	Homo sapiens (human)
platelet alpha granule lumen	Amyloid-beta precursor protein	Homo sapiens (human)
neuromuscular junction	Amyloid-beta precursor protein	Homo sapiens (human)
endosome lumen	Amyloid-beta precursor protein	Homo sapiens (human)
trans-Golgi network membrane	Amyloid-beta precursor protein	Homo sapiens (human)
ciliary rootlet	Amyloid-beta precursor protein	Homo sapiens (human)
dendritic spine	Amyloid-beta precursor protein	Homo sapiens (human)
dendritic shaft	Amyloid-beta precursor protein	Homo sapiens (human)
perikaryon	Amyloid-beta precursor protein	Homo sapiens (human)
membrane raft	Amyloid-beta precursor protein	Homo sapiens (human)
apical part of cell	Amyloid-beta precursor protein	Homo sapiens (human)
synapse	Amyloid-beta precursor protein	Homo sapiens (human)
perinuclear region of cytoplasm	Amyloid-beta precursor protein	Homo sapiens (human)
presynaptic active zone	Amyloid-beta precursor protein	Homo sapiens (human)
spindle midzone	Amyloid-beta precursor protein	Homo sapiens (human)
recycling endosome	Amyloid-beta precursor protein	Homo sapiens (human)
extracellular exosome	Amyloid-beta precursor protein	Homo sapiens (human)
receptor complex	Amyloid-beta precursor protein	Homo sapiens (human)
early endosome	Amyloid-beta precursor protein	Homo sapiens (human)
membrane raft	Amyloid-beta precursor protein	Homo sapiens (human)
cell surface	Amyloid-beta precursor protein	Homo sapiens (human)
Golgi apparatus	Amyloid-beta precursor protein	Homo sapiens (human)
plasma membrane	Amyloid-beta precursor protein	Homo sapiens (human)
extracellular region	Heat shock protein HSP 90-alpha	Homo sapiens (human)
nucleus	Heat shock protein HSP 90-alpha	Homo sapiens (human)
nucleoplasm	Heat shock protein HSP 90-alpha	Homo sapiens (human)
cytoplasm	Heat shock protein HSP 90-alpha	Homo sapiens (human)
mitochondrion	Heat shock protein HSP 90-alpha	Homo sapiens (human)
cytosol	Heat shock protein HSP 90-alpha	Homo sapiens (human)
plasma membrane	Heat shock protein HSP 90-alpha	Homo sapiens (human)
cell surface	Heat shock protein HSP 90-alpha	Homo sapiens (human)
membrane	Heat shock protein HSP 90-alpha	Homo sapiens (human)
basolateral plasma membrane	Heat shock protein HSP 90-alpha	Homo sapiens (human)
apical plasma membrane	Heat shock protein HSP 90-alpha	Homo sapiens (human)
brush border membrane	Heat shock protein HSP 90-alpha	Homo sapiens (human)
secretory granule lumen	Heat shock protein HSP 90-alpha	Homo sapiens (human)
melanosome	Heat shock protein HSP 90-alpha	Homo sapiens (human)
neuronal cell body	Heat shock protein HSP 90-alpha	Homo sapiens (human)
lysosomal lumen	Heat shock protein HSP 90-alpha	Homo sapiens (human)
dendritic growth cone	Heat shock protein HSP 90-alpha	Homo sapiens (human)
axonal growth cone	Heat shock protein HSP 90-alpha	Homo sapiens (human)
perinuclear region of cytoplasm	Heat shock protein HSP 90-alpha	Homo sapiens (human)
collagen-containing extracellular matrix	Heat shock protein HSP 90-alpha	Homo sapiens (human)
extracellular exosome	Heat shock protein HSP 90-alpha	Homo sapiens (human)
endocytic vesicle lumen	Heat shock protein HSP 90-alpha	Homo sapiens (human)
sperm mitochondrial sheath	Heat shock protein HSP 90-alpha	Homo sapiens (human)
sperm plasma membrane	Heat shock protein HSP 90-alpha	Homo sapiens (human)
ficolin-1-rich granule lumen	Heat shock protein HSP 90-alpha	Homo sapiens (human)
protein-containing complex	Heat shock protein HSP 90-alpha	Homo sapiens (human)
plasma membrane	Heat shock protein HSP 90-alpha	Homo sapiens (human)
neuronal cell body	Heat shock protein HSP 90-alpha	Homo sapiens (human)
perinuclear region of cytoplasm	Heat shock protein HSP 90-alpha	Homo sapiens (human)
myelin sheath	Heat shock protein HSP 90-alpha	Homo sapiens (human)
cytosol	Heat shock protein HSP 90-alpha	Homo sapiens (human)
nucleus	Heat shock protein HSP 90-alpha	Homo sapiens (human)
cytoplasm	Cytochrome P450 3A4	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 3A4	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 3A4	Homo sapiens (human)
extracellular region	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
extracellular space	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
nuclear envelope	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
nuclear envelope lumen	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
nucleoplasm	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
cytosol	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
nuclear matrix	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
nuclear membrane	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
secretory granule lumen	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
perinuclear region of cytoplasm	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
ficolin-1-rich granule lumen	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
nuclear envelope	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
extracellular region	Leukotriene A-4 hydrolase	Homo sapiens (human)
nucleoplasm	Leukotriene A-4 hydrolase	Homo sapiens (human)
cytosol	Leukotriene A-4 hydrolase	Homo sapiens (human)
extracellular exosome	Leukotriene A-4 hydrolase	Homo sapiens (human)
tertiary granule lumen	Leukotriene A-4 hydrolase	Homo sapiens (human)
ficolin-1-rich granule lumen	Leukotriene A-4 hydrolase	Homo sapiens (human)
cytosol	Leukotriene A-4 hydrolase	Homo sapiens (human)
nucleus	Leukotriene A-4 hydrolase	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 2C8	Homo sapiens (human)
plasma membrane	Cytochrome P450 2C8	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C8	Homo sapiens (human)
cytoplasm	Cytochrome P450 2C8	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C8	Homo sapiens (human)
mitochondrion	Cytochrome P450 2D6	Homo sapiens (human)
endoplasmic reticulum	Cytochrome P450 2D6	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 2D6	Homo sapiens (human)
cytoplasm	Cytochrome P450 2D6	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2D6	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 2C9	Homo sapiens (human)
plasma membrane	Cytochrome P450 2C9	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C9	Homo sapiens (human)
cytoplasm	Cytochrome P450 2C9	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C9	Homo sapiens (human)
lipid droplet	Polyunsaturated fatty acid lipoxygenase ALOX15	Homo sapiens (human)
cytosol	Polyunsaturated fatty acid lipoxygenase ALOX15	Homo sapiens (human)
plasma membrane	Polyunsaturated fatty acid lipoxygenase ALOX15	Homo sapiens (human)
cytoplasmic side of plasma membrane	Polyunsaturated fatty acid lipoxygenase ALOX15	Homo sapiens (human)
membrane	Polyunsaturated fatty acid lipoxygenase ALOX15	Homo sapiens (human)
plasma membrane	Polyunsaturated fatty acid lipoxygenase ALOX15	Homo sapiens (human)
cytosol	Polyunsaturated fatty acid lipoxygenase ALOX15	Homo sapiens (human)
cytoplasm	Polyunsaturated fatty acid lipoxygenase ALOX12	Homo sapiens (human)
cytosol	Polyunsaturated fatty acid lipoxygenase ALOX12	Homo sapiens (human)
membrane	Polyunsaturated fatty acid lipoxygenase ALOX12	Homo sapiens (human)
sarcolemma	Polyunsaturated fatty acid lipoxygenase ALOX12	Homo sapiens (human)
extracellular exosome	Polyunsaturated fatty acid lipoxygenase ALOX12	Homo sapiens (human)
cytosol	Polyunsaturated fatty acid lipoxygenase ALOX12	Homo sapiens (human)
sarcolemma	Polyunsaturated fatty acid lipoxygenase ALOX12	Homo sapiens (human)
plasma membrane	Glutamate receptor 2	Rattus norvegicus (Norway rat)
mitochondrion	Amine oxidase [flavin-containing] A	Homo sapiens (human)
mitochondrial outer membrane	Amine oxidase [flavin-containing] A	Homo sapiens (human)
cytosol	Amine oxidase [flavin-containing] A	Homo sapiens (human)
mitochondrion	Amine oxidase [flavin-containing] A	Homo sapiens (human)
female germ cell nucleus	DNA (cytosine-5)-methyltransferase 1	Homo sapiens (human)
nucleus	DNA (cytosine-5)-methyltransferase 1	Homo sapiens (human)
nucleoplasm	DNA (cytosine-5)-methyltransferase 1	Homo sapiens (human)
replication fork	DNA (cytosine-5)-methyltransferase 1	Homo sapiens (human)
pericentric heterochromatin	DNA (cytosine-5)-methyltransferase 1	Homo sapiens (human)
nucleus	DNA (cytosine-5)-methyltransferase 1	Homo sapiens (human)
mitochondrion	Amine oxidase [flavin-containing] B	Homo sapiens (human)
mitochondrial envelope	Amine oxidase [flavin-containing] B	Homo sapiens (human)
mitochondrial outer membrane	Amine oxidase [flavin-containing] B	Homo sapiens (human)
dendrite	Amine oxidase [flavin-containing] B	Homo sapiens (human)
neuronal cell body	Amine oxidase [flavin-containing] B	Homo sapiens (human)
mitochondrion	Amine oxidase [flavin-containing] B	Homo sapiens (human)
nucleus	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
cytoplasm	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
cis-Golgi network	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
cytosol	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
plasma membrane	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
cell-cell junction	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
phosphatidylinositol 3-kinase complex, class IA	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
membrane	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
perinuclear region of cytoplasm	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
perinuclear endoplasmic reticulum membrane	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
phosphatidylinositol 3-kinase complex	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
nucleus	Proteasome subunit beta type-5	Homo sapiens (human)
cytoplasm	Proteasome subunit beta type-5	Homo sapiens (human)
proteasome complex	Proteasome subunit beta type-5	Homo sapiens (human)
nucleus	Proteasome subunit beta type-5	Homo sapiens (human)
nucleoplasm	Proteasome subunit beta type-5	Homo sapiens (human)
centrosome	Proteasome subunit beta type-5	Homo sapiens (human)
cytosol	Proteasome subunit beta type-5	Homo sapiens (human)
extracellular exosome	Proteasome subunit beta type-5	Homo sapiens (human)
proteasome core complex	Proteasome subunit beta type-5	Homo sapiens (human)
proteasome core complex, beta-subunit complex	Proteasome subunit beta type-5	Homo sapiens (human)
cytosol	Proteasome subunit beta type-5	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 2C19	Homo sapiens (human)
plasma membrane	Cytochrome P450 2C19	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C19	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C19	Homo sapiens (human)
cytoplasm	Cytochrome P450 2C19	Homo sapiens (human)
nuclear inner membrane	Prostaglandin G/H synthase 2	Homo sapiens (human)
nuclear outer membrane	Prostaglandin G/H synthase 2	Homo sapiens (human)
cytoplasm	Prostaglandin G/H synthase 2	Homo sapiens (human)
endoplasmic reticulum	Prostaglandin G/H synthase 2	Homo sapiens (human)
endoplasmic reticulum lumen	Prostaglandin G/H synthase 2	Homo sapiens (human)
endoplasmic reticulum membrane	Prostaglandin G/H synthase 2	Homo sapiens (human)
caveola	Prostaglandin G/H synthase 2	Homo sapiens (human)
neuron projection	Prostaglandin G/H synthase 2	Homo sapiens (human)
protein-containing complex	Prostaglandin G/H synthase 2	Homo sapiens (human)
neuron projection	Prostaglandin G/H synthase 2	Homo sapiens (human)
cytoplasm	Prostaglandin G/H synthase 2	Homo sapiens (human)
extracellular region	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
nucleus	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
endosome	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
early endosome	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
endoplasmic reticulum	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
Golgi apparatus	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
plasma membrane	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
external side of plasma membrane	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
cell junction	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
membrane raft	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
anchoring junction	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
sorting endosome	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
plasma membrane	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
receptor complex	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
endoplasmic reticulum	Receptor-type tyrosine-protein kinase FLT3	Homo sapiens (human)
endoplasmic reticulum lumen	Receptor-type tyrosine-protein kinase FLT3	Homo sapiens (human)
plasma membrane	Receptor-type tyrosine-protein kinase FLT3	Homo sapiens (human)
endosome membrane	Receptor-type tyrosine-protein kinase FLT3	Homo sapiens (human)
receptor complex	Receptor-type tyrosine-protein kinase FLT3	Homo sapiens (human)
plasma membrane	Receptor-type tyrosine-protein kinase FLT3	Homo sapiens (human)
plasma membrane	Delta-type opioid receptor	Homo sapiens (human)
synaptic vesicle membrane	Delta-type opioid receptor	Homo sapiens (human)
dendrite membrane	Delta-type opioid receptor	Homo sapiens (human)
presynaptic membrane	Delta-type opioid receptor	Homo sapiens (human)
axon terminus	Delta-type opioid receptor	Homo sapiens (human)
spine apparatus	Delta-type opioid receptor	Homo sapiens (human)
postsynaptic density membrane	Delta-type opioid receptor	Homo sapiens (human)
neuronal dense core vesicle	Delta-type opioid receptor	Homo sapiens (human)
plasma membrane	Delta-type opioid receptor	Homo sapiens (human)
neuron projection	Delta-type opioid receptor	Homo sapiens (human)
cytosol	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
phosphatidylinositol 3-kinase complex, class IA	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
intercalated disc	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
lamellipodium	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
perinuclear region of cytoplasm	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
phosphatidylinositol 3-kinase complex	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
phosphatidylinositol 3-kinase complex, class IB	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
plasma membrane	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
cytoplasm	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
nucleus	Histone deacetylase 4	Homo sapiens (human)
nucleoplasm	Histone deacetylase 4	Homo sapiens (human)
cytoplasm	Histone deacetylase 4	Homo sapiens (human)
cytosol	Histone deacetylase 4	Homo sapiens (human)
nuclear speck	Histone deacetylase 4	Homo sapiens (human)
histone deacetylase complex	Histone deacetylase 4	Homo sapiens (human)
chromatin	Histone deacetylase 4	Homo sapiens (human)
transcription repressor complex	Histone deacetylase 4	Homo sapiens (human)
virion membrane	Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus
endoplasmic reticulum membrane	Glutamate receptor ionotropic, NMDA 2B	Rattus norvegicus (Norway rat)
plasma membrane	Glutamate receptor ionotropic, NMDA 2B	Rattus norvegicus (Norway rat)
nuclear body	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
nucleus	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
nucleoplasm	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
nucleolus	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
cytoplasm	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
cytosol	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
plasma membrane	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
transcription repressor complex	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
endocytic vesicle membrane	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
protein-containing complex	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
cell periphery	Apoptosis regulator BAX	Homo sapiens (human)
nucleus	Apoptosis regulator BAX	Homo sapiens (human)
nuclear envelope	Apoptosis regulator BAX	Homo sapiens (human)
cytoplasm	Apoptosis regulator BAX	Homo sapiens (human)
mitochondrion	Apoptosis regulator BAX	Homo sapiens (human)
mitochondrial outer membrane	Apoptosis regulator BAX	Homo sapiens (human)
endoplasmic reticulum	Apoptosis regulator BAX	Homo sapiens (human)
endoplasmic reticulum membrane	Apoptosis regulator BAX	Homo sapiens (human)
cytosol	Apoptosis regulator BAX	Homo sapiens (human)
membrane	Apoptosis regulator BAX	Homo sapiens (human)
extracellular exosome	Apoptosis regulator BAX	Homo sapiens (human)
mitochondrial permeability transition pore complex	Apoptosis regulator BAX	Homo sapiens (human)
pore complex	Apoptosis regulator BAX	Homo sapiens (human)
Bcl-2 family protein complex	Apoptosis regulator BAX	Homo sapiens (human)
BAX complex	Apoptosis regulator BAX	Homo sapiens (human)
BAK complex	Apoptosis regulator BAX	Homo sapiens (human)
mitochondrial outer membrane	Apoptosis regulator BAX	Homo sapiens (human)
plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
cell surface	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
perinuclear region of cytoplasm	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated potassium channel complex	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
inward rectifier potassium channel complex	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
extracellular region	Platelet-activating factor acetylhydrolase	Homo sapiens (human)
low-density lipoprotein particle	Platelet-activating factor acetylhydrolase	Homo sapiens (human)
high-density lipoprotein particle	Platelet-activating factor acetylhydrolase	Homo sapiens (human)
nucleus	Histone deacetylase 1	Homo sapiens (human)
nucleoplasm	Histone deacetylase 1	Homo sapiens (human)
cytoplasm	Histone deacetylase 1	Homo sapiens (human)
cytosol	Histone deacetylase 1	Homo sapiens (human)
NuRD complex	Histone deacetylase 1	Homo sapiens (human)
neuronal cell body	Histone deacetylase 1	Homo sapiens (human)
Sin3-type complex	Histone deacetylase 1	Homo sapiens (human)
histone deacetylase complex	Histone deacetylase 1	Homo sapiens (human)
chromatin	Histone deacetylase 1	Homo sapiens (human)
heterochromatin	Histone deacetylase 1	Homo sapiens (human)
transcription repressor complex	Histone deacetylase 1	Homo sapiens (human)
protein-containing complex	Histone deacetylase 1	Homo sapiens (human)
nucleus	Histone deacetylase 1	Homo sapiens (human)
nucleoplasm	Histone deacetylase 1	Rattus norvegicus (Norway rat)
nucleoplasm	Histone deacetylase 3	Rattus norvegicus (Norway rat)
nucleus	Histone deacetylase 7	Homo sapiens (human)
nucleoplasm	Histone deacetylase 7	Homo sapiens (human)
cytoplasm	Histone deacetylase 7	Homo sapiens (human)
cytosol	Histone deacetylase 7	Homo sapiens (human)
chromosome, telomeric region	Histone deacetylase 2	Homo sapiens (human)
nucleus	Histone deacetylase 2	Homo sapiens (human)
nucleoplasm	Histone deacetylase 2	Homo sapiens (human)
cytoplasm	Histone deacetylase 2	Homo sapiens (human)
NuRD complex	Histone deacetylase 2	Homo sapiens (human)
Sin3-type complex	Histone deacetylase 2	Homo sapiens (human)
histone deacetylase complex	Histone deacetylase 2	Homo sapiens (human)
chromatin	Histone deacetylase 2	Homo sapiens (human)
protein-containing complex	Histone deacetylase 2	Homo sapiens (human)
ESC/E(Z) complex	Histone deacetylase 2	Homo sapiens (human)
nucleus	Histone deacetylase 2	Homo sapiens (human)
plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
cell surface	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
intercellular canaliculus	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
nucleus	Polyamine deacetylase HDAC10	Homo sapiens (human)
nucleoplasm	Polyamine deacetylase HDAC10	Homo sapiens (human)
cytoplasm	Polyamine deacetylase HDAC10	Homo sapiens (human)
cytosol	Polyamine deacetylase HDAC10	Homo sapiens (human)
intracellular membrane-bounded organelle	Polyamine deacetylase HDAC10	Homo sapiens (human)
histone deacetylase complex	Polyamine deacetylase HDAC10	Homo sapiens (human)
nucleus	Histone deacetylase 11	Homo sapiens (human)
plasma membrane	Histone deacetylase 11	Homo sapiens (human)
histone deacetylase complex	Histone deacetylase 11	Homo sapiens (human)
extracellular region	Carboxypeptidase B2	Homo sapiens (human)
extracellular exosome	Carboxypeptidase B2	Homo sapiens (human)
extracellular space	Carboxypeptidase B2	Homo sapiens (human)
nucleus	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
nucleoplasm	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
nuclear speck	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
chromatin	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
nucleus	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
Elg1 RFC-like complex	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
nucleus	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
cytoplasm	Ataxin-2	Homo sapiens (human)
Golgi apparatus	Ataxin-2	Homo sapiens (human)
trans-Golgi network	Ataxin-2	Homo sapiens (human)
cytosol	Ataxin-2	Homo sapiens (human)
cytoplasmic stress granule	Ataxin-2	Homo sapiens (human)
membrane	Ataxin-2	Homo sapiens (human)
perinuclear region of cytoplasm	Ataxin-2	Homo sapiens (human)
ribonucleoprotein complex	Ataxin-2	Homo sapiens (human)

Bioassays (5938)

Assay ID	Title	Year	Journal	Article
AID504749	qHTS profiling for inhibitors of Plasmodium falciparum proliferation	2011	Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043	Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347124	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347119	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347117	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347121	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347111	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347109	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347127	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347113	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347110	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347118	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347126	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347116	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347129	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347112	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347128	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347123	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347122	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347125	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347114	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID977608	Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB	2005	Journal of molecular biology, Nov-18, Volume: 354, Issue:1	Crystal structure of a bacterial class 2 histone deacetylase homologue.
AID1811	Experimentally measured binding affinity data derived from PDB	2005	Journal of molecular biology, Nov-18, Volume: 354, Issue:1	Crystal structure of a bacterial class 2 histone deacetylase homologue.
AID1347160	Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347159	Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1401372	Inhibition of HDAC1 in human HeLa-S3 cell lysates preincubated for 15 mins followed by HDAC-Glo substrate addition measured after 30 to 40 mins by fluorimetric method	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
AID1702152	Metabolic stability in human liver pooled microsomes assessed as half-life at 5 uM incubated upto 60 mins in presence of beta-NADPH by LC-MS analysis	2018	Journal of medicinal chemistry, 02-22, Volume: 61, Issue:4	Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma.
AID652754	Inhibition of recombinant human HDAC10 using Fluor-de-Lys as substrate after 30 mins by spectrophotometry	2011	ACS medicinal chemistry letters, Jul-21, Volume: 2, Issue:9	Potential Agents for Treating Cystic Fibrosis: Cyclic Tetrapeptides that Restore Trafficking and Activity of ΔF508-CFTR.
AID723461	Inhibition of human HDAC8 by fluorescence assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1482122	Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay	2017	Journal of medicinal chemistry, 04-27, Volume: 60, Issue:8	Exploring Derivatives of Quinazoline Alkaloid l-Vasicine as Cap Groups in the Design and Biological Mechanistic Evaluation of Novel Antitumor Histone Deacetylase Inhibitors.
AID1478598	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	2017	European journal of medicinal chemistry, Jun-16, Volume: 133	Design, synthesis and biological evaluation of quinoline derivatives as HDAC class I inhibitors.
AID1622905	Inhibition of recombinant human His-tagged HDAC1 (482 residues) expressed in baculovirus infected insect cells using Boc Lys(Ac)-AMC as substrate preincubated for 5 mins followed by substrate addition and measured after 30 mins by fluorescence assay	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.
AID1819530	Antitumor activity against mouse B16-F10 cells implanted in C57BL/6J mouse assessed as reduction on tumor size at 60 mg/kg, IG administered for 12 days	2022	Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4	Discovery of DNA-Targeting HDAC Inhibitors with Potent Antitumor Efficacy In Vivo That Trigger Antitumor Immunity.
AID1225984	Inhibition of recombinant C-terminal His-tagged full length human HDAC2 expressed in baculovirus infected insect Sf9 cells using fluorogenic HDAC substrate 3 after 30 mins by fluorescence assay	2015	ACS medicinal chemistry letters, Mar-12, Volume: 6, Issue:3	Discovery of Novel Multiacting Topoisomerase I/II and Histone Deacetylase Inhibitors.
AID1312847	Inhibition of full length C-terminal His/FLAG-tagged human recombinant HDAC1 expressed in baculovirus infected insect Sf9 cells using Ac-peptide-AMC as substrate assessed as release of AMC preincubated for 15 mins followed by substrate addition measured a	2016	Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11	Development of Purine-Based Hydroxamic Acid Derivatives: Potent Histone Deacetylase Inhibitors with Marked in Vitro and in Vivo Antitumor Activities.
AID1630606	Inhibition of recombinant N-terminal FLAG-tagged human HDAC10 (2 to 631 residues) expressed in baculovirus expression system using fluorogenic substrate at 10 uM by fluorescence assay	2016	Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21	Synthesis and biological evaluation of santacruzamate A analogues for anti-proliferative and immunomodulatory activity.
AID723431	Potentiation of 2.5 uM cisplatin-induced toxicity in 1 uM cisplatin resistant human CAL27 cells at 1.5 uM pretreated for 48 hrs followed by 1 uM cisplatin treatment by MTT assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1200977	Inhibition of HDAC1/HDAC2/HDAC3 in human HeLa cells assessed as induction of p21 gene expression at 10 uM after 15 hrs by luciferase reporter gene assay relative to HDAC1 inhibitor SNDX-275	2015	Journal of medicinal chemistry, Mar-26, Volume: 58, Issue:6	Design and synthesis of orally bioavailable aminopyrrolidinone histone deacetylase 6 inhibitors.
AID1861334	Inhibition of HDAC in human DOHH-2 cells assessed as Down-regulation of STAT3 phosphorylation at Y705 residue at 2.5 uM measured by Western blot analysis	2022	Bioorganic & medicinal chemistry letters, 09-01, Volume: 71	Bioevaluation of a dual PI3K/HDAC inhibitor for the treatment of diffuse large B-cell lymphoma.
AID1164174	Cell cycle arrest in human K562 cells assessed as block at G1 phase at 40 uM after 24 hrs using propidium iodide staining by FACScan flow cytometry	2014	ACS medicinal chemistry letters, Sep-11, Volume: 5, Issue:9	Novel antiproliferative chimeric compounds with marked histone deacetylase inhibitory activity.
AID1832683	Antiproliferative activity against human HeLa cells assessed as inhibition of cell proliferation incubated for 48 hrs by CCK8 assay	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Cysteine derivatives as acetyl lysine mimics to inhibit zinc-dependent histone deacetylases for treating cancer.
AID1664987	Cytotoxicity against human 2C4 cells assessed as reduction in cell viability at 2000 nM incubated for 20 hrs	2020	ACS medicinal chemistry letters, Jul-09, Volume: 11, Issue:7	Selective Class I HDAC Inhibitors Based on Aryl Ketone Zinc Binding Induce HIV-1 Protein for Clearance.
AID760375	Cytotoxicity against human BxPC3 cells after 72 hrs by MTS assay	2013	ACS medicinal chemistry letters, Aug-08, Volume: 4, Issue:8	Tropolones as lead-like natural products: the development of potent and selective histone deacetylase inhibitors.
AID1548728	Inhibition of recombinant human C-terminal GST/His-tagged HDAC3 (1 to 428 residues) co-expressed with human N-terminal GST-tagged NCOR2 (395 to 489 residues) in baculovirus infected Sf9 cells using Boc-Lys(acetyl)-AMC as substrate preincubated for 1 hr fo	2020	Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10	Design of Hydrazide-Bearing HDACIs Based on Panobinostat and Their p53 and FLT3-ITD Dependency in Antileukemia Activity.
AID1164182	Inhibition of human recombinant HDAC1 using modified Boc-Lys(Ac)-AMC MAL as substrate at 5 uM after 1 hr by fluorescent activity assay	2014	ACS medicinal chemistry letters, Sep-11, Volume: 5, Issue:9	Novel antiproliferative chimeric compounds with marked histone deacetylase inhibitory activity.
AID1861253	Antiproliferative activity against human ES2 cells assessed as reduction in cell viability measured after 7 days	2022	Bioorganic & medicinal chemistry letters, 09-01, Volume: 71	Design, synthesis and antitumor activity study of PARP-1/HDAC dual targeting inhibitors.
AID476646	Antiproliferative activity against human K562 cells after 48 hrs by cell titer-glo assay	2010	Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8	Modified cap group suberoylanilide hydroxamic acid histone deacetylase inhibitor derivatives reveal improved selective antileukemic activity.
AID1859930	Inhibition of HDAC in human U-937 cells assessed as increase in acetylation level of H3K9-14ac at 10 uM measured after 24 to 48 hrs by Western blot analysis	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Azetidin-2-one-based small molecules as dual hHDAC6/HDAC8 inhibitors: Investigation of their mechanism of action and impact of dual inhibition profile on cell viability.
AID732144	Inhibition of HDAC5 (unknown origin) assessed as fluorescence intensity measured after 60 mins incubation at room temperature by trypsin-free microfluidic lab-on-a-chip assay	2013	Journal of medicinal chemistry, Feb-28, Volume: 56, Issue:4	Potent and selective inhibition of histone deacetylase 6 (HDAC6) does not require a surface-binding motif.
AID1753840	Inhibition of HDAC8 (unknown origin)	2021	European journal of medicinal chemistry, Jun-05, Volume: 218	Identification of novel 1,3-diaryl-1,2,4-triazole-capped histone deacetylase 6 inhibitors with potential anti-gastric cancer activity.
AID1915584	Inhibition of HDAC1 (unknown origin) at 0.1 microM relative to control	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors.
AID462789	Inhibition of HDAC8 expressed in Escherichia coli assessed as Boc-Lys (acetyl)-AMC substrate hydrolysis by fluorimetric assay	2010	Bioorganic & medicinal chemistry, Mar-01, Volume: 18, Issue:5	Design, synthesis and preliminary activity assay of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives as novel Histone deacetylases (HDACs) inhibitors.
AID1861311	Induction of apoptosis in human OCILY3 cells measured by flow cytometry analysis	2022	Bioorganic & medicinal chemistry letters, 09-01, Volume: 71	Bioevaluation of a dual PI3K/HDAC inhibitor for the treatment of diffuse large B-cell lymphoma.
AID1449334	Inhibition of HDAC1 in human CAL27 cells assessed as accumulation of histone 3 acetylation at 1 uM after 24 hrs by immunoblot analysis	2017	Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13	Alkoxyurea-Based Histone Deacetylase Inhibitors Increase Cisplatin Potency in Chemoresistant Cancer Cell Lines.
AID1514611	Induction of apoptosis in human HepG2 cells assessed as late apoptotic cells at 2.5 uM after 48 hrs by annexin V-FITC/propidium iodide staining based assay (Rvb = 1.8 %)	2019	Bioorganic & medicinal chemistry letters, 01-01, Volume: 29, Issue:1	Development of hydroxamate-based histone deacetylase inhibitors containing 1,2,4-oxadiazole moiety core with antitumor activities.
AID1671980	Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay	2019	Bioorganic & medicinal chemistry, 04-01, Volume: 27, Issue:7	Synthesis and biological evaluation of paclitaxel and vorinostat co-prodrugs for overcoming drug resistance in cancer therapy in vitro.
AID1128544	Inhibition of human HDAC-1 using RHKK(Ac) as substrate	2014	European journal of medicinal chemistry, Apr-09, Volume: 76	4,5,6,7-Tetrahydro-isoxazolo-[4,5-c]-pyridines as a new class of cytotoxic Hsp90 inhibitors.
AID749703	Inhibition of HDAC6 in human HeLa cells using Fluor-de-Lys as substrate after 15 mins by fluorescence assay	2013	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 23, Issue:11	Dual-acting histone deacetylase-topoisomerase I inhibitors.
AID1141816	Oral bioavailability in ICR mouse at 10 mg/kg by LC-MS/MS analysis	2014	Journal of medicinal chemistry, May-22, Volume: 57, Issue:10	Azaindolylsulfonamides, with a more selective inhibitory effect on histone deacetylase 6 activity, exhibit antitumor activity in colorectal cancer HCT116 cells.
AID723421	Potentiation of 25 uM cisplatin-induced toxicity in 1 uM cisplatin resistant human MDA-MB-231 cells at 0.5 uM pretreated for 48 hrs followed by 1 uM cisplatin treatment by MTT assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1849168	Cytotoxicity against human Jurkat cells assessed as inhibition of cell growth measured after 72 hrs by CellTiter-Glo luminescent assay	2022	Journal of medicinal chemistry, 11-24, Volume: 65, Issue:22	Development of Fluorinated Peptoid-Based Histone Deacetylase (HDAC) Inhibitors for Therapy-Resistant Acute Leukemia.
AID1816188	Inhibition of recombinant HDAC8 (unknown origin) using Ac-peptide-AMC as substrate incubated for 240 mins by microplate reader analysis
AID1231812	Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Discovery, bioactivity and docking simulation of Vorinostat analogues containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors and antitumor agents.
AID1614192	Induction of apoptosis in human MV4-11 cells assessed as necrotic cells at 1 uM after 48 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 0.17%)
AID1469378	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	2018	Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7	Discovery of N1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7 H-pyrrolo[2,3- d]pyrimidin-2-yl)amino)phenyl)- N8-hydroxyoctanediamide as a Novel Inhibitor Targeting Cyclin-dependent Kinase 4/9 (CDK4/9) and Histone Deacetlyase1 (HDAC1) against Malignant Cancer
AID297488	Cytotoxicity against human HCT116 cells	2007	Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18	2-aroylindoles and 2-aroylbenzofurans with N-hydroxyacrylamide substructures as a novel series of rationally designed histone deacetylase inhibitors.
AID1578905	Induction of apoptosis in human Bel7402 cells assessed as increase in cleaved PARP level at 5 uM after 72 hrs by Western blot analysis	2019	Journal of natural products, 06-28, Volume: 82, Issue:6	Hydroxamic Acid Derivatives of β-Carboline/Hydroxycinnamic Acid Hybrids Inducing Apoptosis and Autophagy through the PI3K/Akt/mTOR Pathways.
AID1639366	Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay	2019	Bioorganic & medicinal chemistry, 04-15, Volume: 27, Issue:8	Design, synthesis and activity evaluation of indole-based double - Branched HDAC1 inhibitors.
AID1486302	Antiproliferative activity against human MDA-MB-231 cells after 5 days by MTT assay	2017	Bioorganic & medicinal chemistry, 08-01, Volume: 25, Issue:15	Olaparib hydroxamic acid derivatives as dual PARP and HDAC inhibitors for cancer therapy.
AID1578524	Oral bioavailability in Balb/c nude mouse at 50 mg/kg measured upto 24 hrs by LC/MS/MS analysis	2020	ACS medicinal chemistry letters, Jan-09, Volume: 11, Issue:1	Class I/IIb-Selective HDAC Inhibitor Exhibits Oral Bioavailability and Therapeutic Efficacy in Acute Myeloid Leukemia.
AID1441706	Anti-inflammatory activity in BLM-induced C57BL/6 mouse model of acute lung neutrophilic inflammation assessed as reduction in number of neutrophils in BALF at 25 and 50 mg/kg, ip qd for 7 days post BLM challenge measured on day 7	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
AID1170742	Inhibition of human recombinant HDAC3 using [Ac-Leu-Gly-Lys(Ac)-AMC substrate incubated for 15 to 30 mins	2014	Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22	Methyl effect in azumamides provides insight into histone deacetylase inhibition by macrocycles.
AID1321731	Inhibition of class 1 histone deacetylase in human SH-SY5Y cells assessed as increase in histone H3K9 acetylation at 500 nM after 2 hrs by Western blot analysis relative to control	2016	Journal of medicinal chemistry, 10-13, Volume: 59, Issue:19	Design, Synthesis, and Biological Evaluation of First-in-Class Dual Acting Histone Deacetylases (HDACs) and Phosphodiesterase 5 (PDE5) Inhibitors for the Treatment of Alzheimer's Disease.
AID1548287	Induction of apoptosis in bortezomib resistant human KM3/BTZ cells assessed as necrotic cells level at 50 nM incubated for 24 hrs by Annexin V-FITC/PI staining based FCAS analysis (Rvb = 0.11%)
AID1622907	Inhibition of HDAC in human HeLa nuclear extract using Fluor-de-lys as substrate measured after 60 mins by fluorescence assay	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.
AID1730868	Cytotoxicity against human FHC cells assessed as reduction of cell viability incubated for 72 hrs by MTT assay	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Design, synthesis and evaluation of novel ErbB/HDAC multitargeted inhibitors with selectivity in EGFR
AID748110	Inhibition of HDAC5 (unknown origin) after 60 mins by fluorescence assay	2013	Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11	Discovery of the first histone deacetylase 6/8 dual inhibitors.
AID1855269	Antitumor activity against mouse MC38 cells xenografted in C57BL/6 mouse assessed as tumor growth inhibition at 100 mg/kg, ip administered every 2 days for 16 consecutive days	2022	European journal of medicinal chemistry, Nov-05, Volume: 241	Discovery of 2,5-diphenyl-1,3,4-thiadiazole derivatives as HDAC inhibitors with DNA binding affinity.
AID1469383	Induction of apoptosis in human HepG2 cells assessed as early apoptotic cells at 10 uM after 48 hrs by annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 0.3%)	2018	Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7	Discovery of N1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7 H-pyrrolo[2,3- d]pyrimidin-2-yl)amino)phenyl)- N8-hydroxyoctanediamide as a Novel Inhibitor Targeting Cyclin-dependent Kinase 4/9 (CDK4/9) and Histone Deacetlyase1 (HDAC1) against Malignant Cancer
AID1605980	Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	2020	Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8	Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors.
AID1876341	Inhibition of recombinant full length human HDAC3 expressed in insect Sf9 cells by EMSA analysis	2021	Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12	Development of HDAC Inhibitors Exhibiting Therapeutic Potential in T-Cell Prolymphocytic Leukemia.
AID586611	Antimalarial activity against Plasmodium falciparum assessed as parasites growth inhibition using giemsa staining after 24 to 56 hrs by microscopic analysis in presence of 10% human serum	2011	Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3	Ex vivo activity of histone deacetylase inhibitors against multidrug-resistant clinical isolates of Plasmodium falciparum and P. vivax.
AID1547245	Inhibition of GST-tagged BRD4 bromodomain (unknown origin) using biotinylated histone H4KAc peptide (1 to 21 residues) as substrate by HTRF assay	2020	Journal of medicinal chemistry, 04-09, Volume: 63, Issue:7	Discovery of Thieno[2,3-
AID1441704	Anti-inflammatory activity in LPS-induced C57BL/6 mouse model of acute lung injury assessed as reduction in hyperemia of pulmonary alveolar septa at 10 to 50 mg/kg, ip pretreated for 1 hr followed LPS challenge measured after 24 hrs by hematoxylin and eos	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
AID1129789	Induction of apoptosis in human Jurkat cells assessed as early apoptotic cells at 10 uM after 24 hrs by annexin V-FITC/propidium iodide staining-based FACS flow cytometric analysis (Rvb = 0.32%)	2014	Bioorganic & medicinal chemistry, Apr-01, Volume: 22, Issue:7	Studies on the antiproliferative effects of tropolone derivatives in Jurkat T-lymphocyte cells.
AID1466400	Antitumor activity against human HCT116 cells xenografted in BALB/c nude mouse assessed as tumor growth inhibition at 100 mg/kg/day administered via oral gavage for 16 days measured every 3 days	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	Selective HDAC inhibitors with potent oral activity against leukemia and colorectal cancer: Design, structure-activity relationship and anti-tumor activity study.
AID1441636	Inhibition of recombinant human N-terminal His-tagged 15-LOX-1 expressed in Escherichia coli using arachidonic acid as substrate measured every 2 min intervals for 20 mins by fluorescence analysis	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
AID1436791	Growth inhibition of human NCI-H292 cells in LDL depleted FBS containing medium after 72 hrs using compound after sonication in presence of LDL by MTT assay	2017	Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4	Synthesis of Vorinostat and cholesterol conjugate to enhance the cancer cell uptake selectivity.
AID1547262	Inhibition of human recombinant His-tagged BRD2 BD1 domain expressed in Escherichia coli BL21(DE3)-R3-pRARE2 cells by AlphaScreen assay	2020	Journal of medicinal chemistry, 04-09, Volume: 63, Issue:7	Discovery of Thieno[2,3-
AID1887683	Cytotoxicity against human AGS cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	Design, synthesis and biological evaluation of novel o-aminobenzamide derivatives as potential anti-gastric cancer agents in vitro and in vivo.
AID544091	Antimalarial activity against drug-resistant Plasmodium falciparum W2	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Antimalarial activity of phenylthiazolyl-bearing hydroxamate-based histone deacetylase inhibitors.
AID1206737	Cytotoxicity against human HEL cells assessed as growth inhibition after 48 hrs by MTT assay	2015	Journal of medicinal chemistry, May-28, Volume: 58, Issue:10	Design, synthesis, and antitumor evaluation of novel histone deacetylase inhibitors equipped with a phenylsulfonylfuroxan module as a nitric oxide donor.
AID1478586	Induction of apoptosis in human K562 cells assessed as necrotic cells at 1 uM after 24 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometry (Rvb = 0.035%)	2017	European journal of medicinal chemistry, Jun-16, Volume: 133	Design, synthesis and biological evaluation of quinoline derivatives as HDAC class I inhibitors.
AID374818	Inhibition of human C-terminal FLAG-tagged HDAC3 in HEK293 cells	2009	Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11	Discovery of a potent class I selective ketone histone deacetylase inhibitor with antitumor activity in vivo and optimized pharmacokinetic properties.
AID1063056	Inhibition of recombinant HDAC1 (unknown origin) using Fluor-de-Lys-SIRT1 as substrate by fluorescence assay	2014	Journal of natural products, Jan-24, Volume: 77, Issue:1	Protein kinase and HDAC inhibitors from the endophytic fungus Epicoccum nigrum.
AID1141763	Cytotoxicity against human H460 cells by MTT assay	2014	Journal of medicinal chemistry, May-22, Volume: 57, Issue:10	Azaindolylsulfonamides, with a more selective inhibitory effect on histone deacetylase 6 activity, exhibit antitumor activity in colorectal cancer HCT116 cells.
AID1655804	Cytotoxicity against human RH4 cells assessed as reduction in cell viability at 0.25 uM incubated for 72 hrs by CellTiter-Glo Luminescent cell viability assay relative to control	2020	ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5	Design of First-in-Class Dual EZH2/HDAC Inhibitor: Biochemical Activity and Biological Evaluation in Cancer Cells.
AID1762489	Inhibition of N-terminal GST-tagged and C-terminal His-tagged human HDAC4 (627 to 1084 residues) expressed in baculovirus infected Sf9 cells using Boc Lys(TFA)-AMC as substrate preincubated for 5 mins followed by substrate addition and further incubated f	2021	European journal of medicinal chemistry, Jul-05, Volume: 219	Synthesis and biological evaluation of phenothiazine derivative-containing hydroxamic acids as potent class II histone deacetylase inhibitors.
AID1550094	Inhibition of HDAC in human HeLa nuclear extract using Boc-Lys(acetyl)-AMC as substrate preincubated for 5 mins followed by substrate addition and measured after 30 mins by fluorescence assay	2019	Journal of medicinal chemistry, 04-25, Volume: 62, Issue:8	Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies.
AID1899586	Inhibition of HDAC class 2b in human HT-29 cells using Boc-Lys-Ac as substrate incubated for 3 hrs by microplate reader assay
AID748111	Inhibition of HDAC4 (unknown origin) after 60 mins by fluorescence assay	2013	Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11	Discovery of the first histone deacetylase 6/8 dual inhibitors.
AID760378	Cytotoxicity against human HUT78 cells after 72 hrs by MTS assay	2013	ACS medicinal chemistry letters, Aug-08, Volume: 4, Issue:8	Tropolones as lead-like natural products: the development of potent and selective histone deacetylase inhibitors.
AID1449317	Antiproliferative activity against human CAL27 cells measured after 72 hrs by MTT assay	2017	Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13	Alkoxyurea-Based Histone Deacetylase Inhibitors Increase Cisplatin Potency in Chemoresistant Cancer Cell Lines.
AID1282233	Selectivity ratio of IC50 for human recombinant HDAC8 to IC50 for human recombinant HDAC6	2016	Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4	Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
AID247931	Concentration required to inhibit human PC-3 prostate carcinoma cells	2005	Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15	A new simple and high-yield synthesis of suberoylanilide hydroxamic acid and its inhibitory effect alone or in combination with retinoids on proliferation of human prostate cancer cells.
AID463865	Inhibition of human HDAC in human HeLa cell nuclear extract after 15 mins by colorimetric assay	2010	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 20, Issue:6	SelSA, selenium analogs of SAHA as potent histone deacetylase inhibitors.
AID1865305	Antitumor immunity against mouse 4T1 cells xenografted in BALB/c syngeneic mouse model assessed as fold increase in proportion of CD8+ T cells in spleen at 40 mg/kg, po qd for 12 days by flow cytometry analysis relative to control	2022	Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18	Discovery of Novel Src Homology-2 Domain-Containing Phosphatase 2 and Histone Deacetylase Dual Inhibitors with Potent Antitumor Efficacy and Enhanced Antitumor Immunity.
AID1739585	Inhibition of HDAC6 in human HL-60 cells assessed as ratio of acetylated tubulin/GAPDH at 10 uM incubated for 4 hrs by Western blot analysis relative to DMSO	2020	European journal of medicinal chemistry, Aug-15, Volume: 200	Design, synthesis, and biological evaluation of dual targeting inhibitors of histone deacetylase 6/8 and bromodomain BRPF1.
AID1365025	Selectivity ratio of IC50 for recombinant human His-tagged HDAC6 expressed in baculovirus infected insect cells to IC50 for recombinant human HDAC1 (482 residues) expressed in baculovirus infected insect cells	2017	Bioorganic & medicinal chemistry letters, 09-15, Volume: 27, Issue:18	Rational design, synthesis and preliminary antitumor activity evaluation of a chlorambucil derivative with potent DNA/HDAC dual-targeting inhibitory activity.
AID1473740	Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1174700	Induction of apoptosis in human U937 cells assessed as late apoptotic cells at 1.5 uM after 24 hrs by annexin-V/propidium iodide staining-based flow cytometry (Rvb = 2.77%)	2015	European journal of medicinal chemistry, Jan-07, Volume: 89	Development of 3-hydroxycinnamamide-based HDAC inhibitors with potent in vitro and in vivo anti-tumor activity.
AID1762497	Inhibition of HDAC3 (unknown origin)	2021	European journal of medicinal chemistry, Jul-05, Volume: 219	Synthesis and biological evaluation of phenothiazine derivative-containing hydroxamic acids as potent class II histone deacetylase inhibitors.
AID1707465	Synergistic antifungal activity against Candida albicans 0304103 incubated for 48 hrs in presence of fluconazole by microdilution assay	2021	Journal of medicinal chemistry, 01-28, Volume: 64, Issue:2	Novel Carboline Fungal Histone Deacetylase (HDAC) Inhibitors for Combinational Treatment of Azole-Resistant Candidiasis.
AID1348917	Inhibition of C-terminal His-tagged/N-terminal GST-tagged full length recombinant human HDAC3/NcoR2 expressed in baculovirus infected Sf9 insect cells using KI 177 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Discovery of aliphatic-chain hydroxamates containing indole derivatives with potent class I histone deacetylase inhibitory activities.
AID1826592	Synergistic antiproliferative effect on HEL cells assessed as combination index at 0.0046 uM in presence of 3-Fluoro-10-hydroxy-14-methyl-8,13,13b,14-tetrahydro-7H-indolo[2',3':3,4]pyrido[2,1-b]quinazolin-5-one	2022	Journal of medicinal chemistry, 03-24, Volume: 65, Issue:6	Evodiamine-Inspired Topoisomerase-Histone Deacetylase Dual Inhibitors: Novel Orally Active Antitumor Agents for Leukemia Therapy.
AID623021	Inhibition of human HDAC8 expressed in Escherichia coli using Boc-Lys (acetyl)-AMC as substrate treated for 5 mins before substrate addition measured after 30 mins by fluorescence assay	2011	European journal of medicinal chemistry, Nov, Volume: 46, Issue:11	Design, synthesis and primary activity assay of tripeptidomimetics as histone deacetylase inhibitors with linear linker and branched cap group.
AID1055717	Antiproliferative activity against human SW620 cells after 48 hrs by SRB assay	2013	European journal of medicinal chemistry, , Volume: 70	Novel isatin-based hydroxamic acids as histone deacetylase inhibitors and antitumor agents.
AID1273878	Inhibition of human CYP2D6 using 3-[2-(N,N-diethyl-N-methylamino)ethyl]-7-methoxy-4-methylcoumarin as substrate at 10 uM after 30 mins by fluorimetric analysis	2016	European journal of medicinal chemistry, Jan-27, Volume: 108	Synthesis, biological characterization and molecular modeling insights of spirochromanes as potent HDAC inhibitors.
AID1754767	Downregulation of HDAC11 gene expression in human MCF7 cells at 3 uM incubated for 24 hrs by whole transcriptome analysis	2021	Bioorganic & medicinal chemistry, 07-15, Volume: 42	Discovery of novel class of histone deacetylase inhibitors as potential anticancer agents.
AID1201642	Inhibition of HDAC (unknown origin) using Fluor de Lys substrate after 2 hrs by microplate reader	2015	European journal of medicinal chemistry, May-05, Volume: 95	Macrocyclic compounds as anti-cancer agents: design and synthesis of multi-acting inhibitors against HDAC, FLT3 and JAK2.
AID1239052	Cytotoxicity against human HCT116 cells assessed as cell viability after 72 hrs by CCK8 assay	2015	Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17	Design, synthesis and biological evaluation of isoquinoline-based derivatives as novel histone deacetylase inhibitors.
AID156319	Inhibitory activity against PC-3 cell line	2004	Bioorganic & medicinal chemistry letters, Feb-09, Volume: 14, Issue:3	QSAR studies of PC-3 cell line inhibition activity of TSA and SAHA-like hydroxamic acids.
AID476653	Toxicity in FVB mouse assessed as effect on mean platelet volume at 50 mg/kg, po administered 5 times per week for 2 weeks measured during test (Rvb = 8.4 +/- 0.5 microm^3)	2010	Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8	Modified cap group suberoylanilide hydroxamic acid histone deacetylase inhibitor derivatives reveal improved selective antileukemic activity.
AID461258	Antiproliferative activity against human SKHEP1 cells after hrs by ATP content assay	2010	Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5	Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer.
AID717659	Inhibition of HDAC6 using Fluor-de-Lys as substrate assessed as remaining activity at 3.125 x 10'-8 M pretreated for 30 mins before substrate addition by fluorescence assay	2012	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23	The structural requirements of histone deacetylase inhibitors: suberoylanilide hydroxamic acid analogs modified at the C6 position.
AID1511152	Antiproliferative activity against human HCT116 cells incubated for 48 hrs by MTT assay	2019	ACS medicinal chemistry letters, Aug-08, Volume: 10, Issue:8	Design, Synthesis, and Biological Evaluation of 2,4-Imidazolinedione Derivatives as HDAC6 Isoform-Selective Inhibitors.
AID1550151	Antitumor activity against HEL cells xenografted in BALB/c nu mouse assessed as reduction in tumor volume at 60 mg/kg/day, ip administered for 16 days and measured every 3 days during compound dosing co-treated with 70 mg/kg/day, ip ruxolitinib by caliper	2019	Journal of medicinal chemistry, 04-25, Volume: 62, Issue:8	Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies.
AID1355710	Antifungal activity against FLC resistant Candida albicans 100 after 48 hrs in presence of fluconazol by checkerboard microdilution method	2018	Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14	Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections.
AID1415639	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	2017	MedChemComm, Jun-01, Volume: 8, Issue:6	Development of novel β-carboline-based hydroxamate derivatives as HDAC inhibitors with DNA damage and apoptosis inducing abilities.
AID1742177	Inhibition of recombinant human His-tagged HDAC1 expressed in insect cells using Ac-Leu-Gly-Lys(Ac)-AMC as substrate measured after 30 mins by fluorescence assay	2020	European journal of medicinal chemistry, Nov-01, Volume: 205	Design, synthesis and biological evaluation of novel HDAC inhibitors with improved pharmacokinetic profile in breast cancer.
AID723146	Potentiation of 40 uM cisplatin-induced toxicity in 1 uM cisplatin resistant human MDA-MB-231 cells at 1 uM pretreated for 48 hrs followed by 1 uM cisplatin treatment by MTT assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1177045	Inhibition of human HDAC6 using RHKK(Ac) as substrate by fluorimetric analysis	2015	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 25, Issue:3	Hydroxamic acid based histone deacetylase inhibitors with confirmed activity against the malaria parasite.
AID1548250	Inhibition of HDAC8 (unknown origin) pre-incubated for 5 mins before fluorogenic substrate Boc-Lys (acetyl)-AMC or Boc-Lys (triflouroacetyl)-AMC addition and measured after 30 mins by fluorescence based assay
AID1742653	Cytotoxicity against human SUM159PT cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Design and synthesis of novel Flavone-based histone deacetylase inhibitors antagonizing activation of STAT3 in breast cancer.
AID408888	Cytotoxicity against human BxPC3 cells after 72 hrs by MTT assay	2008	Journal of medicinal chemistry, Jun-26, Volume: 51, Issue:12	A series of potent and selective, triazolylphenyl-based histone deacetylases inhibitors with activity against pancreatic cancer cells and Plasmodium falciparum.
AID1177042	Inhibition of human HDAC1 using RHKK(Ac) as substrate by fluorimetric analysis	2015	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 25, Issue:3	Hydroxamic acid based histone deacetylase inhibitors with confirmed activity against the malaria parasite.
AID1563940	Inhibition of recombinant HDAC1 (unknown origin) measured after 30 mins by fluorescence assay	2019	European journal of medicinal chemistry, Oct-15, Volume: 180	Design, synthesis, and biological evaluation of a new class of histone acetyltransferase p300 inhibitors.
AID1737142	Induction of cell cycle arrest in human HCT116 cells assessed as cell accumulation at S phase at 3 uM after 24 hrs by Rnase/PI staining based flow cytometric analysis (Rvb = 25.2%)	2020	European journal of medicinal chemistry, Apr-15, Volume: 192	Design, synthesis and biological evaluation of novel indazole-based derivatives as potent HDAC inhibitors via fragment-based virtual screening.
AID618023	Antitumor activity against mouse H22 cells xenografted in Kunming mouse assessed as reduction of pulmonary metastatic nodes in lungs at 90 mg/kg, po qd for 14 days	2011	Journal of medicinal chemistry, Aug-11, Volume: 54, Issue:15	Discovery of a tetrahydroisoquinoline-based hydroxamic acid derivative (ZYJ-34c) as histone deacetylase inhibitor with potent oral antitumor activities.
AID1403154	Inhibition of HDAC6 (unknown origin)	2018	European journal of medicinal chemistry, Jan-20, Volume: 144	Development of novel β-carboline-based hydroxamate derivatives as HDAC inhibitors with antiproliferative and antimetastatic activities in human cancer cells.
AID1633989	Inhibition of HDAC1 in human HuH7 cells assessed as increase in histone H3 K9/K14 acetylation at varying concentrations incubated for 24 hrs by Western blot analysis	2019	Bioorganic & medicinal chemistry letters, 08-15, Volume: 29, Issue:16	Synthesis of N'-propylhydrazide analogs of hydroxamic inhibitors of histone deacetylases (HDACs) and evaluation of their impact on activities of HDACs and replication of hepatitis C virus (HCV).
AID1203895	Antiproliferative activity against human U937 cells assessed as inhibition of cell growth after 72 hrs by MTT-based assay	2015	European journal of medicinal chemistry, , Volume: 96	Discovery and preliminary evaluation of 2-aminobenzamide and hydroxamate derivatives containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors.
AID1848630	Cytotoxicity against human RXF 393 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay	2022	Journal of medicinal chemistry, 11-10, Volume: 65, Issue:21	First-in-Class Dual Mechanism Ferroptosis-HDAC Inhibitor Hybrids.
AID414731	Cytotoxicity against human A549 cells after 72 hrs by alamar-blue cell viability assay	2009	Journal of medicinal chemistry, Apr-23, Volume: 52, Issue:8	Design of chimeric histone deacetylase- and tyrosine kinase-inhibitors: a series of imatinib hybrides as potent inhibitors of wild-type and mutant BCR-ABL, PDGF-Rbeta, and histone deacetylases.
AID1269327	Cytotoxicity against human MCF7 cells assessed as cell growth at 25 uM measured at 72 hrs by CyQuant proliferation assay relative to control	2016	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2	Bromotyrosine-derived metabolites from an Indonesian marine sponge in the family Aplysinellidae (Order Verongiida).
AID382342	Inhibition of human HDAC in HeLa cells by flour de lys assay	2008	Bioorganic & medicinal chemistry, May-01, Volume: 16, Issue:9	Synthesis and structure-activity relationship of histone deacetylase (HDAC) inhibitors with triazole-linked cap group.
AID663390	Growth inhibition of human RXF393 cells after 72 hrs by MTS assay	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Discovery and extensive in vitro evaluations of NK-HDAC-1: a chiral histone deacetylase inhibitor as a promising lead.
AID80353	Concentration required to inhibit the partially purified HDAC enzyme by 50% obtained from H1299 cell lysate	2002	Journal of medicinal chemistry, Feb-14, Volume: 45, Issue:4	Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates.
AID729522	Inhibition of HDAC1/HDAC3/HDAC5/HDAC8 in human HeLa nuclear extract using Boc-Lys(acetyl)-AMC as substrate incubated for 5 mins prior to substrate measured after 30 mins by spectrophotometric analysis	2013	Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7	Novel leucine ureido derivatives as inhibitors of aminopeptidase N (APN).
AID1390015	Selectivity ratio of IC50 for full length recombinant human C-terminal FLAG/His-tagged HDAC1 expressed in baculovirus infected sf9 cells to IC50 for full length recombinant human N-terminal GST-tagged HDAC6 expressed in baculovirus infected sf9 cells	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Design, synthesis and biological evaluation of novel hydroxamic acid based histone deacetylase 6 selective inhibitors bearing phenylpyrazol scaffold as surface recognition motif.
AID1808554	Inhibition of recombinant human N-terminal FLAG tagged HDAC10 (2 to 631 residues) expressed in baculovirus infected Sf9 insect cells using fluorogenic substrate measured after 60 mins by FRET assay	2021	Journal of medicinal chemistry, 04-08, Volume: 64, Issue:7	Structure-Based Design of a Selective Class I Histone Deacetylase (HDAC) Near-Infrared (NIR) Probe for Epigenetic Regulation Detection in Triple-Negative Breast Cancer (TNBC).
AID1597931	Inhibition of HDAC1 (unknown origin) using Boc-Lys(Ac)-AMC as substrate incubated for 60 mins by fluorescence assay	2019	Bioorganic & medicinal chemistry letters, 09-15, Volume: 29, Issue:18	Anti-tumor activity evaluation of novel tubulin and HDAC dual-targeting inhibitors.
AID1702059	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter-Glo luminescent assay	2018	Journal of medicinal chemistry, 02-22, Volume: 61, Issue:4	Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma.
AID1739596	Antiproliferative activity against human THP-1 assessed as reduction in cell growth at 1 uM by CellTiter-non radioactive cell proliferation assay	2020	European journal of medicinal chemistry, Aug-15, Volume: 200	Design, synthesis, and biological evaluation of dual targeting inhibitors of histone deacetylase 6/8 and bromodomain BRPF1.
AID480069	Cytotoxicity against human HCT116 cells after 71 hrs by MTS assay	2010	Bioorganic & medicinal chemistry letters, May-15, Volume: 20, Issue:10	Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl)benzamides.
AID1433304	Induction of apoptosis in p53 null human U937 cells assessed as decrease in XIAP expression level by measuring ratio of XIAP to beta-actin level at 2 uM after 24 hrs by Western blot analysis relative to control	2016	Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17	Synthesis and Antileukemic Activities of Piperlongumine and HDAC Inhibitor Hybrids against Acute Myeloid Leukemia Cells.
AID711159	Inhibition of HDAC1 by fluorometric assay	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	Rapid discovery of highly potent and selective inhibitors of histone deacetylase 8 using click chemistry to generate candidate libraries.
AID1415641	Antiproliferative activity against human LoVo cells after 48 hrs by MTT assay	2017	MedChemComm, Jun-01, Volume: 8, Issue:6	Development of novel β-carboline-based hydroxamate derivatives as HDAC inhibitors with DNA damage and apoptosis inducing abilities.
AID1127327	Inhibition of human HDAC6 using fluorogenic tetrapeptide RHKKAc as substrate	2014	European journal of medicinal chemistry, May-22, Volume: 79	Influence of the adamantyl moiety on the activity of biphenylacrylohydroxamic acid-based HDAC inhibitors.
AID1203893	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth after 72 hrs by MTT-based assay	2015	European journal of medicinal chemistry, , Volume: 96	Discovery and preliminary evaluation of 2-aminobenzamide and hydroxamate derivatives containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors.
AID1404297	Antiproliferative activity against human A549 cells after 72 hrs by resazurin dye based fluorescence assay	2018	ACS medicinal chemistry letters, Feb-08, Volume: 9, Issue:2	Biocompatible Boron-Containing Prodrugs of Belinostat for the Potential Treatment of Solid Tumors.
AID1487005	Selectivity index, ratio of IC50 for HDAC8 (unknown origin) to IC50 for HDAC2 (unknown origin)	2017	Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15	The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity.
AID1605976	Antiproliferative activity against human OVCAR3 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	2020	Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8	Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors.
AID1469325	Induction of apoptosis in human MDA-MB-231 cells assessed as early apoptotic cells at 10 uM after 48 hrs by annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 0.4%)	2018	Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7	Discovery of N1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7 H-pyrrolo[2,3- d]pyrimidin-2-yl)amino)phenyl)- N8-hydroxyoctanediamide as a Novel Inhibitor Targeting Cyclin-dependent Kinase 4/9 (CDK4/9) and Histone Deacetlyase1 (HDAC1) against Malignant Cancer
AID274035	Microsome stability: percent compound remaining	2007	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2	Identification and optimisation of a series of substituted 5-pyridin-2-yl-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.
AID1260652	Cytotoxicity against human MV411 cells
AID420640	Inhibition of HDAC6 in human IGROV1 cells assessed as alpha-tubulin acetylation at IC50 after 24 hrs by Western blot	2009	European journal of medicinal chemistry, May, Volume: 44, Issue:5	Design, synthesis, and evaluation of biphenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors.
AID1547263	Inhibition of HDAC11 (unknown origin) using biotinylated histone H3 KAc peptide (1 to 21 residues) as substrate by HTRF assay	2020	Journal of medicinal chemistry, 04-09, Volume: 63, Issue:7	Discovery of Thieno[2,3-
AID1578477	Inhibition of recombinant full length human HDAC8 expressed in baculovirus infected Sf9 cells using FAM-RHKK-TFAc as substrate incubated for 3 hrs by electrophoretic mobility shift assay	2020	ACS medicinal chemistry letters, Jan-09, Volume: 11, Issue:1	Class I/IIb-Selective HDAC Inhibitor Exhibits Oral Bioavailability and Therapeutic Efficacy in Acute Myeloid Leukemia.
AID1274873	Inhibition of HDAC3 (unknown origin)	2016	European journal of medicinal chemistry, Jan-27, Volume: 108	Orally available stilbene derivatives as potent HDAC inhibitors with antiproliferative activities and antitumor effects in human tumor xenografts.
AID1275636	Inhibition of recombinant human HDAC3 using Boc-Lys(Ac)-AMC as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by fluorescence-based assay	2016	European journal of medicinal chemistry, Feb-15, Volume: 109	Identification of N-(6-mercaptohexyl)-3-(4-pyridyl)-1H-pyrazole-5-carboxamide and its disulfide prodrug as potent histone deacetylase inhibitors with in vitro and in vivo anti-tumor efficacy.
AID1861264	Selectivity index, ratio of IC50 for inhibition of HDAC3 (unknown origin) to IC50 for inhibition of HDAC6 (unknown origin)	2022	Bioorganic & medicinal chemistry letters, 09-01, Volume: 71	Design, synthesis and antitumor activity study of PARP-1/HDAC dual targeting inhibitors.
AID1293556	Antiproliferative activity against human IGROV1 cells assessed as reduction in cell number after 72 hrs by cell counter analysis	2016	European journal of medicinal chemistry, Apr-13, Volume: 112	Biphenyl-4-yl-acrylohydroxamic acids: Identification of a novel indolyl-substituted HDAC inhibitor with antitumor activity.
AID1690835	Inhibition of recombinant human N-terminal GST-tagged/C-terminal His-tagged HDAC4 (627 to 1084 residues) expressed in baculovirus expression system using Boc-Lys(TFA)-AMC as substrate preincubated for 5 mins followed by substrate addition and measured aft	2020	European journal of medicinal chemistry, Apr-15, Volume: 192	Synthesis and biological evaluation of acridine-based histone deacetylase inhibitors as multitarget agents against Alzheimer's disease.
AID274033	Inhibition of MDA-MB-231 cell proliferation (mean of two experiments)	2007	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2	Identification and optimisation of a series of substituted 5-pyridin-2-yl-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.
AID670972	Inhibition of human recombinant His6-tagged and GST-fuses HDAC6 expressed in insect High5 cells using Boc-Lys(eacetyl)- AMC as substrate after 3 hrs by fluorescence assay	2012	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14	CCLab--a multi-objective genetic algorithm based combinatorial library design software and an application for histone deacetylase inhibitor design.
AID1888417	Inhibition of fungal filamentation in azole-resistant Candida albicans 0304103 assessed as reduction in yeast-hypha transition at 64 ug/ml in presence of fluconazole by inverted microscopic analysis	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	Heat shock protein 90 (Hsp90)/Histone deacetylase (HDAC) dual inhibitors for the treatment of azoles-resistant Candida albicans.
AID1848558	Inhibition of HDAC in human NCI-H522 cells	2022	Journal of medicinal chemistry, 11-10, Volume: 65, Issue:21	First-in-Class Dual Mechanism Ferroptosis-HDAC Inhibitor Hybrids.
AID1469323	Induction of apoptosis in human MDA-MB-231 cells assessed as necrotic cells at 10 uM after 48 hrs by annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 1.97%)	2018	Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7	Discovery of N1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7 H-pyrrolo[2,3- d]pyrimidin-2-yl)amino)phenyl)- N8-hydroxyoctanediamide as a Novel Inhibitor Targeting Cyclin-dependent Kinase 4/9 (CDK4/9) and Histone Deacetlyase1 (HDAC1) against Malignant Cancer
AID456795	Inhibition of HDAC in human HeLa cell nuclear extracts after 15 mins by fluorescence assay	2010	Bioorganic & medicinal chemistry, Jan-01, Volume: 18, Issue:1	Antimalarial and antileishmanial activities of histone deacetylase inhibitors with triazole-linked cap group.
AID297487	Cytotoxicity against human HCT15 cells	2007	Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18	2-aroylindoles and 2-aroylbenzofurans with N-hydroxyacrylamide substructures as a novel series of rationally designed histone deacetylase inhibitors.
AID717791	Inhibition of HDAC3 using Fluor-de-Lys as substrate assessed as remaining activity at 1.25 x 10'-7 M pretreated for 30 mins before substrate addition by fluorescence assay	2012	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23	The structural requirements of histone deacetylase inhibitors: suberoylanilide hydroxamic acid analogs modified at the C6 position.
AID243474	Percentage inhibition against histone deacetylase of HeLa cells at 100 uM	2005	Bioorganic & medicinal chemistry letters, Jan-17, Volume: 15, Issue:2	Identification of a potent non-hydroxamate histone deacetylase inhibitor by mechanism-based drug design.
AID1548301	Induction of cell cycle arrest in bortezomib resistant human KM3/BTZ cells assessed as accumulation at S phase at 100 nM incubated for 24 hrs by propidium iodide staining based flow cytometry (Rvb = 46%)
AID308049	Inhibition of human HDAC 1	2007	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 17, Issue:14	Aminosuberoyl hydroxamic acids (ASHAs): a potent new class of HDAC inhibitors.
AID438220	Selectivity ratio of IC50 for HDAC6 to IC50 for HDAC1/2 from human HeLa cells	2009	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23	Design and synthesis of novel histone deacetylase inhibitor derived from nuclear localization signal peptide.
AID659643	Inhibition of HDAC in human DU145 cells assessed as histone H3 hyperacetylation at 2.5 to 5 uM after 24 hrs by Western blot analysis	2012	Journal of medicinal chemistry, Feb-23, Volume: 55, Issue:4	Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors.
AID744378	Inhibition of HDAC1/3/5/8 in human HeLa cell extract using Boc-Lys-(acetyl)-AMC as substrate incubated for 5 mins prior to substrate addition measured after 30 mins by fluorometric analysis	2013	Bioorganic & medicinal chemistry, May-01, Volume: 21, Issue:9	Novel indoline-2,3-dione derivatives as inhibitors of aminopeptidase N (APN).
AID723434	Potentiation of 2.5 uM cisplatin-induced toxicity in 1 uM cisplatin resistant human CAL27 cells at 0.25 uM pretreated for 48 hrs followed by 1 uM cisplatin treatment by MTT assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1170741	Inhibition of human recombinant HDAC2 using [Ac-Leu-Gly-Lys(Ac)-AMC substrate incubated for 15 to 30 mins	2014	Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22	Methyl effect in azumamides provides insight into histone deacetylase inhibition by macrocycles.
AID737907	Selectivity index, ratio of IC50 for human HS68 cells to IC50 for human A549 cells	2013	Journal of medicinal chemistry, May-09, Volume: 56, Issue:9	Design and synthesis of dual-action inhibitors targeting histone deacetylases and 3-hydroxy-3-methylglutaryl coenzyme A reductase for cancer treatment.
AID1164189	Inhibition of HDAC in human U937 cells assessed as hyperacetylation of histone H4 at Lys 16 residue at 5 uM after 24 hrs by Western blot analysis relative to control	2014	ACS medicinal chemistry letters, Sep-11, Volume: 5, Issue:9	Novel antiproliferative chimeric compounds with marked histone deacetylase inhibitory activity.
AID1348918	Inhibition of C-terminal His-tagged recombinant human HDAC8 (1 to 377 residues) expressed in baculovirus infected Sf9 insect cells using Boc-Lys(TFA)-AMC as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by fluores	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Discovery of aliphatic-chain hydroxamates containing indole derivatives with potent class I histone deacetylase inhibitory activities.
AID541646	Inhibition of human HDAC3 by fluorimetric assay	2010	Journal of medicinal chemistry, Dec-09, Volume: 53, Issue:23	Non-natural macrocyclic inhibitors of histone deacetylases: design, synthesis, and activity.
AID1182315	Antiproliferative activity against human PANC1 cells after 48 hrs by MTT assay	2014	Journal of natural products, Jul-25, Volume: 77, Issue:7	A potent HDAC inhibitor, 1-alaninechlamydocin, from a Tolypocladium sp. induces G2/M cell cycle arrest and apoptosis in MIA PaCa-2 cells.
AID616000	Antiproliferative activity against human A549 cells after 48 hrs by SRB assay	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Synthesis and evaluation of aliphatic-chain hydroxamates capped with osthole derivatives as histone deacetylase inhibitors.
AID1547270	Inhibition of HDAC1 (unknown origin) using biotinylated histone H3 KAc peptide (1 to 21 residues) as substrate by HTRF assay	2020	Journal of medicinal chemistry, 04-09, Volume: 63, Issue:7	Discovery of Thieno[2,3-
AID1821268	Antiproliferative activity against human L02 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	2022	European journal of medicinal chemistry, Feb-05, Volume: 229	Discovery of phthalazino[1,2-b]-quinazolinone derivatives as multi-target HDAC inhibitors for the treatment of hepatocellular carcinoma via activating the p53 signal pathway.
AID90342	In vitro inhibitory activity against histone deacetylase (HDAC) isolated from HeLa nuclear extract	2003	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24	Novel histone deacetylase inhibitors: design, synthesis, enzyme inhibition, and binding mode study of SAHA-based non-hydroxamates.
AID1698864	Antiproliferative against human MCF-7 cells assessed as reduction in cell viability by MTT assay	2020	Bioorganic & medicinal chemistry letters, 12-01, Volume: 30, Issue:23	Design, synthesis and biological evaluation of novel c-Met/HDAC dual inhibitors.
AID1907400	Antiproliferative activity against mouse MC38 cells after 72 hrs by CCK-8 assay	2022	European journal of medicinal chemistry, Jun-05, Volume: 236	Dual-acting antitumor agents targeting the A
AID408884	Inhibition of HDAC10	2008	Journal of medicinal chemistry, Jun-26, Volume: 51, Issue:12	A series of potent and selective, triazolylphenyl-based histone deacetylases inhibitors with activity against pancreatic cancer cells and Plasmodium falciparum.
AID1550326	Synergistic antiproliferative activity against human K562 cells assessed as reduction in cell viability after 48 hrs in presence of ruxolitinib by MTT assay	2019	Journal of medicinal chemistry, 04-25, Volume: 62, Issue:8	Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies.
AID613293	Plasma concentration in human at 800 mg/kg, po administered as single dose	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Optimization of the in vitro cardiac safety of hydroxamate-based histone deacetylase inhibitors.
AID1633995	Therapeutic index, ratio of CC50 for human HuH7 cells to EC50 for antiviral activity against HCV infected in human HuH7-luc/neo cells assessed as inhibition of DNA replication i	2019	Bioorganic & medicinal chemistry letters, 08-15, Volume: 29, Issue:16	Synthesis of N'-propylhydrazide analogs of hydroxamic inhibitors of histone deacetylases (HDACs) and evaluation of their impact on activities of HDACs and replication of hepatitis C virus (HCV).
AID1321738	Inhibition of PDE5A in human SH-SY5Y cells assessed as increase in CREB phosphorylation at Ser133 residue at 500 nM after 30 mins by Western blot analysis relative to control	2016	Journal of medicinal chemistry, 10-13, Volume: 59, Issue:19	Design, Synthesis, and Biological Evaluation of First-in-Class Dual Acting Histone Deacetylases (HDACs) and Phosphodiesterase 5 (PDE5) Inhibitors for the Treatment of Alzheimer's Disease.
AID1246509	Inhibition of HDAC3 (unknown origin) using RHKK(Ac) fluorogenic acetylated peptide substrate by fluorometric assay	2015	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 25, Issue:19	Discovery of 1-hydroxypyridine-2-thiones as selective histone deacetylase inhibitors and their potential application for treating leukemia.
AID1873387	Inhibition of HDAC7 (unknown origin)	2022	Bioorganic & medicinal chemistry letters, 08-15, Volume: 70	Comparison of three zinc binding groups for HDAC inhibitors - A potency, selectivity and enzymatic kinetics study.
AID1234889	Inhibition of HDAC3 (unknown origin) using Boc-Lys (acetyl)-AMC as substrate preincubated for 30 mins before substrate addition measured after 20 mins by UV-vis spectrophotometer analysis	2015	Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15	Design, synthesis and preliminary biological evaluation of indoline-2,3-dione derivatives as novel HDAC inhibitors.
AID527044	Cytotoxicity against human NCI-H23 by SRB assay	2010	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22	Selenium-containing analogs of SAHA induce cytotoxicity in lung cancer cells.
AID723448	Potentiation of 0.5 uM cisplatin-induced toxicity in 0.5 uM cisplatin resistant human KYSE-510 cells at 0.25 uM pretreated for 48 hrs followed by 0.5 uM cisplatin treatment by MTT assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1550327	Synergistic antiproliferative activity against human K562 cells assessed as combination index after 48 hrs in presence of ruxolitinib by MTT assay	2019	Journal of medicinal chemistry, 04-25, Volume: 62, Issue:8	Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies.
AID1873419	Inhibition of HDAC3 (unknown origin) at 5 uM preincubated for 1 hr followed by 100-fold dilution and subsequent substrate addition measured immediately	2022	Bioorganic & medicinal chemistry letters, 08-15, Volume: 70	Comparison of three zinc binding groups for HDAC inhibitors - A potency, selectivity and enzymatic kinetics study.
AID1677508	Inhibition of class 1 HDAC in human HeLa cells assessed as increase in acetylation of H3 substrate at 0.3 to 3 uM after 6 to 12 hrs by Western blot analysis	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	HDAC-Bax Multiple Ligands Enhance Bax-Dependent Apoptosis in HeLa Cells.
AID1572343	Selectivity ratio of IC50 for recombinant C-terminal His/FLAG-tagged human HDAC1 to IC50 for N-terminal GST-tagged human HDAC6	2019	Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3	Synthesis and Biological Investigation of Phenothiazine-Based Benzhydroxamic Acids as Selective Histone Deacetylase 6 Inhibitors.
AID591327	Inhibition of HDAC in human HeLa cells at 1 uM by fluorescent activity assay	2011	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8	Alkyl piperidine and piperazine hydroxamic acids as HDAC inhibitors.
AID1406984	Inhibition of HDAC6 in human NB4 cells assessed as levels of alpha-tubulin acetylation at 1 uM after 30 hrs by Western blot analysis relative to control	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Novel spiroindoline HDAC inhibitors: Synthesis, molecular modelling and biological studies.
AID1667068	Inhibition of human recombinant HDAC8 using fluorogenic HDAC substrate class 2A preincubated for 30 mins followed by substrate addition and measured after 15 mins by fluorogenic assay	2020	Bioorganic & medicinal chemistry, 03-15, Volume: 28, Issue:6	Pyrimethamine conjugated histone deacetylase inhibitors: Design, synthesis and evidence for triple negative breast cancer selective cytotoxicity.
AID1886187	Inhibition of HDAC8 in human HeLa cells using BOC-K(Ac)-AMC as substrate measured after 30 mins by fluorescence based microtiter plate reader assay	2022	Journal of medicinal chemistry, 08-25, Volume: 65, Issue:16	Discovery of a Novel Vascular Disrupting Agent Inhibiting Tubulin Polymerization and HDACs with Potent Antitumor Effects.
AID288446	Inhibition of HDAC in HeLa cells by fluorescent activity assay	2007	Journal of medicinal chemistry, May-31, Volume: 50, Issue:11	Structure-activity relationship studies of a series of novel delta-lactam-based histone deacetylase inhibitors.
AID420326	Inhibition of HDAC from human HeLa cells by fluorogenic enzyme assay	2009	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 19, Issue:13	Non-isotopic dual parameter competition assay suitable for high-throughput screening of histone deacetylases.
AID1487040	Inhibition of HDAC in human HeLa-S3 cells lysates assessed as remaining enzyme activity at 1 x 10'-7 M pre-incubated for 15 mins before HDAC-Glo I/II substrate addition and measured after 30 mins post substrate addition	2017	Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15	The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity.
AID446347	Oral bioavailability in CD1 mouse at 15 mg/kg	2010	Journal of medicinal chemistry, Jan-28, Volume: 53, Issue:2	Synthesis and biological evaluation of N-hydroxyphenylacrylamides and N-hydroxypyridin-2-ylacrylamides as novel histone deacetylase inhibitors.
AID527038	Cytotoxicity against human A549 cells by SRB assay	2010	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22	Selenium-containing analogs of SAHA induce cytotoxicity in lung cancer cells.
AID1873389	Inhibition of HDAC9 (unknown origin)	2022	Bioorganic & medicinal chemistry letters, 08-15, Volume: 70	Comparison of three zinc binding groups for HDAC inhibitors - A potency, selectivity and enzymatic kinetics study.
AID1875510	Selectivity index, ratio of IC50 for cytotoxicity against HMEC cells to GI50 for antiproliferative activity against human MDA-MB-231 cells	2022	ACS medicinal chemistry letters, Oct-13, Volume: 13, Issue:10	Cancer-Cell-Selective Targeting by Arylcyclopropylamine-Vorinostat Conjugates.
AID1203892	Antiproliferative activity against human HCT116 cells assessed as inhibition of cell growth after 72 hrs by MTT-based assay	2015	European journal of medicinal chemistry, , Volume: 96	Discovery and preliminary evaluation of 2-aminobenzamide and hydroxamate derivatives containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors.
AID481559	Cytotoxicity against human Bel7402 cells assessed as growth inhibition at 1 ug/ml after 24 hrs by MTT assay	2010	Bioorganic & medicinal chemistry letters, May-15, Volume: 20, Issue:10	Synthesis and anticancer evaluation of alpha-lipoic acid derivatives.
AID1821346	Toxicity in mouse xenografted with human HepG2 cells assessed as necrosis in spleen at 12 mg/kg, ip administered every 2 days for 4 weeks by H and E staining based microscopic method	2022	European journal of medicinal chemistry, Feb-05, Volume: 229	Discovery of phthalazino[1,2-b]-quinazolinone derivatives as multi-target HDAC inhibitors for the treatment of hepatocellular carcinoma via activating the p53 signal pathway.
AID1348912	Inhibition of class 1 HDAC in human HeLa nuclear extracts using Boc-Lys(Ac)-AMC as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by fluorescence assay	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Discovery of aliphatic-chain hydroxamates containing indole derivatives with potent class I histone deacetylase inhibitory activities.
AID1486999	Inhibition of HDAC1 (unknown origin) by ELISA-based assay	2017	Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15	The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity.
AID496805	Inhibition of human HDAC5	2010	Nature chemical biology, Mar, Volume: 6, Issue:3	Chemical phylogenetics of histone deacetylases.
AID1917530	Inhibition of HDAC1 (unknown origin) measured by fluorescence based assay	2022	Bioorganic & medicinal chemistry, 11-01, Volume: 73	Identification of PI3K/HDAC Dual-targeted inhibitors with subtype selectivity as potential therapeutic agents against solid Tumors: Building HDAC6 potency in a Quinazolinone-based PI3Kδ-selective template.
AID1441663	Anti-inflammatory activity in LPS-induced C57BL/6 mouse model of acute lung injury assessed as reduction in IL-6 mRNA level at 25 mg/kg, ip pretreated for 1 hr followed LPS challenge after 24 hrs by qRT-PCR method	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
AID659494	Inhibition of HDAC6 in human HeLa cell nuclear extract using Fluor de Lys as substrate after 15 mins by fluorometric analysis	2012	Journal of medicinal chemistry, Feb-23, Volume: 55, Issue:4	Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors.
AID1890313	Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay	2022	European journal of medicinal chemistry, Apr-05, Volume: 233	Novel biphenyl-based scaffold as potent and selective histone deacetylase 6 (HDAC6) inhibitors: Identification, development and pharmacological evaluation.
AID1783069	Antifungal activity against fluconazole-sensitive Candida albicans 10061 assessed as inhibition of fungal growth	2021	European journal of medicinal chemistry, Oct-05, Volume: 221	Lanosterol 14α-demethylase (CYP51)/histone deacetylase (HDAC) dual inhibitors for treatment of Candida tropicalis and Cryptococcus neoformans infections.
AID81711	Concentration required to inhibit the HCT116 cell growth by 50%.	2002	Journal of medicinal chemistry, Feb-14, Volume: 45, Issue:4	Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates.
AID1676599	Binding affinity to cupric ion assessed as accounting ratio by measuring total compound detected/total compound adsorbed at 2.55 umol by immobilized metal-ion affinity chromatography	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
AID1655898	Inhibition of HDAC6 in human RH4 cells assessed as acetylated alpha-tubulin level at 0.15 uM incubated for 96 hrs by Western blot analysis (Rvb = 1 No_unit)	2020	ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5	Design of First-in-Class Dual EZH2/HDAC Inhibitor: Biochemical Activity and Biological Evaluation in Cancer Cells.
AID1061950	Inhibition of human HDAC8 using RHK(Ac)K(Ac) as substrate by fluorimetric analysis	2014	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1	Lactam based 7-amino suberoylamide hydroxamic acids as potent HDAC inhibitors.
AID322418	Cell cycle arrest in human LNCap cells assessed as accumulation at S phase relative to control at 1 uM	2008	Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6	Improved synthesis of histone deacetylase inhibitors (HDIs) (MS-275 and CI-994) and inhibitory effects of HDIs alone or in combination with RAMBAs or retinoids on growth of human LNCaP prostate cancer cells and tumor xenografts.
AID1280270	Inhibition of class1 HDAC in human HeLa cells assessed as ratio of acetylated histone H3 to GAPDH level at 1 uM after 4 hrs by Western blot analysis relative to control	2016	Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4	Synthesis and Biological Investigation of Oxazole Hydroxamates as Highly Selective Histone Deacetylase 6 (HDAC6) Inhibitors.
AID348805	Antiproliferative activity against human A549 cells after 72 hrs by celltiter-blue viability assay	2008	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20	Optimization of a series of potent and selective ketone histone deacetylase inhibitors.
AID352523	Antiproliferative activity against human MIAPaCa2 cells by MTT assay	2009	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11	Isoxazole moiety in the linker region of HDAC inhibitors adjacent to the Zn-chelating group: effects on HDAC biology and antiproliferative activity.
AID1896934	Cytotoxicity against human L02 cells assessed as reduction in cell viability by CCK8 assay	2022	Bioorganic & medicinal chemistry, Nov-05, Volume: 75	Novel bioactive hybrid Celecoxib-HDAC Inhibitor, induces apoptosis in human acute lymphoblastic leukemia cells.
AID489913	Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay	2010	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 20, Issue:13	Design, synthesis and anticancer activity of piperazine hydroxamates and their histone deacetylase (HDAC) inhibitory activity.
AID1753836	Selectivity index, ratio of IC50 for inhibition of recombinant human HDAC1 to IC50 for inhibition of recombinant human HDAC6	2021	European journal of medicinal chemistry, Jun-05, Volume: 218	Identification of novel 1,3-diaryl-1,2,4-triazole-capped histone deacetylase 6 inhibitors with potential anti-gastric cancer activity.
AID1433271	Inhibition of HDAC6 in p53 null human U937 cells assessed as hyper acetylation of alpha tubulin at 1 uM after 4 hrs by Western blot analysis	2016	Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17	Synthesis and Antileukemic Activities of Piperlongumine and HDAC Inhibitor Hybrids against Acute Myeloid Leukemia Cells.
AID353357	Cell cycle arrest in human SH-SY5Y cells assessed as accumulation at G2/M phase at 3 uM after 16 hrs by flow cytometry	2009	Journal of medicinal chemistry, May-14, Volume: 52, Issue:9	Synthesis, biological evaluation, and molecular docking of Ugi products containing a zinc-chelating moiety as novel inhibitors of histone deacetylases.
AID463864	Inhibition of human HDAC in human HeLa cell nuclear extract at 50 nM after 15 mins by colorimetric assay	2010	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 20, Issue:6	SelSA, selenium analogs of SAHA as potent histone deacetylase inhibitors.
AID297499	Cytotoxicity against human CCRF-CEM cells	2007	Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18	2-aroylindoles and 2-aroylbenzofurans with N-hydroxyacrylamide substructures as a novel series of rationally designed histone deacetylase inhibitors.
AID1312883	Antitumor activity against human HCT116 cells xenografted in Balb/c nude mouse assessed as change in tumor mass at 50 mg/kg, ip administered every 2 days for 8 days measured every 2 days of compound dosing relative to control	2016	Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11	Development of Purine-Based Hydroxamic Acid Derivatives: Potent Histone Deacetylase Inhibitors with Marked in Vitro and in Vivo Antitumor Activities.
AID1466064	Inhibition of recombinant human full length HDAC8 using Fluor-de-Lys as substrate after 60 mins by spectrofluorimetric analysis	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	4-Indolyl-N-hydroxyphenylacrylamides as potent HDAC class I and IIB inhibitors in vitro and in vivo.
AID1816225	Induction of apoptosis in mouse 4T1 cells assessed as rly apoptotic cells at 5 uM measured after 48 hrs in presence of ruxolitinib by annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 1.12%)
AID526537	Growth inhibition of human NCI-H23 cells	2010	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22	Property based optimization of δ-lactam HDAC inhibitors for metabolic stability.
AID1361627	Inhibition of human recombinant full length HDAC1 using fluorogenic substrate 3 after 30 mins by fluorescence assay	2018	Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16	Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents.
AID297478	Cytotoxicity against human NCI H69 cells	2007	Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18	2-aroylindoles and 2-aroylbenzofurans with N-hydroxyacrylamide substructures as a novel series of rationally designed histone deacetylase inhibitors.
AID1234897	Antiproliferative activity against human H7402 cells after 48 hrs by MTT assay	2015	Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15	Design, synthesis and preliminary biological evaluation of indoline-2,3-dione derivatives as novel HDAC inhibitors.
AID1418667	Inhibition of recombinant human HDAC3 using fluorogenic HDAC substrate after 30 mins by fluorescence analysis	2018	Bioorganic & medicinal chemistry, 11-15, Volume: 26, Issue:21	Design, synthesis, and biological evaluation of histone deacetylase inhibitors possessing glutathione peroxidase-like and antioxidant activities against Alzheimer's disease.
AID1863424	Cytotoxicity against human NCI-H727 cells assessed as cell viability after 48 hrs by MTT assay	2022	European journal of medicinal chemistry, Oct-05, Volume: 240	Accommodation of ring C expanded deoxyvasicinone in the HDAC inhibitory pharmacophore culminates into a tractable anti-lung cancer agent and pH-responsive nanocarrier.
AID1658889	Inhibition of HDAC1 (unknown origin) using Boc-Lys(Ac)-pNA as substrate preincubated for 20 mins followed by substrate addition and further incubated for 90 mins by fluorescence assay	2020	Journal of medicinal chemistry, 07-09, Volume: 63, Issue:13	Synthesis and Anticancer Activity of Novel Actinonin Derivatives as HsPDF Inhibitors.
AID1690836	Inhibition of recombinant human C-terminal His-tagged HDAC5 (656 to 1122 residues) expressed in baculovirus infected Sf9 insect cells using fluorogenic HDAC 2A substrate preincubated for 5 mins followed by substrate addition and measured after 30 mins by	2020	European journal of medicinal chemistry, Apr-15, Volume: 192	Synthesis and biological evaluation of acridine-based histone deacetylase inhibitors as multitarget agents against Alzheimer's disease.
AID1127003	Induction of apoptosis in human U937 cells assessed as necrotic cells using annexin-V/propidium iodide staining at 0.25 uM after 24 hrs by flow cytometry analysis (Rvb = 0.06%)	2014	Journal of medicinal chemistry, Apr-24, Volume: 57, Issue:8	Discovery of the first N-hydroxycinnamamide-based histone deacetylase 1/3 dual inhibitors with potent oral antitumor activity.
AID1754752	Inhibition of C-terminal 6XHis-tagged human recombinant full length HDAC2 (1 to 488 residues) expressed in baculovirus-infected Sf9 cells assessed as reduction in 7-amino-4-methylcoumarin release measured every 5 mins by fluorescence based analysis	2021	Bioorganic & medicinal chemistry, 07-15, Volume: 42	Discovery of novel class of histone deacetylase inhibitors as potential anticancer agents.
AID1622964	Inhibition of HDAC10 (unknown origin) using (FAM)-labeled acetylated peptide as substrate measured after 17 hrs by fluorescence assay	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.
AID524988	Inhibition of HDAC7 in human homozygous Fdelta508 primary bronchial epithelial cells assessed as increase in CFTR protein level at 1 uM for 8 days by immunoblot analysis	2010	Nature chemical biology, Jan, Volume: 6, Issue:1	Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.
AID734734	Cytotoxicity against human LNCAP cells assessed as growth inhibition by MTS assay	2013	Journal of medicinal chemistry, May-09, Volume: 56, Issue:9	3-Hydroxypyridin-2-thione as novel zinc binding group for selective histone deacetylase inhibition.
AID1541565	Inhibition of class 1 HDAC in human Cal27CisR cells assessed as potentiation of cisplatin-induced cytotoxicity by measuring cisplatin IC50 at 0.5 uM preincubated for 48 hrs followed by cisplatin addition and measured after 72 hrs by MTT assay (Rvb = 63.2	2019	Journal of medicinal chemistry, 12-26, Volume: 62, Issue:24	Synthesis of Peptoid-Based Class I-Selective Histone Deacetylase Inhibitors with Chemosensitizing Properties.
AID760494	Cytotoxicity against human Hs578T cells after 48 hrs by SRB assay	2013	ACS medicinal chemistry letters, Aug-08, Volume: 4, Issue:8	Development of a chimeric c-Src kinase and HDAC inhibitor.
AID1164029	Inhibition of human recombinant HDAC5 after 60 mins by fluorimetric assay	2014	European journal of medicinal chemistry, Oct-30, Volume: 86	Design, synthesis, and biological evaluation of 1, 3-disubstituted-pyrazole derivatives as new class I and IIb histone deacetylase inhibitors.
AID1623525	Inhibition of human recombinant HDAC3 using fluorogenic HDAC substrate-3 by fluorescence assay	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	A novel class of anthraquinone-based HDAC6 inhibitors.
AID1848582	Inhibition of full length his6/FLAG-tagged human recombinant HDAC1(1 to 482 residues) expressed in Sf9 insect cells	2022	Journal of medicinal chemistry, 11-10, Volume: 65, Issue:21	First-in-Class Dual Mechanism Ferroptosis-HDAC Inhibitor Hybrids.
AID1126964	Selectivity ratio of IC50 for HDAC6 (unknown origin) to IC50 for HDAC3 (unknown origin)	2014	Journal of medicinal chemistry, Apr-24, Volume: 57, Issue:8	Discovery of the first N-hydroxycinnamamide-based histone deacetylase 1/3 dual inhibitors with potent oral antitumor activity.
AID1469333	Cytotoxicity against human T47D cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	2018	Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7	Discovery of N1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7 H-pyrrolo[2,3- d]pyrimidin-2-yl)amino)phenyl)- N8-hydroxyoctanediamide as a Novel Inhibitor Targeting Cyclin-dependent Kinase 4/9 (CDK4/9) and Histone Deacetlyase1 (HDAC1) against Malignant Cancer
AID1622965	Inhibition of HDAC6 (unknown origin) using (FAM)-labeled acetylated peptide as substrate measured after 17 hrs by fluorescence assay	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.
AID1816205	Induction of apoptosis in human MDA-MB-231 cells assessed as viable cells at 2.5 uM measured after 48 hrs by annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 85.7%)
AID628446	Induction of apoptosis in human HepG2 cells assessed as hyperacetylation of p53 after 24 hrs by Western blot analysis	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Design, synthesis, docking, and biological evaluation of novel diazide-containing isoxazole- and pyrazole-based histone deacetylase probes.
AID1578884	Antiproliferative activity against human Bel7402 cells after 72 hrs by MTT assay	2019	Journal of natural products, 06-28, Volume: 82, Issue:6	Hydroxamic Acid Derivatives of β-Carboline/Hydroxycinnamic Acid Hybrids Inducing Apoptosis and Autophagy through the PI3K/Akt/mTOR Pathways.
AID1848619	Cytotoxicity against human COLO 205 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay	2022	Journal of medicinal chemistry, 11-10, Volume: 65, Issue:21	First-in-Class Dual Mechanism Ferroptosis-HDAC Inhibitor Hybrids.
AID619048	Competitive inhibition of HDAC3 using KI-104 as substrate by fluorescence assay	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile.
AID1702091	Induction of apoptosis in human MV4-11 cells assessed as increase in caspase 3/7 activity measured at 24 hrs in presence of Z-DEVD-R110 or (Z-Asp-Glu-Val-Asp)2-rhodamine110 by fluorescence based microplate reader analysis	2018	Journal of medicinal chemistry, 02-22, Volume: 61, Issue:4	Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma.
AID461259	Antiproliferative activity against human Capan1 cells after hrs by ATP content assay	2010	Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5	Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer.
AID1361647	Induction of apoptosis in human A549 cells assessed as viable cells at 1 uM after 48 hrs by FITC-Annexin V/propidium iodide staining based flow cytometric analysis (Rvb = 93.01%)	2018	Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16	Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents.
AID1401483	Selectivity ratio of IC50 for recombinant full-length C-terminal His-tagged HDAC8 expressed in baculovirus infected Sf9 insect cell to IC50 for HDAC3 in human HeLa-S3 cell lysates	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
AID1449684	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	2017	Bioorganic & medicinal chemistry, 05-01, Volume: 25, Issue:9	Development of N-hydroxycinnamamide-based HDAC inhibitors with improved HDAC inhibitory activity and in vitro antitumor activity.
AID1550085	Antiproliferative activity against HEL cells harboring JAK2 V617F mutant assessed as reduction in cell viability after 48 hrs by MTT assay	2019	Journal of medicinal chemistry, 04-25, Volume: 62, Issue:8	Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies.
AID1653142	Cytotoxicity against human MGC803 cells assessed as reduction in cell viability	2019	European journal of medicinal chemistry, Mar-01, Volume: 165	Quinolone hybrids and their anti-cancer activities: An overview.
AID1164923	Induction of cell differentiation in human BE(2)-C cells assessed as increase in acetylated tubulin at 2 to 10 uM after 24 hrs by immunoblot method relative to vehicle-treated control	2014	Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19	Identification of a novel aminotetralin class of HDAC6 and HDAC8 selective inhibitors.
AID1900937	Toxicity in mouse bearing intracranial tumor assessed as median survival time at 25 mg/kg, ip in presence of clorgyline for 10 days (Rvb=13.8 days)	2022	Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
AID1476157	Antiproliferative activity against human KG1 cells after 48 hrs by CellTiter-Glo luminescent assay	2017	Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20	Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat.
AID1742720	Induction of apoptosis in mouse 4T1 cells assessed as early apoptotic cells at 5 uM incubated for 72 hrs by annexinV-FITC and PI staining based flow cytometry analysis (Rvb = 1.65 %)	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Design and synthesis of novel Flavone-based histone deacetylase inhibitors antagonizing activation of STAT3 in breast cancer.
AID1689777	Antiproliferative activity against human A375 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay	2020	European journal of medicinal chemistry, Mar-01, Volume: 189	Discovery of novel cyclin-dependent kinase (CDK) and histone deacetylase (HDAC) dual inhibitors with potent in vitro and in vivo anticancer activity.
AID1855259	Antiproliferative activity against human HEL cells after 48 hrs by CCK-8 assay	2022	European journal of medicinal chemistry, Nov-05, Volume: 241	Discovery of 2,5-diphenyl-1,3,4-thiadiazole derivatives as HDAC inhibitors with DNA binding affinity.
AID1266818	Inhibition of HDAC1 in human HeLa cell nuclear extract using Boc-Lys (Ac)-AMC as substrate after 60 mins by fluorometric analysis	2015	Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23	Novel β-Carboline/Hydroxamic Acid Hybrids Targeting Both Histone Deacetylase and DNA Display High Anticancer Activity via Regulation of the p53 Signaling Pathway.
AID1659650	Inhibition of HDAC6 (unknown origin)	2020	Bioorganic & medicinal chemistry letters, 06-01, Volume: 30, Issue:11	Environment-sensitive fluorescent inhibitors of histone deacetylase.
AID616005	Inhibition of HDAC6 using Boc-Lys(Ac)-AMC as substrate incubated 30 mins before substrate addition measured after 30 mins post substrate addition by fluorescence assay	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Synthesis and evaluation of aliphatic-chain hydroxamates capped with osthole derivatives as histone deacetylase inhibitors.
AID1702048	Antiproliferative activity against human PLC-PRF-5 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay	2018	Journal of medicinal chemistry, 02-22, Volume: 61, Issue:4	Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma.
AID1165114	Cytotoxicity against human LNCAP cells	2014	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 24, Issue:20	The antileishmanial activity of isoforms 6- and 8-selective histone deacetylase inhibitors.
AID1410011	Reactivation of latent HIV1 infected in human U1 cells assessed as increase in p24 production after 48 hrs by ELISA	2018	ACS medicinal chemistry letters, Mar-08, Volume: 9, Issue:3	Elimination of HIV-1 Latently Infected Cells by Gnidimacrin and a Selective HDAC Inhibitor.
AID1598137	Activation of Tat-mediated HIV1 transcription in J-Lat 10.6 cells harboring LTR driven GFP reporter co-expressing CMV driven RFP reporter assessed as maximum LTR activity at 5 uM incubated for 48 hr by FACSCalibur flow cytometry relative to control	2019	Journal of medicinal chemistry, 05-23, Volume: 62, Issue:10	Identification of 5-Substituted 2-Acylaminothiazoles That Activate Tat-Mediated Transcription in HIV-1 Latency Models.
AID1702066	Inhibition of N-terminal GST-tagged human HDAC7 (518 to end residues) expressed in baculovirus infected Sf9 cells using fluorogenic HDAC class2a as substrate measured after 30 mins by fluorescence based assay	2018	Journal of medicinal chemistry, 02-22, Volume: 61, Issue:4	Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma.
AID1422517	Inhibition of HDAC in MEF assessed as increase in histone H4K8 acetylation at 2 uM after 6 hrs by Western blot analysis	2018	European journal of medicinal chemistry, Nov-05, Volume: 159	In search of constrained FTY720 and phytosphingosine analogs as dual acting anticancer agents targeting metabolic and epigenetic pathways.
AID1515840	Inhibition of recombinant C-terminal His/FLAG-tagged HDAC1 (unknown origin) expressed in baculovirus infected Sf9 insect cells using Ac-peptide as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr	2019	Journal of medicinal chemistry, 08-08, Volume: 62, Issue:15	Design, Synthesis, and Biological Evaluation of 4-Methyl Quinazoline Derivatives as Anticancer Agents Simultaneously Targeting Phosphoinositide 3-Kinases and Histone Deacetylases.
AID1865252	Synergistic antiproliferative activity against human MV4-11 cells assessed as combination index measured in presence of SHP099 by Chou-Talalay method	2022	Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18	Discovery of Novel Src Homology-2 Domain-Containing Phosphatase 2 and Histone Deacetylase Dual Inhibitors with Potent Antitumor Efficacy and Enhanced Antitumor Immunity.
AID90687	Inhibitory concentration against maize Histone deacetylase 2	2003	Journal of medicinal chemistry, Nov-20, Volume: 46, Issue:24	Histone deacetylase inhibitors.
AID1885693	Antitumor activity at human A549 cells xenografted in BALB/c mouse assessed as reduction in tumor growth at 12 umol/kg, iv administered for 20 days and measured every 3 days for 21 days in presence of CDDO-Me	2022	Journal of medicinal chemistry, 08-11, Volume: 65, Issue:15	Redox-Activatable Theranostic Co-Prodrug for Precise Tumor Diagnosis and Selective Combination Chemotherapy.
AID1421612	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	Design and synthesis of potent dual inhibitors of JAK2 and HDAC based on fusing the pharmacophores of XL019 and vorinostat.
AID1060991	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	2014	Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1	Synthesis and anticancer activities of thieno[3,2-d]pyrimidines as novel HDAC inhibitors.
AID1401902	Inhibition of human recombinant HDAC1 using Fluor de Lys-Green as substrate preincubated for 5 mins followed by substrate addition and measured after 1 hr by fluorescence assay	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
AID723151	Potentiation of 8 uM cisplatin-induced toxicity in 5 uM cisplatin resistant human A2780 cells at 0.5 uM pretreated for 48 hrs followed by 5 uM cisplatin treatment by MTT assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1855260	Antiproliferative activity against human MOLT-4 cells after 48 hrs by CCK-8 assay	2022	European journal of medicinal chemistry, Nov-05, Volume: 241	Discovery of 2,5-diphenyl-1,3,4-thiadiazole derivatives as HDAC inhibitors with DNA binding affinity.
AID1730850	Antiproliferative activity against human NCI-H1975 cells incubated for 72 hrs by MTT assay	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Design, synthesis and evaluation of novel ErbB/HDAC multitargeted inhibitors with selectivity in EGFR
AID1759728	Inhibition of class 1 HDAC in quiescent human primary T-cell model of VSV-G pseudotyped HIV-1 latency assessed as reactivation of HIV latency incubated for 24 hrs in presence of 10% FBS by NanoGlo luciferase assay	2021	ACS medicinal chemistry letters, Apr-08, Volume: 12, Issue:4	Redefining the Histone Deacetylase Inhibitor Pharmacophore: High Potency with No Zinc Cofactor Interaction.
AID1848279	Inhibition of HDAC6 (unknown origin) at 100 nM	2022	Bioorganic & medicinal chemistry, Nov-15, Volume: 74	Design, synthesis and biological evaluation of novel pyrazinone derivatives as PI3K/HDAC dual inhibitors.
AID274027	Clearance after i.v. dosing at 1 mg kg-1	2007	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2	Identification and optimisation of a series of substituted 5-pyridin-2-yl-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.
AID1127001	Induction of apoptosis in human U937 cells assessed as late apoptotic cells using annexin-V/propidium iodide staining at 0.5 uM after 24 hrs by flow cytometry analysis (Rvb = 2.13%)	2014	Journal of medicinal chemistry, Apr-24, Volume: 57, Issue:8	Discovery of the first N-hydroxycinnamamide-based histone deacetylase 1/3 dual inhibitors with potent oral antitumor activity.
AID1246517	Inhibition of HDAC9 (unknown origin) using Boc-Lys(trifluoroacetyl)-AMC fluorogenic acetylated peptide substrate by fluorometric assay	2015	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 25, Issue:19	Discovery of 1-hydroxypyridine-2-thiones as selective histone deacetylase inhibitors and their potential application for treating leukemia.
AID1566817	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Discovery of 1,2,4-oxadiazole-Containing hydroxamic acid derivatives as histone deacetylase inhibitors potential application in cancer therapy.
AID1861329	Inhibition of HDAC in human OCILY3 cells assessed as effect on total Stat3 levels at 2.5 uM in presence of 10 uM piclitisib measured by Western blot analysis	2022	Bioorganic & medicinal chemistry letters, 09-01, Volume: 71	Bioevaluation of a dual PI3K/HDAC inhibitor for the treatment of diffuse large B-cell lymphoma.
AID775833	Inhibition of human recombinant MMP-12 using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2.AcOH as substrate at 10 uM preincubated for 30 mins prior to substrate addition measured for 30 mins by fluorescence assay relative to control	2013	Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20	Investigating the selectivity of metalloenzyme inhibitors.
AID1639368	Antiproliferative activity against human HEL cells after 48 hrs by MTT assay	2019	Bioorganic & medicinal chemistry, 04-15, Volume: 27, Issue:8	Design, synthesis and activity evaluation of indole-based double - Branched HDAC1 inhibitors.
AID1426429	Selectivity index, ratio of IC50 for HEK293 cells to IC50 for drug-sensitive Plasmodium falciparum 3D7 infected in erythrocytes	2017	European journal of medicinal chemistry, Feb-15, Volume: 127	Synthesis, biological characterisation and structure activity relationships of aromatic bisamidines active against Plasmodium falciparum.
AID1855255	Antiproliferative activity against human HeLa cells after 48 hrs by CCK-8 assay	2022	European journal of medicinal chemistry, Nov-05, Volume: 241	Discovery of 2,5-diphenyl-1,3,4-thiadiazole derivatives as HDAC inhibitors with DNA binding affinity.
AID274062	Inhibition of HDAC activity measured by HDAC Fluorescent Activity Assay (mean of two experiments)	2007	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2	Identification and optimisation of a series of substituted 5-(1H-pyrazol-3-yl)-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.
AID1702084	Antiproliferative activity against human MOLT-4 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay	2018	Journal of medicinal chemistry, 02-22, Volume: 61, Issue:4	Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma.
AID1821339	Toxicity in mouse xenografted with human HepG2 cells assessed as cellular inflammation in lung at 12 mg/kg, ip administered every 2 days for 4 weeks by H and E staining based microscopic method	2022	European journal of medicinal chemistry, Feb-05, Volume: 229	Discovery of phthalazino[1,2-b]-quinazolinone derivatives as multi-target HDAC inhibitors for the treatment of hepatocellular carcinoma via activating the p53 signal pathway.
AID328807	Antiproliferative activity against human A549 cells by CellTiter-Blue cell viability assay	2008	Journal of medicinal chemistry, Apr-24, Volume: 51, Issue:8	A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo.
AID1401537	Antiproliferative activity against human A2780 cells after 72 hrs by SRB assay	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors.
AID723139	Potentiation of 3.16 uM cisplatin-induced toxicity in 0.5 uM cisplatin resistant human KYSE-510 cells at 0.5 uM pretreated for 48 hrs followed by 0.5 uM cisplatin treatment by MTT assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID352762	Toxicity against human HCT116 cells xenografted nude mouse assessed as body weight loss at 150 mg/kg, ip administered once daily for 18 days	2009	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11	Histone deacetylase inhibitors with a primary amide zinc binding group display antitumor activity in xenograft model.
AID420515	Cell cycle arrest in cisplatin-resistant human IGROV1 cells assessed as partial accumulation at G2/M phase at IC90 using propidium-iodide staining by flow-cytometry	2009	European journal of medicinal chemistry, May, Volume: 44, Issue:5	Design, synthesis, and evaluation of biphenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors.
AID1810050	Antiproliferative activity against mouse MC38 cells measured after 72 hrs by CCK8 assay
AID1206744	Cytotoxicity against human KG1 cells assessed as growth inhibition after 48 hrs by MTT assay	2015	Journal of medicinal chemistry, May-28, Volume: 58, Issue:10	Design, synthesis, and antitumor evaluation of novel histone deacetylase inhibitors equipped with a phenylsulfonylfuroxan module as a nitric oxide donor.
AID1541444	Inhibition of human recombinant full length C-terminal His-tagged HDAC3 (1 to 428 residues)/N-terminal GST-tagged NCOR2 (395 to 489 residues) expressed in baculovirus infected Sf9 insect cells using Boc-Lys(epsilon-acetyl)-AMC as substrate incubated for 9	2019	Journal of medicinal chemistry, 12-26, Volume: 62, Issue:24	Synthesis of Peptoid-Based Class I-Selective Histone Deacetylase Inhibitors with Chemosensitizing Properties.
AID1639369	Antiproliferative activity against human U937 cells after 48 hrs by MTT assay	2019	Bioorganic & medicinal chemistry, 04-15, Volume: 27, Issue:8	Design, synthesis and activity evaluation of indole-based double - Branched HDAC1 inhibitors.
AID609490	Antiproliferative activity against human HCT116 cells	2011	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16	The design, synthesis and structure-activity relationships of novel isoindoline-based histone deacetylase inhibitors.
AID615998	Inhibition of HDAC from human HeLa nuclear extract using Boc-Lys(Ac)-AMC as substrate incubated 30 mins before substrate addition measured after 30 mins post substrate addition by fluorescence assay	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Synthesis and evaluation of aliphatic-chain hydroxamates capped with osthole derivatives as histone deacetylase inhibitors.
AID1752944	Inhibition of N-terminal GST-tagged full length human recombinant HDAC6 expressed in baculovirus infected Sf9 cells using ZMAL (Z-Lys(Ac)-AMC) fluorogenic substrate incubated for 90 mins by fluorescence based assay
AID303348	Inhibition of HDAC1 in presence of DTT	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	The first biologically active synthetic analogues of FK228, the depsipeptide histone deacetylase inhibitor.
AID723474	Cytotoxicity against cisplatin resistant human KYSE-510 cells after 72 hrs by MTT assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1266813	Antiproliferative activity against human SW480 cells assessed as cell viability after 48 hrs by MTT assay	2015	Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23	Novel β-Carboline/Hydroxamic Acid Hybrids Targeting Both Histone Deacetylase and DNA Display High Anticancer Activity via Regulation of the p53 Signaling Pathway.
AID1915595	Inhibition of HDAC8 (unknown origin)	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors.
AID331957	Increase in histone H3 acetylation in human HEK-TE cells at 5 uM after 6 hrs by Western blot analysis	2008	Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9	Identification of long chain alkylidenemalonates as novel small molecule modulators of histone acetyltransferases.
AID546548	Inhibition of human recombinant HDAC6 expressed in HEK293 cells	2010	Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24	Novel chimeric histone deacetylase inhibitors: a series of lapatinib hybrides as potent inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and histone deacetylase activity.
AID594124	Inhibition of full length HDAC2 assessed as 7-amino-4-methylcoumarin release from fluorophore conjugated substrate after 5 mins by fluorescence assay	2011	Bioorganic & medicinal chemistry letters, May-01, Volume: 21, Issue:9	Discovery of histone deacetylase 8 selective inhibitors.
AID1462230	Inhibition of BRD4 (unknown origin)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Structure-based design, synthesis and in vitro antiproliferative effects studies of novel dual BRD4/HDAC inhibitors.
AID1659234	Inhibition of human HDAC1 after 30 mins by microplate reader analysis	2020	Bioorganic & medicinal chemistry letters, 04-15, Volume: 30, Issue:8	Structural determinants of affinity and selectivity in the binding of inhibitors to histone deacetylase 6.
AID274076	Inhibition of PC3 cell proliferation (mean of two experiments)	2007	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2	Identification and optimisation of a series of substituted 5-(1H-pyrazol-3-yl)-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.
AID591331	Antiproliferative activity against human HCT116 cells after 5 days by Alamar blue assay	2011	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8	Alkyl piperidine and piperazine hydroxamic acids as HDAC inhibitors.
AID1482102	Inhibition of HDAC 5 in human HeLa nuclear extract using fluorogenic HDAC class 2A substrate measured after 60 mins by fluorometric analysis	2017	Journal of medicinal chemistry, 04-27, Volume: 60, Issue:8	Exploring Derivatives of Quinazoline Alkaloid l-Vasicine as Cap Groups in the Design and Biological Mechanistic Evaluation of Novel Antitumor Histone Deacetylase Inhibitors.
AID1233265	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability after 72 hrs by MTT assay	2015	Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11	Novel Bioactive Hybrid Compound Dual Targeting Estrogen Receptor and Histone Deacetylase for the Treatment of Breast Cancer.
AID1260643	Inhibition of human recombinant HDAC7 at 20 uM using Boc-Lys(Tfa)-AMC as substrate after 30 to 60 mins by microplate reader assay
AID392406	Inhibition of HDAC1 in human 293T cells after 16 hrs by fluorimetry	2009	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 19, Issue:2	Sulfamides as novel histone deacetylase inhibitors.
AID1401341	Inhibition of HDAC in human HeLa-S3 cell lysates preincubated for 15 mins followed by HDAC-Glo substrate addition measured after 35 mins by fluorimetric method	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
AID1401370	Inhibition of HDAC in human HeLa-S3 cell lysates assessed as residual activity at 5 x 10'-8 M preincubated for 15 mins followed by HDAC-Glo substrate addition measured after 35 mins by fluorimetric method relative to control	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
AID1246510	Inhibition of HDAC8 (unknown origin) using RHK(Ac)K(Ac) fluorogenic acetylated peptide substrate by fluorometric assay	2015	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 25, Issue:19	Discovery of 1-hydroxypyridine-2-thiones as selective histone deacetylase inhibitors and their potential application for treating leukemia.
AID1326521	Inhibition of full length recombinant human HDAC6 expressed in baculovirus expression system assessed as release of 7-amino-4-methylcoumarin by fluorogenic assay	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	2-(Phenylsulfonyl)quinoline N-hydroxyacrylamides as potent anticancer agents inhibiting histone deacetylase.
AID1431821	Selectivity ratio of IC50 for human KDAC6 to IC50 for human KDAC8	2017	European journal of medicinal chemistry, Feb-15, Volume: 127	Design and synthesis of benzodiazepine analogs as isoform-selective human lysine deacetylase inhibitors.
AID1915596	Inhibition of HDAC4 (unknown origin)	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors.
AID1622906	Inhibition of recombinant human His-tagged HDAC6 expressed in baculovirus infected insect cells using Boc Lys(Ac)-AMC as substrate preincubated for 5 mins followed by substrate addition and measured after 30 mins by fluorescence assay	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.
AID1250649	Inhibition of recombinant human HDAC10 after 60 mins by fluorescence assay	2015	Journal of medicinal chemistry, Oct-08, Volume: 58, Issue:19	Discovery of Novel Class I Histone Deacetylase Inhibitors with Promising in Vitro and in Vivo Antitumor Activities.
AID1061954	Inhibition of human HDAC2 using RHKK(Ac) as substrate by fluorimetric analysis	2014	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1	Lactam based 7-amino suberoylamide hydroxamic acids as potent HDAC inhibitors.
AID1127330	Inhibition of human HDAC9 using fluorogenic tetrapeptide RHKKAc as substrate	2014	European journal of medicinal chemistry, May-22, Volume: 79	Influence of the adamantyl moiety on the activity of biphenylacrylohydroxamic acid-based HDAC inhibitors.
AID1898917	Inhibition of HDAC1/2 in human NCI-H460 cells at 7.4 uM assessed as increase in H4 acetylation measured by Western blot analysis	2022	European journal of medicinal chemistry, Jan-15, Volume: 228	Antitumor activity of novel POLA1-HDAC11 dual inhibitors.
AID1127320	Antiproliferative activity against human HCT116 cells assessed as growth inhibition after 72 hrs	2014	European journal of medicinal chemistry, May-22, Volume: 79	Influence of the adamantyl moiety on the activity of biphenylacrylohydroxamic acid-based HDAC inhibitors.
AID1141785	Inhibition of HDAC6 in human HCT116 cells assessed as increase in HSP90 acetylation at 0.3 to 1 uM by coimmunoprecipitation analysis	2014	Journal of medicinal chemistry, May-22, Volume: 57, Issue:10	Azaindolylsulfonamides, with a more selective inhibitory effect on histone deacetylase 6 activity, exhibit antitumor activity in colorectal cancer HCT116 cells.
AID765378	Inhibition of recombinant human HDAC4 enzyme using Ac-LeuGlyLys (tfa)-AMC as substrate at 50 uM after 15 to 30 mins	2013	Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16	Total synthesis and full histone deacetylase inhibitory profiling of Azumamides A-E as well as β²- epi-Azumamide E and β³-epi-Azumamide E.
AID1177051	Antiprotozoan activity against Trypanosoma cruzi Tulahuen C4 amastigotes	2015	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 25, Issue:3	Hydroxamic acid based histone deacetylase inhibitors with confirmed activity against the malaria parasite.
AID1861663	Inhibition of HDAC1/HDAC2/HDAC3 in human HCT-116 cells assessed as increase in accumulation of acetylated histone H3 at 2000 nM measured after 48 hrs by Western blot analysis	2022	Bioorganic & medicinal chemistry letters, 09-15, Volume: 72	Exploration of 4-(1H-indol-3-yl)cyclohex-3-en-1-amine analogues as HDAC inhibitors: Design, synthesis, biological evaluation and modelling studies.
AID1623526	Inhibition of human recombinant HDAC8 using fluorogenic HDAC substrate class 2A by fluorescence assay	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	A novel class of anthraquinone-based HDAC6 inhibitors.
AID1482128	Cytotoxicity against human FR2 cells assessed as growth inhibition after 48 hrs by MTT assay	2017	Journal of medicinal chemistry, 04-27, Volume: 60, Issue:8	Exploring Derivatives of Quinazoline Alkaloid l-Vasicine as Cap Groups in the Design and Biological Mechanistic Evaluation of Novel Antitumor Histone Deacetylase Inhibitors.
AID1482133	Induction of mitochondrial membrane potential loss in human HL60 cells at 1 uM measured after 48 hrs by Rh123 dye-based flow cytometric analysis (Rvb = 5.6%)	2017	Journal of medicinal chemistry, 04-27, Volume: 60, Issue:8	Exploring Derivatives of Quinazoline Alkaloid l-Vasicine as Cap Groups in the Design and Biological Mechanistic Evaluation of Novel Antitumor Histone Deacetylase Inhibitors.
AID1855262	Induction of apoptosis in human HCT-116 cells assessed as late apoptotic cells at 1.5 uM incubated for 48 hrs by PI and annexin V-FITC staining based flow cytometry (Rvb = 3.4%)	2022	European journal of medicinal chemistry, Nov-05, Volume: 241	Discovery of 2,5-diphenyl-1,3,4-thiadiazole derivatives as HDAC inhibitors with DNA binding affinity.
AID1129007	Inhibition of human HDAC-5 using RHKK(Ac) as substrate by fluorescence assay	2014	Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6	Synthesis and evaluation of new Hsp90 inhibitors based on a 1,4,5-trisubstituted 1,2,3-triazole scaffold.
AID1548267	Induction of cell cycle arrest in human KM3 cells assessed as reduction in cell cycle progression in S phase at 100 nM incubated for 24 hrs by propidium iodide staining based flow cytometry
AID1816226	Induction of apoptosis in mouse 4T1 cells assessed as late apoptotic cells at 5 uM measured after 48 hrs in presence of ruxolitinib by annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 4.99%)
AID628437	Inhibition of human recombinant HDAC1 using fluorophore-conjugated substrate Boc-L-Lys(Ac)-AMC after 60 mins	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Design, synthesis, docking, and biological evaluation of novel diazide-containing isoxazole- and pyrazole-based histone deacetylase probes.
AID1478599	Inhibition of Class 1 histone deacetylase in human K562 cells using Boc-Lys (acetyl)-AMC as substrate preincubated with compound for 3 hrs followed by substrate addition measured after 3 hrs by fluorometric analysis	2017	European journal of medicinal chemistry, Jun-16, Volume: 133	Design, synthesis and biological evaluation of quinoline derivatives as HDAC class I inhibitors.
AID274020	Clearance after i.v. dosing at 1 mg kg-1	2007	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2	Identification and optimisation of a series of substituted 5-pyridin-2-yl-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.
AID1165116	Cytotoxicity against human Jurkat gamma1 cells	2014	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 24, Issue:20	The antileishmanial activity of isoforms 6- and 8-selective histone deacetylase inhibitors.
AID316879	Inhibition of human CEM cells assessed as viability	2008	Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6	Histone deacetylase inhibitors: from bench to clinic.
AID1462222	Antiproliferative activity against human OCI-AML2 cells after 72 hrs by MTT assay	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Structure-based design, synthesis and in vitro antiproliferative effects studies of novel dual BRD4/HDAC inhibitors.
AID593556	Inhibition of human HDAC11 using ArgHisLysLys(Ac) fluorogenic peptide as a substrate by fluorimetric assay	2011	Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7	Oxime amides as a novel zinc binding group in histone deacetylase inhibitors: synthesis, biological activity, and computational evaluation.
AID1348920	Inhibition of full length recombinant human HDAC5 preincubated for 5 mins followed by substrate addition measured after 30 mins by fluorescence assay	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Discovery of aliphatic-chain hydroxamates containing indole derivatives with potent class I histone deacetylase inhibitory activities.
AID1689778	Antiproliferative activity against human Hela cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay	2020	European journal of medicinal chemistry, Mar-01, Volume: 189	Discovery of novel cyclin-dependent kinase (CDK) and histone deacetylase (HDAC) dual inhibitors with potent in vitro and in vivo anticancer activity.
AID1129780	Cell cycle arrest in human Jurkat cells assessed as accumulation at G0/G1-phase at 10 uM after 24 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 2.39%)	2014	Bioorganic & medicinal chemistry, Apr-01, Volume: 22, Issue:7	Studies on the antiproliferative effects of tropolone derivatives in Jurkat T-lymphocyte cells.
AID1816222	Induction of apoptosis in mouse 4T1 cells assessed as late apoptotic cells at 5 uM measured after 48 hrs by annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 4.99%)
AID1600659	Inhibition of recombinant human full length C-terminal Flag/His-tagged HDAC1 expressed in baculovirus infected Sf9 cells using ZMAL as substrate incubated for 90 mins by fluorometric method	2019	Bioorganic & medicinal chemistry, 10-01, Volume: 27, Issue:19	Fluorescent analogs of peptoid-based HDAC inhibitors: Synthesis, biological activity and cellular uptake kinetics.
AID1848564	Cytotoxicity against human WI-38 cells assessed as reduction in cell survival incubated for 30 mins by methylene blue staining based analysis	2022	Journal of medicinal chemistry, 11-10, Volume: 65, Issue:21	First-in-Class Dual Mechanism Ferroptosis-HDAC Inhibitor Hybrids.
AID344920	Inhibition of HDAC1	2008	Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22	Inhibitor scaffolds for 2-oxoglutarate-dependent histone lysine demethylases.
AID1200971	Inhibition of HDAC1 (unknown origin) using RHKK(Ac)AMC as substrate	2015	Journal of medicinal chemistry, Mar-26, Volume: 58, Issue:6	Design and synthesis of orally bioavailable aminopyrrolidinone histone deacetylase 6 inhibitors.
AID420514	Cell cycle arrest in cisplatin-resistant human IGROV1 cells assessed as partial accumulation at G2/M phase at IC80 using propidium-iodide staining by flow-cytometry	2009	European journal of medicinal chemistry, May, Volume: 44, Issue:5	Design, synthesis, and evaluation of biphenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors.
AID541652	Inhibition of human HDAC6 by fluorimetric assay	2010	Journal of medicinal chemistry, Dec-09, Volume: 53, Issue:23	Non-natural macrocyclic inhibitors of histone deacetylases: design, synthesis, and activity.
AID1246508	Inhibition of HDAC2 (unknown origin) using RHKK(Ac) fluorogenic acetylated peptide substrate by fluorometric assay	2015	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 25, Issue:19	Discovery of 1-hydroxypyridine-2-thiones as selective histone deacetylase inhibitors and their potential application for treating leukemia.
AID1452274	Inhibition of HDAC6 (unknown origin) preincubated for 15 mins followed by substrate addition measured after 60 mins by fluorescence assay	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	Design, synthesis and anticancer potential of NSC-319745 hydroxamic acid derivatives as DNMT and HDAC inhibitors.
AID420643	Inhibition of HDAC6 in human IGROV1 cells assessed as alpha-tubulin acetylation at IC80 after 48 hrs by Western blot	2009	European journal of medicinal chemistry, May, Volume: 44, Issue:5	Design, synthesis, and evaluation of biphenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors.
AID1336950	Induction of cell cycle arrest in human LNCAP cells assessed as accumulation at greater G2 phase at 2.5 uM after 24 hrs by propidium iodide staining based FACS analysis (Rvb = 0.20%)	2017	Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3	Bifunctional conjugates with potent inhibitory activity towards cyclooxygenase and histone deacetylase.
AID1349716	Inhibition of recombinant human full length C-terminal flag-tagged HDAC6 expressed in baculovirus infected Sf9 insect cells after 30 mins by fluorescence assay	2018	ACS medicinal chemistry letters, Jan-11, Volume: 9, Issue:1	Dual NAMPT/HDAC Inhibitors as a New Strategy for Multitargeting Antitumor Drug Discovery.
AID1742744	Genotoxicity in Salmonella typhimurium TA1537 by Ames test	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Design and synthesis of novel Flavone-based histone deacetylase inhibitors antagonizing activation of STAT3 in breast cancer.
AID1742186	Inhibition of recombinant human N-terminal His-tagged HDAC11 expressed in baculovirus infected Sf9 insect cells using Ac-Arg-His-Lys(Ac)-Lys(Ac)-AMC as substrate measured after 30 mins by fluorescence assay	2020	European journal of medicinal chemistry, Nov-01, Volume: 205	Design, synthesis and biological evaluation of novel HDAC inhibitors with improved pharmacokinetic profile in breast cancer.
AID1572358	Induction of apoptosis in human T24 cells at 1 to 10 uM after 48 hrs by propidium iodide-staining based FACS analysis	2019	Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3	Synthesis and Biological Investigation of Phenothiazine-Based Benzhydroxamic Acids as Selective Histone Deacetylase 6 Inhibitors.
AID1667099	Cell cycle arrest in human MDA-MB-231 cells assessed as accumulation of cells at G2 phase at 5 uM incubated for 48 hrs RNase/PI staining based flow cytometry assay (Rvb = 17.4 %)	2020	Bioorganic & medicinal chemistry, 03-15, Volume: 28, Issue:6	Pyrimethamine conjugated histone deacetylase inhibitors: Design, synthesis and evidence for triple negative breast cancer selective cytotoxicity.
AID525029	Inhibition of HDAC7 in human homozygous Fdelta508 primary bronchial epithelial cells assessed as increase in forskolin and genistein-stimulated Fdelta508 CFTR channel activity at 10 uM after 24 hrs relative to control	2010	Nature chemical biology, Jan, Volume: 6, Issue:1	Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.
AID288455	Inhibition of tumor growth in MDA-MB-231 cells xenografted BALA/c nude mouse at 30 mg/kg, ip	2007	Journal of medicinal chemistry, May-31, Volume: 50, Issue:11	Structure-activity relationship studies of a series of novel delta-lactam-based histone deacetylase inhibitors.
AID1162484	Inhibition of HDAC1 (unknown origin) using Boc-Lys(Ac)-AMC as substrate by fluorescence assay	2014	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 24, Issue:19	Design, synthesis and evaluation of novel HDAC inhibitors as potential antitumor agents.
AID420505	Antiproliferative activity against human IGROV1 cells after 72 hrs	2009	European journal of medicinal chemistry, May, Volume: 44, Issue:5	Design, synthesis, and evaluation of biphenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors.
AID1384235	Effective permeability of the compound at 50 uM after 18 hrs by UV spectroscopy based PAMPA	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease.
AID1280281	Selectivity index, ratio of HDAC6 inhibition in human HL60 cells assessed as ratio of acetylated tubulin to GAPDH level at 10 uM over class1 HDAC inhibition in human HL60 cells assessed as ratio of acetylated histone H3 to GAPDH level at 10 uM	2016	Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4	Synthesis and Biological Investigation of Oxazole Hydroxamates as Highly Selective Histone Deacetylase 6 (HDAC6) Inhibitors.
AID1349715	Inhibition of human recombinant HDAC3/GST-tagged NCOR1 DAD (397 to 503 residues) expressed in baculovirus expression system after 30 mins by fluorescence assay	2018	ACS medicinal chemistry letters, Jan-11, Volume: 9, Issue:1	Dual NAMPT/HDAC Inhibitors as a New Strategy for Multitargeting Antitumor Drug Discovery.
AID273167	Inhibition of maize HD1A	2006	Journal of medicinal chemistry, Oct-05, Volume: 49, Issue:20	Synthesis and biological properties of novel, uracil-containing histone deacetylase inhibitors.
AID1128560	Inhibition of human HDAC-7 using RHKK(Ac) as substrate	2014	European journal of medicinal chemistry, Apr-09, Volume: 76	4,5,6,7-Tetrahydro-isoxazolo-[4,5-c]-pyridines as a new class of cytotoxic Hsp90 inhibitors.
AID1541449	Cytotoxicity against human A2780 cells assessed as reduction in cell survival measured after 72 hrs by MTT assay	2019	Journal of medicinal chemistry, 12-26, Volume: 62, Issue:24	Synthesis of Peptoid-Based Class I-Selective Histone Deacetylase Inhibitors with Chemosensitizing Properties.
AID1816236	Antitumor activity in human MDA-MB-231 cells xenografted in BALB/c mouse assessed as tumor growth inhibition at 100 mg/kg, po administered daily for 14 days measured twice per week
AID273177	Induction of granulocytic differentiation of U937 cells measured as CD11c expression level after 48 hrs at 5 uM	2006	Journal of medicinal chemistry, Oct-05, Volume: 49, Issue:20	Synthesis and biological properties of novel, uracil-containing histone deacetylase inhibitors.
AID1816171	Inhibition of JAK/STAT pathway in human MDA-MB-231 cells at 3 to 10 uM incubated for 12 hrs in presence of INCB by chemiluminescence based Western blotting analysis
AID1274879	Inhibition of HDAC9 (unknown origin)	2016	European journal of medicinal chemistry, Jan-27, Volume: 108	Orally available stilbene derivatives as potent HDAC inhibitors with antiproliferative activities and antitumor effects in human tumor xenografts.
AID1275632	Inhibition of HDAC in human HeLa cell nuclear extract using Boc-Lys(Ac)-AMC as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by fluorescence-based assay	2016	European journal of medicinal chemistry, Feb-15, Volume: 109	Identification of N-(6-mercaptohexyl)-3-(4-pyridyl)-1H-pyrazole-5-carboxamide and its disulfide prodrug as potent histone deacetylase inhibitors with in vitro and in vivo anti-tumor efficacy.
AID1742722	Induction of apoptosis in mouse 4T1 cells assessed as necrotic cells at 5 uM incubated for 72 hrs by annexinV-FITC and PI staining based flow cytometry analysis (Rvb = 5.00 %)	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Design and synthesis of novel Flavone-based histone deacetylase inhibitors antagonizing activation of STAT3 in breast cancer.
AID1873410	Inhibition of HDAC3 (unknown origin) preincubated for 30 mins	2022	Bioorganic & medicinal chemistry letters, 08-15, Volume: 70	Comparison of three zinc binding groups for HDAC inhibitors - A potency, selectivity and enzymatic kinetics study.
AID1235256	Inhibition of HDAC1/2 in human HeLa cell nuclear extracts preincubated for 5 mins followed by substrate addition measured after 0.5 hrs by Color de Lys assay	2015	Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15	Design, synthesis and preliminary bioactivity evaluations of substituted quinoline hydroxamic acid derivatives as novel histone deacetylase (HDAC) inhibitors.
AID1486998	Inhibition of HDAC in human HeLa-S3 cells lysates pre-incubated for 15 mins before HDAC-Glo I/II substrate addition and measured after 30 mins post substrate addition	2017	Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15	The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity.
AID1548256	Inhibition of class 1 HDAC n human HeLa cell nuclear extracts pre-incubated for 5 mins before fluorogenic substrate Boc-Lys (acetyl)-AMC addition and measured after 30 mins by fluorescence based assay
AID1653099	Antiproliferative activity against human HeLa cells by CCK8 assay	2019	European journal of medicinal chemistry, Mar-01, Volume: 165	Quinolone hybrids and their anti-cancer activities: An overview.
AID1885673	Synergistic antiproliferative activity against human L02 cells at 2.5 to 12.5 uM measured after 72 hrs in presence of CDDO-Me by MTT assay	2022	Journal of medicinal chemistry, 08-11, Volume: 65, Issue:15	Redox-Activatable Theranostic Co-Prodrug for Precise Tumor Diagnosis and Selective Combination Chemotherapy.
AID723159	Potentiation of 5 uM cisplatin-induced toxicity in 1 uM cisplatin resistant human CAL27 cells at 0.5 uM pretreated for 48 hrs followed by 1 uM cisplatin treatment by MTT assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1548726	Inhibition of recombinant HDAC1 (unknown origin) using Boc-Lys(acetyl)-AMC as substrate preincubated for 1 hr followed by substrate addition and measured after 2 hrs by fluorescence based micro plate reader analysis	2020	Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10	Design of Hydrazide-Bearing HDACIs Based on Panobinostat and Their p53 and FLT3-ITD Dependency in Antileukemia Activity.
AID1769652	Inhibition of ALK L1196M mutant (unknown origin)	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	Discovery of 2,4-pyrimidinediamine derivatives as potent dual inhibitors of ALK and HDAC.
AID1441677	Anti-inflammatory activity in BLM-induced C57BL/6 mouse model of acute lung neutrophilic inflammation assessed as reduction neutrophil count at 25 mg/kg, ip qd for 7 days post BLM challenge measured on day 7	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
AID1821276	Antiproliferative activity against human RS4-11 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	2022	European journal of medicinal chemistry, Feb-05, Volume: 229	Discovery of phthalazino[1,2-b]-quinazolinone derivatives as multi-target HDAC inhibitors for the treatment of hepatocellular carcinoma via activating the p53 signal pathway.
AID297493	Cytotoxicity against human Hec-1-A cells	2007	Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18	2-aroylindoles and 2-aroylbenzofurans with N-hydroxyacrylamide substructures as a novel series of rationally designed histone deacetylase inhibitors.
AID1826642	Induction of apoptosis in HEL cells assessed as apoptotic cells at 0.5 uM incubated for 48 hrs by annexin V-FITC/PI staining based flow cytometry (Rvb = 4.23%)	2022	Journal of medicinal chemistry, 03-24, Volume: 65, Issue:6	Evodiamine-Inspired Topoisomerase-Histone Deacetylase Dual Inhibitors: Novel Orally Active Antitumor Agents for Leukemia Therapy.
AID221993	Compound was tested for anti-proliferative activity in human bone marrow cells	2004	Bioorganic & medicinal chemistry letters, Jan-19, Volume: 14, Issue:2	Design, synthesis, and activity of HDAC inhibitors with a N-formyl hydroxylamine head group.
AID1511150	Antiproliferative activity against human HL60 cells incubated for 48 hrs by MTT assay	2019	ACS medicinal chemistry letters, Aug-08, Volume: 10, Issue:8	Design, Synthesis, and Biological Evaluation of 2,4-Imidazolinedione Derivatives as HDAC6 Isoform-Selective Inhibitors.
AID1677520	Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	HDAC-Bax Multiple Ligands Enhance Bax-Dependent Apoptosis in HeLa Cells.
AID1177050	Antiprotozoan activity against Trypanosoma brucei rhodesiense STIB 900 trypomastigotes	2015	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 25, Issue:3	Hydroxamic acid based histone deacetylase inhibitors with confirmed activity against the malaria parasite.
AID1281847	Inhibition of full length His6-tagged GST-fused recombinant human HDAC1 expressed in High5 insect cells using Ac-Lys-Tyr-Lys (e-acetyl)-AMC as substrate after 24 hrs by fluorescence assay	2016	European journal of medicinal chemistry, Apr-13, Volume: 112	Design, synthesis and biological evaluation of bisthiazole-based trifluoromethyl ketone derivatives as potent HDAC inhibitors with improved cellular efficacy.
AID1901767	Cytotoxicity against human MM1.S cells assessed as inhibition of cell growth incubated for 72 hrs measured by spectrophotometer analysis	2022	Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4	Discovery of HDAC6-Selective Inhibitor NN-390 with
AID593553	Inhibition of human HDAC8 using ArgHisLysLys(Ac) fluorogenic peptide as a substrate by fluorimetric assay	2011	Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7	Oxime amides as a novel zinc binding group in histone deacetylase inhibitors: synthesis, biological activity, and computational evaluation.
AID1690106	Inhibition of HDAC in human HeLa cell nuclear extract using fluorescence substrate incubated for 30 mins by fluorescence based assay	2020	European journal of medicinal chemistry, Mar-15, Volume: 190	Isoindoline scaffold-based dual inhibitors of HDAC6 and HSP90 suppressing the growth of lung cancer in vitro and in vivo.
AID1478589	Induction of apoptosis in human K562 cells assessed as viable cells at 1 uM after 24 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometry (Rvb = 92.4%)	2017	European journal of medicinal chemistry, Jun-16, Volume: 133	Design, synthesis and biological evaluation of quinoline derivatives as HDAC class I inhibitors.
AID1864254	Cytotoxicity against human BT-549 cells harboring wild type BRCA1 and wild type BRCA2 assessed as reduction in cell viability	2022	Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18	Discovery of a Novel G-Quadruplex and Histone Deacetylase (HDAC) Dual-Targeting Agent for the Treatment of Triple-Negative Breast Cancer.
AID1898936	Induction of DNA damage in human MM473 cells at 7.4 uM assessed as increase in p-H2AX levels and measured by Western blot analysis	2022	European journal of medicinal chemistry, Jan-15, Volume: 228	Antitumor activity of novel POLA1-HDAC11 dual inhibitors.
AID1441696	Protection against BLM-induced lung fibrosis in C57BL/6 mouse assessed as reduction in hydroxyproline level at 50 mg/kg, ip qd for 7 days post BLM challenge measured on day 14 relative to control	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
AID1164179	Cell cycle arrest in human U937 cells assessed as block at G2-M phase at 5 uM after 24 to 96 hrs using propidium iodide staining by FACScan flow cytometry	2014	ACS medicinal chemistry letters, Sep-11, Volume: 5, Issue:9	Novel antiproliferative chimeric compounds with marked histone deacetylase inhibitory activity.
AID1651330	Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by Sulforhodamine B assay	2020	Bioorganic & medicinal chemistry, 02-01, Volume: 28, Issue:3	Synthesis and biological evaluation of 2-quinolineacrylamides.
AID461269	Antiproliferative activity against human CAL27 cells	2010	Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5	Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer.
AID732444	Inhibition of human MDA-MB-231 cell proliferation after 48 hrs by MTT assay	2013	ACS medicinal chemistry letters, Feb-14, Volume: 4, Issue:2	Development of
AID748100	Inhibition of HDAC1 in human HeLa cells assessed as increase in histone H3 acetylation at 10 uM after 48 hrs by Western blotting analysis	2013	Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11	Discovery of the first histone deacetylase 6/8 dual inhibitors.
AID1178594	Inhibition of rat liver HDAC at 0.1 uM pre-incubated for 15 mins before Boc-Lys(Ac)-AMC substrate addition and measured after 30 mins by fluorometry	2014	Bioorganic & medicinal chemistry, Jul-15, Volume: 22, Issue:14	Design and synthesis of novel and highly-active pan-histone deacetylase (pan-HDAC) inhibitors.
AID1390024	Antiproliferative activity against human U937 cells after 48 hrs by MTT assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Structure optimization and preliminary bioactivity evaluation of N-hydroxybenzamide-based HDAC inhibitors with Y-shaped cap.
AID1720112	Inhibition of EGFR (unknown origin)	2020	Journal of medicinal chemistry, 09-10, Volume: 63, Issue:17	Dual-Target Inhibitors Based on HDACs: Novel Antitumor Agents for Cancer Therapy.
AID465159	Growth inhibition of human SU-8686 cells after 72 hrs by MTS assay	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Synthesis and biological evaluation of triazol-4-ylphenyl-bearing histone deacetylase inhibitors as anticancer agents.
AID723449	Potentiation of 1 uM cisplatin-induced toxicity in 1 uM cisplatin resistant human CAL27 cells at 1.5 uM pretreated for 48 hrs followed by 1 uM cisplatin treatment by MTT assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1348923	Inhibition of N-terminal GST-tagged human HDAC6 using Boc-Lys(Ac)-AMC as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by fluorescence assay	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Discovery of aliphatic-chain hydroxamates containing indole derivatives with potent class I histone deacetylase inhibitory activities.
AID1622978	Inhibition of HDAC8 (unknown origin) expressed in Escherichia coli using BML-KI-178 as substrate preincubated up to 3 hrs and measured after 35 mins by fluorescence assay	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.
AID1587859	Inhibition of tubastatin-Alexa647-tracer binding to recombinant GST-tagged HDAC10 (unknown origin) measured after 1 hr by TR-FRET assay	2019	Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9	Selective Inhibition of Histone Deacetylase 10: Hydrogen Bonding to the Gatekeeper Residue is Implicated.
AID1566040	Inhibition of recombinant human HDAC6 using Ac-peptide-AMC as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence based assay	2019	European journal of medicinal chemistry, Nov-15, Volume: 182	A fluorine scan on the Zn
AID1164797	Half life in human hepatocytes at 5 uM by LCMS/MS analysis	2014	Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20	ST7612AA1, a thioacetate-ω(γ-lactam carboxamide) derivative selected from a novel generation of oral HDAC inhibitors.
AID1174690	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	2015	European journal of medicinal chemistry, Jan-07, Volume: 89	Development of 3-hydroxycinnamamide-based HDAC inhibitors with potent in vitro and in vivo anti-tumor activity.
AID1234890	Inhibition of HDAC6 (unknown origin) using Boc-Lys (acetyl)-AMC as substrate preincubated for 30 mins before substrate addition measured after 20 mins by UV-vis spectrophotometer analysis	2015	Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15	Design, synthesis and preliminary biological evaluation of indoline-2,3-dione derivatives as novel HDAC inhibitors.
AID1441666	Anti-inflammatory activity in LPS-induced C57BL/6 mouse model of acute lung injury assessed as reduction in IL-6 level pretreated at 25 mg/kg, ip pretreated for 1 hr followed LPS challenge after 24 hrs by ELISA	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
AID481572	Cytotoxicity against mouse S180 cells assessed as growth inhibition at 10 ug/ml after 24 hrs by MTT assay	2010	Bioorganic & medicinal chemistry letters, May-15, Volume: 20, Issue:10	Synthesis and anticancer evaluation of alpha-lipoic acid derivatives.
AID586609	Antimalarial activity against ring stage of Plasmodium falciparum assessed as parasites growth inhibition using giemsa staining after 24 to 56 hrs by microscopic analysis in presence of 10% human serum	2011	Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3	Ex vivo activity of histone deacetylase inhibitors against multidrug-resistant clinical isolates of Plasmodium falciparum and P. vivax.
AID1201644	Inhibition of human recombinant JAK2 using Z'LYTETry6 peptide substrate after 1 hr by microplate reader	2015	European journal of medicinal chemistry, May-05, Volume: 95	Macrocyclic compounds as anti-cancer agents: design and synthesis of multi-acting inhibitors against HDAC, FLT3 and JAK2.
AID1206738	Cytotoxicity against human HCT116 cells assessed as growth inhibition after 48 hrs by MTT assay	2015	Journal of medicinal chemistry, May-28, Volume: 58, Issue:10	Design, synthesis, and antitumor evaluation of novel histone deacetylase inhibitors equipped with a phenylsulfonylfuroxan module as a nitric oxide donor.
AID1439780	Inhibition of human HDAC4 using Boc-Lys(trifluoroacetyl)-AMC as substrate preincubated for 30 mins followed by substrate addition measured after 60 mins by trypsin-based fluorescence assay	2017	Bioorganic & medicinal chemistry letters, 04-01, Volume: 27, Issue:7	Perfluorinated hydroxamic acids are potent and selective inhibitors of HDAC-like enzymes from Pseudomonas aeruginosa.
AID1312848	Inhibition of full length recombinant human His-tagged p110 alpha/p85 alpha expressed in baculovirus expression system incubated for 1 hr by kinase-glo assay	2016	Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11	Development of Purine-Based Hydroxamic Acid Derivatives: Potent Histone Deacetylase Inhibitors with Marked in Vitro and in Vivo Antitumor Activities.
AID1390812	Antiproliferative activity against human RPMI8226 cells after 72 hrs by MTT assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel 6-aryl substituted 4-pyrrolidineaminoquinazoline derivatives as potent phosphoinositide 3-kinase delta (PI3Kδ) inhibitors.
AID1421928	Selectivity index, ratio of IC50 for HEK293 cells to IC50 for Plasmodium falciparum 3D7 infected in human erythrocytes	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	One-pot, multi-component synthesis and structure-activity relationships of peptoid-based histone deacetylase (HDAC) inhibitors targeting malaria parasites.
AID1547266	Inhibition of HDAC8 (unknown origin) using biotinylated histone H3 KAc peptide (1 to 21 residues) as substrate by HTRF assay	2020	Journal of medicinal chemistry, 04-09, Volume: 63, Issue:7	Discovery of Thieno[2,3-
AID1234901	Antiproliferative activity against human KG1 cells after 48 hrs by MTT assay	2015	Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15	Design, synthesis and preliminary biological evaluation of indoline-2,3-dione derivatives as novel HDAC inhibitors.
AID737914	Inhibition of HMG-CoA reductase in human A549 cells after 5 mins by spectrophotometric analysis	2013	Journal of medicinal chemistry, May-09, Volume: 56, Issue:9	Design and synthesis of dual-action inhibitors targeting histone deacetylases and 3-hydroxy-3-methylglutaryl coenzyme A reductase for cancer treatment.
AID1775546	Inhibition of HDAC2 (unknown origin)	2021	Journal of medicinal chemistry, 03-25, Volume: 64, Issue:6	Design and Synthesis of Novel Epigenetic Inhibitors Targeting Histone Deacetylases, DNA Methyltransferase 1, and Lysine Methyltransferase G9a with
AID1337261	Antiproliferative activity against human MDA-MB-231 cells up to 72 hrs by MTT assay	2016	Journal of medicinal chemistry, Sep-22, Volume: 59, Issue:18	Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines.
AID308050	Antiproliferative activity against mouse SC9 cells by MTS assay	2007	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 17, Issue:14	Aminosuberoyl hydroxamic acids (ASHAs): a potent new class of HDAC inhibitors.
AID1566818	Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Discovery of 1,2,4-oxadiazole-Containing hydroxamic acid derivatives as histone deacetylase inhibitors potential application in cancer therapy.
AID1739588	Inhibition of HDAC6 in human HL-60 cells assessed as ratio of acetylated H3/GAPDH at 10 uM incubated for 4 hrs by Western blot analysis relative to DMSO	2020	European journal of medicinal chemistry, Aug-15, Volume: 200	Design, synthesis, and biological evaluation of dual targeting inhibitors of histone deacetylase 6/8 and bromodomain BRPF1.
AID1848611	Cytotoxicity against human SF-539 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay	2022	Journal of medicinal chemistry, 11-10, Volume: 65, Issue:21	First-in-Class Dual Mechanism Ferroptosis-HDAC Inhibitor Hybrids.
AID1742760	In vivo inhibition of HDAC in tumor of mouse 4T1 cells xenografted in BALB/c mouse assessed as increase in acetylated alpha-tubulin expression by immunohistochemistry method	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Design and synthesis of novel Flavone-based histone deacetylase inhibitors antagonizing activation of STAT3 in breast cancer.
AID1753644	Inhibition of HDAC6 in human SH-SY5Y cells assessed as increase in acetylated histone H3 levels at 1 uM incubated for 24 hrs by Western blot analysis	2021	European journal of medicinal chemistry, Jun-05, Volume: 218	Design, synthesis and biological evaluation of brain penetrant benzazepine-based histone deacetylase 6 inhibitors for alleviating stroke-induced brain infarction.
AID1129006	Inhibition of human HDAC-4 using RHKK(Ac) as substrate by fluorescence assay	2014	Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6	Synthesis and evaluation of new Hsp90 inhibitors based on a 1,4,5-trisubstituted 1,2,3-triazole scaffold.
AID663403	Half life in artificial gastric fluid	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Discovery and extensive in vitro evaluations of NK-HDAC-1: a chiral histone deacetylase inhibitor as a promising lead.
AID1398823	Antagonist activity at ERalpha in human MCF7 cells assessed as suppression of CDC6 mRNA expression at 5 uM after 24 hrs by QIAzol reagent based RT-qPCR analysis	2018	Bioorganic & medicinal chemistry, 08-15, Volume: 26, Issue:15	Incorporation of histone deacetylase inhibitory activity into the core of tamoxifen - A new hybrid design paradigm.
AID717656	Inhibition of HDAC6 using Fluor-de-Lys as substrate assessed as remaining activity at 2.5 x 10'-7 M pretreated for 30 mins before substrate addition by fluorescence assay	2012	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23	The structural requirements of histone deacetylase inhibitors: suberoylanilide hydroxamic acid analogs modified at the C6 position.
AID1235258	Cytotoxicity against human PC3 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	2015	Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15	Design, synthesis and preliminary bioactivity evaluations of substituted quinoline hydroxamic acid derivatives as novel histone deacetylase (HDAC) inhibitors.
AID1751995	Inhibition of HDAC6 (unknown origin)	2021	Bioorganic & medicinal chemistry letters, 10-01, Volume: 49	Discovery of novel pyrazolopyrimidine derivatives as potent mTOR/HDAC bi-functional inhibitors via pharmacophore-merging strategy.
AID1753843	Selectivity index, ratio of IC50 for inhibition of HDAC8 (unknown origin) to IC50 for inhibition of HDAC6 (unknown origin)	2021	European journal of medicinal chemistry, Jun-05, Volume: 218	Identification of novel 1,3-diaryl-1,2,4-triazole-capped histone deacetylase 6 inhibitors with potential anti-gastric cancer activity.
AID1141786	Inhibition of HDAC1 (unknown origin) using RHKK(Ac) (379 to 382) p53 peptide as substrate by fluorescence assay	2014	Journal of medicinal chemistry, May-22, Volume: 57, Issue:10	Azaindolylsulfonamides, with a more selective inhibitory effect on histone deacetylase 6 activity, exhibit antitumor activity in colorectal cancer HCT116 cells.
AID1164042	Antiproliferative activity against human MOLT4 cells assessed as growth inhibition after 72 hrs by CCK-8 assay	2014	European journal of medicinal chemistry, Oct-30, Volume: 86	Design, synthesis, and biological evaluation of 1, 3-disubstituted-pyrazole derivatives as new class I and IIb histone deacetylase inhibitors.
AID1614138	Antiproliferative activity against human MV4-11 cells after 72 hrs by MTT assay
AID461267	Antiproliferative activity against human SCC15 cells	2010	Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5	Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer.
AID1754757	Inhibition of C-terminal His-tagged human HDAC9 (604 to 1066 residues) expressed in baculovirus-infected Sf9 cells assessed as reduction in 7-amino-4-methylcoumarin release measured every 5 mins by fluorescence based analysis	2021	Bioorganic & medicinal chemistry, 07-15, Volume: 42	Discovery of novel class of histone deacetylase inhibitors as potential anticancer agents.
AID616001	Antiproliferative activity against human Hep3B cells after 48 hrs by SRB assay	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Synthesis and evaluation of aliphatic-chain hydroxamates capped with osthole derivatives as histone deacetylase inhibitors.
AID1655788	Inhibition of human recombinant HDAC2 using AMC-K(Ac)GL as substrate by fluorescence based assay	2020	ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5	Design of First-in-Class Dual EZH2/HDAC Inhibitor: Biochemical Activity and Biological Evaluation in Cancer Cells.
AID499808	Antileishmanial activity against Leishmania donovani promastigotes after 72 hrs by alamar blue assay	2010	Journal of medicinal chemistry, Aug-26, Volume: 53, Issue:16	Non-peptide macrocyclic histone deacetylase inhibitors derived from tricyclic ketolide skeleton.
AID1275644	Growth inhibition of human A549 cells after 96 hrs by MTT assay	2016	European journal of medicinal chemistry, Feb-15, Volume: 109	Identification of N-(6-mercaptohexyl)-3-(4-pyridyl)-1H-pyrazole-5-carboxamide and its disulfide prodrug as potent histone deacetylase inhibitors with in vitro and in vivo anti-tumor efficacy.
AID1401532	Antiproliferative activity against human A431 cells after 72 hrs by SRB assay	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors.
AID1482115	Cytotoxicity against human THP1 cells assessed as growth inhibition after 48 hrs by MTT assay	2017	Journal of medicinal chemistry, 04-27, Volume: 60, Issue:8	Exploring Derivatives of Quinazoline Alkaloid l-Vasicine as Cap Groups in the Design and Biological Mechanistic Evaluation of Novel Antitumor Histone Deacetylase Inhibitors.
AID1848622	Cytotoxicity against human HCT-15 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay	2022	Journal of medicinal chemistry, 11-10, Volume: 65, Issue:21	First-in-Class Dual Mechanism Ferroptosis-HDAC Inhibitor Hybrids.
AID780573	Growth inhibition of human HeLa cells after 48 hrs by MTT assay	2013	Bioorganic & medicinal chemistry, Nov-15, Volume: 21, Issue:22	Development of novel ferulic acid derivatives as potent histone deacetylase inhibitors.
AID445124	Inhibition of human recombinant HDAC1 expressed in baculovirus assessed as residual activity at 5 uM	2009	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 19, Issue:22	Novel N-hydroxybenzamide-based HDAC inhibitors with branched CAP group.
AID1864225	Inhibition of full length recombinant N-terminal GST-tagged human HDAC8 expressed in baculovirus infected Sf9 insect cells incubated for 50 mins by Glo- luminescence assay	2022	Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18	Discovery of a Novel G-Quadruplex and Histone Deacetylase (HDAC) Dual-Targeting Agent for the Treatment of Triple-Negative Breast Cancer.
AID420324	Inhibition of HDAC1 by fluorogenic enzyme assay	2009	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 19, Issue:13	Non-isotopic dual parameter competition assay suitable for high-throughput screening of histone deacetylases.
AID1363798	Inhibition of chymotrypsin-like activity of 20S proteasome in human SEM cells using Suc-LLVY aminoluciferin as substrate after 2 hrs by proteasome-Glo assay	2018	Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22	Discovery of the First-in-Class Dual Histone Deacetylase-Proteasome Inhibitor.
AID1478594	Antiproliferative activity against human MOLT4 cells after 48 hrs by MTT assay	2017	European journal of medicinal chemistry, Jun-16, Volume: 133	Design, synthesis and biological evaluation of quinoline derivatives as HDAC class I inhibitors.
AID1808549	Inhibition of recombinant human N-terminal GST-tagged/C-terminal His-tagged HDAC4 (627 to 1084 residues) expressed in baculovirus infected Sf9 insect cells using fluorogenic substrate measured after 60 mins by FRET assay	2021	Journal of medicinal chemistry, 04-08, Volume: 64, Issue:7	Structure-Based Design of a Selective Class I Histone Deacetylase (HDAC) Near-Infrared (NIR) Probe for Epigenetic Regulation Detection in Triple-Negative Breast Cancer (TNBC).
AID723129	Potentiation of 50 uM cisplatin-induced toxicity in 1 uM cisplatin resistant human MDA-MB-231 cells at 1.5 uM pretreated for 48 hrs followed by 1 uM cisplatin treatment by MTT assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1349730	Antitumor activity against human HCT116 cells xenografted in BALB/C nude mouse assessed as tumor growth inhibition at 25 mg/kg, ip bid administered for 21 consecutive days measured every 3 days	2018	ACS medicinal chemistry letters, Jan-11, Volume: 9, Issue:1	Dual NAMPT/HDAC Inhibitors as a New Strategy for Multitargeting Antitumor Drug Discovery.
AID1227025	Retention time of the compound in HEPES buffer treated with SAHA-TAP at pH 7.4 by LC-MS analysis in presence of GSH	2015	Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11	Dual-Mode HDAC Prodrug for Covalent Modification and Subsequent Inhibitor Release.
AID347873	Growth inhibition of human Melanoma cells at 10 uM relative to control	2008	Journal of medicinal chemistry, Dec-11, Volume: 51, Issue:23	Histone deacetylase inhibitors through click chemistry.
AID1193536	Inhibition of isolated rat liver HDAC using substrate containing acetylated lysine side chain assessed as release of fluorophore at 0.01 uM by Fluor de Lys assay	2015	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7	Benzofused hydroxamic acids: useful fragments for the preparation of histone deacetylase inhibitors. Part 2: 7-fluorobenzothiophenes and benzofurans.
AID1890331	Stability in human plasma incubated for 6 hrs in presence of NADPH and measured by LC-MS/MS analysis	2022	European journal of medicinal chemistry, Apr-05, Volume: 233	Novel biphenyl-based scaffold as potent and selective histone deacetylase 6 (HDAC6) inhibitors: Identification, development and pharmacological evaluation.
AID1421918	Gametocytocidal activity against synchronized Plasmodium falciparum NF54 mature stage 5 gametocytes after 48 hrs by ATP bioluminescence assay	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	One-pot, multi-component synthesis and structure-activity relationships of peptoid-based histone deacetylase (HDAC) inhibitors targeting malaria parasites.
AID286790	Inhibition of HDAC3	2007	Journal of medicinal chemistry, May-17, Volume: 50, Issue:10	Bispyridinium dienes: histone deacetylase inhibitors with selective activities.
AID1497925	Induction of CRBN ubiquitin ligase-mediated HDAC2 degradation in human MCF7 cells assessed as decrease in HDAC2 levels at 10 uM after 12 hrs by immunoblotting analysis	2018	Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14	Development of the first small molecule histone deacetylase 6 (HDAC6) degraders.
AID1541446	Inhibition of recombinant human full length C-terminal His/FLAG-tagged HDAC1 expressed in baculovirus infected Sf9 insect cells using ZMAL as substrate incubated for 90 mins by fluorescence assay	2019	Journal of medicinal chemistry, 12-26, Volume: 62, Issue:24	Synthesis of Peptoid-Based Class I-Selective Histone Deacetylase Inhibitors with Chemosensitizing Properties.
AID105415	Antiproliferative activity against MDA-435 (human breast carcinoma) cell line.	2003	Bioorganic & medicinal chemistry letters, Jun-02, Volume: 13, Issue:11	Indole amide hydroxamic acids as potent inhibitors of histone deacetylases.
AID1758461	Inhibition of human recombinant HDAC1 using Ac-Leu-Gly-Lys(Ac)-AMC as substrate by measuring fluorescence intensity incubated for 30 mins by microplate reader assay	2021	European journal of medicinal chemistry, May-05, Volume: 217	Novel dual-mode antitumor chlorin-based derivatives as potent photosensitizers and histone deacetylase inhibitors for photodynamic therapy and chemotherapy.
AID1671982	Cell cycle arrest in human HCT-116 cells assessed as accumulation at G2/M phase measured after 24 hrs	2019	Bioorganic & medicinal chemistry, 04-01, Volume: 27, Issue:7	Synthesis and biological evaluation of paclitaxel and vorinostat co-prodrugs for overcoming drug resistance in cancer therapy in vitro.
AID1861258	Inhibition of HDAC2 (unknown origin)	2022	Bioorganic & medicinal chemistry letters, 09-01, Volume: 71	Design, synthesis and antitumor activity study of PARP-1/HDAC dual targeting inhibitors.
AID1652193	Inhibition of human recombinant HDAC8 expressed in Escherichia coli BL21(DE3) cells using Boc-Lys(TFA)-AMC as substrate preincubated for 5 followed by substrate addition and measured after 30 mins by fluorescence based assay	2020	ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5	New Dual CK2/HDAC1 Inhibitors with Nanomolar Inhibitory Activity against Both Enzymes.
AID1769643	Antiproliferative activity against human SH-SY5Y cells harboring ALK F1174L mutant assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 assay	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	Discovery of 2,4-pyrimidinediamine derivatives as potent dual inhibitors of ALK and HDAC.
AID366640	Inhibition of HDAC1 after 17 hrs	2008	Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15	Use of the nitrile oxide cycloaddition (NOC) reaction for molecular probe generation: a new class of enzyme selective histone deacetylase inhibitors (HDACIs) showing picomolar activity at HDAC6.
AID1545987	Antiproliferative activity against human SW620 cells assessed as reduction in cell viability after 48 hrs by MTT assay	2019	European journal of medicinal chemistry, Dec-01, Volume: 183	1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships.
AID1614191	Induction of apoptosis in human MV4-11 cells assessed as late apoptotic cells at 1 uM after 48 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 5.03%)
AID1861251	Inhibition of HDAC derived from human HeLa cell nucleus	2022	Bioorganic & medicinal chemistry letters, 09-01, Volume: 71	Design, synthesis and antitumor activity study of PARP-1/HDAC dual targeting inhibitors.
AID1896935	Cytotoxicity against human MCF-10A cells assessed as reduction in cell viability by CCK8 assay	2022	Bioorganic & medicinal chemistry, Nov-05, Volume: 75	Novel bioactive hybrid Celecoxib-HDAC Inhibitor, induces apoptosis in human acute lymphoblastic leukemia cells.
AID1235257	Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	2015	Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15	Design, synthesis and preliminary bioactivity evaluations of substituted quinoline hydroxamic acid derivatives as novel histone deacetylase (HDAC) inhibitors.
AID1493591	Inhibition of human recombinant full-length HDAC6 expressed in baculovirus infected Sf9 cells using Boc-Lys(acetyl)-AMC as substrate after 30 mins by fluorescence assay	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Discovery of a fluorescent probe with HDAC6 selective inhibition.
AID1901055	Inhibition of HDAC2 (unknown origin) using trypsin and Ac-peptide as substrates	2022	European journal of medicinal chemistry, Feb-15, Volume: 230	Novel PHD2/HDACs hybrid inhibitors protect against cisplatin-induced acute kidney injury.
AID603544	Selectivity ratio of IC50 for HDAC8 to IC50 for HDAC in human HeLa cell nuclear extracts	2011	Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8	Development of tetrahydroisoquinoline-based hydroxamic acid derivatives: potent histone deacetylase inhibitors with marked in vitro and in vivo antitumor activities.
AID1655787	Inhibition of human recombinant HDAC1 using AMC-K(Ac)GL as substrate by fluorescence based assay	2020	ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5	Design of First-in-Class Dual EZH2/HDAC Inhibitor: Biochemical Activity and Biological Evaluation in Cancer Cells.
AID593554	Inhibition of human HDAC9 using ArgHisLysLys(Ac) fluorogenic peptide as a substrate by fluorimetric assay	2011	Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7	Oxime amides as a novel zinc binding group in histone deacetylase inhibitors: synthesis, biological activity, and computational evaluation.
AID1312849	Cytotoxicity against human MV4-11 cells assessed as growth inhibition after 24 hrs by MTT assay	2016	Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11	Development of Purine-Based Hydroxamic Acid Derivatives: Potent Histone Deacetylase Inhibitors with Marked in Vitro and in Vivo Antitumor Activities.
AID1326511	Antiproliferative activity against human HCT116 cells after 48 hrs by SRB assay	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	2-(Phenylsulfonyl)quinoline N-hydroxyacrylamides as potent anticancer agents inhibiting histone deacetylase.
AID1589336	Inhibition of HDAC1 (unknown origin) using Fluor de Lys substrate by fluorescence assay relative to control	2019	European journal of medicinal chemistry, Apr-15, Volume: 168	Design, synthesis and biological evaluation of novel isoindolinone derivatives as potent histone deacetylase inhibitors.
AID1659651	Inhibition of HDAC7 (unknown origin)	2020	Bioorganic & medicinal chemistry letters, 06-01, Volume: 30, Issue:11	Environment-sensitive fluorescent inhibitors of histone deacetylase.
AID1886183	Inhibition of HDAC1 in human HeLa cells using BOC-K(Ac)-AMC as substrate measured after 30 mins by fluorescence based microtiter plate reader assay	2022	Journal of medicinal chemistry, 08-25, Volume: 65, Issue:16	Discovery of a Novel Vascular Disrupting Agent Inhibiting Tubulin Polymerization and HDACs with Potent Antitumor Effects.
AID1599724	Cytotoxicity against human Meso163 cells assessed as cell permeability measured after 72 hrs by CellTox Green assay	2019	ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6	Extending Cross Metathesis To Identify Selective HDAC Inhibitors: Synthesis, Biological Activities, and Modeling.
AID1266823	Inhibition of HDAC in human HCT116 cells assessed as increase in acetyl-histone H3 expression at 5 uM after 48 hrs by immunoblotting analysis	2015	Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23	Novel β-Carboline/Hydroxamic Acid Hybrids Targeting Both Histone Deacetylase and DNA Display High Anticancer Activity via Regulation of the p53 Signaling Pathway.
AID1321701	Inhibition of HDAC2 (unknown origin)	2016	Journal of medicinal chemistry, 10-13, Volume: 59, Issue:19	Design, Synthesis, and Biological Evaluation of First-in-Class Dual Acting Histone Deacetylases (HDACs) and Phosphodiesterase 5 (PDE5) Inhibitors for the Treatment of Alzheimer's Disease.
AID1598099	Activation of Tat-mediated HIV1 transcription in HEK293- FlpIn-FM cells harboring LTR driven CBR reporter co-expressing CMV driven CBG reporter assessed as maximum LTR activity at 2.5 uM incubated for 48 hr using Chroma-Glo substrate by luciferase dual re	2019	Journal of medicinal chemistry, 05-23, Volume: 62, Issue:10	Identification of 5-Substituted 2-Acylaminothiazoles That Activate Tat-Mediated Transcription in HIV-1 Latency Models.
AID297498	Cytotoxicity against human EOL1cells	2007	Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18	2-aroylindoles and 2-aroylbenzofurans with N-hydroxyacrylamide substructures as a novel series of rationally designed histone deacetylase inhibitors.
AID760372	Inhibition of HDAC in human jurkat cells assessed as increase in H4K12 acetylation after 12 hrs by FACS analysis relative to control	2013	ACS medicinal chemistry letters, Aug-08, Volume: 4, Issue:8	Tropolones as lead-like natural products: the development of potent and selective histone deacetylase inhibitors.
AID723436	Potentiation of 10 uM cisplatin-induced toxicity in 1 uM cisplatin resistant human MDA-MB-231 cells at 1 uM pretreated for 48 hrs followed by 1 uM cisplatin treatment by MTT assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID90693	Binding affinity against Histone deacetylase 2 (HD2) in maize, expressed as binding constant (pKi)	2002	Journal of medicinal chemistry, Apr-25, Volume: 45, Issue:9	Binding mode analysis of 3-(4-benzoyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-propenamide: a new synthetic histone deacetylase inhibitor inducing histone hyperacetylation, growth inhibition, and terminal cell differentiation.
AID352516	Inhibition of human recombinant HDAC1	2009	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11	Isoxazole moiety in the linker region of HDAC inhibitors adjacent to the Zn-chelating group: effects on HDAC biology and antiproliferative activity.
AID1126987	Inhibition of HDAC2 in human U937 cells assessed as increase of intracellular acetylated histone H3 level at 1 uM after 24 hrs by Western blot analysis	2014	Journal of medicinal chemistry, Apr-24, Volume: 57, Issue:8	Discovery of the first N-hydroxycinnamamide-based histone deacetylase 1/3 dual inhibitors with potent oral antitumor activity.
AID1263066	Selectivity ratio of IC50 for human A549 cells to IC50 for African green monkey Vero cells	2015	Bioorganic & medicinal chemistry, Dec-15, Volume: 23, Issue:24	A structure-activity relationship of non-peptide macrocyclic histone deacetylase inhibitors and their anti-proliferative and anti-inflammatory activities.
AID1614233	Induction of apoptosis in human MM1S cells assessed as viable cells at 1 uM after 48 hrs in presence of 0.3 uM RAPA by Annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 98.9%)
AID1898896	Resistance index, ratio of IC50 for human NCI-H460 cells to IC50 for H460-R9A cells	2022	European journal of medicinal chemistry, Jan-15, Volume: 228	Antitumor activity of novel POLA1-HDAC11 dual inhibitors.
AID1578497	Induction of apoptosis in human MV4-11 cells assessed as early apoptotic cells at 0.25 uM incubated for 18 hrs by annexin V FITC and PI based flow cytometry (Rvb = 19.46 to 22.17 %)	2020	ACS medicinal chemistry letters, Jan-09, Volume: 11, Issue:1	Class I/IIb-Selective HDAC Inhibitor Exhibits Oral Bioavailability and Therapeutic Efficacy in Acute Myeloid Leukemia.
AID737916	Inhibition of recombinant HDAC2 (unknown origin) after 10 mins by fluorimetric analysis	2013	Journal of medicinal chemistry, May-09, Volume: 56, Issue:9	Design and synthesis of dual-action inhibitors targeting histone deacetylases and 3-hydroxy-3-methylglutaryl coenzyme A reductase for cancer treatment.
AID760498	Cytotoxicity against human U251 cells after 48 hrs by SRB assay	2013	ACS medicinal chemistry letters, Aug-08, Volume: 4, Issue:8	Development of a chimeric c-Src kinase and HDAC inhibitor.
AID269669	Antiproliferative activity against human PC3 cells by SRB assay	2006	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 16, Issue:15	Synthesis, enzymatic inhibition, and cancer cell growth inhibition of novel delta-lactam-based histone deacetylase (HDAC) inhibitors.
AID1614197	Induction of apoptosis in human MV4-11 cells assessed as viable cells at 1 uM after 48 hrs in presence of 0.3 uM RAPA by Annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 84.1%)
AID1128558	Inhibition of human HDAC-5 using RHKK(Ac) as substrate	2014	European journal of medicinal chemistry, Apr-09, Volume: 76	4,5,6,7-Tetrahydro-isoxazolo-[4,5-c]-pyridines as a new class of cytotoxic Hsp90 inhibitors.
AID308651	Increase in p27kip1 gene expression in PANC1 cells after 24 hrs relative to control	2007	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17	Design, synthesis, and evaluation of isoindolinone-hydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors.
AID1597932	Inhibition of HDAC6 (unknown origin) using Boc-Lys(Ac)-AMC as substrate incubated for 60 mins by fluorescence assay	2019	Bioorganic & medicinal chemistry letters, 09-15, Volume: 29, Issue:18	Anti-tumor activity evaluation of novel tubulin and HDAC dual-targeting inhibitors.
AID723466	Inhibition of human HDAC1 by fluorescence assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1659655	Antiproliferative activity against human PC3 cells incubated for 24 hrs by CCK8 assay	2020	Bioorganic & medicinal chemistry letters, 06-01, Volume: 30, Issue:11	Environment-sensitive fluorescent inhibitors of histone deacetylase.
AID329919	Induction of apoptosis in human U937 cells	2008	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8	Novel uracil-based 2-aminoanilide and 2-aminoanilide-like derivatives: histone deacetylase inhibition and in-cell activities.
AID753164	Cytotoxicity against human A549 cells	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and biological characterization of spiro[2H-(1,3)-benzoxazine-2,4'-piperidine] based histone deacetylase inhibitors.
AID1898898	Antiproliferative activity against multi-drug resistant human A2780-DX cells incubated for 24 hrs followed by incubating in drug-free medium for 48 hrs and measured by SRB assay	2022	European journal of medicinal chemistry, Jan-15, Volume: 228	Antitumor activity of novel POLA1-HDAC11 dual inhibitors.
AID1282292	Toxicity in Balb/c nude mouse xenografted with human HCT116 cells assessed as death at 50 mg/kg, ip q2d for 9 days	2016	Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4	Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
AID1816196	Inhibition of HDAC in human BT-549 cells assessed as increase in level of acetyl-H3K9/14 substrate at 3 uM incubated for 12 hrs by chemiluminescence based Western blotting analysis
AID1859929	Inhibition of HDAC in human U-937 cells assessed as increase in acetylation level of HSP90 at 10 uM measured after 24 to 48 hrs by Western blot analysis	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Azetidin-2-one-based small molecules as dual hHDAC6/HDAC8 inhibitors: Investigation of their mechanism of action and impact of dual inhibition profile on cell viability.
AID1547332	Inhibition of HDAC in human HCT116 cells assessed as activation of IL6-JAK-STAT signaling pathway by measuring increase in OSM mRNA level at 10 uM after 24 hrs by RT-PCR analysis	2020	Journal of medicinal chemistry, 04-09, Volume: 63, Issue:7	Discovery of Thieno[2,3-
AID1566039	Inhibition of human recombinant full length C-terminal His-tagged HDAC3 (1 to 428 residues)/N-terminal GST-tagged NCOR2 (395 to 489 residues) expressed in baculovirus infected Sf9 cells using Ac-peptide-AMC as substrate preincubated for 15 mins followed b	2019	European journal of medicinal chemistry, Nov-15, Volume: 182	A fluorine scan on the Zn
AID1702055	Inhibition of HDAC1 in human HeLa nuclear extract using Boc-Lys(Ac)-AMC as substrate measured after 2 hrs by fluorescence based assay	2018	Journal of medicinal chemistry, 02-22, Volume: 61, Issue:4	Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma.
AID1234910	Toxicity in human H7402 cells xenografted mouse assessed as change in toxic effect at 100 mg/kg/day, po for 16 days	2015	Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15	Design, synthesis and preliminary biological evaluation of indoline-2,3-dione derivatives as novel HDAC inhibitors.
AID1566803	Inhibition of recombinant full length human HDAC2 expressed in sf9 insect cells using Ac-peptide-AMC as substrate after 1 hr by fluorescence assay	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Discovery of 1,2,4-oxadiazole-Containing hydroxamic acid derivatives as histone deacetylase inhibitors potential application in cancer therapy.
AID1614196	Induction of apoptosis in human MV4-11 cells assessed as necrotic cells at 1 uM after 48 hrs in presence of 0.3 uM RAPA by Annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 0.17%)
AID1379287	Inhibition of recombinant human full length HDAC1 expressed in baculovirus infected Sf9 insect cells using biotinylated lysine 9 acetylated histone H3 (1 to 21 residues) as substrate incubated for 5 mins followed by substrate addition measured after 60 mi	2017	ACS medicinal chemistry letters, Aug-10, Volume: 8, Issue:8	Design, Synthesis, and Biological Evaluation of the First c-Met/HDAC Inhibitors Based on Pyridazinone Derivatives.
AID524996	Inhibition of HDAC8 by in vitro deacetylation assay	2010	Nature chemical biology, Jan, Volume: 6, Issue:1	Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.
AID1702237	Oral bioavailability in Balb/c mouse at 50 mg/kg measured up to 24 hrs by LC/MS/MS analysis	2018	Journal of medicinal chemistry, 02-22, Volume: 61, Issue:4	Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma.
AID1848632	Cytotoxicity against human TK-10 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay	2022	Journal of medicinal chemistry, 11-10, Volume: 65, Issue:21	First-in-Class Dual Mechanism Ferroptosis-HDAC Inhibitor Hybrids.
AID1605972	Antiproliferative activity against human U251 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	2020	Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8	Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors.
AID1449335	Inhibition of HDAC1 in human Cal27CisR cells assessed as accumulation of histone 3 acetylation at 1 uM after 24 hrs by immunoblot analysis	2017	Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13	Alkoxyurea-Based Histone Deacetylase Inhibitors Increase Cisplatin Potency in Chemoresistant Cancer Cell Lines.
AID1832671	Inhibition of HDAC1 (unknown origin) using Boc-Lys(acetyl)-AMC as fluorogenic substrate measured after 1 hr by flourescence plate reader method	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Cysteine derivatives as acetyl lysine mimics to inhibit zinc-dependent histone deacetylases for treating cancer.
AID1175813	Cytotoxicity against human RPMI8226 cells after 72 hrs by MTS assay	2014	Journal of natural products, Dec-26, Volume: 77, Issue:12	Reniochalistatins A-E, cyclic peptides from the marine sponge Reniochalina stalagmitis.
AID1349719	Inhibition of recombinant full length human C-terminal His/flag-tagged HDAC1 expressed in baculovirus infected Sf9 insect cells after 30 mins by fluorescence assay	2018	ACS medicinal chemistry letters, Jan-11, Volume: 9, Issue:1	Dual NAMPT/HDAC Inhibitors as a New Strategy for Multitargeting Antitumor Drug Discovery.
AID675298	Inhibition of HDAC in human HeLa cell extracts using Fluor de Lys as substrate at 1 uM by fluorescence assay	2012	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17	Set-up of a new series of HDAC inhibitors: the 5,11-dihydrodibenzo[b,e]azepin-6-ones as privileged structures.
AID1177052	Antiprotozoan activity against Leishmania donovani MHOM- ET-67/L82 amastigotes	2015	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 25, Issue:3	Hydroxamic acid based histone deacetylase inhibitors with confirmed activity against the malaria parasite.
AID1415638	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	2017	MedChemComm, Jun-01, Volume: 8, Issue:6	Development of novel β-carboline-based hydroxamate derivatives as HDAC inhibitors with DNA damage and apoptosis inducing abilities.
AID420641	Inhibition of HDAC6 in human IGROV1 cells assessed as alpha-tubulin acetylation at IC50 after 48 hrs by Western blot	2009	European journal of medicinal chemistry, May, Volume: 44, Issue:5	Design, synthesis, and evaluation of biphenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors.
AID628209	Antiproliferative activity against human SH-SY5Y cells after 24 hrs by XTT assay	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Design, synthesis, docking, and biological evaluation of novel diazide-containing isoxazole- and pyrazole-based histone deacetylase probes.
AID588211	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID461255	Antiproliferative activity against human H460 cells after hrs by ATP content assay	2010	Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5	Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer.
AID723423	Potentiation of 5 uM cisplatin-induced toxicity in 5 uM cisplatin resistant human A2780 cells at 1.5 uM pretreated for 48 hrs followed by 5 uM cisplatin treatment by MTT assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1173506	Inhibition of N-terminal GST-tagged human HDAC10 (1 to 481 residues) using Arg-His-Lys-Lys(Ac) substrate incubated for 2 hrs by fluorescence assay	2014	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 24, Issue:23	Histone deacetylase inhibitors derived from 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine and related heterocycles selective for the HDAC6 isoform.
AID1851613	Anticancer activity against human MDA-MB-231 cells assessed as inhibition of cell proliferation	2022	Bioorganic & medicinal chemistry letters, 10-15, Volume: 74	Design, synthesis, and antitumor study of a series of novel 1-Oxa-4-azaspironenone derivatives.
AID1263147	Antiproliferative activity against human MDA-MB-231 cells treated for 48 hrs followed by refreshed every 96 hrs measured on day 10 by Lowry assay	2015	Bioorganic & medicinal chemistry, Dec-15, Volume: 23, Issue:24	Design, synthesis and evaluation of antiestrogen and histone deacetylase inhibitor molecular hybrids.
AID1709354	Selectivity ratio of IC50 for human HCT-116 cells to IC50 for human NAMALVA cells	2021	Bioorganic & medicinal chemistry, 04-01, Volume: 35	Structure-activity relationship and mechanistic studies for a series of cinnamyl hydroxamate histone deacetylase inhibitors.
AID1764248	Inhibition of HDAC in human CAL-27 cells using Boc-Lys (acetyl)-AMC as substrate preincubated for 18 hrs followed by susbtrate addition and measured after 3 hrs by fluorescence microplate reader assay	2021	European journal of medicinal chemistry, Feb-05, Volume: 211	Synergistic induction of apoptosis in resistant head and neck carcinoma and leukemia by alkoxyamide-based histone deacetylase inhibitors.
AID1303691	Cytotoxicity against human K562 cells assessed as decrease in cell viability after 48 hrs by cell titer-glo luminescence assay	2016	Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13	Synergistic potentiation of (-)-lomaiviticin A cytotoxicity by the ATR inhibitor VE-821.
AID1765329	Selectivity index, ratio of IC50 for human recombinant full length HDAC1 to IC50 for human recombinant full length HDAC2	2021	European journal of medicinal chemistry, Oct-15, Volume: 222	A first-in-class anticancer dual HDAC2/FAK inhibitors bearing hydroxamates/benzamides capped by pyridinyl-1,2,4-triazoles.
AID1541554	Inhibition of class 1 HDAC in human CAL27 cells assessed as increase in histone H3 acetylation at 1 uM measured after 24 hrs by immunoblot analysis	2019	Journal of medicinal chemistry, 12-26, Volume: 62, Issue:24	Synthesis of Peptoid-Based Class I-Selective Histone Deacetylase Inhibitors with Chemosensitizing Properties.
AID755615	Cytotoxicity against SAHA-resistant human A549 cells assessed as growth inhibition after 48 hrs by MTT assay	2013	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13	Discovery of a small molecular compound simultaneously targeting RXR and HADC: design, synthesis, molecular docking and bioassay.
AID1162487	Growth inhibition of human HL60 cells after 72 hrs by CellTiter Glo assay	2014	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 24, Issue:19	Design, synthesis and evaluation of novel HDAC inhibitors as potential antitumor agents.
AID1282260	Cytotoxicity against human A549 cells after 72 hrs by MTT assay	2016	Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4	Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
AID1361643	Cell cycle arrest in human A549 cells assessed as accumulation of cells at G2 phase at 1 uM after 48 hrs by flow cytometric analysis (Rvb = 19.81%)	2018	Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16	Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents.
AID1449683	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	2017	Bioorganic & medicinal chemistry, 05-01, Volume: 25, Issue:9	Development of N-hydroxycinnamamide-based HDAC inhibitors with improved HDAC inhibitory activity and in vitro antitumor activity.
AID84276	Inhibitory concentration against HT1080 cells proliferation	2003	Journal of medicinal chemistry, Nov-20, Volume: 46, Issue:24	Histone deacetylase inhibitors.
AID374831	Antiproliferative activity against human U937 cells after 72 hrs by celltiter-blue cell viability assay	2009	Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11	Discovery of a potent class I selective ketone histone deacetylase inhibitor with antitumor activity in vivo and optimized pharmacokinetic properties.
AID1065629	Inhibition of human recombinant full length HDAC1 using (Ac)Arg-Gly-Lys(Ac) as substrate after 60 mins by fluorescence assay	2013	Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24	Design, synthesis, and biological evaluation of potent and selective class IIa histone deacetylase (HDAC) inhibitors as a potential therapy for Huntington's disease.
AID1821314	Antitumor activity against human HepG2 cells xenografted in mouse assessed as TGI at 12 mg/kg, ip administered every 2 days for 4 weeks	2022	European journal of medicinal chemistry, Feb-05, Volume: 229	Discovery of phthalazino[1,2-b]-quinazolinone derivatives as multi-target HDAC inhibitors for the treatment of hepatocellular carcinoma via activating the p53 signal pathway.
AID775829	Inhibition of mushroom tyrosinase assessed as L-DOPA conversion to melanin at 10 uM preincubated for 10 mins prior to substrate addition measured after 10 mins by spectrophotometric analysis	2013	Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20	Investigating the selectivity of metalloenzyme inhibitors.
AID1339579	Inhibition of HDAC1/HDAC2/HDAC3 in human U937 cells assessed as increase in histone H3 acetylation at 2 uM after 18 hrs by Western blot method	2017	ACS medicinal chemistry letters, Mar-09, Volume: 8, Issue:3	Structural Requirements of HDAC Inhibitors: SAHA Analogues Modified at the C2 Position Display HDAC6/8 Selectivity.
AID1421613	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	Design and synthesis of potent dual inhibitors of JAK2 and HDAC based on fusing the pharmacophores of XL019 and vorinostat.
AID618011	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	2011	Journal of medicinal chemistry, Aug-11, Volume: 54, Issue:15	Discovery of a tetrahydroisoquinoline-based hydroxamic acid derivative (ZYJ-34c) as histone deacetylase inhibitor with potent oral antitumor activities.
AID1293557	Antiproliferative activity against human H460 cells assessed as reduction in cell number after 72 hrs by cell counter analysis	2016	European journal of medicinal chemistry, Apr-13, Volume: 112	Biphenyl-4-yl-acrylohydroxamic acids: Identification of a novel indolyl-substituted HDAC inhibitor with antitumor activity.
AID748098	Inhibition of HDAC3 in human HeLa cells assessed as increase in histone H3 acetylation at 10 uM after 48 hrs by Western blotting analysis	2013	Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11	Discovery of the first histone deacetylase 6/8 dual inhibitors.
AID310125	Growth inhibition of human NB4 cells by SRB assay	2007	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 17, Issue:22	Omega-alkoxy analogues of SAHA (vorinostat) as inhibitors of HDAC: a study of chain-length and stereochemical dependence.
AID1055714	Antiproliferative activity against human PC3 cells after 48 hrs by SRB assay	2013	European journal of medicinal chemistry, , Volume: 70	Novel isatin-based hydroxamic acids as histone deacetylase inhibitors and antitumor agents.
AID628452	Inhibition of HDAC in human HepG2 cells assessed as increase in histone H4 acetylation at 1 to 10 uM after 6 hrs by Western blot analysis	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Design, synthesis, docking, and biological evaluation of novel diazide-containing isoxazole- and pyrazole-based histone deacetylase probes.
AID1355709	Antifungal activity against FLC resistant Candida albicans 100 assessed as fluconazol MIC50 after 48 hrs by checkerboard microdilution method	2018	Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14	Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections.
AID760388	Inhibition of human recombinant HDAC8 by Michaelis-Menten equation analysis	2013	ACS medicinal chemistry letters, Aug-08, Volume: 4, Issue:8	Tropolones as lead-like natural products: the development of potent and selective histone deacetylase inhibitors.
AID1422518	Inhibition of HDAC in MEF assessed as increase in histone H4 acetylation at 2 uM after 6 hrs by Western blot analysis	2018	European journal of medicinal chemistry, Nov-05, Volume: 159	In search of constrained FTY720 and phytosphingosine analogs as dual acting anticancer agents targeting metabolic and epigenetic pathways.
AID366645	Inhibition of HDAC10 after 17 hrs	2008	Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15	Use of the nitrile oxide cycloaddition (NOC) reaction for molecular probe generation: a new class of enzyme selective histone deacetylase inhibitors (HDACIs) showing picomolar activity at HDAC6.
AID1785331	Inhibition of HDAC in human HeLa nuclear extract at 1000 nM using Boc-Lys(acetyl)-AMC as substrate measured after 1 hr by fluorescence microplate reader assay relative to control
AID1861307	Induction of cell cycle arrest in human DOHH-2 cells assessed as accumulation at G2/M phase in presence of pictilisib measured by flow cytometry analysis	2022	Bioorganic & medicinal chemistry letters, 09-01, Volume: 71	Bioevaluation of a dual PI3K/HDAC inhibitor for the treatment of diffuse large B-cell lymphoma.
AID343689	Inhibition of nuclear HDAC isolated from human HeLa cells	2008	Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13	Trithiocarbonates as a novel class of HDAC inhibitors: SAR studies, isoenzyme selectivity, and pharmacological profiles.
AID1410329	Antiproliferative activity against human HCT116 cells after 48 hrs by CCK-8 assay	2018	ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4	Discovery of Novel Indoleamine 2,3-Dioxygenase 1 (IDO1) and Histone Deacetylase (HDAC) Dual Inhibitors.
AID1730852	Antiproliferation activity against human SK-BR-3 cells incubated for 72 hrs by MTT assay	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Design, synthesis and evaluation of novel ErbB/HDAC multitargeted inhibitors with selectivity in EGFR
AID1246527	Resistance index, ratio of IC50 for imatinib resistant human IR-K562 cells to IC50 for human K562 cells	2015	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 25, Issue:19	Discovery of 1-hydroxypyridine-2-thiones as selective histone deacetylase inhibitors and their potential application for treating leukemia.
AID1783107	Inhibition of HDAC6 (unknown origin) using Ac-LeuGlyLy-s(Ac)-AMC as substrate preincubated for 10 mins followed by substrate addition and further incubated for 2 hrs by fluorescence microtiter plate reader assay	2021	European journal of medicinal chemistry, Oct-05, Volume: 221	Design, synthesis and biological evaluation of 3, 4-disubstituted-imidazolidine-2, 5-dione derivatives as HDAC6 selective inhibitors.
AID527207	Induction of autophagy in human A549 cells assessed as increase in LC3II after 3 hrs relative to control	2010	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22	Selenium-containing analogs of SAHA induce cytotoxicity in lung cancer cells.
AID1578150	Cytotoxicity against human SC9 cells	2020	European journal of medicinal chemistry, Jan-01, Volume: 185	N-alkyl-hydroxybenzoyl anilide hydroxamates as dual inhibitors of HDAC and HSP90, downregulating IFN-γ induced PD-L1 expression.
AID462792	Antiproliferative activity against human HL60 cells after 48 hrs by MTT assay	2010	Bioorganic & medicinal chemistry, Mar-01, Volume: 18, Issue:5	Design, synthesis and preliminary activity assay of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives as novel Histone deacetylases (HDACs) inhibitors.
AID1709350	Cytotoxicity against human HS5 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	2021	Bioorganic & medicinal chemistry, 04-01, Volume: 35	Structure-activity relationship and mechanistic studies for a series of cinnamyl hydroxamate histone deacetylase inhibitors.
AID476828	Toxicity in FVB mouse assessed as effect on number of RBC at 50 mg/kg, po administered 5 times per week for 2 weeks (Rvb = 7.7 +/- 0.1 10^6/mm^3)	2010	Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8	Modified cap group suberoylanilide hydroxamic acid histone deacetylase inhibitor derivatives reveal improved selective antileukemic activity.
AID1166498	Inhibition of human recombinant full length HDAC6 using (Boc-Lys (-acetyl)-AMC substrate after 30 mins	2014	Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21	Design, synthesis and biological evaluation of 4-anilinothieno[2,3-d]pyrimidine-based hydroxamic acid derivatives as novel histone deacetylase inhibitors.
AID760376	Cytotoxicity against human HCT116 cells after 72 hrs by MTS assay	2013	ACS medicinal chemistry letters, Aug-08, Volume: 4, Issue:8	Tropolones as lead-like natural products: the development of potent and selective histone deacetylase inhibitors.
AID1543944	Inhibition of human recombinant HDAC6 using Boc-Lys (Ac)-AMC as substrate incubated for 60 mins and measured after 30 mins by fluorescence assay	2019	European journal of medicinal chemistry, Apr-15, Volume: 168	β-Carboline and N-hydroxycinnamamide hybrids as anticancer agents for drug-resistant hepatocellular carcinoma.
AID1727729	Inhibition of HDAC1 (unknown origin) by fluorescence based assay	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	Discovery of selective HDAC/BRD4 dual inhibitors as epigenetic probes.
AID1785008	Antimigratory activity in human HepG2 cells assessed as reduction in wound closure at 6 uM measured after 48 hrs by scratch wound healing assay	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Design, synthesis and biological evaluation of novel hybrids targeting mTOR and HDACs for potential treatment of hepatocellular carcinoma.
AID1459953	Inhibition of recombinant human HDAC1 using fluorogenic substrate by fluorescence assay	2017	European journal of medicinal chemistry, Jan-05, Volume: 125	3-Aroylindoles display antitumor activity in vitro and in vivo: Effects of N1-substituents on biological activity.
AID1709351	Selectivity index, ratio of IC50 for human HS5 cells to IC50 for human Jurkat cells	2021	Bioorganic & medicinal chemistry, 04-01, Volume: 35	Structure-activity relationship and mechanistic studies for a series of cinnamyl hydroxamate histone deacetylase inhibitors.
AID1783067	Antifungal activity against fluconazole-sensitive Candida albicans 7781 assessed as inhibition of fungal growth	2021	European journal of medicinal chemistry, Oct-05, Volume: 221	Lanosterol 14α-demethylase (CYP51)/histone deacetylase (HDAC) dual inhibitors for treatment of Candida tropicalis and Cryptococcus neoformans infections.
AID1487088	Growth inhibition of human Jurkat cells assessed as cell viability at 1 uM incubated for 44 hrs by MTT assay	2017	Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15	The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity.
AID1826625	Synergistic antiproliferative effect on HEL cells assessed as fractional inhibitory concentration index at 0.04 uM in presence of 3-Fluoro-10-hydroxy-14-methyl-8,13,13b,14-tetrahydro-7H-indolo[2',3':3,4]pyrido[2,1-b]quinazolin-5-one	2022	Journal of medicinal chemistry, 03-24, Volume: 65, Issue:6	Evodiamine-Inspired Topoisomerase-Histone Deacetylase Dual Inhibitors: Novel Orally Active Antitumor Agents for Leukemia Therapy.
AID1901153	Inhibition of HDAC3 (unknown origin) using FAM-RHKK(Ac)-NH2/FAM-RHKK(trifluoroacetyl)-NH2 as substrate preincubated for 15 mins followed by substrate addition and measured after 3 hrs by microfluidic chip based fluorescence assay	2022	Bioorganic & medicinal chemistry, 02-15, Volume: 56	Synthesis and biological evaluation of aminobenzamides containing purine moiety as class I histone deacetylases inhibitors.
AID1901155	Inhibition of HDAC6 (unknown origin) using FAM-RHKK(Ac)-NH2/FAM-RHKK(trifluoroacetyl)-NH2 as substrate preincubated for 15 mins followed by substrate addition and measured after 3 hrs by microfluidic chip based fluorescence assay	2022	Bioorganic & medicinal chemistry, 02-15, Volume: 56	Synthesis and biological evaluation of aminobenzamides containing purine moiety as class I histone deacetylases inhibitors.
AID1127017	Antitumor activity against human U937 cells xenografted in BALB/c nu mouse assessed as tumor growth inhibition at 100 mg/kg, po qd for 16 days relative to control	2014	Journal of medicinal chemistry, Apr-24, Volume: 57, Issue:8	Discovery of the first N-hydroxycinnamamide-based histone deacetylase 1/3 dual inhibitors with potent oral antitumor activity.
AID1785329	Inhibition of full length human CDK4 (1 to 303 residues)/N-terminal GST-fusion tagged CyclinD3 (1 to 292 residues) expressed in baculovirus expression system at 100 nM preincubated for 10 mins followed by substrate and ATP addition by mobility shift assay
AID1848575	Induction of ferroptosis in human NCI-H522 cells assessed as induction of lipid peroxidase accumulation at 5 uM incubated for 1 day by C11-BODIPY-581/591 staining based flow cytometry analysis	2022	Journal of medicinal chemistry, 11-10, Volume: 65, Issue:21	First-in-Class Dual Mechanism Ferroptosis-HDAC Inhibitor Hybrids.
AID1863423	Cytotoxicity against human HOP-62 cells assessed as cell viability after 48 hrs by MTT assay	2022	European journal of medicinal chemistry, Oct-05, Volume: 240	Accommodation of ring C expanded deoxyvasicinone in the HDAC inhibitory pharmacophore culminates into a tractable anti-lung cancer agent and pH-responsive nanocarrier.
AID1873403	Inhibition of HDAC1 (unknown origin) preincubated for 120 mins	2022	Bioorganic & medicinal chemistry letters, 08-15, Volume: 70	Comparison of three zinc binding groups for HDAC inhibitors - A potency, selectivity and enzymatic kinetics study.
AID1900942	Toxicity in mouse bearing intracranial tumor assessed as median survival time at 50 mg/kg, ip in presence of clorgyline for 10 days (Rvb=13.8 days)	2022	Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
AID1754799	Downregulation of SIRT6 gene expression in human MCF7 cells at 3 uM incubated for 24 hrs by whole transcriptome analysis	2021	Bioorganic & medicinal chemistry, 07-15, Volume: 42	Discovery of novel class of histone deacetylase inhibitors as potential anticancer agents.
AID1433259	Antiproliferative activity against Ara-C resistant human HL60 cells after 72 hrs by MTT assay	2016	Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17	Synthesis and Antileukemic Activities of Piperlongumine and HDAC Inhibitor Hybrids against Acute Myeloid Leukemia Cells.
AID316941	Inhibition of HDAC9	2008	Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6	Histone deacetylase inhibitors: from bench to clinic.
AID1487011	Selectivity index, ratio of IC50 for HDAC1 (unknown origin) to IC50 for HDAC8 (unknown origin)	2017	Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15	The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity.
AID1784193	Inhibition of recombinant human HDAC6 using ZMAL as substrate incubated for 90 mins by fluorescence based micro plate assay	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Synthesis, structure-activity relationships, cocrystallization and cellular characterization of novel smHDAC8 inhibitors for the treatment of schistosomiasis.
AID1812442	Inhibition of human recombinant HDAC1 using Tosyl-Gly-ProLys(Ac)-AMC as substrate measured after 60 mins by fluorescence assay	2021	Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14	Procainamide-SAHA Fused Inhibitors of hHDAC6 Tackle Multidrug-Resistant Malaria Parasites.
AID1861660	Inhibition of colony formation in human HCT-116 cells at 2000 nM	2022	Bioorganic & medicinal chemistry letters, 09-15, Volume: 72	Exploration of 4-(1H-indol-3-yl)cyclohex-3-en-1-amine analogues as HDAC inhibitors: Design, synthesis, biological evaluation and modelling studies.
AID1865265	Inhibition of recombinant N-terminal GST-tagged human HDAC5 expressed in HEK293 cells using Ac-LeuGlyLys (TFA)-AMC substrate preincubated for 5 mins followed by substrate addition and measured after 30 mins by fluorescence based microplate reader analysis	2022	Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18	Discovery of Novel Src Homology-2 Domain-Containing Phosphatase 2 and Histone Deacetylase Dual Inhibitors with Potent Antitumor Efficacy and Enhanced Antitumor Immunity.
AID482939	Inhibition of HDAC1	2010	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11	Acylurea connected straight chain hydroxamates as novel histone deacetylase inhibitors: Synthesis, SAR, and in vivo antitumor activity.
AID632972	Cytotoxicity against human MCF7 cells	2011	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 21, Issue:24	Benzothiazole-containing hydroxamic acids as histone deacetylase inhibitors and antitumor agents.
AID1275651	Antitumor activity against human HCT116 cells xenografted in athymic nude mouse assessed as tumor growth inhibition at 40 mg/kg, ip qd administered for 14 days measured every other day during compound dosing	2016	European journal of medicinal chemistry, Feb-15, Volume: 109	Identification of N-(6-mercaptohexyl)-3-(4-pyridyl)-1H-pyrazole-5-carboxamide and its disulfide prodrug as potent histone deacetylase inhibitors with in vitro and in vivo anti-tumor efficacy.
AID1572380	Antiproliferative activity against human MCF7 cells after 72 hrs by CellTiter blue-reagent based assay	2019	Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3	Synthesis and Biological Investigation of Phenothiazine-Based Benzhydroxamic Acids as Selective Histone Deacetylase 6 Inhibitors.
AID1398807	Inhibition of HDAC3 in human MCF7 cells assessed as increase in acetylated histone H4 expression after 8 hrs by Western blot analysis	2018	Bioorganic & medicinal chemistry, 08-15, Volume: 26, Issue:15	Incorporation of histone deacetylase inhibitory activity into the core of tamoxifen - A new hybrid design paradigm.
AID1398822	Antagonist activity at ERalpha in human MCF7 cells assessed as suppression of MYBL2 mRNA expression at 5 uM after 24 hrs by QIAzol reagent based RT-qPCR analysis	2018	Bioorganic & medicinal chemistry, 08-15, Volume: 26, Issue:15	Incorporation of histone deacetylase inhibitory activity into the core of tamoxifen - A new hybrid design paradigm.
AID90522	Inhibitory concentration against rat liver Histone deacetylase	2003	Journal of medicinal chemistry, Nov-20, Volume: 46, Issue:24	Histone deacetylase inhibitors.
AID1063055	Inhibition of recombinant HDAC8 (unknown origin) using Fluor-de-Lys-HDAC8 as substrate by fluorescence assay	2014	Journal of natural products, Jan-24, Volume: 77, Issue:1	Protein kinase and HDAC inhibitors from the endophytic fungus Epicoccum nigrum.
AID1677513	Binding affinity to full length His-tagged Bcl-xl (unknown origin) preincubated for 30 min followed by 5-FAM Bid-BH3 addition and measured after 20 mins by fluorescence polarization assay	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	HDAC-Bax Multiple Ligands Enhance Bax-Dependent Apoptosis in HeLa Cells.
AID1525778	Inhibition of HADC2 (unknown origin)	2020	Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1	Old but Gold: Tracking the New Guise of Histone Deacetylase 6 (HDAC6) Enzyme as a Biomarker and Therapeutic Target in Rare Diseases.
AID1597941	Antiproliferative activity against human BGC823 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	2019	Bioorganic & medicinal chemistry letters, 09-15, Volume: 29, Issue:18	Anti-tumor activity evaluation of novel tubulin and HDAC dual-targeting inhibitors.
AID723430	Potentiation of 0.75 uM cisplatin-induced toxicity in 0.5 uM cisplatin resistant human KYSE-510 cells at 0.25 uM pretreated for 48 hrs followed by 0.5 uM cisplatin treatment by MTT assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1469394	Induction of apoptosis in human Hep3B cells assessed as live cells at 10 uM after 48 hrs by annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 97.9%)	2018	Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7	Discovery of N1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7 H-pyrrolo[2,3- d]pyrimidin-2-yl)amino)phenyl)- N8-hydroxyoctanediamide as a Novel Inhibitor Targeting Cyclin-dependent Kinase 4/9 (CDK4/9) and Histone Deacetlyase1 (HDAC1) against Malignant Cancer
AID1245688	Inhibition of Class 1 histone deacetylase in human PC3 cells using Boc-Lys (acetyl)-AMC as substrate preincubated for 3 hrs followed by substrate addition measured after 3 hrs by fluorescence assay	2015	Bioorganic & medicinal chemistry, Oct-01, Volume: 23, Issue:19	Development of N-hydroxybenzamide derivatives with indole-containing cap group as histone deacetylases inhibitors.
AID1518827	Antimalarial activity against ring stage Plasmodium falciparum 3D7 incubated for 48 hrs by Hoechst 33342 staining based fluorescence based assay	2019	European journal of medicinal chemistry, Dec-15, Volume: 184	Discovery of a potent histone deacetylase (HDAC) 3/6 selective dual inhibitor.
AID663356	Growth inhibition of human NCI-H522 cells after 72 hrs by MTS assay	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Discovery and extensive in vitro evaluations of NK-HDAC-1: a chiral histone deacetylase inhibitor as a promising lead.
AID1900929	Toxicity in mouse bearing intracranial tumor assessed as median survival time at 50 mg/kg, ip for 10 days (Rvb= 13.8 days)	2022	Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
AID1901148	Inhibition of HDAC in human HeLa cell nuclear extracts using color de Lys as substrate measured after 30 mins by colorimetric assay	2022	Bioorganic & medicinal chemistry, 02-15, Volume: 56	Synthesis and biological evaluation of aminobenzamides containing purine moiety as class I histone deacetylases inhibitors.
AID1129005	Inhibition of human HDAC-3/NCOR2 using RHKK(Ac) as substrate by fluorescence assay	2014	Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6	Synthesis and evaluation of new Hsp90 inhibitors based on a 1,4,5-trisubstituted 1,2,3-triazole scaffold.
AID546545	Inhibition of HDAC in human HeLa cell nuclear extracts	2010	Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24	Novel chimeric histone deacetylase inhibitors: a series of lapatinib hybrides as potent inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and histone deacetylase activity.
AID1141804	Antitumor activity against human HCT116 cells xenografted in nude athymic mouse assessed as tumor growth inhibition at 200 mg/kg/day, po after 2 to 16 days relative to control	2014	Journal of medicinal chemistry, May-22, Volume: 57, Issue:10	Azaindolylsulfonamides, with a more selective inhibitory effect on histone deacetylase 6 activity, exhibit antitumor activity in colorectal cancer HCT116 cells.
AID1239051	Cytotoxicity against human RPMI8226 cells assessed as cell viability after 72 hrs by CCK8 assay	2015	Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17	Design, synthesis and biological evaluation of isoquinoline-based derivatives as novel histone deacetylase inhibitors.
AID1321733	Inhibition of HDAC6 in human SH-SY5Y cells assessed as increase in alpha-tubulin acetylation at Lys 40 residue at 100 nM after 2 hrs by Western blot analysis relative to control	2016	Journal of medicinal chemistry, 10-13, Volume: 59, Issue:19	Design, Synthesis, and Biological Evaluation of First-in-Class Dual Acting Histone Deacetylases (HDACs) and Phosphodiesterase 5 (PDE5) Inhibitors for the Treatment of Alzheimer's Disease.
AID1421603	Inhibition of HDAC6 (unknown origin)	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	Design and synthesis of potent dual inhibitors of JAK2 and HDAC based on fusing the pharmacophores of XL019 and vorinostat.
AID765213	Cytotoxicity against human A2780 cells	2013	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17	Identification of novel HDAC inhibitors through cell based screening and their evaluation as potential anticancer agents.
AID476833	Toxicity in FVB mouse assessed as effect on hematocrit at 50 mg/kg, po administered 5 times per week for 2 weeks measured during test	2010	Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8	Modified cap group suberoylanilide hydroxamic acid histone deacetylase inhibitor derivatives reveal improved selective antileukemic activity.
AID1282251	Cytotoxicity against human RPMI8226 cells after 72 hrs by MTT assay	2016	Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4	Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
AID1597925	Antiproliferative activity against human LoVo cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	2019	Bioorganic & medicinal chemistry letters, 09-15, Volume: 29, Issue:18	Anti-tumor activity evaluation of novel tubulin and HDAC dual-targeting inhibitors.
AID1303629	Potentiation of 0.1 nM (-)-lomaiviticin A-induced cytotoxicity against human K562 cells assessed as combination index at 0.5 uM after 48 hrs by cell titer-glo luminescence assay	2016	Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13	Synergistic potentiation of (-)-lomaiviticin A cytotoxicity by the ATR inhibitor VE-821.
AID1576455	Cytotoxicity against human MCF10F cells assessed as reduction in cell viability after 48 hrs by SRB assay
AID1855258	Antiproliferative activity against human K562 cells after 48 hrs by CCK-8 assay	2022	European journal of medicinal chemistry, Nov-05, Volume: 241	Discovery of 2,5-diphenyl-1,3,4-thiadiazole derivatives as HDAC inhibitors with DNA binding affinity.
AID1282252	Cytotoxicity against human MV4-11 cells after 72 hrs by MTT assay	2016	Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4	Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
AID1541550	Inhibition of HDAC6 in human CAL27 cells assessed as acetylation of alpha-tubulin at 1 uM measured after 24 hrs by immunoblot analysis	2019	Journal of medicinal chemistry, 12-26, Volume: 62, Issue:24	Synthesis of Peptoid-Based Class I-Selective Histone Deacetylase Inhibitors with Chemosensitizing Properties.
AID1737156	Induction of apoptosis in human HCT-116 cells assessed as necrotic cells at 1 uM after 24 hrs by Annexin V-FITC/PI staining based flow cytometric analysis (Rvb = 0.51%)	2020	European journal of medicinal chemistry, Apr-15, Volume: 192	Design, synthesis and biological evaluation of novel indazole-based derivatives as potent HDAC inhibitors via fragment-based virtual screening.
AID1330926	Inhibition of HDAC1 (unknown origin) using acetylated peptide substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by fluorescence analysis	2017	Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1	Synthesis and investigation of novel 6-(1,2,3-triazol-4-yl)-4-aminoquinazolin derivatives possessing hydroxamic acid moiety for cancer therapy.
AID1515903	Antiproliferative activity against human K562 cells after 96 hrs by MTT assay	2019	Journal of medicinal chemistry, 08-08, Volume: 62, Issue:15	Design, Synthesis, and Biological Evaluation of 4-Methyl Quinazoline Derivatives as Anticancer Agents Simultaneously Targeting Phosphoinositide 3-Kinases and Histone Deacetylases.
AID1518830	Selectivity index, ratio of EC50 for human MDA-MB-231 cells to IC50 for ring stage Plasmodium falciparum K1	2019	European journal of medicinal chemistry, Dec-15, Volume: 184	Discovery of a potent histone deacetylase (HDAC) 3/6 selective dual inhibitor.
AID734732	Cytotoxicity against human Jurkat cells assessed as growth inhibition after 72 hrs by MTS assay	2013	Journal of medicinal chemistry, May-09, Volume: 56, Issue:9	3-Hydroxypyridin-2-thione as novel zinc binding group for selective histone deacetylase inhibition.
AID1865292	Antitumor activity against human MV4-11 cells xenografted in BALB/c nude mouse assessed as tumor growth inhibition at 40 mg/kg, po qd administered for 20 days	2022	Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18	Discovery of Novel Src Homology-2 Domain-Containing Phosphatase 2 and Histone Deacetylase Dual Inhibitors with Potent Antitumor Efficacy and Enhanced Antitumor Immunity.
AID1897390	Induction of cell cycle arrest in human SNU-16 cells assessed as accumulation of cells at G0/G1 phase at 0.03 to 1 uM incubated for 24 hrs by PI staining based flow cytometry analysis
AID1876473	Induction of apoptosis in human HCT-116 cells assessed as late apoptotic cells at 1 uM incubated for 48 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 5.80 %)	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	Design, synthesis, and biological evaluation of indole-based hydroxamic acid derivatives as histone deacetylase inhibitors.
AID710841	Inhibition of HDAC by fluorescence assay	2012	Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23	Property-based optimization of hydroxamate-based γ-lactam HDAC inhibitors to improve their metabolic stability and pharmacokinetic profiles.
AID1515915	Antiproliferative activity against human HuH7 cells after 96 hrs by MTT assay	2019	Journal of medicinal chemistry, 08-08, Volume: 62, Issue:15	Design, Synthesis, and Biological Evaluation of 4-Methyl Quinazoline Derivatives as Anticancer Agents Simultaneously Targeting Phosphoinositide 3-Kinases and Histone Deacetylases.
AID1897395	Induction of apoptosis in human SNU-16 cells assessed as dead cells at 0.03 uM incubated for 72 hrs by annexin-V/FITC propidium iodide staining based flow cytometry analysis (Rvb = 2.65%)
AID1234888	Inhibition of HDAC1 (unknown origin) using Boc-Lys (acetyl)-AMC as substrate preincubated for 30 mins before substrate addition measured after 20 mins by UV-vis spectrophotometer analysis	2015	Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15	Design, synthesis and preliminary biological evaluation of indoline-2,3-dione derivatives as novel HDAC inhibitors.
AID1355687	Inhibition of JAK2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition and measured after 25 mins in presence of ATP	2018	Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14	Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections.
AID476829	Toxicity in FVB mouse assessed as effect on mean cell volume of red cells at 50 mg/kg, po administered 5 times per week for 2 weeks measured during test (Rvb = 43.7 +/- 0.4 microm^3)	2010	Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8	Modified cap group suberoylanilide hydroxamic acid histone deacetylase inhibitor derivatives reveal improved selective antileukemic activity.
AID328826	Antitumor activity against human HCT116 cells xenografted BALB/c mouse assessed as tumor growth inhibition at 100 mg/kg, ip administered for 5 days per week for 2.5 weeks	2008	Journal of medicinal chemistry, Apr-24, Volume: 51, Issue:8	A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo.
AID1398799	Inhibition of full length recombinant human N-terminal GST-tagged HDAC6 expressed in Sf9 cells using Ac-Leu-Gly-Lys(Ac)-AMC as substrate measured after 30 mins by fluorescence assay	2018	Bioorganic & medicinal chemistry, 08-15, Volume: 26, Issue:15	Incorporation of histone deacetylase inhibitory activity into the core of tamoxifen - A new hybrid design paradigm.
AID723439	Potentiation of 1 uM cisplatin-induced toxicity in 5 uM cisplatin resistant human A2780 cells at 1 uM pretreated for 48 hrs followed by 5 uM cisplatin treatment by MTT assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1431819	Selectivity ratio of IC50 for human KDAC3 to IC50 for human KDAC8	2017	European journal of medicinal chemistry, Feb-15, Volume: 127	Design and synthesis of benzodiazepine analogs as isoform-selective human lysine deacetylase inhibitors.
AID723726	Inhibition of HDAC in human A2780 cells after 18 hrs by fluorescence assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID246080	Effective Concentration of compound to inhibit the growth of human LOX-IMVI cells	2005	Journal of medicinal chemistry, Feb-24, Volume: 48, Issue:4	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates.
AID1688027	Induction of apoptosis in human HL-60 cells assessed as increase in accumulation at sub-G1 phase at 0.5 uM after 24 hrs by propidium iodide staining based flow cytometry (Rvb = 2.72 %)	2020	European journal of medicinal chemistry, Feb-15, Volume: 188	A 18β-glycyrrhetinic acid conjugate with Vorinostat degrades HDAC3 and HDAC6 with improved antitumor effects.
AID1888591	Cytotoxicity against human HL7702 cells measured after 72 hrs by MTT assay
AID1481747	Antiproliferative activity against human RPMI8266 cells after 72 hrs by MTT assay	2017	Bioorganic & medicinal chemistry letters, 05-01, Volume: 27, Issue:9	Design and synthesis of novel 6-aryl substituted 4-anilinequinazoline derivatives as potential PI3Kδ inhibitors.
AID1732192	Cytotoxicity against human HL-60 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	2021	European journal of medicinal chemistry, Apr-05, Volume: 215	CAP rigidification of MS-275 and chidamide leads to enhanced antiproliferative effects mediated through HDAC1, 2 and tubulin polymerization inhibition.
AID1422521	Inhibition of human recombinant HDAC1 at 2 uM after 15 to 30 mins by fluorometric method	2018	European journal of medicinal chemistry, Nov-05, Volume: 159	In search of constrained FTY720 and phytosphingosine analogs as dual acting anticancer agents targeting metabolic and epigenetic pathways.
AID659495	Inhibition of HDAC8 in human HeLa cell nuclear extract using Fluor de Lys as substrate after 15 mins by fluorometric analysis	2012	Journal of medicinal chemistry, Feb-23, Volume: 55, Issue:4	Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors.
AID1246525	Therapeutic index, ratio of CC50 for HEK293 cells to IC50 for human THP1 cells	2015	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 25, Issue:19	Discovery of 1-hydroxypyridine-2-thiones as selective histone deacetylase inhibitors and their potential application for treating leukemia.
AID1441657	Anti-inflammatory activity in LPS-induced C57BL/6 mouse model of acute lung injury assessed as reduction in protein concentration in BALF at 25 mg/kg, ip pretreated for 1 hr followed LPS challenge measured after 24 hrs	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
AID1537556	Selectivity index, ratio of IC50 for recombinant full length C-terminal FLAG/His-tagged human HDAC1 expressed in baculovirus infected Sf9 cells to IC50 for recombinant full length N-terminal GST-tagged human HDAC6 expressed in baculovirus infected Sf9 cel	2019	MedChemComm, Jul-01, Volume: 10, Issue:7	Design, synthesis and biological evaluation of β-peptoid-capped HDAC inhibitors with anti-neuroblastoma and anti-glioblastoma activity.
AID1451833	Inhibition of GST tagged full length human recombinant HDAC8 (H90 to 30H) expressed in Baculovirus infected Sf9 insect cells using Ac-Leu-Gly-Lys(Tfa)-AMC as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by fluore	2017	Journal of medicinal chemistry, 10-12, Volume: 60, Issue:19	Small Molecule Inhibitors Simultaneously Targeting Cancer Metabolism and Epigenetics: Discovery of Novel Nicotinamide Phosphoribosyltransferase (NAMPT) and Histone Deacetylase (HDAC) Dual Inhibitors.
AID1915523	Inhibition of HDAC-1 (unknown origin) expressed in Escherichia coli BL21 (DE3) in HeLa nuclear extract using KI177 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by Bradford reagent method	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors.
AID1164176	Cell cycle arrest in human MCF7 cells assessed as block at G1 phase at 5 uM after 24 to 96 hrs using propidium iodide staining by FACScan flow cytometry	2014	ACS medicinal chemistry letters, Sep-11, Volume: 5, Issue:9	Novel antiproliferative chimeric compounds with marked histone deacetylase inhibitory activity.
AID1165104	Antileishmanial activity against promastigote stage of Leishmania donovani after 72 hrs by Alamar blue assay	2014	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 24, Issue:20	The antileishmanial activity of isoforms 6- and 8-selective histone deacetylase inhibitors.
AID1215086	Activation of human PXR expressed in human HepG2 (DPX-2) cells after 24 hrs by luciferase reporter gene based luminescent analysis	2011	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1	Identification of clinically used drugs that activate pregnane X receptors.
AID1502989	Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay	2017	European journal of medicinal chemistry, Nov-10, Volume: 140	Design and synthesis of tranylcypromine derivatives as novel LSD1/HDACs dual inhibitors for cancer treatment.
AID1205625	Inhibition of HDAC in human HeLa cell nuclear extract using Fluor de Lys as substrate incubated with compound for 30 mins by microtiter-plate reading flourimeter analysis	2015	Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8	Discovery of Orally Available Runt-Related Transcription Factor 3 (RUNX3) Modulators for Anticancer Chemotherapy by Epigenetic Activation and Protein Stabilization.
AID1785339	Inhibition of HDAC8 (unknown origin) measured after 30 mins by fluorescence microplate reader assay
AID723161	Potentiation of 25 uM cisplatin-induced toxicity in 1 uM cisplatin resistant human MDA-MB-231 cells at 1.5 uM pretreated for 48 hrs followed by 1 uM cisplatin treatment by MTT assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1702068	Inhibition of C-terminal His-tagged human HDAC9 (604 to 1066 residues) expressed in baculovirus infected Sf9 cells using fluorogenic HDAC class2a as substrate measured after 30 mins by fluorescence based assay	2018	Journal of medicinal chemistry, 02-22, Volume: 61, Issue:4	Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma.
AID392398	Inhibition of human recombinant C-terminal FLAG-tagged HDAC1 expressed in baculovirus by fluorimetry	2009	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 19, Issue:2	Sulfamides as novel histone deacetylase inhibitors.
AID1704068	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay	2020	European journal of medicinal chemistry, Oct-15, Volume: 204	Discovery of Novel c-Mesenchymal-Epithelia transition factor and histone deacetylase dual inhibitors.
AID420318	Inhibition of Bordetella / Alcaligenes strain FB188 HDAH by fluorimetric assay	2009	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 19, Issue:13	Non-isotopic dual parameter competition assay suitable for high-throughput screening of histone deacetylases.
AID1303621	Potentiation of 0.025 nM (-)-lomaiviticin A-induced cytotoxicity against human K562 cells assessed as fraction ratio affected at 0.125 uM after 48 hrs by cell titer-glo luminescence assay	2016	Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13	Synergistic potentiation of (-)-lomaiviticin A cytotoxicity by the ATR inhibitor VE-821.
AID723153	Potentiation of 1 uM cisplatin-induced toxicity in 0.5 uM cisplatin resistant human KYSE-510 cells at 1.5 uM pretreated for 48 hrs followed by 0.5 uM cisplatin treatment by MTT assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1401506	Inhibition of HDAC6 in human U937 cells assessed as increase in acetyl-alpha-tubulin levels at 5 uM after 18 hrs by Western blot method	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
AID1275592	Inhibition of human recombinant HDAC3 using acetyllysine tripeptide coupled with 7-amino-4-methylcoumarin as substrate by fluorescence assay	2016	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4	Dissecting structure-activity-relationships of crebinostat: Brain penetrant HDAC inhibitors for neuroepigenetic regulation.
AID1361642	Cell cycle arrest in human A549 cells assessed as accumulation of cells at S phase at 1 uM after 48 hrs by flow cytometric analysis (Rvb = 31.18%)	2018	Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16	Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents.
AID1709356	Cytotoxicity against human Jurkat cells assessed as reduction in cell viability measured after 24 hrs MTT assay	2021	Bioorganic & medicinal chemistry, 04-01, Volume: 35	Structure-activity relationship and mechanistic studies for a series of cinnamyl hydroxamate histone deacetylase inhibitors.
AID1623537	Selectivity index, ratio of IC50 for HDAC10 (unknown origin) to IC50 for human recombinant HDAC6	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	A novel class of anthraquinone-based HDAC6 inhibitors.
AID1686353	Drug metabolism in human liver microsomes assessed as o-glucuronidated metabolite formation in absence of UDP glucuronic acid incubated for 12 hrs at 37 degC by electrospray ionization liquid chromatography mass spectrometry	2016	Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21	Development of Allosteric Hydrazide-Containing Class I Histone Deacetylase Inhibitors for Use in Acute Myeloid Leukemia.
AID1832804	Inhibition of human HDAC2 assessed as target activity using fluorogenic substrate ZMAL for 90 min by microplate reader at 355nm	2021	Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19	4-Acyl Pyrrole Capped HDAC Inhibitors: A New Scaffold for Hybrid Inhibitors of BET Proteins and Histone Deacetylases as Antileukemia Drug Leads.
AID1858656	Cytotoxicity against human SMMC-7721 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	Paradigm shift of "classical" HDAC inhibitors to "hybrid" HDAC inhibitors in therapeutic interventions.
AID639798	Oral bioavailability in mouse	2011	Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8	Discovery, synthesis, and pharmacological evaluation of spiropiperidine hydroxamic acid based derivatives as structurally novel histone deacetylase (HDAC) inhibitors.
AID1848593	Induction of cell cycle arrest in human NCI-H522 cells assessed as accumulation at G1 phase 5 uM incubated for 24 to 72 hrs by PI staining based flow cytometric analysis	2022	Journal of medicinal chemistry, 11-10, Volume: 65, Issue:21	First-in-Class Dual Mechanism Ferroptosis-HDAC Inhibitor Hybrids.
AID316905	Inhibition of human LOX-IMVI cells	2008	Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6	Histone deacetylase inhibitors: from bench to clinic.
AID1293569	Inhibition of human recombinant C-terminal His-tagged HDAC8 (1 to 377 residues) expressed in insect cells using RHK-K(Ac)-AMC as substrate incubated for 60 mins by fluorescence assay	2016	European journal of medicinal chemistry, Apr-13, Volume: 112	Biphenyl-4-yl-acrylohydroxamic acids: Identification of a novel indolyl-substituted HDAC inhibitor with antitumor activity.
AID1572352	Inhibition of HDAC in human HL60 cells assessed as acetylated H3/GAPDH ratio at 0.1 uM after 4 hrs by Western blot assay relative to control	2019	Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3	Synthesis and Biological Investigation of Phenothiazine-Based Benzhydroxamic Acids as Selective Histone Deacetylase 6 Inhibitors.
AID519584	Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 infected in O+ human erythrocytes by [3H]hypoxanthine incorporation assay	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Potent antimalarial activity of histone deacetylase inhibitor analogues.
AID1826651	Antitumor activity against HEL cells xenografted in BALB/C mouse assessed as T/C value at 10 mg/kg, po qd for 14 days consecutively by caliper method relative to control	2022	Journal of medicinal chemistry, 03-24, Volume: 65, Issue:6	Evodiamine-Inspired Topoisomerase-Histone Deacetylase Dual Inhibitors: Novel Orally Active Antitumor Agents for Leukemia Therapy.
AID1864226	Inhibition of full length recombinant N-terminal GST-tagged human HDAC4 (612 to end residues)expressed in baculovirus infected Sf9 insect cells incubated for 50 mins by Glo- luminescence assay	2022	Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18	Discovery of a Novel G-Quadruplex and Histone Deacetylase (HDAC) Dual-Targeting Agent for the Treatment of Triple-Negative Breast Cancer.
AID1390009	Inhibition of HDAC in human HeLa nuclear extract using Boc-Lys-(Ac)-AMC as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by fluorescence assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Design, synthesis and biological evaluation of novel hydroxamic acid based histone deacetylase 6 selective inhibitors bearing phenylpyrazol scaffold as surface recognition motif.
AID1821270	Inhibition of HDAC1 (unknown origin) incubated for 30 mins by microplate reader assay	2022	European journal of medicinal chemistry, Feb-05, Volume: 229	Discovery of phthalazino[1,2-b]-quinazolinone derivatives as multi-target HDAC inhibitors for the treatment of hepatocellular carcinoma via activating the p53 signal pathway.
AID461262	Antiproliferative activity against human MDA-MB-231 cells after hrs by ATP content assay	2010	Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5	Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer.
AID1293570	Inhibition of human HDAC9 using RHK-K(Ac)-AMC as substrate incubated for 60 mins by fluorescence assay	2016	European journal of medicinal chemistry, Apr-13, Volume: 112	Biphenyl-4-yl-acrylohydroxamic acids: Identification of a novel indolyl-substituted HDAC inhibitor with antitumor activity.
AID1487000	Inhibition of HDAC2 (unknown origin) by ELISA-based assay	2017	Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15	The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity.
AID1511131	Inhibition of HDAC2 (unknown origin) using Ac-LeuGlyLys(Ac)-AMC as substrate preincubated for 5 mins followed by substrate addition and measured after 60 mins by fluorescence based assay	2019	ACS medicinal chemistry letters, Aug-08, Volume: 10, Issue:8	Design, Synthesis, and Biological Evaluation of 2,4-Imidazolinedione Derivatives as HDAC6 Isoform-Selective Inhibitors.
AID1614232	Induction of apoptosis in human MM1S cells assessed as necrotic cells at 1 uM after 48 hrs in presence of 0.3 uM RAPA by Annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 0.32%)
AID1614227	Induction of apoptosis in human MM1S cells assessed as late apoptotic cells at 1 uM after 48 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 0.42%)
AID1622901	Cytotoxicity against human A549 cells after 72 hrs by CellTiter-Glo assay	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.
AID1897399	Induction of apoptosis in human SNU-16 cells assessed as dead cells at 0.1 uM incubated for 72 hrs by annexin-V/FITC propidium iodide staining based flow cytometry analysis (Rvb = 2.65%)
AID669760	Growth inhibition of human A549 cells after 48 hrs by SRB assay	2012	Journal of medicinal chemistry, Apr-26, Volume: 55, Issue:8	Synthesis and biological evaluation of 1-arylsulfonyl-5-(N-hydroxyacrylamide)indoles as potent histone deacetylase inhibitors with antitumor activity in vivo.
AID759305	Inhibition of human recombinant HDAC1 after 30 mins by fluorescence assay	2013	Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14	Histone deacetylase inhibitors equipped with estrogen receptor modulation activity.
AID1449680	Antiproliferative activity against human MOLT4 cells after 48 hrs by MTT assay	2017	Bioorganic & medicinal chemistry, 05-01, Volume: 25, Issue:9	Development of N-hydroxycinnamamide-based HDAC inhibitors with improved HDAC inhibitory activity and in vitro antitumor activity.
AID384318	Selectivity for IC50 of maize histone deacetylase 1B over IC50 of maize histone deacetylase 1A	2008	European journal of medicinal chemistry, Mar, Volume: 43, Issue:3	Class II-selective histone deacetylase inhibitors. Part 2: alignment-independent GRIND 3-D QSAR, homology and docking studies.
AID524995	Inhibition of HDAC10 by in vitro deacetylation assay	2010	Nature chemical biology, Jan, Volume: 6, Issue:1	Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.
AID663399	Growth inhibition of human MDA-MB-231 cells after 72 hrs by MTS assay	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Discovery and extensive in vitro evaluations of NK-HDAC-1: a chiral histone deacetylase inhibitor as a promising lead.
AID546564	Cytotoxicity against human SKOV3 cells overexpressing HER2 by resazurin dye reduction assay	2010	Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24	Novel chimeric histone deacetylase inhibitors: a series of lapatinib hybrides as potent inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and histone deacetylase activity.
AID1550087	Activation of JAK in human MDA-MB-231 cells assessed as upregulation of p-STAT3-Tyr705 level at 5 uM after 12 hrs by Western blot analysis	2019	Journal of medicinal chemistry, 04-25, Volume: 62, Issue:8	Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies.
AID762186	Cytotoxicity against human MCF7 cells assessed as growth inhibition by measuring cellular ATP level after 72 hrs by cell-titer glo assay	2013	Journal of medicinal chemistry, Aug-08, Volume: 56, Issue:15	Discovery of potent, isoform-selective inhibitors of histone deacetylase containing chiral heterocyclic capping groups and a N-(2-aminophenyl)benzamide binding unit.
AID1245680	Inhibition of Class 1 histone deacetylase isolated from human HeLa cell nuclear extracts using Boc-Lys (acetyl)-AMC as substrate preincubated for 10 mins followed by substrate addition measured after 30 mins by fluorescence assay	2015	Bioorganic & medicinal chemistry, Oct-01, Volume: 23, Issue:19	Development of N-hydroxybenzamide derivatives with indole-containing cap group as histone deacetylases inhibitors.
AID1742686	Induction of cell cycle arrest in mouse 4T1 cells assessed as G2/M phase accumulation at 2 uM incubated for 24 hrs by PI staining based flow cytometry analysis (Rvb = 38.51 %)	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Design and synthesis of novel Flavone-based histone deacetylase inhibitors antagonizing activation of STAT3 in breast cancer.
AID1061948	Cytotoxicity against human H460 cells	2014	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1	Lactam based 7-amino suberoylamide hydroxamic acids as potent HDAC inhibitors.
AID1401369	Inhibition of HDAC in human HeLa-S3 cell lysates assessed as residual activity at 1 x 10'-7 M preincubated for 15 mins followed by HDAC-Glo substrate addition measured after 35 mins by fluorimetric method relative to control	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
AID1545980	Antiproliferative activity against human LoVo cells by MTT assay	2019	European journal of medicinal chemistry, Dec-01, Volume: 183	1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships.
AID420512	Cell cycle arrest in cisplatin-resistant human IGROV1 cells assessed as partial accumulation at S phase at IC80 using propidium-iodide staining by flow-cytometry	2009	European journal of medicinal chemistry, May, Volume: 44, Issue:5	Design, synthesis, and evaluation of biphenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors.
AID1464872	Inhibition of HDAC8 (unknown origin)	2017	Bioorganic & medicinal chemistry letters, 11-01, Volume: 27, Issue:21	Design, synthesis and biological evaluation of novel histone deacetylase inhibitors incorporating 4-aminoquinazolinyl systems as capping groups.
AID1702088	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay	2018	Journal of medicinal chemistry, 02-22, Volume: 61, Issue:4	Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma.
AID605529	Antiproliferative activity against human LoVo cells after 72 hrs by WST-1 assay	2010	Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24	Discovery of 2-(6-{[(6-fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a class I selective orally active histone deacetylase inhibitor.
AID1454680	Decrease in alcohol intake in rat assessed as operant alcohol self-administration at 50 mg/kg, ip administered once in a week relative to control	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Class I HDAC Inhibitors: Potential New Epigenetic Therapeutics for Alcohol Use Disorder (AUD).
AID1578153	Antiproliferative activity against human A549 cells assessed as cell growth inhibition after 48 hrs by sulforhodamine B assay	2020	European journal of medicinal chemistry, Jan-01, Volume: 185	N-alkyl-hydroxybenzoyl anilide hydroxamates as dual inhibitors of HDAC and HSP90, downregulating IFN-γ induced PD-L1 expression.
AID1482130	Antitumor activity against mouse P388 cells implanted in CDF1 mouse assessed as increase in median survival time at 50 mg/kg, ip administered for 9 consecutive days	2017	Journal of medicinal chemistry, 04-27, Volume: 60, Issue:8	Exploring Derivatives of Quinazoline Alkaloid l-Vasicine as Cap Groups in the Design and Biological Mechanistic Evaluation of Novel Antitumor Histone Deacetylase Inhibitors.
AID723142	Potentiation of 10 uM cisplatin-induced toxicity in 1 uM cisplatin resistant human CAL27 cells at 1 uM pretreated for 48 hrs followed by 1 uM cisplatin treatment by MTT assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1752936	Inhibition of C-terminal FLAG/His-tagged human recombinant HDAC1 (1 to 482 residues) expressed in baculovirus infected Sf9 cells using ZMAL (Z-Lys(Ac)-AMC) as fluorogenic substrate incubated for 90 mins by fluorescence based assay
AID1753834	Inhibition of recombinant full length human HDAC6 expressed in baculovirus infected Sf9 cells using Z-(Ac)-Lys-AMC as substrate incubated for 40 mins by fluorescence based assay	2021	European journal of medicinal chemistry, Jun-05, Volume: 218	Identification of novel 1,3-diaryl-1,2,4-triazole-capped histone deacetylase 6 inhibitors with potential anti-gastric cancer activity.
AID1279129	Inhibition of C-terminal His-tagged human recombinant HDAC8 expressed in Sf9 cells after 30 mins by microtiter plate reader analysis	2016	Bioorganic & medicinal chemistry, Apr-01, Volume: 24, Issue:7	Design and synthesis of a new generation of substituted purine hydroxamate analogs as histone deacetylase inhibitors.
AID1702083	Antiproliferative activity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay	2018	Journal of medicinal chemistry, 02-22, Volume: 61, Issue:4	Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma.
AID226263	Fold selectivity for classI HDAC	2003	Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23	Discovery of (aryloxopropenyl)pyrrolyl hydroxyamides as selective inhibitors of class IIa histone deacetylase homologue HD1-A.
AID350727	Growth inhibition of human HCT116 cells after 48 hrs by sulforhodamine B assay	2009	Journal of medicinal chemistry, May-14, Volume: 52, Issue:9	Design, synthesis, and biological activity of boronic acid-based histone deacetylase inhibitors.
AID286789	Inhibition of HDAC2	2007	Journal of medicinal chemistry, May-17, Volume: 50, Issue:10	Bispyridinium dienes: histone deacetylase inhibitors with selective activities.
AID524823	Inhibition of HDAC7 in human homozygous Fdelta508 primary bronchial epithelial cells assessed as increase in mutant Fdelta508 CFTR protein level at 1 uM for 8 days by immunoblot analysis	2010	Nature chemical biology, Jan, Volume: 6, Issue:1	Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.
AID1384233	Inhibition of PDE5 in human SH-SY5Y cells assessed as induction of phosphorylated CREB level at 500 nM after 30 mins by Western blot analysis relative to control	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease.
AID1280308	Inhibition of human KDAC6	2016	Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4	Design and Synthesis of Simplified Largazole Analogues as Isoform-Selective Human Lysine Deacetylase Inhibitors.
AID1469375	Cytotoxicity against human MDA-MB-468 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	2018	Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7	Discovery of N1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7 H-pyrrolo[2,3- d]pyrimidin-2-yl)amino)phenyl)- N8-hydroxyoctanediamide as a Novel Inhibitor Targeting Cyclin-dependent Kinase 4/9 (CDK4/9) and Histone Deacetlyase1 (HDAC1) against Malignant Cancer
AID1876476	Induction of cell cycle arrest in human HCT-116 cells assessed as increase in accumulation of cells at G2/M phase at 1 uM incubated for 24 hrs by flow cytometry analysis	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	Design, synthesis, and biological evaluation of indole-based hydroxamic acid derivatives as histone deacetylase inhibitors.
AID1141778	Induction of apoptosis in human HCT116 cells assessed as accumulation at sub-G1 phase at 1 uM by propidium iodide staining-based flow cytometric analysis	2014	Journal of medicinal chemistry, May-22, Volume: 57, Issue:10	Azaindolylsulfonamides, with a more selective inhibitory effect on histone deacetylase 6 activity, exhibit antitumor activity in colorectal cancer HCT116 cells.
AID1915571	Inhibition of HDAC (unknown origin)	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors.
AID492806	Cell cycle arrest in human NB4 cells assessed as increase in accumulation at pre-G1 phase at 5 uM after 24 hrs by FACS analysis	2010	Journal of medicinal chemistry, Jun-24, Volume: 53, Issue:12	Synthesis and biological characterization of the histone deacetylase inhibitor largazole and C7- modified analogues.
AID723465	Inhibition of human HDAC2 by fluorescence assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1390026	Antiproliferative activity against human SK-N-BE(2) cells after 48 hrs by MTT assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Structure optimization and preliminary bioactivity evaluation of N-hydroxybenzamide-based HDAC inhibitors with Y-shaped cap.
AID1821341	Toxicity in mouse xenografted with human HepG2 cells assessed as spleen edema at 12 mg/kg, ip administered every 2 days for 4 weeks by H and E staining based microscopic method	2022	European journal of medicinal chemistry, Feb-05, Volume: 229	Discovery of phthalazino[1,2-b]-quinazolinone derivatives as multi-target HDAC inhibitors for the treatment of hepatocellular carcinoma via activating the p53 signal pathway.
AID1282241	Inhibition of recombinant HDAC5 (unknown origin) using AMC labeled AC-peptide as substrate incubated for 1 hr by fluorescence analysis	2016	Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4	Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
AID461257	Antiproliferative activity against human Hep3B2 cells after hrs by ATP content assay	2010	Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5	Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer.
AID1279124	Inhibition of HDAC1/2 in human HeLa cell nuclear extract using color de Lys as substrate preincubated for 5 mins followed by substrate addition measured after 30 min by microtiter plate reader analysis	2016	Bioorganic & medicinal chemistry, Apr-01, Volume: 24, Issue:7	Design and synthesis of a new generation of substituted purine hydroxamate analogs as histone deacetylase inhibitors.
AID1653097	Antiproliferative activity against human MCF7 cells by CCK8 assay	2019	European journal of medicinal chemistry, Mar-01, Volume: 165	Quinolone hybrids and their anti-cancer activities: An overview.
AID1275634	Inhibition of recombinant human HDAC6 using Boc-Lys(Ac)-AMC as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by fluorescence-based assay	2016	European journal of medicinal chemistry, Feb-15, Volume: 109	Identification of N-(6-mercaptohexyl)-3-(4-pyridyl)-1H-pyrazole-5-carboxamide and its disulfide prodrug as potent histone deacetylase inhibitors with in vitro and in vivo anti-tumor efficacy.
AID71648	Inhibitory concentration against friend cells proliferation	2003	Journal of medicinal chemistry, Nov-20, Volume: 46, Issue:24	Histone deacetylase inhibitors.
AID734731	Cytotoxicity against human Jurkat gamma1 cells assessed as growth inhibition after 72 hrs by MTS assay	2013	Journal of medicinal chemistry, May-09, Volume: 56, Issue:9	3-Hydroxypyridin-2-thione as novel zinc binding group for selective histone deacetylase inhibition.
AID1282287	Toxicity in Balb/c nude mouse xenografted with human HCT116 cells assessed as change in body weight at 100 mg/kg, po q2d for 8 days	2016	Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4	Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
AID1605978	Antiproliferative activity against human Caki1 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	2020	Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8	Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors.
AID1859932	Inhibition of HDAC in human HCT-116 cells assessed as increase in acetylation level of HSP90 at 10 uM measured after 24 to 48 hrs by Western blot analysis	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Azetidin-2-one-based small molecules as dual hHDAC6/HDAC8 inhibitors: Investigation of their mechanism of action and impact of dual inhibition profile on cell viability.
AID1754815	Inhibition of HDAC in human MCF7 cells assessed as increase in acetylated histone H3 mRNA level at 3 uM incubated for 24 hrs by whole transcriptome analysis	2021	Bioorganic & medicinal chemistry, 07-15, Volume: 42	Discovery of novel class of histone deacetylase inhibitors as potential anticancer agents.
AID274100	Effect of compound on Candida albicans sensitivity to Fluconazole: Minimum inhibitory concentration required to inhibit the growth of 90% of isolates after 48h.	2007	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 17, Issue:5	Discovery of uracil-based histone deacetylase inhibitors able to reduce acquired antifungal resistance and trailing growth in Candida albicans.
AID1326520	Inhibition of full length recombinant human HDAC2 expressed in baculovirus expression system assessed as release of 7-amino-4-methylcoumarin by fluorogenic assay	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	2-(Phenylsulfonyl)quinoline N-hydroxyacrylamides as potent anticancer agents inhibiting histone deacetylase.
AID1887691	Cytotoxicity against human WI-38 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	Design, synthesis and biological evaluation of novel o-aminobenzamide derivatives as potential anti-gastric cancer agents in vitro and in vivo.
AID1808551	Inhibition of recombinant human N-terminal GST-tagged HDAC7 expressed in baculovirus infected Sf9 insect cells using fluorogenic substrate measured after 60 mins by FRET assay	2021	Journal of medicinal chemistry, 04-08, Volume: 64, Issue:7	Structure-Based Design of a Selective Class I Histone Deacetylase (HDAC) Near-Infrared (NIR) Probe for Epigenetic Regulation Detection in Triple-Negative Breast Cancer (TNBC).
AID1246518	Cytotoxicity against human K562 cells assessed as reduction in cell viability	2015	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 25, Issue:19	Discovery of 1-hydroxypyridine-2-thiones as selective histone deacetylase inhibitors and their potential application for treating leukemia.
AID1653138	Cytotoxicity against human HCT116 cells assessed as reduction in cell viability by SRB assay	2019	European journal of medicinal chemistry, Mar-01, Volume: 165	Quinolone hybrids and their anti-cancer activities: An overview.
AID1478593	Inhibition of HDAC8 (unknown origin) using substrate after 30 mins by fluorometric analysis	2017	European journal of medicinal chemistry, Jun-16, Volume: 133	Design, synthesis and biological evaluation of quinoline derivatives as HDAC class I inhibitors.
AID1633670	Neurotoxicity against rat CGN cells assessed as cell viability at 50 uM incubated for 24 hrs by MTT assay	2019	ACS medicinal chemistry letters, Apr-11, Volume: 10, Issue:4	Novel Sustainable-by-Design HDAC Inhibitors for the Treatment of Alzheimer's Disease.
AID1200999	Cmax in ICR mouse at 50 mg/kg, po	2015	Journal of medicinal chemistry, Mar-26, Volume: 58, Issue:6	Design and synthesis of orally bioavailable aminopyrrolidinone histone deacetylase 6 inhibitors.
AID1469313	Induction of apoptosis in human T47D cells assessed as live cells at 10 uM after 48 hrs by annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 85.3%)	2018	Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7	Discovery of N1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7 H-pyrrolo[2,3- d]pyrimidin-2-yl)amino)phenyl)- N8-hydroxyoctanediamide as a Novel Inhibitor Targeting Cyclin-dependent Kinase 4/9 (CDK4/9) and Histone Deacetlyase1 (HDAC1) against Malignant Cancer
AID1819514	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	2022	Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4	Discovery of DNA-Targeting HDAC Inhibitors with Potent Antitumor Efficacy In Vivo That Trigger Antitumor Immunity.
AID1550109	Antiproliferative activity against human Jurkat cells assessed as reduction in cell viability after 48 hrs by MTT assay	2019	Journal of medicinal chemistry, 04-25, Volume: 62, Issue:8	Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies.
AID1165109	Antileishmanial activity against amastigote stage of Leishmania donovani infected in human THP1 cells after 48 hrs by Alamar blue assay	2014	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 24, Issue:20	The antileishmanial activity of isoforms 6- and 8-selective histone deacetylase inhibitors.
AID1487089	Growth inhibition of human Jurkat cells assessed as cell viability at 10 uM incubated for 44 hrs by MTT assay	2017	Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15	The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity.
AID489911	Inhibition of human HDAC8	2010	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 20, Issue:13	Design, synthesis and anticancer activity of piperazine hydroxamates and their histone deacetylase (HDAC) inhibitory activity.
AID1282239	Inhibition of recombinant HDAC3 (unknown origin) using AMC labeled AC-peptide as substrate incubated for 1 hr by fluorescence analysis	2016	Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4	Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
AID723141	Potentiation of 10 uM cisplatin-induced toxicity in 1 uM cisplatin resistant human CAL27 cells at 1.5 uM pretreated for 48 hrs followed by 1 uM cisplatin treatment by MTT assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1380941	Antiproliferative activity against human ACHN cells after 72 hrs by MTT assay	2018	Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12	Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously.
AID1478596	Antiproliferative activity against human K562 cells after 48 hrs by MTT assay	2017	European journal of medicinal chemistry, Jun-16, Volume: 133	Design, synthesis and biological evaluation of quinoline derivatives as HDAC class I inhibitors.
AID1303624	Potentiation of 0.5 nM (-)-lomaiviticin A-induced cytotoxicity against human K562 cells assessed as fraction ratio affected at 2.5 uM after 48 hrs by cell titer-glo luminescence assay	2016	Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13	Synergistic potentiation of (-)-lomaiviticin A cytotoxicity by the ATR inhibitor VE-821.
AID1764803	Selectivity index, ratio of IC50 for recombinant human HDAC8 using Boc-Lys(TFA)-AMC as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins by fluorescence-based assay to IC50 recombinant for human HDAC6 using Ac-GA	2021	Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8	Tetrahydroquinoline-Capped Histone Deacetylase 6 Inhibitor SW-101 Ameliorates Pathological Phenotypes in a Charcot-Marie-Tooth Type 2A Mouse Model.
AID723457	Potentiation of cisplatin-induced toxicity in cisplatin resistant human CAL27 cells at 1 uM pretreated for 48 hrs followed by cisplatin treatment by MTT assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1848586	Inhibition of full length C-terminal his-tagged human recombinant HDAC8 expressed in Sf9 insect cells	2022	Journal of medicinal chemistry, 11-10, Volume: 65, Issue:21	First-in-Class Dual Mechanism Ferroptosis-HDAC Inhibitor Hybrids.
AID1404296	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by resazurin dye based fluorescence assay	2018	ACS medicinal chemistry letters, Feb-08, Volume: 9, Issue:2	Biocompatible Boron-Containing Prodrugs of Belinostat for the Potential Treatment of Solid Tumors.
AID1482104	Inhibition of HDAC 10 in human HeLa nuclear extract measured after 60 mins by fluorometric analysis	2017	Journal of medicinal chemistry, 04-27, Volume: 60, Issue:8	Exploring Derivatives of Quinazoline Alkaloid l-Vasicine as Cap Groups in the Design and Biological Mechanistic Evaluation of Novel Antitumor Histone Deacetylase Inhibitors.
AID440819	Inhibition of recombinant C-terminal FLAG-tagged HDAC1 expressed in baculovirus after 10 mins by fluorimetric analysis	2009	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 19, Issue:19	Diphenylmethylene hydroxamic acids as selective class IIa histone deacetylase inhibitors.
AID1193538	Antiproliferative activity against human HCT116 cells after 5 days by Alamar Blue assay	2015	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7	Benzofused hydroxamic acids: useful fragments for the preparation of histone deacetylase inhibitors. Part 2: 7-fluorobenzothiophenes and benzofurans.
AID723476	Cytotoxicity against cisplatin sensitive human CAL27 cells after 72 hrs by MTT assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1406985	Inhibition of HDAC6 in human NB4 cells assessed as levels of alpha-tubulin acetylation at 5 uM after 30 hrs by Western blot analysis relative to control	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Novel spiroindoline HDAC inhibitors: Synthesis, molecular modelling and biological studies.
AID1720097	Inhibition of BRD4 (unknown origin) at 10 uM relative to control	2020	Journal of medicinal chemistry, 09-10, Volume: 63, Issue:17	Dual-Target Inhibitors Based on HDACs: Novel Antitumor Agents for Cancer Therapy.
AID1886250	Antitumor activity against mouse H22 cells allografted in ICR mouse assessed as reduction in tumor weight at 25 mg/kg, ip administered qd measured after 21 days	2022	Journal of medicinal chemistry, 08-25, Volume: 65, Issue:16	Discovery of a Novel Vascular Disrupting Agent Inhibiting Tubulin Polymerization and HDACs with Potent Antitumor Effects.
AID1548273	Induction of cell cycle arrest in human RPMI8226 cells assessed as accumulation at S phase at 100 nM incubated for 24 hrs by propidium iodide staining based flow cytometry (Rvb = 23.5%)
AID350715	Inhibition of HDAC in human HeLa cell nuclear extracts by fluorimetry	2009	Journal of medicinal chemistry, May-14, Volume: 52, Issue:9	Design, synthesis, and biological activity of boronic acid-based histone deacetylase inhibitors.
AID1633993	Antiviral activity against HCV infected in human HuH7-luc/neo cells assessed as inhibition of DNA replication incubated for 3 days by luciferase reporter gene assay	2019	Bioorganic & medicinal chemistry letters, 08-15, Volume: 29, Issue:16	Synthesis of N'-propylhydrazide analogs of hydroxamic inhibitors of histone deacetylases (HDACs) and evaluation of their impact on activities of HDACs and replication of hepatitis C virus (HCV).
AID1865250	Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	2022	Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18	Discovery of Novel Src Homology-2 Domain-Containing Phosphatase 2 and Histone Deacetylase Dual Inhibitors with Potent Antitumor Efficacy and Enhanced Antitumor Immunity.
AID480068	Inhibition of human recombinant HDAC2 preincubated for 24 hrs followed by 1 hr reaction with substrate by protease coupled end-point assay	2010	Bioorganic & medicinal chemistry letters, May-15, Volume: 20, Issue:10	Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl)benzamides.
AID1451823	Cytotoxicity in human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay	2017	Journal of medicinal chemistry, 10-12, Volume: 60, Issue:19	Small Molecule Inhibitors Simultaneously Targeting Cancer Metabolism and Epigenetics: Discovery of Novel Nicotinamide Phosphoribosyltransferase (NAMPT) and Histone Deacetylase (HDAC) Dual Inhibitors.
AID1702064	Inhibition of HDAC5 (unknown origin) using fluorogenic HDAC class2a as substrate measured after 30 mins by fluorescence based assay	2018	Journal of medicinal chemistry, 02-22, Volume: 61, Issue:4	Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma.
AID1688038	Induction of apoptosis in human HL-60 cells assessed as live cells at 2 uM measured after 24 hrs by Annexin-V/FITC and propidium iodide staining based flow cytometry (Rvb = 89.29 %)	2020	European journal of medicinal chemistry, Feb-15, Volume: 188	A 18β-glycyrrhetinic acid conjugate with Vorinostat degrades HDAC3 and HDAC6 with improved antitumor effects.
AID350716	Inhibition of human recombinant HDAC1 by fluorimetry	2009	Journal of medicinal chemistry, May-14, Volume: 52, Issue:9	Design, synthesis, and biological activity of boronic acid-based histone deacetylase inhibitors.
AID1164917	Antiproliferative activity against human NCI-H929 cells assessed as growth inhibition after 72 hrs by CCK-8 assay	2014	Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19	Identification of a novel aminotetralin class of HDAC6 and HDAC8 selective inhibitors.
AID1164780	Inhibition of HDAC1 (unknown origin) using fluorogenic tetrapeptide RHKK(Ac) substrate by fluorescence assay	2014	Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20	ST7612AA1, a thioacetate-ω(γ-lactam carboxamide) derivative selected from a novel generation of oral HDAC inhibitors.
AID580927	Inhibition of HDAC activity in human HeLa cells at 0.1 uM after 24 hrs	2010	ACS medicinal chemistry letters, Nov-11, Volume: 1, Issue:8	Antiproliferative and differentiating activities of a novel series of histone deacetylase inhibitors.
AID1441630	Inhibition of recombinant human LTA4H aminopeptidase activity expressed in Escherichia coli BL21 (DE3) pLysS assessed as formation of p-NA from Ala-p-NA preincubated for 10 mins followed by substrate addition measured after 10 mins	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
AID710836	Cytotoxicity against human NCI-H23 cells assessed as growth inhibition by SRB assay	2012	Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23	Property-based optimization of hydroxamate-based γ-lactam HDAC inhibitors to improve their metabolic stability and pharmacokinetic profiles.
AID732878	Inhibition of HDAC in human HeLa cell nuclear extract using Boc-Lys(acetyl)-AMC as substrate preincubated with enzyme for 5 mins prior to substrate addition measured after 30 mins by fluorescence assay	2013	ACS medicinal chemistry letters, Feb-14, Volume: 4, Issue:2	Development of
AID749390	Inhibition of human recombinant HDAC1 expressed in High5 insect cells using Ac-Lys-Tyr-Lys(-acetyl)-AMC as substrate after 24 hrs by fluorescence assay	2013	Bioorganic & medicinal chemistry, Jun-01, Volume: 21, Issue:11	The discovery of colchicine-SAHA hybrids as a new class of antitumor agents.
AID1200970	Inhibition of HDAC6 in human A549 cells assessed as induction of tubulin acetylation after 17 to 18 hrs by ELISA	2015	Journal of medicinal chemistry, Mar-26, Volume: 58, Issue:6	Design and synthesis of orally bioavailable aminopyrrolidinone histone deacetylase 6 inhibitors.
AID1784970	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Design, synthesis and biological evaluation of novel hybrids targeting mTOR and HDACs for potential treatment of hepatocellular carcinoma.
AID1764247	Inhibition of HDAC in human A2780 cells using Boc-Lys (acetyl)-AMC as substrate preincubated for 18 hrs followed by susbtrate addition and measured after 3 hrs by fluorescence microplate reader assay	2021	European journal of medicinal chemistry, Feb-05, Volume: 211	Synergistic induction of apoptosis in resistant head and neck carcinoma and leukemia by alkoxyamide-based histone deacetylase inhibitors.
AID1129783	Cell cycle arrest in human Jurkat cells assessed as accumulation at G2/M-phase at 10 uM after 24 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 14.30%)	2014	Bioorganic & medicinal chemistry, Apr-01, Volume: 22, Issue:7	Studies on the antiproliferative effects of tropolone derivatives in Jurkat T-lymphocyte cells.
AID1622961	Inhibition of HDAC2 (unknown origin) using (FAM)-labeled acetylated peptide as substrate measured after 17 hrs by fluorescence assay	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.
AID1549138	Antifungal activity against azole-resistant Candida albicans 7781 after 48 hrs by spectrophotometry-based serial microdilution method	2020	Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10	Discovery of Novel Fungal Lanosterol 14α-Demethylase (CYP51)/Histone Deacetylase Dual Inhibitors to Treat Azole-Resistant Candidiasis.
AID765393	Inhibition of recombinant human HDAC1 enzyme using flurogenic Ac-LeuGlyLys (Ac)-AMC as substrate after 15 to 30 mins	2013	Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16	Total synthesis and full histone deacetylase inhibitory profiling of Azumamides A-E as well as β²- epi-Azumamide E and β³-epi-Azumamide E.
AID1234904	Antiproliferative activity against human 3AO cells after 48 hrs by MTT assay	2015	Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15	Design, synthesis and preliminary biological evaluation of indoline-2,3-dione derivatives as novel HDAC inhibitors.
AID1174701	Induction of apoptosis in human U937 cells assessed as dead cells at 1.5 uM after 24 hrs by annexin-V/propidium iodide staining-based flow cytometry (Rvb = 0.95%)	2015	European journal of medicinal chemistry, Jan-07, Volume: 89	Development of 3-hydroxycinnamamide-based HDAC inhibitors with potent in vitro and in vivo anti-tumor activity.
AID1543943	Inhibition of human recombinant HDAC3 using Boc-Lys (Ac)-AMC as substrate incubated for 60 mins and measured after 30 mins by fluorescence assay	2019	European journal of medicinal chemistry, Apr-15, Volume: 168	β-Carboline and N-hydroxycinnamamide hybrids as anticancer agents for drug-resistant hepatocellular carcinoma.
AID1572351	Inhibition of HDAC in human HL60 cells assessed as acetylated H3/GAPDH ratio at 1 uM after 4 hrs by Western blot assay relative to control	2019	Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3	Synthesis and Biological Investigation of Phenothiazine-Based Benzhydroxamic Acids as Selective Histone Deacetylase 6 Inhibitors.
AID1737656	Cytotoxicity against human KG -1 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
AID1785349	Antiproliferative activity against human HeLa cells assessed as cell growth inhibition measured after 48 hrs by CCK8 assay
AID1605973	Antiproliferative activity against human LOXIMVI cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	2020	Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8	Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors.
AID1897393	Induction of apoptosis in human SNU-16 cells assessed as early apoptotic cells at 0.03 uM incubated for 72 hrs by annexin-V/FITC propidium iodide staining based flow cytometry analysis (Rvb = 3.02%)
AID1303626	Potentiation of 5 nM (-)-lomaiviticin A-induced cytotoxicity against human K562 cells assessed as fraction ratio affected at 25 uM after 48 hrs by cell titer-glo luminescence assay	2016	Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13	Synergistic potentiation of (-)-lomaiviticin A cytotoxicity by the ATR inhibitor VE-821.
AID604139	Inhibition of histone acetyltransferase in human U937 cells assessed as increase of pan-acetylated histone H4 level at 5 uM after 24 hrs by Western blotting	2011	Bioorganic & medicinal chemistry, Jun-15, Volume: 19, Issue:12	Modulation of the activity of histone acetyltransferases by long chain alkylidenemalonates (LoCAMs).
AID1742680	Induction of cell cycle arrest in human MDA-MB-231 cells assessed as G2/M phase accumulation at 2 uM incubated for 24 hrs PI staining based by flow cytometry analysis (Rvb = 27.08 %)	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Design and synthesis of novel Flavone-based histone deacetylase inhibitors antagonizing activation of STAT3 in breast cancer.
AID1398814	Antagonist activity at ERalpha in human MCF7 cells assessed as suppression of GREB1 mRNA expression at 5 uM after 24 hrs by QIAzol reagent based RT-qPCR analysis	2018	Bioorganic & medicinal chemistry, 08-15, Volume: 26, Issue:15	Incorporation of histone deacetylase inhibitory activity into the core of tamoxifen - A new hybrid design paradigm.
AID481550	Cytotoxicity against human HO8910 cells assessed as growth inhibition at 10 ug/ml after 24 hrs by MTT assay	2010	Bioorganic & medicinal chemistry letters, May-15, Volume: 20, Issue:10	Synthesis and anticancer evaluation of alpha-lipoic acid derivatives.
AID1548244	Inhibition of HDAC1/2 in human HeLa cell nuclear extracts pre-incubated for 5 mins before fluorogenic substrate Boc-Lys (acetyl)-AMC or Boc-Lys (triflouroacetyl)-AMC addition and measured after 30 mins by fluorescence based assay
AID1650410	Inhibition of recombinant human HDAC6	2020	Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1	Novel alkoxyamide-based histone deacetylase inhibitors reverse cisplatin resistance in chemoresistant cancer cells.
AID1753842	Selectivity index, ratio of IC50 for inhibition of HDAC3 (unknown origin) to IC50 for inhibition of HDAC6 (unknown origin)	2021	European journal of medicinal chemistry, Jun-05, Volume: 218	Identification of novel 1,3-diaryl-1,2,4-triazole-capped histone deacetylase 6 inhibitors with potential anti-gastric cancer activity.
AID663338	Growth inhibition of human PC3 cells after 72 hrs by MTS assay	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Discovery and extensive in vitro evaluations of NK-HDAC-1: a chiral histone deacetylase inhibitor as a promising lead.
AID1655792	Inhibition of human recombinant HDAC6 using AMC-K(Ac)GL as substrate by fluorescence based assay	2020	ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5	Design of First-in-Class Dual EZH2/HDAC Inhibitor: Biochemical Activity and Biological Evaluation in Cancer Cells.
AID1698863	Inhibition of c-MET (unknown origin)	2020	Bioorganic & medicinal chemistry letters, 12-01, Volume: 30, Issue:23	Design, synthesis and biological evaluation of novel c-Met/HDAC dual inhibitors.
AID1888466	Inhibition of purified human HDAC1 using Ac-Leu-Gly-(e-Ac)Lys-AMC by fluorometric HDAC assay	2022	Bioorganic & medicinal chemistry letters, 01-01, Volume: 55	Dual-function antiandrogen/HDACi hybrids based on enzalutamide and entinostat.
AID1511971	Inhibition of recombinant: C-terminal His-tagged human HDAC2 (1 to 426 residues)/N-terminal GDT-tagged NCOR2 (395 to 489 residues) expressed in baculovirus infected Sf9 insect cells using ZMAL (Z-Lys(Ac)-AMC) as substrate incubated for 90 mins by fluoresc	2019	ACS medicinal chemistry letters, Sep-12, Volume: 10, Issue:9	Fluorinated Analogues of the Histone Deacetylase Inhibitor Vorinostat (Zolinza): Validation of a Chiral Hybrid Bioisostere, BITE.
AID1578498	Induction of apoptosis in human MV4-11 cells assessed as viable cells at 0.5 uM incubated for 18 hrs by annexin V FITC and PI based flow cytometry (Rvb = 53.01 to 53.07 %)	2020	ACS medicinal chemistry letters, Jan-09, Volume: 11, Issue:1	Class I/IIb-Selective HDAC Inhibitor Exhibits Oral Bioavailability and Therapeutic Efficacy in Acute Myeloid Leukemia.
AID1659647	Inhibition of HDAC1 (unknown origin)	2020	Bioorganic & medicinal chemistry letters, 06-01, Volume: 30, Issue:11	Environment-sensitive fluorescent inhibitors of histone deacetylase.
AID90529	Inhibitory concentration against histone deacetylase	2003	Journal of medicinal chemistry, Nov-20, Volume: 46, Issue:24	Histone deacetylase inhibitors.
AID717660	Inhibition of HDAC3 using Fluor-de-Lys as substrate assessed as remaining activity at 2.5 x 10'-7 M pretreated for 30 mins before substrate addition by fluorescence assay	2012	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23	The structural requirements of histone deacetylase inhibitors: suberoylanilide hydroxamic acid analogs modified at the C6 position.
AID619138	Half life in rat liver microsomes	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile.
AID663471	Solubility in neutral water	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Discovery and extensive in vitro evaluations of NK-HDAC-1: a chiral histone deacetylase inhibitor as a promising lead.
AID481555	Cytotoxicity against human KB cells assessed as growth inhibition at 1 ug/ml after 24 hrs by MTT assay	2010	Bioorganic & medicinal chemistry letters, May-15, Volume: 20, Issue:10	Synthesis and anticancer evaluation of alpha-lipoic acid derivatives.
AID632975	Cytotoxicity against human NCI-H460 cells	2011	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 21, Issue:24	Benzothiazole-containing hydroxamic acids as histone deacetylase inhibitors and antitumor agents.
AID1469384	Induction of apoptosis in human HepG2 cells assessed as late apoptotic cells at 10 uM after 48 hrs by annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 0.64%)	2018	Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7	Discovery of N1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7 H-pyrrolo[2,3- d]pyrimidin-2-yl)amino)phenyl)- N8-hydroxyoctanediamide as a Novel Inhibitor Targeting Cyclin-dependent Kinase 4/9 (CDK4/9) and Histone Deacetlyase1 (HDAC1) against Malignant Cancer
AID1742761	In vivo inhibition of STAT-3 in tumor of mouse 4T1 cells xenografted in BALB/c mouse assessed as decrease in STAT-3 phosphorylation by immunohistochemistry method	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Design and synthesis of novel Flavone-based histone deacetylase inhibitors antagonizing activation of STAT3 in breast cancer.
AID1848304	Induction of apoptosis in human MV4-11 cells assessed as necrotic cells at 1 uM incubated for 48 hrs by Annexin V-FITC/PI staining based flow cytometry (Rvb = 0.51%)	2022	Bioorganic & medicinal chemistry, Nov-15, Volume: 74	Design, synthesis and biological evaluation of novel pyrazinone derivatives as PI3K/HDAC dual inhibitors.
AID274016	Percent inhibition of CYP450 2C9 at 1 uM concentration	2007	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2	Identification and optimisation of a series of substituted 5-pyridin-2-yl-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.
AID348798	Inhibition of HDAC3	2008	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20	Optimization of a series of potent and selective ketone histone deacetylase inhibitors.
AID440822	Inhibition of human recombinant N-terminal FLAG-tagged HDAC5 (620-1122) expressed in baculovirus after 10 mins by fluorimetric analysis	2009	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 19, Issue:19	Diphenylmethylene hydroxamic acids as selective class IIa histone deacetylase inhibitors.
AID1201645	Antiproliferative activity against human HL60 cells assessed as growth inhibition after 48 hrs by CellTiter-Glo assay	2015	European journal of medicinal chemistry, May-05, Volume: 95	Macrocyclic compounds as anti-cancer agents: design and synthesis of multi-acting inhibitors against HDAC, FLT3 and JAK2.
AID1518807	Inhibition of HDAC6 in human KMS-12-BM cells assessed as increase in Ac-Tubulin level at 2.5 to 5 uM incubated for 24 hrs by Western blot analysis	2019	European journal of medicinal chemistry, Dec-15, Volume: 184	Discovery of a potent histone deacetylase (HDAC) 3/6 selective dual inhibitor.
AID1655801	Cytotoxicity against human U937 cells assessed as reduction in cell viability incubated for 72 hrs by CellTiter-Glo Luminescent cell viability assay	2020	ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5	Design of First-in-Class Dual EZH2/HDAC Inhibitor: Biochemical Activity and Biological Evaluation in Cancer Cells.
AID1764292	Inhibition of HDAC in human CAL-27 cells assessed as potentiation of cisplatin-induced cytotoxicity by measuring cisplatin IC50 at 0.7 uM pretreated for 48 hrs followed by cisplatin addition and measured after 72 hrs by MTT assay (Rvb = 3.57 uM)	2021	European journal of medicinal chemistry, Feb-05, Volume: 211	Synergistic induction of apoptosis in resistant head and neck carcinoma and leukemia by alkoxyamide-based histone deacetylase inhibitors.
AID1901160	Antiproliferative activity against human HepG2 cells measured after 48 hrs by MTT assay	2022	Bioorganic & medicinal chemistry, 02-15, Volume: 56	Synthesis and biological evaluation of aminobenzamides containing purine moiety as class I histone deacetylases inhibitors.
AID1422512	Inhibition of HDAC in mouse FL5.12 cells assessed as increase in histone H3 acetylation at 5 uM after 6 hrs by Western blot analysis	2018	European journal of medicinal chemistry, Nov-05, Volume: 159	In search of constrained FTY720 and phytosphingosine analogs as dual acting anticancer agents targeting metabolic and epigenetic pathways.
AID1205626	Induction of RUNX transcriptional activation in mouse C2C12-6xOSE2 cells at 1 uM after 24 hrs by luciferase reporter assay relative to FGF-2	2015	Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8	Discovery of Orally Available Runt-Related Transcription Factor 3 (RUNX3) Modulators for Anticancer Chemotherapy by Epigenetic Activation and Protein Stabilization.
AID1162217	Cell cycle arrest in human HL60 cells assessed as accumulation at sub-G1 phase at 1 uM by propidium iodide staining-based flow cytometry (Rvb = 2.1%)	2014	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 24, Issue:19	Design, synthesis and biological evaluation of β-boswellic acid based HDAC inhibitors as inducers of cancer cell death.
AID1676592	Binding affinity to Gallium ion assessed as performance ratio ratio by measuring product of accounting ratio and retention ratio at 2.55 umol by immobilized metal-ion affinity chromatography	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
AID1396991	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	2018	Bioorganic & medicinal chemistry, 08-07, Volume: 26, Issue:14	Design, synthesis and anticancer evaluation of acridine hydroxamic acid derivatives as dual Topo and HDAC inhibitors.
AID1589335	Inhibition of HDAC1 (unknown origin) using Fluor de Lys substrate at 50 uM by fluorescence assay relative to control	2019	European journal of medicinal chemistry, Apr-15, Volume: 168	Design, synthesis and biological evaluation of novel isoindolinone derivatives as potent histone deacetylase inhibitors.
AID1861345	Inhibition of HDAC in human OCILY3 cells assessed as effect on pS6 levels at 2.5 uM in presence of 10 uM piclitisib measured by Western blot analysis	2022	Bioorganic & medicinal chemistry letters, 09-01, Volume: 71	Bioevaluation of a dual PI3K/HDAC inhibitor for the treatment of diffuse large B-cell lymphoma.
AID352760	Antitumor activity against human HCT116 cells xenografted nude mouse assessed as tumor growth inhibition at 150 mg/kg, ip administered once daily for 18 days relative to control	2009	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11	Histone deacetylase inhibitors with a primary amide zinc binding group display antitumor activity in xenograft model.
AID1901159	Antiproliferative activity against human MDA-MB-231 cells measured after 48 hrs by MTT assay	2022	Bioorganic & medicinal chemistry, 02-15, Volume: 56	Synthesis and biological evaluation of aminobenzamides containing purine moiety as class I histone deacetylases inhibitors.
AID723453	Potentiation of 5 uM cisplatin-induced toxicity in 1 uM cisplatin resistant human MDA-MB-231 cells at 0.5 uM pretreated for 48 hrs followed by 1 uM cisplatin treatment by MTT assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1349720	Cytotoxicity against human HCT116 cells assessed as inhibition of cell growth after 72 hrs by MTT assay	2018	ACS medicinal chemistry letters, Jan-11, Volume: 9, Issue:1	Dual NAMPT/HDAC Inhibitors as a New Strategy for Multitargeting Antitumor Drug Discovery.
AID1888585	Antiproliferative activity against human HT-29 cells measured after 72 hrs by MTT assay
AID310185	Growth inhibition of human ACHN cells by SRB assay	2007	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 17, Issue:22	Modification of cap group in delta-lactam-based histone deacetylase (HDAC) inhibitors.
AID723127	Potentiation of 45 uM cisplatin-induced toxicity in 1 uM cisplatin resistant human CAL27 cells at 0.5 uM pretreated for 48 hrs followed by 1 uM cisplatin treatment by MTT assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID308649	Increase in p21WAF1/CIP1 gene expression in PANC1 cells at 0.1 uM after 48 hrs relative to control	2007	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17	Design, synthesis, and evaluation of isoindolinone-hydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors.
AID1383986	Inhibition of HDAC2 (unknown origin) using Boc-Lys(acetyl)-AMC as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by fluorescence assay	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	Discovery of meta-sulfamoyl N-hydroxybenzamides as HDAC8 selective inhibitors.
AID605299	Antiproliferative activity against human HCT116 cells after 72 hrs by WST-1 assay	2010	Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24	Discovery of 2-(6-{[(6-fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a class I selective orally active histone deacetylase inhibitor.
AID1355690	Antiproliferative activity against human K562 cells after 48 hrs by CCK-8 assay	2018	Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14	Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections.
AID1380942	Antiproliferative activity against human AGS cells after 72 hrs by MTT assay	2018	Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12	Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously.
AID669761	Inhibition of human recombinant HDAC1 after 30 mins by fluorometric assay	2012	Journal of medicinal chemistry, Apr-26, Volume: 55, Issue:8	Synthesis and biological evaluation of 1-arylsulfonyl-5-(N-hydroxyacrylamide)indoles as potent histone deacetylase inhibitors with antitumor activity in vivo.
AID1129778	Cell cycle arrest in human Jurkat cells assessed as accumulation at S-phase at 10 uM after 12 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 19.5%)	2014	Bioorganic & medicinal chemistry, Apr-01, Volume: 22, Issue:7	Studies on the antiproliferative effects of tropolone derivatives in Jurkat T-lymphocyte cells.
AID328800	Inhibition of HDAC7 expressed in Escherichia coli	2008	Journal of medicinal chemistry, Apr-24, Volume: 51, Issue:8	A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo.
AID1825921	Inhibition of recombinant human full length C-terminal His tagged HDAC2 (1 to 488 residues) expressed in baculovirus-infected Sf9 insect cells using Ac-peptide as substrate incubated for 4 hrs
AID1784973	Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Design, synthesis and biological evaluation of novel hybrids targeting mTOR and HDACs for potential treatment of hepatocellular carcinoma.
AID1848321	Induction of cell cycle arrest in human MV4-11 cells assessed as accumulation of cells at S phase at 1 uM incubated for 48 hrs by AnnexinV/PI staining based flow cytometry (Rvb = 45.5%)	2022	Bioorganic & medicinal chemistry, Nov-15, Volume: 74	Design, synthesis and biological evaluation of novel pyrazinone derivatives as PI3K/HDAC dual inhibitors.
AID723132	Potentiation of 50 uM cisplatin-induced toxicity in 1 uM cisplatin resistant human MDA-MB-231 cells at 0.25 uM pretreated for 48 hrs followed by 1 uM cisplatin treatment by MTT assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1476147	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	2017	Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20	Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat.
AID723156	Potentiation of 1 uM cisplatin-induced toxicity in 0.5 uM cisplatin resistant human KYSE-510 cells at 0.25 uM pretreated for 48 hrs followed by 0.5 uM cisplatin treatment by MTT assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID609492	Thermodynamic solubility of the compound at pH 6.8	2011	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16	The design, synthesis and structure-activity relationships of novel isoindoline-based histone deacetylase inhibitors.
AID1321726	Lipophilicity, log D of the compound at pH 7.4	2016	Journal of medicinal chemistry, 10-13, Volume: 59, Issue:19	Design, Synthesis, and Biological Evaluation of First-in-Class Dual Acting Histone Deacetylases (HDACs) and Phosphodiesterase 5 (PDE5) Inhibitors for the Treatment of Alzheimer's Disease.
AID1783066	Antifungal activity against fluconazole-sensitive Candida albicans 0304103 assessed as inhibition of fungal growth	2021	European journal of medicinal chemistry, Oct-05, Volume: 221	Lanosterol 14α-demethylase (CYP51)/histone deacetylase (HDAC) dual inhibitors for treatment of Candida tropicalis and Cryptococcus neoformans infections.
AID1739597	Antiproliferative activity against human HL60 assessed as reduction in cell growth at 1 uM by CellTiter-non radioactive cell proliferation assay	2020	European journal of medicinal chemistry, Aug-15, Volume: 200	Design, synthesis, and biological evaluation of dual targeting inhibitors of histone deacetylase 6/8 and bromodomain BRPF1.
AID1901763	Inhibition of full length human recombinant HDAC8 expressed in Sf9 baculovirus system using FAM-labeled acetylated peptide as substrate by measuring fluorescence intensity by EMSA method	2022	Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4	Discovery of HDAC6-Selective Inhibitor NN-390 with
AID1401387	Inhibition of HDAC3 in human HeLa-S3 cell lysates assessed as remaining activity at 1 uM preincubated for 15 mins followed by HDAC-Glo substrate addition measured after 30 to 40 mins by fluorimetric method relative to control	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
AID481558	Cytotoxicity against human Bel7402 cells assessed as growth inhibition at 10 ug/ml after 24 hrs by MTT assay	2010	Bioorganic & medicinal chemistry letters, May-15, Volume: 20, Issue:10	Synthesis and anticancer evaluation of alpha-lipoic acid derivatives.
AID1742649	Cytotoxicity against mouse 4T1 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Design and synthesis of novel Flavone-based histone deacetylase inhibitors antagonizing activation of STAT3 in breast cancer.
AID273168	Inhibition of maize HD1B	2006	Journal of medicinal chemistry, Oct-05, Volume: 49, Issue:20	Synthesis and biological properties of novel, uracil-containing histone deacetylase inhibitors.
AID1861260	Inhibition of HDAC4 (unknown origin)	2022	Bioorganic & medicinal chemistry letters, 09-01, Volume: 71	Design, synthesis and antitumor activity study of PARP-1/HDAC dual targeting inhibitors.
AID1864241	Inhibition of HDAC in human MDA-MB-231 cells assessed as increase in acetylated H3 level at 1.25 to 5 uM by Western blot analysis	2022	Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18	Discovery of a Novel G-Quadruplex and Histone Deacetylase (HDAC) Dual-Targeting Agent for the Treatment of Triple-Negative Breast Cancer.
AID1312851	Cytotoxicity against human HCT116 cells assessed as growth inhibition after 24 hrs by MTT assay	2016	Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11	Development of Purine-Based Hydroxamic Acid Derivatives: Potent Histone Deacetylase Inhibitors with Marked in Vitro and in Vivo Antitumor Activities.
AID723422	Potentiation of 25 uM cisplatin-induced toxicity in 1 uM cisplatin resistant human MDA-MB-231 cells at 0.25 uM pretreated for 48 hrs followed by 1 uM cisplatin treatment by MTT assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1164187	Inhibition of human recombinant HDAC6 using Z-MAL as substrate after 1 hr by fluorescent activity assay	2014	ACS medicinal chemistry letters, Sep-11, Volume: 5, Issue:9	Novel antiproliferative chimeric compounds with marked histone deacetylase inhibitory activity.
AID775843	Inhibition of HDAC2 (unknown origin)-mediated deacetylation preincubated for 5 mins prior to substrate addition measured after 30 mins by fluorescence assay	2013	Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20	Investigating the selectivity of metalloenzyme inhibitors.
AID1754742	Induction of apoptosis in human MCF7 cells assessed as downregulation of c-Myc gene expression at 1 uM measured after 24 hrs whole transcriptome analysis	2021	Bioorganic & medicinal chemistry, 07-15, Volume: 42	Discovery of novel class of histone deacetylase inhibitors as potential anticancer agents.
AID1464885	Terminal half life in Sprague-Dawley rat 2 mg/kg, iv administered via bolus by LC-MS/MS analysis	2017	Bioorganic & medicinal chemistry letters, 11-01, Volume: 27, Issue:21	Design, synthesis and biological evaluation of novel histone deacetylase inhibitors incorporating 4-aminoquinazolinyl systems as capping groups.
AID723148	Potentiation of 40 uM cisplatin-induced toxicity in 1 uM cisplatin resistant human MDA-MB-231 cells at 0.25 uM pretreated for 48 hrs followed by 1 uM cisplatin treatment by MTT assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1493601	Inhibition of HDAC6 in human A549 cells assessed as increase in acetylated alpha-tubulin levels at 500 nM after 3 hrs by Western blot analysis	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Discovery of a fluorescent probe with HDAC6 selective inhibition.
AID1239049	Inhibition of recombinant His6-tagged GST-fused human HDAC3 expressed in baculovirus infected insect High5 cells using Ac-Lys-Tyr-Lys(epsilon-acetyl)-AMC as substrate after 24 hrs	2015	Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17	Design, synthesis and biological evaluation of isoquinoline-based derivatives as novel histone deacetylase inhibitors.
AID243847	Inhibitory activity against human histone deacetylase 4 (HDAC4) at 5 uM	2005	Journal of medicinal chemistry, May-05, Volume: 48, Issue:9	Class II (IIa)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl)pyrrolyl hydroxyamides.
AID441872	Inhibition of human recombinant HDAC8 using fluorescent acetylated substrate	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Binding ensemble profiling with photoaffinity labeling (BEProFL) approach: mapping the binding poses of HDAC8 inhibitors.
AID1688030	Induction of apoptosis in human HL-60 cells assessed as live cells at 0.5 uM measured after 24 hrs by Annexin-V/FITC and propidium iodide staining based flow cytometry (Rvb = 89.29 %)	2020	European journal of medicinal chemistry, Feb-15, Volume: 188	A 18β-glycyrrhetinic acid conjugate with Vorinostat degrades HDAC3 and HDAC6 with improved antitumor effects.
AID1897380	Antiproliferative activity against human SNU-16 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
AID708273	Growth inhibition of human MGC803 cells incubated for 72 hrs by WST dye reduction assay	2012	Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20	Pharmacokinetic optimization of class-selective histone deacetylase inhibitors and identification of associated candidate predictive biomarkers of hepatocellular carcinoma tumor response.
AID421215	Antitumor activity against human MCF10A cells	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Recent advances in the development of polyamine analogues as antitumor agents.
AID525000	Inhibition of HDAC4 by in vitro deacetylation assay	2010	Nature chemical biology, Jan, Volume: 6, Issue:1	Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.
AID1127321	Antiproliferative activity against human IGROV1 cells assessed as growth inhibition after 72 hrs	2014	European journal of medicinal chemistry, May-22, Volume: 79	Influence of the adamantyl moiety on the activity of biphenylacrylohydroxamic acid-based HDAC inhibitors.
AID1633436	Induction of neurogenesis in human SH-SY5Y cells assessed as stimulation of neurite outgrowth at 10 uM incubated for 72 hrs by phase contrast microscopic analysis	2019	ACS medicinal chemistry letters, Apr-11, Volume: 10, Issue:4	Discovery of the First-in-Class GSK-3β/HDAC Dual Inhibitor as Disease-Modifying Agent To Combat Alzheimer's Disease.
AID1065945	Inhibition of HDAC6 in human LNCAP cells assessed as increase in tubulin acetylation at 2.31 to 20 uM after 4 hrs by Western blotting analysis	2013	Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24	Synthesis and structure-activity relationship of 3-hydroxypyridine-2-thione-based histone deacetylase inhibitors.
AID639775	Inhibition of KDM4E	2011	Journal of medicinal chemistry, Dec-22, Volume: 54, Issue:24	Lysine demethylases inhibitors.
AID1361654	Induction of apoptosis in human A549 cells assessed as necrotic cells at 5 uM after 48 hrs by FITC-Annexin V/propidium iodide staining based flow cytometric analysis (Rvb = 0.52%)	2018	Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16	Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents.
AID628438	Selectivity ratio of IC50 for human recombinant HDAC8 to IC50 for human recombinant HDAC3/NCoR2	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Design, synthesis, docking, and biological evaluation of novel diazide-containing isoxazole- and pyrazole-based histone deacetylase probes.
AID1469376	Induction of apoptosis in human A549 cells assessed as live cells at 10 uM after 48 hrs by annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 92.7%)	2018	Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7	Discovery of N1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7 H-pyrrolo[2,3- d]pyrimidin-2-yl)amino)phenyl)- N8-hydroxyoctanediamide as a Novel Inhibitor Targeting Cyclin-dependent Kinase 4/9 (CDK4/9) and Histone Deacetlyase1 (HDAC1) against Malignant Cancer
AID373077	Inhibition of human recombinant HDAC4	2009	European journal of medicinal chemistry, Mar, Volume: 44, Issue:3	Novel amide derivatives as inhibitors of histone deacetylase: design, synthesis and SAR.
AID1855245	Inhibition of HDAC8 in human HeLa cell nuclear extract using Boc-Lys(Ac)-AMC or Boc-Lys(triflouroacetyl)-AMC as substrate incubated for 30 mins and measured by fluorescence assay	2022	European journal of medicinal chemistry, Nov-05, Volume: 241	Discovery of 2,5-diphenyl-1,3,4-thiadiazole derivatives as HDAC inhibitors with DNA binding affinity.
AID732154	Inhibition of HDAC2 (unknown origin) assessed as fluorescence intensity measured after 60 mins incubation at room temperature by trypsin-free microfluidic lab-on-a-chip assay	2013	Journal of medicinal chemistry, Feb-28, Volume: 56, Issue:4	Potent and selective inhibition of histone deacetylase 6 (HDAC6) does not require a surface-binding motif.
AID652751	Inhibition of recombinant human HDAC7 using Fluor-de-Lys as substrate after 30 mins by spectrophotometry	2011	ACS medicinal chemistry letters, Jul-21, Volume: 2, Issue:9	Potential Agents for Treating Cystic Fibrosis: Cyclic Tetrapeptides that Restore Trafficking and Activity of ΔF508-CFTR.
AID1915562	Inhibition of human HDAC1 incubated for 30 mins by SpectraMax M2 microplate reader analysis	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors.
AID1688023	Inhibition of recombinant human C-terminal FLAG/His-tagged HDAC1 (1 to 482 residues) expressed in Sf9 insect cells using Boc-Lys (Ac)-AMC as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence based	2020	European journal of medicinal chemistry, Feb-15, Volume: 188	A 18β-glycyrrhetinic acid conjugate with Vorinostat degrades HDAC3 and HDAC6 with improved antitumor effects.
AID1702154	Metabolic stability in rat liver microsomes assessed as half-life at 5 uM incubated upto 60 mins in presence of beta-NADPH by LC-MS analysis	2018	Journal of medicinal chemistry, 02-22, Volume: 61, Issue:4	Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma.
AID1863169	Inhibition of HDAC6 (unknown origin) using fluorogenic substrate incubated for 30 mins by fluorescence plate reader	2022	European journal of medicinal chemistry, Oct-05, Volume: 240	Design, synthesis, and biological evalution of bifunctional inhibitors against Hsp90-HDAC6 interplay.
AID1129796	Induction of apoptosis in human Jurkat cells assessed as caspase 3/7 activation at 10 uM after 48 hrs by luminescence assay (Rvb = 109,510 +/- 4710.453 no unit)	2014	Bioorganic & medicinal chemistry, Apr-01, Volume: 22, Issue:7	Studies on the antiproliferative effects of tropolone derivatives in Jurkat T-lymphocyte cells.
AID1897402	Induction of apoptosis in human SNU-16 cells assessed as late apoptotic cells at 0.3 uM incubated for 72 hrs by annexin-V/FITC propidium iodide staining based flow cytometry analysis (Rvb = 3.41%)
AID605537	Antiproliferative activity against human COR-L23 cells after 72 hrs by WST-1 assay	2010	Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24	Discovery of 2-(6-{[(6-fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a class I selective orally active histone deacetylase inhibitor.
AID481552	Cytotoxicity against human HO8910 cells assessed as growth inhibition at 0.1 ug/ml after 24 hrs by MTT assay	2010	Bioorganic & medicinal chemistry letters, May-15, Volume: 20, Issue:10	Synthesis and anticancer evaluation of alpha-lipoic acid derivatives.
AID482959	Octanol-water distribution coefficient, log D of the compound	2010	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11	Acylurea connected straight chain hydroxamates as novel histone deacetylase inhibitors: Synthesis, SAR, and in vivo antitumor activity.
AID723450	Potentiation of 1 uM cisplatin-induced toxicity in 1 uM cisplatin resistant human CAL27 cells at 0.5 uM pretreated for 48 hrs followed by 1 uM cisplatin treatment by MTT assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1487095	Inhibition of HDAC8 (unknown origin)	2017	Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15	Cyclic tetrapeptide HDAC inhibitors as potential therapeutics for spinal muscular atrophy: Screening with iPSC-derived neuronal cells.
AID1418672	GPx-like activity of the compound assessed as velocity for cumene hydroperoxide reduction at 80 uM in presence of GSH and NADPH by spectrophotometric analysis	2018	Bioorganic & medicinal chemistry, 11-15, Volume: 26, Issue:21	Design, synthesis, and biological evaluation of histone deacetylase inhibitors possessing glutathione peroxidase-like and antioxidant activities against Alzheimer's disease.
AID689653	Inhibition of HDAC8 after 45 mins by microplate fluorometric analysis	2012	Bioorganic & medicinal chemistry, Oct-01, Volume: 20, Issue:19	Design, synthesis and evaluation of novel metalloproteinase inhibitors based on L-tyrosine scaffold.
AID1189851	Antiviral activity against HCV genotype 1b infected in human Huh7 cells after 3 days by luciferase reporter gene assay	2015	Journal of medicinal chemistry, Jan-22, Volume: 58, Issue:2	Hydroxamic acids block replication of hepatitis C virus.
AID1434351	Inhibition of HDAC (unknown origin) expressed in mouse C2C12-6xOSE cells assessed as increase in RUNX3 transcriptional activation at 1 uM measured after 24 hrs by luciferase reporter gene assay relative to FGF2	2017	European journal of medicinal chemistry, Jan-27, Volume: 126	Improving potency and metabolic stability by introducing an alkenyl linker to pyridine-based histone deacetylase inhibitors for orally available RUNX3 modulators.
AID456799	Cytotoxicity against african green monkey Vero cells after 1 to 2 days by neutral red assay	2010	Bioorganic & medicinal chemistry, Jan-01, Volume: 18, Issue:1	Antimalarial and antileishmanial activities of histone deacetylase inhibitors with triazole-linked cap group.
AID473182	Induction of HDAC-mediated H3/H4 histone acetylation in human HepG2 cells at 5 uM after 6 hrs by indirect ELISA	2010	Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5	Biological and biophysical properties of the histone deacetylase inhibitor suberoylanilide hydroxamic acid are affected by the presence of short alkyl groups on the phenyl ring.
AID1303625	Potentiation of 1 nM (-)-lomaiviticin A-induced cytotoxicity against human K562 cells assessed as fraction ratio affected at 5 uM after 48 hrs by cell titer-glo luminescence assay	2016	Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13	Synergistic potentiation of (-)-lomaiviticin A cytotoxicity by the ATR inhibitor VE-821.
AID1312929	Inhibition of HDAC6 in human MV4-11 cells assessed as upregulation of acetylated alpha-tubulin level at 2 uM after 6 hrs by Western blot method	2016	Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11	Development of Purine-Based Hydroxamic Acid Derivatives: Potent Histone Deacetylase Inhibitors with Marked in Vitro and in Vivo Antitumor Activities.
AID723458	Potentiation of cisplatin-induced toxicity in cisplatin resistant human A2780 cells at 1 uM pretreated for 48 hrs followed by cisplatin treatment by MTT assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1764284	Inhibition of HDAC in human CAL-27 cells assessed as potentiation of cisplatin-induced cytotoxicity by measuring cisplatin IC50 at 0.7 uM pretreated for 48 hrs followed by cisplatin addition and measured after 72 hrs by MTT assay relative to cisplatin alo	2021	European journal of medicinal chemistry, Feb-05, Volume: 211	Synergistic induction of apoptosis in resistant head and neck carcinoma and leukemia by alkoxyamide-based histone deacetylase inhibitors.
AID274028	AUC after oral dosing at 5 mg kg-1	2007	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2	Identification and optimisation of a series of substituted 5-pyridin-2-yl-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.
AID1742705	Induction of apoptosis in human MDA-MB-231 cells assessed as late apoptotic cells at 5 uM incubated for 72 hrs by annexinV-FITC and PI staining based flow cytometry analysis (Rvb = 3.79 %)	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Design and synthesis of novel Flavone-based histone deacetylase inhibitors antagonizing activation of STAT3 in breast cancer.
AID623097	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay	2011	European journal of medicinal chemistry, Nov, Volume: 46, Issue:11	Design, synthesis and primary activity assay of tripeptidomimetics as histone deacetylase inhibitors with linear linker and branched cap group.
AID1389950	Cytotoxic activity against human MCF7 cells after 24 hrs by MTT assay	2018	Bioorganic & medicinal chemistry letters, 04-01, Volume: 28, Issue:6	Novel polyamine-based Histone deacetylases-Lysine demethylase 1 dual binding inhibitors.
AID1487044	Inhibition of HDAC1 (unknown origin) assessed as remaining enzyme activity at 1 uM by ELISA-based assay	2017	Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15	The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity.
AID1260641	Inhibition of human recombinant HDAC5 at 20 uM using Boc-Lys(Tfa)-AMC as substrate after 30 to 60 mins by microplate reader assay
AID1282255	Cytotoxicity against human A2780 cells after 72 hrs by MTT assay	2016	Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4	Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
AID1541562	Inhibition of class 1 HDAC in human Cal27CisR cells assessed as increase in histone H3 acetylation at 1 uM measured after 24 hrs by immunoblot analysis	2019	Journal of medicinal chemistry, 12-26, Volume: 62, Issue:24	Synthesis of Peptoid-Based Class I-Selective Histone Deacetylase Inhibitors with Chemosensitizing Properties.
AID1266837	Induction of DNA damage in human HCT116 cells assessed as histone H2AX phosphorylation at S139 at 1 to 5 uM after 12 hrs by western blot analysis	2015	Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23	Novel β-Carboline/Hydroxamic Acid Hybrids Targeting Both Histone Deacetylase and DNA Display High Anticancer Activity via Regulation of the p53 Signaling Pathway.
AID626566	Growth inhibition of human HCT116 cells after 5 days by alamar blue assay	2011	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 21, Issue:22	4-N-Hydroxy-4-[1-(sulfonyl)piperidin-4-yl]-butyramides as HDAC inhibitors.
AID310184	Growth inhibition of human HCT15 cells by SRB assay	2007	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 17, Issue:22	Modification of cap group in delta-lactam-based histone deacetylase (HDAC) inhibitors.
AID1873390	Inhibition of HDAC10 (unknown origin)	2022	Bioorganic & medicinal chemistry letters, 08-15, Volume: 70	Comparison of three zinc binding groups for HDAC inhibitors - A potency, selectivity and enzymatic kinetics study.
AID297489	Cytotoxicity against human PC3 cells	2007	Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18	2-aroylindoles and 2-aroylbenzofurans with N-hydroxyacrylamide substructures as a novel series of rationally designed histone deacetylase inhibitors.
AID764215	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	2013	Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17	Novel N-hydroxyfurylacrylamide-based histone deacetylase (HDAC) inhibitors with branched CAP group (Part 2).
AID1819522	Downregulation of SSRP-1 expression in human KG-1 cells assessed as chromatin damage at 0.5 to 2.5 uM measured after 24 hrs by Western blot analysis	2022	Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4	Discovery of DNA-Targeting HDAC Inhibitors with Potent Antitumor Efficacy In Vivo That Trigger Antitumor Immunity.
AID723452	Potentiation of 5 uM cisplatin-induced toxicity in 1 uM cisplatin resistant human MDA-MB-231 cells at 1.5 uM pretreated for 48 hrs followed by 1 uM cisplatin treatment by MTT assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1543932	Antiproliferative activity against human HCT116 cells incubated for 48 hrs by MTT assay	2019	European journal of medicinal chemistry, Apr-15, Volume: 168	β-Carboline and N-hydroxycinnamamide hybrids as anticancer agents for drug-resistant hepatocellular carcinoma.
AID1821275	Antiproliferative activity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	2022	European journal of medicinal chemistry, Feb-05, Volume: 229	Discovery of phthalazino[1,2-b]-quinazolinone derivatives as multi-target HDAC inhibitors for the treatment of hepatocellular carcinoma via activating the p53 signal pathway.
AID1816710	Inhibition of HDAC2 (unknown origin) using Ac-peptide as substrate preincubated for 15 mins followed by substrate addition by fluorescence based microplate reader analysis	2021	European journal of medicinal chemistry, Aug-05, Volume: 220	Design, synthesis, and biological evaluation of novel dual inhibitors targeting lysine specific demethylase 1 (LSD1) and histone deacetylases (HDAC) for treatment of gastric cancer.
AID274071	Steady state volume of distribution (Vdss) after i.v. dosing at 1 mg kg-1	2007	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2	Identification and optimisation of a series of substituted 5-(1H-pyrazol-3-yl)-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.
AID723144	Potentiation of 10 uM cisplatin-induced toxicity in 1 uM cisplatin resistant human CAL27 cells at 0.25 uM pretreated for 48 hrs followed by 1 uM cisplatin treatment by MTT assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1206747	Induction of nitric oxide release in human HEL cells at 100 uM after 3 to 5 hrs by Griess assay	2015	Journal of medicinal chemistry, May-28, Volume: 58, Issue:10	Design, synthesis, and antitumor evaluation of novel histone deacetylase inhibitors equipped with a phenylsulfonylfuroxan module as a nitric oxide donor.
AID1873388	Inhibition of HDAC8 (unknown origin)	2022	Bioorganic & medicinal chemistry letters, 08-15, Volume: 70	Comparison of three zinc binding groups for HDAC inhibitors - A potency, selectivity and enzymatic kinetics study.
AID1742655	Cytotoxicity against human T47D cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Design and synthesis of novel Flavone-based histone deacetylase inhibitors antagonizing activation of STAT3 in breast cancer.
AID1895827	Inhibition of HDAC6 (unknown origin)	2021	European journal of medicinal chemistry, Dec-15, Volume: 226	Inhibition of Histone Deacetylase 6 (HDAC6) as a therapeutic strategy for Alzheimer's disease: A review (2010-2020).
AID723454	Potentiation of 5 uM cisplatin-induced toxicity in 1 uM cisplatin resistant human MDA-MB-231 cells at 0.25 uM pretreated for 48 hrs followed by 1 uM cisplatin treatment by MTT assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1174695	Inhibition of HDAC6 (unknown origin)	2015	European journal of medicinal chemistry, Jan-07, Volume: 89	Development of 3-hydroxycinnamamide-based HDAC inhibitors with potent in vitro and in vivo anti-tumor activity.
AID1614139	Antiproliferative activity against human OCI-AML2 cells after 72 hrs by MTT assay
AID1658891	Inhibition of HDAC6 (unknown origin) using Boc-Lys(Ac)-pNA as substrate preincubated for 20 mins followed by substrate addition and further incubated for 90 mins by fluorescence assay	2020	Journal of medicinal chemistry, 07-09, Volume: 63, Issue:13	Synthesis and Anticancer Activity of Novel Actinonin Derivatives as HsPDF Inhibitors.
AID1063037	Inhibition of recombinant HDAC6 (unknown origin) using Fluor-de-Lys-SIRT1 as substrate by fluorescence assay	2014	Journal of natural products, Jan-24, Volume: 77, Issue:1	Protein kinase and HDAC inhibitors from the endophytic fungus Epicoccum nigrum.
AID1476121	Inhibition of N-terminal GST tagged human HDAC6 (1 to 1215 residues) expressed in baculovirus infected insect cells using RHKKAc as substrate in presence of ATP	2017	Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20	Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat.
AID1389952	Cytotoxic activity against human MCF7 cells assessed as reduction in cell viability at 16 uM after 24 hrs by MTT assay relative to control	2018	Bioorganic & medicinal chemistry letters, 04-01, Volume: 28, Issue:6	Novel polyamine-based Histone deacetylases-Lysine demethylase 1 dual binding inhibitors.
AID1126993	Induction of apoptosis in human U937 cells assessed as late apoptotic cells using annexin-V/propidium iodide staining at 1 uM after 12 hrs by flow cytometry analysis (Rvb = 1.83%)	2014	Journal of medicinal chemistry, Apr-24, Volume: 57, Issue:8	Discovery of the first N-hydroxycinnamamide-based histone deacetylase 1/3 dual inhibitors with potent oral antitumor activity.
AID1861337	Inhibition of HDAC in human OCILY3 cells assessed as Down-regulation of STAT3 phosphorylation at Y705 residue at 2.5 uM in presence of 10 uM piclitisib measured by Western blot analysis	2022	Bioorganic & medicinal chemistry letters, 09-01, Volume: 71	Bioevaluation of a dual PI3K/HDAC inhibitor for the treatment of diffuse large B-cell lymphoma.
AID1141771	Cytotoxicity against human MKN45 cells by MTT assay	2014	Journal of medicinal chemistry, May-22, Volume: 57, Issue:10	Azaindolylsulfonamides, with a more selective inhibitory effect on histone deacetylase 6 activity, exhibit antitumor activity in colorectal cancer HCT116 cells.
AID1396985	Inhibition of HDAC1 (unknown origin) using Ac-peptide as substrate pretreated for 15 mins followed by substrate addition and measured after 1 hr by fluorescence assay	2018	Bioorganic & medicinal chemistry, 08-07, Volume: 26, Issue:14	Design, synthesis and anticancer evaluation of acridine hydroxamic acid derivatives as dual Topo and HDAC inhibitors.
AID1541563	Inhibition of class 1 HDAC in human CAL27 cells assessed as potentiation of cisplatin-induced cytotoxicity by measuring cisplatin IC50 at 0.5 uM preincubated for 48 hrs followed by cisplatin addition and measured after 72 hrs by MTT assay (Rvb = 9.79 uM)	2019	Journal of medicinal chemistry, 12-26, Volume: 62, Issue:24	Synthesis of Peptoid-Based Class I-Selective Histone Deacetylase Inhibitors with Chemosensitizing Properties.
AID1730861	Antiproliferative activity against human NCI-H820 cells incubated for 72 hrs by MTT assay	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Design, synthesis and evaluation of novel ErbB/HDAC multitargeted inhibitors with selectivity in EGFR
AID1848617	Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay	2022	Journal of medicinal chemistry, 11-10, Volume: 65, Issue:21	First-in-Class Dual Mechanism Ferroptosis-HDAC Inhibitor Hybrids.
AID605398	Inhibition of HDAC6 in human HCT116 cells assessed as induction of alpha-tubulin acetylation after 30 hrs by Western blot analysis	2010	Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24	Discovery of 2-(6-{[(6-fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a class I selective orally active histone deacetylase inhibitor.
AID1543938	Antiproliferative activity against human Bel7402/5-FU cells incubated for 48 hrs by MTT assay	2019	European journal of medicinal chemistry, Apr-15, Volume: 168	β-Carboline and N-hydroxycinnamamide hybrids as anticancer agents for drug-resistant hepatocellular carcinoma.
AID1165115	Cytotoxicity against human Jurkat cells	2014	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 24, Issue:20	The antileishmanial activity of isoforms 6- and 8-selective histone deacetylase inhibitors.
AID1739568	Antiproliferative activity against human HL60 assessed as reduction in cell growth at 100 uM by CellTiter-non radioactive cell proliferation assay	2020	European journal of medicinal chemistry, Aug-15, Volume: 200	Design, synthesis, and biological evaluation of dual targeting inhibitors of histone deacetylase 6/8 and bromodomain BRPF1.
AID1754814	Inhibition of HDAC in human MCF7 cells assessed as increase in acetylated histone H2A mRNA level at 3 uM incubated for 24 hrs by whole transcriptome analysis	2021	Bioorganic & medicinal chemistry, 07-15, Volume: 42	Discovery of novel class of histone deacetylase inhibitors as potential anticancer agents.
AID1873406	Inhibition of HDAC2 (unknown origin) preincubated for 60 mins	2022	Bioorganic & medicinal chemistry letters, 08-15, Volume: 70	Comparison of three zinc binding groups for HDAC inhibitors - A potency, selectivity and enzymatic kinetics study.
AID1759720	Inhibition of recombinant human FLAG-tagged HDAC3 expressed in human HEK293F cells co-expressing His6-tagged SMRT (1 to 899 residues) using Fluor-de-lys substrate as substrate incubated for 3 hrs followed by substrate addition and measured after 60 mins b	2021	ACS medicinal chemistry letters, Apr-08, Volume: 12, Issue:4	Redefining the Histone Deacetylase Inhibitor Pharmacophore: High Potency with No Zinc Cofactor Interaction.
AID461253	Antiproliferative activity against human HCC827 cells after hrs by ATP content assay	2010	Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5	Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer.
AID619049	Competitive inhibition of HDAC4 using KI-104 as substrate by fluorescence assay	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile.
AID723135	Potentiation of 10 uM cisplatin-induced toxicity in 5 uM cisplatin resistant human A2780 cells at 0.5 uM pretreated for 48 hrs followed by 5 uM cisplatin treatment by MTT assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1898902	Antiproliferative activity against human MM487 cells incubated for 24 hrs followed by incubating in drug-free medium for 48 hrs and measured by SRB assay	2022	European journal of medicinal chemistry, Jan-15, Volume: 228	Antitumor activity of novel POLA1-HDAC11 dual inhibitors.
AID1439351	Antiproliferative activity against human RPMI8226 cells after 72 hrs by CellTiter 96 AQueous Non-Radioactive assay	2017	European journal of medicinal chemistry, Mar-10, Volume: 128	Design, synthesis and biological evaluation of thienopyrimidine hydroxamic acid based derivatives as structurally novel histone deacetylase (HDAC) inhibitors.
AID1690837	Inhibition of recombinant human C-terminal His-tagged HDAC9 (604 to 1066 residues) expressed in baculovirus infected Sf9 cells using fluorogenic HDAC 2A substrate preincubated for 5 mins followed by substrate addition and measured after 30 mins by fluores	2020	European journal of medicinal chemistry, Apr-15, Volume: 192	Synthesis and biological evaluation of acridine-based histone deacetylase inhibitors as multitarget agents against Alzheimer's disease.
AID1784987	Inhibition of HDAC3 (unknown origin) using Ac-peptide as a substrate pretreated for 15 mins followed by substrate addition	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Design, synthesis and biological evaluation of novel hybrids targeting mTOR and HDACs for potential treatment of hepatocellular carcinoma.
AID663375	Growth inhibition of human SNB19 cells after 72 hrs by MTS assay	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Discovery and extensive in vitro evaluations of NK-HDAC-1: a chiral histone deacetylase inhibitor as a promising lead.
AID1164026	Inhibition of human recombinant HDAC3 after 60 mins by fluorimetric assay	2014	European journal of medicinal chemistry, Oct-30, Volume: 86	Design, synthesis, and biological evaluation of 1, 3-disubstituted-pyrazole derivatives as new class I and IIb histone deacetylase inhibitors.
AID1633439	Immunomodulatory activity in LPS treated Wistar rat primary microglial cells assessed as effect on TREM2 expression level at 5 to 50 uM incubated for 24 hrs by western blot analysis	2019	ACS medicinal chemistry letters, Apr-11, Volume: 10, Issue:4	Discovery of the First-in-Class GSK-3β/HDAC Dual Inhibitor as Disease-Modifying Agent To Combat Alzheimer's Disease.
AID80076	Inhibitory activity against H1299 human lung carcinoma cell growth	2003	Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21	N-hydroxy-3-phenyl-2-propenamides as novel inhibitors of human histone deacetylase with in vivo antitumor activity: discovery of (2E)-N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide (NVP-LAQ824).
AID1336936	Inhibition of class 1 HDAC in human LNCAP cells assessed as acetylated histone H4 accumulation at 10 uM after 24 hrs by Western blot analysis	2017	Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3	Bifunctional conjugates with potent inhibitory activity towards cyclooxygenase and histone deacetylase.
AID1542181	Inhibition of HDAC3 (unknown origin)	2019	Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7	Kinase and Histone Deacetylase Hybrid Inhibitors for Cancer Therapy.
AID324956	Inhibition of HDAC6 in HEK293 cells	2008	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 18, Issue:6	Probing the elusive catalytic activity of vertebrate class IIa histone deacetylases.
AID1273866	Inhibition of HDAC in human HeLa cells nuclear extract using Fluor de lys as substrate after 15 mins by fluorometric analysis	2016	European journal of medicinal chemistry, Jan-27, Volume: 108	Synthesis, biological characterization and molecular modeling insights of spirochromanes as potent HDAC inhibitors.
AID1401530	Antiproliferative activity against human NCI-H460 cells after 72 hrs by SRB assay	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors.
AID1605966	Antiproliferative activity against human SR cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	2020	Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8	Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors.
AID725670	Inhibition of C-terminal His-tagged and C-terminal FLAG-tagged full length human recombinant HDAC1 expressed in baculovirus expression system using fluorogenic acetylated peptide as substrate preincubated with enzyme for 10 mins prior to substrate additio	2013	ACS medicinal chemistry letters, Jan-10, Volume: 4, Issue:1	Biological evaluation of new largazole analogues: alteration of macrocyclic scaffold with click chemistry.
AID1848277	Inhibition of PI3Kalpha (unknown origin) by mobility shift assay	2022	Bioorganic & medicinal chemistry, Nov-15, Volume: 74	Design, synthesis and biological evaluation of novel pyrazinone derivatives as PI3K/HDAC dual inhibitors.
AID476836	Toxicity in FVB mouse assessed as effect on body weight at 50 mg/kg, po administered 5 times per week for 2 weeks	2010	Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8	Modified cap group suberoylanilide hydroxamic acid histone deacetylase inhibitor derivatives reveal improved selective antileukemic activity.
AID1739571	Inhibition of HDAC6 in human THP-1 cells assessed as ratio of acetylated tubulin/GAPDH at 10 uM incubated for 4 hrs by Western blot analysis relative to DMSO	2020	European journal of medicinal chemistry, Aug-15, Volume: 200	Design, synthesis, and biological evaluation of dual targeting inhibitors of histone deacetylase 6/8 and bromodomain BRPF1.
AID1361641	Cell cycle arrest in human A549 cells assessed as accumulation of cells at G1 phase at 1 uM after 48 hrs by flow cytometric analysis (Rvb = 49.01%)	2018	Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16	Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents.
AID1865272	Inhibition of SHP2 in human MV4-11 cells assessed as downregulation of ERK phosphorylation incubated for 24 hrs by Western blot analysis	2022	Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18	Discovery of Novel Src Homology-2 Domain-Containing Phosphatase 2 and Histone Deacetylase Dual Inhibitors with Potent Antitumor Efficacy and Enhanced Antitumor Immunity.
AID1462215	Inhibition of recombinant human HDAC1 at 0.1 uM after 30 mins by fluorescence assay relative to control	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Structure-based design, synthesis and in vitro antiproliferative effects studies of novel dual BRD4/HDAC inhibitors.
AID1890309	Inhibition of HDAC2 (unknown origin) using Boc-Lys-(acetyl)-AMC as substrate incubated for 0.5 hr and measured after 20 mins by fluorescence assay	2022	European journal of medicinal chemistry, Apr-05, Volume: 233	Novel biphenyl-based scaffold as potent and selective histone deacetylase 6 (HDAC6) inhibitors: Identification, development and pharmacological evaluation.
AID1173505	Inhibition of full length C-terminal 6x-His tagged human HDAC8 using Arg-His-Lys(Ac)-Lys(Ac) substrate incubated for 2 hrs by fluorescence assay	2014	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 24, Issue:23	Histone deacetylase inhibitors derived from 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine and related heterocycles selective for the HDAC6 isoform.
AID1547271	Inhibition of HDAC7 (unknown origin) using biotinylated histone H3 KAc peptide (1 to 21 residues) as substrate by HTRF assay	2020	Journal of medicinal chemistry, 04-09, Volume: 63, Issue:7	Discovery of Thieno[2,3-
AID1688026	Inhibition of recombinant C-terminal FLAG-tagged full length human HDAC6 expressed in baculovirus infected Sf9 cells using Boc-Lys(Ac)-AMC as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence base	2020	European journal of medicinal chemistry, Feb-15, Volume: 188	A 18β-glycyrrhetinic acid conjugate with Vorinostat degrades HDAC3 and HDAC6 with improved antitumor effects.
AID1826595	Inhibition of full-length recombinant human HDAC1 expressed in Baculovirus expression system using Ac-Leu-Gly-Lys(Ac)-AMC as substrate preincubated for 5 mins followed by substrate addition and further incubated for 30 mins by fluorescence based microtite	2022	Journal of medicinal chemistry, 03-24, Volume: 65, Issue:6	Evodiamine-Inspired Topoisomerase-Histone Deacetylase Dual Inhibitors: Novel Orally Active Antitumor Agents for Leukemia Therapy.
AID1348922	Inhibition of C-terminal His-tagged recombinant human HDAC9 expressed in baculovirus infected Sf9 insect cells preincubated for 5 mins followed by substrate addition measured after 30 mins by fluorescence assay	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Discovery of aliphatic-chain hydroxamates containing indole derivatives with potent class I histone deacetylase inhibitory activities.
AID1234887	Inhibition of HDAC1/2 in human HeLa cell nuclear extract using Boc-Lys (acetyl)-AMC as substrate preincubated for 30 mins before substrate addition measured after 20 mins by UV-vis spectrophotometer analysis	2015	Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15	Design, synthesis and preliminary biological evaluation of indoline-2,3-dione derivatives as novel HDAC inhibitors.
AID1421924	Cytotoxicity against human NFF cells after 72 hrs by sulforhodamine B assay	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	One-pot, multi-component synthesis and structure-activity relationships of peptoid-based histone deacetylase (HDAC) inhibitors targeting malaria parasites.
AID1873405	Inhibition of HDAC2 (unknown origin) preincubated for 30 mins	2022	Bioorganic & medicinal chemistry letters, 08-15, Volume: 70	Comparison of three zinc binding groups for HDAC inhibitors - A potency, selectivity and enzymatic kinetics study.
AID1898937	Induction of DNA damage in human MM487 cells at 7.4 uM assessed as increase in p-H2AX levels and measured by Western blot analysis	2022	European journal of medicinal chemistry, Jan-15, Volume: 228	Antitumor activity of novel POLA1-HDAC11 dual inhibitors.
AID669757	Growth inhibition of human Hep3B cells after 48 hrs by SRB assay	2012	Journal of medicinal chemistry, Apr-26, Volume: 55, Issue:8	Synthesis and biological evaluation of 1-arylsulfonyl-5-(N-hydroxyacrylamide)indoles as potent histone deacetylase inhibitors with antitumor activity in vivo.
AID1348919	Inhibition of N-terminal GST/C-terminal His-tagged recombinant human HDAC4 (648 to 1057 residues) expressed in baculovirus infected Sf9 insect cells using Boc-Lys(TFA)-AMC as substrate preincubated for 5 mins followed by substrate addition measured after	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Discovery of aliphatic-chain hydroxamates containing indole derivatives with potent class I histone deacetylase inhibitory activities.
AID1826597	Antiproliferative activity against human A549 cells assessed as cell growth inhibition incubated for 8 hrs by CCK8 assay	2022	Journal of medicinal chemistry, 03-24, Volume: 65, Issue:6	Evodiamine-Inspired Topoisomerase-Histone Deacetylase Dual Inhibitors: Novel Orally Active Antitumor Agents for Leukemia Therapy.
AID1164025	Inhibition of human recombinant HDAC2 after 60 mins by fluorimetric assay	2014	European journal of medicinal chemistry, Oct-30, Volume: 86	Design, synthesis, and biological evaluation of 1, 3-disubstituted-pyrazole derivatives as new class I and IIb histone deacetylase inhibitors.
AID1816235	Antitumor activity in human MDA-MB-231 cells xenografted in BALB/c mouse assessed as tumor growth inhibition at 100 mg/kg, po administered daily for 14 days presence of ruxolitinib measured twice per week
AID603532	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	2011	Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8	Development of tetrahydroisoquinoline-based hydroxamic acid derivatives: potent histone deacetylase inhibitors with marked in vitro and in vivo antitumor activities.
AID723140	Potentiation of 3.16 uM cisplatin-induced toxicity in 0.5 uM cisplatin resistant human KYSE-510 cells at 0.25 uM pretreated for 48 hrs followed by 0.5 uM cisplatin treatment by MTT assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1361639	Inhibition of HDAC in human A549 cells assessed as increase in histone H4 acetylation after 24 hrs by Western blot analysis	2018	Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16	Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents.
AID619052	Competitive inhibition of HDAC7 using KI-104 as substrate by fluorescence assay	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile.
AID1882977	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth by MTT assay	2022	European journal of medicinal chemistry, Jul-05, Volume: 237	Design, synthesis, and evaluation of a novel series of mono-indolylbenzoquinones derivatives for the potential treatment of breast cancer.
AID1832686	Inhibition of full length human HDAC2 using Boc-Lys(acetyl)-AMC as fluorogenic substrate measured after 1 hr by flourescence plate reader method	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Cysteine derivatives as acetyl lysine mimics to inhibit zinc-dependent histone deacetylases for treating cancer.
AID1671984	Cell cycle arrest in human MCF7/ADR cells assessed as accumulation at G2/M phase measured after 24 hrs	2019	Bioorganic & medicinal chemistry, 04-01, Volume: 27, Issue:7	Synthesis and biological evaluation of paclitaxel and vorinostat co-prodrugs for overcoming drug resistance in cancer therapy in vitro.
AID1856989	Inhibition of HDAC6 (unknown origin) preincubated for 5 mins followed by substrate addition and measured after 30 mins by multimode microplate reader analysis	2022	Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19	Histone Deacetylase and Enhancer of Zeste Homologue 2 Dual Inhibitors Presenting a Synergistic Effect for the Treatment of Hematological Malignancies.
AID711157	Inhibition of HDAC8 by fluorometric assay	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	Rapid discovery of highly potent and selective inhibitors of histone deacetylase 8 using click chemistry to generate candidate libraries.
AID446341	Inhibition of histone acetylation in human K562 cells at 0.5 uM by flow cytofluorometry relative to control	2010	Journal of medicinal chemistry, Jan-28, Volume: 53, Issue:2	Synthesis and biological evaluation of N-hydroxyphenylacrylamides and N-hydroxypyridin-2-ylacrylamides as novel histone deacetylase inhibitors.
AID1164193	Inhibition of HDAC in human MCF7 cells assessed as hyperacetylation of histone H4 at Lys 16 residue at 5 uM after 24 hrs by Western blot analysis relative to control	2014	ACS medicinal chemistry letters, Sep-11, Volume: 5, Issue:9	Novel antiproliferative chimeric compounds with marked histone deacetylase inhibitory activity.
AID1578493	Induction of apoptosis in human MV4-11 cells assessed as early apoptotic cells at 2 uM incubated for 18 hrs by annexin V FITC and PI based flow cytometry (Rvb = 19.46 to 22.17 %)	2020	ACS medicinal chemistry letters, Jan-09, Volume: 11, Issue:1	Class I/IIb-Selective HDAC Inhibitor Exhibits Oral Bioavailability and Therapeutic Efficacy in Acute Myeloid Leukemia.
AID1541452	Inhibition of HDAC in human A2780 cells using Boc-Lys(epsilon-Ac)-AMC as substrate preincubated for 18 hrs followed by substrate addition and measured after 3 hrs by fluorescence assay	2019	Journal of medicinal chemistry, 12-26, Volume: 62, Issue:24	Synthesis of Peptoid-Based Class I-Selective Histone Deacetylase Inhibitors with Chemosensitizing Properties.
AID545854	Inhibition of human HDAC in HeLa cells by fluorescent activity assay	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Novel inhibitor of Plasmodium histone deacetylase that cures P. berghei-infected mice.
AID1765326	Inhibition of human full-length recombinant HDAC3 preincubated for 5 mins followed by HDAC substrate addition and further incubated for 45 mins by fluorescence microplate reader assay	2021	European journal of medicinal chemistry, Oct-15, Volume: 222	A first-in-class anticancer dual HDAC2/FAK inhibitors bearing hydroxamates/benzamides capped by pyridinyl-1,2,4-triazoles.
AID1819521	Downregulation of SPT16 expression in human KG-1 cells assessed as chromatin damage at 0.5 to 2.5 uM measured after 24 hrs by Western blot analysis	2022	Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4	Discovery of DNA-Targeting HDAC Inhibitors with Potent Antitumor Efficacy In Vivo That Trigger Antitumor Immunity.
AID723478	Cytotoxicity against cisplatin sensitive human MDA-MB-231 cells after 72 hrs by MTT assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1293558	Antiproliferative activity against human LoVo cells assessed as reduction in cell number after 72 hrs by cell counter analysis	2016	European journal of medicinal chemistry, Apr-13, Volume: 112	Biphenyl-4-yl-acrylohydroxamic acids: Identification of a novel indolyl-substituted HDAC inhibitor with antitumor activity.
AID1543937	Antiproliferative activity against human Bel7402 cells incubated for 48 hrs by MTT assay	2019	European journal of medicinal chemistry, Apr-15, Volume: 168	β-Carboline and N-hydroxycinnamamide hybrids as anticancer agents for drug-resistant hepatocellular carcinoma.
AID1633424	Inhibition of GSK3beta in human SH-SY5Y cells assessed as reduction in copper-induced tau hyperphosphorylation at 10 uM preincubated for 1 hr followed by copper addition and measured after 26 hrs by ELISA	2019	ACS medicinal chemistry letters, Apr-11, Volume: 10, Issue:4	Discovery of the First-in-Class GSK-3β/HDAC Dual Inhibitor as Disease-Modifying Agent To Combat Alzheimer's Disease.
AID723441	Potentiation of 0.5 uM cisplatin-induced toxicity in 0.5 uM cisplatin resistant human KYSE-510 cells at 1 uM pretreated for 48 hrs followed by 0.5 uM cisplatin treatment by MTT assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1415647	Inhibition of HDAC2 in human HepG2 cells assessed as increase in acetylated-histone H3 level at 5 uM after 48 hrs by Western blot analysis	2017	MedChemComm, Jun-01, Volume: 8, Issue:6	Development of novel β-carboline-based hydroxamate derivatives as HDAC inhibitors with DNA damage and apoptosis inducing abilities.
AID1260642	Inhibition of human recombinant HDAC6 at 20 uM using Boc-Lys(Ac)-AMC as substrate after 30 to 60 mins by microplate reader assay
AID1633994	Cytotoxicity against human HuH7 cells assessed as reduction in cell viability incubated for 3 days by MTT assay	2019	Bioorganic & medicinal chemistry letters, 08-15, Volume: 29, Issue:16	Synthesis of N'-propylhydrazide analogs of hydroxamic inhibitors of histone deacetylases (HDACs) and evaluation of their impact on activities of HDACs and replication of hepatitis C virus (HCV).
AID269672	Antiproliferative activity against human ACHN cells by SRB assay	2006	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 16, Issue:15	Synthesis, enzymatic inhibition, and cancer cell growth inhibition of novel delta-lactam-based histone deacetylase (HDAC) inhibitors.
AID1548266	Induction of apoptosis in human RPMI8226 cells assessed as induction of caspase-3/7 activation incubated for 24 hrs by fluorometric assay
AID1833062	Anticancer activity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	2021	Bioorganic & medicinal chemistry, 11-15, Volume: 50	Effect of phenylurea hydroxamic acids on histone deacetylase and VEGFR-2.
AID1129773	Increase in p21 mRNA level in human Jurkat cells at 10 uM after 24 hrs by quantitative RT-PCR analysis	2014	Bioorganic & medicinal chemistry, Apr-01, Volume: 22, Issue:7	Studies on the antiproliferative effects of tropolone derivatives in Jurkat T-lymphocyte cells.
AID1915570	Cytotoxicity against human MDA-MB-231 cells	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors.
AID1279127	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	2016	Bioorganic & medicinal chemistry, Apr-01, Volume: 24, Issue:7	Design and synthesis of a new generation of substituted purine hydroxamate analogs as histone deacetylase inhibitors.
AID1897491	Toxicity in BALB/c nude mouse xenografted with human HCT-116 cells assessed as reduction in body weight at 30 mg/kg/day, po administered for 18 days and measured every 3 days
AID300839	Growth inhibition of human hepatocytes after 21 hrs by MTT assay	2007	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17	Pomiferin, histone deacetylase inhibitor isolated from the fruits of Maclura pomifera.
AID327547	Increase in acetylated alpha tubulin level in human HCT116 cells at 10 uM after 24 hrs relative to control	2008	Journal of medicinal chemistry, Apr-24, Volume: 51, Issue:8	Polyaminohydroxamic acids and polyaminobenzamides as isoform selective histone deacetylase inhibitors.
AID1390962	Inhibition of HDAC1 (unknown origin) using Arg-His-Lys-Lys(Ac) as substrate after 2 hrs by fluorescence analysis	2018	Bioorganic & medicinal chemistry letters, 05-01, Volume: 28, Issue:8	Design and synthesis of triple inhibitors of janus kinase (JAK), histone deacetylase (HDAC) and Heat Shock Protein 90 (HSP90).
AID1380948	Antiproliferative activity against human HEL cells after 72 hrs by MTT assay	2018	Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12	Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously.
AID350728	Growth inhibition of human DMS114 cells after 48 hrs by sulforhodamine B assay	2009	Journal of medicinal chemistry, May-14, Volume: 52, Issue:9	Design, synthesis, and biological activity of boronic acid-based histone deacetylase inhibitors.
AID1282262	Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay	2016	Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4	Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
AID476651	Toxicity in FVB mouse assessed as effect on number of platelets at 50 mg/kg, po administered 5 times per week for 2 weeks measured during test (Rvb = 454 +/- 93 10^3/mm^3)	2010	Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8	Modified cap group suberoylanilide hydroxamic acid histone deacetylase inhibitor derivatives reveal improved selective antileukemic activity.
AID347869	Growth inhibition of human Breast cancer cells at 10 uM relative to control	2008	Journal of medicinal chemistry, Dec-11, Volume: 51, Issue:23	Histone deacetylase inhibitors through click chemistry.
AID1281856	Antiproliferative activity against human JeKo1 cells after 72 hrs by CellTiter 96 aqueous non-radioactive cell proliferation assay	2016	European journal of medicinal chemistry, Apr-13, Volume: 112	Design, synthesis and biological evaluation of bisthiazole-based trifluoromethyl ketone derivatives as potent HDAC inhibitors with improved cellular efficacy.
AID631666	Inhibition of human recombinant full-length HDAC1 using fluorophore conjugated substrate by fluorescence assay	2011	Journal of medicinal chemistry, Aug-11, Volume: 54, Issue:15	In vivo PET imaging of histone deacetylases by 18F-suberoylanilide hydroxamic acid (18F-SAHA).
AID723157	Potentiation of 5 uM cisplatin-induced toxicity in 1 uM cisplatin resistant human CAL27 cells at 1.5 uM pretreated for 48 hrs followed by 1 uM cisplatin treatment by MTT assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1548914	Induction of apoptosis in human RS4:11 cells harboring wild type p53/FLT3 assessed as cleavage of pro-caspase 3 at 5000 nM after 24 hrs by Western blot analysis	2020	Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10	Design of Hydrazide-Bearing HDACIs Based on Panobinostat and Their p53 and FLT3-ITD Dependency in Antileukemia Activity.
AID1164027	Inhibition of human recombinant HDAC8 after 60 mins by fluorimetric assay	2014	European journal of medicinal chemistry, Oct-30, Volume: 86	Design, synthesis, and biological evaluation of 1, 3-disubstituted-pyrazole derivatives as new class I and IIb histone deacetylase inhibitors.
AID538409	Inhibition of recombinant human HDAC6 using Boc-Lys(Ac)-AMC as substrate by fluorometric analysis	2010	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 20, Issue:23	Inhibitors selective for HDAC6 in enzymes and cells.
AID1250654	Antiproliferative activity against human MOLT4 cells after 72 hrs by CCK8 assay	2015	Journal of medicinal chemistry, Oct-08, Volume: 58, Issue:19	Discovery of Novel Class I Histone Deacetylase Inhibitors with Promising in Vitro and in Vivo Antitumor Activities.
AID1900913	Cytotoxicity against human TMZ-resistant U251 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	2022	Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
AID1633672	Inhibition of HDAC in mouse N9 cells assessed as suppression of LPS-induced decrease in histone H3 acetylation at 5 to 25 uM incubated for 24 hrs by Western blot analysis	2019	ACS medicinal chemistry letters, Apr-11, Volume: 10, Issue:4	Novel Sustainable-by-Design HDAC Inhibitors for the Treatment of Alzheimer's Disease.
AID1722283	Inhibition of human recombinant HDAC6 expressed in baculovirus infected High5 insect cells using Boc-Lys(eacety1)-AMC as substrate incubated for 3 hrs measured after 30 mins by microplate reader based spectrophotometric analysis	2020	Bioorganic & medicinal chemistry, 09-01, Volume: 28, Issue:17	The design of a novel near-infrared fluorescent HDAC inhibitor and image of tumor cells.
AID1758464	Dark toxicity in human HCT-116 cells assessed as reduction in cell viability incubated under dark for 48 hrs measured after 48 hrs by CCK8 assay	2021	European journal of medicinal chemistry, May-05, Volume: 217	Novel dual-mode antitumor chlorin-based derivatives as potent photosensitizers and histone deacetylase inhibitors for photodynamic therapy and chemotherapy.
AID1605979	Antiproliferative activity against human RXF393 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	2020	Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8	Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors.
AID482970	Toxicity in human PC3 cells xenografted nude mouse	2010	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11	Acylurea connected straight chain hydroxamates as novel histone deacetylase inhibitors: Synthesis, SAR, and in vivo antitumor activity.
AID1201650	Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 48 hrs by SRB assay	2015	European journal of medicinal chemistry, May-05, Volume: 95	Macrocyclic compounds as anti-cancer agents: design and synthesis of multi-acting inhibitors against HDAC, FLT3 and JAK2.
AID1293568	Inhibition of human recombinant N-terminal GST-tagged HDAC7 (518 to 991 residues) expressed in insect cells using RHK-K(Ac)-AMC as substrate incubated for 60 mins by fluorescence assay	2016	European journal of medicinal chemistry, Apr-13, Volume: 112	Biphenyl-4-yl-acrylohydroxamic acids: Identification of a novel indolyl-substituted HDAC inhibitor with antitumor activity.
AID1352480	Inhibition of HDAC1 in human HeLa cells after 72 hrs by ELISA	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Spirohydantoins and 1,2,4-triazole-3-carboxamide derivatives as inhibitors of histone deacetylase: Design, synthesis, and biological evaluation.
AID274024	Bioavailability after i.p. dosing at 5 mg kg-1	2007	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2	Identification and optimisation of a series of substituted 5-pyridin-2-yl-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.
AID1201649	Antiproliferative activity against human HCT116 cells assessed as growth inhibition after 48 hrs by SRB assay	2015	European journal of medicinal chemistry, May-05, Volume: 95	Macrocyclic compounds as anti-cancer agents: design and synthesis of multi-acting inhibitors against HDAC, FLT3 and JAK2.
AID488237	Inhibition of HDAC2 after 10 mins by fluorometric assay	2010	Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11	Vitamin D receptor agonist/histone deacetylase inhibitor molecular hybrids.
AID1266826	Cytotoxicity against rat IEC-18 cells assessed as survival after 48 hrs by MTT assay	2015	Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23	Novel β-Carboline/Hydroxamic Acid Hybrids Targeting Both Histone Deacetylase and DNA Display High Anticancer Activity via Regulation of the p53 Signaling Pathway.
AID1819505	Inhibition of HDAC6 (unknown origin) using fluorogenic substrate incubated for 30 mins by fluorescence based assay	2022	Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4	Discovery of DNA-Targeting HDAC Inhibitors with Potent Antitumor Efficacy In Vivo That Trigger Antitumor Immunity.
AID603538	Antitumor activity against human MDA-MB-231 cells xenografted in athymic nude mouse assessed as tumor growth inhibition at 90 mg/kg, ip qd for 21 days	2011	Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8	Development of tetrahydroisoquinoline-based hydroxamic acid derivatives: potent histone deacetylase inhibitors with marked in vitro and in vivo antitumor activities.
AID1864220	Binding affinity to 5' FAM and 3' TAMRA-labeled c-myc G4-quadruplex DNA Pu22 (unknown origin) assessed as change in melting temperature at 1 uM by fluorescence resonance energy transfer assay	2022	Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18	Discovery of a Novel G-Quadruplex and Histone Deacetylase (HDAC) Dual-Targeting Agent for the Treatment of Triple-Negative Breast Cancer.
AID1677500	Induction of apoptosis in human HeLA cells at 3 uM after 48 hr by annexin V FITC and propidium iodide staining based flow cytometric analysis	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	HDAC-Bax Multiple Ligands Enhance Bax-Dependent Apoptosis in HeLa Cells.
AID1240554	Induction of apoptosis in human MDA-MB-231 cells assessed as late apoptotic cells at 4 uM after 24 hrs using Annexin V-FITC and propidium iodide staining by flow cytometry (Rvb = 4.04%)	2015	Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17	Design, synthesis and biological evaluation of saccharin-based N-hydroxybenzamides as histone deacetylases (HDACs) inhibitors.
AID328809	Antiproliferative activity against human A2780 cells by CellTiter-Blue cell viability assay	2008	Journal of medicinal chemistry, Apr-24, Volume: 51, Issue:8	A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo.
AID723124	Potentiation of 8 uM cisplatin-induced toxicity in 0.5 uM cisplatin resistant human KYSE-510 cells at 0.25 uM pretreated for 48 hrs followed by 0.5 uM cisplatin treatment by MTT assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1248352	Inhibition of human full length MMP2 using Mca-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 as substrate at 10 uM incubated for 2 hrs prior to testing measured for 15 mins by fluorometric analysis relative to control	2015	Bioorganic & medicinal chemistry, Oct-15, Volume: 23, Issue:20	Synthesis of chiral ND-322, ND-364 and ND-364 derivatives as selective inhibitors of human gelatinase.
AID663359	Growth inhibition of human HCT15 cells after 72 hrs by MTS assay	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Discovery and extensive in vitro evaluations of NK-HDAC-1: a chiral histone deacetylase inhibitor as a promising lead.
AID525015	Inhibition of HDAC7 in human CFBE41o- cell line assessed as increase in stability of Fdelta508 CFTR protein at 5 uM after 24 hrs by pulse chase analysis	2010	Nature chemical biology, Jan, Volume: 6, Issue:1	Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.
AID1810053	Displacement of [3H]SCH58261 from adenosine A2A receptor membrane (unknown origin) measured after 60 mins by scintillation counting analysis
AID1737141	Induction of cell cycle arrest in human HCT116 cells assessed as cell accumulation at G0/G1 phase at 3 uM after 24 hrs by Rnase/PI staining based flow cytometric analysis (Rvb = 48.4%)	2020	European journal of medicinal chemistry, Apr-15, Volume: 192	Design, synthesis and biological evaluation of novel indazole-based derivatives as potent HDAC inhibitors via fragment-based virtual screening.
AID255817	Inhibitory concentration against Histone deacetylase 1A in maize	2005	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 15, Issue:21	Exploring the connection unit in the HDAC inhibitor pharmacophore model: novel uracil-based hydroxamates.
AID545860	Antimalarial activity against sPlasmodium falciparum VS/1 assessed as parasite growth inhibition after 48 hrs by standard growth inhibition assay	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Novel inhibitor of Plasmodium histone deacetylase that cures P. berghei-infected mice.
AID1441634	Inhibition of recombinant human N-terminal His-tagged 5-LOX expressed in Escherichia coli assessed as conversion of arachidonic acid to HpETEs measured for 300 secs by UV-visible spectrophotometric analysis	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
AID1548302	Induction of cell cycle arrest in bortezomib resistant human KM3/BTZ cells assessed as accumulation at G2/M phase at 100 nM incubated for 24 hrs by propidium iodide staining based flow cytometry (Rvb = 9.1%)
AID609508	Cytotoxicity against human HCT116 cells after 24 hrs by MTT assay	2011	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16	Synthesis and biological evaluation of piperamide analogues as HDAC inhibitors.
AID748099	Inhibition of HDAC2 in human HeLa cells assessed as increase in histone H3 acetylation at 10 uM after 48 hrs by Western blotting analysis	2013	Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11	Discovery of the first histone deacetylase 6/8 dual inhibitors.
AID1384225	Inhibition of HDAC6 in human SH-SY5Y cells assessed as induction of tubulin K-40 acetylation level at 500 nM after 2 hrs by Western blot analysis relative to control	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease.
AID1861328	Inhibition of HDAC in human DOHH-2 cells assessed as effect on total Stat3 levels at 2.5 uM in presence of 10 uM piclitisib measured by Western blot analysis	2022	Bioorganic & medicinal chemistry letters, 09-01, Volume: 71	Bioevaluation of a dual PI3K/HDAC inhibitor for the treatment of diffuse large B-cell lymphoma.
AID1873385	Inhibition of HDAC5 (unknown origin)	2022	Bioorganic & medicinal chemistry letters, 08-15, Volume: 70	Comparison of three zinc binding groups for HDAC inhibitors - A potency, selectivity and enzymatic kinetics study.
AID1777023	Selectivity index, ratio of IC50 for HDAC1 (unknown origin) to IC50 for HDAC6 (unknown origin)	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Intracellular fluorescence competition assay for inhibitor engagement of histone deacetylase.
AID1384219	Inhibition of full length human recombinant C-terminal FLAG/His-tagged HDAC1 expressed in baculovirus infected sf9 cells assessed residence time preincubated fopr 2 hrs followed by dilution and subsequent fluorogenic HDAC substrate 3 addition measured at	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease.
AID545861	Antimalarial activity against chloroquine-resistant Plasmodium falciparum FCB1 assessed as parasite growth inhibition after 48 hrs by standard growth inhibition assay	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Novel inhibitor of Plasmodium histone deacetylase that cures P. berghei-infected mice.
AID456801	Selectivity index, ratio of IC50 for african green monkey (Cercopithecus aethiops) Vero cells to IC50 for chloroquine-resistant Plasmodium falciparum W2	2010	Bioorganic & medicinal chemistry, Jan-01, Volume: 18, Issue:1	Antimalarial and antileishmanial activities of histone deacetylase inhibitors with triazole-linked cap group.
AID1737137	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay	2020	European journal of medicinal chemistry, Apr-15, Volume: 192	Design, synthesis and biological evaluation of novel indazole-based derivatives as potent HDAC inhibitors via fragment-based virtual screening.
AID1454051	Inhibition of BRD4 in human HL60 cells assessed as reduction in C-myc production after 24 hrs by ELISA	2017	Bioorganic & medicinal chemistry, 07-15, Volume: 25, Issue:14	Synthesis and evaluation of novel dual BRD4/HDAC inhibitors.
AID348391	Inhibition of HDAC in human NB4 cells assessed as induction of histone H4 acetylation after 6 hrs by Western blot analysis	2008	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 18, Issue:18	Design, synthesis and preliminary biological evaluation of new hydroxamate histone deacetylase inhibitors as potential antileukemic agents.
AID1832691	Inhibition of human N-terminal GST tagged HDAC7 (518 to end residues) expressed in baculovirus infected Sf9 insect cells using Boc-Lys(acetyl)-AMC as fluorogenic substrate measured after 1 hr by flourescence plate reader method	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Cysteine derivatives as acetyl lysine mimics to inhibit zinc-dependent histone deacetylases for treating cancer.
AID366644	Inhibition of HDAC6 after 17 hrs	2008	Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15	Use of the nitrile oxide cycloaddition (NOC) reaction for molecular probe generation: a new class of enzyme selective histone deacetylase inhibitors (HDACIs) showing picomolar activity at HDAC6.
AID1848587	Inhibition of full length N-terminal GST/C-terminal his-tagged human recombinant HDAC4 (627 to 1084 residues) expressed in Sf9 insect cells	2022	Journal of medicinal chemistry, 11-10, Volume: 65, Issue:21	First-in-Class Dual Mechanism Ferroptosis-HDAC Inhibitor Hybrids.
AID445134	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	2009	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 19, Issue:22	Novel N-hydroxybenzamide-based HDAC inhibitors with branched CAP group.
AID1449333	Inhibition of HDAC6 in human Cal27CisR cells assessed accumulation of acetylated alpha tubulin at 1 uM after 24 hrs by immunoblot analysis	2017	Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13	Alkoxyurea-Based Histone Deacetylase Inhibitors Increase Cisplatin Potency in Chemoresistant Cancer Cell Lines.
AID1890315	Antiproliferative activity against mouse CT26 cells after 72 hrs by MTT assay	2022	European journal of medicinal chemistry, Apr-05, Volume: 233	Novel biphenyl-based scaffold as potent and selective histone deacetylase 6 (HDAC6) inhibitors: Identification, development and pharmacological evaluation.
AID1127012	Induction of apoptosis in human U937 cells assessed as viable cells using annexin-V/propidium iodide staining at 0.125 to 1 uM by flow cytometry analysis	2014	Journal of medicinal chemistry, Apr-24, Volume: 57, Issue:8	Discovery of the first N-hydroxycinnamamide-based histone deacetylase 1/3 dual inhibitors with potent oral antitumor activity.
AID618331	Antitumor activity against human HCT116 cells xenografted in nude BALB/c mouse assessed as tumor growth inhibition at 200 mg/kg, po qd for 21 days measured on day 15	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile.
AID723119	Potentiation of 20 uM cisplatin-induced toxicity in 5 uM cisplatin resistant human A2780 cells at 0.5 uM pretreated for 48 hrs followed by 5 uM cisplatin treatment by MTT assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1771468	Inhibition of tubulin polymerization (unknown origin) measured after 1 min by fluorescence assay	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Discovery of novel tubulin/HDAC dual-targeting inhibitors with strong antitumor and antiangiogenic potency.
AID482954	Solubility at pH 7	2010	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11	Acylurea connected straight chain hydroxamates as novel histone deacetylase inhibitors: Synthesis, SAR, and in vivo antitumor activity.
AID1476120	Inhibition of C-terminal FLAG His tagged full length human recombinant HDAC1 (1 to 482 residues) expressed in baculovirus infected sf21 cells at 10 uM using RHKKAc as substrate in presence of ATP relative to control	2017	Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20	Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat.
AID655471	Restoration of CFTR deltaF508 mutant trafficking to cell surface in human CFBE41o cells co-expressing halide-sensitive YFP-H148Q/I142L assessed as fluorescence quenching at 1 uM after 24 hrs relative to control	2011	ACS medicinal chemistry letters, Jul-21, Volume: 2, Issue:9	Potential Agents for Treating Cystic Fibrosis: Cyclic Tetrapeptides that Restore Trafficking and Activity of ΔF508-CFTR.
AID1875503	Inhibition of LSD1 (unknown origin) using H3K4me2 peptide as substrate preincubated for 15 mins followed by substrate addition and measured after 30 mins by fluorescence based analysis	2022	ACS medicinal chemistry letters, Oct-13, Volume: 13, Issue:10	Cancer-Cell-Selective Targeting by Arylcyclopropylamine-Vorinostat Conjugates.
AID1614129	Inhibition of recombinant full length C-terminal His-tagged human HDAC8 expressed in baculovirus expression system using Ac-peptide-AMC as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by fluorescence assay
AID1826623	Synergistic antiproliferative effect on HEL cells assessed as fractional inhibitory concentration index at 0.37 uM in presence of 3-Fluoro-10-hydroxy-14-methyl-8,13,13b,14-tetrahydro-7H-indolo[2',3':3,4]pyrido[2,1-b]quinazolin-5-one	2022	Journal of medicinal chemistry, 03-24, Volume: 65, Issue:6	Evodiamine-Inspired Topoisomerase-Histone Deacetylase Dual Inhibitors: Novel Orally Active Antitumor Agents for Leukemia Therapy.
AID1898527	Acute toxicity in po dosed ICR mouse assessed as maximum tolerated dose measured after 7 days	2021	Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11	Discovery of STAT3 and Histone Deacetylase (HDAC) Dual-Pathway Inhibitors for the Treatment of Solid Cancer.
AID1449323	Inhibition of HDAC in human CAL27 cells using Boc-Lys(epsilon-Ac)-AMC as substrate preincubated for 18 hrs followed by substrate addition measured after 3 hrs by fluorescence assay	2017	Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13	Alkoxyurea-Based Histone Deacetylase Inhibitors Increase Cisplatin Potency in Chemoresistant Cancer Cell Lines.
AID1709366	Induction of apoptosis in human NAMALVA cells assessed as early apoptotic cells at IC50 measured after 48 hrs by Annexin V-FITC/7AAD staining based flow cytometry (Rvb = 5.07%)	2021	Bioorganic & medicinal chemistry, 04-01, Volume: 35	Structure-activity relationship and mechanistic studies for a series of cinnamyl hydroxamate histone deacetylase inhibitors.
AID723435	Potentiation of 10 uM cisplatin-induced toxicity in 1 uM cisplatin resistant human MDA-MB-231 cells at 1.5 uM pretreated for 48 hrs followed by 1 uM cisplatin treatment by MTT assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1537560	Antiproliferative activity against human NB-1 cells assessed as reduction in cell viability incubated for 72 hrs by cell-titer Glo assay	2019	MedChemComm, Jul-01, Volume: 10, Issue:7	Design, synthesis and biological evaluation of β-peptoid-capped HDAC inhibitors with anti-neuroblastoma and anti-glioblastoma activity.
AID1578479	Inhibition of recombinant full length human HDAC6 expressed in baculovirus infected Sf9 cells assessed as inhibitory constant using FAM-RHKK-Ac as substrate incubated for 5 hrs by electrophoretic mobility shift assay	2020	ACS medicinal chemistry letters, Jan-09, Volume: 11, Issue:1	Class I/IIb-Selective HDAC Inhibitor Exhibits Oral Bioavailability and Therapeutic Efficacy in Acute Myeloid Leukemia.
AID1065637	Inhibition of human recombinant HDAC5 catalytic domain using Boc_Lys_TFA as substrate after 60 mins by fluorescence assay	2013	Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24	Design, synthesis, and biological evaluation of potent and selective class IIa histone deacetylase (HDAC) inhibitors as a potential therapy for Huntington's disease.
AID1390022	Antiproliferative activity against human Jurkat cells after 48 hrs by MTT assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Structure optimization and preliminary bioactivity evaluation of N-hydroxybenzamide-based HDAC inhibitors with Y-shaped cap.
AID1740130	Inhibition of human C-terminal His-tagged HDAC3 (1 to 428 residues)/human N-terminal GST-tagged NcoR2 (395 to 489 residues) expressed in sf9 cells using acetyl-Lys(Ac)-AMC as substrate	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight.
AID1816712	Inhibition of HDAC11 (unknown origin) using Ac-peptide as substrate preincubated for 15 mins followed by substrate addition by fluorescence based microplate reader analysis	2021	European journal of medicinal chemistry, Aug-05, Volume: 220	Design, synthesis, and biological evaluation of novel dual inhibitors targeting lysine specific demethylase 1 (LSD1) and histone deacetylases (HDAC) for treatment of gastric cancer.
AID1864268	Antitumor activity against human MDA-MB-231 cells xenografted in BALB/c-nu/nu mouse assessed as increment ratio at 10 mg/kg, ip measured for 31 days	2022	Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18	Discovery of a Novel G-Quadruplex and Histone Deacetylase (HDAC) Dual-Targeting Agent for the Treatment of Triple-Negative Breast Cancer.
AID1548263	Antiproliferative activity against human HL7702 cells incubated for 48 hrs by MTT assay
AID1650440	Inhibition of class 1 histone deacetylase in human Cal27CisR cells assessed as increase in H3 histone acetylation at 3 uM incubated for 24 hrs by immunoblot analysis	2020	Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1	Novel alkoxyamide-based histone deacetylase inhibitors reverse cisplatin resistance in chemoresistant cancer cells.
AID1702195	Antitumor activity against human HepG2 cells xenografted in Ncr nude mouse assessed as tumor growth inhibition at 60 mg/kg, po QD with 5 days on and 2 days off dosing schedule for 2 weeks cotreated with 75 mg/kg pictilisib and measured at day 14	2018	Journal of medicinal chemistry, 02-22, Volume: 61, Issue:4	Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma.
AID1127322	Antiproliferative activity against p53 defective cis-platinum-resistant human IGROV1/Pt1 cells assessed as growth inhibition after 72 hrs	2014	European journal of medicinal chemistry, May-22, Volume: 79	Influence of the adamantyl moiety on the activity of biphenylacrylohydroxamic acid-based HDAC inhibitors.
AID1482174	Cytotoxicity against human MCF7 cells assessed as growth inhibition at 5 uM after 48 hrs by MTT assay relative to control	2017	Journal of medicinal chemistry, 04-27, Volume: 60, Issue:8	Exploring Derivatives of Quinazoline Alkaloid l-Vasicine as Cap Groups in the Design and Biological Mechanistic Evaluation of Novel Antitumor Histone Deacetylase Inhibitors.
AID1282300	Inhibition of HDAC6 in human HCT116 cells assessed as upregulation of alpha tubulin acetylation at 10 to 1000 nM after 6 hrs by Western blot analysis	2016	Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4	Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
AID1848585	Inhibition of full length C-terminal his6/FLAG-tagged human recombinant HDAC3 (1 to 2383 residues) expressed in Sf9 insect cells	2022	Journal of medicinal chemistry, 11-10, Volume: 65, Issue:21	First-in-Class Dual Mechanism Ferroptosis-HDAC Inhibitor Hybrids.
AID350723	Ratio of GI50 for human MKN45 cells to IC50 for human recombinant HDAC1	2009	Journal of medicinal chemistry, May-14, Volume: 52, Issue:9	Design, synthesis, and biological activity of boronic acid-based histone deacetylase inhibitors.
AID1541457	Inhibition of recombinant human C-terminal His-fusion tagged/N-terminal Strep-2 tagged HDAC8 (1 to 377 residues) expressed in insect cells using Boc-Lys(TFa)-AMC as substrate preincubated for 5 mins followed by substrate addition measured after 90 mins by	2019	Journal of medicinal chemistry, 12-26, Volume: 62, Issue:24	Synthesis of Peptoid-Based Class I-Selective Histone Deacetylase Inhibitors with Chemosensitizing Properties.
AID1890339	Antitumor immunity in C57BL/6 mouse xenografted with mouse CT26 cells assessed as increase in CD3+ CD8+ cytotoxic T cells at 100 mg/kg, po administered once daily for 21 days measured by flow cytometry analysis	2022	European journal of medicinal chemistry, Apr-05, Volume: 233	Novel biphenyl-based scaffold as potent and selective histone deacetylase 6 (HDAC6) inhibitors: Identification, development and pharmacological evaluation.
AID1390020	Inhibition of HDAC in human HeLa cell nuclear extract using Boc-Lys (acetyl)-AMC as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by fluorescence assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Structure optimization and preliminary bioactivity evaluation of N-hydroxybenzamide-based HDAC inhibitors with Y-shaped cap.
AID1441659	Anti-inflammatory activity in LPS-induced C57BL/6 mouse model of acute lung injury assessed as reduction in pulmonary edema by measuring lung wet/dry ratio at 25 mg/kg, ip pretreated for 1 hr followed LPS challenge after 24 hrs by Evans blue dye based met	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
AID374829	Antiproliferative activity against human A2780 cells after 72 hrs by celltiter-blue cell viability assay	2009	Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11	Discovery of a potent class I selective ketone histone deacetylase inhibitor with antitumor activity in vivo and optimized pharmacokinetic properties.
AID1650437	Inhibition of HDAC6 in human Cal27CisR cells assessed as increase in acetylated alpha-tubulin at 3 uM incubated for 24 hrs by immunoblot analysis	2020	Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1	Novel alkoxyamide-based histone deacetylase inhibitors reverse cisplatin resistance in chemoresistant cancer cells.
AID274102	Inhibition of maize HD1-B (mean)	2007	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 17, Issue:5	Discovery of uracil-based histone deacetylase inhibitors able to reduce acquired antifungal resistance and trailing growth in Candida albicans.
AID411262	Cytotoxicity against HMEC after 72 hrs by trypan blue exclusion assay	2009	Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2	Non-peptide macrocyclic histone deacetylase inhibitors.
AID1282231	Inhibition of human recombinant HDAC8 using AMC labeled AC-peptide as substrate incubated for 1 hr by fluorescence analysis	2016	Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4	Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
AID350729	Growth inhibition of human LOXIMVI cells after 48 hrs by sulforhodamine B assay	2009	Journal of medicinal chemistry, May-14, Volume: 52, Issue:9	Design, synthesis, and biological activity of boronic acid-based histone deacetylase inhibitors.
AID1861343	Inhibition of HDAC in human OCILY3 cells assessed as effect on pS6 levels at 2.5 uM measured by Western blot analysis	2022	Bioorganic & medicinal chemistry letters, 09-01, Volume: 71	Bioevaluation of a dual PI3K/HDAC inhibitor for the treatment of diffuse large B-cell lymphoma.
AID1698862	Inhibition of HDAC1 (unknown origin)	2020	Bioorganic & medicinal chemistry letters, 12-01, Volume: 30, Issue:23	Design, synthesis and biological evaluation of novel c-Met/HDAC dual inhibitors.
AID1578886	Inhibition of HDAC1 (unknown origin) using Boc-Lys (Ac)-AMC as substrate incubated for 60 mins by fluorimetric assay	2019	Journal of natural products, 06-28, Volume: 82, Issue:6	Hydroxamic Acid Derivatives of β-Carboline/Hydroxycinnamic Acid Hybrids Inducing Apoptosis and Autophagy through the PI3K/Akt/mTOR Pathways.
AID1245682	Cytotoxicity against human HEL cells assessed as growth inhibition after 48 hrs by MTT assay	2015	Bioorganic & medicinal chemistry, Oct-01, Volume: 23, Issue:19	Development of N-hydroxybenzamide derivatives with indole-containing cap group as histone deacetylases inhibitors.
AID1548257	Inhibition of class 2 HDAC n human HeLa cell nuclear extracts pre-incubated for 5 mins before fluorogenic substrate Boc-Lys (triflouroacetyl)-AMC addition and measured after 30 mins by fluorescence based assay
AID1775568	Inhibition of human DNMT1 enzyme using polydeoxy-inosine polydeoxy-cytosine DNA as substrate incubated for 15 mins in presence of SAM by TR-FRET assay	2021	Journal of medicinal chemistry, 03-25, Volume: 64, Issue:6	Design and Synthesis of Novel Epigenetic Inhibitors Targeting Histone Deacetylases, DNA Methyltransferase 1, and Lysine Methyltransferase G9a with
AID1650416	Cytotoxicity against human CAL27 cells assessed as reduction in cell viability by MTT assay	2020	Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1	Novel alkoxyamide-based histone deacetylase inhibitors reverse cisplatin resistance in chemoresistant cancer cells.
AID1537554	Inhibition of recombinant full length C-terminal FLAG/His-tagged human HDAC1 expressed in baculovirus infected Sf9 cells using Z-Lys(Ac)-AMC as substrate incubated for 90 mins followed by trypsin addition and measured after 30 mins by fluorescence based a	2019	MedChemComm, Jul-01, Volume: 10, Issue:7	Design, synthesis and biological evaluation of β-peptoid-capped HDAC inhibitors with anti-neuroblastoma and anti-glioblastoma activity.
AID443633	Inhibition of mouse recombinant serine racemase expressed in Escherichia coli MC1061 assessed as formation of D-serine at 5 mM after 30 mins by HPLC analysis	2009	Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19	Hydroxamic acids as a novel family of serine racemase inhibitors: mechanistic analysis reveals different modes of interaction with the pyridoxal-5'-phosphate cofactor.
AID1563941	Inhibition of recombinant HDAC2 (unknown origin) measured after 30 mins by fluorescence assay	2019	European journal of medicinal chemistry, Oct-15, Volume: 180	Design, synthesis, and biological evaluation of a new class of histone acetyltransferase p300 inhibitors.
AID1848596	Cytotoxicity against human CCRF-CEM cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay	2022	Journal of medicinal chemistry, 11-10, Volume: 65, Issue:21	First-in-Class Dual Mechanism Ferroptosis-HDAC Inhibitor Hybrids.
AID1855249	Binding affinity to pBR322 DNA (unknown origin) at 50 uM after 30 mins by Agarose gel electrophoresis	2022	European journal of medicinal chemistry, Nov-05, Volume: 241	Discovery of 2,5-diphenyl-1,3,4-thiadiazole derivatives as HDAC inhibitors with DNA binding affinity.
AID316892	Inhibition of HDAC1	2008	Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6	Histone deacetylase inhibitors: from bench to clinic.
AID274029	Oral bioavailability after oral dosing at 5 mg kg-1	2007	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2	Identification and optimisation of a series of substituted 5-pyridin-2-yl-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.
AID1688021	Cytotoxicity against human PC-3 cells assessed as reduction in cell viability after 96 hrs by MTT assay	2020	European journal of medicinal chemistry, Feb-15, Volume: 188	A 18β-glycyrrhetinic acid conjugate with Vorinostat degrades HDAC3 and HDAC6 with improved antitumor effects.
AID525020	Inhibition of HDAC in human CFBE41o- cell line assessed as total CFTR protein level including CFTR glycoform at 1 uM by immunoblot analysis	2010	Nature chemical biology, Jan, Volume: 6, Issue:1	Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.
AID1201651	Antiproliferative activity against human MDA-MB-435 cells assessed as growth inhibition after 48 hrs by SRB assay	2015	European journal of medicinal chemistry, May-05, Volume: 95	Macrocyclic compounds as anti-cancer agents: design and synthesis of multi-acting inhibitors against HDAC, FLT3 and JAK2.
AID1451821	Inhibition of human recombinant HDAC1 (1 to 482 residues) expressed in Baculovirus using Ac-Leu-Gly-Lys(Ac)-AMC as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by fluorescence assay	2017	Journal of medicinal chemistry, 10-12, Volume: 60, Issue:19	Small Molecule Inhibitors Simultaneously Targeting Cancer Metabolism and Epigenetics: Discovery of Novel Nicotinamide Phosphoribosyltransferase (NAMPT) and Histone Deacetylase (HDAC) Dual Inhibitors.
AID1231808	Inhibition of recombinant HDAC2 (unknown origin) incubated for 10 mins using Boc-Lys(acetyl)-AMC fluorogenic substrate by homogeneous fluorescence release assay	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Discovery, bioactivity and docking simulation of Vorinostat analogues containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors and antitumor agents.
AID1263067	Selectivity ratio of IC50 for human MCF7 cells to IC50 for African green monkey Vero cells	2015	Bioorganic & medicinal chemistry, Dec-15, Volume: 23, Issue:24	A structure-activity relationship of non-peptide macrocyclic histone deacetylase inhibitors and their anti-proliferative and anti-inflammatory activities.
AID1389954	Cytotoxic activity against human MCF7 cells assessed as reduction in cell viability at 70 uM after 24 hrs by MTT assay relative to control	2018	Bioorganic & medicinal chemistry letters, 04-01, Volume: 28, Issue:6	Novel polyamine-based Histone deacetylases-Lysine demethylase 1 dual binding inhibitors.
AID1686356	Competitive type inhibition of C-terminal His-tagged recombinant human HDAC3 expressed in Sf9 cells pre-incubated for 2 hrs before acetylated lysine-aminomethyl coumarin-BOC addition and measured after 2 hrs by fluorescence based assay based L-B plot anal	2016	Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21	Development of Allosteric Hydrazide-Containing Class I Histone Deacetylase Inhibitors for Use in Acute Myeloid Leukemia.
AID663353	Growth inhibition of human NCI-H23 cells after 72 hrs by MTS assay	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Discovery and extensive in vitro evaluations of NK-HDAC-1: a chiral histone deacetylase inhibitor as a promising lead.
AID1174685	Antiproliferative activity against human KG1 cells after 48 hrs by MTT assay	2015	European journal of medicinal chemistry, Jan-07, Volume: 89	Development of 3-hydroxycinnamamide-based HDAC inhibitors with potent in vitro and in vivo anti-tumor activity.
AID1401535	Antiproliferative activity against human DU145 cells after 72 hrs by SRB assay	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors.
AID1897405	Induction of apoptosis in human SNU-16 cells assessed as early apoptotic cells at 1 uM incubated for 72 hrs by annexin-V/FITC propidium iodide staining based flow cytometry analysis (Rvb = 3.02%)
AID1293561	Antiproliferative activity against mitoxantrone resistant human HT-29 cells assessed as reduction in cell number after 72 hrs by cell counter analysis	2016	European journal of medicinal chemistry, Apr-13, Volume: 112	Biphenyl-4-yl-acrylohydroxamic acids: Identification of a novel indolyl-substituted HDAC inhibitor with antitumor activity.
AID723451	Potentiation of 1 uM cisplatin-induced toxicity in 1 uM cisplatin resistant human CAL27 cells at 0.25 uM pretreated for 48 hrs followed by 1 uM cisplatin treatment by MTT assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID723160	Potentiation of 5 uM cisplatin-induced toxicity in 1 uM cisplatin resistant human CAL27 cells at 0.25 uM pretreated for 48 hrs followed by 1 uM cisplatin treatment by MTT assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1888407	Synergistic antifungal activity against azole-resistant Candida albicans 0304103 assessed as fractional inhibitory concentration index in presence of fluconazole incubated for 48 hrs by CLSI based checkerboard microdilution assay	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	Heat shock protein 90 (Hsp90)/Histone deacetylase (HDAC) dual inhibitors for the treatment of azoles-resistant Candida albicans.
AID1166499	Antiproliferative activity against human RPMI8226 cells after 72 hrs by WST8 assay	2014	Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21	Design, synthesis and biological evaluation of 4-anilinothieno[2,3-d]pyrimidine-based hydroxamic acid derivatives as novel histone deacetylase inhibitors.
AID1511153	Antiproliferative activity against human A549 cells incubated for 48 hrs by MTT assay	2019	ACS medicinal chemistry letters, Aug-08, Volume: 10, Issue:8	Design, Synthesis, and Biological Evaluation of 2,4-Imidazolinedione Derivatives as HDAC6 Isoform-Selective Inhibitors.
AID1275590	Inhibition of human recombinant HDAC1 using acetyllysine tripeptide coupled with 7-amino-4-methylcoumarin as substrate by fluorescence assay	2016	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4	Dissecting structure-activity-relationships of crebinostat: Brain penetrant HDAC inhibitors for neuroepigenetic regulation.
AID1464870	Inhibition of HDAC1 (unknown origin)	2017	Bioorganic & medicinal chemistry letters, 11-01, Volume: 27, Issue:21	Design, synthesis and biological evaluation of novel histone deacetylase inhibitors incorporating 4-aminoquinazolinyl systems as capping groups.
AID622258	Inhibition of HDAC1 assessed as residual activity at 125 nM after 30 mins by Fluor de Lys fluorescence assay	2011	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 21, Issue:20	The structural requirements of histone deacetylase inhibitors: Suberoylanilide hydroxamic acid analogs modified at the C3 position display isoform selectivity.
AID1386704	Inhibition of HDAC in human GM18407 cells harboring NPC1 R404Q/M1142T mutant assessed as restoration of cholesterol trafficking at 0.001 to 5 uM after 48 hrs by filipin-staining based fluorescence microscopic analysis	2018	Journal of natural products, 09-28, Volume: 81, Issue:9	GEX1A, a Polyketide from Streptomyces chromofuscus, Corrects the Cellular Defects Associated with Niemann-Pick Type C1 in Human Fibroblasts.
AID1848628	Cytotoxicity against human ACHN cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay	2022	Journal of medicinal chemistry, 11-10, Volume: 65, Issue:21	First-in-Class Dual Mechanism Ferroptosis-HDAC Inhibitor Hybrids.
AID329926	Induction of granulocytic differentiation in human U937 cells assessed as CD11c expression at 5 uM after 30 hrs	2008	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8	Novel uracil-based 2-aminoanilide and 2-aminoanilide-like derivatives: histone deacetylase inhibition and in-cell activities.
AID286792	Effect on alpha tubulin acetylation in U937 cells at 1 uM after 24 hrs by Western blot analysis	2007	Journal of medicinal chemistry, May-17, Volume: 50, Issue:10	Bispyridinium dienes: histone deacetylase inhibitors with selective activities.
AID613328	Antitumor activity against human HCT116 cells xenografted in athymic nude mouse model assessed as change in tumor volume at 150 mg/kg, ip qd for 21 days relative to control	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Optimization of the in vitro cardiac safety of hydroxamate-based histone deacetylase inhibitors.
AID723444	Potentiation of 1 uM cisplatin-induced toxicity in 5 uM cisplatin resistant human A2780 cells at 0.5 uM pretreated for 48 hrs followed by 5 uM cisplatin treatment by MTT assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1890514	Inhibition of HDAC8 (unknown origin)	2022	Bioorganic & medicinal chemistry letters, 05-15, Volume: 64	Design, synthesis, and biological evaluation of β-carboline 1,3,4-oxadiazole based hybrids as HDAC inhibitors with potential antitumor effects.
AID328796	Inhibition of HDAC4 expressed in Escherichia coli	2008	Journal of medicinal chemistry, Apr-24, Volume: 51, Issue:8	A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo.
AID760502	Inhibition of HDAC11 (unknown origin) using fluorogenic peptide from p53 residues (379 to 382) (RHKK(Ac)) as substrate by fluorescence assay	2013	ACS medicinal chemistry letters, Aug-08, Volume: 4, Issue:8	Development of a chimeric c-Src kinase and HDAC inhibitor.
AID1511127	Induction of apoptosis in human in human HL60 cells at 0.45 uM incubated for 48 hrs by annexin V-FITC and PI staining based flow cytometric analysis	2019	ACS medicinal chemistry letters, Aug-08, Volume: 10, Issue:8	Design, Synthesis, and Biological Evaluation of 2,4-Imidazolinedione Derivatives as HDAC6 Isoform-Selective Inhibitors.
AID297477	Cytotoxicity against human A549 cells	2007	Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18	2-aroylindoles and 2-aroylbenzofurans with N-hydroxyacrylamide substructures as a novel series of rationally designed histone deacetylase inhibitors.
AID1421611	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	Design and synthesis of potent dual inhibitors of JAK2 and HDAC based on fusing the pharmacophores of XL019 and vorinostat.
AID1742628	Inhibition of HDAC in human MDA-MB-231 cells assessed as increase in acetylated Histone H3 incubated for 8 hrs by Western blot analysis	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Design and synthesis of novel Flavone-based histone deacetylase inhibitors antagonizing activation of STAT3 in breast cancer.
AID765376	Inhibition of recombinant human HDAC7 enzyme using Ac-LeuGlyLys (tfa)-AMC as substrate at 50 uM after 15 to 30 mins	2013	Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16	Total synthesis and full histone deacetylase inhibitory profiling of Azumamides A-E as well as β²- epi-Azumamide E and β³-epi-Azumamide E.
AID609497	Half life in rat liver microsomes	2011	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16	The design, synthesis and structure-activity relationships of novel isoindoline-based histone deacetylase inhibitors.
AID1441637	Inhibition of LTA4H epoxide hydrolase in C57BL/6 mouse neutrophils assessed as suppression of fMLP-induced neutrophil migration pretreated for 30 mins followed by stimulation with fMLP for 1 hr by chemotaxis assay	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
AID421197	Antitumor activity against human MCF7 cells	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Recent advances in the development of polyamine analogues as antitumor agents.
AID605393	Inhibition of human recombinant HDAC2 using fluor de Lys as substrate by fluorometric analysis	2010	Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24	Discovery of 2-(6-{[(6-fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a class I selective orally active histone deacetylase inhibitor.
AID1164198	Antiproliferative activity against human MCF7 cells assessed as reduction in doubling time at 5 uM after 10 to 18 hrs by real-time mode analysis	2014	ACS medicinal chemistry letters, Sep-11, Volume: 5, Issue:9	Novel antiproliferative chimeric compounds with marked histone deacetylase inhibitory activity.
AID1861648	Antiproliferative activity against human HCT-116 cells measured after 72 hrs	2022	Bioorganic & medicinal chemistry letters, 09-15, Volume: 72	Exploration of 4-(1H-indol-3-yl)cyclohex-3-en-1-amine analogues as HDAC inhibitors: Design, synthesis, biological evaluation and modelling studies.
AID316878	Inhibition of HDAC in human CEM cells	2008	Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6	Histone deacetylase inhibitors: from bench to clinic.
AID421217	Inhibition of HDAC3 from human HeLa cells at 5 uM	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Recent advances in the development of polyamine analogues as antitumor agents.
AID1061952	Inhibition of human HDAC6 using RHKK(Ac) as substrate by fluorimetric analysis	2014	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1	Lactam based 7-amino suberoylamide hydroxamic acids as potent HDAC inhibitors.
AID1847778	Inhibition of HDAC6 in human HeLa cells using Boc-Lys(Ac)-AMC as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by fluorescence based analysis	2021	Bioorganic & medicinal chemistry, 12-15, Volume: 52	From natural products to HDAC inhibitors: An overview of drug discovery and design strategy.
AID1855244	Inhibition of HDAC6 in human HeLa cell nuclear extract using Boc-Lys(Ac)-AMC or Boc-Lys(triflouroacetyl)-AMC as substrate incubated for 30 mins and measured by fluorescence assay	2022	European journal of medicinal chemistry, Nov-05, Volume: 241	Discovery of 2,5-diphenyl-1,3,4-thiadiazole derivatives as HDAC inhibitors with DNA binding affinity.
AID1639364	Antiproliferative activity against human SK-N-BE(2) cells after 48 hrs by MTT assay	2019	Bioorganic & medicinal chemistry, 04-15, Volume: 27, Issue:8	Design, synthesis and activity evaluation of indole-based double - Branched HDAC1 inhibitors.
AID1812434	Antiplasmodial activity against asynchronous asexual culture of Plasmodium falciparum NF54 assessed as parasite growth inhibition	2021	Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14	Procainamide-SAHA Fused Inhibitors of hHDAC6 Tackle Multidrug-Resistant Malaria Parasites.
AID1403152	Inhibition of HDAC1 (unknown origin)	2018	European journal of medicinal chemistry, Jan-20, Volume: 144	Development of novel β-carboline-based hydroxamate derivatives as HDAC inhibitors with antiproliferative and antimetastatic activities in human cancer cells.
AID481565	Cytotoxicity against human PC3 cells assessed as growth inhibition after 24 hrs by MTT assay	2010	Bioorganic & medicinal chemistry letters, May-15, Volume: 20, Issue:10	Synthesis and anticancer evaluation of alpha-lipoic acid derivatives.
AID1129012	Inhibition of human HDAC-10 using RHKK(Ac) as substrate by fluorescence assay	2014	Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6	Synthesis and evaluation of new Hsp90 inhibitors based on a 1,4,5-trisubstituted 1,2,3-triazole scaffold.
AID1337256	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	2016	Journal of medicinal chemistry, Sep-22, Volume: 59, Issue:18	Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines.
AID1439771	Inhibition of Pseudomonas aeruginosa PA0321 using Boc-Lys(trifluoroacetyl)-AMC as substrate preincubated for 30 mins followed by substrate addition measured after 60 mins by trypsin-based fluorescence assay	2017	Bioorganic & medicinal chemistry letters, 04-01, Volume: 27, Issue:7	Perfluorinated hydroxamic acids are potent and selective inhibitors of HDAC-like enzymes from Pseudomonas aeruginosa.
AID1542187	Inhibition of HDAC9 (unknown origin)	2019	Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7	Kinase and Histone Deacetylase Hybrid Inhibitors for Cancer Therapy.
AID1655894	Inhibition of EZH2 in human U937 cells assessed as H3K27me3 level at 0.5 uM incubated for 120 hrs by Western blot analysis (Rvb = 1 No_unit)	2020	ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5	Design of First-in-Class Dual EZH2/HDAC Inhibitor: Biochemical Activity and Biological Evaluation in Cancer Cells.
AID1865262	Inhibition of full length recombinant his-tagged human HDAC2 using Ac-LeuGlyLys (Ac) AMC substrate preincubated for 5 mins followed by substrate addition and measured after 30 mins by fluorescence based microplate reader analysis	2022	Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18	Discovery of Novel Src Homology-2 Domain-Containing Phosphatase 2 and Histone Deacetylase Dual Inhibitors with Potent Antitumor Efficacy and Enhanced Antitumor Immunity.
AID1201646	Antiproliferative activity against human MV4-11 cells assessed as growth inhibition after 48 hrs by CellTiter-Glo assay	2015	European journal of medicinal chemistry, May-05, Volume: 95	Macrocyclic compounds as anti-cancer agents: design and synthesis of multi-acting inhibitors against HDAC, FLT3 and JAK2.
AID1235116	Cytotoxicity against human ES2 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	2015	Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15	Synthesis and biological evaluation of novel histone deacetylases inhibitors with nitric oxide releasing activity.
AID1597936	Antiproliferative activity against human HCT116 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	2019	Bioorganic & medicinal chemistry letters, 09-15, Volume: 29, Issue:18	Anti-tumor activity evaluation of novel tubulin and HDAC dual-targeting inhibitors.
AID1281867	Induction of apoptosis in human RPMI8226 cells assessed as late apoptotic cells at 3 uM after 48 hrs by annexin V-FITC/propidium iodide staining-based flow cytometry (Rvb = 4.4%)	2016	European journal of medicinal chemistry, Apr-13, Volume: 112	Design, synthesis and biological evaluation of bisthiazole-based trifluoromethyl ketone derivatives as potent HDAC inhibitors with improved cellular efficacy.
AID1515916	Antiproliferative activity against human Bel7402 cells after 96 hrs by MTT assay	2019	Journal of medicinal chemistry, 08-08, Volume: 62, Issue:15	Design, Synthesis, and Biological Evaluation of 4-Methyl Quinazoline Derivatives as Anticancer Agents Simultaneously Targeting Phosphoinositide 3-Kinases and Histone Deacetylases.
AID1777021	Inhibition of HDAC1 (unknown origin)	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Intracellular fluorescence competition assay for inhibitor engagement of histone deacetylase.
AID408882	Inhibition of HDAC3	2008	Journal of medicinal chemistry, Jun-26, Volume: 51, Issue:12	A series of potent and selective, triazolylphenyl-based histone deacetylases inhibitors with activity against pancreatic cancer cells and Plasmodium falciparum.
AID1234896	Antiproliferative activity against human U937 cells after 48 hrs by MTT assay	2015	Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15	Design, synthesis and preliminary biological evaluation of indoline-2,3-dione derivatives as novel HDAC inhibitors.
AID744873	Cytotoxicity against human U251 cells by MTT assay	2013	Bioorganic & medicinal chemistry letters, May-01, Volume: 23, Issue:9	Discovery of adamantane based highly potent HDAC inhibitors.
AID1676601	Binding affinity to Zinc ion assessed as retention ratio by measuring compound detected in elution fraction/total compound detected at 2.55 umol by immobilized metal-ion affinity chromatography	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
AID1515909	Antiproliferative activity against human NCI-H1299 cells after 96 hrs by MTT assay	2019	Journal of medicinal chemistry, 08-08, Volume: 62, Issue:15	Design, Synthesis, and Biological Evaluation of 4-Methyl Quinazoline Derivatives as Anticancer Agents Simultaneously Targeting Phosphoinositide 3-Kinases and Histone Deacetylases.
AID1664992	Inhibition of class 1 HDAC in CD4 positive cells derived from HIV-infected patient assessed as reactivation of HIV latency by measuring increase in HIV gag p24 level at 400 nM incubated for 72 hrs	2020	ACS medicinal chemistry letters, Jul-09, Volume: 11, Issue:7	Selective Class I HDAC Inhibitors Based on Aryl Ketone Zinc Binding Induce HIV-1 Protein for Clearance.
AID1861326	Inhibition of HDAC in human DOHH-2 cells assessed as effect on total Stat3 levels at 2.5 uM measured by Western blot analysis	2022	Bioorganic & medicinal chemistry letters, 09-01, Volume: 71	Bioevaluation of a dual PI3K/HDAC inhibitor for the treatment of diffuse large B-cell lymphoma.
AID1550127	Induction of apoptosis in human K562 cells assessed as early apoptotic cells at 1 uM after 24 hrs by Annexin-V/propidium iodide staining-based flow cytometric analysis (Rvb = 7.55%)	2019	Journal of medicinal chemistry, 04-25, Volume: 62, Issue:8	Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies.
AID255813	Inhibitory concentration against Histone deacetylase 2 in maize	2005	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 15, Issue:21	Exploring the connection unit in the HDAC inhibitor pharmacophore model: novel uracil-based hydroxamates.
AID1890311	Inhibition of HDAC8 (unknown origin) using Boc-Lys-(triflouroacetyl)-AMC as substrate incubated for 0.5 hr and measured after 20 mins by fluorescence assay	2022	European journal of medicinal chemistry, Apr-05, Volume: 233	Novel biphenyl-based scaffold as potent and selective histone deacetylase 6 (HDAC6) inhibitors: Identification, development and pharmacological evaluation.
AID1200972	Inhibition of HDAC6 (unknown origin) using RHKK(Ac)AMC as substrate	2015	Journal of medicinal chemistry, Mar-26, Volume: 58, Issue:6	Design and synthesis of orally bioavailable aminopyrrolidinone histone deacetylase 6 inhibitors.
AID1614120	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
AID1164916	Inhibition of HDAC11 (unknown origin) using fluorogenic peptide as substrate by fluorescence assay	2014	Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19	Identification of a novel aminotetralin class of HDAC6 and HDAC8 selective inhibitors.
AID1722285	Inhibition of HDAC6 in human Hela cells assessed as accumulation of alpha tubulin acetylation at 1.25 to 5 uM incubated for 24 hrs by Western blot analysis	2020	Bioorganic & medicinal chemistry, 09-01, Volume: 28, Issue:17	The design of a novel near-infrared fluorescent HDAC inhibitor and image of tumor cells.
AID1248356	Inhibition of HDAC1/2 in human HeLa cells using Boc-Lys (acetyl)-AMC as substrate incubated for 2 hrs prior to substrate addition measured after 30 mins by fluorescence assay	2015	Bioorganic & medicinal chemistry, Oct-15, Volume: 23, Issue:20	Synthesis of chiral ND-322, ND-364 and ND-364 derivatives as selective inhibitors of human gelatinase.
AID723133	Potentiation of 10 uM cisplatin-induced toxicity in 5 uM cisplatin resistant human A2780 cells at 1.5 uM pretreated for 48 hrs followed by 5 uM cisplatin treatment by MTT assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1915524	Inhibition of HDAC-6 (unknown origin) expressed in Escherichia coli BL21 (DE3) in HeLa nuclear extract using Boc-Lys(TFA)-AMC as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by Bradford reagent method	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors.
AID1173500	Inhibition of full length C-terminal 6x-His tagged human HDAC2 using Arg-His-Lys-Lys(Ac) substrate incubated for 2 hrs by fluorescence assay	2014	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 24, Issue:23	Histone deacetylase inhibitors derived from 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine and related heterocycles selective for the HDAC6 isoform.
AID1326515	Inhibition of HDAC in human PC3 cells assessed as increase in amount of acetylated histone H3 after 48 hrs by Western blot analysis	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	2-(Phenylsulfonyl)quinoline N-hydroxyacrylamides as potent anticancer agents inhibiting histone deacetylase.
AID717792	Inhibition of HDAC3 using Fluor-de-Lys as substrate assessed as remaining activity at 6.25 x 10'-8 M pretreated for 30 mins before substrate addition by fluorescence assay	2012	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23	The structural requirements of histone deacetylase inhibitors: suberoylanilide hydroxamic acid analogs modified at the C6 position.
AID476835	Toxicity in FVB mouse assessed as effect on body weight at 50 mg/kg, po administered 5 times per week for 2 weeks measured during test	2010	Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8	Modified cap group suberoylanilide hydroxamic acid histone deacetylase inhibitor derivatives reveal improved selective antileukemic activity.
AID1597934	Antiproliferative activity against human A549 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	2019	Bioorganic & medicinal chemistry letters, 09-15, Volume: 29, Issue:18	Anti-tumor activity evaluation of novel tubulin and HDAC dual-targeting inhibitors.
AID1614245	Inhibition of HDAC1/2/3 in human MV4-11 cells assessed as increase in H3 acetylation at 1 uM after 6 hrs by Western blot analysis
AID1063035	Inhibition of recombinant HDAC11 (unknown origin) using Fluor-de-Lys-SIRT1 as substrate by fluorescence assay	2014	Journal of natural products, Jan-24, Volume: 77, Issue:1	Protein kinase and HDAC inhibitors from the endophytic fungus Epicoccum nigrum.
AID1614259	Toxicity against NOD/SCID mouse xenografted with human MM1S cells assessed as mouse survival at 50 mg/kg, po qd administered for 10 days
AID1754753	Inhibition of C-terminal His-tagged human recombinant full length HDAC3 (1 to 428 residues)/N-terminal GST-tagged human recombinant NCOR2 (395 to 489 residues) expressed in baculovirus-infected Sf9 cells assessed as reduction in 7-amino-4-methylcoumarin r	2021	Bioorganic & medicinal chemistry, 07-15, Volume: 42	Discovery of novel class of histone deacetylase inhibitors as potential anticancer agents.
AID1808552	Inhibition of recombinant human C-terminal His-tagged HDAC9 (604 to 1066 residues) expressed in baculovirus infected Sf9 insect cells using fluorogenic substrate measured after 60 mins by FRET assay	2021	Journal of medicinal chemistry, 04-08, Volume: 64, Issue:7	Structure-Based Design of a Selective Class I Histone Deacetylase (HDAC) Near-Infrared (NIR) Probe for Epigenetic Regulation Detection in Triple-Negative Breast Cancer (TNBC).
AID1274877	Inhibition of HDAC7 (unknown origin)	2016	European journal of medicinal chemistry, Jan-27, Volume: 108	Orally available stilbene derivatives as potent HDAC inhibitors with antiproliferative activities and antitumor effects in human tumor xenografts.
AID1511136	Inhibition of HDAC7 (unknown origin) using Ac-LeuGlyLys(tfa)-AMC as substrate preincubated for 5 mins followed by substrate addition and measured after 60 mins by fluorescence based assay	2019	ACS medicinal chemistry letters, Aug-08, Volume: 10, Issue:8	Design, Synthesis, and Biological Evaluation of 2,4-Imidazolinedione Derivatives as HDAC6 Isoform-Selective Inhibitors.
AID734736	Inhibition of HDAC1 (unknown origin) at 10 uM after 60 mins by SAMDI spectrophotometric analysis relative to control	2013	Journal of medicinal chemistry, May-09, Volume: 56, Issue:9	3-Hydroxypyridin-2-thione as novel zinc binding group for selective histone deacetylase inhibition.
AID1915564	Inhibition of human HDAC6 incubated for 30 mins by SpectraMax M2 microplate reader analysis	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors.
AID675299	Inhibition of HDAC in human HeLa cell extracts using Fluor de Lys as substrate by fluorescence assay	2012	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17	Set-up of a new series of HDAC inhibitors: the 5,11-dihydrodibenzo[b,e]azepin-6-ones as privileged structures.
AID603533	Cytotoxicity against human K562 cells after 48 hrs by MTT assay	2011	Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8	Development of tetrahydroisoquinoline-based hydroxamic acid derivatives: potent histone deacetylase inhibitors with marked in vitro and in vivo antitumor activities.
AID1751994	Selectivity ratio of IC50 for HDAC11 (unknown origin) to IC50 for HDAC1 (unknown origin)	2021	Bioorganic & medicinal chemistry letters, 10-01, Volume: 49	Discovery of novel pyrazolopyrimidine derivatives as potent mTOR/HDAC bi-functional inhibitors via pharmacophore-merging strategy.
AID663395	Growth inhibition of human MDA-MB-468 cells after 72 hrs by MTS assay	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Discovery and extensive in vitro evaluations of NK-HDAC-1: a chiral histone deacetylase inhibitor as a promising lead.
AID1765327	Inhibition of human full-length recombinant HDAC6 preincubated for 5 mins followed by HDAC substrate addition and further incubated for 45 mins by fluorescence microplate reader assay	2021	European journal of medicinal chemistry, Oct-15, Volume: 222	A first-in-class anticancer dual HDAC2/FAK inhibitors bearing hydroxamates/benzamides capped by pyridinyl-1,2,4-triazoles.
AID723447	Potentiation of 0.5 uM cisplatin-induced toxicity in 0.5 uM cisplatin resistant human KYSE-510 cells at 0.5 uM pretreated for 48 hrs followed by 0.5 uM cisplatin treatment by MTT assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1511130	Inhibition of HDAC3 (unknown origin) using Ac-LeuGlyLys(Ac)-AMC as substrate preincubated for 5 mins followed by substrate addition and measured after 60 mins by fluorescence based assay	2019	ACS medicinal chemistry letters, Aug-08, Volume: 10, Issue:8	Design, Synthesis, and Biological Evaluation of 2,4-Imidazolinedione Derivatives as HDAC6 Isoform-Selective Inhibitors.
AID1704065	Inhibition of c-MET(unknown origin) using FAM labelled peptide substrate at 100 nM preincubated for 10 mins followed by substrate addition and measured by microplate reader method	2020	European journal of medicinal chemistry, Oct-15, Volume: 204	Discovery of Novel c-Mesenchymal-Epithelia transition factor and histone deacetylase dual inhibitors.
AID1622963	Inhibition of HDAC8 (unknown origin) using (FAM)-labeled acetylated peptide as substrate measured after 17 hrs by fluorescence assay	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.
AID538408	Inhibition of recombinant human HDAC1 using Cbz-Lys(TFAc)-AMC as substrate by fluorometric analysis	2010	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 20, Issue:23	Inhibitors selective for HDAC6 in enzymes and cells.
AID1890510	Inhibition of HDAC1 (unknown origin)	2022	Bioorganic & medicinal chemistry letters, 05-15, Volume: 64	Design, synthesis, and biological evaluation of β-carboline 1,3,4-oxadiazole based hybrids as HDAC inhibitors with potential antitumor effects.
AID1324233	Inhibition of HDAC6 in human LNCAP cells assessed as inhibition of DHT-induced alpha-tubulin deacetylation by measuring increase in alpha-tubulin acetylation at 10 uM measured after 24 hrs relative to control	2016	Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21	Targeting prostate cancer with compounds possessing dual activity as androgen receptor antagonists and HDAC6 inhibitors.
AID1441698	Anti-inflammatory activity in BLM-induced C57BL/6 mouse model of acute lung neutrophilic inflammation assessed as reduction in total cell number in BALF at 25 and 50 mg/kg, ip qd for 7 days post BLM challenge measured on day 7	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
AID1274871	Inhibition of HDAC1 (unknown origin)	2016	European journal of medicinal chemistry, Jan-27, Volume: 108	Orally available stilbene derivatives as potent HDAC inhibitors with antiproliferative activities and antitumor effects in human tumor xenografts.
AID488238	Inhibition of HDAC3 after 10 mins by fluorometric assay	2010	Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11	Vitamin D receptor agonist/histone deacetylase inhibitor molecular hybrids.
AID546549	Inhibition of Flag tagged human recombinant HDAC3 expressed in Sf21 cells coexpressing SMRT DAD domain	2010	Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24	Novel chimeric histone deacetylase inhibitors: a series of lapatinib hybrides as potent inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and histone deacetylase activity.
AID1863422	Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay	2022	European journal of medicinal chemistry, Oct-05, Volume: 240	Accommodation of ring C expanded deoxyvasicinone in the HDAC inhibitory pharmacophore culminates into a tractable anti-lung cancer agent and pH-responsive nanocarrier.
AID1127002	Induction of apoptosis in human U937 cells assessed as early apoptotic cells using annexin-V/propidium iodide staining at 0.5 uM after 24 hrs by flow cytometry analysis (Rvb = 1.57%)	2014	Journal of medicinal chemistry, Apr-24, Volume: 57, Issue:8	Discovery of the first N-hydroxycinnamamide-based histone deacetylase 1/3 dual inhibitors with potent oral antitumor activity.
AID1127333	Induction of apoptosis in human IGROV1 cells at IC80 after 72 hrs by TUNEL and flow cytometry analysis (Rvb = 4%)	2014	European journal of medicinal chemistry, May-22, Volume: 79	Influence of the adamantyl moiety on the activity of biphenylacrylohydroxamic acid-based HDAC inhibitors.
AID1760297	Antiproliferative activity against human KG-1 cells incubated for 72 hrs by MTT assay	2020	European journal of medicinal chemistry, Dec-15, Volume: 208	Recent progress on HDAC inhibitors with dual targeting capabilities for cancer treatment.
AID1578475	Inhibition of recombinant full length human HDAC3 expressed in baculovirus infected Sf9 cells using FAM-RHKK-Ac as substrate incubated for 3 hrs by electrophoretic mobility shift assay	2020	ACS medicinal chemistry letters, Jan-09, Volume: 11, Issue:1	Class I/IIb-Selective HDAC Inhibitor Exhibits Oral Bioavailability and Therapeutic Efficacy in Acute Myeloid Leukemia.
AID1599783	Inhibition of HDAC6 in human Meso163 cells assessed as upregulation of p21 mRNA expression at 2.5 uM after 24 hrs by RT-Sybr green PCR analysis	2019	ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6	Extending Cross Metathesis To Identify Selective HDAC Inhibitors: Synthesis, Biological Activities, and Modeling.
AID420503	Antiproliferative activity against human H460 cells after 72 hrs	2009	European journal of medicinal chemistry, May, Volume: 44, Issue:5	Design, synthesis, and evaluation of biphenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors.
AID373081	Inhibition of human recombinant HDAC8	2009	European journal of medicinal chemistry, Mar, Volume: 44, Issue:3	Novel amide derivatives as inhibitors of histone deacetylase: design, synthesis and SAR.
AID663334	Growth inhibition of human K562 cells after 72 hrs by MTS assay	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Discovery and extensive in vitro evaluations of NK-HDAC-1: a chiral histone deacetylase inhibitor as a promising lead.
AID1127329	Inhibition of human HDAC8 using fluorogenic tetrapeptide RHKKAc as substrate	2014	European journal of medicinal chemistry, May-22, Volume: 79	Influence of the adamantyl moiety on the activity of biphenylacrylohydroxamic acid-based HDAC inhibitors.
AID1441700	Inhibition of recombinant human LTA4H Epoxide Hydrolase expressed in Escherichia coli BL21 (DE3) pLysS at 10 uM preincubated for 10 mins followed by addition of LTA4 as substrate measured after 15 mins by reverse-phase HPLC analysis	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
AID1702090	Antiproliferative activity against human SNU-398 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay	2018	Journal of medicinal chemistry, 02-22, Volume: 61, Issue:4	Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma.
AID1742752	Antitumor activity against human MDA-MB-231 cells xenografted in nude mouse assessed as tumor growth inhibition at 150 mg/kg, po administered for 34 days and measured on day 34	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Design and synthesis of novel Flavone-based histone deacetylase inhibitors antagonizing activation of STAT3 in breast cancer.
AID1647328	Anti-vascular cognitive impairment activity against bilateral common carotid artery occlusion-induced vascular dementia C57BL/6J mouse model assessed as improvement in short-term non-spatial working memory by measuring increase in novel object recognition	2020	European journal of medicinal chemistry, Feb-01, Volume: 187	Protective effects of 10,11-dihydro-5H-dibenzo[b,f]azepine hydroxamates on vascular cognitive impairment.
AID765222	Cytotoxicity against human SKOV3 cells	2013	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17	Identification of novel HDAC inhibitors through cell based screening and their evaluation as potential anticancer agents.
AID1816192	Inhibition of JAK1 (unknown origin) preincubated for 60 mins followed by reagent A addition and measured after 60 mins in presence of ATP by using microplate reader method
AID1622980	Cytotoxicity against human MDA-MB-231 cells	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.
AID1164039	Antiproliferative activity against human HT1080 cells assessed as growth inhibition after 72 hrs by CCK-8 assay	2014	European journal of medicinal chemistry, Oct-30, Volume: 86	Design, synthesis, and biological evaluation of 1, 3-disubstituted-pyrazole derivatives as new class I and IIb histone deacetylase inhibitors.
AID1651331	Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability incubated for 48 hrs by Sulforhodamine B assay	2020	Bioorganic & medicinal chemistry, 02-01, Volume: 28, Issue:3	Synthesis and biological evaluation of 2-quinolineacrylamides.
AID1690842	Inhibition of recombinant human C-terminal FLAG/His-tagged HDAC1 (1 to 482 residues) expressed in Sf9 insect cells using fluor de lys SIRT1 as substrate preincubated for 5 mins followed by substrate addition and measured after 30 mins by fluorescence assa	2020	European journal of medicinal chemistry, Apr-15, Volume: 192	Synthesis and biological evaluation of acridine-based histone deacetylase inhibitors as multitarget agents against Alzheimer's disease.
AID456796	Antileishmanial activity against Leishmania donovani promastigotes after 72 hrs by alamar blue assay	2010	Bioorganic & medicinal chemistry, Jan-01, Volume: 18, Issue:1	Antimalarial and antileishmanial activities of histone deacetylase inhibitors with triazole-linked cap group.
AID1293563	Inhibition of full length human recombinant C-terminal FLAG-His-tagged HDAC1 (1 to 482 residues) expressed in sf21 cells using RHK-K(Ac)-AMC as substrate incubated for 60 mins by fluorescence assay	2016	European journal of medicinal chemistry, Apr-13, Volume: 112	Biphenyl-4-yl-acrylohydroxamic acids: Identification of a novel indolyl-substituted HDAC inhibitor with antitumor activity.
AID1336925	Cytotoxicity against human LNCAP cells assessed as cell growth inhibition after 72 hrs by MTT assay	2017	Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3	Bifunctional conjugates with potent inhibitory activity towards cyclooxygenase and histone deacetylase.
AID1380966	Inhibition of HDAC1/HDAC2/HDAC3 in human HeLa cells assessed as increase in intracellular acetyl-histone H4 levels at 100 nM after 6 hrs by Western blot analysis	2018	Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12	Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously.
AID1547267	Inhibition of HDAC5 (unknown origin) using biotinylated histone H3 KAc peptide (1 to 21 residues) as substrate by HTRF assay	2020	Journal of medicinal chemistry, 04-09, Volume: 63, Issue:7	Discovery of Thieno[2,3-
AID1887064	Cytotoxicity against human NCI-H522 cells assessed as reduction in cell viability incubated for 3 days by methylene blue staining based analysis	2022	Journal of medicinal chemistry, 09-08, Volume: 65, Issue:17	Tunable Cysteine-Targeting Electrophilic Heteroaromatic Warheads Induce Ferroptosis.
AID1890314	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	2022	European journal of medicinal chemistry, Apr-05, Volume: 233	Novel biphenyl-based scaffold as potent and selective histone deacetylase 6 (HDAC6) inhibitors: Identification, development and pharmacological evaluation.
AID1449325	Inhibition of HDAC in human Cal27CisR cells using Boc-Lys(epsilon-Ac)-AMC as substrate preincubated for 18 hrs followed by substrate addition measured after 3 hrs by fluorescence assay	2017	Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13	Alkoxyurea-Based Histone Deacetylase Inhibitors Increase Cisplatin Potency in Chemoresistant Cancer Cell Lines.
AID1578148	Antiproliferative activity against human HT1080 cells	2020	European journal of medicinal chemistry, Jan-01, Volume: 185	N-alkyl-hydroxybenzoyl anilide hydroxamates as dual inhibitors of HDAC and HSP90, downregulating IFN-γ induced PD-L1 expression.
AID1235114	Cytotoxicity against HEL cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	2015	Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15	Synthesis and biological evaluation of novel histone deacetylases inhibitors with nitric oxide releasing activity.
AID723475	Cytotoxicity against cisplatin resistant human CAL27 cells after 72 hrs by MTT assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1174682	Antiproliferative activity against human U937 cells after 48 hrs by MTT assay	2015	European journal of medicinal chemistry, Jan-07, Volume: 89	Development of 3-hydroxycinnamamide-based HDAC inhibitors with potent in vitro and in vivo anti-tumor activity.
AID329918	Induction of p21 expression in human U937 cells	2008	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8	Novel uracil-based 2-aminoanilide and 2-aminoanilide-like derivatives: histone deacetylase inhibition and in-cell activities.
AID663389	Growth inhibition of human ACHN cells after 72 hrs by MTS assay	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Discovery and extensive in vitro evaluations of NK-HDAC-1: a chiral histone deacetylase inhibitor as a promising lead.
AID414719	Inhibition of HDAC in human HeLa cells assessed as induction of cellular histone H3 hyperacetylation	2009	Journal of medicinal chemistry, Apr-23, Volume: 52, Issue:8	Design of chimeric histone deacetylase- and tyrosine kinase-inhibitors: a series of imatinib hybrides as potent inhibitors of wild-type and mutant BCR-ABL, PDGF-Rbeta, and histone deacetylases.
AID1915594	Inhibition of HDAC2 (unknown origin)	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors.
AID1751997	Inhibition of HDAC11 (unknown origin)	2021	Bioorganic & medicinal chemistry letters, 10-01, Volume: 49	Discovery of novel pyrazolopyrimidine derivatives as potent mTOR/HDAC bi-functional inhibitors via pharmacophore-merging strategy.
AID1599726	Cytotoxicity against human ADCA72 cells assessed as cell permeability measured after 72 hrs by CellTox Green assay	2019	ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6	Extending Cross Metathesis To Identify Selective HDAC Inhibitors: Synthesis, Biological Activities, and Modeling.
AID1605937	Antiproliferative activity against human Hs578T cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	2020	Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8	Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors.
AID511063	Inhibition of HDAC1	2010	European journal of medicinal chemistry, Sep, Volume: 45, Issue:9	Design and synthesis of novel isoxazole-based HDAC inhibitors.
AID1865258	Inhibition of recombinant human HDAC using fluorogenic substrate preincubated for 5 mins followed by substrate addition and measured after 30 mins by fluorescence based microplate reader analysis	2022	Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18	Discovery of Novel Src Homology-2 Domain-Containing Phosphatase 2 and Histone Deacetylase Dual Inhibitors with Potent Antitumor Efficacy and Enhanced Antitumor Immunity.
AID420513	Cell cycle arrest in cisplatin-resistant human IGROV1 cells assessed as partial accumulation at S phase at IC90 using propidium-iodide staining by flow-cytometry	2009	European journal of medicinal chemistry, May, Volume: 44, Issue:5	Design, synthesis, and evaluation of biphenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors.
AID1469289	Induction of apoptosis in human A549 cells assessed as late apoptotic cells at 10 uM after 48 hrs by annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 0.88%)	2018	Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7	Discovery of N1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7 H-pyrrolo[2,3- d]pyrimidin-2-yl)amino)phenyl)- N8-hydroxyoctanediamide as a Novel Inhibitor Targeting Cyclin-dependent Kinase 4/9 (CDK4/9) and Histone Deacetlyase1 (HDAC1) against Malignant Cancer
AID411257	Selectivity for ratio of IC50 for human HDAC6 to IC50 for human HDAC1/2 by fluorimetric assay	2009	Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2	Non-peptide macrocyclic histone deacetylase inhibitors.
AID90352	In vitro inhibitory activity against human histone deacetylase (HDAC) using HeLa nuclear extract	2004	Bioorganic & medicinal chemistry letters, Jun-21, Volume: 14, Issue:12	Thiol-based SAHA analogues as potent histone deacetylase inhibitors.
AID1915526	Antiproliferative activity against human DU-145 cells incubated for 48 hrs by Sulforhodamine B staining method	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors.
AID1614229	Induction of apoptosis in human MM1S cells assessed as viable cells at 1 uM after 48 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 98.9%)
AID1821956	Inhibition of HDAC in human HeLa nuclear extracts using fluorometric substrate at 1 uM incubated for 30 mins by fluorescence plate reader analysis relative to control
AID1865308	Antitumor immunity against mouse 4T1 cells xenografted in BALB/c syngeneic mouse model assessed as increase in proportion of dendritic cell in lymph node at 40 mg/kg, po qd for 12 days by flow cytometry analysis (Rvb = 17%)	2022	Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18	Discovery of Novel Src Homology-2 Domain-Containing Phosphatase 2 and Histone Deacetylase Dual Inhibitors with Potent Antitumor Efficacy and Enhanced Antitumor Immunity.
AID353356	Inhibition of HDAC in human SHSY5Y cells by fluorimetric cellular activity assay	2009	Journal of medicinal chemistry, May-14, Volume: 52, Issue:9	Synthesis, biological evaluation, and molecular docking of Ugi products containing a zinc-chelating moiety as novel inhibitors of histone deacetylases.
AID527041	Cytotoxicity against human NCI-H226 by SRB assay	2010	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22	Selenium-containing analogs of SAHA induce cytotoxicity in lung cancer cells.
AID1591852	Inhibition of recombinant human full-length C-terminal FLAG-tagged HDAC1 expressed in baculovirus expression system at 1000 nM using Ac-peptide-AMC as substrate preincubated for 15 mins followed by substrate addition by fluorescence assay relative to cont	2019	Bioorganic & medicinal chemistry letters, 08-15, Volume: 29, Issue:16	Discovery of novel 9H-purin derivatives as dual inhibitors of HDAC1 and CDK2.
AID411256	Inhibition of HDAC6 from human HeLa cells nuclear extract by cell free fluorimetric assay	2009	Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2	Non-peptide macrocyclic histone deacetylase inhibitors.
AID1127009	Induction of apoptosis in human U937 cells assessed as late apoptotic cells using annexin-V/propidium iodide staining at 0.125 uM after 24 hrs by flow cytometry analysis (Rvb = 2.13%)	2014	Journal of medicinal chemistry, Apr-24, Volume: 57, Issue:8	Discovery of the first N-hydroxycinnamamide-based histone deacetylase 1/3 dual inhibitors with potent oral antitumor activity.
AID1164925	Induction of HDAC6 expression in human BE(2)-C cells at 10 uM after 24 hrs by immunoblot method relative to vehicle-treated control	2014	Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19	Identification of a novel aminotetralin class of HDAC6 and HDAC8 selective inhibitors.
AID331898	Displacement of fluorescent 5-(3-(3-(4-((4-((7-(hydroxyamino)-7-oxoheptyl)carbamoyl)phenylamino)methyl)-1H-1,2,3-triazol-1-yl)propyl)thioureido)-2-(3-hydroxy-6-oxo-6H-xanthen-9-yl)benzoic acid from HDAC in human HeLa nuclear cell extract by fluorescence p	2008	Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9	Development of a fluorescence polarization based assay for histone deacetylase ligand discovery.
AID750108	Inhibition of HDAC in human HeLa cells using Fluor de Lys as substrate at 10 uM by fluorescence assay	2013	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 23, Issue:11	Design, synthesis and biological evaluation of indeno[1,2-d]thiazole derivatives as potent histone deacetylase inhibitors.
AID1240553	Induction of apoptosis in human MDA-MB-231 cells assessed as early apoptotic cells at 1 uM after 24 hrs using Annexin V-FITC and propidium iodide staining by flow cytometry (Rvb = 2.60%)	2015	Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17	Design, synthesis and biological evaluation of saccharin-based N-hydroxybenzamides as histone deacetylases (HDACs) inhibitors.
AID663368	Growth inhibition of human NCI-ADR-RES cells after 72 hrs by MTS assay	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Discovery and extensive in vitro evaluations of NK-HDAC-1: a chiral histone deacetylase inhibitor as a promising lead.
AID708270	Growth inhibition of human HGC27 cells incubated for 72 hrs by WST dye reduction assay	2012	Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20	Pharmacokinetic optimization of class-selective histone deacetylase inhibitors and identification of associated candidate predictive biomarkers of hepatocellular carcinoma tumor response.
AID1514594	Inhibition of HDAC1 (unknown origin) at 20 nM using Boc-Lys (Ac)-AMC as substrate measured after 60 mins by ELISA relative to control	2019	Bioorganic & medicinal chemistry letters, 01-01, Volume: 29, Issue:1	Development of hydroxamate-based histone deacetylase inhibitors containing 1,2,4-oxadiazole moiety core with antitumor activities.
AID243846	Inhibitory activity against human histone deacetylase 1 (HDAC1) at 5 uM	2005	Journal of medicinal chemistry, May-05, Volume: 48, Issue:9	Class II (IIa)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl)pyrrolyl hydroxyamides.
AID274019	Steady state volume of distribution (Vdss) after i.v. dosing at 1 mg kg-1	2007	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2	Identification and optimisation of a series of substituted 5-pyridin-2-yl-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.
AID723158	Potentiation of 5 uM cisplatin-induced toxicity in 1 uM cisplatin resistant human CAL27 cells at 1 uM pretreated for 48 hrs followed by 1 uM cisplatin treatment by MTT assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1622937	Inhibition of recombinant human C-terminal His-tagged HDAC9 (604 to 1066 residues) expressed in baculovirus infected insect cells using 7-AMC-labelled HDAC substrate measured after 30 mins by fluorescence assay	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.
AID358682	Increase in E2F1 mRNA expression in rat ST14A cells after 72 hrs by RT-PCR relative to control	2007	The Journal of biological chemistry, Aug-24, Volume: 282, Issue:34	Loss of huntingtin function complemented by small molecules acting as repressor element 1/neuron restrictive silencer element silencer modulators.
AID1545830	Antiproliferative activity against human HCT116 cells by MTT assay	2019	European journal of medicinal chemistry, Dec-01, Volume: 183	1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships.
AID1723743	Inhibition of human recombinant HDAC6 using ZMAL (Z-Lys(Ac)-AMC) fluorogenic substrate incubated for 90 mins by fluorescence based assay	2020	Journal of medicinal chemistry, 09-24, Volume: 63, Issue:18	Multicomponent Synthesis, Binding Mode, and Structure-Activity Relationship of Selective Histone Deacetylase 6 (HDAC6) Inhibitors with Bifurcated Capping Groups.
AID473031	Ex vivo inhibition of human HDAC5 in human Caco-2 cells by fluorometric cellular activity assay	2010	Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5	Biological and biophysical properties of the histone deacetylase inhibitor suberoylanilide hydroxamic acid are affected by the presence of short alkyl groups on the phenyl ring.
AID604038	Inhibition of histone acetyltransferase in human U937 cells assessed as increase of histone H3 acetylation level at 5 uM after 15 mins by Western blotting	2011	Bioorganic & medicinal chemistry, Jun-15, Volume: 19, Issue:12	Modulation of the activity of histone acetyltransferases by long chain alkylidenemalonates (LoCAMs).
AID1454055	Growth inhibition of human T47D cells after 3 days by WST1 assay	2017	Bioorganic & medicinal chemistry, 07-15, Volume: 25, Issue:14	Synthesis and evaluation of novel dual BRD4/HDAC inhibitors.
AID1861655	Inhibition of HDAC3 (unknown origin)	2022	Bioorganic & medicinal chemistry letters, 09-15, Volume: 72	Exploration of 4-(1H-indol-3-yl)cyclohex-3-en-1-amine analogues as HDAC inhibitors: Design, synthesis, biological evaluation and modelling studies.
AID421218	Inhibition of HDAC8 from human HeLa cells at 5 uM	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Recent advances in the development of polyamine analogues as antitumor agents.
AID1812441	Inhibition of Plasmodium falciparum NF54 HDAC using extract measured after 60 mins by fluorescence assay	2021	Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14	Procainamide-SAHA Fused Inhibitors of hHDAC6 Tackle Multidrug-Resistant Malaria Parasites.
AID1614121	Antiproliferative activity against human Raji cells after 72 hrs by MTT assay
AID631667	Inhibition of human recombinant full-length HDAC2 using fluorophore conjugated substrate by fluorescence assay	2011	Journal of medicinal chemistry, Aug-11, Volume: 54, Issue:15	In vivo PET imaging of histone deacetylases by 18F-suberoylanilide hydroxamic acid (18F-SAHA).
AID1164032	Inhibition of human recombinant HDAC6 after 60 mins by fluorimetric assay	2014	European journal of medicinal chemistry, Oct-30, Volume: 86	Design, synthesis, and biological evaluation of 1, 3-disubstituted-pyrazole derivatives as new class I and IIb histone deacetylase inhibitors.
AID1808553	Inhibition of recombinant human full length N-terminal GST-tagged HDAC6 expressed in Sf9 cells using fluorogenic substrate measured after 60 mins by FRET assay	2021	Journal of medicinal chemistry, 04-08, Volume: 64, Issue:7	Structure-Based Design of a Selective Class I Histone Deacetylase (HDAC) Near-Infrared (NIR) Probe for Epigenetic Regulation Detection in Triple-Negative Breast Cancer (TNBC).
AID274096	Inhibition of maize HD1-A (mean)	2007	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 17, Issue:5	Discovery of uracil-based histone deacetylase inhibitors able to reduce acquired antifungal resistance and trailing growth in Candida albicans.
AID1421923	Antimalarial activity against Plasmodium falciparum Dd2 infected in human erythrocytes assessed as reduction in [3H]-hypoxanthine incorporation preincubated for 48 hrs followed by [3H]-hypoxanthine addition measured after 24 hrs by scintillation counting	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	One-pot, multi-component synthesis and structure-activity relationships of peptoid-based histone deacetylase (HDAC) inhibitors targeting malaria parasites.
AID749702	Inhibition of HDAC8 in human HeLa cells using Fluor-de-Lys as substrate after 15 mins by fluorescence assay	2013	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 23, Issue:11	Dual-acting histone deacetylase-topoisomerase I inhibitors.
AID1699973	Inhibition of recombinant human HDAC6 using Boc-Lys(Ac)-AMC as substrate incubated for 60 mins by fluorimetric assay	2020	Bioorganic & medicinal chemistry letters, 12-15, Volume: 30, Issue:24	Discovery of thiosemicarbazone-containing compounds with potent anti-proliferation activity against drug-resistant K562/A02 cells.
AID1890515	Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	2022	Bioorganic & medicinal chemistry letters, 05-15, Volume: 64	Design, synthesis, and biological evaluation of β-carboline 1,3,4-oxadiazole based hybrids as HDAC inhibitors with potential antitumor effects.
AID1518829	Selectivity index, ratio of EC50 for human MDA-MB-231 cells to IC50 for ring stage Plasmodium falciparum 3D7	2019	European journal of medicinal chemistry, Dec-15, Volume: 184	Discovery of a potent histone deacetylase (HDAC) 3/6 selective dual inhibitor.
AID1742660	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Design and synthesis of novel Flavone-based histone deacetylase inhibitors antagonizing activation of STAT3 in breast cancer.
AID445122	Inhibition of HDAC	2009	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 19, Issue:22	Novel N-hydroxybenzamide-based HDAC inhibitors with branched CAP group.
AID1401507	Inhibition of HDAC1/2/3 in human U937 cells assessed as increase in acetyl-histone H3 levels at 5 uM after 18 hrs by Western blot method	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
AID1848600	Cytotoxicity against human RPMI-8226 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay	2022	Journal of medicinal chemistry, 11-10, Volume: 65, Issue:21	First-in-Class Dual Mechanism Ferroptosis-HDAC Inhibitor Hybrids.
AID1897406	Induction of apoptosis in human SNU-16 cells assessed as late apoptotic cells at 1 uM incubated for 72 hrs by annexin-V/FITC propidium iodide staining based flow cytometry analysis (Rvb = 3.41%)
AID723162	Potentiation of 25 uM cisplatin-induced toxicity in 1 uM cisplatin resistant human MDA-MB-231 cells at 1 uM pretreated for 48 hrs followed by 1 uM cisplatin treatment by MTT assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1129785	Cell cycle arrest in human Jurkat cells assessed as accumulation at G1-phase at 10 uM after 36 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 59.10%)	2014	Bioorganic & medicinal chemistry, Apr-01, Volume: 22, Issue:7	Studies on the antiproliferative effects of tropolone derivatives in Jurkat T-lymphocyte cells.
AID1754781	Upregulation of NFkB2 gene expression in human MCF7 cells at 3 uM incubated for 24 hrs by whole transcriptome analysis	2021	Bioorganic & medicinal chemistry, 07-15, Volume: 42	Discovery of novel class of histone deacetylase inhibitors as potential anticancer agents.
AID1401531	Antiproliferative activity against human Capan1 cells after 72 hrs by SRB assay	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors.
AID1730855	Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Design, synthesis and evaluation of novel ErbB/HDAC multitargeted inhibitors with selectivity in EGFR
AID1816213	Induction of apoptosis in human MDA-MB-231 cells assessed as early apoptotic cells at 2.5 uM measured after 48 hrs in presence of ruxolitinib by annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 3.09%)
AID1203889	Inhibition of recombinant HDAC1 (unknown origin) using fluorogenic substrate Boc-Lys (acetyl)-AMC after 20 mins by homogeneous fluorescence release assay	2015	European journal of medicinal chemistry, , Volume: 96	Discovery and preliminary evaluation of 2-aminobenzamide and hydroxamate derivatives containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors.
AID723145	Potentiation of 40 uM cisplatin-induced toxicity in 1 uM cisplatin resistant human MDA-MB-231 cells at 1.5 uM pretreated for 48 hrs followed by 1 uM cisplatin treatment by MTT assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1698861	Inhibition of c-MET (unknown origin) at 100 nM relative to control	2020	Bioorganic & medicinal chemistry letters, 12-01, Volume: 30, Issue:23	Design, synthesis and biological evaluation of novel c-Met/HDAC dual inhibitors.
AID723117	Potentiation of 20 uM cisplatin-induced toxicity in 5 uM cisplatin resistant human A2780 cells at 1.5 uM pretreated for 48 hrs followed by 5 uM cisplatin treatment by MTT assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1614231	Induction of apoptosis in human MM1S cells assessed as late apoptotic cells at 1 uM after 48 hrs in presence of 0.3 uM RAPA by Annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 0.42%)
AID1189854	Therapeutic index, ratio of CC50 for human HuH7 cells to EC50 for HCV genotype 1b infected in human Huh7 cells	2015	Journal of medicinal chemistry, Jan-22, Volume: 58, Issue:2	Hydroxamic acids block replication of hepatitis C virus.
AID1764802	Selectivity index, ratio of IC50 for recombinant human HDAC1 using Ac-GAK(Ac)-AMC as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins by fluorescence-based assay to IC50 for recombinant human HDAC6 using Ac-GAK(	2021	Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8	Tetrahydroquinoline-Capped Histone Deacetylase 6 Inhibitor SW-101 Ameliorates Pathological Phenotypes in a Charcot-Marie-Tooth Type 2A Mouse Model.
AID1784990	Cytotoxicity against human L02 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Design, synthesis and biological evaluation of novel hybrids targeting mTOR and HDACs for potential treatment of hepatocellular carcinoma.
AID781052	Inhibition of HDAC in human HeLa cell nuclear extracts using Fluor de Lys as substrate at 1 uM by fluorescence assay	2013	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 23, Issue:23	Design, synthesis and biological evaluation of di-substituted cinnamic hydroxamic acids bearing urea/thiourea unit as potent histone deacetylase inhibitors.
AID1246519	Cytotoxicity against imatinib resistant human IR-K562 cells assessed as reduction in cell viability	2015	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 25, Issue:19	Discovery of 1-hydroxypyridine-2-thiones as selective histone deacetylase inhibitors and their potential application for treating leukemia.
AID90195	Concentration required to inhibit Histone Deacetylase (HDAC) from K562 erythroleukemia cells	2002	Bioorganic & medicinal chemistry letters, Oct-21, Volume: 12, Issue:20	Succinimide hydroxamic acids as potent inhibitors of histone deacetylase (HDAC).
AID488236	Inhibition of HDAC in human SCC4 cells assessed as increase in histone acetylation at 1 uM after 24 hrs by Western blot analysis	2010	Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11	Vitamin D receptor agonist/histone deacetylase inhibitor molecular hybrids.
AID1312850	Cytotoxicity against human A2780S cells assessed as growth inhibition after 24 hrs by MTT assay	2016	Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11	Development of Purine-Based Hydroxamic Acid Derivatives: Potent Histone Deacetylase Inhibitors with Marked in Vitro and in Vivo Antitumor Activities.
AID1421911	Inhibition of recombinant full length human C-terminal His/FLAG tagged HDAC1 expressed in baculovirus infected Sf9 insect cells using ZMAL as substrate measured after 90 mins by fluorescence assay	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	One-pot, multi-component synthesis and structure-activity relationships of peptoid-based histone deacetylase (HDAC) inhibitors targeting malaria parasites.
AID1178598	Inhibition of human HDAC8 pre-incubated for 30 mins before substrate addition and measured after 30 mins by HDAC-Glo I/II assay	2014	Bioorganic & medicinal chemistry, Jul-15, Volume: 22, Issue:14	Design and synthesis of novel and highly-active pan-histone deacetylase (pan-HDAC) inhibitors.
AID1233266	Antiproliferative activity against human DU145 cells assessed as inhibition of cell viability after 72 hrs by MTT assay	2015	Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11	Novel Bioactive Hybrid Compound Dual Targeting Estrogen Receptor and Histone Deacetylase for the Treatment of Breast Cancer.
AID1200984	Half life in ICR mouse at 10 mg/kg, iv	2015	Journal of medicinal chemistry, Mar-26, Volume: 58, Issue:6	Design and synthesis of orally bioavailable aminopyrrolidinone histone deacetylase 6 inhibitors.
AID1410328	Antiproliferative activity against human A549 cells after 48 hrs by CCK-8 assay	2018	ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4	Discovery of Novel Indoleamine 2,3-Dioxygenase 1 (IDO1) and Histone Deacetylase (HDAC) Dual Inhibitors.
AID760492	Cytotoxicity against human MALME-3M cells after 48 hrs by SRB assay	2013	ACS medicinal chemistry letters, Aug-08, Volume: 4, Issue:8	Development of a chimeric c-Src kinase and HDAC inhibitor.
AID1380945	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay	2018	Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12	Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously.
AID603541	Antitumor activity against human MDA-MB-231 cells xenografted in athymic nude mouse assessed as tumor growth delay at 90 mg/kg, ip qd for 21 days	2011	Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8	Development of tetrahydroisoquinoline-based hydroxamic acid derivatives: potent histone deacetylase inhibitors with marked in vitro and in vivo antitumor activities.
AID81123	Percent of HL-60 cells (from human acute promyelocytic leukemia) to develop the ability to reduce nitroblue tetrazolium after administration (1 uM)	1995	Journal of medicinal chemistry, Apr-14, Volume: 38, Issue:8	The synthesis of N-hydroxy-N'-phenyloctanediamide and its inhibitory effect on proliferation of AXC rat prostate cancer cells.
AID1330948	Antiproliferative activity against human NCI-H1975 expressing EGFR T790M/L858R mutant assessed as reduction in cell viability measured after 48 hrs by MTT assay	2017	Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1	Synthesis and investigation of novel 6-(1,2,3-triazol-4-yl)-4-aminoquinazolin derivatives possessing hydroxamic acid moiety for cancer therapy.
AID1873418	Inhibition of HDAC2 (unknown origin) at 5 uM preincubated for 1 hr followed by 100-fold dilution and subsequent substrate addition measured immediately	2022	Bioorganic & medicinal chemistry letters, 08-15, Volume: 70	Comparison of three zinc binding groups for HDAC inhibitors - A potency, selectivity and enzymatic kinetics study.
AID723477	Cytotoxicity against cisplatin resistant human MDA-MB-231 cells after 72 hrs by MTT assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1361635	Inhibition of HDAC8 (unknown origin) after 30 mins by fluorescence assay	2018	Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16	Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents.
AID1737152	Induction of apoptosis in human HCT-116 cells assessed as late apoptotic cells at 3 uM after 24 hrs by Annexin V-FITC/PI staining based flow cytometric analysis (Rvb = 5.14%)	2020	European journal of medicinal chemistry, Apr-15, Volume: 192	Design, synthesis and biological evaluation of novel indazole-based derivatives as potent HDAC inhibitors via fragment-based virtual screening.
AID1441667	Plasma concentration in human	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
AID710834	Cytotoxicity against human NUGC3 cells assessed as growth inhibition by SRB assay	2012	Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23	Property-based optimization of hydroxamate-based γ-lactam HDAC inhibitors to improve their metabolic stability and pharmacokinetic profiles.
AID1476156	Antiproliferative activity against human XG6 cells after 48 hrs by CellTiter-Glo luminescent assay	2017	Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20	Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat.
AID1667093	Cell cycle arrest in human MDA-MB-231 cells assessed as accumulation of cells at G1 phase at 5 uM incubated for 48 hrs RNase/PI staining based flow cytometry assay (Rvb = 64.3 %)	2020	Bioorganic & medicinal chemistry, 03-15, Volume: 28, Issue:6	Pyrimethamine conjugated histone deacetylase inhibitors: Design, synthesis and evidence for triple negative breast cancer selective cytotoxicity.
AID316906	Inhibition of human SKOV3 cells	2008	Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6	Histone deacetylase inhibitors: from bench to clinic.
AID348390	Inhibition of HDAC in human NB4 cells assessed as induction of histone H3 acetylation after 6 hrs by Western blot analysis	2008	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 18, Issue:18	Design, synthesis and preliminary biological evaluation of new hydroxamate histone deacetylase inhibitors as potential antileukemic agents.
AID663331	Inhibition of HDAC in human HeLa cell nuclear extracts using Ac-Arg-Gly-Lys(Ac)-AMC substrate by fluorimetry	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Discovery and extensive in vitro evaluations of NK-HDAC-1: a chiral histone deacetylase inhibitor as a promising lead.
AID1469489	Antitumor activity against mouse Fluc-labeled 4T1 cells implanted in Balb/c mouse assessed as tumor growth inhibition at 130 mg/kg, ip administered daily for 18 days measured after 8 to 25 days by bioluminescence assay relative to control	2018	Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7	Discovery of N1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7 H-pyrrolo[2,3- d]pyrimidin-2-yl)amino)phenyl)- N8-hydroxyoctanediamide as a Novel Inhibitor Targeting Cyclin-dependent Kinase 4/9 (CDK4/9) and Histone Deacetlyase1 (HDAC1) against Malignant Cancer
AID655470	Inhibition of HDAC1 in human HeLa cells nuclear extract using Fluor-de-Lys as substrate after 30 mins by spectrophotometry	2011	ACS medicinal chemistry letters, Jul-21, Volume: 2, Issue:9	Potential Agents for Treating Cystic Fibrosis: Cyclic Tetrapeptides that Restore Trafficking and Activity of ΔF508-CFTR.
AID1178597	Inhibition of human HDAC3 pre-incubated for 30 mins before substrate addition and measured after 30 mins by HDAC-Glo I/II assay	2014	Bioorganic & medicinal chemistry, Jul-15, Volume: 22, Issue:14	Design and synthesis of novel and highly-active pan-histone deacetylase (pan-HDAC) inhibitors.
AID1469436	Inhibition of HDAC1 in human HepG2 cells assessed as increase in acetylated-histone H3 level at 5 uM after 48 hrs by Western blot method	2018	Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7	Discovery of N1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7 H-pyrrolo[2,3- d]pyrimidin-2-yl)amino)phenyl)- N8-hydroxyoctanediamide as a Novel Inhibitor Targeting Cyclin-dependent Kinase 4/9 (CDK4/9) and Histone Deacetlyase1 (HDAC1) against Malignant Cancer
AID1141787	Inhibition of HDAC2 (unknown origin) using RHKK(Ac) (379 to 382) p53 peptide as substrate by fluorescence assay	2014	Journal of medicinal chemistry, May-22, Volume: 57, Issue:10	Azaindolylsulfonamides, with a more selective inhibitory effect on histone deacetylase 6 activity, exhibit antitumor activity in colorectal cancer HCT116 cells.
AID1141788	Inhibition of HDAC6 (unknown origin) using RHKK(Ac) (379 to 382) p53 peptide as substrate by fluorescence assay	2014	Journal of medicinal chemistry, May-22, Volume: 57, Issue:10	Azaindolylsulfonamides, with a more selective inhibitory effect on histone deacetylase 6 activity, exhibit antitumor activity in colorectal cancer HCT116 cells.
AID723121	Potentiation of 8 uM cisplatin-induced toxicity in 0.5 uM cisplatin resistant human KYSE-510 cells at 1.5 uM pretreated for 48 hrs followed by 0.5 uM cisplatin treatment by MTT assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1239048	Inhibition of recombinant His6-tagged GST-fused human HDAC1 expressed in baculovirus infected insect High5 cells using Ac-Lys-Tyr-Lys(epsilon-acetyl)-AMC as substrate after 24 hrs	2015	Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17	Design, synthesis and biological evaluation of isoquinoline-based derivatives as novel histone deacetylase inhibitors.
AID1576448	Inhibition of HDAC (unknown origin) nuclear extract at 0.5 uM relative to control
AID1861664	Inhibition of HDAC1/HDAC2/HDAC3 in human HCT-116 cells assessed as increase in accumulation of acetylated histone H4 at 2000 nM measured after 48 hrs by Western blot analysis	2022	Bioorganic & medicinal chemistry letters, 09-15, Volume: 72	Exploration of 4-(1H-indol-3-yl)cyclohex-3-en-1-amine analogues as HDAC inhibitors: Design, synthesis, biological evaluation and modelling studies.
AID481557	Cytotoxicity against human Bel7402 cells assessed as growth inhibition at 100 ug/ml after 24 hrs by MTT assay	2010	Bioorganic & medicinal chemistry letters, May-15, Volume: 20, Issue:10	Synthesis and anticancer evaluation of alpha-lipoic acid derivatives.
AID473030	Ex vivo inhibition of human HDAC3 in human Caco-2 cells by fluorometric cellular activity assay	2010	Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5	Biological and biophysical properties of the histone deacetylase inhibitor suberoylanilide hydroxamic acid are affected by the presence of short alkyl groups on the phenyl ring.
AID1547268	Inhibition of HDAC4 (unknown origin) using biotinylated histone H3 KAc peptide (1 to 21 residues) as substrate by HTRF assay	2020	Journal of medicinal chemistry, 04-09, Volume: 63, Issue:7	Discovery of Thieno[2,3-
AID1155320	Antimalarial activity against Plasmodium falciparum infected in erythrocytes after 2 hrs	2014	European journal of medicinal chemistry, Jul-23, Volume: 82	Discovery of HDAC inhibitors with potent activity against multiple malaria parasite life cycle stages.
AID1742756	In vivo inhibition of HDAC in tumor of human MDA-MB-231 cells xenografted in BALB/c mouse assessed as increase in acetylated histone-H3 expression by immunohistochemistry method	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Design and synthesis of novel Flavone-based histone deacetylase inhibitors antagonizing activation of STAT3 in breast cancer.
AID1178596	Inhibition of human HDAC2 pre-incubated for 30 mins before substrate addition and measured after 30 mins by HDAC-Glo I/II assay	2014	Bioorganic & medicinal chemistry, Jul-15, Volume: 22, Issue:14	Design and synthesis of novel and highly-active pan-histone deacetylase (pan-HDAC) inhibitors.
AID1763822	Inhibition of human recombinant HDAC6 incubated for 15 mins by fluorogenic assay	2021	Bioorganic & medicinal chemistry, 06-15, Volume: 40	Novel hybrid conjugates with dual estrogen receptor α degradation and histone deacetylase inhibitory activities for breast cancer therapy.
AID1819516	Antiproliferative activity against human KG-1 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	2022	Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4	Discovery of DNA-Targeting HDAC Inhibitors with Potent Antitumor Efficacy In Vivo That Trigger Antitumor Immunity.
AID274117	Inhibition of HeLa cell proliferation	2006	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 16, Issue:23	A series of novel, potent, and selective histone deacetylase inhibitors.
AID723134	Potentiation of 10 uM cisplatin-induced toxicity in 5 uM cisplatin resistant human A2780 cells at 1 uM pretreated for 48 hrs followed by 5 uM cisplatin treatment by MTT assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1421929	Selectivity index, ratio of IC50 for HEK293 cells to IC50 for Plasmodium falciparum Dd2 infected in human erythrocytes	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	One-pot, multi-component synthesis and structure-activity relationships of peptoid-based histone deacetylase (HDAC) inhibitors targeting malaria parasites.
AID1274875	Inhibition of HDAC5 (unknown origin)	2016	European journal of medicinal chemistry, Jan-27, Volume: 108	Orally available stilbene derivatives as potent HDAC inhibitors with antiproliferative activities and antitumor effects in human tumor xenografts.
AID623022	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	2011	European journal of medicinal chemistry, Nov, Volume: 46, Issue:11	Design, synthesis and primary activity assay of tripeptidomimetics as histone deacetylase inhibitors with linear linker and branched cap group.
AID1274835	Toxicity in SCID mouse xenografted with human NCI-H460 cells assessed as body weight loss at 50 mg/kg, po qd administered for 15 consecutive days measured daily during compound dosing relative to vehicle-treated control	2016	European journal of medicinal chemistry, Jan-27, Volume: 108	Orally available stilbene derivatives as potent HDAC inhibitors with antiproliferative activities and antitumor effects in human tumor xenografts.
AID1572347	Inhibition of HDAC6 in human HL60 cells assessed as acetylated tubulin/GAPDH ratio at 10 uM after 4 hrs by Western blot assay relative to control	2019	Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3	Synthesis and Biological Investigation of Phenothiazine-Based Benzhydroxamic Acids as Selective Histone Deacetylase 6 Inhibitors.
AID348799	Inhibition of HDAC6	2008	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20	Optimization of a series of potent and selective ketone histone deacetylase inhibitors.
AID1403157	Antiproliferative activity against human SMMC7721 cells after 48 hrs by MTT assay	2018	European journal of medicinal chemistry, Jan-20, Volume: 144	Development of novel β-carboline-based hydroxamate derivatives as HDAC inhibitors with antiproliferative and antimetastatic activities in human cancer cells.
AID274170	Antiproliferative activity against H1299 cells	2006	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 16, Issue:20	Synthesis of rigid trichostatin A analogs as HDAC inhibitors.
AID286793	Increase in histone H3 acetylation in U937 cells at 5 uM after 24 hrs by Western blot analysis	2007	Journal of medicinal chemistry, May-17, Volume: 50, Issue:10	Bispyridinium dienes: histone deacetylase inhibitors with selective activities.
AID316910	Inhibition of human HDAC8	2008	Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6	Histone deacetylase inhibitors: from bench to clinic.
AID723728	Cytotoxicity against cisplatin resistant human A2780 cells after 72 hrs by MTT assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1251316	Inhibition of HDAC1 (unknown origin)	2015	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 25, Issue:20	Investigation on the ZBG-functionality of phenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase inhibitors.
AID723125	Potentiation of 45 uM cisplatin-induced toxicity in 1 uM cisplatin resistant human CAL27 cells at 1.5 uM pretreated for 48 hrs followed by 1 uM cisplatin treatment by MTT assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID765385	Inhibition of recombinant human HDAC6 enzyme using flurogenic Ac-LeuGlyLys (Ac)-AMC as substrate after 15 to 30 mins	2013	Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16	Total synthesis and full histone deacetylase inhibitory profiling of Azumamides A-E as well as β²- epi-Azumamide E and β³-epi-Azumamide E.
AID1486303	Antiproliferative activity against human MCF10A cells after 72 hrs by MTT assay	2017	Bioorganic & medicinal chemistry, 08-01, Volume: 25, Issue:15	Olaparib hydroxamic acid derivatives as dual PARP and HDAC inhibitors for cancer therapy.
AID1181307	Inhibition of HDAC6 in human U937 cells assessed as increase in acetyl-alpha-tubulin level at 5 uM by Western blotting method	2014	Journal of medicinal chemistry, Jul-24, Volume: 57, Issue:14	1,3,4-Oxadiazole-containing histone deacetylase inhibitors: anticancer activities in cancer cells.
AID105419	Antiproliferative activity against human MDA-435 breast carcinoma cell line	2003	Bioorganic & medicinal chemistry letters, Nov-03, Volume: 13, Issue:21	A novel series of histone deacetylase inhibitors incorporating hetero aromatic ring systems as connection units.
AID313729	Inhibition of HDAC1	2008	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2	Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2).
AID708274	Growth inhibition of human SKHEP1 cells incubated for 72 hrs by WST dye reduction assay	2012	Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20	Pharmacokinetic optimization of class-selective histone deacetylase inhibitors and identification of associated candidate predictive biomarkers of hepatocellular carcinoma tumor response.
AID748109	Inhibition of HDAC6 (unknown origin) after 60 mins by fluorescence assay	2013	Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11	Discovery of the first histone deacetylase 6/8 dual inhibitors.
AID1225988	Induction of apoptosis in human HCT116 cells assessed as early apoptotic cells at 5 uM after 48 hrs by annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 2.76%)	2015	ACS medicinal chemistry letters, Mar-12, Volume: 6, Issue:3	Discovery of Novel Multiacting Topoisomerase I/II and Histone Deacetylase Inhibitors.
AID1865302	Toxicity in BALB/c mouse model allografted with mouse 4T1 cells assessed as effect on lung at 40 mg/kg, po qd administered for 12 days	2022	Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18	Discovery of Novel Src Homology-2 Domain-Containing Phosphatase 2 and Histone Deacetylase Dual Inhibitors with Potent Antitumor Efficacy and Enhanced Antitumor Immunity.
AID316877	Inhibition of human liver HDAC	2008	Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6	Histone deacetylase inhibitors: from bench to clinic.
AID734738	Inhibition of HDAC8 (unknown origin) after 60 mins by SAMDI spectrophotometric analysis	2013	Journal of medicinal chemistry, May-09, Volume: 56, Issue:9	3-Hydroxypyridin-2-thione as novel zinc binding group for selective histone deacetylase inhibition.
AID1630598	Inhibition of recombinant full length C-terminal His-tagged human HDAC2 expressed in baculovirus expression system using fluorogenic substrate at 10 uM by fluorescence assay	2016	Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21	Synthesis and biological evaluation of santacruzamate A analogues for anti-proliferative and immunomodulatory activity.
AID760496	Cytotoxicity against human DU145 cells after 48 hrs by SRB assay	2013	ACS medicinal chemistry letters, Aug-08, Volume: 4, Issue:8	Development of a chimeric c-Src kinase and HDAC inhibitor.
AID310182	Growth inhibition of human MDA-MB-231 cells by SRB assay	2007	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 17, Issue:22	Modification of cap group in delta-lactam-based histone deacetylase (HDAC) inhibitors.
AID1437245	Cytotoxicity against human LNCAP cells assessed as growth inhibition after 72 hrs by MTS assay	2017	Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4	Design, synthesis and evaluation of antiproliferative activity of melanoma-targeted histone deacetylase inhibitors.
AID465157	Growth inhibition of human MIAPaCa2 cells after 72 hrs by MTS assay	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Synthesis and biological evaluation of triazol-4-ylphenyl-bearing histone deacetylase inhibitors as anticancer agents.
AID1764816	Inhibition of Nanoluc-fused HDAC6 CD2 (unknown origin) expressed in HEK293 cells incubated for 2 hrs by NANOBRET assay	2021	Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8	Tetrahydroquinoline-Capped Histone Deacetylase 6 Inhibitor SW-101 Ameliorates Pathological Phenotypes in a Charcot-Marie-Tooth Type 2A Mouse Model.
AID1723742	Inhibition of human recombinant HDAC1 using ZMAL (Z-Lys(Ac)-AMC) fluorogenic substrate incubated for 90 mins by fluorescence based assay	2020	Journal of medicinal chemistry, 09-24, Volume: 63, Issue:18	Multicomponent Synthesis, Binding Mode, and Structure-Activity Relationship of Selective Histone Deacetylase 6 (HDAC6) Inhibitors with Bifurcated Capping Groups.
AID373079	Inhibition of human recombinant HDAC6	2009	European journal of medicinal chemistry, Mar, Volume: 44, Issue:3	Novel amide derivatives as inhibitors of histone deacetylase: design, synthesis and SAR.
AID1597974	Inhibition of HDAC in human HeLA cell nuclear extracts	2019	Bioorganic & medicinal chemistry letters, 09-15, Volume: 29, Issue:18	Anti-tumor activity evaluation of novel tubulin and HDAC dual-targeting inhibitors.
AID1141241	Inhibition of MMP2 (unknown origin) using succinylated gelatin as substrate preincubated for 10 mins before substrate addition measured after 30 mins by spectrophotometry	2014	Bioorganic & medicinal chemistry, Jun-01, Volume: 22, Issue:11	Design, synthesis and preliminary evaluation of α-sulfonyl γ-(glycinyl-amino)proline peptidomimetics as matrix metalloproteinase inhibitors.
AID1709357	Cytotoxicity against human Jurkat cells assessed as reduction in cell viability measured after 48 hrs MTT assay	2021	Bioorganic & medicinal chemistry, 04-01, Volume: 35	Structure-activity relationship and mechanistic studies for a series of cinnamyl hydroxamate histone deacetylase inhibitors.
AID1275655	Toxicity in athymic nude mouse xenografted with human HCT116 cells assessed as mortality at 40 mg/kg, ip qd administered for 14 days measured every other day during compound dosing	2016	European journal of medicinal chemistry, Feb-15, Volume: 109	Identification of N-(6-mercaptohexyl)-3-(4-pyridyl)-1H-pyrazole-5-carboxamide and its disulfide prodrug as potent histone deacetylase inhibitors with in vitro and in vivo anti-tumor efficacy.
AID1401905	Selectivity ratio of IC50 for human recombinant HDAC1 to IC50 for human recombinant HDAC6	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
AID1482173	Cytotoxicity against human A549 cells assessed as growth inhibition at 5 uM after 48 hrs by MTT assay relative to control	2017	Journal of medicinal chemistry, 04-27, Volume: 60, Issue:8	Exploring Derivatives of Quinazoline Alkaloid l-Vasicine as Cap Groups in the Design and Biological Mechanistic Evaluation of Novel Antitumor Histone Deacetylase Inhibitors.
AID1482121	Cytotoxicity against human PC3 cells assessed as growth inhibition after 48 hrs by MTT assay	2017	Journal of medicinal chemistry, 04-27, Volume: 60, Issue:8	Exploring Derivatives of Quinazoline Alkaloid l-Vasicine as Cap Groups in the Design and Biological Mechanistic Evaluation of Novel Antitumor Histone Deacetylase Inhibitors.
AID420499	Toxicity in athymic nude Swiss mouse bearing human H460 cells assessed as tolerance at 20 to 100 mg/kg, po QD administered 5 days a week for 4 weeks	2009	European journal of medicinal chemistry, May, Volume: 44, Issue:5	Design, synthesis, and evaluation of biphenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors.
AID1348934	Upregulation of CDH1 gene expression in human A549 cells at IC50 after 12 hrs by RT-PCR method	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Discovery of aliphatic-chain hydroxamates containing indole derivatives with potent class I histone deacetylase inhibitory activities.
AID1754766	Downregulation of HDAC10 gene expression in human MCF7 cells at 3 uM incubated for 24 hrs by whole transcriptome analysis	2021	Bioorganic & medicinal chemistry, 07-15, Volume: 42	Discovery of novel class of histone deacetylase inhibitors as potential anticancer agents.
AID759311	Cytotoxicity against ERalpha-deficient human DU145 cells expressing ERbeta assessed as growth inhibition after 72 hrs by MTT assay	2013	Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14	Histone deacetylase inhibitors equipped with estrogen receptor modulation activity.
AID1166500	Antiproliferative activity against human HCT116 cells after 72 hrs by WST8 assay	2014	Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21	Design, synthesis and biological evaluation of 4-anilinothieno[2,3-d]pyrimidine-based hydroxamic acid derivatives as novel histone deacetylase inhibitors.
AID1688029	Induction of apoptosis in human HL-60 cells assessed as increase in accumulation at sub-G1 phase at 2 uM after 24 hrs by propidium iodide staining based flow cytometry (Rvb = 2.72 %)	2020	European journal of medicinal chemistry, Feb-15, Volume: 188	A 18β-glycyrrhetinic acid conjugate with Vorinostat degrades HDAC3 and HDAC6 with improved antitumor effects.
AID1600735	Inhibition of HDAC in human CAL27 cells using Boc-Lys(epsilon-Ac)-AMC as substrate preincubated for 18 hrs followed by substrate addition and further incubation for 3 hrs by microplate reader based fluorescence assay	2019	Bioorganic & medicinal chemistry, 10-01, Volume: 27, Issue:19	Novel α,β-unsaturated hydroxamic acid derivatives overcome cisplatin resistance.
AID1622927	Inhibition of maize HD2 using [3H]acetate-labelled histone as substrate by liquid scintillation counting method	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.
AID1542184	Inhibition of HDAC6 (unknown origin)	2019	Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7	Kinase and Histone Deacetylase Hybrid Inhibitors for Cancer Therapy.
AID288454	Growth inhibition of NCI-H23 cells by SRB assay	2007	Journal of medicinal chemistry, May-31, Volume: 50, Issue:11	Structure-activity relationship studies of a series of novel delta-lactam-based histone deacetylase inhibitors.
AID374817	Inhibition of human C-terminal FLAG-tagged HDAC2 in HEK293 cells	2009	Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11	Discovery of a potent class I selective ketone histone deacetylase inhibitor with antitumor activity in vivo and optimized pharmacokinetic properties.
AID1514602	Inhibition of HDAC1 in human HepG2 cells assessed as acetylated histone H4 levels at 1.25 uM by Western blot analysis relative to beta-actin (Rvb = 1 No_unit)	2019	Bioorganic & medicinal chemistry letters, 01-01, Volume: 29, Issue:1	Development of hydroxamate-based histone deacetylase inhibitors containing 1,2,4-oxadiazole moiety core with antitumor activities.
AID1887065	Selectivity ratio of IC50 for human HCT-116 cells to IC50 for human NCI-H522 cells by methylene blue staining based analysis	2022	Journal of medicinal chemistry, 09-08, Volume: 65, Issue:17	Tunable Cysteine-Targeting Electrophilic Heteroaromatic Warheads Induce Ferroptosis.
AID675297	Inhibition of HDAC in human HeLa cell extracts using Fluor de Lys as substrate at 0.1 uM by fluorescence assay	2012	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17	Set-up of a new series of HDAC inhibitors: the 5,11-dihydrodibenzo[b,e]azepin-6-ones as privileged structures.
AID1266092	Inhibition of HDAC1 (unknown origin) by fluorimetric assay	2016	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1	Cross metathesis with hydroxamate and benzamide BOC-protected alkenes to access HDAC inhibitors and their biological evaluation highlighted intrinsic activity of BOC-protected dihydroxamates.
AID1702070	Inhibition of human full length HDAC11 expressed in baculovirus infected Sf9 cells using fluorogenic HDAC class2a as substrate measured after 30 mins by fluorescence based assay	2018	Journal of medicinal chemistry, 02-22, Volume: 61, Issue:4	Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma.
AID1410323	Inhibition of recombinant human full length HDAC1 using fluorogenic substrate 3 after 30 mins by fluorescence assay	2018	ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4	Discovery of Novel Indoleamine 2,3-Dioxygenase 1 (IDO1) and Histone Deacetylase (HDAC) Dual Inhibitors.
AID723128	Potentiation of 45 uM cisplatin-induced toxicity in 1 uM cisplatin resistant human CAL27 cells at 0.25 uM pretreated for 48 hrs followed by 1 uM cisplatin treatment by MTT assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1469283	Induction of apoptosis in human HepG2 cells assessed as live cells at 10 uM after 48 hrs by annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 96.7%)	2018	Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7	Discovery of N1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7 H-pyrrolo[2,3- d]pyrimidin-2-yl)amino)phenyl)- N8-hydroxyoctanediamide as a Novel Inhibitor Targeting Cyclin-dependent Kinase 4/9 (CDK4/9) and Histone Deacetlyase1 (HDAC1) against Malignant Cancer
AID1667080	Inhibition of STAT3 in human MDA-MB-231 cells assessed as downregulation of Bcl-xL expression after 24 hrs by western blot analysis	2020	Bioorganic & medicinal chemistry, 03-15, Volume: 28, Issue:6	Pyrimethamine conjugated histone deacetylase inhibitors: Design, synthesis and evidence for triple negative breast cancer selective cytotoxicity.
AID1863434	Inhibition of HDAC2 (unknown origin) by colorimetric method	2022	European journal of medicinal chemistry, Oct-05, Volume: 240	Accommodation of ring C expanded deoxyvasicinone in the HDAC inhibitory pharmacophore culminates into a tractable anti-lung cancer agent and pH-responsive nanocarrier.
AID1421626	Antiproliferative activity against human Jurkat cells after 72 hrs by MTT assay	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	Design and synthesis of potent dual inhibitors of JAK2 and HDAC based on fusing the pharmacophores of XL019 and vorinostat.
AID1727745	Induction of cell cycle arrest in human MV4-11 cells assessed as accumulation at G0/G1 phase after 24 hrs by flow cytometry	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	Discovery of selective HDAC/BRD4 dual inhibitors as epigenetic probes.
AID344916	Inhibition of 2-oxoglutarate-dependent human JMJD2E in presence of excess 2-oxoglutarate and 10 uM Fe2 by FDH coupled assay	2008	Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22	Inhibitor scaffolds for 2-oxoglutarate-dependent histone lysine demethylases.
AID1859931	Inhibition of HDAC in human HCT-116 cells assessed as increase in acetylation level of alpha-tubulin at 10 uM measured after 24 to 48 hrs by Western blot analysis	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Azetidin-2-one-based small molecules as dual hHDAC6/HDAC8 inhibitors: Investigation of their mechanism of action and impact of dual inhibition profile on cell viability.
AID672028	Inhibition of human recombinant HDAC8 expressed in Escherichia coli using BML-KI-178 as substrate preincubated with compound for 5 mins at 10 uM measured after 35 mins by spectrofluorometric analysis	2012	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 22, Issue:15	Design, synthesis, modeling, biological evaluation and photoaffinity labeling studies of novel series of photoreactive benzamide probes for histone deacetylase 2.
AID1321724	Cytotoxicity against mouse primary glial cells assessed as reduction in cell viability after 72 hrs by luminescence based ATPlite assay	2016	Journal of medicinal chemistry, 10-13, Volume: 59, Issue:19	Design, Synthesis, and Biological Evaluation of First-in-Class Dual Acting Histone Deacetylases (HDACs) and Phosphodiesterase 5 (PDE5) Inhibitors for the Treatment of Alzheimer's Disease.
AID711145	Inhibition of HDAC8 at 0.3 uM in presence of 10 mol% Cu(I) by fluorometric assay	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	Rapid discovery of highly potent and selective inhibitors of histone deacetylase 8 using click chemistry to generate candidate libraries.
AID1851615	Cytotoxicity against HUVEC cells assessed as inhibition of cell growth	2022	Bioorganic & medicinal chemistry letters, 10-15, Volume: 74	Design, synthesis, and antitumor study of a series of novel 1-Oxa-4-azaspironenone derivatives.
AID1702087	Antiproliferative activity against human SU-DHL-6 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay	2018	Journal of medicinal chemistry, 02-22, Volume: 61, Issue:4	Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma.
AID526532	Growth inhibition of human PC3 cells	2010	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22	Property based optimization of δ-lactam HDAC inhibitors for metabolic stability.
AID1622974	Inhibition of HDAC8 (unknown origin)	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.
AID1754763	Downregulation of HDAC5 gene expression in human MCF7 cells at 3 uM incubated for 24 hrs by whole transcriptome analysis	2021	Bioorganic & medicinal chemistry, 07-15, Volume: 42	Discovery of novel class of histone deacetylase inhibitors as potential anticancer agents.
AID1901761	Inhibition of full length human recombinant HDAC3 expressed in Sf9 baculovirus system using FAM-labeled acetylated peptide as substrate by measuring fluorescence intensity by EMSA method	2022	Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4	Discovery of HDAC6-Selective Inhibitor NN-390 with
AID723473	Cytotoxicity against cisplatin sensitive human KYSE-510 cells after 72 hrs by MTT assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID420501	Antiproliferative activity against human NB4 cells after 72 hrs	2009	European journal of medicinal chemistry, May, Volume: 44, Issue:5	Design, synthesis, and evaluation of biphenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors.
AID695300	Induction of Oct3/4 gene expression in C57BL/6 MEF at 100 nM after 24 hrs by quantitative RT-PCR analysis relative to control	2012	Bioorganic & medicinal chemistry, Apr-15, Volume: 20, Issue:8	Development of programmable small DNA-binding molecules with epigenetic activity for induction of core pluripotency genes.
AID1379282	Inhibition of class 2 HDAC in human SH-SY5Y cells assessed as increase in acetylation of alpha-tubulin at 10 uM after 24 hrs by Western blot analysis	2017	ACS medicinal chemistry letters, Aug-10, Volume: 8, Issue:8	Design, Synthesis, and Biological Evaluation of Tetrahydroisoquinoline-Based Histone Deacetylase 8 Selective Inhibitors.
AID1401505	Cytotoxicity against human Jurkat cells assessed as cell viability at 10 uM after 44 hrs by MTT assay relative to control	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
AID1466379	Toxicity in BALB/c nude mouse xenografted with human HCT116 cells assessed as body weight at 100 mg/kg/day administered via oral gavage for 16 days (Rvb = 19.91 +/- 1.26 g)	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	Selective HDAC inhibitors with potent oral activity against leukemia and colorectal cancer: Design, structure-activity relationship and anti-tumor activity study.
AID1812435	Cytotoxicity against human Hep-G2 cells assessed as inhibition of cell proliferation measured after 72 hrs by ATPlite assay	2021	Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14	Procainamide-SAHA Fused Inhibitors of hHDAC6 Tackle Multidrug-Resistant Malaria Parasites.
AID1399552	Antiproliferative activity against human A549 cells after 72 hrs by SRB assay	2018	Bioorganic & medicinal chemistry, 09-01, Volume: 26, Issue:16	A series of camptothecin prodrugs exhibit HDAC inhibition activity.
AID1572354	Antiproliferative activity against human HuH7 cells after 72 hrs by CellTiter blue-reagent based assay	2019	Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3	Synthesis and Biological Investigation of Phenothiazine-Based Benzhydroxamic Acids as Selective Histone Deacetylase 6 Inhibitors.
AID1730862	Inhibition of EGFR exon19 deletion/T790M/C797S double mutant (unknown origin) expressed in Ba/F3 cells assessed as reduction in cell viability after 72 hrs by MTT assay	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Design, synthesis and evaluation of novel ErbB/HDAC multitargeted inhibitors with selectivity in EGFR
AID723131	Potentiation of 50 uM cisplatin-induced toxicity in 1 uM cisplatin resistant human MDA-MB-231 cells at 0.5 uM pretreated for 48 hrs followed by 1 uM cisplatin treatment by MTT assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1597971	Induction of cell cycle arrest in human A549 cells assessed as accumulation at G2/M phase at 10 uM incubated for 36 hrs by propidium iodide staining based flow cytometry (Rvb = 10.83%)	2019	Bioorganic & medicinal chemistry letters, 09-15, Volume: 29, Issue:18	Anti-tumor activity evaluation of novel tubulin and HDAC dual-targeting inhibitors.
AID269670	Antiproliferative activity against human HCT15 cells by SRB assay	2006	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 16, Issue:15	Synthesis, enzymatic inhibition, and cancer cell growth inhibition of novel delta-lactam-based histone deacetylase (HDAC) inhibitors.
AID1182314	Antiproliferative activity against human MIAPaCa2 cells after 48 hrs by MTT assay	2014	Journal of natural products, Jul-25, Volume: 77, Issue:7	A potent HDAC inhibitor, 1-alaninechlamydocin, from a Tolypocladium sp. induces G2/M cell cycle arrest and apoptosis in MIA PaCa-2 cells.
AID609505	Inhibition of human recombinant HDAC1 expressed in baculovirus infected insect High5 cells using Ac-Lys-Tyr-Lys(epsilon-acetyl)-AMC as substrate by fluorescence assay	2011	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16	Synthesis and biological evaluation of piperamide analogues as HDAC inhibitors.
AID1459947	Antiproliferative activity against human HCT116 cells measured after 48 hrs by sulforhodamine-B assay	2017	European journal of medicinal chemistry, Jan-05, Volume: 125	3-Aroylindoles display antitumor activity in vitro and in vivo: Effects of N1-substituents on biological activity.
AID344917	Inhibition of 2-oxoglutarate-dependent human JMJD2E in presence of excess H3K9me3 peptide and 10 uM Fe2 by FDH coupled assay	2008	Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22	Inhibitor scaffolds for 2-oxoglutarate-dependent histone lysine demethylases.
AID373074	Inhibition of human recombinant HDAC1	2009	European journal of medicinal chemistry, Mar, Volume: 44, Issue:3	Novel amide derivatives as inhibitors of histone deacetylase: design, synthesis and SAR.
AID90702	Inhibition of Histone deacetylase 6 (HDAC6) of HeLa nuclear extracts	2004	Bioorganic & medicinal chemistry letters, Jan-19, Volume: 14, Issue:2	Design, synthesis, and activity of HDAC inhibitors with a N-formyl hydroxylamine head group.
AID1415649	Inhibition of HDAC6 in human HepG2 cells assessed as increase in acetylated-alpha tubulin level at 5 uM after 48 hrs by Western blot analysis	2017	MedChemComm, Jun-01, Volume: 8, Issue:6	Development of novel β-carboline-based hydroxamate derivatives as HDAC inhibitors with DNA damage and apoptosis inducing abilities.
AID1398806	Cytotoxicity against ER negative human MCF10A cells treated every 2 days for 4 days measured after 7 days by CellTiter-Glo luminescence assay	2018	Bioorganic & medicinal chemistry, 08-15, Volume: 26, Issue:15	Incorporation of histone deacetylase inhibitory activity into the core of tamoxifen - A new hybrid design paradigm.
AID723443	Potentiation of 1 uM cisplatin-induced toxicity in 5 uM cisplatin resistant human A2780 cells at 1.5 uM pretreated for 48 hrs followed by 5 uM cisplatin treatment by MTT assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1275633	Inhibition of recombinant human HDAC1 using Boc-Lys(Ac)-AMC as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by fluorescence-based assay	2016	European journal of medicinal chemistry, Feb-15, Volume: 109	Identification of N-(6-mercaptohexyl)-3-(4-pyridyl)-1H-pyrazole-5-carboxamide and its disulfide prodrug as potent histone deacetylase inhibitors with in vitro and in vivo anti-tumor efficacy.
AID1371070	Antiparasitic activity against tachyzoite stage of Toxoplasma gondii	2017	Journal of medicinal chemistry, 06-22, Volume: 60, Issue:12	Lysine Deacetylase Inhibitors in Parasites: Past, Present, and Future Perspectives.
AID1622983	Cytotoxicity against human PC3 cells	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.
AID1875511	Selectivity index, ratio of IC50 for cytotoxicity against HMEC cells to GI50 for antiproliferative activity against human NCI-H526 cells	2022	ACS medicinal chemistry letters, Oct-13, Volume: 13, Issue:10	Cancer-Cell-Selective Targeting by Arylcyclopropylamine-Vorinostat Conjugates.
AID1493590	Inhibition of human recombinant full-length HDAC1 (1 to 482 residues) expressed in baculovirus using Boc-Lys(acetyl)-AMC as substrate after 30 mins by fluorescence assay	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Discovery of a fluorescent probe with HDAC6 selective inhibition.
AID1622899	Inhibition of HDAC in human HeLa nuclear extract at 100 uM using Fluor-de-lys as substrate measured after 15 mins by fluorescence assay	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.
AID1861649	Antiproliferative activity against human MCF7 cells measured after 72 hrs	2022	Bioorganic & medicinal chemistry letters, 09-15, Volume: 72	Exploration of 4-(1H-indol-3-yl)cyclohex-3-en-1-amine analogues as HDAC inhibitors: Design, synthesis, biological evaluation and modelling studies.
AID1126959	Inhibition of HDAC1 (unknown origin) using Boc-Lys(acetyl)-AMC as substrate after 30 mins by fluorescence assay	2014	Journal of medicinal chemistry, Apr-24, Volume: 57, Issue:8	Discovery of the first N-hydroxycinnamamide-based histone deacetylase 1/3 dual inhibitors with potent oral antitumor activity.
AID1129009	Inhibition of human HDAC-7 using RHKK(Ac) as substrate by fluorescence assay	2014	Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6	Synthesis and evaluation of new Hsp90 inhibitors based on a 1,4,5-trisubstituted 1,2,3-triazole scaffold.
AID487874	Antiproliferative activity against human A549 cells after 48 hrs	2010	Bioorganic & medicinal chemistry, Jun-15, Volume: 18, Issue:12	New aryldithiolethione derivatives as potent histone deacetylase inhibitors.
AID1240556	Induction of apoptosis in human MDA-MB-231 cells assessed as total apoptotic cells at 1 uM after 24 hrs using Annexin V-FITC and propidium iodide staining by flow cytometry	2015	Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17	Design, synthesis and biological evaluation of saccharin-based N-hydroxybenzamides as histone deacetylases (HDACs) inhibitors.
AID1578896	Inhibition of HDAC in human Bel7402 cells assessed as increase in acetylated alpha-tubulin expression at 5 uM incubated for 72 hrs by Western blot analysis	2019	Journal of natural products, 06-28, Volume: 82, Issue:6	Hydroxamic Acid Derivatives of β-Carboline/Hydroxycinnamic Acid Hybrids Inducing Apoptosis and Autophagy through the PI3K/Akt/mTOR Pathways.
AID1742182	Inhibition of recombinant human full-length N-terminal GST-tagged HDAC5 expressed in baculovirus infected Sf9 insect cells using AcLeu-Gly-Lys(Tfa)-AMC as substrate measured after 30 mins by fluorescence assay	2020	European journal of medicinal chemistry, Nov-01, Volume: 205	Design, synthesis and biological evaluation of novel HDAC inhibitors with improved pharmacokinetic profile in breast cancer.
AID1861255	Antiproliferative activity against human A549 cells assessed as reduction in cell viability	2022	Bioorganic & medicinal chemistry letters, 09-01, Volume: 71	Design, synthesis and antitumor activity study of PARP-1/HDAC dual targeting inhibitors.
AID1652195	Antiproliferative activity against human PC3 cells incubated for 96 hrs by resazurin assay	2020	ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5	New Dual CK2/HDAC1 Inhibitors with Nanomolar Inhibitory Activity against Both Enzymes.
AID1785337	Inhibition of recombiant human HDAC6 using fluorogenic HDAC substrate 3 measured after 30 mins by fluorescence microplate reader assay
AID1433298	Induction of DNA damage in p53 null human U937 cells assessed as decrease in Rad51 expression level by measuring ratio of Rad51 to beta-actin level at 2 uM after 24 hrs by Western blot analysis relative to control	2016	Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17	Synthesis and Antileukemic Activities of Piperlongumine and HDAC Inhibitor Hybrids against Acute Myeloid Leukemia Cells.
AID1633990	Inhibition of HDAC2 in human HuH7 cells assessed as increase in histone H3 K9/K14 acetylation at varying concentrations incubated for 24 hrs by Western blot analysis	2019	Bioorganic & medicinal chemistry letters, 08-15, Volume: 29, Issue:16	Synthesis of N'-propylhydrazide analogs of hydroxamic inhibitors of histone deacetylases (HDACs) and evaluation of their impact on activities of HDACs and replication of hepatitis C virus (HCV).
AID765374	Inhibition of recombinant human HDAC9 enzyme using Ac-LeuGlyLys (tfa)-AMC as substrate at 50 uM after 15 to 30 mins	2013	Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16	Total synthesis and full histone deacetylase inhibitory profiling of Azumamides A-E as well as β²- epi-Azumamide E and β³-epi-Azumamide E.
AID1126960	Inhibition of HDAC2 (unknown origin) using Boc-Lys(acetyl)-AMC as substrate after 30 mins by fluorescence assay	2014	Journal of medicinal chemistry, Apr-24, Volume: 57, Issue:8	Discovery of the first N-hydroxycinnamamide-based histone deacetylase 1/3 dual inhibitors with potent oral antitumor activity.
AID772639	Inhibition of full length FLAG-tagged recombinant HDAC3 (unknown origin) transfected in human HeLa cells assessed as deacetylation of [3H]-acetylated histones after 2 hrs by scintillation counting analysis	2013	Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18	Potent histone deacetylase inhibitors derived from 4-(aminomethyl)-N-hydroxybenzamide with high selectivity for the HDAC6 isoform.
AID1898895	Antiproliferative activity against human H460-R9A cells incubated for 24 hrs followed by incubating in drug-free medium for 48 hrs and measured by SRB assay	2022	European journal of medicinal chemistry, Jan-15, Volume: 228	Antitumor activity of novel POLA1-HDAC11 dual inhibitors.
AID1576449	Inhibition of recombinant HDAC1 (unknown origin) expressed in baculovirus expression system using Ac-peptide-AMC as substrate preincubated for 15 mins followed by substrate addition by fluorescence based protease coupled assay
AID1876344	Inhibition of recombinant full length HDAC11 (unknown origin) expressed in insect Sf9 cells by EMSA analysis	2021	Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12	Development of HDAC Inhibitors Exhibiting Therapeutic Potential in T-Cell Prolymphocytic Leukemia.
AID708279	Growth inhibition of human SMMC7721 cells incubated for 72 hrs by WST dye reduction assay	2012	Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20	Pharmacokinetic optimization of class-selective histone deacetylase inhibitors and identification of associated candidate predictive biomarkers of hepatocellular carcinoma tumor response.
AID445136	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	2009	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 19, Issue:22	Novel N-hydroxybenzamide-based HDAC inhibitors with branched CAP group.
AID1873401	Inhibition of HDAC1 (unknown origin) preincubated for 60 mins	2022	Bioorganic & medicinal chemistry letters, 08-15, Volume: 70	Comparison of three zinc binding groups for HDAC inhibitors - A potency, selectivity and enzymatic kinetics study.
AID1542183	Inhibition of HDAC5 (unknown origin)	2019	Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7	Kinase and Histone Deacetylase Hybrid Inhibitors for Cancer Therapy.
AID541650	Inhibition of human HDAC7 by fluorimetric assay	2010	Journal of medicinal chemistry, Dec-09, Volume: 53, Issue:23	Non-natural macrocyclic inhibitors of histone deacetylases: design, synthesis, and activity.
AID1785350	Antiproliferative activity against human K562 cells assessed as cell growth inhibition measured after 48 hrs by CCK8 assay
AID1380987	Antitumor activity against human HT-29 cells xenografted in BALB/c nu mouse assessed as tumor growth inhibition at 100 mg/kg, po administered for 25 consecutive days measured every 3 days during compound dosing relative to control	2018	Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12	Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously.
AID628439	Inhibition of human recombinant HDAC8 using Fluor de Lys as substrate	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Design, synthesis, docking, and biological evaluation of novel diazide-containing isoxazole- and pyrazole-based histone deacetylase probes.
AID1202584	Inhibition of His-tagged HDAC6 (unknown origin) expressed in Escherichia coli BL21(DE3) after 60 mins by MALDI mass spectrometry	2015	European journal of medicinal chemistry, , Volume: 96	Design and structure activity relationship of tumor-homing histone deacetylase inhibitors conjugated to folic and pteroic acids.
AID760493	Cytotoxicity against human HCT116 cells after 48 hrs by SRB assay	2013	ACS medicinal chemistry letters, Aug-08, Volume: 4, Issue:8	Development of a chimeric c-Src kinase and HDAC inhibitor.
AID1126978	Antiproliferative activity against HEL cells after 48 hrs by MTT assay	2014	Journal of medicinal chemistry, Apr-24, Volume: 57, Issue:8	Discovery of the first N-hydroxycinnamamide-based histone deacetylase 1/3 dual inhibitors with potent oral antitumor activity.
AID628208	Antiproliferative activity against human SH-SY5Y cells after 48 hrs by XTT assay	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Design, synthesis, docking, and biological evaluation of novel diazide-containing isoxazole- and pyrazole-based histone deacetylase probes.
AID723471	Inhibition of HDAC in cisplatin resistant human MDA-MB-231 cells after 18 hrs by fluorescence assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1783064	Antifungal activity against Cryptococcus neoformans H99 assessed as inhibition of fungal growth incubated for 72 hrs by two-fold serial microdilution method	2021	European journal of medicinal chemistry, Oct-05, Volume: 221	Lanosterol 14α-demethylase (CYP51)/histone deacetylase (HDAC) dual inhibitors for treatment of Candida tropicalis and Cryptococcus neoformans infections.
AID1486323	Genotoxicity in Salmonella typhimurium TA102 at 50 times antiproliferative IC50 by Ames test	2017	Bioorganic & medicinal chemistry, 08-01, Volume: 25, Issue:15	Olaparib hydroxamic acid derivatives as dual PARP and HDAC inhibitors for cancer therapy.
AID749697	Cytotoxicity against human DU145 cells assessed as inhibition of cell viability after 72 hrs by MTS assay	2013	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 23, Issue:11	Dual-acting histone deacetylase-topoisomerase I inhibitors.
AID1063058	Inhibition of recombinant HDAC3 (unknown origin) using Fluor-de-Lys-SIRT1 as substrate by fluorescence assay	2014	Journal of natural products, Jan-24, Volume: 77, Issue:1	Protein kinase and HDAC inhibitors from the endophytic fungus Epicoccum nigrum.
AID737910	Cytotoxicity against mouse MEF cells after 72 hrs by MTT assay	2013	Journal of medicinal chemistry, May-09, Volume: 56, Issue:9	Design and synthesis of dual-action inhibitors targeting histone deacetylases and 3-hydroxy-3-methylglutaryl coenzyme A reductase for cancer treatment.
AID420508	Induction of apoptosis in human IGROV1 cells at IC80 after 72 hrs by TUNEL assay	2009	European journal of medicinal chemistry, May, Volume: 44, Issue:5	Design, synthesis, and evaluation of biphenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors.
AID1547315	Increase in phosphorylated STAT3 expression in tumor tissue of BALB/cAnNCrl mouse xenografted with human HCT116 cells at 30 mg/kg, po administered on day 1 to day 19 measured on day 19 by immunohistochemical analysis	2020	Journal of medicinal chemistry, 04-09, Volume: 63, Issue:7	Discovery of Thieno[2,3-
AID1591721	Inhibition of Class 1 histone deacetylase in mouse RAW264.7cells cells assessed as increase in histone acetylation at 0.3 to 3 uM after 24 hrs by Western blot analysis	2019	Bioorganic & medicinal chemistry, 08-01, Volume: 27, Issue:15	Structure-activity relationship study of thiazolyl-hydroxamate derivatives as selective histone deacetylase 6 inhibitors.
AID1280280	Inhibition of class1 HDAC in human HL60 cells assessed as ratio of acetylated histone H3 to GAPDH level at 0.1 uM after 4 hrs by Western blot analysis relative to control	2016	Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4	Synthesis and Biological Investigation of Oxazole Hydroxamates as Highly Selective Histone Deacetylase 6 (HDAC6) Inhibitors.
AID1451824	Cytotoxicity in human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay	2017	Journal of medicinal chemistry, 10-12, Volume: 60, Issue:19	Small Molecule Inhibitors Simultaneously Targeting Cancer Metabolism and Epigenetics: Discovery of Novel Nicotinamide Phosphoribosyltransferase (NAMPT) and Histone Deacetylase (HDAC) Dual Inhibitors.
AID1888410	Cytotoxicity against human HaCaT cells assessed as inhibition of cell growth	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	Heat shock protein 90 (Hsp90)/Histone deacetylase (HDAC) dual inhibitors for the treatment of azoles-resistant Candida albicans.
AID723442	Potentiation of 5 uM cisplatin-induced toxicity in 1 uM cisplatin resistant human MDA-MB-231 cells at 1 uM pretreated for 48 hrs followed by 1 uM cisplatin treatment by MTT assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1201643	Inhibition of human recombinant FLT3 after 1 hr by LanthaScreen assay platform	2015	European journal of medicinal chemistry, May-05, Volume: 95	Macrocyclic compounds as anti-cancer agents: design and synthesis of multi-acting inhibitors against HDAC, FLT3 and JAK2.
AID445137	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	2009	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 19, Issue:22	Novel N-hydroxybenzamide-based HDAC inhibitors with branched CAP group.
AID663339	Growth inhibition of human MDA-MB-231 cells after 72 hrs by MTT assay	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Discovery and extensive in vitro evaluations of NK-HDAC-1: a chiral histone deacetylase inhibitor as a promising lead.
AID1173504	Inhibition of N-terminal GST-tagged human HDAC7 (518 to end residues) using fluorogenic acetyl-Lys(trifluoroacetyl)-AMC substrate incubated for 2 hrs by fluorescence assay	2014	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 24, Issue:23	Histone deacetylase inhibitors derived from 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine and related heterocycles selective for the HDAC6 isoform.
AID1127326	Inhibition of human HDAC5 using fluorogenic tetrapeptide RHKKAc as substrate	2014	European journal of medicinal chemistry, May-22, Volume: 79	Influence of the adamantyl moiety on the activity of biphenylacrylohydroxamic acid-based HDAC inhibitors.
AID1739589	Inhibition of HDAC6 in human HL-60 cells assessed as ratio of acetylated H3/GAPDH at 1 uM incubated for 4 hrs by Western blot analysis relative to DMSO	2020	European journal of medicinal chemistry, Aug-15, Volume: 200	Design, synthesis, and biological evaluation of dual targeting inhibitors of histone deacetylase 6/8 and bromodomain BRPF1.
AID482973	Antitumor activity against human PC3 cells xenografted in nude mouse assessed as inhibition of tumor growth at 160 mg/kg, ip administered for 21 days measured or day 22	2010	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11	Acylurea connected straight chain hydroxamates as novel histone deacetylase inhibitors: Synthesis, SAR, and in vivo antitumor activity.
AID603534	Cytotoxicity against human NB4 cells after 48 hrs by MTT assay	2011	Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8	Development of tetrahydroisoquinoline-based hydroxamic acid derivatives: potent histone deacetylase inhibitors with marked in vitro and in vivo antitumor activities.
AID663367	Growth inhibition of human OVCAR8 cells after 72 hrs by MTS assay	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Discovery and extensive in vitro evaluations of NK-HDAC-1: a chiral histone deacetylase inhibitor as a promising lead.
AID1282285	Toxicity in Balb/c nude mouse xenografted with human HCT116 cells assessed as change in body weight at 50 mg/kg, ip q2d for 9 days	2016	Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4	Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
AID1541443	Inhibition of human full length N-terminal GST-tagged HDAC6 expressed in baculovirus infected Sf9 insect cells ZMAL as substrate incubated for 90 mins by fluorescence assay	2019	Journal of medicinal chemistry, 12-26, Volume: 62, Issue:24	Synthesis of Peptoid-Based Class I-Selective Histone Deacetylase Inhibitors with Chemosensitizing Properties.
AID1650408	Inhibition of HDAC6 in human CAL27 cells assessed as increase in acetylated alpha-tubulin at 3 uM incubated for 24 hrs by immunoblot analysis	2020	Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1	Novel alkoxyamide-based histone deacetylase inhibitors reverse cisplatin resistance in chemoresistant cancer cells.
AID208380	Concentration required to inhibit complete cell proliferation of T/5 cells	1995	Journal of medicinal chemistry, Apr-14, Volume: 38, Issue:8	The synthesis of N-hydroxy-N'-phenyloctanediamide and its inhibitory effect on proliferation of AXC rat prostate cancer cells.
AID673991	Inhibition of recombinant HDAC2 using Ac-Lys(Ac)-AMC as substrate after 30 mins by fluorescence analysis	2012	ACS medicinal chemistry letters, Jun-14, Volume: 3, Issue:6	Discovery of HDAC Inhibitors That Lack an Active Site Zn(2+)-Binding Functional Group.
AID1282259	Cytotoxicity against human H460 cells after 72 hrs by MTT assay	2016	Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4	Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
AID1864253	Cytotoxicity against human SUM159PT cells harboring wild type BRCA1 and wild type BRCA2 assessed as reduction in cell viability	2022	Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18	Discovery of a Novel G-Quadruplex and Histone Deacetylase (HDAC) Dual-Targeting Agent for the Treatment of Triple-Negative Breast Cancer.
AID1888420	Inhibition of human HDAC	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	Heat shock protein 90 (Hsp90)/Histone deacetylase (HDAC) dual inhibitors for the treatment of azoles-resistant Candida albicans.
AID759308	Therapeutic index, ratio of IC50 for african green monkey Vero cells to IC50 for human MCF7 cells expressing ERalpha and ERbeta	2013	Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14	Histone deacetylase inhibitors equipped with estrogen receptor modulation activity.
AID1449319	Antiproliferative activity against human Cal27CisR cells measured after 72 hrs by MTT assay	2017	Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13	Alkoxyurea-Based Histone Deacetylase Inhibitors Increase Cisplatin Potency in Chemoresistant Cancer Cell Lines.
AID1684873	Toxicity in mouse LL/2 cells inoculated C57BL/6J mouse assessed as effect on body weight by measuring initial body weight at 25 mg/kg, ip administered for 12 days measured for every 2 days (Rvb = 18.4 +/- 0.4 g)
AID1549162	Inhibition of HDAC in azole-resistant Candida albicans 0304103 protoplasts using Boc-Lys(Ac)-AMC as substrate preincubated for 12 hrs followed by substrate addition and measured after 4 hrs by fluorimetry	2020	Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10	Discovery of Novel Fungal Lanosterol 14α-Demethylase (CYP51)/Histone Deacetylase Dual Inhibitors to Treat Azole-Resistant Candidiasis.
AID1614228	Induction of apoptosis in human MM1S cells assessed as necrotic cells at 1 uM after 48 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 0.32%)
AID1235260	Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	2015	Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15	Design, synthesis and preliminary bioactivity evaluations of substituted quinoline hydroxamic acid derivatives as novel histone deacetylase (HDAC) inhibitors.
AID1742721	Induction of apoptosis in mouse 4T1 cells assessed as late apoptotic cells at 5 uM incubated for 72 hrs by annexinV-FITC and PI staining based flow cytometry analysis (Rvb = 2.24 %)	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Design and synthesis of novel Flavone-based histone deacetylase inhibitors antagonizing activation of STAT3 in breast cancer.
AID723427	Potentiation of 0.75 uM cisplatin-induced toxicity in 0.5 uM cisplatin resistant human KYSE-510 cells at 1.5 uM pretreated for 48 hrs followed by 0.5 uM cisplatin treatment by MTT assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1396959	Antiproliferative activity against human HCT116 cells	2018	Bioorganic & medicinal chemistry letters, 08-15, Volume: 28, Issue:15	Merging of ruxolitinib and vorinostat leads to highly potent inhibitors of JAK2 and histone deacetylase 6 (HDAC6).
AID1330946	Antiproliferative activity against human A431 cells expressing EGFR/HER2 assessed as reduction in cell viability measured after 48 hrs by MTT assay	2017	Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1	Synthesis and investigation of novel 6-(1,2,3-triazol-4-yl)-4-aminoquinazolin derivatives possessing hydroxamic acid moiety for cancer therapy.
AID1398802	Cytotoxicity against ER positive human MCF7 cells treated every 2 days for 4 days measured after 7 days by CellTiter-Glo luminescence assay	2018	Bioorganic & medicinal chemistry, 08-15, Volume: 26, Issue:15	Incorporation of histone deacetylase inhibitory activity into the core of tamoxifen - A new hybrid design paradigm.
AID525024	Inhibition of HDAC in human CFBE41o- cell line assessed as increase in CFTR mRNA at 1 uM by RT-PCR	2010	Nature chemical biology, Jan, Volume: 6, Issue:1	Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.
AID1898901	Antiproliferative activity against human MM473 cells incubated for 24 hrs followed by incubating in drug-free medium for 48 hrs and measured by SRB assay	2022	European journal of medicinal chemistry, Jan-15, Volume: 228	Antitumor activity of novel POLA1-HDAC11 dual inhibitors.
AID1127004	Induction of apoptosis in human U937 cells assessed as viable cells using annexin-V/propidium iodide staining at 0.25 uM after 24 hrs by flow cytometry analysis (Rvb = 96.24%)	2014	Journal of medicinal chemistry, Apr-24, Volume: 57, Issue:8	Discovery of the first N-hydroxycinnamamide-based histone deacetylase 1/3 dual inhibitors with potent oral antitumor activity.
AID605622	Cell cycle arrest in human HCT116 cells assessed as accumulation at G2/M phase at 300 nM after 15 hrs by propidium iodide staining based flow cytometric analysis	2010	Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24	Discovery of 2-(6-{[(6-fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a class I selective orally active histone deacetylase inhibitor.
AID1758470	Inhibition of human recombinant HDAC10 using Ac-Leu-Gly-Lys(Ac)-AMC as substrate by measuring fluorescence intensity incubated for 30 mins by microplate reader assay	2021	European journal of medicinal chemistry, May-05, Volume: 217	Novel dual-mode antitumor chlorin-based derivatives as potent photosensitizers and histone deacetylase inhibitors for photodynamic therapy and chemotherapy.
AID1227024	Half life in patient serum at 400 mg single dose	2015	Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11	Dual-Mode HDAC Prodrug for Covalent Modification and Subsequent Inhibitor Release.
AID732871	Inhibition of HDAC2 in human MDA-MB-231 cells assessed as decrease in acetylation levels of histone H4 at 1 uM by Western blot analysis	2013	ACS medicinal chemistry letters, Feb-14, Volume: 4, Issue:2	Development of
AID411260	Cytotoxicity against human DU145 cells after 72 hrs by trypan blue exclusion assay	2009	Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2	Non-peptide macrocyclic histone deacetylase inhibitors.
AID1165117	Inhibition of HDAC6 in human LNCAP cells assessed as tubulin acetylation by Western blot analysis	2014	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 24, Issue:20	The antileishmanial activity of isoforms 6- and 8-selective histone deacetylase inhibitors.
AID1901156	Inhibition of HDAC4 (unknown origin) using FAM-RHKK(Ac)-NH2/FAM-RHKK(trifluoroacetyl)-NH2 as substrate preincubated for 15 mins followed by substrate addition and measured after 3 hrs by microfluidic chip based fluorescence assay	2022	Bioorganic & medicinal chemistry, 02-15, Volume: 56	Synthesis and biological evaluation of aminobenzamides containing purine moiety as class I histone deacetylases inhibitors.
AID1280275	Inhibition of HDAC6 in human HL60 cells assessed as ratio of acetylated tubulin to GAPDH level at 10 uM after 4 hrs by Western blot analysis relative to control	2016	Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4	Synthesis and Biological Investigation of Oxazole Hydroxamates as Highly Selective Histone Deacetylase 6 (HDAC6) Inhibitors.
AID246069	Effective Concentration of compound to inhibit the growth of human SNB-78 cells	2005	Journal of medicinal chemistry, Feb-24, Volume: 48, Issue:4	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates.
AID1576454	Cytotoxicity against human MCF10A cells assessed as reduction in cell viability after 48 hrs by SRB assay
AID269917	Selectivity index, EC50 for histone H4 acetylation/EC50 for alpha-tubulin acetylation in HCT116 cells	2006	Journal of medicinal chemistry, Aug-10, Volume: 49, Issue:16	Highly potent and selective histone deacetylase 6 inhibitors designed based on a small-molecular substrate.
AID1126980	Antiproliferative activity against human HL60 cells after 48 hrs by MTT assay	2014	Journal of medicinal chemistry, Apr-24, Volume: 57, Issue:8	Discovery of the first N-hydroxycinnamamide-based histone deacetylase 1/3 dual inhibitors with potent oral antitumor activity.
AID1917528	Inhibition of PI3Kdelta (unknown origin) measured by ADP-Glo assay	2022	Bioorganic & medicinal chemistry, 11-01, Volume: 73	Identification of PI3K/HDAC Dual-targeted inhibitors with subtype selectivity as potential therapeutic agents against solid Tumors: Building HDAC6 potency in a Quinazolinone-based PI3Kδ-selective template.
AID1633435	Induction of neurogenesis in human SH-SY5Y cells assessed as upregulation of N-myc mRNA at 1 uM incubated for 24 hrs by RT-PCR analysis	2019	ACS medicinal chemistry letters, Apr-11, Volume: 10, Issue:4	Discovery of the First-in-Class GSK-3β/HDAC Dual Inhibitor as Disease-Modifying Agent To Combat Alzheimer's Disease.
AID616004	Inhibition of HDAC4 using Boc-Lys(TFA)-AMC as substrate incubated 30 mins before substrate addition measured after 30 mins post substrate addition by fluorescence assay	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Synthesis and evaluation of aliphatic-chain hydroxamates capped with osthole derivatives as histone deacetylase inhibitors.
AID440820	Inhibition of recombinant C-terminal FLAG-tagged HDAC2 expressed in baculovirus after 10 mins by fluorimetric analysis	2009	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 19, Issue:19	Diphenylmethylene hydroxamic acids as selective class IIa histone deacetylase inhibitors.
AID1466061	Inhibition of recombinant human full length HDAC1 using Fluor-de-Lys as substrate after 60 mins by spectrofluorimetric analysis	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	4-Indolyl-N-hydroxyphenylacrylamides as potent HDAC class I and IIB inhibitors in vitro and in vivo.
AID1765324	Inhibition of human full-length recombinant HDAC1 preincubated for 5 mins followed by HDAC substrate addition and further incubated for 45 mins by fluorescence microplate reader assay	2021	European journal of medicinal chemistry, Oct-15, Volume: 222	A first-in-class anticancer dual HDAC2/FAK inhibitors bearing hydroxamates/benzamides capped by pyridinyl-1,2,4-triazoles.
AID1129004	Inhibition of human HDAC-2 using RHKK(Ac) as substrate by fluorescence assay	2014	Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6	Synthesis and evaluation of new Hsp90 inhibitors based on a 1,4,5-trisubstituted 1,2,3-triazole scaffold.
AID1863438	Inhibition of HDAC6 (unknown origin) by colorimetric method	2022	European journal of medicinal chemistry, Oct-05, Volume: 240	Accommodation of ring C expanded deoxyvasicinone in the HDAC inhibitory pharmacophore culminates into a tractable anti-lung cancer agent and pH-responsive nanocarrier.
AID1126958	Inhibition of HDAC in human HeLa nuclear extracts using Boc-Lys(acetyl)-AMC as substrate after 30 mins by fluorescence assay	2014	Journal of medicinal chemistry, Apr-24, Volume: 57, Issue:8	Discovery of the first N-hydroxycinnamamide-based histone deacetylase 1/3 dual inhibitors with potent oral antitumor activity.
AID1469380	Inhibition of HDAC1 (unknown origin)	2018	Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7	Discovery of N1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7 H-pyrrolo[2,3- d]pyrimidin-2-yl)amino)phenyl)- N8-hydroxyoctanediamide as a Novel Inhibitor Targeting Cyclin-dependent Kinase 4/9 (CDK4/9) and Histone Deacetlyase1 (HDAC1) against Malignant Cancer
AID1234895	Antiproliferative activity against human K562 cells after 48 hrs by MTT assay	2015	Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15	Design, synthesis and preliminary biological evaluation of indoline-2,3-dione derivatives as novel HDAC inhibitors.
AID1614123	Antiproliferative activity against human MM1S cells after 72 hrs by MTT assay
AID488235	Inhibition of HDAC in human SCC4 cells assessed as increase in tubulin acetylation at 1 uM after 24 hrs by Western blot analysis	2010	Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11	Vitamin D receptor agonist/histone deacetylase inhibitor molecular hybrids.
AID1751993	Selectivity ratio of IC50 for HDAC8 (unknown origin) to IC50 for HDAC1 (unknown origin)	2021	Bioorganic & medicinal chemistry letters, 10-01, Volume: 49	Discovery of novel pyrazolopyrimidine derivatives as potent mTOR/HDAC bi-functional inhibitors via pharmacophore-merging strategy.
AID1421916	Gametocytocidal activity against transgenic GFP-fused Plasmodium falciparum NF54 early stage gametocytes after 72 hrs by Mitotracker Red CMH2XRos staining based imaging method	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	One-pot, multi-component synthesis and structure-activity relationships of peptoid-based histone deacetylase (HDAC) inhibitors targeting malaria parasites.
AID748982	Inhibition of HDAC4 (unknown origin)	2013	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 23, Issue:11	A cyclodextrin-capped histone deacetylase inhibitor.
AID350724	Ratio of GI50 for human MKN45 cells to IC50 for human recombinant HDAC2	2009	Journal of medicinal chemistry, May-14, Volume: 52, Issue:9	Design, synthesis, and biological activity of boronic acid-based histone deacetylase inhibitors.
AID1486307	Antiproliferative activity against human HCC1937 cells after 3 days by MTT assay	2017	Bioorganic & medicinal chemistry, 08-01, Volume: 25, Issue:15	Olaparib hydroxamic acid derivatives as dual PARP and HDAC inhibitors for cancer therapy.
AID1275643	Growth inhibition of human MDA-MB-231 cells after 96 hrs by MTT assay	2016	European journal of medicinal chemistry, Feb-15, Volume: 109	Identification of N-(6-mercaptohexyl)-3-(4-pyridyl)-1H-pyrazole-5-carboxamide and its disulfide prodrug as potent histone deacetylase inhibitors with in vitro and in vivo anti-tumor efficacy.
AID732877	Inhibition of HDAC1 (unknown origin) using Boc-Lys(acetyl)-AMC as substrate preincubated with enzyme for 5 mins prior to substrate addition measured after 30 mins by fluorescence assay	2013	ACS medicinal chemistry letters, Feb-14, Volume: 4, Issue:2	Development of
AID1548269	Inhibition of class 1 HDAC in human RPMI8226 cells assessed as increase in Ac-H3 accumulation at 10 to 1000 nM incubated for 24 hrs Western blotting analysis
AID1514608	Induction of apoptosis in human HepG2 cells assessed as early apoptotic cells at 1.25 uM after 48 hrs by annexin V-FITC/propidium iodide staining based assay (Rvb = 3.2 %)	2019	Bioorganic & medicinal chemistry letters, 01-01, Volume: 29, Issue:1	Development of hydroxamate-based histone deacetylase inhibitors containing 1,2,4-oxadiazole moiety core with antitumor activities.
AID511066	Inhibition of HDAC6	2010	European journal of medicinal chemistry, Sep, Volume: 45, Issue:9	Design and synthesis of novel isoxazole-based HDAC inhibitors.
AID732145	Inhibition of HDAC3 (unknown origin) assessed as fluorescence intensity measured after 60 mins incubation at room temperature by trypsin-free microfluidic lab-on-a-chip assay	2013	Journal of medicinal chemistry, Feb-28, Volume: 56, Issue:4	Potent and selective inhibition of histone deacetylase 6 (HDAC6) does not require a surface-binding motif.
AID1164775	Stability of the compound in aqueous solution at pH 1.2 after 24 hrs	2014	Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20	ST7612AA1, a thioacetate-ω(γ-lactam carboxamide) derivative selected from a novel generation of oral HDAC inhibitors.
AID1466056	Inhibition of HDAC in human HeLa cell nuclear extract using Ac-Lys(Ac)-pNA as substrate after 30 mins by fluorescence assay	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	4-Indolyl-N-hydroxyphenylacrylamides as potent HDAC class I and IIB inhibitors in vitro and in vivo.
AID1623536	Selectivity index, ratio of IC50 for human recombinant HDAC7 to IC50 for human recombinant HDAC6	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	A novel class of anthraquinone-based HDAC6 inhibitors.
AID1127000	Induction of apoptosis in human U937 cells assessed as viable cells using annexin-V/propidium iodide staining at 0.5 uM after 24 hrs by flow cytometry analysis (Rvb = 96.24%)	2014	Journal of medicinal chemistry, Apr-24, Volume: 57, Issue:8	Discovery of the first N-hydroxycinnamamide-based histone deacetylase 1/3 dual inhibitors with potent oral antitumor activity.
AID1486674	Inhibition of HDAC1 (unknown origin) at 10 uM using Ac-Leu-GlyLys(Ac)-AMC as substrate preincubated for 10 mins followed by substrate addition measured after 30 mins by fluorescence analysis	2017	Bioorganic & medicinal chemistry, 08-01, Volume: 25, Issue:15	Design, synthesis and tumor cell growth inhibitory activity of 3-nitro-2H-cheromene derivatives as histone deacetylaes inhibitors.
AID663337	Growth inhibition of human OVCAR3 cells after 72 hrs by MTS assay	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Discovery and extensive in vitro evaluations of NK-HDAC-1: a chiral histone deacetylase inhibitor as a promising lead.
AID748984	Inhibition of HDAC2 (unknown origin)	2013	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 23, Issue:11	A cyclodextrin-capped histone deacetylase inhibitor.
AID1543967	Induction of DNA damage in human Bel7402/5-FU cells assessed as increase in phosphorylated H2AX levels at 5.0 uM incubated for 72 hrs by Western blot assay	2019	European journal of medicinal chemistry, Apr-15, Volume: 168	β-Carboline and N-hydroxycinnamamide hybrids as anticancer agents for drug-resistant hepatocellular carcinoma.
AID1742661	Cytotoxicity against human SMMC-7721 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Design and synthesis of novel Flavone-based histone deacetylase inhibitors antagonizing activation of STAT3 in breast cancer.
AID1898919	Inhibition of POLA1 in human NCI-H460 cells at 7.4 uM assessed as upregulation of p21 expression and measured by Western blot analysis	2022	European journal of medicinal chemistry, Jan-15, Volume: 228	Antitumor activity of novel POLA1-HDAC11 dual inhibitors.
AID1273876	Inhibition of human CYP1A2 using 3-cyano-7-ethoxycoumarin as substrate at 10 uM after 15 mins by fluorimetric analysis	2016	European journal of medicinal chemistry, Jan-27, Volume: 108	Synthesis, biological characterization and molecular modeling insights of spirochromanes as potent HDAC inhibitors.
AID473032	Ex vivo inhibition of human HDAC7 in human Caco-2 cells by fluorometric cellular activity assay	2010	Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5	Biological and biophysical properties of the histone deacetylase inhibitor suberoylanilide hydroxamic acid are affected by the presence of short alkyl groups on the phenyl ring.
AID420654	Toxicity in athymic nude Swiss mouse bearing human HCT116 cells assessed as body weight loss at 100 mg/kg, po QD administered 5 days a week for 4 weeks	2009	European journal of medicinal chemistry, May, Volume: 44, Issue:5	Design, synthesis, and evaluation of biphenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors.
AID717818	Inhibition of HDAC in human Hela cell lysate using Fluor-de-Lys as substrate assessed as remaining activity at 2.5 x 10'-7 M pretreated for 30 mins before substrate addition by fluorescence assay	2012	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23	The structural requirements of histone deacetylase inhibitors: suberoylanilide hydroxamic acid analogs modified at the C6 position.
AID1518810	Effect on human KMS-12-BM cells assessed as increase in H3K9Me2 level at 2.5 to 5 uM incubated for 24 hrs by Western blot analysis	2019	European journal of medicinal chemistry, Dec-15, Volume: 184	Discovery of a potent histone deacetylase (HDAC) 3/6 selective dual inhibitor.
AID443647	Binding affinity to pyridoxal-5'-phosphate assessed as formation of syn- and anti-PLP-aldoxime by NMR spectroscopy	2009	Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19	Hydroxamic acids as a novel family of serine racemase inhibitors: mechanistic analysis reveals different modes of interaction with the pyridoxal-5'-phosphate cofactor.
AID1141777	Induction of apoptosis in human HCT116 cells assessed as accumulation at sub-G1 phase after 24 hrs by propidium iodide staining-based flow cytometric analysis	2014	Journal of medicinal chemistry, May-22, Volume: 57, Issue:10	Azaindolylsulfonamides, with a more selective inhibitory effect on histone deacetylase 6 activity, exhibit antitumor activity in colorectal cancer HCT116 cells.
AID489914	Cytotoxicity against human U251 cells after 48 hrs by MTT assay	2010	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 20, Issue:13	Design, synthesis and anticancer activity of piperazine hydroxamates and their histone deacetylase (HDAC) inhibitory activity.
AID1280272	Selectivity index, ratio of HDAC6 inhibition in human HeLa cells assessed as ratio of acetylated tubulin to GAPDH level at 10 uM over class1 HDAC inhibition in human HeLa cells assessed as ratio of acetylated histone H3 to GAPDH level at 10 uM	2016	Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4	Synthesis and Biological Investigation of Oxazole Hydroxamates as Highly Selective Histone Deacetylase 6 (HDAC6) Inhibitors.
AID1742179	Inhibition of recombinant human GST-fused HDAC3/NCOR1 (397 to 503 residues) expressed in baculovirus infected insect cells using Ac-Leu-Gly-Lys(Ac)-AMC as substrate measured after 30 mins by fluorescence assay	2020	European journal of medicinal chemistry, Nov-01, Volume: 205	Design, synthesis and biological evaluation of novel HDAC inhibitors with improved pharmacokinetic profile in breast cancer.
AID616003	Inhibition of human HDAC8 using Boc-Lys(TFA)-AMC as substrate incubated 30 mins before substrate addition measured after 30 mins post substrate addition by fluorescence assay	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Synthesis and evaluation of aliphatic-chain hydroxamates capped with osthole derivatives as histone deacetylase inhibitors.
AID760377	Cytotoxicity against human Jurkat cells after 72 hrs by MTS assay	2013	ACS medicinal chemistry letters, Aug-08, Volume: 4, Issue:8	Tropolones as lead-like natural products: the development of potent and selective histone deacetylase inhibitors.
AID1478585	Induction of apoptosis in human K562 cells assessed as viable cells at 2 uM after 24 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometry (Rvb = 92.4%)	2017	European journal of medicinal chemistry, Jun-16, Volume: 133	Design, synthesis and biological evaluation of quinoline derivatives as HDAC class I inhibitors.
AID526534	Growth inhibition of human ACHN cells	2010	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22	Property based optimization of δ-lactam HDAC inhibitors for metabolic stability.
AID1263142	Antagonist activity at luciferase-fused ERalpha in human HEK293 cells expressing eYFP assessed as reduction of E2-induced estrogenic activity after 2 hrs by BRET assay	2015	Bioorganic & medicinal chemistry, Dec-15, Volume: 23, Issue:24	Design, synthesis and evaluation of antiestrogen and histone deacetylase inhibitor molecular hybrids.
AID1371076	Gametocytocidal activity against transgenic GFP-fused Plasmodium falciparum NF54 late stage gametocytes after 72 hrs by Mitotracker Red CMH2XRos staining based microscopic method	2017	Journal of medicinal chemistry, 06-22, Volume: 60, Issue:12	Lysine Deacetylase Inhibitors in Parasites: Past, Present, and Future Perspectives.
AID411258	Cytotoxicity against human SKMES1 cells after 72 hrs by trypan blue exclusion assay	2009	Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2	Non-peptide macrocyclic histone deacetylase inhibitors.
AID1361633	Inhibition of HDAC3 (unknown origin) after 30 mins by fluorescence assay	2018	Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16	Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents.
AID1742178	Inhibition of human full-length C-terminal FLAG-tagged HDAC2 expressed in baculovirus infected Sf9 insect cells using Ac-Leu-Gly-Lys(Ac)-AMC as substrate measured after 30 mins by fluorescence assay	2020	European journal of medicinal chemistry, Nov-01, Volume: 205	Design, synthesis and biological evaluation of novel HDAC inhibitors with improved pharmacokinetic profile in breast cancer.
AID1737155	Induction of apoptosis in human HCT-116 cells assessed as necrotic cells at 3 uM after 24 hrs by Annexin V-FITC/PI staining based flow cytometric analysis (Rvb = 0.51%)	2020	European journal of medicinal chemistry, Apr-15, Volume: 192	Design, synthesis and biological evaluation of novel indazole-based derivatives as potent HDAC inhibitors via fragment-based virtual screening.
AID1330925	Inhibition of HER2 (unknown origin) assessed as remaining ATP level measured after 15 mins by luminescence analysis	2017	Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1	Synthesis and investigation of novel 6-(1,2,3-triazol-4-yl)-4-aminoquinazolin derivatives possessing hydroxamic acid moiety for cancer therapy.
AID1383999	Inhibition of HDAC1/2/3 in human HeLa cells assessed as increase in acetyl-histone H4 level at 2 uM after 12 hrs by Western blot analysis	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	Discovery of meta-sulfamoyl N-hydroxybenzamides as HDAC8 selective inhibitors.
AID1667082	Inhibition of STAT3 in human MDA-MB-231 cells assessed as change in Bcl-2 expression at 0.8 to 1.6 uM after 24 hrs by western blot analysis	2020	Bioorganic & medicinal chemistry, 03-15, Volume: 28, Issue:6	Pyrimethamine conjugated histone deacetylase inhibitors: Design, synthesis and evidence for triple negative breast cancer selective cytotoxicity.
AID1742656	Cytotoxicity against human Bcap37 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Design and synthesis of novel Flavone-based histone deacetylase inhibitors antagonizing activation of STAT3 in breast cancer.
AID440821	Inhibition of human recombinant N-terminal FLAG-tagged HDAC4 (612-1034) expressed in baculovirus after 10 mins by fluorimetric analysis	2009	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 19, Issue:19	Diphenylmethylene hydroxamic acids as selective class IIa histone deacetylase inhibitors.
AID1246522	Cytotoxicity against HEK293 cells assessed as reduction in cell viability	2015	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 25, Issue:19	Discovery of 1-hydroxypyridine-2-thiones as selective histone deacetylase inhibitors and their potential application for treating leukemia.
AID1469374	Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	2018	Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7	Discovery of N1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7 H-pyrrolo[2,3- d]pyrimidin-2-yl)amino)phenyl)- N8-hydroxyoctanediamide as a Novel Inhibitor Targeting Cyclin-dependent Kinase 4/9 (CDK4/9) and Histone Deacetlyase1 (HDAC1) against Malignant Cancer
AID1548262	Antiproliferative activity against human GES-1 cells incubated for 48 hrs by MTT assay
AID1650412	Inhibition of recombinant human HDAC2	2020	Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1	Novel alkoxyamide-based histone deacetylase inhibitors reverse cisplatin resistance in chemoresistant cancer cells.
AID347867	Growth inhibition of human lung cancer cells at 10 uM relative to control	2008	Journal of medicinal chemistry, Dec-11, Volume: 51, Issue:23	Histone deacetylase inhibitors through click chemistry.
AID1811394	Antitumor activity against human MCF7 cells xenografted in BALB/c nude mouse assessed as TGI at 50 mg/kg, po administered 3 times week for 21 days	2021	European journal of medicinal chemistry, Dec-15, Volume: 226	Development of novel tetrahydroisoquinoline-hydroxamate conjugates as potent dual SERDs/HDAC inhibitors for the treatment of breast cancer.
AID1826627	Synergistic antiproliferative effect on HEL cells assessed as fractional inhibitory concentration index at 0.0046 uM in presence of 3-Fluoro-10-hydroxy-14-methyl-8,13,13b,14-tetrahydro-7H-indolo[2',3':3,4]pyrido[2,1-b]quinazolin-5-one	2022	Journal of medicinal chemistry, 03-24, Volume: 65, Issue:6	Evodiamine-Inspired Topoisomerase-Histone Deacetylase Dual Inhibitors: Novel Orally Active Antitumor Agents for Leukemia Therapy.
AID1873413	Inhibition of HDAC3 (unknown origin) preincubated for 120 mins	2022	Bioorganic & medicinal chemistry letters, 08-15, Volume: 70	Comparison of three zinc binding groups for HDAC inhibitors - A potency, selectivity and enzymatic kinetics study.
AID482946	Inhibition of HDAC6	2010	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11	Acylurea connected straight chain hydroxamates as novel histone deacetylase inhibitors: Synthesis, SAR, and in vivo antitumor activity.
AID1622902	Cytotoxicity against human K562 cells after 72 hrs by CellTiter-Glo assay	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.
AID1550120	Induction of apoptosis in HEL cells assessed as late apoptotic cells at 1 uM after 24 hrs by Annexin-V/propidium iodide staining-based flow cytometric analysis (Rvb = 0.023%)	2019	Journal of medicinal chemistry, 04-25, Volume: 62, Issue:8	Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies.
AID1279128	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay	2016	Bioorganic & medicinal chemistry, Apr-01, Volume: 24, Issue:7	Design and synthesis of a new generation of substituted purine hydroxamate analogs as histone deacetylase inhibitors.
AID1266839	Activation of p53 in human HCT116 cell at 0.1 to 5 uM after 12 hrs by western blot analysis	2015	Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23	Novel β-Carboline/Hydroxamic Acid Hybrids Targeting Both Histone Deacetylase and DNA Display High Anticancer Activity via Regulation of the p53 Signaling Pathway.
AID1861250	Inhibition of PARP-1 derived from human HeLa cell nucleus	2022	Bioorganic & medicinal chemistry letters, 09-01, Volume: 71	Design, synthesis and antitumor activity study of PARP-1/HDAC dual targeting inhibitors.
AID1164172	Antiproliferative activity against human K562 cells assessed as growth inhibition after 48 hrs by trypan blue dye exclusion method	2014	ACS medicinal chemistry letters, Sep-11, Volume: 5, Issue:9	Novel antiproliferative chimeric compounds with marked histone deacetylase inhibitory activity.
AID1231813	Antiproliferative activity against human NCI-H661 cells incubated for 72 hrs by MTT assay	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Discovery, bioactivity and docking simulation of Vorinostat analogues containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors and antitumor agents.
AID1401480	Selectivity ratio of IC50 for HDAC6 in human HeLa-S3 cell lysates to IC50 for HDAC3 in human HeLa-S3 cell lysates	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
AID481573	Cytotoxicity against mouse S180 cells assessed as growth inhibition at 1 ug/ml after 24 hrs by MTT assay	2010	Bioorganic & medicinal chemistry letters, May-15, Volume: 20, Issue:10	Synthesis and anticancer evaluation of alpha-lipoic acid derivatives.
AID1055716	Antiproliferative activity against human MCF7 cells after 48 hrs by SRB assay	2013	European journal of medicinal chemistry, , Volume: 70	Novel isatin-based hydroxamic acids as histone deacetylase inhibitors and antitumor agents.
AID1515905	Antiproliferative activity against human MDA-MB-453 cells after 96 hrs by MTT assay	2019	Journal of medicinal chemistry, 08-08, Volume: 62, Issue:15	Design, Synthesis, and Biological Evaluation of 4-Methyl Quinazoline Derivatives as Anticancer Agents Simultaneously Targeting Phosphoinositide 3-Kinases and Histone Deacetylases.
AID1821272	Inhibition of HDAC3 (unknown origin) incubated for 30 mins by microplate reader assay	2022	European journal of medicinal chemistry, Feb-05, Volume: 229	Discovery of phthalazino[1,2-b]-quinazolinone derivatives as multi-target HDAC inhibitors for the treatment of hepatocellular carcinoma via activating the p53 signal pathway.
AID1647331	Anti-vascular cognitive impairment activity against bilateral common carotid artery occlusion-induced vascular dementia C57BL/6J mouse model assessed as ratio of cerebral blood flow in left parietal area at 25 mg/kg, ip administered post surgery measured	2020	European journal of medicinal chemistry, Feb-01, Volume: 187	Protective effects of 10,11-dihydro-5H-dibenzo[b,f]azepine hydroxamates on vascular cognitive impairment.
AID1709347	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	2021	Bioorganic & medicinal chemistry, 04-01, Volume: 35	Structure-activity relationship and mechanistic studies for a series of cinnamyl hydroxamate histone deacetylase inhibitors.
AID1865299	Toxicity in BALB/c mouse model allografted with mouse 4T1 cells assessed as effect on heart at 40 mg/kg, po qd administered for 12 days	2022	Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18	Discovery of Novel Src Homology-2 Domain-Containing Phosphatase 2 and Histone Deacetylase Dual Inhibitors with Potent Antitumor Efficacy and Enhanced Antitumor Immunity.
AID297476	Cytotoxicity against human NCI H460 cells	2007	Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18	2-aroylindoles and 2-aroylbenzofurans with N-hydroxyacrylamide substructures as a novel series of rationally designed histone deacetylase inhibitors.
AID1129786	Cell cycle arrest in human Jurkat cells assessed as accumulation at S-phase at 10 uM after 36 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 23%)	2014	Bioorganic & medicinal chemistry, Apr-01, Volume: 22, Issue:7	Studies on the antiproliferative effects of tropolone derivatives in Jurkat T-lymphocyte cells.
AID1231807	Inhibition of recombinant HDAC1 (unknown origin) incubated for 10 mins using Boc-Lys(acetyl)-AMC fluorogenic substrate by homogeneous fluorescence release assay	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Discovery, bioactivity and docking simulation of Vorinostat analogues containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors and antitumor agents.
AID1355731	Protection against spleen enlargement in SCID mouse xenografted with human HEL cells at 10 mg/kg, ip qd	2018	Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14	Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections.
AID1667096	Cell cycle arrest in human MDA-MB-231 cells assessed as accumulation of cells at S phase at 5 uM incubated for 48 hrs RNase/PI staining based flow cytometry assay (Rvb = 11.5 %)	2020	Bioorganic & medicinal chemistry, 03-15, Volume: 28, Issue:6	Pyrimethamine conjugated histone deacetylase inhibitors: Design, synthesis and evidence for triple negative breast cancer selective cytotoxicity.
AID1548284	Induction of apoptosis in bortezomib resistant human KM3/BTZ cells assessed as viable cells level at 50 nM incubated for 24 hrs by Annexin V-FITC/PI staining based FCAS analysis (Rvb = 98.1%)
AID313732	Inhibition of HDAC4	2008	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2	Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2).
AID1441631	Inhibition of recombinant human LTA4H Epoxide Hydrolase expressed in Escherichia coli BL21 (DE3) pLysS preincubated for 10 mins followed by addition of LTA4 as substrate measured after 15 mins by reverse-phase HPLC analysis	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
AID672022	Inhibition of human recombinant HDAC1 using Boc-L-Lys (Ac)-AMC as substrate preincubated with compound for 3 hrs measured after 35 mins by spectrofluorometric analysis	2012	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 22, Issue:15	Design, synthesis, modeling, biological evaluation and photoaffinity labeling studies of novel series of photoreactive benzamide probes for histone deacetylase 2.
AID1486295	Antiproliferative activity against human T47D cells after 72 hrs by MTT assay	2017	Bioorganic & medicinal chemistry, 08-01, Volume: 25, Issue:15	Olaparib hydroxamic acid derivatives as dual PARP and HDAC inhibitors for cancer therapy.
AID723425	Potentiation of 5 uM cisplatin-induced toxicity in 5 uM cisplatin resistant human A2780 cells at 0.5 uM pretreated for 48 hrs followed by 5 uM cisplatin treatment by MTT assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1164024	Inhibition of human recombinant HDAC1 after 60 mins by fluorimetric assay	2014	European journal of medicinal chemistry, Oct-30, Volume: 86	Design, synthesis, and biological evaluation of 1, 3-disubstituted-pyrazole derivatives as new class I and IIb histone deacetylase inhibitors.
AID1421627	Antiproliferative activity against human KMS-12-BM cells after 72 hrs by MTT assay	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	Design and synthesis of potent dual inhibitors of JAK2 and HDAC based on fusing the pharmacophores of XL019 and vorinostat.
AID1422516	Inhibition of HDAC in MEF assessed as increase in histone H4K5 acetylation at 2 uM after 6 hrs by Western blot analysis	2018	European journal of medicinal chemistry, Nov-05, Volume: 159	In search of constrained FTY720 and phytosphingosine analogs as dual acting anticancer agents targeting metabolic and epigenetic pathways.
AID1437240	Inhibition of HDAC1 (unknown origin)	2017	Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4	Design, synthesis and evaluation of antiproliferative activity of melanoma-targeted histone deacetylase inhibitors.
AID1129770	Inhibition of HDAC in human Jurkat cells assessed as increase in H3K23 acetylation at 10 uM after 12 hrs by FACS flow cytometric analysis relative to control	2014	Bioorganic & medicinal chemistry, Apr-01, Volume: 22, Issue:7	Studies on the antiproliferative effects of tropolone derivatives in Jurkat T-lymphocyte cells.
AID1572349	Inhibition of HDAC6 in human HL60 cells assessed as acetylated tubulin/GAPDH ratio at 0.1 uM after 4 hrs by Western blot assay relative to control	2019	Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3	Synthesis and Biological Investigation of Phenothiazine-Based Benzhydroxamic Acids as Selective Histone Deacetylase 6 Inhibitors.
AID1888581	Inhibition of recombinant human HDAC1 expressed in baculovirus infection system using Ac-peptide-AMC as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence assay
AID1274878	Inhibition of HDAC8 (unknown origin)	2016	European journal of medicinal chemistry, Jan-27, Volume: 108	Orally available stilbene derivatives as potent HDAC inhibitors with antiproliferative activities and antitumor effects in human tumor xenografts.
AID655477	Inhibition of recombinant human HDAC2 using Fluor-de-Lys as substrate after 30 mins by spectrophotometry	2011	ACS medicinal chemistry letters, Jul-21, Volume: 2, Issue:9	Potential Agents for Treating Cystic Fibrosis: Cyclic Tetrapeptides that Restore Trafficking and Activity of ΔF508-CFTR.
AID1537557	Antiproliferative activity against human CHP134 cells assessed as reduction in cell viability incubated for 72 hrs by cell-titer Glo assay	2019	MedChemComm, Jul-01, Volume: 10, Issue:7	Design, synthesis and biological evaluation of β-peptoid-capped HDAC inhibitors with anti-neuroblastoma and anti-glioblastoma activity.
AID1266093	Inhibition of HDAC2 (unknown origin) by fluorimetric assay	2016	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1	Cross metathesis with hydroxamate and benzamide BOC-protected alkenes to access HDAC inhibitors and their biological evaluation highlighted intrinsic activity of BOC-protected dihydroxamates.
AID775832	Inhibition of human carbonic anhydrase 2 assessed as p-nitrophenyl acetate conversion to p-nitrophenolate anion at 10 uM preincubated for 10 mins prior to substrate addition measured for 20 mins by spectrophotometric analysis relative to control	2013	Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20	Investigating the selectivity of metalloenzyme inhibitors.
AID1206768	Inhibition of full length human recombinant HDAC11 expressed in baculovirus infected insect S9 cells after 30 mins by fluorescence assay	2015	Journal of medicinal chemistry, May-28, Volume: 58, Issue:10	Design, synthesis, and antitumor evaluation of novel histone deacetylase inhibitors equipped with a phenylsulfonylfuroxan module as a nitric oxide donor.
AID1514609	Induction of apoptosis in human HepG2 cells assessed as late apoptotic cells at 1.25 uM after 48 hrs by annexin V-FITC/propidium iodide staining based assay (Rvb = 1.8 %)	2019	Bioorganic & medicinal chemistry letters, 01-01, Volume: 29, Issue:1	Development of hydroxamate-based histone deacetylase inhibitors containing 1,2,4-oxadiazole moiety core with antitumor activities.
AID90359	Concentration required for inhibition of histone deacetylase HD2 in vitro.	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	3-(4-Aroyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-propenamides as a new class of synthetic histone deacetylase inhibitors. 2. Effect of pyrrole-C2 and/or -C4 substitutions on biological activity.
AID316876	Inhibition of human SQ20B cells	2008	Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6	Histone deacetylase inhibitors: from bench to clinic.
AID1821964	Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay
AID1769648	Inhibition of recombinant human C-terminal His/FLAG-tagged HDAC1 (1 to 482 residues) expressed in Sf9 insect cells using Ac-peptide-AMC as substrate preincubated for 15 mins followed by addition of substrate and trypsin measured by flourescence assay	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	Discovery of 2,4-pyrimidinediamine derivatives as potent dual inhibitors of ALK and HDAC.
AID1398800	Inhibition of human full length C-terminal His-tagged HDAC3/N-terminal GST-tagged human NCOR2 (395 to 489 residues) expressed in baculovirus expression system using Ac-Leu-Gly-Lys(Ac)-AMC as substrate measured after 30 mins by fluorescence assay	2018	Bioorganic & medicinal chemistry, 08-15, Volume: 26, Issue:15	Incorporation of histone deacetylase inhibitory activity into the core of tamoxifen - A new hybrid design paradigm.
AID1421903	Antiplasmodial activity against multidrug-resistant asexual ring stage Plasmodium falciparum Dd2 infected in human erythrocytes by [3H]-hypoxanthine incorporation assay	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	One-pot, multi-component synthesis and structure-activity relationships of peptoid-based histone deacetylase (HDAC) inhibitors targeting malaria parasites.
AID1832687	Inhibition of C-terminal His-tagged recombinant human HDAC3 (1 to 428 residues)/N-terminal GST-tagged recombinant human NCoR2 (395 to 489 residues) co-expressed in baculovirus infected Sf9 cells using Boc-Lys(acetyl)-AMC as fluorogenic substrate measured	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Cysteine derivatives as acetyl lysine mimics to inhibit zinc-dependent histone deacetylases for treating cancer.
AID1811370	Inhibition of HDAC6 (unknown origin) at 1 uM using Ac-peptide as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence assay relative to control	2021	European journal of medicinal chemistry, Dec-15, Volume: 226	Development of novel tetrahydroisoquinoline-hydroxamate conjugates as potent dual SERDs/HDAC inhibitors for the treatment of breast cancer.
AID1890335	Stability in human liver microsomes assessed as clearance and measured by LC-MS/MS analysis	2022	European journal of medicinal chemistry, Apr-05, Volume: 233	Novel biphenyl-based scaffold as potent and selective histone deacetylase 6 (HDAC6) inhibitors: Identification, development and pharmacological evaluation.
AID1246516	Inhibition of HDAC7 (unknown origin) using Boc-Lys(trifluoroacetyl)-AMC fluorogenic acetylated peptide substrate by fluorometric assay	2015	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 25, Issue:19	Discovery of 1-hydroxypyridine-2-thiones as selective histone deacetylase inhibitors and their potential application for treating leukemia.
AID525027	Inhibition of HDAC7 in human CFBE41o- cell line assessed as correction of mutant Fdelta508 CFTR trafficking to cell surface as glycoform at 5 uM by Immunoblot analysis	2010	Nature chemical biology, Jan, Volume: 6, Issue:1	Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.
AID663380	Growth inhibition of human M14 cells after 72 hrs by MTS assay	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Discovery and extensive in vitro evaluations of NK-HDAC-1: a chiral histone deacetylase inhibitor as a promising lead.
AID1352483	Inhibition of HDAC6 in human HeLa cells after 72 hrs by ELISA	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Spirohydantoins and 1,2,4-triazole-3-carboxamide derivatives as inhibitors of histone deacetylase: Design, synthesis, and biological evaluation.
AID1832801	Inhibition of human recombinant HDAC1 assessed as fluorescence using fluorogenic substrate ZMAL incubated for 90 min by microplate reader	2021	Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19	4-Acyl Pyrrole Capped HDAC Inhibitors: A New Scaffold for Hybrid Inhibitors of BET Proteins and Histone Deacetylases as Antileukemia Drug Leads.
AID631669	Inhibition of human recombinant full-length HDAC6 using fluorophore conjugated substrate by fluorescence assay	2011	Journal of medicinal chemistry, Aug-11, Volume: 54, Issue:15	In vivo PET imaging of histone deacetylases by 18F-suberoylanilide hydroxamic acid (18F-SAHA).
AID434538	Cytotoxicity against human H460 cells after 24 hrs by sulforhodamine B assay	2009	Bioorganic & medicinal chemistry letters, May-15, Volume: 19, Issue:10	Exploring bis-(indolyl)methane moiety as an alternative and innovative CAP group in the design of histone deacetylase (HDAC) inhibitors.
AID663382	Growth inhibition of human SK-MEL-2 cells after 72 hrs by MTS assay	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Discovery and extensive in vitro evaluations of NK-HDAC-1: a chiral histone deacetylase inhibitor as a promising lead.
AID1205627	Growth inhibition of human PC3 cells after 5 days by sulforhodamine B assay	2015	Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8	Discovery of Orally Available Runt-Related Transcription Factor 3 (RUNX3) Modulators for Anticancer Chemotherapy by Epigenetic Activation and Protein Stabilization.
AID482975	Antitumor activity against human HCT116 cells xenografted in BALB/c mouse at 200 mg/kg, po after 21 days	2010	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11	Acylurea connected straight chain hydroxamates as novel histone deacetylase inhibitors: Synthesis, SAR, and in vivo antitumor activity.
AID711158	Inhibition of HDAC2 by fluorometric assay	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	Rapid discovery of highly potent and selective inhibitors of histone deacetylase 8 using click chemistry to generate candidate libraries.
AID1227047	Cytotoxicity against human HH cells assessed as cell proliferation after 70 hrs by MTS assay	2015	Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11	Dual-Mode HDAC Prodrug for Covalent Modification and Subsequent Inhibitor Release.
AID1861327	Inhibition of HDAC in human OCILY3 cells assessed as effect on total Stat3 levels at 2.5 uM measured by Western blot analysis	2022	Bioorganic & medicinal chemistry letters, 09-01, Volume: 71	Bioevaluation of a dual PI3K/HDAC inhibitor for the treatment of diffuse large B-cell lymphoma.
AID316885	Antiproliferative activity against human A549 cells	2008	Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6	Histone deacetylase inhibitors: from bench to clinic.
AID1690104	Growth inhibition of human NCI-H1975 cells incubated for 48 hrs by SRB assay	2020	European journal of medicinal chemistry, Mar-15, Volume: 190	Isoindoline scaffold-based dual inhibitors of HDAC6 and HSP90 suppressing the growth of lung cancer in vitro and in vivo.
AID288451	Growth inhibition of PC3 cells by SRB assay	2007	Journal of medicinal chemistry, May-31, Volume: 50, Issue:11	Structure-activity relationship studies of a series of novel delta-lactam-based histone deacetylase inhibitors.
AID316880	Inhibition of mouse liver HDAC1	2008	Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6	Histone deacetylase inhibitors: from bench to clinic.
AID274073	AUC after oral dosing at 5 mg kg-1	2007	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2	Identification and optimisation of a series of substituted 5-(1H-pyrazol-3-yl)-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.
AID1720096	Inhibition of HDAC (unknown origin)	2020	Journal of medicinal chemistry, 09-10, Volume: 63, Issue:17	Dual-Target Inhibitors Based on HDACs: Novel Antitumor Agents for Cancer Therapy.
AID619041	Inhibition of full length recombinant HDAC1 using Fluor de Lys as substrate by fluorescence assay	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile.
AID1548291	Induction of apoptosis in bortezomib resistant human KM3/BTZ cells assessed as necrotic cells level at 200 nM incubated for 24 hrs by Annexin V-FITC/PI staining based FCAS analysis (Rvb = 0.11%)
AID473185	Induction of P21WAF1 gene expression in human Caco-2 cells at 5 uM after 24 hrs by Western blotting	2010	Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5	Biological and biophysical properties of the histone deacetylase inhibitor suberoylanilide hydroxamic acid are affected by the presence of short alkyl groups on the phenyl ring.
AID540211	Fraction unbound in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1478591	Inhibition of HDAC1 (unknown origin) using substrate after 30 mins by fluorometric analysis	2017	European journal of medicinal chemistry, Jun-16, Volume: 133	Design, synthesis and biological evaluation of quinoline derivatives as HDAC class I inhibitors.
AID1164781	Inhibition of HDAC2 (unknown origin) using fluorogenic tetrapeptide RHKK(Ac) substrate by fluorescence assay	2014	Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20	ST7612AA1, a thioacetate-ω(γ-lactam carboxamide) derivative selected from a novel generation of oral HDAC inhibitors.
AID1688025	Inhibition of C-terminal His-tagged recombinant human HDAC3 (1 to 428 residues)/N-terminal GST-tagged recombinant human NCoR2 (395 to 489 residues) co-expressed in baculovirus infected Sf9 cells using Boc-Lys(Ac)-AMC as substrate preincubated for 15 mins	2020	European journal of medicinal chemistry, Feb-15, Volume: 188	A 18β-glycyrrhetinic acid conjugate with Vorinostat degrades HDAC3 and HDAC6 with improved antitumor effects.
AID1826600	Antiproliferative activity against human K562 cells assessed as cell growth inhibition incubated for 8 hrs by CCK8 assay	2022	Journal of medicinal chemistry, 03-24, Volume: 65, Issue:6	Evodiamine-Inspired Topoisomerase-Histone Deacetylase Dual Inhibitors: Novel Orally Active Antitumor Agents for Leukemia Therapy.
AID1129011	Inhibition of human HDAC-9 using RHKK(Ac) as substrate by fluorescence assay	2014	Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6	Synthesis and evaluation of new Hsp90 inhibitors based on a 1,4,5-trisubstituted 1,2,3-triazole scaffold.
AID1205633	Induction of myc-tagged RUNX3 acetylation in human HEK293 cells assessed as acetylated RUNX3 level at 1 uM after 24 hrs by immunoprecipitation analysis relative to TSA	2015	Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8	Discovery of Orally Available Runt-Related Transcription Factor 3 (RUNX3) Modulators for Anticancer Chemotherapy by Epigenetic Activation and Protein Stabilization.
AID1537567	Cell cycle arrest in human G55T2 cells assessed as accumulation in S phase at 3 uM incubated for 72 hrs by propidium iodide based flow cytometry (Rvb = 14.7 %)	2019	MedChemComm, Jul-01, Volume: 10, Issue:7	Design, synthesis and biological evaluation of β-peptoid-capped HDAC inhibitors with anti-neuroblastoma and anti-glioblastoma activity.
AID1876339	Cytotoxicity against human MRC9 cells assessed as cell viability incubated for 72 hrs by Cell titer- blue assay	2021	Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12	Development of HDAC Inhibitors Exhibiting Therapeutic Potential in T-Cell Prolymphocytic Leukemia.
AID1898497	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	2021	Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11	Discovery of STAT3 and Histone Deacetylase (HDAC) Dual-Pathway Inhibitors for the Treatment of Solid Cancer.
AID1515881	Induction of apoptosis in human HCT116 cells assessed as live cells at 500 nM after 48 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 89.6%)	2019	Journal of medicinal chemistry, 08-08, Volume: 62, Issue:15	Design, Synthesis, and Biological Evaluation of 4-Methyl Quinazoline Derivatives as Anticancer Agents Simultaneously Targeting Phosphoinositide 3-Kinases and Histone Deacetylases.
AID343687	Inhibition of recombinant HDAC1 expressed in HEK293 cells	2008	Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13	Trithiocarbonates as a novel class of HDAC inhibitors: SAR studies, isoenzyme selectivity, and pharmacological profiles.
AID1599774	Inhibition of HDAC6 in human A549 cells assessed as increase in alpha tubulin acetylation at 2.5 uM measured after 6 to 20 hrs by Western blot analysis	2019	ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6	Extending Cross Metathesis To Identify Selective HDAC Inhibitors: Synthesis, Biological Activities, and Modeling.
AID1535345	Growth inhibition of human RPMI8226 cells after 72 hrs by MTT assay	2019	Bioorganic & medicinal chemistry letters, 02-01, Volume: 29, Issue:3	Design, synthesis, and bioactivity evaluation of novel Bcl-2/HDAC dual-target inhibitors for the treatment of multiple myeloma.
AID1127323	Inhibition of human HDAC1 using fluorogenic tetrapeptide RHKKAc as substrate	2014	European journal of medicinal chemistry, May-22, Volume: 79	Influence of the adamantyl moiety on the activity of biphenylacrylohydroxamic acid-based HDAC inhibitors.
AID420502	Inhibition of HDAC2 in human HeLa cells	2009	European journal of medicinal chemistry, May, Volume: 44, Issue:5	Design, synthesis, and evaluation of biphenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors.
AID1614195	Induction of apoptosis in human MV4-11 cells assessed as late apoptotic cells at 1 uM after 48 hrs in presence of 0.3 uM RAPA by Annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 5.03%)
AID1164786	Inhibition of HDAC11 (unknown origin) using fluorogenic tetrapeptide RHKK(Ac) substrate by fluorescence assay	2014	Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20	ST7612AA1, a thioacetate-ω(γ-lactam carboxamide) derivative selected from a novel generation of oral HDAC inhibitors.
AID1812439	Inhibition of human HDAC using human HeLa cell nuclear extract measured after 60 mins by fluorescence assay	2021	Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14	Procainamide-SAHA Fused Inhibitors of hHDAC6 Tackle Multidrug-Resistant Malaria Parasites.
AID84275	Antiproliferative activity against human HT1080 fibrosarcoma cell line	2003	Bioorganic & medicinal chemistry letters, Nov-03, Volume: 13, Issue:21	A novel series of histone deacetylase inhibitors incorporating hetero aromatic ring systems as connection units.
AID481547	Cytotoxicity against human NCI-H460 cells assessed as growth inhibition at 1 ug/ml after 24 hrs by MTT assay	2010	Bioorganic & medicinal chemistry letters, May-15, Volume: 20, Issue:10	Synthesis and anticancer evaluation of alpha-lipoic acid derivatives.
AID1742185	Inhibition of recombinant human C-terminal His-tagged HDAC10 expressed in baculovirus infected Sf9 insect cells using Ac-Arg-His-Lys(Ac)-Lys(Ac)-AMC as substrate measured after 30 mins by fluorescence assay	2020	European journal of medicinal chemistry, Nov-01, Volume: 205	Design, synthesis and biological evaluation of novel HDAC inhibitors with improved pharmacokinetic profile in breast cancer.
AID449261	Antiproliferative activity against human HCT116 cells after 2 days by MTT assay	2009	European journal of medicinal chemistry, Nov, Volume: 44, Issue:11	Design, synthesis and preliminary biological evaluation of N-hydroxy-4-(3-phenylpropanamido)benzamide (HPPB) derivatives as novel histone deacetylase inhibitors.
AID765384	Inhibition of recombinant human HDAC10 enzyme using tetrapeptide Ac-ArgThr-Lys(Ac)Lys(Ac)-AMC as substrate after 15 to 30 mins	2013	Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16	Total synthesis and full histone deacetylase inhibitory profiling of Azumamides A-E as well as β²- epi-Azumamide E and β³-epi-Azumamide E.
AID1250656	Antiproliferative activity against human HLF cells after 72 hrs by CCK8 assay	2015	Journal of medicinal chemistry, Oct-08, Volume: 58, Issue:19	Discovery of Novel Class I Histone Deacetylase Inhibitors with Promising in Vitro and in Vivo Antitumor Activities.
AID1164180	Induction of apoptosis in human U937 cells using annexin-V/PI staining after 48 hrs by flow cytometry	2014	ACS medicinal chemistry letters, Sep-11, Volume: 5, Issue:9	Novel antiproliferative chimeric compounds with marked histone deacetylase inhibitory activity.
AID1431820	Selectivity ratio of IC50 for human KDAC8 to IC50 for human KDAC6	2017	European journal of medicinal chemistry, Feb-15, Volume: 127	Design and synthesis of benzodiazepine analogs as isoform-selective human lysine deacetylase inhibitors.
AID1897372	Inhibition of FGFR4 (unknown origin)
AID382344	Viability of human DU145 cells after 72 hrs by MTS assay	2008	Bioorganic & medicinal chemistry, May-01, Volume: 16, Issue:9	Synthesis and structure-activity relationship of histone deacetylase (HDAC) inhibitors with triazole-linked cap group.
AID274074	Oral bioavailability after oral dosing at 5 mg kg-1	2007	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2	Identification and optimisation of a series of substituted 5-(1H-pyrazol-3-yl)-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.
AID1390017	Antiproliferative activity against human HepG2 cells after 96 hrs by MTT assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Design, synthesis and biological evaluation of novel hydroxamic acid based histone deacetylase 6 selective inhibitors bearing phenylpyrazol scaffold as surface recognition motif.
AID1441640	Anti-inflammatory activity in LPS-induced C57BL/6 mouse model of acute lung injury assessed as reduction in pathological changes at 10 to 50 mg/kg, ip pretreated for 1 hr followed LPS challenge measured after 24 hrs by hematoxylin and eosin staining based	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
AID725667	Inhibition of C-terminal His-tagged human recombinant HDAC9 (amino acids 604- 1066) expressed in baculovirus expression system using fluorogenic acetylated peptide as substrate preincubated with enzyme for 10 mins prior to substrate addition measured afte	2013	ACS medicinal chemistry letters, Jan-10, Volume: 4, Issue:1	Biological evaluation of new largazole analogues: alteration of macrocyclic scaffold with click chemistry.
AID652765	Induction of CFTR deltaF508 mutant mRNA expression in cystic fibrosis patient lung cells relative to control	2011	ACS medicinal chemistry letters, Jul-21, Volume: 2, Issue:9	Potential Agents for Treating Cystic Fibrosis: Cyclic Tetrapeptides that Restore Trafficking and Activity of ΔF508-CFTR.
AID1727730	Inhibition of HDAC6 (unknown origin) by fluorescence based assay	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	Discovery of selective HDAC/BRD4 dual inhibitors as epigenetic probes.
AID1873392	Antiproliferative activity against human MV4-11 cells	2022	Bioorganic & medicinal chemistry letters, 08-15, Volume: 70	Comparison of three zinc binding groups for HDAC inhibitors - A potency, selectivity and enzymatic kinetics study.
AID1518784	Antiproliferative activity against human KMS-12-BM cells incubated for 48 hrs by CellTiter-Glo luminescent cell viability assay	2019	European journal of medicinal chemistry, Dec-15, Volume: 184	Discovery of a potent histone deacetylase (HDAC) 3/6 selective dual inhibitor.
AID1655790	Inhibition of human recombinant HDAC4 using AMC-K(TFA)GL as substrate by fluorescence based assay	2020	ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5	Design of First-in-Class Dual EZH2/HDAC Inhibitor: Biochemical Activity and Biological Evaluation in Cancer Cells.
AID328832	Toxicity in ip dosed BALB/c mouse assessed as maximum tolerated dose	2008	Journal of medicinal chemistry, Apr-24, Volume: 51, Issue:8	A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo.
AID1518785	Antiproliferative activity against human NCI-H929 cells incubated for 48 hrs by CellTiter-Glo luminescent cell viability assay	2019	European journal of medicinal chemistry, Dec-15, Volume: 184	Discovery of a potent histone deacetylase (HDAC) 3/6 selective dual inhibitor.
AID1848322	Induction of cell cycle arrest in human MV4-11 cells assessed as accumulation of cells at G2/M phase at 1 uM incubated for 48 hrs by AnnexinV/PI staining based flow cytometry (Rvb = 11.5%)	2022	Bioorganic & medicinal chemistry, Nov-15, Volume: 74	Design, synthesis and biological evaluation of novel pyrazinone derivatives as PI3K/HDAC dual inhibitors.
AID1897398	Induction of apoptosis in human SNU-16 cells assessed as late apoptotic cells at 0.1 uM incubated for 72 hrs by annexin-V/FITC propidium iodide staining based flow cytometry analysis (Rvb = 3.41%)
AID1274881	Inhibition of HDAC11 (unknown origin)	2016	European journal of medicinal chemistry, Jan-27, Volume: 108	Orally available stilbene derivatives as potent HDAC inhibitors with antiproliferative activities and antitumor effects in human tumor xenografts.
AID329915	Inhibition of human HDAC4 in U937 cells by immunoprecipitation assay	2008	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8	Novel uracil-based 2-aminoanilide and 2-aminoanilide-like derivatives: histone deacetylase inhibition and in-cell activities.
AID1821267	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	2022	European journal of medicinal chemistry, Feb-05, Volume: 229	Discovery of phthalazino[1,2-b]-quinazolinone derivatives as multi-target HDAC inhibitors for the treatment of hepatocellular carcinoma via activating the p53 signal pathway.
AID747266	Growth inhibition of human HeLa cells by MTT assay	2013	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 23, Issue:11	Design, synthesis, and biological evaluation of novel histone deacetylase 1 inhibitors through click chemistry.
AID1384229	Inhibition of class-1 HDAC in human SH-SY5Y cells assessed as induction of AcH3K9 level at 100 nM after 2 hrs by Western blot analysis relative to control	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease.
AID297497	Cytotoxicity against human K562 cells	2007	Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18	2-aroylindoles and 2-aroylbenzofurans with N-hydroxyacrylamide substructures as a novel series of rationally designed histone deacetylase inhibitors.
AID1752940	Antiplasmodial activity against drug-sensitive asexual intraerythrocytic stage of Plasmodium falciparum 3D7 infected in human O+ erythrocytes assessed as inhibition of parasite growth incubated for 48 hrs followed by addition of [3H]hypoxanthine for 24 hr
AID1633422	Inhibition of HDAC6 in human SH-SY5Y cells assessed as increase in acetylation of alpha-tubulin at 5 uM incubated for 30 hrs by Western blot analysis	2019	ACS medicinal chemistry letters, Apr-11, Volume: 10, Issue:4	Discovery of the First-in-Class GSK-3β/HDAC Dual Inhibitor as Disease-Modifying Agent To Combat Alzheimer's Disease.
AID1227032	Inhibition of human recombinant HDAC6 using MAZ1600 as fluorogenic substrate measured every 5 mins by optimized homogenous fluorescence based assay	2015	Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11	Dual-Mode HDAC Prodrug for Covalent Modification and Subsequent Inhibitor Release.
AID1915563	Inhibition of human HDAC2 incubated for 30 mins by SpectraMax M2 microplate reader analysis	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors.
AID603543	Inhibition of HDAC6 in human HeLa cell nuclear extract after 30 mins by fluorescence microplate reader	2011	Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8	Development of tetrahydroisoquinoline-based hydroxamic acid derivatives: potent histone deacetylase inhibitors with marked in vitro and in vivo antitumor activities.
AID90671	Inhibitory activity afgainst maize Histone deacetylase 1-A	2003	Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23	Discovery of (aryloxopropenyl)pyrrolyl hydroxyamides as selective inhibitors of class IIa histone deacetylase homologue HD1-A.
AID1545817	Antiproliferative activity against human MCF7 cells by MTT assay	2019	European journal of medicinal chemistry, Dec-01, Volume: 183	1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships.
AID1633437	Immunomodulatory activity in LPS treated Wistar rat primary microglial cells assessed as decrease in NOS2 expression level at 5 to 50 uM incubated for 24 hrs by western blot analysis	2019	ACS medicinal chemistry letters, Apr-11, Volume: 10, Issue:4	Discovery of the First-in-Class GSK-3β/HDAC Dual Inhibitor as Disease-Modifying Agent To Combat Alzheimer's Disease.
AID1754777	Induction of apoptosis in human MCF7 cells assessed as reduction in Bcl3 gene expression at 3 uM incubated for 24 hrs by whole transcriptome analysis	2021	Bioorganic & medicinal chemistry, 07-15, Volume: 42	Discovery of novel class of histone deacetylase inhibitors as potential anticancer agents.
AID1742668	Cytotoxicity against human HEK293T cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Design and synthesis of novel Flavone-based histone deacetylase inhibitors antagonizing activation of STAT3 in breast cancer.
AID732873	Inhibition of HDAC2a in human MDA-MB-231 cell lysate using Boc-Lys(trifluroacetyl)-AMC as substrate at 10 uM preincubated with enzyme for 5 mins prior to substrate addition measured after 30 mins by fluorescence assay	2013	ACS medicinal chemistry letters, Feb-14, Volume: 4, Issue:2	Development of
AID723118	Potentiation of 20 uM cisplatin-induced toxicity in 5 uM cisplatin resistant human A2780 cells at 1 uM pretreated for 48 hrs followed by 5 uM cisplatin treatment by MTT assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID417069	Activation of mouse Wnt3a signaling expressed in HEK293 STF cells assessed as increase in transcriptional activity after 24 hrs by luciferase reporter gene-based lactate dehydrogenase assay	2009	Bioorganic & medicinal chemistry, Mar-15, Volume: 17, Issue:6	Psammaplin A as a general activator of cell-based signaling assays via HDAC inhibition and studies on some bromotyrosine derivatives.
AID1518781	Inhibition of human HDAC1 using Arg-His-Lys-Lys (Ac) as substrate incubated for 2 hrs by fluorescence assay	2019	European journal of medicinal chemistry, Dec-15, Volume: 184	Discovery of a potent histone deacetylase (HDAC) 3/6 selective dual inhibitor.
AID1742667	Cytotoxicity against human PC-3 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Design and synthesis of novel Flavone-based histone deacetylase inhibitors antagonizing activation of STAT3 in breast cancer.
AID1623529	Inhibition of human recombinant HDAC7 using fluorogenic HDAC substrate class 2A by fluorescence assay	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	A novel class of anthraquinone-based HDAC6 inhibitors.
AID1742759	In vivo inhibition of HDAC in tumor of mouse 4T1 cells xenografted in BALB/c mouse assessed as increase in acetylated histone-H3 expression by immunohistochemistry method	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Design and synthesis of novel Flavone-based histone deacetylase inhibitors antagonizing activation of STAT3 in breast cancer.
AID1281852	Antiproliferative activity against human RPMI8226 cells after 72 hrs by CellTiter 96 aqueous non-radioactive cell proliferation assay	2016	European journal of medicinal chemistry, Apr-13, Volume: 112	Design, synthesis and biological evaluation of bisthiazole-based trifluoromethyl ketone derivatives as potent HDAC inhibitors with improved cellular efficacy.
AID1139707	Growth inhibition of human HeLa cells after 48 hrs by MTT assay	2014	Bioorganic & medicinal chemistry, May-01, Volume: 22, Issue:9	Search for novel histone deacetylase inhibitors. Part II: design and synthesis of novel isoferulic acid derivatives.
AID1231809	Inhibition of recombinant HDAC8 (unknown origin) incubated for 10 mins using Boc-Lys(acetyl)-AMC fluorogenic substrate by homogeneous fluorescence release assay	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Discovery, bioactivity and docking simulation of Vorinostat analogues containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors and antitumor agents.
AID723428	Potentiation of 0.75 uM cisplatin-induced toxicity in 0.5 uM cisplatin resistant human KYSE-510 cells at 1 uM pretreated for 48 hrs followed by 0.5 uM cisplatin treatment by MTT assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1819515	Antiproliferative activity against HEL cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	2022	Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4	Discovery of DNA-Targeting HDAC Inhibitors with Potent Antitumor Efficacy In Vivo That Trigger Antitumor Immunity.
AID1129793	Induction of apoptosis in human Jurkat cells assessed as caspase 3/7 activation at 10 uM after 6 hrs by luminescence assay (Rvb = 59,417 +/- 10002.74 no unit)	2014	Bioorganic & medicinal chemistry, Apr-01, Volume: 22, Issue:7	Studies on the antiproliferative effects of tropolone derivatives in Jurkat T-lymphocyte cells.
AID1449214	Inhibition of C-terminal FLAG/His-tagged recombinant human HDAC1 expressed in baculovirus infected Sf9 insect cells using Z-(Ac)Lys-AMC as substrate measured after 90 mins by fluorescence assay	2017	Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13	Design, Multicomponent Synthesis, and Anticancer Activity of a Focused Histone Deacetylase (HDAC) Inhibitor Library with Peptoid-Based Cap Groups.
AID1548245	Inhibition of HDAC1 (unknown origin) pre-incubated for 5 mins before fluorogenic substrate Boc-Lys (acetyl)-AMC or Boc-Lys (triflouroacetyl)-AMC addition and measured after 30 mins by fluorescence based assay
AID1578155	Antiproliferative activity against human NCI-H1975 cells assessed as cell growth inhibition after 48 hrs by sulforhodamine B assay	2020	European journal of medicinal chemistry, Jan-01, Volume: 185	N-alkyl-hydroxybenzoyl anilide hydroxamates as dual inhibitors of HDAC and HSP90, downregulating IFN-γ induced PD-L1 expression.
AID1547344	Inhibition of HDAC in human HCT116 cells assessed as activation of IL6-JAK-STAT signaling pathway by measuring increase in LIFR expression at 10 uM after 24 hrs by Western blot analysis	2020	Journal of medicinal chemistry, 04-09, Volume: 63, Issue:7	Discovery of Thieno[2,3-
AID1339586	Growth inhibition of human MOLM13 cells after 44 hrs by MTT assay	2017	ACS medicinal chemistry letters, Mar-09, Volume: 8, Issue:3	Structural Requirements of HDAC Inhibitors: SAHA Analogues Modified at the C2 Position Display HDAC6/8 Selectivity.
AID1754773	Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay	2021	Bioorganic & medicinal chemistry, 07-15, Volume: 42	Discovery of novel class of histone deacetylase inhibitors as potential anticancer agents.
AID723446	Potentiation of 0.5 uM cisplatin-induced toxicity in 0.5 uM cisplatin resistant human KYSE-510 cells at 1.5 uM pretreated for 48 hrs followed by 0.5 uM cisplatin treatment by MTT assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1348933	Upregulation of TIMP3 gene expression in human A549 cells at IC50 after 12 hrs by RT-PCR method	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Discovery of aliphatic-chain hydroxamates containing indole derivatives with potent class I histone deacetylase inhibitory activities.
AID1355715	Synergistic antifungal activity against FLC resistant Candida albicans 100 assessed as FIC index after 48 hrs by checkerboard microdilution method	2018	Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14	Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections.
AID717806	Inhibition of HDAC1 using Fluor-de-Lys as substrate assessed as remaining activity at 125 nM pretreated for 30 mins before substrate addition by fluorescence assay	2012	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23	The structural requirements of histone deacetylase inhibitors: suberoylanilide hydroxamic acid analogs modified at the C6 position.
AID1296349	Inhibition of recombinant human HDAC6 using Cbz-(Ac)Lys-AMC as substrate preincubated for 90 mins followed by trypsin addition measured after 20 mins by fluorescence assay	2016	Journal of medicinal chemistry, Mar-24, Volume: 59, Issue:6	Structure-Based Design and Synthesis of Novel Inhibitors Targeting HDAC8 from Schistosoma mansoni for the Treatment of Schistosomiasis.
AID1537561	Antiproliferative activity against human G55T2 cells assessed as reduction in cell viability incubated for 72 hrs by WST-8 assay	2019	MedChemComm, Jul-01, Volume: 10, Issue:7	Design, synthesis and biological evaluation of β-peptoid-capped HDAC inhibitors with anti-neuroblastoma and anti-glioblastoma activity.
AID759301	Cytotoxicity against human MCF7 cells expressing ERalpha and ERbeta assessed as growth inhibition after 72 hrs by MTT assay	2013	Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14	Histone deacetylase inhibitors equipped with estrogen receptor modulation activity.
AID670099	Antitumor activity against human A549 cells xenografted in nude mouse assessed as time to end point at 200 mg/kg, po administered QD till end point	2012	Journal of medicinal chemistry, Apr-26, Volume: 55, Issue:8	Synthesis and biological evaluation of 1-arylsulfonyl-5-(N-hydroxyacrylamide)indoles as potent histone deacetylase inhibitors with antitumor activity in vivo.
AID1200975	Intrinsic clearance in human liver microsomes at 1 uM preincubated for 10 mins followed by NADPH addition measured over 30 mins by LC-MS/MS analysis	2015	Journal of medicinal chemistry, Mar-26, Volume: 58, Issue:6	Design and synthesis of orally bioavailable aminopyrrolidinone histone deacetylase 6 inhibitors.
AID1888406	Synergistic antifungal activity against azole-resistant Candida albicans 0304103 assessed as fractional inhibitory concentration incubated for 48 hrs by CLSI based checkerboard microdilution assay	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	Heat shock protein 90 (Hsp90)/Histone deacetylase (HDAC) dual inhibitors for the treatment of azoles-resistant Candida albicans.
AID1348915	Inhibition of C-terminal FLAG/His-tagged full length recombinant human HDAC1 expressed in baculovirus infected Sf9 insect cells using KI 177 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by fluorescence assay	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Discovery of aliphatic-chain hydroxamates containing indole derivatives with potent class I histone deacetylase inhibitory activities.
AID1578917	Inhibition of PI3K/AKT/mTOR signaling in human Bel7402 cells assessed as reduction in AKT phosphorylation at 5 uM after 24 to 72 hrs by Western blot analysis	2019	Journal of natural products, 06-28, Volume: 82, Issue:6	Hydroxamic Acid Derivatives of β-Carboline/Hydroxycinnamic Acid Hybrids Inducing Apoptosis and Autophagy through the PI3K/Akt/mTOR Pathways.
AID302099	Antiproliferative activity against H661 cells after 48 hrs	2007	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 17, Issue:22	Antiproliferative activities of a library of hybrids between indanones and HDAC inhibitor SAHA and MS-275 analogues.
AID603536	Cytotoxicity against human ES2 cells after 48 hrs by MTT assay	2011	Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8	Development of tetrahydroisoquinoline-based hydroxamic acid derivatives: potent histone deacetylase inhibitors with marked in vitro and in vivo antitumor activities.
AID1126998	Induction of apoptosis in human U937 cells assessed as early apoptotic cells using annexin-V/propidium iodide staining at 1 uM after 24 hrs by flow cytometry analysis (Rvb = 1.57%)	2014	Journal of medicinal chemistry, Apr-24, Volume: 57, Issue:8	Discovery of the first N-hydroxycinnamamide-based histone deacetylase 1/3 dual inhibitors with potent oral antitumor activity.
AID1563943	Inhibition of recombinant HDAC6 (unknown origin) measured after 30 mins by fluorescence assay	2019	European journal of medicinal chemistry, Oct-15, Volume: 180	Design, synthesis, and biological evaluation of a new class of histone acetyltransferase p300 inhibitors.
AID1864240	Inhibition of HDAC in human MDA-MB-231 cells incubated for 45 mins by luminescence assay	2022	Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18	Discovery of a Novel G-Quadruplex and Histone Deacetylase (HDAC) Dual-Targeting Agent for the Treatment of Triple-Negative Breast Cancer.
AID1422513	Inhibition of HDAC in MEF assessed as increase in histone H3K9 acetylation at 2 uM after 6 hrs by Western blot analysis	2018	European journal of medicinal chemistry, Nov-05, Volume: 159	In search of constrained FTY720 and phytosphingosine analogs as dual acting anticancer agents targeting metabolic and epigenetic pathways.
AID1170746	Inhibition of human recombinant HDAC11 using [Ac-Leu-Gly-Lys(Ac)-AMC substrate incubated for 15 to 30 mins	2014	Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22	Methyl effect in azumamides provides insight into histone deacetylase inhibition by macrocycles.
AID1282254	Cytotoxicity against human Ramos cells after 72 hrs by MTT assay	2016	Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4	Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
AID1548729	Inhibition of recombinant HDAC6 (unknown origin) using Boc-Lys(acetyl)-AMC as substrate preincubated for 1 hr followed by substrate addition and measured after 2 hrs by fluorescence based micro plate reader analysis	2020	Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10	Design of Hydrazide-Bearing HDACIs Based on Panobinostat and Their p53 and FLT3-ITD Dependency in Antileukemia Activity.
AID1697202	Inhibition of HDAC6 (unknown origin)	2020	Bioorganic & medicinal chemistry letters, 11-15, Volume: 30, Issue:22	Design, synthesis and evaluation of novel indirubin-based N-hydroxybenzamides, N-hydroxypropenamides and N-hydroxyheptanamides as histone deacetylase inhibitors and antitumor agents.
AID289928	Antiproliferative activity against human H661 cells after 48 hrs	2007	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 17, Issue:4	Synthesis and biological evaluation of the suberoylanilide hydroxamic acid (SAHA) beta-glucuronide and beta-galactoside for application in selective prodrug chemotherapy.
AID343688	Inhibition of recombinant HDAC6 expressed in HEK293 cells	2008	Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13	Trithiocarbonates as a novel class of HDAC inhibitors: SAR studies, isoenzyme selectivity, and pharmacological profiles.
AID300836	Growth inhibition of human MDA-MB-231 cells after 21 hrs by MTT assay	2007	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17	Pomiferin, histone deacetylase inhibitor isolated from the fruits of Maclura pomifera.
AID1511133	Inhibition of HDAC6 (unknown origin) using Ac-LeuGlyLys(Ac)-AMC as substrate preincubated for 5 mins followed by substrate addition and measured after 60 mins by fluorescence based assay	2019	ACS medicinal chemistry letters, Aug-08, Volume: 10, Issue:8	Design, Synthesis, and Biological Evaluation of 2,4-Imidazolinedione Derivatives as HDAC6 Isoform-Selective Inhibitors.
AID1821273	Inhibition of HDAC6 (unknown origin) incubated for 30 mins by microplate reader assay	2022	European journal of medicinal chemistry, Feb-05, Volume: 229	Discovery of phthalazino[1,2-b]-quinazolinone derivatives as multi-target HDAC inhibitors for the treatment of hepatocellular carcinoma via activating the p53 signal pathway.
AID1622960	Inhibition of HDAC1 (unknown origin) using (FAM)-labeled acetylated peptide as substrate measured after 17 hrs by fluorescence assay	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.
AID1731760	Metabolic stability in Sprague-Dawley rat liver microsomes assessed as half life at 5 uM preincubated for 5 mins followed by NADPH addition and measured after 60 mins by LCMS analysis	2021	Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4	HDAC7 Inhibition by Phenacetyl and Phenylbenzoyl Hydroxamates.
AID1401476	Selectivity ratio of IC50 for HDAC3 in human HeLa-S3 cell lysates to IC50 for HDAC6 in human HeLa-S3 cell lysates	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
AID1599730	Cytotoxicity against human ADCA72 cells assessed as decrease in cell viability measured after 72 hrs by CellTiter-Glo Luminescent assay	2019	ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6	Extending Cross Metathesis To Identify Selective HDAC Inhibitors: Synthesis, Biological Activities, and Modeling.
AID1865267	Inhibition of recombinant his-tagged human HDAC6 using Ac-LeuGlyLys (Ac) AMC substrate preincubated for 5 mins followed by substrate addition and measured after 30 mins by fluorescence based microplate reader analysis	2022	Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18	Discovery of Novel Src Homology-2 Domain-Containing Phosphatase 2 and Histone Deacetylase Dual Inhibitors with Potent Antitumor Efficacy and Enhanced Antitumor Immunity.
AID1326516	Inhibition of HDAC in human HCT116 cells assessed as increase in amount of acetylated alpha-tubulin after 48 hrs by Western blot analysis	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	2-(Phenylsulfonyl)quinoline N-hydroxyacrylamides as potent anticancer agents inhibiting histone deacetylase.
AID747268	Inhibition of human recombinant HDAC7 incubated for 10 mins prior to substrate addition measured after 60 mins by spectrophotometric analysis	2013	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 23, Issue:11	Design, synthesis, and biological evaluation of novel histone deacetylase 1 inhibitors through click chemistry.
AID1409640	Inhibition of HDAC in human HeLa cells using Boc-K(Ac)-AMC as substrate by fluorescence assay	2018	ACS medicinal chemistry letters, Mar-08, Volume: 9, Issue:3	Histone Deacetylase Inhibitors as Treatment for Targeting Multiple Components in Cancer Therapy.
AID1785346	Inhibition of full length human CDK6 (1 to 326 end residues)/N-terminal GST-fusion tagged CyclinD3 (1 to 292 residues) expressed in baculovirus expression system preincubated for 10 mins followed by substrate and ATP addition by mobility shift assay
AID1250655	Antiproliferative activity against human U937 cells after 72 hrs by CCK8 assay	2015	Journal of medicinal chemistry, Oct-08, Volume: 58, Issue:19	Discovery of Novel Class I Histone Deacetylase Inhibitors with Promising in Vitro and in Vivo Antitumor Activities.
AID1266810	Antiproliferative activity against human HCT116 cells assessed as cell viability after 48 hrs by MTT assay	2015	Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23	Novel β-Carboline/Hydroxamic Acid Hybrids Targeting Both Histone Deacetylase and DNA Display High Anticancer Activity via Regulation of the p53 Signaling Pathway.
AID1591856	Inhibition of wild-type human N-terminal GST-tagged CDK2/cycA2 expressed in Sf21 insect cells using FAM-labelled substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins by fluorescence assay	2019	Bioorganic & medicinal chemistry letters, 08-15, Volume: 29, Issue:16	Discovery of novel 9H-purin derivatives as dual inhibitors of HDAC1 and CDK2.
AID1869146	Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by CCK8 assay
AID674000	Growth inhibition of human HeLa cells after 72 hrs by XTT assay	2012	ACS medicinal chemistry letters, Jun-14, Volume: 3, Issue:6	Discovery of HDAC Inhibitors That Lack an Active Site Zn(2+)-Binding Functional Group.
AID1451832	Inhibition of GST tagged human recombinant HDAC4 (H86 to 31G) expressed in Baculovirus infected Sf9 insect cells using Ac-Leu-Gly-Lys(Tfa)-AMC as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by fluorescence assay	2017	Journal of medicinal chemistry, 10-12, Volume: 60, Issue:19	Small Molecule Inhibitors Simultaneously Targeting Cancer Metabolism and Epigenetics: Discovery of Novel Nicotinamide Phosphoribosyltransferase (NAMPT) and Histone Deacetylase (HDAC) Dual Inhibitors.
AID1576466	Induction of apoptosis in human A549 cells assessed as late apoptotic cells at 5 uM after 72 hrs by Annexin V-phycoerythrin/7-AAD staining based flow cytometric analysis (Rvb = 1.84%)
AID274015	Inhibition of HDAC activity measured by HDAC Fluorescent Activity Assay (mean of two experiments)	2007	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2	Identification and optimisation of a series of substituted 5-pyridin-2-yl-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.
AID1401534	Antiproliferative activity against human HT-29 cells after 72 hrs by SRB assay	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors.
AID499800	Inhibition of HDAC8	2010	Journal of medicinal chemistry, Aug-26, Volume: 53, Issue:16	Non-peptide macrocyclic histone deacetylase inhibitors derived from tricyclic ketolide skeleton.
AID1462217	Antiproliferative activity against human MV4-11 cells after 72 hrs by MTT assay	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Structure-based design, synthesis and in vitro antiproliferative effects studies of novel dual BRD4/HDAC inhibitors.
AID1887682	Cytotoxicity against human SGC-7901 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	Design, synthesis and biological evaluation of novel o-aminobenzamide derivatives as potential anti-gastric cancer agents in vitro and in vivo.
AID329920	Induction of granulocytic differentiation in human U937 cells	2008	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8	Novel uracil-based 2-aminoanilide and 2-aminoanilide-like derivatives: histone deacetylase inhibition and in-cell activities.
AID546547	Inhibition of human recombinant HDAC1 expressed in HEK293 cells	2010	Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24	Novel chimeric histone deacetylase inhibitors: a series of lapatinib hybrides as potent inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and histone deacetylase activity.
AID90685	Inhibition of Histone deacetylase 2 (HDAC2) activity of HeLa nuclear extracts	2004	Bioorganic & medicinal chemistry letters, Jan-19, Volume: 14, Issue:2	Design, synthesis, and activity of HDAC inhibitors with a N-formyl hydroxylamine head group.
AID1449324	Inhibition of HDAC in human A2780CisR cells using Boc-Lys(epsilon-Ac)-AMC as substrate preincubated for 18 hrs followed by substrate addition measured after 3 hrs by fluorescence assay	2017	Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13	Alkoxyurea-Based Histone Deacetylase Inhibitors Increase Cisplatin Potency in Chemoresistant Cancer Cell Lines.
AID1890328	Induction of apoptosis in mouse CT26 cells assessed as apoptotic cells at 6 uM measured by Annexin V-FITC/PI staining based flow cytometry method	2022	European journal of medicinal chemistry, Apr-05, Volume: 233	Novel biphenyl-based scaffold as potent and selective histone deacetylase 6 (HDAC6) inhibitors: Identification, development and pharmacological evaluation.
AID373073	Inhibition of HDAC from human HeLa cells	2009	European journal of medicinal chemistry, Mar, Volume: 44, Issue:3	Novel amide derivatives as inhibitors of histone deacetylase: design, synthesis and SAR.
AID465152	Inhibition of HDAC8 assessed as blockade of decorboxylation of carboxyfluorescein labeled acetylated peptide substrate after 17 hrs	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Synthesis and biological evaluation of triazol-4-ylphenyl-bearing histone deacetylase inhibitors as anticancer agents.
AID1482118	Cytotoxicity against human COLO205 cells assessed as growth inhibition after 48 hrs by MTT assay	2017	Journal of medicinal chemistry, 04-27, Volume: 60, Issue:8	Exploring Derivatives of Quinazoline Alkaloid l-Vasicine as Cap Groups in the Design and Biological Mechanistic Evaluation of Novel Antitumor Histone Deacetylase Inhibitors.
AID1129800	Induction of apoptosis in human Jurkat cells assessed as caspase 8 responsive cells level at 10 uM after 24 hrs by FACS flow cytometric analysis (Rvb = 0.32%)	2014	Bioorganic & medicinal chemistry, Apr-01, Volume: 22, Issue:7	Studies on the antiproliferative effects of tropolone derivatives in Jurkat T-lymphocyte cells.
AID1162486	Growth inhibition of human PC3 cells after 72 hrs by CellTiter Glo assay	2014	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 24, Issue:19	Design, synthesis and evaluation of novel HDAC inhibitors as potential antitumor agents.
AID1566037	Inhibition of recombinant full length C-terminal FLAG/His-tagged human HDAC1 expressed in baculovirus infected Sf9 cells using Ac-peptide-AMC as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence b	2019	European journal of medicinal chemistry, Nov-15, Volume: 182	A fluorine scan on the Zn
AID316931	Inhibition of HDAC3	2008	Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6	Histone deacetylase inhibitors: from bench to clinic.
AID1441670	Anti-inflammatory activity in BLM-induced C57BL/6 mouse model of acute lung neutrophilic inflammation assessed as reduction in macrophage number in BALF at 25 and 50 mg/kg, ip qd for 7 days post BLM challenge measured on day 7	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
AID496806	Inhibition of human HDAC6	2010	Nature chemical biology, Mar, Volume: 6, Issue:3	Chemical phylogenetics of histone deacetylases.
AID723126	Potentiation of 45 uM cisplatin-induced toxicity in 1 uM cisplatin resistant human CAL27 cells at 1 uM pretreated for 48 hrs followed by 1 uM cisplatin treatment by MTT assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1164184	Inhibition of human recombinant HDAC6 using Z-MAL as substrate at 5 uM after 1 hr by fluorescent activity assay	2014	ACS medicinal chemistry letters, Sep-11, Volume: 5, Issue:9	Novel antiproliferative chimeric compounds with marked histone deacetylase inhibitory activity.
AID1380946	Antiproliferative activity against human HT1080 cells after 72 hrs by MTT assay	2018	Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12	Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously.
AID1164038	Antiproliferative activity against human A549 cells assessed as growth inhibition after 72 hrs by CCK-8 assay	2014	European journal of medicinal chemistry, Oct-30, Volume: 86	Design, synthesis, and biological evaluation of 1, 3-disubstituted-pyrazole derivatives as new class I and IIb histone deacetylase inhibitors.
AID1225986	Induction of apoptosis in human HCT116 cells assessed as late apoptotic cells at 5 uM after 24 hrs by annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 1.05%)	2015	ACS medicinal chemistry letters, Mar-12, Volume: 6, Issue:3	Discovery of Novel Multiacting Topoisomerase I/II and Histone Deacetylase Inhibitors.
AID316896	Inhibition of human HDAC1	2008	Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6	Histone deacetylase inhibitors: from bench to clinic.
AID1898925	Antiproliferative activity against human NCI-H460 cells at 7.4 uM assessed as reduction in PIN1 level and measured by Western blot analysis	2022	European journal of medicinal chemistry, Jan-15, Volume: 228	Antitumor activity of novel POLA1-HDAC11 dual inhibitors.
AID1339584	Growth inhibition of human Jurkat cells at 1 to 10 uM after 44 hrs by MTT assay	2017	ACS medicinal chemistry letters, Mar-09, Volume: 8, Issue:3	Structural Requirements of HDAC Inhibitors: SAHA Analogues Modified at the C2 Position Display HDAC6/8 Selectivity.
AID310181	Growth inhibition of human PC3 cells by SRB assay	2007	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 17, Issue:22	Modification of cap group in delta-lactam-based histone deacetylase (HDAC) inhibitors.
AID1502979	Antiproliferative activity against human SW620 cells incubated for 72 hrs by MTT assay	2017	European journal of medicinal chemistry, Nov-10, Volume: 140	Design and synthesis of tranylcypromine derivatives as novel LSD1/HDACs dual inhibitors for cancer treatment.
AID316908	Inhibition of human St4 cells	2008	Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6	Histone deacetylase inhibitors: from bench to clinic.
AID344919	Inhibition of 2-oxoglutarate-dependent human JMJD2E in presence of 50 uM Fe by FDH coupled assay	2008	Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22	Inhibitor scaffolds for 2-oxoglutarate-dependent histone lysine demethylases.
AID482950	Inhibition of HDAC11	2010	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11	Acylurea connected straight chain hydroxamates as novel histone deacetylase inhibitors: Synthesis, SAR, and in vivo antitumor activity.
AID1177056	Antiprotozoan activity against Leishmania donovani MHOM- ET-67/L82 amastigotes at 1 uM	2015	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 25, Issue:3	Hydroxamic acid based histone deacetylase inhibitors with confirmed activity against the malaria parasite.
AID1614133	Inhibition of recombinant full length human HDAC4 expressed in baculovirus infected sf9 cells using Ac-peptide-AMC as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by fluorescence assay
AID663371	Growth inhibition of human DU145 cells after 72 hrs by MTS assay	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Discovery and extensive in vitro evaluations of NK-HDAC-1: a chiral histone deacetylase inhibitor as a promising lead.
AID1164784	Inhibition of HDAC8 (unknown origin) using fluorogenic tetrapeptide RHK(Ac)K(Ac) substrate by fluorescence assay	2014	Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20	ST7612AA1, a thioacetate-ω(γ-lactam carboxamide) derivative selected from a novel generation of oral HDAC inhibitors.
AID1901228	Half life in dog liver microsomes by LC-MS/MS analysis	2022	Bioorganic & medicinal chemistry, 02-15, Volume: 56	Synthesis and biological evaluation of aminobenzamides containing purine moiety as class I histone deacetylases inhibitors.
AID90681	Inhibition of mouse HDAC1	2004	Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6	3-(4-Aroyl-1-methyl-1H-pyrrol-2-yl)-N-hydroxy-2-propenamides as a new class of synthetic histone deacetylase inhibitors. 3. Discovery of novel lead compounds through structure-based drug design and docking studies.
AID1742662	Cytotoxicity against human Bel-7402 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Design and synthesis of novel Flavone-based histone deacetylase inhibitors antagonizing activation of STAT3 in breast cancer.
AID604039	Inhibition of histone acetyltransferase in human MCF7 cells assessed as increase of alpha-tubulin acetylation level at 5 uM after 15 mins by Western blotting	2011	Bioorganic & medicinal chemistry, Jun-15, Volume: 19, Issue:12	Modulation of the activity of histone acetyltransferases by long chain alkylidenemalonates (LoCAMs).
AID732146	Inhibition of HDAC1 (unknown origin) assessed as fluorescence intensity measured after 60 mins incubation at room temperature by trypsin-free microfluidic lab-on-a-chip assay	2013	Journal of medicinal chemistry, Feb-28, Volume: 56, Issue:4	Potent and selective inhibition of histone deacetylase 6 (HDAC6) does not require a surface-binding motif.
AID228859	Activity in histone hyperacetylation assay in cells	2004	Bioorganic & medicinal chemistry letters, Jan-19, Volume: 14, Issue:2	Design, synthesis, and activity of HDAC inhibitors with a N-formyl hydroxylamine head group.
AID1250657	Antiproliferative activity against human WI38 cells after 72 hrs by CCK8 assay	2015	Journal of medicinal chemistry, Oct-08, Volume: 58, Issue:19	Discovery of Novel Class I Histone Deacetylase Inhibitors with Promising in Vitro and in Vivo Antitumor Activities.
AID1464877	Anti-proliferative activity against human A549 cells after 48 hrs by MTT assay	2017	Bioorganic & medicinal chemistry letters, 11-01, Volume: 27, Issue:21	Design, synthesis and biological evaluation of novel histone deacetylase inhibitors incorporating 4-aminoquinazolinyl systems as capping groups.
AID1763817	Antiproliferative activity against African green monkey Vero cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	2021	Bioorganic & medicinal chemistry, 06-15, Volume: 40	Novel hybrid conjugates with dual estrogen receptor α degradation and histone deacetylase inhibitory activities for breast cancer therapy.
AID1819545	Antitumor immunity against mouse B16-F10 cells implanted in C57BL/6J mouse assessed as fold increase in proportion of macrophages in spleen by flow cytometry analysis relative to control	2022	Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4	Discovery of DNA-Targeting HDAC Inhibitors with Potent Antitumor Efficacy In Vivo That Trigger Antitumor Immunity.
AID605298	Inhibition of HDAC in human HeLa cells nuclear extract using fluor de Lys as substrate preincubated for 5 mins by fluorometric analysis	2010	Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24	Discovery of 2-(6-{[(6-fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a class I selective orally active histone deacetylase inhibitor.
AID1676591	Binding affinity to Nickel cation assessed as accounting ratio by measuring total compound detected/total compound adsorbed at 2.55 umol by immobilized metal-ion affinity chromatography	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
AID723445	Potentiation of 1 uM cisplatin-induced toxicity in 5 uM cisplatin resistant human A2780 cells at 0.25 uM pretreated for 48 hrs followed by 5 uM cisplatin treatment by MTT assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1403159	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	2018	European journal of medicinal chemistry, Jan-20, Volume: 144	Development of novel β-carboline-based hydroxamate derivatives as HDAC inhibitors with antiproliferative and antimetastatic activities in human cancer cells.
AID1296347	Inhibition of recombinant human HDAC8 using Fluor de Lys as substrate preincubated for 90 mins followed by BML-KI176 addition measured after 45 mins by fluorescence assay	2016	Journal of medicinal chemistry, Mar-24, Volume: 59, Issue:6	Structure-Based Design and Synthesis of Novel Inhibitors Targeting HDAC8 from Schistosoma mansoni for the Treatment of Schistosomiasis.
AID1482119	Cytotoxicity against human Caco2 cells assessed as growth inhibition after 48 hrs by MTT assay	2017	Journal of medicinal chemistry, 04-27, Volume: 60, Issue:8	Exploring Derivatives of Quinazoline Alkaloid l-Vasicine as Cap Groups in the Design and Biological Mechanistic Evaluation of Novel Antitumor Histone Deacetylase Inhibitors.
AID1225978	Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTT assay	2015	ACS medicinal chemistry letters, Mar-12, Volume: 6, Issue:3	Discovery of Novel Multiacting Topoisomerase I/II and Histone Deacetylase Inhibitors.
AID1260656	Binding affinity to human recombinant HDAC8 by fluorescence assay
AID1737149	Induction of apoptosis in human HCT-116 cells assessed as early apoptotic cells at 3 uM after 24 hrs by Annexin V-FITC/PI staining based flow cytometric analysis (Rvb = 4.01%)	2020	European journal of medicinal chemistry, Apr-15, Volume: 192	Design, synthesis and biological evaluation of novel indazole-based derivatives as potent HDAC inhibitors via fragment-based virtual screening.
AID1848320	Induction of cell cycle arrest in human MV4-11 cells assessed as accumulation of cells at G0/G1 phase at 1 uM incubated for 48 hrs by AnnexinV/PI staining based flow cytometry (Rvb = 33.1%)	2022	Bioorganic & medicinal chemistry, Nov-15, Volume: 74	Design, synthesis and biological evaluation of novel pyrazinone derivatives as PI3K/HDAC dual inhibitors.
AID1614230	Induction of apoptosis in human MM1S cells assessed as early apoptotic cells at 1 uM after 48 hrs in presence of 0.3 uM RAPA by Annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 0.38%)
AID1737134	Inhibition of recombinant human C-terminal His-tagged HDAC2 (1 to end residues) expressed in sf9 insect cells using Boc-Lys(Ac)-AMC as substrate incubated for 60 mins by fluorescence assay	2020	European journal of medicinal chemistry, Apr-15, Volume: 192	Design, synthesis and biological evaluation of novel indazole-based derivatives as potent HDAC inhibitors via fragment-based virtual screening.
AID353355	Inhibition of HDAC in human SHSY5Y cells at 10 uM by fluorimetric cellular activity assay	2009	Journal of medicinal chemistry, May-14, Volume: 52, Issue:9	Synthesis, biological evaluation, and molecular docking of Ugi products containing a zinc-chelating moiety as novel inhibitors of histone deacetylases.
AID1401536	Antiproliferative activity against human HepG2 cells after 72 hrs by SRB assay	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors.
AID1622935	Inhibition of human N-terminal GST-tagged HDAC7 (518 to end residues) expressed in baculovirus infected Sf9 insect cells using 7-AMC-labelled HDAC substrate measured after 30 mins by fluorescence assay	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.
AID1361626	Antiproliferative activity against human HCT116 cells after 72 hrs by CCK8 assay	2018	Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16	Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents.
AID1275645	Growth inhibition of human PC3 cells after 96 hrs by MTT assay	2016	European journal of medicinal chemistry, Feb-15, Volume: 109	Identification of N-(6-mercaptohexyl)-3-(4-pyridyl)-1H-pyrazole-5-carboxamide and its disulfide prodrug as potent histone deacetylase inhibitors with in vitro and in vivo anti-tumor efficacy.
AID373078	Inhibition of human recombinant HDAC5	2009	European journal of medicinal chemistry, Mar, Volume: 44, Issue:3	Novel amide derivatives as inhibitors of histone deacetylase: design, synthesis and SAR.
AID1174687	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay	2015	European journal of medicinal chemistry, Jan-07, Volume: 89	Development of 3-hydroxycinnamamide-based HDAC inhibitors with potent in vitro and in vivo anti-tumor activity.
AID1473738	Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID525018	Inhibition of HDAC in human CFBE41o- cell line assessed as increase in mutant Fdelta508 CFTR protein level at 5 uM after 4 hrs by immunoblot analysis	2010	Nature chemical biology, Jan, Volume: 6, Issue:1	Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.
AID1821323	Antitumor activity against human HepG2 cells xenografted in mouse assessed as upregulation of acetylated alpha tubulin level at 12 mg/kg, ip administered every 2 days for 4 weeks by western blot analysis	2022	European journal of medicinal chemistry, Feb-05, Volume: 229	Discovery of phthalazino[1,2-b]-quinazolinone derivatives as multi-target HDAC inhibitors for the treatment of hepatocellular carcinoma via activating the p53 signal pathway.
AID1164195	Inhibition of HDAC in human MCF7 cells assessed as hyperacetylation of p53 at Lys 382 residue at 5 uM after 24 hrs by Western blot analysis relative to control	2014	ACS medicinal chemistry letters, Sep-11, Volume: 5, Issue:9	Novel antiproliferative chimeric compounds with marked histone deacetylase inhibitory activity.
AID1348921	Inhibition of N-terminal GST-tagged human HDAC7 expressed in baculovirus infected Sf9 insect cells preincubated for 5 mins followed by substrate addition measured after 30 mins by fluorescence assay	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Discovery of aliphatic-chain hydroxamates containing indole derivatives with potent class I histone deacetylase inhibitory activities.
AID465149	Inhibition of HDAC1 assessed as blockade of decorboxylation of carboxyfluorescein labeled acetylated peptide substrate after 17 hrs	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Synthesis and biological evaluation of triazol-4-ylphenyl-bearing histone deacetylase inhibitors as anticancer agents.
AID1547345	Inhibition of HDAC in human HCT116 cells assessed as activation of IL6-JAK-STAT signaling pathway by measuring increase in JAK1 expression at 10 uM after 24 hrs by Western blot analysis	2020	Journal of medicinal chemistry, 04-09, Volume: 63, Issue:7	Discovery of Thieno[2,3-
AID1129013	Inhibition of human HDAC-11 using RHKK(Ac) as substrate by fluorescence assay	2014	Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6	Synthesis and evaluation of new Hsp90 inhibitors based on a 1,4,5-trisubstituted 1,2,3-triazole scaffold.
AID663404	Half life in artificial intestinal fluid	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Discovery and extensive in vitro evaluations of NK-HDAC-1: a chiral histone deacetylase inhibitor as a promising lead.
AID1441650	Anti-inflammatory activity in LPS-induced C57BL/6 mouse model of acute lung injury assessed as reduction in TNFalpha level pretreated intraperitoneally for 1 hr followed LPS challenge after 24 hrs by ELISA	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
AID1859933	Inhibition of HDAC in human HCT-116 cells assessed as increase in acetylation level of H3K9-14ac at 10 uM measured after 24 to 48 hrs by Western blot analysis	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Azetidin-2-one-based small molecules as dual hHDAC6/HDAC8 inhibitors: Investigation of their mechanism of action and impact of dual inhibition profile on cell viability.
AID1067347	Inhibition of HDAC1/2 in human HeLa cell extracts using acetylated histone peptide as substrate after 30 mins	2014	Bioorganic & medicinal chemistry, Mar-01, Volume: 22, Issue:5	Design, synthesis and preliminary bioactivity studies of 1,2-dihydrobenzo[d]isothiazol-3-one-1,1-dioxide hydroxamic acid derivatives as novel histone deacetylase inhibitors.
AID1864676	Inhibition of full length recombinant human HDAC6 in MV4-11 cells assessed as upregulation of acetylated histone H3 at 1 uM measured upto 24 hrs by western blot analysis
AID1578883	Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay	2019	Journal of natural products, 06-28, Volume: 82, Issue:6	Hydroxamic Acid Derivatives of β-Carboline/Hydroxycinnamic Acid Hybrids Inducing Apoptosis and Autophagy through the PI3K/Akt/mTOR Pathways.
AID488277	Inhibition of HDAC8	2010	Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11	On the inhibition of histone deacetylase 8.
AID1126976	Antiproliferative activity against human U937 cells after 48 hrs by MTT assay	2014	Journal of medicinal chemistry, Apr-24, Volume: 57, Issue:8	Discovery of the first N-hydroxycinnamamide-based histone deacetylase 1/3 dual inhibitors with potent oral antitumor activity.
AID1754772	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay	2021	Bioorganic & medicinal chemistry, 07-15, Volume: 42	Discovery of novel class of histone deacetylase inhibitors as potential anticancer agents.
AID1174681	Antiproliferative activity against human U266 cells after 48 hrs by MTT assay	2015	European journal of medicinal chemistry, Jan-07, Volume: 89	Development of 3-hydroxycinnamamide-based HDAC inhibitors with potent in vitro and in vivo anti-tumor activity.
AID1294804	Inhibition of His-tagged human HDAC11 expressed in Sf9 cells using Ac-Arg-Gly-Lys(Ac)-AMC as substrate at 0.5 uM by fluorometric assay	2016	Bioorganic & medicinal chemistry letters, 05-15, Volume: 26, Issue:10	A sub-milligram-synthesis protocol for in vitro screening of HDAC11 inhibitors.
AID604081	Inhibition of JMJD2E pre-incubated for 30 mins	2011	Bioorganic & medicinal chemistry, Jun-15, Volume: 19, Issue:12	Inhibitors of histone demethylases.
AID1415648	Inhibition of HDAC3 in human HepG2 cells assessed as increase in acetylated-histone H3 level at 5 uM after 48 hrs by Western blot analysis	2017	MedChemComm, Jun-01, Volume: 8, Issue:6	Development of novel β-carboline-based hydroxamate derivatives as HDAC inhibitors with DNA damage and apoptosis inducing abilities.
AID1542182	Inhibition of HDAC4 (unknown origin)	2019	Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7	Kinase and Histone Deacetylase Hybrid Inhibitors for Cancer Therapy.
AID1785352	Synergistic antiproliferative activity against human A549 cells assessed as combination index in presence of palbociclib by Chou-Talalay method
AID1865243	Antiproliferative activity against human SW1990 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	2022	Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18	Discovery of Novel Src Homology-2 Domain-Containing Phosphatase 2 and Histone Deacetylase Dual Inhibitors with Potent Antitumor Efficacy and Enhanced Antitumor Immunity.
AID544093	Antimalarial activity against drug-resistant Plasmodium falciparum TM90C2A	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Antimalarial activity of phenylthiazolyl-bearing hydroxamate-based histone deacetylase inhibitors.
AID652753	Inhibition of recombinant human HDAC9 using Fluor-de-Lys as substrate after 30 mins by spectrophotometry	2011	ACS medicinal chemistry letters, Jul-21, Volume: 2, Issue:9	Potential Agents for Treating Cystic Fibrosis: Cyclic Tetrapeptides that Restore Trafficking and Activity of ΔF508-CFTR.
AID1155322	Selectivity index, ratio of IC50 for erythrocytes (unknown origin) to IC50 for Plasmodium falciparum	2014	European journal of medicinal chemistry, Jul-23, Volume: 82	Discovery of HDAC inhibitors with potent activity against multiple malaria parasite life cycle stages.
AID1250647	Inhibition of recombinant human HDAC9 after 60 mins by fluorescence assay	2015	Journal of medicinal chemistry, Oct-08, Volume: 58, Issue:19	Discovery of Novel Class I Histone Deacetylase Inhibitors with Promising in Vitro and in Vivo Antitumor Activities.
AID1434362	Inhibition of HDAC in HEK293 cells assessed as ratio of acetylated-RUNX3 level to histone-3 acetylation level at 1 uM measured after 24 hrs by Western blot analysis relative to control	2017	European journal of medicinal chemistry, Jan-27, Volume: 126	Improving potency and metabolic stability by introducing an alkenyl linker to pyridine-based histone deacetylase inhibitors for orally available RUNX3 modulators.
AID1882466	Inhibition of HDAC3 (unknown origin)	2022	Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4	Chasing a Breath of Fresh Air in Cystic Fibrosis (CF): Therapeutic Potential of Selective HDAC6 Inhibitors to Tackle Multiple Pathways in CF Pathophysiology.
AID1336933	Inhibition of HDAC6 in human LNCAP cells assessed as acetylated tubulin accumulation in cytosol at 10 uM after 24 hrs by Western blot analysis	2017	Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3	Bifunctional conjugates with potent inhibitory activity towards cyclooxygenase and histone deacetylase.
AID663392	Growth inhibition of human TK10 cells after 72 hrs by MTS assay	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Discovery and extensive in vitro evaluations of NK-HDAC-1: a chiral histone deacetylase inhibitor as a promising lead.
AID525025	Inhibition of HDAC in human CFBE41o- cell line assessed as increase in CFTR mRNA at 0.1 uM by RT-PCR	2010	Nature chemical biology, Jan, Volume: 6, Issue:1	Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.
AID476834	Toxicity in FVB mouse assessed as effect on hematocrit at 50 mg/kg, po administered 5 times per week for 2 weeks	2010	Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8	Modified cap group suberoylanilide hydroxamic acid histone deacetylase inhibitor derivatives reveal improved selective antileukemic activity.
AID1739582	Inhibition of HDAC6 in human THP-1 cells assessed as ratio of acetylated H3/GAPDH at 10 uM incubated for 4 hrs by Western blot analysis relative to DMSO	2020	European journal of medicinal chemistry, Aug-15, Volume: 200	Design, synthesis, and biological evaluation of dual targeting inhibitors of histone deacetylase 6/8 and bromodomain BRPF1.
AID274036	Hepatocyte stability	2007	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2	Identification and optimisation of a series of substituted 5-pyridin-2-yl-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.
AID476642	Antiproliferative activity against human HT-29 cells after 48 hrs by cell titer-glo assay	2010	Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8	Modified cap group suberoylanilide hydroxamic acid histone deacetylase inhibitor derivatives reveal improved selective antileukemic activity.
AID1469334	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	2018	Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7	Discovery of N1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7 H-pyrrolo[2,3- d]pyrimidin-2-yl)amino)phenyl)- N8-hydroxyoctanediamide as a Novel Inhibitor Targeting Cyclin-dependent Kinase 4/9 (CDK4/9) and Histone Deacetlyase1 (HDAC1) against Malignant Cancer
AID622255	Inhibition of HDAC1 after 30 mins by Fluor de Lys fluorescence assay	2011	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 21, Issue:20	The structural requirements of histone deacetylase inhibitors: Suberoylanilide hydroxamic acid analogs modified at the C3 position display isoform selectivity.
AID1676597	Binding affinity to cupric ion assessed as performance ratio ratio by measuring product of accounting ratio and retention ratio at 2.55 umol by immobilized metal-ion affinity chromatography	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
AID1251317	Inhibition of HDAC6 (unknown origin)	2015	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 25, Issue:20	Investigation on the ZBG-functionality of phenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase inhibitors.
AID1566805	Inhibition of recombinant full length C-terminal His-tagged human HDAC8 expressed in baculovirus infected in Sf9 cells using Ac-peptide-AMC as substrate after 1 hr by fluorescence assay	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Discovery of 1,2,4-oxadiazole-Containing hydroxamic acid derivatives as histone deacetylase inhibitors potential application in cancer therapy.
AID1164185	Inhibition of human recombinant HDAC1 using modified Boc-Lys(Ac)-AMC MAL as substrate after 1 hr by fluorescent activity assay	2014	ACS medicinal chemistry letters, Sep-11, Volume: 5, Issue:9	Novel antiproliferative chimeric compounds with marked histone deacetylase inhibitory activity.
AID1887684	Cytotoxicity against human BGC-823 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	Design, synthesis and biological evaluation of novel o-aminobenzamide derivatives as potential anti-gastric cancer agents in vitro and in vivo.
AID329917	Induction of alpha tubulin hyperacetylation in human U937 cells	2008	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8	Novel uracil-based 2-aminoanilide and 2-aminoanilide-like derivatives: histone deacetylase inhibition and in-cell activities.
AID1578887	Inhibition of human HDAC3 using Boc-Lys (Ac)-AMC as substrate incubated for 60 mins by fluorimetric assay	2019	Journal of natural products, 06-28, Volume: 82, Issue:6	Hydroxamic Acid Derivatives of β-Carboline/Hydroxycinnamic Acid Hybrids Inducing Apoptosis and Autophagy through the PI3K/Akt/mTOR Pathways.
AID1751985	Antiproliferative activity against human A549 cells assessed as reduction in cell viability	2021	Bioorganic & medicinal chemistry letters, 10-01, Volume: 49	Discovery of novel pyrazolopyrimidine derivatives as potent mTOR/HDAC bi-functional inhibitors via pharmacophore-merging strategy.
AID445135	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	2009	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 19, Issue:22	Novel N-hydroxybenzamide-based HDAC inhibitors with branched CAP group.
AID1352479	Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Spirohydantoins and 1,2,4-triazole-3-carboxamide derivatives as inhibitors of histone deacetylase: Design, synthesis, and biological evaluation.
AID1832796	Cytotoxicity against human HL-60 cells assessed as cell viability at 5 uM by CellTiter-Glo luminescent assay	2021	Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19	4-Acyl Pyrrole Capped HDAC Inhibitors: A New Scaffold for Hybrid Inhibitors of BET Proteins and Histone Deacetylases as Antileukemia Drug Leads.
AID1890350	Selectivity ratio of IC50 for recombinant human HDAC1 over IC50 for recombinant human HDAC6	2022	European journal of medicinal chemistry, Apr-05, Volume: 233	Novel biphenyl-based scaffold as potent and selective histone deacetylase 6 (HDAC6) inhibitors: Identification, development and pharmacological evaluation.
AID672030	Selectivity ratio of IC50 for human HDAC2 preincubated with compound for 3 hrs to IC50 for human HDAC1 preincubated with compound for 3 hrs	2012	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 22, Issue:15	Design, synthesis, modeling, biological evaluation and photoaffinity labeling studies of novel series of photoreactive benzamide probes for histone deacetylase 2.
AID1633434	Induction of neurogenesis in human SH-SY5Y cells assessed as upregulation of MAP-2 mRNA at 1 uM incubated for 24 hrs by RT-PCR analysis	2019	ACS medicinal chemistry letters, Apr-11, Volume: 10, Issue:4	Discovery of the First-in-Class GSK-3β/HDAC Dual Inhibitor as Disease-Modifying Agent To Combat Alzheimer's Disease.
AID748983	Inhibition of HDAC1 (unknown origin)	2013	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 23, Issue:11	A cyclodextrin-capped histone deacetylase inhibitor.
AID1441703	Anti-inflammatory activity in LPS-induced C57BL/6 mouse model of acute lung injury assessed as intact alveolar structure at 10 to 50 mg/kg, ip pretreated for 1 hr followed LPS challenge measured after 24 hrs by hematoxylin and eosin staining based microsc	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
AID1742222	Tmax in Beagle dog at 20 mg/kg, po by LC-MS/MS analysis	2020	European journal of medicinal chemistry, Nov-01, Volume: 205	Design, synthesis and biological evaluation of novel HDAC inhibitors with improved pharmacokinetic profile in breast cancer.
AID1821338	Toxicity in mouse xenografted with human HepG2 cells assessed as cellular inflammation in heart at 12 mg/kg, ip administered every 2 days for 4 weeks by H and E staining based microscopic method	2022	European journal of medicinal chemistry, Feb-05, Volume: 229	Discovery of phthalazino[1,2-b]-quinazolinone derivatives as multi-target HDAC inhibitors for the treatment of hepatocellular carcinoma via activating the p53 signal pathway.
AID622254	Inhibition of human HDAC in HeLa cells after 30 mins by Fluor de Lys fluorescence assay	2011	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 21, Issue:20	The structural requirements of histone deacetylase inhibitors: Suberoylanilide hydroxamic acid analogs modified at the C3 position display isoform selectivity.
AID1355096	Antiproliferative activity against human MM1S cells after 72 hrs by MTS assay
AID1886184	Inhibition of HDAC2 in human HeLa cells using BOC-K(Ac)-AMC as substrate measured after 30 mins by fluorescence based microtiter plate reader assay	2022	Journal of medicinal chemistry, 08-25, Volume: 65, Issue:16	Discovery of a Novel Vascular Disrupting Agent Inhibiting Tubulin Polymerization and HDACs with Potent Antitumor Effects.
AID1742669	Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Design and synthesis of novel Flavone-based histone deacetylase inhibitors antagonizing activation of STAT3 in breast cancer.
AID274068	Oral bioavailability after oral dosing at 5 mg kg-1	2007	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2	Identification and optimisation of a series of substituted 5-(1H-pyrazol-3-yl)-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.
AID1421913	Inhibition of HDAC in synchronized trophozoite stage Plasmodium falciparum 3D7 infected in human erythrocytes assessed as increase in acetylated H4 level at 5 times IC50 after 3 hrs by Western blot analysis relative to control	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	One-pot, multi-component synthesis and structure-activity relationships of peptoid-based histone deacetylase (HDAC) inhibitors targeting malaria parasites.
AID1566822	Antiproliferative activity against human Raji cells after 72 hrs by MTT assay	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Discovery of 1,2,4-oxadiazole-Containing hydroxamic acid derivatives as histone deacetylase inhibitors potential application in cancer therapy.
AID1487006	Selectivity index, ratio of IC50 for HDAC8 (unknown origin) to IC50 for HDAC3 (unknown origin)	2017	Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15	The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity.
AID1754775	Induction of apoptosis in human MCF7 cells assessed as increase in caspase 3/7 activity at 1 to 3 uM measured after 48 hrs by ELISA	2021	Bioorganic & medicinal chemistry, 07-15, Volume: 42	Discovery of novel class of histone deacetylase inhibitors as potential anticancer agents.
AID1816189	Inhibition of recombinant HDAC4 (unknown origin) using Ac-peptide-AMC as substrate incubated for 240 mins by microplate reader analysis
AID1263060	Inhibition of NTHi-induced NF-kappaB activation in human BEAS-2B cells treated 1 hr before NTHi stimulation measured after 5 hrs by luciferase assay	2015	Bioorganic & medicinal chemistry, Dec-15, Volume: 23, Issue:24	A structure-activity relationship of non-peptide macrocyclic histone deacetylase inhibitors and their anti-proliferative and anti-inflammatory activities.
AID1702141	Inhibition of HDAC6 in human MCF7 cells assessed as increase in acetylated alpha-tubulin at Lys40 residue incubated for 3 hrs by ELISA	2018	Journal of medicinal chemistry, 02-22, Volume: 61, Issue:4	Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma.
AID1404300	Antiproliferative activity against human SK-MEL-28 cells after 72 hrs by resazurin dye based fluorescence assay	2018	ACS medicinal chemistry letters, Feb-08, Volume: 9, Issue:2	Biocompatible Boron-Containing Prodrugs of Belinostat for the Potential Treatment of Solid Tumors.
AID1396989	Antiproliferative activity against human U937 cells after 48 hrs by MTT assay	2018	Bioorganic & medicinal chemistry, 08-07, Volume: 26, Issue:14	Design, synthesis and anticancer evaluation of acridine hydroxamic acid derivatives as dual Topo and HDAC inhibitors.
AID1231814	Antiproliferative activity against human U937 cells incubated for 72 hrs by MTT assay	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Discovery, bioactivity and docking simulation of Vorinostat analogues containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors and antitumor agents.
AID755622	Cytotoxicity against human HGC27 cells assessed as growth inhibition after 72 hrs by MTT assay	2013	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13	Discovery of a small molecular compound simultaneously targeting RXR and HADC: design, synthesis, molecular docking and bioassay.
AID1754769	Inhibition of HDAC in human MCF7 cells assessed as increase in histone H2A acetylation at 1 to 3 uM incubated for 24 hrs by Western blot analysis	2021	Bioorganic & medicinal chemistry, 07-15, Volume: 42	Discovery of novel class of histone deacetylase inhibitors as potential anticancer agents.
AID1164035	Antiproliferative activity against human HeLa cells assessed as growth inhibition after 72 hrs by CCK-8 assay	2014	European journal of medicinal chemistry, Oct-30, Volume: 86	Design, synthesis, and biological evaluation of 1, 3-disubstituted-pyrazole derivatives as new class I and IIb histone deacetylase inhibitors.
AID1742650	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Design and synthesis of novel Flavone-based histone deacetylase inhibitors antagonizing activation of STAT3 in breast cancer.
AID717826	Inhibition of HDAC1 using Fluor-de-Lys as substrate compound pretreated for 30 mins before substrate addition by fluorescence assay	2012	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23	The structural requirements of histone deacetylase inhibitors: suberoylanilide hydroxamic acid analogs modified at the C6 position.
AID1754762	Downregulation of HDAC4 gene expression in human MCF7 cells at 3 uM incubated for 24 hrs by whole transcriptome analysis	2021	Bioorganic & medicinal chemistry, 07-15, Volume: 42	Discovery of novel class of histone deacetylase inhibitors as potential anticancer agents.
AID1263146	Antiproliferative activity against human MCF7 cells treated for 48 hrs followed by refreshed every 96 hrs measured on day 10 by Lowry assay	2015	Bioorganic & medicinal chemistry, Dec-15, Volume: 23, Issue:24	Design, synthesis and evaluation of antiestrogen and histone deacetylase inhibitor molecular hybrids.
AID481549	Cytotoxicity against human HO8910 cells assessed as growth inhibition at 100 ug/ml after 24 hrs by MTT assay	2010	Bioorganic & medicinal chemistry letters, May-15, Volume: 20, Issue:10	Synthesis and anticancer evaluation of alpha-lipoic acid derivatives.
AID1352482	Inhibition of HDAC4 in human HeLa cells after 72 hrs by ELISA	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Spirohydantoins and 1,2,4-triazole-3-carboxamide derivatives as inhibitors of histone deacetylase: Design, synthesis, and biological evaluation.
AID1652192	Inhibition of human recombinant HDAC6 expressed in Escherichia coli BL21(DE3) cells using Boc-Lys(Ac)-AMC as substrate preincubated for 5 followed by substrate addition and measured after 30 mins by fluorescence based assay	2020	ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5	New Dual CK2/HDAC1 Inhibitors with Nanomolar Inhibitory Activity against Both Enzymes.
AID1861652	Cytotoxicity against human L02 cells measured after 72 hrs	2022	Bioorganic & medicinal chemistry letters, 09-15, Volume: 72	Exploration of 4-(1H-indol-3-yl)cyclohex-3-en-1-amine analogues as HDAC inhibitors: Design, synthesis, biological evaluation and modelling studies.
AID1826612	Synergistic antiproliferative effect on HEL cells assessed as fractional inhibitory concentration index at 10 uM in presence of 3-Fluoro-10-hydroxy-14-methyl-8,13,13b,14-tetrahydro-7H-indolo[2',3':3,4]pyrido[2,1-b]quinazolin-5-one	2022	Journal of medicinal chemistry, 03-24, Volume: 65, Issue:6	Evodiamine-Inspired Topoisomerase-Histone Deacetylase Dual Inhibitors: Novel Orally Active Antitumor Agents for Leukemia Therapy.
AID1164033	Inhibition of human recombinant HDAC10 after 60 mins by fluorimetric assay	2014	European journal of medicinal chemistry, Oct-30, Volume: 86	Design, synthesis, and biological evaluation of 1, 3-disubstituted-pyrazole derivatives as new class I and IIb histone deacetylase inhibitors.
AID1563944	Inhibition of recombinant HDAC8 (unknown origin) measured after 30 mins by fluorescence assay	2019	European journal of medicinal chemistry, Oct-15, Volume: 180	Design, synthesis, and biological evaluation of a new class of histone acetyltransferase p300 inhibitors.
AID618083	Toxicity in athymic nu/nu Harlan mouse xenografted with human HCT116 cells assessed as body weight loss at 200 mg/kg, po QD for 21 days measured on day 19	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile.
AID1326526	Antitumor activity against human HCT116 cells xenografted in nude mouse assessed as tumor growth inhibition at 200 mg/kg, po qd	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	2-(Phenylsulfonyl)quinoline N-hydroxyacrylamides as potent anticancer agents inhibiting histone deacetylase.
AID1398815	Antagonist activity at ERalpha in human MCF7 cells assessed as suppression of TFF1 mRNA expression at 5 uM after 24 hrs by QIAzol reagent based RT-qPCR analysis	2018	Bioorganic & medicinal chemistry, 08-15, Volume: 26, Issue:15	Incorporation of histone deacetylase inhibitory activity into the core of tamoxifen - A new hybrid design paradigm.
AID1821266	Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	2022	European journal of medicinal chemistry, Feb-05, Volume: 229	Discovery of phthalazino[1,2-b]-quinazolinone derivatives as multi-target HDAC inhibitors for the treatment of hepatocellular carcinoma via activating the p53 signal pathway.
AID1380952	Inhibition of HDAC1 (unknown origin) using fluorogenic substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by fluorescence-based assay	2018	Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12	Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously.
AID1464878	Anti-proliferative activity against human MRC5 cells after 48 hrs by MTT assay	2017	Bioorganic & medicinal chemistry letters, 11-01, Volume: 27, Issue:21	Design, synthesis and biological evaluation of novel histone deacetylase inhibitors incorporating 4-aminoquinazolinyl systems as capping groups.
AID652748	Inhibition of recombinant human HDAC4 using Fluor-de-Lys as substrate after 30 mins by spectrophotometry	2011	ACS medicinal chemistry letters, Jul-21, Volume: 2, Issue:9	Potential Agents for Treating Cystic Fibrosis: Cyclic Tetrapeptides that Restore Trafficking and Activity of ΔF508-CFTR.
AID1702092	Induction of cell death in human MV4-11 cells measured at 48 hrs by fluorescence based microplate reader analysis	2018	Journal of medicinal chemistry, 02-22, Volume: 61, Issue:4	Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma.
AID765383	Inhibition of recombinant human HDAC11 enzyme using Ac-LeuGlyLys(Ac)-AMC as substrate after 15 to 30 mins	2013	Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16	Total synthesis and full histone deacetylase inhibitory profiling of Azumamides A-E as well as β²- epi-Azumamide E and β³-epi-Azumamide E.
AID609496	Cardiac safety index, Ratio of IC50 for human ERG to IC50 for human HCT116 cells	2011	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16	The design, synthesis and structure-activity relationships of novel isoindoline-based histone deacetylase inhibitors.
AID1454054	Growth inhibition of human MDA-MB-231 cells after 3 days by WST1 assay	2017	Bioorganic & medicinal chemistry, 07-15, Volume: 25, Issue:14	Synthesis and evaluation of novel dual BRD4/HDAC inhibitors.
AID322414	Antiproliferative activity against human LNCap by MTT assay	2008	Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6	Improved synthesis of histone deacetylase inhibitors (HDIs) (MS-275 and CI-994) and inhibitory effects of HDIs alone or in combination with RAMBAs or retinoids on growth of human LNCaP prostate cancer cells and tumor xenografts.
AID1246512	Inhibition of HDAC10 (unknown origin) using RHKK(Ac) fluorogenic acetylated peptide substrate by fluorometric assay	2015	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 25, Issue:19	Discovery of 1-hydroxypyridine-2-thiones as selective histone deacetylase inhibitors and their potential application for treating leukemia.
AID1401906	Selectivity ratio of IC50 for human recombinant HDAC2 to IC50 for human recombinant HDAC6	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
AID316903	Inhibition of human HCT116 cells	2008	Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6	Histone deacetylase inhibitors: from bench to clinic.
AID1699972	Inhibition of recombinant human HDAC1 using Boc-Lys(Ac)-AMC as substrate incubated for 60 mins by fluorimetric assay	2020	Bioorganic & medicinal chemistry letters, 12-15, Volume: 30, Issue:24	Discovery of thiosemicarbazone-containing compounds with potent anti-proliferation activity against drug-resistant K562/A02 cells.
AID1126994	Induction of apoptosis in human U937 cells assessed as early apoptotic cells using annexin-V/propidium iodide staining at 1 uM after 12 hrs by flow cytometry analysis (Rvb = 1.58%)	2014	Journal of medicinal chemistry, Apr-24, Volume: 57, Issue:8	Discovery of the first N-hydroxycinnamamide-based histone deacetylase 1/3 dual inhibitors with potent oral antitumor activity.
AID1864270	Antitumor activity against human MDA-MB-231 cells xenografted in BALB/c-nu/nu mouse assessed as tumor growth inhibition at 10 mg/kg, ip measured for 31 days	2022	Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18	Discovery of a Novel G-Quadruplex and Histone Deacetylase (HDAC) Dual-Targeting Agent for the Treatment of Triple-Negative Breast Cancer.
AID732449	Inhibition of human U937 cell proliferation after 48 hrs by MTT assay	2013	ACS medicinal chemistry letters, Feb-14, Volume: 4, Issue:2	Development of
AID737915	Inhibition of recombinant HDAC6 (unknown origin) after 10 mins by fluorimetric analysis	2013	Journal of medicinal chemistry, May-09, Volume: 56, Issue:9	Design and synthesis of dual-action inhibitors targeting histone deacetylases and 3-hydroxy-3-methylglutaryl coenzyme A reductase for cancer treatment.
AID1751987	Antiproliferative activity against human MV4-11 cells harboring FLT3-ITD mutant assessed as reduction in cell viability	2021	Bioorganic & medicinal chemistry letters, 10-01, Volume: 49	Discovery of novel pyrazolopyrimidine derivatives as potent mTOR/HDAC bi-functional inhibitors via pharmacophore-merging strategy.
AID1542180	Inhibition of HDAC2 (unknown origin)	2019	Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7	Kinase and Histone Deacetylase Hybrid Inhibitors for Cancer Therapy.
AID1269323	Cytotoxicity against human U251MG cells assessed as cell growth at 25 uM measured at 72 hrs by CyQuant proliferation assay relative to control	2016	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2	Bromotyrosine-derived metabolites from an Indonesian marine sponge in the family Aplysinellidae (Order Verongiida).
AID711146	Inhibition of HDAC8 at 0.3 uM in absence of Cu(I) by fluorometric assay	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	Rapid discovery of highly potent and selective inhibitors of histone deacetylase 8 using click chemistry to generate candidate libraries.
AID759300	Cytotoxicity against ERalpha and ERbeta-deficient human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTT assay	2013	Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14	Histone deacetylase inhibitors equipped with estrogen receptor modulation activity.
AID1752946	Antiplasmodial activity against liver stage exo-erythrocytic forms of Plasmodium berghei sporozoites infected in human HepG2-A16-CD81EGFP cells assessed as inhibition of parasite growth compound incubated with cells for 24 hrs prior to infection and measu
AID760512	Inhibition of HDAC1 (unknown origin) using fluorogenic peptide from p53 residues (379 to 382) (RHKK(Ac)) as substrate by fluorescence assay	2013	ACS medicinal chemistry letters, Aug-08, Volume: 4, Issue:8	Development of a chimeric c-Src kinase and HDAC inhibitor.
AID411254	Inhibition of HDAC8 from human HeLa cells nuclear extract by cell free fluorimetric assay	2009	Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2	Non-peptide macrocyclic histone deacetylase inhibitors.
AID1816223	Induction of apoptosis in mouse 4T1 cells assessed as necrotic cells at 5 uM measured after 48 hrs by annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 4.35%)
AID350721	Growth inhibition of human MKN45 cells after 48 hrs by sulforhodamine B assay	2009	Journal of medicinal chemistry, May-14, Volume: 52, Issue:9	Design, synthesis, and biological activity of boronic acid-based histone deacetylase inhibitors.
AID663361	Growth inhibition of human KM12 cells after 72 hrs by MTS assay	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Discovery and extensive in vitro evaluations of NK-HDAC-1: a chiral histone deacetylase inhibitor as a promising lead.
AID1459946	Antiproliferative activity against human A549 cells measured after 48 hrs by sulforhodamine-B assay	2017	European journal of medicinal chemistry, Jan-05, Volume: 125	3-Aroylindoles display antitumor activity in vitro and in vivo: Effects of N1-substituents on biological activity.
AID1548265	Induction of apoptosis in human RPMI8226 cells incubated for 24 hrs by Annexin V-FITC/PI staining based flow cytometry
AID1550121	Induction of apoptosis in HEL cells assessed as necrotic apoptotic cells at 1 uM after 24 hrs by Annexin-V/propidium iodide staining-based flow cytometric analysis (Rvb = 0.011%)	2019	Journal of medicinal chemistry, 04-25, Volume: 62, Issue:8	Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies.
AID748107	Inhibition of HDAC9 (unknown origin) after 60 mins by fluorescence assay	2013	Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11	Discovery of the first histone deacetylase 6/8 dual inhibitors.
AID1754754	Inhibition of N-terminal GST-tagged/C-terminal His-tagged human recombinant HDAC4 (627 to 1084 residues) expressed in baculovirus-infected Sf9 cells assessed as reduction in 7-amino-4-methylcoumarin release measured every 5 mins by fluorescence based anal	2021	Bioorganic & medicinal chemistry, 07-15, Volume: 42	Discovery of novel class of histone deacetylase inhibitors as potential anticancer agents.
AID628451	Inhibition of HDAC in human HepG2 cells assessed as increase in histone H4 acetylation at 1 to 10 uM after 24 hrs by Western blot analysis	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Design, synthesis, docking, and biological evaluation of novel diazide-containing isoxazole- and pyrazole-based histone deacetylase probes.
AID1246520	Cytotoxicity against human THP1 cells assessed as reduction in cell viability	2015	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 25, Issue:19	Discovery of 1-hydroxypyridine-2-thiones as selective histone deacetylase inhibitors and their potential application for treating leukemia.
AID1550104	Inhibition of HDAC2 in human A549 cells assessed as increase in acetyl histone H4 level at 80 to 400 nM after 6 hrs by Western blot analysis	2019	Journal of medicinal chemistry, 04-25, Volume: 62, Issue:8	Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies.
AID1441688	Anti-inflammatory activity in BLM-induced C57BL/6 mouse model of acute lung injury assessed as reduction in IL-6 level in BALF at 25 and 50 mg/kg, ip qd for 7 days post BLM challenge measured on day 7 by ELISA	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
AID1246511	Inhibition of HDAC6 (unknown origin) using RHKK(Ac) fluorogenic acetylated peptide substrate by fluorometric assay	2015	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 25, Issue:19	Discovery of 1-hydroxypyridine-2-thiones as selective histone deacetylase inhibitors and their potential application for treating leukemia.
AID1764251	Inhibition of recombinant human full length C-terminal GST-fusion tagged HDAC2 expressed in baculovirus infected insect cells using Boc-Lys(Ac)-AMC as substrate preincubated for 5 mins followed by substrate addition measured after 90 mins by fluorimetry	2021	European journal of medicinal chemistry, Feb-05, Volume: 211	Synergistic induction of apoptosis in resistant head and neck carcinoma and leukemia by alkoxyamide-based histone deacetylase inhibitors.
AID461266	Antiproliferative activity against human LNCAP cells	2010	Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5	Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer.
AID1178595	Inhibition of human HDAC1 pre-incubated for 30 mins before substrate addition and measured after 30 mins by HDAC-Glo I/II assay	2014	Bioorganic & medicinal chemistry, Jul-15, Volume: 22, Issue:14	Design and synthesis of novel and highly-active pan-histone deacetylase (pan-HDAC) inhibitors.
AID503663	Effect on FXN mRNA expression in human GM15850 cells at 5 uM after 12 hrs by qRT-PCR analysis	2006	Nature chemical biology, Oct, Volume: 2, Issue:10	Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia.
AID1469395	Induction of apoptosis in human Hep3B cells assessed as early apoptotic cells at 10 uM after 48 hrs by annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 1.91%)	2018	Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7	Discovery of N1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7 H-pyrrolo[2,3- d]pyrimidin-2-yl)amino)phenyl)- N8-hydroxyoctanediamide as a Novel Inhibitor Targeting Cyclin-dependent Kinase 4/9 (CDK4/9) and Histone Deacetlyase1 (HDAC1) against Malignant Cancer
AID1566038	Inhibition of recombinant full length human HDAC2 expressed in baculovirus infected Sf9 cells using Ac-peptide-AMC as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence based assay	2019	European journal of medicinal chemistry, Nov-15, Volume: 182	A fluorine scan on the Zn
AID1233268	Therapeutic index, ratio of IC50 for african green monkey Vero cells to IC50 for human MCF7 cells	2015	Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11	Novel Bioactive Hybrid Compound Dual Targeting Estrogen Receptor and Histone Deacetylase for the Treatment of Breast Cancer.
AID1293566	Inhibition of human recombinant C-terminal His-tagged HDAC5 (657 to 1123 residues) expressed in insect cells using RHK-K(Ac)-AMC as substrate incubated for 60 mins by fluorescence assay	2016	European journal of medicinal chemistry, Apr-13, Volume: 112	Biphenyl-4-yl-acrylohydroxamic acids: Identification of a novel indolyl-substituted HDAC inhibitor with antitumor activity.
AID1775548	Inhibition of HDAC6 (unknown origin)	2021	Journal of medicinal chemistry, 03-25, Volume: 64, Issue:6	Design and Synthesis of Novel Epigenetic Inhibitors Targeting Histone Deacetylases, DNA Methyltransferase 1, and Lysine Methyltransferase G9a with
AID628449	Induction of apoptosis in human HepG2 cells assessed as hyperacetylation of p53 at 1 to 10 uM by Western blot analysis	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Design, synthesis, docking, and biological evaluation of novel diazide-containing isoxazole- and pyrazole-based histone deacetylase probes.
AID775830	Inhibition of human recombinant ACE/CD143 somatic form using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2.AcOH as substrate at 10 uM preincubated for 10 mins prior to substrate addition measured for 30 mins by spectrophotometric analysis	2013	Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20	Investigating the selectivity of metalloenzyme inhibitors.
AID1129776	Cell cycle arrest in human Jurkat cells assessed as accumulation at G0/G1-phase at 10 uM after 12 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 4.16%)	2014	Bioorganic & medicinal chemistry, Apr-01, Volume: 22, Issue:7	Studies on the antiproliferative effects of tropolone derivatives in Jurkat T-lymphocyte cells.
AID1578882	Antiproliferative activity against human SMMC7721 cells after 72 hrs by MTT assay	2019	Journal of natural products, 06-28, Volume: 82, Issue:6	Hydroxamic Acid Derivatives of β-Carboline/Hydroxycinnamic Acid Hybrids Inducing Apoptosis and Autophagy through the PI3K/Akt/mTOR Pathways.
AID663372	Growth inhibition of human SF268 cells after 72 hrs by MTS assay	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Discovery and extensive in vitro evaluations of NK-HDAC-1: a chiral histone deacetylase inhibitor as a promising lead.
AID1355744	In vivo antifungal activity against FLC resistant Candida albicans 0304103 infected in ICR mouse assessed as mouse survival at 5 mg/kg, ip qd up to 20 days in co-treated with 1 mg/kg, ip qd fluconazol (Rvb = 4.5 day)	2018	Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14	Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections.
AID541645	Inhibition of human HDAC2 by fluorimetric assay	2010	Journal of medicinal chemistry, Dec-09, Volume: 53, Issue:23	Non-natural macrocyclic inhibitors of histone deacetylases: design, synthesis, and activity.
AID373075	Inhibition of human recombinant HDAC2	2009	European journal of medicinal chemistry, Mar, Volume: 44, Issue:3	Novel amide derivatives as inhibitors of histone deacetylase: design, synthesis and SAR.
AID1273879	Inhibition of human CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate at 10 uM after 30 mins by fluorimetric analysis	2016	European journal of medicinal chemistry, Jan-27, Volume: 108	Synthesis, biological characterization and molecular modeling insights of spirochromanes as potent HDAC inhibitors.
AID613327	Antitumor activity against human HCT116 cells xenografted in athymic nude mouse model assessed as tumor growth inhibition at 5 mg/kg, iv	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Optimization of the in vitro cardiac safety of hydroxamate-based histone deacetylase inhibitors.
AID1614136	Inhibition of recombinant full length C-terminal His-tagged human HDAC9 expressed in baculovirus expression system using Ac-peptide-AMC as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by fluorescence assay
AID1865295	Antiproliferative activity against mouse 4T1 cells assessed as cell viability incubated for 72 hrs by CCK-8 assay	2022	Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18	Discovery of Novel Src Homology-2 Domain-Containing Phosphatase 2 and Histone Deacetylase Dual Inhibitors with Potent Antitumor Efficacy and Enhanced Antitumor Immunity.
AID652759	Increase of HDAC7-meidated histone H3 acetylation in human CFBE41o cells at 0.2 to 5 uM by Western blot analysis	2011	ACS medicinal chemistry letters, Jul-21, Volume: 2, Issue:9	Potential Agents for Treating Cystic Fibrosis: Cyclic Tetrapeptides that Restore Trafficking and Activity of ΔF508-CFTR.
AID1174688	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	2015	European journal of medicinal chemistry, Jan-07, Volume: 89	Development of 3-hydroxycinnamamide-based HDAC inhibitors with potent in vitro and in vivo anti-tumor activity.
AID420504	Antiproliferative activity against human HCT116 cells after 72 hrs	2009	European journal of medicinal chemistry, May, Volume: 44, Issue:5	Design, synthesis, and evaluation of biphenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors.
AID1633674	Immunomodulatory activity in mouse N9 cells assessed as increase in LPS-induced MRC1 expression at 5 to 25 uM incubated for 24 hrs by Western blot analysis	2019	ACS medicinal chemistry letters, Apr-11, Volume: 10, Issue:4	Novel Sustainable-by-Design HDAC Inhibitors for the Treatment of Alzheimer's Disease.
AID1321621	Antiproliferative activity against human A549 cells measured after 72 hrs by WST1 assay	2016	Bioorganic & medicinal chemistry letters, 10-01, Volume: 26, Issue:19	Design, synthesis and in vitro evaluation of amidoximes as histone deacetylase inhibitors for cancer therapy.
AID1433255	Antiproliferative activity against human MV4-11 cells after 72 hrs by MTT assay	2016	Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17	Synthesis and Antileukemic Activities of Piperlongumine and HDAC Inhibitor Hybrids against Acute Myeloid Leukemia Cells.
AID1141766	Cytotoxicity against human HSC3 cells by MTT assay	2014	Journal of medicinal chemistry, May-22, Volume: 57, Issue:10	Azaindolylsulfonamides, with a more selective inhibitory effect on histone deacetylase 6 activity, exhibit antitumor activity in colorectal cancer HCT116 cells.
AID1406993	Inhibition of HDAC6 in human SH-SY5Y cells assessed as levels of alpha-tubulin acetylation at 5 uM after 30 hrs by Western blot analysis relative to control	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Novel spiroindoline HDAC inhibitors: Synthesis, molecular modelling and biological studies.
AID1476160	Antiproliferative activity against human NKYS cells after 48 hrs by CellTiter-Glo luminescent assay	2017	Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20	Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat.
AID1469300	Induction of apoptosis in human NCI-H460 cells assessed as early apoptotic cells at 10 uM after 48 hrs by annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 0.11%)	2018	Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7	Discovery of N1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7 H-pyrrolo[2,3- d]pyrimidin-2-yl)amino)phenyl)- N8-hydroxyoctanediamide as a Novel Inhibitor Targeting Cyclin-dependent Kinase 4/9 (CDK4/9) and Histone Deacetlyase1 (HDAC1) against Malignant Cancer
AID1688033	Induction of apoptosis in human HL-60 cells assessed as necrotic cells at 0.5 uM measured after 24 hrs by Annexin-V/FITC and propidium iodide staining based flow cytometry (Rvb = 1.01 %)	2020	European journal of medicinal chemistry, Feb-15, Volume: 188	A 18β-glycyrrhetinic acid conjugate with Vorinostat degrades HDAC3 and HDAC6 with improved antitumor effects.
AID1826621	Synergistic antiproliferative effect on HEL cells assessed as fractional inhibitory concentration index at 3.33 uM in presence of 3-Fluoro-10-hydroxy-14-methyl-8,13,13b,14-tetrahydro-7H-indolo[2',3':3,4]pyrido[2,1-b]quinazolin-5-one	2022	Journal of medicinal chemistry, 03-24, Volume: 65, Issue:6	Evodiamine-Inspired Topoisomerase-Histone Deacetylase Dual Inhibitors: Novel Orally Active Antitumor Agents for Leukemia Therapy.
AID524997	Inhibition of HDAC7 by in vitro deacetylation assay	2010	Nature chemical biology, Jan, Volume: 6, Issue:1	Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.
AID1486298	Antiproliferative activity against human HCC827 cells after 72 hrs by MTT assay	2017	Bioorganic & medicinal chemistry, 08-01, Volume: 25, Issue:15	Olaparib hydroxamic acid derivatives as dual PARP and HDAC inhibitors for cancer therapy.
AID1126982	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	2014	Journal of medicinal chemistry, Apr-24, Volume: 57, Issue:8	Discovery of the first N-hydroxycinnamamide-based histone deacetylase 1/3 dual inhibitors with potent oral antitumor activity.
AID1547354	Inhibition of HDAC in human HCT116 cells assessed as induction of autophagy at marginal level by measuring p62 degradation at 10 uM measured after 24 hrs by Western blot analysis	2020	Journal of medicinal chemistry, 04-09, Volume: 63, Issue:7	Discovery of Thieno[2,3-
AID1462227	Inhibition of BRD4/HDAC1 in human OCI-AML2 cells assessed as reduction in myc expression levels at 1 uM after 24 hrs by Western blot analysis	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Structure-based design, synthesis and in vitro antiproliferative effects studies of novel dual BRD4/HDAC inhibitors.
AID525034	In vivo inhibition of HDAC	2010	Nature chemical biology, Jan, Volume: 6, Issue:1	Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.
AID1206742	Cytotoxicity against human MDA cells assessed as growth inhibition after 48 hrs by MTT assay	2015	Journal of medicinal chemistry, May-28, Volume: 58, Issue:10	Design, synthesis, and antitumor evaluation of novel histone deacetylase inhibitors equipped with a phenylsulfonylfuroxan module as a nitric oxide donor.
AID1280259	Inhibition of human HDAC1 using (Z-(Ac)Lys-AMC) as substrate after 90 mins by fluorescence analysis	2016	Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4	Synthesis and Biological Investigation of Oxazole Hydroxamates as Highly Selective Histone Deacetylase 6 (HDAC6) Inhibitors.
AID723437	Potentiation of 10 uM cisplatin-induced toxicity in 1 uM cisplatin resistant human MDA-MB-231 cells at 0.5 uM pretreated for 48 hrs followed by 1 uM cisplatin treatment by MTT assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID404445	Cytotoxicity against human SU 86.86 cells after 72 hrs by MTT assay	2008	Journal of medicinal chemistry, Jun-26, Volume: 51, Issue:12	A series of potent and selective, triazolylphenyl-based histone deacetylases inhibitors with activity against pancreatic cancer cells and Plasmodium falciparum.
AID90340	Inhibition of Histone deacetylase (HDAC)of HeLa nuclear extracts	2004	Bioorganic & medicinal chemistry letters, Jan-19, Volume: 14, Issue:2	Design, synthesis, and activity of HDAC inhibitors with a N-formyl hydroxylamine head group.
AID1398804	Cytotoxicity against ER negative human MDA-MB-231 cells treated every 2 days for 4 days measured after 7 days by CellTiter-Glo luminescence assay	2018	Bioorganic & medicinal chemistry, 08-15, Volume: 26, Issue:15	Incorporation of histone deacetylase inhibitory activity into the core of tamoxifen - A new hybrid design paradigm.
AID1441668	Plasma concentration in mouse by liquid chromatography mass spectrometry	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
AID1885700	Toxicity in ICR mouse assessed as effect on ALT level at 12 umol/kg, ip measured after 12 hrs in presence of CDDO-Me	2022	Journal of medicinal chemistry, 08-11, Volume: 65, Issue:15	Redox-Activatable Theranostic Co-Prodrug for Precise Tumor Diagnosis and Selective Combination Chemotherapy.
AID1888421	Inhibition of fungal HDAC using Boc-Lys (acetyl)-AMC as substrate preincubated for 12 hrs followed by substrate addition and measured after 6 hrs by fluorescence-based analysis	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	Heat shock protein 90 (Hsp90)/Histone deacetylase (HDAC) dual inhibitors for the treatment of azoles-resistant Candida albicans.
AID374819	Inhibition of wild type His-tagged HDAC5 catalytic domain T678-L1122 expressed in Escherichia coli	2009	Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11	Discovery of a potent class I selective ketone histone deacetylase inhibitor with antitumor activity in vivo and optimized pharmacokinetic properties.
AID1390810	Antiproliferative activity against human Ramos cells after 72 hrs by MTT assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel 6-aryl substituted 4-pyrrolidineaminoquinazoline derivatives as potent phosphoinositide 3-kinase delta (PI3Kδ) inhibitors.
AID527320	Growth inhibition of human U937 cells after 72 hrs by SRB assay	2010	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22	Design and synthesis of novel pyrimidine hydroxamic acid inhibitors of histone deacetylases.
AID750110	Inhibition of HDAC in human HeLa cells using Fluor de Lys as substrate at 1 uM by fluorescence assay	2013	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 23, Issue:11	Design, synthesis and biological evaluation of indeno[1,2-d]thiazole derivatives as potent histone deacetylase inhibitors.
AID1482142	Induction of mitochondrial membrane potential loss in human MOLT4 cells assessed as intact mitochondrial membrane potential at 1 uM measured after 48 hrs by Rh123 dye-based flow cytometric analysis (Rvb = 90.4%)	2017	Journal of medicinal chemistry, 04-27, Volume: 60, Issue:8	Exploring Derivatives of Quinazoline Alkaloid l-Vasicine as Cap Groups in the Design and Biological Mechanistic Evaluation of Novel Antitumor Histone Deacetylase Inhibitors.
AID1727742	Inhibition of HDAC8 (unknown origin) by fluorescence based assay	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	Discovery of selective HDAC/BRD4 dual inhibitors as epigenetic probes.
AID1464886	Oral bioavailability in Sprague-Dawley rat 20 mg/kg administered via gavage by LC-MS/MS analysis	2017	Bioorganic & medicinal chemistry letters, 11-01, Volume: 27, Issue:21	Design, synthesis and biological evaluation of novel histone deacetylase inhibitors incorporating 4-aminoquinazolinyl systems as capping groups.
AID1578919	Inhibition of PI3K/AKT/mTOR signaling in human Bel7402 cells assessed as reduction in mTOR phosphorylation at 5 uM after 24 to 72 hrs by Western blot analysis	2019	Journal of natural products, 06-28, Volume: 82, Issue:6	Hydroxamic Acid Derivatives of β-Carboline/Hydroxycinnamic Acid Hybrids Inducing Apoptosis and Autophagy through the PI3K/Akt/mTOR Pathways.
AID476645	Antiproliferative activity against human HL60 cells after 48 hrs by cell titer-glo assay	2010	Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8	Modified cap group suberoylanilide hydroxamic acid histone deacetylase inhibitor derivatives reveal improved selective antileukemic activity.
AID1164766	Efflux ratio of permeability from apical to basolateral side to basolateral to apical side of human Caco2 cells in presence of digoxin	2014	Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20	ST7612AA1, a thioacetate-ω(γ-lactam carboxamide) derivative selected from a novel generation of oral HDAC inhibitors.
AID1578494	Induction of apoptosis in human MV4-11 cells assessed as late apoptotic cells at 0.25 uM incubated for 18 hrs by annexin V FITC and PI based flow cytometry (Rvb = 9.2 to 9.63 %)	2020	ACS medicinal chemistry letters, Jan-09, Volume: 11, Issue:1	Class I/IIb-Selective HDAC Inhibitor Exhibits Oral Bioavailability and Therapeutic Efficacy in Acute Myeloid Leukemia.
AID1422519	Inhibition of human recombinant HDAC1 at 2 uM after 15 to 30 mins by COLOR DE LYS-based colorimetric method	2018	European journal of medicinal chemistry, Nov-05, Volume: 159	In search of constrained FTY720 and phytosphingosine analogs as dual acting anticancer agents targeting metabolic and epigenetic pathways.
AID1572341	Inhibition of recombinant C-terminal His/FLAG-tagged human HDAC1 expressed in baculovirus expression system using fluorogenic ZMAL as substrate incubated for 90 mins by fluorescence assay	2019	Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3	Synthesis and Biological Investigation of Phenothiazine-Based Benzhydroxamic Acids as Selective Histone Deacetylase 6 Inhibitors.
AID619139	Half life in dog liver microsomes	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile.
AID352517	Inhibition of human recombinant HDAC3	2009	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11	Isoxazole moiety in the linker region of HDAC inhibitors adjacent to the Zn-chelating group: effects on HDAC biology and antiproliferative activity.
AID1511967	Inhibition of full length recombinant FLAG/His-tagged C-terminal human HDAC1 expressed in baculovirus infected Sf9 insect cells using ZMAL (Z-Lys(Ac)-AMC) as substrate incubated for 90 mins by fluorescence based assay	2019	ACS medicinal chemistry letters, Sep-12, Volume: 10, Issue:9	Fluorinated Analogues of the Histone Deacetylase Inhibitor Vorinostat (Zolinza): Validation of a Chiral Hybrid Bioisostere, BITE.
AID1566813	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Discovery of 1,2,4-oxadiazole-Containing hydroxamic acid derivatives as histone deacetylase inhibitors potential application in cancer therapy.
AID313731	Inhibition of HDAC3	2008	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2	Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2).
AID1164774	Toxicity in human A2780 cells xenografted athymic nude mouse assessed as body weight loss at 100 mg/kg, po qd for 5 days a week for 2 weeks	2014	Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20	ST7612AA1, a thioacetate-ω(γ-lactam carboxamide) derivative selected from a novel generation of oral HDAC inhibitors.
AID1864679	Inhibition of full length recombinant human HDAC6 in expressing mouse J774.A1 cells assessed as upregulation of acetylated histone H3 at 1 uM measured after 0.1 to 24 hrs by western blot analysis
AID764218	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	2013	Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17	Novel N-hydroxyfurylacrylamide-based histone deacetylase (HDAC) inhibitors with branched CAP group (Part 2).
AID1433253	Antiproliferative activity against human CMY cells after 72 hrs by MTT assay	2016	Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17	Synthesis and Antileukemic Activities of Piperlongumine and HDAC Inhibitor Hybrids against Acute Myeloid Leukemia Cells.
AID1434356	Growth inhibition of human HCT15 cells measured after 5 days by sulforhodamine-B assay	2017	European journal of medicinal chemistry, Jan-27, Volume: 126	Improving potency and metabolic stability by introducing an alkenyl linker to pyridine-based histone deacetylase inhibitors for orally available RUNX3 modulators.
AID1566806	Inhibition of recombinant full length human HDAC4 expressed in sf9 insect cells using Ac-peptide-AMC as substrate after 1 hr by fluorescence assay	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Discovery of 1,2,4-oxadiazole-Containing hydroxamic acid derivatives as histone deacetylase inhibitors potential application in cancer therapy.
AID1502986	Inhibition of C-terminal His-tagged and C-terminal FLAG-tagged human HDAC1 expressed in baculovirus expression system using Ac-peptide substrate incubated for 15 mins by fluorescence based assay	2017	European journal of medicinal chemistry, Nov-10, Volume: 140	Design and synthesis of tranylcypromine derivatives as novel LSD1/HDACs dual inhibitors for cancer treatment.
AID1737136	Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability after 72 hrs by MTT assay	2020	European journal of medicinal chemistry, Apr-15, Volume: 192	Design, synthesis and biological evaluation of novel indazole-based derivatives as potent HDAC inhibitors via fragment-based virtual screening.
AID1434352	Inhibition of HDAC in human HeLa cell nuclear extract using acetylated lysine side chain of histone as substrate measured after 30 mins by fluorometric assay	2017	European journal of medicinal chemistry, Jan-27, Volume: 126	Improving potency and metabolic stability by introducing an alkenyl linker to pyridine-based histone deacetylase inhibitors for orally available RUNX3 modulators.
AID1141242	Inhibition of pig kidney microsomal APN using L-Leu-p-nitroanilide as substrate preincubated for 5 mins before substrate addition measured after 30 mins by spectrophotometry	2014	Bioorganic & medicinal chemistry, Jun-01, Volume: 22, Issue:11	Design, synthesis and preliminary evaluation of α-sulfonyl γ-(glycinyl-amino)proline peptidomimetics as matrix metalloproteinase inhibitors.
AID1783063	Antifungal activity against fluconazole-resistant Candida tropicalis 3890 assessed as inhibition of fungal growth incubated for 48 hrs by two-fold serial microdilution method	2021	European journal of medicinal chemistry, Oct-05, Volume: 221	Lanosterol 14α-demethylase (CYP51)/histone deacetylase (HDAC) dual inhibitors for treatment of Candida tropicalis and Cryptococcus neoformans infections.
AID1754759	Downregulation of HDAC2 gene expression in human MCF7 cells at 3 uM incubated for 24 hrs by whole transcriptome analysis	2021	Bioorganic & medicinal chemistry, 07-15, Volume: 42	Discovery of novel class of histone deacetylase inhibitors as potential anticancer agents.
AID593551	Inhibition of human HDAC6 using ArgHisLysLys(Ac) fluorogenic peptide as a substrate by fluorimetric assay	2011	Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7	Oxime amides as a novel zinc binding group in histone deacetylase inhibitors: synthesis, biological activity, and computational evaluation.
AID541654	Inhibition of human HDAC11 by fluorimetric assay	2010	Journal of medicinal chemistry, Dec-09, Volume: 53, Issue:23	Non-natural macrocyclic inhibitors of histone deacetylases: design, synthesis, and activity.
AID1234898	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	2015	Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15	Design, synthesis and preliminary biological evaluation of indoline-2,3-dione derivatives as novel HDAC inhibitors.
AID1260637	Inhibition of human recombinant HDAC1 at 20 uM using Boc-Lys(Ac)-AMC as substrate after 30 to 60 mins by microplate reader assay
AID1401545	Antiproliferative activity against human KM-H2 cells after 72 hrs by MTT assay	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors.
AID1600657	Inhibition of recombinant human C-terminal GST/His-tagged HDAC3 (1 to 428 residues) co-expressed with human N-terminal GST-tagged NCOR2 (395 to 489 residues) in baculovirus infected Sf9 cells using ZMAL as substrate incubated for 90 mins by fluorometric m	2019	Bioorganic & medicinal chemistry, 10-01, Volume: 27, Issue:19	Fluorescent analogs of peptoid-based HDAC inhibitors: Synthesis, biological activity and cellular uptake kinetics.
AID1784989	Inhibition of HDAC6 (unknown origin) using Ac-peptide as a substrate pretreated for 15 mins followed by substrate addition	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Design, synthesis and biological evaluation of novel hybrids targeting mTOR and HDACs for potential treatment of hepatocellular carcinoma.
AID1848278	Inhibition of PI3Kalpha (unknown origin) at 1 uM by mobility shift assay	2022	Bioorganic & medicinal chemistry, Nov-15, Volume: 74	Design, synthesis and biological evaluation of novel pyrazinone derivatives as PI3K/HDAC dual inhibitors.
AID755620	Cytotoxicity against human DU145 cells assessed as growth inhibition after 72 hrs by MTT assay	2013	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13	Discovery of a small molecular compound simultaneously targeting RXR and HADC: design, synthesis, molecular docking and bioassay.
AID1518806	Inhibition of HDAC1/2/3 in human KMS-12-BM cells assessed as increase in Ac-H3 level at 2.5 to 5 uM incubated for 24 hrs by Western blot analysis	2019	European journal of medicinal chemistry, Dec-15, Volume: 184	Discovery of a potent histone deacetylase (HDAC) 3/6 selective dual inhibitor.
AID1587865	Inhibition of human recombinant full length C-terminal His-tagged HDAC3 (1 to 428 residues)/N-terminal GST-tagged NCOR2 (395 to 489 residues) expressed in baculovirus infected insect cells measured after 40 mins by HDAC-Glo1/2 luminescent assay	2019	Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9	Selective Inhibition of Histone Deacetylase 10: Hydrogen Bonding to the Gatekeeper Residue is Implicated.
AID1449332	Inhibition of HDAC6 in human CAL27 cells assessed as accumulation of acetylated alpha tubulin at 1 uM after 24 hrs by immunoblot analysis	2017	Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13	Alkoxyurea-Based Histone Deacetylase Inhibitors Increase Cisplatin Potency in Chemoresistant Cancer Cell Lines.
AID1861257	Antiproliferative activity against human CAPAN-1 cells assessed as reduction in cell viability	2022	Bioorganic & medicinal chemistry letters, 09-01, Volume: 71	Design, synthesis and antitumor activity study of PARP-1/HDAC dual targeting inhibitors.
AID1473739	Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1511140	Inhibition of HDAC11 (unknown origin) using Ac-LeuGlyLys(Ac)-AMC as substrate preincubated for 5 mins followed by substrate addition and measured after 60 mins by fluorescence based assay	2019	ACS medicinal chemistry letters, Aug-08, Volume: 10, Issue:8	Design, Synthesis, and Biological Evaluation of 2,4-Imidazolinedione Derivatives as HDAC6 Isoform-Selective Inhibitors.
AID461260	Antiproliferative activity against human BxPC3 cells after hrs by ATP content assay	2010	Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5	Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer.
AID1758462	Dark toxicity in human A549 cells assessed as reduction in cell viability incubated under dark for 48 hrs measured after 48 hrs by CCK8 assay	2021	European journal of medicinal chemistry, May-05, Volume: 217	Novel dual-mode antitumor chlorin-based derivatives as potent photosensitizers and histone deacetylase inhibitors for photodynamic therapy and chemotherapy.
AID1394887	Inhibition of FITC-geldanamycin binding to HSP90alpha (unknown origin) after 3 hrs by fluorescence polarization assay	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	1-Aroylindoline-hydroxamic acids as anticancer agents, inhibitors of HSP90 and HDAC.
AID1599729	Cytotoxicity against human A549 cells assessed as decrease in cell viability measured after 72 hrs by CellTiter-Glo Luminescent assay	2019	ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6	Extending Cross Metathesis To Identify Selective HDAC Inhibitors: Synthesis, Biological Activities, and Modeling.
AID1667069	Antiproliferative activity in human A549 cells assessed as inhibition of cell viability after 72 hrs by MTS assay	2020	Bioorganic & medicinal chemistry, 03-15, Volume: 28, Issue:6	Pyrimethamine conjugated histone deacetylase inhibitors: Design, synthesis and evidence for triple negative breast cancer selective cytotoxicity.
AID487873	Inhibition of HDAC in human HeLa cells extracts after 60 mins by fluorescence assay	2010	Bioorganic & medicinal chemistry, Jun-15, Volume: 18, Issue:12	New aryldithiolethione derivatives as potent histone deacetylase inhibitors.
AID1421927	Selectivity index, ratio of IC50 for human NFF cells to IC50 for Plasmodium falciparum Dd2 infected in human erythrocytes	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	One-pot, multi-component synthesis and structure-activity relationships of peptoid-based histone deacetylase (HDAC) inhibitors targeting malaria parasites.
AID1849159	Selectivity index, ratio of IC50 for inhibition of recombinant human C-terminal FLAG/His-tagged HDAC1 (1 to 482 residues) expressed in Sf9 insect cells to IC50 for inhibition of recombinant human N-terminal GST-tagged HDAC6 (1 to 1215 residues) expressed	2022	Journal of medicinal chemistry, 11-24, Volume: 65, Issue:22	Development of Fluorinated Peptoid-Based Histone Deacetylase (HDAC) Inhibitors for Therapy-Resistant Acute Leukemia.
AID1754770	Inhibition of HDAC in human MCF7 cells assessed as increase in histone H3 acetylation at 1 to 3 uM incubated for 24 hrs by Western blot analysis	2021	Bioorganic & medicinal chemistry, 07-15, Volume: 42	Discovery of novel class of histone deacetylase inhibitors as potential anticancer agents.
AID1548276	Antiproliferative activity against bortezomib resistant human KM3/BTZ cells assessed combination index in presence of bortezomib at 1:1 compound to bortezomib ratio incubated for 48 hrs by MTT assay
AID1281866	Induction of apoptosis in human RPMI8226 cells assessed as dead cells at 3 uM after 48 hrs by annexin V-FITC/propidium iodide staining-based flow cytometry (Rvb = 2%)	2016	European journal of medicinal chemistry, Apr-13, Volume: 112	Design, synthesis and biological evaluation of bisthiazole-based trifluoromethyl ketone derivatives as potent HDAC inhibitors with improved cellular efficacy.
AID1469437	Inhibition of HDAC1 in human Hep3B cells assessed as increase in acetylated-histone H3 level at 5 uM after 48 hrs by Western blot method	2018	Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7	Discovery of N1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7 H-pyrrolo[2,3- d]pyrimidin-2-yl)amino)phenyl)- N8-hydroxyoctanediamide as a Novel Inhibitor Targeting Cyclin-dependent Kinase 4/9 (CDK4/9) and Histone Deacetlyase1 (HDAC1) against Malignant Cancer
AID1821344	Toxicity in mouse xenografted with human HepG2 cells assessed as liver edema at 12 mg/kg, ip administered every 2 days for 4 weeks by H and E staining based microscopic method	2022	European journal of medicinal chemistry, Feb-05, Volume: 229	Discovery of phthalazino[1,2-b]-quinazolinone derivatives as multi-target HDAC inhibitors for the treatment of hepatocellular carcinoma via activating the p53 signal pathway.
AID1543960	Induction of apoptosis in human Bel7402/5-FU cells assessed as live cells at 5.0 uM incubated for 72 hrs by FITC-Annexin V/PI staining based flow cytometry (Rvb = 93.12%)	2019	European journal of medicinal chemistry, Apr-15, Volume: 168	β-Carboline and N-hydroxycinnamamide hybrids as anticancer agents for drug-resistant hepatocellular carcinoma.
AID1676588	Binding affinity to Zinc ion assessed as performance ratio ratio by measuring product of accounting ratio and retention ratio at 2.55 umol by immobilized metal-ion affinity chromatography	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
AID1785338	Inhibition of HDAC7 (unknown origin) measured after 30 mins by fluorescence microplate reader assay
AID1225983	Inhibition of recombinant C-terminal His-tagged full length human HDAC3/NcoR2 complex expressed in baculovirus infected insect Sf9 cells using fluorogenic HDAC substrate 3 after 30 mins by fluorescence assay	2015	ACS medicinal chemistry letters, Mar-12, Volume: 6, Issue:3	Discovery of Novel Multiacting Topoisomerase I/II and Histone Deacetylase Inhibitors.
AID1361650	Induction of apoptosis in human A549 cells assessed as necrotic cells at 1 uM after 48 hrs by FITC-Annexin V/propidium iodide staining based flow cytometric analysis (Rvb = 0.52%)	2018	Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16	Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents.
AID663374	Growth inhibition of human SF539 cells after 72 hrs by MTS assay	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Discovery and extensive in vitro evaluations of NK-HDAC-1: a chiral histone deacetylase inhibitor as a promising lead.
AID292436	Inhibition of HDAC in HeLa cells	2007	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17	Trithiocarbonates: exploration of a new head group for HDAC inhibitors.
AID1356280	Cytotoxicity against human MV4-11 cells assessed as reduction in cell viability after 72 hrs by MTT assay
AID1263145	Inhibition of human recombinant HDAC6 using Boc-Lys(Ac)-AMC as substrate after 30 mins by fluorescence assay	2015	Bioorganic & medicinal chemistry, Dec-15, Volume: 23, Issue:24	Design, synthesis and evaluation of antiestrogen and histone deacetylase inhibitor molecular hybrids.
AID1441680	Anti-inflammatory activity in BLM-induced C57BL/6 mouse model of acute lung neutrophilic inflammation assessed as LTB4 level at 50 mg/kg, ip qd for 7 days post BLM challenge measured on day 7 (Rvb = 139.23 pg/ml)	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
AID1355707	Antifungal activity against FLC resistant Candida albicans 0304103 after 48 hrs in presence of fluconazol by checkerboard microdilution method	2018	Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14	Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections.
AID663393	Growth inhibition of human UO31 cells after 72 hrs by MTS assay	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Discovery and extensive in vitro evaluations of NK-HDAC-1: a chiral histone deacetylase inhibitor as a promising lead.
AID1514601	Inhibition of HDAC1 in human HepG2 cells assessed as acetylated histone H3 levels at 5 uM by Western blot analysis relative to beta-actin (Rvb = 0.5 No_unit)	2019	Bioorganic & medicinal chemistry letters, 01-01, Volume: 29, Issue:1	Development of hydroxamate-based histone deacetylase inhibitors containing 1,2,4-oxadiazole moiety core with antitumor activities.
AID652763	Inhibition of HDAC6 in human HeLa cells nuclear extract using Fluor-de-Lys as substrate after 30 mins by spectrophotometry	2011	ACS medicinal chemistry letters, Jul-21, Volume: 2, Issue:9	Potential Agents for Treating Cystic Fibrosis: Cyclic Tetrapeptides that Restore Trafficking and Activity of ΔF508-CFTR.
AID350732	Growth inhibition of human PC3 cells after 48 hrs by sulforhodamine B assay	2009	Journal of medicinal chemistry, May-14, Volume: 52, Issue:9	Design, synthesis, and biological activity of boronic acid-based histone deacetylase inhibitors.
AID1201653	Antiproliferative activity against human OVCAR5 cells assessed as growth inhibition after 48 hrs by SRB assay	2015	European journal of medicinal chemistry, May-05, Volume: 95	Macrocyclic compounds as anti-cancer agents: design and synthesis of multi-acting inhibitors against HDAC, FLT3 and JAK2.
AID1816195	Inhibition of HDAC in human BT-549 cells assessed as increase in level of acetyl alpha tubulin substrate at 3 uM incubated for 12 hrs by chemiluminescence based Western blotting analysis
AID1819549	Antitumor immunity against mouse B16-F10 cells implanted in C57BL/6J mouse assessed as fold increase in downregulation of CD200R expression in spleen by flow cytometry analysis relative to control	2022	Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4	Discovery of DNA-Targeting HDAC Inhibitors with Potent Antitumor Efficacy In Vivo That Trigger Antitumor Immunity.
AID1915578	Inhibition of VEGFR2 (unknown origin)	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors.
AID71776	Tested in vivo for the inhibition of proliferation of friend leukemic cells	2002	Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15	Structure-activity relationships on phenylalanine-containing inhibitors of histone deacetylase: in vitro enzyme inhibition, induction of differentiation, and inhibition of proliferation in Friend leukemic cells.
AID482967	Volume of distribution at steady state in mouse at 10 mg/kg, iv	2010	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11	Acylurea connected straight chain hydroxamates as novel histone deacetylase inhibitors: Synthesis, SAR, and in vivo antitumor activity.
AID527042	Cytotoxicity against human NCI-H460 by SRB assay	2010	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22	Selenium-containing analogs of SAHA induce cytotoxicity in lung cancer cells.
AID1897506	Antiangiogenic activity against BALB/c mouse xenografted with human HCT-116 cells assessed as downregulation of CD31 expression in tumor at 30 mg/kg/day, po administered for 18 days by immunohistochemical staining based analysis
AID593552	Inhibition of human HDAC7 using ArgHisLysLys(Ac) fluorogenic peptide as a substrate by fluorimetric assay	2011	Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7	Oxime amides as a novel zinc binding group in histone deacetylase inhibitors: synthesis, biological activity, and computational evaluation.
AID1754778	Downregulation of NFkB1 gene expression in human MCF7 cells at 3 uM incubated for 24 hrs by whole transcriptome analysis	2021	Bioorganic & medicinal chemistry, 07-15, Volume: 42	Discovery of novel class of histone deacetylase inhibitors as potential anticancer agents.
AID1890438	Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth measured after 74 hrs by SRB assay	2022	Bioorganic & medicinal chemistry, 04-15, Volume: 60	Design, synthesis, and antitumor activity evaluation of novel acyl sulfonamide spirodienones.
AID1273872	Inhibition of HDAC6 (unknown origin)	2016	European journal of medicinal chemistry, Jan-27, Volume: 108	Synthesis, biological characterization and molecular modeling insights of spirochromanes as potent HDAC inhibitors.
AID1487016	Inhibition of HDAC2 in human U937 cells assessed as increase in acetylated-histone H3 level at 5 uM incubated for 18 hrs by Western blot method	2017	Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15	The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity.
AID1482141	Induction of mitochondrial membrane potential loss in human MOLT4 cells at 1 uM measured after 48 hrs by Rh123 dye-based flow cytometric analysis (Rvb = 9.6%)	2017	Journal of medicinal chemistry, 04-27, Volume: 60, Issue:8	Exploring Derivatives of Quinazoline Alkaloid l-Vasicine as Cap Groups in the Design and Biological Mechanistic Evaluation of Novel Antitumor Histone Deacetylase Inhibitors.
AID541655	Growth inhibition of human H460 cells after 48 hrs by SRB assay	2010	Journal of medicinal chemistry, Dec-09, Volume: 53, Issue:23	Non-natural macrocyclic inhibitors of histone deacetylases: design, synthesis, and activity.
AID273179	Induction of apoptosis in U937 cells at 5 uM by AnnexinV/PI double staining	2006	Journal of medicinal chemistry, Oct-05, Volume: 49, Issue:20	Synthesis and biological properties of novel, uracil-containing histone deacetylase inhibitors.
AID1901173	Inhibition of HDAC1/HDAC2/HDAC3 in human HCT-116 cells assessed as increase in accumulation of acetylated H3K9 at 5 uM treated for 48 hrs by Western blot analysis	2022	Bioorganic & medicinal chemistry, 02-15, Volume: 56	Synthesis and biological evaluation of aminobenzamides containing purine moiety as class I histone deacetylases inhibitors.
AID1917531	Selectivity index, ratio IC50 for inhibition of HDAC6 (unknown origin) to IC50 for inhibition of HDAC1 (unknown origin)	2022	Bioorganic & medicinal chemistry, 11-01, Volume: 73	Identification of PI3K/HDAC Dual-targeted inhibitors with subtype selectivity as potential therapeutic agents against solid Tumors: Building HDAC6 potency in a Quinazolinone-based PI3Kδ-selective template.
AID780576	Growth inhibition of human MCF7 cells after 48 hrs by MTT assay	2013	Bioorganic & medicinal chemistry, Nov-15, Volume: 21, Issue:22	Development of novel ferulic acid derivatives as potent histone deacetylase inhibitors.
AID411255	Selectivity for ratio of IC50 for human HDAC8 to IC50 for human HDAC1/2 by fluorimetric assay	2009	Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2	Non-peptide macrocyclic histone deacetylase inhibitors.
AID663345	Growth inhibition of human HL-60(TB) cells after 72 hrs by MTS assay	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Discovery and extensive in vitro evaluations of NK-HDAC-1: a chiral histone deacetylase inhibitor as a promising lead.
AID1361652	Induction of apoptosis in human A549 cells assessed as early apoptotic cells at 5 uM after 48 hrs by FITC-Annexin V/propidium iodide staining based flow cytometric analysis (Rvb = 3.10%)	2018	Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16	Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents.
AID1572357	Induction of apoptosis in human MDA-MB-231 cells at 1 to 10 uM after 48 hrs by propidium iodide-staining based FACS analysis	2019	Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3	Synthesis and Biological Investigation of Phenothiazine-Based Benzhydroxamic Acids as Selective Histone Deacetylase 6 Inhibitors.
AID1898526	Cytotoxicity against human L02 cells assessed as reduction in cell viability at 32 uM incubated for 48 hrs by MTT assay relative to control	2021	Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11	Discovery of STAT3 and Histone Deacetylase (HDAC) Dual-Pathway Inhibitors for the Treatment of Solid Cancer.
AID1363818	Cytotoxicity against human PBMC after 72 hrs by CellTiter-Glo luminescent cell viability assay	2018	Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22	Discovery of the First-in-Class Dual Histone Deacetylase-Proteasome Inhibitor.
AID1630597	Inhibition of recombinant full length C-terminal FLAG-tagged/C-terminal His-tagged human HDAC1 using fluorogenic substrate at 10 uM by fluorescence assay	2016	Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21	Synthesis and biological evaluation of santacruzamate A analogues for anti-proliferative and immunomodulatory activity.
AID310123	Inhibition of HDAC2 in HeLa cell lysates	2007	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 17, Issue:22	Omega-alkoxy analogues of SAHA (vorinostat) as inhibitors of HDAC: a study of chain-length and stereochemical dependence.
AID1415671	Half life in rat liver microsomes at 5 uM in presence of NADPH by LC-MS analysis	2017	MedChemComm, Jun-01, Volume: 8, Issue:6	Development of novel β-carboline-based hydroxamate derivatives as HDAC inhibitors with DNA damage and apoptosis inducing abilities.
AID1863440	Inhibition of HDAC8 (unknown origin) by colorimetric method	2022	European journal of medicinal chemistry, Oct-05, Volume: 240	Accommodation of ring C expanded deoxyvasicinone in the HDAC inhibitory pharmacophore culminates into a tractable anti-lung cancer agent and pH-responsive nanocarrier.
AID241474	Inhibitory concentration against maize histone deacetylase 2	2005	Journal of medicinal chemistry, May-05, Volume: 48, Issue:9	Class II (IIa)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl)pyrrolyl hydroxyamides.
AID723426	Potentiation of 5 uM cisplatin-induced toxicity in 5 uM cisplatin resistant human A2780 cells at 0.25 uM pretreated for 48 hrs followed by 5 uM cisplatin treatment by MTT assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1177054	Antiprotozoan activity against Giardia lamblia G1	2015	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 25, Issue:3	Hydroxamic acid based histone deacetylase inhibitors with confirmed activity against the malaria parasite.
AID1886185	Inhibition of HDAC3 in human HeLa cells using BOC-K(Ac)-AMC as substrate measured after 30 mins by fluorescence based microtiter plate reader assay	2022	Journal of medicinal chemistry, 08-25, Volume: 65, Issue:16	Discovery of a Novel Vascular Disrupting Agent Inhibiting Tubulin Polymerization and HDACs with Potent Antitumor Effects.
AID1487014	Inhibition of HDAC6 in human U937 cells assessed as increase in acetylated-alpha-tubulin level at 5 uM incubated for 18 hrs by Western blot method	2017	Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15	The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity.
AID1759727	Inhibition of class 1 HDAC in human Jurkat 2C4 model of HIV latency assessed as reactivation of HIV latency incubated for 18 to 24 hrs in presence of 5% heat inactivated NHS by Steady-Glo luciferase assay	2021	ACS medicinal chemistry letters, Apr-08, Volume: 12, Issue:4	Redefining the Histone Deacetylase Inhibitor Pharmacophore: High Potency with No Zinc Cofactor Interaction.
AID1403156	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	2018	European journal of medicinal chemistry, Jan-20, Volume: 144	Development of novel β-carboline-based hydroxamate derivatives as HDAC inhibitors with antiproliferative and antimetastatic activities in human cancer cells.
AID723123	Potentiation of 8 uM cisplatin-induced toxicity in 0.5 uM cisplatin resistant human KYSE-510 cells at 0.5 uM pretreated for 48 hrs followed by 0.5 uM cisplatin treatment by MTT assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID240810	Inhibitory concentration against human histone deacetylase	2005	Journal of medicinal chemistry, Feb-24, Volume: 48, Issue:4	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates.
AID1421909	Selectivity index, ratio of IC50 for human HepG2A16 cells to IC50 for drug-sensitive asexual ring stage Plasmodium falciparum 3D7 infected in human erythrocytes	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	One-pot, multi-component synthesis and structure-activity relationships of peptoid-based histone deacetylase (HDAC) inhibitors targeting malaria parasites.
AID708770	Inhibition of HDAC in human HeLa cells nuclear extracts by fluorometric assay	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	Rapid discovery of highly potent and selective inhibitors of histone deacetylase 8 using click chemistry to generate candidate libraries.
AID1126986	Inhibition of HDAC1 in human U937 cells assessed as increase of intracellular acetylated histone H3 level at 1 uM after 24 hrs by Western blot analysis	2014	Journal of medicinal chemistry, Apr-24, Volume: 57, Issue:8	Discovery of the first N-hydroxycinnamamide-based histone deacetylase 1/3 dual inhibitors with potent oral antitumor activity.
AID525010	Inhibition of HDAC7 in human CFBE41o- cell line assessed as increase in Fdelta508 CFTR protein trafficking at 1 uM every 24 hrs by immunoblot analysis	2010	Nature chemical biology, Jan, Volume: 6, Issue:1	Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.
AID1415652	Inhibition of HDAC4 in human HepG2 cells assessed as increase in acetylated-histone H3 level at 5 uM after 48 hrs by Western blot analysis	2017	MedChemComm, Jun-01, Volume: 8, Issue:6	Development of novel β-carboline-based hydroxamate derivatives as HDAC inhibitors with DNA damage and apoptosis inducing abilities.
AID1653139	Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability by SRB assay	2019	European journal of medicinal chemistry, Mar-01, Volume: 165	Quinolone hybrids and their anti-cancer activities: An overview.
AID1280279	Inhibition of class1 HDAC in human HL60 cells assessed as ratio of acetylated histone H3 to GAPDH level at 1 uM after 4 hrs by Western blot analysis relative to control	2016	Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4	Synthesis and Biological Investigation of Oxazole Hydroxamates as Highly Selective Histone Deacetylase 6 (HDAC6) Inhibitors.
AID1433250	Antiproliferative activity against human OCI-AML3 cells after 72 hrs by MTT assay	2016	Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17	Synthesis and Antileukemic Activities of Piperlongumine and HDAC Inhibitor Hybrids against Acute Myeloid Leukemia Cells.
AID371222	Cytotoxicity against human HCT116 cells	2008	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 18, Issue:24	Alpha-mercaptoketone based histone deacetylase inhibitors.
AID473175	Induction of HDAC-mediated histone acetylation in human Caco-2 cells at 5 uM after 6 hrs by indirect ELISA	2010	Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5	Biological and biophysical properties of the histone deacetylase inhibitor suberoylanilide hydroxamic acid are affected by the presence of short alkyl groups on the phenyl ring.
AID1233250	Inhibition of human recombinant HDAC1 after 15 mins by fluorogenic assay	2015	Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11	Novel Bioactive Hybrid Compound Dual Targeting Estrogen Receptor and Histone Deacetylase for the Treatment of Breast Cancer.
AID1783070	Antifungal activity against fluconazole-sensitive Candida albicans 9770 assessed as inhibition of fungal growth	2021	European journal of medicinal chemistry, Oct-05, Volume: 221	Lanosterol 14α-demethylase (CYP51)/histone deacetylase (HDAC) dual inhibitors for treatment of Candida tropicalis and Cryptococcus neoformans infections.
AID1897404	Induction of apoptosis in human SNU-16 cells assessed as live cells at 1 uM incubated for 72 hrs by annexin-V/FITC propidium iodide staining based flow cytometry analysis (Rvb = 90.92%)
AID320398	Induction of tubulin hyperacetylation in human MCF7 cells at 10 uM by Western blot	2008	Journal of medicinal chemistry, Mar-13, Volume: 51, Issue:5	Structure-activity studies on splitomicin derivatives as sirtuin inhibitors and computational prediction of binding mode.
AID1667088	Inhibition of STAT3 in human MDA-MB-231 cells assessed as slight down regulation of pSTAT3 expression at 50 to 100 uM after 24 hrs by western blot analysis	2020	Bioorganic & medicinal chemistry, 03-15, Volume: 28, Issue:6	Pyrimethamine conjugated histone deacetylase inhibitors: Design, synthesis and evidence for triple negative breast cancer selective cytotoxicity.
AID1543972	Induction of autophagy in human Bel7402/5-FU cells assessed as up regulation of LC3-2 levels at 5.0 uM incubated for 72 hrs by Western blot assay	2019	European journal of medicinal chemistry, Apr-15, Volume: 168	β-Carboline and N-hydroxycinnamamide hybrids as anticancer agents for drug-resistant hepatocellular carcinoma.
AID310183	Growth inhibition of human NUGC3 cells by SRB assay	2007	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 17, Issue:22	Modification of cap group in delta-lactam-based histone deacetylase (HDAC) inhibitors.
AID717805	Inhibition of HDAC3 using Fluor-de-Lys as substrate assessed as remaining activity at 125 nM pretreated for 30 mins before substrate addition by fluorescence assay	2012	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23	The structural requirements of histone deacetylase inhibitors: suberoylanilide hydroxamic acid analogs modified at the C6 position.
AID1855254	Antiproliferative activity against human HCT-116 cells after 48 hrs by CCK-8 assay	2022	European journal of medicinal chemistry, Nov-05, Volume: 241	Discovery of 2,5-diphenyl-1,3,4-thiadiazole derivatives as HDAC inhibitors with DNA binding affinity.
AID759303	Inhibition of human recombinant HDAC8 after 30 mins by fluorescence assay	2013	Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14	Histone deacetylase inhibitors equipped with estrogen receptor modulation activity.
AID725669	Inhibition of C-terminal His-tagged full length human recombinant HDAC2 expressed in baculovirus expression system using fluorogenic acetylated peptide as substrate preincubated with enzyme for 10 mins prior to substrate addition measured after 60 mins by	2013	ACS medicinal chemistry letters, Jan-10, Volume: 4, Issue:1	Biological evaluation of new largazole analogues: alteration of macrocyclic scaffold with click chemistry.
AID482952	Antiproliferative activity against human A2780 cells	2010	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11	Acylurea connected straight chain hydroxamates as novel histone deacetylase inhibitors: Synthesis, SAR, and in vivo antitumor activity.
AID1404301	Antiproliferative activity against human NCI-H460 cells after 72 hrs by resazurin dye based fluorescence assay	2018	ACS medicinal chemistry letters, Feb-08, Volume: 9, Issue:2	Biocompatible Boron-Containing Prodrugs of Belinostat for the Potential Treatment of Solid Tumors.
AID1754756	Inhibition of N-terminal GST-tagged human HDAC7 (518 to end residues) expressed in baculovirus-infected Sf9 cells assessed as reduction in 7-amino-4-methylcoumarin release measured every 5 mins by fluorescence based analysis	2021	Bioorganic & medicinal chemistry, 07-15, Volume: 42	Discovery of novel class of histone deacetylase inhibitors as potential anticancer agents.
AID446348	Hepatic blood flow in mouse	2010	Journal of medicinal chemistry, Jan-28, Volume: 53, Issue:2	Synthesis and biological evaluation of N-hydroxyphenylacrylamides and N-hydroxypyridin-2-ylacrylamides as novel histone deacetylase inhibitors.
AID1816214	Induction of apoptosis in human MDA-MB-231 cells assessed as late apoptotic cells at 2.5 uM measured after 48 hrs in presence of ruxolitinib by annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 5.8%)
AID1173507	Inhibition of full length N-terminal GST-tagged human HDAC11 using Arg-His-Lys-Lys(Ac) substrate incubated for 2 hrs by fluorescence assay	2014	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 24, Issue:23	Histone deacetylase inhibitors derived from 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine and related heterocycles selective for the HDAC6 isoform.
AID1371051	Antilieshmanial activity against promastigote stage of Leishmania donovani by fluorimetric assay	2017	Journal of medicinal chemistry, 06-22, Volume: 60, Issue:12	Lysine Deacetylase Inhibitors in Parasites: Past, Present, and Future Perspectives.
AID1473741	Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1709368	Induction of apoptosis in human NAMALVA cells assessed as necrotic cells at IC50 measured after 48 hrs by Annexin V-FITC/7AAD staining based flow cytometry (Rvb = 1.05%)	2021	Bioorganic & medicinal chemistry, 04-01, Volume: 35	Structure-activity relationship and mechanistic studies for a series of cinnamyl hydroxamate histone deacetylase inhibitors.
AID1785334	Inhibition of C-terminal His-tagged recombinant human HDAC3 (1 to 428 residues)/N-terminal GST-tagged recombinant human NCoR2 (395 to 489 residues) co-expressed in baculovirus infected Sf9 cells measured after 30 mins by fluorescence microplate reader ass
AID327541	Inhibition of human HDAC in HeLa cells at 1 uM	2008	Journal of medicinal chemistry, Apr-24, Volume: 51, Issue:8	Polyaminohydroxamic acids and polyaminobenzamides as isoform selective histone deacetylase inhibitors.
AID90839	Inhibition of Histone deacetylase 8 (HDAC8) of HeLa nuclear extracts	2004	Bioorganic & medicinal chemistry letters, Jan-19, Volume: 14, Issue:2	Design, synthesis, and activity of HDAC inhibitors with a N-formyl hydroxylamine head group.
AID499799	Inhibition of HDAC in human HeLa cell nuclear extracts	2010	Journal of medicinal chemistry, Aug-26, Volume: 53, Issue:16	Non-peptide macrocyclic histone deacetylase inhibitors derived from tricyclic ketolide skeleton.
AID1897494	Toxicity in BALB/c nude mouse xenografted with human SNU-16 cells assessed as reduction in body weight at 50 mg/kg/day, ip administered for 18 days and measured every 3 days
AID1141784	Inhibition of HDAC in human HCT116 cells assessed as increase in alpha-tubulin acetylation after 3 hrs by Western blotting analysis	2014	Journal of medicinal chemistry, May-22, Volume: 57, Issue:10	Azaindolylsulfonamides, with a more selective inhibitory effect on histone deacetylase 6 activity, exhibit antitumor activity in colorectal cancer HCT116 cells.
AID1215096	Activation of human PXR expressed in human HepG2 (DPX-2) cells after 24 hrs by luciferase reporter gene based luminescent analysis relative to rifampicin	2011	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1	Identification of clinically used drugs that activate pregnane X receptors.
AID1401903	Inhibition of human recombinant HDAC2 using Fluor de Lys-Green as substrate preincubated for 5 mins followed by substrate addition and measured after 1 hr by fluorescence assay	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
AID1631200	Inhibition of HDAC8 (unknown origin) using fluorophore-conjugated substrate by fluorescence assay	2016	ACS medicinal chemistry letters, Oct-13, Volume: 7, Issue:10	Development of a Potent and Selective HDAC8 Inhibitor.
AID1164907	Inhibition of HDAC2 (unknown origin) using fluorogenic peptide as substrate by fluorescence assay	2014	Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19	Identification of a novel aminotetralin class of HDAC6 and HDAC8 selective inhibitors.
AID663365	Growth inhibition of human OVCAR4 cells after 72 hrs by MTS assay	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Discovery and extensive in vitro evaluations of NK-HDAC-1: a chiral histone deacetylase inhibitor as a promising lead.
AID663366	Growth inhibition of human OVCAR5 cells after 72 hrs by MTS assay	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Discovery and extensive in vitro evaluations of NK-HDAC-1: a chiral histone deacetylase inhibitor as a promising lead.
AID1811379	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell growth measured after 2 days by CCK8 assay	2021	European journal of medicinal chemistry, Dec-15, Volume: 226	Development of novel tetrahydroisoquinoline-hydroxamate conjugates as potent dual SERDs/HDAC inhibitors for the treatment of breast cancer.
AID723440	Potentiation of 1 uM cisplatin-induced toxicity in 1 uM cisplatin resistant human CAL27 cells at 1 uM pretreated for 48 hrs followed by 1 uM cisplatin treatment by MTT assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1128562	Inhibition of human HDAC-10 using RHKK(Ac) as substrate	2014	European journal of medicinal chemistry, Apr-09, Volume: 76	4,5,6,7-Tetrahydro-isoxazolo-[4,5-c]-pyridines as a new class of cytotoxic Hsp90 inhibitors.
AID1633438	Immunomodulatory activity in LPS treated Wistar rat primary microglial cells assessed as decrease in MRC1 expression level at 5 to 50 uM incubated for 24 hrs by western blot analysis	2019	ACS medicinal chemistry letters, Apr-11, Volume: 10, Issue:4	Discovery of the First-in-Class GSK-3β/HDAC Dual Inhibitor as Disease-Modifying Agent To Combat Alzheimer's Disease.
AID308647	Antiproliferative activity against human drug-resistant PT45 cells	2007	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17	Design, synthesis, and evaluation of isoindolinone-hydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors.
AID90345	Ability to inhibit recombinant human histone deacetylase 1 (HDAC-1); Potent inhibitor	2004	Bioorganic & medicinal chemistry letters, Jan-05, Volume: 14, Issue:1	(2-amino-phenyl)-amides of omega-substituted alkanoic acids as new histone deacetylase inhibitors.
AID1454031	Inhibition of recombinant human N-terminal His-tagged BRD4 bromodomain 1 (49 to 170 residues) expressed in Escherichia coli at 100 uM using biotinylated peptide containing acetylated lysine as substrate pretreated for 15 mins followed by substrate additio	2017	Bioorganic & medicinal chemistry, 07-15, Volume: 25, Issue:14	Synthesis and evaluation of novel dual BRD4/HDAC inhibitors.
AID1410362	Antitumor activity against mouse LLC cells implanted in immunocompetent C57BL/6 mouse assessed as tumor growth inhibition at 100 mg/kg, po qd administered via gavage for 14 consecutive days measured every 4 days relative to control	2018	ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4	Discovery of Novel Indoleamine 2,3-Dioxygenase 1 (IDO1) and Histone Deacetylase (HDAC) Dual Inhibitors.
AID374830	Antiproliferative activity against human MCF7 cells after 72 hrs by celltiter-blue cell viability assay	2009	Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11	Discovery of a potent class I selective ketone histone deacetylase inhibitor with antitumor activity in vivo and optimized pharmacokinetic properties.
AID1164921	Induction of cell differentiation in human BE(2)-C cells assessed as neurite outgrowth at 2 uM by CCK-8 assay	2014	Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19	Identification of a novel aminotetralin class of HDAC6 and HDAC8 selective inhibitors.
AID1168913	Inhibition of HDAC1/HDAC2 in human HeLa cell extract incubated for 5 mins prior to substrate addition measured after 30 mins by microtitre plate reader analysis	2014	Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21	Improved antiproliferative activity of 1,3,4-thiadiazole-containing histone deacetylase (HDAC) inhibitors by introduction of the heteroaromatic surface recognition motif.
AID1547264	Inhibition of HDAC10 (unknown origin) using biotinylated histone H3 KAc peptide (1 to 21 residues) as substrate by HTRF assay	2020	Journal of medicinal chemistry, 04-09, Volume: 63, Issue:7	Discovery of Thieno[2,3-
AID591330	Inhibition of HDAC in human HeLa cells by fluorescent activity assay	2011	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8	Alkyl piperidine and piperazine hydroxamic acids as HDAC inhibitors.
AID761581	Antiproliferative activity against human A549 cells after 72 hrs by CellTiter-Glo assay	2013	European journal of medicinal chemistry, Aug, Volume: 66	Design, synthesis and preliminary evaluation of a series of histone deacetylase inhibitors carrying a benzodiazepine ring.
AID258011	Inhibition of HDAC in human leukemic CEM cells	2006	Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2	Aromatic sulfide inhibitors of histone deacetylase based on arylsulfinyl-2,4-hexadienoic acid hydroxyamides.
AID1322159	Inhibition of recombinant human full length GST-tagged HDAC8 expressed in Escherichia coli DH5alpha (DE3) assessed as inhibition of deacetylation activity using Fluor-de-Lys as substrate measured after 15 mins by fluorimetric assay	2016	Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21	Design and synthesis of novel HDAC8 inhibitory 2,5-disubstituted-1,3,4-oxadiazoles containing glycine and alanine hybrids with anti cancer activity.
AID1433270	Inhibition of HDAC in p53 null human U937 cells assessed as hyper acetylation of histone H4 at 1 uM after 4 hrs by Western blot analysis	2016	Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17	Synthesis and Antileukemic Activities of Piperlongumine and HDAC Inhibitor Hybrids against Acute Myeloid Leukemia Cells.
AID1476151	Antiproliferative activity against human HEL 92.1.7 cells after 36 hrs by PrestoBlue dye based assay	2017	Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20	Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat.
AID1275585	Inhibition of HDAC in mouse forebrain assessed as acetylation of histone H3K9 at 10 uM after 24 hrs by immunofluorescence-based detection analysis	2016	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4	Dissecting structure-activity-relationships of crebinostat: Brain penetrant HDAC inhibitors for neuroepigenetic regulation.
AID1655800	Cytotoxicity against human U937 cells assessed as reduction in cell viability at 0.25 uM incubated for 72 hrs by CellTiter-Glo Luminescent cell viability assay relative to control	2020	ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5	Design of First-in-Class Dual EZH2/HDAC Inhibitor: Biochemical Activity and Biological Evaluation in Cancer Cells.
AID723470	Inhibition of HDAC in cisplatin sensitive human CAL27 cells after 18 hrs by fluorescence assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1200976	Intrinsic clearance in mouse liver microsomes at 1 uM preincubated for 10 mins followed by NADPH addition measured over 30 mins by LC-MS/MS analysis	2015	Journal of medicinal chemistry, Mar-26, Volume: 58, Issue:6	Design and synthesis of orally bioavailable aminopyrrolidinone histone deacetylase 6 inhibitors.
AID618093	Toxicity in nude BALB/c mouse xenografted with human HCT116 cells assessed as body weight loss at 200 mg/kg, po QD for 21 days measured on day 19	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile.
AID456797	Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D6 infected in African green monkey (Cercopithecus aethiops) Vero cells assessed as parasite LDH activity after 72 hrs by Malstat reagent method	2010	Bioorganic & medicinal chemistry, Jan-01, Volume: 18, Issue:1	Antimalarial and antileishmanial activities of histone deacetylase inhibitors with triazole-linked cap group.
AID761577	Induction of apoptosis in human NB4 cells after 48 hrs by Annexin V test	2013	European journal of medicinal chemistry, Aug, Volume: 66	Design, synthesis and preliminary evaluation of a series of histone deacetylase inhibitors carrying a benzodiazepine ring.
AID1426425	Antiparasitic activity against drug-resistant Plasmodium falciparum Dd2 infected in erythrocytes assessed as growth inhibition after 48 hrs by [3H]-hypoxanthine incorporation assay	2017	European journal of medicinal chemistry, Feb-15, Volume: 127	Synthesis, biological characterisation and structure activity relationships of aromatic bisamidines active against Plasmodium falciparum.
AID1742224	AUC (0 to t) in Beagle dog at 20 mg/kg, po by LC-MS/MS analysis	2020	European journal of medicinal chemistry, Nov-01, Volume: 205	Design, synthesis and biological evaluation of novel HDAC inhibitors with improved pharmacokinetic profile in breast cancer.
AID105420	Concentration required for the antiproliferation of Human MDA-435 breast carcinoma cells	2002	Bioorganic & medicinal chemistry letters, Oct-21, Volume: 12, Issue:20	Succinimide hydroxamic acids as potent inhibitors of histone deacetylase (HDAC).
AID672033	Ratio of IC50 for human HDAC2 preincubated for 3 hrs to IC50 for human HDAC2 preincubated for 5 mins	2012	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 22, Issue:15	Design, synthesis, modeling, biological evaluation and photoaffinity labeling studies of novel series of photoreactive benzamide probes for histone deacetylase 2.
AID1600733	Antiproliferative activity against human CAL27 cells after 72 hrs by microplate reader based MTT assay	2019	Bioorganic & medicinal chemistry, 10-01, Volume: 27, Issue:19	Novel α,β-unsaturated hydroxamic acid derivatives overcome cisplatin resistance.
AID1462024	Antiproliferative activity against human U937 cells after 48 hrs by MTT assay	2017	Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17	Discovery of a tetrahydroisoquinoline-based HDAC inhibitor with improved plasma stability.
AID1863175	Selectivity index, ratio of IC50 for HDAC3 (unknown origin) to IC50 for HDAC6 (unknown origin)	2022	European journal of medicinal chemistry, Oct-05, Volume: 240	Design, synthesis, and biological evalution of bifunctional inhibitors against Hsp90-HDAC6 interplay.
AID1410326	Antiproliferative activity against mouse LLC cells after 48 hrs by CCK-8 assay	2018	ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4	Discovery of Novel Indoleamine 2,3-Dioxygenase 1 (IDO1) and Histone Deacetylase (HDAC) Dual Inhibitors.
AID1865300	Toxicity in BALB/c mouse model allografted with mouse 4T1 cells assessed as effect on liver at 40 mg/kg, po qd administered for 12 days	2022	Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18	Discovery of Novel Src Homology-2 Domain-Containing Phosphatase 2 and Histone Deacetylase Dual Inhibitors with Potent Antitumor Efficacy and Enhanced Antitumor Immunity.
AID1330924	Inhibition of wild-type EGFR (unknown origin) assessed as remaining ATP level measured after 15 mins by luminescence analysis	2017	Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1	Synthesis and investigation of novel 6-(1,2,3-triazol-4-yl)-4-aminoquinazolin derivatives possessing hydroxamic acid moiety for cancer therapy.
AID1467045	Effect on renilla recombinant luciferase protein expressed in HEK293 cells at 10 uM after 24 hrs in presence of 10 uM cycloheximide by renilla luciferase reporter gene assay	2017	Journal of medicinal chemistry, 06-08, Volume: 60, Issue:11	Discovery of a Small Molecule Probe That Post-Translationally Stabilizes the Survival Motor Neuron Protein for the Treatment of Spinal Muscular Atrophy.
AID1324232	Antagonist activity at AR in human LNCAP cells assessed as suppression of DHT-induced AR protein level at 10 uM measured after 24 hrs relative to control	2016	Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21	Targeting prostate cancer with compounds possessing dual activity as androgen receptor antagonists and HDAC6 inhibitors.
AID1410324	Inhibition of recombinant human GST-tagged IDO1 (1 to 404 residues) using D-Tryptophan as substrate	2018	ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4	Discovery of Novel Indoleamine 2,3-Dioxygenase 1 (IDO1) and Histone Deacetylase (HDAC) Dual Inhibitors.
AID316902	Inhibition of human SNB78 cells	2008	Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6	Histone deacetylase inhibitors: from bench to clinic.
AID1409642	Inhibition of HDAC in human K562 cells using Boc-K(Ac)-AMC as substrate by fluorescence assay	2018	ACS medicinal chemistry letters, Mar-08, Volume: 9, Issue:3	Histone Deacetylase Inhibitors as Treatment for Targeting Multiple Components in Cancer Therapy.
AID1758467	Inhibition of human recombinant HDAC3 using Ac-Leu-Gly-Lys(Ac)-AMC as substrate by measuring fluorescence intensity incubated for 30 mins by microplate reader assay	2021	European journal of medicinal chemistry, May-05, Volume: 217	Novel dual-mode antitumor chlorin-based derivatives as potent photosensitizers and histone deacetylase inhibitors for photodynamic therapy and chemotherapy.
AID414718	Inhibition of human recombinant HDAC6 expressed in HEK293 cells	2009	Journal of medicinal chemistry, Apr-23, Volume: 52, Issue:8	Design of chimeric histone deacetylase- and tyrosine kinase-inhibitors: a series of imatinib hybrides as potent inhibitors of wild-type and mutant BCR-ABL, PDGF-Rbeta, and histone deacetylases.
AID1168916	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	2014	Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21	Improved antiproliferative activity of 1,3,4-thiadiazole-containing histone deacetylase (HDAC) inhibitors by introduction of the heteroaromatic surface recognition motif.
AID1466057	Growth inhibition of human PC3 cells after 48 hrs by sulforhodamine B assay	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	4-Indolyl-N-hydroxyphenylacrylamides as potent HDAC class I and IIB inhibitors in vitro and in vivo.
AID246082	Effective Concentration of compound to inhibit the growth of human RXF-631L cells	2005	Journal of medicinal chemistry, Feb-24, Volume: 48, Issue:4	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates.
AID1464879	Inhibition of recombinant human ERG expressed in HEK293 cells at -80 mV holding potential measured for 9 mins by Qpatch clamp method	2017	Bioorganic & medicinal chemistry letters, 11-01, Volume: 27, Issue:21	Design, synthesis and biological evaluation of novel histone deacetylase inhibitors incorporating 4-aminoquinazolinyl systems as capping groups.
AID1769649	Inhibition of HDAC2 (unknown origin)	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	Discovery of 2,4-pyrimidinediamine derivatives as potent dual inhibitors of ALK and HDAC.
AID613114	Cell cycle arrest in human U937 cells assessed as accumulation at G1 phase at 5 uM after 30 hrs by propidium iodide staining based flow cytometry	2011	Bioorganic & medicinal chemistry, Jun-15, Volume: 19, Issue:12	Epigenetic profiling of the antitumor natural product psammaplin A and its analogues.
AID1897401	Induction of apoptosis in human SNU-16 cells assessed as early apoptotic cells at 0.3 uM incubated for 72 hrs by annexin-V/FITC propidium iodide staining based flow cytometry analysis (Rvb = 3.02%)
AID1260647	Inhibition of human recombinant HDAC11 at 20 uM using Boc-Lys(Tfa)-AMC as substrate after 30 to 60 mins by microplate reader assay
AID1784974	Antiproliferative activity against human CNE-2 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Design, synthesis and biological evaluation of novel hybrids targeting mTOR and HDACs for potential treatment of hepatocellular carcinoma.
AID1816697	Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability after 72 hrs by CellTiter-Glo assay	2021	European journal of medicinal chemistry, Aug-05, Volume: 220	Design, synthesis, and biological evaluation of novel dual inhibitors targeting lysine specific demethylase 1 (LSD1) and histone deacetylases (HDAC) for treatment of gastric cancer.
AID669763	Inhibition of human recombinant HDAC6 after 30 mins by fluorometric assay	2012	Journal of medicinal chemistry, Apr-26, Volume: 55, Issue:8	Synthesis and biological evaluation of 1-arylsulfonyl-5-(N-hydroxyacrylamide)indoles as potent histone deacetylase inhibitors with antitumor activity in vivo.
AID1361640	Inhibition of HDAC6 in human A549 cells assessed as increase in alpha-tubulin acetylation at 2.5 to 5 uM after 24 hrs by Western blot analysis	2018	Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16	Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents.
AID1399810	Solubility in PG/EtOH (96%) at 30 mg/mL after 24 hrs by UV-spectrometric method	2018	Bioorganic & medicinal chemistry letters, 09-15, Volume: 28, Issue:17	Squaramides as novel class I and IIB histone deacetylase inhibitors for topical treatment of cutaneous t-cell lymphoma.
AID723456	Potentiation of cisplatin-induced toxicity in cisplatin resistant human KYSE-510 cells at 1 uM pretreated for 48 hrs followed by cisplatin treatment by MTT assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1861306	Induction of cell cycle arrest in human DOHH-2 cells assessed as accumulation at G2/M phase measured by flow cytometry analysis	2022	Bioorganic & medicinal chemistry letters, 09-01, Volume: 71	Bioevaluation of a dual PI3K/HDAC inhibitor for the treatment of diffuse large B-cell lymphoma.
AID1279125	Inhibition of C-terminal GST-tagged human recombinant HDAC2 expressed in Sf9 cells after 30 mins by microtiter plate reader analysis	2016	Bioorganic & medicinal chemistry, Apr-01, Volume: 24, Issue:7	Design and synthesis of a new generation of substituted purine hydroxamate analogs as histone deacetylase inhibitors.
AID476652	Toxicity in FVB mouse assessed as effect on number of platelets at 50 mg/kg, po administered 5 times per week for 2 weeks (Rvb = 514 +/- 42.8 10^3/mm^3)	2010	Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8	Modified cap group suberoylanilide hydroxamic acid histone deacetylase inhibitor derivatives reveal improved selective antileukemic activity.
AID1600732	Inhibition of HDAC in human A2780 cells using Boc-Lys(epsilon-Ac)-AMC as substrate preincubated for 18 hrs followed by substrate addition and further incubation for 3 hrs by microplate reader based fluorescence assay	2019	Bioorganic & medicinal chemistry, 10-01, Volume: 27, Issue:19	Novel α,β-unsaturated hydroxamic acid derivatives overcome cisplatin resistance.
AID1355729	Toxicity in BALB/C nude mouse xenografted with human HEL cells at 10 mg/kg, ip bid treated for 21 consecutive days	2018	Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14	Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections.
AID1193537	Inhibition of isolated rat liver HDAC using substrate containing acetylated lysine side chain assessed as release of fluorophore at 0.1 uM by Fluor de Lys assay	2015	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7	Benzofused hydroxamic acids: useful fragments for the preparation of histone deacetylase inhibitors. Part 2: 7-fluorobenzothiophenes and benzofurans.
AID737918	Inhibition of recombinant HMG-CoA reductase (unknown origin) after 10 mins by spectrophotometric analysis	2013	Journal of medicinal chemistry, May-09, Volume: 56, Issue:9	Design and synthesis of dual-action inhibitors targeting histone deacetylases and 3-hydroxy-3-methylglutaryl coenzyme A reductase for cancer treatment.
AID1235259	Cytotoxicity against human K562 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	2015	Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15	Design, synthesis and preliminary bioactivity evaluations of substituted quinoline hydroxamic acid derivatives as novel histone deacetylase (HDAC) inhibitors.
AID1730857	Inhibition of HDAC1 (unknown origin)	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Design, synthesis and evaluation of novel ErbB/HDAC multitargeted inhibitors with selectivity in EGFR
AID1865241	Antiproliferative activity against human KYSE520 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	2022	Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18	Discovery of Novel Src Homology-2 Domain-Containing Phosphatase 2 and Histone Deacetylase Dual Inhibitors with Potent Antitumor Efficacy and Enhanced Antitumor Immunity.
AID1633654	Inhibition of human recombinant HDAC6 using ZMAL (Z-(Ac)Lys-AMC fluorogenic substrate incubated for 90 mins by fluorescence method	2019	ACS medicinal chemistry letters, Apr-11, Volume: 10, Issue:4	Novel Sustainable-by-Design HDAC Inhibitors for the Treatment of Alzheimer's Disease.
AID672021	Inhibition of human recombinant HDAC1 using Boc-L-Lys (Ac)-AMC as substrate preincubated with compound for 5 mins measured after 35 mins by spectrofluorometric analysis	2012	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 22, Issue:15	Design, synthesis, modeling, biological evaluation and photoaffinity labeling studies of novel series of photoreactive benzamide probes for histone deacetylase 2.
AID331899	Displacement of fluorescent 5-(3-(3-(4-((4-((7-(hydroxyamino)-7-oxoheptyl)carbamoyl)phenylamino)methyl)-1H-1,2,3-triazol-1-yl)propyl)thioureido)-2-(3-hydroxy-6-oxo-6H-xanthen-9-yl)benzoic acid from human HDAC3/NcoR2 by fluorescence polarization assay	2008	Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9	Development of a fluorescence polarization based assay for histone deacetylase ligand discovery.
AID1225976	Cytotoxicity against HLF assessed as growth inhibition after 72 hrs by MTT assay	2015	ACS medicinal chemistry letters, Mar-12, Volume: 6, Issue:3	Discovery of Novel Multiacting Topoisomerase I/II and Histone Deacetylase Inhibitors.
AID1401377	Inhibition of HDAC1 in human HeLa-S3 cell lysates assessed as remaining activity at 1 uM preincubated for 15 mins followed by HDAC-Glo substrate addition measured after 30 to 40 mins by fluorimetric method relative to control	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
AID1449216	Inhibition of full length human recombinant C-terminal His-tagged HDAC3/NcoR2 expressed in baculovirus infected Sf9 insect cells using Boc-Lys(epsilon-Ac)-AMC as substrate measured after 90 mins by fluorescence assay	2017	Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13	Design, Multicomponent Synthesis, and Anticancer Activity of a Focused Histone Deacetylase (HDAC) Inhibitor Library with Peptoid-Based Cap Groups.
AID613122	Inhibition of HDAC1 in human U937 cells assessed as up-regulation of p21 / WAF1 at 5 uM after 24 hrs by Western blot analysis	2011	Bioorganic & medicinal chemistry, Jun-15, Volume: 19, Issue:12	Epigenetic profiling of the antitumor natural product psammaplin A and its analogues.
AID1493593	Inhibition of human recombinant full-length C-terminal GST-tagged HDAC3 expressed in baculovirus infected Sf9 cells using Boc-Lys(acetyl)-AMC as substrate after 30 mins by fluorescence assay	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Discovery of a fluorescent probe with HDAC6 selective inhibition.
AID622257	Inhibition of HDAC6 after 30 mins by Fluor de Lys fluorescence assay	2011	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 21, Issue:20	The structural requirements of histone deacetylase inhibitors: Suberoylanilide hydroxamic acid analogs modified at the C3 position display isoform selectivity.
AID1451848	Antitumor activity against human HCT116 cells xenografted in BALB/C nude mouse assessed as tumor growth inhibition at 25 mg/kg, ip bid administered for 21 consecutive days measured after 30 to 33 days post implantation relative to control	2017	Journal of medicinal chemistry, 10-12, Volume: 60, Issue:19	Small Molecule Inhibitors Simultaneously Targeting Cancer Metabolism and Epigenetics: Discovery of Novel Nicotinamide Phosphoribosyltransferase (NAMPT) and Histone Deacetylase (HDAC) Dual Inhibitors.
AID1783110	Inhibition of HDAC8 (unknown origin) using Ac-LeuGlyLys(tfa)-AMC as substrate preincubated for 10 mins followed by substrate addition and further incubated for incubated for 1 hrs by fluorescence microtiter plate reader assay	2021	European journal of medicinal chemistry, Oct-05, Volume: 221	Design, synthesis and biological evaluation of 3, 4-disubstituted-imidazolidine-2, 5-dione derivatives as HDAC6 selective inhibitors.
AID1486306	Antiproliferative activity against human Raji cells after 3 days by MTT assay	2017	Bioorganic & medicinal chemistry, 08-01, Volume: 25, Issue:15	Olaparib hydroxamic acid derivatives as dual PARP and HDAC inhibitors for cancer therapy.
AID1511157	Inhibition of HDAC in human HL60 cells assessed as increase in acetylation of H3 at 0.08 to 1.6 uM incubated for 24 hrs by western blot analysis	2019	ACS medicinal chemistry letters, Aug-08, Volume: 10, Issue:8	Design, Synthesis, and Biological Evaluation of 2,4-Imidazolinedione Derivatives as HDAC6 Isoform-Selective Inhibitors.
AID1811367	Antiproliferative activity against human MCF7 cells assessed as reduction in cell growth measured after 6 days by WST8 assay	2021	European journal of medicinal chemistry, Dec-15, Volume: 226	Development of novel tetrahydroisoquinoline-hydroxamate conjugates as potent dual SERDs/HDAC inhibitors for the treatment of breast cancer.
AID1061949	Inhibition of human HDAC11 using RHKK(Ac) as substrate by fluorimetric analysis	2014	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1	Lactam based 7-amino suberoylamide hydroxamic acids as potent HDAC inhibitors.
AID1622973	Inhibition of HDAC4 (unknown origin)	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.
AID1897382	Antiproliferative activity against human A2780 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
AID1614122	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
AID1832685	Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 48 hrs by CCK8 assay	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Cysteine derivatives as acetyl lysine mimics to inhibit zinc-dependent histone deacetylases for treating cancer.
AID1415640	Antiproliferative activity against human SMMC7721 cells after 48 hrs by MTT assay	2017	MedChemComm, Jun-01, Volume: 8, Issue:6	Development of novel β-carboline-based hydroxamate derivatives as HDAC inhibitors with DNA damage and apoptosis inducing abilities.
AID1326509	Inhibition of C-terminal His/FLAG-tagged full length recombinant human HDAC1 expressed in baculovirus expression system assessed as release of 7-amino-4-methylcoumarin by fluorogenic assay	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	2-(Phenylsulfonyl)quinoline N-hydroxyacrylamides as potent anticancer agents inhibiting histone deacetylase.
AID1459954	Inhibition of recombinant human HDAC2 using fluorogenic substrate by fluorescence assay	2017	European journal of medicinal chemistry, Jan-05, Volume: 125	3-Aroylindoles display antitumor activity in vitro and in vivo: Effects of N1-substituents on biological activity.
AID1888405	Synergistic antifungal activity against azole-resistant Candida albicans 0304103 assessed as fractional inhibitory concentration in presence of fluconazole incubated for 48 hrs by CLSI based checkerboard microdilution assay	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	Heat shock protein 90 (Hsp90)/Histone deacetylase (HDAC) dual inhibitors for the treatment of azoles-resistant Candida albicans.
AID1764250	Antiproliferative activity against human CAL-27 cells assessed as reduction in cell viability after 72 hrs by MTT assay	2021	European journal of medicinal chemistry, Feb-05, Volume: 211	Synergistic induction of apoptosis in resistant head and neck carcinoma and leukemia by alkoxyamide-based histone deacetylase inhibitors.
AID1275646	Growth inhibition of human Aspc-1 cells after 96 hrs by MTT assay	2016	European journal of medicinal chemistry, Feb-15, Volume: 109	Identification of N-(6-mercaptohexyl)-3-(4-pyridyl)-1H-pyrazole-5-carboxamide and its disulfide prodrug as potent histone deacetylase inhibitors with in vitro and in vivo anti-tumor efficacy.
AID540209	Volume of distribution at steady state in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1441684	Anti-inflammatory activity in BLM-induced C57BL/6 mouse model of acute lung injury assessed as reduction in IL-1beta mRNA level in BALF compound administered intraperitoneally once daily for 7 days post BLM challenge measured on day 7 by qRT-PCR method	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
AID1487043	Inhibition of HDAC in human HeLa-S3 cells lysates assessed as remaining enzyme activity at 2.5 x 10'-8 M pre-incubated for 15 mins before HDAC-Glo I/II substrate addition and measured after 30 mins post substrate addition	2017	Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15	The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity.
AID1650413	Inhibition of HDAC in human A2780 cells	2020	Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1	Novel alkoxyamide-based histone deacetylase inhibitors reverse cisplatin resistance in chemoresistant cancer cells.
AID1821966	Cytotoxicity against human Jurkat cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
AID1250640	Inhibition of recombinant human HDAC1 after 60 mins by fluorescence assay	2015	Journal of medicinal chemistry, Oct-08, Volume: 58, Issue:19	Discovery of Novel Class I Histone Deacetylase Inhibitors with Promising in Vitro and in Vivo Antitumor Activities.
AID669758	Growth inhibition of human MDA-MB-231 cells after 48 hrs by SRB assay	2012	Journal of medicinal chemistry, Apr-26, Volume: 55, Issue:8	Synthesis and biological evaluation of 1-arylsulfonyl-5-(N-hydroxyacrylamide)indoles as potent histone deacetylase inhibitors with antitumor activity in vivo.
AID1720109	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by MTT assay	2020	Journal of medicinal chemistry, 09-10, Volume: 63, Issue:17	Dual-Target Inhibitors Based on HDACs: Novel Antitumor Agents for Cancer Therapy.
AID1808542	Inhibition of recombinant human full length HDAC11 expressed in baculovirus infected Sf9 cells measured after 60 mins by FRET assay	2021	Journal of medicinal chemistry, 04-08, Volume: 64, Issue:7	Structure-Based Design of a Selective Class I Histone Deacetylase (HDAC) Near-Infrared (NIR) Probe for Epigenetic Regulation Detection in Triple-Negative Breast Cancer (TNBC).
AID723155	Potentiation of 1 uM cisplatin-induced toxicity in 0.5 uM cisplatin resistant human KYSE-510 cells at 0.5 uM pretreated for 48 hrs followed by 0.5 uM cisplatin treatment by MTT assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1181305	Inhibition of human recombinant HDAC6 pre-incubated at room temperature for 15 min before substrate addition by fluorimetric assay	2014	Journal of medicinal chemistry, Jul-24, Volume: 57, Issue:14	1,3,4-Oxadiazole-containing histone deacetylase inhibitors: anticancer activities in cancer cells.
AID544094	Cytotoxicity against mouse RAW264.7 cells by MTT assay	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Antimalarial activity of phenylthiazolyl-bearing hydroxamate-based histone deacetylase inhibitors.
AID1478588	Induction of apoptosis in human K562 cells assessed as early apoptotic cells at 1 uM after 24 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometry (Rvb = 4.78%)	2017	European journal of medicinal chemistry, Jun-16, Volume: 133	Design, synthesis and biological evaluation of quinoline derivatives as HDAC class I inhibitors.
AID1677511	Inhibition of HDAC2 (unknown origin) in using Boc-Lys(acetyl)-AMC or Boc-Lys (triflouroacetyl)-AMC as substrate preincubated for 5 mins followed by substrate addition and measured after 30 mins by fluorescence assay	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	HDAC-Bax Multiple Ligands Enhance Bax-Dependent Apoptosis in HeLa Cells.
AID618020	Antitumor activity against human HCT116 cells xenografted in BALB/c nu mouse assessed as tumor growth inhibition at 90 mg/kg, po qd for 19 days relative to control	2011	Journal of medicinal chemistry, Aug-11, Volume: 54, Issue:15	Discovery of a tetrahydroisoquinoline-based hydroxamic acid derivative (ZYJ-34c) as histone deacetylase inhibitor with potent oral antitumor activities.
AID1855242	Inhibition of HDAC1/HDAC2 in human HeLa cell nuclear extract using Boc-Lys(Ac)-AMC as substrate and measured by fluorometric method	2022	European journal of medicinal chemistry, Nov-05, Volume: 241	Discovery of 2,5-diphenyl-1,3,4-thiadiazole derivatives as HDAC inhibitors with DNA binding affinity.
AID489912	Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay	2010	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 20, Issue:13	Design, synthesis and anticancer activity of piperazine hydroxamates and their histone deacetylase (HDAC) inhibitory activity.
AID663396	Growth inhibition of human Hs 578T cells after 72 hrs by MTS assay	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Discovery and extensive in vitro evaluations of NK-HDAC-1: a chiral histone deacetylase inhibitor as a promising lead.
AID1361648	Induction of apoptosis in human A549 cells assessed as early apoptotic cells at 1 uM after 48 hrs by FITC-Annexin V/propidium iodide staining based flow cytometric analysis (Rvb = 3.10%)	2018	Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16	Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents.
AID1389949	Inhibition of human recombinant LSD1/CoREST3 expressed in Escherichia coli using monomethylatedH3meK4 peptide as substrate preincubated for 15 mins followed by substrate addition measured after 12 mins by fluorescence based assay	2018	Bioorganic & medicinal chemistry letters, 04-01, Volume: 28, Issue:6	Novel polyamine-based Histone deacetylases-Lysine demethylase 1 dual binding inhibitors.
AID1855247	Binding affinity to calf thymus DNA at 50 uM incubated for 30 mins and measured by fluorescence spectroscopy	2022	European journal of medicinal chemistry, Nov-05, Volume: 241	Discovery of 2,5-diphenyl-1,3,4-thiadiazole derivatives as HDAC inhibitors with DNA binding affinity.
AID421213	Inhibition of HDAC from human HeLa cells assessed as of histone H3 acetylation at 5 uM	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Recent advances in the development of polyamine analogues as antitumor agents.
AID316898	Inhibition of HDAC2	2008	Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6	Histone deacetylase inhibitors: from bench to clinic.
AID1865264	Inhibition of recombinant his-tagged human HDAC8 using Boc-Lys (TFA)-AMC substrate preincubated for 5 mins followed by substrate addition and measured after 30 mins by fluorescence based microplate reader analysis	2022	Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18	Discovery of Novel Src Homology-2 Domain-Containing Phosphatase 2 and Histone Deacetylase Dual Inhibitors with Potent Antitumor Efficacy and Enhanced Antitumor Immunity.
AID1410012	Reactivation of latent HIV1 infected in human U1 cells assessed as increase in p24 production after 48 hrs by ELISA relative to vorinostat	2018	ACS medicinal chemistry letters, Mar-08, Volume: 9, Issue:3	Elimination of HIV-1 Latently Infected Cells by Gnidimacrin and a Selective HDAC Inhibitor.
AID1336937	Inhibition of HDAC in human LNCAP cells assessed as down regulation of androgen receptor expression at 10 uM after 24 hrs by Western blot analysis	2017	Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3	Bifunctional conjugates with potent inhibitory activity towards cyclooxygenase and histone deacetylase.
AID1578147	Inhibition of HDAC in human K562 nuclear extract	2020	European journal of medicinal chemistry, Jan-01, Volume: 185	N-alkyl-hydroxybenzoyl anilide hydroxamates as dual inhibitors of HDAC and HSP90, downregulating IFN-γ induced PD-L1 expression.
AID1065960	Cytotoxicity against human Jurkat cells assessed as growth inhibition after 72 hrs by MTS assay	2013	Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24	Synthesis and structure-activity relationship of 3-hydroxypyridine-2-thione-based histone deacetylase inhibitors.
AID732152	Inhibition of HDAC6 (unknown origin) assessed as fluorescence intensity measured after 60 mins incubation at room temperature by trypsin-free microfluidic lab-on-a-chip assay	2013	Journal of medicinal chemistry, Feb-28, Volume: 56, Issue:4	Potent and selective inhibition of histone deacetylase 6 (HDAC6) does not require a surface-binding motif.
AID1848629	Cytotoxicity against human CAKI-1 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay	2022	Journal of medicinal chemistry, 11-10, Volume: 65, Issue:21	First-in-Class Dual Mechanism Ferroptosis-HDAC Inhibitor Hybrids.
AID404446	Cytotoxicity against nontransformed human microvascular epithelial cells	2008	Journal of medicinal chemistry, Jun-26, Volume: 51, Issue:12	A series of potent and selective, triazolylphenyl-based histone deacetylases inhibitors with activity against pancreatic cancer cells and Plasmodium falciparum.
AID619045	Antiproliferative activity against human PC3 cells after 96 hrs by celltiter 96 assay	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile.
AID1652190	Inhibition of human recombinant HDAC1 expressed in Escherichia coli BL21(DE3) cells using KL177 as substrate preincubated for 5 followed by substrate addition and measured after 30 mins by fluorescence based assay	2020	ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5	New Dual CK2/HDAC1 Inhibitors with Nanomolar Inhibitory Activity against Both Enzymes.
AID1550108	Antiproliferative activity against human MOLT4 cells assessed as reduction in cell viability after 48 hrs by MTT assay	2019	Journal of medicinal chemistry, 04-25, Volume: 62, Issue:8	Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies.
AID420500	Toxicity in athymic nude Swiss mouse bearing human H460 cells assessed as death administered QD 5 days a week for 2 weeks	2009	European journal of medicinal chemistry, May, Volume: 44, Issue:5	Design, synthesis, and evaluation of biphenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors.
AID1202591	Cytotoxicity against human KB cells after 72 hrs by MTS assay	2015	European journal of medicinal chemistry, , Volume: 96	Design and structure activity relationship of tumor-homing histone deacetylase inhibitors conjugated to folic and pteroic acids.
AID1127325	Inhibition of human HDAC4 using fluorogenic tetrapeptide RHKKAc as substrate	2014	European journal of medicinal chemistry, May-22, Volume: 79	Influence of the adamantyl moiety on the activity of biphenylacrylohydroxamic acid-based HDAC inhibitors.
AID449260	Inhibition of HDAC1/HDAC2 from human Hela nuclear extracts using [3H]acetylated histone peptide by colorimetry	2009	European journal of medicinal chemistry, Nov, Volume: 44, Issue:11	Design, synthesis and preliminary biological evaluation of N-hydroxy-4-(3-phenylpropanamido)benzamide (HPPB) derivatives as novel histone deacetylase inhibitors.
AID672031	Selectivity ratio of IC50 for human HDAC2 preincubated with compound for 24 hrs to IC50 for human HDAC1 preincubated with compound for 3 hrs	2012	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 22, Issue:15	Design, synthesis, modeling, biological evaluation and photoaffinity labeling studies of novel series of photoreactive benzamide probes for histone deacetylase 2.
AID1753838	Inhibition of HDAC2 (unknown origin)	2021	European journal of medicinal chemistry, Jun-05, Volume: 218	Identification of novel 1,3-diaryl-1,2,4-triazole-capped histone deacetylase 6 inhibitors with potential anti-gastric cancer activity.
AID672029	Inhibition of human recombinant HDAC8 expressed in Escherichia coli using BML-KI-178 as substrate preincubated with compound for 3 hrs at 10 uM measured after 35 mins by spectrofluorometric analysis	2012	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 22, Issue:15	Design, synthesis, modeling, biological evaluation and photoaffinity labeling studies of novel series of photoreactive benzamide probes for histone deacetylase 2.
AID1293553	Inhibition of HDAC in human HeLa nuclear extract using BOC-Ac-Lys-AMC as substrate incubated for 90 mins by fluorescence assay	2016	European journal of medicinal chemistry, Apr-13, Volume: 112	Biphenyl-4-yl-acrylohydroxamic acids: Identification of a novel indolyl-substituted HDAC inhibitor with antitumor activity.
AID1367346	Antiproliferative activity against human HCT116 cells by MTT assay	2017	Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24	Synthesis and biological evaluation of Santacruzamate-A based analogues.
AID1598104	Activation of non-specific gene expression in human J-Lat 10.6 cells harboring LTR driven GFP reporter co-expressing CMV driven RFP reporter assessed as CMV driven gene expression incubated for 48 hr by FACSCalibur flow cytometry	2019	Journal of medicinal chemistry, 05-23, Volume: 62, Issue:10	Identification of 5-Substituted 2-Acylaminothiazoles That Activate Tat-Mediated Transcription in HIV-1 Latency Models.
AID503689	Inhibition of HDAC in human GM15850 cells assessed as increase in histone H4 lysine 12 acetylation of FXN gene at 2.5 uM after 96 hrs by chromatin immunoprecipitation assay	2006	Nature chemical biology, Oct, Volume: 2, Issue:10	Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia.
AID605542	Antiproliferative activity against human MCR5-SV2 cells after 72 hrs by WST-1 assay	2010	Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24	Discovery of 2-(6-{[(6-fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a class I selective orally active histone deacetylase inhibitor.
AID717797	Inhibition of HDAC1 using Fluor-de-Lys as substrate assessed as remaining activity at 3.125 x 10'-8 M pretreated for 30 mins before substrate addition by fluorescence assay	2012	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23	The structural requirements of histone deacetylase inhibitors: suberoylanilide hydroxamic acid analogs modified at the C6 position.
AID723143	Potentiation of 10 uM cisplatin-induced toxicity in 1 uM cisplatin resistant human CAL27 cells at 0.5 uM pretreated for 48 hrs followed by 1 uM cisplatin treatment by MTT assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1273869	Antiproliferative activity against human HCT116 cells assessed as cell viability after 72 hrs by CellTitre-Glo luminescent assay	2016	European journal of medicinal chemistry, Jan-27, Volume: 108	Synthesis, biological characterization and molecular modeling insights of spirochromanes as potent HDAC inhibitors.
AID1689779	Antiproliferative activity against human SMMC7721 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay	2020	European journal of medicinal chemistry, Mar-01, Volume: 189	Discovery of novel cyclin-dependent kinase (CDK) and histone deacetylase (HDAC) dual inhibitors with potent in vitro and in vivo anticancer activity.
AID1292165	Induction of apoptosis in human HCT116 cells assessed as apoptotic cells at 5 uM after 24 hrs by annexin V-FITC/propidium iodide staining based flow cytometric analysis	2016	European journal of medicinal chemistry, Jun-10, Volume: 115	Novel spiropyrazolone antitumor scaffold with potent activity: Design, synthesis and structure-activity relationship.
AID1403158	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	2018	European journal of medicinal chemistry, Jan-20, Volume: 144	Development of novel β-carboline-based hydroxamate derivatives as HDAC inhibitors with antiproliferative and antimetastatic activities in human cancer cells.
AID628440	Inhibition of human recombinant HDAC3/NCoR2 using fluorophore-conjugated substrate Boc-L-Lys(Ac)-AMC	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Design, synthesis, docking, and biological evaluation of novel diazide-containing isoxazole- and pyrazole-based histone deacetylase probes.
AID1389958	Inhibition of HDAC in human MCF7 cell nuclear extract using acetylated lysine as substrate at 35 uM after 1 hr in presence of tranylcypromine by colorimetric analysis relative to control	2018	Bioorganic & medicinal chemistry letters, 04-01, Volume: 28, Issue:6	Novel polyamine-based Histone deacetylases-Lysine demethylase 1 dual binding inhibitors.
AID1337290	Antiproliferative activity against human KHYG cells after 48 hrs by CellTiter-Glo assay	2016	Journal of medicinal chemistry, Sep-22, Volume: 59, Issue:18	Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines.
AID274098	Effect of compound on Candida albicans sensitivity to Fluconazole: Minimum inhibitory concentration required to inhibit the growth of 90% of isolates after 24h.	2007	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 17, Issue:5	Discovery of uracil-based histone deacetylase inhibitors able to reduce acquired antifungal resistance and trailing growth in Candida albicans.
AID1248353	Inhibition of human full length MMP9 using Mca-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 as substrate at 10 uM incubated for 2 hrs prior to testing measured for 15 mins by fluorometric analysis relative to control	2015	Bioorganic & medicinal chemistry, Oct-15, Volume: 23, Issue:20	Synthesis of chiral ND-322, ND-364 and ND-364 derivatives as selective inhibitors of human gelatinase.
AID1321620	Antiproliferative activity against human HCT116 cells measured after 72 hrs by WST1 assay	2016	Bioorganic & medicinal chemistry letters, 10-01, Volume: 26, Issue:19	Design, synthesis and in vitro evaluation of amidoximes as histone deacetylase inhibitors for cancer therapy.
AID1439781	Inhibition of human HDAC5 using Boc-Lys(trifluoroacetyl)-AMC as substrate preincubated for 30 mins followed by substrate addition measured after 60 mins by trypsin-based fluorescence assay	2017	Bioorganic & medicinal chemistry letters, 04-01, Volume: 27, Issue:7	Perfluorinated hydroxamic acids are potent and selective inhibitors of HDAC-like enzymes from Pseudomonas aeruginosa.
AID246068	Effective Concentration of compound to inhibit the growth of human HCT116 cells	2005	Journal of medicinal chemistry, Feb-24, Volume: 48, Issue:4	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates.
AID1065968	Inhibition of HDAC6 (unknown origin) expressed in Escherichia coli BL21 (DE3) using GRKacYGC as substrate after 60 mins by SAMDI mass spectrometric analysis	2013	Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24	Synthesis and structure-activity relationship of 3-hydroxypyridine-2-thione-based histone deacetylase inhibitors.
AID313735	Inhibition of HDAC7	2008	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2	Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2).
AID1321702	Inhibition of HDAC3 (unknown origin)	2016	Journal of medicinal chemistry, 10-13, Volume: 59, Issue:19	Design, Synthesis, and Biological Evaluation of First-in-Class Dual Acting Histone Deacetylases (HDACs) and Phosphodiesterase 5 (PDE5) Inhibitors for the Treatment of Alzheimer's Disease.
AID1900912	Cytotoxicity against human TMZ-sensitive U251 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	2022	Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
AID1482169	Cytotoxicity against human COLO205 cells assessed as growth inhibition at 5 uM after 48 hrs by MTT assay relative to control	2017	Journal of medicinal chemistry, 04-27, Volume: 60, Issue:8	Exploring Derivatives of Quinazoline Alkaloid l-Vasicine as Cap Groups in the Design and Biological Mechanistic Evaluation of Novel Antitumor Histone Deacetylase Inhibitors.
AID408886	Selectivity for HDAC6 over HDAC1	2008	Journal of medicinal chemistry, Jun-26, Volume: 51, Issue:12	A series of potent and selective, triazolylphenyl-based histone deacetylases inhibitors with activity against pancreatic cancer cells and Plasmodium falciparum.
AID1449328	Inhibition of human HDAC8 using Z-L-Lys(epsilon-trifluoroacetyl)-AMC as substrate measured after 90 mins by fluorescence assay	2017	Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13	Alkoxyurea-Based Histone Deacetylase Inhibitors Increase Cisplatin Potency in Chemoresistant Cancer Cell Lines.
AID1572381	Antiproliferative activity against human THP1 cells after 72 hrs by CellTiter blue-reagent based assay	2019	Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3	Synthesis and Biological Investigation of Phenothiazine-Based Benzhydroxamic Acids as Selective Histone Deacetylase 6 Inhibitors.
AID488274	Inhibition of HDAC2	2010	Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11	On the inhibition of histone deacetylase 8.
AID655475	Restoration of CFTR deltaF508 mutant trafficking to cell surface as glycoforms in human CFBE41o cells at 5 uM after 24 hrs by Western blotting	2011	ACS medicinal chemistry letters, Jul-21, Volume: 2, Issue:9	Potential Agents for Treating Cystic Fibrosis: Cyclic Tetrapeptides that Restore Trafficking and Activity of ΔF508-CFTR.
AID274072	Clearance after i.v. dosing at 1 mg kg-1	2007	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2	Identification and optimisation of a series of substituted 5-(1H-pyrazol-3-yl)-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.
AID1401478	Selectivity ratio of IC50 for HDAC2 in human HeLa-S3 cell lysates to IC50 for recombinant full-length C-terminal His-tagged HDAC8 expressed in baculovirus infected Sf9 insect cell	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
AID1622982	Cytotoxicity against human RWPE1 cells	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.
AID1441702	Inhibition of LTA4H in C57BL/6 mouse assessed as reduction in LTB4 production pre-incubated for 30 mins before 5-(methylamino)-2-({(2R,3R,6S,8S,9R,11R)-3,9,11-trimethyl-8-[(1S)-1-methyl-2-oxo-2-(1H-pyrrol-2-yl)ethyl]-1,7-dioxaspiro[5.5]undec-2-yl}methyl)-	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
AID586614	Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D6 assessed as inhibition of [3H]hypoxanthine incorporation	2011	Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3	Ex vivo activity of histone deacetylase inhibitors against multidrug-resistant clinical isolates of Plasmodium falciparum and P. vivax.
AID352748	Inhibition of C-terminal FLAG tagged HDAC3	2009	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11	Histone deacetylase inhibitors with a primary amide zinc binding group display antitumor activity in xenograft model.
AID1487047	Inhibition of HDAC6 (unknown origin) assessed as remaining enzyme activity at 1 uM by ELISA-based assay	2017	Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15	The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity.
AID1819534	Toxicity in C57BL/6J mouse implanted with mouse B16-F10 cells assessed as liver damage at 60 mg/kg, IG administered for 12 days H and E staining based histopathological analysis	2022	Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4	Discovery of DNA-Targeting HDAC Inhibitors with Potent Antitumor Efficacy In Vivo That Trigger Antitumor Immunity.
AID1785351	Antiproliferative activity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by CCK8 assay
AID1384208	Inhibition of HDAC3 (unknown origin)	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease.
AID723136	Potentiation of 10 uM cisplatin-induced toxicity in 5 uM cisplatin resistant human A2780 cells at 0.25 uM pretreated for 48 hrs followed by 5 uM cisplatin treatment by MTT assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1623531	Inhibition of human recombinant HDAC6 using fluorogenic HDAC substrate-3 by fluorescence assay	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	A novel class of anthraquinone-based HDAC6 inhibitors.
AID352753	Antiproliferative activity against human A549 cells after 72 hrs by celltiter-blue cell viability assay	2009	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11	Histone deacetylase inhibitors with a primary amide zinc binding group display antitumor activity in xenograft model.
AID1572360	Inhibition of human HDAC6 in human T24 cells assessed as up-regulation of GRP78 by measuring volume intensity at 10 uM after 48 hrs by Western blot analysis relative to control	2019	Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3	Synthesis and Biological Investigation of Phenothiazine-Based Benzhydroxamic Acids as Selective Histone Deacetylase 6 Inhibitors.
AID1702142	Inhibition of PI3K/AKT/mTOR signaling in human HepG2 cells assessed as reduction in EGF-stimulated phosphorylation of Akt at S473 residue incubated for 3 hrs followed by stimulation with 50 ng/ml growth factor EGF for 15 mins by by ELISA	2018	Journal of medicinal chemistry, 02-22, Volume: 61, Issue:4	Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma.
AID1566819	Antiproliferative activity against human ARD cells after 72 hrs by MTT assay	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Discovery of 1,2,4-oxadiazole-Containing hydroxamic acid derivatives as histone deacetylase inhibitors potential application in cancer therapy.
AID1848565	Ratio of IC50 for cytotoxicity against human WI-38 cells to IC50 for cytotoxicity against human NCI-H522	2022	Journal of medicinal chemistry, 11-10, Volume: 65, Issue:21	First-in-Class Dual Mechanism Ferroptosis-HDAC Inhibitor Hybrids.
AID1689812	Antiproliferative activity against human H460 cells assessed as inhibition of cell growth at 2 uM measured after 72 hrs by CCK-8 assay relative to control	2020	European journal of medicinal chemistry, Mar-01, Volume: 189	Discovery of novel cyclin-dependent kinase (CDK) and histone deacetylase (HDAC) dual inhibitors with potent in vitro and in vivo anticancer activity.
AID1174692	Inhibition of HDAC1 (unknown origin)	2015	European journal of medicinal chemistry, Jan-07, Volume: 89	Development of 3-hydroxycinnamamide-based HDAC inhibitors with potent in vitro and in vivo anti-tumor activity.
AID297485	Cytotoxicity against human non-proliferating RKOp21 cells	2007	Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18	2-aroylindoles and 2-aroylbenzofurans with N-hydroxyacrylamide substructures as a novel series of rationally designed histone deacetylase inhibitors.
AID1233267	Antiproliferative activity against african green monkey Vero cells assessed as inhibition of cell viability after 72 hrs by MTT assay	2015	Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11	Novel Bioactive Hybrid Compound Dual Targeting Estrogen Receptor and Histone Deacetylase for the Treatment of Breast Cancer.
AID353353	Cytotoxicity against human SH-SY5Y cells assessed as cell viability at 10 uM after 48 hrs by MTT assay relative to control	2009	Journal of medicinal chemistry, May-14, Volume: 52, Issue:9	Synthesis, biological evaluation, and molecular docking of Ugi products containing a zinc-chelating moiety as novel inhibitors of histone deacetylases.
AID1826629	Synergistic antiproliferative effect on HEL cells assessed as combination index at 3.33 uM in presence of 3-Fluoro-10-hydroxy-14-methyl-8,13,13b,14-tetrahydro-7H-indolo[2',3':3,4]pyrido[2,1-b]quinazolin-5-one	2022	Journal of medicinal chemistry, 03-24, Volume: 65, Issue:6	Evodiamine-Inspired Topoisomerase-Histone Deacetylase Dual Inhibitors: Novel Orally Active Antitumor Agents for Leukemia Therapy.
AID328805	Antiproliferative activity against human HeLa cells by CellTiter-Blue cell viability assay	2008	Journal of medicinal chemistry, Apr-24, Volume: 51, Issue:8	A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo.
AID1337195	Inhibition of full length human recombinant C-terminal FLAG/His-tagged HDAC1 (1 to 482 residues) expressed in sf21 cells preincubated with enzyme followed by fluorogenic Arg-His-Lys-Lys(Ac)-AMC substrate addition measured after 2 hrs by fluorescence assay	2016	Journal of medicinal chemistry, Sep-22, Volume: 59, Issue:18	Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines.
AID1758469	Inhibition of human recombinant HDAC8 using Ac-Leu-Gly-Lys(Ac)-AMC as substrate by measuring fluorescence intensity incubated for 30 mins by microplate reader assay	2021	European journal of medicinal chemistry, May-05, Volume: 217	Novel dual-mode antitumor chlorin-based derivatives as potent photosensitizers and histone deacetylase inhibitors for photodynamic therapy and chemotherapy.
AID1441686	Anti-inflammatory activity in BLM-induced C57BL/6 mouse model of acute lung injury assessed as reduction in IL-1beta level in BALF at 25 and 50 mg/kg, ip qd for 7 days post BLM challenge measured on day 7 by ELISA	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
AID1578889	Inhibition of human HDAC8 using Boc-Lys (Ac)-AMC as substrate incubated for 60 mins by fluorimetric assay	2019	Journal of natural products, 06-28, Volume: 82, Issue:6	Hydroxamic Acid Derivatives of β-Carboline/Hydroxycinnamic Acid Hybrids Inducing Apoptosis and Autophagy through the PI3K/Akt/mTOR Pathways.
AID527045	Cytotoxicity against human H441 by SRB assay	2010	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22	Selenium-containing analogs of SAHA induce cytotoxicity in lung cancer cells.
AID1578503	Induction of apoptosis in human MV4-11 cells assessed as late apoptotic cells at 2 uM incubated for 18 hrs by annexin V FITC and PI based flow cytometry (Rvb = 9.2 to 9.63 %)	2020	ACS medicinal chemistry letters, Jan-09, Volume: 11, Issue:1	Class I/IIb-Selective HDAC Inhibitor Exhibits Oral Bioavailability and Therapeutic Efficacy in Acute Myeloid Leukemia.
AID1649505	Antileishmanial activity against Leishmania infantum MON-1 intracellular amastigotes infected in Swiss mouse BMDM measured after 48 hrs by Giemsa staining based optical microscopic analysis	2020	Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11
AID1753635	Inhibition of human HDAC6 preincubated for 15 mins followed by substrate addition by fluorescence-based assay	2021	European journal of medicinal chemistry, Jun-05, Volume: 218	Design, synthesis and biological evaluation of brain penetrant benzazepine-based histone deacetylase 6 inhibitors for alleviating stroke-induced brain infarction.
AID1886237	Antivascular activity against HUVEC cells assessed as inhibition of capillary-like tubule formation at 1 uM measured after 6 hrs by inverted microscopy	2022	Journal of medicinal chemistry, 08-25, Volume: 65, Issue:16	Discovery of a Novel Vascular Disrupting Agent Inhibiting Tubulin Polymerization and HDACs with Potent Antitumor Effects.
AID1677494	Antiproliferative activity against siRNA-induced BAX knock down human HeLa cells after 48 hrs by MTT assay	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	HDAC-Bax Multiple Ligands Enhance Bax-Dependent Apoptosis in HeLa Cells.
AID324948	Inhibition of HDAC1 in HEK293 cells	2008	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 18, Issue:6	Probing the elusive catalytic activity of vertebrate class IIa histone deacetylases.
AID1227049	Cytotoxicity against human Jurkat cells assessed as cell proliferation after 70 hrs by MTS assay	2015	Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11	Dual-Mode HDAC Prodrug for Covalent Modification and Subsequent Inhibitor Release.
AID1754782	Induction of cell cycle arrest in human MCF7 cells assessed as accumulation at G1/S phase at 1 uM incubated for 4 hrs by PI staining based flow cytometric analysis	2021	Bioorganic & medicinal chemistry, 07-15, Volume: 42	Discovery of novel class of histone deacetylase inhibitors as potential anticancer agents.
AID1783093	Inhibition of HDAC in Cryptococcus neoformans H99 using Boc-Lys(Ac)-AMC as substrate preincubated with protoplast for 12 hrs followed by incubation with substrate for 6 hrs by fluorimetric assay	2021	European journal of medicinal chemistry, Oct-05, Volume: 221	Lanosterol 14α-demethylase (CYP51)/histone deacetylase (HDAC) dual inhibitors for treatment of Candida tropicalis and Cryptococcus neoformans infections.
AID252895	Concentration required to inhibit growth of human LNCaP prostate cancer cells	2005	Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15	A new simple and high-yield synthesis of suberoylanilide hydroxamic acid and its inhibitory effect alone or in combination with retinoids on proliferation of human prostate cancer cells.
AID1126996	Induction of apoptosis in human U937 cells assessed as viable cells using annexin-V/propidium iodide staining at 1 uM after 24 hrs by flow cytometry analysis (Rvb = 96.24%)	2014	Journal of medicinal chemistry, Apr-24, Volume: 57, Issue:8	Discovery of the first N-hydroxycinnamamide-based histone deacetylase 1/3 dual inhibitors with potent oral antitumor activity.
AID1882456	Inhibition of HDAC1 (unknown origin)	2022	Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4	Chasing a Breath of Fresh Air in Cystic Fibrosis (CF): Therapeutic Potential of Selective HDAC6 Inhibitors to Tackle Multiple Pathways in CF Pathophysiology.
AID1065638	Inhibition of human recombinant HDAC4 catalytic domain using Boc_Lys_TFA as substrate after 60 mins by fluorescence assay	2013	Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24	Design, synthesis, and biological evaluation of potent and selective class IIa histone deacetylase (HDAC) inhibitors as a potential therapy for Huntington's disease.
AID1410325	Inhibition of recombinant human GST-tagged IDO1 (1 to 404 residues) at 1 uM using D-Tryptophan as substrate relative to control	2018	ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4	Discovery of Novel Indoleamine 2,3-Dioxygenase 1 (IDO1) and Histone Deacetylase (HDAC) Dual Inhibitors.
AID1336923	Cytotoxicity against human A549 cells assessed as cell growth inhibition after 72 hrs by MTT assay	2017	Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3	Bifunctional conjugates with potent inhibitory activity towards cyclooxygenase and histone deacetylase.
AID1545988	Antiproliferative activity against human Aspc-1 cells assessed as reduction in cell viability after 48 hrs by MTT assay	2019	European journal of medicinal chemistry, Dec-01, Volume: 183	1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships.
AID1614135	Inhibition of recombinant full length N-terminal GST-tagged human HDAC7 expressed in baculovirus expression system using Ac-peptide-AMC as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by fluorescence assay
AID1383987	Inhibition of HDAC6 (unknown origin) using Boc-Lys(acetyl)-AMC as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by fluorescence assay	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	Discovery of meta-sulfamoyl N-hydroxybenzamides as HDAC8 selective inhibitors.
AID772655	Inhibition of full length FLAG-tagged recombinant HDAC1 (unknown origin) transfected in human HeLa cells assessed as deacetylation of [3H]-acetylated histones after 2 hrs by scintillation counting analysis	2013	Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18	Potent histone deacetylase inhibitors derived from 4-(aminomethyl)-N-hydroxybenzamide with high selectivity for the HDAC6 isoform.
AID723730	Cytotoxicity against human A2780 cells after 72 hrs by MTT assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1349725	Inhibition of recombinant human N-terminal GST-tagged HDAC4 (612 to end residues) expressed in baculovirus infected Sf9 insect cells after 30 mins by fluorescence assay	2018	ACS medicinal chemistry letters, Jan-11, Volume: 9, Issue:1	Dual NAMPT/HDAC Inhibitors as a New Strategy for Multitargeting Antitumor Drug Discovery.
AID1434358	Growth inhibition of human NUGC3 cells measured after 5 days by sulforhodamine-B assay	2017	European journal of medicinal chemistry, Jan-27, Volume: 126	Improving potency and metabolic stability by introducing an alkenyl linker to pyridine-based histone deacetylase inhibitors for orally available RUNX3 modulators.
AID1482129	Cytotoxicity against human MCF10A cells assessed as growth inhibition after 48 hrs by MTT assay	2017	Journal of medicinal chemistry, 04-27, Volume: 60, Issue:8	Exploring Derivatives of Quinazoline Alkaloid l-Vasicine as Cap Groups in the Design and Biological Mechanistic Evaluation of Novel Antitumor Histone Deacetylase Inhibitors.
AID1686352	Drug metabolism in human liver microsomes assessed as o-glucuronidated metabolite formation in presence of UDP glucuronic acid incubated for 12 hrs at 37 degC by electrospray ionization liquid chromatography mass spectrometry	2016	Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21	Development of Allosteric Hydrazide-Containing Class I Histone Deacetylase Inhibitors for Use in Acute Myeloid Leukemia.
AID1690834	Inhibition of recombinant human N-terminal GST-tagged HDAC7 (518 to end residues) expressed in baculovirus infected Sf9 cells using fluorogenic HDAC 2A substrate preincubated for 5 mins followed by substrate addition and measured after 30 mins by fluoresc	2020	European journal of medicinal chemistry, Apr-15, Volume: 192	Synthesis and biological evaluation of acridine-based histone deacetylase inhibitors as multitarget agents against Alzheimer's disease.
AID1386691	Inhibition of HDAC in human GM18453 cells harboring NPC1 mutant assessed as increase in 250 kDa NPC1 protein expression at 5 uM pretreated for 48 hrs followed by PNGaseF addition and measured after overnight incubation by Western blot analysis	2018	Journal of natural products, 09-28, Volume: 81, Issue:9	GEX1A, a Polyketide from Streptomyces chromofuscus, Corrects the Cellular Defects Associated with Niemann-Pick Type C1 in Human Fibroblasts.
AID1225981	Inhibition of recombinant C-terminal His-tagged full length human HDAC8 expressed in baculovirus infected insect Sf9 cells using fluorogenic HDAC class 2a substrate after 30 mins by fluorescence assay	2015	ACS medicinal chemistry letters, Mar-12, Volume: 6, Issue:3	Discovery of Novel Multiacting Topoisomerase I/II and Histone Deacetylase Inhibitors.
AID1558003	Inhibition of HDAC6 CD2 (unknown origin) expressed in HEK293 cells cotransfected with nano-luciferase incubated for 2 hrs followed by NanoBRET NanoGlo Substrate addition by NanoBRET assay	2019	Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18	Discovery of a New Isoxazole-3-hydroxamate-Based Histone Deacetylase 6 Inhibitor SS-208 with Antitumor Activity in Syngeneic Melanoma Mouse Models.
AID496803	Inhibition of human HDAC3	2010	Nature chemical biology, Mar, Volume: 6, Issue:3	Chemical phylogenetics of histone deacetylases.
AID1812443	Inhibition of human recombinant HDAC2 using Tosyl-Gly-ProLys(Ac)-AMC as substrate measured after 60 mins by fluorescence assay	2021	Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14	Procainamide-SAHA Fused Inhibitors of hHDAC6 Tackle Multidrug-Resistant Malaria Parasites.
AID781050	Antiproliferative activity against human HCT116 cells after 48 hrs by sulforhodamine B assay	2013	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 23, Issue:23	Design, synthesis and biological evaluation of di-substituted cinnamic hydroxamic acids bearing urea/thiourea unit as potent histone deacetylase inhibitors.
AID1548891	Induction of apoptosis in human MV4-11 cells harboring wild type p53/FLT3-ITD mutant assessed as cleavage of pro-caspase 3 at 5000 nM after 24 hrs by Western blot analysis	2020	Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10	Design of Hydrazide-Bearing HDACIs Based on Panobinostat and Their p53 and FLT3-ITD Dependency in Antileukemia Activity.
AID481556	Cytotoxicity against human KB cells assessed as growth inhibition at 0.1 ug/ml after 24 hrs by MTT assay	2010	Bioorganic & medicinal chemistry letters, May-15, Volume: 20, Issue:10	Synthesis and anticancer evaluation of alpha-lipoic acid derivatives.
AID420635	Inhibition of HDAC6 in human IGROV1 cells assessed as alpha-tubulin acetylation at IC80 after 4 hrs by Western blot	2009	European journal of medicinal chemistry, May, Volume: 44, Issue:5	Design, synthesis, and evaluation of biphenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors.
AID546562	Cytotoxicity against human CAL27 cells overexpressing EGFR by resazurin dye reduction assay	2010	Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24	Novel chimeric histone deacetylase inhibitors: a series of lapatinib hybrides as potent inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and histone deacetylase activity.
AID1576467	Induction of apoptosis in human A549 cells assessed as necrotic cells at 5 uM after 72 hrs by Annexin V-phycoerythrin/7-AAD staining based flow cytometric analysis (Rvb = 0.45%)
AID1614194	Induction of apoptosis in human MV4-11 cells assessed as early apoptotic cells at 1 uM after 48 hrs in presence of 0.3 uM RAPA by Annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 10.7%)
AID525003	Inhibition of HDAC1 by in vitro deacetylation assay	2010	Nature chemical biology, Jan, Volume: 6, Issue:1	Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.
AID1832798	Cytotoxicity against human MOLT-4 cells assessed as cell viability at 5 uM by CellTiter-Glo luminescent assay	2021	Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19	4-Acyl Pyrrole Capped HDAC Inhibitors: A New Scaffold for Hybrid Inhibitors of BET Proteins and Histone Deacetylases as Antileukemia Drug Leads.
AID1543933	Antiproliferative activity against human H1299 cells incubated for 48 hrs by MTT assay	2019	European journal of medicinal chemistry, Apr-15, Volume: 168	β-Carboline and N-hydroxycinnamamide hybrids as anticancer agents for drug-resistant hepatocellular carcinoma.
AID1543969	Induction of autophagy in human Bel7402/5-FU cells assessed as increase in red fluorescence at 5.0 uM incubated for 72 hrs by acridine orange staining based fluorescence microscopy	2019	European journal of medicinal chemistry, Apr-15, Volume: 168	β-Carboline and N-hydroxycinnamamide hybrids as anticancer agents for drug-resistant hepatocellular carcinoma.
AID723137	Potentiation of 3.16 uM cisplatin-induced toxicity in 0.5 uM cisplatin resistant human KYSE-510 cells at 1.5 uM pretreated for 48 hrs followed by 0.5 uM cisplatin treatment by MTT assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1730851	Antiproliferative activity against human A431 cells incubated for 72 hrs by MTT assay	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Design, synthesis and evaluation of novel ErbB/HDAC multitargeted inhibitors with selectivity in EGFR
AID1174693	Inhibition of HDAC2 (unknown origin)	2015	European journal of medicinal chemistry, Jan-07, Volume: 89	Development of 3-hydroxycinnamamide-based HDAC inhibitors with potent in vitro and in vivo anti-tumor activity.
AID1737657	Cytotoxicity against human THP-1 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
AID1863176	Selectivity index, ratio of IC50 for HDAC7 (unknown origin) to IC50 for HDAC6 (unknown origin)	2022	European journal of medicinal chemistry, Oct-05, Volume: 240	Design, synthesis, and biological evalution of bifunctional inhibitors against Hsp90-HDAC6 interplay.
AID1451820	Inhibition of human recombinant NAMPT using NAM as substrate preincubated for 5 mins followed by substrate addition measured after 15 mins by fluorescence assay	2017	Journal of medicinal chemistry, 10-12, Volume: 60, Issue:19	Small Molecule Inhibitors Simultaneously Targeting Cancer Metabolism and Epigenetics: Discovery of Novel Nicotinamide Phosphoribosyltransferase (NAMPT) and Histone Deacetylase (HDAC) Dual Inhibitors.
AID1441709	Protection against BLM-induced lung fibrosis in C57BL/6 mouse assessed as TGF-beta1 level at 25 and 50 mg/kg, ip qd for 7 days post BLM challenge measured on day 14 by by qRT-PCR method	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
AID1764254	Inhibition of recombinant human C-terminal His-fusion tagged/N-terminal Strep2 tagged HDAC8 (1 to 377 residues) expressed in insect cells using Boc-Lys(TFA)-AMC as substrate preincubated for 5 mins followed by substrate addition measured after 90 mins by	2021	European journal of medicinal chemistry, Feb-05, Volume: 211	Synergistic induction of apoptosis in resistant head and neck carcinoma and leukemia by alkoxyamide-based histone deacetylase inhibitors.
AID473189	Growth inhibition of human BJ cells at 0.05 to 100 uM after 48 hrs by MTT assay	2010	Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5	Biological and biophysical properties of the histone deacetylase inhibitor suberoylanilide hydroxamic acid are affected by the presence of short alkyl groups on the phenyl ring.
AID1487003	Inhibition of HDAC8 (unknown origin) by ELISA-based assay	2017	Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15	The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity.
AID1227031	Inhibition of human recombinant HDAC3 using MAZ1600 as fluorogenic substrate measured every 5 mins by optimized homogenous fluorescence based assay	2015	Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11	Dual-Mode HDAC Prodrug for Covalent Modification and Subsequent Inhibitor Release.
AID1401540	Antiproliferative activity against human Maver2 cells after 72 hrs by MTT assay	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors.
AID1434354	Growth inhibition of human MDA-MB-231 cells measured after 5 days by sulforhodamine-B assay	2017	European journal of medicinal chemistry, Jan-27, Volume: 126	Improving potency and metabolic stability by introducing an alkenyl linker to pyridine-based histone deacetylase inhibitors for orally available RUNX3 modulators.
AID352747	Inhibition of C-terminal FLAG tagged HDAC2	2009	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11	Histone deacetylase inhibitors with a primary amide zinc binding group display antitumor activity in xenograft model.
AID1441685	Anti-inflammatory activity in BLM-induced C57BL/6 mouse model of acute lung injury assessed as reduction in IL-6 mRNA level in BALF compound administered intraperitoneally once daily for 7 days post BLM challenge measured on day 7 by qRT-PCR method	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
AID1469385	Induction of apoptosis in human HepG2 cells assessed as necrotic cells at 10 uM after 48 hrs by annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 2.32%)	2018	Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7	Discovery of N1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7 H-pyrrolo[2,3- d]pyrimidin-2-yl)amino)phenyl)- N8-hydroxyoctanediamide as a Novel Inhibitor Targeting Cyclin-dependent Kinase 4/9 (CDK4/9) and Histone Deacetlyase1 (HDAC1) against Malignant Cancer
AID316886	Antiproliferative activity against human SKBR3 cells	2008	Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6	Histone deacetylase inhibitors: from bench to clinic.
AID482944	Inhibition of HDAC4	2010	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11	Acylurea connected straight chain hydroxamates as novel histone deacetylase inhibitors: Synthesis, SAR, and in vivo antitumor activity.
AID1281851	Antiproliferative activity against human MM1S cells after 72 hrs by CellTiter 96 aqueous non-radioactive cell proliferation assay	2016	European journal of medicinal chemistry, Apr-13, Volume: 112	Design, synthesis and biological evaluation of bisthiazole-based trifluoromethyl ketone derivatives as potent HDAC inhibitors with improved cellular efficacy.
AID1898525	Cytotoxicity against human MCF-10 A cells assessed as reduction in cell viability at 32 uM incubated for 48 hrs by MTT assay relative to control	2021	Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11	Discovery of STAT3 and Histone Deacetylase (HDAC) Dual-Pathway Inhibitors for the Treatment of Solid Cancer.
AID465153	Inhibition of HDAC10 assessed as blockade of decorboxylation of carboxyfluorescein labeled acetylated peptide substrate after 17 hrs	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Synthesis and biological evaluation of triazol-4-ylphenyl-bearing histone deacetylase inhibitors as anticancer agents.
AID723429	Potentiation of 0.75 uM cisplatin-induced toxicity in 0.5 uM cisplatin resistant human KYSE-510 cells at 0.5 uM pretreated for 48 hrs followed by 0.5 uM cisplatin treatment by MTT assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1785336	Inhibition of HDAC5 (unknown origin) measured after 30 mins by fluorescence microplate reader assay
AID1227022	Binding affinity to human HDAC8 C153A mutant assessed as loss of activity at 2 to 8 uM by Fluor-de-Lys activity assay	2015	Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11	Dual-Mode HDAC Prodrug for Covalent Modification and Subsequent Inhibitor Release.
AID1882467	Inhibition of HDAC8 (unknown origin)	2022	Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4	Chasing a Breath of Fresh Air in Cystic Fibrosis (CF): Therapeutic Potential of Selective HDAC6 Inhibitors to Tackle Multiple Pathways in CF Pathophysiology.
AID580940	Antitumor activity against human HCT116 cells xenografted in athymic nude mouse assessed as decrease in tumor volume at 50 mg/kg, iv administered once daily for 5 days per week by caliper measurement	2010	ACS medicinal chemistry letters, Nov-11, Volume: 1, Issue:8	Antiproliferative and differentiating activities of a novel series of histone deacetylase inhibitors.
AID1720098	Growth inhibition of human THP-1 cells	2020	Journal of medicinal chemistry, 09-10, Volume: 63, Issue:17	Dual-Target Inhibitors Based on HDACs: Novel Antitumor Agents for Cancer Therapy.
AID1373249	Inhibition of HDAC8 (unknown origin) at 1 uM preincubated for 10 mins followed by Ac-Leu-GlyLys(Ac)-AMC substrate addition measured after 30 mins by fluorescence based assay relative to control	2018	Bioorganic & medicinal chemistry, 02-01, Volume: 26, Issue:3	Design, synthesis and evaluate of novel dual FGFR1 and HDAC inhibitors bearing an indazole scaffold.
AID760008	Downregulation of Gli1 mRNA expression in human DaOY cells at 2.5 uM relative to DMSO-treated control	2013	ACS medicinal chemistry letters, Jul-11, Volume: 4, Issue:7	Identification of vitamin d3-based hedgehog pathway inhibitors that incorporate an aromatic a-ring isostere.
AID1406978	Inhibition of class 1 HDAC in human NB4 cells assessed as levels of histone H3 acetylation at lysine 9/14 at 1 uM after 30 hrs by Western blot analysis relative to control	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Novel spiroindoline HDAC inhibitors: Synthesis, molecular modelling and biological studies.
AID1774969	Inhibition of HDAC6 (unknown origin) using Boc-Lys(acetyl)-AMC as substrate at 10 uM preincubated for 5 mins followed by substrate addition and measured after 30 mins by fluorescence assay	2021	ACS medicinal chemistry letters, Dec-09, Volume: 12, Issue:12	Design, Synthesis, and Biological Evaluation of APN and AKT Dual-Target Inhibitors.
AID258010	Inhibition of HDAC in rat liver homogenate	2006	Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2	Aromatic sulfide inhibitors of histone deacetylase based on arylsulfinyl-2,4-hexadienoic acid hydroxyamides.
AID1821962	Selectivity index, ratio of IC50 for inhibition of recombinant human N-terminal GST tagged HDAC6 expressed in baculovirus infected Sf9 insect cells to IC50 for inhibition of recombinant human His-tagged HDAC3 expressed in baculovirus insect cells
AID1280266	Inhibition of HDAC6 in human HeLa cells assessed as ratio of acetylated tubulin to GAPDH level at 10 uM for 4 hrs by Western blot analysis relative to control	2016	Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4	Synthesis and Biological Investigation of Oxazole Hydroxamates as Highly Selective Histone Deacetylase 6 (HDAC6) Inhibitors.
AID1303627	Potentiation of 0.025 nM (-)-lomaiviticin A-induced cytotoxicity against human K562 cells assessed as combination index at 0.125 uM after 48 hrs by cell titer-glo luminescence assay	2016	Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13	Synergistic potentiation of (-)-lomaiviticin A cytotoxicity by the ATR inhibitor VE-821.
AID1469397	Induction of apoptosis in human Hep3B cells assessed as necrotic cells at 10 uM after 48 hrs by annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 4.97%)	2018	Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7	Discovery of N1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7 H-pyrrolo[2,3- d]pyrimidin-2-yl)amino)phenyl)- N8-hydroxyoctanediamide as a Novel Inhibitor Targeting Cyclin-dependent Kinase 4/9 (CDK4/9) and Histone Deacetlyase1 (HDAC1) against Malignant Cancer
AID1155321	Cytotoxicity against erythrocytes (unknown origin)	2014	European journal of medicinal chemistry, Jul-23, Volume: 82	Discovery of HDAC inhibitors with potent activity against multiple malaria parasite life cycle stages.
AID1203890	Inhibition of recombinant HDAC2 (unknown origin) using fluorogenic substrate Boc-Lys (acetyl)-AMC after 20 mins by homogeneous fluorescence release assay	2015	European journal of medicinal chemistry, , Volume: 96	Discovery and preliminary evaluation of 2-aminobenzamide and hydroxamate derivatives containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors.
AID1677514	Binding affinity to full length His-tagged Mcl1 (unknown origin) preincubated for 30 min followed by 5-FAM Bid-BH3 addition and measured after 20 mins by fluorescence polarization assay	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	HDAC-Bax Multiple Ligands Enhance Bax-Dependent Apoptosis in HeLa Cells.
AID760499	Cytotoxicity against human KM12 cells after 48 hrs by SRB assay	2013	ACS medicinal chemistry letters, Aug-08, Volume: 4, Issue:8	Development of a chimeric c-Src kinase and HDAC inhibitor.
AID1339585	Growth inhibition of human Jurkat cells after 44 hrs by MTT assay	2017	ACS medicinal chemistry letters, Mar-09, Volume: 8, Issue:3	Structural Requirements of HDAC Inhibitors: SAHA Analogues Modified at the C2 Position Display HDAC6/8 Selectivity.
AID525016	Inhibition of HDAC in human CFBE41o- cell line assessed as hyperacetylation of histone H3 at 5 uM after 8 hrs by immunoblot analysis	2010	Nature chemical biology, Jan, Volume: 6, Issue:1	Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.
AID1282299	Inhibition of HDAC1/2/3 in human HCT116 cells assessed as upregulation of histone H3 acetylation at 10 to 1000 nM after 6 hrs by Western blot analysis	2016	Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4	Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
AID618097	Toxicity in athymic nu/nu Harlan mouse xenografted with human HCT116 cells assessed as mouse survival at 200 mg/kg, po QD for 21 days measured on day 22	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile.
AID1379286	Inhibition of recombinant human His-tagged c-Met cytoplasmic domain (956 to 1390 residues) expressed in baculovirus expression system using poly (Glu,Tyr)4:1 as substrate after 60 mins by spectrophotometric analysis	2017	ACS medicinal chemistry letters, Aug-10, Volume: 8, Issue:8	Design, Synthesis, and Biological Evaluation of the First c-Met/HDAC Inhibitors Based on Pyridazinone Derivatives.
AID1383994	Antiproliferative activity against human K562 cells after 48 hrs by MTT assay	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	Discovery of meta-sulfamoyl N-hydroxybenzamides as HDAC8 selective inhibitors.
AID1754810	Upregulation of SIRT4 gene expression in human MCF7 cells at 3 uM incubated for 24 hrs by whole transcriptome analysis	2021	Bioorganic & medicinal chemistry, 07-15, Volume: 42	Discovery of novel class of histone deacetylase inhibitors as potential anticancer agents.
AID594125	Inhibition of full length HDAC8 assessed as 7-amino-4-methylcoumarin release from fluorophore conjugated substrate after 5 mins by fluorescence assay	2011	Bioorganic & medicinal chemistry letters, May-01, Volume: 21, Issue:9	Discovery of histone deacetylase 8 selective inhibitors.
AID1206750	Induction of apoptosis in human HEL cells at 0.5 to 2 uM after 24 hrs by 7-AAD-annexin-V/propidium iodide staining-based flow cytometric analysis	2015	Journal of medicinal chemistry, May-28, Volume: 58, Issue:10	Design, synthesis, and antitumor evaluation of novel histone deacetylase inhibitors equipped with a phenylsulfonylfuroxan module as a nitric oxide donor.
AID1688028	Induction of apoptosis in human HL-60 cells assessed as increase in accumulation at sub-G1 phase at 1 uM after 24 hrs by propidium iodide staining based flow cytometry (Rvb = 2.72 %)	2020	European journal of medicinal chemistry, Feb-15, Volume: 188	A 18β-glycyrrhetinic acid conjugate with Vorinostat degrades HDAC3 and HDAC6 with improved antitumor effects.
AID525031	Inhibition of HDAC7 in human primary bronchial epithelial cells assessed as induction of mutant Fdelta508 CFTR protein apical surface localization at 5 uM	2010	Nature chemical biology, Jan, Volume: 6, Issue:1	Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.
AID1066162	Antimigratory activity against human HCT116 cells at 50 uM after 72 hrs	2014	Journal of medicinal chemistry, Jan-09, Volume: 57, Issue:1	Pan-histone demethylase inhibitors simultaneously targeting Jumonji C and lysine-specific demethylases display high anticancer activities.
AID1178600	Inhibition of human HDAC9 pre-incubated for 30 mins before substrate addition and measured after 30 mins by HDAC-Glo I/II assay	2014	Bioorganic & medicinal chemistry, Jul-15, Volume: 22, Issue:14	Design and synthesis of novel and highly-active pan-histone deacetylase (pan-HDAC) inhibitors.
AID1348913	Cytotoxicity against human PC3 cells assessed as growth inhibition after 48 hrs by SRB assay	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Discovery of aliphatic-chain hydroxamates containing indole derivatives with potent class I histone deacetylase inhibitory activities.
AID1404299	Antiproliferative activity against human MCF7 cells after 72 hrs by resazurin dye based fluorescence assay	2018	ACS medicinal chemistry letters, Feb-08, Volume: 9, Issue:2	Biocompatible Boron-Containing Prodrugs of Belinostat for the Potential Treatment of Solid Tumors.
AID348392	Antiproliferative activity against human NB4 cells after 48 hrs	2008	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 18, Issue:18	Design, synthesis and preliminary biological evaluation of new hydroxamate histone deacetylase inhibitors as potential antileukemic agents.
AID619044	Antiproliferative activity against human HCT116 cells after 96 hrs by celltiter 96 assay	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile.
AID1652194	Antiproliferative activity against human LNCAP cells incubated for 96 hrs by resazurin assay	2020	ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5	New Dual CK2/HDAC1 Inhibitors with Nanomolar Inhibitory Activity against Both Enzymes.
AID1511128	Induction of apoptosis in human in human HL60 cells at 0.25 uM incubated for 48 hrs by annexin V-FITC and PI staining based flow cytometric analysis	2019	ACS medicinal chemistry letters, Aug-08, Volume: 10, Issue:8	Design, Synthesis, and Biological Evaluation of 2,4-Imidazolinedione Derivatives as HDAC6 Isoform-Selective Inhibitors.
AID670517	Antiproliferative activity against human HL60 cells after 48 hrs by MTT assay	2012	Bioorganic & medicinal chemistry, Jul-15, Volume: 20, Issue:14	Synthesis and biological evaluation of N-aryl salicylamides with a hydroxamic acid moiety at 5-position as novel HDAC-EGFR dual inhibitors.
AID723122	Potentiation of 8 uM cisplatin-induced toxicity in 0.5 uM cisplatin resistant human KYSE-510 cells at 1 uM pretreated for 48 hrs followed by 0.5 uM cisplatin treatment by MTT assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1275245	Inhibition of VEGFR2 (unknown origin) preincubated for 5 mins followed by addition of ATP/gastrin precursor(Tyr87) biotinylated peptide cocktail incubated for 30 mins by ELISA	2016	European journal of medicinal chemistry, Feb-15, Volume: 109	Design, synthesis and biological evaluation of N-phenylquinazolin-4-amine hybrids as dual inhibitors of VEGFR-2 and HDAC.
AID1742757	In vivo inhibition of HDAC in tumor of human MDA-MB-231 cells xenografted in BALB/c mouse assessed as increase in acetylated alpha-tubulin expression by immunohistochemistry method	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Design and synthesis of novel Flavone-based histone deacetylase inhibitors antagonizing activation of STAT3 in breast cancer.
AID1155331	Selectivity index, ratio of IC50 for human HepG2 cells to IC50 for asexual blood stage of Plasmodium falciparum 3D7	2014	European journal of medicinal chemistry, Jul-23, Volume: 82	Discovery of HDAC inhibitors with potent activity against multiple malaria parasite life cycle stages.
AID90353	Inhibitory concentration against human histone deacetylase	2003	Journal of medicinal chemistry, Nov-20, Volume: 46, Issue:24	Histone deacetylase inhibitors.
AID747264	Growth inhibition of human BGC823 cells by MTT assay	2013	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 23, Issue:11	Design, synthesis, and biological evaluation of novel histone deacetylase 1 inhibitors through click chemistry.
AID732142	Inhibition of HDAC9 (unknown origin) assessed as fluorescence intensity measured after 60 mins incubation at room temperature by trypsin-free microfluidic lab-on-a-chip assay	2013	Journal of medicinal chemistry, Feb-28, Volume: 56, Issue:4	Potent and selective inhibition of histone deacetylase 6 (HDAC6) does not require a surface-binding motif.
AID762187	Cytotoxicity against human DU145 cells assessed as growth inhibition by measuring cellular ATP level after 72 hrs by cell-titer glo assay	2013	Journal of medicinal chemistry, Aug-08, Volume: 56, Issue:15	Discovery of potent, isoform-selective inhibitors of histone deacetylase containing chiral heterocyclic capping groups and a N-(2-aminophenyl)benzamide binding unit.
AID1784971	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Design, synthesis and biological evaluation of novel hybrids targeting mTOR and HDACs for potential treatment of hepatocellular carcinoma.
AID760507	Inhibition of HDAC6 (unknown origin) using fluorogenic peptide from p53 residues (379 to 382) (RHKK(Ac)) as substrate by fluorescence assay	2013	ACS medicinal chemistry letters, Aug-08, Volume: 4, Issue:8	Development of a chimeric c-Src kinase and HDAC inhibitor.
AID1273871	Inhibition of HDAC3 (unknown origin)	2016	European journal of medicinal chemistry, Jan-27, Volume: 108	Synthesis, biological characterization and molecular modeling insights of spirochromanes as potent HDAC inhibitors.
AID1742630	Inhibition of STAT3 in human MDA-MB-231 cells assessed as reduction in STAT-3 phosphorylation at 2.5 to 40 uM incubated for 8 hrs by Western blot analysis	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Design and synthesis of novel Flavone-based histone deacetylase inhibitors antagonizing activation of STAT3 in breast cancer.
AID1399544	Inhibition of recombinant human HDAC6 expressed in baculovirus infected High5 insect cells using Boc-Lys (epsilon-acetyl)-AMC as substrate after 3 hrs by fluorescence assay	2018	Bioorganic & medicinal chemistry, 09-01, Volume: 26, Issue:16	A series of camptothecin prodrugs exhibit HDAC inhibition activity.
AID1572356	Antiproliferative activity against human T24 cells after 72 hrs by CellTiter blue-reagent based assay	2019	Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3	Synthesis and Biological Investigation of Phenothiazine-Based Benzhydroxamic Acids as Selective Histone Deacetylase 6 Inhibitors.
AID1650419	Inhibition of class 1 histone deacetylase in human CAL27 cells assessed as increase in H3 histone acetylation at 3 uM incubated for 24 hrs by immunoblot analysis	2020	Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1	Novel alkoxyamide-based histone deacetylase inhibitors reverse cisplatin resistance in chemoresistant cancer cells.
AID1433256	Antiproliferative activity against human MOLM13 cells harboring wild type p53/FLT3-ITD mutant after 72 hrs by MTT assay	2016	Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17	Synthesis and Antileukemic Activities of Piperlongumine and HDAC Inhibitor Hybrids against Acute Myeloid Leukemia Cells.
AID723149	Potentiation of 8 uM cisplatin-induced toxicity in 5 uM cisplatin resistant human A2780 cells at 1.5 uM pretreated for 48 hrs followed by 5 uM cisplatin treatment by MTT assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1449215	Inhibition of N-terminal GST-tagged recombinant human HDAC6 expressed in baculovirus infected Sf9 insect cells using Z-(Ac)Lys-AMC as substrate measured after 90 mins by fluorescence assay	2017	Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13	Design, Multicomponent Synthesis, and Anticancer Activity of a Focused Histone Deacetylase (HDAC) Inhibitor Library with Peptoid-Based Cap Groups.
AID1653140	Cytotoxicity against human U251 cells assessed as reduction in cell viability by SRB assay	2019	European journal of medicinal chemistry, Mar-01, Volume: 165	Quinolone hybrids and their anti-cancer activities: An overview.
AID1855243	Inhibition of HDAC1 in human HeLa cell nuclear extract using Boc-Lys(Ac)-AMC or Boc-Lys(triflouroacetyl)-AMC as substrate incubated for 30 mins and measured by fluorescence assay	2022	European journal of medicinal chemistry, Nov-05, Volume: 241	Discovery of 2,5-diphenyl-1,3,4-thiadiazole derivatives as HDAC inhibitors with DNA binding affinity.
AID1467237	Inhibition of recombinant C-terminal His-tagged HDAC11 (unknown origin) expressed in baculovirus infected Sf9 cells at 2 uM using Ac-Arg-Gly-Lys(Ac)-AMC as substrate pretreated for 3 hrs followed by substrate addition measured within 30 mins by fluorometr	2017	Bioorganic & medicinal chemistry letters, 07-01, Volume: 27, Issue:13	Stabilizing HDAC11 with SAHA to assay slow-binding benzamide inhibitors.
AID1293564	Inhibition of human recombinant C-terminal His-tagged, N-terminal GST-tagged HDAC4 (627 to 1084 residues) expressed in insect cells using RHK-K(Ac)-AMC as substrate incubated for 60 mins by fluorescence assay	2016	European journal of medicinal chemistry, Apr-13, Volume: 112	Biphenyl-4-yl-acrylohydroxamic acids: Identification of a novel indolyl-substituted HDAC inhibitor with antitumor activity.
AID1650414	Cytotoxicity against human A2780 cells assessed as reduction in cell viability by MTT assay	2020	Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1	Novel alkoxyamide-based histone deacetylase inhibitors reverse cisplatin resistance in chemoresistant cancer cells.
AID619043	Antiproliferative activity against human A2780 cells after 96 hrs by celltiter 96 assay	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile.
AID663362	Growth inhibition of human SW620 cells after 72 hrs by MTS assay	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Discovery and extensive in vitro evaluations of NK-HDAC-1: a chiral histone deacetylase inhibitor as a promising lead.
AID1280261	Inhibition of human HDAC8 using Z-L-Lys(eta-trifluoroacetyl)-AMC as substrate after 90 mins by fluorescence analysis	2016	Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4	Synthesis and Biological Investigation of Oxazole Hydroxamates as Highly Selective Histone Deacetylase 6 (HDAC6) Inhibitors.
AID1722282	Inhibition of human recombinant HDAC3 expressed in baculovirus infected High5 insect cells using Ac-Lys-Tyr-Lys(e-acetyl)-AMC as substrate incubated for 24 hrs measured after 30 mins by microplate reader based spectrophotometric analysis	2020	Bioorganic & medicinal chemistry, 09-01, Volume: 28, Issue:17	The design of a novel near-infrared fluorescent HDAC inhibitor and image of tumor cells.
AID1890308	Inhibition of recombinant human HDAC6 using Boc-Lys-(acetyl)-AMC as substrate incubated for 0.5 hr and measured after 20 mins by fluorescence assay	2022	European journal of medicinal chemistry, Apr-05, Volume: 233	Novel biphenyl-based scaffold as potent and selective histone deacetylase 6 (HDAC6) inhibitors: Identification, development and pharmacological evaluation.
AID1321712	Inhibition of HDAC in human SH-SY5Y cells assessed as increase in histone H3K9 acetylation at 50 nM after 2 hrs by AlphaLisa assay relative to control	2016	Journal of medicinal chemistry, 10-13, Volume: 59, Issue:19	Design, Synthesis, and Biological Evaluation of First-in-Class Dual Acting Histone Deacetylases (HDACs) and Phosphodiesterase 5 (PDE5) Inhibitors for the Treatment of Alzheimer's Disease.
AID527318	Growth inhibition of human HCT116 cells after 72 hrs by SRB assay	2010	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22	Design and synthesis of novel pyrimidine hydroxamic acid inhibitors of histone deacetylases.
AID748106	Inhibition of HDAC8 (unknown origin) after 60 mins by fluorescence assay	2013	Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11	Discovery of the first histone deacetylase 6/8 dual inhibitors.
AID1873420	Inhibition of HDAC1 (unknown origin) at 1 uM preincubated for 1 hr followed by 100-fold dilution and subsequent substrate addition measured immediately	2022	Bioorganic & medicinal chemistry letters, 08-15, Volume: 70	Comparison of three zinc binding groups for HDAC inhibitors - A potency, selectivity and enzymatic kinetics study.
AID652752	Inhibition of recombinant human HDAC8 using Arg-His-Lys(Ac)-Lys(Ac)-AMC as substrate after 30 mins by spectrophotometry	2011	ACS medicinal chemistry letters, Jul-21, Volume: 2, Issue:9	Potential Agents for Treating Cystic Fibrosis: Cyclic Tetrapeptides that Restore Trafficking and Activity of ΔF508-CFTR.
AID717794	Inhibition of HDAC1 using Fluor-de-Lys as substrate assessed as remaining activity at 2.5 x 10'-7 M pretreated for 30 mins before substrate addition by fluorescence assay	2012	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23	The structural requirements of histone deacetylase inhibitors: suberoylanilide hydroxamic acid analogs modified at the C6 position.
AID1462218	Inhibition of human BRD4 bromo domain 2 at 5 uM	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Structure-based design, synthesis and in vitro antiproliferative effects studies of novel dual BRD4/HDAC inhibitors.
AID603545	Selectivity ratio of IC50 for HDAC8 to IC50 for HDAC6 in human HeLa cell nuclear extracts	2011	Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8	Development of tetrahydroisoquinoline-based hydroxamic acid derivatives: potent histone deacetylase inhibitors with marked in vitro and in vivo antitumor activities.
AID717796	Inhibition of HDAC1 using Fluor-de-Lys as substrate assessed as remaining activity at 6.25 x 10'-8 M pretreated for 30 mins before substrate addition by fluorescence assay	2012	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23	The structural requirements of histone deacetylase inhibitors: suberoylanilide hydroxamic acid analogs modified at the C6 position.
AID1688045	Upregulation of acetylated alpha-tubulin level in human HL-60 cells at 2 uM measured after 12 hrs by Western blot analysis	2020	European journal of medicinal chemistry, Feb-15, Volume: 188	A 18β-glycyrrhetinic acid conjugate with Vorinostat degrades HDAC3 and HDAC6 with improved antitumor effects.
AID1915567	Cytotoxicity against human RWPE-1 cells	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors.
AID525013	Inhibition of HDAC7 expressed in hamster BHK cell line assessed as increase in plasma membrane Fdelta508 CFTR protein at 5 uM by immunofluorescence method	2010	Nature chemical biology, Jan, Volume: 6, Issue:1	Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.
AID628288	Antiproliferative activity against human HepG2 cells after 24 hrs by XTT assay	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Design, synthesis, docking, and biological evaluation of novel diazide-containing isoxazole- and pyrazole-based histone deacetylase probes.
AID748113	Inhibition of HDAC2 (unknown origin) after 60 mins by fluorescence assay	2013	Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11	Discovery of the first histone deacetylase 6/8 dual inhibitors.
AID1597940	Antiproliferative activity against human MGC803 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	2019	Bioorganic & medicinal chemistry letters, 09-15, Volume: 29, Issue:18	Anti-tumor activity evaluation of novel tubulin and HDAC dual-targeting inhibitors.
AID414750	Cytotoxicity against human EOL-1 cells after 72 hrs by alamar-blue cell viability assay	2009	Journal of medicinal chemistry, Apr-23, Volume: 52, Issue:8	Design of chimeric histone deacetylase- and tyrosine kinase-inhibitors: a series of imatinib hybrides as potent inhibitors of wild-type and mutant BCR-ABL, PDGF-Rbeta, and histone deacetylases.
AID1754765	Downregulation of HDAC6 gene expression in human MCF7 cells at 3 uM incubated for 24 hrs by whole transcriptome analysis	2021	Bioorganic & medicinal chemistry, 07-15, Volume: 42	Discovery of novel class of histone deacetylase inhibitors as potential anticancer agents.
AID1469301	Induction of apoptosis in human NCI-H460 cells assessed as live cells at 10 uM after 48 hrs by annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 97.3%)	2018	Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7	Discovery of N1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7 H-pyrrolo[2,3- d]pyrimidin-2-yl)amino)phenyl)- N8-hydroxyoctanediamide as a Novel Inhibitor Targeting Cyclin-dependent Kinase 4/9 (CDK4/9) and Histone Deacetlyase1 (HDAC1) against Malignant Cancer
AID1597933	Antiproliferative activity against human HeLa cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	2019	Bioorganic & medicinal chemistry letters, 09-15, Volume: 29, Issue:18	Anti-tumor activity evaluation of novel tubulin and HDAC dual-targeting inhibitors.
AID670516	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	2012	Bioorganic & medicinal chemistry, Jul-15, Volume: 20, Issue:14	Synthesis and biological evaluation of N-aryl salicylamides with a hydroxamic acid moiety at 5-position as novel HDAC-EGFR dual inhibitors.
AID1384206	Inhibition of HDAC1 (unknown origin)	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease.
AID1688040	Induction of apoptosis in human HL-60 cells assessed as late apoptotic cells at 2 uM measured after 24 hrs by Annexin-V/FITC and propidium iodide staining based flow cytometry (Rvb = 7.24 %)	2020	European journal of medicinal chemistry, Feb-15, Volume: 188	A 18β-glycyrrhetinic acid conjugate with Vorinostat degrades HDAC3 and HDAC6 with improved antitumor effects.
AID525033	Inhibition of HDAC in human primary bronchial epithelial cells assessed as induction of mutant Fdelta508 CFTR protein apical surface localization at 5 uM	2010	Nature chemical biology, Jan, Volume: 6, Issue:1	Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.
AID1337254	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	2016	Journal of medicinal chemistry, Sep-22, Volume: 59, Issue:18	Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines.
AID1129782	Cell cycle arrest in human Jurkat cells assessed as accumulation at S-phase at 10 uM after 24 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 20.90%)	2014	Bioorganic & medicinal chemistry, Apr-01, Volume: 22, Issue:7	Studies on the antiproliferative effects of tropolone derivatives in Jurkat T-lymphocyte cells.
AID1174686	Antiproliferative activity against human HL60 cells after 48 hrs by MTT assay	2015	European journal of medicinal chemistry, Jan-07, Volume: 89	Development of 3-hydroxycinnamamide-based HDAC inhibitors with potent in vitro and in vivo anti-tumor activity.
AID1848302	Induction of apoptosis in human MV4-11 cells assessed as early apoptotic cells at 1 uM incubated for 48 hrs by Annexin V-FITC/PI staining based flow cytometry (Rvb = 0.95%)	2022	Bioorganic & medicinal chemistry, Nov-15, Volume: 74	Design, synthesis and biological evaluation of novel pyrazinone derivatives as PI3K/HDAC dual inhibitors.
AID663387	Growth inhibition of human 786-0 cells after 72 hrs by MTS assay	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Discovery and extensive in vitro evaluations of NK-HDAC-1: a chiral histone deacetylase inhibitor as a promising lead.
AID1689772	Antiproliferative activity against human H460 cells assessed as inhibition of cell growth at 8 uM measured after 72 hrs by CCK-8 assay relative to control	2020	European journal of medicinal chemistry, Mar-01, Volume: 189	Discovery of novel cyclin-dependent kinase (CDK) and histone deacetylase (HDAC) dual inhibitors with potent in vitro and in vivo anticancer activity.
AID1742225	AUC (0 to infinity) in Beagle dog at 20 mg/kg, po by LC-MS/MS analysis	2020	European journal of medicinal chemistry, Nov-01, Volume: 205	Design, synthesis and biological evaluation of novel HDAC inhibitors with improved pharmacokinetic profile in breast cancer.
AID1476183	Inhibition of N-terminal GST tagged human HDAC6 (1 to 1215 residues) expressed in baculovirus infected insect cells at 10 uM using RHKKAc as substrate in presence of ATP	2017	Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20	Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat.
AID1784185	Inhibition of Schistosoma mansoni HDAC8 using Fluor de Lys as substrate incubated for 90 mins by fluorescence method	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Synthesis, structure-activity relationships, cocrystallization and cellular characterization of novel smHDAC8 inhibitors for the treatment of schistosomiasis.
AID1915601	Cytotoxicity against human SMMC-7721 cells	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors.
AID760510	Inhibition of HDAC3 (unknown origin) using fluorogenic peptide from p53 residues (379 to 382) (RHKK(Ac)) as substrate by fluorescence assay	2013	ACS medicinal chemistry letters, Aug-08, Volume: 4, Issue:8	Development of a chimeric c-Src kinase and HDAC inhibitor.
AID737911	Cytotoxicity against human A549 cells after 72 hrs by MTT assay	2013	Journal of medicinal chemistry, May-09, Volume: 56, Issue:9	Design and synthesis of dual-action inhibitors targeting histone deacetylases and 3-hydroxy-3-methylglutaryl coenzyme A reductase for cancer treatment.
AID1399811	Solubility in pH 7.4 phosphate buffer solution at 100 uM after 24 hrs by HPLC method	2018	Bioorganic & medicinal chemistry letters, 09-15, Volume: 28, Issue:17	Squaramides as novel class I and IIB histone deacetylase inhibitors for topical treatment of cutaneous t-cell lymphoma.
AID1482097	Inhibition of HDAC 1 in human HeLa nuclear extract using HDAC substrate-3 measured after 60 mins by fluorometric analysis	2017	Journal of medicinal chemistry, 04-27, Volume: 60, Issue:8	Exploring Derivatives of Quinazoline Alkaloid l-Vasicine as Cap Groups in the Design and Biological Mechanistic Evaluation of Novel Antitumor Histone Deacetylase Inhibitors.
AID1676596	Binding affinity to Ferric ion assessed as retention ratio by measuring compound detected in elution fraction/total compound detected at 2.55 umol by immobilized metal-ion affinity chromatography	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
AID1547346	Inhibition of HDAC in human HCT116 cells assessed as activation of IL6-JAK-STAT signaling pathway by measuring increase in STAT3 phosphorylation at 10 uM after 24 hrs by Western blot analysis	2020	Journal of medicinal chemistry, 04-09, Volume: 63, Issue:7	Discovery of Thieno[2,3-
AID619047	Competitive inhibition of HDAC2 using KI-104 as substrate by fluorescence assay	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile.
AID256473	Selectivity for class I (HD1B) against class II (HD1A) histone deacetylases	2005	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 15, Issue:21	Exploring the connection unit in the HDAC inhibitor pharmacophore model: novel uracil-based hydroxamates.
AID274101	Inhibition of maize HD2 (mean)	2007	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 17, Issue:5	Discovery of uracil-based histone deacetylase inhibitors able to reduce acquired antifungal resistance and trailing growth in Candida albicans.
AID328808	Antiproliferative activity against human G401 cells by CellTiter-Blue cell viability assay	2008	Journal of medicinal chemistry, Apr-24, Volume: 51, Issue:8	A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo.
AID1403170	Antimigratory activity in human HepG2 cells at 1 uM after 24 hrs by wound-healing assay	2018	European journal of medicinal chemistry, Jan-20, Volume: 144	Development of novel β-carboline-based hydroxamate derivatives as HDAC inhibitors with antiproliferative and antimetastatic activities in human cancer cells.
AID1753839	Inhibition of HDAC3 (unknown origin)	2021	European journal of medicinal chemistry, Jun-05, Volume: 218	Identification of novel 1,3-diaryl-1,2,4-triazole-capped histone deacetylase 6 inhibitors with potential anti-gastric cancer activity.
AID1398821	Antagonist activity at ERalpha in human MCF7 cells assessed as suppression of CCND1 mRNA expression at 5 uM after 24 hrs by QIAzol reagent based RT-qPCR analysis	2018	Bioorganic & medicinal chemistry, 08-15, Volume: 26, Issue:15	Incorporation of histone deacetylase inhibitory activity into the core of tamoxifen - A new hybrid design paradigm.
AID1816202	Antiproliferative activity against human CAL-51 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay
AID1655888	Inhibition of HDAC in human U937 cells assessed as Ac-H3 level at 0.5 uM incubated for 96 hrs by Western blot analysis (Rvb = 1 No_unit)	2020	ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5	Design of First-in-Class Dual EZH2/HDAC Inhibitor: Biochemical Activity and Biological Evaluation in Cancer Cells.
AID1127005	Induction of apoptosis in human U937 cells assessed as late apoptotic cells using annexin-V/propidium iodide staining at 0.25 uM after 24 hrs by flow cytometry analysis (Rvb = 2.13%)	2014	Journal of medicinal chemistry, Apr-24, Volume: 57, Issue:8	Discovery of the first N-hydroxycinnamamide-based histone deacetylase 1/3 dual inhibitors with potent oral antitumor activity.
AID764216	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	2013	Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17	Novel N-hydroxyfurylacrylamide-based histone deacetylase (HDAC) inhibitors with branched CAP group (Part 2).
AID385230	Inhibition of HDAC6	2008	Journal of medicinal chemistry, May-22, Volume: 51, Issue:10	Structural origin of selectivity in class II-selective histone deacetylase inhibitors.
AID374828	Antiproliferative activity against human G401 cells after 72 hrs by celltiter-blue cell viability assay	2009	Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11	Discovery of a potent class I selective ketone histone deacetylase inhibitor with antitumor activity in vivo and optimized pharmacokinetic properties.
AID626564	Inhibition of HDAC in human HeLa cell extract assessed as fluorophore release at 10 uM by fluorescence spectrophotometry	2011	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 21, Issue:22	4-N-Hydroxy-4-[1-(sulfonyl)piperidin-4-yl]-butyramides as HDAC inhibitors.
AID747259	Growth inhibition of human A431 cells by MTT assay	2013	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 23, Issue:11	Design, synthesis, and biological evaluation of novel histone deacetylase 1 inhibitors through click chemistry.
AID1547272	Inhibition of HDAC6 (unknown origin) using biotinylated histone H3 KAc peptide (1 to 21 residues) as substrate by HTRF assay	2020	Journal of medicinal chemistry, 04-09, Volume: 63, Issue:7	Discovery of Thieno[2,3-
AID1467239	Inhibition of recombinant C-terminal His-tagged HDAC11 (unknown origin) expressed in baculovirus infected Sf9 cells at 0.2 uM using Ac-Arg-Gly-Lys(Ac)-AMC as substrate pretreated for 3 hrs followed by substrate addition measured after 30 mins by fluoromet	2017	Bioorganic & medicinal chemistry letters, 07-01, Volume: 27, Issue:13	Stabilizing HDAC11 with SAHA to assay slow-binding benzamide inhibitors.
AID1622929	Inhibition of recombinant human FLAG/His-tagged HDAC1 expressed in baculovirus expression system using 7-AMC-labelled HDAC substrate measured after 30 mins by fluorescence assay	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.
AID1235111	Cytotoxicity against mouse B16 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	2015	Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15	Synthesis and biological evaluation of novel histone deacetylases inhibitors with nitric oxide releasing activity.
AID1361632	Inhibition of HDAC2 (unknown origin) after 30 mins by fluorescence assay	2018	Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16	Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents.
AID1486297	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay	2017	Bioorganic & medicinal chemistry, 08-01, Volume: 25, Issue:15	Olaparib hydroxamic acid derivatives as dual PARP and HDAC inhibitors for cancer therapy.
AID1873424	Inhibition of HDAC in human MV4-11 cells assessed as histone H3 acetylation preincubated for 3 hrs followed by compound washout and measured within 30 mins by Western blot analysis	2022	Bioorganic & medicinal chemistry letters, 08-15, Volume: 70	Comparison of three zinc binding groups for HDAC inhibitors - A potency, selectivity and enzymatic kinetics study.
AID764647	Inhibition of HDAC1/HDAC3/HDAC5/HDAC8 in human HeLa nuclear extract using Boc-Lys(acetyl)-AMC as substrate incubated for 5 mins prior to substrate measured after 30 mins by spectrophotometric analysis	2013	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17	Novel β-dicarbonyl derivatives as inhibitors of aminopeptidase N (APN).
AID1886186	Inhibition of HDAC6 in human HeLa cells using BOC-K(Ac)-AMC as substrate measured after 30 mins by fluorescence based microtiter plate reader assay	2022	Journal of medicinal chemistry, 08-25, Volume: 65, Issue:16	Discovery of a Novel Vascular Disrupting Agent Inhibiting Tubulin Polymerization and HDACs with Potent Antitumor Effects.
AID95277	Compound was tested for anti-proliferative activity in Jurkat human leukemia cell line	2004	Bioorganic & medicinal chemistry letters, Jan-19, Volume: 14, Issue:2	Design, synthesis, and activity of HDAC inhibitors with a N-formyl hydroxylamine head group.
AID1282257	Cytotoxicity against human SKBR3 cells after 72 hrs by MTT assay	2016	Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4	Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
AID1422495	Cytotoxicity against mouse FL5.12 cells assessed as vacuole formation at 10 uM after 3 hrs by fluorescence microscopic analysis	2018	European journal of medicinal chemistry, Nov-05, Volume: 159	In search of constrained FTY720 and phytosphingosine analogs as dual acting anticancer agents targeting metabolic and epigenetic pathways.
AID1441699	Inhibition of recombinant human LTA4H aminopeptidase activity expressed in Escherichia coli BL21 (DE3) pLysS assessed as formation of p-NA from Ala-p-NA at 10 uM preincubated for 10 mins followed by substrate addition measured after 10 mins	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
AID1775545	Inhibition of HDAC1 (unknown origin)	2021	Journal of medicinal chemistry, 03-25, Volume: 64, Issue:6	Design and Synthesis of Novel Epigenetic Inhibitors Targeting Histone Deacetylases, DNA Methyltransferase 1, and Lysine Methyltransferase G9a with
AID1633653	Inhibition of human recombinant HDAC1 using ZMAL (Z-(Ac)Lys-AMC fluorogenic substrate incubated for 90 mins by fluorescence method	2019	ACS medicinal chemistry letters, Apr-11, Volume: 10, Issue:4	Novel Sustainable-by-Design HDAC Inhibitors for the Treatment of Alzheimer's Disease.
AID1655793	Inhibition of human recombinant HDAC8 using AMC-K(Ac)GL as substrate by fluorescence based assay	2020	ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5	Design of First-in-Class Dual EZH2/HDAC Inhibitor: Biochemical Activity and Biological Evaluation in Cancer Cells.
AID473179	Induction of HDAC-mediated histone acetylation in human HepG2 cells at 5 uM after 6 hrs by indirect ELISA	2010	Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5	Biological and biophysical properties of the histone deacetylase inhibitor suberoylanilide hydroxamic acid are affected by the presence of short alkyl groups on the phenyl ring.
AID1256442	Inhibition VEGFR2 (unknown origin) for 30 mins by ELISA	2015	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22	Hybrids from 4-anilinoquinazoline and hydroxamic acid as dual inhibitors of vascular endothelial growth factor receptor-2 and histone deacetylase.
AID1441648	Anti-inflammatory activity in LPS-induced C57BL/6 mouse model of acute lung injury assessed as reduction in IL-1beta mRNA level pretreated intraperitoneally for 1 hr followed LPS challenge after 24 hrs by qRT-PCR method	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
AID1821347	Toxicity in mouse xenografted with human HepG2 cells assessed as necrosis in heart at 12 mg/kg, ip administered every 2 days for 4 weeks by H and E staining based microscopic method	2022	European journal of medicinal chemistry, Feb-05, Volume: 229	Discovery of phthalazino[1,2-b]-quinazolinone derivatives as multi-target HDAC inhibitors for the treatment of hepatocellular carcinoma via activating the p53 signal pathway.
AID1308510	Antiproliferative activity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by Alamar blue assay	2016	Bioorganic & medicinal chemistry letters, 06-15, Volume: 26, Issue:12	Targeting epigenetic reader and eraser: Rational design, synthesis and in vitro evaluation of dimethylisoxazoles derivatives as BRD4/HDAC dual inhibitors.
AID1737148	Induction of apoptosis in human HCT-116 cells assessed as early apoptotic cells at 10 uM after 24 hrs by Annexin V-FITC/PI staining based flow cytometric analysis (Rvb = 4.01%)	2020	European journal of medicinal chemistry, Apr-15, Volume: 192	Design, synthesis and biological evaluation of novel indazole-based derivatives as potent HDAC inhibitors via fragment-based virtual screening.
AID350718	Inhibition of human recombinant HDAC8 by fluorimetry	2009	Journal of medicinal chemistry, May-14, Volume: 52, Issue:9	Design, synthesis, and biological activity of boronic acid-based histone deacetylase inhibitors.
AID1275642	Growth inhibition of human HT-29 cells after 96 hrs by MTT assay	2016	European journal of medicinal chemistry, Feb-15, Volume: 109	Identification of N-(6-mercaptohexyl)-3-(4-pyridyl)-1H-pyrazole-5-carboxamide and its disulfide prodrug as potent histone deacetylase inhibitors with in vitro and in vivo anti-tumor efficacy.
AID1280271	Inhibition of class1 HDAC in human HeLa cells assessed as ratio of acetylated histone H3 to GAPDH level at 0.1 uM after 4 hrs by Western blot analysis relative to control	2016	Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4	Synthesis and Biological Investigation of Oxazole Hydroxamates as Highly Selective Histone Deacetylase 6 (HDAC6) Inhibitors.
AID765211	Cytotoxicity against human A2780C/P cells	2013	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17	Identification of novel HDAC inhibitors through cell based screening and their evaluation as potential anticancer agents.
AID1164776	Stability of the compound in aqueous solution at pH 7.4 after 24 hrs	2014	Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20	ST7612AA1, a thioacetate-ω(γ-lactam carboxamide) derivative selected from a novel generation of oral HDAC inhibitors.
AID1280282	Selectivity index, ratio of HDAC6 inhibition in human HL60 cells assessed as ratio of acetylated tubulin to GAPDH level at 1 uM over class1 HDAC inhibition in human HL60 cells assessed as ratio of acetylated histone H3 to GAPDH level at 1 uM	2016	Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4	Synthesis and Biological Investigation of Oxazole Hydroxamates as Highly Selective Histone Deacetylase 6 (HDAC6) Inhibitors.
AID1566820	Antiproliferative activity against human MM1S cells after 72 hrs by MTT assay	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Discovery of 1,2,4-oxadiazole-Containing hydroxamic acid derivatives as histone deacetylase inhibitors potential application in cancer therapy.
AID1281848	Inhibition of full length His6-tagged GST-fused recombinant human HDAC3 expressed in High5 insect cells using Ac-Lys-Tyr-Lys (e-acetyl)-AMC as substrate after 24 hrs by fluorescence assay	2016	European journal of medicinal chemistry, Apr-13, Volume: 112	Design, synthesis and biological evaluation of bisthiazole-based trifluoromethyl ketone derivatives as potent HDAC inhibitors with improved cellular efficacy.
AID663333	Growth inhibition of human HepG2 cells after 72 hrs by MTT assay	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Discovery and extensive in vitro evaluations of NK-HDAC-1: a chiral histone deacetylase inhibitor as a promising lead.
AID1548286	Induction of apoptosis in bortezomib resistant human KM3/BTZ cells assessed as late apoptotic cells level at 50 nM incubated for 24 hrs by Annexin V-FITC/PI staining based FCAS analysis (Rvb = 0.38%)
AID1863168	Inhibition of HDAC7 (unknown origin) using fluorogenic substrate incubated for 30 mins by fluorescence plate reader	2022	European journal of medicinal chemistry, Oct-05, Volume: 240	Design, synthesis, and biological evalution of bifunctional inhibitors against Hsp90-HDAC6 interplay.
AID663475	Efflux ratio, ratio of apparent permeability from basolateral to apical side over apparent permeability from apical to basolateral side in human Caco2 cells at 10 uM	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Discovery and extensive in vitro evaluations of NK-HDAC-1: a chiral histone deacetylase inhibitor as a promising lead.
AID352520	Inhibition of human recombinant HDAC10	2009	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11	Isoxazole moiety in the linker region of HDAC inhibitors adjacent to the Zn-chelating group: effects on HDAC biology and antiproliferative activity.
AID1482166	Cytotoxicity against human THP1 cells assessed as growth inhibition at 5 uM after 48 hrs by MTT assay relative to control	2017	Journal of medicinal chemistry, 04-27, Volume: 60, Issue:8	Exploring Derivatives of Quinazoline Alkaloid l-Vasicine as Cap Groups in the Design and Biological Mechanistic Evaluation of Novel Antitumor Histone Deacetylase Inhibitors.
AID420320	Binding affinity to Bordetella / Alcaligenes strain FB188 HDAC by FRET assay	2009	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 19, Issue:13	Non-isotopic dual parameter competition assay suitable for high-throughput screening of histone deacetylases.
AID1785344	Inhibition of full length human CDK2 (1 to 298 end residues)/N-terminal GST-tagged CyclinA2 (1 to 432 residues) expressed in baculovirus expression system preincubated for 10 mins followed by substrate and ATP addition by mobility shift assay
AID239792	Selectivity for class I HDACs as ratio of IC50 for maize histone deacetylase 1-A and 1-B	2005	Journal of medicinal chemistry, May-05, Volume: 48, Issue:9	Class II (IIa)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl)pyrrolyl hydroxyamides.
AID1897397	Induction of apoptosis in human SNU-16 cells assessed as early apoptotic cells at 0.1 uM incubated for 72 hrs by annexin-V/FITC propidium iodide staining based flow cytometry analysis (Rvb = 3.02%)
AID1127324	Inhibition of human HDAC3 complexed with NCOR2 using fluorogenic tetrapeptide RHKKAc as susbtrate	2014	European journal of medicinal chemistry, May-22, Volume: 79	Influence of the adamantyl moiety on the activity of biphenylacrylohydroxamic acid-based HDAC inhibitors.
AID1164191	Inhibition of HDAC6 in human U937 cells assessed as hyperacetylation of tubulin at 5 uM after 24 hrs by Western blot analysis relative to control	2014	ACS medicinal chemistry letters, Sep-11, Volume: 5, Issue:9	Novel antiproliferative chimeric compounds with marked histone deacetylase inhibitory activity.
AID1164909	Inhibition of HDAC4 (unknown origin) using fluorogenic peptide as substrate by fluorescence assay	2014	Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19	Identification of a novel aminotetralin class of HDAC6 and HDAC8 selective inhibitors.
AID1754771	Inhibition of HDAC in human MCF7 cells assessed as increase in histone H4 acetylation at 1 to 3 uM incubated for 24 hrs by Western blot analysis	2021	Bioorganic & medicinal chemistry, 07-15, Volume: 42	Discovery of novel class of histone deacetylase inhibitors as potential anticancer agents.
AID1917541	Inhibition of HDAC8 (unknown origin) measured by fluorescence based assay	2022	Bioorganic & medicinal chemistry, 11-01, Volume: 73	Identification of PI3K/HDAC Dual-targeted inhibitors with subtype selectivity as potential therapeutic agents against solid Tumors: Building HDAC6 potency in a Quinazolinone-based PI3Kδ-selective template.
AID1469311	Induction of apoptosis in human T47D cells assessed as late apoptotic cells at 10 uM after 48 hrs by annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 6.16%)	2018	Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7	Discovery of N1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7 H-pyrrolo[2,3- d]pyrimidin-2-yl)amino)phenyl)- N8-hydroxyoctanediamide as a Novel Inhibitor Targeting Cyclin-dependent Kinase 4/9 (CDK4/9) and Histone Deacetlyase1 (HDAC1) against Malignant Cancer
AID420634	Inhibition of HDAC6 in human IGROV1 cells assessed as alpha-tubulin acetylation at IC50 after 4 hrs by Western blot	2009	European journal of medicinal chemistry, May, Volume: 44, Issue:5	Design, synthesis, and evaluation of biphenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors.
AID246077	Effective Concentration of compound to inhibit the growth of human SK-OV-3 cells	2005	Journal of medicinal chemistry, Feb-24, Volume: 48, Issue:4	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates.
AID1572355	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by CellTiter blue-reagent based assay	2019	Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3	Synthesis and Biological Investigation of Phenothiazine-Based Benzhydroxamic Acids as Selective Histone Deacetylase 6 Inhibitors.
AID1826601	Antiproliferative activity against HEL cells assessed as cell growth inhibition incubated for 8 hrs by CCK8 assay	2022	Journal of medicinal chemistry, 03-24, Volume: 65, Issue:6	Evodiamine-Inspired Topoisomerase-Histone Deacetylase Dual Inhibitors: Novel Orally Active Antitumor Agents for Leukemia Therapy.
AID1451831	Inhibition of human recombinant HDAC3/GST tagged NCOR1 (397 to 503 residues) expressed in insect cells using Ac-Leu-Gly-Lys(Ac)-AMC as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by fluorescence assay	2017	Journal of medicinal chemistry, 10-12, Volume: 60, Issue:19	Small Molecule Inhibitors Simultaneously Targeting Cancer Metabolism and Epigenetics: Discovery of Novel Nicotinamide Phosphoribosyltransferase (NAMPT) and Histone Deacetylase (HDAC) Dual Inhibitors.
AID1739581	Inhibition of HDAC6 in human THP-1 cells assessed as ratio of acetylated tubulin/GAPDH at 0.1 uM incubated for 4 hrs by Western blot analysis relative to DMSO	2020	European journal of medicinal chemistry, Aug-15, Volume: 200	Design, synthesis, and biological evaluation of dual targeting inhibitors of histone deacetylase 6/8 and bromodomain BRPF1.
AID1826598	Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition incubated for 8 hrs by CCK8 assay	2022	Journal of medicinal chemistry, 03-24, Volume: 65, Issue:6	Evodiamine-Inspired Topoisomerase-Histone Deacetylase Dual Inhibitors: Novel Orally Active Antitumor Agents for Leukemia Therapy.
AID1856988	Inhibition of HDAC1 (unknown origin) preincubated for 5 mins followed by substrate addition and measured after 30 mins by multimode microplate reader analysis	2022	Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19	Histone Deacetylase and Enhancer of Zeste Homologue 2 Dual Inhibitors Presenting a Synergistic Effect for the Treatment of Hematological Malignancies.
AID663381	Growth inhibition of human MDA-MB-435 cells after 72 hrs by MTS assay	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Discovery and extensive in vitro evaluations of NK-HDAC-1: a chiral histone deacetylase inhibitor as a promising lead.
AID1515910	Antiproliferative activity against human Capan2 cells after 96 hrs by MTT assay	2019	Journal of medicinal chemistry, 08-08, Volume: 62, Issue:15	Design, Synthesis, and Biological Evaluation of 4-Methyl Quinazoline Derivatives as Anticancer Agents Simultaneously Targeting Phosphoinositide 3-Kinases and Histone Deacetylases.
AID1704067	Inhibition of c-MET(unknown origin) using FAM labelled peptide substrate preincubated for 10 mins followed by substrate addition and measured by microplate reader method	2020	European journal of medicinal chemistry, Oct-15, Volume: 204	Discovery of Novel c-Mesenchymal-Epithelia transition factor and histone deacetylase dual inhibitors.
AID1784976	Antiproliferative activity against human Huh-7 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Design, synthesis and biological evaluation of novel hybrids targeting mTOR and HDACs for potential treatment of hepatocellular carcinoma.
AID1576456	Cytotoxicity against human BEAS2B cells assessed as reduction in cell viability after 48 hrs by SRB assay
AID1205628	Growth inhibition of human MDA-MB-231 cells after 5 days by sulforhodamine B assay	2015	Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8	Discovery of Orally Available Runt-Related Transcription Factor 3 (RUNX3) Modulators for Anticancer Chemotherapy by Epigenetic Activation and Protein Stabilization.
AID1251321	Growth inhibition of human NB4 cells after 72 hrs	2015	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 25, Issue:20	Investigation on the ZBG-functionality of phenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase inhibitors.
AID1600729	Inhibition of N-terminal GST-tagged recombinant human HDAC6 (1 to 1215 residues) expressed in Baculovirus infected insect cells using Boc-Lys(Ac)-AMC as substrate preincubated for 5 mins followed by substrate addition and further incubation for 90 mins me	2019	Bioorganic & medicinal chemistry, 10-01, Volume: 27, Issue:19	Novel α,β-unsaturated hydroxamic acid derivatives overcome cisplatin resistance.
AID1355713	Antifungal activity against FLC resistant Candida albicans 0710922 after 48 hrs in presence of fluconazol by checkerboard microdilution method	2018	Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14	Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections.
AID1751992	Selectivity ratio of IC50 for HDAC6 (unknown origin) to IC50 for HDAC1 (unknown origin)	2021	Bioorganic & medicinal chemistry letters, 10-01, Volume: 49	Discovery of novel pyrazolopyrimidine derivatives as potent mTOR/HDAC bi-functional inhibitors via pharmacophore-merging strategy.
AID1206752	Cell cycle arrest in human HEL cells assessed as accumulation at G2 phase at 0.5 uM after 48 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 5.28%)	2015	Journal of medicinal chemistry, May-28, Volume: 58, Issue:10	Design, synthesis, and antitumor evaluation of novel histone deacetylase inhibitors equipped with a phenylsulfonylfuroxan module as a nitric oxide donor.
AID1476149	Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay	2017	Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20	Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat.
AID1525780	Inhibition of HADC8 (unknown origin)	2020	Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1	Old but Gold: Tracking the New Guise of Histone Deacetylase 6 (HDAC6) Enzyme as a Biomarker and Therapeutic Target in Rare Diseases.
AID274018	Half life after i.v. dosing at 1 mg kg-1	2007	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2	Identification and optimisation of a series of substituted 5-pyridin-2-yl-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.
AID1659653	Antiproliferative activity against human MOLT4 cells incubated for 24 hrs by CCK8 assay	2020	Bioorganic & medicinal chemistry letters, 06-01, Volume: 30, Issue:11	Environment-sensitive fluorescent inhibitors of histone deacetylase.
AID316944	Inhibition of mouse SC9 cells	2008	Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6	Histone deacetylase inhibitors: from bench to clinic.
AID753165	Cytotoxicity against human HCT116 cells	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and biological characterization of spiro[2H-(1,3)-benzoxazine-2,4'-piperidine] based histone deacetylase inhibitors.
AID628285	Antiproliferative activity against human HepG2 cells after 72 hrs by XTT assay	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Design, synthesis, docking, and biological evaluation of novel diazide-containing isoxazole- and pyrazole-based histone deacetylase probes.
AID1893824	Inhibition of HDAC in human HeLa nuclear extract measured after 30 mins by fluorescence based assay	2021	European journal of medicinal chemistry, Jan-15, Volume: 210	2-Aminothiazole: A privileged scaffold for the discovery of anti-cancer agents.
AID322416	Cell cycle arrest in human LNCap cells assessed as accumulation at G1 phase relative to control at 1 uM	2008	Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6	Improved synthesis of histone deacetylase inhibitors (HDIs) (MS-275 and CI-994) and inhibitory effects of HDIs alone or in combination with RAMBAs or retinoids on growth of human LNCaP prostate cancer cells and tumor xenografts.
AID723150	Potentiation of 8 uM cisplatin-induced toxicity in 5 uM cisplatin resistant human A2780 cells at 1 uM pretreated for 48 hrs followed by 5 uM cisplatin treatment by MTT assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID659493	Inhibition of HDAC1 in human HeLa cell nuclear extract using Fluor de Lys as substrate after 15 mins by fluorometric analysis	2012	Journal of medicinal chemistry, Feb-23, Volume: 55, Issue:4	Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors.
AID1478584	Induction of apoptosis in human K562 cells assessed as early apoptotic cells at 2 uM after 24 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometry (Rvb = 4.78%)	2017	European journal of medicinal chemistry, Jun-16, Volume: 133	Design, synthesis and biological evaluation of quinoline derivatives as HDAC class I inhibitors.
AID1503841	Inhibition of recombinant human full length HDAC6 expressed in baculovirus infected Sf9 insect cells using p53 (379 to 382 residues) derived RHKKAc as substrate preincubated for 5 to 10 mins followed by substrate addition measured after 2 hrs by fluoresce	2017	ACS medicinal chemistry letters, Oct-12, Volume: 8, Issue:10	Synthesis and Pharmacological Evaluation of Selective Histone Deacetylase 6 Inhibitors in Melanoma Models.
AID1742741	Genotoxicity in Salmonella typhimurium TA98 by Ames test	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Design and synthesis of novel Flavone-based histone deacetylase inhibitors antagonizing activation of STAT3 in breast cancer.
AID1485126	Cell cycle arrest in human U373 cells assessed as accumulation at sub-G1 phase at 2 uM after 24 to 48 hrs by propidium iodide staining-based flow cytometry	2017	Journal of medicinal chemistry, 06-08, Volume: 60, Issue:11	Discovery and Characterization of R/S-N-3-Cyanophenyl-N'-(6-tert-butoxycarbonylamino-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-4-yl)urea, a New Histone Deacetylase Class III Inhibitor Exerting Antiproliferative Activity against Cancer Cell Lines.
AID1821343	Toxicity in mouse xenografted with human HepG2 cells assessed as lung edema at 12 mg/kg, ip administered every 2 days for 4 weeks by H and E staining based microscopic method	2022	European journal of medicinal chemistry, Feb-05, Volume: 229	Discovery of phthalazino[1,2-b]-quinazolinone derivatives as multi-target HDAC inhibitors for the treatment of hepatocellular carcinoma via activating the p53 signal pathway.
AID1206739	Cytotoxicity against human HeLa cells assessed as growth inhibition after 48 hrs by MTT assay	2015	Journal of medicinal chemistry, May-28, Volume: 58, Issue:10	Design, synthesis, and antitumor evaluation of novel histone deacetylase inhibitors equipped with a phenylsulfonylfuroxan module as a nitric oxide donor.
AID1688035	Induction of apoptosis in human HL-60 cells assessed as early apoptotic cells at 1 uM measured after 24 hrs by Annexin-V/FITC and propidium iodide staining based flow cytometry (Rvb = 2.46 %)	2020	European journal of medicinal chemistry, Feb-15, Volume: 188	A 18β-glycyrrhetinic acid conjugate with Vorinostat degrades HDAC3 and HDAC6 with improved antitumor effects.
AID348792	Inhibition of human recombinant C-terminally flag tagged HDAC1	2008	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20	Optimization of a series of potent and selective ketone histone deacetylase inhibitors.
AID1280267	Inhibition of HDAC6 in human HeLa cells assessed as ratio of acetylated tubulin to GAPDH level at 1 uM after 4 hrs by Western blot analysis relative to control	2016	Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4	Synthesis and Biological Investigation of Oxazole Hydroxamates as Highly Selective Histone Deacetylase 6 (HDAC6) Inhibitors.
AID1486300	Antiproliferative activity against human K562 cells after 72 hrs by MTT assay	2017	Bioorganic & medicinal chemistry, 08-01, Volume: 25, Issue:15	Olaparib hydroxamic acid derivatives as dual PARP and HDAC inhibitors for cancer therapy.
AID1784988	Inhibition of HDAC8 (unknown origin) using Ac-peptide as a substrate pretreated for 15 mins followed by substrate addition	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Design, synthesis and biological evaluation of novel hybrids targeting mTOR and HDACs for potential treatment of hepatocellular carcinoma.
AID1816711	Inhibition of HDAC8 (unknown origin) using Ac-peptide as substrate preincubated for 15 mins followed by substrate addition by fluorescence based microplate reader analysis	2021	European journal of medicinal chemistry, Aug-05, Volume: 220	Design, synthesis, and biological evaluation of novel dual inhibitors targeting lysine specific demethylase 1 (LSD1) and histone deacetylases (HDAC) for treatment of gastric cancer.
AID748985	Inhibition of HDAC3 (unknown origin)	2013	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 23, Issue:11	A cyclodextrin-capped histone deacetylase inhibitor.
AID1857036	Antitumor activity against human MV4-11 cells xenografted in BALB/c nude mouse assessed as tumor growth inhibition at 100 mg/kg, ip administered for 20 days by vernier caliper analysis	2022	Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19	Histone Deacetylase and Enhancer of Zeste Homologue 2 Dual Inhibitors Presenting a Synergistic Effect for the Treatment of Hematological Malignancies.
AID1168914	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay	2014	Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21	Improved antiproliferative activity of 1,3,4-thiadiazole-containing histone deacetylase (HDAC) inhibitors by introduction of the heteroaromatic surface recognition motif.
AID1600731	Inhibition of C-terminal GST-tagged recombinant human HDAC2 (1 to 488 residues) expressed in Baculovirus infected insect cells using Boc-Lys(Ac)-AMC as substrate preincubated for 5 mins followed by substrate addition and further incubation for 90 mins mea	2019	Bioorganic & medicinal chemistry, 10-01, Volume: 27, Issue:19	Novel α,β-unsaturated hydroxamic acid derivatives overcome cisplatin resistance.
AID1821349	Toxicity in mouse xenografted with human HepG2 cells assessed as necrosis in liver at 12 mg/kg, ip administered every 2 days for 4 weeks by H and E staining based microscopic method	2022	European journal of medicinal chemistry, Feb-05, Volume: 229	Discovery of phthalazino[1,2-b]-quinazolinone derivatives as multi-target HDAC inhibitors for the treatment of hepatocellular carcinoma via activating the p53 signal pathway.
AID327544	Increase in p21waf1 re-expression in human HCT116 cells at 10 uM after 24 hrs relative to control	2008	Journal of medicinal chemistry, Apr-24, Volume: 51, Issue:8	Polyaminohydroxamic acids and polyaminobenzamides as isoform selective histone deacetylase inhibitors.
AID619192	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	2011	Journal of medicinal chemistry, Aug-11, Volume: 54, Issue:15	Discovery of a tetrahydroisoquinoline-based hydroxamic acid derivative (ZYJ-34c) as histone deacetylase inhibitor with potent oral antitumor activities.
AID84278	Concentration required for the antiproliferation of Human HT1080 fibrosarcoma cells	2002	Bioorganic & medicinal chemistry letters, Oct-21, Volume: 12, Issue:20	Succinimide hydroxamic acids as potent inhibitors of histone deacetylase (HDAC).
AID1600658	Inhibition of recombinant human full length C-terminal Flag-tagged HDAC2 expressed in baculovirus infected Sf9 cells using ZMAL as substrate incubated for 90 mins by fluorometric method	2019	Bioorganic & medicinal chemistry, 10-01, Volume: 27, Issue:19	Fluorescent analogs of peptoid-based HDAC inhibitors: Synthesis, biological activity and cellular uptake kinetics.
AID1234892	Selectivity ratio of IC50 for HDAC3 (unknown origin) to IC50 for HDAC6 (unknown origin)	2015	Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15	Design, synthesis and preliminary biological evaluation of indoline-2,3-dione derivatives as novel HDAC inhibitors.
AID1282245	Inhibition of recombinant HDAC11 (unknown origin) using AMC labeled AC-peptide as substrate incubated for 1 hr by fluorescence analysis	2016	Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4	Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
AID1677493	Cytotoxicity against human L02 cells assessed as reduction in cell viability after 48 hrs by MTT assay	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	HDAC-Bax Multiple Ligands Enhance Bax-Dependent Apoptosis in HeLa Cells.
AID308652	Increase in p27kip1 gene expression in PANC1 cells after 48 hrs relative to control	2007	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17	Design, synthesis, and evaluation of isoindolinone-hydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors.
AID619161	Oral bioavailability in nude BALB/c mouse at 50 mg/kg	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile.
AID1206740	Cytotoxicity against human U937 cells assessed as growth inhibition after 48 hrs by MTT assay	2015	Journal of medicinal chemistry, May-28, Volume: 58, Issue:10	Design, synthesis, and antitumor evaluation of novel histone deacetylase inhibitors equipped with a phenylsulfonylfuroxan module as a nitric oxide donor.
AID1848626	Cytotoxicity against human 786-0 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay	2022	Journal of medicinal chemistry, 11-10, Volume: 65, Issue:21	First-in-Class Dual Mechanism Ferroptosis-HDAC Inhibitor Hybrids.
AID1897469	Inhibition of HDAC in human HCT-116 cells assessed as reduction in phosphorylated STAT3 level at 0.11 to 1 uM incubated for 36 hrs by Western blot analysis
AID1545831	Antiproliferative activity against human HepG2 cells by MTT assay	2019	European journal of medicinal chemistry, Dec-01, Volume: 183	1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships.
AID1282230	Inhibition of human recombinant HDAC6 using AMC labeled AC-peptide as substrate incubated for 1 hr by fluorescence analysis	2016	Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4	Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
AID473180	Induction of HDAC-mediated histone hyperacetylation in human HepG2 cells at 5 uM after 6 hrs by indirect ELISA	2010	Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5	Biological and biophysical properties of the histone deacetylase inhibitor suberoylanilide hydroxamic acid are affected by the presence of short alkyl groups on the phenyl ring.
AID1266085	Inhibition of human HDAC in HeLa cells nuclear extract at 12.5 uM by fluorimetric assay	2016	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1	Cross metathesis with hydroxamate and benzamide BOC-protected alkenes to access HDAC inhibitors and their biological evaluation highlighted intrinsic activity of BOC-protected dihydroxamates.
AID723462	Inhibition of human HDAC6 by fluorescence assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID328799	Inhibition of HDAC6 at 10 uM	2008	Journal of medicinal chemistry, Apr-24, Volume: 51, Issue:8	A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo.
AID1826628	Synergistic antiproliferative effect on HEL cells assessed as combination index at 10 uM in presence of 3-Fluoro-10-hydroxy-14-methyl-8,13,13b,14-tetrahydro-7H-indolo[2',3':3,4]pyrido[2,1-b]quinazolin-5-one	2022	Journal of medicinal chemistry, 03-24, Volume: 65, Issue:6	Evodiamine-Inspired Topoisomerase-Histone Deacetylase Dual Inhibitors: Novel Orally Active Antitumor Agents for Leukemia Therapy.
AID1418669	Antioxidant activity assessed as inhibition of AAPH-induced peroxyl radical generation measured as trolox equivalent at 10 to 100 uM preincubated for 10 mins followed by AAPH addition and measured every minute for 120 mins by ORAC-FL assay	2018	Bioorganic & medicinal chemistry, 11-15, Volume: 26, Issue:21	Design, synthesis, and biological evaluation of histone deacetylase inhibitors possessing glutathione peroxidase-like and antioxidant activities against Alzheimer's disease.
AID1439349	Inhibition of full length recombinant human GST fused His6-tagged HDAC3 expressed in baculovirus infected High5 cells using Ac-Lys-Tyr-Lys(epsilon-acetyl)-AMC as substrate measured after 24 hrs	2017	European journal of medicinal chemistry, Mar-10, Volume: 128	Design, synthesis and biological evaluation of thienopyrimidine hydroxamic acid based derivatives as structurally novel histone deacetylase (HDAC) inhibitors.
AID1597938	Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	2019	Bioorganic & medicinal chemistry letters, 09-15, Volume: 29, Issue:18	Anti-tumor activity evaluation of novel tubulin and HDAC dual-targeting inhibitors.
AID605535	Antiproliferative activity against human MIAPaCa2 cells after 72 hrs by WST-1 assay	2010	Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24	Discovery of 2-(6-{[(6-fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a class I selective orally active histone deacetylase inhibitor.
AID1775566	Inhibition of full length human N-terminal GST-tagged HDAC6 using fluorogenic acetylated peptide as substrate incubated for 30 mins by fluorescence plate reader assay	2021	Journal of medicinal chemistry, 03-25, Volume: 64, Issue:6	Design and Synthesis of Novel Epigenetic Inhibitors Targeting Histone Deacetylases, DNA Methyltransferase 1, and Lysine Methyltransferase G9a with
AID1702065	Inhibition of recombinant human N-terminal GST-tagged HDAC6 expressed in baculovirus infected Sf9 cells using fluorogenic HDAC substrate 3 measured after 30 mins by fluorescence based assay	2018	Journal of medicinal chemistry, 02-22, Volume: 61, Issue:4	Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma.
AID374821	Inhibition of wild type His-tagged HDAC7 catalytic domain T515-L952 expressed in Escherichia coli	2009	Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11	Discovery of a potent class I selective ketone histone deacetylase inhibitor with antitumor activity in vivo and optimized pharmacokinetic properties.
AID1201648	Antiproliferative activity against human HEL cells assessed as growth inhibition after 48 hrs by CellTiter-Glo assay	2015	European journal of medicinal chemistry, May-05, Volume: 95	Macrocyclic compounds as anti-cancer agents: design and synthesis of multi-acting inhibitors against HDAC, FLT3 and JAK2.
AID1126992	Induction of apoptosis in human U937 cells assessed as viable cells using annexin-V/propidium iodide staining at 1 uM after 12 hrs by flow cytometry analysis (Rvb = 96.42%)	2014	Journal of medicinal chemistry, Apr-24, Volume: 57, Issue:8	Discovery of the first N-hydroxycinnamamide-based histone deacetylase 1/3 dual inhibitors with potent oral antitumor activity.
AID1599792	Inhibition of HDAC6 in human A549 cells assessed as upregulation of p21 mRNA expression at 2.5 uM after 24 hrs by RT-Sybr green PCR analysis	2019	ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6	Extending Cross Metathesis To Identify Selective HDAC Inhibitors: Synthesis, Biological Activities, and Modeling.
AID538413	Selectivity index, ratio of IC50 for recombinant human HDAC1 to IC50 for recombinant human HDAC6	2010	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 20, Issue:23	Inhibitors selective for HDAC6 in enzymes and cells.
AID1775563	Inhibition of full length human C-terminal His-tagged/C-terminal Flag-tagged HDAC1 using fluorogenic acetylated peptide as substrate incubated for 30 mins by fluorescence plate reader assay	2021	Journal of medicinal chemistry, 03-25, Volume: 64, Issue:6	Design and Synthesis of Novel Epigenetic Inhibitors Targeting Histone Deacetylases, DNA Methyltransferase 1, and Lysine Methyltransferase G9a with
AID274067	AUC after i.p. dosing at 5 mg kg-1	2007	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2	Identification and optimisation of a series of substituted 5-(1H-pyrazol-3-yl)-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.
AID545853	Inhibition of HDAC in Plasmodium falciparum 3D7 by fluorescent activity assay	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Novel inhibitor of Plasmodium histone deacetylase that cures P. berghei-infected mice.
AID1861256	Antiproliferative activity against human HCC1937 cells assessed as reduction in cell viability	2022	Bioorganic & medicinal chemistry letters, 09-01, Volume: 71	Design, synthesis and antitumor activity study of PARP-1/HDAC dual targeting inhibitors.
AID1065967	Inhibition of HDAC8 catalytic domain (unknown origin) expressed in Escherichia coli BL21 (DE3) using GRKacFGC as substrate after 60 mins by SAMDI mass spectrometric analysis	2013	Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24	Synthesis and structure-activity relationship of 3-hydroxypyridine-2-thione-based histone deacetylase inhibitors.
AID476827	Toxicity in FVB mouse assessed as effect on number of RBC at 50 mg/kg, po administered 5 times per week for 2 weeks measured during test (Rvb = 8.1 +/- 0.2 10^6/mm^3)	2010	Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8	Modified cap group suberoylanilide hydroxamic acid histone deacetylase inhibitor derivatives reveal improved selective antileukemic activity.
AID1441692	Protection against BLM-induced lung fibrosis in C57BL/6 mouse assessed as TGF-beta1 level at 50 mg/kg, ip qd for 7 days post BLM challenge measured on day 7 by ELISA (Rvb = 75.39 pg/ml)	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
AID1434359	Inhibition of HDAC in HEK293 cells assessed as myc-tagged RUNX3 acetylation by measuring ratio of acetylated-RUNX3 level to beta-actin level at 1 uM measured after 24 hrs by Western blot analysis relative to control	2017	European journal of medicinal chemistry, Jan-27, Volume: 126	Improving potency and metabolic stability by introducing an alkenyl linker to pyridine-based histone deacetylase inhibitors for orally available RUNX3 modulators.
AID1764799	Inhibition of recombinant human HDAC6 using Ac-GAK(Ac)-AMC as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins by fluorescence-based assay	2021	Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8	Tetrahydroquinoline-Capped Histone Deacetylase 6 Inhibitor SW-101 Ameliorates Pathological Phenotypes in a Charcot-Marie-Tooth Type 2A Mouse Model.
AID1851614	Anticancer activity against human HeLa cells assessed as inhibition of cell proliferation	2022	Bioorganic & medicinal chemistry letters, 10-15, Volume: 74	Design, synthesis, and antitumor study of a series of novel 1-Oxa-4-azaspironenone derivatives.
AID1401371	Inhibition of HDAC in human HeLa-S3 cell lysates assessed as residual activity at 2.5 x 10'-8 M preincubated for 15 mins followed by HDAC-Glo substrate addition measured after 35 mins by fluorimetric method relative to control	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
AID1431818	Selectivity ratio of IC50 for human KDAC8 to IC50 for human KDAC3	2017	European journal of medicinal chemistry, Feb-15, Volume: 127	Design and synthesis of benzodiazepine analogs as isoform-selective human lysine deacetylase inhibitors.
AID605536	Antiproliferative activity against human A549 cells after 72 hrs by WST-1 assay	2010	Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24	Discovery of 2-(6-{[(6-fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a class I selective orally active histone deacetylase inhibitor.
AID732153	Inhibition of HDAC4 (unknown origin) assessed as fluorescence intensity measured after 60 mins incubation at room temperature by trypsin-free microfluidic lab-on-a-chip assay	2013	Journal of medicinal chemistry, Feb-28, Volume: 56, Issue:4	Potent and selective inhibition of histone deacetylase 6 (HDAC6) does not require a surface-binding motif.
AID1864680	Inhibition of full length recombinant human HDAC6 expressing in mouse J774.A1 cells assessed as upregulation of acetylated histone H4 at 1 uM measured after 0.1 to 24 hrs by western blot analysis
AID1900934	Toxicity in mouse bearing intracranial tumor assessed as last day of survival at 25 mg/kg, ip in presence of clorgyline for 10 days (Rvb=16 days)	2022	Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
AID476643	Antiproliferative activity against human U937 cells after 48 hrs by cell titer-glo assay	2010	Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8	Modified cap group suberoylanilide hydroxamic acid histone deacetylase inhibitor derivatives reveal improved selective antileukemic activity.
AID1623538	Selectivity index, ratio of IC50 for human recombinant HDAC11 to IC50 for human recombinant HDAC6	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	A novel class of anthraquinone-based HDAC6 inhibitors.
AID1833061	Anticancer activity against human PC-3 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	2021	Bioorganic & medicinal chemistry, 11-15, Volume: 50	Effect of phenylurea hydroxamic acids on histone deacetylase and VEGFR-2.
AID1518787	Antiproliferative activity against human MOLM14 cells incubated for 48 hrs by CellTiter-Glo luminescent cell viability assay	2019	European journal of medicinal chemistry, Dec-15, Volume: 184	Discovery of a potent histone deacetylase (HDAC) 3/6 selective dual inhibitor.
AID274032	Inhibition of HCT116 cell proliferation (mean of two experiments)	2007	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2	Identification and optimisation of a series of substituted 5-pyridin-2-yl-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.
AID488276	Inhibition of HDAC6	2010	Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11	On the inhibition of histone deacetylase 8.
AID1401544	Antiproliferative activity against human L428 cells after 72 hrs by MTT assay	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors.
AID1449329	Inhibition of recombinant human N-terminal GST-tagged/C-terminal His-tagged HDAC4 expressed in insect cells using Boc-K(Ac)-AMC as substrate by fluorescence assay	2017	Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13	Alkoxyurea-Based Histone Deacetylase Inhibitors Increase Cisplatin Potency in Chemoresistant Cancer Cell Lines.
AID411253	Inhibition of HDAC1/2 from human HeLa cells nuclear extract by cell free fluorimetric assay	2009	Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2	Non-peptide macrocyclic histone deacetylase inhibitors.
AID1888582	Inhibition of recombinant HDAC6 (unknown origin) using Ac-peptide-AMC as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence assay
AID420652	Toxicity in athymic nude Swiss mouse bearing human H460 cells assessed as body weight loss at 100 mg/kg, po QD administered 5 days a week for 2 weeks	2009	European journal of medicinal chemistry, May, Volume: 44, Issue:5	Design, synthesis, and evaluation of biphenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors.
AID1535346	Growth inhibition of human U266 cells after 72 hrs by MTT assay	2019	Bioorganic & medicinal chemistry letters, 02-01, Volume: 29, Issue:3	Design, synthesis, and bioactivity evaluation of novel Bcl-2/HDAC dual-target inhibitors for the treatment of multiple myeloma.
AID1915585	Inhibition of HDAC3 (unknown origin)	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors.
AID1614137	Inhibition of recombinant full length N-terminal GST-tagged human HDAC11 expressed in baculovirus expression system using Ac-peptide-AMC as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by fluorescence assay
AID723455	Potentiation of cisplatin-induced toxicity in cisplatin resistant human MDA-MB-231 cells at 1 uM pretreated for 48 hrs followed by cisplatin treatment by MTT assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1566808	Inhibition of recombinant N-terminal GST-tagged human HDAC7 (518 to end residues) expressed in Sf9 cells using Ac-peptide-AMC as substrate after 1 hr by fluorescence assay	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Discovery of 1,2,4-oxadiazole-Containing hydroxamic acid derivatives as histone deacetylase inhibitors potential application in cancer therapy.
AID1785348	Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition measured after 48 hrs by CCK8 assay
AID1816184	Inhibition of HDAC6 (unknown origin) incubated for 60 mins by microplate reader analysis
AID669762	Inhibition of human recombinant HDAC2 after 30 mins by fluorometric assay	2012	Journal of medicinal chemistry, Apr-26, Volume: 55, Issue:8	Synthesis and biological evaluation of 1-arylsulfonyl-5-(N-hydroxyacrylamide)indoles as potent histone deacetylase inhibitors with antitumor activity in vivo.
AID1545761	Inhibition of HDAC in human K562 cell extracts using (QSY-7)-RGGRGLGK(Ac)-GGARRHRK(TAMRA)NH2 as substrate preincubated for 30 mins followed by addition of endoproteinase Lys-C and measured after 2 hrs by fluorescence assay	2019	European journal of medicinal chemistry, Dec-01, Volume: 183	Indole: A privileged scaffold for the design of anti-cancer agents.
AID1890351	Antitumor immunity in C57BL/6 mouse xenografted with mouse CT26 cells assessed as increase in CD3+ cytotoxic T cells at 50 mg/kg, po administered once daily for 21 days measured by flow cytometry analysis	2022	European journal of medicinal chemistry, Apr-05, Volume: 233	Novel biphenyl-based scaffold as potent and selective histone deacetylase 6 (HDAC6) inhibitors: Identification, development and pharmacological evaluation.
AID1861654	Inhibition of HDAC2 (unknown origin)	2022	Bioorganic & medicinal chemistry letters, 09-15, Volume: 72	Exploration of 4-(1H-indol-3-yl)cyclohex-3-en-1-amine analogues as HDAC inhibitors: Design, synthesis, biological evaluation and modelling studies.
AID1515882	Induction of apoptosis in human HCT116 cells assessed as early apoptotic cells at 500 nM after 48 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 1.33%)	2019	Journal of medicinal chemistry, 08-08, Volume: 62, Issue:15	Design, Synthesis, and Biological Evaluation of 4-Methyl Quinazoline Derivatives as Anticancer Agents Simultaneously Targeting Phosphoinositide 3-Kinases and Histone Deacetylases.
AID1898938	Induction of DNA damage in human A2780 cells at 7.4 uM assessed as increase in p-H2AX levels and measured by Western blot analysis	2022	European journal of medicinal chemistry, Jan-15, Volume: 228	Antitumor activity of novel POLA1-HDAC11 dual inhibitors.
AID631668	Inhibition of human recombinant full-length HDAC3 using fluorophore conjugated substrate by fluorescence assay	2011	Journal of medicinal chemistry, Aug-11, Volume: 54, Issue:15	In vivo PET imaging of histone deacetylases by 18F-suberoylanilide hydroxamic acid (18F-SAHA).
AID1697198	Cytotoxicity against human PC3 cells by colorimetric method	2020	Bioorganic & medicinal chemistry letters, 11-15, Volume: 30, Issue:22	Design, synthesis and evaluation of novel indirubin-based N-hydroxybenzamides, N-hydroxypropenamides and N-hydroxyheptanamides as histone deacetylase inhibitors and antitumor agents.
AID395034	Antitumor activity against human HCT116 cells xenografted in athymic mouse assessed as tumor growth inhibition at 200 mg/kg, ip qd for 21 days measured on day 22	2009	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 19, Issue:5	N-Hydroxy-1,2-disubstituted-1H-benzimidazol-5-yl acrylamides as novel histone deacetylase inhibitors: design, synthesis, SAR studies, and in vivo antitumor activity.
AID723138	Potentiation of 3.16 uM cisplatin-induced toxicity in 0.5 uM cisplatin resistant human KYSE-510 cells at 1 uM pretreated for 48 hrs followed by 0.5 uM cisplatin treatment by MTT assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1164924	Induction of cell differentiation in human BE(2)-C cells assessed as increase in TrkA expression at 2 to 10 uM after 24 hrs by immunoblot method relative to vehicle-treated control	2014	Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19	Identification of a novel aminotetralin class of HDAC6 and HDAC8 selective inhibitors.
AID492801	Inhibition of human recombinant HDAC1 at 5 uM after 15 mins by fluorimetric assay	2010	Journal of medicinal chemistry, Jun-24, Volume: 53, Issue:12	Synthesis and biological characterization of the histone deacetylase inhibitor largazole and C7- modified analogues.
AID1174683	Antiproliferative activity against human K562 cells after 48 hrs by MTT assay	2015	European journal of medicinal chemistry, Jan-07, Volume: 89	Development of 3-hydroxycinnamamide-based HDAC inhibitors with potent in vitro and in vivo anti-tumor activity.
AID760497	Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay	2013	ACS medicinal chemistry letters, Aug-08, Volume: 4, Issue:8	Development of a chimeric c-Src kinase and HDAC inhibitor.
AID1599777	Inhibition of HDAC6 in human Meso163 cells assessed as upregulation of E-cadherin mRNA expression at 2.5 uM after 24 hrs by RT-Sybr green PCR analysis	2019	ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6	Extending Cross Metathesis To Identify Selective HDAC Inhibitors: Synthesis, Biological Activities, and Modeling.
AID1861657	Inhibition of HDAC8 (unknown origin)	2022	Bioorganic & medicinal chemistry letters, 09-15, Volume: 72	Exploration of 4-(1H-indol-3-yl)cyclohex-3-en-1-amine analogues as HDAC inhibitors: Design, synthesis, biological evaluation and modelling studies.
AID622260	Inhibition of HDAC6 assessed as residual activity at 125 nM after 30 mins by Fluor de Lys fluorescence assay	2011	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 21, Issue:20	The structural requirements of histone deacetylase inhibitors: Suberoylanilide hydroxamic acid analogs modified at the C3 position display isoform selectivity.
AID1702200	Toxicity in Ncr nude mouse xenografted with human HepG2 cells assessed as change in body weight at 60 mg/kg, po QD with 5 days on and 2 days off dosing schedule for 2 weeks cotreated with 75 mg/kg pictilisib and measured at day 14 (Rvb = -0.8%)	2018	Journal of medicinal chemistry, 02-22, Volume: 61, Issue:4	Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma.
AID1865270	Inhibition of HDAC in human MV4-11 cells assessed as upregulation of acetylated alpha-tubulin level incubated for 24 hrs by Western blot analysis	2022	Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18	Discovery of Novel Src Homology-2 Domain-Containing Phosphatase 2 and Histone Deacetylase Dual Inhibitors with Potent Antitumor Efficacy and Enhanced Antitumor Immunity.
AID1754779	Downregulation of RELA (p65 ) gene expression in human MCF7 cells at 3 uM incubated for 24 hrs by whole transcriptome analysis	2021	Bioorganic & medicinal chemistry, 07-15, Volume: 42	Discovery of novel class of histone deacetylase inhibitors as potential anticancer agents.
AID1280268	Inhibition of HDAC6 in human HeLa cells assessed as ratio of acetylated tubulin to GAPDH level at 0.1 uM after 4 hrs by Western blot analysis relative to control	2016	Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4	Synthesis and Biological Investigation of Oxazole Hydroxamates as Highly Selective Histone Deacetylase 6 (HDAC6) Inhibitors.
AID1655902	Inhibition of EZH2 in human RH4 cells assessed as H3K27me3 level at 0.15 uM incubated for 96 hrs by Western blot analysis (Rvb = 1 No_unit)	2020	ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5	Design of First-in-Class Dual EZH2/HDAC Inhibitor: Biochemical Activity and Biological Evaluation in Cancer Cells.
AID1282242	Inhibition of recombinant HDAC7 (unknown origin) using AMC labeled AC-peptide as substrate incubated for 1 hr by fluorescence analysis	2016	Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4	Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
AID1566810	Inhibition of recombinant full length HDAC6 (unknown origin) using Ac-peptide-AMC as substrate after 1 hr by fluorescence assay	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Discovery of 1,2,4-oxadiazole-Containing hydroxamic acid derivatives as histone deacetylase inhibitors potential application in cancer therapy.
AID1556028	Inhibition of SIRT1 in human MCF7 cells assessed as H3K9Ac expression at 0.1 uM measured after 24 hrs by Western blot analysis relative to H3	2019	Journal of medicinal chemistry, 06-27, Volume: 62, Issue:12	Identification of Diketopiperazine-Containing 2-Anilinobenzamides as Potent Sirtuin 2 (SIRT2)-Selective Inhibitors Targeting the "Selectivity Pocket", Substrate-Binding Site, and NAD
AID704015	Inhibition of human recombinant HDAC8 using fluor de Lys as substrate preincubated for 5 mins followed by substrate addition measured after 25 mins by microplate reader analysis	2012	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 22, Issue:21	Novel histone deacetylase 8 ligands without a zinc chelating group: exploring an 'upside-down' binding pose.
AID1469373	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	2018	Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7	Discovery of N1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7 H-pyrrolo[2,3- d]pyrimidin-2-yl)amino)phenyl)- N8-hydroxyoctanediamide as a Novel Inhibitor Targeting Cyclin-dependent Kinase 4/9 (CDK4/9) and Histone Deacetlyase1 (HDAC1) against Malignant Cancer
AID288450	Growth inhibition of LOX-IMVI cells by SRB assay	2007	Journal of medicinal chemistry, May-31, Volume: 50, Issue:11	Structure-activity relationship studies of a series of novel delta-lactam-based histone deacetylase inhibitors.
AID723438	Potentiation of 10 uM cisplatin-induced toxicity in 1 uM cisplatin resistant human MDA-MB-231 cells at 0.25 uM pretreated for 48 hrs followed by 1 uM cisplatin treatment by MTT assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID732446	Inhibition of human ES2 cell proliferation after 48 hrs by MTT assay	2013	ACS medicinal chemistry letters, Feb-14, Volume: 4, Issue:2	Development of
AID482940	Inhibition of HDAC1 in human COLO205 cells assessed as induction of histone H3 acetylation	2010	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11	Acylurea connected straight chain hydroxamates as novel histone deacetylase inhibitors: Synthesis, SAR, and in vivo antitumor activity.
AID492811	Inhibition of HDAC in human NB4 cells assessed as increase in acetylate tubulin level at 5 uM after 24 hrs by Western blot analysis	2010	Journal of medicinal chemistry, Jun-24, Volume: 53, Issue:12	Synthesis and biological characterization of the histone deacetylase inhibitor largazole and C7- modified analogues.
AID461250	Inhibition of HDAC in human HeLa cell nuclear extract	2010	Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5	Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer.
AID723130	Potentiation of 50 uM cisplatin-induced toxicity in 1 uM cisplatin resistant human MDA-MB-231 cells at 1 uM pretreated for 48 hrs followed by 1 uM cisplatin treatment by MTT assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1917529	Inhibition of HDAC6 (unknown origin) measured by fluorescence based assay	2022	Bioorganic & medicinal chemistry, 11-01, Volume: 73	Identification of PI3K/HDAC Dual-targeted inhibitors with subtype selectivity as potential therapeutic agents against solid Tumors: Building HDAC6 potency in a Quinazolinone-based PI3Kδ-selective template.
AID1688024	Inhibition of recombinant human HDAC2 expressed in baculovirus infected Sf9 cells using Boc-Lys(Ac)-AMC as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence based assay	2020	European journal of medicinal chemistry, Feb-15, Volume: 188	A 18β-glycyrrhetinic acid conjugate with Vorinostat degrades HDAC3 and HDAC6 with improved antitumor effects.
AID672026	Inhibition of human recombinant HDAC3 using Boc-L-Lys (Ac)-AMC as substrate preincubated with compound for 5 mins at 10 uM measured after 35 mins by spectrofluorometric analysis	2012	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 22, Issue:15	Design, synthesis, modeling, biological evaluation and photoaffinity labeling studies of novel series of photoreactive benzamide probes for histone deacetylase 2.
AID663384	Growth inhibition of human SK-MEL-5 cells after 72 hrs by MTS assay	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Discovery and extensive in vitro evaluations of NK-HDAC-1: a chiral histone deacetylase inhibitor as a promising lead.
AID420321	Inhibition of Bordetella / Alcaligenes strain FB188 HDAC6 by fluorescence polarization assay	2009	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 19, Issue:13	Non-isotopic dual parameter competition assay suitable for high-throughput screening of histone deacetylases.
AID1702086	Antiproliferative activity against human Ramos cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay	2018	Journal of medicinal chemistry, 02-22, Volume: 61, Issue:4	Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma.
AID1864243	Inhibition of HDAC in human MDA-MB-231 cells assessed as increase in acetylated alpha-tubulin level at 1.25 to 5 uM by Western blot analysis	2022	Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18	Discovery of a Novel G-Quadruplex and Histone Deacetylase (HDAC) Dual-Targeting Agent for the Treatment of Triple-Negative Breast Cancer.
AID1321730	Inhibition of class 1 histone deacetylase in human SH-SY5Y cells assessed as increase in histone H3K9 acetylation at 100 nM after 2 hrs by Western blot analysis relative to control	2016	Journal of medicinal chemistry, 10-13, Volume: 59, Issue:19	Design, Synthesis, and Biological Evaluation of First-in-Class Dual Acting Histone Deacetylases (HDACs) and Phosphodiesterase 5 (PDE5) Inhibitors for the Treatment of Alzheimer's Disease.
AID1550118	Induction of apoptosis in HEL cells assessed as viable cells at 1 uM after 24 hrs by Annexin-V/propidium iodide staining-based flow cytometric analysis (Rvb = 87.5%)	2019	Journal of medicinal chemistry, 04-25, Volume: 62, Issue:8	Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies.
AID476644	Antiproliferative activity against human Jurkat JA16 cells after 48 hrs by cell titer-glo assay	2010	Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8	Modified cap group suberoylanilide hydroxamic acid histone deacetylase inhibitor derivatives reveal improved selective antileukemic activity.
AID593547	Inhibition of human HDAC1 using ArgHisLysLys(Ac) fluorogenic peptide as a substrate by fluorimetric assay	2011	Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7	Oxime amides as a novel zinc binding group in histone deacetylase inhibitors: synthesis, biological activity, and computational evaluation.
AID414986	Cytotoxicity against human CCRF-CEM cells after 72 hrs by alamar-blue cell viability assay	2009	Journal of medicinal chemistry, Apr-23, Volume: 52, Issue:8	Design of chimeric histone deacetylase- and tyrosine kinase-inhibitors: a series of imatinib hybrides as potent inhibitors of wild-type and mutant BCR-ABL, PDGF-Rbeta, and histone deacetylases.
AID1308521	Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability incubated for 72 hrs by Alamar blue assay	2016	Bioorganic & medicinal chemistry letters, 06-15, Volume: 26, Issue:12	Targeting epigenetic reader and eraser: Rational design, synthesis and in vitro evaluation of dimethylisoxazoles derivatives as BRD4/HDAC dual inhibitors.
AID1762495	Inhibition of HDAC1 (unknown origin)	2021	European journal of medicinal chemistry, Jul-05, Volume: 219	Synthesis and biological evaluation of phenothiazine derivative-containing hydroxamic acids as potent class II histone deacetylase inhibitors.
AID1200974	Solubility of the compound in PBS measured after overnight incubation by LYSA assay	2015	Journal of medicinal chemistry, Mar-26, Volume: 58, Issue:6	Design and synthesis of orally bioavailable aminopyrrolidinone histone deacetylase 6 inhibitors.
AID1246513	Inhibition of HDAC11 (unknown origin) using RHKK(Ac) fluorogenic acetylated peptide substrate by fluorometric assay	2015	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 25, Issue:19	Discovery of 1-hydroxypyridine-2-thiones as selective histone deacetylase inhibitors and their potential application for treating leukemia.
AID1248351	Inhibition of human full length MMP9 using Mca-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 as substrate incubated for 2 hrs prior to testing measured for 15 mins by fluorometric analysis	2015	Bioorganic & medicinal chemistry, Oct-15, Volume: 23, Issue:20	Synthesis of chiral ND-322, ND-364 and ND-364 derivatives as selective inhibitors of human gelatinase.
AID1649504	Cytotoxicity against Swiss mouse BMDM assessed as reduction in cell viability measured after 72 hrs by tryphan blue assay	2020	Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11
AID1487001	Inhibition of HDAC3 (unknown origin) by ELISA-based assay	2017	Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15	The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity.
AID1433294	Induction of DNA damage in p53 null human U937 cells at 2 uM after 20 hrs by SYBR gold staining based alkaline comet assay	2016	Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17	Synthesis and Antileukemic Activities of Piperlongumine and HDAC Inhibitor Hybrids against Acute Myeloid Leukemia Cells.
AID1537559	Antiproliferative activity against human SK-N-AS cells assessed as reduction in cell viability incubated for 72 hrs by cell-titer Glo assay	2019	MedChemComm, Jul-01, Volume: 10, Issue:7	Design, synthesis and biological evaluation of β-peptoid-capped HDAC inhibitors with anti-neuroblastoma and anti-glioblastoma activity.
AID90212	Inhibitory activity against histone deacetylase (HDAC1 and HDAC2) isolated from K562 erythroleukemia cells	2003	Bioorganic & medicinal chemistry letters, Nov-03, Volume: 13, Issue:21	A novel series of histone deacetylase inhibitors incorporating hetero aromatic ring systems as connection units.
AID1390963	Inhibition of HDAC6 (unknown origin) using Arg-His-Lys-Lys(Ac) as substrate after 2 hrs by fluorescence analysis	2018	Bioorganic & medicinal chemistry letters, 05-01, Volume: 28, Issue:8	Design and synthesis of triple inhibitors of janus kinase (JAK), histone deacetylase (HDAC) and Heat Shock Protein 90 (HSP90).
AID343694	Inhibition of HDAC in human HeLa cells assessed as induction of histone H3 hyperacetylation after 24 hrs	2008	Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13	Trithiocarbonates as a novel class of HDAC inhibitors: SAR studies, isoenzyme selectivity, and pharmacological profiles.
AID1126985	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	2014	Journal of medicinal chemistry, Apr-24, Volume: 57, Issue:8	Discovery of the first N-hydroxycinnamamide-based histone deacetylase 1/3 dual inhibitors with potent oral antitumor activity.
AID748112	Inhibition of HDAC3 (unknown origin) after 60 mins by fluorescence assay	2013	Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11	Discovery of the first histone deacetylase 6/8 dual inhibitors.
AID1439348	Inhibition of full length recombinant human GST fused His6-tagged HDAC1 expressed in baculovirus infected High5 cells using Ac-Lys-Tyr-Lys(epsilon-acetyl)-AMC as substrate measured after 24 hrs	2017	European journal of medicinal chemistry, Mar-10, Volume: 128	Design, synthesis and biological evaluation of thienopyrimidine hydroxamic acid based derivatives as structurally novel histone deacetylase (HDAC) inhibitors.
AID616002	Inhibition of HDAC1 using KI-177 as substrate incubated 30 mins before substrate addition measured after 30 mins post substrate addition by fluorescence assay	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Synthesis and evaluation of aliphatic-chain hydroxamates capped with osthole derivatives as histone deacetylase inhibitors.
AID1901163	Antiproliferative activity against human K562 cells measured after 48 hrs by MTT assay	2022	Bioorganic & medicinal chemistry, 02-15, Volume: 56	Synthesis and biological evaluation of aminobenzamides containing purine moiety as class I histone deacetylases inhibitors.
AID1401475	Selectivity ratio of IC50 for HDAC2 in human HeLa-S3 cell lysates to IC50 for HDAC6 in human HeLa-S3 cell lysates	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
AID1451822	Cytotoxicity in human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay	2017	Journal of medicinal chemistry, 10-12, Volume: 60, Issue:19	Small Molecule Inhibitors Simultaneously Targeting Cancer Metabolism and Epigenetics: Discovery of Novel Nicotinamide Phosphoribosyltransferase (NAMPT) and Histone Deacetylase (HDAC) Dual Inhibitors.
AID1235115	Cytotoxicity against human KG1 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	2015	Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15	Synthesis and biological evaluation of novel histone deacetylases inhibitors with nitric oxide releasing activity.
AID1280283	Selectivity index, ratio of HDAC6 inhibition in human HL60 cells assessed as ratio of acetylated tubulin to GAPDH level at 0.1 uM over class1 HDAC inhibition in human HL60 cells assessed as ratio of acetylated histone H3 to GAPDH level at 0.1 uM	2016	Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4	Synthesis and Biological Investigation of Oxazole Hydroxamates as Highly Selective Histone Deacetylase 6 (HDAC6) Inhibitors.
AID316909	Inhibition of human DU145 cells	2008	Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6	Histone deacetylase inhibitors: from bench to clinic.
AID663397	Growth inhibition of human BT549 cells after 72 hrs by MTS assay	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Discovery and extensive in vitro evaluations of NK-HDAC-1: a chiral histone deacetylase inhibitor as a promising lead.
AID1709348	Cytotoxicity against human Jurkat cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	2021	Bioorganic & medicinal chemistry, 04-01, Volume: 35	Structure-activity relationship and mechanistic studies for a series of cinnamyl hydroxamate histone deacetylase inhibitors.
AID1398820	Antagonist activity at ERalpha in human MCF7 cells assessed as suppression of MKI67 mRNA expression at 5 uM after 24 hrs by QIAzol reagent based RT-qPCR analysis	2018	Bioorganic & medicinal chemistry, 08-15, Volume: 26, Issue:15	Incorporation of histone deacetylase inhibitory activity into the core of tamoxifen - A new hybrid design paradigm.
AID1348937	Effect on CDH1 gene expression in human PC3 cells at IC50 after 12 hrs by RT-PCR method	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Discovery of aliphatic-chain hydroxamates containing indole derivatives with potent class I histone deacetylase inhibitory activities.
AID619056	Competitive inhibition of HDAC11 using KI-104 as substrate by fluorescence assay	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile.
AID420516	Inhibition of HDAC in human IGROV1 cells assessed as histone-H4 acetylation at IC50 after 4 hrs by Western blot	2009	European journal of medicinal chemistry, May, Volume: 44, Issue:5	Design, synthesis, and evaluation of biphenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors.
AID1832800	Inhibition of human recombinant HDAC6 assessed as fluorescence using fluorogenic substrate ZMAL incubated for 90 min by microplate reader	2021	Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19	4-Acyl Pyrrole Capped HDAC Inhibitors: A New Scaffold for Hybrid Inhibitors of BET Proteins and Histone Deacetylases as Antileukemia Drug Leads.
AID329921	Inhibition of human HDAC1 in U937 cells at 5 uM	2008	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8	Novel uracil-based 2-aminoanilide and 2-aminoanilide-like derivatives: histone deacetylase inhibition and in-cell activities.
AID1514597	Antiproliferative activity against human HCCLM3 cells after 48 hrs by MTT assay	2019	Bioorganic & medicinal chemistry letters, 01-01, Volume: 29, Issue:1	Development of hydroxamate-based histone deacetylase inhibitors containing 1,2,4-oxadiazole moiety core with antitumor activities.
AID1578478	Inhibition of recombinant full length human HDAC11 expressed in baculovirus infected Sf9 cells using FAM-RHKK-TFAc as substrate incubated for 17 hrs by electrophoretic mobility shift assay	2020	ACS medicinal chemistry letters, Jan-09, Volume: 11, Issue:1	Class I/IIb-Selective HDAC Inhibitor Exhibits Oral Bioavailability and Therapeutic Efficacy in Acute Myeloid Leukemia.
AID1833060	Anticancer activity against human SK-HEP1 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	2021	Bioorganic & medicinal chemistry, 11-15, Volume: 50	Effect of phenylurea hydroxamic acids on histone deacetylase and VEGFR-2.
AID329931	Induction of apoptosis in human U937 cells at 5 uM after 30 hrs	2008	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8	Novel uracil-based 2-aminoanilide and 2-aminoanilide-like derivatives: histone deacetylase inhibition and in-cell activities.
AID269673	Antiproliferative activity against human MDA-MB-231 cells by SRB assay	2006	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 16, Issue:15	Synthesis, enzymatic inhibition, and cancer cell growth inhibition of novel delta-lactam-based histone deacetylase (HDAC) inhibitors.
AID1409641	Inhibition of HDAC in human A549 cells using Boc-K(Ac)-AMC as substrate by fluorescence assay	2018	ACS medicinal chemistry letters, Mar-08, Volume: 9, Issue:3	Histone Deacetylase Inhibitors as Treatment for Targeting Multiple Components in Cancer Therapy.
AID1875507	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 3 days by alamar blue assay	2022	ACS medicinal chemistry letters, Oct-13, Volume: 13, Issue:10	Cancer-Cell-Selective Targeting by Arylcyclopropylamine-Vorinostat Conjugates.
AID1380947	Antiproliferative activity against human KG1 cells after 72 hrs by MTT assay	2018	Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12	Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously.
AID605531	Antiproliferative activity against human DU145 cells after 72 hrs by WST-1 assay	2010	Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24	Discovery of 2-(6-{[(6-fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a class I selective orally active histone deacetylase inhibitor.
AID1599780	Inhibition of HDAC6 in human Meso163 cells assessed as upregulation of semaphorin 3F mRNA expression at 2.5 uM after 24 hrs by RT-Sybr green PCR analysis	2019	ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6	Extending Cross Metathesis To Identify Selective HDAC Inhibitors: Synthesis, Biological Activities, and Modeling.
AID613341	Inhibition of human ERG by automated Q-patch assay	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Optimization of the in vitro cardiac safety of hydroxamate-based histone deacetylase inhibitors.
AID1765323	Antiproliferative activity against human CAKI-1 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay	2021	European journal of medicinal chemistry, Oct-15, Volume: 222	A first-in-class anticancer dual HDAC2/FAK inhibitors bearing hydroxamates/benzamides capped by pyridinyl-1,2,4-triazoles.
AID1848559	Inhibition of HDAC in human HCT-116 cells	2022	Journal of medicinal chemistry, 11-10, Volume: 65, Issue:21	First-in-Class Dual Mechanism Ferroptosis-HDAC Inhibitor Hybrids.
AID1407000	Induction of cell cycle arrest in human NB4 cells assessed as accumulation at G1 phase after 30 hrs by propidium iodide-based FACS analysis	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Novel spiroindoline HDAC inhibitors: Synthesis, molecular modelling and biological studies.
AID723152	Potentiation of 8 uM cisplatin-induced toxicity in 5 uM cisplatin resistant human A2780 cells at 0.25 uM pretreated for 48 hrs followed by 5 uM cisplatin treatment by MTT assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1622962	Inhibition of HDAC3 (unknown origin) using (FAM)-labeled acetylated peptide as substrate measured after 17 hrs by fluorescence assay	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.
AID350719	Inhibition of human recombinant HDAC6 by fluorimetry	2009	Journal of medicinal chemistry, May-14, Volume: 52, Issue:9	Design, synthesis, and biological activity of boronic acid-based histone deacetylase inhibitors.
AID1742678	Induction of cell cycle arrest in human MDA-MB-231 cells assessed as G0/G1 phase accumulation at 2 uM incubated for 24 hrs by PI staining based flow cytometry analysis (Rvb = 29.10 %)	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Design and synthesis of novel Flavone-based histone deacetylase inhibitors antagonizing activation of STAT3 in breast cancer.
AID1401546	Antiproliferative activity against human DG75 cells after 72 hrs by MTT assay	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors.
AID1126984	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	2014	Journal of medicinal chemistry, Apr-24, Volume: 57, Issue:8	Discovery of the first N-hydroxycinnamamide-based histone deacetylase 1/3 dual inhibitors with potent oral antitumor activity.
AID545855	Antimalarial activity against Plasmodium falciparum 7G8 assessed as parasite growth inhibition after 48 hrs by standard growth inhibition assay	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Novel inhibitor of Plasmodium histone deacetylase that cures P. berghei-infected mice.
AID1441633	Inhibition of recombinant human cPLA2alpha expressed in Sf9 cells assessed as formation of 7-hydroxycoumarin from of 7-hydroxycoumarinyl-gamma-linolenate by fluorospectrometer analysis	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
AID328829	Toxicity against human HCT116 cells xenografted BALB/c mouse assessed as body weight loss at 100 mg/kg, ip administered 5 days per week for 2.5 weeks	2008	Journal of medicinal chemistry, Apr-24, Volume: 51, Issue:8	A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo.
AID1742184	Inhibition of recombinant human full-length N-terminal GST-tagged HDAC9 (1 to 1069 residues) expressed in wheat germ expression system using Ac-Leu-Gly-Lys(Tfa)-AMC as substrate measured after 30 mins by fluorescence assay	2020	European journal of medicinal chemistry, Nov-01, Volume: 205	Design, synthesis and biological evaluation of novel HDAC inhibitors with improved pharmacokinetic profile in breast cancer.
AID659641	Inhibition of HDAC in human DU145 cells assessed as histone H4 acetylation at 2.5 to 5 uM after 24 hrs by Western blot analysis	2012	Journal of medicinal chemistry, Feb-23, Volume: 55, Issue:4	Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors.
AID1622914	Inhibition of HDAC6 (unknown origin)	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.
AID1655889	Inhibition of HDAC in human U937 cells assessed as Ac-H3 level at 0.5 uM incubated for 120 hrs by Western blot analysis (Rvb = 1 No_unit)	2020	ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5	Design of First-in-Class Dual EZH2/HDAC Inhibitor: Biochemical Activity and Biological Evaluation in Cancer Cells.
AID1742658	Cytotoxicity against human A-375 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Design and synthesis of novel Flavone-based histone deacetylase inhibitors antagonizing activation of STAT3 in breast cancer.
AID1848620	Cytotoxicity against human HCC 2998 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay	2022	Journal of medicinal chemistry, 11-10, Volume: 65, Issue:21	First-in-Class Dual Mechanism Ferroptosis-HDAC Inhibitor Hybrids.
AID1406992	Inhibition of HDAC6 in human SH-SY5Y cells assessed as levels of alpha-tubulin acetylation at 1 uM after 30 hrs by Western blot analysis relative to control	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Novel spiroindoline HDAC inhibitors: Synthesis, molecular modelling and biological studies.
AID1548248	Inhibition of HDAC4 (unknown origin) pre-incubated for 5 mins before fluorogenic substrate Boc-Lys (acetyl)-AMC or Boc-Lys (triflouroacetyl)-AMC addition and measured after 30 mins by fluorescence based assay
AID605620	Cell cycle arrest in human HCT116 cells assessed as accumulation at G1 phase at 300 nM after 15 hrs by propidium iodide staining based flow cytometric analysis	2010	Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24	Discovery of 2-(6-{[(6-fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a class I selective orally active histone deacetylase inhibitor.
AID1763816	Antiproliferative activity against human DU-145 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	2021	Bioorganic & medicinal chemistry, 06-15, Volume: 40	Novel hybrid conjugates with dual estrogen receptor α degradation and histone deacetylase inhibitory activities for breast cancer therapy.
AID753149	Inhibition of HDAC3 (unknown origin)	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and biological characterization of spiro[2H-(1,3)-benzoxazine-2,4'-piperidine] based histone deacetylase inhibitors.
AID1897365	Inhibition of HDAC1 (unknown origin)
AID1690833	Inhibition of class 1 HDAC in human HeLa cell nuclear extract using Boc-Lys(Ac)-AMC as substrate preincubated for 5 mins followed by substrate addition and measured after 30 mins by fluorescence assay	2020	European journal of medicinal chemistry, Apr-15, Volume: 192	Synthesis and biological evaluation of acridine-based histone deacetylase inhibitors as multitarget agents against Alzheimer's disease.
AID1165110	Cytotoxicity against human THP1 cells after 48 hrs by Alamar blue assay	2014	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 24, Issue:20	The antileishmanial activity of isoforms 6- and 8-selective histone deacetylase inhibitors.
AID420317	Displacement of Atto700-HA from Bordetella / Alcaligenes strain FB188 HDAH by fluorescence anisotropy	2009	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 19, Issue:13	Non-isotopic dual parameter competition assay suitable for high-throughput screening of histone deacetylases.
AID274065	Clearance after i.v. dosing at 1 mg kg-1	2007	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2	Identification and optimisation of a series of substituted 5-(1H-pyrazol-3-yl)-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.
AID1245686	Cytotoxicity against human HCT116 cells assessed as growth inhibition after 48 hrs by MTT assay	2015	Bioorganic & medicinal chemistry, Oct-01, Volume: 23, Issue:19	Development of N-hydroxybenzamide derivatives with indole-containing cap group as histone deacetylases inhibitors.
AID1576453	Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by SRB assay
AID1739572	Inhibition of HDAC6 in human THP-1 cells assessed as ratio of acetylated tubulin/GAPDH at 1 uM incubated for 4 hrs by Western blot analysis relative to DMSO	2020	European journal of medicinal chemistry, Aug-15, Volume: 200	Design, synthesis, and biological evaluation of dual targeting inhibitors of histone deacetylase 6/8 and bromodomain BRPF1.
AID1901227	Half life in rat liver microsomes by LC-MS/MS analysis	2022	Bioorganic & medicinal chemistry, 02-15, Volume: 56	Synthesis and biological evaluation of aminobenzamides containing purine moiety as class I histone deacetylases inhibitors.
AID1433260	Antiproliferative activity against Ara-C resistant human CMK cells after 72 hrs by MTT assay	2016	Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17	Synthesis and Antileukemic Activities of Piperlongumine and HDAC Inhibitor Hybrids against Acute Myeloid Leukemia Cells.
AID541651	Inhibition of human HDAC9 by fluorimetric assay	2010	Journal of medicinal chemistry, Dec-09, Volume: 53, Issue:23	Non-natural macrocyclic inhibitors of histone deacetylases: design, synthesis, and activity.
AID1129784	Cell cycle arrest in human Jurkat cells assessed as accumulation at G0/G1-phase at 10 uM after 36 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 1.80%)	2014	Bioorganic & medicinal chemistry, Apr-01, Volume: 22, Issue:7	Studies on the antiproliferative effects of tropolone derivatives in Jurkat T-lymphocyte cells.
AID1164192	Inhibition of HDAC in human MCF7 cells assessed as hyperacetylation of histone H1 at Lys 9/4 residues at 5 uM after 24 hrs by Western blot analysis relative to control	2014	ACS medicinal chemistry letters, Sep-11, Volume: 5, Issue:9	Novel antiproliferative chimeric compounds with marked histone deacetylase inhibitory activity.
AID1742183	Inhibition of HDAC7 (unknown origin) using AcLeu-Gly-Lys(Tfa)-AMC as substrate measured after 30 mins by fluorescence assay	2020	European journal of medicinal chemistry, Nov-01, Volume: 205	Design, synthesis and biological evaluation of novel HDAC inhibitors with improved pharmacokinetic profile in breast cancer.
AID1848616	Cytotoxicity against human DU-145 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay	2022	Journal of medicinal chemistry, 11-10, Volume: 65, Issue:21	First-in-Class Dual Mechanism Ferroptosis-HDAC Inhibitor Hybrids.
AID1727741	Inhibition of HDAC4 (unknown origin) by fluorescence based assay	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	Discovery of selective HDAC/BRD4 dual inhibitors as epigenetic probes.
AID482945	Inhibition of HDAC5	2010	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11	Acylurea connected straight chain hydroxamates as novel histone deacetylase inhibitors: Synthesis, SAR, and in vivo antitumor activity.
AID1566041	Inhibition of full length C-terminal His-tagged human HDAC8 expressed in baculovirus infected Sf9 cells using Ac-peptide-AMC as substrate preincubated for 15 mins followed by substrate addition and measured after 240 mins by fluorescence based assay	2019	European journal of medicinal chemistry, Nov-15, Volume: 182	A fluorine scan on the Zn
AID1293565	Inhibition of full length human recombinant C-terminal His-tagged HDAC3 (1 to 428 residues)/human recombinant N-terminal GST-tagged NCOR2 (395 to 489 residues) expressed in insect cells using RHK-K(Ac)-AMC as substrate incubated for 60 mins by fluorescenc	2016	European journal of medicinal chemistry, Apr-13, Volume: 112	Biphenyl-4-yl-acrylohydroxamic acids: Identification of a novel indolyl-substituted HDAC inhibitor with antitumor activity.
AID1832805	Inhibition of human HDAC3 assessed as target activity using fluorogenic substrate ZMAL for 90 min by microplate reader at 355nm	2021	Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19	4-Acyl Pyrrole Capped HDAC Inhibitors: A New Scaffold for Hybrid Inhibitors of BET Proteins and Histone Deacetylases as Antileukemia Drug Leads.
AID1861263	Selectivity index, ratio of IC50 for inhibition of HDAC2 (unknown origin) to IC50 for inhibition of HDAC6 (unknown origin)	2022	Bioorganic & medicinal chemistry letters, 09-01, Volume: 71	Design, synthesis and antitumor activity study of PARP-1/HDAC dual targeting inhibitors.
AID753148	Inhibition of HDAC2 (unknown origin)	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and biological characterization of spiro[2H-(1,3)-benzoxazine-2,4'-piperidine] based histone deacetylase inhibitors.
AID1650415	Inhibition of HDAC in human Cal27 cells	2020	Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1	Novel alkoxyamide-based histone deacetylase inhibitors reverse cisplatin resistance in chemoresistant cancer cells.
AID753146	Inhibition of HDAC6 (unknown origin)	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and biological characterization of spiro[2H-(1,3)-benzoxazine-2,4'-piperidine] based histone deacetylase inhibitors.
AID1361646	Cell cycle arrest in human A549 cells assessed as accumulation of cells at G2 phase at 5 uM after 48 hrs by flow cytometric analysis (Rvb = 19.81%)	2018	Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16	Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents.
AID1614128	Inhibition of recombinant full length HDAC3 (unknown origin) using Ac-peptide-AMC as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by fluorescence assay
AID511062	Inhibition of HDAC in human HeLa cells at 1 uM after 15 mins	2010	European journal of medicinal chemistry, Sep, Volume: 45, Issue:9	Design and synthesis of novel isoxazole-based HDAC inhibitors.
AID1550129	Induction of apoptosis in human K562 cells assessed as necrotic apoptotic cells at 1 uM after 24 hrs by Annexin-V/propidium iodide staining-based flow cytometric analysis (Rvb = 0.827%)	2019	Journal of medicinal chemistry, 04-25, Volume: 62, Issue:8	Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies.
AID1775547	Inhibition of HDAC3 (unknown origin)	2021	Journal of medicinal chemistry, 03-25, Volume: 64, Issue:6	Design and Synthesis of Novel Epigenetic Inhibitors Targeting Histone Deacetylases, DNA Methyltransferase 1, and Lysine Methyltransferase G9a with
AID1832799	Binding affinity to human BRD4 domain 1 (unknown origin) assessed as dissociation constant by isothermal titration calorimetry assay	2021	Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19	4-Acyl Pyrrole Capped HDAC Inhibitors: A New Scaffold for Hybrid Inhibitors of BET Proteins and Histone Deacetylases as Antileukemia Drug Leads.
AID1737143	Induction of cell cycle arrest in human HCT116 cells assessed as cell accumulation at G2/M phase at 3 uM after 24 hrs by Rnase/PI staining based flow cytometric analysis (Rvb = 26.4%)	2020	European journal of medicinal chemistry, Apr-15, Volume: 192	Design, synthesis and biological evaluation of novel indazole-based derivatives as potent HDAC inhibitors via fragment-based virtual screening.
AID781047	Antiproliferative activity against human NCI-H460 cells after 48 hrs by sulforhodamine B assay	2013	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 23, Issue:23	Design, synthesis and biological evaluation of di-substituted cinnamic hydroxamic acids bearing urea/thiourea unit as potent histone deacetylase inhibitors.
AID1487015	Inhibition of HDAC1 in human U937 cells assessed as increase in acetylated-histone H3 level at 5 uM incubated for 18 hrs by Western blot method	2017	Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15	The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity.
AID1873402	Inhibition of HDAC1 (unknown origin) preincubated for 90 mins	2022	Bioorganic & medicinal chemistry letters, 08-15, Volume: 70	Comparison of three zinc binding groups for HDAC inhibitors - A potency, selectivity and enzymatic kinetics study.
AID90663	Inhibition of Histone deacetylase 1 (HDAC1) of HeLa nuclear extracts	2004	Bioorganic & medicinal chemistry letters, Jan-19, Volume: 14, Issue:2	Design, synthesis, and activity of HDAC inhibitors with a N-formyl hydroxylamine head group.
AID414980	Inhibition of Plasmodium falciparum HDAC1 expressed in Drosophila melanogaster S2 cells	2009	Journal of medicinal chemistry, Apr-23, Volume: 52, Issue:8	Identification and characterization of small molecule inhibitors of a class I histone deacetylase from Plasmodium falciparum.
AID663360	Growth inhibition of human HT-29 cells after 72 hrs by MTS assay	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Discovery and extensive in vitro evaluations of NK-HDAC-1: a chiral histone deacetylase inhibitor as a promising lead.
AID1591715	Inhibition of human recombinant HDAC1 using fluorogenic HDAC substrate 3 pre-incubated for 30 mins followed by HDAC developer addition and measured after 15 mins by fluorogenic assay	2019	Bioorganic & medicinal chemistry, 08-01, Volume: 27, Issue:15	Structure-activity relationship study of thiazolyl-hydroxamate derivatives as selective histone deacetylase 6 inhibitors.
AID1826626	Synergistic antiproliferative effect on HEL cells assessed as fractional inhibitory concentration index at 0.014 uM in presence of 3-Fluoro-10-hydroxy-14-methyl-8,13,13b,14-tetrahydro-7H-indolo[2',3':3,4]pyrido[2,1-b]quinazolin-5-one	2022	Journal of medicinal chemistry, 03-24, Volume: 65, Issue:6	Evodiamine-Inspired Topoisomerase-Histone Deacetylase Dual Inhibitors: Novel Orally Active Antitumor Agents for Leukemia Therapy.
AID404450	Antimalarial activity against Plasmodium falciparum TM91C235 by hypoxanthine uptake	2008	Journal of medicinal chemistry, Jun-26, Volume: 51, Issue:12	A series of potent and selective, triazolylphenyl-based histone deacetylases inhibitors with activity against pancreatic cancer cells and Plasmodium falciparum.
AID385229	Inhibition of HDAC1	2008	Journal of medicinal chemistry, May-22, Volume: 51, Issue:10	Structural origin of selectivity in class II-selective histone deacetylase inhibitors.
AID1771455	Antiproliferative activity against human U-937 cells assessed as cell growth inhibition after 72 hrs by CCK8 assay	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Discovery of novel tubulin/HDAC dual-targeting inhibitors with strong antitumor and antiangiogenic potency.
AID544096	Selectivity index, ratio of LC50 for mouse RAW264.7 cells to IC50 for Plasmodium falciparum	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Antimalarial activity of phenylthiazolyl-bearing hydroxamate-based histone deacetylase inhibitors.
AID605396	Inhibition of human recombinant HDAC6 using fluor de Lys as substrate by fluorometric analysis	2010	Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24	Discovery of 2-(6-{[(6-fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a class I selective orally active histone deacetylase inhibitor.
AID1832797	Cytotoxicity against human TALL-1 cells assessed as cell viability at 5 uM by CellTiter-Glo luminescent assay	2021	Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19	4-Acyl Pyrrole Capped HDAC Inhibitors: A New Scaffold for Hybrid Inhibitors of BET Proteins and Histone Deacetylases as Antileukemia Drug Leads.
AID90197	Inhibitory concentration against histone deacetylase activity	2001	Journal of medicinal chemistry, Jun-21, Volume: 44, Issue:13	3-(4-aroyl-1H-pyrrol-2-yl)-N-hydroxy-2-propenamides, a new class of synthetic histone deacetylase inhibitors.
AID1339567	Inhibition of HDAC1 in human HeLaS3 cells preincubated for 15 mins followed by HDAC-Glo substrate addition measured after 30 to 45 mins by ELISA	2017	ACS medicinal chemistry letters, Mar-09, Volume: 8, Issue:3	Structural Requirements of HDAC Inhibitors: SAHA Analogues Modified at the C2 Position Display HDAC6/8 Selectivity.
AID717824	Inhibition of HDAC3 using Fluor-de-Lys as substrate compound pretreated for 30 mins before substrate addition by fluorescence assay	2012	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23	The structural requirements of histone deacetylase inhibitors: suberoylanilide hydroxamic acid analogs modified at the C6 position.
AID1578898	Induction of apoptosis in human Bel7402 cells assessed as annexin-V positive cells at 5 uM after 72 hrs by Annexin-V/PI staining based flow cytometry relative to control	2019	Journal of natural products, 06-28, Volume: 82, Issue:6	Hydroxamic Acid Derivatives of β-Carboline/Hydroxycinnamic Acid Hybrids Inducing Apoptosis and Autophagy through the PI3K/Akt/mTOR Pathways.
AID1742175	Inhibition of recombinant human His-tagged HDAC6 expressed in baculovirus infected insect cells using Ac-Leu-Gly-Lys(Ac)-AMC as substrate measured after 30 mins by fluorescence assay	2020	European journal of medicinal chemistry, Nov-01, Volume: 205	Design, synthesis and biological evaluation of novel HDAC inhibitors with improved pharmacokinetic profile in breast cancer.
AID1764801	Inhibition of recombinant human HDAC8 using Boc-Lys(TFA)-AMC as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins by fluorescence-based assay	2021	Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8	Tetrahydroquinoline-Capped Histone Deacetylase 6 Inhibitor SW-101 Ameliorates Pathological Phenotypes in a Charcot-Marie-Tooth Type 2A Mouse Model.
AID499814	Inhibition of Plasmodium falciparum HDAC1	2010	Journal of medicinal chemistry, Aug-26, Volume: 53, Issue:16	Non-peptide macrocyclic histone deacetylase inhibitors derived from tricyclic ketolide skeleton.
AID1421602	Inhibition of HDAC1 (unknown origin)	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	Design and synthesis of potent dual inhibitors of JAK2 and HDAC based on fusing the pharmacophores of XL019 and vorinostat.
AID1439773	Inhibition of Pseudomonas aeruginosa PA3774 using Boc-Lys(trifluoroacetyl)-AMC as substrate preincubated for 30 mins followed by substrate addition measured after 60 mins by trypsin-based fluorescence assay	2017	Bioorganic & medicinal chemistry letters, 04-01, Volume: 27, Issue:7	Perfluorinated hydroxamic acids are potent and selective inhibitors of HDAC-like enzymes from Pseudomonas aeruginosa.
AID1476119	Inhibition of C-terminal FLAG His tagged full length human recombinant HDAC1 (1 to 482 residues) expressed in baculovirus infected sf21 cells using RHKKAc as substrate in presence of ATP	2017	Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20	Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat.
AID274034	Microsome stability: percent compound remaining	2007	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2	Identification and optimisation of a series of substituted 5-pyridin-2-yl-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.
AID1709361	Induction of apoptosis in human Jurkat cells assessed as necrotic cells at IC50 measured after 48 hrs by Annexin V-FITC/7AAD staining based flow cytometry (Rvb = 0.23%)	2021	Bioorganic & medicinal chemistry, 04-01, Volume: 35	Structure-activity relationship and mechanistic studies for a series of cinnamyl hydroxamate histone deacetylase inhibitors.
AID527319	Growth inhibition of human HeLa cells after 72 hrs by SRB assay	2010	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22	Design and synthesis of novel pyrimidine hydroxamic acid inhibitors of histone deacetylases.
AID1825926	Inhibition of recombinant human full length N-terminal GST tagged HDAC6 (1 to 1215 residues) expressed in baculovirus-infected Sf9 cells using Ac-peptide as substrate incubated for 4 hrs
AID308648	Increase in p21WAF1/CIP1 gene expression in PANC1 cells after 24 hrs relative to control	2007	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17	Design, synthesis, and evaluation of isoindolinone-hydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors.
AID663398	Growth inhibition of human T47D cells after 72 hrs by MTS assay	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Discovery and extensive in vitro evaluations of NK-HDAC-1: a chiral histone deacetylase inhibitor as a promising lead.
AID747252	Inhibition of human recombinant HDAC1 incubated for 10 mins prior to substrate addition measured after 60 mins by spectrophotometric analysis	2013	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 23, Issue:11	Design, synthesis, and biological evaluation of novel histone deacetylase 1 inhibitors through click chemistry.
AID1737146	Induction of apoptosis in human HCT-116 cells assessed as viable cells at 3 uM after 24 hrs by Annexin V-FITC/PI staining based flow cytometric analysis (Rvb = 90.34%)	2020	European journal of medicinal chemistry, Apr-15, Volume: 192	Design, synthesis and biological evaluation of novel indazole-based derivatives as potent HDAC inhibitors via fragment-based virtual screening.
AID1742762	Induction of apoptosis in mouse 4T1 cells implanted in BALB/c mouse assessed as increase in caspase-3 cleavage by immunohistochemistry method	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Design and synthesis of novel Flavone-based histone deacetylase inhibitors antagonizing activation of STAT3 in breast cancer.
AID1690840	Disaggregation of self-induced amyloid beta (1 to 42) (unknown origin) preformed fibrils at 10 uM measured after 24 hrs by thioflavin-T fluorescence assay relative to control	2020	European journal of medicinal chemistry, Apr-15, Volume: 192	Synthesis and biological evaluation of acridine-based histone deacetylase inhibitors as multitarget agents against Alzheimer's disease.
AID329922	Inhibition of human HDAC4 in U937 cells at 5 uM	2008	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8	Novel uracil-based 2-aminoanilide and 2-aminoanilide-like derivatives: histone deacetylase inhibition and in-cell activities.
AID1578480	Cytotoxicity against human MV4-11 cells assessed as reduction in cell viability incubated for 72 hrs by cell-titer blue assay	2020	ACS medicinal chemistry letters, Jan-09, Volume: 11, Issue:1	Class I/IIb-Selective HDAC Inhibitor Exhibits Oral Bioavailability and Therapeutic Efficacy in Acute Myeloid Leukemia.
AID1764800	Inhibition of recombinant human HDAC1 using Ac-GAK(Ac)-AMC as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins by fluorescence-based assay	2021	Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8	Tetrahydroquinoline-Capped Histone Deacetylase 6 Inhibitor SW-101 Ameliorates Pathological Phenotypes in a Charcot-Marie-Tooth Type 2A Mouse Model.
AID618017	Antitumor activity against human MDA-MB-231 cells xenografted in BALB/c nu mouse assessed as tumor growth inhibition at 90 mg/kg, po qd for 19 days relative to control	2011	Journal of medicinal chemistry, Aug-11, Volume: 54, Issue:15	Discovery of a tetrahydroisoquinoline-based hydroxamic acid derivative (ZYJ-34c) as histone deacetylase inhibitor with potent oral antitumor activities.
AID1384231	Inhibition of class-1 HDAC in human SH-SY5Y cells assessed as induction of AcH3K9 level at 1000 nM after 2 hrs by Western blot analysis relative to control	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease.
AID384317	Inhibition of maize histone deacetylase 1A	2008	European journal of medicinal chemistry, Mar, Volume: 43, Issue:3	Class II-selective histone deacetylase inhibitors. Part 2: alignment-independent GRIND 3-D QSAR, homology and docking studies.
AID446336	Metabolic stability in human liver microsomes assessed as half life	2010	Journal of medicinal chemistry, Jan-28, Volume: 53, Issue:2	Synthesis and biological evaluation of N-hydroxyphenylacrylamides and N-hydroxypyridin-2-ylacrylamides as novel histone deacetylase inhibitors.
AID350731	Growth inhibition of human RXF631L cells after 48 hrs by sulforhodamine B assay	2009	Journal of medicinal chemistry, May-14, Volume: 52, Issue:9	Design, synthesis, and biological activity of boronic acid-based histone deacetylase inhibitors.
AID1321700	Inhibition of HDAC1 (unknown origin)	2016	Journal of medicinal chemistry, 10-13, Volume: 59, Issue:19	Design, Synthesis, and Biological Evaluation of First-in-Class Dual Acting Histone Deacetylases (HDACs) and Phosphodiesterase 5 (PDE5) Inhibitors for the Treatment of Alzheimer's Disease.
AID1739584	Inhibition of HDAC6 in human THP-1 cells assessed as ratio of acetylated H3/GAPDH at 0.1 uM incubated for 4 hrs by Western blot analysis relative to DMSO	2020	European journal of medicinal chemistry, Aug-15, Volume: 200	Design, synthesis, and biological evaluation of dual targeting inhibitors of histone deacetylase 6/8 and bromodomain BRPF1.
AID300834	Growth inhibition of human ACHN cells after 21 hrs by MTT assay	2007	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17	Pomiferin, histone deacetylase inhibitor isolated from the fruits of Maclura pomifera.
AID1486676	Inhibition of HDAC6 (unknown origin) at 10 uM using Ac-Leu-GlyLys(Ac)-AMC as substrate preincubated for 10 mins followed by substrate addition measured after 30 mins by fluorescence analysis	2017	Bioorganic & medicinal chemistry, 08-01, Volume: 25, Issue:15	Design, synthesis and tumor cell growth inhibitory activity of 3-nitro-2H-cheromene derivatives as histone deacetylaes inhibitors.
AID1543954	Induction of apoptosis in human Bel7402/5-FU cells assessed as late apoptotic cells at 5.0 uM incubated for 72 hrs by FITC-Annexin V/PI staining based flow cytometry (Rvb = 1.01%)	2019	European journal of medicinal chemistry, Apr-15, Volume: 168	β-Carboline and N-hydroxycinnamamide hybrids as anticancer agents for drug-resistant hepatocellular carcinoma.
AID1915602	Cytotoxicity against human A2780P cells	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors.
AID652749	Inhibition of recombinant human HDAC5 using Fluor-de-Lys as substrate after 30 mins by spectrophotometry	2011	ACS medicinal chemistry letters, Jul-21, Volume: 2, Issue:9	Potential Agents for Treating Cystic Fibrosis: Cyclic Tetrapeptides that Restore Trafficking and Activity of ΔF508-CFTR.
AID1566816	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Discovery of 1,2,4-oxadiazole-Containing hydroxamic acid derivatives as histone deacetylase inhibitors potential application in cancer therapy.
AID710837	Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition by SRB assay	2012	Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23	Property-based optimization of hydroxamate-based γ-lactam HDAC inhibitors to improve their metabolic stability and pharmacokinetic profiles.
AID1599722	Inhibition of HDAC in human MeT-5A cells assessed as increase in transfected YFP fused histone H3 acetylation treated at 8 hrs after YFP fused H3 transfection measured after 24 hrs incubation by BRET assay	2019	ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6	Extending Cross Metathesis To Identify Selective HDAC Inhibitors: Synthesis, Biological Activities, and Modeling.
AID1865263	Inhibition of recombinant his-tagged human HDAC3 using Ac-LeuGlyLys (Ac) AMC substrate preincubated for 5 mins followed by substrate addition and measured after 30 mins by fluorescence based microplate reader analysis	2022	Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18	Discovery of Novel Src Homology-2 Domain-Containing Phosphatase 2 and Histone Deacetylase Dual Inhibitors with Potent Antitumor Efficacy and Enhanced Antitumor Immunity.
AID1886181	Inhibition of HDAC in human HeLa cells using BOC-K(Ac)-AMC as substrate at 10 uM measured after 30 mins by fluorescence based microtiter plate reader assay relative to control	2022	Journal of medicinal chemistry, 08-25, Volume: 65, Issue:16	Discovery of a Novel Vascular Disrupting Agent Inhibiting Tubulin Polymerization and HDACs with Potent Antitumor Effects.
AID1518782	Antiproliferative activity against human MDA-MB-231 cells incubated for 72 hrs by MTT assay	2019	European journal of medicinal chemistry, Dec-15, Volume: 184	Discovery of a potent histone deacetylase (HDAC) 3/6 selective dual inhibitor.
AID1812445	Inhibition of human recombinant HDAC6 using Tosyl-Gly-ProLys(Ac)-AMC as substrate measured after 60 mins by fluorescence assay	2021	Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14	Procainamide-SAHA Fused Inhibitors of hHDAC6 Tackle Multidrug-Resistant Malaria Parasites.
AID1129772	Increase in p21 protein expression in human Jurkat cells at 10 uM after 24 hrs by FACS flow cytometric analysis	2014	Bioorganic & medicinal chemistry, Apr-01, Volume: 22, Issue:7	Studies on the antiproliferative effects of tropolone derivatives in Jurkat T-lymphocyte cells.
AID526536	Growth inhibition of human HCT15 cells	2010	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22	Property based optimization of δ-lactam HDAC inhibitors for metabolic stability.
AID1336947	Induction of cell cycle arrest in human LNCAP cells assessed as accumulation at G1 phase at 2.5 uM after 24 hrs by propidium iodide staining based FACS analysis (Rvb = 69.5%)	2017	Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3	Bifunctional conjugates with potent inhibitory activity towards cyclooxygenase and histone deacetylase.
AID1365022	Inhibition of recombinant human HDAC1 (482 residues) expressed in baculovirus infected insect cells preincubated with enzyme followed by flour de lys-green substrate addition measured after 1 hr by fluorescence assay	2017	Bioorganic & medicinal chemistry letters, 09-15, Volume: 27, Issue:18	Rational design, synthesis and preliminary antitumor activity evaluation of a chlorambucil derivative with potent DNA/HDAC dual-targeting inhibitory activity.
AID1533327	Inhibition of full length human N-terminal FLAG-tagged HDAC8 (1 to 377 residues) expressed in HEK293 cells preincubated for 15 mins followed by Boc-[trifluoroacetyl-Lys]-AMC substrate addition measured after 30 mins by fluorimetric method	2018	ACS medicinal chemistry letters, Dec-13, Volume: 9, Issue:12	Molecular Basis for the Selective Inhibition of Histone Deacetylase 6 by a Mercaptoacetamide Inhibitor.
AID1515908	Antiproliferative activity against human NCI-H460 cells after 96 hrs by MTT assay	2019	Journal of medicinal chemistry, 08-08, Volume: 62, Issue:15	Design, Synthesis, and Biological Evaluation of 4-Methyl Quinazoline Derivatives as Anticancer Agents Simultaneously Targeting Phosphoinositide 3-Kinases and Histone Deacetylases.
AID1469335	Cytotoxicity against human NCI-H1299 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	2018	Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7	Discovery of N1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7 H-pyrrolo[2,3- d]pyrimidin-2-yl)amino)phenyl)- N8-hydroxyoctanediamide as a Novel Inhibitor Targeting Cyclin-dependent Kinase 4/9 (CDK4/9) and Histone Deacetlyase1 (HDAC1) against Malignant Cancer
AID1622986	Inhibition of HDAC8 in human HeLa nuclear extract using Boc-Lys(acetyl)-AMC as substrate measured after 30 mins by fluorescence assay	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.
AID1742229	Antimetastatic activity against CM-Dil labeled human MDA-MB-231 cells xenografted in Zebrafish AB assessed as reduction in tail metastasis at 2.5 ug/ml measured after 5 days by fluorescence microscopic analysis	2020	European journal of medicinal chemistry, Nov-01, Volume: 205	Design, synthesis and biological evaluation of novel HDAC inhibitors with improved pharmacokinetic profile in breast cancer.
AID1873381	Inhibition of HDAC1 (unknown origin)	2022	Bioorganic & medicinal chemistry letters, 08-15, Volume: 70	Comparison of three zinc binding groups for HDAC inhibitors - A potency, selectivity and enzymatic kinetics study.
AID1476158	Antiproliferative activity against human MOLM14 cells after 48 hrs by CellTiter-Glo luminescent assay	2017	Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20	Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat.
AID540210	Clearance in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1294805	Inhibition of His-tagged human HDAC11 expressed in Sf9 cells using Ac-Arg-Gly-Lys(Ac)-AMC as substrate by fluorometric assay	2016	Bioorganic & medicinal chemistry letters, 05-15, Volume: 26, Issue:10	A sub-milligram-synthesis protocol for in vitro screening of HDAC11 inhibitors.
AID760508	Inhibition of HDAC5 (unknown origin) using Boc-Lys(trifluoroacetyl)-AMC as substrate by fluorescence assay	2013	ACS medicinal chemistry letters, Aug-08, Volume: 4, Issue:8	Development of a chimeric c-Src kinase and HDAC inhibitor.
AID1282275	Antitumor activity against human MV4-11 cells xenografted in NOD/SCID mouse assessed as tumor mass change at 50 mg/kg, ip q2d for 12 days	2016	Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4	Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
AID1406988	Inhibition of HDAC6 in human U87 cells assessed as levels of alpha-tubulin acetylation at 1 uM after 30 hrs by Western blot analysis relative to control	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Novel spiroindoline HDAC inhibitors: Synthesis, molecular modelling and biological studies.
AID1597937	Antiproliferative activity against human NCI-H460 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	2019	Bioorganic & medicinal chemistry letters, 09-15, Volume: 29, Issue:18	Anti-tumor activity evaluation of novel tubulin and HDAC dual-targeting inhibitors.
AID1547248	Antiproliferative activity against human DLD1 cells assessed as reduction in cell viability measured after 24 to 48 hrs by MTT assay	2020	Journal of medicinal chemistry, 04-09, Volume: 63, Issue:7	Discovery of Thieno[2,3-
AID1177043	Inhibition of human HDAC2 using RHKK(Ac) as substrate by fluorimetric analysis	2015	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 25, Issue:3	Hydroxamic acid based histone deacetylase inhibitors with confirmed activity against the malaria parasite.
AID1848627	Cytotoxicity against human A498 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay	2022	Journal of medicinal chemistry, 11-10, Volume: 65, Issue:21	First-in-Class Dual Mechanism Ferroptosis-HDAC Inhibitor Hybrids.
AID621737	Inhibition of HDAC1 by fluorescent activity assay	2011	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19	2,5-Disubstituted-1,3,4-oxadiazoles/thiadiazole as surface recognition moiety: design and synthesis of novel hydroxamic acid based histone deacetylase inhibitors.
AID1202593	Cytotoxicity against human HeLa cells after 72 hrs by MTS assay	2015	European journal of medicinal chemistry, , Volume: 96	Design and structure activity relationship of tumor-homing histone deacetylase inhibitors conjugated to folic and pteroic acids.
AID90691	Inhibition of maize Histone deacetylase 2	2004	Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6	3-(4-Aroyl-1-methyl-1H-pyrrol-2-yl)-N-hydroxy-2-propenamides as a new class of synthetic histone deacetylase inhibitors. 3. Discovery of novel lead compounds through structure-based drug design and docking studies.
AID1275638	Inhibition of recombinant human HDAC4 using Boc-Lys(TFA)-AMC as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by fluorescence-based assay	2016	European journal of medicinal chemistry, Feb-15, Volume: 109	Identification of N-(6-mercaptohexyl)-3-(4-pyridyl)-1H-pyrazole-5-carboxamide and its disulfide prodrug as potent histone deacetylase inhibitors with in vitro and in vivo anti-tumor efficacy.
AID1478601	Induction of apoptosis in human K562 cells after 24 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometric method	2017	European journal of medicinal chemistry, Jun-16, Volume: 133	Design, synthesis and biological evaluation of quinoline derivatives as HDAC class I inhibitors.
AID1702100	Inhibition of HDAC in human PC-3 cells assessed as increase in acetylation of histone H3 at K9 residue at 10 uM incubated for 24 hrs by Western blot analysis	2018	Journal of medicinal chemistry, 02-22, Volume: 61, Issue:4	Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma.
AID604082	Inhibition of JMJD2E	2011	Bioorganic & medicinal chemistry, Jun-15, Volume: 19, Issue:12	Inhibitors of histone demethylases.
AID303347	Inhibition of HDAC in HeLa nuclear extract in presence of DTT	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	The first biologically active synthetic analogues of FK228, the depsipeptide histone deacetylase inhibitor.
AID421216	Inhibition of HDAC1 from human HeLa cells at 5 uM	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Recent advances in the development of polyamine analogues as antitumor agents.
AID605527	Inhibition of HDAC1 in human HCT116 cells assessed as induction of histone H3K9 acetylation after 30 hrs by Western blot analysis	2010	Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24	Discovery of 2-(6-{[(6-fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a class I selective orally active histone deacetylase inhibitor.
AID717820	Inhibition of HDAC in human Hela cell lysate using Fluor-de-Lys as substrate assessed as remaining activity at 1.25 x 10'-7 M pretreated for 30 mins before substrate addition by fluorescence assay	2012	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23	The structural requirements of histone deacetylase inhibitors: suberoylanilide hydroxamic acid analogs modified at the C6 position.
AID1439352	Antiproliferative activity against human HCT116 cells after 72 hrs by CellTiter 96 AQueous Non-Radioactive assay	2017	European journal of medicinal chemistry, Mar-10, Volume: 128	Design, synthesis and biological evaluation of thienopyrimidine hydroxamic acid based derivatives as structurally novel histone deacetylase (HDAC) inhibitors.
AID747253	Growth inhibition of human DU145 cells by MTT assay	2013	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 23, Issue:11	Design, synthesis, and biological evaluation of novel histone deacetylase 1 inhibitors through click chemistry.
AID1215092	Activation of human PXR expressed in human HepG2 (DPX-2) cells assessed as induction of CYP3A4 up to 46 uM after 24 hrs by luminescent analysis	2011	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1	Identification of clinically used drugs that activate pregnane X receptors.
AID1398819	Antagonist activity at ERalpha in human MCF7 cells assessed as suppression of E2F1 mRNA expression at 5 uM after 24 hrs by QIAzol reagent based RT-qPCR analysis	2018	Bioorganic & medicinal chemistry, 08-15, Volume: 26, Issue:15	Incorporation of histone deacetylase inhibitory activity into the core of tamoxifen - A new hybrid design paradigm.
AID1543945	Inhibition of human recombinant HDAC8 using Boc-Lys (Ac)-AMC as substrate incubated for 60 mins and measured after 30 mins by fluorescence assay	2019	European journal of medicinal chemistry, Apr-15, Volume: 168	β-Carboline and N-hydroxycinnamamide hybrids as anticancer agents for drug-resistant hepatocellular carcinoma.
AID499812	Selectivity index, ratio of IC50 for african green monkey (Cercopithecus aethiops) Vero cells to IC50 for Plasmodium falciparum D6	2010	Journal of medicinal chemistry, Aug-26, Volume: 53, Issue:16	Non-peptide macrocyclic histone deacetylase inhibitors derived from tricyclic ketolide skeleton.
AID1206754	Antitumor activity against human HEL cells xenografted in BALB/c-nu mouse assessed as inhibition of tumor growth at 120 mg/kg/day, po administered for 21 days measured every 3 days during compound dosing relative to control	2015	Journal of medicinal chemistry, May-28, Volume: 58, Issue:10	Design, synthesis, and antitumor evaluation of novel histone deacetylase inhibitors equipped with a phenylsulfonylfuroxan module as a nitric oxide donor.
AID1594438	Inhibition of C-terminal GST-tagged full-length human HDAC1 expressed in Sf9 cells at 10 uM pre-incubated for 10 mins before substrate addition and measured after 20 mins by fluorescence assay	2019	Bioorganic & medicinal chemistry letters, 05-15, Volume: 29, Issue:10	Identification of ortho-hydroxy anilide as a novel scaffold for lysine demethylase 5 inhibitors.
AID622256	Inhibition of HDAC3 after 30 mins by Fluor de Lys fluorescence assay	2011	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 21, Issue:20	The structural requirements of histone deacetylase inhibitors: Suberoylanilide hydroxamic acid analogs modified at the C3 position display isoform selectivity.
AID1514599	Inhibition of HDAC1 in human HepG2 cells assessed as acetylated histone H3 levels at 1.25 uM by Western blot analysis relative to beta-actin (Rvb = 0.5 No_unit)	2019	Bioorganic & medicinal chemistry letters, 01-01, Volume: 29, Issue:1	Development of hydroxamate-based histone deacetylase inhibitors containing 1,2,4-oxadiazole moiety core with antitumor activities.
AID672034	Ratio of IC50 for human HDAC2 preincubated for 24 hrs to IC50 for human HDAC2 preincubated for 5 mins	2012	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 22, Issue:15	Design, synthesis, modeling, biological evaluation and photoaffinity labeling studies of novel series of photoreactive benzamide probes for histone deacetylase 2.
AID1202585	Inhibition of His-tagged HDAC8 (unknown origin) expressed in Escherichia coli BL21(DE3) after 60 mins by MALDI mass spectrometry	2015	European journal of medicinal chemistry, , Volume: 96	Design and structure activity relationship of tumor-homing histone deacetylase inhibitors conjugated to folic and pteroic acids.
AID1466062	Inhibition of recombinant human full length HDAC4 using Fluor-de-Lys as substrate after 60 mins by spectrofluorimetric analysis	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	4-Indolyl-N-hydroxyphenylacrylamides as potent HDAC class I and IIB inhibitors in vitro and in vivo.
AID655474	Restoration of CFTR deltaF508 mutant trafficking to cell surface as glycoforms in human CFBE41o cells at 1 uM after 24 hrs by Western blotting	2011	ACS medicinal chemistry letters, Jul-21, Volume: 2, Issue:9	Potential Agents for Treating Cystic Fibrosis: Cyclic Tetrapeptides that Restore Trafficking and Activity of ΔF508-CFTR.
AID1240552	Induction of apoptosis in human MDA-MB-231 cells assessed as late apoptotic cells at 1 uM after 24 hrs using Annexin V-FITC and propidium iodide staining by flow cytometry (Rvb = 4.04%)	2015	Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17	Design, synthesis and biological evaluation of saccharin-based N-hydroxybenzamides as histone deacetylases (HDACs) inhibitors.
AID492803	Inhibition of human recombinant HDAC1 after 15 mins by fluorimetric assay	2010	Journal of medicinal chemistry, Jun-24, Volume: 53, Issue:12	Synthesis and biological characterization of the histone deacetylase inhibitor largazole and C7- modified analogues.
AID1548290	Induction of apoptosis in bortezomib resistant human KM3/BTZ cells assessed as late apoptotic cells level at 200 nM incubated for 24 hrs by Annexin V-FITC/PI staining based FCAS analysis (Rvb = 0.38%)
AID1326528	Toxicity in nude mouse xenografted with human HCT116 cells assessed as change in body weight at 200 mg/kg, po qd	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	2-(Phenylsulfonyl)quinoline N-hydroxyacrylamides as potent anticancer agents inhibiting histone deacetylase.
AID1865261	Inhibition of recombinant his-tagged human HDAC1 using Ac-LeuGlyLys (Ac) AMC substrate preincubated for 5 mins followed by substrate addition and measured after 30 mins by fluorescence based microplate reader analysis	2022	Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18	Discovery of Novel Src Homology-2 Domain-Containing Phosphatase 2 and Histone Deacetylase Dual Inhibitors with Potent Antitumor Efficacy and Enhanced Antitumor Immunity.
AID1469299	Induction of apoptosis in human NCI-H460 cells assessed as late apoptotic cells at 10 uM after 48 hrs by annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 1.29%)	2018	Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7	Discovery of N1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7 H-pyrrolo[2,3- d]pyrimidin-2-yl)amino)phenyl)- N8-hydroxyoctanediamide as a Novel Inhibitor Targeting Cyclin-dependent Kinase 4/9 (CDK4/9) and Histone Deacetlyase1 (HDAC1) against Malignant Cancer
AID1890310	Inhibition of HDAC3 (unknown origin)	2022	European journal of medicinal chemistry, Apr-05, Volume: 233	Novel biphenyl-based scaffold as potent and selective histone deacetylase 6 (HDAC6) inhibitors: Identification, development and pharmacological evaluation.
AID1897466	Inhibition of HDAC in human HCT-116 cells assessed as upregulation of acetyl-histone 3 level at 1.25 to 5 uM incubated for 36 hrs by Western blot analysis
AID1363797	Inhibition of chymotrypsin-like activity of 20S proteasome in human HL60 cells using Suc-LLVY aminoluciferin as substrate after 2 hrs by proteasome-Glo assay	2018	Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22	Discovery of the First-in-Class Dual Histone Deacetylase-Proteasome Inhibitor.
AID310186	Antitumor activity against MDA-MB-231 cells xenografted BALB/c nude mouse at 30 mg/kg, ip for 15 days	2007	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 17, Issue:22	Modification of cap group in delta-lactam-based histone deacetylase (HDAC) inhibitors.
AID526533	Growth inhibition of human MDA-MB-231 cells	2010	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22	Property based optimization of δ-lactam HDAC inhibitors for metabolic stability.
AID1273873	Metabolic stability in mouse liver microsomes assessed as compound remaining at 1 uM preincubated for 10 mins measured after 30 mins by LC-MS/MS analysis	2016	European journal of medicinal chemistry, Jan-27, Volume: 108	Synthesis, biological characterization and molecular modeling insights of spirochromanes as potent HDAC inhibitors.
AID1739587	Inhibition of HDAC6 in human HL-60 cells assessed as ratio of acetylated tubulin/GAPDH at 0.1 uM incubated for 4 hrs by Western blot analysis relative to DMSO	2020	European journal of medicinal chemistry, Aug-15, Volume: 200	Design, synthesis, and biological evaluation of dual targeting inhibitors of histone deacetylase 6/8 and bromodomain BRPF1.
AID1900917	Induction of apoptosis in mouse GL26 cells assessed as caspase-mediated PARP1 cleavage at 1.25 to 5 uM incubated for 48 hrs by Western blot analysis	2022	Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
AID352524	Antiproliferative activity against human Panc 04.03 cells by MTT assay	2009	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11	Isoxazole moiety in the linker region of HDAC inhibitors adjacent to the Zn-chelating group: effects on HDAC biology and antiproliferative activity.
AID347807	Inhibition of human HDAC8 at 0.50 uM	2008	Journal of medicinal chemistry, Dec-11, Volume: 51, Issue:23	Histone deacetylase inhibitors through click chemistry.
AID1486294	Inhibition of HDAC6 (unknown origin) using acetylated peptide substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by fluorescence analysis	2017	Bioorganic & medicinal chemistry, 08-01, Volume: 25, Issue:15	Olaparib hydroxamic acid derivatives as dual PARP and HDAC inhibitors for cancer therapy.
AID593548	Inhibition of human HDAC3 using ArgHisLysLys(Ac) fluorogenic peptide as a substrate by fluorimetric assay	2011	Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7	Oxime amides as a novel zinc binding group in histone deacetylase inhibitors: synthesis, biological activity, and computational evaluation.
AID652764	Inhibition of HDAC8 in human HeLa cells nuclear extract using Arg-His-Lys(Ac)-Lys(Ac)-AMC as substrate after 30 mins by spectrophotometry	2011	ACS medicinal chemistry letters, Jul-21, Volume: 2, Issue:9	Potential Agents for Treating Cystic Fibrosis: Cyclic Tetrapeptides that Restore Trafficking and Activity of ΔF508-CFTR.
AID1141761	Inhibition of HDAC in human HeLa cell nuclear extract using Boc-Lys(Ac)-AMC as substrate after 30 mins by fluorimetric analysis	2014	Journal of medicinal chemistry, May-22, Volume: 57, Issue:10	Azaindolylsulfonamides, with a more selective inhibitory effect on histone deacetylase 6 activity, exhibit antitumor activity in colorectal cancer HCT116 cells.
AID1890323	Inhibition of HDAC1 in mouse CT26 cells assessed as accumulation of acetylated H3 level at 6 uM after 24 hrs by Western blotting analysis	2022	European journal of medicinal chemistry, Apr-05, Volume: 233	Novel biphenyl-based scaffold as potent and selective histone deacetylase 6 (HDAC6) inhibitors: Identification, development and pharmacological evaluation.
AID1426428	Selectivity index, ratio of IC50 for HEK293 cells to IC50 for drug-resistant Plasmodium falciparum Dd2 infected in erythrocytes	2017	European journal of medicinal chemistry, Feb-15, Volume: 127	Synthesis, biological characterisation and structure activity relationships of aromatic bisamidines active against Plasmodium falciparum.
AID663358	Growth inhibition of human HCT116 cells after 72 hrs by MTS assay	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Discovery and extensive in vitro evaluations of NK-HDAC-1: a chiral histone deacetylase inhibitor as a promising lead.
AID775834	Inhibition of human recombinant MMP-2 using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2.AcOH as substrate at 10 uM preincubated for 30 mins prior to substrate addition measured for 30 mins by fluorescence assay relative to control	2013	Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20	Investigating the selectivity of metalloenzyme inhibitors.
AID1355714	Synergistic antifungal activity against FLC resistant Candida albicans 0304103 assessed as FIC index after 48 hrs by checkerboard microdilution method	2018	Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14	Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections.
AID1742223	Cmax in Beagle dog at 20 mg/kg, po by LC-MS/MS analysis	2020	European journal of medicinal chemistry, Nov-01, Volume: 205	Design, synthesis and biological evaluation of novel HDAC inhibitors with improved pharmacokinetic profile in breast cancer.
AID1769653	Inhibition of ALK G1202R mutant (unknown origin)	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	Discovery of 2,4-pyrimidinediamine derivatives as potent dual inhibitors of ALK and HDAC.
AID1141783	Inhibition of HDAC in human HCT116 cells assessed as increase in histone-H3 acetylation after 3 hrs by Western blotting analysis	2014	Journal of medicinal chemistry, May-22, Volume: 57, Issue:10	Azaindolylsulfonamides, with a more selective inhibitory effect on histone deacetylase 6 activity, exhibit antitumor activity in colorectal cancer HCT116 cells.
AID353354	Cytotoxicity against human SH-SY5Y cells assessed as cell viability after 48 hrs by MTT assay	2009	Journal of medicinal chemistry, May-14, Volume: 52, Issue:9	Synthesis, biological evaluation, and molecular docking of Ugi products containing a zinc-chelating moiety as novel inhibitors of histone deacetylases.
AID1622904	Inhibition of HDAC1 (unknown origin) using Ac-peptide as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence assay	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.
AID1676594	Binding affinity to gallium ion assessed as accounting ratio by measuring total compound detected/total compound adsorbed at 2.55 umol by immobilized metal-ion affinity chromatography	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
AID1633416	Inhibition of human recombinant GSK3beta up to 50 uM using GSM as substrate incubated for 30 mins by luminescence based assay	2019	ACS medicinal chemistry letters, Apr-11, Volume: 10, Issue:4	Discovery of the First-in-Class GSK-3β/HDAC Dual Inhibitor as Disease-Modifying Agent To Combat Alzheimer's Disease.
AID1383985	Inhibition of HDAC1/2 in human HeLa nuclear extract using Boc-Lys(acetyl)-AMC as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by fluorescence assay	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	Discovery of meta-sulfamoyl N-hydroxybenzamides as HDAC8 selective inhibitors.
AID1704064	Inhibition of human C-terminal Flag tagged HDAC1 (1 to 482 residues) expressed in SF9 cells using Ac-peptide substrate at 100 nM preincubated for 15 mins followed by substrate addition and measured after 60 mins by microplate reader method	2020	European journal of medicinal chemistry, Oct-15, Volume: 204	Discovery of Novel c-Mesenchymal-Epithelia transition factor and histone deacetylase dual inhibitors.
AID1811364	Inhibition of HDAC4 (unknown origin)	2021	European journal of medicinal chemistry, Dec-15, Volume: 226	Development of novel tetrahydroisoquinoline-hydroxamate conjugates as potent dual SERDs/HDAC inhibitors for the treatment of breast cancer.
AID1864238	Stabilization of FAM-labeled DNA Pu22 (unknown origin ) double strand assessed as G4-quadruplex formation incubated for 30 mins in presence of potassium ions by electrophoresis mobility shift assay	2022	Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18	Discovery of a Novel G-Quadruplex and Histone Deacetylase (HDAC) Dual-Targeting Agent for the Treatment of Triple-Negative Breast Cancer.
AID1826596	Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 8 hrs by CCK8 assay	2022	Journal of medicinal chemistry, 03-24, Volume: 65, Issue:6	Evodiamine-Inspired Topoisomerase-Histone Deacetylase Dual Inhibitors: Novel Orally Active Antitumor Agents for Leukemia Therapy.
AID1547282	Inhibition of HDAC in human HCT116 cells assessed as increase in acetylated histone H3 expression level measured after 24 hrs by Western blot analysis	2020	Journal of medicinal chemistry, 04-09, Volume: 63, Issue:7	Discovery of Thieno[2,3-
AID1653143	Cytotoxicity against human PC3 cells assessed as reduction in cell viability	2019	European journal of medicinal chemistry, Mar-01, Volume: 165	Quinolone hybrids and their anti-cancer activities: An overview.
AID481554	Cytotoxicity against human KB cells assessed as growth inhibition at 10 ug/ml after 24 hrs by MTT assay	2010	Bioorganic & medicinal chemistry letters, May-15, Volume: 20, Issue:10	Synthesis and anticancer evaluation of alpha-lipoic acid derivatives.
AID1380954	Inhibition of HDAC3 (unknown origin) using fluorogenic Boc-Lys(acetyl)-AMC as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by fluorescence-based assay	2018	Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12	Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously.
AID1383988	Inhibition of HDAC8 (unknown origin) using Boc-Lys(trifluoroacetyl)-AMC as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by fluorescence assay	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	Discovery of meta-sulfamoyl N-hydroxybenzamides as HDAC8 selective inhibitors.
AID1410014	Selectivity index, ratio of CC50 for human U937 cells to EC50 for reactivation of latent HIV1 infected in human U1 cells	2018	ACS medicinal chemistry letters, Mar-08, Volume: 9, Issue:3	Elimination of HIV-1 Latently Infected Cells by Gnidimacrin and a Selective HDAC Inhibitor.
AID1337293	Therapeutic index, ratio of IC50 for mouse TAMH cells to IC50 for human cancer cells	2016	Journal of medicinal chemistry, Sep-22, Volume: 59, Issue:18	Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines.
AID1848583	Inhibition of full length C-terminal his6-tagged human recombinant HDAC2 (1 to 488 residues)	2022	Journal of medicinal chemistry, 11-10, Volume: 65, Issue:21	First-in-Class Dual Mechanism Ferroptosis-HDAC Inhibitor Hybrids.
AID1702067	Inhibition of recombinant human full length C-terminal His-tagged HDAC8 expressed in baculovirus infected Sf9 cells using fluorogenic HDAC class2a as substrate measured after 30 mins by fluorescence based assay	2018	Journal of medicinal chemistry, 02-22, Volume: 61, Issue:4	Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma.
AID1415668	Induction of apoptosis in human HepG2 cells assessed as increase in cleaved PARP expression at 5 uM after 48 hrs by Western blot analysis	2017	MedChemComm, Jun-01, Volume: 8, Issue:6	Development of novel β-carboline-based hydroxamate derivatives as HDAC inhibitors with DNA damage and apoptosis inducing abilities.
AID446345	Clearance in CD1 mouse at 15 mg/kg, po	2010	Journal of medicinal chemistry, Jan-28, Volume: 53, Issue:2	Synthesis and biological evaluation of N-hydroxyphenylacrylamides and N-hydroxypyridin-2-ylacrylamides as novel histone deacetylase inhibitors.
AID1415646	Inhibition of HDAC1 in human HepG2 cells assessed as increase in acetylated-histone H3 level at 5 uM after 48 hrs by Western blot analysis	2017	MedChemComm, Jun-01, Volume: 8, Issue:6	Development of novel β-carboline-based hydroxamate derivatives as HDAC inhibitors with DNA damage and apoptosis inducing abilities.
AID1433291	Induction of apoptosis in p53 null human U937 cells at 2 uM preincubated with NAC for 3 hrs followed by compound addition measured after 24 hrs by annexin V-FITC/PI staining based flow cytometry	2016	Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17	Synthesis and Antileukemic Activities of Piperlongumine and HDAC Inhibitor Hybrids against Acute Myeloid Leukemia Cells.
AID1821965	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay
AID1890332	Stability in mouse liver microsomes assessed as half-life and measured by LC-MS/MS analysis	2022	European journal of medicinal chemistry, Apr-05, Volume: 233	Novel biphenyl-based scaffold as potent and selective histone deacetylase 6 (HDAC6) inhibitors: Identification, development and pharmacological evaluation.
AID780580	Inhibition of Topoisomerase 2 (unknown origin) assessed as impairment of pBR322 DNA decatenation at 100 uM after 30 mins by agarose gel electrophoresis	2013	Bioorganic & medicinal chemistry, Nov-15, Volume: 21, Issue:22	The discovery and optimization of novel dual inhibitors of topoisomerase II and histone deacetylase.
AID1487042	Inhibition of HDAC in human HeLa-S3 cells lysates assessed as remaining enzyme activity at 5 x 10'-8 M pre-incubated for 15 mins before HDAC-Glo I/II substrate addition and measured after 30 mins post substrate addition	2017	Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15	The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity.
AID384316	Inhibition of maize histone deacetylase 1B	2008	European journal of medicinal chemistry, Mar, Volume: 43, Issue:3	Class II-selective histone deacetylase inhibitors. Part 2: alignment-independent GRIND 3-D QSAR, homology and docking studies.
AID90682	Inhibition of in vitro enzyme activity measured in a highly purified maize Histone deacetylase 2 preparation	2002	Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15	Structure-activity relationships on phenylalanine-containing inhibitors of histone deacetylase: in vitro enzyme inhibition, induction of differentiation, and inhibition of proliferation in Friend leukemic cells.
AID1240549	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay	2015	Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17	Design, synthesis and biological evaluation of saccharin-based N-hydroxybenzamides as histone deacetylases (HDACs) inhibitors.
AID1487046	Inhibition of HDAC3 (unknown origin) assessed as remaining enzyme activity at 1 uM by ELISA-based assay	2017	Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15	The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity.
AID1326518	Inhibition of HDAC in human HCT116 cells assessed as increase in amount of acetylated histone H3 at 0.3 uM after 48 hrs by Western blot analysis	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	2-(Phenylsulfonyl)quinoline N-hydroxyacrylamides as potent anticancer agents inhibiting histone deacetylase.
AID1312876	Antitumor activity against human MV4-11 cells xenografted in NOD/SCID mouse assessed as change in tumor mass at 50 mg/kg, ip administered every 2 days for 11 days measured every 2 days of compound dosing relative to control	2016	Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11	Development of Purine-Based Hydroxamic Acid Derivatives: Potent Histone Deacetylase Inhibitors with Marked in Vitro and in Vivo Antitumor Activities.
AID1783062	Antifungal activity against fluconazole-resistant Candida tropicalis 5008 assessed as inhibition of fungal growth incubated for 48 hrs by two-fold serial microdilution method	2021	European journal of medicinal chemistry, Oct-05, Volume: 221	Lanosterol 14α-demethylase (CYP51)/histone deacetylase (HDAC) dual inhibitors for treatment of Candida tropicalis and Cryptococcus neoformans infections.
AID1898953	Induction of cell cycle arrest in human NCI-H460 cells assessed as accumulation of cells at S phase at 4.2 uM after 72 hrs by flow cytometry (Rvb = 32.1%)	2022	European journal of medicinal chemistry, Jan-15, Volume: 228	Antitumor activity of novel POLA1-HDAC11 dual inhibitors.
AID541653	Inhibition of human HDAC10 by fluorimetric assay	2010	Journal of medicinal chemistry, Dec-09, Volume: 53, Issue:23	Non-natural macrocyclic inhibitors of histone deacetylases: design, synthesis, and activity.
AID476832	Toxicity in FVB mouse assessed as effect on number of WBC at 50 mg/kg, po administered 5 times per week for 2 weeks (Rvb = 9.1 +/- 0.2 10^3/mm^3)	2010	Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8	Modified cap group suberoylanilide hydroxamic acid histone deacetylase inhibitor derivatives reveal improved selective antileukemic activity.
AID1548268	Induction of cell cycle arrest in human KM3 cells assessed as reduction in cell cycle progression in G2/M phase at 100 nM incubated for 24 hrs by propidium iodide staining based flow cytometry
AID1578505	Induction of apoptosis in human MV4-11 cells assessed as early apoptotic cells at 4 uM incubated for 18 hrs by annexin V FITC and PI based flow cytometry (Rvb = 19.46 to 22.17 %)	2020	ACS medicinal chemistry letters, Jan-09, Volume: 11, Issue:1	Class I/IIb-Selective HDAC Inhibitor Exhibits Oral Bioavailability and Therapeutic Efficacy in Acute Myeloid Leukemia.
AID1861653	Inhibition of HDAC1 (unknown origin)	2022	Bioorganic & medicinal chemistry letters, 09-15, Volume: 72	Exploration of 4-(1H-indol-3-yl)cyclohex-3-en-1-amine analogues as HDAC inhibitors: Design, synthesis, biological evaluation and modelling studies.
AID1422514	Inhibition of HDAC in MEF assessed as increase in histone H3K18 acetylation at 2 uM after 6 hrs by Western blot analysis	2018	European journal of medicinal chemistry, Nov-05, Volume: 159	In search of constrained FTY720 and phytosphingosine analogs as dual acting anticancer agents targeting metabolic and epigenetic pathways.
AID1431817	Selectivity ratio of IC50 for human KDAC3 to IC50 for human KDAC6	2017	European journal of medicinal chemistry, Feb-15, Volume: 127	Design and synthesis of benzodiazepine analogs as isoform-selective human lysine deacetylase inhibitors.
AID274099	Effect of compound on Candida albicans sensitivity to Fluconazole: Minimum inhibitory concentration required to inhibit the growth of 50% of isolates after 48h.	2007	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 17, Issue:5	Discovery of uracil-based histone deacetylase inhibitors able to reduce acquired antifungal resistance and trailing growth in Candida albicans.
AID1497923	Induction of CRBN ubiquitin ligase-mediated HDAC6 degradation in human MCF7 cells assessed as decrease in HDAC6 levels at 10 uM after 12 hrs by immunoblotting analysis	2018	Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14	Development of the first small molecule histone deacetylase 6 (HDAC6) degraders.
AID1200973	Inhibition of HDAC8 (unknown origin) using RHK(Ac)K(Ac)AMC as substrate	2015	Journal of medicinal chemistry, Mar-26, Volume: 58, Issue:6	Design and synthesis of orally bioavailable aminopyrrolidinone histone deacetylase 6 inhibitors.
AID1848594	Induction of cell cycle arrest in human NCI-H522 cells assessed as accumulation at G2/M phase 5 uM incubated for 24 to 72 hrs by PI staining based flow cytometric analysis	2022	Journal of medicinal chemistry, 11-10, Volume: 65, Issue:21	First-in-Class Dual Mechanism Ferroptosis-HDAC Inhibitor Hybrids.
AID1383989	Antiproliferative activity against human Jurkat cells after 48 hrs by MTT assay	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	Discovery of meta-sulfamoyl N-hydroxybenzamides as HDAC8 selective inhibitors.
AID1751984	Inhibition of HDAC1 (unknown origin)	2021	Bioorganic & medicinal chemistry letters, 10-01, Volume: 49	Discovery of novel pyrazolopyrimidine derivatives as potent mTOR/HDAC bi-functional inhibitors via pharmacophore-merging strategy.
AID1826650	Antitumor activity against HEL cells xenografted in BALB/C mouse assessed as tumor growth inhibition at 10 mg/kg, po qd for 14 days consecutively by caliper method relative to control	2022	Journal of medicinal chemistry, 03-24, Volume: 65, Issue:6	Evodiamine-Inspired Topoisomerase-Histone Deacetylase Dual Inhibitors: Novel Orally Active Antitumor Agents for Leukemia Therapy.
AID1203896	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth after 72 hrs by MTT-based assay	2015	European journal of medicinal chemistry, , Volume: 96	Discovery and preliminary evaluation of 2-aminobenzamide and hydroxamate derivatives containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors.
AID1816212	Induction of apoptosis in human MDA-MB-231 cells assessed as viable cells at 2.5 uM measured after 48 hrs in presence of ruxolitinib by annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 85.7%)
AID663391	Growth inhibition of human SN12C cells after 72 hrs by MTS assay	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Discovery and extensive in vitro evaluations of NK-HDAC-1: a chiral histone deacetylase inhibitor as a promising lead.
AID1282240	Inhibition of recombinant HDAC4 (unknown origin) using AMC labeled AC-peptide as substrate incubated for 1 hr by fluorescence analysis	2016	Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4	Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
AID1597930	Inhibition of HDAC in human HeLa cell nuclear extracts at 1 uM	2019	Bioorganic & medicinal chemistry letters, 09-15, Volume: 29, Issue:18	Anti-tumor activity evaluation of novel tubulin and HDAC dual-targeting inhibitors.
AID1515914	Antiproliferative activity against human HepG2 cells after 96 hrs by MTT assay	2019	Journal of medicinal chemistry, 08-08, Volume: 62, Issue:15	Design, Synthesis, and Biological Evaluation of 4-Methyl Quinazoline Derivatives as Anticancer Agents Simultaneously Targeting Phosphoinositide 3-Kinases and Histone Deacetylases.
AID304373	Inhibition of HDAC	2007	Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26	Dual inhibitors of inosine monophosphate dehydrogenase and histone deacetylases for cancer treatment.
AID1441662	Anti-inflammatory activity in LPS-induced C57BL/6 mouse model of acute lung injury assessed as reduction in IL-1beta mRNA level at 25 mg/kg, ip pretreated for 1 hr followed LPS challenge after 24 hrs by qRT-PCR method	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
AID1547300	Inhibition of HDAC in human HCT116 cells assessed as induction of autophagy at marginal level by measuring LC3-I cleavage to LC3-II at 10 uM measured after 24 hrs by Western blot analysis	2020	Journal of medicinal chemistry, 04-09, Volume: 63, Issue:7	Discovery of Thieno[2,3-
AID1550084	Antiproliferative activity against human K562 cells assessed as reduction in cell viability after 48 hrs by MTT assay	2019	Journal of medicinal chemistry, 04-25, Volume: 62, Issue:8	Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies.
AID411259	Cytotoxicity against human NCI-H69 cells after 72 hrs by trypan blue exclusion assay	2009	Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2	Non-peptide macrocyclic histone deacetylase inhibitors.
AID1614131	Inhibition of recombinant full length N-terminal FLAG-tagged human HDAC10 expressed in baculovirus infected sf9 cells using Ac-peptide-AMC as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by fluorescence assay
AID1816206	Induction of apoptosis in human MDA-MB-231 cells assessed as early apoptotic cells at 2.5 uM measured after 48 hrs by annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 3.09%)
AID1384230	Inhibition of class-1 HDAC in human SH-SY5Y cells assessed as induction of AcH3K9 level at 500 nM after 2 hrs by Western blot analysis relative to control	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease.
AID1599728	Cytotoxicity against human Meso163 cells assessed as decrease in cell viability measured after 72 hrs by CellTiter-Glo Luminescent assay	2019	ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6	Extending Cross Metathesis To Identify Selective HDAC Inhibitors: Synthesis, Biological Activities, and Modeling.
AID1702199	Toxicity in Ncr nude mouse xenografted with human HepG2 cells assessed as animal survival at 60 mg/kg, po QD with 5 days on and 2 days off dosing schedule for 2 weeks cotreated with 75 mg/kg pictilisib and measured at day 12	2018	Journal of medicinal chemistry, 02-22, Volume: 61, Issue:4	Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma.
AID1436790	Growth inhibition of human NCI-H292 cells in FBS containing medium after 72 hrs using compound after sonication in presence of LDL by MTT assay	2017	Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4	Synthesis of Vorinostat and cholesterol conjugate to enhance the cancer cell uptake selectivity.
AID1855261	Induction of apoptosis in human HCT-116 cells assessed as early apoptotic cells at 1.5 uM incubated for 48 hrs by PI and annexin V-FITC staining based flow cytometry (Rvb = 3.4%)	2022	European journal of medicinal chemistry, Nov-05, Volume: 241	Discovery of 2,5-diphenyl-1,3,4-thiadiazole derivatives as HDAC inhibitors with DNA binding affinity.
AID1742719	Induction of apoptosis in mouse 4T1 cells assessed as viable cells at 5 uM incubated for 72 hrs by annexinV-FITC and PI staining based flow cytometry analysis (Rvb = 91.1 %)	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Design and synthesis of novel Flavone-based histone deacetylase inhibitors antagonizing activation of STAT3 in breast cancer.
AID496801	Inhibition of human HDAC1	2010	Nature chemical biology, Mar, Volume: 6, Issue:3	Chemical phylogenetics of histone deacetylases.
AID1126966	Selectivity ratio of IC50 for HDAC6 (unknown origin) to IC50 for HDAC1 (unknown origin)	2014	Journal of medicinal chemistry, Apr-24, Volume: 57, Issue:8	Discovery of the first N-hydroxycinnamamide-based histone deacetylase 1/3 dual inhibitors with potent oral antitumor activity.
AID1825927	Inhibition of recombinant human full length C-terminal His-tagged HDAC8 expressed in baculovirus-infected Sf9 insect cells using Ac-peptide as substrate incubated for 4 hrs followed by trypsin addition and further incubated for 2 hrs
AID761585	Inhibition of HDAC in human HeLa cell extract using fluor de Lys as substrate at 1 uM after 15 mins by fluorometric analysis	2013	European journal of medicinal chemistry, Aug, Volume: 66	Design, synthesis and preliminary evaluation of a series of histone deacetylase inhibitors carrying a benzodiazepine ring.
AID90351	Concentration required to inhibit human Histone deacetylase (HDAC) enzyme by 50%	2002	Journal of medicinal chemistry, Feb-14, Volume: 45, Issue:4	Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates.
AID1164178	Cell cycle arrest in human U937 cells assessed as block at G1 phase at 5 uM after 24 to 96 hrs using propidium iodide staining by FACScan flow cytometry	2014	ACS medicinal chemistry letters, Sep-11, Volume: 5, Issue:9	Novel antiproliferative chimeric compounds with marked histone deacetylase inhibitory activity.
AID1399809	Clearance in human hepatocytes assessed per million cells at 1 uM after 5 to 90 mins by LC-MS/MS analysis	2018	Bioorganic & medicinal chemistry letters, 09-15, Volume: 28, Issue:17	Squaramides as novel class I and IIB histone deacetylase inhibitors for topical treatment of cutaneous t-cell lymphoma.
AID374827	Antiproliferative activity against human P53 expressing A549 cells after 72 hrs by celltiter-blue cell viability assay	2009	Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11	Discovery of a potent class I selective ketone histone deacetylase inhibitor with antitumor activity in vivo and optimized pharmacokinetic properties.
AID274063	Half life after i.v. dosing at 1 mg kg-1	2007	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2	Identification and optimisation of a series of substituted 5-(1H-pyrazol-3-yl)-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.
AID404449	Antimalarial activity against Plasmodium falciparum W2 by hypoxanthine uptake	2008	Journal of medicinal chemistry, Jun-26, Volume: 51, Issue:12	A series of potent and selective, triazolylphenyl-based histone deacetylases inhibitors with activity against pancreatic cancer cells and Plasmodium falciparum.
AID255818	Inhibitory concentration against Histone deacetylase 1B in maize	2005	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 15, Issue:21	Exploring the connection unit in the HDAC inhibitor pharmacophore model: novel uracil-based hydroxamates.
AID1543929	Inhibition of HDAC1 (unknown origin) using Boc-Lys (Ac)-AMC as substrate incubated for 60 mins and measured after 30 mins by fluorescence assay	2019	European journal of medicinal chemistry, Apr-15, Volume: 168	β-Carboline and N-hydroxycinnamamide hybrids as anticancer agents for drug-resistant hepatocellular carcinoma.
AID525021	Inhibition of HDAC in human CFBE41o- cell line assessed as total CFTR protein level including CFTR glycoform at 5 uM by immunoblot analysis	2010	Nature chemical biology, Jan, Volume: 6, Issue:1	Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.
AID1487045	Inhibition of HDAC2 (unknown origin) assessed as remaining enzyme activity at 1 uM by ELISA-based assay	2017	Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15	The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity.
AID1127007	Induction of apoptosis in human U937 cells assessed as necrotic cells using annexin-V/propidium iodide staining at 0.125 uM after 24 hrs by flow cytometry analysis (Rvb = 0.06%)	2014	Journal of medicinal chemistry, Apr-24, Volume: 57, Issue:8	Discovery of the first N-hydroxycinnamamide-based histone deacetylase 1/3 dual inhibitors with potent oral antitumor activity.
AID1821345	Toxicity in mouse xenografted with human HepG2 cells assessed as kidney edema at 12 mg/kg, ip administered every 2 days for 4 weeks by H and E staining based microscopic method	2022	European journal of medicinal chemistry, Feb-05, Volume: 229	Discovery of phthalazino[1,2-b]-quinazolinone derivatives as multi-target HDAC inhibitors for the treatment of hepatocellular carcinoma via activating the p53 signal pathway.
AID748114	Inhibition of HDAC1 (unknown origin) after 60 mins by fluorescence assay	2013	Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11	Discovery of the first histone deacetylase 6/8 dual inhibitors.
AID1901229	Half life in human liver microsomes by LC-MS/MS analysis	2022	Bioorganic & medicinal chemistry, 02-15, Volume: 56	Synthesis and biological evaluation of aminobenzamides containing purine moiety as class I histone deacetylases inhibitors.
AID473191	Growth inhibition of human BJ cells after 48 hrs by MTT assay	2010	Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5	Biological and biophysical properties of the histone deacetylase inhibitor suberoylanilide hydroxamic acid are affected by the presence of short alkyl groups on the phenyl ring.
AID1503585	Inhibition of C-terminal His-tagged human recombinant full-length HDAC8 expressed in baculovirus expression system assessed as reduction in 7-amino-4-methylcoumarin by fluorescence based assay	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Serendipitous discovery of potent human head and neck squamous cell carcinoma anti-cancer molecules: A fortunate failure of a rational molecular design.
AID637888	Inhibition of recombinant human HDAC1 using Boc-L-Lys(acetyl)-MCA as substrate by fluorogenic enzymatic assay	2012	Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2	Synthesis and biochemical analysis of 2,2,3,3,4,4,5,5,6,6,7,7-dodecafluoro-N-hydroxy-octanediamides as inhibitors of human histone deacetylases.
AID1234893	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	2015	Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15	Design, synthesis and preliminary biological evaluation of indoline-2,3-dione derivatives as novel HDAC inhibitors.
AID1543930	Antiproliferative activity against human SMMC7721 cells incubated for 48 hrs by MTT assay	2019	European journal of medicinal chemistry, Apr-15, Volume: 168	β-Carboline and N-hydroxycinnamamide hybrids as anticancer agents for drug-resistant hepatocellular carcinoma.
AID1887681	Cytotoxicity against human GES1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	Design, synthesis and biological evaluation of novel o-aminobenzamide derivatives as potential anti-gastric cancer agents in vitro and in vivo.
AID1550325	Synergistic antiproliferative activity against HEL cells harboring JAK2 V617F mutant assessed as combination index after 48 hrs in presence of ruxolitinib by MTT assay	2019	Journal of medicinal chemistry, 04-25, Volume: 62, Issue:8	Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies.
AID1848601	Cytotoxicity against human NCI-H23 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay	2022	Journal of medicinal chemistry, 11-10, Volume: 65, Issue:21	First-in-Class Dual Mechanism Ferroptosis-HDAC Inhibitor Hybrids.
AID1502981	Antiproliferative activity against human MGC803 cells incubated for 72 hrs by MTT assay	2017	European journal of medicinal chemistry, Nov-10, Volume: 140	Design and synthesis of tranylcypromine derivatives as novel LSD1/HDACs dual inhibitors for cancer treatment.
AID1702058	Antiproliferative activity against human PC-3 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter-Glo luminescent assay	2018	Journal of medicinal chemistry, 02-22, Volume: 61, Issue:4	Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma.
AID1885672	Synergistic antiproliferative activity against human HFL1 cells at 2.5 to 12.5 uM measured after 72 hrs in presence of CDDO-Me by MTT assay	2022	Journal of medicinal chemistry, 08-11, Volume: 65, Issue:15	Redox-Activatable Theranostic Co-Prodrug for Precise Tumor Diagnosis and Selective Combination Chemotherapy.
AID473190	Growth inhibition of human MUF cells at 0.05 to 100 uM after 48 hrs by MTT assay	2010	Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5	Biological and biophysical properties of the histone deacetylase inhibitor suberoylanilide hydroxamic acid are affected by the presence of short alkyl groups on the phenyl ring.
AID618087	Toxicity in athymic nu/nu Harlan mouse xenografted with human HCT116 cells assessed as body weight loss at 200 mg/kg, po QD for 21 days measured on day 8	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile.
AID246081	Effective Concentration of compound to inhibit the growth of human NCI-H226 cells	2005	Journal of medicinal chemistry, Feb-24, Volume: 48, Issue:4	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates.
AID1469491	Antitumor activity against mouse Fluc-labeled 4T1 cells implanted in Balb/c mouse assessed as reduction in tumor weight at 130 mg/kg, ip administered daily for 18 days measured after 8 to 25 days	2018	Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7	Discovery of N1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7 H-pyrrolo[2,3- d]pyrimidin-2-yl)amino)phenyl)- N8-hydroxyoctanediamide as a Novel Inhibitor Targeting Cyclin-dependent Kinase 4/9 (CDK4/9) and Histone Deacetlyase1 (HDAC1) against Malignant Cancer
AID1421902	Antiplasmodial activity against drug-sensitive asexual ring stage Plasmodium falciparum 3D7 infected in human erythrocytes by [3H]-hypoxanthine incorporation assay	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	One-pot, multi-component synthesis and structure-activity relationships of peptoid-based histone deacetylase (HDAC) inhibitors targeting malaria parasites.
AID732874	Inhibition of HDAC6 (unknown origin) using Boc-Lys(acetyl)-AMC as substrate preincubated with enzyme for 5 mins prior to substrate addition measured after 30 mins by fluorescence assay	2013	ACS medicinal chemistry letters, Feb-14, Volume: 4, Issue:2	Development of
AID1293562	Antiproliferative activity human HCT116 cells assessed as reduction in cell number after 72 hrs by cell counter analysis	2016	European journal of medicinal chemistry, Apr-13, Volume: 112	Biphenyl-4-yl-acrylohydroxamic acids: Identification of a novel indolyl-substituted HDAC inhibitor with antitumor activity.
AID1459948	Antiproliferative activity against human PC3 cells measured after 48 hrs by sulforhodamine-B assay	2017	European journal of medicinal chemistry, Jan-05, Volume: 125	3-Aroylindoles display antitumor activity in vitro and in vivo: Effects of N1-substituents on biological activity.
AID1549141	Antifungal activity against azole-sensitive Cryptococcus neoformans H99 after 72 hrs by spectrophotometry-based serial microdilution method	2020	Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10	Discovery of Novel Fungal Lanosterol 14α-Demethylase (CYP51)/Histone Deacetylase Dual Inhibitors to Treat Azole-Resistant Candidiasis.
AID1481749	Antiproliferative activity against human Raji cells after 72 hrs by MTT assay	2017	Bioorganic & medicinal chemistry letters, 05-01, Volume: 27, Issue:9	Design and synthesis of novel 6-aryl substituted 4-anilinequinazoline derivatives as potential PI3Kδ inhibitors.
AID1901171	Inhibition of HDAC1/HDAC2/HDAC3 in human HCT-116 cells assessed as increase in accumulation of acetylated H3K9 at 5 uM preincubated for 6 hrs followed by compound washout and measured after 12 hrs by Western blot analysis	2022	Bioorganic & medicinal chemistry, 02-15, Volume: 56	Synthesis and biological evaluation of aminobenzamides containing purine moiety as class I histone deacetylases inhibitors.
AID1511969	Selectivity index, ratio of IC50 for full length recombinant FLAG/His-tagged C-terminal human HDAC1 expressed in baculovirus infected Sf9 insect cells to IC50 for full length recombinant GST-tagged N-terminal human HDAC6 expressed in baculovirus infected	2019	ACS medicinal chemistry letters, Sep-12, Volume: 10, Issue:9	Fluorinated Analogues of the Histone Deacetylase Inhibitor Vorinostat (Zolinza): Validation of a Chiral Hybrid Bioisostere, BITE.
AID1848301	Induction of apoptosis in human MV4-11 cells assessed as viable cells at 1 uM incubated for 48 hrs by Annexin V-FITC/PI staining based flow cytometry (Rvb = 96.5%)	2022	Bioorganic & medicinal chemistry, Nov-15, Volume: 74	Design, synthesis and biological evaluation of novel pyrazinone derivatives as PI3K/HDAC dual inhibitors.
AID632973	Cytotoxicity against human PC3 cells	2011	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 21, Issue:24	Benzothiazole-containing hydroxamic acids as histone deacetylase inhibitors and antitumor agents.
AID1702062	Inhibition of recombinant human C-terminal His-tagged HDAC3 (1 to 428 end residues)/N-terminal GST-tagged recombinant human NCoR2 (395 to 489 residues) expressed in baculovirus infected Sf9 cells using fluorogenic HDAC substrate 3 measured after 30 mins b	2018	Journal of medicinal chemistry, 02-22, Volume: 61, Issue:4	Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma.
AID1848624	Cytotoxicity against human KM12 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay	2022	Journal of medicinal chemistry, 11-10, Volume: 65, Issue:21	First-in-Class Dual Mechanism Ferroptosis-HDAC Inhibitor Hybrids.
AID1888416	Inhibition of fungal filamentation in azole-resistant Candida albicans 0304103 assessed as reduction in yeast-hypha transition at 64 ug/ml by inverted microscopic analysis	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	Heat shock protein 90 (Hsp90)/Histone deacetylase (HDAC) dual inhibitors for the treatment of azoles-resistant Candida albicans.
AID1127008	Induction of apoptosis in human U937 cells assessed as viable cells using annexin-V/propidium iodide staining at 0.125 uM after 24 hrs by flow cytometry analysis (Rvb = 96.24%)	2014	Journal of medicinal chemistry, Apr-24, Volume: 57, Issue:8	Discovery of the first N-hydroxycinnamamide-based histone deacetylase 1/3 dual inhibitors with potent oral antitumor activity.
AID1614127	Inhibition of recombinant full length human HDAC2 expressed in baculovirus expression system using Ac-peptide-AMC as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by fluorescence assay
AID1312869	Inhibition of HDAC1/2/3 in human A2780S cells assessed as histone H3 acetylation incubated for 6 hrs by cytoblot assay	2016	Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11	Development of Purine-Based Hydroxamic Acid Derivatives: Potent Histone Deacetylase Inhibitors with Marked in Vitro and in Vivo Antitumor Activities.
AID1389951	Cytotoxic activity against human MCF7 cells assessed as reduction in cell viability at 4 uM after 24 hrs by MTT assay relative to control	2018	Bioorganic & medicinal chemistry letters, 04-01, Volume: 28, Issue:6	Novel polyamine-based Histone deacetylases-Lysine demethylase 1 dual binding inhibitors.
AID347868	Growth inhibition of human Colon cancer cells at 10 uM relative to control	2008	Journal of medicinal chemistry, Dec-11, Volume: 51, Issue:23	Histone deacetylase inhibitors through click chemistry.
AID1732193	Cytotoxicity against human KG-1 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	2021	European journal of medicinal chemistry, Apr-05, Volume: 215	CAP rigidification of MS-275 and chidamide leads to enhanced antiproliferative effects mediated through HDAC1, 2 and tubulin polymerization inhibition.
AID1873383	Inhibition of HDAC3 (unknown origin)	2022	Bioorganic & medicinal chemistry letters, 08-15, Volume: 70	Comparison of three zinc binding groups for HDAC inhibitors - A potency, selectivity and enzymatic kinetics study.
AID761582	Inhibition of full length His-tagged human recombinant HDAC6 expressed in baculovirus system using fluor de Lys as substrate by fluorometric analysis	2013	European journal of medicinal chemistry, Aug, Volume: 66	Design, synthesis and preliminary evaluation of a series of histone deacetylase inhibitors carrying a benzodiazepine ring.
AID208381	Concentration required to reassume their usual morphology of T/5 cells	1995	Journal of medicinal chemistry, Apr-14, Volume: 38, Issue:8	The synthesis of N-hydroxy-N'-phenyloctanediamide and its inhibitory effect on proliferation of AXC rat prostate cancer cells.
AID1476146	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay	2017	Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20	Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat.
AID1547350	Antitumor activity against human HCT116 cells xenografted in BALB/cAnNCrl mouse assessed as tumor growth inhibition at 30 mg/kg, po administered on day 1 to day 19	2020	Journal of medicinal chemistry, 04-09, Volume: 63, Issue:7	Discovery of Thieno[2,3-
AID1401376	Inhibition of human recombinant full-length C-terminal His-tagged HDAC8 expressed in baculovirus infected Sf9 insect cell preincubated for 15 mins followed by HDAC-Glo substrate addition measured after 30 mins by fluorimetric method	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
AID297482	Cytotoxicity against human SKBR3 cells	2007	Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18	2-aroylindoles and 2-aroylbenzofurans with N-hydroxyacrylamide substructures as a novel series of rationally designed histone deacetylase inhibitors.
AID1518783	Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay	2019	European journal of medicinal chemistry, Dec-15, Volume: 184	Discovery of a potent histone deacetylase (HDAC) 3/6 selective dual inhibitor.
AID347875	Growth inhibition of human CNS cancer cells at 10 uM relative to control	2008	Journal of medicinal chemistry, Dec-11, Volume: 51, Issue:23	Histone deacetylase inhibitors through click chemistry.
AID1361651	Induction of apoptosis in human A549 cells assessed as viable cells at 5 uM after 48 hrs by FITC-Annexin V/propidium iodide staining based flow cytometric analysis (Rvb = 93.01%)	2018	Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16	Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents.
AID1515913	Antiproliferative activity against human HGC27 cells after 96 hrs by MTT assay	2019	Journal of medicinal chemistry, 08-08, Volume: 62, Issue:15	Design, Synthesis, and Biological Evaluation of 4-Methyl Quinazoline Derivatives as Anticancer Agents Simultaneously Targeting Phosphoinositide 3-Kinases and Histone Deacetylases.
AID1545842	Antiproliferative activity against human A549 cells by MTT assay	2019	European journal of medicinal chemistry, Dec-01, Volume: 183	1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships.
AID297472	Inhibition of HDAC in HeLa cells assessed as induction of human histone H3 hyperacetylation	2007	Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18	2-aroylindoles and 2-aroylbenzofurans with N-hydroxyacrylamide substructures as a novel series of rationally designed histone deacetylase inhibitors.
AID1861305	Induction of cell cycle arrest in human DOHH-2 cells assessed as accumulation at S phase measured by flow cytometry analysis	2022	Bioorganic & medicinal chemistry letters, 09-01, Volume: 71	Bioevaluation of a dual PI3K/HDAC inhibitor for the treatment of diffuse large B-cell lymphoma.
AID1550324	Synergistic antiproliferative activity against HEL cells harboring JAK2 V617F mutant assessed as reduction in cell viability after 48 hrs in presence of ruxolitinib by MTT assay	2019	Journal of medicinal chemistry, 04-25, Volume: 62, Issue:8	Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies.
AID527043	Cytotoxicity against human NCI-H522 by SRB assay	2010	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22	Selenium-containing analogs of SAHA induce cytotoxicity in lung cancer cells.
AID1901174	Inhibition of HDAC1/HDAC2/HDAC3 in human HCT-116 cells assessed as increase in accumulation of acetylated H4K5 at 5 uM treated for 48 hrs by Western blot analysis	2022	Bioorganic & medicinal chemistry, 02-15, Volume: 56	Synthesis and biological evaluation of aminobenzamides containing purine moiety as class I histone deacetylases inhibitors.
AID1816966	Cytotoxicity against human CEM cells assessed as cell death incubated for 20 hrs measured by DNS assay	2021	Journal of medicinal chemistry, 05-27, Volume: 64, Issue:10	Thiazolidinedione "Magic Bullets" Simultaneously Targeting PPARγ and HDACs: Design, Synthesis, and Investigations of their
AID1864216	Inhibition of HDAC in human HeLa nuclear extract incubated for 30 mins by fluorescence-based Glo-luminescence assay	2022	Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18	Discovery of a Novel G-Quadruplex and Histone Deacetylase (HDAC) Dual-Targeting Agent for the Treatment of Triple-Negative Breast Cancer.
AID1689773	Inhibition of human recombinant HDAC1 at 10 uM preincubated for 10 mins followed by addition of substrate fluor De Lys SIRT1 deacetylase measured after 30 mins by fluorescent plate reader analysis relative to control	2020	European journal of medicinal chemistry, Mar-01, Volume: 189	Discovery of novel cyclin-dependent kinase (CDK) and histone deacetylase (HDAC) dual inhibitors with potent in vitro and in vivo anticancer activity.
AID1164902	Inhibition of HDAC6 in human A549 cells assessed as tubulin acetylation after 17 to 18 hrs by cytoblot assay	2014	Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19	Identification of a novel aminotetralin class of HDAC6 and HDAC8 selective inhibitors.
AID1482120	Cytotoxicity against human MIAPaCa2 cells assessed as growth inhibition after 48 hrs by MTT assay	2017	Journal of medicinal chemistry, 04-27, Volume: 60, Issue:8	Exploring Derivatives of Quinazoline Alkaloid l-Vasicine as Cap Groups in the Design and Biological Mechanistic Evaluation of Novel Antitumor Histone Deacetylase Inhibitors.
AID1707507	Inhibition of human HDAC1 pre-incubated for 5 mins before substrate addition and measured after 30 mins by fluorescence based assay	2021	Journal of medicinal chemistry, 01-28, Volume: 64, Issue:2	Novel Carboline Fungal Histone Deacetylase (HDAC) Inhibitors for Combinational Treatment of Azole-Resistant Candidiasis.
AID1816200	Antiproliferative activity against human BT-549 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay
AID605538	Antiproliferative activity against doxorubicin-resistant human COR-L23 cells after 72 hrs by WST-1 assay	2010	Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24	Discovery of 2-(6-{[(6-fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a class I selective orally active histone deacetylase inhibitor.
AID1355706	Antifungal activity against FLC resistant Candida albicans 0304103 assessed as fluconazol MIC50 after 48 hrs by checkerboard microdilution method	2018	Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14	Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections.
AID1677515	Binding affinity to full length His-tagged Bcl2 (unknown origin) preincubated for 30 min followed by 5-FAM Bid-BH3 addition and measured after 20 mins by fluorescence polarization assay	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	HDAC-Bax Multiple Ligands Enhance Bax-Dependent Apoptosis in HeLa Cells.
AID1888590	Antiproliferative activity against human HepG2 cells measured after 72 hrs by MTT assay
AID1164906	Inhibition of HDAC1 (unknown origin) using fluorogenic peptide as substrate by fluorescence assay	2014	Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19	Identification of a novel aminotetralin class of HDAC6 and HDAC8 selective inhibitors.
AID1336944	Induction of cell cycle arrest in human LNCAP cells assessed as accumulation at lesser G1 phase at 2.5 uM after 24 hrs by propidium iodide staining based FACS analysis (Rvb = 1.59%)	2017	Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3	Bifunctional conjugates with potent inhibitory activity towards cyclooxygenase and histone deacetylase.
AID1742221	Half life in Beagle dog at 20 mg/kg, po by LC-MS/MS analysis	2020	European journal of medicinal chemistry, Nov-01, Volume: 205	Design, synthesis and biological evaluation of novel HDAC inhibitors with improved pharmacokinetic profile in breast cancer.
AID1901172	Inhibition of HDAC1/HDAC2/HDAC3 in human HCT-116 cells assessed as increase in accumulation of acetylated H4K5 at 5 uM preincubated for 6 hrs followed by compound washout and measured after 12 hrs by Western blot analysis	2022	Bioorganic & medicinal chemistry, 02-15, Volume: 56	Synthesis and biological evaluation of aminobenzamides containing purine moiety as class I histone deacetylases inhibitors.
AID732876	Inhibition of HDAC2 (unknown origin) using Boc-Lys(acetyl)-AMC as substrate preincubated with enzyme for 5 mins prior to substrate addition measured after 30 mins by fluorescence assay	2013	ACS medicinal chemistry letters, Feb-14, Volume: 4, Issue:2	Development of
AID1639365	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	2019	Bioorganic & medicinal chemistry, 04-15, Volume: 27, Issue:8	Design, synthesis and activity evaluation of indole-based double - Branched HDAC1 inhibitors.
AID1898906	Antiproliferative activity against human Z138 cells incubated for 24 hrs followed by incubating in drug-free medium for 48 hrs and measured by SRB assay	2022	European journal of medicinal chemistry, Jan-15, Volume: 228	Antitumor activity of novel POLA1-HDAC11 dual inhibitors.
AID1515911	Antiproliferative activity against human SW1990 cells after 96 hrs by MTT assay	2019	Journal of medicinal chemistry, 08-08, Volume: 62, Issue:15	Design, Synthesis, and Biological Evaluation of 4-Methyl Quinazoline Derivatives as Anticancer Agents Simultaneously Targeting Phosphoinositide 3-Kinases and Histone Deacetylases.
AID313734	Inhibition of HDAC6	2008	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2	Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2).
AID324949	Inhibition of HDAC3 in HEK293 cells	2008	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 18, Issue:6	Probing the elusive catalytic activity of vertebrate class IIa histone deacetylases.
AID717817	Inhibition of HDAC in human Hela cell lysate using Fluor-de-Lys as substrate assessed as remaining activity at 5 x 10'-7 M pretreated for 30 mins before substrate addition by fluorescence assay	2012	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23	The structural requirements of histone deacetylase inhibitors: suberoylanilide hydroxamic acid analogs modified at the C6 position.
AID1390025	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Structure optimization and preliminary bioactivity evaluation of N-hydroxybenzamide-based HDAC inhibitors with Y-shaped cap.
AID482957	Half life in rat liver microsome	2010	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11	Acylurea connected straight chain hydroxamates as novel histone deacetylase inhibitors: Synthesis, SAR, and in vivo antitumor activity.
AID1205630	Growth inhibition of human HCT15 cells after 5 days by sulforhodamine B assay	2015	Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8	Discovery of Orally Available Runt-Related Transcription Factor 3 (RUNX3) Modulators for Anticancer Chemotherapy by Epigenetic Activation and Protein Stabilization.
AID1467240	Inhibition of recombinant C-terminal His-tagged HDAC11 (unknown origin) expressed in baculovirus infected Sf9 cells at 2 uM using Ac-Arg-Gly-Lys(Ac)-AMC as substrate pretreated for 3 hrs followed by substrate addition measured after 30 mins by fluorometri	2017	Bioorganic & medicinal chemistry letters, 07-01, Volume: 27, Issue:13	Stabilizing HDAC11 with SAHA to assay slow-binding benzamide inhibitors.
AID1129779	Cell cycle arrest in human Jurkat cells assessed as accumulation at G2/M-phase at 10 uM after 12 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 10%)	2014	Bioorganic & medicinal chemistry, Apr-01, Volume: 22, Issue:7	Studies on the antiproliferative effects of tropolone derivatives in Jurkat T-lymphocyte cells.
AID476641	Antiproliferative activity against human SK-BR-3 cells after 48 hrs by cell titer-glo assay	2010	Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8	Modified cap group suberoylanilide hydroxamic acid histone deacetylase inhibitor derivatives reveal improved selective antileukemic activity.
AID525019	Inhibition of HDAC in human CFBE41o- cell line assessed as increase in CFTR protein level at 1 uM after 1 hr by immunoblot analysis	2010	Nature chemical biology, Jan, Volume: 6, Issue:1	Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.
AID1269319	Cytotoxicity against human A2780S cells assessed as cell growth at 25 uM measured at 72 hrs by CyQuant proliferation assay relative to control	2016	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2	Bromotyrosine-derived metabolites from an Indonesian marine sponge in the family Aplysinellidae (Order Verongiida).
AID1240548	Inhibition of HDAC1/2 in human HeLa cells nuclear extracts using acetylated histone peptide as substrate after 30 mins by Color de Lys assay	2015	Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17	Design, synthesis and biological evaluation of saccharin-based N-hydroxybenzamides as histone deacetylases (HDACs) inhibitors.
AID765198	Cytotoxicity against human MDA-MB-231 cells	2013	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17	Identification of novel HDAC inhibitors through cell based screening and their evaluation as potential anticancer agents.
AID1466065	Inhibition of HDAC in human PC3 cells assessed as increase in histone H3 acetylation at 1 uM after 24 hrs by Western blot analysis	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	4-Indolyl-N-hydroxyphenylacrylamides as potent HDAC class I and IIB inhibitors in vitro and in vivo.
AID1742657	Cytotoxicity against human B16-F10 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Design and synthesis of novel Flavone-based histone deacetylase inhibitors antagonizing activation of STAT3 in breast cancer.
AID663388	Growth inhibition of human A498 cells after 72 hrs by MTS assay	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Discovery and extensive in vitro evaluations of NK-HDAC-1: a chiral histone deacetylase inhibitor as a promising lead.
AID482966	Clearance in mouse at 10 mg/kg, iv	2010	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11	Acylurea connected straight chain hydroxamates as novel histone deacetylase inhibitors: Synthesis, SAR, and in vivo antitumor activity.
AID1141768	Cytotoxicity against human A549 cells by MTT assay	2014	Journal of medicinal chemistry, May-22, Volume: 57, Issue:10	Azaindolylsulfonamides, with a more selective inhibitory effect on histone deacetylase 6 activity, exhibit antitumor activity in colorectal cancer HCT116 cells.
AID1337288	Antiproliferative activity against human MOLM14 cells harboring FLT3-ITD mutant after 48 hrs by CellTiter-Glo assay	2016	Journal of medicinal chemistry, Sep-22, Volume: 59, Issue:18	Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines.
AID1730888	Inhibition of EGFR in human NCI-H1975 cells assessed as reduction in EGFR phosphorylation at Tyr-1068 residues at 1 uM after 48 hrs by Western blot analysis	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Design, synthesis and evaluation of novel ErbB/HDAC multitargeted inhibitors with selectivity in EGFR
AID1887685	Cytotoxicity against human MGC-803 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	Design, synthesis and biological evaluation of novel o-aminobenzamide derivatives as potential anti-gastric cancer agents in vitro and in vivo.
AID1141797	Selectivity ratio of IC50 for HDAC1 (unknown origin) to IC50 for HDAC6 (unknown origin)	2014	Journal of medicinal chemistry, May-22, Volume: 57, Issue:10	Azaindolylsulfonamides, with a more selective inhibitory effect on histone deacetylase 6 activity, exhibit antitumor activity in colorectal cancer HCT116 cells.
AID670513	Inhibition of EGFR derived from human A431 cell membrane assessed as inhibition of poly-Glu-Tyr phosphorylation after 30 mins by ELISA assay	2012	Bioorganic & medicinal chemistry, Jul-15, Volume: 20, Issue:14	Synthesis and biological evaluation of N-aryl salicylamides with a hydroxamic acid moiety at 5-position as novel HDAC-EGFR dual inhibitors.
AID1623533	Inhibition of human recombinant HDAC11 using fluorogenic HDAC substrate class 2A by fluorescence assay	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	A novel class of anthraquinone-based HDAC6 inhibitors.
AID1863441	Inhibition of HDAC9 (unknown origin) by colorimetric method	2022	European journal of medicinal chemistry, Oct-05, Volume: 240	Accommodation of ring C expanded deoxyvasicinone in the HDAC inhibitory pharmacophore culminates into a tractable anti-lung cancer agent and pH-responsive nanocarrier.
AID1454032	Inhibition of HDAC in human HeLa nuclear extract using Fluor de Lys as substrate by fluorimetric method	2017	Bioorganic & medicinal chemistry, 07-15, Volume: 25, Issue:14	Synthesis and evaluation of novel dual BRD4/HDAC inhibitors.
AID1066163	Cytotoxicity against human HCT116 cells at 50 uM after 72 hrs	2014	Journal of medicinal chemistry, Jan-09, Volume: 57, Issue:1	Pan-histone demethylase inhibitors simultaneously targeting Jumonji C and lysine-specific demethylases display high anticancer activities.
AID609498	Half life in human liver microsomes	2011	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16	The design, synthesis and structure-activity relationships of novel isoindoline-based histone deacetylase inhibitors.
AID1548288	Induction of apoptosis in bortezomib resistant human KM3/BTZ cells assessed as viable cells level at 200 nM incubated for 24 hrs by Annexin V-FITC/PI staining based FCAS analysis (Rvb = 98.1%)
AID1742704	Induction of apoptosis in human MDA-MB-231 cells assessed as early apoptotic cells at 5 uM incubated for 72 hrs by annexinV-FITC and PI staining based flow cytometry analysis (Rvb = 5.57 %)	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Design and synthesis of novel Flavone-based histone deacetylase inhibitors antagonizing activation of STAT3 in breast cancer.
AID623020	Inhibition of human HDAC1 expressed in Escherichia coli using fluorogenic substrate treated for 5 mins before substrate addition measured after 30 mins by fluorescence assay	2011	European journal of medicinal chemistry, Nov, Volume: 46, Issue:11	Design, synthesis and primary activity assay of tripeptidomimetics as histone deacetylase inhibitors with linear linker and branched cap group.
AID1466058	Growth inhibition of human A549 cells after 48 hrs by sulforhodamine B assay	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	4-Indolyl-N-hydroxyphenylacrylamides as potent HDAC class I and IIB inhibitors in vitro and in vivo.
AID672023	Inhibition of human recombinant HDAC2 using Boc-L-Lys (Ac)-AMC as substrate preincubated with compound for 5 mins measured after 35 mins by spectrofluorometric analysis	2012	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 22, Issue:15	Design, synthesis, modeling, biological evaluation and photoaffinity labeling studies of novel series of photoreactive benzamide probes for histone deacetylase 2.
AID1764252	Inhibition of recombinant human N-terminal GST-fusion tagged/C-terminal GST-tagged HDAC4 (627 to 1084 residues) expressed in baculovirus infected insect cells using Boc-Lys(TFA)-AMC as substrate preincubated for 5 mins followed by substrate addition measu	2021	European journal of medicinal chemistry, Feb-05, Volume: 211	Synergistic induction of apoptosis in resistant head and neck carcinoma and leukemia by alkoxyamide-based histone deacetylase inhibitors.
AID269674	Antiproliferative activity against human NCI-H23 cells by SRB assay	2006	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 16, Issue:15	Synthesis, enzymatic inhibition, and cancer cell growth inhibition of novel delta-lactam-based histone deacetylase (HDAC) inhibitors.
AID524991	Inhibition of HDAC7 in human homozygous Fdelta508 primary bronchial epithelial cells assessed as increase in short circuit currents at 1 uM for 4, 6, and 8 days relative to control	2010	Nature chemical biology, Jan, Volume: 6, Issue:1	Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.
AID1702155	n-Octanol/water distribution coefficient, logD of the compound at pH 7.4	2018	Journal of medicinal chemistry, 02-22, Volume: 61, Issue:4	Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma.
AID1769654	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 assay	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	Discovery of 2,4-pyrimidinediamine derivatives as potent dual inhibitors of ALK and HDAC.
AID663347	Growth inhibition of human MOLT4 cells after 72 hrs by MTS assay	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Discovery and extensive in vitro evaluations of NK-HDAC-1: a chiral histone deacetylase inhibitor as a promising lead.
AID90350	Inhibitory activity against histone deacetylase (HDAC) enzyme obtained from H1299 human lung carcinoma cell lysates	2003	Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21	N-hydroxy-3-phenyl-2-propenamides as novel inhibitors of human histone deacetylase with in vivo antitumor activity: discovery of (2E)-N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide (NVP-LAQ824).
AID1141243	Inhibition of HDAC in human HeLa nuclear extract using Boc-Lys (acetyl)-AMC as fluorogenic substrate after 30 mins by spectrophotometry	2014	Bioorganic & medicinal chemistry, Jun-01, Volume: 22, Issue:11	Design, synthesis and preliminary evaluation of α-sulfonyl γ-(glycinyl-amino)proline peptidomimetics as matrix metalloproteinase inhibitors.
AID1897805	Inhibition of recombinant full length C-terminal His/Flag-tagged human HDAC1 (1 to 482 residues) using Z-Lys(Ac)-AMC as substrate preincubated for 90 mins followed by trypsin addition and measured after 30 mins by fluorescence based microplate reader anal	2022	Journal of medicinal chemistry, 12-22, Volume: 65, Issue:24	Solid-Phase Synthesis of Cereblon-Recruiting Selective Histone Deacetylase 6 Degraders (HDAC6 PROTACs) with Antileukemic Activity.
AID1742684	Induction of cell cycle arrest in mouse 4T1 cells assessed as G0/G1 phase accumulation at 2 uM incubated for 24 hrs by PI staining based flow cytometry analysis (Rvb = 42.06 %)	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Design and synthesis of novel Flavone-based histone deacetylase inhibitors antagonizing activation of STAT3 in breast cancer.
AID1170740	Inhibition of human recombinant HDAC1 using [Ac-Leu-Gly-Lys(Ac)-AMC substrate incubated for 15 to 30 mins	2014	Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22	Methyl effect in azumamides provides insight into histone deacetylase inhibition by macrocycles.
AID443645	Binding affinity to pyridoxal-5'-phosphate assessed as formation of PLP-aldoxime at 5 mM after 1 hr by UV/vis spectroscopy	2009	Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19	Hydroxamic acids as a novel family of serine racemase inhibitors: mechanistic analysis reveals different modes of interaction with the pyridoxal-5'-phosphate cofactor.
AID1178599	Inhibition of human HDAC4 pre-incubated for 30 mins before substrate addition and measured after 30 mins by HDAC-Glo I/II assay	2014	Bioorganic & medicinal chemistry, Jul-15, Volume: 22, Issue:14	Design and synthesis of novel and highly-active pan-histone deacetylase (pan-HDAC) inhibitors.
AID1487096	Inhibition of HDAC6 (unknown origin)	2017	Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15	Cyclic tetrapeptide HDAC inhibitors as potential therapeutics for spinal muscular atrophy: Screening with iPSC-derived neuronal cells.
AID1164196	Inhibition of HDAC6 in human MCF7 cells assessed as hyperacetylation of tubulin at 5 uM after 24 hrs by Western blot analysis relative to control	2014	ACS medicinal chemistry letters, Sep-11, Volume: 5, Issue:9	Novel antiproliferative chimeric compounds with marked histone deacetylase inhibitory activity.
AID1486299	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	2017	Bioorganic & medicinal chemistry, 08-01, Volume: 25, Issue:15	Olaparib hydroxamic acid derivatives as dual PARP and HDAC inhibitors for cancer therapy.
AID1155329	Antimalarial activity against asexual blood stage of Plasmodium falciparum 3D7 infected in human serum assessed as [3H]hypoxanthine incorporation incubated for 48 hrs prior to 3H]hypoxanthine addition measured after 24 hrs by liquid scintillation counting	2014	European journal of medicinal chemistry, Jul-23, Volume: 82	Discovery of HDAC inhibitors with potent activity against multiple malaria parasite life cycle stages.
AID1487008	Selectivity index, ratio of IC50 for HDAC1 (unknown origin) to IC50 for HDAC6 (unknown origin)	2017	Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15	The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity.
AID1732191	Cytotoxicity against human HuT78 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	2021	European journal of medicinal chemistry, Apr-05, Volume: 215	CAP rigidification of MS-275 and chidamide leads to enhanced antiproliferative effects mediated through HDAC1, 2 and tubulin polymerization inhibition.
AID1401543	Antiproliferative activity against human OCI-LY3 cells after 72 hrs by MTT assay	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors.
AID414981	Antimalarial activity against Plasmodium falciparum 3D7 by [3H]hypoxanthine uptake	2009	Journal of medicinal chemistry, Apr-23, Volume: 52, Issue:8	Identification and characterization of small molecule inhibitors of a class I histone deacetylase from Plasmodium falciparum.
AID1751986	Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability	2021	Bioorganic & medicinal chemistry letters, 10-01, Volume: 49	Discovery of novel pyrazolopyrimidine derivatives as potent mTOR/HDAC bi-functional inhibitors via pharmacophore-merging strategy.
AID243634	In vitro inhibition against human Histone deacetylase	2005	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 15, Issue:5	Chemistry and biology of mercaptoacetamides as novel histone deacetylase inhibitors.
AID1401368	Inhibition of HDAC in human HeLa-S3 cell lysates assessed as residual activity at 2 x 10'-7 M preincubated for 15 mins followed by HDAC-Glo substrate addition measured after 35 mins by fluorimetric method relative to control	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
AID1164926	Effect on p21 expression in human BE(2)-C cells at 10 uM after 24 hrs by immunoblot method relative to vehicle-treated control	2014	Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19	Identification of a novel aminotetralin class of HDAC6 and HDAC8 selective inhibitors.
AID1227043	Stability in human plasma assessed as compound remaining after 1 hr by HPLC analysis	2015	Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11	Dual-Mode HDAC Prodrug for Covalent Modification and Subsequent Inhibitor Release.
AID1303631	Potentiation of 1 nM (-)-lomaiviticin A-induced cytotoxicity against human K562 cells assessed as combination index at 5 uM after 48 hrs by cell titer-glo luminescence assay	2016	Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13	Synergistic potentiation of (-)-lomaiviticin A cytotoxicity by the ATR inhibitor VE-821.
AID1515883	Induction of apoptosis in human HCT116 cells assessed as late apoptotic cells at 500 nM after 48 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 3.87%)	2019	Journal of medicinal chemistry, 08-08, Volume: 62, Issue:15	Design, Synthesis, and Biological Evaluation of 4-Methyl Quinazoline Derivatives as Anticancer Agents Simultaneously Targeting Phosphoinositide 3-Kinases and Histone Deacetylases.
AID1671983	Cell cycle arrest in human MCF7 cells assessed as accumulation at G2/M phase measured after 24 hrs	2019	Bioorganic & medicinal chemistry, 04-01, Volume: 27, Issue:7	Synthesis and biological evaluation of paclitaxel and vorinostat co-prodrugs for overcoming drug resistance in cancer therapy in vitro.
AID1273877	Inhibition of human CYP2C19 using 3-cyano-7-ethoxycoumarin as substrate at 10 uM after 30 mins by fluorimetric analysis	2016	European journal of medicinal chemistry, Jan-27, Volume: 108	Synthesis, biological characterization and molecular modeling insights of spirochromanes as potent HDAC inhibitors.
AID1399812	Inhibition of human recombinant HDAC1 using Fluor de Lys as substrate after 2 hrs by fluorescence method	2018	Bioorganic & medicinal chemistry letters, 09-15, Volume: 28, Issue:17	Squaramides as novel class I and IIB histone deacetylase inhibitors for topical treatment of cutaneous t-cell lymphoma.
AID1861656	Inhibition of HDAC6 (unknown origin)	2022	Bioorganic & medicinal chemistry letters, 09-15, Volume: 72	Exploration of 4-(1H-indol-3-yl)cyclohex-3-en-1-amine analogues as HDAC inhibitors: Design, synthesis, biological evaluation and modelling studies.
AID1849167	Cytotoxicity against human HL-60 cells assessed as inhibition of cell growth measured after 72 hrs by CellTiter-Glo luminescent assay	2022	Journal of medicinal chemistry, 11-24, Volume: 65, Issue:22	Development of Fluorinated Peptoid-Based Histone Deacetylase (HDAC) Inhibitors for Therapy-Resistant Acute Leukemia.
AID1164785	Inhibition of HDAC10 (unknown origin) using fluorogenic tetrapeptide RHKK(Ac) substrate by fluorescence assay	2014	Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20	ST7612AA1, a thioacetate-ω(γ-lactam carboxamide) derivative selected from a novel generation of oral HDAC inhibitors.
AID1622942	Cytotoxicity against human AML cells	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.
AID420506	Antiproliferative activity against cisplatin-resistant human IGROV1 cells after 72 hrs	2009	European journal of medicinal chemistry, May, Volume: 44, Issue:5	Design, synthesis, and evaluation of biphenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors.
AID663341	Inhibition of HDAC in human MDA-MB-231 cells assessed as stimulation of histone H3 acetylation incubated for 24 hrs by Western blot	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Discovery and extensive in vitro evaluations of NK-HDAC-1: a chiral histone deacetylase inhibitor as a promising lead.
AID1832681	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation incubated for 48 hrs by CCK8 assay	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Cysteine derivatives as acetyl lysine mimics to inhibit zinc-dependent histone deacetylases for treating cancer.
AID1312868	Inhibition of HDAC6 in human A2780S cells assessed as tubulin acetylation incubated for 6 hrs by cytoblot assay	2016	Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11	Development of Purine-Based Hydroxamic Acid Derivatives: Potent Histone Deacetylase Inhibitors with Marked in Vitro and in Vivo Antitumor Activities.
AID316895	Inhibition of human MCF7 cells	2008	Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6	Histone deacetylase inhibitors: from bench to clinic.
AID544399	Antimalarial activity against Plasmodium falciparum infected in mouse RAW264.7 cells	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Antimalarial activity of phenylthiazolyl-bearing hydroxamate-based histone deacetylase inhibitors.
AID723424	Potentiation of 5 uM cisplatin-induced toxicity in 5 uM cisplatin resistant human A2780 cells at 1 uM pretreated for 48 hrs followed by 5 uM cisplatin treatment by MTT assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1754780	Downregulation of RELB gene expression in human MCF7 cells at 3 uM incubated for 24 hrs by whole transcriptome analysis	2021	Bioorganic & medicinal chemistry, 07-15, Volume: 42	Discovery of novel class of histone deacetylase inhibitors as potential anticancer agents.
AID1864242	Inhibition of HDAC in human MDA-MB-231 cells assessed as increase in acetylated H4 level at 1.25 to 5 uM by Western blot analysis	2022	Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18	Discovery of a Novel G-Quadruplex and Histone Deacetylase (HDAC) Dual-Targeting Agent for the Treatment of Triple-Negative Breast Cancer.
AID329916	Induction of histone H4 hyperacetylation in human U937 cells	2008	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8	Novel uracil-based 2-aminoanilide and 2-aminoanilide-like derivatives: histone deacetylase inhibition and in-cell activities.
AID1876462	Inhibition of HDAC6 (unknown origin) using Boc-Lys(Ac)-AMC as substrate incubated for 60 mins by fluorescence plate reader assay	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	Design, synthesis, and biological evaluation of indole-based hydroxamic acid derivatives as histone deacetylase inhibitors.
AID759309	Cytotoxicity against african green monkey Vero cells assessed as growth inhibition after 72 hrs by MTT assay	2013	Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14	Histone deacetylase inhibitors equipped with estrogen receptor modulation activity.
AID1599723	Cytotoxicity against human Meso13 cells assessed as cell permeability measured after 72 hrs by CellTox Green assay	2019	ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6	Extending Cross Metathesis To Identify Selective HDAC Inhibitors: Synthesis, Biological Activities, and Modeling.
AID297486	Cytotoxicity against human proliferating RKOp21 cells	2007	Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18	2-aroylindoles and 2-aroylbenzofurans with N-hydroxyacrylamide substructures as a novel series of rationally designed histone deacetylase inhibitors.
AID1164028	Inhibition of human recombinant HDAC4 after 60 mins by fluorimetric assay	2014	European journal of medicinal chemistry, Oct-30, Volume: 86	Design, synthesis, and biological evaluation of 1, 3-disubstituted-pyrazole derivatives as new class I and IIb histone deacetylase inhibitors.
AID732447	Inhibition of human PC3 cell proliferation after 48 hrs by MTT assay	2013	ACS medicinal chemistry letters, Feb-14, Volume: 4, Issue:2	Development of
AID1155335	Antimalarial activity against exo-erythrocytic form of Plasmodium berghei infected in human HepG2 cells	2014	European journal of medicinal chemistry, Jul-23, Volume: 82	Discovery of HDAC inhibitors with potent activity against multiple malaria parasite life cycle stages.
AID1541450	Cytotoxicity against human CAL27 cells assessed as reduction in cell survival measured after 72 hrs by MTT assay	2019	Journal of medicinal chemistry, 12-26, Volume: 62, Issue:24	Synthesis of Peptoid-Based Class I-Selective Histone Deacetylase Inhibitors with Chemosensitizing Properties.
AID1821967	Antiproliferative activity against mouse B16-F10 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay
AID1587864	Inhibition of recombinant full-length C-terminal His-tagged human HDAC2 expressed in baculovirus infected Sf9 insect cells measured after 40 mins by HDAC-Glo1/2 luminescent assay	2019	Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9	Selective Inhibition of Histone Deacetylase 10: Hydrogen Bonding to the Gatekeeper Residue is Implicated.
AID1816207	Induction of apoptosis in human MDA-MB-231 cells assessed as late apoptotic cells at 2.5 uM measured after 48 hrs by annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 5.8%)
AID1418670	GPx-like activity of the compound assessed as velocity for H2O2 reduction at 80 uM in presence of GSH and NADPH by spectrophotometric analysis	2018	Bioorganic & medicinal chemistry, 11-15, Volume: 26, Issue:21	Design, synthesis, and biological evaluation of histone deacetylase inhibitors possessing glutathione peroxidase-like and antioxidant activities against Alzheimer's disease.
AID1441635	Inhibition of recombinant human N-terminal His-tagged 12-LOX expressed in Escherichia coli assessed as conversion of arachidonic acid to HETEs measured for 300 secs by UV-visible spectrophotometric analysis	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
AID1915538	Inhibition of HDAC6 (unknown origin)	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors.
AID328801	Inhibition of HDAC8 expressed in Escherichia coli	2008	Journal of medicinal chemistry, Apr-24, Volume: 51, Issue:8	A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo.
AID1312925	Inhibition of HDAC1/2/3 in human MV4-11 cells assessed as upregulation of acetylated histone H3 level at 2 uM after 6 hrs by Western blot method	2016	Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11	Development of Purine-Based Hydroxamic Acid Derivatives: Potent Histone Deacetylase Inhibitors with Marked in Vitro and in Vivo Antitumor Activities.
AID1279130	Antiproliferative activity against human KG1 cells after 48 hrs by MTT assay	2016	Bioorganic & medicinal chemistry, Apr-01, Volume: 24, Issue:7	Design and synthesis of a new generation of substituted purine hydroxamate analogs as histone deacetylase inhibitors.
AID1605977	Antiproliferative activity against human A498 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	2020	Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8	Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors.
AID1821342	Toxicity in mouse xenografted with human HepG2 cells assessed as heart edema at 12 mg/kg, ip administered every 2 days for 4 weeks by H and E staining based microscopic method	2022	European journal of medicinal chemistry, Feb-05, Volume: 229	Discovery of phthalazino[1,2-b]-quinazolinone derivatives as multi-target HDAC inhibitors for the treatment of hepatocellular carcinoma via activating the p53 signal pathway.
AID1614226	Induction of apoptosis in human MM1S cells assessed as early apoptotic cells at 1 uM after 48 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 0.38%)
AID1848625	Cytotoxicity against human SW620 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay	2022	Journal of medicinal chemistry, 11-10, Volume: 65, Issue:21	First-in-Class Dual Mechanism Ferroptosis-HDAC Inhibitor Hybrids.
AID1469326	Induction of apoptosis in human MDA-MB-231 cells assessed as live cells at 10 uM after 48 hrs by annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 98.1%)	2018	Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7	Discovery of N1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7 H-pyrrolo[2,3- d]pyrimidin-2-yl)amino)phenyl)- N8-hydroxyoctanediamide as a Novel Inhibitor Targeting Cyclin-dependent Kinase 4/9 (CDK4/9) and Histone Deacetlyase1 (HDAC1) against Malignant Cancer
AID1548258	Antiproliferative activity against human RPMI8226 cells incubated for 48 hrs by MTT assay
AID1832682	Antiproliferative activity against human MCF-7 cells assessed as inhibition of cell proliferation incubated for 48 hrs by CCK8 assay	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Cysteine derivatives as acetyl lysine mimics to inhibit zinc-dependent histone deacetylases for treating cancer.
AID670012	Inhibition of human recombinant HDAC6 using Boc-lys(Ac)-AMC as substrate preincubated for 20 mins with substrate measured after 60 mins by fluorescence analysis	2012	Journal of medicinal chemistry, Feb-23, Volume: 55, Issue:4	Defining the mechanism of action and enzymatic selectivity of psammaplin A against its epigenetic targets.
AID781051	Inhibition of HDAC in human HeLa cell nuclear extracts using Fluor de Lys as substrate by fluorescence assay	2013	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 23, Issue:23	Design, synthesis and biological evaluation of di-substituted cinnamic hydroxamic acids bearing urea/thiourea unit as potent histone deacetylase inhibitors.
AID1296346	Inhibition of recombinant Schistosoma mansoni HDAC8 expressed in Escherichia coli using Fluor de Lys as substrate preincubated for 90 mins followed by BML-KI176 addition measured after 45 mins by fluorescence assay	2016	Journal of medicinal chemistry, Mar-24, Volume: 59, Issue:6	Structure-Based Design and Synthesis of Novel Inhibitors Targeting HDAC8 from Schistosoma mansoni for the Treatment of Schistosomiasis.
AID1653119	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability	2019	European journal of medicinal chemistry, Mar-01, Volume: 165	Quinolone hybrids and their anti-cancer activities: An overview.
AID1816381	Inhibition of JAK2 (unknown origin) assessed as inhibition rate at 10 nM incubated for 60 mins by microplate reader analysis relative to control
AID1647330	Anti-vascular cognitive impairment activity against bilateral common carotid artery occlusion-induced vascular dementia C57BL/6J mouse model assessed as ratio of cerebral blood flow in right parietal area at 25 mg/kg, ip administered post surgery measured	2020	European journal of medicinal chemistry, Feb-01, Volume: 187	Protective effects of 10,11-dihydro-5H-dibenzo[b,f]azepine hydroxamates on vascular cognitive impairment.
AID329928	Inhibition of human HDAC4 in U937 cells assessed as residual activity at 5 uM	2008	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8	Novel uracil-based 2-aminoanilide and 2-aminoanilide-like derivatives: histone deacetylase inhibition and in-cell activities.
AID760518	Therapeutic index, ratio of GI50 for human HMEC to GI50 for human SK-BR-3 cells	2013	ACS medicinal chemistry letters, Aug-08, Volume: 4, Issue:8	Development of a chimeric c-Src kinase and HDAC inhibitor.
AID1622931	Inhibition of human recombinant full length C-terminal His-tagged HDAC3 (1 to 428 residues)/N-terminal GST-tagged NCOR2 (395 to 489 residues) expressed in insect cells using 7-AMC-labelled HDAC substrate measured after 30 mins by fluorescence assay	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.
AID1856998	Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	2022	Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19	Histone Deacetylase and Enhancer of Zeste Homologue 2 Dual Inhibitors Presenting a Synergistic Effect for the Treatment of Hematological Malignancies.
AID1365026	Selectivity ratio of IC50 for recombinant human His-tagged HDAC6 expressed in baculovirus infected insect cells to IC50 for recombinant human HDAC2	2017	Bioorganic & medicinal chemistry letters, 09-15, Volume: 27, Issue:18	Rational design, synthesis and preliminary antitumor activity evaluation of a chlorambucil derivative with potent DNA/HDAC dual-targeting inhibitory activity.
AID1415653	Inhibition of HDAC8 in human HepG2 cells assessed as increase in acetylated-histone H3 level at 5 uM after 48 hrs by Western blot analysis	2017	MedChemComm, Jun-01, Volume: 8, Issue:6	Development of novel β-carboline-based hydroxamate derivatives as HDAC inhibitors with DNA damage and apoptosis inducing abilities.
AID1774968	Inhibition of HDAC in human HeLa nuclear extract at 10 uM using Boc-Lys(acetyl)-AMC as substrate preincubated for 5 mins followed by substrate addition and measured after 30 mins by fluorescence assay	2021	ACS medicinal chemistry letters, Dec-09, Volume: 12, Issue:12	Design, Synthesis, and Biological Evaluation of APN and AKT Dual-Target Inhibitors.
AID1819504	Inhibition of HDAC2 (unknown origin) using fluorogenic substrate incubated for 30 mins by fluorescence based assay	2022	Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4	Discovery of DNA-Targeting HDAC Inhibitors with Potent Antitumor Efficacy In Vivo That Trigger Antitumor Immunity.
AID1361631	Antiproliferative activity against human NCI-H1299 cells after 72 hrs by CCK8 assay	2018	Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16	Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents.
AID1482100	Inhibition of HDAC 8 in human HeLa nuclear extract using fluorogenic HDAC class 2A substrate measured after 60 mins by fluorometric analysis	2017	Journal of medicinal chemistry, 04-27, Volume: 60, Issue:8	Exploring Derivatives of Quinazoline Alkaloid l-Vasicine as Cap Groups in the Design and Biological Mechanistic Evaluation of Novel Antitumor Histone Deacetylase Inhibitors.
AID1396961	Antiproliferative activity against human MCF7 cells	2018	Bioorganic & medicinal chemistry letters, 08-15, Volume: 28, Issue:15	Merging of ruxolitinib and vorinostat leads to highly potent inhibitors of JAK2 and histone deacetylase 6 (HDAC6).
AID1898903	Antiproliferative activity against human Ramos cells incubated for 24 hrs followed by incubating in drug-free medium for 48 hrs and measured by SRB assay	2022	European journal of medicinal chemistry, Jan-15, Volume: 228	Antitumor activity of novel POLA1-HDAC11 dual inhibitors.
AID1915568	Cytotoxicity against human PC-3 cells	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors.
AID1502978	Antiproliferative activity against human PC3 cells incubated for 72 hrs by MTT assay	2017	European journal of medicinal chemistry, Nov-10, Volume: 140	Design and synthesis of tranylcypromine derivatives as novel LSD1/HDACs dual inhibitors for cancer treatment.
AID1566804	Inhibition of human recombinant full length C-terminal His-tagged HDAC3 (1 to 428 residues)/N-terminal GST-tagged NCOR2 (395 to 489 residues) expressed in Sf9 cells using Ac-peptide-AMC as substrate after 1 hr by fluorescence assay	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Discovery of 1,2,4-oxadiazole-Containing hydroxamic acid derivatives as histone deacetylase inhibitors potential application in cancer therapy.
AID760504	Inhibition of HDAC9 (unknown origin) using Boc-Lys(trifluoroacetyl)-AMC as substrate by fluorescence assay	2013	ACS medicinal chemistry letters, Aug-08, Volume: 4, Issue:8	Development of a chimeric c-Src kinase and HDAC inhibitor.
AID1166496	Inhibition of human recombinant full length HDAC1 using (Ac)-Lys-Tyr-Lys(-acetyl)-AMC substrate after 30 mins	2014	Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21	Design, synthesis and biological evaluation of 4-anilinothieno[2,3-d]pyrimidine-based hydroxamic acid derivatives as novel histone deacetylase inhibitors.
AID1502987	Inhibition of C-terminal His-tagged full length human HDAC2 expressed in baculovirus expression system using Ac-peptide substrate incubated for 15 mins by fluorescence based assay	2017	European journal of medicinal chemistry, Nov-10, Volume: 140	Design and synthesis of tranylcypromine derivatives as novel LSD1/HDACs dual inhibitors for cancer treatment.
AID526535	Growth inhibition of human NUGC3 cells	2010	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22	Property based optimization of δ-lactam HDAC inhibitors for metabolic stability.
AID1337289	Antiproliferative activity against human NKYS cells after 48 hrs by CellTiter-Glo assay	2016	Journal of medicinal chemistry, Sep-22, Volume: 59, Issue:18	Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines.
AID1709352	Selectivity index, ratio of IC50 for human HS5 cells to IC50 for human NAMALVA cells	2021	Bioorganic & medicinal chemistry, 04-01, Volume: 35	Structure-activity relationship and mechanistic studies for a series of cinnamyl hydroxamate histone deacetylase inhibitors.
AID524994	Inhibition of HDAC9 by in vitro deacetylation assay	2010	Nature chemical biology, Jan, Volume: 6, Issue:1	Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.
AID1578156	Inhibition of HDAC in human HeLa nuclear extract using Boc-Lys(acetyl)-AMC as substrate measured after 30 mins by fluorescence assay	2020	European journal of medicinal chemistry, Jan-01, Volume: 185	N-alkyl-hydroxybenzoyl anilide hydroxamates as dual inhibitors of HDAC and HSP90, downregulating IFN-γ induced PD-L1 expression.
AID1742176	Antiproliferative activity against human MDA-MB-231 cells measured after 24 hrs by MTT assay	2020	European journal of medicinal chemistry, Nov-01, Volume: 205	Design, synthesis and biological evaluation of novel HDAC inhibitors with improved pharmacokinetic profile in breast cancer.
AID1742750	Antitumor activity against human MDA-MB-231 cells xenografted in BALB/c mouse assessed as tumor growth inhibition at 150 mg/kg, po administered for 34 days and measured on day 34	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Design and synthesis of novel Flavone-based histone deacetylase inhibitors antagonizing activation of STAT3 in breast cancer.
AID1482098	Inhibition of HDAC 2 in human HeLa nuclear extract using HDAC substrate-3 measured after 60 mins by fluorometric analysis	2017	Journal of medicinal chemistry, 04-27, Volume: 60, Issue:8	Exploring Derivatives of Quinazoline Alkaloid l-Vasicine as Cap Groups in the Design and Biological Mechanistic Evaluation of Novel Antitumor Histone Deacetylase Inhibitors.
AID1234906	Antitumor activity against human H7402 cells xenografted in mouse assessed as tumor increment ratio at 100 mg/kg/day, po for 16 days relative to control	2015	Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15	Design, synthesis and preliminary biological evaluation of indoline-2,3-dione derivatives as novel HDAC inhibitors.
AID609507	Inhibition of human recombinant HDAC6 expressed in baculovirus infected insect High5 cells using Boc-Lys(epsilon-acetyl)-AMC as substrate by fluorescence assay	2011	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16	Synthesis and biological evaluation of piperamide analogues as HDAC inhibitors.
AID374822	Inhibition of C-terminal His-tagged HDAC8 expressed in Escherichia coli	2009	Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11	Discovery of a potent class I selective ketone histone deacetylase inhibitor with antitumor activity in vivo and optimized pharmacokinetic properties.
AID1437239	Inhibition of HDAC6 (unknown origin)	2017	Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4	Design, synthesis and evaluation of antiproliferative activity of melanoma-targeted histone deacetylase inhibitors.
AID1702060	Inhibition of full length recombinant human C-terminal FLAG/His-tagged HDAC1 (1 to 482 end residues) expressed in baculovirus infected Sf9 cells using fluorogenic HDAC substrate 3 measured after 30 mins by fluorescence based assay	2018	Journal of medicinal chemistry, 02-22, Volume: 61, Issue:4	Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma.
AID545858	Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 assessed as parasite growth inhibition after 48 hrs by standard growth inhibition assay	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Novel inhibitor of Plasmodium histone deacetylase that cures P. berghei-infected mice.
AID618013	Cell cycle arrest in human MDA-MB-231 cells assessed as accumulation at G2 phase at 5 uM after 48 hrs using propidium iodide staining by flow cytometric analysis	2011	Journal of medicinal chemistry, Aug-11, Volume: 54, Issue:15	Discovery of a tetrahydroisoquinoline-based hydroxamic acid derivative (ZYJ-34c) as histone deacetylase inhibitor with potent oral antitumor activities.
AID1380956	Inhibition of HDAC8 (unknown origin) using fluorogenic Boc-Lys(trifluoroacetyl)-AMC as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by fluorescence-based assay	2018	Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12	Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously.
AID1384207	Inhibition of HDAC2 (unknown origin)	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease.
AID503688	Inhibition of HDAC in human GM15850 cells assessed as increase in histone H4 lysine 5 acetylation of FXN gene at 2.5 uM after 96 hrs by chromatin immunoprecipitation assay	2006	Nature chemical biology, Oct, Volume: 2, Issue:10	Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia.
AID652757	Down regulation of HDAC7 in human CFBE41o cells at 0.2 to 5 uM by Western blot analysis	2011	ACS medicinal chemistry letters, Jul-21, Volume: 2, Issue:9	Potential Agents for Treating Cystic Fibrosis: Cyclic Tetrapeptides that Restore Trafficking and Activity of ΔF508-CFTR.
AID1269317	Cytotoxicity against mouse NIH/3T3 cells assessed as cell growth at 25 uM measured at 72 hrs by CyQuant proliferation assay relative to control	2016	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2	Bromotyrosine-derived metabolites from an Indonesian marine sponge in the family Aplysinellidae (Order Verongiida).
AID1742739	Inhibition of human ERG	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Design and synthesis of novel Flavone-based histone deacetylase inhibitors antagonizing activation of STAT3 in breast cancer.
AID374811	Inhibition of human C-terminal FLAG-tagged HDAC1 in HEK293 cells	2009	Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11	Discovery of a potent class I selective ketone histone deacetylase inhibitor with antitumor activity in vivo and optimized pharmacokinetic properties.
AID1431811	Selectivity ratio of IC50 for human KDAC3 to IC50 for human KDAC1	2017	European journal of medicinal chemistry, Feb-15, Volume: 127	Design and synthesis of benzodiazepine analogs as isoform-selective human lysine deacetylase inhibitors.
AID1888584	Antiproliferative activity against human A-431 cells measured after 72 hrs by MTT assay
AID519587	Toxicity in neonatal foreskin fibroblasts	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Potent antimalarial activity of histone deacetylase inhibitor analogues.
AID1355708	Antifungal activity against FLC resistant Candida albicans 100 after 48 hrs by checkerboard microdilution method	2018	Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14	Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections.
AID1449327	Inhibition of full length human recombinant N-terminal GST-tagged HDAC6 expressed in baculovirus infected sf9 cells Z-(Ac)Lys-AMC as substrate measured after 90 mins by fluorescence assay	2017	Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13	Alkoxyurea-Based Histone Deacetylase Inhibitors Increase Cisplatin Potency in Chemoresistant Cancer Cell Lines.
AID1415667	Induction of apoptosis in human HepG2 cells assessed as increase in cleaved caspase3 expression at 5 uM after 48 hrs by Western blot analysis	2017	MedChemComm, Jun-01, Volume: 8, Issue:6	Development of novel β-carboline-based hydroxamate derivatives as HDAC inhibitors with DNA damage and apoptosis inducing abilities.
AID1336948	Induction of cell cycle arrest in human LNCAP cells assessed as accumulation at S phase at 2.5 uM after 24 hrs by propidium iodide staining based FACS analysis (Rvb = 27.1%)	2017	Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3	Bifunctional conjugates with potent inhibitory activity towards cyclooxygenase and histone deacetylase.
AID1859937	Antiproliferation activity against human U-937 cells assessed as reduction in cell viability at 5 to 50 uM measured after 48 hrs by CCK-8 assay	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Azetidin-2-one-based small molecules as dual hHDAC6/HDAC8 inhibitors: Investigation of their mechanism of action and impact of dual inhibition profile on cell viability.
AID1205629	Growth inhibition of human ACHN cells after 5 days by sulforhodamine B assay	2015	Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8	Discovery of Orally Available Runt-Related Transcription Factor 3 (RUNX3) Modulators for Anticancer Chemotherapy by Epigenetic Activation and Protein Stabilization.
AID1127331	Inhibition of human HDAC10 using fluorogenic tetrapeptide RHKKAc as substrate	2014	European journal of medicinal chemistry, May-22, Volume: 79	Influence of the adamantyl moiety on the activity of biphenylacrylohydroxamic acid-based HDAC inhibitors.
AID1173502	Inhibition of N-terminal GST-tagged human HDAC4 (627 to 1085 residues) using fluorogenic acetyl-Lys(trifluoroacetyl)-AMC substrate incubated for 2 hrs by fluorescence assay	2014	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 24, Issue:23	Histone deacetylase inhibitors derived from 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine and related heterocycles selective for the HDAC6 isoform.
AID717819	Inhibition of HDAC in human Hela cell lysate using Fluor-de-Lys as substrate assessed as remaining activity at 6.25 x 10'-8 M pretreated for 30 mins before substrate addition by fluorescence assay	2012	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23	The structural requirements of histone deacetylase inhibitors: suberoylanilide hydroxamic acid analogs modified at the C6 position.
AID1401504	Cytotoxicity against human Jurkat cells assessed as cell viability at 1 uM after 44 hrs by MTT assay relative to control	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
AID488273	Inhibition of HDAC1	2010	Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11	On the inhibition of histone deacetylase 8.
AID373085	Antitumor activity in mouse P388 cells xenografted B6D2F1 mouse assessed as increase in life span at 60 mg/kg/day, ip administered 3 to 7 days postxenografting	2009	European journal of medicinal chemistry, Mar, Volume: 44, Issue:3	Novel amide derivatives as inhibitors of histone deacetylase: design, synthesis and SAR.
AID781048	Antiproliferative activity against human MDA-MB-435 cells after 48 hrs by sulforhodamine B assay	2013	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 23, Issue:23	Design, synthesis and biological evaluation of di-substituted cinnamic hydroxamic acids bearing urea/thiourea unit as potent histone deacetylase inhibitors.
AID404448	Antimalarial activity against Plasmodium falciparum D6 by hypoxanthine uptake	2008	Journal of medicinal chemistry, Jun-26, Volume: 51, Issue:12	A series of potent and selective, triazolylphenyl-based histone deacetylases inhibitors with activity against pancreatic cancer cells and Plasmodium falciparum.
AID392408	Induction of histone H3 acetylation in human T24 cells after 3 hrs by ELISA	2009	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 19, Issue:2	Sulfamides as novel histone deacetylase inhibitors.
AID1487090	Increase in SMN2 mRNA expression in induced pluripotent stem cell derived from human GM03813 cells isolated from SMA patient homozygous for deletion of exons 7 and 8 in SMN1 gene and containing 3 SMN2 gene copies at 0.1 uM by PCR assay relative to untreat	2017	Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15	Cyclic tetrapeptide HDAC inhibitors as potential therapeutics for spinal muscular atrophy: Screening with iPSC-derived neuronal cells.
AID420511	Cell cycle arrest in human IGROV1 cells assessed as accumulation at sub-G1 phase at IC90 after 24 hrs using propidium-iodide staining by flow-cytometry	2009	European journal of medicinal chemistry, May, Volume: 44, Issue:5	Design, synthesis, and evaluation of biphenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors.
AID482953	Antiproliferative activity against human PC3 cells	2010	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11	Acylurea connected straight chain hydroxamates as novel histone deacetylase inhibitors: Synthesis, SAR, and in vivo antitumor activity.
AID1129787	Cell cycle arrest in human Jurkat cells assessed as accumulation at G2/M-phase at 10 uM after 36 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 14.20%)	2014	Bioorganic & medicinal chemistry, Apr-01, Volume: 22, Issue:7	Studies on the antiproliferative effects of tropolone derivatives in Jurkat T-lymphocyte cells.
AID1336924	Cytotoxicity against human HCT116 cells assessed as cell growth inhibition after 72 hrs by MTT assay	2017	Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3	Bifunctional conjugates with potent inhibitory activity towards cyclooxygenase and histone deacetylase.
AID1384209	Inhibition of HDAC6 (unknown origin)	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease.
AID1511156	Inhibition of HDAC6 in human HL60 cells assessed as increase in acetylation of alpha tubulin at 0.08 to 1.6 uM incubated for 24 hrs by western blot analysis	2019	ACS medicinal chemistry letters, Aug-08, Volume: 10, Issue:8	Design, Synthesis, and Biological Evaluation of 2,4-Imidazolinedione Derivatives as HDAC6 Isoform-Selective Inhibitors.
AID1702135	Inhibition of PI3K/AKT/mTOR signaling in human HuH-7 cells assessed as AKT S473 phosphorylation level at 10 uM incubated for 4 hrs including last 12 mins stimulation with 20 ng/ml growth factor VEGF by Western blot analysis (Rvb = 100 %)	2018	Journal of medicinal chemistry, 02-22, Volume: 61, Issue:4	Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma.
AID1812467	Antiplasmodial activity against Plasmodium falciparum stage IIb-III gametocytes assessed as abnormal morphology by measuring rounded/swollen at highest concentration measured after 72 hrs using Geimsa staining based assay	2021	Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14	Procainamide-SAHA Fused Inhibitors of hHDAC6 Tackle Multidrug-Resistant Malaria Parasites.
AID1605974	Antiproliferative activity against human M14 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	2020	Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8	Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors.
AID310126	Growth inhibition of human H460 cells by SRB assay	2007	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 17, Issue:22	Omega-alkoxy analogues of SAHA (vorinostat) as inhibitors of HDAC: a study of chain-length and stereochemical dependence.
AID1275641	Growth inhibition of human HCT116 cells after 96 hrs by MTT assay	2016	European journal of medicinal chemistry, Feb-15, Volume: 109	Identification of N-(6-mercaptohexyl)-3-(4-pyridyl)-1H-pyrazole-5-carboxamide and its disulfide prodrug as potent histone deacetylase inhibitors with in vitro and in vivo anti-tumor efficacy.
AID1390811	Antiproliferative activity against human Raji cells after 72 hrs by MTT assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel 6-aryl substituted 4-pyrrolidineaminoquinazoline derivatives as potent phosphoinositide 3-kinase delta (PI3Kδ) inhibitors.
AID1478582	Induction of apoptosis in human K562 cells assessed as necrotic cells at 2 uM after 24 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometry (Rvb = 0.035%)	2017	European journal of medicinal chemistry, Jun-16, Volume: 133	Design, synthesis and biological evaluation of quinoline derivatives as HDAC class I inhibitors.
AID1386685	Inhibition of HDAC in human GM18453 cells harboring NPC1 mutant assessed as increase in 250 kDa NPC1 protein expression at 5 uM measured after 48 hrs by Western blot analysis	2018	Journal of natural products, 09-28, Volume: 81, Issue:9	GEX1A, a Polyketide from Streptomyces chromofuscus, Corrects the Cellular Defects Associated with Niemann-Pick Type C1 in Human Fibroblasts.
AID1547257	Inhibition of human recombinant His-tagged BRD4 BD2 domain using H-SGRGK(Ac)GGK(Ac)GLGK-(Ac)GGAK(Ac)RHRK(Biotin)-OH as substrate preincubated with enzyme for 30 mins followed by substrate addition measured after 30 mins by AlphaScreen assay	2020	Journal of medicinal chemistry, 04-09, Volume: 63, Issue:7	Discovery of Thieno[2,3-
AID1591854	Inhibition of wild-type human N-terminal GST-tagged CDK2/cycA2 expressed in Sf21 insect cells at 10 nM using FAM-labelled substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins by fluorescence assay relative to contro	2019	Bioorganic & medicinal chemistry letters, 08-15, Volume: 29, Issue:16	Discovery of novel 9H-purin derivatives as dual inhibitors of HDAC1 and CDK2.
AID1266812	Antiproliferative activity against human LoVo cells assessed as cell viability after 48 hrs by MTT assay	2015	Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23	Novel β-Carboline/Hydroxamic Acid Hybrids Targeting Both Histone Deacetylase and DNA Display High Anticancer Activity via Regulation of the p53 Signaling Pathway.
AID1348932	Upregulation of TNFalpha gene expression in human A549 cells at IC50 after 12 hrs by RT-PCR method	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Discovery of aliphatic-chain hydroxamates containing indole derivatives with potent class I histone deacetylase inhibitory activities.
AID1487091	Increase in SMN2 mRNA expression in induced pluripotent stem cell derived from human GM03813 cells isolated from SMA patient homozygous for deletion of exons 7 and 8 in SMN1 gene and containing 3 SMN2 gene copies at 1 uM by PCR assay relative to untreated	2017	Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15	Cyclic tetrapeptide HDAC inhibitors as potential therapeutics for spinal muscular atrophy: Screening with iPSC-derived neuronal cells.
AID1485125	Cell cycle arrest in human Hs683 cells assessed as accumulation at sub-G1 phase at 2 uM after 24 to 48 hrs by propidium iodide staining-based flow cytometry	2017	Journal of medicinal chemistry, 06-08, Volume: 60, Issue:11	Discovery and Characterization of R/S-N-3-Cyanophenyl-N'-(6-tert-butoxycarbonylamino-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-4-yl)urea, a New Histone Deacetylase Class III Inhibitor Exerting Antiproliferative Activity against Cancer Cell Lines.
AID1164927	Effect on acetylated histone H3 expression in human BE(2)-C cells at 10 uM after 24 hrs by immunoblot method relative to vehicle-treated control	2014	Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19	Identification of a novel aminotetralin class of HDAC6 and HDAC8 selective inhibitors.
AID90690	In vitro for anti-HD2 (Histone deacetylase 2) activity in maize	2002	Journal of medicinal chemistry, Apr-25, Volume: 45, Issue:9	Binding mode analysis of 3-(4-benzoyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-propenamide: a new synthetic histone deacetylase inhibitor inducing histone hyperacetylation, growth inhibition, and terminal cell differentiation.
AID1337285	Antiproliferative activity against human KMS-12-BM cells after 48 hrs by CellTiter-Glo assay	2016	Journal of medicinal chemistry, Sep-22, Volume: 59, Issue:18	Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines.
AID1764815	Inhibition of Nanoluc-fused HDAC1 (unknown origin) expressed in HEK293 cells incubated for 2 hrs by NANOBRET assay	2021	Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8	Tetrahydroquinoline-Capped Histone Deacetylase 6 Inhibitor SW-101 Ameliorates Pathological Phenotypes in a Charcot-Marie-Tooth Type 2A Mouse Model.
AID1164918	Antiproliferative activity against human BE(2)-C cells assessed as growth inhibition after 72 hrs by CCK-8 assay	2014	Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19	Identification of a novel aminotetralin class of HDAC6 and HDAC8 selective inhibitors.
AID1784985	Inhibition of HDAC1 (unknown origin) using Ac-peptide as a substrate pretreated for 15 mins followed by substrate addition	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Design, synthesis and biological evaluation of novel hybrids targeting mTOR and HDACs for potential treatment of hepatocellular carcinoma.
AID1764298	Inhibition of class-1 HDAC in human CAL-27 cells assessed as induction of histone H-3 acetylation at 1 uM for 24 hrs by Western blot analysis	2021	European journal of medicinal chemistry, Feb-05, Volume: 211	Synergistic induction of apoptosis in resistant head and neck carcinoma and leukemia by alkoxyamide-based histone deacetylase inhibitors.
AID1173499	Inhibition of full length GST-tagged human HDAC1 using Arg-His-Lys-Lys(Ac) substrate incubated for 2 hrs by fluorescence assay	2014	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 24, Issue:23	Histone deacetylase inhibitors derived from 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine and related heterocycles selective for the HDAC6 isoform.
AID1785342	Inhibition of recombinant human SIRT2 measured after 30 mins by fluorescence microplate reader assay
AID525032	Inhibition of HDAC7 in human primary bronchial epithelial cells assessed as induction of mutant Fdelta508 CFTR protein apical surface localization at 1 uM	2010	Nature chemical biology, Jan, Volume: 6, Issue:1	Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.
AID1383993	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	Discovery of meta-sulfamoyl N-hydroxybenzamides as HDAC8 selective inhibitors.
AID1639367	Antiproliferative activity against human K562 cells after 48 hrs by MTT assay	2019	Bioorganic & medicinal chemistry, 04-15, Volume: 27, Issue:8	Design, synthesis and activity evaluation of indole-based double - Branched HDAC1 inhibitors.
AID603540	Toxicity in human MDA-MB-231 cells xenografted athymic nude mouse assessed as signs of toxicity at 90 mg/kg, ip qd for 21 days	2011	Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8	Development of tetrahydroisoquinoline-based hydroxamic acid derivatives: potent histone deacetylase inhibitors with marked in vitro and in vivo antitumor activities.
AID1690839	Inhibition of amyloid beta (1 to 42) (unknown origin) self aggregation after 24 hrs by thioflavin-T fluorescence method	2020	European journal of medicinal chemistry, Apr-15, Volume: 192	Synthesis and biological evaluation of acridine-based histone deacetylase inhibitors as multitarget agents against Alzheimer's disease.
AID1848584	Inhibition of full length C-terminal FLAG-tagged human recombinant HDAC6 expressed inSf9 insect cells	2022	Journal of medicinal chemistry, 11-10, Volume: 65, Issue:21	First-in-Class Dual Mechanism Ferroptosis-HDAC Inhibitor Hybrids.
AID1275640	Growth inhibition of human MCF7 cells after 96 hrs by MTT assay	2016	European journal of medicinal chemistry, Feb-15, Volume: 109	Identification of N-(6-mercaptohexyl)-3-(4-pyridyl)-1H-pyrazole-5-carboxamide and its disulfide prodrug as potent histone deacetylase inhibitors with in vitro and in vivo anti-tumor efficacy.
AID1688034	Induction of apoptosis in human HL-60 cells assessed as live cells at 1 uM measured after 24 hrs by Annexin-V/FITC and propidium iodide staining based flow cytometry (Rvb = 89.29 %)	2020	European journal of medicinal chemistry, Feb-15, Volume: 188	A 18β-glycyrrhetinic acid conjugate with Vorinostat degrades HDAC3 and HDAC6 with improved antitumor effects.
AID503692	Inhibition of HDAC in human GM15850 cells assessed as increase in histone H4 lysine 16 acetylation of FXN gene at 2.5 uM after 96 hrs by chromatin immunoprecipitation assay	2006	Nature chemical biology, Oct, Volume: 2, Issue:10	Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia.
AID1390010	Inhibition of full length recombinant human C-terminal FLAG/His-tagged HDAC1 expressed in baculovirus infected sf9 cells using Boc-Lys-(Ac)-AMC as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by fluorescence ass	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Design, synthesis and biological evaluation of novel hydroxamic acid based histone deacetylase 6 selective inhibitors bearing phenylpyrazol scaffold as surface recognition motif.
AID1578496	Induction of apoptosis in human MV4-11 cells assessed as viable cells at 0.25 uM incubated for 18 hrs by annexin V FITC and PI based flow cytometry (Rvb = 53.01 to 53.07 %)	2020	ACS medicinal chemistry letters, Jan-09, Volume: 11, Issue:1	Class I/IIb-Selective HDAC Inhibitor Exhibits Oral Bioavailability and Therapeutic Efficacy in Acute Myeloid Leukemia.
AID619142	Apparent permeability from apical to basolateral side of human Caco2 cells	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile.
AID663383	Growth inhibition of human SK-MEL-28 cells after 72 hrs by MTS assay	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Discovery and extensive in vitro evaluations of NK-HDAC-1: a chiral histone deacetylase inhibitor as a promising lead.
AID1816186	Inhibition of HDAC1 (unknown origin) incubated for 60 mins using microplate reader analysis
AID1174705	Antitumor activity against human U937 cells xenografted in athymic nude mouse at 120 mg/kg/day, po after 16 days relative to control	2015	European journal of medicinal chemistry, Jan-07, Volume: 89	Development of 3-hydroxycinnamamide-based HDAC inhibitors with potent in vitro and in vivo anti-tumor activity.
AID1403179	Inhibition of Akt phosphorylation in human HepG2 cells at 2 uM after 48 hrs by Western blot analysis	2018	European journal of medicinal chemistry, Jan-20, Volume: 144	Development of novel β-carboline-based hydroxamate derivatives as HDAC inhibitors with antiproliferative and antimetastatic activities in human cancer cells.
AID1576461	Induction of cell cycle arrest in human A549 cells assessed as accumulation at G2/M phase at 5 uM after 24 hrs by PI/RNaseA staining based flow cytometry analysis relative to control
AID1200982	AUC (0 to infinity) in ICR mouse at 10 mg/kg, iv	2015	Journal of medicinal chemistry, Mar-26, Volume: 58, Issue:6	Design and synthesis of orally bioavailable aminopyrrolidinone histone deacetylase 6 inhibitors.
AID1623528	Inhibition of human recombinant HDAC5 using fluorogenic HDAC substrate class 2A by fluorescence assay	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	A novel class of anthraquinone-based HDAC6 inhibitors.
AID670971	Inhibition of human recombinant His6-tagged and GST-fuses HDAC3 expressed in insect High5 cells using Ac-Lys-Tyr-Lys(e-acetyl)-AMC as substrate after 24 hrs by fluorescence assay	2012	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14	CCLab--a multi-objective genetic algorithm based combinatorial library design software and an application for histone deacetylase inhibitor design.
AID313730	Inhibition of HDAC2	2008	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2	Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2).
AID1449321	Antiproliferative activity against human ONS76 cells after 72 hrs by Celltiter-Glo assay	2017	Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13	Alkoxyurea-Based Histone Deacetylase Inhibitors Increase Cisplatin Potency in Chemoresistant Cancer Cell Lines.
AID297471	Inhibition of recombinant HDAC1 in HeLa cells	2007	Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18	2-aroylindoles and 2-aroylbenzofurans with N-hydroxyacrylamide substructures as a novel series of rationally designed histone deacetylase inhibitors.
AID1373250	Inhibition of HDAC6 (unknown origin) at 1 uM preincubated for 10 mins followed by Ac-Leu-GlyLys(Ac)-AMC substrate addition measured after 30 mins by fluorescence based assay relative to control	2018	Bioorganic & medicinal chemistry, 02-01, Volume: 26, Issue:3	Design, synthesis and evaluate of novel dual FGFR1 and HDAC inhibitors bearing an indazole scaffold.
AID1451829	Inhibition of recombinant HDAC2 (unknown origin) using Ac-Leu-Gly-Lys(Ac)-AMC as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by fluorescence assay	2017	Journal of medicinal chemistry, 10-12, Volume: 60, Issue:19	Small Molecule Inhibitors Simultaneously Targeting Cancer Metabolism and Epigenetics: Discovery of Novel Nicotinamide Phosphoribosyltransferase (NAMPT) and Histone Deacetylase (HDAC) Dual Inhibitors.
AID1511151	Antiproliferative activity against human RPMI8226 cells incubated for 48 hrs by MTT assay	2019	ACS medicinal chemistry letters, Aug-08, Volume: 10, Issue:8	Design, Synthesis, and Biological Evaluation of 2,4-Imidazolinedione Derivatives as HDAC6 Isoform-Selective Inhibitors.
AID1174684	Antiproliferative activity against human HEL cells after 48 hrs by MTT assay	2015	European journal of medicinal chemistry, Jan-07, Volume: 89	Development of 3-hydroxycinnamamide-based HDAC inhibitors with potent in vitro and in vivo anti-tumor activity.
AID619264	Antitumor activity against human HCT116 cells xenografted in nude BALB/c mouse assessed as tumor growth inhibition at 200 mg/kg, po qd for 21 days	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile.
AID1688044	Upregulation of acetylated H3 level in human HL-60 cells at 2 uM measured after 12 hrs by Western blot analysis	2020	European journal of medicinal chemistry, Feb-15, Volume: 188	A 18β-glycyrrhetinic acid conjugate with Vorinostat degrades HDAC3 and HDAC6 with improved antitumor effects.
AID274077	Inhibition of HCT116 cell proliferation (mean of two experiments)	2007	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2	Identification and optimisation of a series of substituted 5-(1H-pyrazol-3-yl)-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.
AID1537566	Cell cycle arrest in human G55T2 cells assessed as accumulation in G0/G1 phase at 3 uM incubated for 72 hrs by propidium iodide based flow cytometry (Rvb = 49.9 %)	2019	MedChemComm, Jul-01, Volume: 10, Issue:7	Design, synthesis and biological evaluation of β-peptoid-capped HDAC inhibitors with anti-neuroblastoma and anti-glioblastoma activity.
AID373076	Inhibition of human recombinant HDAC3	2009	European journal of medicinal chemistry, Mar, Volume: 44, Issue:3	Novel amide derivatives as inhibitors of histone deacetylase: design, synthesis and SAR.
AID1384210	Inhibition of full length human recombinant C-terminal FLAG/His-tagged HDAC1 expressed in baculovirus infected sf9 cells using fluorogenic HDAC substrate 3 after 30 mins by fluorescence assay	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease.
AID316935	Inhibition of HDAC5	2008	Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6	Histone deacetylase inhibitors: from bench to clinic.
AID1164783	Inhibition of HDAC6 (unknown origin) using fluorogenic tetrapeptide RHKK(Ac) substrate by fluorescence assay	2014	Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20	ST7612AA1, a thioacetate-ω(γ-lactam carboxamide) derivative selected from a novel generation of oral HDAC inhibitors.
AID1205632	Growth inhibition of human NUGC3 cells after 5 days by sulforhodamine B assay	2015	Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8	Discovery of Orally Available Runt-Related Transcription Factor 3 (RUNX3) Modulators for Anticancer Chemotherapy by Epigenetic Activation and Protein Stabilization.
AID1336926	Cytotoxicity against human DU145 cells assessed as cell growth inhibition after 72 hrs by MTT assay	2017	Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3	Bifunctional conjugates with potent inhibitory activity towards cyclooxygenase and histone deacetylase.
AID1600656	Inhibition of recombinant human full length C-terminal GST-tagged HDAC6 expressed in baculovirus infected Sf9 cells using ZMAL as substrate incubated for 90 mins by fluorometric method	2019	Bioorganic & medicinal chemistry, 10-01, Volume: 27, Issue:19	Fluorescent analogs of peptoid-based HDAC inhibitors: Synthesis, biological activity and cellular uptake kinetics.
AID1514603	Inhibition of HDAC1 in human HepG2 cells assessed as acetylated histone H4 levels at 2.5 uM by Western blot analysis relative to beta-actin (Rvb = 1 No_unit)	2019	Bioorganic & medicinal chemistry letters, 01-01, Volume: 29, Issue:1	Development of hydroxamate-based histone deacetylase inhibitors containing 1,2,4-oxadiazole moiety core with antitumor activities.
AID348802	Inhibition of HDAC7	2008	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20	Optimization of a series of potent and selective ketone histone deacetylase inhibitors.
AID628436	Inhibition of human recombinant HDAC2 using fluorophore-conjugated substrate Boc-L-Lys(Ac)-AMC after 60 mins	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Design, synthesis, docking, and biological evaluation of novel diazide-containing isoxazole- and pyrazole-based histone deacetylase probes.
AID1677512	Inhibition of HDAC1 (unknown origin) in using Boc-Lys(acetyl)-AMC or Boc-Lys (triflouroacetyl)-AMC as substrate preincubated for 5 mins followed by substrate addition and measured after 30 mins by fluorescence assay	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	HDAC-Bax Multiple Ligands Enhance Bax-Dependent Apoptosis in HeLa Cells.
AID1234909	Toxicity in human H7402 cells xenografted mouse assessed as change in body weight at 100 mg/kg/day, po for 16 days	2015	Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15	Design, synthesis and preliminary biological evaluation of indoline-2,3-dione derivatives as novel HDAC inhibitors.
AID1578500	Induction of apoptosis in human MV4-11 cells assessed as viable cells at 1 uM incubated for 18 hrs by annexin V FITC and PI based flow cytometry (Rvb = 53.01 to 53.07 %)	2020	ACS medicinal chemistry letters, Jan-09, Volume: 11, Issue:1	Class I/IIb-Selective HDAC Inhibitor Exhibits Oral Bioavailability and Therapeutic Efficacy in Acute Myeloid Leukemia.
AID246062	Effective Concentration of compound to inhibit the growth of human St-4 cells	2005	Journal of medicinal chemistry, Feb-24, Volume: 48, Issue:4	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates.
AID1785335	Inhibition of HDAC4 (unknown origin) measured after 30 mins by fluorescence microplate reader assay
AID1572359	Inhibition of human HDAC6 in human T24 cells assessed as up-regulation of PDL1 by measuring volume intensity at 10 uM after 48 hrs by Western blot analysis relative to control	2019	Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3	Synthesis and Biological Investigation of Phenothiazine-Based Benzhydroxamic Acids as Selective Histone Deacetylase 6 Inhibitors.
AID447579	Inhibition of HDAC in human Hela cells nuclear extracts by fluorimetric assay	2009	Bioorganic & medicinal chemistry, Jul-15, Volume: 17, Issue:14	Molecular modifications on carboxylic acid derivatives as potent histone deacetylase inhibitors: Activity and docking studies.
AID607635	Inhibition of HDAC6 in human Hela cells assessed as increase in alpha-tubulin acetylation at 0.6 uM after 16 hrs by immunofluorescence microscopy	2011	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 21, Issue:14	A novel HDAC inhibitor with a hydroxy-pyrimidine scaffold.
AID1355745	Antitumor activity against human HEL cells xenografted in BALB/C nude mouse assessed as tumor growth at 10 mg/kg, ip bid treated for 21 consecutive days relative to control	2018	Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14	Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections.
AID1410327	Antiproliferative activity against mouse CT26 cells after 48 hrs by CCK-8 assay	2018	ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4	Discovery of Novel Indoleamine 2,3-Dioxygenase 1 (IDO1) and Histone Deacetylase (HDAC) Dual Inhibitors.
AID1737150	Induction of apoptosis in human HCT-116 cells assessed as early apoptotic cells at 1 uM after 24 hrs by Annexin V-FITC/PI staining based flow cytometric analysis (Rvb = 4.01%)	2020	European journal of medicinal chemistry, Apr-15, Volume: 192	Design, synthesis and biological evaluation of novel indazole-based derivatives as potent HDAC inhibitors via fragment-based virtual screening.
AID1890518	Cytotoxicity against human L02 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	2022	Bioorganic & medicinal chemistry letters, 05-15, Volume: 64	Design, synthesis, and biological evaluation of β-carboline 1,3,4-oxadiazole based hybrids as HDAC inhibitors with potential antitumor effects.
AID659634	Antiproliferative activity against human DU145 cells after 72 hrs by MTS assay	2012	Journal of medicinal chemistry, Feb-23, Volume: 55, Issue:4	Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors.
AID1821265	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	2022	European journal of medicinal chemistry, Feb-05, Volume: 229	Discovery of phthalazino[1,2-b]-quinazolinone derivatives as multi-target HDAC inhibitors for the treatment of hepatocellular carcinoma via activating the p53 signal pathway.
AID1848615	Cytotoxicity against human PC-3 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay	2022	Journal of medicinal chemistry, 11-10, Volume: 65, Issue:21	First-in-Class Dual Mechanism Ferroptosis-HDAC Inhibitor Hybrids.
AID1861335	Inhibition of HDAC in human OCILY3 cells assessed as Down-regulation of STAT3 phosphorylation at Y705 residue at 2.5 uM measured by Western blot analysis	2022	Bioorganic & medicinal chemistry letters, 09-01, Volume: 71	Bioevaluation of a dual PI3K/HDAC inhibitor for the treatment of diffuse large B-cell lymphoma.
AID1164036	Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 72 hrs by CCK-8 assay	2014	European journal of medicinal chemistry, Oct-30, Volume: 86	Design, synthesis, and biological evaluation of 1, 3-disubstituted-pyrazole derivatives as new class I and IIb histone deacetylase inhibitors.
AID1549163	Inhibition of HDAC in HUVEC using Boc-Lys(Ac)-AMC as substrate preincubated for 12 hrs followed by substrate addition and measured after 4 hrs by fluorimetry	2020	Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10	Discovery of Novel Fungal Lanosterol 14α-Demethylase (CYP51)/Histone Deacetylase Dual Inhibitors to Treat Azole-Resistant Candidiasis.
AID1321732	Inhibition of class 1 histone deacetylase in human SH-SY5Y cells assessed as increase in histone H3K9 acetylation at 1000 nM after 2 hrs by Western blot analysis relative to control	2016	Journal of medicinal chemistry, 10-13, Volume: 59, Issue:19	Design, Synthesis, and Biological Evaluation of First-in-Class Dual Acting Histone Deacetylases (HDACs) and Phosphodiesterase 5 (PDE5) Inhibitors for the Treatment of Alzheimer's Disease.
AID1421915	Inhibition of HDAC in synchronized trophozoite stage Plasmodium falciparum 3D7 infected in human erythrocytes assessed as increase in acetylated H2A.Z level at 5 times IC50 after 3 hrs by Western blot analysis relative to control	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	One-pot, multi-component synthesis and structure-activity relationships of peptoid-based histone deacetylase (HDAC) inhibitors targeting malaria parasites.
AID348803	Inhibition of HDAC8	2008	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20	Optimization of a series of potent and selective ketone histone deacetylase inhibitors.
AID1413067	Inhibition of nuclear HDAC in human SKOV3 cells assessed as increase in acetylated histone H3 levels at 10 uM after 1 hr by immunoblot method	2018	MedChemComm, Jun-01, Volume: 9, Issue:6	Assessment of the trifluoromethyl ketone functionality as an alternative zinc-binding group for selective HDAC6 inhibition.
AID1599765	Inhibition of HDAC6 in human Meso163 cells assessed as increase in histone H3 acetylation at 2.5 uM measured after 6 to 20 hrs by Western blot analysis	2019	ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6	Extending Cross Metathesis To Identify Selective HDAC Inhibitors: Synthesis, Biological Activities, and Modeling.
AID1127328	Inhibition of human HDAC7 using fluorogenic tetrapeptide RHKKAc as substrate	2014	European journal of medicinal chemistry, May-22, Volume: 79	Influence of the adamantyl moiety on the activity of biphenylacrylohydroxamic acid-based HDAC inhibitors.
AID628286	Antiproliferative activity against human HeLa cells after 24 hrs by XTT assay	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Design, synthesis, docking, and biological evaluation of novel diazide-containing isoxazole- and pyrazole-based histone deacetylase probes.
AID1060989	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	2014	Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1	Synthesis and anticancer activities of thieno[3,2-d]pyrimidines as novel HDAC inhibitors.
AID540213	Half life in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1326513	Antiproliferative activity against human A549 cells after 48 hrs by SRB assay	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	2-(Phenylsulfonyl)quinoline N-hydroxyacrylamides as potent anticancer agents inhibiting histone deacetylase.
AID1410330	Antiproliferative activity against human HT-29 cells after 48 hrs by CCK-8 assay	2018	ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4	Discovery of Novel Indoleamine 2,3-Dioxygenase 1 (IDO1) and Histone Deacetylase (HDAC) Dual Inhibitors.
AID1441678	Protection against BLM-induced lung fibrosis in C57BL/6 mouse assessed as TGF-beta1 level at 25 and 50 mg/kg, ip qd for 7 days post BLM challenge measured on day 7 by by qRT-PCR method	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
AID1235110	Cytotoxicity against human U937 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	2015	Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15	Synthesis and biological evaluation of novel histone deacetylases inhibitors with nitric oxide releasing activity.
AID1861254	Antiproliferative activity against human DU-145 cells assessed as reduction in cell viability	2022	Bioorganic & medicinal chemistry letters, 09-01, Volume: 71	Design, synthesis and antitumor activity study of PARP-1/HDAC dual targeting inhibitors.
AID1173501	Inhibition of full length C-terminal 6x-His tagged human HDAC3 using Arg-His-Lys-Lys(Ac) substrate incubated for 2 hrs by fluorescence assay	2014	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 24, Issue:23	Histone deacetylase inhibitors derived from 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine and related heterocycles selective for the HDAC6 isoform.
AID208382	Concentration required to reduce cell proliferation of T/5 cells	1995	Journal of medicinal chemistry, Apr-14, Volume: 38, Issue:8	The synthesis of N-hydroxy-N'-phenyloctanediamide and its inhibitory effect on proliferation of AXC rat prostate cancer cells.
AID1274872	Inhibition of HDAC2 (unknown origin)	2016	European journal of medicinal chemistry, Jan-27, Volume: 108	Orally available stilbene derivatives as potent HDAC inhibitors with antiproliferative activities and antitumor effects in human tumor xenografts.
AID1897369	Inhibition of FGFR1 (unknown origin) at 10 nM relative to control
AID1206756	Antitumor activity against human HEL cells xenografted in BALB/c-nu mouse assessed as decrease in tumor volume at 120 mg/kg/day, po administered for 21 days measured every 3 days during compound dosing relative to control	2015	Journal of medicinal chemistry, May-28, Volume: 58, Issue:10	Design, synthesis, and antitumor evaluation of novel histone deacetylase inhibitors equipped with a phenylsulfonylfuroxan module as a nitric oxide donor.
AID1126981	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay	2014	Journal of medicinal chemistry, Apr-24, Volume: 57, Issue:8	Discovery of the first N-hydroxycinnamamide-based histone deacetylase 1/3 dual inhibitors with potent oral antitumor activity.
AID1401556	Antiproliferative activity against human MM487 cells at 10 uM after 72 hrs by MTT assay relative to control	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors.
AID1599725	Cytotoxicity against human A549 cells assessed as cell permeability measured after 72 hrs by CellTox Green assay	2019	ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6	Extending Cross Metathesis To Identify Selective HDAC Inhibitors: Synthesis, Biological Activities, and Modeling.
AID628211	Antiproliferative activity against human HeLa cells after 72 hrs by XTT assay	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Design, synthesis, docking, and biological evaluation of novel diazide-containing isoxazole- and pyrazole-based histone deacetylase probes.
AID1699970	Antiproliferative activity against human K562/A02 cells overexpressing P-gp by MTT assay	2020	Bioorganic & medicinal chemistry letters, 12-15, Volume: 30, Issue:24	Discovery of thiosemicarbazone-containing compounds with potent anti-proliferation activity against drug-resistant K562/A02 cells.
AID1819523	Induction of apoptosis in human KG-1 cells assessed as total apoptotic cells at 1 uM measured after 24 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry analysis relative to control	2022	Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4	Discovery of DNA-Targeting HDAC Inhibitors with Potent Antitumor Efficacy In Vivo That Trigger Antitumor Immunity.
AID1128978	Inhibition of human HDAC-1 using RHKK(Ac) as substrate by fluorescence assay	2014	Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6	Synthesis and evaluation of new Hsp90 inhibitors based on a 1,4,5-trisubstituted 1,2,3-triazole scaffold.
AID1339569	Inhibition of HDAC3 in human HeLaS3 cells preincubated for 15 mins followed by HDAC-Glo substrate addition measured after 30 to 45 mins by ELISA	2017	ACS medicinal chemistry letters, Mar-09, Volume: 8, Issue:3	Structural Requirements of HDAC Inhibitors: SAHA Analogues Modified at the C2 Position Display HDAC6/8 Selectivity.
AID760509	Inhibition of HDAC4 (unknown origin) using Boc-Lys(trifluoroacetyl)-AMC as substrate by fluorescence assay	2013	ACS medicinal chemistry letters, Aug-08, Volume: 4, Issue:8	Development of a chimeric c-Src kinase and HDAC inhibitor.
AID663354	Growth inhibition of human NCI-H322M cells after 72 hrs by MTS assay	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Discovery and extensive in vitro evaluations of NK-HDAC-1: a chiral histone deacetylase inhibitor as a promising lead.
AID1164913	Inhibition of HDAC8 (unknown origin) using fluorogenic peptide as substrate by fluorescence assay	2014	Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19	Identification of a novel aminotetralin class of HDAC6 and HDAC8 selective inhibitors.
AID1482099	Inhibition of HDAC 3 in human HeLa nuclear extract using HDAC substrate-3 measured after 60 mins by fluorometric analysis	2017	Journal of medicinal chemistry, 04-27, Volume: 60, Issue:8	Exploring Derivatives of Quinazoline Alkaloid l-Vasicine as Cap Groups in the Design and Biological Mechanistic Evaluation of Novel Antitumor Histone Deacetylase Inhibitors.
AID1330947	Antiproliferative activity against human SK-BR-3 cells expressing HER2 assessed as reduction in cell viability measured after 48 hrs by MTT assay	2017	Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1	Synthesis and investigation of novel 6-(1,2,3-triazol-4-yl)-4-aminoquinazolin derivatives possessing hydroxamic acid moiety for cancer therapy.
AID1547261	Inhibition of human recombinant His-tagged BRD2 BD2 domain expressed in Escherichia coli BL21(DE3)-R3-pRARE2 cells by AlphaScreen assay	2020	Journal of medicinal chemistry, 04-09, Volume: 63, Issue:7	Discovery of Thieno[2,3-
AID1548289	Induction of apoptosis in bortezomib resistant human KM3/BTZ cells assessed as early apoptotic cells level at 200 nM incubated for 24 hrs by Annexin V-FITC/PI staining based FCAS analysis (Rvb = 1.39%)
AID663348	Growth inhibition of human SR cells after 72 hrs by MTS assay	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Discovery and extensive in vitro evaluations of NK-HDAC-1: a chiral histone deacetylase inhibitor as a promising lead.
AID723120	Potentiation of 20 uM cisplatin-induced toxicity in 5 uM cisplatin resistant human A2780 cells at 0.25 uM pretreated for 48 hrs followed by 5 uM cisplatin treatment by MTT assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1245687	Cytotoxicity against human PC3 cells assessed as growth inhibition after 48 hrs by MTT assay	2015	Bioorganic & medicinal chemistry, Oct-01, Volume: 23, Issue:19	Development of N-hydroxybenzamide derivatives with indole-containing cap group as histone deacetylases inhibitors.
AID297494	Cytotoxicity against human Saos2 cells	2007	Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18	2-aroylindoles and 2-aroylbenzofurans with N-hydroxyacrylamide substructures as a novel series of rationally designed histone deacetylase inhibitors.
AID1771456	Antiproliferative activity against human A549 cells assessed as cell growth inhibition after 72 hrs by SRB assay	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Discovery of novel tubulin/HDAC dual-targeting inhibitors with strong antitumor and antiangiogenic potency.
AID1861266	Selectivity index, ratio of IC50 for inhibition of HDAC8 (unknown origin) to IC50 for inhibition of HDAC6 (unknown origin)	2022	Bioorganic & medicinal chemistry letters, 09-01, Volume: 71	Design, synthesis and antitumor activity study of PARP-1/HDAC dual targeting inhibitors.
AID420329	Inhibition of HDAC from RT extract	2009	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 19, Issue:13	Non-isotopic dual parameter competition assay suitable for high-throughput screening of histone deacetylases.
AID1462219	Inhibition of human BRD4 bromo domain 2 at 0.5 uM	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Structure-based design, synthesis and in vitro antiproliferative effects studies of novel dual BRD4/HDAC inhibitors.
AID1890312	Antiproliferative activity against mouse B16 cells after 72 hrs by MTT assay	2022	European journal of medicinal chemistry, Apr-05, Volume: 233	Novel biphenyl-based scaffold as potent and selective histone deacetylase 6 (HDAC6) inhibitors: Identification, development and pharmacological evaluation.
AID1361653	Induction of apoptosis in human A549 cells assessed as late apoptotic cells at 5 uM after 48 hrs by FITC-Annexin V/propidium iodide staining based flow cytometric analysis (Rvb = 3.37%)	2018	Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16	Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents.
AID1587866	Inhibition of recombinant human full length C-terminal His-tagged HDAC8 expressed in baculovirus infected insect cells measured after 40 mins by HDAC-Glo1/2 luminescent assay	2019	Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9	Selective Inhibition of Histone Deacetylase 10: Hydrogen Bonding to the Gatekeeper Residue is Implicated.
AID1819533	Toxicity in C57BL/6J mouse implanted with mouse B16-F10 cells assessed as glomerular structure damage in kidney at 60 mg/kg, IG administered for 12 days H and E staining based histopathological analysis	2022	Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4	Discovery of DNA-Targeting HDAC Inhibitors with Potent Antitumor Efficacy In Vivo That Trigger Antitumor Immunity.
AID1655789	Inhibition of human recombinant HDAC3 using AMC-K(Ac)GL as substrate by fluorescence based assay	2020	ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5	Design of First-in-Class Dual EZH2/HDAC Inhibitor: Biochemical Activity and Biological Evaluation in Cancer Cells.
AID1873400	Inhibition of HDAC1 (unknown origin) preincubated for 30 mins	2022	Bioorganic & medicinal chemistry letters, 08-15, Volume: 70	Comparison of three zinc binding groups for HDAC inhibitors - A potency, selectivity and enzymatic kinetics study.
AID1515906	Antiproliferative activity against human HCT8 cells after 96 hrs by MTT assay	2019	Journal of medicinal chemistry, 08-08, Volume: 62, Issue:15	Design, Synthesis, and Biological Evaluation of 4-Methyl Quinazoline Derivatives as Anticancer Agents Simultaneously Targeting Phosphoinositide 3-Kinases and Histone Deacetylases.
AID527317	Inhibition of HDAC in human HeLa cell nuclear extracts by fluorimetric assay	2010	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22	Design and synthesis of novel pyrimidine hydroxamic acid inhibitors of histone deacetylases.
AID1487038	Inhibition of HDAC in human HeLa-S3 cells lysates assessed as remaining enzyme activity at 2 x 10'-7 M pre-incubated for 15 mins before HDAC-Glo I/II substrate addition and measured after 30 mins post substrate addition	2017	Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15	The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity.
AID1550105	Inhibition of HDAC1 in human A549 cells assessed as increase in acetyl histone H4 level at 80 to 400 nM after 6 hrs by Western blot analysis	2019	Journal of medicinal chemistry, 04-25, Volume: 62, Issue:8	Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies.
AID348801	Inhibition of HDAC5	2008	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20	Optimization of a series of potent and selective ketone histone deacetylase inhibitors.
AID760491	Cytotoxicity against human SW620 cells after 48 hrs by SRB assay	2013	ACS medicinal chemistry letters, Aug-08, Volume: 4, Issue:8	Development of a chimeric c-Src kinase and HDAC inhibitor.
AID1702057	Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter-Glo luminescent assay	2018	Journal of medicinal chemistry, 02-22, Volume: 61, Issue:4	Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma.
AID673992	Inhibition of recombinant HDAC3/NCoR2 using Ac-Lys(Ac)-AMC as substrate after 30 mins by fluorescence analysis	2012	ACS medicinal chemistry letters, Jun-14, Volume: 3, Issue:6	Discovery of HDAC Inhibitors That Lack an Active Site Zn(2+)-Binding Functional Group.
AID1361649	Induction of apoptosis in human A549 cells assessed as late apoptotic cells at 1 uM after 48 hrs by FITC-Annexin V/propidium iodide staining based flow cytometric analysis (Rvb = 3.37%)	2018	Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16	Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents.
AID1234894	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay	2015	Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15	Design, synthesis and preliminary biological evaluation of indoline-2,3-dione derivatives as novel HDAC inhibitors.
AID1482101	Inhibition of HDAC 4 in human HeLa nuclear extract using fluorogenic HDAC class 2A substrate measured after 60 mins by fluorometric analysis	2017	Journal of medicinal chemistry, 04-27, Volume: 60, Issue:8	Exploring Derivatives of Quinazoline Alkaloid l-Vasicine as Cap Groups in the Design and Biological Mechanistic Evaluation of Novel Antitumor Histone Deacetylase Inhibitors.
AID1785021	Metabolic stability in rat liver microsomes assessed as parent compound remaining at 10 ug/ml measured after 1 hr in the presence of NADPH by HPLC analysis	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Design, synthesis and biological evaluation of novel hybrids targeting mTOR and HDACs for potential treatment of hepatocellular carcinoma.
AID1865298	Toxicity in BALB/c mouse allografted with mouse 4T1 cells assessed as body weight loss at 40 mg/kg, po qd administered for 12 days	2022	Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18	Discovery of Novel Src Homology-2 Domain-Containing Phosphatase 2 and Histone Deacetylase Dual Inhibitors with Potent Antitumor Efficacy and Enhanced Antitumor Immunity.
AID1511134	Inhibition of HDAC4 (unknown origin) using Ac-LeuGlyLys(tfa)-AMC as substrate preincubated for 5 mins followed by substrate addition and measured after 60 mins by fluorescence based assay	2019	ACS medicinal chemistry letters, Aug-08, Volume: 10, Issue:8	Design, Synthesis, and Biological Evaluation of 2,4-Imidazolinedione Derivatives as HDAC6 Isoform-Selective Inhibitors.
AID1597970	Induction of cell cycle arrest in human A549 cells assessed as accumulation at S phase at 10 uM incubated for 36 hrs by propidium iodide staining based flow cytometry (Rvb = 16.66%)	2019	Bioorganic & medicinal chemistry letters, 09-15, Volume: 29, Issue:18	Anti-tumor activity evaluation of novel tubulin and HDAC dual-targeting inhibitors.
AID1486672	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	2017	Bioorganic & medicinal chemistry, 08-01, Volume: 25, Issue:15	Design, synthesis and tumor cell growth inhibitory activity of 3-nitro-2H-cheromene derivatives as histone deacetylaes inhibitors.
AID1848579	Inhibition of HDAC6 in human NCI-H522 cells assessed as increase in acetylation of tubulin at 2.5 to 10 uM measured for 3 days by Western blot analysis	2022	Journal of medicinal chemistry, 11-10, Volume: 65, Issue:21	First-in-Class Dual Mechanism Ferroptosis-HDAC Inhibitor Hybrids.
AID1174691	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	2015	European journal of medicinal chemistry, Jan-07, Volume: 89	Development of 3-hydroxycinnamamide-based HDAC inhibitors with potent in vitro and in vivo anti-tumor activity.
AID1336949	Induction of cell cycle arrest in human LNCAP cells assessed as accumulation at G2 phase at 2.5 uM after 24 hrs by propidium iodide staining based FACS analysis (Rvb = 1.08%)	2017	Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3	Bifunctional conjugates with potent inhibitory activity towards cyclooxygenase and histone deacetylase.
AID269668	Inhibition of HeLa cell HDAC	2006	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 16, Issue:15	Synthesis, enzymatic inhibition, and cancer cell growth inhibition of novel delta-lactam-based histone deacetylase (HDAC) inhibitors.
AID663335	Growth inhibition of human SW620 cells after 72 hrs by MTS assay	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Discovery and extensive in vitro evaluations of NK-HDAC-1: a chiral histone deacetylase inhibitor as a promising lead.
AID1605968	Antiproliferative activity against human HOP92 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	2020	Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8	Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors.
AID1246507	Inhibition of HDAC1 (unknown origin) using RHKK(Ac) fluorogenic acetylated peptide substrate by fluorometric assay	2015	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 25, Issue:19	Discovery of 1-hydroxypyridine-2-thiones as selective histone deacetylase inhibitors and their potential application for treating leukemia.
AID1825923	Inhibition of recombinant human full length C-terminal His/FLAG tagged HDAC1 (1 to 482 residues) expressed in baculovirus-infected Sf9 cells using Ac-peptide as substrate incubated for 4 hrs
AID1784981	Antiproliferative activity against human PLC-PRF-5 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Design, synthesis and biological evaluation of novel hybrids targeting mTOR and HDACs for potential treatment of hepatocellular carcinoma.
AID1784978	Antiproliferative activity against human SK-HEP1 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Design, synthesis and biological evaluation of novel hybrids targeting mTOR and HDACs for potential treatment of hepatocellular carcinoma.
AID1630599	Inhibition of recombinant full length C-terminal His-tagged human HDAC3/GST-tagged human Ncor2 (395 to 489 residues) expressed in baculovirus expression system using fluorogenic substrate at 10 uM by fluorescence assay	2016	Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21	Synthesis and biological evaluation of santacruzamate A analogues for anti-proliferative and immunomodulatory activity.
AID316907	Inhibition of human RFX631L cells	2008	Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6	Histone deacetylase inhibitors: from bench to clinic.
AID1623532	Inhibition of HDAC10 (unknown origin) by fluorescence assay	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	A novel class of anthraquinone-based HDAC6 inhibitors.
AID1847777	Inhibition of HDAC1 in human HeLa cells using Boc-Lys(Ac)-AMC as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by fluorescence based analysis	2021	Bioorganic & medicinal chemistry, 12-15, Volume: 52	From natural products to HDAC inhibitors: An overview of drug discovery and design strategy.
AID1282279	Antitumor activity against human HCT116 cells xenografted in Balb/c nude mouse assessed as tumor mass change at 100 mg/kg, po q2d for 8 days	2016	Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4	Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
AID269671	Antiproliferative activity against human LOX-IMVI cells by SRB assay	2006	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 16, Issue:15	Synthesis, enzymatic inhibition, and cancer cell growth inhibition of novel delta-lactam-based histone deacetylase (HDAC) inhibitors.
AID1433234	Induction of cell death in p53 null human U937 cells at 1 to 4 uM after 24 hrs by annexin V-FITC/PI staining based flow cytometry	2016	Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17	Synthesis and Antileukemic Activities of Piperlongumine and HDAC Inhibitor Hybrids against Acute Myeloid Leukemia Cells.
AID420517	Inhibition of HDAC in human IGROV1 cells assessed as histone-H4 acetylation at IC80 after 4 hrs by Western blot	2009	European journal of medicinal chemistry, May, Volume: 44, Issue:5	Design, synthesis, and evaluation of biphenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors.
AID1380955	Inhibition of HDAC6 (unknown origin) using fluorogenic Boc-Lys(acetyl)-AMC as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by fluorescence-based assay	2018	Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12	Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously.
AID1421921	Selectivity index, ratio of IC50 for human HepG2A16 cells to IC50 for exo-erythrocytic stage of GFP-Luc-fused Plasmodium berghei ANKA infected in human HepG2 cells	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	One-pot, multi-component synthesis and structure-activity relationships of peptoid-based histone deacetylase (HDAC) inhibitors targeting malaria parasites.
AID385231	Inhibition of HDAC9	2008	Journal of medicinal chemistry, May-22, Volume: 51, Issue:10	Structural origin of selectivity in class II-selective histone deacetylase inhibitors.
AID775828	Inhibition of TPCK-treated trypsin (unknown origin) at 10 uM preincubated for 10 mins prior to substrate addition measured for 30 mins by spectrophotometric analysis	2013	Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20	Investigating the selectivity of metalloenzyme inhibitors.
AID1339570	Inhibition of HDAC6 in human HeLaS3 cells preincubated for 15 mins followed by HDAC-Glo substrate addition measured after 30 to 45 mins by ELISA	2017	ACS medicinal chemistry letters, Mar-09, Volume: 8, Issue:3	Structural Requirements of HDAC Inhibitors: SAHA Analogues Modified at the C2 Position Display HDAC6/8 Selectivity.
AID1493592	Inhibition of human recombinant full-length C-terminal GST-tagged HDAC2 expressed in baculovirus infected Sf9 cells using Boc-Lys(acetyl)-AMC as substrate after 30 mins by fluorescence assay	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Discovery of a fluorescent probe with HDAC6 selective inhibition.
AID1783108	Inhibition of HDAC1 (unknown origin) using Ac-LeuGlyLys(Ac)-AMC as substrate preincubated for 10 mins followed by substrate addition and further incubated for incubated for 1 hrs by fluorescence microtiter plate reader assay	2021	European journal of medicinal chemistry, Oct-05, Volume: 221	Design, synthesis and biological evaluation of 3, 4-disubstituted-imidazolidine-2, 5-dione derivatives as HDAC6 selective inhibitors.
AID1861344	Inhibition of HDAC in human DOHH-2 cells assessed as effect on pS6 levels at 2.5 uM in presence of 10 uM piclitisib measured by Western blot analysis	2022	Bioorganic & medicinal chemistry letters, 09-01, Volume: 71	Bioevaluation of a dual PI3K/HDAC inhibitor for the treatment of diffuse large B-cell lymphoma.
AID1865266	Inhibition of recombinant human HDAC7 using Ac-LeuGlyLys (TFA)-AMC substrate preincubated for 5 mins followed by substrate addition and measured after 30 mins by fluorescence based microplate reader analysis	2022	Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18	Discovery of Novel Src Homology-2 Domain-Containing Phosphatase 2 and Histone Deacetylase Dual Inhibitors with Potent Antitumor Efficacy and Enhanced Antitumor Immunity.
AID1464876	Anti-proliferative activity against human K562 cells after 48 hrs by MTT assay	2017	Bioorganic & medicinal chemistry letters, 11-01, Volume: 27, Issue:21	Design, synthesis and biological evaluation of novel histone deacetylase inhibitors incorporating 4-aminoquinazolinyl systems as capping groups.
AID603218	Inhibition of HDAC in human HeLa cell extracts assessed as conversion of dithiothreitol to dithiol after 1 hr by Flour-de-Lys assay	2011	Bioorganic & medicinal chemistry, Jun-15, Volume: 19, Issue:12	Total synthesis of largazole and analogues: HDAC inhibition, antiproliferative activity and metabolic stability.
AID1441647	Anti-inflammatory activity in LPS-induced C57BL/6 mouse model of acute lung injury assessed as reduction in TNFalpha mRNA level pretreated intraperitoneally for 1 hr followed LPS challenge after 24 hrs by qRT-PCR method	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
AID1476148	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	2017	Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20	Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat.
AID481560	Cytotoxicity against human Bel7402 cells assessed as growth inhibition at 0.1 ug/ml after 24 hrs by MTT assay	2010	Bioorganic & medicinal chemistry letters, May-15, Volume: 20, Issue:10	Synthesis and anticancer evaluation of alpha-lipoic acid derivatives.
AID1864227	Inhibition of full length recombinant N-terminal GST-tagged human HDAC6 expressed in baculovirus infected Sf9 insect cells incubated for 50 mins by Glo- luminescence assay	2022	Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18	Discovery of a Novel G-Quadruplex and Histone Deacetylase (HDAC) Dual-Targeting Agent for the Treatment of Triple-Negative Breast Cancer.
AID482955	Thermodynamic solubility at pH 7.4	2010	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11	Acylurea connected straight chain hydroxamates as novel histone deacetylase inhibitors: Synthesis, SAR, and in vivo antitumor activity.
AID663373	Growth inhibition of human SF295 cells after 72 hrs by MTS assay	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Discovery and extensive in vitro evaluations of NK-HDAC-1: a chiral histone deacetylase inhibitor as a promising lead.
AID1275591	Inhibition of human recombinant HDAC2 using acetyllysine tripeptide coupled with 7-amino-4-methylcoumarin as substrate by fluorescence assay	2016	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4	Dissecting structure-activity-relationships of crebinostat: Brain penetrant HDAC inhibitors for neuroepigenetic regulation.
AID749389	Inhibition of human recombinant HDAC3 expressed in High5 insect cells using Ac-Lys-Tyr-Lys(-acetyl)-AMC as substrate after 24 hrs by fluorescence assay	2013	Bioorganic & medicinal chemistry, Jun-01, Volume: 21, Issue:11	The discovery of colchicine-SAHA hybrids as a new class of antitumor agents.
AID1697196	Inhibition of HDAC in human HeLa nuclear extract using fluoroscence-labeled acetylated peptide as substrate by fluorometric assay	2020	Bioorganic & medicinal chemistry letters, 11-15, Volume: 30, Issue:22	Design, synthesis and evaluation of novel indirubin-based N-hydroxybenzamides, N-hydroxypropenamides and N-hydroxyheptanamides as histone deacetylase inhibitors and antitumor agents.
AID1600661	Antiproliferative activity against human OE19 cells assessed as reduction in cell viability incubated for 72 hrs by presto blue assay	2019	Bioorganic & medicinal chemistry, 10-01, Volume: 27, Issue:19	Fluorescent analogs of peptoid-based HDAC inhibitors: Synthesis, biological activity and cellular uptake kinetics.
AID300832	Inhibition of HDAC in HeLa cells	2007	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17	Pomiferin, histone deacetylase inhibitor isolated from the fruits of Maclura pomifera.
AID673998	Growth inhibition of human HL60 cells after 72 hrs by XTT assay	2012	ACS medicinal chemistry letters, Jun-14, Volume: 3, Issue:6	Discovery of HDAC Inhibitors That Lack an Active Site Zn(2+)-Binding Functional Group.
AID753166	Cytotoxicity against human K562 cells	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and biological characterization of spiro[2H-(1,3)-benzoxazine-2,4'-piperidine] based histone deacetylase inhibitors.
AID618100	Toxicity in nude BALB/c mouse xenografted with human HCT116 cells assessed as mouse survival at 200 mg/kg, po QD for 21 days measured on day 22	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile.
AID1533326	Inhibition of full length human N-terminal FLAG-tagged HDAC6 (1 to 1215 residues) expressed in HEK293 cells preincubated for 15 mins followed by acetyl-Gly-Ala-[acetyl-Lys]-AMC substrate addition measured after 30 mins by fluorimetric method	2018	ACS medicinal chemistry letters, Dec-13, Volume: 9, Issue:12	Molecular Basis for the Selective Inhibition of Histone Deacetylase 6 by a Mercaptoacetamide Inhibitor.
AID476648	Therapeutic ratio, EC50 for human PBMC to EC50 for human 937 cells	2010	Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8	Modified cap group suberoylanilide hydroxamic acid histone deacetylase inhibitor derivatives reveal improved selective antileukemic activity.
AID1821274	Inhibition of HDAC8 (unknown origin) incubated for 30 mins by microplate reader assay	2022	European journal of medicinal chemistry, Feb-05, Volume: 229	Discovery of phthalazino[1,2-b]-quinazolinone derivatives as multi-target HDAC inhibitors for the treatment of hepatocellular carcinoma via activating the p53 signal pathway.
AID525009	Inhibition of HDAC7 in human CFBE41o- cell line assessed as increase in stabilization of Fdelta508 CFTR protein at 1 uM after 5 days pretreatment by immunoblot analysis	2010	Nature chemical biology, Jan, Volume: 6, Issue:1	Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.
AID1266819	Inhibition of HDAC6 in human HeLa cell nuclear extract using Boc-Lys (Ac)-AMC as substrate after 60 mins by fluorometric analysis	2015	Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23	Novel β-Carboline/Hydroxamic Acid Hybrids Targeting Both Histone Deacetylase and DNA Display High Anticancer Activity via Regulation of the p53 Signaling Pathway.
AID663394	Growth inhibition of human MCF10A cells after 48 hrs by MTT assay	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Discovery and extensive in vitro evaluations of NK-HDAC-1: a chiral histone deacetylase inhibitor as a promising lead.
AID1248349	Inhibition of human full length MMP2 using Mca-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 as substrate incubated for 2 hrs prior to testing measured for 15 mins by fluorometric analysis	2015	Bioorganic & medicinal chemistry, Oct-15, Volume: 23, Issue:20	Synthesis of chiral ND-322, ND-364 and ND-364 derivatives as selective inhibitors of human gelatinase.
AID1709358	Induction of apoptosis in human Jurkat cells assessed as viable cells at IC50 measured after 48 hrs by Annexin V-FITC/7AAD staining based flow cytometry (Rvb = 85.2%)	2021	Bioorganic & medicinal chemistry, 04-01, Volume: 35	Structure-activity relationship and mechanistic studies for a series of cinnamyl hydroxamate histone deacetylase inhibitors.
AID1855246	Binding affinity to calf thymus DNA at 50 uM incubated for 30 mins and measured by UV-vis absorption spectroscopy	2022	European journal of medicinal chemistry, Nov-05, Volume: 241	Discovery of 2,5-diphenyl-1,3,4-thiadiazole derivatives as HDAC inhibitors with DNA binding affinity.
AID1566812	Inhibition of recombinant full length human HDAC11 expressed in baculovirus infected Sf9 cells using Ac-peptide-AMC as substrate after 1 hr by fluorescence assay	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Discovery of 1,2,4-oxadiazole-Containing hydroxamic acid derivatives as histone deacetylase inhibitors potential application in cancer therapy.
AID1337292	Antiproliferative activity against mouse TAMH cells after 24 hrs by CellTiter-Glo assay	2016	Journal of medicinal chemistry, Sep-22, Volume: 59, Issue:18	Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines.
AID1201652	Antiproliferative activity against human NCI-H460 cells assessed as growth inhibition after 48 hrs by SRB assay	2015	European journal of medicinal chemistry, May-05, Volume: 95	Macrocyclic compounds as anti-cancer agents: design and synthesis of multi-acting inhibitors against HDAC, FLT3 and JAK2.
AID1848280	Inhibition of HDAC6 (unknown origin)	2022	Bioorganic & medicinal chemistry, Nov-15, Volume: 74	Design, synthesis and biological evaluation of novel pyrazinone derivatives as PI3K/HDAC dual inhibitors.
AID622259	Inhibition of HDAC3 assessed as residual activity at 125 nM after 30 mins by Fluor de Lys fluorescence assay	2011	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 21, Issue:20	The structural requirements of histone deacetylase inhibitors: Suberoylanilide hydroxamic acid analogs modified at the C3 position display isoform selectivity.
AID1655791	Inhibition of human recombinant HDAC5 using AMC-K(TFA)GL as substrate by fluorescence based assay	2020	ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5	Design of First-in-Class Dual EZH2/HDAC Inhibitor: Biochemical Activity and Biological Evaluation in Cancer Cells.
AID465150	Inhibition of HDAC2 assessed as blockade of decorboxylation of carboxyfluorescein labeled acetylated peptide substrate after 17 hrs	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Synthesis and biological evaluation of triazol-4-ylphenyl-bearing histone deacetylase inhibitors as anticancer agents.
AID297492	Cytotoxicity against human A431 cells	2007	Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18	2-aroylindoles and 2-aroylbenzofurans with N-hydroxyacrylamide substructures as a novel series of rationally designed histone deacetylase inhibitors.
AID1600730	Inhibition of C-terminal His-tagged/N-terminal GST-tagged recombinant human HDAC4 (627 to 1084 residues) expressed in Baculovirus infected insect cells using Boc-Lys(TFa)-AMC as substrate preincubated for 5 mins followed by substrate addition and further	2019	Bioorganic & medicinal chemistry, 10-01, Volume: 27, Issue:19	Novel α,β-unsaturated hydroxamic acid derivatives overcome cisplatin resistance.
AID1126991	Induction of apoptosis in human U937 cells assessed as necrotic cells using annexin-V/propidium iodide staining at 1 uM after 12 hrs by flow cytometry analysis (Rvb = 0.17%)	2014	Journal of medicinal chemistry, Apr-24, Volume: 57, Issue:8	Discovery of the first N-hydroxycinnamamide-based histone deacetylase 1/3 dual inhibitors with potent oral antitumor activity.
AID366643	Inhibition of HDAC8 after 17 hrs	2008	Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15	Use of the nitrile oxide cycloaddition (NOC) reaction for molecular probe generation: a new class of enzyme selective histone deacetylase inhibitors (HDACIs) showing picomolar activity at HDAC6.
AID1454056	Growth inhibition of human A2780 cells after 3 days by WST1 assay	2017	Bioorganic & medicinal chemistry, 07-15, Volume: 25, Issue:14	Synthesis and evaluation of novel dual BRD4/HDAC inhibitors.
AID1861261	Inhibition of HDAC6 (unknown origin)	2022	Bioorganic & medicinal chemistry letters, 09-01, Volume: 71	Design, synthesis and antitumor activity study of PARP-1/HDAC dual targeting inhibitors.
AID1401474	Selectivity ratio of IC50 for HDAC1 in human HeLa-S3 cell lysates to IC50 for HDAC6 in human HeLa-S3 cell lysates	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
AID1127010	Induction of apoptosis in human U937 cells assessed as early apoptotic cells using annexin-V/propidium iodide staining at 0.125 uM after 24 hrs by flow cytometry analysis (Rvb = 1.57%)	2014	Journal of medicinal chemistry, Apr-24, Volume: 57, Issue:8	Discovery of the first N-hydroxycinnamamide-based histone deacetylase 1/3 dual inhibitors with potent oral antitumor activity.
AID1890341	Antitumor immunity in C57BL/6 mouse xenografted with mouse CT26 cells assessed as decrease in number of CD4+CD25+ CD127- T regulatory cells at 100 mg/kg, po administered once daily for 21 days measured by flow cytometry analysis	2022	European journal of medicinal chemistry, Apr-05, Volume: 233	Novel biphenyl-based scaffold as potent and selective histone deacetylase 6 (HDAC6) inhibitors: Identification, development and pharmacological evaluation.
AID1915551	Antiproliferative activity against non-small cell lung cancer cell line (unknown origin)	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors.
AID1825804	Toxicity in ip dosed BALB/c mouse assessed as maximum tolerated dose measured after 2 weeks	2022	Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4	Development of a Novel, Small-Molecule Brain-Penetrant Histone Deacetylase Inhibitor That Enhances Spatial Memory Formation in Mice.
AID350730	Growth inhibition of human SKOV3 cells after 48 hrs by sulforhodamine B assay	2009	Journal of medicinal chemistry, May-14, Volume: 52, Issue:9	Design, synthesis, and biological activity of boronic acid-based histone deacetylase inhibitors.
AID1566825	Antiproliferative activity against human AML patient derived primary leukemia cells after 72 hrs by MTT assay	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Discovery of 1,2,4-oxadiazole-Containing hydroxamic acid derivatives as histone deacetylase inhibitors potential application in cancer therapy.
AID1235112	Cytotoxicity against human PC3 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	2015	Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15	Synthesis and biological evaluation of novel histone deacetylases inhibitors with nitric oxide releasing activity.
AID1280278	Inhibition of class1 HDAC in human HL60 cells assessed as ratio of acetylated histone H3 to GAPDH level at 10 uM after 4 hrs by Western blot analysis relative to control	2016	Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4	Synthesis and Biological Investigation of Oxazole Hydroxamates as Highly Selective Histone Deacetylase 6 (HDAC6) Inhibitors.
AID1227029	Inhibition of human recombinant HDAC1 using MAZ1600 as fluorogenic substrate measured every 5 mins by optimized homogenous fluorescence based assay	2015	Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11	Dual-Mode HDAC Prodrug for Covalent Modification and Subsequent Inhibitor Release.
AID1548271	Induction of cell cycle arrest in human RPMI8226 cells assessed as accumulation at G1 phase at 100 nM incubated for 24 hrs by propidium iodide staining based flow cytometry (Rvb = 48.6%)
AID1819527	Antiproliferative activity against mouse B16-F10 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	2022	Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4	Discovery of DNA-Targeting HDAC Inhibitors with Potent Antitumor Efficacy In Vivo That Trigger Antitumor Immunity.
AID414720	Cytotoxicity against human HeLa cells after 72 hrs by alamar-blue cell viability assay	2009	Journal of medicinal chemistry, Apr-23, Volume: 52, Issue:8	Design of chimeric histone deacetylase- and tyrosine kinase-inhibitors: a series of imatinib hybrides as potent inhibitors of wild-type and mutant BCR-ABL, PDGF-Rbeta, and histone deacetylases.
AID1459945	Inhibition of HDAC activity in human HeLa cell nuclear extract using fluorometric substrate measured after 30 mins by fluorescence assay	2017	European journal of medicinal chemistry, Jan-05, Volume: 125	3-Aroylindoles display antitumor activity in vitro and in vivo: Effects of N1-substituents on biological activity.
AID1200988	Oral bioavailability in ICR mouse at 50 mg/kg	2015	Journal of medicinal chemistry, Mar-26, Volume: 58, Issue:6	Design and synthesis of orally bioavailable aminopyrrolidinone histone deacetylase 6 inhibitors.
AID1600728	Inhibition of C-terminal His-fusion tagged/N-terminal Strep-2 tagged recombinant human HDAC8 (1 to 377 residues) expressed in insect cells using Boc-Lys(TFa)-AMC as substrate preincubated for 5 mins followed by substrate addition and further incubation fo	2019	Bioorganic & medicinal chemistry, 10-01, Volume: 27, Issue:19	Novel α,β-unsaturated hydroxamic acid derivatives overcome cisplatin resistance.
AID525007	Inhibition of HDAC7 in Fdelta508 CFTR-expressing human CFBE41o- cell line assessed as increase in cAMP-stimulated iodide efflux in at 5 uM after 24 hrs relative to control	2010	Nature chemical biology, Jan, Volume: 6, Issue:1	Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.
AID632971	Cytotoxicity against human SW620 cells	2011	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 21, Issue:24	Benzothiazole-containing hydroxamic acids as histone deacetylase inhibitors and antitumor agents.
AID1739583	Inhibition of HDAC6 in human THP-1 cells assessed as ratio of acetylated H3/GAPDH at 1 uM incubated for 4 hrs by Western blot analysis relative to DMSO	2020	European journal of medicinal chemistry, Aug-15, Volume: 200	Design, synthesis, and biological evaluation of dual targeting inhibitors of histone deacetylase 6/8 and bromodomain BRPF1.
AID1336954	Inhibition of HDAC in human BEAS2B cells assessed as reduction of NTHi-induced NFkappaB activation at 1 uM preincubated for 1 hr followed by NTHi stimulation for 5 hrs by luciferase reporter gene assay	2017	Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3	Bifunctional conjugates with potent inhibitory activity towards cyclooxygenase and histone deacetylase.
AID618181	Antitumor activity against human A2780 cells xenografted in nude BALB/c mouse assessed as tumor growth inhibition at 200 mg/kg, po qd for 21 days measured on day 9	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile.
AID613295	Antiproliferative activity against human HCT116 cells assessed as growth inhibition	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Optimization of the in vitro cardiac safety of hydroxamate-based histone deacetylase inhibitors.
AID1848633	Cytotoxicity against human UO-31 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay	2022	Journal of medicinal chemistry, 11-10, Volume: 65, Issue:21	First-in-Class Dual Mechanism Ferroptosis-HDAC Inhibitor Hybrids.
AID1466060	Growth inhibition of human AsPC1 cells after 48 hrs by sulforhodamine B assay	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	4-Indolyl-N-hydroxyphenylacrylamides as potent HDAC class I and IIB inhibitors in vitro and in vivo.
AID619260	Antitumor activity against human HCT116 cells xenografted in athymic nu/nu Harlan mouse assessed as tumor growth inhibition at 200 mg/kg, po qd for 21 days measured on day 22	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile.
AID1686358	Cytotoxicity against human MV4-11 cells assessed as reduction in cell viability incubated for 48 hrs by Cell-titer-blue cell viability assay	2016	Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21	Development of Allosteric Hydrazide-Containing Class I Histone Deacetylase Inhibitors for Use in Acute Myeloid Leukemia.
AID1292166	Induction of apoptosis in human HCT116 cells assessed as apoptotic cells at 5 uM after 48 hrs by annexin V-FITC/propidium iodide staining based flow cytometric analysis	2016	European journal of medicinal chemistry, Jun-10, Volume: 115	Novel spiropyrazolone antitumor scaffold with potent activity: Design, synthesis and structure-activity relationship.
AID1898908	Antiproliferative activity against human THP-1 cells incubated for 24 hrs followed by incubating in drug-free medium for 48 hrs and measured by SRB assay	2022	European journal of medicinal chemistry, Jan-15, Volume: 228	Antitumor activity of novel POLA1-HDAC11 dual inhibitors.
AID605395	Inhibition of human recombinant HDAC5 using fluor de Lys as substrate by fluorometric analysis	2010	Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24	Discovery of 2-(6-{[(6-fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a class I selective orally active histone deacetylase inhibitor.
AID1293571	Inhibition of human HDAC10 using RHK-K(Ac)-AMC as substrate incubated for 60 mins by fluorescence assay	2016	European journal of medicinal chemistry, Apr-13, Volume: 112	Biphenyl-4-yl-acrylohydroxamic acids: Identification of a novel indolyl-substituted HDAC inhibitor with antitumor activity.
AID1826622	Synergistic antiproliferative effect on HEL cells assessed as fractional inhibitory concentration index at 1.11 uM in presence of 3-Fluoro-10-hydroxy-14-methyl-8,13,13b,14-tetrahydro-7H-indolo[2',3':3,4]pyrido[2,1-b]quinazolin-5-one	2022	Journal of medicinal chemistry, 03-24, Volume: 65, Issue:6	Evodiamine-Inspired Topoisomerase-Histone Deacetylase Dual Inhibitors: Novel Orally Active Antitumor Agents for Leukemia Therapy.
AID481569	Antitumor activity against mouse S180 cells xenografted in ICR mouse assessed as inhibition of tumor weight at 100 mg/kg, ig administered 2 days after tumor inoculation qd for 7 days relative to control	2010	Bioorganic & medicinal chemistry letters, May-15, Volume: 20, Issue:10	Synthesis and anticancer evaluation of alpha-lipoic acid derivatives.
AID1227050	Cytotoxicity against mouse NIH/3T3 cells assessed as cell proliferation after 70 hrs by MTS assay	2015	Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11	Dual-Mode HDAC Prodrug for Covalent Modification and Subsequent Inhibitor Release.
AID1739590	Inhibition of HDAC6 in human HL-60 cells assessed as ratio of acetylated H3/GAPDH at 0.1 uM incubated for 4 hrs by Western blot analysis relative to DMSO	2020	European journal of medicinal chemistry, Aug-15, Volume: 200	Design, synthesis, and biological evaluation of dual targeting inhibitors of histone deacetylase 6/8 and bromodomain BRPF1.
AID1578484	Cytotoxicity against human MRC9 cells assessed as reduction in cell viability incubated for 72 hrs by cell-titer blue assay	2020	ACS medicinal chemistry letters, Jan-09, Volume: 11, Issue:1	Class I/IIb-Selective HDAC Inhibitor Exhibits Oral Bioavailability and Therapeutic Efficacy in Acute Myeloid Leukemia.
AID1599768	Inhibition of HDAC6 in human Meso163 cells assessed as increase in alpha tubulin acetylation at 2.5 uM measured after 6 to 20 hrs by Western blot analysis	2019	ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6	Extending Cross Metathesis To Identify Selective HDAC Inhibitors: Synthesis, Biological Activities, and Modeling.
AID1421910	Selectivity index, ratio of IC50 for human HepG2A16 cells to IC50 for multidrug-resistant asexual ring stage Plasmodium falciparum Dd2 infected in human erythrocytes	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	One-pot, multi-component synthesis and structure-activity relationships of peptoid-based histone deacetylase (HDAC) inhibitors targeting malaria parasites.
AID1550095	Inhibition of recombinant human JAK2 at 10 uM using Ulight-CAGAGAIETDKEYYTVKD as substrate measured after 60 mins by LANCE assay	2019	Journal of medicinal chemistry, 04-25, Volume: 62, Issue:8	Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies.
AID1848281	Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell proliferation incubated for 72 hrs by CCK8 assay	2022	Bioorganic & medicinal chemistry, Nov-15, Volume: 74	Design, synthesis and biological evaluation of novel pyrazinone derivatives as PI3K/HDAC dual inhibitors.
AID1275647	Cytotoxicity against HEK293 cells assessed as growth inhibition after 96 hrs by MTT assay	2016	European journal of medicinal chemistry, Feb-15, Volume: 109	Identification of N-(6-mercaptohexyl)-3-(4-pyridyl)-1H-pyrazole-5-carboxamide and its disulfide prodrug as potent histone deacetylase inhibitors with in vitro and in vivo anti-tumor efficacy.
AID420510	Cell cycle arrest in human IGROV1 cells assessed as accumulation at sub-G1 phase at IC80 after 24 hrs using propidium-iodide staining by flow-cytometry	2009	European journal of medicinal chemistry, May, Volume: 44, Issue:5	Design, synthesis, and evaluation of biphenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors.
AID1275639	Inhibition of recombinant human HDAC11 using Boc-Lys(TFA)-AMC as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by fluorescence-based assay	2016	European journal of medicinal chemistry, Feb-15, Volume: 109	Identification of N-(6-mercaptohexyl)-3-(4-pyridyl)-1H-pyrazole-5-carboxamide and its disulfide prodrug as potent histone deacetylase inhibitors with in vitro and in vivo anti-tumor efficacy.
AID274110	Inhibition of HDAC1 (mean IC50)	2006	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 16, Issue:23	A series of novel, potent, and selective histone deacetylase inhibitors.
AID1915574	Inhibition of HDAC1 in human HeLa cell nuclear extract using Bos-Lys(acetyl)-AMC as substrate preincubated for 5 mins followed by substrate addition incubated for 30 mins	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors.
AID1401541	Antiproliferative activity against human JeKo1 cells after 72 hrs by MTT assay	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors.
AID1129797	Inhibition of HDAC in human Jurkat cells assessed as perforin expression after 48 hrs by FACS flow cytometric analysis relative to control	2014	Bioorganic & medicinal chemistry, Apr-01, Volume: 22, Issue:7	Studies on the antiproliferative effects of tropolone derivatives in Jurkat T-lymphocyte cells.
AID1355691	Antiproliferative activity against human HEL cells after 48 hrs by CCK-8 assay	2018	Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14	Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections.
AID1282298	Inhibition of HDAC6 in human MV4-11 cells assessed as upregulation of alpha tubulin acetylation at 10 to 1000 nM after 6 hrs by Western blot analysis	2016	Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4	Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
AID1421625	Antiproliferative activity against human HEL 92.1.7 cells after 72 hrs by MTT assay	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	Design and synthesis of potent dual inhibitors of JAK2 and HDAC based on fusing the pharmacophores of XL019 and vorinostat.
AID1865251	Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability incubated for 72 hrs in presence of SHP099 by CCK-8 assay	2022	Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18	Discovery of Novel Src Homology-2 Domain-Containing Phosphatase 2 and Histone Deacetylase Dual Inhibitors with Potent Antitumor Efficacy and Enhanced Antitumor Immunity.
AID765206	Cytotoxicity against human H69 cells	2013	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17	Identification of novel HDAC inhibitors through cell based screening and their evaluation as potential anticancer agents.
AID619042	Antiproliferative activity against human COLO205 cells after 96 hrs by celltiter 96 assay	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile.
AID1128555	Inhibition of human HDAC-2 using RHKK(Ac) as substrate	2014	European journal of medicinal chemistry, Apr-09, Volume: 76	4,5,6,7-Tetrahydro-isoxazolo-[4,5-c]-pyridines as a new class of cytotoxic Hsp90 inhibitors.
AID1280306	Inhibition of human KDAC1	2016	Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4	Design and Synthesis of Simplified Largazole Analogues as Isoform-Selective Human Lysine Deacetylase Inhibitors.
AID1623527	Inhibition of human recombinant HDAC4 using fluorogenic HDAC substrate class 2A by fluorescence assay	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	A novel class of anthraquinone-based HDAC6 inhibitors.
AID1379289	Antiproliferative activity against human HCT116 cells after 72 hrs by SRB assay	2017	ACS medicinal chemistry letters, Aug-10, Volume: 8, Issue:8	Design, Synthesis, and Biological Evaluation of the First c-Met/HDAC Inhibitors Based on Pyridazinone Derivatives.
AID1704066	Inhibition of human C-terminal Flag tagged HDAC1 (1 to 482 residues) expressed in SF9 cells using Ac-peptide substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by microplate reader method	2020	European journal of medicinal chemistry, Oct-15, Volume: 204	Discovery of Novel c-Mesenchymal-Epithelia transition factor and histone deacetylase dual inhibitors.
AID461268	Antiproliferative activity against human SCC25 cells	2010	Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5	Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer.
AID1769655	Antiproliferative activity against human SKNBE2 cells harboring wild type ALK assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 assay	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	Discovery of 2,4-pyrimidinediamine derivatives as potent dual inhibitors of ALK and HDAC.
AID588212	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1633676	Neuroprotective activity against low serum/K+ deprivation-induced toxicity in rat CGN cells assessed as increase in cell viability at 5 to 25 uM pre-treated for 6 hrs followed by 24 hrs co-treatment with serum/K+ starvation and measured after 24 hrs by MT	2019	ACS medicinal chemistry letters, Apr-11, Volume: 10, Issue:4	Novel Sustainable-by-Design HDAC Inhibitors for the Treatment of Alzheimer's Disease.
AID1337280	Antiproliferative activity against human Jurkat cells	2016	Journal of medicinal chemistry, Sep-22, Volume: 59, Issue:18	Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines.
AID1875508	Antiproliferative activity against human NCI-H526 cells assessed as inhibition of cell growth incubated for 3 days by alamar blue assay	2022	ACS medicinal chemistry letters, Oct-13, Volume: 13, Issue:10	Cancer-Cell-Selective Targeting by Arylcyclopropylamine-Vorinostat Conjugates.
AID1464875	Anti-proliferative activity against human HCT116 cells after 48 hrs by MTT assay	2017	Bioorganic & medicinal chemistry letters, 11-01, Volume: 27, Issue:21	Design, synthesis and biological evaluation of novel histone deacetylase inhibitors incorporating 4-aminoquinazolinyl systems as capping groups.
AID375039	Toxicity in ip dosed BALB/c nu/nu mouse assessed as maximum tolerated dose	2009	Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11	Discovery of a potent class I selective ketone histone deacetylase inhibitor with antitumor activity in vivo and optimized pharmacokinetic properties.
AID1339578	Inhibition of HDAC6 in human U937 cells assessed as increase in alpha-tubulin acetylation at Lys-40 residue at 2 uM after 18 hrs by Western blot method	2017	ACS medicinal chemistry letters, Mar-09, Volume: 8, Issue:3	Structural Requirements of HDAC Inhibitors: SAHA Analogues Modified at the C2 Position Display HDAC6/8 Selectivity.
AID1614253	Antitumor activity against human MM1S cells xenografted in NOD/SCID mouse assessed as tumor growth inhibition at 50 mg/kg, iv qd administered for 10 days and measured every 2 days post last dose by caliper method relative to control
AID1655896	Inhibition of HDAC6 in human RH4 cells assessed as acetylated alpha-tubulin level at 0.15 uM incubated for 72 hrs by Western blot analysis (Rvb = 1 No_unit)	2020	ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5	Design of First-in-Class Dual EZH2/HDAC Inhibitor: Biochemical Activity and Biological Evaluation in Cancer Cells.
AID1752942	Selectivity index, ratio of IC50 for cytotoxicity against human HepG2-A16-CD81EGFP cells to IC50 for antiplasmodial activity against drug-sensitive asexual intraerythrocytic stage of Plasmodium falciparum 3D7 infected in human O+ erythrocytes
AID1486324	Genotoxicity in Salmonella typhimurium TA1535 at 50 times antiproliferative IC50 by Ames test	2017	Bioorganic & medicinal chemistry, 08-01, Volume: 25, Issue:15	Olaparib hydroxamic acid derivatives as dual PARP and HDAC inhibitors for cancer therapy.
AID1511139	Inhibition of HDAC10 (unknown origin) using Ac-ArgThr- Lys(Ac)Lys(Ac)-AMC as substrate preincubated for 5 mins followed by substrate addition and measured after 60 mins by fluorescence based assay	2019	ACS medicinal chemistry letters, Aug-08, Volume: 10, Issue:8	Design, Synthesis, and Biological Evaluation of 2,4-Imidazolinedione Derivatives as HDAC6 Isoform-Selective Inhibitors.
AID322420	Cell cycle arrest in human LNCap cells assessed as accumulation at G2/M phase relative to control at 1 uM	2008	Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6	Improved synthesis of histone deacetylase inhibitors (HDIs) (MS-275 and CI-994) and inhibitory effects of HDIs alone or in combination with RAMBAs or retinoids on growth of human LNCaP prostate cancer cells and tumor xenografts.
AID1441645	Anti-inflammatory activity in LPS-induced C57BL/6 mouse model of acute lung injury assessed as reduction in neutrophil infiltration by measuring MPO activity at 10 to 50 mg/kg, ip pretreated for 1 hr followed LPS challenge measured after 24 hrs	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
AID1215095	Competitive binding affinity to human PXR LBD (111 to 434) by TR-FRET assay relative to SR12813	2011	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1	Identification of clinically used drugs that activate pregnane X receptors.
AID1690103	Growth inhibition of human A549 cells incubated for 48 hrs by SRB assay	2020	European journal of medicinal chemistry, Mar-15, Volume: 190	Isoindoline scaffold-based dual inhibitors of HDAC6 and HSP90 suppressing the growth of lung cancer in vitro and in vivo.
AID1462221	Inhibition of recombinant human HDAC1 after 30 mins by fluorescence assay	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Structure-based design, synthesis and in vitro antiproliferative effects studies of novel dual BRD4/HDAC inhibitors.
AID1128556	Inhibition of human HDAC-3/NCOR-2 using RHKK(Ac) as substrate	2014	European journal of medicinal chemistry, Apr-09, Volume: 76	4,5,6,7-Tetrahydro-isoxazolo-[4,5-c]-pyridines as a new class of cytotoxic Hsp90 inhibitors.
AID347808	Inhibition of human HDAC1	2008	Journal of medicinal chemistry, Dec-11, Volume: 51, Issue:23	Histone deacetylase inhibitors through click chemistry.
AID1535340	Inhibition of full length recombinant human N-terminal GST-tagged HDAC6 expressed in baculovirus infected sf9 cells preincubated for 5 mins followed by biotinylated H3K9-Ac substrate addition and measured after 60 mins by HTRF assay	2019	Bioorganic & medicinal chemistry letters, 02-01, Volume: 29, Issue:3	Design, synthesis, and bioactivity evaluation of novel Bcl-2/HDAC dual-target inhibitors for the treatment of multiple myeloma.
AID546546	Inhibition of HDAC assessed as histone H3K'9+14 acetylation levels by cell based histone H3 hyperacetylation assay	2010	Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24	Novel chimeric histone deacetylase inhibitors: a series of lapatinib hybrides as potent inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and histone deacetylase activity.
AID105421	Inhibitory concentration against MDA-435 cells proliferation	2003	Journal of medicinal chemistry, Nov-20, Volume: 46, Issue:24	Histone deacetylase inhibitors.
AID1248354	Inhibition of porcine kidney microsomal APN using L-Leu-para-nitroanilide as substrate at 10 uM incubated for 2 hrs prior to substrate addition measured after 30 mins by plate reader analysis relative to control	2015	Bioorganic & medicinal chemistry, Oct-15, Volume: 23, Issue:20	Synthesis of chiral ND-322, ND-364 and ND-364 derivatives as selective inhibitors of human gelatinase.
AID1263143	Antagonist activity at ERalpha in human T47D-KBLuc cells assessed as inhibition of E2-induced transcriptional activity by luciferase reporter gene assay	2015	Bioorganic & medicinal chemistry, Dec-15, Volume: 23, Issue:24	Design, synthesis and evaluation of antiestrogen and histone deacetylase inhibitor molecular hybrids.
AID1066166	Cytotoxicity against human LNCAP cells at 50 uM after 72 hrs	2014	Journal of medicinal chemistry, Jan-09, Volume: 57, Issue:1	Pan-histone demethylase inhibitors simultaneously targeting Jumonji C and lysine-specific demethylases display high anticancer activities.
AID1897384	Antiproliferative activity against human Jurkat cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
AID1503842	Selectivity index, ratio of IC50 for recombinant human full length HDAC1 expressed in baculovirus infected Sf9 insect cells to IC50 for recombinant human full length HDAC6 expressed in baculovirus infected Sf9 insect cells	2017	ACS medicinal chemistry letters, Oct-12, Volume: 8, Issue:10	Synthesis and Pharmacological Evaluation of Selective Histone Deacetylase 6 Inhibitors in Melanoma Models.
AID1742745	Genotoxicity in Salmonella typhimurium WP2 uvrA (pKM 101) by Ames test	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Design and synthesis of novel Flavone-based histone deacetylase inhibitors antagonizing activation of STAT3 in breast cancer.
AID1383991	Antiproliferative activity against human SK-N-BE(2) cells after 48 hrs by MTT assay	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	Discovery of meta-sulfamoyl N-hydroxybenzamides as HDAC8 selective inhibitors.
AID1454679	Decrease in alcohol intake in C57BL/6J mouse at 50 mg/kg, ip relative to control	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Class I HDAC Inhibitors: Potential New Epigenetic Therapeutics for Alcohol Use Disorder (AUD).
AID1487017	Inhibition of HDAC3 in human U937 cells assessed as increase in acetylated-histone H3 level at 5 uM incubated for 18 hrs by Western blot method	2017	Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15	The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity.
AID527321	Growth inhibition of human HUT78 cells after 72 hrs by SRB assay	2010	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22	Design and synthesis of novel pyrimidine hydroxamic acid inhibitors of histone deacetylases.
AID1434357	Growth inhibition of human NCI-H23 cells measured after 5 days by sulforhodamine-B assay	2017	European journal of medicinal chemistry, Jan-27, Volume: 126	Improving potency and metabolic stability by introducing an alkenyl linker to pyridine-based histone deacetylase inhibitors for orally available RUNX3 modulators.
AID1821961	Inhibition of full length recombinant human C-terminal His tagged HDAC8 expressed in baculovirus infected Sf9 insect cells using Ac-Leu-GlyLys (Tfa)-AMC as substrate preincubated for 5 mins followed by substrate addition and measured after 30 mins by fluo
AID1849166	Cytotoxicity against human HAL-01 cells assessed as inhibition of cell growth measured after 72 hrs by CellTiter-Glo luminescent assay	2022	Journal of medicinal chemistry, 11-24, Volume: 65, Issue:22	Development of Fluorinated Peptoid-Based Histone Deacetylase (HDAC) Inhibitors for Therapy-Resistant Acute Leukemia.
AID1547256	Inhibition of human recombinant His-tagged BRDT BD1 domain expressed in Escherichia coli BL21(DE3)-R3-pRARE2 cells by AlphaScreen assay	2020	Journal of medicinal chemistry, 04-09, Volume: 63, Issue:7	Discovery of Thieno[2,3-
AID1885254	Inhibition of KDM4E (unknown origin)	2022	Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14	Recent Advances with KDM4 Inhibitors and Potential Applications.
AID1832688	Inhibition of human HDAC4 using Boc-Lys(acetyl)-AMC as fluorogenic substrate measured after 1 hr by flourescence plate reader method	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Cysteine derivatives as acetyl lysine mimics to inhibit zinc-dependent histone deacetylases for treating cancer.
AID637887	Inhibition of Bordetella FB188 HDAH using Boc-L-Lys(acetyl)-MCA as substrate by fluorogenic enzymatic assay	2012	Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2	Synthesis and biochemical analysis of 2,2,3,3,4,4,5,5,6,6,7,7-dodecafluoro-N-hydroxy-octanediamides as inhibitors of human histone deacetylases.
AID1164034	Inhibition of human recombinant HDAC11 after 60 mins by fluorimetric assay	2014	European journal of medicinal chemistry, Oct-30, Volume: 86	Design, synthesis, and biological evaluation of 1, 3-disubstituted-pyrazole derivatives as new class I and IIb histone deacetylase inhibitors.
AID1677495	induction of apoptosis in siRNA-induced BAX knock down human HeLa cells at 0.3 to 3 uM after after 48 hr by annexin V FITC and propidium iodide staining based flow cytometric analysis	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	HDAC-Bax Multiple Ligands Enhance Bax-Dependent Apoptosis in HeLa Cells.
AID1165105	Antileishmanial activity against axenic amastigote stage of Leishmania donovani after 72 hrs by Alamar blue assay	2014	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 24, Issue:20	The antileishmanial activity of isoforms 6- and 8-selective histone deacetylase inhibitors.
AID1707466	Synergistic antifungal activity against Candida albicans 0304103 assessed as fluconazole MIC incubated for 48 hrs in presence of fluconazole by microdilution assay (Rvb = fluconazole alone MIC = >64 ug/ml)	2021	Journal of medicinal chemistry, 01-28, Volume: 64, Issue:2	Novel Carboline Fungal Histone Deacetylase (HDAC) Inhibitors for Combinational Treatment of Azole-Resistant Candidiasis.
AID420638	Inhibition of HDAC in human IGROV1 cells assessed as p53 acetylation at IC80 after 24 hrs by Western blot	2009	European journal of medicinal chemistry, May, Volume: 44, Issue:5	Design, synthesis, and evaluation of biphenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors.
AID1065635	Inhibition of human recombinant HDAC9 catalytic domain using Boc_Lys_TFA as substrate after 60 mins by fluorescence assay	2013	Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24	Design, synthesis, and biological evaluation of potent and selective class IIa histone deacetylase (HDAC) inhibitors as a potential therapy for Huntington's disease.
AID1529549	Induction of apoptosis in human BL2 cells assessed as late apoptotic cells at 10 nM after 48 hrs by annexin V-FITC/propidium iodide double staining-based flow cytometry (Rvb = 2.1%)	2018	Journal of medicinal chemistry, Aug-09, Volume: 61, Issue:15	Design and Synthesis of Tubulin and Histone Deacetylase Inhibitor Based on iso-Combretastatin A-4.
AID1819546	Antitumor immunity against mouse B16-F10 cells implanted in C57BL/6J mouse assessed as fold increase in CD86 expression by flow cytometry analysis relative to control	2022	Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4	Discovery of DNA-Targeting HDAC Inhibitors with Potent Antitumor Efficacy In Vivo That Trigger Antitumor Immunity.
AID1578903	Induction of apoptosis in human Bel7402 cells assessed as increase in cleaved caspase-3 level at 5 uM after 72 hrs by Western blot analysis	2019	Journal of natural products, 06-28, Volume: 82, Issue:6	Hydroxamic Acid Derivatives of β-Carboline/Hydroxycinnamic Acid Hybrids Inducing Apoptosis and Autophagy through the PI3K/Akt/mTOR Pathways.
AID1401555	Antiproliferative activity against human MM473 cells at 10 uM after 72 hrs by MTT assay relative to control	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors.
AID481567	Antitumor activity against mouse S180 cells xenografted in ICR mouse assessed as reduction of tumor weight at 100 mg/kg, ig administered 2 days after tumor inoculation qd for 7 days	2010	Bioorganic & medicinal chemistry letters, May-15, Volume: 20, Issue:10	Synthesis and anticancer evaluation of alpha-lipoic acid derivatives.
AID1653098	Antiproliferative activity against human PC3 cells by CCK8 assay	2019	European journal of medicinal chemistry, Mar-01, Volume: 165	Quinolone hybrids and their anti-cancer activities: An overview.
AID1266811	Antiproliferative activity against human SW620 cells assessed as cell viability after 48 hrs by MTT assay	2015	Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23	Novel β-Carboline/Hydroxamic Acid Hybrids Targeting Both Histone Deacetylase and DNA Display High Anticancer Activity via Regulation of the p53 Signaling Pathway.
AID1775564	Inhibition of full length human C-terminal His-tagged HDAC2 using fluorogenic acetylated peptide as substrate incubated for 30 mins by fluorescence plate reader assay	2021	Journal of medicinal chemistry, 03-25, Volume: 64, Issue:6	Design and Synthesis of Novel Epigenetic Inhibitors Targeting Histone Deacetylases, DNA Methyltransferase 1, and Lysine Methyltransferase G9a with
AID1250643	Inhibition of recombinant human HDAC8 after 60 mins by fluorescence assay	2015	Journal of medicinal chemistry, Oct-08, Volume: 58, Issue:19	Discovery of Novel Class I Histone Deacetylase Inhibitors with Promising in Vitro and in Vivo Antitumor Activities.
AID1380968	Inhibition of VEGF-stimulated VEGFR2 phosphorylation in human HUVEC cells at 100 nM preincubated for 2 hrs followed by VEGF stimulation by Western blot analysis	2018	Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12	Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously.
AID1380949	Antiproliferative activity against human MOLT4 cells after 72 hrs by MTT assay	2018	Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12	Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously.
AID1873384	Inhibition of HDAC4 (unknown origin)	2022	Bioorganic & medicinal chemistry letters, 08-15, Volume: 70	Comparison of three zinc binding groups for HDAC inhibitors - A potency, selectivity and enzymatic kinetics study.
AID373084	Antitumor activity in mouse P388 cells xenografted B6D2F1 mouse assessed as increase in life span at 20 mg/kg/day, ip administered 3 to 7 days postxenografting	2009	European journal of medicinal chemistry, Mar, Volume: 44, Issue:3	Novel amide derivatives as inhibitors of histone deacetylase: design, synthesis and SAR.
AID1441649	Anti-inflammatory activity in LPS-induced C57BL/6 mouse model of acute lung injury assessed as reduction in IL-6 mRNA level pretreated intraperitoneally for 1 hr followed LPS challenge after 24 hrs by qRT-PCR method	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
AID1280277	Inhibition of HDAC6 in human HL60 cells assessed as ratio of acetylated tubulin to GAPDH level at 0.1 uM after 4 hrs by Western blot analysis relative to control	2016	Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4	Synthesis and Biological Investigation of Oxazole Hydroxamates as Highly Selective Histone Deacetylase 6 (HDAC6) Inhibitors.
AID1898904	Antiproliferative activity against human L-428 cells incubated for 24 hrs followed by incubating in drug-free medium for 48 hrs and measured by SRB assay	2022	European journal of medicinal chemistry, Jan-15, Volume: 228	Antitumor activity of novel POLA1-HDAC11 dual inhibitors.
AID274037	Hepatocyte stability	2007	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2	Identification and optimisation of a series of substituted 5-pyridin-2-yl-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.
AID90680	Inhibition of mouse Histone deacetylase 1 (HDAC1) receptor	2004	Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6	3-(4-Aroyl-1-methyl-1H-pyrrol-2-yl)-N-hydroxy-2-propenamides as a new class of synthetic histone deacetylase inhibitors. 3. Discovery of novel lead compounds through structure-based drug design and docking studies.
AID1727731	Inhibition of His-tagged BRD4 bromodomain 1 (unknown origin) using [Lys (5,8,12,16) Ac] H4(1-21) as substrate by fluorescence based assay	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	Discovery of selective HDAC/BRD4 dual inhibitors as epigenetic probes.
AID1709353	Selectivity ratio of IC50 for human HCT-116 cells to IC50 for human Jurkat cells	2021	Bioorganic & medicinal chemistry, 04-01, Volume: 35	Structure-activity relationship and mechanistic studies for a series of cinnamyl hydroxamate histone deacetylase inhibitors.
AID1865242	Antiproliferative activity against human ASPC1 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	2022	Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18	Discovery of Novel Src Homology-2 Domain-Containing Phosphatase 2 and Histone Deacetylase Dual Inhibitors with Potent Antitumor Efficacy and Enhanced Antitumor Immunity.
AID352518	Inhibition of human recombinant HDAC6	2009	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11	Isoxazole moiety in the linker region of HDAC inhibitors adjacent to the Zn-chelating group: effects on HDAC biology and antiproliferative activity.
AID1702089	Antiproliferative activity against human SK-HEP1 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay	2018	Journal of medicinal chemistry, 02-22, Volume: 61, Issue:4	Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma.
AID613340	Antiproliferative activity against human H1299 cells	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Optimization of the in vitro cardiac safety of hydroxamate-based histone deacetylase inhibitors.
AID1697200	Inhibition of HDAC2 (unknown origin)	2020	Bioorganic & medicinal chemistry letters, 11-15, Volume: 30, Issue:22	Design, synthesis and evaluation of novel indirubin-based N-hydroxybenzamides, N-hydroxypropenamides and N-hydroxyheptanamides as histone deacetylase inhibitors and antitumor agents.
AID1865244	Antiproliferative activity against human BXPC-3 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	2022	Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18	Discovery of Novel Src Homology-2 Domain-Containing Phosphatase 2 and Histone Deacetylase Dual Inhibitors with Potent Antitumor Efficacy and Enhanced Antitumor Immunity.
AID343690	Inhibition of HDAC in human HeLa cells	2008	Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13	Trithiocarbonates as a novel class of HDAC inhibitors: SAR studies, isoenzyme selectivity, and pharmacological profiles.
AID1401554	Antiproliferative activity against human MM432 cells at 10 uM after 72 hrs by MTT assay relative to control	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors.
AID1234891	Selectivity ratio of IC50 for HDAC3 (unknown origin) to IC50 for HDAC1 (unknown origin)	2015	Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15	Design, synthesis and preliminary biological evaluation of indoline-2,3-dione derivatives as novel HDAC inhibitors.
AID1591853	Inhibition of recombinant human full-length C-terminal FLAG-tagged HDAC1 expressed in baculovirus expression system using Ac-peptide-AMC as substrate preincubated for 15 mins followed by substrate addition by fluorescence assay	2019	Bioorganic & medicinal chemistry letters, 08-15, Volume: 29, Issue:16	Discovery of novel 9H-purin derivatives as dual inhibitors of HDAC1 and CDK2.
AID540212	Mean residence time in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1413071	Antiproliferative activity against human SKOV3 cells at 10 uM measured every 2 hrs for 200 hrs by IncuCyte ZOOM cell confluence assay	2018	MedChemComm, Jun-01, Volume: 9, Issue:6	Assessment of the trifluoromethyl ketone functionality as an alternative zinc-binding group for selective HDAC6 inhibition.
AID1864219	Binding affinity to 5' FAM-labeled c-myc G4-quadruplex DNA Pu22 (unknown origin) at 50 uM by fluorescence quench assay	2022	Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18	Discovery of a Novel G-Quadruplex and Histone Deacetylase (HDAC) Dual-Targeting Agent for the Treatment of Triple-Negative Breast Cancer.
AID1707464	Antifungal activity against Candida albicans 0304103 incubated for 48 hrs by microdilution assay	2021	Journal of medicinal chemistry, 01-28, Volume: 64, Issue:2	Novel Carboline Fungal Histone Deacetylase (HDAC) Inhibitors for Combinational Treatment of Azole-Resistant Candidiasis.
AID1326519	Inhibition of HDAC in human PC3 cells assessed as increase in amount of acetylated histone H3 at 0.3 uM after 48 hrs by Western blot analysis	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	2-(Phenylsulfonyl)quinoline N-hydroxyacrylamides as potent anticancer agents inhibiting histone deacetylase.
AID1702061	Inhibition of HDAC2 (unknown origin) using fluorogenic HDAC substrate 3 incubated for 30 mins by fluorescence based assay	2018	Journal of medicinal chemistry, 02-22, Volume: 61, Issue:4	Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma.
AID1811362	Inhibition of HDAC6 (unknown origin) using Ac-peptide as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence assay	2021	European journal of medicinal chemistry, Dec-15, Volume: 226	Development of novel tetrahydroisoquinoline-hydroxamate conjugates as potent dual SERDs/HDAC inhibitors for the treatment of breast cancer.
AID545890	Specificity index, ratio for IC50 for human HDAC in HeLa cells to IC50 for HDAC in Plasmodium falciparum 3D7	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Novel inhibitor of Plasmodium histone deacetylase that cures P. berghei-infected mice.
AID1543951	Induction of apoptosis in human Bel7402/5-FU cells assessed as early apoptotic cells at 5.0 uM incubated for 72 hrs by FITC-Annexin V/PI staining based flow cytometry (Rvb = 3.60%)	2019	European journal of medicinal chemistry, Apr-15, Volume: 168	β-Carboline and N-hydroxycinnamamide hybrids as anticancer agents for drug-resistant hepatocellular carcinoma.
AID1861262	Inhibition of HDAC8 (unknown origin)	2022	Bioorganic & medicinal chemistry letters, 09-01, Volume: 71	Design, synthesis and antitumor activity study of PARP-1/HDAC dual targeting inhibitors.
AID482965	Apparent permeability from apical to basolateral side of Caco-2 cells	2010	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11	Acylurea connected straight chain hydroxamates as novel histone deacetylase inhibitors: Synthesis, SAR, and in vivo antitumor activity.
AID1415657	Binding affinity to calf thymus DNA assessed as decrease in maximum absorption wavelength by UV-Vis spectroscopic titration method	2017	MedChemComm, Jun-01, Volume: 8, Issue:6	Development of novel β-carboline-based hydroxamate derivatives as HDAC inhibitors with DNA damage and apoptosis inducing abilities.
AID1764256	Induction of histone H-3 expression in human CAL-27 cells for 24 hrs by Western blot analysis	2021	European journal of medicinal chemistry, Feb-05, Volume: 211	Synergistic induction of apoptosis in resistant head and neck carcinoma and leukemia by alkoxyamide-based histone deacetylase inhibitors.
AID1469310	Induction of apoptosis in human T47D cells assessed as necrotic cells at 10 uM after 48 hrs by annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 0.8%)	2018	Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7	Discovery of N1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7 H-pyrrolo[2,3- d]pyrimidin-2-yl)amino)phenyl)- N8-hydroxyoctanediamide as a Novel Inhibitor Targeting Cyclin-dependent Kinase 4/9 (CDK4/9) and Histone Deacetlyase1 (HDAC1) against Malignant Cancer
AID1548261	Antiproliferative activity against HUVEC cells incubated for 48 hrs by MTT assay
AID1336927	Cytotoxicity against African green monkey Vero cells assessed as cell growth inhibition after 72 hrs by MTT assay	2017	Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3	Bifunctional conjugates with potent inhibitory activity towards cyclooxygenase and histone deacetylase.
AID1126963	Selectivity ratio of IC50 for HDAC2 (unknown origin) to IC50 for HDAC3 (unknown origin)	2014	Journal of medicinal chemistry, Apr-24, Volume: 57, Issue:8	Discovery of the first N-hydroxycinnamamide-based histone deacetylase 1/3 dual inhibitors with potent oral antitumor activity.
AID1697203	Induction of apoptosis in human SW620 cells assessed as early apoptotic cells by flow cytometry	2020	Bioorganic & medicinal chemistry letters, 11-15, Volume: 30, Issue:22	Design, synthesis and evaluation of novel indirubin-based N-hydroxybenzamides, N-hydroxypropenamides and N-hydroxyheptanamides as histone deacetylase inhibitors and antitumor agents.
AID134163	Antitumor activity against HT1080 cell line in mouse xenograft model after orally dosed once every other day at 100 mg/kg	2003	Bioorganic & medicinal chemistry letters, Jun-02, Volume: 13, Issue:11	Indole amide hydroxamic acids as potent inhibitors of histone deacetylases.
AID1542185	Inhibition of HDAC7 (unknown origin)	2019	Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7	Kinase and Histone Deacetylase Hybrid Inhibitors for Cancer Therapy.
AID1873409	Inhibition of HDAC3 (unknown origin) preincubated for 5 mins	2022	Bioorganic & medicinal chemistry letters, 08-15, Volume: 70	Comparison of three zinc binding groups for HDAC inhibitors - A potency, selectivity and enzymatic kinetics study.
AID1873408	Inhibition of HDAC2 (unknown origin) preincubated for 120 mins	2022	Bioorganic & medicinal chemistry letters, 08-15, Volume: 70	Comparison of three zinc binding groups for HDAC inhibitors - A potency, selectivity and enzymatic kinetics study.
AID669759	Growth inhibition of human PC3 cells after 48 hrs by SRB assay	2012	Journal of medicinal chemistry, Apr-26, Volume: 55, Issue:8	Synthesis and biological evaluation of 1-arylsulfonyl-5-(N-hydroxyacrylamide)indoles as potent histone deacetylase inhibitors with antitumor activity in vivo.
AID1073051	Reactivation of latent HIV1 NL4-3-Luc expression in human naive CD4+ T cells treated 7 days post-infection measured after 48 hrs by luminescence plate reader analysis	2014	Journal of natural products, Mar-28, Volume: 77, Issue:3	Study of marine natural products including resorcyclic acid lactones from Humicola fuscoatra that reactivate latent HIV-1 expression in an in vitro model of central memory CD4+ T cells.
AID1688036	Induction of apoptosis in human HL-60 cells assessed as late apoptotic cells at 1 uM measured after 24 hrs by Annexin-V/FITC and propidium iodide staining based flow cytometry (Rvb = 7.24 %)	2020	European journal of medicinal chemistry, Feb-15, Volume: 188	A 18β-glycyrrhetinic acid conjugate with Vorinostat degrades HDAC3 and HDAC6 with improved antitumor effects.
AID1742685	Induction of cell cycle arrest in mouse 4T1 cells assessed as S phase accumulation at 2 uM incubated for 24 hrs by PI staining based flow cytometry analysis (Rvb = 19.43 %)	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Design and synthesis of novel Flavone-based histone deacetylase inhibitors antagonizing activation of STAT3 in breast cancer.
AID1702063	Inhibition of recombinant human N-terminal GST-tagged and C-terminal His-tagged HDAC4 (627 to 1084 end residues) expressed in baculovirus infected Sf9 cells using fluorogenic HDAC class2a as substrate measured after 30 mins by fluorescence based assay	2018	Journal of medicinal chemistry, 02-22, Volume: 61, Issue:4	Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma.
AID1060990	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	2014	Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1	Synthesis and anticancer activities of thieno[3,2-d]pyrimidines as novel HDAC inhibitors.
AID1141770	Cytotoxicity against human TSGH cells by MTT assay	2014	Journal of medicinal chemistry, May-22, Volume: 57, Issue:10	Azaindolylsulfonamides, with a more selective inhibitory effect on histone deacetylase 6 activity, exhibit antitumor activity in colorectal cancer HCT116 cells.
AID1177047	Inhibition of human HDAC10 using RHKK(Ac) as substrate by fluorimetric analysis	2015	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 25, Issue:3	Hydroxamic acid based histone deacetylase inhibitors with confirmed activity against the malaria parasite.
AID300835	Growth inhibition of human NCI-H23 cells after 21 hrs by MTT assay	2007	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17	Pomiferin, histone deacetylase inhibitor isolated from the fruits of Maclura pomifera.
AID438216	Inhibition of HDAC1/2 from human HeLa cells	2009	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23	Design and synthesis of novel histone deacetylase inhibitor derived from nuclear localization signal peptide.
AID605541	Antiproliferative activity against human U937 cells after 72 hrs by WST-1 assay	2010	Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24	Discovery of 2-(6-{[(6-fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a class I selective orally active histone deacetylase inhibitor.
AID1164031	Inhibition of human recombinant HDAC9 after 60 mins by fluorimetric assay	2014	European journal of medicinal chemistry, Oct-30, Volume: 86	Design, synthesis, and biological evaluation of 1, 3-disubstituted-pyrazole derivatives as new class I and IIb histone deacetylase inhibitors.
AID1898981	Induction of cell cycle arrest in human H460-R9A cells assessed as accumulation of cells at S phase at 1.9 uM after 72 hrs by flow cytometry (Rvb = 34.5%)	2022	European journal of medicinal chemistry, Jan-15, Volume: 228	Antitumor activity of novel POLA1-HDAC11 dual inhibitors.
AID723463	Inhibition of human HDAC5 by fluorescence assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1605969	Antiproliferative activity against human HCC2998 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	2020	Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8	Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors.
AID1251322	Growth inhibition of human H460 cells after 72 hrs	2015	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 25, Issue:20	Investigation on the ZBG-functionality of phenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase inhibitors.
AID1518780	Inhibition of human HDAC6 using Arg-His-Lys-Lys (Ac) as substrate incubated for 2 hrs by fluorescence assay	2019	European journal of medicinal chemistry, Dec-15, Volume: 184	Discovery of a potent histone deacetylase (HDAC) 3/6 selective dual inhibitor.
AID1848623	Cytotoxicity against human HT-29 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay	2022	Journal of medicinal chemistry, 11-10, Volume: 65, Issue:21	First-in-Class Dual Mechanism Ferroptosis-HDAC Inhibitor Hybrids.
AID591326	Inhibition of HDAC in human HeLa cells at 0.1 uM by fluorescent activity assay	2011	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8	Alkyl piperidine and piperazine hydroxamic acids as HDAC inhibitors.
AID1547260	Inhibition of human recombinant His-tagged BRD3 BD1 domain expressed in Escherichia coli BL21(DE3)-R3-pRARE2 cells by AlphaScreen assay	2020	Journal of medicinal chemistry, 04-09, Volume: 63, Issue:7	Discovery of Thieno[2,3-
AID1348936	Effect on TIMP3 gene expression in human PC3 cells at IC50 after 12 hrs by RT-PCR method	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Discovery of aliphatic-chain hydroxamates containing indole derivatives with potent class I histone deacetylase inhibitory activities.
AID1401484	Cytotoxicity against human U937 cells assessed as decrease in cell viability after 44 hrs by MTT assay	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
AID1861259	Inhibition of HDAC3 (unknown origin)	2022	Bioorganic & medicinal chemistry letters, 09-01, Volume: 71	Design, synthesis and antitumor activity study of PARP-1/HDAC dual targeting inhibitors.
AID1384232	Inhibition of HDAC6 in human SH-SY5Y cells assessed as induction of tubulin K-40 acetylation level after 2 hrs by Western blot analysis	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease.
AID1401373	Inhibition of HDAC2 in human HeLa-S3 cell lysates preincubated for 15 mins followed by HDAC-Glo substrate addition measured after 30 to 40 mins by fluorimetric method	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
AID1127318	Inhibition of HDAC2 in human HeLa cells using KI-104 as substrate after 40 mins by fluorescence analysis	2014	European journal of medicinal chemistry, May-22, Volume: 79	Influence of the adamantyl moiety on the activity of biphenylacrylohydroxamic acid-based HDAC inhibitors.
AID1126988	Inhibition of HDAC3 in human U937 cells assessed as increase of intracellular acetylated histone H4 level at 1 uM after 24 hrs by Western blot analysis	2014	Journal of medicinal chemistry, Apr-24, Volume: 57, Issue:8	Discovery of the first N-hydroxycinnamamide-based histone deacetylase 1/3 dual inhibitors with potent oral antitumor activity.
AID1067346	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay	2014	Bioorganic & medicinal chemistry, Mar-01, Volume: 22, Issue:5	Design, synthesis and preliminary bioactivity studies of 1,2-dihydrobenzo[d]isothiazol-3-one-1,1-dioxide hydroxamic acid derivatives as novel histone deacetylase inhibitors.
AID1704069	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay	2020	European journal of medicinal chemistry, Oct-15, Volume: 204	Discovery of Novel c-Mesenchymal-Epithelia transition factor and histone deacetylase dual inhibitors.
AID1821957	Inhibition of HDAC in human HeLa nuclear extracts using fluorometric substrate incubated for 30 mins by fluorescence plate reader analysis
AID1478600	Inhibition of Class 2a histone deacetylase in human K562 cells using Boc-Lys-(epsilon-trifluoromethylacetyl)-AMC as substrate preincubated with compound for 3 hrs followed by substrate addition measured after 3 hrs by fluorometric analysis	2017	European journal of medicinal chemistry, Jun-16, Volume: 133	Design, synthesis and biological evaluation of quinoline derivatives as HDAC class I inhibitors.
AID1622977	Inhibition of human recombinant full length C-terminal His-tagged HDAC3 (1 to 428 residues)/N-terminal GST-tagged NCOR2 (395 to 489 residues) expressed in insect cells using Boc-l-Lys(Ac)-AMC as substrate preincubated up to 3 hrs and measured after 35 min	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.
AID1915572	Inhibition of EGFR (unknown origin)	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors.
AID288453	Growth inhibition of human MDA-MB-231 cells by SRB assay	2007	Journal of medicinal chemistry, May-31, Volume: 50, Issue:11	Structure-activity relationship studies of a series of novel delta-lactam-based histone deacetylase inhibitors.
AID1246526	Therapeutic index, ratio of CC50 for HEK293 cells to IC50 for human U937 cells	2015	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 25, Issue:19	Discovery of 1-hydroxypyridine-2-thiones as selective histone deacetylase inhibitors and their potential application for treating leukemia.
AID1487013	Selectivity index, ratio of IC50 for HDAC3 (unknown origin) to IC50 for HDAC8 (unknown origin)	2017	Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15	The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity.
AID1282290	Toxicity in NOD/SCID mouse xenografted with human MV4-11 cells assessed as death at 50 mg/kg, ip q2d for 12 days	2016	Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4	Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
AID1751996	Inhibition of HDAC8 (unknown origin)	2021	Bioorganic & medicinal chemistry letters, 10-01, Volume: 49	Discovery of novel pyrazolopyrimidine derivatives as potent mTOR/HDAC bi-functional inhibitors via pharmacophore-merging strategy.
AID366648	Antiproliferative activity against human MiaPaca2 cells after 72 hrs by MTT assay	2008	Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15	Use of the nitrile oxide cycloaddition (NOC) reaction for molecular probe generation: a new class of enzyme selective histone deacetylase inhibitors (HDACIs) showing picomolar activity at HDAC6.
AID1260646	Inhibition of human recombinant HDAC10 at 20 uM using Boc-Lys(Ac)-AMC as substrate after 30 to 60 mins by microplate reader assay
AID1260639	Inhibition of human recombinant HDAC3 at 20 uM using Boc-Lys(Ac)-AMC as substrate after 30 to 60 mins by microplate reader assay
AID1550126	Induction of apoptosis in human K562 cells assessed as viable cells at 1 uM after 24 hrs by Annexin-V/propidium iodide staining-based flow cytometric analysis (Rvb = 85.7%)	2019	Journal of medicinal chemistry, 04-25, Volume: 62, Issue:8	Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies.
AID1754768	Downregulation of SIRT1 gene expression in human MCF7 cells at 3 uM incubated for 24 hrs by whole transcriptome analysis	2021	Bioorganic & medicinal chemistry, 07-15, Volume: 42	Discovery of novel class of histone deacetylase inhibitors as potential anticancer agents.
AID373082	Inhibition of human recombinant HDAC9	2009	European journal of medicinal chemistry, Mar, Volume: 44, Issue:3	Novel amide derivatives as inhibitors of histone deacetylase: design, synthesis and SAR.
AID1898979	Induction of cell cycle arrest in human H460-R9A cells assessed as accumulation of cells at sub-G1 phase at 1.9 uM after 72 hrs by flow cytometry (Rvb = 1.5%)	2022	European journal of medicinal chemistry, Jan-15, Volume: 228	Antitumor activity of novel POLA1-HDAC11 dual inhibitors.
AID1129008	Inhibition of human HDAC-6 using RHKK(Ac) as substrate by fluorescence assay	2014	Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6	Synthesis and evaluation of new Hsp90 inhibitors based on a 1,4,5-trisubstituted 1,2,3-triazole scaffold.
AID1466063	Inhibition of recombinant human full length HDAC6 using Fluor-de-Lys as substrate after 60 mins by spectrofluorimetric analysis	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	4-Indolyl-N-hydroxyphenylacrylamides as potent HDAC class I and IIB inhibitors in vitro and in vivo.
AID482958	Half life in mouse liver microsome	2010	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11	Acylurea connected straight chain hydroxamates as novel histone deacetylase inhibitors: Synthesis, SAR, and in vivo antitumor activity.
AID1547246	Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability measured after 24 to 48 hrs by MTT assay	2020	Journal of medicinal chemistry, 04-09, Volume: 63, Issue:7	Discovery of Thieno[2,3-
AID1848634	Cytotoxicity against human Hs578Bst cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay	2022	Journal of medicinal chemistry, 11-10, Volume: 65, Issue:21	First-in-Class Dual Mechanism Ferroptosis-HDAC Inhibitor Hybrids.
AID1901161	Antiproliferative activity against human A549 cells measured after 48 hrs by MTT assay	2022	Bioorganic & medicinal chemistry, 02-15, Volume: 56	Synthesis and biological evaluation of aminobenzamides containing purine moiety as class I histone deacetylases inhibitors.
AID1164770	Antitumor activity against human A2780 cells xenografted in athymic nude mouse assessed as tumor volume inhibition at 100 mg/kg, po qd for 5 days a week for 2 weeks	2014	Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20	ST7612AA1, a thioacetate-ω(γ-lactam carboxamide) derivative selected from a novel generation of oral HDAC inhibitors.
AID1141798	Selectivity ratio of IC50 for HDAC2 (unknown origin) to IC50 for HDAC6 (unknown origin)	2014	Journal of medicinal chemistry, May-22, Volume: 57, Issue:10	Azaindolylsulfonamides, with a more selective inhibitory effect on histone deacetylase 6 activity, exhibit antitumor activity in colorectal cancer HCT116 cells.
AID404451	Antimalarial activity against Plasmodium falciparum TM90C2A by hypoxanthine uptake	2008	Journal of medicinal chemistry, Jun-26, Volume: 51, Issue:12	A series of potent and selective, triazolylphenyl-based histone deacetylases inhibitors with activity against pancreatic cancer cells and Plasmodium falciparum.
AID1326512	Antiproliferative activity against human PC3 cells after 48 hrs by SRB assay	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	2-(Phenylsulfonyl)quinoline N-hydroxyacrylamides as potent anticancer agents inhibiting histone deacetylase.
AID734728	Inhibition of HDAC6 in human LNCAP cells assessed as increase in tubulin polymerization after 4 hrs by Western blotting analysis	2013	Journal of medicinal chemistry, May-09, Volume: 56, Issue:9	3-Hydroxypyridin-2-thione as novel zinc binding group for selective histone deacetylase inhibition.
AID1349724	Inhibition of HDAC2 (unknown origin)	2018	ACS medicinal chemistry letters, Jan-11, Volume: 9, Issue:1	Dual NAMPT/HDAC Inhibitors as a New Strategy for Multitargeting Antitumor Drug Discovery.
AID615999	Antiproliferative activity against human PC3 cells after 48 hrs by SRB assay	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Synthesis and evaluation of aliphatic-chain hydroxamates capped with osthole derivatives as histone deacetylase inhibitors.
AID1784969	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Design, synthesis and biological evaluation of novel hybrids targeting mTOR and HDACs for potential treatment of hepatocellular carcinoma.
AID1826632	Synergistic antiproliferative effect on HEL cells assessed as combination index at 0.12 uM in presence of 3-Fluoro-10-hydroxy-14-methyl-8,13,13b,14-tetrahydro-7H-indolo[2',3':3,4]pyrido[2,1-b]quinazolin-5-one	2022	Journal of medicinal chemistry, 03-24, Volume: 65, Issue:6	Evodiamine-Inspired Topoisomerase-Histone Deacetylase Dual Inhibitors: Novel Orally Active Antitumor Agents for Leukemia Therapy.
AID1742648	Induction of apoptosis in human MDA-MB-231 cells xenografted in BALB/c mouse assessed as increase in caspase-3 cleavage by immunohistochemistry method	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Design and synthesis of novel Flavone-based histone deacetylase inhibitors antagonizing activation of STAT3 in breast cancer.
AID1731758	Inhibition of recombinant human HDAC7 using Ac-LGK(TFA)-AMC as substrate pre-incubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence based assay	2021	Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4	HDAC7 Inhibition by Phenacetyl and Phenylbenzoyl Hydroxamates.
AID1873412	Inhibition of HDAC3 (unknown origin) preincubated for 90 mins	2022	Bioorganic & medicinal chemistry letters, 08-15, Volume: 70	Comparison of three zinc binding groups for HDAC inhibitors - A potency, selectivity and enzymatic kinetics study.
AID1181306	Inhibition of HDAC1 in human U937 cells assessed as increase in acetyl-histone H3 level at 5 uM by Western blotting method	2014	Journal of medicinal chemistry, Jul-24, Volume: 57, Issue:14	1,3,4-Oxadiazole-containing histone deacetylase inhibitors: anticancer activities in cancer cells.
AID1225987	Induction of apoptosis in human HCT116 cells assessed as necrotic cells at 5 uM after 24 hrs by annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 8%)	2015	ACS medicinal chemistry letters, Mar-12, Volume: 6, Issue:3	Discovery of Novel Multiacting Topoisomerase I/II and Histone Deacetylase Inhibitors.
AID1225989	Induction of apoptosis in human HCT116 cells assessed as late apoptotic cells at 5 uM after 48 hrs by annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 3.03%)	2015	ACS medicinal chemistry letters, Mar-12, Volume: 6, Issue:3	Discovery of Novel Multiacting Topoisomerase I/II and Histone Deacetylase Inhibitors.
AID765377	Inhibition of recombinant human HDAC5 enzyme using Ac-LeuGlyLys (tfa)-AMC as substrate at 50 uM after 15 to 30 mins	2013	Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16	Total synthesis and full histone deacetylase inhibitory profiling of Azumamides A-E as well as β²- epi-Azumamide E and β³-epi-Azumamide E.
AID1206743	Cytotoxicity against human ES2 cells assessed as growth inhibition after 48 hrs by MTT assay	2015	Journal of medicinal chemistry, May-28, Volume: 58, Issue:10	Design, synthesis, and antitumor evaluation of novel histone deacetylase inhibitors equipped with a phenylsulfonylfuroxan module as a nitric oxide donor.
AID605539	Antiproliferative activity against human MOLT4 cells after 72 hrs by WST-1 assay	2010	Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24	Discovery of 2-(6-{[(6-fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a class I selective orally active histone deacetylase inhibitor.
AID274069	Bioavailability after i.p. dosing at 5 mg kg-1	2007	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2	Identification and optimisation of a series of substituted 5-(1H-pyrazol-3-yl)-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.
AID672032	Ratio of IC50 for human HDAC1 preincubated for 3 hrs to IC50 for human HDAC1 preincubated for 5 mins	2012	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 22, Issue:15	Design, synthesis, modeling, biological evaluation and photoaffinity labeling studies of novel series of photoreactive benzamide probes for histone deacetylase 2.
AID1449322	Inhibition of HDAC in human A2780 cells using Boc-Lys(epsilon-Ac)-AMC as substrate preincubated for 18 hrs followed by substrate addition measured after 3 hrs by fluorescence assay	2017	Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13	Alkoxyurea-Based Histone Deacetylase Inhibitors Increase Cisplatin Potency in Chemoresistant Cancer Cell Lines.
AID366650	Antiproliferative activity against human SU.86.86 cells after 72 hrs by MTT assay	2008	Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15	Use of the nitrile oxide cycloaddition (NOC) reaction for molecular probe generation: a new class of enzyme selective histone deacetylase inhibitors (HDACIs) showing picomolar activity at HDAC6.
AID80246	Inhibitory activity against HCT116 human colon cell growth	2003	Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21	N-hydroxy-3-phenyl-2-propenamides as novel inhibitors of human histone deacetylase with in vivo antitumor activity: discovery of (2E)-N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide (NVP-LAQ824).
AID1699974	Inhibition of recombinant human HDAC8 using Boc-Lys(Ac)-AMC as substrate incubated for 60 mins by fluorimetric assay	2020	Bioorganic & medicinal chemistry letters, 12-15, Volume: 30, Issue:24	Discovery of thiosemicarbazone-containing compounds with potent anti-proliferation activity against drug-resistant K562/A02 cells.
AID1737153	Induction of apoptosis in human HCT-116 cells assessed as late apoptotic cells at 1 uM after 24 hrs by Annexin V-FITC/PI staining based flow cytometric analysis (Rvb = 5.14%)	2020	European journal of medicinal chemistry, Apr-15, Volume: 192	Design, synthesis and biological evaluation of novel indazole-based derivatives as potent HDAC inhibitors via fragment-based virtual screening.
AID1861252	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 7 days	2022	Bioorganic & medicinal chemistry letters, 09-01, Volume: 71	Design, synthesis and antitumor activity study of PARP-1/HDAC dual targeting inhibitors.
AID1056037	Antiproliferative activity against human A549 cells after 48 hrs	2013	Journal of natural products, Nov-22, Volume: 76, Issue:11	Total synthesis of schizocommunin and revision of its structure.
AID1164175	Cell cycle arrest in human K562 cells assessed as block at G2-M phase at 40 uM after 24 hrs using propidium iodide staining by FACScan flow cytometry	2014	ACS medicinal chemistry letters, Sep-11, Volume: 5, Issue:9	Novel antiproliferative chimeric compounds with marked histone deacetylase inhibitory activity.
AID1250653	Antiproliferative activity against human DU145 cells after 72 hrs by CCK8 assay	2015	Journal of medicinal chemistry, Oct-08, Volume: 58, Issue:19	Discovery of Novel Class I Histone Deacetylase Inhibitors with Promising in Vitro and in Vivo Antitumor Activities.
AID1162218	Cell cycle arrest in human HL60 cells assessed as accumulation at G1 phase at 1 uM by propidium iodide staining-based flow cytometry (Rvb = 58.9%)	2014	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 24, Issue:19	Design, synthesis and biological evaluation of β-boswellic acid based HDAC inhibitors as inducers of cancer cell death.
AID1389960	Inhibition of HDAC1/CoREST3 in HEK293 whole cell extract using fluorescent acetylated histone peptide as substrate after 60 mins by fluorescence based assay	2018	Bioorganic & medicinal chemistry letters, 04-01, Volume: 28, Issue:6	Novel polyamine-based Histone deacetylases-Lysine demethylase 1 dual binding inhibitors.
AID1234900	Antiproliferative activity against human HEL cells after 48 hrs by MTT assay	2015	Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15	Design, synthesis and preliminary biological evaluation of indoline-2,3-dione derivatives as novel HDAC inhibitors.
AID1266835	Induction of caspase-3 cleavage in human HCT116 cells at 1 to 5 uM after 48 hrs by western blot analysis	2015	Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23	Novel β-Carboline/Hydroxamic Acid Hybrids Targeting Both Histone Deacetylase and DNA Display High Anticancer Activity via Regulation of the p53 Signaling Pathway.
AID1737135	Inhibition of recombinant human full length C-terminal His-tagged HDAC8 expressed in sf9 insect cells using Boc-Lys(TFA)-AM as substrate incubated for 60 mins by fluorescence assay	2020	European journal of medicinal chemistry, Apr-15, Volume: 192	Design, synthesis and biological evaluation of novel indazole-based derivatives as potent HDAC inhibitors via fragment-based virtual screening.
AID519583	Antimalarial activity against chloroquine-resistant Plasmodium falciparum Dd2 infected in O+ human erythrocytes by [3H]hypoxanthine incorporation assay	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Potent antimalarial activity of histone deacetylase inhibitor analogues.
AID382343	Viability of human DU145 cells after 72 hrs by trypan blue staining	2008	Bioorganic & medicinal chemistry, May-01, Volume: 16, Issue:9	Synthesis and structure-activity relationship of histone deacetylase (HDAC) inhibitors with triazole-linked cap group.
AID90520	Inhibition of in vitro enzyme activity measured in partially purified rat liver Histone deacetylase preparation	2002	Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15	Structure-activity relationships on phenylalanine-containing inhibitors of histone deacetylase: in vitro enzyme inhibition, induction of differentiation, and inhibition of proliferation in Friend leukemic cells.
AID1281854	Antiproliferative activity against human LP-1 cells after 72 hrs by CellTiter 96 aqueous non-radioactive cell proliferation assay	2016	European journal of medicinal chemistry, Apr-13, Volume: 112	Design, synthesis and biological evaluation of bisthiazole-based trifluoromethyl ketone derivatives as potent HDAC inhibitors with improved cellular efficacy.
AID1542179	Inhibition of HDAC1 (unknown origin)	2019	Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7	Kinase and Histone Deacetylase Hybrid Inhibitors for Cancer Therapy.
AID1762492	Inhibition of N-terminal GST-tagged full length human HDAC6 expressed in baculovirus-infected Sf9 cells using Boc-Lys (acetyl)-AMC as substrate preincubated for 5 mins followed by substrate addition and further incubated for 30 mins by fluorescence based	2021	European journal of medicinal chemistry, Jul-05, Volume: 219	Synthesis and biological evaluation of phenothiazine derivative-containing hydroxamic acids as potent class II histone deacetylase inhibitors.
AID1401533	Antiproliferative activity against human HeLa cells after 72 hrs by SRB assay	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors.
AID1821959	Inhibition of recombinant human His-tagged HDAC3 expressed in baculovirus insect cells using Ac-Leu-Gly-Lys (Ac)-AMC as substrate preincubated for 5 mins followed by substrate addition and measured after 30 mins by fluorescence microtiter plate reader ass
AID1848566	Ratio of IC50 for cytotoxicity against human RPE cells to IC50 for cytotoxicity against human HCT-116 cells	2022	Journal of medicinal chemistry, 11-10, Volume: 65, Issue:21	First-in-Class Dual Mechanism Ferroptosis-HDAC Inhibitor Hybrids.
AID1898924	Antiproliferative activity against human NCI-H460 cells at 7.4 uM assessed as reduction in p-ERK1/2 level and measured by Western blot analysis	2022	European journal of medicinal chemistry, Jan-15, Volume: 228	Antitumor activity of novel POLA1-HDAC11 dual inhibitors.
AID90665	Inhibitory activity against human Histone deacetylase 1	2004	Journal of medicinal chemistry, Jun-17, Volume: 47, Issue:13	On the function of the 14 A long internal cavity of histone deacetylase-like protein: implications for the design of histone deacetylase inhibitors.
AID1915525	Antiproliferative activity against human PC-3 cells incubated for 48 hrs by Sulforhodamine B staining method	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors.
AID760520	Cytotoxicity against human SK-BR-3 cells after 72 hrs by WST1 assay	2013	ACS medicinal chemistry letters, Aug-08, Volume: 4, Issue:8	Development of a chimeric c-Src kinase and HDAC inhibitor.
AID1282232	Selectivity ratio of IC50 for human recombinant HDAC1 to IC50 for human recombinant HDAC6	2016	Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4	Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
AID1384234	Inhibition of PDE5 in human SH-SY5Y cells assessed as induction of phosphorylated CREB level at 500 nM after 2 hrs by Western blot analysis relative to control	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease.
AID1449217	Inhibition of full length human recombinant C-terminal FLAG-tagged HDAC2 expressed in baculovirus infected Sf9 insect cells using Boc-Lys(epsilon-Ac)-AMC as substrate measured after 90 mins by fluorescence assay	2017	Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13	Design, Multicomponent Synthesis, and Anticancer Activity of a Focused Histone Deacetylase (HDAC) Inhibitor Library with Peptoid-Based Cap Groups.
AID1898982	Induction of cell cycle arrest in human H460-R9A cells assessed as accumulation of cells at G2/M phase at 1.9 uM after 72 hrs by flow cytometry (Rvb = 15.4%)	2022	European journal of medicinal chemistry, Jan-15, Volume: 228	Antitumor activity of novel POLA1-HDAC11 dual inhibitors.
AID473029	Ex vivo inhibition of human HDAC1 in human Caco-2 cells by fluorometric cellular activity assay	2010	Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5	Biological and biophysical properties of the histone deacetylase inhibitor suberoylanilide hydroxamic acid are affected by the presence of short alkyl groups on the phenyl ring.
AID1549139	Antifungal activity against azole-resistant Candida albicans 4108 after 48 hrs by spectrophotometry-based serial microdilution method	2020	Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10	Discovery of Novel Fungal Lanosterol 14α-Demethylase (CYP51)/Histone Deacetylase Dual Inhibitors to Treat Azole-Resistant Candidiasis.
AID525022	Inhibition of HDAC in human CFBE41o- cell line assessed as increase in total CFTR protein level including CFTR glycoform at 0.1 uM by immunoblot analysis	2010	Nature chemical biology, Jan, Volume: 6, Issue:1	Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.
AID1901765	Selectivity ratio of IC50 for full length human recombinant HDAC8 to IC50 for full length human recombinant HDAC6	2022	Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4	Discovery of HDAC6-Selective Inhibitor NN-390 with
AID1550150	Antitumor activity against HEL cells xenografted in BALB/c nu mouse assessed as reduction in tumor volume at 100 mg/kg/day, ip administered for 16 days and measured every 3 days during compound dosing by caliper method relative to control	2019	Journal of medicinal chemistry, 04-25, Volume: 62, Issue:8	Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies.
AID1848592	Induction of cell cycle arrest in human NCI-H522 cells assessed as accumulation at S phase 5 uM incubated for 24 to 72 hrs by PI staining based flow cytometric analysis	2022	Journal of medicinal chemistry, 11-10, Volume: 65, Issue:21	First-in-Class Dual Mechanism Ferroptosis-HDAC Inhibitor Hybrids.
AID1459955	Inhibition of recombinant human HDAC6 using fluorogenic substrate by fluorescence assay	2017	European journal of medicinal chemistry, Jan-05, Volume: 125	3-Aroylindoles display antitumor activity in vitro and in vivo: Effects of N1-substituents on biological activity.
AID1459956	Selectivity ratio of IC50 for recombinant human HDAC1 to IC50 for recombinant human HDAC6	2017	European journal of medicinal chemistry, Jan-05, Volume: 125	3-Aroylindoles display antitumor activity in vitro and in vivo: Effects of N1-substituents on biological activity.
AID1742758	In vivo inhibition of STAT-3 in tumor of human MDA-MB-231 cells xenografted in BALB/c mouse assessed as decrease in STAT-3 phosphorylation by immunohistochemistry method	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Design and synthesis of novel Flavone-based histone deacetylase inhibitors antagonizing activation of STAT3 in breast cancer.
AID1832684	Antiproliferative activity against human K562 cells assessed as inhibition of cell proliferation incubated for 48 hrs by CCK8 assay	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Cysteine derivatives as acetyl lysine mimics to inhibit zinc-dependent histone deacetylases for treating cancer.
AID1401591	Resistance index, ratio of IC50 for human A2780/DX cells to IC50 for human A2780 cells	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors.
AID618184	Toxicity in nude BALB/c mouse xenografted with human A2780 cells assessed as maximum body weight loss at 200 mg/kg, po QD for 21 days measured on day 13	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile.
AID1055355	Inhibition of human recombinant HDAC2 after 30 mins by fluorescence assay	2013	Journal of natural products, Nov-22, Volume: 76, Issue:11	Santacruzamate A, a potent and selective histone deacetylase inhibitor from the Panamanian marine cyanobacterium cf. Symploca sp.
AID723154	Potentiation of 1 uM cisplatin-induced toxicity in 0.5 uM cisplatin resistant human KYSE-510 cells at 1 uM pretreated for 48 hrs followed by 0.5 uM cisplatin treatment by MTT assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID90672	Inhibitory activity against maize Histone deacetylase 1-B	2003	Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23	Discovery of (aryloxopropenyl)pyrrolyl hydroxyamides as selective inhibitors of class IIa histone deacetylase homologue HD1-A.
AID1548727	Inhibition of recombinant human HDAC2 expressed in baculovirus expression system using Boc-Lys(acetyl)-AMC as substrate preincubated for 1 hr followed by substrate addition and measured after 2 hrs by fluorescence based micro plate reader analysis	2020	Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10	Design of Hydrazide-Bearing HDACIs Based on Panobinostat and Their p53 and FLT3-ITD Dependency in Antileukemia Activity.
AID765204	Cytotoxicity against human Hep3B cells	2013	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17	Identification of novel HDAC inhibitors through cell based screening and their evaluation as potential anticancer agents.
AID273180	Cell cycle arrest in U937 cells by accumulation at S/G2/M phase at 5 uM after 48 hrs	2006	Journal of medicinal chemistry, Oct-05, Volume: 49, Issue:20	Synthesis and biological properties of novel, uracil-containing histone deacetylase inhibitors.
AID663474	Apparent permeability from apical to basolateral side in human Caco2 cells at 10 uM	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Discovery and extensive in vitro evaluations of NK-HDAC-1: a chiral histone deacetylase inhibitor as a promising lead.
AID1260640	Inhibition of human recombinant HDAC4 at 20 uM using Boc-Lys(Tfa)-AMC as substrate after 30 to 60 mins by microplate reader assay
AID328797	Inhibition of HDAC4 gain-of-function phenotype expressed in Escherichia coli	2008	Journal of medicinal chemistry, Apr-24, Volume: 51, Issue:8	A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo.
AID1139706	Inhibition of HDAC in human HeLa cell nuclear extract using acetylated lysine as substrate after 30 mins by spectrophotometric analysis	2014	Bioorganic & medicinal chemistry, May-01, Volume: 22, Issue:9	Search for novel histone deacetylase inhibitors. Part II: design and synthesis of novel isoferulic acid derivatives.
AID1067344	Antiproliferative activity against human K562 cells after 48 hrs by MTT assay	2014	Bioorganic & medicinal chemistry, Mar-01, Volume: 22, Issue:5	Design, synthesis and preliminary bioactivity studies of 1,2-dihydrobenzo[d]isothiazol-3-one-1,1-dioxide hydroxamic acid derivatives as novel histone deacetylase inhibitors.
AID1765322	Antiproliferative activity against human A498 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay	2021	European journal of medicinal chemistry, Oct-15, Volume: 222	A first-in-class anticancer dual HDAC2/FAK inhibitors bearing hydroxamates/benzamides capped by pyridinyl-1,2,4-triazoles.
AID1454681	Decrease in alcohol intake in C57BL/6J mouse at 100 mg/kg, ip relative to control	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Class I HDAC Inhibitors: Potential New Epigenetic Therapeutics for Alcohol Use Disorder (AUD).
AID1548275	Antiproliferative activity against bortezomib resistant human KM3/BTZ cells in presence of bortezomib incubated for 48 hrs by MTT assay
AID1811393	Toxicity in Balb/c mouse xenografted with human MCF7 cells assessed as change in organ morphology at 50 mg/kg, po administered 3 times week for 21 days by H and E staining based analysis	2021	European journal of medicinal chemistry, Dec-15, Volume: 226	Development of novel tetrahydroisoquinoline-hydroxamate conjugates as potent dual SERDs/HDAC inhibitors for the treatment of breast cancer.
AID1282277	Antitumor activity against human HCT116 cells xenografted in Balb/c nude mouse assessed as tumor mass change at 50 mg/kg, ip q2d for 9 days	2016	Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4	Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
AID1250642	Inhibition of recombinant human HDAC3 after 60 mins by fluorescence assay	2015	Journal of medicinal chemistry, Oct-08, Volume: 58, Issue:19	Discovery of Novel Class I Histone Deacetylase Inhibitors with Promising in Vitro and in Vivo Antitumor Activities.
AID1141767	Cytotoxicity against human HONE1 cells by MTT assay	2014	Journal of medicinal chemistry, May-22, Volume: 57, Issue:10	Azaindolylsulfonamides, with a more selective inhibitory effect on histone deacetylase 6 activity, exhibit antitumor activity in colorectal cancer HCT116 cells.
AID663363	Growth inhibition of human IGROV1 cells after 72 hrs by MTS assay	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Discovery and extensive in vitro evaluations of NK-HDAC-1: a chiral histone deacetylase inhibitor as a promising lead.
AID1777025	Inhibition of HDAC in human A549 cells assessed as reduction in fluorescent APS probe fluorescence intensity at 10 uM preincubated with compound for 2 hrs followed by co-incubation with APS probe for 1 hr by flow cytometry	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Intracellular fluorescence competition assay for inhibitor engagement of histone deacetylase.
AID481570	Antitumor activity against mouse S180 cells xenografted in ICR mouse assessed as inhibition of tumor weight at 200 mg/kg, ig administered 2 days after tumor inoculation qd for 7 days relative to control	2010	Bioorganic & medicinal chemistry letters, May-15, Volume: 20, Issue:10	Synthesis and anticancer evaluation of alpha-lipoic acid derivatives.
AID273173	Inhibition of mouse HDAC1	2006	Journal of medicinal chemistry, Oct-05, Volume: 49, Issue:20	Synthesis and biological properties of novel, uracil-containing histone deacetylase inhibitors.
AID1251315	Inhibition of human HDAC2 after 40 mins by fluorescence analysis	2015	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 25, Issue:20	Investigation on the ZBG-functionality of phenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase inhibitors.
AID1783092	Inhibition of HDAC in Candida tropicalis 5008 using Boc-Lys(Ac)-AMC as substrate preincubated with protoplast for 12 hrs followed by incubation with substrate for 6 hrs by fluorimetric assay	2021	European journal of medicinal chemistry, Oct-05, Volume: 221	Lanosterol 14α-demethylase (CYP51)/histone deacetylase (HDAC) dual inhibitors for treatment of Candida tropicalis and Cryptococcus neoformans infections.
AID1699971	Resistance index, ratio of of IC50 for human K562/A02 cells to IC50 for human K562 cells	2020	Bioorganic & medicinal chemistry letters, 12-15, Volume: 30, Issue:24	Discovery of thiosemicarbazone-containing compounds with potent anti-proliferation activity against drug-resistant K562/A02 cells.
AID603530	Cytotoxicity against human A549 cells after 48 hrs by MTT assay	2011	Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8	Development of tetrahydroisoquinoline-based hydroxamic acid derivatives: potent histone deacetylase inhibitors with marked in vitro and in vivo antitumor activities.
AID1514600	Inhibition of HDAC1 in human HepG2 cells assessed as acetylated histone H3 levels at 2.5 uM by Western blot analysis relative to beta-actin (Rvb = 0.5 No_unit)	2019	Bioorganic & medicinal chemistry letters, 01-01, Volume: 29, Issue:1	Development of hydroxamate-based histone deacetylase inhibitors containing 1,2,4-oxadiazole moiety core with antitumor activities.
AID1549164	Inhibition of HDAC1 (unknown origin) after 30 mins by fluorescence based assay	2020	Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10	Discovery of Novel Fungal Lanosterol 14α-Demethylase (CYP51)/Histone Deacetylase Dual Inhibitors to Treat Azole-Resistant Candidiasis.
AID1819517	Antiproliferative activity against human K562 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	2022	Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4	Discovery of DNA-Targeting HDAC Inhibitors with Potent Antitumor Efficacy In Vivo That Trigger Antitumor Immunity.
AID1856995	Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	2022	Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19	Histone Deacetylase and Enhancer of Zeste Homologue 2 Dual Inhibitors Presenting a Synergistic Effect for the Treatment of Hematological Malignancies.
AID1266834	Induction of PARP cleavage in human HCT116 cells at 1 to 5 uM after 48 hrs by western blot analysis	2015	Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23	Novel β-Carboline/Hydroxamic Acid Hybrids Targeting Both Histone Deacetylase and DNA Display High Anticancer Activity via Regulation of the p53 Signaling Pathway.
AID1398808	Inhibition of HDAC6 in human MCF7 cells assessed as increase in acetylated alpha-tubulin expression after 8 hrs by Western blot analysis	2018	Bioorganic & medicinal chemistry, 08-15, Volume: 26, Issue:15	Incorporation of histone deacetylase inhibitory activity into the core of tamoxifen - A new hybrid design paradigm.
AID316873	Inhibition of human HT1080 cells	2008	Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6	Histone deacetylase inhibitors: from bench to clinic.
AID1821960	Inhibition of recombinant human N-terminal GST tagged HDAC6 expressed in baculovirus infected Sf9 insect cells using Ac-Leu-Gly-Lys (Ac)-AMC as substrate preincubated for 5 mins followed by substrate addition and measured after 30 mins by fluorescence mic
AID316925	Inhibition of human HepG2 cells	2008	Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6	Histone deacetylase inhibitors: from bench to clinic.
AID1168915	Antiproliferative activity against human K562 cells after 48 hrs by MTT assay	2014	Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21	Improved antiproliferative activity of 1,3,4-thiadiazole-containing histone deacetylase (HDAC) inhibitors by introduction of the heteroaromatic surface recognition motif.
AID1274880	Inhibition of HDAC10 (unknown origin)	2016	European journal of medicinal chemistry, Jan-27, Volume: 108	Orally available stilbene derivatives as potent HDAC inhibitors with antiproliferative activities and antitumor effects in human tumor xenografts.
AID1653144	Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability	2019	European journal of medicinal chemistry, Mar-01, Volume: 165	Quinolone hybrids and their anti-cancer activities: An overview.
AID331900	Displacement of fluorescent 5-(3-(3-(4-((4-((7-(hydroxyamino)-7-oxoheptyl)carbamoyl)phenylamino)methyl)-1H-1,2,3-triazol-1-yl)propyl)thioureido)-2-(3-hydroxy-6-oxo-6H-xanthen-9-yl)benzoic acid from human HDAC6 by fluorescence polarization assay	2008	Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9	Development of a fluorescence polarization based assay for histone deacetylase ligand discovery.
AID1833070	Antiangiogenesis activity in human Endothelial progenitor cell assessed as inhibition of cell growth measured for 48 hrs	2021	Bioorganic & medicinal chemistry, 11-15, Volume: 50	Effect of phenylurea hydroxamic acids on histone deacetylase and VEGFR-2.
AID1861651	Antiproliferative activity against human A549 cells measured after 72 hrs	2022	Bioorganic & medicinal chemistry letters, 09-15, Volume: 72	Exploration of 4-(1H-indol-3-yl)cyclohex-3-en-1-amine analogues as HDAC inhibitors: Design, synthesis, biological evaluation and modelling studies.
AID1337308	Inhibition of HDAC6 in HEL 92.1.7 cells harboring JAK2 V617F mutant assessed as increase in acetylated tubulin level at 0.1 uM after 1 hr by immunoblot method	2016	Journal of medicinal chemistry, Sep-22, Volume: 59, Issue:18	Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines.
AID1406989	Inhibition of HDAC6 in human U87 cells assessed as levels of alpha-tubulin acetylation at 5 uM after 30 hrs by Western blot analysis relative to control	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Novel spiroindoline HDAC inhibitors: Synthesis, molecular modelling and biological studies.
AID1482123	Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by MTT assay	2017	Journal of medicinal chemistry, 04-27, Volume: 60, Issue:8	Exploring Derivatives of Quinazoline Alkaloid l-Vasicine as Cap Groups in the Design and Biological Mechanistic Evaluation of Novel Antitumor Histone Deacetylase Inhibitors.
AID1707467	Synergistic antifungal activity against Candida albicans 0304103 assessed as potentiation of fluconazole antifungal activity by measuring FICI incubated for 48 hrs in presence of fluconazole by checkerboard microdilution assay	2021	Journal of medicinal chemistry, 01-28, Volume: 64, Issue:2	Novel Carboline Fungal Histone Deacetylase (HDAC) Inhibitors for Combinational Treatment of Azole-Resistant Candidiasis.
AID1888588	Antiproliferative activity against human MDA-MB-231 cells measured after 72 hrs by MTT assay
AID395031	Toxicity in ip dosed athymic mouse assessed as maximum tolerated dose	2009	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 19, Issue:5	N-Hydroxy-1,2-disubstituted-1H-benzimidazol-5-yl acrylamides as novel histone deacetylase inhibitors: design, synthesis, SAR studies, and in vivo antitumor activity.
AID1263061	Inhibition of NTHi-induced NF-kappaB activation in human BEAS-2B cells at 1 uM treated 1 hr before NTHi stimulation measured after 5 hrs by luciferase assay relative to control	2015	Bioorganic & medicinal chemistry, Dec-15, Volume: 23, Issue:24	A structure-activity relationship of non-peptide macrocyclic histone deacetylase inhibitors and their anti-proliferative and anti-inflammatory activities.
AID1707508	Inhibition of human HDAC6 pre-incubated for 5 mins before substrate addition and measured after 30 mins by fluorescence based assay	2021	Journal of medicinal chemistry, 01-28, Volume: 64, Issue:2	Novel Carboline Fungal Histone Deacetylase (HDAC) Inhibitors for Combinational Treatment of Azole-Resistant Candidiasis.
AID1566815	Antiproliferative activity against human SKOV3 cells after 72 hrs by MTT assay	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Discovery of 1,2,4-oxadiazole-Containing hydroxamic acid derivatives as histone deacetylase inhibitors potential application in cancer therapy.
AID619053	Competitive inhibition of HDAC8 using KI-104 as substrate by fluorescence assay	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile.
AID1688041	Induction of apoptosis in human HL-60 cells assessed as necrotic cells at 2 uM measured after 24 hrs by Annexin-V/FITC and propidium iodide staining based flow cytometry (Rvb = 1.01 %)	2020	European journal of medicinal chemistry, Feb-15, Volume: 188	A 18β-glycyrrhetinic acid conjugate with Vorinostat degrades HDAC3 and HDAC6 with improved antitumor effects.
AID1206751	Cell cycle arrest in human HEL cells assessed as accumulation at G1 phase at 0.5 uM after 48 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 47.87%)	2015	Journal of medicinal chemistry, May-28, Volume: 58, Issue:10	Design, synthesis, and antitumor evaluation of novel histone deacetylase inhibitors equipped with a phenylsulfonylfuroxan module as a nitric oxide donor.
AID1550106	Inhibition of HDAC3 in human A549 cells assessed as increase in acetyl histone H4 level at 80 to 400 nM after 6 hrs by Western blot analysis	2019	Journal of medicinal chemistry, 04-25, Volume: 62, Issue:8	Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies.
AID1266100	Inhibition of HDAC6 in human HeLa cells assessed as inhibition of tubulin deacetylation incubated for overnight by cELISA	2016	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1	Cross metathesis with hydroxamate and benzamide BOC-protected alkenes to access HDAC inhibitors and their biological evaluation highlighted intrinsic activity of BOC-protected dihydroxamates.
AID723468	Inhibition of HDAC in cisplatin sensitive human KYSE-510 cells after 18 hrs by fluorescence assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1280260	Inhibition of human HDAC6 using (Z-(Ac)Lys-AMC) as substrate after 90 mins by fluorescence analysis	2016	Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4	Synthesis and Biological Investigation of Oxazole Hydroxamates as Highly Selective Histone Deacetylase 6 (HDAC6) Inhibitors.
AID456798	Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 infected in African green monkey (Cercopithecus aethiops) Vero cells assessed as parasite LDH activity after 72 hrs by Malstat reagent method	2010	Bioorganic & medicinal chemistry, Jan-01, Volume: 18, Issue:1	Antimalarial and antileishmanial activities of histone deacetylase inhibitors with triazole-linked cap group.
AID755621	Cytotoxicity against human GBC-SD cells assessed as growth inhibition after 72 hrs by MTT assay	2013	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13	Discovery of a small molecular compound simultaneously targeting RXR and HADC: design, synthesis, molecular docking and bioassay.
AID1269325	Cytotoxicity against human A549 cells assessed as cell growth at 25 uM measured at 72 hrs by CyQuant proliferation assay relative to control	2016	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2	Bromotyrosine-derived metabolites from an Indonesian marine sponge in the family Aplysinellidae (Order Verongiida).
AID775831	Inhibition of HDAC2 (unknown origin)-mediated deacetylation at 10 uM preincubated for 5 mins prior to substrate addition measured after 30 mins by fluorescence assay	2013	Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20	Investigating the selectivity of metalloenzyme inhibitors.
AID1622932	Inhibition of recombinant human N-terminal GST-tagged/C-terminal His-tagged HDAC4 (627 to 1084 residues) expressed in baculovirus infected Sf21 insect cells using 7-AMC-labelled HDAC substrate measured after 30 mins by fluorescence assay	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.
AID461263	Antiproliferative activity against human SK-BR-3 cells after hrs by ATP content assay	2010	Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5	Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer.
AID1065971	Inhibition of HDAC1 (unknown origin) expressed in Escherichia coli BL21 (DE3) using GRKacFGC as substrate after 60 mins by SAMDI mass spectrometric analysis	2013	Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24	Synthesis and structure-activity relationship of 3-hydroxypyridine-2-thione-based histone deacetylase inhibitors.
AID499803	Selectivity ratio IC50 for HDAC6 to IC50 for HDAC in human HeLa cells nuclear extract	2010	Journal of medicinal chemistry, Aug-26, Volume: 53, Issue:16	Non-peptide macrocyclic histone deacetylase inhibitors derived from tricyclic ketolide skeleton.
AID1379285	Inhibition of class 1 HDAC in human SH-SY5Y cells assessed as increase in acetylation of histone H3 at 10 uM after 24 hrs by Western blot analysis	2017	ACS medicinal chemistry letters, Aug-10, Volume: 8, Issue:8	Design, Synthesis, and Biological Evaluation of Tetrahydroisoquinoline-Based Histone Deacetylase 8 Selective Inhibitors.
AID1819532	Toxicity in C57BL/6J mouse implanted with mouse B16-F10 cells assessed as lung damage at 60 mg/kg, IG administered for 12 days H and E staining based histopathological analysis	2022	Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4	Discovery of DNA-Targeting HDAC Inhibitors with Potent Antitumor Efficacy In Vivo That Trigger Antitumor Immunity.
AID609494	Inhibition of CYP3A4	2011	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16	The design, synthesis and structure-activity relationships of novel isoindoline-based histone deacetylase inhibitors.
AID1398812	Antagonist activity at ERalpha in human MCF7 cells assessed as suppression of MYC mRNA expression at 5 uM after 24 hrs by QIAzol reagent based RT-qPCR analysis	2018	Bioorganic & medicinal chemistry, 08-15, Volume: 26, Issue:15	Incorporation of histone deacetylase inhibitory activity into the core of tamoxifen - A new hybrid design paradigm.
AID1547284	Effect on histone H3 expression level in human HCT116 cells measured after 24 hrs by Western blot analysis	2020	Journal of medicinal chemistry, 04-09, Volume: 63, Issue:7	Discovery of Thieno[2,3-
AID1861342	Inhibition of HDAC in human DOHH-2 cells assessed as effect on pS6 levels at 2.5 uM measured by Western blot analysis	2022	Bioorganic & medicinal chemistry letters, 09-01, Volume: 71	Bioevaluation of a dual PI3K/HDAC inhibitor for the treatment of diffuse large B-cell lymphoma.
AID527040	Cytotoxicity against human NCI-H1299 by SRB assay	2010	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22	Selenium-containing analogs of SAHA induce cytotoxicity in lung cancer cells.
AID1765332	Selectivity index, ratio of IC50 for human full-length recombinant C-terminal His-tagged HDAC8 expressed in baculovirus infected Sf9 insect cells to IC50 for human recombinant full length HDAC2	2021	European journal of medicinal chemistry, Oct-15, Volume: 222	A first-in-class anticancer dual HDAC2/FAK inhibitors bearing hydroxamates/benzamides capped by pyridinyl-1,2,4-triazoles.
AID1558002	Inhibition of HDAC1 (unknown origin) expressed in HEK293 cells cotransfected with nano-luciferase incubated for 2 hrs followed by NanoBRET NanoGlo Substrate addition by NanoBRET assay	2019	Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18	Discovery of a New Isoxazole-3-hydroxamate-Based Histone Deacetylase 6 Inhibitor SS-208 with Antitumor Activity in Syngeneic Melanoma Mouse Models.
AID1811392	Toxicity in Balb/c mouse xenografted with human MCF7 cells assessed as body weight loss at 50 mg/kg, po administered 3 times week for 21 days in presence of fulvestrant	2021	European journal of medicinal chemistry, Dec-15, Volume: 226	Development of novel tetrahydroisoquinoline-hydroxamate conjugates as potent dual SERDs/HDAC inhibitors for the treatment of breast cancer.
AID755618	Cytotoxicity against human Hep3B cells assessed as growth inhibition after 72 hrs by MTT assay	2013	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13	Discovery of a small molecular compound simultaneously targeting RXR and HADC: design, synthesis, molecular docking and bioassay.
AID1441643	Anti-inflammatory activity in LPS-induced C57BL/6 mouse model of acute lung injury assessed as reduction in total number of leucocytes in BALF at 10 to 50 mg/kg, ip pretreated for 1 hr followed LPS challenge measured after 24 hrs	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
AID273176	Induction of granulocytic differentiation of U937 cells measured as CD11c expression level after 48 hrs at 1 uM	2006	Journal of medicinal chemistry, Oct-05, Volume: 49, Issue:20	Synthesis and biological properties of novel, uracil-containing histone deacetylase inhibitors.
AID1394884	Antiproliferative activity against human HCT116 cells after 48 hrs by sulforhodamine B assay	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	1-Aroylindoline-hydroxamic acids as anticancer agents, inhibitors of HSP90 and HDAC.
AID1401538	Antiproliferative activity against human A2780/DX cells after 72 hrs by SRB assay	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors.
AID1572344	Inhibition of recombinant human HDAC8 expressed in baculovirus expression system using fluorogenic Arg-His-Lys(Ac)-Lys(Ac) as substrate incubated for 90 mins by fluorescence assay	2019	Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3	Synthesis and Biological Investigation of Phenothiazine-Based Benzhydroxamic Acids as Selective Histone Deacetylase 6 Inhibitors.
AID1275635	Inhibition of recombinant human HDAC2 using Boc-Lys(Ac)-AMC as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by fluorescence-based assay	2016	European journal of medicinal chemistry, Feb-15, Volume: 109	Identification of N-(6-mercaptohexyl)-3-(4-pyridyl)-1H-pyrazole-5-carboxamide and its disulfide prodrug as potent histone deacetylase inhibitors with in vitro and in vivo anti-tumor efficacy.
AID324950	Inhibition of HDAC4 H976Y mutant expressed in Escherichia coli	2008	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 18, Issue:6	Probing the elusive catalytic activity of vertebrate class IIa histone deacetylases.
AID1775565	Inhibition of full length human C-terminal His-tagged HDAC3/human N-terminal GST-agged NCOR2 using fluorogenic acetylated peptide as substrate incubated for 30 mins by fluorescence plate reader assay	2021	Journal of medicinal chemistry, 03-25, Volume: 64, Issue:6	Design and Synthesis of Novel Epigenetic Inhibitors Targeting Histone Deacetylases, DNA Methyltransferase 1, and Lysine Methyltransferase G9a with
AID1399813	Pro-apoptotic activity in human HUT78 cells after 18 hrs by caspase-Glo 3/7 assay	2018	Bioorganic & medicinal chemistry letters, 09-15, Volume: 28, Issue:17	Squaramides as novel class I and IIB histone deacetylase inhibitors for topical treatment of cutaneous t-cell lymphoma.
AID1431822	Selectivity ratio of IC50 for human KDAC1 to IC50 for human KDAC6	2017	European journal of medicinal chemistry, Feb-15, Volume: 127	Design and synthesis of benzodiazepine analogs as isoform-selective human lysine deacetylase inhibitors.
AID1466066	Inhibition of HDAC in human PC3 cells assessed as increase in alpha-tubulin acetylation at 1 uM after 24 hrs by Western blot analysis	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	4-Indolyl-N-hydroxyphenylacrylamides as potent HDAC class I and IIB inhibitors in vitro and in vivo.
AID1863435	Inhibition of HDAC3 (unknown origin) by colorimetric method	2022	European journal of medicinal chemistry, Oct-05, Volume: 240	Accommodation of ring C expanded deoxyvasicinone in the HDAC inhibitory pharmacophore culminates into a tractable anti-lung cancer agent and pH-responsive nanocarrier.
AID723433	Potentiation of 2.5 uM cisplatin-induced toxicity in 1 uM cisplatin resistant human CAL27 cells at 0.5 uM pretreated for 48 hrs followed by 1 uM cisplatin treatment by MTT assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1330944	Cytotoxicity against human A549 cells expressing EGFR and KRAS mutant assessed as reduction in cell viability measured after 48 hrs by MTT assay	2017	Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1	Synthesis and investigation of novel 6-(1,2,3-triazol-4-yl)-4-aminoquinazolin derivatives possessing hydroxamic acid moiety for cancer therapy.
AID1547333	Inhibition of HDAC in human HCT116 cells assessed as activation of IL6-JAK-STAT signaling pathway by measuring increase in LIF mRNA level at 10 uM after 24 hrs by RT-PCR analysis	2020	Journal of medicinal chemistry, 04-09, Volume: 63, Issue:7	Discovery of Thieno[2,3-
AID1439350	Inhibition of full length recombinant human GST fused His6-tagged HDAC6 expressed in baculovirus infected High5 cells using Boc-Lys(epsilon-acetyl)-AMC as substrate measured after 3 hrs	2017	European journal of medicinal chemistry, Mar-10, Volume: 128	Design, synthesis and biological evaluation of thienopyrimidine hydroxamic acid based derivatives as structurally novel histone deacetylase (HDAC) inhibitors.
AID316927	Inhibition of human CCD1059SK cells	2008	Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6	Histone deacetylase inhibitors: from bench to clinic.
AID499809	Antimalarial activity against Plasmodium falciparum D6 after 72 hrs by alamar blue assay	2010	Journal of medicinal chemistry, Aug-26, Volume: 53, Issue:16	Non-peptide macrocyclic histone deacetylase inhibitors derived from tricyclic ketolide skeleton.
AID669756	Inhibition of HDAC in human HeLa cell nuclear extract after 30 mins by fluorescence microplate reader	2012	Journal of medicinal chemistry, Apr-26, Volume: 55, Issue:8	Synthesis and biological evaluation of 1-arylsulfonyl-5-(N-hydroxyacrylamide)indoles as potent histone deacetylase inhibitors with antitumor activity in vivo.
AID90696	Inhibition of maize histone deacetylase 2	2004	Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6	3-(4-Aroyl-1-methyl-1H-pyrrol-2-yl)-N-hydroxy-2-propenamides as a new class of synthetic histone deacetylase inhibitors. 3. Discovery of novel lead compounds through structure-based drug design and docking studies.
AID1127006	Induction of apoptosis in human U937 cells assessed as early apoptotic cells using annexin-V/propidium iodide staining at 0.25 uM after 24 hrs by flow cytometry analysis (Rvb = 1.57%)	2014	Journal of medicinal chemistry, Apr-24, Volume: 57, Issue:8	Discovery of the first N-hydroxycinnamamide-based histone deacetylase 1/3 dual inhibitors with potent oral antitumor activity.
AID1164177	Cell cycle arrest in human MCF7 cells assessed as block at G2-M phase at 5 uM after 24 to 96 hrs using propidium iodide staining by FACScan flow cytometry	2014	ACS medicinal chemistry letters, Sep-11, Volume: 5, Issue:9	Novel antiproliferative chimeric compounds with marked histone deacetylase inhibitory activity.
AID1622985	Inhibition of HDAC6 in human HeLa nuclear extract using Boc-Lys(acetyl)-AMC as substrate measured after 30 mins by fluorescence assay	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.
AID748981	Inhibition of HDAC6 (unknown origin)	2013	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 23, Issue:11	A cyclodextrin-capped histone deacetylase inhibitor.
AID1819548	Antitumor immunity against mouse B16-F10 cells implanted in C57BL/6J mouse assessed as fold reduction in Treg cells in spleen by flow cytometry analysis relative to control	2022	Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4	Discovery of DNA-Targeting HDAC Inhibitors with Potent Antitumor Efficacy In Vivo That Trigger Antitumor Immunity.
AID618016	Antitumor activity against human MDA-MB-231 cells xenografted in BALB/c nu mouse assessed as tumor growth inhibition at 90 mg/kg, ip qd for 19 days relative to control	2011	Journal of medicinal chemistry, Aug-11, Volume: 54, Issue:15	Discovery of a tetrahydroisoquinoline-based hydroxamic acid derivative (ZYJ-34c) as histone deacetylase inhibitor with potent oral antitumor activities.
AID1633426	Cytotoxicity against human SH-SY5Y cells at 10 uM incubated for 24 hrs by MTS assay	2019	ACS medicinal chemistry letters, Apr-11, Volume: 10, Issue:4	Discovery of the First-in-Class GSK-3β/HDAC Dual Inhibitor as Disease-Modifying Agent To Combat Alzheimer's Disease.
AID274095	Inhibition of mouse HDAC1 (mean)	2007	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 17, Issue:5	Discovery of uracil-based histone deacetylase inhibitors able to reduce acquired antifungal resistance and trailing growth in Candida albicans.
AID663402	Lipophilicity, log D of the compound in pH 7.4 PBS buffer	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Discovery and extensive in vitro evaluations of NK-HDAC-1: a chiral histone deacetylase inhibitor as a promising lead.
AID723147	Potentiation of 40 uM cisplatin-induced toxicity in 1 uM cisplatin resistant human MDA-MB-231 cells at 0.5 uM pretreated for 48 hrs followed by 1 uM cisplatin treatment by MTT assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1282302	Inhibition of HDAC1/2/3 in human MV4-11 cells assessed as upregulation of histone H3 acetylation at 10 to 1000 nM after 6 hrs by Western blot analysis	2016	Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4	Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
AID1754764	Downregulation of HDAC7 gene expression in human MCF7 cells at 3 uM incubated for 24 hrs by whole transcriptome analysis	2021	Bioorganic & medicinal chemistry, 07-15, Volume: 42	Discovery of novel class of histone deacetylase inhibitors as potential anticancer agents.
AID723464	Inhibition of human HDAC4 by fluorescence assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1550119	Induction of apoptosis in HEL cells assessed as early apoptotic cells at 1 uM after 24 hrs by Annexin-V/propidium iodide staining-based flow cytometric analysis (Rvb = 12.5%)	2019	Journal of medicinal chemistry, 04-25, Volume: 62, Issue:8	Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies.
AID1281855	Antiproliferative activity against human Mino cells after 72 hrs by CellTiter 96 aqueous non-radioactive cell proliferation assay	2016	European journal of medicinal chemistry, Apr-13, Volume: 112	Design, synthesis and biological evaluation of bisthiazole-based trifluoromethyl ketone derivatives as potent HDAC inhibitors with improved cellular efficacy.
AID1177046	Inhibition of human HDAC8 using RHK(Ac)K(Ac) as substrate by fluorimetric analysis	2015	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 25, Issue:3	Hydroxamic acid based histone deacetylase inhibitors with confirmed activity against the malaria parasite.
AID1129790	Induction of apoptosis in human Jurkat cells assessed as late apoptotic cells at 10 uM after 24 hrs by annexin V-FITC/propidium iodide staining-based FACS flow cytometric analysis (Rvb = 0.0401%)	2014	Bioorganic & medicinal chemistry, Apr-01, Volume: 22, Issue:7	Studies on the antiproliferative effects of tropolone derivatives in Jurkat T-lymphocyte cells.
AID1451830	Inhibition of human recombinant HDAC6 expressed in Baculovirus infected Sf9 cells using Ac-Leu-Gly-Lys(Ac)-AMC as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by fluorescence assay	2017	Journal of medicinal chemistry, 10-12, Volume: 60, Issue:19	Small Molecule Inhibitors Simultaneously Targeting Cancer Metabolism and Epigenetics: Discovery of Novel Nicotinamide Phosphoribosyltransferase (NAMPT) and Histone Deacetylase (HDAC) Dual Inhibitors.
AID1754790	Downregulation of HDAC8 gene expression in human MCF7 cells at 3 uM incubated for 24 hrs by whole transcriptome analysis	2021	Bioorganic & medicinal chemistry, 07-15, Volume: 42	Discovery of novel class of histone deacetylase inhibitors as potential anticancer agents.
AID1898910	Antiproliferative activity against human MDA-MB-436 cells incubated for 24 hrs followed by incubating in drug-free medium for 48 hrs and measured by SRB assay	2022	European journal of medicinal chemistry, Jan-15, Volume: 228	Antitumor activity of novel POLA1-HDAC11 dual inhibitors.
AID1846147	Inhibition of HDAC (unknown origin) incubated for 30 mins by ELISA method	2021	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 38	Current status in the discovery of dual BET/HDAC inhibitors.
AID499810	Antimalarial activity against Plasmodium falciparum W2 after 72 hrs by alamar blue assay	2010	Journal of medicinal chemistry, Aug-26, Volume: 53, Issue:16	Non-peptide macrocyclic histone deacetylase inhibitors derived from tricyclic ketolide skeleton.
AID420639	Inhibition of HDAC in human IGROV1 cells assessed as p53 acetylation at IC80 after 48 hrs by Western blot	2009	European journal of medicinal chemistry, May, Volume: 44, Issue:5	Design, synthesis, and evaluation of biphenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors.
AID1784979	Antiproliferative activity against human Bel-7402 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Design, synthesis and biological evaluation of novel hybrids targeting mTOR and HDACs for potential treatment of hepatocellular carcinoma.
AID1141765	Cytotoxicity against human HCT116 cells by MTT assay	2014	Journal of medicinal chemistry, May-22, Volume: 57, Issue:10	Azaindolylsulfonamides, with a more selective inhibitory effect on histone deacetylase 6 activity, exhibit antitumor activity in colorectal cancer HCT116 cells.
AID1720111	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability in presence of erlotinib by MTT assay	2020	Journal of medicinal chemistry, 09-10, Volume: 63, Issue:17	Dual-Target Inhibitors Based on HDACs: Novel Antitumor Agents for Cancer Therapy.
AID1759726	Fraction unbound in rat plasma	2021	ACS medicinal chemistry letters, Apr-08, Volume: 12, Issue:4	Redefining the Histone Deacetylase Inhibitor Pharmacophore: High Potency with No Zinc Cofactor Interaction.
AID1482170	Cytotoxicity against human Caco2 cells assessed as growth inhibition at 5 uM after 48 hrs by MTT assay relative to control	2017	Journal of medicinal chemistry, 04-27, Volume: 60, Issue:8	Exploring Derivatives of Quinazoline Alkaloid l-Vasicine as Cap Groups in the Design and Biological Mechanistic Evaluation of Novel Antitumor Histone Deacetylase Inhibitors.
AID1550101	Inhibition of HDAC6 (unknown origin) using Boc-Lys(acetyl)-AMC as substrate preincubated for 5 mins followed by substrate addition and measured after 30 mins by fluorescence assay	2019	Journal of medicinal chemistry, 04-25, Volume: 62, Issue:8	Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies.
AID1890512	Inhibition of HDAC3 (unknown origin)	2022	Bioorganic & medicinal chemistry letters, 05-15, Volume: 64	Design, synthesis, and biological evaluation of β-carboline 1,3,4-oxadiazole based hybrids as HDAC inhibitors with potential antitumor effects.
AID1467235	Inhibition of recombinant C-terminal His-tagged HDAC11 (unknown origin) expressed in baculovirus infected Sf9 cells at 0.02 uM using Ac-Arg-Gly-Lys(Ac)-AMC as substrate pretreated for 3 hrs followed by substrate addition measured within 30 mins by fluorom	2017	Bioorganic & medicinal chemistry letters, 07-01, Volume: 27, Issue:13	Stabilizing HDAC11 with SAHA to assay slow-binding benzamide inhibitors.
AID503691	Inhibition of HDAC in human GM15850 cells assessed as increase in histone H4 lysine 8 acetylation of FXN gene at 2.5 uM after 96 hrs by chromatin immunoprecipitation assay	2006	Nature chemical biology, Oct, Volume: 2, Issue:10	Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia.
AID1771457	Antiproliferative activity against human MGC-803 cells assessed as cell growth inhibition after 72 hrs by SRB assay	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Discovery of novel tubulin/HDAC dual-targeting inhibitors with strong antitumor and antiangiogenic potency.
AID519597	Selectivity index, ratio of IC50 for neonatal foreskin fibroblasts to IC50 for chloroquine-resistant Plasmodium falciparum Dd2	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Potent antimalarial activity of histone deacetylase inhibitor analogues.
AID1469298	Induction of apoptosis in human NCI-H460 cells assessed as necrotic cells at 10 uM after 48 hrs by annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 1.34%)	2018	Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7	Discovery of N1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7 H-pyrrolo[2,3- d]pyrimidin-2-yl)amino)phenyl)- N8-hydroxyoctanediamide as a Novel Inhibitor Targeting Cyclin-dependent Kinase 4/9 (CDK4/9) and Histone Deacetlyase1 (HDAC1) against Malignant Cancer
AID1572353	Ratio of inhibition of HDAC6 in human HL60 cells assessed as acetylated tubulin/GAPDH ratio at 10 uM to inhibition of HDAC in human HL60 cells assessed as acetylated H3/GAPDH ratio at 10 uM	2019	Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3	Synthesis and Biological Investigation of Phenothiazine-Based Benzhydroxamic Acids as Selective Histone Deacetylase 6 Inhibitors.
AID1421914	Inhibition of HDAC in synchronized trophozoite stage Plasmodium falciparum 3D7 infected in human erythrocytes assessed as increase in acetylated H2B/H2Bv level at 5 times IC50 after 3 hrs by Western blot analysis relative to control	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	One-pot, multi-component synthesis and structure-activity relationships of peptoid-based histone deacetylase (HDAC) inhibitors targeting malaria parasites.
AID1890321	Inhibition of HDAC1 in mouse B16 cells assessed as accumulation of acetylated H3 level at 6 uM after 24 hrs by Western blotting analysis	2022	European journal of medicinal chemistry, Apr-05, Volume: 233	Novel biphenyl-based scaffold as potent and selective histone deacetylase 6 (HDAC6) inhibitors: Identification, development and pharmacological evaluation.
AID541648	Inhibition of human HDAC4 by fluorimetric assay	2010	Journal of medicinal chemistry, Dec-09, Volume: 53, Issue:23	Non-natural macrocyclic inhibitors of histone deacetylases: design, synthesis, and activity.
AID1869147	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by CCK8 assay
AID352521	Antiproliferative activity against human BxPC3 cells by MTT assay	2009	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11	Isoxazole moiety in the linker region of HDAC inhibitors adjacent to the Zn-chelating group: effects on HDAC biology and antiproliferative activity.
AID1164903	Inhibition of HDAC1/2/3 in human HeLa cells assessed as p21 gene expression at 3 uM after 15 hrs by luciferase reporter gene assay relative to SNDX-275	2014	Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19	Identification of a novel aminotetralin class of HDAC6 and HDAC8 selective inhibitors.
AID1605967	Antiproliferative activity against human HOP62 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	2020	Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8	Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors.
AID1622933	Inhibition of recombinant human C-terminal His-tagged HDAC5 (656 to 1122 residues) expressed in baculovirus-infected insect cells using 7-AMC-labelled HDAC substrate measured after 30 mins by fluorescence assay	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.
AID461265	Antiproliferative activity against human MDA-MB-468 cells	2010	Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5	Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer.
AID1655900	Inhibition of EZH2 in human RH4 cells assessed as H3K27me3 level at 0.15 uM incubated for 72 hrs by Western blot analysis (Rvb = 1 No_unit)	2020	ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5	Design of First-in-Class Dual EZH2/HDAC Inhibitor: Biochemical Activity and Biological Evaluation in Cancer Cells.
AID1758463	Phototoxicity in human A549 cells assessed as reduction in cell viability irradiated 10 j/cm2 for 24 hrs followed by incubated for 24 hrs by CCK8 assay	2021	European journal of medicinal chemistry, May-05, Volume: 217	Novel dual-mode antitumor chlorin-based derivatives as potent photosensitizers and histone deacetylase inhibitors for photodynamic therapy and chemotherapy.
AID395023	Antiproliferative activity against human COLO205 cells after 96 hrs by celltiter assay	2009	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 19, Issue:5	N-Hydroxy-1,2-disubstituted-1H-benzimidazol-5-yl acrylamides as novel histone deacetylase inhibitors: design, synthesis, SAR studies, and in vivo antitumor activity.
AID1855253	Downregulation of SSRP-1 expression in human HCT-116 cells at 1.5 uM measured after 24 hrs by Western blot analysis	2022	European journal of medicinal chemistry, Nov-05, Volume: 241	Discovery of 2,5-diphenyl-1,3,4-thiadiazole derivatives as HDAC inhibitors with DNA binding affinity.
AID461301	Antitumor activity against human HepG2 cells xenografted in nude CD1 mouse at 72 mg/kg, iv daily relative to control	2010	Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5	Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer.
AID1380939	Inhibition of VEGFR-2 (unknown origin) at 0.2 uM after 40 mins by kinase-Glo assay relative to control	2018	Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12	Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously.
AID1543957	Induction of apoptosis in human Bel7402/5-FU cells assessed as necrotic cells at 5.0 uM incubated for 72 hrs by FITC-Annexin V/PI staining based flow cytometry (Rvb = 2.27%)	2019	European journal of medicinal chemistry, Apr-15, Volume: 168	β-Carboline and N-hydroxycinnamamide hybrids as anticancer agents for drug-resistant hepatocellular carcinoma.
AID1762491	Inhibition of C-terminal His-tagged human HDAC9 (604 to 1066 residues) expressed in baculovirus-infected Sf9 cells using Boc Lys(TFA)-AMC as substrate preincubated for 5 mins followed by substrate addition and further incubated for 30 mins by fluorogenic	2021	European journal of medicinal chemistry, Jul-05, Volume: 219	Synthesis and biological evaluation of phenothiazine derivative-containing hydroxamic acids as potent class II histone deacetylase inhibitors.
AID1396990	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay	2018	Bioorganic & medicinal chemistry, 08-07, Volume: 26, Issue:14	Design, synthesis and anticancer evaluation of acridine hydroxamic acid derivatives as dual Topo and HDAC inhibitors.
AID1126983	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	2014	Journal of medicinal chemistry, Apr-24, Volume: 57, Issue:8	Discovery of the first N-hydroxycinnamamide-based histone deacetylase 1/3 dual inhibitors with potent oral antitumor activity.
AID1462025	Antiproliferative activity against human U266 cells after 48 hrs by MTT assay	2017	Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17	Discovery of a tetrahydroisoquinoline-based HDAC inhibitor with improved plasma stability.
AID1758468	Inhibition of human recombinant HDAC6 using Ac-Leu-Gly-Lys(Ac)-AMC as substrate by measuring fluorescence intensity incubated for 30 mins by microplate reader assay	2021	European journal of medicinal chemistry, May-05, Volume: 217	Novel dual-mode antitumor chlorin-based derivatives as potent photosensitizers and histone deacetylase inhibitors for photodynamic therapy and chemotherapy.
AID1702139	Inhibition of PI3K/AKT/mTOR signaling in human HuH-7 cells assessed as PS6 Ser240/244 phosphorylation level at 10 uM incubated for 4 hrs including last 12 mins stimulation with 20 ng/ml growth factor VEGF by Western blot analysis (Rvb = 100 %)	2018	Journal of medicinal chemistry, 02-22, Volume: 61, Issue:4	Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma.
AID1901766	Cytotoxicity against human MV4-11 cells assessed as inhibition of cell growth incubated for 72 hrs measured by spectrophotometer analysis	2022	Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4	Discovery of HDAC6-Selective Inhibitor NN-390 with
AID1865268	Inhibition of recombinant his-tagged human HDAC10 using Ac-ArgHisLys (Ac) Lys (Ac)-AMC substrate preincubated for 5 mins followed by substrate addition and measured after 30 mins by fluorescence based microplate reader analysis	2022	Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18	Discovery of Novel Src Homology-2 Domain-Containing Phosphatase 2 and Histone Deacetylase Dual Inhibitors with Potent Antitumor Efficacy and Enhanced Antitumor Immunity.
AID1441658	Anti-inflammatory activity in LPS-induced C57BL/6 mouse model of acute lung injury assessed as reduction MPO activity at 25 mg/kg, ip pretreated for 1 hr followed LPS challenge measured after 24 hrs	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
AID465155	Growth inhibition of human BxPC3 cells after 72 hrs by MTS assay	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Synthesis and biological evaluation of triazol-4-ylphenyl-bearing histone deacetylase inhibitors as anticancer agents.
AID723469	Inhibition of HDAC in cisplatin resistant human CAL27 cells after 18 hrs by fluorescence assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1677517	Binding affinity to recombinant human full length His-tagged BAX expressed in Escherichia coli BL21 (DE3) cells preincubated for 30 min followed by FITC-BIM addition and measured after 20 mins by fluorescence polarization assay	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	HDAC-Bax Multiple Ligands Enhance Bax-Dependent Apoptosis in HeLa Cells.
AID1174699	Induction of apoptosis in human U937 cells assessed as early apoptotic cells at 1.5 uM after 24 hrs by annexin-V/propidium iodide staining-based flow cytometry (Rvb = 3.81%)	2015	European journal of medicinal chemistry, Jan-07, Volume: 89	Development of 3-hydroxycinnamamide-based HDAC inhibitors with potent in vitro and in vivo anti-tumor activity.
AID618024	Inhibition of MMP2	2011	Journal of medicinal chemistry, Aug-11, Volume: 54, Issue:15	Discovery of a tetrahydroisoquinoline-based hydroxamic acid derivative (ZYJ-34c) as histone deacetylase inhibitor with potent oral antitumor activities.
AID1825881	Cytotoxicity against human HepG2 cells incubated for 72 hrs by CCK-8 assay
AID274022	AUC after i.p. dosing at 5 mg kg-1	2007	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2	Identification and optimisation of a series of substituted 5-pyridin-2-yl-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.
AID1256444	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	2015	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22	Hybrids from 4-anilinoquinazoline and hydroxamic acid as dual inhibitors of vascular endothelial growth factor receptor-2 and histone deacetylase.
AID1785347	Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition measured after 48 hrs by CCK8 assay
AID1816698	Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability at 10 uM after 72 hrs by CellTiter-Glo assay	2021	European journal of medicinal chemistry, Aug-05, Volume: 220	Design, synthesis, and biological evaluation of novel dual inhibitors targeting lysine specific demethylase 1 (LSD1) and histone deacetylases (HDAC) for treatment of gastric cancer.
AID1667066	Inhibition of human recombinant HDAC1 using fluorogenic HDAC substrate preincubated for 30 mins followed by substrate addition and measured after 15 mins by fluorogenic assay	2020	Bioorganic & medicinal chemistry, 03-15, Volume: 28, Issue:6	Pyrimethamine conjugated histone deacetylase inhibitors: Design, synthesis and evidence for triple negative breast cancer selective cytotoxicity.
AID1783109	Inhibition of HDAC2 (unknown origin) using Ac-LeuGlyLys(Ac)-AMC as substrate preincubated for 10 mins followed by substrate addition and further incubated for incubated for 1 hrs by fluorescence microtiter plate reader assay	2021	European journal of medicinal chemistry, Oct-05, Volume: 221	Design, synthesis and biological evaluation of 3, 4-disubstituted-imidazolidine-2, 5-dione derivatives as HDAC6 selective inhibitors.
AID1897806	Inhibition of recombinant full length N-terminal GST-tagged human HDAC6 (1 to 1215 residues) using Z-Lys(Ac)-AMC as substrate preincubated for 90 mins followed by trypsin addition and measured after 30 mins by fluorescence based microplate reader analysis	2022	Journal of medicinal chemistry, 12-22, Volume: 65, Issue:24	Solid-Phase Synthesis of Cereblon-Recruiting Selective Histone Deacetylase 6 Degraders (HDAC6 PROTACs) with Antileukemic Activity.
AID1282237	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	2016	Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4	Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
AID1394883	Antiproliferative activity against human A549 cells after 48 hrs by sulforhodamine B assay	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	1-Aroylindoline-hydroxamic acids as anticancer agents, inhibitors of HSP90 and HDAC.
AID481548	Cytotoxicity against human NCI-H460 cells assessed as growth inhibition at 0.1 ug/ml after 24 hrs by MTT assay	2010	Bioorganic & medicinal chemistry letters, May-15, Volume: 20, Issue:10	Synthesis and anticancer evaluation of alpha-lipoic acid derivatives.
AID1164908	Inhibition of HDAC3 (unknown origin) using fluorogenic peptide as substrate by fluorescence assay	2014	Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19	Identification of a novel aminotetralin class of HDAC6 and HDAC8 selective inhibitors.
AID1742679	Induction of cell cycle arrest in human MDA-MB-231 cells assessed as S phase accumulation at 2 uM incubated for 24 hrs by PI staining based flow cytometry analysis (Rvb = 43.82 %)	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Design and synthesis of novel Flavone-based histone deacetylase inhibitors antagonizing activation of STAT3 in breast cancer.
AID1890436	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth measured after 74 hrs by SRB assay	2022	Bioorganic & medicinal chemistry, 04-15, Volume: 60	Design, synthesis, and antitumor activity evaluation of novel acyl sulfonamide spirodienones.
AID1606020	Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability at 1 to 2 uM after 72 hrs by tryphan blue assay	2020	Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8	Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors.
AID310127	Growth inhibition of human HCT116 cells by SRB assay	2007	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 17, Issue:22	Omega-alkoxy analogues of SAHA (vorinostat) as inhibitors of HDAC: a study of chain-length and stereochemical dependence.
AID1365024	Inhibition of recombinant human His-tagged HDAC6 expressed in baculovirus infected insect cells preincubated with enzyme followed by flour de lys-green substrate addition measured after 1 hr by fluorescence assay	2017	Bioorganic & medicinal chemistry letters, 09-15, Volume: 27, Issue:18	Rational design, synthesis and preliminary antitumor activity evaluation of a chlorambucil derivative with potent DNA/HDAC dual-targeting inhibitory activity.
AID303349	Inhibition of HDAC6 in presence of DTT	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	The first biologically active synthetic analogues of FK228, the depsipeptide histone deacetylase inhibitor.
AID1441646	Anti-inflammatory activity in LPS-induced C57BL/6 mouse model of acute lung injury assessed as reduction in pulmonary edema by measuring lung wet and dry ratio at 10 to 50 mg/kg, ip pretreated for 1 hr followed LPS challenge after 24 hrs	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
AID1869149	Antiproliferative activity against human SGC-7901 cells assessed as reduction in cell viability incubated for 48 hrs by CCK8 assay
AID1690843	Inhibition of recombinant human C-terminal His-tagged HDAC2 (1 to 488 residues) expressed in Sf9 insect cells using fluor de lys SIRT1 as substrate preincubated for 5 mins followed by substrate addition and measured after 30 mins by fluorescence assay	2020	European journal of medicinal chemistry, Apr-15, Volume: 192	Synthesis and biological evaluation of acridine-based histone deacetylase inhibitors as multitarget agents against Alzheimer's disease.
AID1545756	Inhibition of HDAC3 (unknown origin)	2019	European journal of medicinal chemistry, Dec-01, Volume: 183	Indole: A privileged scaffold for the design of anti-cancer agents.
AID1753646	Inhibition of HDAC6 in human SH-SY5Y cells assessed as fold increase in ratio of acetylated histone H3 to histone H3 at 1 uM incubated for 24 hrs by Western blot analysis	2021	European journal of medicinal chemistry, Jun-05, Volume: 218	Design, synthesis and biological evaluation of brain penetrant benzazepine-based histone deacetylase 6 inhibitors for alleviating stroke-induced brain infarction.
AID1227033	Inhibition of human recombinant HDAC8 using MAZ1675 as fluorogenic substrate measured every 5 mins by optimized homogenous fluorescence based assay	2015	Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11	Dual-Mode HDAC Prodrug for Covalent Modification and Subsequent Inhibitor Release.
AID316934	Inhibition of HDAC4	2008	Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6	Histone deacetylase inhibitors: from bench to clinic.
AID1459957	Selectivity ratio of IC50 for recombinant human HDAC2 to IC50 for recombinant human HDAC6	2017	European journal of medicinal chemistry, Jan-05, Volume: 125	3-Aroylindoles display antitumor activity in vitro and in vivo: Effects of N1-substituents on biological activity.
AID1177044	Inhibition of human HDAC3 using RHKK(Ac) as substrate by fluorimetric analysis	2015	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 25, Issue:3	Hydroxamic acid based histone deacetylase inhibitors with confirmed activity against the malaria parasite.
AID1337196	Inhibition of full length human recombinant N-terminal GST-tagged HDAC6 (1 to 1215 residues) expressed in sf9 cells preincubated with enzyme followed by fluorogenic Arg-His-Lys-Lys(Ac)-AMC substrate addition measured after 2 hrs by fluorescence assay	2016	Journal of medicinal chemistry, Sep-22, Volume: 59, Issue:18	Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines.
AID1897381	Antiproliferative activity against human KATO III stomach cancer cell line assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
AID1128563	Inhibition of human HDAC-11 using RHKK(Ac) as substrate	2014	European journal of medicinal chemistry, Apr-09, Volume: 76	4,5,6,7-Tetrahydro-isoxazolo-[4,5-c]-pyridines as a new class of cytotoxic Hsp90 inhibitors.
AID1201647	Antiproliferative activity against human K562 cells assessed as growth inhibition after 48 hrs by CellTiter-Glo assay	2015	European journal of medicinal chemistry, May-05, Volume: 95	Macrocyclic compounds as anti-cancer agents: design and synthesis of multi-acting inhibitors against HDAC, FLT3 and JAK2.
AID1275077	Inhibition of recombinant human HDAC1	2016	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2	Novel thiol-based histone deacetylase inhibitors bearing 3-phenyl-1H-pyrazole-5-carboxamide scaffold as surface recognition motif: Design, synthesis and SAR study.
AID1164188	Inhibition of HDAC in human U937 cells assessed as hyperacetylation of histone H1 at Lys 9/4 residues at 5 uM after 24 hrs by Western blot analysis relative to control	2014	ACS medicinal chemistry letters, Sep-11, Volume: 5, Issue:9	Novel antiproliferative chimeric compounds with marked histone deacetylase inhibitory activity.
AID1545944	Antiproliferative activity against human K562 cells by MTT assay	2019	European journal of medicinal chemistry, Dec-01, Volume: 183	1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships.
AID1572350	Inhibition of HDAC in human HL60 cells assessed as acetylated H3/GAPDH ratio at 10 uM after 4 hrs by Western blot assay relative to control	2019	Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3	Synthesis and Biological Investigation of Phenothiazine-Based Benzhydroxamic Acids as Selective Histone Deacetylase 6 Inhibitors.
AID546559	Cytotoxicity against human A549 cells overexpressing HDAC by resazurin dye reduction assay	2010	Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24	Novel chimeric histone deacetylase inhibitors: a series of lapatinib hybrides as potent inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and histone deacetylase activity.
AID1336940	Inhibition of HDAC in human LNCAP cells assessed as down regulation of COX2 expression at 10 uM after 24 hrs by Western blot analysis	2017	Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3	Bifunctional conjugates with potent inhibitory activity towards cyclooxygenase and histone deacetylase.
AID1764253	Inhibition of recombinant human N-terminal GST-tagged HDAC6 (1 to 1215 residues) expressed in baculovirus infected insect cells using Boc-Lys(Ac)-AMC as substrate preincubated for 5 mins followed by substrate addition measured after 90 mins by fluorimetry	2021	European journal of medicinal chemistry, Feb-05, Volume: 211	Synergistic induction of apoptosis in resistant head and neck carcinoma and leukemia by alkoxyamide-based histone deacetylase inhibitors.
AID1282243	Inhibition of recombinant HDAC9 (unknown origin) using AMC labeled AC-peptide as substrate incubated for 1 hr by fluorescence analysis	2016	Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4	Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
AID1622984	Inhibition of HDAC2 in human HeLa nuclear extract using Boc-Lys(acetyl)-AMC as substrate measured after 30 mins by fluorescence assay	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.
AID1566814	Antiproliferative activity against human A2780S cells after 72 hrs by MTT assay	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Discovery of 1,2,4-oxadiazole-Containing hydroxamic acid derivatives as histone deacetylase inhibitors potential application in cancer therapy.
AID1614247	Inhibition of HDAC6 in human MV4-11 cells assessed as increase in alpha-tubulin acetylation at 1 uM after 6 hrs by Western blot analysis
AID1752947	Selective index, ratio of IC50 for human HepG2-A16-CD81EGFP cells to IC50 for antiplasmodial activity against liver stage exo-erythrocytic forms of Plasmodium berghei sporozoites infected in human HepG2-A16-CD81EGFP cells
AID348804	Antiproliferative activity against human HCT116 cells after 72 hrs by celltiter-blue viability assay	2008	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20	Optimization of a series of potent and selective ketone histone deacetylase inhibitors.
AID297491	Cytotoxicity against human Cal27 cells	2007	Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18	2-aroylindoles and 2-aroylbenzofurans with N-hydroxyacrylamide substructures as a novel series of rationally designed histone deacetylase inhibitors.
AID1422520	Inhibition of HDAC in human HeLa cell extract at 2 uM after 15 to 30 mins by COLOR DE LYS-based colorimetric method	2018	European journal of medicinal chemistry, Nov-05, Volume: 159	In search of constrained FTY720 and phytosphingosine analogs as dual acting anticancer agents targeting metabolic and epigenetic pathways.
AID525001	Inhibition of HDAC2 by in vitro deacetylation assay	2010	Nature chemical biology, Jan, Volume: 6, Issue:1	Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.
AID503668	Cytotoxicity against human GM15850 cells at 5 uM after 96 hrs by trypan blue exclusion assay	2006	Nature chemical biology, Oct, Volume: 2, Issue:10	Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia.
AID1515917	Antitumor activity against human HCT116 cells xenografted in athymic nude BALB/c mouse assessed as tumor growth inhibition at 100 mpk, ip measured 2 times every week relative to control	2019	Journal of medicinal chemistry, 08-08, Volume: 62, Issue:15	Design, Synthesis, and Biological Evaluation of 4-Methyl Quinazoline Derivatives as Anticancer Agents Simultaneously Targeting Phosphoinositide 3-Kinases and Histone Deacetylases.
AID1671981	Cytotoxicity against human MCF7/ADR cells after 72 hrs by SRB assay	2019	Bioorganic & medicinal chemistry, 04-01, Volume: 27, Issue:7	Synthesis and biological evaluation of paclitaxel and vorinostat co-prodrugs for overcoming drug resistance in cancer therapy in vitro.
AID499813	Selectivity index, ratio of IC50 for african green monkey (Cercopithecus aethiops) Vero cells to IC50 for Plasmodium falciparum W2	2010	Journal of medicinal chemistry, Aug-26, Volume: 53, Issue:16	Non-peptide macrocyclic histone deacetylase inhibitors derived from tricyclic ketolide skeleton.
AID1600734	Antiproliferative activity against human A2780 cells after 72 hrs by microplate reader based MTT assay	2019	Bioorganic & medicinal chemistry, 10-01, Volume: 27, Issue:19	Novel α,β-unsaturated hydroxamic acid derivatives overcome cisplatin resistance.
AID1065633	Inhibition of human recombinant full length HDAC6 after 60 mins by fluorescence assay	2013	Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24	Design, synthesis, and biological evaluation of potent and selective class IIa histone deacetylase (HDAC) inhibitors as a potential therapy for Huntington's disease.
AID1406987	Inhibition of class 1 HDAC in human U87 cells assessed as levels of histone H3 acetylation at lysine 9/14 at 5 uM after 30 hrs by Western blot analysis relative to control	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Novel spiroindoline HDAC inhibitors: Synthesis, molecular modelling and biological studies.
AID1550128	Induction of apoptosis in human K562 cells assessed as late apoptotic cells at 1 uM after 24 hrs by Annexin-V/propidium iodide staining-based flow cytometric analysis (Rvb = 5.87%)	2019	Journal of medicinal chemistry, 04-25, Volume: 62, Issue:8	Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies.
AID750106	Cytotoxicity against human MCF7 cells after 48 hrs by Sulforhodamine B assay	2013	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 23, Issue:11	Design, synthesis and biological evaluation of indeno[1,2-d]thiazole derivatives as potent histone deacetylase inhibitors.
AID1816201	Antiproliferative activity against human MDA-MB-468 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay
AID1688032	Induction of apoptosis in human HL-60 cells assessed as late apoptotic cells at 0.5 uM measured after 24 hrs by Annexin-V/FITC and propidium iodide staining based flow cytometry (Rvb = 7.24 %)	2020	European journal of medicinal chemistry, Feb-15, Volume: 188	A 18β-glycyrrhetinic acid conjugate with Vorinostat degrades HDAC3 and HDAC6 with improved antitumor effects.
AID1282256	Cytotoxicity against human SKOV3 cells after 72 hrs by MTT assay	2016	Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4	Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
AID1897379	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
AID1225975	Induction of apoptosis in human HCT116 cells assessed as early apoptotic cells at 5 uM after 24 hrs by annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 2.27%)	2015	ACS medicinal chemistry letters, Mar-12, Volume: 6, Issue:3	Discovery of Novel Multiacting Topoisomerase I/II and Histone Deacetylase Inhibitors.
AID1349726	Inhibition of recombinant human full length C-terminal His-tagged HDAC8 expressed in baculovirus infected Sf9 insect cells after 30 mins by fluorescence assay	2018	ACS medicinal chemistry letters, Jan-11, Volume: 9, Issue:1	Dual NAMPT/HDAC Inhibitors as a New Strategy for Multitargeting Antitumor Drug Discovery.
AID1784986	Inhibition of HDAC2 (unknown origin) using Ac-peptide as a substrate pretreated for 15 mins followed by substrate addition	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Design, synthesis and biological evaluation of novel hybrids targeting mTOR and HDACs for potential treatment of hepatocellular carcinoma.
AID1246515	Inhibition of HDAC5 (unknown origin) using Boc-Lys(trifluoroacetyl)-AMC fluorogenic acetylated peptide substrate by fluorometric assay	2015	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 25, Issue:19	Discovery of 1-hydroxypyridine-2-thiones as selective histone deacetylase inhibitors and their potential application for treating leukemia.
AID1511137	Inhibition of HDAC8 (unknown origin) using Ac-LeuGlyLys(tfa)-AMC as substrate preincubated for 5 mins followed by substrate addition and measured after 60 mins by fluorescence based assay	2019	ACS medicinal chemistry letters, Aug-08, Volume: 10, Issue:8	Design, Synthesis, and Biological Evaluation of 2,4-Imidazolinedione Derivatives as HDAC6 Isoform-Selective Inhibitors.
AID1464871	Inhibition of HDAC6 (unknown origin)	2017	Bioorganic & medicinal chemistry letters, 11-01, Volume: 27, Issue:21	Design, synthesis and biological evaluation of novel histone deacetylase inhibitors incorporating 4-aminoquinazolinyl systems as capping groups.
AID663376	Growth inhibition of human SNB75 cells after 72 hrs by MTS assay	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Discovery and extensive in vitro evaluations of NK-HDAC-1: a chiral histone deacetylase inhibitor as a promising lead.
AID1434355	Growth inhibition of human ACHN cells measured after 5 days by sulforhodamine-B assay	2017	European journal of medicinal chemistry, Jan-27, Volume: 126	Improving potency and metabolic stability by introducing an alkenyl linker to pyridine-based histone deacetylase inhibitors for orally available RUNX3 modulators.
AID1759721	Inhibition of class 1 HDAC in human Jurkat 2C4 model of HIV latency assessed as reactivation of HIV latency incubated for 18 to 24 hrs in presence of 0.1 % heat inactivated NHS by Steady-Glo luciferase assay	2021	ACS medicinal chemistry letters, Apr-08, Volume: 12, Issue:4	Redefining the Histone Deacetylase Inhibitor Pharmacophore: High Potency with No Zinc Cofactor Interaction.
AID1293554	Inhibition of human recombinant HDAC2 using Fluor de Lys Green as substrate incubated for 30 mins by fluorescence assay	2016	European journal of medicinal chemistry, Apr-13, Volume: 112	Biphenyl-4-yl-acrylohydroxamic acids: Identification of a novel indolyl-substituted HDAC inhibitor with antitumor activity.
AID1917542	Inhibition of HDAC11 (unknown origin) measured by fluorescence based assay	2022	Bioorganic & medicinal chemistry, 11-01, Volume: 73	Identification of PI3K/HDAC Dual-targeted inhibitors with subtype selectivity as potential therapeutic agents against solid Tumors: Building HDAC6 potency in a Quinazolinone-based PI3Kδ-selective template.
AID672025	Inhibition of human recombinant HDAC2 using Boc-L-Lys (Ac)-AMC as substrate preincubated with compound for 24 hrs measured after 35 mins by spectrofluorometric analysis	2012	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 22, Issue:15	Design, synthesis, modeling, biological evaluation and photoaffinity labeling studies of novel series of photoreactive benzamide probes for histone deacetylase 2.
AID1478583	Induction of apoptosis in human K562 cells assessed as late apoptotic cells at 2 uM after 24 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometry (Rvb = 2.83%)	2017	European journal of medicinal chemistry, Jun-16, Volume: 133	Design, synthesis and biological evaluation of quinoline derivatives as HDAC class I inhibitors.
AID1406986	Inhibition of class 1 HDAC in human U87 cells assessed as levels of histone H3 acetylation at lysine 9/14 at 1 uM after 30 hrs by Western blot analysis relative to control	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Novel spiroindoline HDAC inhibitors: Synthesis, molecular modelling and biological studies.
AID1537569	Cell cycle arrest in human G55T2 cells assessed as accumulation in subG0 phase at 3 uM incubated for 72 hrs by propidium iodide based flow cytometry (Rvb = 4.5 %)	2019	MedChemComm, Jul-01, Volume: 10, Issue:7	Design, synthesis and biological evaluation of β-peptoid-capped HDAC inhibitors with anti-neuroblastoma and anti-glioblastoma activity.
AID1897403	Induction of apoptosis in human SNU-16 cells assessed as dead cells at 0.3 uM incubated for 72 hrs by annexin-V/FITC propidium iodide staining based flow cytometry analysis (Rvb = 2.65%)
AID482943	Inhibition of HDAC3	2010	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11	Acylurea connected straight chain hydroxamates as novel histone deacetylase inhibitors: Synthesis, SAR, and in vivo antitumor activity.
AID1321713	Inhibition of HDAC in human SH-SY5Y cells assessed as increase in histone H3K9 acetylation at 50 nM in presence of >400 nM sildenafil after 2 hrs by AlphaLisa assay relative to control	2016	Journal of medicinal chemistry, 10-13, Volume: 59, Issue:19	Design, Synthesis, and Biological Evaluation of First-in-Class Dual Acting Histone Deacetylases (HDACs) and Phosphodiesterase 5 (PDE5) Inhibitors for the Treatment of Alzheimer's Disease.
AID1245684	Cytotoxicity against human U937 cells assessed as growth inhibition after 48 hrs by MTT assay	2015	Bioorganic & medicinal chemistry, Oct-01, Volume: 23, Issue:19	Development of N-hydroxybenzamide derivatives with indole-containing cap group as histone deacetylases inhibitors.
AID652755	Inhibition of recombinant human HDAC11 using Fluor-de-Lys as substrate after 30 mins by spectrophotometry	2011	ACS medicinal chemistry letters, Jul-21, Volume: 2, Issue:9	Potential Agents for Treating Cystic Fibrosis: Cyclic Tetrapeptides that Restore Trafficking and Activity of ΔF508-CFTR.
AID1280284	Cytotoxicity against human HL60 cells after 72 hrs by cell titre 96 aqueous cell proliferation assay	2016	Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4	Synthesis and Biological Investigation of Oxazole Hydroxamates as Highly Selective Histone Deacetylase 6 (HDAC6) Inhibitors.
AID723432	Potentiation of 2.5 uM cisplatin-induced toxicity in 1 uM cisplatin resistant human CAL27 cells at 1 uM pretreated for 48 hrs followed by 1 uM cisplatin treatment by MTT assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1251320	Growth inhibition of human HCT116 cells after 72 hrs	2015	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 25, Issue:20	Investigation on the ZBG-functionality of phenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase inhibitors.
AID1274874	Inhibition of HDAC4 (unknown origin)	2016	European journal of medicinal chemistry, Jan-27, Volume: 108	Orally available stilbene derivatives as potent HDAC inhibitors with antiproliferative activities and antitumor effects in human tumor xenografts.
AID496808	Activity of human HDAC8	2010	Nature chemical biology, Mar, Volume: 6, Issue:3	Chemical phylogenetics of histone deacetylases.
AID1348935	Effect on TNFalpha gene expression in human PC3 cells at IC50 after 12 hrs by RT-PCR method	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Discovery of aliphatic-chain hydroxamates containing indole derivatives with potent class I histone deacetylase inhibitory activities.
AID481553	Cytotoxicity against human KB cells assessed as growth inhibition at 100 ug/ml after 24 hrs by MTT assay	2010	Bioorganic & medicinal chemistry letters, May-15, Volume: 20, Issue:10	Synthesis and anticancer evaluation of alpha-lipoic acid derivatives.
AID1485111	Inhibition of SIRT1 in human U373 cells assessed as increase of histone H4 acetylation at 2 uM after 8 hrs by Western blotting method relative to control	2017	Journal of medicinal chemistry, 06-08, Volume: 60, Issue:11	Discovery and Characterization of R/S-N-3-Cyanophenyl-N'-(6-tert-butoxycarbonylamino-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-4-yl)urea, a New Histone Deacetylase Class III Inhibitor Exerting Antiproliferative Activity against Cancer Cell Lines.
AID488239	Inhibition of HDAC6 after 10 mins by fluorometric assay	2010	Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11	Vitamin D receptor agonist/histone deacetylase inhibitor molecular hybrids.
AID1873399	Inhibition of HDAC1 (unknown origin) preincubated for 5 mins	2022	Bioorganic & medicinal chemistry letters, 08-15, Volume: 70	Comparison of three zinc binding groups for HDAC inhibitors - A potency, selectivity and enzymatic kinetics study.
AID1548249	Inhibition of HDAC6 (unknown origin) pre-incubated for 5 mins before fluorogenic substrate Boc-Lys (acetyl)-AMC or Boc-Lys (triflouroacetyl)-AMC addition and measured after 30 mins by fluorescence based assay
AID288447	Inhibition of LPS-stimulated TNFalpha production in RAW264.7 cells after 24 hrs by ELISA	2007	Journal of medicinal chemistry, May-31, Volume: 50, Issue:11	Structure-activity relationship studies of a series of novel delta-lactam-based histone deacetylase inhibitors.
AID1280264	Selectivity ratio of IC50 for human HDAC6 to IC50 for human HDAC8	2016	Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4	Synthesis and Biological Investigation of Oxazole Hydroxamates as Highly Selective Histone Deacetylase 6 (HDAC6) Inhibitors.
AID628450	Induction of apoptosis in human HepG2 cells assessed as cleavage of caspase 3 at 1 to 10 uM after 14 hrs by Western blot analysis	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Design, synthesis, docking, and biological evaluation of novel diazide-containing isoxazole- and pyrazole-based histone deacetylase probes.
AID1728925	Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured after 5 days by beckman coulter counting method	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Synthesis and anticancer activity evaluation of naphthalene-substituted triazole spirodienones.
AID1380950	Antiproliferative activity against human K562 cells after 72 hrs by MTT assay	2018	Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12	Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously.
AID1876340	Cytotoxicity against human MV4-11 cells assessed as cell viability incubated for 72 hrs by Cell titer-blue assay	2021	Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12	Development of HDAC Inhibitors Exhibiting Therapeutic Potential in T-Cell Prolymphocytic Leukemia.
AID1174702	Induction of apoptosis in human U937 cells assessed as viable cells at 1.5 uM after 24 hrs by annexin-V/propidium iodide staining-based flow cytometry (Rvb = 92.47%)	2015	European journal of medicinal chemistry, Jan-07, Volume: 89	Development of 3-hydroxycinnamamide-based HDAC inhibitors with potent in vitro and in vivo anti-tumor activity.
AID1478595	Antiproliferative activity against human HEL cells after 48 hrs by MTT assay	2017	European journal of medicinal chemistry, Jun-16, Volume: 133	Design, synthesis and biological evaluation of quinoline derivatives as HDAC class I inhibitors.
AID1576451	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by SRB assay
AID663349	Growth inhibition of human A549/ATCC cells after 72 hrs by MTS assay	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Discovery and extensive in vitro evaluations of NK-HDAC-1: a chiral histone deacetylase inhibitor as a promising lead.
AID1260653	Inhibition of human recombinant HDAC1 by microplate reader assay
AID1622938	Inhibition of recombinant human N-terminal FLAG-tagged HDAC10 (2 to 631 residues) expressed in baculovirus infected using 7-AMC-labelled HDAC substrate measured after 30 mins by fluorescence assay	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.
AID1848613	Cytotoxicity against human LOX IMVI cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay	2022	Journal of medicinal chemistry, 11-10, Volume: 65, Issue:21	First-in-Class Dual Mechanism Ferroptosis-HDAC Inhibitor Hybrids.
AID1810049	Antiproliferative activity against mouse CT26 cells measured after 72 hrs by CCK8 assay
AID1206766	Inhibition of full length human recombinant HDAC6 expressed in baculovirus infected insect S9 cells using Ac-Leu-GlyLys(Tfa)-AMC as substrate after 30 mins by fluorescence assay	2015	Journal of medicinal chemistry, May-28, Volume: 58, Issue:10	Design, synthesis, and antitumor evaluation of novel histone deacetylase inhibitors equipped with a phenylsulfonylfuroxan module as a nitric oxide donor.
AID1709365	Induction of apoptosis in human NAMALVA cells assessed as viable cells at IC50 measured after 48 hrs by Annexin V-FITC/7AAD staining based flow cytometry (Rvb = 90.4%)	2021	Bioorganic & medicinal chemistry, 04-01, Volume: 35	Structure-activity relationship and mechanistic studies for a series of cinnamyl hydroxamate histone deacetylase inhibitors.
AID1816193	Inhibition of JAK3 (unknown origin) preincubated for 60 mins followed by reagent A addition and measured after 60 mins in presence of ATP by using microplate reader method
AID663364	Growth inhibition of human OVCAR3 cells after 72 hrs by MTS assay	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Discovery and extensive in vitro evaluations of NK-HDAC-1: a chiral histone deacetylase inhibitor as a promising lead.
AID1401539	Antiproliferative activity against human Mino cells after 72 hrs by MTT assay	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors.
AID352751	Inhibition of His-tagged HDAC8 catalytic domain expressed in Escherichia coli	2009	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11	Histone deacetylase inhibitors with a primary amide zinc binding group display antitumor activity in xenograft model.
AID1330945	Cytotoxicity against human BT474 cells expressing HER2 assessed as reduction in cell viability measured after 48 hrs by MTT assay	2017	Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1	Synthesis and investigation of novel 6-(1,2,3-triazol-4-yl)-4-aminoquinazolin derivatives possessing hydroxamic acid moiety for cancer therapy.
AID1383995	Antiproliferative activity against human HEL cells after 48 hrs by MTT assay	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	Discovery of meta-sulfamoyl N-hydroxybenzamides as HDAC8 selective inhibitors.
AID1652197	Antiproliferative activity against human A549 cells incubated for 96 hrs by resazurin assay	2020	ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5	New Dual CK2/HDAC1 Inhibitors with Nanomolar Inhibitory Activity against Both Enzymes.
AID1401375	Inhibition of HDAC6 in human HeLa-S3 cell lysates preincubated for 15 mins followed by HDAC-Glo substrate addition measured after 30 to 40 mins by fluorimetric method	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
AID1449326	Inhibition of recombinant full length human C-terminal FLAG/His-tagged HDAC1 expressed in baculovirus infected sf9 cells using Z-(Ac)Lys-AMC as substrate measured after 90 mins by fluorescence assay	2017	Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13	Alkoxyurea-Based Histone Deacetylase Inhibitors Increase Cisplatin Potency in Chemoresistant Cancer Cell Lines.
AID744876	Cytotoxicity against human NCI-H460 cells by MTT assay	2013	Bioorganic & medicinal chemistry letters, May-01, Volume: 23, Issue:9	Discovery of adamantane based highly potent HDAC inhibitors.
AID621738	Antiproliferative activity against human HCT116 cells by MTT assay	2011	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19	2,5-Disubstituted-1,3,4-oxadiazoles/thiadiazole as surface recognition moiety: design and synthesis of novel hydroxamic acid based histone deacetylase inhibitors.
AID628448	Induction of apoptosis in human HepG2 cells assessed as cleavage of caspase 3 at 1 to 10 uM after 24 hrs by Western blot analysis	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Design, synthesis, docking, and biological evaluation of novel diazide-containing isoxazole- and pyrazole-based histone deacetylase probes.
AID1566811	Inhibition of recombinant N-terminal FLAG-tagged human HDAC10 (2 to 631 residues) expressed in baculovirus infected Sf9 cells using Ac-peptide-AMC as substrate after 1 hr by fluorescence assay	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Discovery of 1,2,4-oxadiazole-Containing hydroxamic acid derivatives as histone deacetylase inhibitors potential application in cancer therapy.
AID605534	Antiproliferative activity against human MG63 cells after 72 hrs by WST-1 assay	2010	Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24	Discovery of 2-(6-{[(6-fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a class I selective orally active histone deacetylase inhibitor.
AID1266820	Inhibition of HDAC8 in human HeLa cell nuclear extract using Boc-Lys (Ac)-AMC as substrate after 60 mins by fluorometric analysis	2015	Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23	Novel β-Carboline/Hydroxamic Acid Hybrids Targeting Both Histone Deacetylase and DNA Display High Anticancer Activity via Regulation of the p53 Signaling Pathway.
AID300837	Growth inhibition of human LOX-IMVI cells after 21 hrs by MTT assay	2007	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17	Pomiferin, histone deacetylase inhibitor isolated from the fruits of Maclura pomifera.
AID755625	Inhibition of HDAC in human HL60 cells using Boc-Lys(Ac)-pNA as substrate at 5 umol/L incubated for 24 hrs prior to substrate addition measured after 90 mins by fluorescence assay	2013	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13	Discovery of a small molecular compound simultaneously targeting RXR and HADC: design, synthesis, molecular docking and bioassay.
AID1897383	Antiproliferative activity against human K562 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
AID1623530	Inhibition of human recombinant HDAC9 using fluorogenic HDAC substrate class 2A by fluorescence assay	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	A novel class of anthraquinone-based HDAC6 inhibitors.
AID732151	Inhibition of HDAC8 (unknown origin) assessed as fluorescence intensity measured after 60 mins incubation at room temperature by trypsin-free microfluidic lab-on-a-chip assay	2013	Journal of medicinal chemistry, Feb-28, Volume: 56, Issue:4	Potent and selective inhibition of histone deacetylase 6 (HDAC6) does not require a surface-binding motif.
AID1280263	Selectivity ratio of IC50 for human HDAC6 to IC50 for human HDAC1	2016	Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4	Synthesis and Biological Investigation of Oxazole Hydroxamates as Highly Selective Histone Deacetylase 6 (HDAC6) Inhibitors.
AID1355730	Toxicity in BALB/C nude mouse xenografted with human HEL cells assessed as reduction in body weight at 10 mg/kg, ip bid treated for 21 consecutive days	2018	Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14	Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections.
AID717657	Inhibition of HDAC6 using Fluor-de-Lys as substrate assessed as remaining activity at 1.25 x 10'-7 M pretreated for 30 mins before substrate addition by fluorescence assay	2012	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23	The structural requirements of histone deacetylase inhibitors: suberoylanilide hydroxamic acid analogs modified at the C6 position.
AID747260	Growth inhibition of human HT1080 cells by MTT assay	2013	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 23, Issue:11	Design, synthesis, and biological evaluation of novel histone deacetylase 1 inhibitors through click chemistry.
AID1225985	Inhibition of recombinant full length human HDAC1 (1 to 482) expressed in baculovirus infected insect Sf9 cells using fluorogenic HDAC substrate 3 after 30 mins by fluorescence assay	2015	ACS medicinal chemistry letters, Mar-12, Volume: 6, Issue:3	Discovery of Novel Multiacting Topoisomerase I/II and Histone Deacetylase Inhibitors.
AID594123	Inhibition of full length HDAC3/NCoR2 assessed as 7-amino-4-methylcoumarin release from fluorophore conjugated substrate after 5 mins by fluorescence assay	2011	Bioorganic & medicinal chemistry letters, May-01, Volume: 21, Issue:9	Discovery of histone deacetylase 8 selective inhibitors.
AID1396958	Antiproliferative activity against human MDA-MB-231 cells	2018	Bioorganic & medicinal chemistry letters, 08-15, Volume: 28, Issue:15	Merging of ruxolitinib and vorinostat leads to highly potent inhibitors of JAK2 and histone deacetylase 6 (HDAC6).
AID1396986	Inhibition of HDAC6 (unknown origin) using Ac-peptide as substrate pretreated for 15 mins followed by substrate addition and measured after 1 hr by fluorescence assay	2018	Bioorganic & medicinal chemistry, 08-07, Volume: 26, Issue:14	Design, synthesis and anticancer evaluation of acridine hydroxamic acid derivatives as dual Topo and HDAC inhibitors.
AID1630589	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTS-PMS assay	2016	Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21	Synthesis and biological evaluation of santacruzamate A analogues for anti-proliferative and immunomodulatory activity.
AID1548274	Antiproliferative activity against bortezomib resistant human KM3/BTZ cells incubated for 48 hrs by MTT assay
AID775827	Binding affinity to human holo-transferrin assessed as pseudo-first-order rate constant measured as removal of ferric ion at 1 mM measured for 1 hr by UV-vis spectrophotometric analysis	2013	Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20	Investigating the selectivity of metalloenzyme inhibitors.
AID1783065	Antifungal activity against fluconazole-sensitive Candida albicans SC5314 assessed as inhibition of fungal growth	2021	European journal of medicinal chemistry, Oct-05, Volume: 221	Lanosterol 14α-demethylase (CYP51)/histone deacetylase (HDAC) dual inhibitors for treatment of Candida tropicalis and Cryptococcus neoformans infections.
AID1515907	Antiproliferative activity against human U87 cells after 96 hrs by MTT assay	2019	Journal of medicinal chemistry, 08-08, Volume: 62, Issue:15	Design, Synthesis, and Biological Evaluation of 4-Methyl Quinazoline Derivatives as Anticancer Agents Simultaneously Targeting Phosphoinositide 3-Kinases and Histone Deacetylases.
AID1578481	Cytotoxicity against human MOLM13 cells assessed as reduction in cell viability incubated for 72 hrs by cell-titer blue assay	2020	ACS medicinal chemistry letters, Jan-09, Volume: 11, Issue:1	Class I/IIb-Selective HDAC Inhibitor Exhibits Oral Bioavailability and Therapeutic Efficacy in Acute Myeloid Leukemia.
AID1856997	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	2022	Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19	Histone Deacetylase and Enhancer of Zeste Homologue 2 Dual Inhibitors Presenting a Synergistic Effect for the Treatment of Hematological Malignancies.
AID1164190	Inhibition of HDAC in human U937 cells assessed as hyperacetylation of p21 at 5 uM after 24 hrs by Western blot analysis relative to control	2014	ACS medicinal chemistry letters, Sep-11, Volume: 5, Issue:9	Novel antiproliferative chimeric compounds with marked histone deacetylase inhibitory activity.
AID1380953	Inhibition of HDAC2 (unknown origin) using fluorogenic Boc-Lys(acetyl)-AMC as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by fluorescence-based assay	2018	Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12	Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously.
AID1441660	Inhibition of LTB4 biosynthesis in LPS-induced C57BL/6 mouse model of acute lung injury BLAF at 25 mg/kg, ip by ELISA	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
AID1548285	Induction of apoptosis in bortezomib resistant human KM3/BTZ cells assessed as early apoptotic cells level at 50 nM incubated for 24 hrs by Annexin V-FITC/PI staining based FCAS analysis (Rvb = 1.39%)
AID1816220	Induction of apoptosis in mouse 4T1 cells assessed as viable cells at 5 uM measured after 48 hrs by annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 89.5%)
AID1742748	Antitumor activity against mouse 4T1 cells xenografted in BALB/c mouse assessed as tumor growth inhibition at 150 mg/kg, po administered for 22 days and measured on day 22	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Design and synthesis of novel Flavone-based histone deacetylase inhibitors antagonizing activation of STAT3 in breast cancer.
AID373083	Antiproliferative activity against human HeLa cells after 4 hrs by WST-1 assay	2009	European journal of medicinal chemistry, Mar, Volume: 44, Issue:3	Novel amide derivatives as inhibitors of histone deacetylase: design, synthesis and SAR.
AID1263144	Inhibition of human recombinant HDAC3 using Boc-Lys(Ac)-AMC as substrate after 30 mins by fluorescence assay	2015	Bioorganic & medicinal chemistry, Dec-15, Volume: 23, Issue:24	Design, synthesis and evaluation of antiestrogen and histone deacetylase inhibitor molecular hybrids.
AID1534485	Inhibition of HDAC6 in mouse LL/2 cells assessed as reduction in PD-L1 expression at 10 uM after 24 hrs by Western blot analysis	2019	Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2	Quinazolin-2,4-dione-Based Hydroxamic Acids as Selective Histone Deacetylase-6 Inhibitors for Treatment of Non-Small Cell Lung Cancer.
AID1819500	Antitumor activity against mouse B16-F10 cells implanted in C57BL/6J mouse assessed as reduction on tumor weight at 60 mg/kg, IG administered for 12 days	2022	Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4	Discovery of DNA-Targeting HDAC Inhibitors with Potent Antitumor Efficacy In Vivo That Trigger Antitumor Immunity.
AID373087	Antitumor activity in mouse P388 cells xenografted B6D2F1 mouse assessed as increase in life span at 100 mg/kg/day, ip administered 3 to 7 days postxenografting	2009	European journal of medicinal chemistry, Mar, Volume: 44, Issue:3	Novel amide derivatives as inhibitors of histone deacetylase: design, synthesis and SAR.
AID1890435	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth measured after 74 hrs by SRB assay	2022	Bioorganic & medicinal chemistry, 04-15, Volume: 60	Design, synthesis, and antitumor activity evaluation of novel acyl sulfonamide spirodienones.
AID1181314	Induction of apoptosis in human U937 cells assessed as accumulation at pre-G1 phase at 5 uM after 48 hrs by propidium iodide staining based FACS method	2014	Journal of medicinal chemistry, Jul-24, Volume: 57, Issue:14	1,3,4-Oxadiazole-containing histone deacetylase inhibitors: anticancer activities in cancer cells.
AID1882978	Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth by MTT assay	2022	European journal of medicinal chemistry, Jul-05, Volume: 237	Design, synthesis, and evaluation of a novel series of mono-indolylbenzoquinones derivatives for the potential treatment of breast cancer.
AID492802	Inhibition of human recombinant HDAC4 at 5 uM after 15 mins by fluorimetric assay	2010	Journal of medicinal chemistry, Jun-24, Volume: 53, Issue:12	Synthesis and biological characterization of the histone deacetylase inhibitor largazole and C7- modified analogues.
AID1821348	Toxicity in mouse xenografted with human HepG2 cells assessed as necrosis in lung at 12 mg/kg, ip administered every 2 days for 4 weeks by H and E staining based microscopic method	2022	European journal of medicinal chemistry, Feb-05, Volume: 229	Discovery of phthalazino[1,2-b]-quinazolinone derivatives as multi-target HDAC inhibitors for the treatment of hepatocellular carcinoma via activating the p53 signal pathway.
AID1126977	Antiproliferative activity against human K562 cells after 48 hrs by MTT assay	2014	Journal of medicinal chemistry, Apr-24, Volume: 57, Issue:8	Discovery of the first N-hydroxycinnamamide-based histone deacetylase 1/3 dual inhibitors with potent oral antitumor activity.
AID1737145	Induction of apoptosis in human HCT-116 cells assessed as viable cells at 10 uM after 24 hrs by Annexin V-FITC/PI staining based flow cytometric analysis (Rvb = 90.34%)	2020	European journal of medicinal chemistry, Apr-15, Volume: 192	Design, synthesis and biological evaluation of novel indazole-based derivatives as potent HDAC inhibitors via fragment-based virtual screening.
AID1622981	Cytotoxicity against African green monkey Vero cells	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.
AID1754774	Induction of apoptosis in human MCF7 cells assessed as downregulation of c-Myc protein expression at 1 to 3 uM measured after 48 hrs western blot analysis	2021	Bioorganic & medicinal chemistry, 07-15, Volume: 42	Discovery of novel class of histone deacetylase inhibitors as potential anticancer agents.
AID1282261	Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay	2016	Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4	Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
AID1784991	Selectivity index, ratio of IC50 for cytotoxicity against human L02 cells to IC50 for antiproliferative activity against human HepG2 cells	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Design, synthesis and biological evaluation of novel hybrids targeting mTOR and HDACs for potential treatment of hepatocellular carcinoma.
AID414721	Inhibition of wild-type c-Abl by liquid scintillation counting	2009	Journal of medicinal chemistry, Apr-23, Volume: 52, Issue:8	Design of chimeric histone deacetylase- and tyrosine kinase-inhibitors: a series of imatinib hybrides as potent inhibitors of wild-type and mutant BCR-ABL, PDGF-Rbeta, and histone deacetylases.
AID1384215	Inhibition of full length human recombinant C-terminal FLAG/His-tagged HDAC1 expressed in baculovirus infected sf9 cells using fluorogenic HDAC substrate 3 after 4 hrs fluorescence assay	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease.
AID1502984	Inhibition of MAOB (unknown origin) using beetle luciferin as substrate by MAO-Glo assay	2017	European journal of medicinal chemistry, Nov-10, Volume: 140	Design and synthesis of tranylcypromine derivatives as novel LSD1/HDACs dual inhibitors for cancer treatment.
AID1339571	Inhibition of full length human C-terminal His-tag HDAC8 expressed in baculovirus expression system preincubated for 15 mins followed by HDAC-Glo substrate addition measured after 30 to 45 mins by ELISA	2017	ACS medicinal chemistry letters, Mar-09, Volume: 8, Issue:3	Structural Requirements of HDAC Inhibitors: SAHA Analogues Modified at the C2 Position Display HDAC6/8 Selectivity.
AID1785343	Inhibition of recombinant human SIRT5 measured after 30 mins by fluorescence microplate reader assay
AID1876465	Antiproliferative activity against human SGC-7901 cells assessed as reduction in cell viability incubated for 72 hrs by WST-8 assay	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	Design, synthesis, and biological evaluation of indole-based hydroxamic acid derivatives as histone deacetylase inhibitors.
AID1622936	Inhibition of recombinant full-length human C-terminal HDAC8 expressed in baculovirus infected Sf9 insect cells using 7-AMC-labelled HDAC substrate measured after 30 mins by fluorescence assay	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.
AID84266	Antiproliferative activity against HT1080 (human fibrosarcoma) cell line.	2003	Bioorganic & medicinal chemistry letters, Jun-02, Volume: 13, Issue:11	Indole amide hydroxamic acids as potent inhibitors of histone deacetylases.
AID1865240	Induction of apoptosis in human MV4-11 cells incubated for 24 hrs by AnnexinV-FITC/propidium iodide staining based flow cytometry	2022	Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18	Discovery of Novel Src Homology-2 Domain-Containing Phosphatase 2 and Histone Deacetylase Dual Inhibitors with Potent Antitumor Efficacy and Enhanced Antitumor Immunity.
AID1597953	Induction of apoptosis in human A549 cells assessed as live cells at 10 uM incubated for 72 hrs by Annexin V-FITC/propidium iodide-staining based flow cytometric analysis (Rvb = 89.8%)	2019	Bioorganic & medicinal chemistry letters, 09-15, Volume: 29, Issue:18	Anti-tumor activity evaluation of novel tubulin and HDAC dual-targeting inhibitors.
AID1849157	Inhibition of recombinant human C-terminal FLAG/His-tagged HDAC1 (1 to 482 residues) expressed in Sf9 insect cells using Z-Lys(Ac)-AMC as fluorogenic substrate incubated for 90 mins by microplate reader analysis	2022	Journal of medicinal chemistry, 11-24, Volume: 65, Issue:22	Development of Fluorinated Peptoid-Based Histone Deacetylase (HDAC) Inhibitors for Therapy-Resistant Acute Leukemia.
AID1422515	Inhibition of HDAC in MEF assessed as increase in histone H3 acetylation at 2 uM after 6 hrs by Western blot analysis	2018	European journal of medicinal chemistry, Nov-05, Volume: 159	In search of constrained FTY720 and phytosphingosine analogs as dual acting anticancer agents targeting metabolic and epigenetic pathways.
AID1256443	Inhibition of human HDAC in HeLa cell nuclear extract by fluorometric assay using Fluor de Lys substrate	2015	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22	Hybrids from 4-anilinoquinazoline and hydroxamic acid as dual inhibitors of vascular endothelial growth factor receptor-2 and histone deacetylase.
AID637891	Inhibition of recombinant human HDAC8 using Boc-L-Lys(trifluoroacetyl)-MCA as substrate by fluorogenic enzymatic assay	2012	Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2	Synthesis and biochemical analysis of 2,2,3,3,4,4,5,5,6,6,7,7-dodecafluoro-N-hydroxy-octanediamides as inhibitors of human histone deacetylases.
AID1227044	Stability in human plasma assessed as compound remaining after 2 hrs by HPLC analysis	2015	Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11	Dual-Mode HDAC Prodrug for Covalent Modification and Subsequent Inhibitor Release.
AID753167	Inhibition of HDAC in human Hela cell nuclear extract after 15 mins	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and biological characterization of spiro[2H-(1,3)-benzoxazine-2,4'-piperidine] based histone deacetylase inhibitors.
AID1753833	Inhibition of recombinant human HDAC1 at 100 nM using Z-(Ac)-Lys-AMC as substrate incubated for 40 mins by fluorescence based assay relative to control	2021	European journal of medicinal chemistry, Jun-05, Volume: 218	Identification of novel 1,3-diaryl-1,2,4-triazole-capped histone deacetylase 6 inhibitors with potential anti-gastric cancer activity.
AID1266091	Cytotoxicity against human MeT-5A cells	2016	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1	Cross metathesis with hydroxamate and benzamide BOC-protected alkenes to access HDAC inhibitors and their biological evaluation highlighted intrinsic activity of BOC-protected dihydroxamates.
AID1702103	Inhibition of PI3K/AKT/mTOR signaling in human PC-3 cells assessed as reduction in phosphorylation of Akt at S473 residue at 10 uM incubated for 24 hrs by Western blot analysis	2018	Journal of medicinal chemistry, 02-22, Volume: 61, Issue:4	Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma.
AID755616	Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay	2013	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13	Discovery of a small molecular compound simultaneously targeting RXR and HADC: design, synthesis, molecular docking and bioassay.
AID316904	Inhibition of human NCI-H226 cells	2008	Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6	Histone deacetylase inhibitors: from bench to clinic.
AID1816215	Induction of apoptosis in human MDA-MB-231 cells assessed as necrotic cells at 2.5 uM measured after 48 hrs in presence of ruxolitinib by annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 5.38%)
AID1478597	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	2017	European journal of medicinal chemistry, Jun-16, Volume: 133	Design, synthesis and biological evaluation of quinoline derivatives as HDAC class I inhibitors.
AID525014	Inhibition of HDAC7 in human CFBE41o- cell line assessed as increase in rate of maturation of CFTR protein to its glycoform at 5 uM after 24 hrs by pulse chase analysis	2010	Nature chemical biology, Jan, Volume: 6, Issue:1	Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.
AID1502980	Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay	2017	European journal of medicinal chemistry, Nov-10, Volume: 140	Design and synthesis of tranylcypromine derivatives as novel LSD1/HDACs dual inhibitors for cancer treatment.
AID1063057	Inhibition of recombinant HDAC2 (unknown origin) using Fluor-de-Lys-SIRT1 as substrate by fluorescence assay	2014	Journal of natural products, Jan-24, Volume: 77, Issue:1	Protein kinase and HDAC inhibitors from the endophytic fungus Epicoccum nigrum.
AID1917543	Selectivity index, ratio IC50 for inhibition of HDAC8 (unknown origin) to IC50 for inhibition of HDAC6 (unknown origin)	2022	Bioorganic & medicinal chemistry, 11-01, Volume: 73	Identification of PI3K/HDAC Dual-targeted inhibitors with subtype selectivity as potential therapeutic agents against solid Tumors: Building HDAC6 potency in a Quinazolinone-based PI3Kδ-selective template.
AID1487092	Inhibition of HDAC1 (unknown origin)	2017	Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15	Cyclic tetrapeptide HDAC inhibitors as potential therapeutics for spinal muscular atrophy: Screening with iPSC-derived neuronal cells.
AID519582	Antimalarial activity against Plasmodium falciparum	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Potent antimalarial activity of histone deacetylase inhibitor analogues.
AID1272258	Cytotoxicity against human MCF7 cells after 72 hrs by CCK8 assay	2016	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3	Novel hydroxyamides and amides containing D-glucopyranose or D-fructose units: Biological assays in MCF-7 and MDST8 cell lines.
AID1676602	Binding affinity to ferric ion assessed as accounting ratio by measuring total compound detected/total compound adsorbed at 2.55 umol by immobilized metal-ion affinity chromatography	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
AID1469379	Cytotoxicity against mouse 4T1 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	2018	Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7	Discovery of N1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7 H-pyrrolo[2,3- d]pyrimidin-2-yl)amino)phenyl)- N8-hydroxyoctanediamide as a Novel Inhibitor Targeting Cyclin-dependent Kinase 4/9 (CDK4/9) and Histone Deacetlyase1 (HDAC1) against Malignant Cancer
AID1754789	Downregulation of HDAC3 gene expression in human MCF7 cells at 3 uM incubated for 24 hrs by whole transcriptome analysis	2021	Bioorganic & medicinal chemistry, 07-15, Volume: 42	Discovery of novel class of histone deacetylase inhibitors as potential anticancer agents.
AID316899	Inhibition of HDAC6	2008	Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6	Histone deacetylase inhibitors: from bench to clinic.
AID1380967	Inhibition of HDAC6 in human HeLa cells assessed as increase in intracellular acetyl-tubulin levels at 100 nM after 6 hrs by Western blot analysis	2018	Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12	Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously.
AID273166	Inhibition of maize HD2	2006	Journal of medicinal chemistry, Oct-05, Volume: 49, Issue:20	Synthesis and biological properties of novel, uracil-containing histone deacetylase inhibitors.
AID780585	Antiproliferative activity against human HCT116 cells assessed as cell viability after 72 hrs by MTT assay	2013	Bioorganic & medicinal chemistry, Nov-15, Volume: 21, Issue:22	The discovery and optimization of novel dual inhibitors of topoisomerase II and histone deacetylase.
AID1174680	Inhibition of HDAC in human HeLa cell extract using Boc-Lys (acetyl)-AMC as substrate incubated for 10 mins prior to substrate addition measured after 30 mins by fluorescence assay	2015	European journal of medicinal chemistry, Jan-07, Volume: 89	Development of 3-hydroxycinnamamide-based HDAC inhibitors with potent in vitro and in vivo anti-tumor activity.
AID546561	Cytotoxicity against human A431 cells overexpressing EGFR by resazurin dye reduction assay	2010	Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24	Novel chimeric histone deacetylase inhibitors: a series of lapatinib hybrides as potent inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and histone deacetylase activity.
AID710835	Cytotoxicity against human HCT15 cells assessed as growth inhibition by SRB assay	2012	Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23	Property-based optimization of hydroxamate-based γ-lactam HDAC inhibitors to improve their metabolic stability and pharmacokinetic profiles.
AID1764288	Inhibition of HDAC in human Cal27CisR cells assessed as potentiation of cisplatin-induced cytotoxicity by measuring cisplatin IC50 at 0.7 uM pretreated for 48 hrs followed by cisplatin addition and measured after 72 hrs by MTT assay (Rvb = 3.57 uM)	2021	European journal of medicinal chemistry, Feb-05, Volume: 211	Synergistic induction of apoptosis in resistant head and neck carcinoma and leukemia by alkoxyamide-based histone deacetylase inhibitors.
AID1303622	Potentiation of 0.05 nM (-)-lomaiviticin A-induced cytotoxicity against human K562 cells assessed as fraction ratio affected at 0.25 uM after 48 hrs by cell titer-glo luminescence assay	2016	Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13	Synergistic potentiation of (-)-lomaiviticin A cytotoxicity by the ATR inhibitor VE-821.
AID1406990	Inhibition of class 1 HDAC in human SH-SY5Y cells assessed as levels of histone H3 acetylation at lysine 9/14 at 1 uM after 30 hrs by Western blot analysis relative to control	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Novel spiroindoline HDAC inhibitors: Synthesis, molecular modelling and biological studies.
AID1684872	Toxicity in mouse LL/2 cells inoculated C57BL/6J mouse assessed as effect on body weight by measuring end body weight at 25 mg/kg, ip administered for 12 days and measured for every 2 days (Rvb = 18.1 +/- 0.2 g)
AID628453	Antiproliferative activity against human SH-SY5Y cells after 72 hrs by XTT assay	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Design, synthesis, docking, and biological evaluation of novel diazide-containing isoxazole- and pyrazole-based histone deacetylase probes.
AID347806	Inhibition of human HDAC1 at 0.50 uM	2008	Journal of medicinal chemistry, Dec-11, Volume: 51, Issue:23	Histone deacetylase inhibitors through click chemistry.
AID1383990	Antiproliferative activity against human MOLT4 cells after 48 hrs by MTT assay	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	Discovery of meta-sulfamoyl N-hydroxybenzamides as HDAC8 selective inhibitors.
AID1418666	Inhibition of recombinant human HDAC6 using fluorogenic HDAC substrate preincubated for 15 mins followed by substrate addition and measured after 30 mins by fluorescence analysis	2018	Bioorganic & medicinal chemistry, 11-15, Volume: 26, Issue:21	Design, synthesis, and biological evaluation of histone deacetylase inhibitors possessing glutathione peroxidase-like and antioxidant activities against Alzheimer's disease.
AID1597969	Induction of cell cycle arrest in human A549 cells assessed as accumulation at G0/G1 phase at 10 uM incubated for 36 hrs by propidium iodide staining based flow cytometry (Rvb = 72.51%)	2019	Bioorganic & medicinal chemistry letters, 09-15, Volume: 29, Issue:18	Anti-tumor activity evaluation of novel tubulin and HDAC dual-targeting inhibitors.
AID519598	Selectivity index, ratio of IC50 for neonatal foreskin fibroblasts to IC50 for chloroquine-sensitive Plasmodium falciparum 3D7	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Potent antimalarial activity of histone deacetylase inhibitor analogues.
AID663369	Growth inhibition of human SKOV3 cells after 72 hrs by MTS assay	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Discovery and extensive in vitro evaluations of NK-HDAC-1: a chiral histone deacetylase inhibitor as a promising lead.
AID1055351	Cytotoxicity against human HUT78 cells after 72 hrs by MTS-PMS assay	2013	Journal of natural products, Nov-22, Volume: 76, Issue:11	Santacruzamate A, a potent and selective histone deacetylase inhibitor from the Panamanian marine cyanobacterium cf. Symploca sp.
AID1873391	Inhibition of HDAC11 (unknown origin)	2022	Bioorganic & medicinal chemistry letters, 08-15, Volume: 70	Comparison of three zinc binding groups for HDAC inhibitors - A potency, selectivity and enzymatic kinetics study.
AID1677510	Inhibition of HDAC8 (unknown origin) in using Boc-Lys(acetyl)-AMC or Boc-Lys (triflouroacetyl)-AMC as substrate preincubated for 5 mins followed by substrate addition and measured after 30 mins by fluorescence assay	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	HDAC-Bax Multiple Ligands Enhance Bax-Dependent Apoptosis in HeLa Cells.
AID482949	Inhibition of HDAC10	2010	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11	Acylurea connected straight chain hydroxamates as novel histone deacetylase inhibitors: Synthesis, SAR, and in vivo antitumor activity.
AID1614190	Induction of apoptosis in human MV4-11 cells assessed as early apoptotic cells at 1 uM after 48 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 10.7%)
AID1421925	Cytotoxicity against HEK293 cells after 48 hrs by resazurin dye based assay	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	One-pot, multi-component synthesis and structure-activity relationships of peptoid-based histone deacetylase (HDAC) inhibitors targeting malaria parasites.
AID1273874	Metabolic stability in human liver microsomes assessed as compound remaining at 1 uM preincubated for 10 mins measured after 30 mins by LC-MS/MS analysis	2016	European journal of medicinal chemistry, Jan-27, Volume: 108	Synthesis, biological characterization and molecular modeling insights of spirochromanes as potent HDAC inhibitors.
AID1502982	Inhibition of recombinant LSD1 (157 to 852 amino acids) (unknown origin) expressed in Escherichia coli BL21(DE) using H3K4me2 substrate by amplex red and horseradish peroxidase based fluorescence assay	2017	European journal of medicinal chemistry, Nov-10, Volume: 140	Design and synthesis of tranylcypromine derivatives as novel LSD1/HDACs dual inhibitors for cancer treatment.
AID1355716	Synergistic antifungal activity against FLC resistant Candida albicans 0710922 assessed as FIC index after 48 hrs by checkerboard microdilution method	2018	Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14	Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections.
AID1486675	Inhibition of HDAC2 (unknown origin) at 10 uM using Ac-Leu-GlyLys(Ac)-AMC as substrate preincubated for 10 mins followed by substrate addition measured after 30 mins by fluorescence analysis	2017	Bioorganic & medicinal chemistry, 08-01, Volume: 25, Issue:15	Design, synthesis and tumor cell growth inhibitory activity of 3-nitro-2H-cheromene derivatives as histone deacetylaes inhibitors.
AID1487007	Selectivity index, ratio of IC50 for HDAC8 (unknown origin) to IC50 for HDAC6 (unknown origin)	2017	Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15	The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity.
AID1363799	Inhibition of chymotrypsin-like activity of 20S proteasome in imatinib-resistant human SUP-B15 cells using Suc-LLVY aminoluciferin as substrate after 2 hrs by proteasome-Glo assay	2018	Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22	Discovery of the First-in-Class Dual Histone Deacetylase-Proteasome Inhibitor.
AID378556	Induction of P21WAF1 gene expression in human ARP1 cells	2005	Journal of natural products, Mar, Volume: 68, Issue:3	4-Hydroxybenzoyl derivative from the aqueous extract of the hydroid Campanularia sp.
AID1056038	Antiproliferative activity against human HeLa cells after 48 hrs	2013	Journal of natural products, Nov-22, Volume: 76, Issue:11	Total synthesis of schizocommunin and revision of its structure.
AID1433251	Antiproliferative activity against human CMS cells after 72 hrs by MTT assay	2016	Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17	Synthesis and Antileukemic Activities of Piperlongumine and HDAC Inhibitor Hybrids against Acute Myeloid Leukemia Cells.
AID619058	Half life in mouse liver microsomes	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile.
AID1065957	Cytotoxicity against human Jurkat gamma1 cells assessed as growth inhibition at 20 uM after 72 hrs by MTS assay	2013	Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24	Synthesis and structure-activity relationship of 3-hydroxypyridine-2-thione-based histone deacetylase inhibitors.
AID1126965	Selectivity ratio of IC50 for HDAC2 (unknown origin) to IC50 for HDAC1 (unknown origin)	2014	Journal of medicinal chemistry, Apr-24, Volume: 57, Issue:8	Discovery of the first N-hydroxycinnamamide-based histone deacetylase 1/3 dual inhibitors with potent oral antitumor activity.
AID1486293	Inhibition of HDAC1 (unknown origin) using acetylated peptide substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by fluorescence analysis	2017	Bioorganic & medicinal chemistry, 08-01, Volume: 25, Issue:15	Olaparib hydroxamic acid derivatives as dual PARP and HDAC inhibitors for cancer therapy.
AID1578149	Inhibition of HDAC1 (unknown origin)	2020	European journal of medicinal chemistry, Jan-01, Volume: 185	N-alkyl-hydroxybenzoyl anilide hydroxamates as dual inhibitors of HDAC and HSP90, downregulating IFN-γ induced PD-L1 expression.
AID683277	Antiproliferative activity against human BE(2)-C cells after 72 hrs by Alamar blue assay	2012	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 22, Issue:19	Amide-based derivatives of β-alanine hydroxamic acid as histone deacetylase inhibitors: attenuation of potency through resonance effects.
AID297473	Cytotoxicity against HeLa cells	2007	Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18	2-aroylindoles and 2-aroylbenzofurans with N-hydroxyacrylamide substructures as a novel series of rationally designed histone deacetylase inhibitors.
AID1164183	Inhibition of human recombinant HDAC4 using (S)-[5-Acetylamino-1-(2-oxo-4-trifluorometyl-2Hchromen-7-ylcarbamoyl)pentl]carbami acid tert-Butyl Ester as substrate at 5 uM after 1 hr by fluorescent activity assay	2014	ACS medicinal chemistry letters, Sep-11, Volume: 5, Issue:9	Novel antiproliferative chimeric compounds with marked histone deacetylase inhibitory activity.
AID1855252	Downregulation of SPT16 expression in human HCT-116 cells at 1.5 uM measured after 24 hrs by Western blot analysis	2022	European journal of medicinal chemistry, Nov-05, Volume: 241	Discovery of 2,5-diphenyl-1,3,4-thiadiazole derivatives as HDAC inhibitors with DNA binding affinity.
AID456800	Selectivity index, ratio of IC50 for african green monkey (Cercopithecus aethiops) Vero cells to IC50 for chloroquine-sensitive Plasmodium falciparum D6	2010	Bioorganic & medicinal chemistry, Jan-01, Volume: 18, Issue:1	Antimalarial and antileishmanial activities of histone deacetylase inhibitors with triazole-linked cap group.
AID618015	Cell cycle arrest in human MDA-MB-231 cells assessed as accumulation at G1 phase at 1 uM after 48 hrs using propidium iodide staining by flow cytometric analysis	2011	Journal of medicinal chemistry, Aug-11, Volume: 54, Issue:15	Discovery of a tetrahydroisoquinoline-based hydroxamic acid derivative (ZYJ-34c) as histone deacetylase inhibitor with potent oral antitumor activities.
AID1537555	Inhibition of recombinant full length N-terminal GST-tagged human HDAC6 expressed in baculovirus infected Sf9 cells using Z-Lys(Ac)-AMC as substrate incubated for 90 mins followed by trypsin addition and measured after 30 mins by fluorescence based assay	2019	MedChemComm, Jul-01, Volume: 10, Issue:7	Design, synthesis and biological evaluation of β-peptoid-capped HDAC inhibitors with anti-neuroblastoma and anti-glioblastoma activity.
AID1065628	Inhibition of human recombinant full length HDAC2 using (Ac)Arg-Gly-Lys(Ac) as substrate after 60 mins by fluorescence assay	2013	Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24	Design, synthesis, and biological evaluation of potent and selective class IIa histone deacetylase (HDAC) inhibitors as a potential therapy for Huntington's disease.
AID1206762	Inhibition of full length human recombinant HDAC1 expressed in baculovirus using Ac-Leu-GlyLys(Ac)-AMC as substrate after 30 mins by fluorescence assay	2015	Journal of medicinal chemistry, May-28, Volume: 58, Issue:10	Design, synthesis, and antitumor evaluation of novel histone deacetylase inhibitors equipped with a phenylsulfonylfuroxan module as a nitric oxide donor.
AID473174	Ex vivo inhibition of human HDAC6 in human Caco-2 cells by fluorometric cellular activity assay	2010	Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5	Biological and biophysical properties of the histone deacetylase inhibitor suberoylanilide hydroxamic acid are affected by the presence of short alkyl groups on the phenyl ring.
AID1386681	Inhibition of HDAC in human GM18453 cells harboring NPC1 mutant assessed as restoration of cholesterol trafficking at 5 uM after 48 hrs by filipin-staining based fluorescence microscopic analysis	2018	Journal of natural products, 09-28, Volume: 81, Issue:9	GEX1A, a Polyketide from Streptomyces chromofuscus, Corrects the Cellular Defects Associated with Niemann-Pick Type C1 in Human Fibroblasts.
AID1622979	Cytotoxicity against human MCF7 cells	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.
AID1065961	Cytotoxicity against androgen-dependent human LNCAP cells assessed as growth inhibition after 72 hrs by MTS assay	2013	Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24	Synthesis and structure-activity relationship of 3-hydroxypyridine-2-thione-based histone deacetylase inhibitors.
AID1514612	Induction of apoptosis in human HepG2 cells assessed as early apoptotic cells at 5 uM after 48 hrs by annexin V-FITC/propidium iodide staining based assay (Rvb = 3.2 %)	2019	Bioorganic & medicinal chemistry letters, 01-01, Volume: 29, Issue:1	Development of hydroxamate-based histone deacetylase inhibitors containing 1,2,4-oxadiazole moiety core with antitumor activities.
AID1274876	Inhibition of HDAC6 (unknown origin)	2016	European journal of medicinal chemistry, Jan-27, Volume: 108	Orally available stilbene derivatives as potent HDAC inhibitors with antiproliferative activities and antitumor effects in human tumor xenografts.
AID1482117	Cytotoxicity against human MOLT4 cells assessed as growth inhibition after 48 hrs by MTT assay	2017	Journal of medicinal chemistry, 04-27, Volume: 60, Issue:8	Exploring Derivatives of Quinazoline Alkaloid l-Vasicine as Cap Groups in the Design and Biological Mechanistic Evaluation of Novel Antitumor Histone Deacetylase Inhibitors.
AID1671979	Cytotoxicity against human HCT-116 cells after 72 hrs by SRB assay	2019	Bioorganic & medicinal chemistry, 04-01, Volume: 27, Issue:7	Synthesis and biological evaluation of paclitaxel and vorinostat co-prodrugs for overcoming drug resistance in cancer therapy in vitro.
AID1548300	Induction of cell cycle arrest in bortezomib resistant human KM3/BTZ cells assessed as accumulation at G1 phase at 100 nM incubated for 24 hrs by propidium iodide staining based flow cytometry (Rvb = 42%)
AID1355712	Antifungal activity against FLC resistant Candida albicans 0710922 assessed as fluconazol MIC50 after 48 hrs by checkerboard microdilution method	2018	Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14	Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections.
AID1356282	Cytotoxicity against human MV4-11 cells assessed as reduction in cell viability at 0.05 to 0.5 uM cotreated with up to 500 nM of 4-CPA measured after 72 hrs by MTT assay
AID1826599	Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition incubated for 8 hrs by CCK8 assay	2022	Journal of medicinal chemistry, 03-24, Volume: 65, Issue:6	Evodiamine-Inspired Topoisomerase-Histone Deacetylase Dual Inhibitors: Novel Orally Active Antitumor Agents for Leukemia Therapy.
AID526531	Inhibition of HDAC	2010	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22	Property based optimization of δ-lactam HDAC inhibitors for metabolic stability.
AID1449218	Inhibition of human recombinant HDAC8 expressed in Escherichia coli using Z-L-Lys(epsilon-trifluoroacetyl)-AMC as substrate measured after 90 mins by fluorescence assay	2017	Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13	Design, Multicomponent Synthesis, and Anticancer Activity of a Focused Histone Deacetylase (HDAC) Inhibitor Library with Peptoid-Based Cap Groups.
AID1764249	Antiproliferative activity against human A2780 cells assessed as reduction in cell viability after 72 hrs by MTT assay	2021	European journal of medicinal chemistry, Feb-05, Volume: 211	Synergistic induction of apoptosis in resistant head and neck carcinoma and leukemia by alkoxyamide-based histone deacetylase inhibitors.
AID1873411	Inhibition of HDAC3 (unknown origin) preincubated for 60 mins	2022	Bioorganic & medicinal chemistry letters, 08-15, Volume: 70	Comparison of three zinc binding groups for HDAC inhibitors - A potency, selectivity and enzymatic kinetics study.
AID1649884	Inhibition of HDAC8 (unknown origin)	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	Histone deacetylase 8 (HDAC8) and its inhibitors with selectivity to other isoforms: An overview.
AID1548247	Inhibition of HDAC3 (unknown origin) pre-incubated for 5 mins before fluorogenic substrate Boc-Lys (acetyl)-AMC or Boc-Lys (triflouroacetyl)-AMC addition and measured after 30 mins by fluorescence based assay
AID1754798	Downregulation of SIRT5 gene expression in human MCF7 cells at 3 uM incubated for 24 hrs by whole transcriptome analysis	2021	Bioorganic & medicinal chemistry, 07-15, Volume: 42	Discovery of novel class of histone deacetylase inhibitors as potential anticancer agents.
AID1901762	Inhibition of full length human recombinant HDAC6 expressed in Sf9 baculovirus system using FAM-labeled acetylated peptide as substrate by measuring fluorescence intensity by EMSA method	2022	Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4	Discovery of HDAC6-Selective Inhibitor NN-390 with
AID1742740	Genotoxicity in Salmonella typhimurium TA97a by Ames test	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Design and synthesis of novel Flavone-based histone deacetylase inhibitors antagonizing activation of STAT3 in breast cancer.
AID308646	Antiproliferative activity against human PANC1 cells	2007	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17	Design, synthesis, and evaluation of isoindolinone-hydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors.
AID1174704	Antitumor activity against human U937 cells xenografted in athymic nude mouse assessed as tumor growth inhibition at 120 mg/kg/day, po after 16 days	2015	European journal of medicinal chemistry, Jan-07, Volume: 89	Development of 3-hydroxycinnamamide-based HDAC inhibitors with potent in vitro and in vivo anti-tumor activity.
AID304371	Inhibition of human IMPDH 1	2007	Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26	Dual inhibitors of inosine monophosphate dehydrogenase and histone deacetylases for cancer treatment.
AID461261	Antiproliferative activity against human MCF7 cells after hrs by ATP content assay	2010	Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5	Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer.
AID1533328	Selectivity ratio of IC50 for full length human N-terminal FLAG-tagged HDAC8 (1 to 377 residues) expressed in HEK293 cells to IC50 for full length human N-terminal FLAG-tagged HDAC6 (1 to 1215 residues) expressed in HEK293 cells	2018	ACS medicinal chemistry letters, Dec-13, Volume: 9, Issue:12	Molecular Basis for the Selective Inhibition of Histone Deacetylase 6 by a Mercaptoacetamide Inhibitor.
AID619057	Half life in human liver microsomes	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile.
AID1164912	Inhibition of HDAC7 (unknown origin) using fluorogenic peptide as substrate by fluorescence assay	2014	Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19	Identification of a novel aminotetralin class of HDAC6 and HDAC8 selective inhibitors.
AID1280273	Selectivity index, ratio of HDAC6 inhibition in human HeLa cells assessed as ratio of acetylated tubulin to GAPDH level at 1 uM over class1 HDAC inhibition in human HeLa cells assessed as ratio of acetylated histone H3 to GAPDH level at 1 uM	2016	Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4	Synthesis and Biological Investigation of Oxazole Hydroxamates as Highly Selective Histone Deacetylase 6 (HDAC6) Inhibitors.
AID328802	Inhibition of HDAC5 at 10 uM	2008	Journal of medicinal chemistry, Apr-24, Volume: 51, Issue:8	A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo.
AID1515912	Antiproliferative activity against human DU145 cells after 96 hrs by MTT assay	2019	Journal of medicinal chemistry, 08-08, Volume: 62, Issue:15	Design, Synthesis, and Biological Evaluation of 4-Methyl Quinazoline Derivatives as Anticancer Agents Simultaneously Targeting Phosphoinositide 3-Kinases and Histone Deacetylases.
AID1605970	Antiproliferative activity against human KM12 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	2020	Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8	Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors.
AID1898905	Antiproliferative activity against human U2932 cells incubated for 24 hrs followed by incubating in drug-free medium for 48 hrs and measured by SRB assay	2022	European journal of medicinal chemistry, Jan-15, Volume: 228	Antitumor activity of novel POLA1-HDAC11 dual inhibitors.
AID492812	Induction of p21WAF1/CIP1 expression in human NB4 cells at 5 uM after 24 hrs by Western blot analysis	2010	Journal of medicinal chemistry, Jun-24, Volume: 53, Issue:12	Synthesis and biological characterization of the histone deacetylase inhibitor largazole and C7- modified analogues.
AID1864266	Antitumor activity against human MDA-MB-231 cells xenografted in BALB/c-nu/nu mouse assessed as reduction in tumor volume at 10 mg/kg, ip measured for 31 days	2022	Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18	Discovery of a Novel G-Quadruplex and Histone Deacetylase (HDAC) Dual-Targeting Agent for the Treatment of Triple-Negative Breast Cancer.
AID1864252	Cytotoxicity against human MDA-MB-468 cells harboring wild type BRCA1 and BRCA2 mutant reduction in assessed as cell viability	2022	Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18	Discovery of a Novel G-Quadruplex and Histone Deacetylase (HDAC) Dual-Targeting Agent for the Treatment of Triple-Negative Breast Cancer.
AID1897367	Inhibition of FGFR1 (unknown origin)
AID1597955	Induction of apoptosis in human A549 cells assessed as late apoptotic cells at 10 uM incubated for 72 hrs by Annexin V-FITC/propidium iodide-staining based flow cytometric analysis (Rvb = 5.69%)	2019	Bioorganic & medicinal chemistry letters, 09-15, Volume: 29, Issue:18	Anti-tumor activity evaluation of novel tubulin and HDAC dual-targeting inhibitors.
AID1897373	Inhibition of HDAC2 (unknown origin)
AID1704070	Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay	2020	European journal of medicinal chemistry, Oct-15, Volume: 204	Discovery of Novel c-Mesenchymal-Epithelia transition factor and histone deacetylase dual inhibitors.
AID1487004	Selectivity index, ratio of IC50 for HDAC8 (unknown origin) to IC50 for HDAC1 (unknown origin)	2017	Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15	The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity.
AID1410013	Cytotoxicity against human U937 cells assessed as reduction in cell viability after 48 hrs by CellTiter-Glo luminescent cell viability assay	2018	ACS medicinal chemistry letters, Mar-08, Volume: 9, Issue:3	Elimination of HIV-1 Latently Infected Cells by Gnidimacrin and a Selective HDAC Inhibitor.
AID609725	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	2011	Bioorganic & medicinal chemistry, Aug-01, Volume: 19, Issue:15	Design, synthesis and biological evaluation of tyrosine-based hydroxamic acid analogs as novel histone deacetylases (HDACs) inhibitors.
AID1578507	Induction of apoptosis in human MV4-11 cells assessed as late apoptotic cells incubated for 18 hrs by annexin V FITC and PI based flow cytometry	2020	ACS medicinal chemistry letters, Jan-09, Volume: 11, Issue:1	Class I/IIb-Selective HDAC Inhibitor Exhibits Oral Bioavailability and Therapeutic Efficacy in Acute Myeloid Leukemia.
AID1876467	Antiproliferative activity against human HL-60 cells assessed as reduction in cell viability incubated for 72 hrs by WST-8 assay	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	Design, synthesis, and biological evaluation of indole-based hydroxamic acid derivatives as histone deacetylase inhibitors.
AID1276240	Inhibition of HDAC1/HDAC2 in human HeLa cells nuclear extract preincubated for 5 mins before Boc-Lys (acetyl)-AMC substrate addition for 30 mins by microplate reader analysis	2016	European journal of medicinal chemistry, Jan-27, Volume: 108	Novel leucine ureido derivatives as aminopeptidase N inhibitors. Design, synthesis and activity evaluation.
AID461256	Antiproliferative activity against human HepG2 cells after hrs by ATP content assay	2010	Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5	Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer.
AID1275656	Toxicity in athymic nude mouse xenografted with human HCT116 cells assessed as reduction in body weight at 40 mg/kg, ip qd administered for 14 days measured every other day during compound dosing	2016	European journal of medicinal chemistry, Feb-15, Volume: 109	Identification of N-(6-mercaptohexyl)-3-(4-pyridyl)-1H-pyrazole-5-carboxamide and its disulfide prodrug as potent histone deacetylase inhibitors with in vitro and in vivo anti-tumor efficacy.
AID1599771	Inhibition of HDAC6 in human A549 cells assessed as increase in histone H3 acetylation at 2.5 uM measured after 6 to 20 hrs by Western blot analysis	2019	ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6	Extending Cross Metathesis To Identify Selective HDAC Inhibitors: Synthesis, Biological Activities, and Modeling.
AID1518828	Antimalarial activity against ring stage Plasmodium falciparum K1 incubated for 48 hrs by Hoechst 33342 staining based fluorescence based assay	2019	European journal of medicinal chemistry, Dec-15, Volume: 184	Discovery of a potent histone deacetylase (HDAC) 3/6 selective dual inhibitor.
AID1890517	Antiproliferative activity against human SW480 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	2022	Bioorganic & medicinal chemistry letters, 05-15, Volume: 64	Design, synthesis, and biological evaluation of β-carboline 1,3,4-oxadiazole based hybrids as HDAC inhibitors with potential antitumor effects.
AID1742706	Induction of apoptosis in human MDA-MB-231 cells assessed as necrotic cells at 5 uM incubated for 72 hrs by annexinV-FITC and PI staining based flow cytometry analysis (Rvb = 0.330 %)	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Design and synthesis of novel Flavone-based histone deacetylase inhibitors antagonizing activation of STAT3 in breast cancer.
AID274075	Inhibition of MCF7 cell proliferation (mean of two experiments)	2007	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2	Identification and optimisation of a series of substituted 5-(1H-pyrazol-3-yl)-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.
AID511067	Inhibition of HDAC10	2010	European journal of medicinal chemistry, Sep, Volume: 45, Issue:9	Design and synthesis of novel isoxazole-based HDAC inhibitors.
AID1275247	Inhibition of HDAC in human HeLa cell nuclear extracts preincubated for 15 mins followed by addition of Fluor de Lys as substrate for 1 hr by fluorometric assay	2016	European journal of medicinal chemistry, Feb-15, Volume: 109	Design, synthesis and biological evaluation of N-phenylquinazolin-4-amine hybrids as dual inhibitors of VEGFR-2 and HDAC.
AID1529548	Induction of apoptosis in human BL2 cells assessed as early apoptotic cells at 10 nM after 48 hrs by annexin V-FITC/propidium iodide double staining-based flow cytometry (Rvb = 8.2%)	2018	Journal of medicinal chemistry, Aug-09, Volume: 61, Issue:15	Design and Synthesis of Tubulin and Histone Deacetylase Inhibitor Based on iso-Combretastatin A-4.
AID1819529	Antitumor activity against mouse B16-F10 cells implanted in C57BL/6J mouse assessed as reduction on tumor volume at 60 mg/kg, IG administered for 12 days	2022	Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4	Discovery of DNA-Targeting HDAC Inhibitors with Potent Antitumor Efficacy In Vivo That Trigger Antitumor Immunity.
AID503687	Inhibition of HDAC in human GM15850 cells assessed as increase in histone H3 lysine 14 acetylation of FXN gene at 2.5 uM after 96 hrs by chromatin immunoprecipitation assay	2006	Nature chemical biology, Oct, Volume: 2, Issue:10	Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia.
AID1434353	Growth inhibition of human PC3 cells measured after 5 days by sulforhodamine-B assay	2017	European journal of medicinal chemistry, Jan-27, Volume: 126	Improving potency and metabolic stability by introducing an alkenyl linker to pyridine-based histone deacetylase inhibitors for orally available RUNX3 modulators.
AID1649503	Cytotoxicity against mouse L929 cells assessed as reduction in cell viability measured after 72 hrs by tryphan blue assay	2020	Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11
AID411261	Cytotoxicity against human primary lung fibroblasts after 72 hrs by trypan blue exclusion assay	2009	Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2	Non-peptide macrocyclic histone deacetylase inhibitors.
AID1399543	Inhibition of recombinant human HDAC3 expressed in baculovirus infected High5 insect cells using Ac-Lys-Tyr-Lys(epsilon-acetyl)-AMC as substrate after 24 hrs by fluorescence assay	2018	Bioorganic & medicinal chemistry, 09-01, Volume: 26, Issue:16	A series of camptothecin prodrugs exhibit HDAC inhibition activity.
AID1379288	Antiproliferative activity against human EBC1 cells after 72 hrs by SRB assay	2017	ACS medicinal chemistry letters, Aug-10, Volume: 8, Issue:8	Design, Synthesis, and Biological Evaluation of the First c-Met/HDAC Inhibitors Based on Pyridazinone Derivatives.
AID1876464	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by WST-8 assay	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	Design, synthesis, and biological evaluation of indole-based hydroxamic acid derivatives as histone deacetylase inhibitors.
AID1622934	Inhibition of recombinant human HDAC6 using 7-AMC-labelled HDAC substrate measured after 30 mins by fluorescence assay	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.
AID1321725	Passive membrane permeability of the compound at 50 uM after 18 hrs by PAMPA	2016	Journal of medicinal chemistry, 10-13, Volume: 59, Issue:19	Design, Synthesis, and Biological Evaluation of First-in-Class Dual Acting Histone Deacetylases (HDACs) and Phosphodiesterase 5 (PDE5) Inhibitors for the Treatment of Alzheimer's Disease.
AID445125	Inhibition of human recombinant his tagged HDAC4 expressed in baculovirus assessed as residual activity at 5 uM	2009	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 19, Issue:22	Novel N-hydroxybenzamide-based HDAC inhibitors with branched CAP group.
AID348797	Inhibition of HDAC2	2008	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20	Optimization of a series of potent and selective ketone histone deacetylase inhibitors.
AID620531	Reactivation of MeCp2 mutant expression in human GM11272 cells at 10 to 100 nM by PCR method	2011	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 21, Issue:18	Clonal Rett Syndrome cell lines to test compounds for activation of wild-type MeCP2 expression.
AID1762500	Cytotoxicity against mouse Neuro2a cells assessed as reduction in cell viability incubated for 24 hrs by Cell Titer-Glo 2.0 Luminescent cell assay	2021	European journal of medicinal chemistry, Jul-05, Volume: 219	Synthesis and biological evaluation of phenothiazine derivative-containing hydroxamic acids as potent class II histone deacetylase inhibitors.
AID1739566	Antiproliferative activity against human THP-1 assessed as reduction in cell growth at 20 uM by CellTiter-non radioactive cell proliferation assay	2020	European journal of medicinal chemistry, Aug-15, Volume: 200	Design, synthesis, and biological evaluation of dual targeting inhibitors of histone deacetylase 6/8 and bromodomain BRPF1.
AID1742181	Inhibition of recombinant human N-terminal GST-tagged HDAC4 (627 to end residues) expressed in baculovirus infected Sf9 insect cells using AcLeu-Gly-Lys(Tfa)-AMC as substrate measured after 30 mins by fluorescence assay	2020	European journal of medicinal chemistry, Nov-01, Volume: 205	Design, synthesis and biological evaluation of novel HDAC inhibitors with improved pharmacokinetic profile in breast cancer.
AID1859953	Cytotoxicity against mouse NIH3T3 cells assessed as inhibition of cell growth by neutral red uptake assay	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Azetidin-2-one-based small molecules as dual hHDAC6/HDAC8 inhibitors: Investigation of their mechanism of action and impact of dual inhibition profile on cell viability.
AID1901158	Antiproliferative activity against human HCT-116 cells measured after 48 hrs by MTT assay	2022	Bioorganic & medicinal chemistry, 02-15, Volume: 56	Synthesis and biological evaluation of aminobenzamides containing purine moiety as class I histone deacetylases inhibitors.
AID1063059	Inhibition of HDAC in human K562 cell extract using Fluor-de-Lys deacetylase as substrate preincubated for 45 mins measured after 15 mins by fluorescence assay	2014	Journal of natural products, Jan-24, Volume: 77, Issue:1	Protein kinase and HDAC inhibitors from the endophytic fungus Epicoccum nigrum.
AID90675	In vitro for anti-HDAC1 (Histone deacetylase 1) activity in mouse A20 cells	2002	Journal of medicinal chemistry, Apr-25, Volume: 45, Issue:9	Binding mode analysis of 3-(4-benzoyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-propenamide: a new synthetic histone deacetylase inhibitor inducing histone hyperacetylation, growth inhibition, and terminal cell differentiation.
AID613298	In vitro cardiac safety index, ratio of IC50 for human ERG to IC50 for human HCT116 cells	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Optimization of the in vitro cardiac safety of hydroxamate-based histone deacetylase inhibitors.
AID1549140	Antifungal activity against azole-resistant Candida tropicalis 5008 after 48 hrs by spectrophotometry-based serial microdilution method	2020	Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10	Discovery of Novel Fungal Lanosterol 14α-Demethylase (CYP51)/Histone Deacetylase Dual Inhibitors to Treat Azole-Resistant Candidiasis.
AID1312892	Toxicity in NOD/SCID mouse xenografted with human MV4-11 cells assessed as mortality at 50 mg/kg, ip administered every 2 days for 11 days	2016	Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11	Development of Purine-Based Hydroxamic Acid Derivatives: Potent Histone Deacetylase Inhibitors with Marked in Vitro and in Vivo Antitumor Activities.
AID1215094	Competitive binding affinity to human PXR LBD (111 to 434) by TR-FRET assay	2011	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1	Identification of clinically used drugs that activate pregnane X receptors.
AID1321734	Inhibition of HDAC6 in human SH-SY5Y cells assessed as increase in alpha-tubulin acetylation at Lys 40 residue at 500 nM after 2 hrs by Western blot analysis relative to control	2016	Journal of medicinal chemistry, 10-13, Volume: 59, Issue:19	Design, Synthesis, and Biological Evaluation of First-in-Class Dual Acting Histone Deacetylases (HDACs) and Phosphodiesterase 5 (PDE5) Inhibitors for the Treatment of Alzheimer's Disease.
AID1355728	Antitumor activity against human HEL cells xenografted in BALB/C nude mouse assessed as tumor growth inhibition at 10 mg/kg, ip bid treated for 21 consecutive days relative to control	2018	Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14	Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections.
AID1511149	Antiproliferative activity against human K562 cells incubated for 48 hrs by MTT assay	2019	ACS medicinal chemistry letters, Aug-08, Volume: 10, Issue:8	Design, Synthesis, and Biological Evaluation of 2,4-Imidazolinedione Derivatives as HDAC6 Isoform-Selective Inhibitors.
AID288448	Inhibition of LPS-stimulated NO production in RAW264.7 cells after 24 hrs by ELISA	2007	Journal of medicinal chemistry, May-31, Volume: 50, Issue:11	Structure-activity relationship studies of a series of novel delta-lactam-based histone deacetylase inhibitors.
AID482956	Half life in human liver microsome	2010	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11	Acylurea connected straight chain hydroxamates as novel histone deacetylase inhibitors: Synthesis, SAR, and in vivo antitumor activity.
AID482947	Inhibition of HDAC7	2010	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11	Acylurea connected straight chain hydroxamates as novel histone deacetylase inhibitors: Synthesis, SAR, and in vivo antitumor activity.
AID750107	Cytotoxicity against human HCT116 cells after 48 hrs by Sulforhodamine B assay	2013	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 23, Issue:11	Design, synthesis and biological evaluation of indeno[1,2-d]thiazole derivatives as potent histone deacetylase inhibitors.
AID1566807	Inhibition of recombinant full length N-terminal GST-tagged human HDAC5 expressed in baculovirus infected Sf9 cells using Ac-peptide-AMC as substrate after 1 hr by fluorescence assay	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Discovery of 1,2,4-oxadiazole-Containing hydroxamic acid derivatives as histone deacetylase inhibitors potential application in cancer therapy.
AID1599727	Cytotoxicity against human Meso13 cells assessed as decrease in cell viability measured after 72 hrs by CellTiter-Glo Luminescent assay	2019	ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6	Extending Cross Metathesis To Identify Selective HDAC Inhibitors: Synthesis, Biological Activities, and Modeling.
AID1816227	Induction of apoptosis in mouse 4T1 cells assessed as necrotic cells at 5 uM measured after 48 hrs in presence of ruxolitinib by annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 4.35%)
AID352749	Inhibition of His-tagged HDAC4 catalytic domain expressed in Escherichia coli	2009	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11	Histone deacetylase inhibitors with a primary amide zinc binding group display antitumor activity in xenograft model.
AID1899585	Inhibition of HDAC class 1 in human HT-29 cells using Boc-Lys-Ac as substrate incubated for 3 hrs by microplate reader assay
AID1296348	Inhibition of recombinant human HDAC1 using Cbz-(Ac)Lys-AMC as substrate preincubated for 90 mins followed by trypsin addition measured after 20 mins by fluorescence assay	2016	Journal of medicinal chemistry, Mar-24, Volume: 59, Issue:6	Structure-Based Design and Synthesis of Novel Inhibitors Targeting HDAC8 from Schistosoma mansoni for the Treatment of Schistosomiasis.
AID603539	Toxicity in human MDA-MB-231 cells xenografted athymic nude mouse assessed as change in body weight at 90 mg/kg, ip qd for 21 days	2011	Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8	Development of tetrahydroisoquinoline-based hydroxamic acid derivatives: potent histone deacetylase inhibitors with marked in vitro and in vivo antitumor activities.
AID1181331	Potentiation of doxorubicin-induced cytotoxicity against human U937 cells assessed as inhibition of cell proliferation at 2.5 uM after 24 hrs by Cell Titer GLo Assay	2014	Journal of medicinal chemistry, Jul-24, Volume: 57, Issue:14	1,3,4-Oxadiazole-containing histone deacetylase inhibitors: anticancer activities in cancer cells.
AID1633669	Neurotoxicity against rat CGN cells assessed as cell viability at 25 uM incubated for 24 hrs by MTT assay	2019	ACS medicinal chemistry letters, Apr-11, Volume: 10, Issue:4	Novel Sustainable-by-Design HDAC Inhibitors for the Treatment of Alzheimer's Disease.
AID1917536	Cytotoxicity against HUVEC cells incubated for 72 hrs by CCK-8 assay	2022	Bioorganic & medicinal chemistry, 11-01, Volume: 73	Identification of PI3K/HDAC Dual-targeted inhibitors with subtype selectivity as potential therapeutic agents against solid Tumors: Building HDAC6 potency in a Quinazolinone-based PI3Kδ-selective template.
AID408880	Inhibition of HDAC1	2008	Journal of medicinal chemistry, Jun-26, Volume: 51, Issue:12	A series of potent and selective, triazolylphenyl-based histone deacetylases inhibitors with activity against pancreatic cancer cells and Plasmodium falciparum.
AID1165113	Cytotoxicity against human DU145 cells	2014	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 24, Issue:20	The antileishmanial activity of isoforms 6- and 8-selective histone deacetylase inhibitors.
AID1742654	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Design and synthesis of novel Flavone-based histone deacetylase inhibitors antagonizing activation of STAT3 in breast cancer.
AID1454053	Growth inhibition of human MCF7 cells after 3 days by WST1 assay	2017	Bioorganic & medicinal chemistry, 07-15, Volume: 25, Issue:14	Synthesis and evaluation of novel dual BRD4/HDAC inhibitors.
AID541644	Inhibition of human HDAC1 by fluorimetric assay	2010	Journal of medicinal chemistry, Dec-09, Volume: 53, Issue:23	Non-natural macrocyclic inhibitors of histone deacetylases: design, synthesis, and activity.
AID1371075	Gametocytocidal activity against transgenic GFP-fused Plasmodium falciparum NF54 early stage gametocytes after 72 hrs by Mitotracker Red CMH2XRos staining based microscopic method	2017	Journal of medicinal chemistry, 06-22, Volume: 60, Issue:12	Lysine Deacetylase Inhibitors in Parasites: Past, Present, and Future Perspectives.
AID1907399	Inhibition of HDAC1 (unknown origin) using trypsin and LGK(Ac)-AMC as substrates incubated for 1 hr and measured by fluorescence assay	2022	European journal of medicinal chemistry, Jun-05, Volume: 236	Dual-acting antitumor agents targeting the A
AID1876466	Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by WST-8 assay	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	Design, synthesis, and biological evaluation of indole-based hydroxamic acid derivatives as histone deacetylase inhibitors.
AID90347	Inhibition of human histone deacetylase (mixture of HDAC1 and HDAC2) prepared from K562 erythroleukemia cells.	2002	Bioorganic & medicinal chemistry letters, Dec-02, Volume: 12, Issue:23	Trifluoromethyl ketones as inhibitors of histone deacetylase.
AID1155336	Antimalarial activity against exo-erythrocytic form of Plasmodium berghei infected in human HepG2 cells after 48 hrs	2014	European journal of medicinal chemistry, Jul-23, Volume: 82	Discovery of HDAC inhibitors with potent activity against multiple malaria parasite life cycle stages.
AID1677509	Up regulation of BAX protein in human HeLa cells at 0.3 to 3 uM after 6 to 12 hrs by Western blot analysis	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	HDAC-Bax Multiple Ligands Enhance Bax-Dependent Apoptosis in HeLa Cells.
AID1206764	Inhibition of full length human recombinant HDAC3 expressed in baculovirus infected insect S9 cells using Ac-Leu-GlyLys(Ac)-AMC as substrate after 30 mins by fluorescence assay	2015	Journal of medicinal chemistry, May-28, Volume: 58, Issue:10	Design, synthesis, and antitumor evaluation of novel histone deacetylase inhibitors equipped with a phenylsulfonylfuroxan module as a nitric oxide donor.
AID603535	Cytotoxicity against human HL60 cells after 48 hrs by MTT assay	2011	Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8	Development of tetrahydroisoquinoline-based hydroxamic acid derivatives: potent histone deacetylase inhibitors with marked in vitro and in vivo antitumor activities.
AID1888586	Antiproliferative activity against human HeLa cells measured after 72 hrs by MTT assay
AID1446915	Inhibition of Schistosoma mansoni KDAC8 using (FAM)-labeled peptide as substrate after 60 mins by microfluidic assay	2017	Bioorganic & medicinal chemistry, 04-01, Volume: 25, Issue:7	Structural insights of SmKDAC8 inhibitors: Targeting Schistosoma epigenetics through a combined structure-based 3D QSAR, in vitro and synthesis strategy.
AID1326514	Inhibition of HDAC in human HCT116 cells assessed as increase in amount of acetylated histone H3 after 48 hrs by Western blot analysis	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	2-(Phenylsulfonyl)quinoline N-hydroxyacrylamides as potent anticancer agents inhibiting histone deacetylase.
AID347870	Growth inhibition of human ovarian cancer cells at 10 uM relative to control	2008	Journal of medicinal chemistry, Dec-11, Volume: 51, Issue:23	Histone deacetylase inhibitors through click chemistry.
AID1550115	Inhibition of JAK in human MDA-MB-231 cells assessed as decrease in upregulation of p-STAT3-Tyr705 level at 5 uM after 12 hrs in presence of ruxolitinib by Western blot analysis	2019	Journal of medicinal chemistry, 04-25, Volume: 62, Issue:8	Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies.
AID674001	Growth inhibition of human MCF7 cells after 72 hrs by XTT assay	2012	ACS medicinal chemistry letters, Jun-14, Volume: 3, Issue:6	Discovery of HDAC Inhibitors That Lack an Active Site Zn(2+)-Binding Functional Group.
AID1898954	Induction of cell cycle arrest in human NCI-H460 cells assessed as accumulation of cells at G2/M phase at 4.2 uM after 72 hrs by flow cytometry (Rvb = 21.1%)	2022	European journal of medicinal chemistry, Jan-15, Volume: 228	Antitumor activity of novel POLA1-HDAC11 dual inhibitors.
AID760495	Cytotoxicity against human MDA-MB-231 cells after 48 hrs by SRB assay	2013	ACS medicinal chemistry letters, Aug-08, Volume: 4, Issue:8	Development of a chimeric c-Src kinase and HDAC inhibitor.
AID780586	Inhibition of human recombinant HDAC6 expressed in baculovirus infected insect high5 cells using Boc-Lys (epsilon-acetyl)-AM) as substrate after 3 to 24 hrs by fluorescence assay	2013	Bioorganic & medicinal chemistry, Nov-15, Volume: 21, Issue:22	The discovery and optimization of novel dual inhibitors of topoisomerase II and histone deacetylase.
AID1200981	Plasma clearance in ICR mouse	2015	Journal of medicinal chemistry, Mar-26, Volume: 58, Issue:6	Design and synthesis of orally bioavailable aminopyrrolidinone histone deacetylase 6 inhibitors.
AID1469372	Cytotoxicity against human Hep3B cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	2018	Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7	Discovery of N1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7 H-pyrrolo[2,3- d]pyrimidin-2-yl)amino)phenyl)- N8-hydroxyoctanediamide as a Novel Inhibitor Targeting Cyclin-dependent Kinase 4/9 (CDK4/9) and Histone Deacetlyase1 (HDAC1) against Malignant Cancer
AID619055	Competitive inhibition of HDAC10 using KI-104 as substrate by fluorescence assay	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile.
AID1280307	Inhibition of human KDAC3	2016	Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4	Design and Synthesis of Simplified Largazole Analogues as Isoform-Selective Human Lysine Deacetylase Inhibitors.
AID1739565	Antiproliferative activity against human THP-1 assessed as reduction in cell growth at 100 uM by CellTiter-non radioactive cell proliferation assay	2020	European journal of medicinal chemistry, Aug-15, Volume: 200	Design, synthesis, and biological evaluation of dual targeting inhibitors of histone deacetylase 6/8 and bromodomain BRPF1.
AID1864264	Antitumor activity against human MDA-MB-231 cells xenografted in BALB/c-nu/nu mouse assessed as reduction in tumor growth at 10 mg/kg, ip measured for 31 days	2022	Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18	Discovery of a Novel G-Quadruplex and Histone Deacetylase (HDAC) Dual-Targeting Agent for the Treatment of Triple-Negative Breast Cancer.
AID1474167	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1486670	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	2017	Bioorganic & medicinal chemistry, 08-01, Volume: 25, Issue:15	Design, synthesis and tumor cell growth inhibitory activity of 3-nitro-2H-cheromene derivatives as histone deacetylaes inhibitors.
AID670101	Antitumor activity against human A549 cells xenografted in nude mouse assessed as tumor growth delay at 200 mg/kg, po administered QD till end point	2012	Journal of medicinal chemistry, Apr-26, Volume: 55, Issue:8	Synthesis and biological evaluation of 1-arylsulfonyl-5-(N-hydroxyacrylamide)indoles as potent histone deacetylase inhibitors with antitumor activity in vivo.
AID1426427	Cytotoxicity against HEK293 cells assessed as decrease in cell viability after 24 hrs by Alamar blue assay	2017	European journal of medicinal chemistry, Feb-15, Volume: 127	Synthesis, biological characterisation and structure activity relationships of aromatic bisamidines active against Plasmodium falciparum.
AID347871	Growth inhibition of human Leukemia cells at 10 uM relative to control	2008	Journal of medicinal chemistry, Dec-11, Volume: 51, Issue:23	Histone deacetylase inhibitors through click chemistry.
AID1825925	Inhibition of human C-terminal His tagged HDAC3 (1 to 428 residues) expressed in baculovirus-infected Sf9 cells using Ac-peptide as substrate incubated for 4 hrs
AID1727732	Inhibition of His-tagged BRD4 bromodomain 2 (unknown origin) using [Lys (5,8,12,16) Ac] H4(1-21) as substrate by fluorescence based assay	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	Discovery of selective HDAC/BRD4 dual inhibitors as epigenetic probes.
AID1441673	Anti-inflammatory activity in BLM-induced C57BL/6 mouse model of acute lung neutrophilic inflammation assessed as reduction in number of lymphocytes in BALF at 10 and 25 mg/kg, ip qd for 7 days post BLM challenge measured on day 7	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
AID420644	Antitumor activity against human H460 cells athymic nude Swiss mouse assessed as tumor volume inhibition at 100 mg/kg, po QD administered 5 days a week for 2 weeks	2009	European journal of medicinal chemistry, May, Volume: 44, Issue:5	Design, synthesis, and evaluation of biphenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors.
AID755627	Inhibition of HDAC isolated from human HeLa cell nuclear extract after 30 mins by fluorescence assay	2013	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13	Discovery of a small molecular compound simultaneously targeting RXR and HADC: design, synthesis, molecular docking and bioassay.
AID1606018	Induction of necrosis in human HEK293 at 1 to 2 uM after 72 hrs by propidium iodide/Annexin-V staining based flow cytometry	2020	Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8	Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors.
AID1659236	Inhibition of human HDAC6 after 30 mins by microplate reader analysis	2020	Bioorganic & medicinal chemistry letters, 04-15, Volume: 30, Issue:8	Structural determinants of affinity and selectivity in the binding of inhibitors to histone deacetylase 6.
AID1482134	Induction of mitochondrial membrane potential loss in human HL60 cells assessed as intact mitochondrial membrane potential at 1 uM measured after 48 hrs by Rh123 dye-based flow cytometric analysis (Rvb = 91.3%)	2017	Journal of medicinal chemistry, 04-27, Volume: 60, Issue:8	Exploring Derivatives of Quinazoline Alkaloid l-Vasicine as Cap Groups in the Design and Biological Mechanistic Evaluation of Novel Antitumor Histone Deacetylase Inhibitors.
AID1556035	Inhibition of SIRT2 in human MCF7 cells assessed as accumulation of acetylated-alpha tubulin at 0.1 uM measured after 24 hrs by Western blot analysis relative to alpha-tubulin	2019	Journal of medicinal chemistry, 06-27, Volume: 62, Issue:12	Identification of Diketopiperazine-Containing 2-Anilinobenzamides as Potent Sirtuin 2 (SIRT2)-Selective Inhibitors Targeting the "Selectivity Pocket", Substrate-Binding Site, and NAD
AID1901054	Inhibition of HDAC1 (unknown origin) using trypsin and Ac-peptide as substrates	2022	European journal of medicinal chemistry, Feb-15, Volume: 230	Novel PHD2/HDACs hybrid inhibitors protect against cisplatin-induced acute kidney injury.
AID637889	Inhibition of recombinant human HDAC6 using Boc-L-Lys(acetyl)-MCA as substrate by fluorogenic enzymatic assay	2012	Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2	Synthesis and biochemical analysis of 2,2,3,3,4,4,5,5,6,6,7,7-dodecafluoro-N-hydroxy-octanediamides as inhibitors of human histone deacetylases.
AID1819506	Inhibition of HDAC8 (unknown origin) using fluorogenic substrate incubated for 30 mins by fluorescence based assay	2022	Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4	Discovery of DNA-Targeting HDAC Inhibitors with Potent Antitumor Efficacy In Vivo That Trigger Antitumor Immunity.
AID1572342	Inhibition of recombinant N-terminal GST-tagged human HDAC6 expressed in baculovirus expression system using fluorogenic ZMAL as substrate incubated for 90 mins by fluorescence assay	2019	Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3	Synthesis and Biological Investigation of Phenothiazine-Based Benzhydroxamic Acids as Selective Histone Deacetylase 6 Inhibitors.
AID1250650	Inhibition of recombinant human HDAC11 after 60 mins by fluorescence assay	2015	Journal of medicinal chemistry, Oct-08, Volume: 58, Issue:19	Discovery of Novel Class I Histone Deacetylase Inhibitors with Promising in Vitro and in Vivo Antitumor Activities.
AID717795	Inhibition of HDAC1 using Fluor-de-Lys as substrate assessed as remaining activity at 1.25 x 10'-7 M pretreated for 30 mins before substrate addition by fluorescence assay	2012	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23	The structural requirements of histone deacetylase inhibitors: suberoylanilide hydroxamic acid analogs modified at the C6 position.
AID749388	Inhibition of human recombinant HDAC6 expressed in High5 insect cells using Boc-Lys (-acetyl)-AM) as substrate after 24 hrs by fluorescence assay	2013	Bioorganic & medicinal chemistry, Jun-01, Volume: 21, Issue:11	The discovery of colchicine-SAHA hybrids as a new class of antitumor agents.
AID1917544	Selectivity index, ratio IC50 for inhibition of HDAC11 (unknown origin) to IC50 for inhibition of HDAC6 (unknown origin)	2022	Bioorganic & medicinal chemistry, 11-01, Volume: 73	Identification of PI3K/HDAC Dual-targeted inhibitors with subtype selectivity as potential therapeutic agents against solid Tumors: Building HDAC6 potency in a Quinazolinone-based PI3Kδ-selective template.
AID527046	Inhibition of AKT phosphorylation in human A549 at 5 uM after 24 hrs by Western blot analysis	2010	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22	Selenium-containing analogs of SAHA induce cytotoxicity in lung cancer cells.
AID350726	Growth inhibition of human SNB78 cells after 48 hrs by sulforhodamine B assay	2009	Journal of medicinal chemistry, May-14, Volume: 52, Issue:9	Design, synthesis, and biological activity of boronic acid-based histone deacetylase inhibitors.
AID545859	Antimalarial activity against Plasmodium falciparum HB3 assessed as parasite growth inhibition after 48 hrs by standard growth inhibition assay	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Novel inhibitor of Plasmodium histone deacetylase that cures P. berghei-infected mice.
AID1321735	Inhibition of HDAC6 in human SH-SY5Y cells assessed as increase in alpha-tubulin acetylation at Lys 40 residue at 1000 nM after 2 hrs by Western blot analysis relative to control	2016	Journal of medicinal chemistry, 10-13, Volume: 59, Issue:19	Design, Synthesis, and Biological Evaluation of First-in-Class Dual Acting Histone Deacetylases (HDACs) and Phosphodiesterase 5 (PDE5) Inhibitors for the Treatment of Alzheimer's Disease.
AID1469312	Induction of apoptosis in human T47D cells assessed as early apoptotic cells at 10 uM after 48 hrs by annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 7.7%)	2018	Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7	Discovery of N1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7 H-pyrrolo[2,3- d]pyrimidin-2-yl)amino)phenyl)- N8-hydroxyoctanediamide as a Novel Inhibitor Targeting Cyclin-dependent Kinase 4/9 (CDK4/9) and Histone Deacetlyase1 (HDAC1) against Malignant Cancer
AID1898900	Antiproliferative activity against human MM432 cells incubated for 24 hrs followed by incubating in drug-free medium for 48 hrs and measured by SRB assay	2022	European journal of medicinal chemistry, Jan-15, Volume: 228	Antitumor activity of novel POLA1-HDAC11 dual inhibitors.
AID1200980	Inhibition of HDAC6 in human NCI-H929 cells assessed as induction of tubulin acetylation after 24 hrs by Western blot analysis	2015	Journal of medicinal chemistry, Mar-26, Volume: 58, Issue:6	Design and synthesis of orally bioavailable aminopyrrolidinone histone deacetylase 6 inhibitors.
AID1266808	Inhibition of HDAC in human HeLa cell nuclear extract using Boc-Lys (Ac)-AMC as substrate after 60 mins by fluorometric analysis	2015	Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23	Novel β-Carboline/Hydroxamic Acid Hybrids Targeting Both Histone Deacetylase and DNA Display High Anticancer Activity via Regulation of the p53 Signaling Pathway.
AID544090	Antimalarial activity against drug-resistant Plasmodium falciparum D6 infected in Aotus lemurinus lemurinus monkey	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Antimalarial activity of phenylthiazolyl-bearing hydroxamate-based histone deacetylase inhibitors.
AID1548260	Antiproliferative activity against human KM3 cells incubated for 48 hrs by MTT assay
AID1373247	Antiproliferative activity against human MCF7 cells after 48 hrs by CCK-8 assay	2018	Bioorganic & medicinal chemistry, 02-01, Volume: 26, Issue:3	Design, synthesis and evaluate of novel dual FGFR1 and HDAC inhibitors bearing an indazole scaffold.
AID1572345	Selectivity ratio of IC50 for recombinant human HDAC8 to IC50 for N-terminal GST-tagged human HDAC6	2019	Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3	Synthesis and Biological Investigation of Phenothiazine-Based Benzhydroxamic Acids as Selective Histone Deacetylase 6 Inhibitors.
AID1861670	Induction of apoptosis in human HCT-116 cells at 2000 nM measured after 48 hrs by Annexin-FITC/propidium iodide staining based flow cytometry	2022	Bioorganic & medicinal chemistry letters, 09-15, Volume: 72	Exploration of 4-(1H-indol-3-yl)cyclohex-3-en-1-amine analogues as HDAC inhibitors: Design, synthesis, biological evaluation and modelling studies.
AID1659646	Inhibition of HDAC in human HeLa cell extracts assessed as inhibition of substrate deacetylation using Boc-Lys (acetyl)-AMC as substrate by fluorescence based assay	2020	Bioorganic & medicinal chemistry letters, 06-01, Volume: 30, Issue:11	Environment-sensitive fluorescent inhibitors of histone deacetylase.
AID1203894	Antiproliferative activity against human NCI-H661 cells assessed as inhibition of cell growth after 72 hrs by MTT-based assay	2015	European journal of medicinal chemistry, , Volume: 96	Discovery and preliminary evaluation of 2-aminobenzamide and hydroxamate derivatives containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors.
AID1469178	Downregulation of HDAC6 protein expression in human MV4-11 cells at 5 uM after 24 hrs by Western blot analysis	2018	Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6	Class I HDAC Inhibitors Display Different Antitumor Mechanism in Leukemia and Prostatic Cancer Cells Depending on Their p53 Status.
AID1861336	Inhibition of HDAC in human DOHH-2 cells assessed as Down-regulation of STAT3 phosphorylation at Y705 residue at 2.5 uM in presence of 10 uM piclitisib measured by Western blot analysis	2022	Bioorganic & medicinal chemistry letters, 09-01, Volume: 71	Bioevaluation of a dual PI3K/HDAC inhibitor for the treatment of diffuse large B-cell lymphoma.
AID328810	Antiproliferative activity against human renal epithelial cells by CellTiter-Blue cell viability assay	2008	Journal of medicinal chemistry, Apr-24, Volume: 51, Issue:8	A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo.
AID1178593	Inhibition of rat liver HDAC at 10 uM pre-incubated for 15 mins before Boc-Lys(Ac)-AMC substrate addition and measured after 30 mins by fluorometry	2014	Bioorganic & medicinal chemistry, Jul-15, Volume: 22, Issue:14	Design and synthesis of novel and highly-active pan-histone deacetylase (pan-HDAC) inhibitors.
AID1758495	Antiproliferation activity against human U-87 MG cells assessed as growth inhibition measured after 1 hr by MTT assay	2021	European journal of medicinal chemistry, May-05, Volume: 217	Pragmatic recruitment of memantine as the capping group for the design of HDAC inhibitors: A preliminary attempt to unravel the enigma of glioblastoma.
AID446342	AUC (0 to infinity) in CD1 mouse at 5 mg/kg, iv	2010	Journal of medicinal chemistry, Jan-28, Volume: 53, Issue:2	Synthesis and biological evaluation of N-hydroxyphenylacrylamides and N-hydroxypyridin-2-ylacrylamides as novel histone deacetylase inhibitors.
AID328794	Inhibition of HDAC2	2008	Journal of medicinal chemistry, Apr-24, Volume: 51, Issue:8	A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo.
AID1250644	Inhibition of recombinant human HDAC4 after 60 mins by fluorescence assay	2015	Journal of medicinal chemistry, Oct-08, Volume: 58, Issue:19	Discovery of Novel Class I Histone Deacetylase Inhibitors with Promising in Vitro and in Vivo Antitumor Activities.
AID1355689	Antiproliferative activity against human HL60 cells after 48 hrs by CCK-8 assay	2018	Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14	Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections.
AID1275637	Inhibition of recombinant human HDAC8 using Boc-Lys(TFA)-AMC as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by fluorescence-based assay	2016	European journal of medicinal chemistry, Feb-15, Volume: 109	Identification of N-(6-mercaptohexyl)-3-(4-pyridyl)-1H-pyrazole-5-carboxamide and its disulfide prodrug as potent histone deacetylase inhibitors with in vitro and in vivo anti-tumor efficacy.
AID1371052	Antilieshmanial activity against amastigote stage of Leishmania donovani by fluorimetric assay	2017	Journal of medicinal chemistry, 06-22, Volume: 60, Issue:12	Lysine Deacetylase Inhibitors in Parasites: Past, Present, and Future Perspectives.
AID1742659	Cytotoxicity against human PLC cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Design and synthesis of novel Flavone-based histone deacetylase inhibitors antagonizing activation of STAT3 in breast cancer.
AID90343	In vitro inhibitory activity against histone deacetylase (HDAC) isolated from HeLa nuclear extract at a concentration of 100 uM	2003	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24	Novel histone deacetylase inhibitors: design, synthesis, enzyme inhibition, and binding mode study of SAHA-based non-hydroxamates.
AID1821322	Antitumor activity against human HepG2 cells xenografted in mouse assessed as upregulation of histone H3 at 12 mg/kg, ip administered every 2 days for 4 weeks by western blot analysis	2022	European journal of medicinal chemistry, Feb-05, Volume: 229	Discovery of phthalazino[1,2-b]-quinazolinone derivatives as multi-target HDAC inhibitors for the treatment of hepatocellular carcinoma via activating the p53 signal pathway.
AID1273868	Antiproliferative activity against human A549 cells assessed as cell viability after 72 hrs by CellTitre-Glo luminescent assay	2016	European journal of medicinal chemistry, Jan-27, Volume: 108	Synthesis, biological characterization and molecular modeling insights of spirochromanes as potent HDAC inhibitors.
AID673999	Growth inhibition of human Jurkat cells after 72 hrs by XTT assay	2012	ACS medicinal chemistry letters, Jun-14, Volume: 3, Issue:6	Discovery of HDAC Inhibitors That Lack an Active Site Zn(2+)-Binding Functional Group.
AID1667067	Inhibition of human recombinant HDAC6 using fluorogenic HDAC substrate 3 preincubated for 30 mins followed by substrate addition and measured after 15 mins by fluorogenic assay	2020	Bioorganic & medicinal chemistry, 03-15, Volume: 28, Issue:6	Pyrimethamine conjugated histone deacetylase inhibitors: Design, synthesis and evidence for triple negative breast cancer selective cytotoxicity.
AID1821340	Toxicity in mouse xenografted with human HepG2 cells assessed as cellular inflammation in kidney at 12 mg/kg, ip administered every 2 days for 4 weeks by H and E staining based microscopic method	2022	European journal of medicinal chemistry, Feb-05, Volume: 229	Discovery of phthalazino[1,2-b]-quinazolinone derivatives as multi-target HDAC inhibitors for the treatment of hepatocellular carcinoma via activating the p53 signal pathway.
AID1206765	Inhibition of human recombinant HDAC4 expressed in baculovirus infected insect S9 cells using Ac-Leu-GlyLys(Tfa)-AMC as substrate after 30 mins by fluorescence assay	2015	Journal of medicinal chemistry, May-28, Volume: 58, Issue:10	Design, synthesis, and antitumor evaluation of novel histone deacetylase inhibitors equipped with a phenylsulfonylfuroxan module as a nitric oxide donor.
AID274012	Percent inhibition of CYP450 2D6 at 1uM concentration	2007	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2	Identification and optimisation of a series of substituted 5-pyridin-2-yl-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.
AID525002	Inhibition of HDAC3 by in vitro deacetylation assay	2010	Nature chemical biology, Jan, Volume: 6, Issue:1	Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.
AID1469288	Induction of apoptosis in human A549 cells assessed as necrotic cells at 10 uM after 48 hrs by annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 5.88%)	2018	Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7	Discovery of N1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7 H-pyrrolo[2,3- d]pyrimidin-2-yl)amino)phenyl)- N8-hydroxyoctanediamide as a Novel Inhibitor Targeting Cyclin-dependent Kinase 4/9 (CDK4/9) and Histone Deacetlyase1 (HDAC1) against Malignant Cancer
AID1659658	Induction of apoptosis in human MOLT4 cells assessed as increase in apoptotic cells at 5 uM incubated for 24 hrs by Annexin V and PE staining based flow cytometric analysis relative to control	2020	Bioorganic & medicinal chemistry letters, 06-01, Volume: 30, Issue:11	Environment-sensitive fluorescent inhibitors of histone deacetylase.
AID1898951	Induction of cell cycle arrest in human NCI-H460 cells assessed as accumulation of cells at sub-G1 phase at 4.2 uM after 72 hrs by flow cytometry (Rvb = 1.1%)	2022	European journal of medicinal chemistry, Jan-15, Volume: 228	Antitumor activity of novel POLA1-HDAC11 dual inhibitors.
AID1245690	Inhibition of Class 2a histone deacetylase in human PC3 cells using Boc-Lys (triflouroacetyl)-AMC as substrate preincubated for 3 hrs followed by substrate addition measured after 3 hrs by fluorescence assay	2015	Bioorganic & medicinal chemistry, Oct-01, Volume: 23, Issue:19	Development of N-hydroxybenzamide derivatives with indole-containing cap group as histone deacetylases inhibitors.
AID1251318	Growth inhibition of human IGROV1 cells after 72 hrs	2015	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 25, Issue:20	Investigation on the ZBG-functionality of phenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase inhibitors.
AID1754784	Induction of cell cycle arrest in human MCF7 cells assessed as accumulation at G2/M phase at 1 uM incubated for 24 hrs by PI staining based flow cytometric analysis	2021	Bioorganic & medicinal chemistry, 07-15, Volume: 42	Discovery of novel class of histone deacetylase inhibitors as potential anticancer agents.
AID1758466	Inhibition of human recombinant HDAC2 using Ac-Leu-Gly-Lys(Ac)-AMC as substrate by measuring fluorescence intensity incubated for 30 mins by microplate reader assay	2021	European journal of medicinal chemistry, May-05, Volume: 217	Novel dual-mode antitumor chlorin-based derivatives as potent photosensitizers and histone deacetylase inhibitors for photodynamic therapy and chemotherapy.
AID1591851	Inhibition of recombinant human full-length C-terminal FLAG-tagged HDAC1 expressed in baculovirus expression system at 10 nM using Ac-peptide-AMC as substrate preincubated for 15 mins followed by substrate addition by fluorescence assay relative to contro	2019	Bioorganic & medicinal chemistry letters, 08-15, Volume: 29, Issue:16	Discovery of novel 9H-purin derivatives as dual inhibitors of HDAC1 and CDK2.
AID760374	Half life in mouse liver microsomes at 0.4 ug/mL by HPLC-MS analysis in presence of NADPH	2013	ACS medicinal chemistry letters, Aug-08, Volume: 4, Issue:8	Tropolones as lead-like natural products: the development of potent and selective histone deacetylase inhibitors.
AID1266841	Induction of p53 activation in human HCT116 cells assessed as upregulation of p21 expression at 0.1 to 5 uM after 12 hrs by western blot analysis	2015	Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23	Novel β-Carboline/Hydroxamic Acid Hybrids Targeting Both Histone Deacetylase and DNA Display High Anticancer Activity via Regulation of the p53 Signaling Pathway.
AID1441694	Protection against BLM-induced lung fibrosis in C57BL/6 mouse assessed as TGF-beta1 level at 50 mg/kg, ip qd for 7 days post BLM challenge measured on day 14 by ELISA (Rvb = 99.30 pg/ml)	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
AID1769650	Inhibition of HDAC6 (unknown origin)	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	Discovery of 2,4-pyrimidinediamine derivatives as potent dual inhibitors of ALK and HDAC.
AID1873407	Inhibition of HDAC2 (unknown origin) preincubated for 90 mins	2022	Bioorganic & medicinal chemistry letters, 08-15, Volume: 70	Comparison of three zinc binding groups for HDAC inhibitors - A potency, selectivity and enzymatic kinetics study.
AID1433258	Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay	2016	Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17	Synthesis and Antileukemic Activities of Piperlongumine and HDAC Inhibitor Hybrids against Acute Myeloid Leukemia Cells.
AID1352478	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Spirohydantoins and 1,2,4-triazole-3-carboxamide derivatives as inhibitors of histone deacetylase: Design, synthesis, and biological evaluation.
AID1441642	Anti-inflammatory activity in LPS-induced C57BL/6 mouse model of acute lung injury assessed as reduction in alveolar vascular permeability at 10 to 50 mg/kg, ip pretreated for 1 hr followed LPS challenge measured after 24 hrs by Evans blue dye based micro	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
AID737908	Selectivity index, ratio of IC50 for mouse MEF cells to IC50 for human A549 cells	2013	Journal of medicinal chemistry, May-09, Volume: 56, Issue:9	Design and synthesis of dual-action inhibitors targeting histone deacetylases and 3-hydroxy-3-methylglutaryl coenzyme A reductase for cancer treatment.
AID1170749	Cytotoxic activity against human EB3 cells after 3 days by MTT assay	2014	Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22	Methyl effect in azumamides provides insight into histone deacetylase inhibition by macrocycles.
AID1129792	Induction of apoptosis in human Jurkat cells assessed as caspase 8 activation at 10 uM after 24 hrs by FACS flow cytometric analysis relative to control	2014	Bioorganic & medicinal chemistry, Apr-01, Volume: 22, Issue:7	Studies on the antiproliferative effects of tropolone derivatives in Jurkat T-lymphocyte cells.
AID297496	Cytotoxicity against human WM 266-4 cells	2007	Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18	2-aroylindoles and 2-aroylbenzofurans with N-hydroxyacrylamide substructures as a novel series of rationally designed histone deacetylase inhibitors.
AID1898495	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	2021	Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11	Discovery of STAT3 and Histone Deacetylase (HDAC) Dual-Pathway Inhibitors for the Treatment of Solid Cancer.
AID1901162	Antiproliferative activity against human SGC-7901 cells measured after 48 hrs by MTT assay	2022	Bioorganic & medicinal chemistry, 02-15, Volume: 56	Synthesis and biological evaluation of aminobenzamides containing purine moiety as class I histone deacetylases inhibitors.
AID1181304	Inhibition of human recombinant HDAC4 using non-histone trifluoroacetyl lysine substrate pre-incubated at room temperature for 15 mins before substrate addition by fluorimetric assay	2014	Journal of medicinal chemistry, Jul-24, Volume: 57, Issue:14	1,3,4-Oxadiazole-containing histone deacetylase inhibitors: anticancer activities in cancer cells.
AID1441656	Anti-inflammatory activity in LPS-induced C57BL/6 mouse model of acute lung injury assessed as reduction in total number of leucocytes in BALF at 25 mg/kg, ip pretreated for 1 hr followed LPS challenge measured after 24 hrs	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
AID482942	Inhibition of HDAC2	2010	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11	Acylurea connected straight chain hydroxamates as novel histone deacetylase inhibitors: Synthesis, SAR, and in vivo antitumor activity.
AID1462023	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay	2017	Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17	Discovery of a tetrahydroisoquinoline-based HDAC inhibitor with improved plasma stability.
AID1819859	Inhibition of full length human HDAC6 using FAM-labeled acetylated peptide as substrate by electrophoretic mobility shift assay	2021	Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5	Unique Molecular Interaction with the Histone Deacetylase 6 Catalytic Tunnel: Crystallographic and Biological Characterization of a Model Chemotype.
AID1600660	Antiproliferative activity against human OE33 cells assessed as reduction in cell viability incubated for 72 hrs by presto blue assay	2019	Bioorganic & medicinal chemistry, 10-01, Volume: 27, Issue:19	Fluorescent analogs of peptoid-based HDAC inhibitors: Synthesis, biological activity and cellular uptake kinetics.
AID1578910	Induction of autophagy in human Bel7402 cells assessed as upregulation of LC3-2 level at 5 uM after 24 to 72 hrs by Western blot analysis	2019	Journal of natural products, 06-28, Volume: 82, Issue:6	Hydroxamic Acid Derivatives of β-Carboline/Hydroxycinnamic Acid Hybrids Inducing Apoptosis and Autophagy through the PI3K/Akt/mTOR Pathways.
AID1303628	Potentiation of 0.05 nM (-)-lomaiviticin A-induced cytotoxicity against human K562 cells assessed as combination index at 0.25 uM after 48 hrs by cell titer-glo luminescence assay	2016	Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13	Synergistic potentiation of (-)-lomaiviticin A cytotoxicity by the ATR inhibitor VE-821.
AID459821	Inhibition of HDAC in human HeLa cell nuclear extract by fluorescence assay	2010	Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2	Fluoroalkene modification of mercaptoacetamide-based histone deacetylase inhibitors.
AID1684874	Antitumor activity against mouse LL/2 cells inoculated in C57BL/6J mouse assessed as tumor growth inhibition at 25 mg/kg, ip administered for 12 days
AID476654	Toxicity in FVB mouse assessed as effect on mean platelet volume at 50 mg/kg, po administered 5 times per week for 2 weeks (Rvb = 8.8 +/- 0.1 microm^3)	2010	Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8	Modified cap group suberoylanilide hydroxamic acid histone deacetylase inhibitor derivatives reveal improved selective antileukemic activity.
AID1066165	Antimigratory activity against human LNCAP cells at 50 uM after 72 hrs	2014	Journal of medicinal chemistry, Jan-09, Volume: 57, Issue:1	Pan-histone demethylase inhibitors simultaneously targeting Jumonji C and lysine-specific demethylases display high anticancer activities.
AID1900903	Cytotoxicity against mouse GL26 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	2022	Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
AID482948	Inhibition of HDAC9	2010	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11	Acylurea connected straight chain hydroxamates as novel histone deacetylase inhibitors: Synthesis, SAR, and in vivo antitumor activity.
AID1170744	Inhibition of human recombinant HDAC6 using [Ac-Leu-Gly-Lys(Ac)-AMC substrate incubated for 15 to 30 mins	2014	Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22	Methyl effect in azumamides provides insight into histone deacetylase inhibition by macrocycles.
AID1898952	Induction of cell cycle arrest in human NCI-H460 cells assessed as accumulation of cells at G0/1 phase at 4.2 uM after 72 hrs by flow cytometry (Rvb = 46.8%)	2022	European journal of medicinal chemistry, Jan-15, Volume: 228	Antitumor activity of novel POLA1-HDAC11 dual inhibitors.
AID1330927	Inhibition of HDAC6 (unknown origin) using acetylated peptide substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by fluorescence analysis	2017	Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1	Synthesis and investigation of novel 6-(1,2,3-triazol-4-yl)-4-aminoquinazolin derivatives possessing hydroxamic acid moiety for cancer therapy.
AID1515902	Antiproliferative activity against human THP1 cells after 96 hrs by MTT assay	2019	Journal of medicinal chemistry, 08-08, Volume: 62, Issue:15	Design, Synthesis, and Biological Evaluation of 4-Methyl Quinazoline Derivatives as Anticancer Agents Simultaneously Targeting Phosphoinositide 3-Kinases and Histone Deacetylases.
AID274070	Half life after i.v. dosing at 1 mg kg-1	2007	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2	Identification and optimisation of a series of substituted 5-(1H-pyrazol-3-yl)-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.
AID408883	Inhibition of HDAC8	2008	Journal of medicinal chemistry, Jun-26, Volume: 51, Issue:12	A series of potent and selective, triazolylphenyl-based histone deacetylases inhibitors with activity against pancreatic cancer cells and Plasmodium falciparum.
AID1591717	Selectivity index, ratio of IC50 for human recombinant HDAC1 to IC50 for human recombinant HDAC6	2019	Bioorganic & medicinal chemistry, 08-01, Volume: 27, Issue:15	Structure-activity relationship study of thiazolyl-hydroxamate derivatives as selective histone deacetylase 6 inhibitors.
AID1722281	Inhibition of human recombinant HDAC1 expressed in baculovirus infected High5 insect cells using Ac-Lys-Tyr-Lys(e-acetyl)-AMC as substrate incubated for 24 hrs measured after 30 mins by microplate reader based spectrophotometric analysis	2020	Bioorganic & medicinal chemistry, 09-01, Volume: 28, Issue:17	The design of a novel near-infrared fluorescent HDAC inhibitor and image of tumor cells.
AID1545859	Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 48 hrs by MTT assay	2019	European journal of medicinal chemistry, Dec-01, Volume: 183	1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships.
AID1659654	Antiproliferative activity against human K562 cells incubated for 24 hrs by CCK8 assay	2020	Bioorganic & medicinal chemistry letters, 06-01, Volume: 30, Issue:11	Environment-sensitive fluorescent inhibitors of histone deacetylase.
AID1622954	Inhibition of HDAC in human HeLa nuclear extract	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.
AID1177055	Cytotoxicity against rat L6 cells	2015	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 25, Issue:3	Hydroxamic acid based histone deacetylase inhibitors with confirmed activity against the malaria parasite.
AID1873404	Inhibition of HDAC2 (unknown origin) preincubated for 5 mins	2022	Bioorganic & medicinal chemistry letters, 08-15, Volume: 70	Comparison of three zinc binding groups for HDAC inhibitors - A potency, selectivity and enzymatic kinetics study.
AID605540	Antiproliferative activity against human HUT78 cells after 72 hrs by WST-1 assay	2010	Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24	Discovery of 2-(6-{[(6-fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a class I selective orally active histone deacetylase inhibitor.
AID1543662	Antiproliferative activity against human PC3 cells incubated for 72 hrs by CellTiter-Glo luminescence assay	2019	European journal of medicinal chemistry, Apr-15, Volume: 168	Discovery of novel triazolo[4,3-b]pyridazin-3-yl-quinoline derivatives as PIM inhibitors.
AID1281849	Inhibition of full length His6-tagged GST-fused recombinant human HDAC4 expressed in High5 insect cells using Ac-Lys-Tyr-Lys (e-acetyl)-AMC as substrate after 24 hrs by fluorescence assay	2016	European journal of medicinal chemistry, Apr-13, Volume: 112	Design, synthesis and biological evaluation of bisthiazole-based trifluoromethyl ketone derivatives as potent HDAC inhibitors with improved cellular efficacy.
AID1676595	Binding affinity to Ferric ion assessed as performance ratio ratio by measuring product of accounting ratio and retention ratio at 2.55 umol by immobilized metal-ion affinity chromatography	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
AID1688042	Induction of HDAC3 degradation in human HL-60 cells assessed as decrease in HDAC3 level at 2 uM incubated for 12 hrs by Western blot analysis	2020	European journal of medicinal chemistry, Feb-15, Volume: 188	A 18β-glycyrrhetinic acid conjugate with Vorinostat degrades HDAC3 and HDAC6 with improved antitumor effects.
AID297479	Cytotoxicity against human MCF7 cells	2007	Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18	2-aroylindoles and 2-aroylbenzofurans with N-hydroxyacrylamide substructures as a novel series of rationally designed histone deacetylase inhibitors.
AID708275	Growth inhibition of human QGY7701 cells incubated for 72 hrs by WST dye reduction assay	2012	Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20	Pharmacokinetic optimization of class-selective histone deacetylase inhibitors and identification of associated candidate predictive biomarkers of hepatocellular carcinoma tumor response.
AID1622908	Inhibition of HDAC in human HeLa cytosolic extract using Fluor-de-lys as substrate measured after 60 mins by fluorescence assay	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.
AID1753832	Inhibition of recombinant full length human HDAC6 expressed in baculovirus infected Sf9 cells at 100 nM using Z-(Ac)-Lys-AMC as substrate incubated for 40 mins by fluorescence based assay relative to control	2021	European journal of medicinal chemistry, Jun-05, Volume: 218	Identification of novel 1,3-diaryl-1,2,4-triazole-capped histone deacetylase 6 inhibitors with potential anti-gastric cancer activity.
AID1676589	Binding affinity to Nickel cation assessed as performance ratio ratio by measuring product of accounting ratio and retention ratio at 2.55 umol by immobilized metal-ion affinity chromatography	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
AID352750	Inhibition of C-terminal FLAG tagged HDAC6	2009	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11	Histone deacetylase inhibitors with a primary amide zinc binding group display antitumor activity in xenograft model.
AID1303692	Potentiation of (-)-lomaiviticin A-induced cytotoxicity against human K562 cells assessed as (-)-lomaiviticin A ED50 at compound to (-)-lomaiviticin A ratio of 5000:1 after 48 hrs by cell titer-glo luminescence assay (Rvb = 0.23776 nM)	2016	Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13	Synergistic potentiation of (-)-lomaiviticin A cytotoxicity by the ATR inhibitor VE-821.
AID1418671	GPx-like activity of the compound assessed as velocity for tert-butyl hydroperoxide reduction at 80 uM in presence of GSH and NADPH by spectrophotometric analysis	2018	Bioorganic & medicinal chemistry, 11-15, Volume: 26, Issue:21	Design, synthesis, and biological evaluation of histone deacetylase inhibitors possessing glutathione peroxidase-like and antioxidant activities against Alzheimer's disease.
AID1876463	Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by WST-8 assay	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	Design, synthesis, and biological evaluation of indole-based hydroxamic acid derivatives as histone deacetylase inhibitors.
AID1578907	Induction of autophagy in human Bel7402 cells assessed as accumulation of autophagic vacuoles at 5 uM after 24 hrs by acridine orange staining based fluorescence microscopic method	2019	Journal of natural products, 06-28, Volume: 82, Issue:6	Hydroxamic Acid Derivatives of β-Carboline/Hydroxycinnamic Acid Hybrids Inducing Apoptosis and Autophagy through the PI3K/Akt/mTOR Pathways.
AID1897470	Inhibition of HDAC in human SNU-16 cells assessed as reduction in phosphorylated STAT3 level at 0.11 to 1 uM incubated for 36 hrs by Western blot analysis
AID1260655	Binding affinity to Zn2+ assessed as Zn2+/compound complex formation by ITC analysis
AID481545	Cytotoxicity against human NCI-H460 cells assessed as growth inhibition at 100 ug/ml after 24 hrs by MTT assay	2010	Bioorganic & medicinal chemistry letters, May-15, Volume: 20, Issue:10	Synthesis and anticancer evaluation of alpha-lipoic acid derivatives.
AID1653096	Antiproliferative activity against human HepG2 cells by CCK8 assay	2019	European journal of medicinal chemistry, Mar-01, Volume: 165	Quinolone hybrids and their anti-cancer activities: An overview.
AID222292	Compound was tested for anti-proliferative activity in human hepatocytes	2004	Bioorganic & medicinal chemistry letters, Jan-19, Volume: 14, Issue:2	Design, synthesis, and activity of HDAC inhibitors with a N-formyl hydroxylamine head group.
AID1659648	Inhibition of HDAC2 (unknown origin)	2020	Bioorganic & medicinal chemistry letters, 06-01, Volume: 30, Issue:11	Environment-sensitive fluorescent inhibitors of histone deacetylase.
AID487875	Inhibition of HDAC in human A549 cells assessed as induction of histone H4 hyperacetylation at IC50 concentration after 24 hrs by Western blot analysis	2010	Bioorganic & medicinal chemistry, Jun-15, Volume: 18, Issue:12	New aryldithiolethione derivatives as potent histone deacetylase inhibitors.
AID1173495	Inhibition of recombinant N-GST-tagged HDAC6 (unknown origin) assessed as reduction in deacetylation of Ac-Arg-Gly-Lys(Ac)-AMC substrate by fluorescence assay	2014	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 24, Issue:23	Histone deacetylase inhibitors derived from 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine and related heterocycles selective for the HDAC6 isoform.
AID1777022	Inhibition of HDAC6 (unknown origin)	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Intracellular fluorescence competition assay for inhibitor engagement of histone deacetylase.
AID1129010	Inhibition of human HDAC-8 using RHKK(Ac) as substrate by fluorescence assay	2014	Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6	Synthesis and evaluation of new Hsp90 inhibitors based on a 1,4,5-trisubstituted 1,2,3-triazole scaffold.
AID1437552	Inhibition of human HDAC1 using H3(1-21)K9 after 60 mins by fluorescence assay	2017	Journal of natural products, 01-27, Volume: 80, Issue:1	Monascustin, an Unusual γ-Lactam from Red Yeast Rice.
AID1055715	Antiproliferative activity against human AsPC1 cells after 48 hrs by SRB assay	2013	European journal of medicinal chemistry, , Volume: 70	Novel isatin-based hydroxamic acids as histone deacetylase inhibitors and antitumor agents.
AID1441690	Protection against BLM-induced lung fibrosis in C57BL/6 mouse assessed as reduction in deposition of collagen fibers at 25 and 50 mg/kg, ip qd for 7 days post BLM challenge measured on day 7 by Massons trichrome staining based method	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
AID1452275	Antiproliferative activity against human K562 cells after 72 hrs by MTT assay	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	Design, synthesis and anticancer potential of NSC-319745 hydroxamic acid derivatives as DNMT and HDAC inhibitors.
AID626563	Inhibition of HDAC in human HeLa cell extract assessed as fluorophore release at 1 uM by fluorescence spectrophotometry	2011	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 21, Issue:22	4-N-Hydroxy-4-[1-(sulfonyl)piperidin-4-yl]-butyramides as HDAC inhibitors.
AID1178601	Inhibition of human HDAC6 pre-incubated for 30 mins before substrate addition and measured after 30 mins by HDAC-Glo I/II assay	2014	Bioorganic & medicinal chemistry, Jul-15, Volume: 22, Issue:14	Design and synthesis of novel and highly-active pan-histone deacetylase (pan-HDAC) inhibitors.
AID511069	Inhibition of HDAC in human HeLa cells at 10 uM after 15 mins	2010	European journal of medicinal chemistry, Sep, Volume: 45, Issue:9	Design and synthesis of novel isoxazole-based HDAC inhibitors.
AID1401374	Inhibition of HDAC3 in human HeLa-S3 cell lysates preincubated for 15 mins followed by HDAC-Glo substrate addition measured after 30 to 40 mins by fluorimetric method	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
AID1865304	Antitumor immunity against mouse 4T1 cells xenografted in BALB/c syngeneic mouse model assessed as fold increase in proportion of CD4+ T cells in spleen at 40 mg/kg, po qd for 12 days by flow cytometry analysis relative to control	2022	Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18	Discovery of Novel Src Homology-2 Domain-Containing Phosphatase 2 and Histone Deacetylase Dual Inhibitors with Potent Antitumor Efficacy and Enhanced Antitumor Immunity.
AID473183	Growth inhibition of human Caco-2 cells after 48 hrs by MTT assay	2010	Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5	Biological and biophysical properties of the histone deacetylase inhibitor suberoylanilide hydroxamic acid are affected by the presence of short alkyl groups on the phenyl ring.
AID748980	Inhibition of HDAC5 (unknown origin)	2013	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 23, Issue:11	A cyclodextrin-capped histone deacetylase inhibitor.
AID1434361	Inhibition of HDAC in HEK293 cells expressing Myc-tagged RUNX3 assessed as histone-3 acetylation by measuring ratio of histone-3 acetylation level to beta-actin level at 1 uM measured after 24 hrs by Western blot analysis relative to control	2017	European journal of medicinal chemistry, Jan-27, Volume: 126	Improving potency and metabolic stability by introducing an alkenyl linker to pyridine-based histone deacetylase inhibitors for orally available RUNX3 modulators.
AID1205631	Growth inhibition of human NCI-H23 cells after 5 days by sulforhodamine B assay	2015	Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8	Discovery of Orally Available Runt-Related Transcription Factor 3 (RUNX3) Modulators for Anticancer Chemotherapy by Epigenetic Activation and Protein Stabilization.
AID586606	Antimalarial activity against trophozoites stage of Plasmodium vivax assessed as parasites growth inhibition using giemsa staining after 24 to 56 hrs by microscopic analysis in presence of 20% human serum	2011	Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3	Ex vivo activity of histone deacetylase inhibitors against multidrug-resistant clinical isolates of Plasmodium falciparum and P. vivax.
AID1065636	Inhibition of human recombinant HDAC7 catalytic domain using Boc_Lys_TFA as substrate after 60 mins by fluorescence assay	2013	Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24	Design, synthesis, and biological evaluation of potent and selective class IIa histone deacetylase (HDAC) inhibitors as a potential therapy for Huntington's disease.
AID1367349	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	2017	Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24	Synthesis and biological evaluation of Santacruzamate-A based analogues.
AID539709	Inhibition of human HDAC after 30 mins	2010	Bioorganic & medicinal chemistry, Dec-15, Volume: 18, Issue:24	Discovery of 1H-benzo[d][1,2,3]triazol-1-yl 3,4,5-trimethoxybenzoate as a potential antiproliferative agent by inhibiting histone deacetylase.
AID1897392	Induction of apoptosis in human SNU-16 cells assessed as live cells at 0.03 uM incubated for 72 hrs by annexin-V/FITC propidium iodide staining based flow cytometry analysis (Rvb = 90.92%)
AID288452	Growth inhibition of ACHN cells by SRB assay	2007	Journal of medicinal chemistry, May-31, Volume: 50, Issue:11	Structure-activity relationship studies of a series of novel delta-lactam-based histone deacetylase inhibitors.
AID1647329	Anti-vascular cognitive impairment activity against bilateral common carotid artery occlusion-induced vascular dementia C57BL/6J mouse model assessed as reversal of hippocampal atrophy by measuring increase in ratio of size of hippocampus to lateral ventr	2020	European journal of medicinal chemistry, Feb-01, Volume: 187	Protective effects of 10,11-dihydro-5H-dibenzo[b,f]azepine hydroxamates on vascular cognitive impairment.
AID1514610	Induction of apoptosis in human HepG2 cells assessed as early apoptotic cells at 2.5 uM after 48 hrs by annexin V-FITC/propidium iodide staining based assay (Rvb = 3.2 %)	2019	Bioorganic & medicinal chemistry letters, 01-01, Volume: 29, Issue:1	Development of hydroxamate-based histone deacetylase inhibitors containing 1,2,4-oxadiazole moiety core with antitumor activities.
AID1545755	Inhibition of HDAC1 (unknown origin)	2019	European journal of medicinal chemistry, Dec-01, Volume: 183	Indole: A privileged scaffold for the design of anti-cancer agents.
AID1605981	Antiproliferative activity against human T47D cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	2020	Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8	Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors.
AID1206767	Inhibition of full length human recombinant HDAC8 expressed in baculovirus infected insect S9 cells using Ac-Leu-GlyLys(Tfa)-AMC as substrate after 30 mins by fluorescence assay	2015	Journal of medicinal chemistry, May-28, Volume: 58, Issue:10	Design, synthesis, and antitumor evaluation of novel histone deacetylase inhibitors equipped with a phenylsulfonylfuroxan module as a nitric oxide donor.
AID1690844	Inhibition of human recombinant C-terminal His-tagged HDAC3 (1 to 428 residues)/N-terminal GST-tagged NCOR2 (395 to 489 residus) expressed in baculovirus infected Sf9 insect cells using fluor de lys SIRT1 as substrate preincubated for 5 mins followed by s	2020	European journal of medicinal chemistry, Apr-15, Volume: 192	Synthesis and biological evaluation of acridine-based histone deacetylase inhibitors as multitarget agents against Alzheimer's disease.
AID1348914	Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by SRB assay	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Discovery of aliphatic-chain hydroxamates containing indole derivatives with potent class I histone deacetylase inhibitory activities.
AID609506	Inhibition of human recombinant HDAC3 expressed in baculovirus infected insect High5 cells using Ac-Lys-Tyr-Lys(epsilon-acetyl)-AMC as substrate by fluorescence assay	2011	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16	Synthesis and biological evaluation of piperamide analogues as HDAC inhibitors.
AID1164905	Solubility of the compound in phosphate buffer at pH 6.5 after 1 to 2 hrs by LYSA	2014	Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19	Identification of a novel aminotetralin class of HDAC6 and HDAC8 selective inhibitors.
AID1322165	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	2016	Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21	Design and synthesis of novel HDAC8 inhibitory 2,5-disubstituted-1,3,4-oxadiazoles containing glycine and alanine hybrids with anti cancer activity.
AID1449681	Antiproliferative activity against human HEL cells after 48 hrs by MTT assay	2017	Bioorganic & medicinal chemistry, 05-01, Volume: 25, Issue:9	Development of N-hydroxycinnamamide-based HDAC inhibitors with improved HDAC inhibitory activity and in vitro antitumor activity.
AID1819503	Inhibition of HDAC1 (unknown origin) using fluorogenic substrate incubated for 30 mins by fluorescence based assay	2022	Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4	Discovery of DNA-Targeting HDAC Inhibitors with Potent Antitumor Efficacy In Vivo That Trigger Antitumor Immunity.
AID1888426	Toxicity in ICR mouse infected with azole-resistant Candida albicans 0304103 assessed as reduction in survival time at 10 mg/kg, ip administered once daily for 5 days	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	Heat shock protein 90 (Hsp90)/Histone deacetylase (HDAC) dual inhibitors for the treatment of azoles-resistant Candida albicans.
AID605530	Antiproliferative activity against human A2780 cells after 72 hrs by WST-1 assay	2010	Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24	Discovery of 2-(6-{[(6-fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a class I selective orally active histone deacetylase inhibitor.
AID408889	Cytotoxicity against human Hup T3 cells after 72 hrs by MTT assay	2008	Journal of medicinal chemistry, Jun-26, Volume: 51, Issue:12	A series of potent and selective, triazolylphenyl-based histone deacetylases inhibitors with activity against pancreatic cancer cells and Plasmodium falciparum.
AID1578506	Induction of apoptosis in human MV4-11 cells assessed as late apoptotic cells at 4 uM incubated for 18 hrs by annexin V FITC and PI based flow cytometry (Rvb = 9.2 to 9.63 %)	2020	ACS medicinal chemistry letters, Jan-09, Volume: 11, Issue:1	Class I/IIb-Selective HDAC Inhibitor Exhibits Oral Bioavailability and Therapeutic Efficacy in Acute Myeloid Leukemia.
AID1785328	Inhibition of full length human CDK2 (1 to 298 end residues)/N-terminal GST-tagged CyclinA2 (1 to 432 residues) expressed in baculovirus expression system at 100 nM preincubated for 10 mins followed by substrate and ATP addition by mobility shift assay re
AID1541453	Inhibition of HDAC in human CAL27 cells using Boc-Lys(epsilon-Ac)-AMC as substrate preincubated for 18 hrs followed by substrate addition and measured after 3 hrs by fluorescence assay	2019	Journal of medicinal chemistry, 12-26, Volume: 62, Issue:24	Synthesis of Peptoid-Based Class I-Selective Histone Deacetylase Inhibitors with Chemosensitizing Properties.
AID1898980	Induction of cell cycle arrest in human H460-R9A cells assessed as accumulation of cells at G0/1 phase at 1.9 uM after 72 hrs by flow cytometry (Rvb = 50.1%)	2022	European journal of medicinal chemistry, Jan-15, Volume: 228	Antitumor activity of novel POLA1-HDAC11 dual inhibitors.
AID604137	Inhibition of histone acetyltransferase in human U937 cells assessed as increase of acetylation of histone H3 at K9 at 5 uM after 24 hrs by Western blotting	2011	Bioorganic & medicinal chemistry, Jun-15, Volume: 19, Issue:12	Modulation of the activity of histone acetyltransferases by long chain alkylidenemalonates (LoCAMs).
AID780587	Inhibition of human recombinant HDAC3 expressed in baculovirus infected insect high5 cells using Ac-Lys-Tyr-Lys (epsilon-acetyl)-AMC as substrate after 3 to 24 hrs by fluorescence assay	2013	Bioorganic & medicinal chemistry, Nov-15, Volume: 21, Issue:22	The discovery and optimization of novel dual inhibitors of topoisomerase II and histone deacetylase.
AID1885698	Toxicity in ICR mouse assessed as effect on AST level at 12 umol/kg, ip measured after 12 hrs in presence of CDDO-Me	2022	Journal of medicinal chemistry, 08-11, Volume: 65, Issue:15	Redox-Activatable Theranostic Co-Prodrug for Precise Tumor Diagnosis and Selective Combination Chemotherapy.
AID1282258	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	2016	Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4	Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
AID1547273	Inhibition of HDAC2 (unknown origin) using biotinylated histone H3 KAc peptide (1 to 21 residues) as substrate by HTRF assay	2020	Journal of medicinal chemistry, 04-09, Volume: 63, Issue:7	Discovery of Thieno[2,3-
AID1898907	Antiproliferative activity against human NB-4 cells incubated for 24 hrs followed by incubating in drug-free medium for 48 hrs and measured by SRB assay	2022	European journal of medicinal chemistry, Jan-15, Volume: 228	Antitumor activity of novel POLA1-HDAC11 dual inhibitors.
AID1647339	Anti-vascular cognitive impairment activity against bilateral common carotid artery occlusion-induced vascular dementia C57BL/6J mouse model assessed as reversal of hippocampal atrophy by measuring increase in hippocampal volume at 25 mg/kg, ip administer	2020	European journal of medicinal chemistry, Feb-01, Volume: 187	Protective effects of 10,11-dihydro-5H-dibenzo[b,f]azepine hydroxamates on vascular cognitive impairment.
AID446335	Metabolic stability in mouse liver microsomes assessed as half life	2010	Journal of medicinal chemistry, Jan-28, Volume: 53, Issue:2	Synthesis and biological evaluation of N-hydroxyphenylacrylamides and N-hydroxypyridin-2-ylacrylamides as novel histone deacetylase inhibitors.
AID1206741	Cytotoxicity against human 3AO cells assessed as growth inhibition after 48 hrs by MTT assay	2015	Journal of medicinal chemistry, May-28, Volume: 58, Issue:10	Design, synthesis, and antitumor evaluation of novel histone deacetylase inhibitors equipped with a phenylsulfonylfuroxan module as a nitric oxide donor.
AID1250646	Inhibition of recombinant human HDAC7 after 60 mins by fluorescence assay	2015	Journal of medicinal chemistry, Oct-08, Volume: 58, Issue:19	Discovery of Novel Class I Histone Deacetylase Inhibitors with Promising in Vitro and in Vivo Antitumor Activities.
AID1783068	Antifungal activity against fluconazole-sensitive Candida albicans 4108 assessed as inhibition of fungal growth	2021	European journal of medicinal chemistry, Oct-05, Volume: 221	Lanosterol 14α-demethylase (CYP51)/histone deacetylase (HDAC) dual inhibitors for treatment of Candida tropicalis and Cryptococcus neoformans infections.
AID1349732	Toxicity in BALB/C nude mouse xenografted with human HCT116 cells assessed as body weight loss at 25 mg/kg, ip bid administered for 21 consecutive days measured every 3 days	2018	ACS medicinal chemistry letters, Jan-11, Volume: 9, Issue:1	Dual NAMPT/HDAC Inhibitors as a New Strategy for Multitargeting Antitumor Drug Discovery.
AID1482172	Cytotoxicity against human PC3 cells assessed as growth inhibition at 5 uM after 48 hrs by MTT assay relative to control	2017	Journal of medicinal chemistry, 04-27, Volume: 60, Issue:8	Exploring Derivatives of Quinazoline Alkaloid l-Vasicine as Cap Groups in the Design and Biological Mechanistic Evaluation of Novel Antitumor Histone Deacetylase Inhibitors.
AID1702137	Inhibition of PI3K/AKT/mTOR signaling in human HuH-7 cells assessed as p70S6K Thr389 phosphorylation level at 10 uM incubated for 4 hrs including last 12 mins stimulation with 20 ng/ml growth factor VEGF by Western blot analysis (Rvb = 100 %)	2018	Journal of medicinal chemistry, 02-22, Volume: 61, Issue:4	Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma.
AID1907401	Antiproliferative activity against mouse CT26 cells after 72 hrs by CCK-8 assay	2022	European journal of medicinal chemistry, Jun-05, Volume: 236	Dual-acting antitumor agents targeting the A
AID1293578	Antitumor activity against human HCT116 cells xenografted in athymic Swiss nude mouse assessed as tumor growth inhibition at 175 mg/kg, po for 5 days a week for 4 weeks relative to control	2016	European journal of medicinal chemistry, Apr-13, Volume: 112	Biphenyl-4-yl-acrylohydroxamic acids: Identification of a novel indolyl-substituted HDAC inhibitor with antitumor activity.
AID1863436	Inhibition of HDAC4 (unknown origin) by colorimetric method	2022	European journal of medicinal chemistry, Oct-05, Volume: 240	Accommodation of ring C expanded deoxyvasicinone in the HDAC inhibitory pharmacophore culminates into a tractable anti-lung cancer agent and pH-responsive nanocarrier.
AID1587863	Inhibition of recombinant full-length C-terminal FLAG-fused/His-tagged human HDAC1 expressed in baculovirus infected Sf9 insect cells measured after 40 mins by HDAC-Glo1/2 luminescent assay	2019	Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9	Selective Inhibition of Histone Deacetylase 10: Hydrogen Bonding to the Gatekeeper Residue is Implicated.
AID1848614	Cytotoxicity against human IGROV-1 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay	2022	Journal of medicinal chemistry, 11-10, Volume: 65, Issue:21	First-in-Class Dual Mechanism Ferroptosis-HDAC Inhibitor Hybrids.
AID1865239	Inhibition of recombinant his-tagged human HDAC11 using Ac-LeuGlyLys (Ac) AMC substrate preincubated for 5 mins followed by substrate addition and measured after 30 mins by fluorescence based microplate reader analysis	2022	Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18	Discovery of Novel Src Homology-2 Domain-Containing Phosphatase 2 and Histone Deacetylase Dual Inhibitors with Potent Antitumor Efficacy and Enhanced Antitumor Immunity.
AID473181	Induction of HDAC-mediated alpha-tubulin acetylation in human HepG2 cells at 5 uM after 6 hrs by indirect ELISA	2010	Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5	Biological and biophysical properties of the histone deacetylase inhibitor suberoylanilide hydroxamic acid are affected by the presence of short alkyl groups on the phenyl ring.
AID683274	Inhibition of HDAC1 by fluorometric assay	2012	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 22, Issue:19	Amide-based derivatives of β-alanine hydroxamic acid as histone deacetylase inhibitors: attenuation of potency through resonance effects.
AID1821277	Antiproliferative activity against human HL-60 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	2022	European journal of medicinal chemistry, Feb-05, Volume: 229	Discovery of phthalazino[1,2-b]-quinazolinone derivatives as multi-target HDAC inhibitors for the treatment of hepatocellular carcinoma via activating the p53 signal pathway.
AID1614251	Antitumor activity against human MM1S cells xenografted in NOD/SCID mouse assessed as tumor growth inhibition at 50 mg/kg, iv qd administered for 10 days and measured every 2 days post last dose in presence of 25 mg/kg RAPA by caliper method relative to c
AID1431813	Selectivity ratio of IC50 for human KDAC6 to IC50 for human KDAC1	2017	European journal of medicinal chemistry, Feb-15, Volume: 127	Design and synthesis of benzodiazepine analogs as isoform-selective human lysine deacetylase inhibitors.
AID1898897	Antiproliferative activity against human A2780 cells incubated for 24 hrs followed by incubating in drug-free medium for 48 hrs and measured by SRB assay	2022	European journal of medicinal chemistry, Jan-15, Volume: 228	Antitumor activity of novel POLA1-HDAC11 dual inhibitors.
AID1888587	Antiproliferative activity against human K562 cells measured after 72 hrs by MTT assay
AID1576452	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by SRB assay
AID1361645	Cell cycle arrest in human A549 cells assessed as accumulation of cells at S phase at 5 uM after 48 hrs by flow cytometric analysis (Rvb = 31.18%)	2018	Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16	Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents.
AID1742228	Antitumor activity against CM-Dil labeled human MDA-MB-231 cells xenografted in Zebrafish AB assessed as tumor growth inhibition at 2.5 ug/ml measured after 5 days by fluorescence microscopic analysis	2020	European journal of medicinal chemistry, Nov-01, Volume: 205	Design, synthesis and biological evaluation of novel HDAC inhibitors with improved pharmacokinetic profile in breast cancer.
AID300838	Growth inhibition of human HCT15 cells after 21 hrs by MTT assay	2007	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17	Pomiferin, histone deacetylase inhibitor isolated from the fruits of Maclura pomifera.
AID1326517	Inhibition of HDAC in human PC3 cells assessed as increase in amount of acetylated alpha-tubulin after 48 hrs by Western blot analysis	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	2-(Phenylsulfonyl)quinoline N-hydroxyacrylamides as potent anticancer agents inhibiting histone deacetylase.
AID1401901	Inhibition of HDAC in human HeLa cell extract using Fluor de Lys-Green as substrate preincubated for 5 mins followed by substrate addition and measured after 1 hr by fluorescence assay	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
AID1578492	Induction of apoptosis in human MV4-11 cells assessed as early apoptotic cells at 1 uM incubated for 18 hrs by annexin V FITC and PI based flow cytometry (Rvb = 19.46 to 22.17 %)	2020	ACS medicinal chemistry letters, Jan-09, Volume: 11, Issue:1	Class I/IIb-Selective HDAC Inhibitor Exhibits Oral Bioavailability and Therapeutic Efficacy in Acute Myeloid Leukemia.
AID1415637	Inhibition of HDAC in human HeLa nuclear extract using Boc-Lys(acetyl)-AMC as substrate measured after 60 mins by fluorescence assay	2017	MedChemComm, Jun-01, Volume: 8, Issue:6	Development of novel β-carboline-based hydroxamate derivatives as HDAC inhibitors with DNA damage and apoptosis inducing abilities.
AID1399542	Inhibition of recombinant human HDAC1 expressed in baculovirus infected High5 insect cells using Ac-Lys-Tyr-Lys(epsilon-acetyl)-AMC as substrate after 24 hrs by fluorescence assay	2018	Bioorganic & medicinal chemistry, 09-01, Volume: 26, Issue:16	A series of camptothecin prodrugs exhibit HDAC inhibition activity.
AID1454057	Growth inhibition of human OVCAR5 cells after 3 days by WST1 assay	2017	Bioorganic & medicinal chemistry, 07-15, Volume: 25, Issue:14	Synthesis and evaluation of novel dual BRD4/HDAC inhibitors.
AID1515839	Antiproliferative activity against human HCT116 cells after 96 hrs by MTT assay	2019	Journal of medicinal chemistry, 08-08, Volume: 62, Issue:15	Design, Synthesis, and Biological Evaluation of 4-Methyl Quinazoline Derivatives as Anticancer Agents Simultaneously Targeting Phosphoinositide 3-Kinases and Histone Deacetylases.
AID1819536	Toxicity in C57BL/6J mouse implanted with mouse B16-F10 cells assessed as spleen damage at 60 mg/kg, IG administered for 12 days H and E staining based histopathological analysis	2022	Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4	Discovery of DNA-Targeting HDAC Inhibitors with Potent Antitumor Efficacy In Vivo That Trigger Antitumor Immunity.
AID240505	Inhibitory concentration against histone deacetylase of HeLa cells	2005	Bioorganic & medicinal chemistry letters, Jan-17, Volume: 15, Issue:2	Identification of a potent non-hydroxamate histone deacetylase inhibitor by mechanism-based drug design.
AID1361634	Inhibition of HDAC6 (unknown origin) after 30 mins by fluorescence assay	2018	Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16	Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents.
AID1119182	Cytotoxicity against human MCF10A cells after 96 hrs by MTA reduction assay	2012	MedChemComm, , Volume: 3, Issue:1	Polyamine-based small molecule epigenetic modulators.
AID414717	Inhibition of human recombinant HDAC1 expressed in HEK293 cells	2009	Journal of medicinal chemistry, Apr-23, Volume: 52, Issue:8	Design of chimeric histone deacetylase- and tyrosine kinase-inhibitors: a series of imatinib hybrides as potent inhibitors of wild-type and mutant BCR-ABL, PDGF-Rbeta, and histone deacetylases.
AID482941	Inhibition of HDAC8	2010	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11	Acylurea connected straight chain hydroxamates as novel histone deacetylase inhibitors: Synthesis, SAR, and in vivo antitumor activity.
AID1441707	Anti-inflammatory activity in BLM-induced C57BL/6 mouse model of acute lung neutrophilic inflammation assessed as reduction in number of lymphocytes in BALF at 25 and 50 mg/kg, ip qd for 7 days post BLM challenge measured on day 7	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
AID1162226	Induction of apoptosis in human HL60 cells assessed as loss of mitochondrial membrane potential in P5 quadrant at 1 uM by Rhodamine123 assay (Rvb = 3.4%)	2014	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 24, Issue:19	Design, synthesis and biological evaluation of β-boswellic acid based HDAC inhibitors as inducers of cancer cell death.
AID541647	Inhibition of human HDAC8 by fluorimetric assay	2010	Journal of medicinal chemistry, Dec-09, Volume: 53, Issue:23	Non-natural macrocyclic inhibitors of histone deacetylases: design, synthesis, and activity.
AID1550158	Toxicity in BALB/c nu mouse xenografted with HEL cells assessed as injury to internal organs at 60 mg/kg/day, ip administered for 16 days and measured post-last dose in presence of ruxolitinib	2019	Journal of medicinal chemistry, 04-25, Volume: 62, Issue:8	Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies.
AID1139708	Growth inhibition of human MDA-MB-231 cells after 48 hrs by MTT assay	2014	Bioorganic & medicinal chemistry, May-01, Volume: 22, Issue:9	Search for novel histone deacetylase inhibitors. Part II: design and synthesis of novel isoferulic acid derivatives.
AID392409	Induction of alpha tubulin acetylation in human T24 cells after 3 hrs by ELISA	2009	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 19, Issue:2	Sulfamides as novel histone deacetylase inhibitors.
AID1384224	Cytotoxicity against human THLE2 cells after 72 hrs by vialight cell proliferation assay	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease.
AID1753837	Antiproliferative activity against human MGC803 cells incubated for 72 hrs by MTT assay	2021	European journal of medicinal chemistry, Jun-05, Volume: 218	Identification of novel 1,3-diaryl-1,2,4-triazole-capped histone deacetylase 6 inhibitors with potential anti-gastric cancer activity.
AID274025	Half life after i.v. dosing at 1 mg kg-1	2007	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2	Identification and optimisation of a series of substituted 5-pyridin-2-yl-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.
AID1380940	Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay	2018	Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12	Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously.
AID1614140	Antiproliferative activity against human OCI-AML3 cells after 72 hrs by MTT assay
AID525017	Inhibition of HDAC in human CFBE41o- cell line assessed as increase in mutant Fdelta508 CFTR mRNA level at 5 uM after 8 hrs by RT-PCR	2010	Nature chemical biology, Jan, Volume: 6, Issue:1	Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.
AID1355711	Antifungal activity against FLC resistant Candida albicans 0710922 after 48 hrs by checkerboard microdilution method	2018	Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14	Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections.
AID1401382	Inhibition of HDAC2 in human HeLa-S3 cell lysates assessed as remaining activity at 1 uM preincubated for 15 mins followed by HDAC-Glo substrate addition measured after 30 to 40 mins by fluorimetric method relative to control	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
AID1664945	Inhibition of class 1 HDAC in human Jurkat model of HIV latency assessed as reactivation of HIV latency incubated for 20 hrs in presence of 5% NHS by Steady-Glo luciferase assay	2020	ACS medicinal chemistry letters, Jul-09, Volume: 11, Issue:7	Selective Class I HDAC Inhibitors Based on Aryl Ketone Zinc Binding Induce HIV-1 Protein for Clearance.
AID1239050	Inhibition of recombinant His6-tagged GST-fused human HDAC6 expressed in baculovirus infected insect High5 cells using Boc-Lys-(epsilon-acetyl)-AMC as substrate after 3 hrs	2015	Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17	Design, synthesis and biological evaluation of isoquinoline-based derivatives as novel histone deacetylase inhibitors.
AID749696	Inhibition of HDAC in human DU145 cells assessed as upregulation of p21waf1 expression at 2.5 to 5 uM after 24 hrs by Western blot analysis	2013	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 23, Issue:11	Dual-acting histone deacetylase-topoisomerase I inhibitors.
AID1623534	Selectivity index, ratio of IC50 for human recombinant HDAC1 to IC50 for human recombinant HDAC6	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	A novel class of anthraquinone-based HDAC6 inhibitors.
AID1762490	Inhibition of N-terminal GST-tagged human HDAC7 (518 to end residues) expressed in baculovirus-infected Sf9 cells using Boc Lys(TFA)-AMC as substrate preincubated for 5 mins followed by substrate addition and further incubated for 30 mins by fluorogenic a	2021	European journal of medicinal chemistry, Jul-05, Volume: 219	Synthesis and biological evaluation of phenothiazine derivative-containing hydroxamic acids as potent class II histone deacetylase inhibitors.
AID1566802	Inhibition of recombinant full length HDAC1 (unknown origin) using Ac-peptide-AMC as substrate after 1 hr by fluorescence assay	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Discovery of 1,2,4-oxadiazole-Containing hydroxamic acid derivatives as histone deacetylase inhibitors potential application in cancer therapy.
AID1462030	Half life in rat plasma at 200 uM by HPLC analysis	2017	Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17	Discovery of a tetrahydroisoquinoline-based HDAC inhibitor with improved plasma stability.
AID1469377	Induction of apoptosis in human A549 cells assessed as early apoptotic cells at 10 uM after 48 hrs by annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 0.41%)	2018	Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7	Discovery of N1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7 H-pyrrolo[2,3- d]pyrimidin-2-yl)amino)phenyl)- N8-hydroxyoctanediamide as a Novel Inhibitor Targeting Cyclin-dependent Kinase 4/9 (CDK4/9) and Histone Deacetlyase1 (HDAC1) against Malignant Cancer
AID1702085	Antiproliferative activity against human Raji cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay	2018	Journal of medicinal chemistry, 02-22, Volume: 61, Issue:4	Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma.
AID1355688	Inhibition of full length human recombinant HDAC1 expressed in baculovirus expression system using (Ac-Leu-Gly-Lys(Ac)-AMC as substrate preincubated for 5 mins followed by substrate addition and measured after 30 mins by fluorescence assay	2018	Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14	Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections.
AID723472	Inhibition of HDAC in cisplatin sensitive human MDA-MB-231 cells after 18 hrs by fluorescence assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1737151	Induction of apoptosis in human HCT-116 cells assessed as late apoptotic cells at 10 uM after 24 hrs by Annexin V-FITC/PI staining based flow cytometric analysis (Rvb = 5.14%)	2020	European journal of medicinal chemistry, Apr-15, Volume: 192	Design, synthesis and biological evaluation of novel indazole-based derivatives as potent HDAC inhibitors via fragment-based virtual screening.
AID1890343	Antitumor immunity in C57BL/6 mouse xenografted with mouse CT26 cells assessed as decrease in number of CD8+IFNgamma+ T cells at 100 mg/kg, po administered once daily for 21 days measured by flow cytometry analysis	2022	European journal of medicinal chemistry, Apr-05, Volume: 233	Novel biphenyl-based scaffold as potent and selective histone deacetylase 6 (HDAC6) inhibitors: Identification, development and pharmacological evaluation.
AID1816194	Inhibition of TYK2 (unknown origin) incubated for 40 min in presence of ATP by microplate reader analysis
AID420509	Induction of apoptosis in human IGROV1 cells at IC90 after 72 hrs by TUNEL assay	2009	European journal of medicinal chemistry, May, Volume: 44, Issue:5	Design, synthesis, and evaluation of biphenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors.
AID781049	Antiproliferative activity against human MCF7 cells after 48 hrs by sulforhodamine B assay	2013	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 23, Issue:23	Design, synthesis and biological evaluation of di-substituted cinnamic hydroxamic acids bearing urea/thiourea unit as potent histone deacetylase inhibitors.
AID292437	Antiproliferative activity against HeLa cells by alamar blue assay	2007	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17	Trithiocarbonates: exploration of a new head group for HDAC inhibitors.
AID1785340	Inhibition of recombinant human HDAC9 measured after 30 mins by fluorescence microplate reader assay
AID1266086	Inhibition of HDAC in human MeT-5A cells assessed as hisone H3 acetylation at 5 uM after 16 hrs by BRET assay	2016	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1	Cross metathesis with hydroxamate and benzamide BOC-protected alkenes to access HDAC inhibitors and their biological evaluation highlighted intrinsic activity of BOC-protected dihydroxamates.
AID1390013	Inhibition of full length recombinant human N-terminal GST-tagged HDAC6 expressed in baculovirus infected sf9 cells using Boc-Lys-(Ac)-AMC as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by fluorescence assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Design, synthesis and biological evaluation of novel hydroxamic acid based histone deacetylase 6 selective inhibitors bearing phenylpyrazol scaffold as surface recognition motif.
AID1758526	Permeability of compound by PAMPA-BBB assay	2021	European journal of medicinal chemistry, May-05, Volume: 217	Pragmatic recruitment of memantine as the capping group for the design of HDAC inhibitors: A preliminary attempt to unravel the enigma of glioblastoma.
AID1702069	Inhibition of N-terminal FLAG-tagged human HDAC10 (2 to 631 residues) expressed in baculovirus infected Sf9 cells using fluorogenic HDAC substrate 3 measured after 30 mins by fluorescence based assay	2018	Journal of medicinal chemistry, 02-22, Volume: 61, Issue:4	Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma.
AID710838	Cytotoxicity against human ACHN cells assessed as growth inhibition by SRB assay	2012	Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23	Property-based optimization of hydroxamate-based γ-lactam HDAC inhibitors to improve their metabolic stability and pharmacokinetic profiles.
AID1482171	Cytotoxicity against human MIAPaCa2 cells assessed as growth inhibition at 5 uM after 48 hrs by MTT assay relative to control	2017	Journal of medicinal chemistry, 04-27, Volume: 60, Issue:8	Exploring Derivatives of Quinazoline Alkaloid l-Vasicine as Cap Groups in the Design and Biological Mechanistic Evaluation of Novel Antitumor Histone Deacetylase Inhibitors.
AID1246514	Inhibition of HDAC4 (unknown origin) using Boc-Lys(trifluoroacetyl)-AMC fluorogenic acetylated peptide substrate by fluorometric assay	2015	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 25, Issue:19	Discovery of 1-hydroxypyridine-2-thiones as selective histone deacetylase inhibitors and their potential application for treating leukemia.
AID1441672	Anti-inflammatory activity in BLM-induced C57BL/6 mouse model of acute lung neutrophilic inflammation assessed as reduction in number of neutrophils in BALF at 10 and 25 mg/kg, ip qd for 7 days post BLM challenge measured on day 7	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
AID1754800	Downregulation of SIRT7 gene expression in human MCF7 cells at 3 uM incubated for 24 hrs by whole transcriptome analysis	2021	Bioorganic & medicinal chemistry, 07-15, Volume: 42	Discovery of novel class of histone deacetylase inhibitors as potential anticancer agents.
AID1754796	Downregulation of SIRT3 gene expression in human MCF7 cells at 3 uM incubated for 24 hrs by whole transcriptome analysis	2021	Bioorganic & medicinal chemistry, 07-15, Volume: 42	Discovery of novel class of histone deacetylase inhibitors as potential anticancer agents.
AID525023	Inhibition of HDAC in human CFBE41o- cell line assessed as increase in CFTR mRNA at 5 uM by RT-PCR	2010	Nature chemical biology, Jan, Volume: 6, Issue:1	Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.
AID1614193	Induction of apoptosis in human MV4-11 cells assessed as viable cells at 1 uM after 48 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 84.1%)
AID1774970	Inhibition of HDAC8 (unknown origin) using Boc-Lys(trifluoroacetyl)-AMC as substrate at 10 uM preincubated for 5 mins followed by substrate addition and measured after 30 mins by fluorescence assay	2021	ACS medicinal chemistry letters, Dec-09, Volume: 12, Issue:12	Design, Synthesis, and Biological Evaluation of APN and AKT Dual-Target Inhibitors.
AID1890336	Antitumor activity against mouse CT26 cells xenografted in C57BL/6 mouse assessed as tumor growth inhibition at 100 mg/kg, po administered once daily for 21 days	2022	European journal of medicinal chemistry, Apr-05, Volume: 233	Novel biphenyl-based scaffold as potent and selective histone deacetylase 6 (HDAC6) inhibitors: Identification, development and pharmacological evaluation.
AID619140	Kinetic solubility of the compound at pH 7 with 2.5% DMSO	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile.
AID1421912	Inhibition of recombinant full length human N-terminal GST-tagged HDAC6 expressed in baculovirus infected Sf9 insect cells using ZMAL as substrate measured after 90 mins by fluorescence assay	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	One-pot, multi-component synthesis and structure-activity relationships of peptoid-based histone deacetylase (HDAC) inhibitors targeting malaria parasites.
AID1337260	Antiproliferative activity against human MCF7 cells up to 72 hrs by MTT assay	2016	Journal of medicinal chemistry, Sep-22, Volume: 59, Issue:18	Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines.
AID1578885	Antiproliferative activity against human HuH7 cells after 72 hrs by MTT assay	2019	Journal of natural products, 06-28, Volume: 82, Issue:6	Hydroxamic Acid Derivatives of β-Carboline/Hydroxycinnamic Acid Hybrids Inducing Apoptosis and Autophagy through the PI3K/Akt/mTOR Pathways.
AID1897396	Induction of apoptosis in human SNU-16 cells assessed as live cells at 0.1 uM incubated for 72 hrs by annexin-V/FITC propidium iodide staining based flow cytometry analysis (Rvb = 90.92%)
AID1898899	Resistance index, ratio of IC50 for human A2780 cells to IC50 for A2780-DX cells	2022	European journal of medicinal chemistry, Jan-15, Volume: 228	Antitumor activity of novel POLA1-HDAC11 dual inhibitors.
AID503690	Inhibition of HDAC in human GM15850 cells assessed as increase in histone H3 lysine 9 acetylation of FXN gene at 2.5 uM after 96 hrs by chromatin immunoprecipitation assay	2006	Nature chemical biology, Oct, Volume: 2, Issue:10	Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia.
AID1810052	Inhibition of HDAC6 (unknown origin) assessed as release of 7-amino-4-methylcoumarin incubated in room temperature for 15 min measured by Spectra max microtitre plate reader
AID511064	Inhibition of HDAC2	2010	European journal of medicinal chemistry, Sep, Volume: 45, Issue:9	Design and synthesis of novel isoxazole-based HDAC inhibitors.
AID1865259	Inhibition of wild type SHP2 (unknown origin) using DiFMUP as substrate preincubated for 30 mins followed by substrate addition and measured after 30 mins by microplate reader method	2022	Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18	Discovery of Novel Src Homology-2 Domain-Containing Phosphatase 2 and Histone Deacetylase Dual Inhibitors with Potent Antitumor Efficacy and Enhanced Antitumor Immunity.
AID461264	Antiproliferative activity against human NCI-H2122 cells	2010	Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5	Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer.
AID663370	Growth inhibition of human PC3 cells after 72 hrs by MTS assay	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Discovery and extensive in vitro evaluations of NK-HDAC-1: a chiral histone deacetylase inhibitor as a promising lead.
AID1373248	Inhibition of HDAC1 (unknown origin) at 1 uM preincubated for 10 mins followed by Ac-Leu-GlyLys(Ac)-AMC substrate addition measured after 30 mins by fluorescence based assay relative to control	2018	Bioorganic & medicinal chemistry, 02-01, Volume: 26, Issue:3	Design, synthesis and evaluate of novel dual FGFR1 and HDAC inhibitors bearing an indazole scaffold.
AID1816191	Inhibition of recombinant HDAC10 (unknown origin) using Ac-peptide-AMC as substrate incubated for 240 mins by microplate reader analysis
AID350717	Inhibition of human recombinant HDAC2 by fluorimetry	2009	Journal of medicinal chemistry, May-14, Volume: 52, Issue:9	Design, synthesis, and biological activity of boronic acid-based histone deacetylase inhibitors.
AID366651	Cytotoxicity against HMEC after 72 hrs by MTT assay	2008	Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15	Use of the nitrile oxide cycloaddition (NOC) reaction for molecular probe generation: a new class of enzyme selective histone deacetylase inhibitors (HDACIs) showing picomolar activity at HDAC6.
AID663385	Growth inhibition of human UACC257 cells after 72 hrs by MTS assay	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Discovery and extensive in vitro evaluations of NK-HDAC-1: a chiral histone deacetylase inhibitor as a promising lead.
AID762189	Cytotoxicity against human A549 cells assessed as growth inhibition by measuring cellular ATP level after 72 hrs by cell-titer glo assay	2013	Journal of medicinal chemistry, Aug-08, Volume: 56, Issue:15	Discovery of potent, isoform-selective inhibitors of histone deacetylase containing chiral heterocyclic capping groups and a N-(2-aminophenyl)benzamide binding unit.
AID623098	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	2011	European journal of medicinal chemistry, Nov, Volume: 46, Issue:11	Design, synthesis and primary activity assay of tripeptidomimetics as histone deacetylase inhibitors with linear linker and branched cap group.
AID1141762	Cytotoxicity against human KB cells by MTT assay	2014	Journal of medicinal chemistry, May-22, Volume: 57, Issue:10	Azaindolylsulfonamides, with a more selective inhibitory effect on histone deacetylase 6 activity, exhibit antitumor activity in colorectal cancer HCT116 cells.
AID1421926	Selectivity index, ratio of IC50 for human NFF cells to IC50 for Plasmodium falciparum 3D7 infected in human erythrocytes	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	One-pot, multi-component synthesis and structure-activity relationships of peptoid-based histone deacetylase (HDAC) inhibitors targeting malaria parasites.
AID1630628	Inhibition of HDAC in human MOLT4 cells assessed as H3K9 acetylation at 2.5 uM after after 24 hrs by Western blot analysis	2016	Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21	Synthesis and biological evaluation of santacruzamate A analogues for anti-proliferative and immunomodulatory activity.
AID352752	Antiproliferative activity against human HCT116 cells after 72 hrs by celltiter-blue cell viability assay	2009	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11	Histone deacetylase inhibitors with a primary amide zinc binding group display antitumor activity in xenograft model.
AID1240551	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	2015	Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17	Design, synthesis and biological evaluation of saccharin-based N-hydroxybenzamides as histone deacetylases (HDACs) inhibitors.
AID1065631	Inhibition of HDAC4 in human Jurkat E6.1 cells using Boc-Lys-TFA as substrate incubated for 2 hrs prior to substrate addition measured after 3 hrs by fluorescence assay	2013	Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24	Design, synthesis, and biological evaluation of potent and selective class IIa histone deacetylase (HDAC) inhibitors as a potential therapy for Huntington's disease.
AID1576464	Induction of apoptosis in human A549 cells assessed as viable cells at 5 uM after 72 hrs by Annexin V-phycoerythrin/7-AAD staining based flow cytometric analysis (Rvb = 96.57%)
AID744874	Cytotoxicity against human HCT116 cells by MTT assay	2013	Bioorganic & medicinal chemistry letters, May-01, Volume: 23, Issue:9	Discovery of adamantane based highly potent HDAC inhibitors.
AID481568	Antitumor activity against mouse S180 cells xenografted in ICR mouse assessed as reduction of tumor weight at 200 mg/kg, ig administered 2 days after tumor inoculation qd for 7 days	2010	Bioorganic & medicinal chemistry letters, May-15, Volume: 20, Issue:10	Synthesis and anticancer evaluation of alpha-lipoic acid derivatives.
AID1901170	Inhibition of HDAC6 in human HCT-116 cells assessed as increase in alpha-tubulin acetylation at 5 uM measured after 6 hrs by Western blot analysis	2022	Bioorganic & medicinal chemistry, 02-15, Volume: 56	Synthesis and biological evaluation of aminobenzamides containing purine moiety as class I histone deacetylases inhibitors.
AID544400	Inhibition of Plasmodium falciparum 3D7 histone deacetylase infected in human erythrocytes assessed as alteration of histone H3 acetylation after 3.5 hrs by SDS-PAGE	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Antimalarial activity of phenylthiazolyl-bearing hydroxamate-based histone deacetylase inhibitors.
AID1639363	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	2019	Bioorganic & medicinal chemistry, 04-15, Volume: 27, Issue:8	Design, synthesis and activity evaluation of indole-based double - Branched HDAC1 inhibitors.
AID1361629	Antiproliferative activity against human A549 cells after 72 hrs by CCK8 assay	2018	Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16	Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents.
AID1864678	Inhibition of full length recombinant human HDAC6 in expressing in mouse J774.A1 cells assessed as accumulation of acetylated alpha-tubulin at 0.1 to 1 uM measured upto 24 hrs by western blot analysis
AID1239056	Inhibition of HDAC in human RPMI8226 cells assessed as upregulation of acetylated alpha-tubulin level at 1 uM after 24 hrs by Western blot analysis	2015	Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17	Design, synthesis and biological evaluation of isoquinoline-based derivatives as novel histone deacetylase inhibitors.
AID1486322	Genotoxicity in Salmonella typhimurium TA100 at 50 times antiproliferative IC50 by Ames test	2017	Bioorganic & medicinal chemistry, 08-01, Volume: 25, Issue:15	Olaparib hydroxamic acid derivatives as dual PARP and HDAC inhibitors for cancer therapy.
AID626565	Inhibition of HDAC in human HeLa cell extract assessed as fluorophore release by fluorescence spectrophotometry	2011	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 21, Issue:22	4-N-Hydroxy-4-[1-(sulfonyl)piperidin-4-yl]-butyramides as HDAC inhibitors.
AID1865294	Antitumor activity against human MV4-11 cells xenografted in BALB/c nude mouse assessed as tumor growth inhibition at 40 mg/kg, po qd administered for 20 days in presence of SHP099	2022	Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18	Discovery of Novel Src Homology-2 Domain-Containing Phosphatase 2 and Histone Deacetylase Dual Inhibitors with Potent Antitumor Efficacy and Enhanced Antitumor Immunity.
AID1548246	Inhibition of HDAC2 (unknown origin) pre-incubated for 5 mins before fluorogenic substrate Boc-Lys (acetyl)-AMC or Boc-Lys (triflouroacetyl)-AMC addition and measured after 30 mins by fluorescence based assay
AID134164	Antitumor activity against HT1080 cell line in mouse xenograft model after orally dosed once every other day at 30 mg/kg	2003	Bioorganic & medicinal chemistry letters, Jun-02, Volume: 13, Issue:11	Indole amide hydroxamic acids as potent inhibitors of histone deacetylases.
AID749705	Inhibition of HDAC in human HeLa cells using Fluor-de-Lys as substrate after 15 mins by fluorescence assay	2013	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 23, Issue:11	Dual-acting histone deacetylase-topoisomerase I inhibitors.
AID1848283	Antiproliferative activity against human K562 cells assessed as inhibition of cell proliferation incubated for 72 hrs by CCK8 assay	2022	Bioorganic & medicinal chemistry, Nov-15, Volume: 74	Design, synthesis and biological evaluation of novel pyrazinone derivatives as PI3K/HDAC dual inhibitors.
AID1127011	Induction of apoptosis in human U937 cells assessed as viable cells using annexin-V/propidium iodide staining after 12 to 24 hrs by flow cytometry analysis	2014	Journal of medicinal chemistry, Apr-24, Volume: 57, Issue:8	Discovery of the first N-hydroxycinnamamide-based histone deacetylase 1/3 dual inhibitors with potent oral antitumor activity.
AID541656	Growth inhibition of human HCT116 cells after 48 hrs by SRB assay	2010	Journal of medicinal chemistry, Dec-09, Volume: 53, Issue:23	Non-natural macrocyclic inhibitors of histone deacetylases: design, synthesis, and activity.
AID619051	Competitive inhibition of HDAC6 using KI-104 as substrate by fluorescence assay	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile.
AID723460	Inhibition of human HDAC11 by fluorescence assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1464867	Inhibition of HDAC in human HeLa nuclear extract using Fluor de Lys as substrate after 15 mins by fluorescence assay	2017	Bioorganic & medicinal chemistry letters, 11-01, Volume: 27, Issue:21	Design, synthesis and biological evaluation of novel histone deacetylase inhibitors incorporating 4-aminoquinazolinyl systems as capping groups.
AID1697197	Cytotoxicity against human SW620 cells by colorimetric method	2020	Bioorganic & medicinal chemistry letters, 11-15, Volume: 30, Issue:22	Design, synthesis and evaluation of novel indirubin-based N-hydroxybenzamides, N-hydroxypropenamides and N-hydroxyheptanamides as histone deacetylase inhibitors and antitumor agents.
AID1816197	Inhibition of JAK in human BT-549 cells assessed as reduction in activation of p-STAT3 at 3 uM incubated for 12 hrs by chemiluminescence based western blotting analysis
AID1215090	Activation of rat PXR expressed in human HepG2 cells after 24 hrs by luciferase reporter gene based luminescent analysis	2011	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1	Identification of clinically used drugs that activate pregnane X receptors.
AID1421614	Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	Design and synthesis of potent dual inhibitors of JAK2 and HDAC based on fusing the pharmacophores of XL019 and vorinostat.
AID1537558	Antiproliferative activity against human IMR32 cells assessed as reduction in cell viability incubated for 72 hrs by cell-titer Glo assay	2019	MedChemComm, Jul-01, Volume: 10, Issue:7	Design, synthesis and biological evaluation of β-peptoid-capped HDAC inhibitors with anti-neuroblastoma and anti-glioblastoma activity.
AID765212	Cytotoxicity against human MiaPaCa cells	2013	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17	Identification of novel HDAC inhibitors through cell based screening and their evaluation as potential anticancer agents.
AID328793	Inhibition of HDAC1	2008	Journal of medicinal chemistry, Apr-24, Volume: 51, Issue:8	A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo.
AID717804	Inhibition of HDAC6 using Fluor-de-Lys as substrate assessed as remaining activity at 125 nM pretreated for 30 mins before substrate addition by fluorescence assay	2012	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23	The structural requirements of histone deacetylase inhibitors: suberoylanilide hydroxamic acid analogs modified at the C6 position.
AID1467238	Inhibition of recombinant C-terminal His-tagged HDAC11 (unknown origin) expressed in baculovirus infected Sf9 cells at 0.02 uM using Ac-Arg-Gly-Lys(Ac)-AMC as substrate pretreated for 3 hrs followed by substrate addition measured after 30 mins by fluorome	2017	Bioorganic & medicinal chemistry letters, 07-01, Volume: 27, Issue:13	Stabilizing HDAC11 with SAHA to assay slow-binding benzamide inhibitors.
AID1605971	Antiproliferative activity against human SNB75 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	2020	Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8	Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors.
AID1205634	Induction of myc-tagged RUNX3 acetylation in human HEK293 cells assessed as RUNX3 level at 1 uM after 24 hrs by immunoprecipitation analysis relative to TSA	2015	Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8	Discovery of Orally Available Runt-Related Transcription Factor 3 (RUNX3) Modulators for Anticancer Chemotherapy by Epigenetic Activation and Protein Stabilization.
AID1380938	Inhibition of HDAC in human HeLa cell nuclear extract using fluorogenic Boc-Lys(acetyl)-AMC as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by fluorescence-based assay	2018	Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12	Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously.
AID663336	Growth inhibition of human COLO205 cells after 72 hrs by MTS assay	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Discovery and extensive in vitro evaluations of NK-HDAC-1: a chiral histone deacetylase inhibitor as a promising lead.
AID1476161	Antiproliferative activity against human KHYG cells after 48 hrs by CellTiter-Glo luminescent assay	2017	Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20	Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat.
AID1698865	Antiproliferative against human A549 cells assessed as reduction in cell viability by MTT assay	2020	Bioorganic & medicinal chemistry letters, 12-01, Volume: 30, Issue:23	Design, synthesis and biological evaluation of novel c-Met/HDAC dual inhibitors.
AID329927	Inhibition of human HDAC1 in U937 cells assessed as residual activity at 5 uM	2008	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8	Novel uracil-based 2-aminoanilide and 2-aminoanilide-like derivatives: histone deacetylase inhibition and in-cell activities.
AID1667090	Inhibition of STAT3 in human MDA-MB-231 cells assessed as downregulation of cyclinD1 expression at 5 to 25 uM after 24 hrs by western blot analysis	2020	Bioorganic & medicinal chemistry, 03-15, Volume: 28, Issue:6	Pyrimethamine conjugated histone deacetylase inhibitors: Design, synthesis and evidence for triple negative breast cancer selective cytotoxicity.
AID1808546	Inhibition of C-terminal His-tagged recombinant human HDAC3 (1 to 428 residues)/N-terminal GST-tagged recombinant human NCoR2 (395 to 489 residues) co-expressed in baculovirus infected Sf9 cells using fluorometric substrate measured after 60 mins by FRET	2021	Journal of medicinal chemistry, 04-08, Volume: 64, Issue:7	Structure-Based Design of a Selective Class I Histone Deacetylase (HDAC) Near-Infrared (NIR) Probe for Epigenetic Regulation Detection in Triple-Negative Breast Cancer (TNBC).
AID1482103	Inhibition of HDAC 9 in human HeLa nuclear extract using fluorogenic HDAC class 2A substrate measured after 60 mins by fluorometric analysis	2017	Journal of medicinal chemistry, 04-27, Volume: 60, Issue:8	Exploring Derivatives of Quinazoline Alkaloid l-Vasicine as Cap Groups in the Design and Biological Mechanistic Evaluation of Novel Antitumor Histone Deacetylase Inhibitors.
AID1164173	Induction of apoptosis in human K562 cells using annexin-V/PI staining by flow cytometry	2014	ACS medicinal chemistry letters, Sep-11, Volume: 5, Issue:9	Novel antiproliferative chimeric compounds with marked histone deacetylase inhibitory activity.
AID1202600	Inhibition of HDAC1 in human KB cells assessed as increase in histone H4 acetylation after 24 hrs by Western blotting analysis	2015	European journal of medicinal chemistry, , Volume: 96	Design and structure activity relationship of tumor-homing histone deacetylase inhibitors conjugated to folic and pteroic acids.
AID1126962	Inhibition of HDAC6 (unknown origin) using Boc-Lys(acetyl)-AMC as substrate after 30 mins by fluorescence assay	2014	Journal of medicinal chemistry, Apr-24, Volume: 57, Issue:8	Discovery of the first N-hydroxycinnamamide-based histone deacetylase 1/3 dual inhibitors with potent oral antitumor activity.
AID482968	Elimination half life in mouse at 10 mg/kg, iv	2010	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11	Acylurea connected straight chain hydroxamates as novel histone deacetylase inhibitors: Synthesis, SAR, and in vivo antitumor activity.
AID1861309	Induction of apoptosis in human DOHH-2 cells measured by flow cytometry analysis	2022	Bioorganic & medicinal chemistry letters, 09-01, Volume: 71	Bioevaluation of a dual PI3K/HDAC inhibitor for the treatment of diffuse large B-cell lymphoma.
AID473193	Growth inhibition of human HepG2 cells after 48 hrs by MTT assay	2010	Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5	Biological and biophysical properties of the histone deacetylase inhibitor suberoylanilide hydroxamic acid are affected by the presence of short alkyl groups on the phenyl ring.
AID1702101	Inhibition of HDAC6 in human PC-3 cells assessed as increase in acetylation of alpha-tubulin at Lys40 residue at 10 uM incubated for 24 hrs by Western blot analysis	2018	Journal of medicinal chemistry, 02-22, Volume: 61, Issue:4	Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma.
AID1164922	Cytotoxicity against human BE(2)-C cells at 2 uM after 3 to 9 days by CCK-8 assay	2014	Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19	Identification of a novel aminotetralin class of HDAC6 and HDAC8 selective inhibitors.
AID1765328	Inhibition of human full-length recombinant C-terminal His-tagged HDAC8 expressed in baculovirus infected Sf9 insect cells preincubated for 5 mins followed by HDAC substrate addition and further incubated for 45 mins by fluorescence microplate reader assa	2021	European journal of medicinal chemistry, Oct-15, Volume: 222	A first-in-class anticancer dual HDAC2/FAK inhibitors bearing hydroxamates/benzamides capped by pyridinyl-1,2,4-triazoles.
AID1393285	Inhibition of human recombinant HDAC1 using Ac-Leu-Gly-Lys(Ac)-AMC as substrate preincubated for 30 mins followed by substrate addition and measured after 15 to 30 mins	2018	Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9	Quest for Novel Chemical Entities through Incorporation of Silicon in Drug Scaffolds.
AID1825882	Cytotoxicity against HEK293T cells incubated for 72 hrs by CCK-8 assay
AID1174689	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	2015	European journal of medicinal chemistry, Jan-07, Volume: 89	Development of 3-hydroxycinnamamide-based HDAC inhibitors with potent in vitro and in vivo anti-tumor activity.
AID1899584	Inhibition of HDAC class 2a in human HT-29 cells using Boc-Lys-TFA as substrate incubated for 3 hrs by microplate reader assay
AID1390014	Inhibition of full length recombinant human C-terminal His-tagged HDAC8 expressed in baculovirus infected sf9 cells using Boc-Lys-(TFA)-AMC as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by fluorescence assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Design, synthesis and biological evaluation of novel hydroxamic acid based histone deacetylase 6 selective inhibitors bearing phenylpyrazol scaffold as surface recognition motif.
AID1816198	Antiproliferative activity against mouse 4T1 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay
AID1482105	Inhibition of HDAC 11 in human HeLa nuclear extract using fluorogenic HDAC class 2A substrate measured after 60 mins by fluorometric analysis	2017	Journal of medicinal chemistry, 04-27, Volume: 60, Issue:8	Exploring Derivatives of Quinazoline Alkaloid l-Vasicine as Cap Groups in the Design and Biological Mechanistic Evaluation of Novel Antitumor Histone Deacetylase Inhibitors.
AID1487010	Selectivity index, ratio of IC50 for HDAC3 (unknown origin) to IC50 for HDAC6 (unknown origin)	2017	Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15	The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity.
AID1518839	Resistance ratio of IC50 for antimalarial activity against ring stage Plasmodium falciparum K1 to IC50 for antimalarial activity against ring stage Plasmodium falciparum 3D7	2019	European journal of medicinal chemistry, Dec-15, Volume: 184	Discovery of a potent histone deacetylase (HDAC) 3/6 selective dual inhibitor.
AID663379	Growth inhibition of human MALME-3M cells after 72 hrs by MTS assay	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Discovery and extensive in vitro evaluations of NK-HDAC-1: a chiral histone deacetylase inhibitor as a promising lead.
AID1832670	Inhibition of HDAC in human HeLa nuclear extract using Boc-Lys(acetyl)-AMC as fluorogenic substrate measured after 1 hr by flourescence plate reader method	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Cysteine derivatives as acetyl lysine mimics to inhibit zinc-dependent histone deacetylases for treating cancer.
AID1865254	Inhibition of human HDAC in human MV4-11 cells assessed as downregulation of ERK phosphorylation at 1 uM measured after 24 hrs by in presence of SHP099 Western blot assay	2022	Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18	Discovery of Novel Src Homology-2 Domain-Containing Phosphatase 2 and Histone Deacetylase Dual Inhibitors with Potent Antitumor Efficacy and Enhanced Antitumor Immunity.
AID1888404	Antifungal activity against azole-resistant Candida albicans 0304103 assessed as fungal growth inhibition incubated for 48 hrs by CLSI based checkerboard microdilution assay	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	Heat shock protein 90 (Hsp90)/Histone deacetylase (HDAC) dual inhibitors for the treatment of azoles-resistant Candida albicans.
AID313736	Inhibition of HDAC8	2008	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2	Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2).
AID603531	Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay	2011	Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8	Development of tetrahydroisoquinoline-based hydroxamic acid derivatives: potent histone deacetylase inhibitors with marked in vitro and in vivo antitumor activities.
AID1730889	Inhibition of EGFR in human NCI-H1975 cells assessed as reduction in EGFR phosphorylation at Tyr-1173 residues at 1 uM after 48 hrs by Western blot analysis	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Design, synthesis and evaluation of novel ErbB/HDAC multitargeted inhibitors with selectivity in EGFR
AID593546	Inhibition of human HDAC2 using ArgHisLysLys(Ac) fluorogenic peptide as a substrate by fluorimetric assay	2011	Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7	Oxime amides as a novel zinc binding group in histone deacetylase inhibitors: synthesis, biological activity, and computational evaluation.
AID1739586	Inhibition of HDAC6 in human HL-60 cells assessed as ratio of acetylated tubulin/GAPDH at 1 uM incubated for 4 hrs by Western blot analysis relative to DMSO	2020	European journal of medicinal chemistry, Aug-15, Volume: 200	Design, synthesis, and biological evaluation of dual targeting inhibitors of histone deacetylase 6/8 and bromodomain BRPF1.
AID1898911	Antiproliferative activity against human U-87 MG cells incubated for 24 hrs followed by incubating in drug-free medium for 48 hrs and measured by SRB assay	2022	European journal of medicinal chemistry, Jan-15, Volume: 228	Antitumor activity of novel POLA1-HDAC11 dual inhibitors.
AID1572379	Antiproliferative activity against human HL60 cells after 72 hrs by CellTiter blue-reagent based assay	2019	Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3	Synthesis and Biological Investigation of Phenothiazine-Based Benzhydroxamic Acids as Selective Histone Deacetylase 6 Inhibitors.
AID1547334	Inhibition of HDAC in human HCT116 cells assessed as activation of IL6-JAK-STAT signaling pathway by measuring increase in CTF1 mRNA level at 10 uM after 24 hrs by RT-PCR analysis	2020	Journal of medicinal chemistry, 04-09, Volume: 63, Issue:7	Discovery of Thieno[2,3-
AID1572378	Ratio of inhibition of HDAC6 in human HL60 cells assessed as acetylated tubulin/GAPDH ratio at 10 uM to inhibition of HDAC in human HL60 cells assessed as acetylated H3/GAPDH ratio at 0.1 uM	2019	Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3	Synthesis and Biological Investigation of Phenothiazine-Based Benzhydroxamic Acids as Selective Histone Deacetylase 6 Inhibitors.
AID404443	Cytotoxicity against human Mia Paca2 cells after 72 hrs by MTT assay	2008	Journal of medicinal chemistry, Jun-26, Volume: 51, Issue:12	A series of potent and selective, triazolylphenyl-based histone deacetylases inhibitors with activity against pancreatic cancer cells and Plasmodium falciparum.
AID663350	Growth inhibition of human EKVX cells after 72 hrs by MTS assay	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Discovery and extensive in vitro evaluations of NK-HDAC-1: a chiral histone deacetylase inhibitor as a promising lead.
AID674002	Growth inhibition of human HEK293 cells after 72 hrs by XTT assay	2012	ACS medicinal chemistry letters, Jun-14, Volume: 3, Issue:6	Discovery of HDAC Inhibitors That Lack an Active Site Zn(2+)-Binding Functional Group.
AID1155337	Selectivity index, ratio of IC50 for human HepG2 cells to IC50 for exo-erythrocytic form of Plasmodium berghei	2014	European journal of medicinal chemistry, Jul-23, Volume: 82	Discovery of HDAC inhibitors with potent activity against multiple malaria parasite life cycle stages.
AID482969	Oral bioavailability in mouse at 10 mg/kg, iv	2010	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11	Acylurea connected straight chain hydroxamates as novel histone deacetylase inhibitors: Synthesis, SAR, and in vivo antitumor activity.
AID1312930	Inhibition of HDAC6 in human HCT116 cells assessed as upregulation of acetylated alpha-tubulin level at 2 uM after 6 hrs by Western blot method	2016	Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11	Development of Purine-Based Hydroxamic Acid Derivatives: Potent Histone Deacetylase Inhibitors with Marked in Vitro and in Vivo Antitumor Activities.
AID1591855	Inhibition of wild-type human N-terminal GST-tagged CDK2/cycA2 expressed in Sf21 insect cells at 100 nM using FAM-labelled substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins by fluorescence assay relative to contr	2019	Bioorganic & medicinal chemistry letters, 08-15, Volume: 29, Issue:16	Discovery of novel 9H-purin derivatives as dual inhibitors of HDAC1 and CDK2.
AID546550	Inhibition of Flag tagged human recombinant HDAC8 expressed in Sf21 cells	2010	Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24	Novel chimeric histone deacetylase inhibitors: a series of lapatinib hybrides as potent inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and histone deacetylase activity.
AID1250641	Inhibition of recombinant human HDAC2 after 60 mins by fluorescence assay	2015	Journal of medicinal chemistry, Oct-08, Volume: 58, Issue:19	Discovery of Novel Class I Histone Deacetylase Inhibitors with Promising in Vitro and in Vivo Antitumor Activities.
AID1486673	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	2017	Bioorganic & medicinal chemistry, 08-01, Volume: 25, Issue:15	Design, synthesis and tumor cell growth inhibitory activity of 3-nitro-2H-cheromene derivatives as histone deacetylaes inhibitors.
AID1832690	Inhibition of HDAC6 (unknown origin) using Boc-Lys(acetyl)-AMC as fluorogenic substrate measured after 1 hr by flourescence plate reader method	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Cysteine derivatives as acetyl lysine mimics to inhibit zinc-dependent histone deacetylases for treating cancer.
AID1441682	Anti-inflammatory activity in BLM-induced C57BL/6 mouse model of acute lung neutrophilic inflammation assessed as protein concentration in BALF at 50 mg/kg, ip qd for 7 days post BLM challenge measured on day 7 (Rvb = 2.39 mg/ml)	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
AID605619	Cell cycle arrest in human HCT116 cells assessed as accumulation at sub-G1 phase at 300 nM after 15 hrs by propidium iodide staining based flow cytometric analysis	2010	Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24	Discovery of 2-(6-{[(6-fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a class I selective orally active histone deacetylase inhibitor.
AID605392	Inhibition of human recombinant HDAC1 using fluor de Lys as substrate by fluorometric analysis	2010	Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24	Discovery of 2-(6-{[(6-fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a class I selective orally active histone deacetylase inhibitor.
AID1599786	Inhibition of HDAC6 in human A549 cells assessed as upregulation of E-cadherin mRNA expression at 2.5 uM after 24 hrs by RT-Sybr green PCR analysis	2019	ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6	Extending Cross Metathesis To Identify Selective HDAC Inhibitors: Synthesis, Biological Activities, and Modeling.
AID708277	Growth inhibition of human Bel7402 cells incubated for 72 hrs by WST dye reduction assay	2012	Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20	Pharmacokinetic optimization of class-selective histone deacetylase inhibitors and identification of associated candidate predictive biomarkers of hepatocellular carcinoma tumor response.
AID1511132	Inhibition of HDAC1 (unknown origin) using Ac-LeuGlyLys(Ac)-AMC as substrate preincubated for 5 mins followed by substrate addition and measured after 60 mins by fluorescence based assay	2019	ACS medicinal chemistry letters, Aug-08, Volume: 10, Issue:8	Design, Synthesis, and Biological Evaluation of 2,4-Imidazolinedione Derivatives as HDAC6 Isoform-Selective Inhibitors.
AID274171	Antiproliferative activity against HCT116 cells	2006	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 16, Issue:20	Synthesis of rigid trichostatin A analogs as HDAC inhibitors.
AID247946	Concentration required to inhibit human LNCaP prostate carcinoma cells	2005	Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15	A new simple and high-yield synthesis of suberoylanilide hydroxamic acid and its inhibitory effect alone or in combination with retinoids on proliferation of human prostate cancer cells.
AID1282238	Inhibition of recombinant HDAC2 (unknown origin) using AMC labeled AC-peptide as substrate incubated for 1 hr by fluorescence analysis	2016	Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4	Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
AID1542186	Inhibition of HDAC8 (unknown origin)	2019	Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7	Kinase and Histone Deacetylase Hybrid Inhibitors for Cancer Therapy.
AID1065632	Inhibition of human recombinant full length HDAC8 using Boc_Lys_TFA as substrate after 60 mins by fluorescence assay	2013	Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24	Design, synthesis, and biological evaluation of potent and selective class IIa histone deacetylase (HDAC) inhibitors as a potential therapy for Huntington's disease.
AID1859928	Inhibition of HDAC in human U-937 cells assessed as increase in acetylation level of alpha-tubulin at 10 uM measured after 24 to 48 hrs by Western blot analysis	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Azetidin-2-one-based small molecules as dual hHDAC6/HDAC8 inhibitors: Investigation of their mechanism of action and impact of dual inhibition profile on cell viability.
AID1890307	Inhibition of recombinant human HDAC1 using Boc-Lys-(acetyl)-AMC as substrate incubated for 0.5 hr and measured after 20 mins by fluorescence assay	2022	European journal of medicinal chemistry, Apr-05, Volume: 233	Novel biphenyl-based scaffold as potent and selective histone deacetylase 6 (HDAC6) inhibitors: Identification, development and pharmacological evaluation.
AID1518786	Antiproliferative activity against human OPM2 cells incubated for 48 hrs by CellTiter-Glo luminescent cell viability assay	2019	European journal of medicinal chemistry, Dec-15, Volume: 184	Discovery of a potent histone deacetylase (HDAC) 3/6 selective dual inhibitor.
AID765392	Inhibition of recombinant human HDAC2 enzyme using flurogenic Ac-LeuGlyLys (Ac)-AMC as substrate after 15 to 30 mins	2013	Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16	Total synthesis and full histone deacetylase inhibitory profiling of Azumamides A-E as well as β²- epi-Azumamide E and β³-epi-Azumamide E.
AID481571	Cytotoxicity against mouse S180 cells assessed as growth inhibition at 100 ug/ml after 24 hrs by MTT assay	2010	Bioorganic & medicinal chemistry letters, May-15, Volume: 20, Issue:10	Synthesis and anticancer evaluation of alpha-lipoic acid derivatives.
AID1293560	Antiproliferative activity against human HT-29 cells assessed as reduction in cell number after 72 hrs by cell counter analysis	2016	European journal of medicinal chemistry, Apr-13, Volume: 112	Biphenyl-4-yl-acrylohydroxamic acids: Identification of a novel indolyl-substituted HDAC inhibitor with antitumor activity.
AID1742629	Inhibition of HDAC in human MDA-MB-231 cells assessed as increase in acetylated alpha-tubulin incubated for 8 hrs by Western blot analysis	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Design and synthesis of novel Flavone-based histone deacetylase inhibitors antagonizing activation of STAT3 in breast cancer.
AID1826631	Synergistic antiproliferative effect on HEL cells assessed as combination index at 0.37 uM in presence of 3-Fluoro-10-hydroxy-14-methyl-8,13,13b,14-tetrahydro-7H-indolo[2',3':3,4]pyrido[2,1-b]quinazolin-5-one	2022	Journal of medicinal chemistry, 03-24, Volume: 65, Issue:6	Evodiamine-Inspired Topoisomerase-Histone Deacetylase Dual Inhibitors: Novel Orally Active Antitumor Agents for Leukemia Therapy.
AID1915537	Inhibition of HDAC1 (unknown origin)	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors.
AID1206736	Inhibition of HDAC1/HDAC2 in human HeLa cells using Boc-Lys(acetyl)-AMC as substrate after 30 mins by fluorescence assay	2015	Journal of medicinal chemistry, May-28, Volume: 58, Issue:10	Design, synthesis, and antitumor evaluation of novel histone deacetylase inhibitors equipped with a phenylsulfonylfuroxan module as a nitric oxide donor.
AID1915552	Antiproliferative activity against breast cancer cell line (unknown origin)	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors.
AID1390016	Antiproliferative activity against human A549 cells after 96 hrs by MTT assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Design, synthesis and biological evaluation of novel hydroxamic acid based histone deacetylase 6 selective inhibitors bearing phenylpyrazol scaffold as surface recognition motif.
AID1431815	Selectivity ratio of IC50 for human KDAC1 to IC50 for human KDAC8	2017	European journal of medicinal chemistry, Feb-15, Volume: 127	Design and synthesis of benzodiazepine analogs as isoform-selective human lysine deacetylase inhibitors.
AID1441652	Anti-inflammatory activity in LPS-induced C57BL/6 mouse model of acute lung injury assessed as reduction in IL-6 level pretreated intraperitoneally for 1 hr followed LPS challenge after 24 hrs by ELISA	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
AID1816689	Inhibition of HDAC6 (unknown origin) using Ac-peptide as substrate preincubated for 15 mins followed by substrate addition by fluorescence assay	2021	European journal of medicinal chemistry, Aug-05, Volume: 220	Design, synthesis, and biological evaluation of novel dual inhibitors targeting lysine specific demethylase 1 (LSD1) and histone deacetylases (HDAC) for treatment of gastric cancer.
AID1312926	Inhibition of HDAC1/2/3 in human HCT116 cells assessed as upregulation of acetylated histone H3 level at 2 uM after 6 hrs by Western blot method	2016	Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11	Development of Purine-Based Hydroxamic Acid Derivatives: Potent Histone Deacetylase Inhibitors with Marked in Vitro and in Vivo Antitumor Activities.
AID760505	Inhibition of HDAC8 (unknown origin) using fluorogenic peptide from p53 residues (379 to 382) (RHK(Ac)K(Ac)) as substrate by fluorescence assay	2013	ACS medicinal chemistry letters, Aug-08, Volume: 4, Issue:8	Development of a chimeric c-Src kinase and HDAC inhibitor.
AID1449675	Inhibition of HDAC in human HeLa cell nuclear extracts using (Boc-Lys(Ac)-AMC as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by fluorescence assay	2017	Bioorganic & medicinal chemistry, 05-01, Volume: 25, Issue:9	Development of N-hydroxycinnamamide-based HDAC inhibitors with improved HDAC inhibitory activity and in vitro antitumor activity.
AID1466059	Growth inhibition of human MDA-MB-231 cells after 48 hrs by sulforhodamine B assay	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	4-Indolyl-N-hydroxyphenylacrylamides as potent HDAC class I and IIB inhibitors in vitro and in vivo.
AID765391	Inhibition of GST-tagged recombinant human HDAC3/NcoR1 enzyme using flurogenic Ac-LeuGlyLys (Ac)-AMC as substrate after 15 to 30 mins	2013	Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16	Total synthesis and full histone deacetylase inhibitory profiling of Azumamides A-E as well as β²- epi-Azumamide E and β³-epi-Azumamide E.
AID1547258	Inhibition of human recombinant His-tagged BRD4 BD1 domain using H-SGRGK(Ac)GGK(Ac)GLGK-(Ac)GGAK(Ac)RHRK(Biotin)-OH as substrate preincubated with enzyme for 30 mins followed by substrate addition measured after 30 mins by AlphaScreen assay	2020	Journal of medicinal chemistry, 04-09, Volume: 63, Issue:7	Discovery of Thieno[2,3-
AID1476150	Antiproliferative activity against human HL60 cells	2017	Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20	Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat.
AID663357	Growth inhibition of human COLO205 cells after 72 hrs by MTS assay	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Discovery and extensive in vitro evaluations of NK-HDAC-1: a chiral histone deacetylase inhibitor as a promising lead.
AID1752945	Selectivity index, ratio of IC50 for C-terminal FLAG/His-tagged human recombinant HDAC1 (1 to 482 residues) expressed in baculovirus infected Sf9 cells to IC50 for N-terminal GST-tagged full length human recombinant HDAC6 expressed in baculovirus infected
AID461254	Antiproliferative activity against human NCI-H358 cells after hrs by ATP content assay	2010	Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5	Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer.
AID652750	Inhibition of recombinant human HDAC6 using Fluor-de-Lys as substrate after 30 mins by spectrophotometry	2011	ACS medicinal chemistry letters, Jul-21, Volume: 2, Issue:9	Potential Agents for Treating Cystic Fibrosis: Cyclic Tetrapeptides that Restore Trafficking and Activity of ΔF508-CFTR.
AID1164915	Inhibition of HDAC10 (unknown origin) using fluorogenic peptide as substrate by fluorescence assay	2014	Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19	Identification of a novel aminotetralin class of HDAC6 and HDAC8 selective inhibitors.
AID1548730	Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability after 48 hrs by CellTiter-Blue dye based spectrophotometric analysis	2020	Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10	Design of Hydrazide-Bearing HDACIs Based on Panobinostat and Their p53 and FLT3-ITD Dependency in Antileukemia Activity.
AID1633991	Inhibition of HDAC3 in human HuH7 cells assessed as increase in histone H3 K9/K14acetylation at varying concentrations incubated for 24 hrs by Western blot analysis	2019	Bioorganic & medicinal chemistry letters, 08-15, Volume: 29, Issue:16	Synthesis of N'-propylhydrazide analogs of hydroxamic inhibitors of histone deacetylases (HDACs) and evaluation of their impact on activities of HDACs and replication of hepatitis C virus (HCV).
AID1622910	Inhibition of recombinant human His-tagged HDAC6 expressed in baculovirus infected insect cells using Fluor-de-lys as substrate measured after 60 mins by fluorescence assay	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.
AID652761	Restoration of CFTR deltaF508 mutant trafficking to cell surface in human CFBE41o cells co-expressing halide-sensitive YFP-H148Q/I142L assessed as fluorescence quenching at 5 uM after 24 hrs relative to control	2011	ACS medicinal chemistry letters, Jul-21, Volume: 2, Issue:9	Potential Agents for Treating Cystic Fibrosis: Cyclic Tetrapeptides that Restore Trafficking and Activity of ΔF508-CFTR.
AID1055352	Selectivity ratio of IC50 for human recombinant HDAC6 to IC50 for human recombinant HDAC2	2013	Journal of natural products, Nov-22, Volume: 76, Issue:11	Santacruzamate A, a potent and selective histone deacetylase inhibitor from the Panamanian marine cyanobacterium cf. Symploca sp.
AID1763821	Inhibition of human recombinant HDAC8 incubated for 15 mins by fluorogenic assay	2021	Bioorganic & medicinal chemistry, 06-15, Volume: 40	Novel hybrid conjugates with dual estrogen receptor α degradation and histone deacetylase inhibitory activities for breast cancer therapy.
AID1622900	Cytotoxicity against human HCT116 cells after 72 hrs by CellTiter-Glo assay	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.
AID1737147	Induction of apoptosis in human HCT-116 cells assessed as viable cells at 1 uM after 24 hrs by Annexin V-FITC/PI staining based flow cytometric analysis (Rvb = 90.34%)	2020	European journal of medicinal chemistry, Apr-15, Volume: 192	Design, synthesis and biological evaluation of novel indazole-based derivatives as potent HDAC inhibitors via fragment-based virtual screening.
AID1826641	Induction of apoptosis in HEL cells assessed as apoptotic cells at 0.1 uM incubated for 48 hrs by annexin V-FITC/PI staining based flow cytometry (Rvb = 3.95%)	2022	Journal of medicinal chemistry, 03-24, Volume: 65, Issue:6	Evodiamine-Inspired Topoisomerase-Histone Deacetylase Dual Inhibitors: Novel Orally Active Antitumor Agents for Leukemia Therapy.
AID781046	Antiproliferative activity against human OVCAR5 cells after 48 hrs by sulforhodamine B assay	2013	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 23, Issue:23	Design, synthesis and biological evaluation of di-substituted cinnamic hydroxamic acids bearing urea/thiourea unit as potent histone deacetylase inhibitors.
AID1742664	Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Design and synthesis of novel Flavone-based histone deacetylase inhibitors antagonizing activation of STAT3 in breast cancer.
AID1876477	Induction of cell cycle arrest in human HCT-116 cells assessed as decrease in accumulation of cells at S phase at 1 uM incubated for 24 hrs by flow cytometry analysis	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	Design, synthesis, and biological evaluation of indole-based hydroxamic acid derivatives as histone deacetylase inhibitors.
AID1578499	Induction of apoptosis in human MV4-11 cells assessed as early apoptotic cells at 0.5 uM incubated for 18 hrs by annexin V FITC and PI based flow cytometry (Rvb = 19.46 to 22.17 %)	2020	ACS medicinal chemistry letters, Jan-09, Volume: 11, Issue:1	Class I/IIb-Selective HDAC Inhibitor Exhibits Oral Bioavailability and Therapeutic Efficacy in Acute Myeloid Leukemia.
AID348800	Inhibition of HDAC4	2008	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20	Optimization of a series of potent and selective ketone histone deacetylase inhibitors.
AID1441632	Binding affinity to recombinant human LTA4H hydrolase assessed as change in melting temperature at 50 uM by SYPRO orange dye-based thermofluor assay	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
AID297500	Cytotoxicity against vincristine resistant human CCRF-CEM cells	2007	Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18	2-aroylindoles and 2-aroylbenzofurans with N-hydroxyacrylamide substructures as a novel series of rationally designed histone deacetylase inhibitors.
AID1543931	Antiproliferative activity against human HepG2 cells incubated for 48 hrs by MTT assay	2019	European journal of medicinal chemistry, Apr-15, Volume: 168	β-Carboline and N-hydroxycinnamamide hybrids as anticancer agents for drug-resistant hepatocellular carcinoma.
AID1864223	Cytotoxicity against human BT-549 cells assessed as reduction in cell viability measured after 48 hrs	2022	Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18	Discovery of a Novel G-Quadruplex and Histone Deacetylase (HDAC) Dual-Targeting Agent for the Treatment of Triple-Negative Breast Cancer.
AID366647	Antiproliferative activity against human HupT3 cells after 72 hrs by MTT assay	2008	Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15	Use of the nitrile oxide cycloaddition (NOC) reaction for molecular probe generation: a new class of enzyme selective histone deacetylase inhibitors (HDACIs) showing picomolar activity at HDAC6.
AID1671970	Retention time of the compound by HPLC method	2019	Bioorganic & medicinal chemistry, 04-01, Volume: 27, Issue:7	Synthesis and biological evaluation of paclitaxel and vorinostat co-prodrugs for overcoming drug resistance in cancer therapy in vitro.
AID734740	Inhibition of HDAC6 (unknown origin) after 60 mins by SAMDI spectrophotometric analysis	2013	Journal of medicinal chemistry, May-09, Volume: 56, Issue:9	3-Hydroxypyridin-2-thione as novel zinc binding group for selective histone deacetylase inhibition.
AID1486296	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	2017	Bioorganic & medicinal chemistry, 08-01, Volume: 25, Issue:15	Olaparib hydroxamic acid derivatives as dual PARP and HDAC inhibitors for cancer therapy.
AID1227053	Cytotoxicity against african green monkey Vero cells cells assessed as cell proliferation after 70 hrs by MTS assay	2015	Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11	Dual-Mode HDAC Prodrug for Covalent Modification and Subsequent Inhibitor Release.
AID1785330	Inhibition of full length human CDK6 (1 to 326 end residues)/N-terminal GST-fusion tagged CyclinD3 (1 to 292 residues) expressed in baculovirus expression system at 100 nM preincubated for 10 mins followed by substrate and ATP addition by mobility shift a
AID1863172	Inhibition of HDAC1 (unknown origin) using fluorogenic substrate incubated for 30 mins by fluorescence plate reader	2022	European journal of medicinal chemistry, Oct-05, Volume: 240	Design, synthesis, and biological evalution of bifunctional inhibitors against Hsp90-HDAC6 interplay.
AID1478590	Inhibition of HDAC1/2 in human HeLa cell nuclear extract using COLOR DE LYS as substrate pretreated for 5 mins followed by substrate addition measured after 30 mins by UV-absorption method	2017	European journal of medicinal chemistry, Jun-16, Volume: 133	Design, synthesis and biological evaluation of quinoline derivatives as HDAC class I inhibitors.
AID446344	Half life in CD1 mouse at 15 mg/kg, po	2010	Journal of medicinal chemistry, Jan-28, Volume: 53, Issue:2	Synthesis and biological evaluation of N-hydroxyphenylacrylamides and N-hydroxypyridin-2-ylacrylamides as novel histone deacetylase inhibitors.
AID1067345	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	2014	Bioorganic & medicinal chemistry, Mar-01, Volume: 22, Issue:5	Design, synthesis and preliminary bioactivity studies of 1,2-dihydrobenzo[d]isothiazol-3-one-1,1-dioxide hydroxamic acid derivatives as novel histone deacetylase inhibitors.
AID1832689	Inhibition of human HDAC5 using Boc-Lys(acetyl)-AMC as fluorogenic substrate measured after 1 hr by flourescence plate reader method	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Cysteine derivatives as acetyl lysine mimics to inhibit zinc-dependent histone deacetylases for treating cancer.
AID347874	Growth inhibition of human prostate cancer cells at 10 uM relative to control	2008	Journal of medicinal chemistry, Dec-11, Volume: 51, Issue:23	Histone deacetylase inhibitors through click chemistry.
AID1578501	Induction of apoptosis in human MV4-11 cells assessed as late apoptotic cells at 1 uM incubated for 18 hrs by annexin V FITC and PI based flow cytometry (Rvb = 9.2 to 9.63 %)	2020	ACS medicinal chemistry letters, Jan-09, Volume: 11, Issue:1	Class I/IIb-Selective HDAC Inhibitor Exhibits Oral Bioavailability and Therapeutic Efficacy in Acute Myeloid Leukemia.
AID1819555	Antitumor activity against mouse B16-F10 cells xenografted in C57BL/6J mouse assessed as change in tumor cell morphology into normal tissue at 60 mg/kg, IG administered for 12 days by H and E staining based histopathological analysis	2022	Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4	Discovery of DNA-Targeting HDAC Inhibitors with Potent Antitumor Efficacy In Vivo That Trigger Antitumor Immunity.
AID1260644	Inhibition of human recombinant HDAC8 at 20 uM using Ac-RHK(Ac)K(Ac)-AMC as substrate after 30 to 60 mins by microplate reader assay
AID1901768	Cytotoxicity against human MRC9 cells assessed as inhibition of cell growth incubated for 72 hrs measured by spectrophotometer analysis	2022	Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4	Discovery of HDAC6-Selective Inhibitor NN-390 with
AID1901786	Binding affinity to full length HDAC6-NanoLuc fusion protein (unknown origin) expressed in HeLa cells assessed as residence time by NanoBRET assay	2022	Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4	Discovery of HDAC6-Selective Inhibitor NN-390 with
AID1525776	Inhibition of HADC6 (unknown origin)	2020	Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1	Old but Gold: Tracking the New Guise of Histone Deacetylase 6 (HDAC6) Enzyme as a Biomarker and Therapeutic Target in Rare Diseases.
AID1898894	Antiproliferative activity against human NCI-H460 cells incubated for 24 hrs followed by incubating in drug-free medium for 48 hrs and measured by SRB assay	2022	European journal of medicinal chemistry, Jan-15, Volume: 228	Antitumor activity of novel POLA1-HDAC11 dual inhibitors.
AID673990	Inhibition of recombinant HDAC1 using Ac-Lys(Ac)-AMC as substrate after 30 mins by fluorescence analysis	2012	ACS medicinal chemistry letters, Jun-14, Volume: 3, Issue:6	Discovery of HDAC Inhibitors That Lack an Active Site Zn(2+)-Binding Functional Group.
AID750109	Inhibition of HDAC in human HeLa cells using Fluor de Lys as substrate by fluorescence assay	2013	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 23, Issue:11	Design, synthesis and biological evaluation of indeno[1,2-d]thiazole derivatives as potent histone deacetylase inhibitors.
AID764219	Inhibition of HDAC in human HeLa cell extract using Fluor deLys as substrate by fluorimetric assay	2013	Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17	Novel N-hydroxyfurylacrylamide-based histone deacetylase (HDAC) inhibitors with branched CAP group (Part 2).
AID1771459	Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition after 72 hrs by SRB assay	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Discovery of novel tubulin/HDAC dual-targeting inhibitors with strong antitumor and antiangiogenic potency.
AID1848631	Cytotoxicity against human SN12C cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay	2022	Journal of medicinal chemistry, 11-10, Volume: 65, Issue:21	First-in-Class Dual Mechanism Ferroptosis-HDAC Inhibitor Hybrids.
AID1337253	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay	2016	Journal of medicinal chemistry, Sep-22, Volume: 59, Issue:18	Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines.
AID208379	Tested for morphological alterations in T/5 cells after administration along with DMSO (0.1%)	1995	Journal of medicinal chemistry, Apr-14, Volume: 38, Issue:8	The synthesis of N-hydroxy-N'-phenyloctanediamide and its inhibitory effect on proliferation of AXC rat prostate cancer cells.
AID732143	Inhibition of HDAC7 (unknown origin) assessed as fluorescence intensity measured after 60 mins incubation at room temperature by trypsin-free microfluidic lab-on-a-chip assay	2013	Journal of medicinal chemistry, Feb-28, Volume: 56, Issue:4	Potent and selective inhibition of histone deacetylase 6 (HDAC6) does not require a surface-binding motif.
AID1464873	Anti-proliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay	2017	Bioorganic & medicinal chemistry letters, 11-01, Volume: 27, Issue:21	Design, synthesis and biological evaluation of novel histone deacetylase inhibitors incorporating 4-aminoquinazolinyl systems as capping groups.
AID1361659	Antitumor activity against human A549 cells xenografted in BALB/C nude mouse assessed as inhibition of tumor growth at 100 mg/kg, po administered once daily for 21 days starting day 11 after tumor cells implantation	2018	Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16	Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents.
AID1890330	Stability in mouse plasma incubated for 6 hrs in presence of NADPH and measured by LC-MS/MS analysis	2022	European journal of medicinal chemistry, Apr-05, Volume: 233	Novel biphenyl-based scaffold as potent and selective histone deacetylase 6 (HDAC6) inhibitors: Identification, development and pharmacological evaluation.
AID1742665	Cytotoxicity against human NCI-1581 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Design and synthesis of novel Flavone-based histone deacetylase inhibitors antagonizing activation of STAT3 in breast cancer.
AID1280269	Inhibition of class1 HDAC in human HeLa cells assessed as ratio of acetylated histone H3 to GAPDH level at 10 uM after 4 hrs by Western blot analysis relative to control	2016	Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4	Synthesis and Biological Investigation of Oxazole Hydroxamates as Highly Selective Histone Deacetylase 6 (HDAC6) Inhibitors.
AID408885	Inhibition of HDAC6	2008	Journal of medicinal chemistry, Jun-26, Volume: 51, Issue:12	A series of potent and selective, triazolylphenyl-based histone deacetylases inhibitors with activity against pancreatic cancer cells and Plasmodium falciparum.
AID1141764	Cytotoxicity against human PC3 cells by MTT assay	2014	Journal of medicinal chemistry, May-22, Volume: 57, Issue:10	Azaindolylsulfonamides, with a more selective inhibitory effect on histone deacetylase 6 activity, exhibit antitumor activity in colorectal cancer HCT116 cells.
AID1467236	Inhibition of recombinant C-terminal His-tagged HDAC11 (unknown origin) expressed in baculovirus infected Sf9 cells at 0.2 uM using Ac-Arg-Gly-Lys(Ac)-AMC as substrate pretreated for 3 hrs followed by substrate addition measured within 30 mins by fluorome	2017	Bioorganic & medicinal chemistry letters, 07-01, Volume: 27, Issue:13	Stabilizing HDAC11 with SAHA to assay slow-binding benzamide inhibitors.
AID670514	Inhibition of HDAC derived from human HeLa cell nuclear extract using Boc-Lys(acetyl)-AMC as substrate incubated for 5 mins prior to substrate addition measured after 30 mins by fluorimetry	2012	Bioorganic & medicinal chemistry, Jul-15, Volume: 20, Issue:14	Synthesis and biological evaluation of N-aryl salicylamides with a hydroxamic acid moiety at 5-position as novel HDAC-EGFR dual inhibitors.
AID1762496	Inhibition of HDAC2 (unknown origin)	2021	European journal of medicinal chemistry, Jul-05, Volume: 219	Synthesis and biological evaluation of phenothiazine derivative-containing hydroxamic acids as potent class II histone deacetylase inhibitors.
AID1897807	Selectivity index, ratio of IC50 for human HDAC1 to IC50 for human HDAC6	2022	Journal of medicinal chemistry, 12-22, Volume: 65, Issue:24	Solid-Phase Synthesis of Cereblon-Recruiting Selective Histone Deacetylase 6 Degraders (HDAC6 PROTACs) with Antileukemic Activity.
AID737909	Cytotoxicity against human HS68 cells after 72 hrs by MTT assay	2013	Journal of medicinal chemistry, May-09, Volume: 56, Issue:9	Design and synthesis of dual-action inhibitors targeting histone deacetylases and 3-hydroxy-3-methylglutaryl coenzyme A reductase for cancer treatment.
AID1182316	Antiproliferative activity against hTERT expressing immortalized human HPNE cells after 48 hrs by MTT assay	2014	Journal of natural products, Jul-25, Volume: 77, Issue:7	A potent HDAC inhibitor, 1-alaninechlamydocin, from a Tolypocladium sp. induces G2/M cell cycle arrest and apoptosis in MIA PaCa-2 cells.
AID1688022	Antiproliferative activity against human HL-60 cells assessed as cell growth inhibition after 72 hrs by trypan blue staining based cell counting assay	2020	European journal of medicinal chemistry, Feb-15, Volume: 188	A 18β-glycyrrhetinic acid conjugate with Vorinostat degrades HDAC3 and HDAC6 with improved antitumor effects.
AID1260645	Inhibition of human recombinant HDAC9 at 20 uM using Boc-Lys(Tfa)-AMC as substrate after 30 to 60 mins by microplate reader assay
AID760511	Inhibition of HDAC2 (unknown origin) using fluorogenic peptide from p53 residues (379 to 382) (RHKK(Ac)) as substrate by fluorescence assay	2013	ACS medicinal chemistry letters, Aug-08, Volume: 4, Issue:8	Development of a chimeric c-Src kinase and HDAC inhibitor.
AID1128557	Inhibition of human HDAC-4 using RHKK(Ac) as substrate	2014	European journal of medicinal chemistry, Apr-09, Volume: 76	4,5,6,7-Tetrahydro-isoxazolo-[4,5-c]-pyridines as a new class of cytotoxic Hsp90 inhibitors.
AID1371071	Antiplasmodial activity against exoerythrocytic-stage of Plasmodium berghei ANKA infected in human HepG2 cells after 53 hrs by DAPI staining-based method	2017	Journal of medicinal chemistry, 06-22, Volume: 60, Issue:12	Lysine Deacetylase Inhibitors in Parasites: Past, Present, and Future Perspectives.
AID765390	Inhibition of recombinant human HDAC8 enzyme using Ac-LeuGlyLys (tfa)-AMC as substrate after 15 to 30 mins	2013	Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16	Total synthesis and full histone deacetylase inhibitory profiling of Azumamides A-E as well as β²- epi-Azumamide E and β³-epi-Azumamide E.
AID1189850	Cytotoxicity against human HuH7 cells assessed as inhibition of cell viability after 3 days by CellTiter 96 assay	2015	Journal of medicinal chemistry, Jan-22, Volume: 58, Issue:2	Hydroxamic acids block replication of hepatitis C virus.
AID663386	Growth inhibition of human UACC62 cells after 72 hrs by MTS assay	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Discovery and extensive in vitro evaluations of NK-HDAC-1: a chiral histone deacetylase inhibitor as a promising lead.
AID1365023	Inhibition of recombinant human HDAC2 preincubated with enzyme followed by flour de lys-green substrate addition measured after 1 hr by fluorescence assay	2017	Bioorganic & medicinal chemistry letters, 09-15, Volume: 27, Issue:18	Rational design, synthesis and preliminary antitumor activity evaluation of a chlorambucil derivative with potent DNA/HDAC dual-targeting inhibitory activity.
AID297481	Cytotoxicity against human MDA-MB-231cells	2007	Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18	2-aroylindoles and 2-aroylbenzofurans with N-hydroxyacrylamide substructures as a novel series of rationally designed histone deacetylase inhibitors.
AID544092	Antimalarial activity against drug-resistant Plasmodium falciparum TM91C235	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Antimalarial activity of phenylthiazolyl-bearing hydroxamate-based histone deacetylase inhibitors.
AID1164186	Inhibition of human recombinant HDAC4 using (S)-[5-Acetylamino-1-(2-oxo-4-trifluorometyl-2Hchromen-7-ylcarbamoyl)pentl]carbami acid tert-Butyl Ester as substrate after 1 hr by fluorescent activity assay	2014	ACS medicinal chemistry letters, Sep-11, Volume: 5, Issue:9	Novel antiproliferative chimeric compounds with marked histone deacetylase inhibitory activity.
AID1383992	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	Discovery of meta-sulfamoyl N-hydroxybenzamides as HDAC8 selective inhibitors.
AID1240550	Antiproliferative activity against human KG1 cells after 48 hrs by MTT assay	2015	Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17	Design, synthesis and biological evaluation of saccharin-based N-hydroxybenzamides as histone deacetylases (HDACs) inhibitors.
AID1771458	Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition after 72 hrs by SRB assay	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Discovery of novel tubulin/HDAC dual-targeting inhibitors with strong antitumor and antiangiogenic potency.
AID1597954	Induction of apoptosis in human A549 cells assessed as early apoptotic cells at 10 uM incubated for 72 hrs by Annexin V-FITC/propidium iodide-staining based flow cytometric analysis (Rvb = 1.8%)	2019	Bioorganic & medicinal chemistry letters, 09-15, Volume: 29, Issue:18	Anti-tumor activity evaluation of novel tubulin and HDAC dual-targeting inhibitors.
AID748979	Inhibition of HDAC in human K562 cells	2013	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 23, Issue:11	A cyclodextrin-capped histone deacetylase inhibitor.
AID655476	Inhibition of recombinant human HDAC1 using Fluor-de-Lys as substrate after 30 mins by spectrophotometry	2011	ACS medicinal chemistry letters, Jul-21, Volume: 2, Issue:9	Potential Agents for Treating Cystic Fibrosis: Cyclic Tetrapeptides that Restore Trafficking and Activity of ΔF508-CFTR.
AID1380985	Antitumor activity against human HT-29 cells xenografted in BALB/c nu mouse assessed as tumor growth level at 100 mg/kg, po administered for 25 consecutive days measured every 3 days during compound dosing relative to control	2018	Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12	Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously.
AID1698860	Inhibition of HDAC1 (unknown origin) at 100 nM relative to control	2020	Bioorganic & medicinal chemistry letters, 12-01, Volume: 30, Issue:23	Design, synthesis and biological evaluation of novel c-Met/HDAC dual inhibitors.
AID1177048	Inhibition of human HDAC11 using RHKK(Ac) as substrate by fluorimetric analysis	2015	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 25, Issue:3	Hydroxamic acid based histone deacetylase inhibitors with confirmed activity against the malaria parasite.
AID1452273	Inhibition of HDAC1 (unknown origin) preincubated for 15 mins followed by substrate addition measured after 60 mins by fluorescence assay	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	Design, synthesis and anticancer potential of NSC-319745 hydroxamic acid derivatives as DNMT and HDAC inhibitors.
AID1303632	Potentiation of 5 nM (-)-lomaiviticin A-induced cytotoxicity against human K562 cells assessed as combination index at 25 uM after 48 hrs by cell titer-glo luminescence assay	2016	Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13	Synergistic potentiation of (-)-lomaiviticin A cytotoxicity by the ATR inhibitor VE-821.
AID1055350	Cytotoxicity against human HCT116 cells after 96 hrs by MTS-PMS assay	2013	Journal of natural products, Nov-22, Volume: 76, Issue:11	Santacruzamate A, a potent and selective histone deacetylase inhibitor from the Panamanian marine cyanobacterium cf. Symploca sp.
AID1915598	Inhibition of HDAC5 (unknown origin)	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors.
AID748978	Inhibition of HDAC8 (unknown origin)	2013	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 23, Issue:11	A cyclodextrin-capped histone deacetylase inhibitor.
AID1647327	Anti-vascular cognitive impairment activity against bilateral common carotid artery occlusion-induced vascular dementia C57BL/6J mouse model assessed as improvement in short-term non-spatial working memory by measuring increase in novel object recognition	2020	European journal of medicinal chemistry, Feb-01, Volume: 187	Protective effects of 10,11-dihydro-5H-dibenzo[b,f]azepine hydroxamates on vascular cognitive impairment.
AID1550102	Inhibition of HDAC8 (unknown origin) using Boc-Lys(trifluoroacetyl)-AMC as substrate preincubated for 5 mins followed by substrate addition and measured after 30 mins by fluorescence assay	2019	Journal of medicinal chemistry, 04-25, Volume: 62, Issue:8	Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies.
AID1383998	Inhibition of HDAC6 in human HeLa cells assessed as increase in acetyl-tubulin level at 2 uM after 12 hrs by Western blot analysis	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	Discovery of meta-sulfamoyl N-hydroxybenzamides as HDAC8 selective inhibitors.
AID1433303	Induction of apoptosis in p53 null human U937 cells assessed as increase in Bim EL expression level by measuring ratio of Bim EL to beta-actin level at 2 uM after 24 hrs by Western blot analysis relative to control	2016	Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17	Synthesis and Antileukemic Activities of Piperlongumine and HDAC Inhibitor Hybrids against Acute Myeloid Leukemia Cells.
AID1730853	Antiproliferation activity against human NCI-H838 cells incubated for 72 hrs by MTT assay	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Design, synthesis and evaluation of novel ErbB/HDAC multitargeted inhibitors with selectivity in EGFR
AID1901764	Inhibition of full length human recombinant HDAC11 expressed in Sf9 baculovirus system using FAM-labeled acetylated peptide as substrate by measuring fluorescence intensity by EMSA method	2022	Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4	Discovery of HDAC6-Selective Inhibitor NN-390 with
AID1275076	Inhibition of HDAC in human HeLa nuclear extract	2016	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2	Novel thiol-based histone deacetylase inhibitors bearing 3-phenyl-1H-pyrazole-5-carboxamide scaffold as surface recognition motif: Design, synthesis and SAR study.
AID1486677	Inhibition of HDAC1 (unknown origin) using Ac-Leu-GlyLys(Ac)-AMC as substrate preincubated for 10 mins followed by substrate addition measured after 30 mins by fluorescence analysis	2017	Bioorganic & medicinal chemistry, 08-01, Volume: 25, Issue:15	Design, synthesis and tumor cell growth inhibitory activity of 3-nitro-2H-cheromene derivatives as histone deacetylaes inhibitors.
AID1597935	Antiproliferative activity against human SGC7901 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	2019	Bioorganic & medicinal chemistry letters, 09-15, Volume: 29, Issue:18	Anti-tumor activity evaluation of novel tubulin and HDAC dual-targeting inhibitors.
AID440823	Inhibition of human recombinant N-terminal FLAG-tagged HDAC7 (438-915) expressed in baculovirus after 10 mins by fluorimetric analysis	2009	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 19, Issue:19	Diphenylmethylene hydroxamic acids as selective class IIa histone deacetylase inhibitors.
AID1155330	Cytotoxicity against human HepG2 cells after 48 hrs	2014	European journal of medicinal chemistry, Jul-23, Volume: 82	Discovery of HDAC inhibitors with potent activity against multiple malaria parasite life cycle stages.
AID619046	Competitive inhibition of HDAC1 using KI-104 as substrate by fluorescence assay	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile.
AID1485113	Inhibition of SIRT2 in human U373 cells assessed as increase of alpha-tubulin acetylation at 2 uM after 8 hrs by Western blotting method relative to control	2017	Journal of medicinal chemistry, 06-08, Volume: 60, Issue:11	Discovery and Characterization of R/S-N-3-Cyanophenyl-N'-(6-tert-butoxycarbonylamino-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-4-yl)urea, a New Histone Deacetylase Class III Inhibitor Exerting Antiproliferative Activity against Cancer Cell Lines.
AID1514595	Inhibition of HDAC1 (unknown origin) using Boc-Lys (Ac)-AMC as substrate measured after 60 mins by ELISA	2019	Bioorganic & medicinal chemistry letters, 01-01, Volume: 29, Issue:1	Development of hydroxamate-based histone deacetylase inhibitors containing 1,2,4-oxadiazole moiety core with antitumor activities.
AID1690838	Inhibition of recombinant human full-length N-terminal GST-tagged HDAC6 expressed in baculovirus infected Sf9 insect cells using Boc-Lys(Ac)-AMC as substrate preincubated for 5 mins followed by substrate addition and measured after 30 mins by fluorescence	2020	European journal of medicinal chemistry, Apr-15, Volume: 192	Synthesis and biological evaluation of acridine-based histone deacetylase inhibitors as multitarget agents against Alzheimer's disease.
AID1864221	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 48 hrs	2022	Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18	Discovery of a Novel G-Quadruplex and Histone Deacetylase (HDAC) Dual-Targeting Agent for the Treatment of Triple-Negative Breast Cancer.
AID1126997	Induction of apoptosis in human U937 cells assessed as late apoptotic cells using annexin-V/propidium iodide staining at 1 uM after 24 hrs by flow cytometry analysis (Rvb = 2.13%)	2014	Journal of medicinal chemistry, Apr-24, Volume: 57, Issue:8	Discovery of the first N-hydroxycinnamamide-based histone deacetylase 1/3 dual inhibitors with potent oral antitumor activity.
AID1356299	Cytotoxicity against human PBMC assessed as reduction in cell viability after 72 hrs by MTT assay
AID1246524	Therapeutic index, ratio of CC50 for HEK293 cells to IC50 for imatinib resistant human IR-K562 cells	2015	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 25, Issue:19	Discovery of 1-hydroxypyridine-2-thiones as selective histone deacetylase inhibitors and their potential application for treating leukemia.
AID1566036	Selectivity index, ratio of IC50 for recombinant human HDAC6 to IC50 for recombinant full length C-terminal FLAG/His-tagged human HDAC1 expressed in baculovirus infected Sf9 cells	2019	European journal of medicinal chemistry, Nov-15, Volume: 182	A fluorine scan on the Zn
AID1826630	Synergistic antiproliferative effect on HEL cells assessed as combination index at 1.11 uM in presence of 3-Fluoro-10-hydroxy-14-methyl-8,13,13b,14-tetrahydro-7H-indolo[2',3':3,4]pyrido[2,1-b]quinazolin-5-one	2022	Journal of medicinal chemistry, 03-24, Volume: 65, Issue:6	Evodiamine-Inspired Topoisomerase-Histone Deacetylase Dual Inhibitors: Novel Orally Active Antitumor Agents for Leukemia Therapy.
AID1321728	Inhibition of class 1 histone deacetylase in human SH-SY5Y cells assessed as increase in histone H3K9 acetylation after 2 hrs by Western blot analysis	2016	Journal of medicinal chemistry, 10-13, Volume: 59, Issue:19	Design, Synthesis, and Biological Evaluation of First-in-Class Dual Acting Histone Deacetylases (HDACs) and Phosphodiesterase 5 (PDE5) Inhibitors for the Treatment of Alzheimer's Disease.
AID1550152	Drug level in BALB/c nu mouse xenografted with HEL cells at 100 mg/kg/day, ip administered for 5 days and measured after 0.5 to 4 hrs by LC-MS/MS analysis	2019	Journal of medicinal chemistry, 04-25, Volume: 62, Issue:8	Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies.
AID414726	Cytotoxicity against human K562 cells after 72 hrs by alamar-blue cell viability assay	2009	Journal of medicinal chemistry, Apr-23, Volume: 52, Issue:8	Design of chimeric histone deacetylase- and tyrosine kinase-inhibitors: a series of imatinib hybrides as potent inhibitors of wild-type and mutant BCR-ABL, PDGF-Rbeta, and histone deacetylases.
AID1597927	Inhibition of HDAC8 (unknown origin) using Boc-Lys(Ac)-AMC as substrate incubated for 60 mins by fluorescence assay	2019	Bioorganic & medicinal chemistry letters, 09-15, Volume: 29, Issue:18	Anti-tumor activity evaluation of novel tubulin and HDAC dual-targeting inhibitors.
AID1897368	Inhibition of FGFR1 (unknown origin) at 100 nM relative to control
AID593550	Inhibition of human HDAC5 using ArgHisLysLys(Ac) fluorogenic peptide as a substrate by fluorimetric assay	2011	Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7	Oxime amides as a novel zinc binding group in histone deacetylase inhibitors: synthesis, biological activity, and computational evaluation.
AID1848578	Inhibition of HDAC in human NCI-H522 cells assessed as increase in acetylation of H3 at 2.5 to 10 uM measured for 3 days by Western blot analysis	2022	Journal of medicinal chemistry, 11-10, Volume: 65, Issue:21	First-in-Class Dual Mechanism Ferroptosis-HDAC Inhibitor Hybrids.
AID1173497	Inhibition of HDAC6 in human HeLa cells assessed as reduction in K40 hyperacetylation of alpha-tubulin incubated for 6 hrs by immunofluorescence assay	2014	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 24, Issue:23	Histone deacetylase inhibitors derived from 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine and related heterocycles selective for the HDAC6 isoform.
AID1481748	Antiproliferative activity against human Ramos cells after 72 hrs by MTT assay	2017	Bioorganic & medicinal chemistry letters, 05-01, Volume: 27, Issue:9	Design and synthesis of novel 6-aryl substituted 4-anilinequinazoline derivatives as potential PI3Kδ inhibitors.
AID1753639	Inhibition of HDAC6 in human SH-SY5Y cells assessed as increase in acetylated alpha-tubulin levels at 1 uM incubated for 24 hrs by Western blot analysis	2021	European journal of medicinal chemistry, Jun-05, Volume: 218	Design, synthesis and biological evaluation of brain penetrant benzazepine-based histone deacetylase 6 inhibitors for alleviating stroke-induced brain infarction.
AID1848282	Antiproliferative activity against human HL-60 cells assessed as inhibition of cell proliferation incubated for 72 hrs by CCK8 assay	2022	Bioorganic & medicinal chemistry, Nov-15, Volume: 74	Design, synthesis and biological evaluation of novel pyrazinone derivatives as PI3K/HDAC dual inhibitors.
AID1622930	Inhibition of recombinant human full-length HDAC2 expressed in baculovirus expression system using 7-AMC-labelled HDAC substrate measured after 30 mins by fluorescence assay	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.
AID1753835	Inhibition of recombinant human HDAC1 using Z-(Ac)-Lys-AMC as substrate incubated for 40 mins by fluorescence based assay	2021	European journal of medicinal chemistry, Jun-05, Volume: 218	Identification of novel 1,3-diaryl-1,2,4-triazole-capped histone deacetylase 6 inhibitors with potential anti-gastric cancer activity.
AID1832692	Inhibition of full length human C-terminal His-tagged HDAC8 expressed in baculovirus infected Sf9 insect cells using Boc-Lys(acetyl)-AMC as fluorogenic substrate measured after 1 hr by flourescence plate reader method	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Cysteine derivatives as acetyl lysine mimics to inhibit zinc-dependent histone deacetylases for treating cancer.
AID1821264	Antiproliferative activity against human PC-3 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	2022	European journal of medicinal chemistry, Feb-05, Volume: 229	Discovery of phthalazino[1,2-b]-quinazolinone derivatives as multi-target HDAC inhibitors for the treatment of hepatocellular carcinoma via activating the p53 signal pathway.
AID1742180	Inhibition of recombinant human full-length C-terminal His-tagged HDAC8 expressed in baculovirus infected Sf9 insect cells using Ac-Leu-Gly-Lys(Tfa)-AMC as substrate measured after 30 mins by fluorescence assay	2020	European journal of medicinal chemistry, Nov-01, Volume: 205	Design, synthesis and biological evaluation of novel HDAC inhibitors with improved pharmacokinetic profile in breast cancer.
AID1394900	Inhibition of HDAC in human HL60 cells assessed as upregulation of acetylated histone H3 levels at 0.1 to 3 uM after 24 hrs by Western blot analysis	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	1-Aroylindoline-hydroxamic acids as anticancer agents, inhibitors of HSP90 and HDAC.
AID1737655	Cytotoxicity against human K562 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
AID1591716	Inhibition of human recombinant HDAC6 using fluorogenic HDAC substrate 3 pre-incubated for 30 mins followed by HDAC developer addition and measured after 15 mins by fluorogenic assay	2019	Bioorganic & medicinal chemistry, 08-01, Volume: 27, Issue:15	Structure-activity relationship study of thiazolyl-hydroxamate derivatives as selective histone deacetylase 6 inhibitors.
AID1633673	Immunomodulatory activity in mouse N9 cells assessed as reduction in LPS-induced iNOS expression at 5 to 25 uM incubated for 24 hrs by Western blot analysis	2019	ACS medicinal chemistry letters, Apr-11, Volume: 10, Issue:4	Novel Sustainable-by-Design HDAC Inhibitors for the Treatment of Alzheimer's Disease.
AID1897467	Inhibition of HDAC in human SNU-16 cells assessed as upregulation of acetyl-histone 3 level at 1.25 to 5 uM incubated for 36 hrs by Western blot analysis
AID438218	Selectivity ratio of IC50 for HDAC8 to IC50 for HDAC1/2 from human HeLa cells	2009	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23	Design and synthesis of novel histone deacetylase inhibitor derived from nuclear localization signal peptide.
AID297495	Cytotoxicity against human U87MG cells	2007	Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18	2-aroylindoles and 2-aroylbenzofurans with N-hydroxyacrylamide substructures as a novel series of rationally designed histone deacetylase inhibitors.
AID1282253	Cytotoxicity against human K562 cells after 72 hrs by MTT assay	2016	Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4	Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
AID717793	Inhibition of HDAC3 using Fluor-de-Lys as substrate assessed as remaining activity at 3.125 x 10'-8 M pretreated for 30 mins before substrate addition by fluorescence assay	2012	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23	The structural requirements of histone deacetylase inhibitors: suberoylanilide hydroxamic acid analogs modified at the C6 position.
AID1576465	Induction of apoptosis in human A549 cells assessed as early apoptotic cells at 5 uM after 72 hrs by Annexin V-phycoerythrin/7-AAD staining based flow cytometric analysis (Rvb = 1.13%)
AID1769657	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 assay	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	Discovery of 2,4-pyrimidinediamine derivatives as potent dual inhibitors of ALK and HDAC.
AID1129794	Induction of apoptosis in human Jurkat cells assessed as caspase 3/7 activation at 10 uM after 12 hrs by luminescence assay (Rvb = 69,935 +/- 7003.63 no unit)	2014	Bioorganic & medicinal chemistry, Apr-01, Volume: 22, Issue:7	Studies on the antiproliferative effects of tropolone derivatives in Jurkat T-lymphocyte cells.
AID1303560	Cytotoxicity against human K562 cells assessed as decrease in cell viability after 24 to 48 hrs by cell titer-glo luminescence assay	2016	Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13	Synergistic potentiation of (-)-lomaiviticin A cytotoxicity by the ATR inhibitor VE-821.
AID492804	Inhibition of human recombinant HDAC4 after 15 mins by fluorimetric assay	2010	Journal of medicinal chemistry, Jun-24, Volume: 53, Issue:12	Synthesis and biological characterization of the histone deacetylase inhibitor largazole and C7- modified analogues.
AID1401392	Inhibition of HDAC6 in human HeLa-S3 cell lysates assessed as remaining activity at 1 uM preincubated for 15 mins followed by HDAC-Glo substrate addition measured after 30 to 40 mins by fluorimetric method relative to control	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
AID1250658	Selectivity ratio of GI50 for human DU145 cells to GI50 for human HLF cells	2015	Journal of medicinal chemistry, Oct-08, Volume: 58, Issue:19	Discovery of Novel Class I Histone Deacetylase Inhibitors with Promising in Vitro and in Vivo Antitumor Activities.
AID1431814	Selectivity ratio of IC50 for human KDAC8 to IC50 for human KDAC1	2017	European journal of medicinal chemistry, Feb-15, Volume: 127	Design and synthesis of benzodiazepine analogs as isoform-selective human lysine deacetylase inhibitors.
AID1653145	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability	2019	European journal of medicinal chemistry, Mar-01, Volume: 165	Quinolone hybrids and their anti-cancer activities: An overview.
AID286791	Effect on alpha tubulin acetylation in U937 cells at 5 uM after 24 hrs by Western blot analysis	2007	Journal of medicinal chemistry, May-17, Volume: 50, Issue:10	Bispyridinium dienes: histone deacetylase inhibitors with selective activities.
AID1597929	Antiproliferative activity against human NCI-H226 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	2019	Bioorganic & medicinal chemistry letters, 09-15, Volume: 29, Issue:18	Anti-tumor activity evaluation of novel tubulin and HDAC dual-targeting inhibitors.
AID1433284	Cytotoxicity against human MCF10A cells assessed as decrease in cell viability at 0.5 to 5 uM after 24 hrs by MTT assay	2016	Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17	Synthesis and Antileukemic Activities of Piperlongumine and HDAC Inhibitor Hybrids against Acute Myeloid Leukemia Cells.
AID711155	Inhibition of HDAC6 by fluorometric assay	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	Rapid discovery of highly potent and selective inhibitors of histone deacetylase 8 using click chemistry to generate candidate libraries.
AID310180	Inhibition of HDAC in HeLa cell lysates	2007	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 17, Issue:22	Modification of cap group in delta-lactam-based histone deacetylase (HDAC) inhibitors.
AID1515983	Inhibition of HDAC in human MM1S cells assessed as increase in histone H3 acetylation at 100 nM measured after 6 hrs by Western blot analysis	2019	Journal of medicinal chemistry, 08-08, Volume: 62, Issue:15	Development of Multifunctional Histone Deacetylase 6 Degraders with Potent Antimyeloma Activity.
AID1676600	Binding affinity to zinc ion assessed as accounting ratio by measuring total compound detected/total compound adsorbed at 2.55 umol by immobilized metal-ion affinity chromatography	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
AID527206	Inhibition of ERK phosphorylation in human A549 at 5 uM after 24 hrs by Western blot analysis	2010	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22	Selenium-containing analogs of SAHA induce cytotoxicity in lung cancer cells.
AID1856994	Antiproliferative activity against human HL-60 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	2022	Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19	Histone Deacetylase and Enhancer of Zeste Homologue 2 Dual Inhibitors Presenting a Synergistic Effect for the Treatment of Hematological Malignancies.
AID329914	Inhibition of human HDAC1 in U937 cells by immunoprecipitation assay	2008	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8	Novel uracil-based 2-aminoanilide and 2-aminoanilide-like derivatives: histone deacetylase inhibition and in-cell activities.
AID465151	Inhibition of HDAC3 assessed as blockade of decorboxylation of carboxyfluorescein labeled acetylated peptide substrate after 17 hrs	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Synthesis and biological evaluation of triazol-4-ylphenyl-bearing histone deacetylase inhibitors as anticancer agents.
AID1723744	Selectivity index, ratio of IC50 for inhibition of human recombinant HDAC1 to IC50 for inhibition of human recombinant HDAC6	2020	Journal of medicinal chemistry, 09-24, Volume: 63, Issue:18	Multicomponent Synthesis, Binding Mode, and Structure-Activity Relationship of Selective Histone Deacetylase 6 (HDAC6) Inhibitors with Bifurcated Capping Groups.
AID1433239	Induction of apoptosis in p53 null human U937 cells at 2 uM after 24 hrs by annexin V-FITC/PI staining based flow cytometry	2016	Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17	Synthesis and Antileukemic Activities of Piperlongumine and HDAC Inhibitor Hybrids against Acute Myeloid Leukemia Cells.
AID1760292	Antiproliferative activity against human A549 cells	2020	European journal of medicinal chemistry, Dec-15, Volume: 208	Recent progress on HDAC inhibitors with dual targeting capabilities for cancer treatment.
AID1525779	Inhibition of HADC3 (unknown origin)	2020	Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1	Old but Gold: Tracking the New Guise of Histone Deacetylase 6 (HDAC6) Enzyme as a Biomarker and Therapeutic Target in Rare Diseases.
AID1421908	Cytotoxicity against human HepG2A16 cells expressing GFP-fused CD81 after 48 hrs by bioluminescence assay	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	One-pot, multi-component synthesis and structure-activity relationships of peptoid-based histone deacetylase (HDAC) inhibitors targeting malaria parasites.
AID708272	Growth inhibition of human SGC7901 cells incubated for 72 hrs by WST dye reduction assay	2012	Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20	Pharmacokinetic optimization of class-selective histone deacetylase inhibitors and identification of associated candidate predictive biomarkers of hepatocellular carcinoma tumor response.
AID1165106	Selectivity ratio of IC50 for axenic amastigote stage of Leishmania donovani to IC50 for amastigote stage of Leishmania donovani infected in human THP1 cells	2014	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 24, Issue:20	The antileishmanial activity of isoforms 6- and 8-selective histone deacetylase inhibitors.
AID619261	Antitumor activity against human HCT116 cells xenografted in athymic nu/nu Harlan mouse assessed as tumor growth inhibition at 300 mg/kg, po qd for 21 days measured on day 22	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile.
AID1312903	Toxicity in Balb/c nude mouse xenografted with human HCT116 cells assessed as body weight loss at 50 mg/kg, ip administered every 2 days for 8 days measured on day 8 post last dose	2016	Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11	Development of Purine-Based Hydroxamic Acid Derivatives: Potent Histone Deacetylase Inhibitors with Marked in Vitro and in Vivo Antitumor Activities.
AID1067343	Antiproliferative activity against human KG1 cells after 48 hrs by MTT assay	2014	Bioorganic & medicinal chemistry, Mar-01, Volume: 22, Issue:5	Design, synthesis and preliminary bioactivity studies of 1,2-dihydrobenzo[d]isothiazol-3-one-1,1-dioxide hydroxamic acid derivatives as novel histone deacetylase inhibitors.
AID1245689	Ratio of IC50 for Class 1 histone deacetylase in human PC3 cells to IC50 for Class 1 histone deacetylase isolated from human HeLa cell nuclear extracts	2015	Bioorganic & medicinal chemistry, Oct-01, Volume: 23, Issue:19	Development of N-hydroxybenzamide derivatives with indole-containing cap group as histone deacetylases inhibitors.
AID90211	Inhibitory activity against Histone deacetylase (HDAC) in K 562 erythroleukemia cells	2003	Bioorganic & medicinal chemistry letters, Nov-17, Volume: 13, Issue:22	Heterocyclic ketones as inhibitors of histone deacetylase.
AID1474166	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID652766	Induction of CFTR deltaF508 mutant protein expression in cystic fibrosis patient lung cells relative to control	2011	ACS medicinal chemistry letters, Jul-21, Volume: 2, Issue:9	Potential Agents for Treating Cystic Fibrosis: Cyclic Tetrapeptides that Restore Trafficking and Activity of ΔF508-CFTR.
AID1785333	Inhibition of HDAC2 (unknown origin) measured after 30 mins by fluorescence microplate reader assay
AID1816224	Induction of apoptosis in mouse 4T1 cells assessed as viable cells at 5 uM measured after 48 hrs in presence of ruxolitinib by annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 89.5%)
AID1437251	Inhibition of HDAC6 in mouse B16F10 cells assessed as accumulation of acetylated tubulin at 20 uM after 24 hrs by Western blot analysis	2017	Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4	Design, synthesis and evaluation of antiproliferative activity of melanoma-targeted histone deacetylase inhibitors.
AID1141769	Cytotoxicity against human MCF7 cells by MTT assay	2014	Journal of medicinal chemistry, May-22, Volume: 57, Issue:10	Azaindolylsulfonamides, with a more selective inhibitory effect on histone deacetylase 6 activity, exhibit antitumor activity in colorectal cancer HCT116 cells.
AID1915569	Cytotoxicity against human MCF7 cells	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors.
AID499802	Inhibition of HDAC6	2010	Journal of medicinal chemistry, Aug-26, Volume: 53, Issue:16	Non-peptide macrocyclic histone deacetylase inhibitors derived from tricyclic ketolide skeleton.
AID605394	Inhibition of human recombinant HDAC3 using fluor de Lys as substrate by fluorometric analysis	2010	Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24	Discovery of 2-(6-{[(6-fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a class I selective orally active histone deacetylase inhibitor.
AID675300	Antiproliferative activity against human HCT116 cells after 5 days by Alamar Blue assay	2012	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17	Set-up of a new series of HDAC inhibitors: the 5,11-dihydrodibenzo[b,e]azepin-6-ones as privileged structures.
AID1303686	Inhibition of HDAC3 in human Jurkat cells extract after 30 mins by immunoprecipitation assay	2016	Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13	Synergistic potentiation of (-)-lomaiviticin A cytotoxicity by the ATR inhibitor VE-821.
AID1826634	Synergistic antiproliferative effect on HEL cells assessed as combination index at 0.014 uM in presence of 3-Fluoro-10-hydroxy-14-methyl-8,13,13b,14-tetrahydro-7H-indolo[2',3':3,4]pyrido[2,1-b]quinazolin-5-one	2022	Journal of medicinal chemistry, 03-24, Volume: 65, Issue:6	Evodiamine-Inspired Topoisomerase-Histone Deacetylase Dual Inhibitors: Novel Orally Active Antitumor Agents for Leukemia Therapy.
AID780575	Inhibition of HDAC in human HeLa cell nuclear extracts using Color de LysTM after 30 mins	2013	Bioorganic & medicinal chemistry, Nov-15, Volume: 21, Issue:22	Development of novel ferulic acid derivatives as potent histone deacetylase inhibitors.
AID1119181	Cytotoxicity against human MCF7 cells after 96 hrs by MTA reduction assay	2012	MedChemComm, , Volume: 3, Issue:1	Polyamine-based small molecule epigenetic modulators.
AID358681	Increase in REST/NRSF mRNA expression in rat ST14A cells after 72 hrs by RT-PCR relative to control	2007	The Journal of biological chemistry, Aug-24, Volume: 282, Issue:34	Loss of huntingtin function complemented by small molecules acting as repressor element 1/neuron restrictive silencer element silencer modulators.
AID609493	Inhibition of human ERG by automated patch clamp assay	2011	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16	The design, synthesis and structure-activity relationships of novel isoindoline-based histone deacetylase inhibitors.
AID637890	Inhibition of recombinant human HDAC7 using Boc-L-Lys(trifluoroacetyl)-MCA as substrate by fluorogenic enzymatic assay	2012	Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2	Synthesis and biochemical analysis of 2,2,3,3,4,4,5,5,6,6,7,7-dodecafluoro-N-hydroxy-octanediamides as inhibitors of human histone deacetylases.
AID1630595	Inhibition of HDAC in human MOLT4 cells assessed as H3K23 acetylation at 2.5 uM after after 24 hrs by Western blot analysis	2016	Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21	Synthesis and biological evaluation of santacruzamate A analogues for anti-proliferative and immunomodulatory activity.
AID699752	Inhibition of SIRT5	2012	Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11	Substrates for efficient fluorometric screening employing the NAD-dependent sirtuin 5 lysine deacylase (KDAC) enzyme.
AID1250666	Inhibition of HDAC6 in human U937 cells assessed as reduction of alpha-tubilin acetylation at 5 nM to 5 uM after 24 hrs by Western blot analysis	2015	Journal of medicinal chemistry, Oct-08, Volume: 58, Issue:19	Discovery of Novel Class I Histone Deacetylase Inhibitors with Promising in Vitro and in Vivo Antitumor Activities.
AID1655786	Inhibition of human EZH2 using core histone as substrate incubated for 1 hr by fluorescence based assay	2020	ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5	Design of First-in-Class Dual EZH2/HDAC Inhibitor: Biochemical Activity and Biological Evaluation in Cancer Cells.
AID1437244	Cytotoxicity against human A375 cells assessed as growth inhibition after 72 hrs by MTS assay	2017	Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4	Design, synthesis and evaluation of antiproliferative activity of melanoma-targeted histone deacetylase inhibitors.
AID1476166	Cytotoxicity against human AC10 cells assessed as cell viability after 24 hrs by CellTiter-Glo assay	2017	Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20	Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat.
AID1246521	Cytotoxicity against human U937 cells assessed as reduction in cell viability	2015	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 25, Issue:19	Discovery of 1-hydroxypyridine-2-thiones as selective histone deacetylase inhibitors and their potential application for treating leukemia.
AID1462223	Antiproliferative activity against human OCI-AML3 cells after 72 hrs by MTT assay	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Structure-based design, synthesis and in vitro antiproliferative effects studies of novel dual BRD4/HDAC inhibitors.
AID1541464	Inhibition of class 1 HDAC in human Cal27CisR cells assessed as potentiation of cisplatin-induced cytotoxicity by measuring fold reduction in cisplatin IC50 at 0.5 uM preincubated for 48 hrs followed by cisplatin addition and measured after 72 hrs by MTT	2019	Journal of medicinal chemistry, 12-26, Volume: 62, Issue:24	Synthesis of Peptoid-Based Class I-Selective Histone Deacetylase Inhibitors with Chemosensitizing Properties.
AID303346	Growth inhibition of MCF7 cells	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	The first biologically active synthetic analogues of FK228, the depsipeptide histone deacetylase inhibitor.
AID90199	Experimental anti-HDAC (anti-histone deacetylase) activity of the compound	2001	Journal of medicinal chemistry, Jun-21, Volume: 44, Issue:13	3-(4-aroyl-1H-pyrrol-2-yl)-N-hydroxy-2-propenamides, a new class of synthetic histone deacetylase inhibitors.
AID760506	Inhibition of HDAC7 (unknown origin) using Boc-Lys(trifluoroacetyl)-AMC as substrate by fluorescence assay	2013	ACS medicinal chemistry letters, Aug-08, Volume: 4, Issue:8	Development of a chimeric c-Src kinase and HDAC inhibitor.
AID1702153	Metabolic stability in mouse liver microsomes assessed as half-life at 5 uM incubated upto 60 mins in presence of beta-NADPH by LC-MS analysis	2018	Journal of medicinal chemistry, 02-22, Volume: 61, Issue:4	Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma.
AID748101	Inhibition of HDAC6 in human HeLa cells assessed as increase in alpha tubulin acetylation at 10 uM after 48 hrs by Western blotting analysis	2013	Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11	Discovery of the first histone deacetylase 6/8 dual inhibitors.
AID1337278	Antiproliferative activity against human HL60 cells	2016	Journal of medicinal chemistry, Sep-22, Volume: 59, Issue:18	Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines.
AID1452276	Antiproliferative activity against human U937 cells after 72 hrs by MTT assay	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	Design, synthesis and anticancer potential of NSC-319745 hydroxamic acid derivatives as DNMT and HDAC inhibitors.
AID1901154	Inhibition of HDAC8 (unknown origin) using FAM-RHKK(Ac)-NH2/FAM-RHKK(trifluoroacetyl)-NH2 as substrate preincubated for 15 mins followed by substrate addition and measured after 3 hrs by microfluidic chip based fluorescence assay	2022	Bioorganic & medicinal chemistry, 02-15, Volume: 56	Synthesis and biological evaluation of aminobenzamides containing purine moiety as class I histone deacetylases inhibitors.
AID1730854	Inhibition of HDAC6 (unknown origin)	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Design, synthesis and evaluation of novel ErbB/HDAC multitargeted inhibitors with selectivity in EGFR
AID663332	Growth inhibition of human A549 cells after 72 hrs by MTT assay	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Discovery and extensive in vitro evaluations of NK-HDAC-1: a chiral histone deacetylase inhibitor as a promising lead.
AID90677	Binding affinity towards HDAC1 (Histone deacetylase 1) in mouse A20 cells, expressed as binding constant (pKi)	2002	Journal of medicinal chemistry, Apr-25, Volume: 45, Issue:9	Binding mode analysis of 3-(4-benzoyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-propenamide: a new synthetic histone deacetylase inhibitor inducing histone hyperacetylation, growth inhibition, and terminal cell differentiation.
AID1478592	Inhibition of HDAC6 (unknown origin) using substrate after 30 mins by fluorometric analysis	2017	European journal of medicinal chemistry, Jun-16, Volume: 133	Design, synthesis and biological evaluation of quinoline derivatives as HDAC class I inhibitors.
AID1688039	Induction of apoptosis in human HL-60 cells assessed as early apoptotic cells at 2 uM measured after 24 hrs by Annexin-V/FITC and propidium iodide staining based flow cytometry (Rvb = 2.46 %)	2020	European journal of medicinal chemistry, Feb-15, Volume: 188	A 18β-glycyrrhetinic acid conjugate with Vorinostat degrades HDAC3 and HDAC6 with improved antitumor effects.
AID1129781	Cell cycle arrest in human Jurkat cells assessed as accumulation at G1-phase at 10 uM after 24 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 60.90%)	2014	Bioorganic & medicinal chemistry, Apr-01, Volume: 22, Issue:7	Studies on the antiproliferative effects of tropolone derivatives in Jurkat T-lymphocyte cells.
AID1808547	Inhibition of recombinant human full length C-terminal His- tagged HDAC2 (1 to 488 residues) expressed in Sf9 insect cells using fluorometric substrate measured after 60 mins by FRET assay	2021	Journal of medicinal chemistry, 04-08, Volume: 64, Issue:7	Structure-Based Design of a Selective Class I Histone Deacetylase (HDAC) Near-Infrared (NIR) Probe for Epigenetic Regulation Detection in Triple-Negative Breast Cancer (TNBC).
AID1845459	Inhibition of HDAC1 (unknown origin)	2021	Journal of medicinal chemistry, 01-14, Volume: 64, Issue:1	Glycogen Synthase Kinase 3β: A New Gold Rush in Anti-Alzheimer's Disease Multitarget Drug Discovery?
AID1515927	Antitumor activity against human HGC27 cells xenografted in athymic nude BALB/c mouse assessed as tumor growth inhibition at 100 mpk, po measured 2 times every week	2019	Journal of medicinal chemistry, 08-08, Volume: 62, Issue:15	Design, Synthesis, and Biological Evaluation of 4-Methyl Quinazoline Derivatives as Anticancer Agents Simultaneously Targeting Phosphoinositide 3-Kinases and Histone Deacetylases.
AID1542188	Inhibition of HDAC10 (unknown origin)	2019	Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7	Kinase and Histone Deacetylase Hybrid Inhibitors for Cancer Therapy.
AID1482116	Cytotoxicity against human HL60 cells assessed as growth inhibition after 48 hrs by MTT assay	2017	Journal of medicinal chemistry, 04-27, Volume: 60, Issue:8	Exploring Derivatives of Quinazoline Alkaloid l-Vasicine as Cap Groups in the Design and Biological Mechanistic Evaluation of Novel Antitumor Histone Deacetylase Inhibitors.
AID1702049	Antiproliferative activity against human Hep3B cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay	2018	Journal of medicinal chemistry, 02-22, Volume: 61, Issue:4	Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma.
AID1454052	Growth inhibition of human K562 cells after 3 days by counting method	2017	Bioorganic & medicinal chemistry, 07-15, Volume: 25, Issue:14	Synthesis and evaluation of novel dual BRD4/HDAC inhibitors.
AID586615	Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 assessed as inhibition of [3H]hypoxanthine incorporation	2011	Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3	Ex vivo activity of histone deacetylase inhibitors against multidrug-resistant clinical isolates of Plasmodium falciparum and P. vivax.
AID1415662	Induction of apoptosis in human HepG2 cells at 5 uM after 48 hrs by Annexin-V FITC/propidium iodide staining based flow cytometry relative to control	2017	MedChemComm, Jun-01, Volume: 8, Issue:6	Development of novel β-carboline-based hydroxamate derivatives as HDAC inhibitors with DNA damage and apoptosis inducing abilities.
AID1888589	Antiproliferative activity against human HCT-116 cells measured after 72 hrs by MTT assay
AID1897374	Inhibition of HDAC8 (unknown origin)
AID1497926	Induction of CRBN ubiquitin ligase-mediated HDAC4 degradation in human MCF7 cells assessed as decrease in HDAC4 levels at 10 uM after 12 hrs by immunoblotting analysis	2018	Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14	Development of the first small molecule histone deacetylase 6 (HDAC6) degraders.
AID1897366	Inhibition of HDAC6 (unknown origin)
AID1760296	Antiproliferative activity against human MDA-MB-468 cells incubated for 72 hrs by MTT assay	2020	European journal of medicinal chemistry, Dec-15, Volume: 208	Recent progress on HDAC inhibitors with dual targeting capabilities for cancer treatment.
AID1390023	Antiproliferative activity against human HEL cells after 48 hrs by MTT assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Structure optimization and preliminary bioactivity evaluation of N-hydroxybenzamide-based HDAC inhibitors with Y-shaped cap.
AID1848612	Cytotoxicity against human SNB-75 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay	2022	Journal of medicinal chemistry, 11-10, Volume: 65, Issue:21	First-in-Class Dual Mechanism Ferroptosis-HDAC Inhibitor Hybrids.
AID1898916	Inhibition of HDAC6 in human NCI-H460 cells at 7.4 uM assessed as increase in alpha-tubulin acetylation measured by Western blot analysis	2022	European journal of medicinal chemistry, Jan-15, Volume: 228	Antitumor activity of novel POLA1-HDAC11 dual inhibitors.
AID1129771	Inhibition of HDAC in human Jurkat cells assessed as increase in H3K9 acetylation at 10 uM after 12 hrs by FACS flow cytometric analysis relative to control	2014	Bioorganic & medicinal chemistry, Apr-01, Volume: 22, Issue:7	Studies on the antiproliferative effects of tropolone derivatives in Jurkat T-lymphocyte cells.
AID1578895	Inhibition of HDAC in human Bel7402 cells assessed as increase in acetylated histone h3 expression at 5 uM incubated for 72 hrs by Western blot analysis	2019	Journal of natural products, 06-28, Volume: 82, Issue:6	Hydroxamic Acid Derivatives of β-Carboline/Hydroxycinnamic Acid Hybrids Inducing Apoptosis and Autophagy through the PI3K/Akt/mTOR Pathways.
AID1356296	Inhibition of HDAC derived from human HeLa nuclear extract at 1 uM by fluorimetric assay relative to control
AID767621	Cytotoxicity against human HT1080 cells	2013	Bioorganic & medicinal chemistry, Oct-01, Volume: 21, Issue:19	Inhibitory effects of p-dodecylaminophenol on the invasiveness of human fibrosarcoma cell line HT1080.
AID1384228	Inhibition of HDAC6 in human SH-SY5Y cells assessed as induction of tubulin K-40 acetylation level at 1000 nM after 2 hrs by Western blot analysis relative to control	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease.
AID1321703	Inhibition of HDAC6 (unknown origin)	2016	Journal of medicinal chemistry, 10-13, Volume: 59, Issue:19	Design, Synthesis, and Biological Evaluation of First-in-Class Dual Acting Histone Deacetylases (HDACs) and Phosphodiesterase 5 (PDE5) Inhibitors for the Treatment of Alzheimer's Disease.
AID1785332	Inhibition of HDAC1 (unknown origin) measured after 30 mins by fluorescence microplate reader assay
AID1164030	Inhibition of human recombinant HDAC7 after 60 mins by fluorimetric assay	2014	European journal of medicinal chemistry, Oct-30, Volume: 86	Design, synthesis, and biological evaluation of 1, 3-disubstituted-pyrazole derivatives as new class I and IIb histone deacetylase inhibitors.
AID1181308	Inhibition of HDAC1 in human U937 cells assessed as increase in p21WAF1/CIP1 level at 5 uM by Western blotting method	2014	Journal of medicinal chemistry, Jul-24, Volume: 57, Issue:14	1,3,4-Oxadiazole-containing histone deacetylase inhibitors: anticancer activities in cancer cells.
AID546563	Cytotoxicity against human SKBR3 cells overexpressing HER2 by resazurin dye reduction assay	2010	Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24	Novel chimeric histone deacetylase inhibitors: a series of lapatinib hybrides as potent inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and histone deacetylase activity.
AID524999	Inhibition of HDAC6 by in vitro deacetylation assay	2010	Nature chemical biology, Jan, Volume: 6, Issue:1	Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.
AID628210	Antiproliferative activity against human HeLa cells after 48 hrs by XTT assay	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Design, synthesis, docking, and biological evaluation of novel diazide-containing isoxazole- and pyrazole-based histone deacetylase probes.
AID1462226	Inhibition of BRD4/HDAC1 in human OCI-AML3 cells assessed as reduction in myc expression levels at 1 uM after 24 hrs by Western blot analysis	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Structure-based design, synthesis and in vitro antiproliferative effects studies of novel dual BRD4/HDAC inhibitors.
AID1763815	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	2021	Bioorganic & medicinal chemistry, 06-15, Volume: 40	Novel hybrid conjugates with dual estrogen receptor α degradation and histone deacetylase inhibitory activities for breast cancer therapy.
AID274064	Steady state volume of distribution (Vdss) after i.v. dosing at 1 mg kg-1	2007	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2	Identification and optimisation of a series of substituted 5-(1H-pyrazol-3-yl)-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.
AID1398801	Cytotoxicity against ER positive human MCF7 cells treated every 2 days for 4 days measured post last dose by CellTiter-Glo luminescence assay	2018	Bioorganic & medicinal chemistry, 08-15, Volume: 26, Issue:15	Incorporation of histone deacetylase inhibitory activity into the core of tamoxifen - A new hybrid design paradigm.
AID1275078	Inhibition of recombinant human HDAC6	2016	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2	Novel thiol-based histone deacetylase inhibitors bearing 3-phenyl-1H-pyrazole-5-carboxamide scaffold as surface recognition motif: Design, synthesis and SAR study.
AID465156	Growth inhibition of human HUPT3 cells after 72 hrs by MTS assay	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Synthesis and biological evaluation of triazol-4-ylphenyl-bearing histone deacetylase inhibitors as anticancer agents.
AID499801	Selectivity ratio IC50 for HDAC8 to IC50 for HDAC in human HeLa cells nuclear extract	2010	Journal of medicinal chemistry, Aug-26, Volume: 53, Issue:16	Non-peptide macrocyclic histone deacetylase inhibitors derived from tricyclic ketolide skeleton.
AID1630602	Inhibition of recombinant full length N-terminal GST-tagged human HDAC6 expressed in baculovirus expression system using fluorogenic substrate at 10 uM by fluorescence assay	2016	Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21	Synthesis and biological evaluation of santacruzamate A analogues for anti-proliferative and immunomodulatory activity.
AID663400	Growth inhibition of human MCF7 cells after 48 hrs by MTT assay	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Discovery and extensive in vitro evaluations of NK-HDAC-1: a chiral histone deacetylase inhibitor as a promising lead.
AID747255	Growth inhibition of HUVEC by MTT assay	2013	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 23, Issue:11	Design, synthesis, and biological evaluation of novel histone deacetylase 1 inhibitors through click chemistry.
AID1541456	Inhibition of recombinant human N-terminal GST-fused and C-terminal His-tagged HDAC4 (627 to 1084 residues) expressed in baculovirus infected insect cells using Boc-Lys(TFa)-AMC as substrate preincubated for 5 mins followed by substrate addition and measu	2019	Journal of medicinal chemistry, 12-26, Volume: 62, Issue:24	Synthesis of Peptoid-Based Class I-Selective Histone Deacetylase Inhibitors with Chemosensitizing Properties.
AID1566809	Inhibition of recombinant C-terminal His-tagged human HDAC9 (604 to 1066 residues) expressed in baculovirus infected Sf9 cells using Ac-peptide-AMC as substrate after 1 hr by fluorescence assay	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Discovery of 1,2,4-oxadiazole-Containing hydroxamic acid derivatives as histone deacetylase inhibitors potential application in cancer therapy.
AID670014	Selectivity index, ratio of IC50 for human recombinant HDAC6 to IC50 for human recombinant HDAC1	2012	Journal of medicinal chemistry, Feb-23, Volume: 55, Issue:4	Defining the mechanism of action and enzymatic selectivity of psammaplin A against its epigenetic targets.
AID1202583	Inhibition of His-tagged HDAC1 (unknown origin) expressed in Escherichia coli BL21(DE3) after 60 mins by MALDI mass spectrometry	2015	European journal of medicinal chemistry, , Volume: 96	Design and structure activity relationship of tumor-homing histone deacetylase inhibitors conjugated to folic and pteroic acids.
AID1282250	Cytotoxicity against human U266 cells after 72 hrs by MTT assay	2016	Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4	Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
AID748108	Inhibition of HDAC7 (unknown origin) after 60 mins by fluorescence assay	2013	Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11	Discovery of the first histone deacetylase 6/8 dual inhibitors.
AID1162219	Cell cycle arrest in human HL60 cells assessed as accumulation at S phase at 1 uM by propidium iodide staining-based flow cytometry (Rvb = 17.3%)	2014	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 24, Issue:19	Design, synthesis and biological evaluation of β-boswellic acid based HDAC inhibitors as inducers of cancer cell death.
AID525035	Inhibition of CFTR transcription assessed as decrease of CFTR protein level at 50 uM by immunoblot method	2010	Nature chemical biology, Jan, Volume: 6, Issue:1	Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.
AID764217	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	2013	Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17	Novel N-hydroxyfurylacrylamide-based histone deacetylase (HDAC) inhibitors with branched CAP group (Part 2).
AID1469396	Induction of apoptosis in human Hep3B cells assessed as late apoptotic cells at 10 uM after 48 hrs by annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 5.25%)	2018	Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7	Discovery of N1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7 H-pyrrolo[2,3- d]pyrimidin-2-yl)amino)phenyl)- N8-hydroxyoctanediamide as a Novel Inhibitor Targeting Cyclin-dependent Kinase 4/9 (CDK4/9) and Histone Deacetlyase1 (HDAC1) against Malignant Cancer
AID1487094	Inhibition of HDAC3 (unknown origin)	2017	Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15	Cyclic tetrapeptide HDAC inhibitors as potential therapeutics for spinal muscular atrophy: Screening with iPSC-derived neuronal cells.
AID1753636	Inhibition of human HDAC1 preincubated for 15 mins followed by substrate addition by fluorescence-based assay	2021	European journal of medicinal chemistry, Jun-05, Volume: 218	Design, synthesis and biological evaluation of brain penetrant benzazepine-based histone deacetylase 6 inhibitors for alleviating stroke-induced brain infarction.
AID1771467	Inhibition of HDAC (unknown origin)	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Discovery of novel tubulin/HDAC dual-targeting inhibitors with strong antitumor and antiangiogenic potency.
AID1630629	Inhibition of HDAC in human MOLT4 cells assessed as H4K12 acetylation at 2.5 uM after after 24 hrs by Western blot analysis	2016	Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21	Synthesis and biological evaluation of santacruzamate A analogues for anti-proliferative and immunomodulatory activity.
AID1055353	Inhibition of human recombinant HDAC6 after 30 mins by fluorescence assay	2013	Journal of natural products, Nov-22, Volume: 76, Issue:11	Santacruzamate A, a potent and selective histone deacetylase inhibitor from the Panamanian marine cyanobacterium cf. Symploca sp.
AID1202595	Cytotoxicity against human A549 cells at 100 uM after 72 hrs by MTS assay	2015	European journal of medicinal chemistry, , Volume: 96	Design and structure activity relationship of tumor-homing histone deacetylase inhibitors conjugated to folic and pteroic acids.
AID1731759	Inhibition of recombinant human HDAC1 using Ac-LGK(Ac)-AMC as substrate preincubated for 30 mins followed by substrate addition and measured after 90 mins by fluorescence based assay	2021	Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4	HDAC7 Inhibition by Phenacetyl and Phenylbenzoyl Hydroxamates.
AID1614134	Inhibition of recombinant full length N-terminal GST-tagged human HDAC5 expressed in baculovirus expression system using Ac-peptide-AMC as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by fluorescence assay
AID1652196	Antiproliferative activity against human MCF7 cells incubated for 96 hrs by resazurin assay	2020	ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5	New Dual CK2/HDAC1 Inhibitors with Nanomolar Inhibitory Activity against Both Enzymes.
AID1763818	Selectivity index, ratio of IC50 for African green monkey Vero cells to IC50 for human MCF7 cells	2021	Bioorganic & medicinal chemistry, 06-15, Volume: 40	Novel hybrid conjugates with dual estrogen receptor α degradation and histone deacetylase inhibitory activities for breast cancer therapy.
AID1622939	Inhibition of recombinant full-length human HDAC11 expressed in baculovirus infected Sf9 insect cells using 7-AMC-labelled HDAC substrate measured after 30 mins by fluorescence assay	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.
AID1266856	Antitumor activity against human HCT116 cells xenografted in BALB/c mouse assessed as tumor weight at 90 mg/kg, po measured twice per week over 22 days (Rvb = 1.38 +/- 0.13 g)	2015	Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23	Novel β-Carboline/Hydroxamic Acid Hybrids Targeting Both Histone Deacetylase and DNA Display High Anticancer Activity via Regulation of the p53 Signaling Pathway.
AID1127332	Inhibition of human HDAC11 using fluorogenic tetrapeptide RHKKAc as substrate	2014	European journal of medicinal chemistry, May-22, Volume: 79	Influence of the adamantyl moiety on the activity of biphenylacrylohydroxamic acid-based HDAC inhibitors.
AID732872	Inhibition of HDAC6 in human MDA-MB-231 cells assessed as acetylation levels of tubulin at 1 uM after 3 to 24 hrs by Western blot analysis	2013	ACS medicinal chemistry letters, Feb-14, Volume: 4, Issue:2	Development of
AID1433296	Induction of DNA damage in p53 null human U937 cells assessed as increase in gammaH2AX expression level by measuring ratio of gammaH2AX to beta-actin level at 2 uM after 24 hrs by Western blot analysis relative to control	2016	Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17	Synthesis and Antileukemic Activities of Piperlongumine and HDAC Inhibitor Hybrids against Acute Myeloid Leukemia Cells.
AID659635	Antiproliferative activity against human SKMES1 cells after 72 hrs by MTS assay	2012	Journal of medicinal chemistry, Feb-23, Volume: 55, Issue:4	Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors.
AID1398805	Cytotoxicity against ER negative human MCF10A cells treated every 2 days for 4 days measured post last dose by CellTiter-Glo luminescence assay	2018	Bioorganic & medicinal chemistry, 08-15, Volume: 26, Issue:15	Incorporation of histone deacetylase inhibitory activity into the core of tamoxifen - A new hybrid design paradigm.
AID1623523	Inhibition of human recombinant HDAC1 using fluorogenic HDAC substrate-3 by fluorescence assay	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	A novel class of anthraquinone-based HDAC6 inhibitors.
AID476650	Toxicity in FVB mouse assessed as mortality at 50 mg/kg, po administered 5 times per week for 2 weeks measured up to 1 month	2010	Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8	Modified cap group suberoylanilide hydroxamic acid histone deacetylase inhibitor derivatives reveal improved selective antileukemic activity.
AID1864228	Inhibition of full length recombinant N-terminal GST-tagged human HDAC11 expressed in baculovirus infected Sf9 insect cells incubated for 50 mins by Glo- luminescence assay	2022	Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18	Discovery of a Novel G-Quadruplex and Histone Deacetylase (HDAC) Dual-Targeting Agent for the Treatment of Triple-Negative Breast Cancer.
AID1348916	Inhibition of full length recombinant human HDAC2 expressed in baculovirus infected Sf9 insect cells using KI 177 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by fluorescence assay	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Discovery of aliphatic-chain hydroxamates containing indole derivatives with potent class I histone deacetylase inhibitory activities.
AID1816687	Inhibition of HDAC1 (unknown origin) using Ac-peptide as substrate preincubated for 15 mins followed by substrate addition by fluorescence assay	2021	European journal of medicinal chemistry, Aug-05, Volume: 220	Design, synthesis, and biological evaluation of novel dual inhibitors targeting lysine specific demethylase 1 (LSD1) and histone deacetylases (HDAC) for treatment of gastric cancer.
AID1486301	Antiproliferative activity against human U937 cells after 72 hrs by MTT assay	2017	Bioorganic & medicinal chemistry, 08-01, Volume: 25, Issue:15	Olaparib hydroxamic acid derivatives as dual PARP and HDAC inhibitors for cancer therapy.
AID274031	Inhibition of MCF7 cell proliferation (mean of two experiments)	2007	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2	Identification and optimisation of a series of substituted 5-pyridin-2-yl-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.
AID1245685	Cytotoxicity against human U266 cells assessed as growth inhibition after 48 hrs by MTT assay	2015	Bioorganic & medicinal chemistry, Oct-01, Volume: 23, Issue:19	Development of N-hydroxybenzamide derivatives with indole-containing cap group as histone deacetylases inhibitors.
AID476649	Toxicity in FVB mouse assessed as mortality at 50 mg/kg, po administered 5 times per week for 2 weeks	2010	Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8	Modified cap group suberoylanilide hydroxamic acid histone deacetylase inhibitor derivatives reveal improved selective antileukemic activity.
AID1128559	Inhibition of human HDAC-6 using RHKK(Ac) as substrate	2014	European journal of medicinal chemistry, Apr-09, Volume: 76	4,5,6,7-Tetrahydro-isoxazolo-[4,5-c]-pyridines as a new class of cytotoxic Hsp90 inhibitors.
AID1233269	Inhibition of human recombinant HDAC6 after 15 mins by fluorogenic assay	2015	Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11	Novel Bioactive Hybrid Compound Dual Targeting Estrogen Receptor and Histone Deacetylase for the Treatment of Breast Cancer.
AID1845908	Reversal of HIV-1 latency infected in GFP-fused human J-Lat C11 cells assessed as increase in GFP expression at 2 uM incubated for 3 hrs by flow cytometry	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	HIV latency reversal agents: A potential path for functional cure?
AID1848621	Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay	2022	Journal of medicinal chemistry, 11-10, Volume: 65, Issue:21	First-in-Class Dual Mechanism Ferroptosis-HDAC Inhibitor Hybrids.
AID732443	Inhibition of human HCT116 cell proliferation after 48 hrs by MTT assay	2013	ACS medicinal chemistry letters, Feb-14, Volume: 4, Issue:2	Development of
AID1239057	Inhibition of HDAC in human RPMI8226 cells assessed as upregulation of acetylated histone H3 level at 1 uM after 24 hrs by Western blot analysis	2015	Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17	Design, synthesis and biological evaluation of isoquinoline-based derivatives as novel histone deacetylase inhibitors.
AID420636	Inhibition of HDAC in human IGROV1 cells assessed as p53 acetylation at IC50 after 24 hrs by Western blot	2009	European journal of medicinal chemistry, May, Volume: 44, Issue:5	Design, synthesis, and evaluation of biphenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors.
AID392399	Inhibition of human recombinant N-terminal histidine-tagged HDAC6 expressed in baculovirus by fluorimetry	2009	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 19, Issue:2	Sulfamides as novel histone deacetylase inhibitors.
AID1702133	Inhibition of HDAC6 in human HuH-7 cells assessed as alpha-tubulin Lys40 acetylation level at 10 uM incubated for 4 hrs including last 12 mins stimulation with 20 ng/ml growth factor VEGF by Western blot analysis (Rvb = 3.8 %)	2018	Journal of medicinal chemistry, 02-22, Volume: 61, Issue:4	Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma.
AID1864222	Cytotoxicity against human SUM159PT cells assessed as reduction in cell viability measured after 48 hrs	2022	Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18	Discovery of a Novel G-Quadruplex and Histone Deacetylase (HDAC) Dual-Targeting Agent for the Treatment of Triple-Negative Breast Cancer.
AID1466402	Antitumor activity against human HCT116 cells xenografted in BALB/c nude mouse assessed as relative tumor increment ratio at 100 mg/kg/day administered via oral gavage for 16 days measured every 3 days	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	Selective HDAC inhibitors with potent oral activity against leukemia and colorectal cancer: Design, structure-activity relationship and anti-tumor activity study.
AID1848588	Induction of ferroptosis in human NCI-H522 cells assessed as viability at 5 uM incubated after 60 hrs by microscopic analysis	2022	Journal of medicinal chemistry, 11-10, Volume: 65, Issue:21	First-in-Class Dual Mechanism Ferroptosis-HDAC Inhibitor Hybrids.
AID1659652	Inhibition of HDAC8 (unknown origin)	2020	Bioorganic & medicinal chemistry letters, 06-01, Volume: 30, Issue:11	Environment-sensitive fluorescent inhibitors of histone deacetylase.
AID652747	Inhibition of recombinant human HDAC3-NCoR2 using Fluor-de-Lys as substrate after 30 mins by spectrophotometry	2011	ACS medicinal chemistry letters, Jul-21, Volume: 2, Issue:9	Potential Agents for Treating Cystic Fibrosis: Cyclic Tetrapeptides that Restore Trafficking and Activity of ΔF508-CFTR.
AID1808550	Inhibition of recombinant human full length N-terminal GST-tagged HDAC5 expressed in baculovirus infected Sf9 insect cells using fluorogenic substrate measured after 60 mins by FRET assay	2021	Journal of medicinal chemistry, 04-08, Volume: 64, Issue:7	Structure-Based Design of a Selective Class I Histone Deacetylase (HDAC) Near-Infrared (NIR) Probe for Epigenetic Regulation Detection in Triple-Negative Breast Cancer (TNBC).
AID1181310	Induction of cell cycle arrest in human U937 cells assessed as accumulation at S phase at 5 uM after 48 hrs by propidium iodide staining based FACS method	2014	Journal of medicinal chemistry, Jul-24, Volume: 57, Issue:14	1,3,4-Oxadiazole-containing histone deacetylase inhibitors: anticancer activities in cancer cells.
AID404444	Cytotoxicity against human Panc 04.03 cells after 72 hrs by MTT assay	2008	Journal of medicinal chemistry, Jun-26, Volume: 51, Issue:12	A series of potent and selective, triazolylphenyl-based histone deacetylases inhibitors with activity against pancreatic cancer cells and Plasmodium falciparum.
AID1865273	Induction of cell cycle arrest in human MV4-11 cells assessed as accumulation at G1 phase at 2.5 uM measured after 24 hrs by flow cytometry	2022	Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18	Discovery of Novel Src Homology-2 Domain-Containing Phosphatase 2 and Histone Deacetylase Dual Inhibitors with Potent Antitumor Efficacy and Enhanced Antitumor Immunity.
AID1225982	Inhibition of recombinant N-terminal GST-tagged full length human HDAC6 expressed in baculovirus infected insect Sf9 cells using fluorogenic HDAC substrate 3 after 30 mins by fluorescence assay	2015	ACS medicinal chemistry letters, Mar-12, Volume: 6, Issue:3	Discovery of Novel Multiacting Topoisomerase I/II and Histone Deacetylase Inhibitors.
AID1627671	Inhibition of HDAC in human HL60 cells assessed as upregulation of alphatubulin acetylation levels at 2 uM after 18 hrs by SDS-PAGE analysis	2016	Bioorganic & medicinal chemistry letters, 09-01, Volume: 26, Issue:17	Synthesis, biological evaluation and molecular modeling studies of psammaplin A and its analogs as potent histone deacetylases inhibitors and cytotoxic agents.
AID1566821	Antiproliferative activity against human RPMI8226 cells after 72 hrs by MTT assay	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Discovery of 1,2,4-oxadiazole-Containing hydroxamic acid derivatives as histone deacetylase inhibitors potential application in cancer therapy.
AID1876461	Inhibition of HDAC1 (unknown origin) using Boc-Lys(Ac)-AMC as substrate incubated for 60 mins by fluorescence plate reader assay	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	Design, synthesis, and biological evaluation of indole-based hydroxamic acid derivatives as histone deacetylase inhibitors.
AID1816685	Inhibition of recombinant LSD1 (157 to 852 residues) (unknown origin) expressed in Escherichia coli BL21 (DE) using H3K4me2 as substrate by amplex red assay	2021	European journal of medicinal chemistry, Aug-05, Volume: 220	Design, synthesis, and biological evaluation of novel dual inhibitors targeting lysine specific demethylase 1 (LSD1) and histone deacetylases (HDAC) for treatment of gastric cancer.
AID545856	Antimalarial activity against Plasmodium falciparum Dd2 assessed as parasite growth inhibition after 48 hrs by standard growth inhibition assay	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Novel inhibitor of Plasmodium histone deacetylase that cures P. berghei-infected mice.
AID1293559	Antiproliferative activity against human LoVo/DX cells assessed as reduction in cell number after 72 hrs by cell counter analysis	2016	European journal of medicinal chemistry, Apr-13, Volume: 112	Biphenyl-4-yl-acrylohydroxamic acids: Identification of a novel indolyl-substituted HDAC inhibitor with antitumor activity.
AID1667075	Inhibition of HDAC1 in human MDA-MB-231 cells assessed as accumulation of acetylated H4 at 1.5 uM by western blot analysis	2020	Bioorganic & medicinal chemistry, 03-15, Volume: 28, Issue:6	Pyrimethamine conjugated histone deacetylase inhibitors: Design, synthesis and evidence for triple negative breast cancer selective cytotoxicity.
AID1164904	Inhibition of HDAC1/2/3 in human HeLa cells assessed as p21 gene expression at 10 uM after 15 hrs by luciferase reporter gene assay relative to SNDX-275	2014	Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19	Identification of a novel aminotetralin class of HDAC6 and HDAC8 selective inhibitors.
AID1384227	Inhibition of HDAC6 in human SH-SY5Y cells assessed as induction of tubulin K-40 acetylation level at 100 nM after 2 hrs by Western blot analysis relative to control	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease.
AID1845320	Inhibition of BRD4 (unknown origin) by ELISA	2021	Bioorganic & medicinal chemistry letters, 01-01, Volume: 31	Current status in the discovery of dual BET/HDAC inhibitors.
AID274013	Inhibition of CYP450 3A4	2007	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2	Identification and optimisation of a series of substituted 5-pyridin-2-yl-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.
AID1410341	Inhibition of HDAC in human HCT116 cells assessed as decrease in acetylated histone H3 levels after 12 hrs by Western blot analysis	2018	ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4	Discovery of Novel Indoleamine 2,3-Dioxygenase 1 (IDO1) and Histone Deacetylase (HDAC) Dual Inhibitors.
AID780574	Growth inhibition of human MDA-MB-231 cells after 48 hrs by MTT assay	2013	Bioorganic & medicinal chemistry, Nov-15, Volume: 21, Issue:22	Development of novel ferulic acid derivatives as potent histone deacetylase inhibitors.
AID1487093	Inhibition of HDAC2 (unknown origin)	2017	Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15	Cyclic tetrapeptide HDAC inhibitors as potential therapeutics for spinal muscular atrophy: Screening with iPSC-derived neuronal cells.
AID1865257	Induction of apoptosis in human MV4-11 cells at 1 uM incubated for 24 hrs in presence of SHP099 by propidium iodide and annexin-V staining based flow cytometry	2022	Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18	Discovery of Novel Src Homology-2 Domain-Containing Phosphatase 2 and Histone Deacetylase Dual Inhibitors with Potent Antitumor Efficacy and Enhanced Antitumor Immunity.
AID663405	Half life in mouse plasma	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Discovery and extensive in vitro evaluations of NK-HDAC-1: a chiral histone deacetylase inhibitor as a promising lead.
AID1439355	Inhibition of HDAC6 in human RPMI8226 cells assessed as increase in tubulin acetylation at 3 uM after 24 hrs by western blot analysis	2017	European journal of medicinal chemistry, Mar-10, Volume: 128	Design, synthesis and biological evaluation of thienopyrimidine hydroxamic acid based derivatives as structurally novel histone deacetylase (HDAC) inhibitors.
AID1887690	Cytotoxicity against human HGC-27 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	Design, synthesis and biological evaluation of novel o-aminobenzamide derivatives as potential anti-gastric cancer agents in vitro and in vivo.
AID1897394	Induction of apoptosis in human SNU-16 cells assessed as late apoptotic cells at 0.03 uM incubated for 72 hrs by annexin-V/FITC propidium iodide staining based flow cytometry analysis (Rvb = 3.41%)
AID626562	Inhibition of HDAC in human HeLa cell extract assessed as fluorophore release at 0.1 uM by fluorescence spectrophotometry	2011	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 21, Issue:22	4-N-Hydroxy-4-[1-(sulfonyl)piperidin-4-yl]-butyramides as HDAC inhibitors.
AID366641	Inhibition of HDAC2 after 17 hrs	2008	Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15	Use of the nitrile oxide cycloaddition (NOC) reaction for molecular probe generation: a new class of enzyme selective histone deacetylase inhibitors (HDACIs) showing picomolar activity at HDAC6.
AID732445	Inhibition of human A549 cell proliferation after 48 hrs by MTT assay	2013	ACS medicinal chemistry letters, Feb-14, Volume: 4, Issue:2	Development of
AID366646	Antiproliferative activity against human BxPC3 cells after 72 hrs by MTT assay	2008	Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15	Use of the nitrile oxide cycloaddition (NOC) reaction for molecular probe generation: a new class of enzyme selective histone deacetylase inhibitors (HDACIs) showing picomolar activity at HDAC6.
AID670104	Antitumor activity against human A549 cells xenografted in nude mouse assessed as tumor growth inhibition at 200 mg/kg, po administered QD till end point	2012	Journal of medicinal chemistry, Apr-26, Volume: 55, Issue:8	Synthesis and biological evaluation of 1-arylsulfonyl-5-(N-hydroxyacrylamide)indoles as potent histone deacetylase inhibitors with antitumor activity in vivo.
AID1487009	Selectivity index, ratio of IC50 for HDAC2 (unknown origin) to IC50 for HDAC6 (unknown origin)	2017	Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15	The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity.
AID1821269	Antiproliferative activity against human HUVEC cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	2022	European journal of medicinal chemistry, Feb-05, Volume: 229	Discovery of phthalazino[1,2-b]-quinazolinone derivatives as multi-target HDAC inhibitors for the treatment of hepatocellular carcinoma via activating the p53 signal pathway.
AID1129777	Cell cycle arrest in human Jurkat cells assessed as accumulation at G1-phase at 10 uM after 12 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 65%)	2014	Bioorganic & medicinal chemistry, Apr-01, Volume: 22, Issue:7	Studies on the antiproliferative effects of tropolone derivatives in Jurkat T-lymphocyte cells.
AID1819502	Inhibition of HDAC in human HeLa nuclear extract using fluorogenic substrate incubated for 30 mins by fluorescence based assay	2022	Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4	Discovery of DNA-Targeting HDAC Inhibitors with Potent Antitumor Efficacy In Vivo That Trigger Antitumor Immunity.
AID1754755	Inhibition of N-terminal GST-tagged human recombinant full length HDAC5 expressed in baculovirus-infected Sf9 cells assessed as reduction in 7-amino-4-methylcoumarin release measured every 5 mins by fluorescence based analysis	2021	Bioorganic & medicinal chemistry, 07-15, Volume: 42	Discovery of novel class of histone deacetylase inhibitors as potential anticancer agents.
AID1765331	Selectivity index, ratio of IC50 for human recombinant full length HDAC6 to IC50 for human recombinant full length HDAC2	2021	European journal of medicinal chemistry, Oct-15, Volume: 222	A first-in-class anticancer dual HDAC2/FAK inhibitors bearing hydroxamates/benzamides capped by pyridinyl-1,2,4-triazoles.
AID327545	Increase in acetylated histone H3 level in human HCT116 cells at 10 uM after 24 hrs relative to control	2008	Journal of medicinal chemistry, Apr-24, Volume: 51, Issue:8	Polyaminohydroxamic acids and polyaminobenzamides as isoform selective histone deacetylase inhibitors.
AID1775567	Inhibition of human G9a enzyme using histone monomethyl-H3K9 peptide as substrate incubated for 1 hr in presence of SAM by TR-FRET assay	2021	Journal of medicinal chemistry, 03-25, Volume: 64, Issue:6	Design and Synthesis of Novel Epigenetic Inhibitors Targeting Histone Deacetylases, DNA Methyltransferase 1, and Lysine Methyltransferase G9a with
AID316893	Inhibition of HDAC8	2008	Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6	Histone deacetylase inhibitors: from bench to clinic.
AID1819513	Antiproliferative activity against human PC3 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	2022	Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4	Discovery of DNA-Targeting HDAC Inhibitors with Potent Antitumor Efficacy In Vivo That Trigger Antitumor Immunity.
AID527039	Cytotoxicity against human NCI-H2126 by SRB assay	2010	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22	Selenium-containing analogs of SAHA induce cytotoxicity in lung cancer cells.
AID1572340	Cytotoxicity against human HepaRG cells assessed as cell viability at 100 uM after 24 hrs by CellTiter blue-reagent based assay relative to control	2019	Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3	Synthesis and Biological Investigation of Phenothiazine-Based Benzhydroxamic Acids as Selective Histone Deacetylase 6 Inhibitors.
AID1234899	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	2015	Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15	Design, synthesis and preliminary biological evaluation of indoline-2,3-dione derivatives as novel HDAC inhibitors.
AID1816968	Cytotoxicity against human HeLa cells assessed as cell death incubated for 20 hrs measured by DNS assay	2021	Journal of medicinal chemistry, 05-27, Volume: 64, Issue:10	Thiazolidinedione "Magic Bullets" Simultaneously Targeting PPARγ and HDACs: Design, Synthesis, and Investigations of their
AID1266095	Inhibition of HDAC6 (unknown origin) by fluorimetric assay	2016	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1	Cross metathesis with hydroxamate and benzamide BOC-protected alkenes to access HDAC inhibitors and their biological evaluation highlighted intrinsic activity of BOC-protected dihydroxamates.
AID1401482	Selectivity ratio of IC50 for recombinant full-length C-terminal His-tagged HDAC8 expressed in baculovirus infected Sf9 insect cell to IC50 for HDAC2 in human HeLa-S3 cell lysates	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
AID1441653	Anti-inflammatory activity in LPS-induced C57BL/6 mouse model of acute lung injury assessed as reduction in TNFalpha level at 25 mg/kg, ip pretreated for 1 hr followed LPS challenge after 24 hrs by ELISA relative to LPS alone	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
AID1401547	Antiproliferative activity against human NB4 cells after 72 hrs by MTT assay	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors.
AID511068	Inhibition of HDAC in human HeLa cells at 0.1 uM after 15 mins	2010	European journal of medicinal chemistry, Sep, Volume: 45, Issue:9	Design and synthesis of novel isoxazole-based HDAC inhibitors.
AID1403160	Antiproliferative activity against human HuH7 cells after 48 hrs by MTT assay	2018	European journal of medicinal chemistry, Jan-20, Volume: 144	Development of novel β-carboline-based hydroxamate derivatives as HDAC inhibitors with antiproliferative and antimetastatic activities in human cancer cells.
AID1861650	Antiproliferative activity against human SW480 cells measured after 72 hrs	2022	Bioorganic & medicinal chemistry letters, 09-15, Volume: 72	Exploration of 4-(1H-indol-3-yl)cyclohex-3-en-1-amine analogues as HDAC inhibitors: Design, synthesis, biological evaluation and modelling studies.
AID1487002	Inhibition of HDAC6 (unknown origin) by ELISA-based assay	2017	Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15	The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity.
AID1769642	Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 assay	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	Discovery of 2,4-pyrimidinediamine derivatives as potent dual inhibitors of ALK and HDAC.
AID1303623	Potentiation of 0.1 nM (-)-lomaiviticin A-induced cytotoxicity against human K562 cells assessed as fraction ratio affected at 0.5 uM after 48 hrs by cell titer-glo luminescence assay	2016	Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13	Synergistic potentiation of (-)-lomaiviticin A cytotoxicity by the ATR inhibitor VE-821.
AID1367347	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	2017	Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24	Synthesis and biological evaluation of Santacruzamate-A based analogues.
AID1548259	Antiproliferative activity against human U266 cells incubated for 48 hrs by MTT assay
AID1863174	Selectivity index, ratio of IC50 for HDAC1 (unknown origin) to IC50 for HDAC6 (unknown origin)	2022	European journal of medicinal chemistry, Oct-05, Volume: 240	Design, synthesis, and biological evalution of bifunctional inhibitors against Hsp90-HDAC6 interplay.
AID420637	Inhibition of HDAC in human IGROV1 cells assessed as p53 acetylation at IC50 after 48 hrs by Western blot	2009	European journal of medicinal chemistry, May, Volume: 44, Issue:5	Design, synthesis, and evaluation of biphenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors.
AID1578154	Antiproliferative activity against human HCT116 cells assessed as cell growth inhibition after 48 hrs by sulforhodamine B assay	2020	European journal of medicinal chemistry, Jan-01, Volume: 185	N-alkyl-hydroxybenzoyl anilide hydroxamates as dual inhibitors of HDAC and HSP90, downregulating IFN-γ induced PD-L1 expression.
AID1812444	Inhibition of human recombinant HDAC3 using Tosyl-Gly-ProLys(Ac)-AMC as substrate measured after 60 mins by fluorescence assay	2021	Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14	Procainamide-SAHA Fused Inhibitors of hHDAC6 Tackle Multidrug-Resistant Malaria Parasites.
AID1848303	Induction of apoptosis in human MV4-11 cells assessed as late apoptotic cells at 1 uM incubated for 48 hrs by Annexin V-FITC/PI staining based flow cytometry (Rvb = 2.04%)	2022	Bioorganic & medicinal chemistry, Nov-15, Volume: 74	Design, synthesis and biological evaluation of novel pyrazinone derivatives as PI3K/HDAC dual inhibitors.
AID717827	Inhibition of HDAC in human Hela cell lysate using Fluor-de-Lys as substrate compound pretreated for 30 mins before substrate addition by fluorescence assay	2012	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23	The structural requirements of histone deacetylase inhibitors: suberoylanilide hydroxamic acid analogs modified at the C6 position.
AID1855256	Antiproliferative activity against human HepG2 cells after 48 hrs by CCK-8 assay	2022	European journal of medicinal chemistry, Nov-05, Volume: 241	Discovery of 2,5-diphenyl-1,3,4-thiadiazole derivatives as HDAC inhibitors with DNA binding affinity.
AID1449320	Antiproliferative activity against human Med8A cells after 72 hrs by Celltiter-Glo assay	2017	Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13	Alkoxyurea-Based Histone Deacetylase Inhibitors Increase Cisplatin Potency in Chemoresistant Cancer Cell Lines.
AID1441651	Anti-inflammatory activity in LPS-induced C57BL/6 mouse model of acute lung injury assessed as reduction in IL-1beta level pretreated intraperitoneally for 1 hr followed LPS challenge after 24 hrs by ELISA	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
AID1896927	Antiproliferative activity against human NALM-6 cells assessed as reduction in cell viability incubated for 48 hrs by CCK8 assay	2022	Bioorganic & medicinal chemistry, Nov-05, Volume: 75	Novel bioactive hybrid Celecoxib-HDAC Inhibitor, induces apoptosis in human acute lymphoblastic leukemia cells.
AID1273870	Inhibition of HDAC2 (unknown origin)	2016	European journal of medicinal chemistry, Jan-27, Volume: 108	Synthesis, biological characterization and molecular modeling insights of spirochromanes as potent HDAC inhibitors.
AID1709359	Induction of apoptosis in human Jurkat cells assessed as early apoptotic cells at IC50 measured after 48 hrs by Annexin V-FITC/7AAD staining based flow cytometry (Rvb = 6.05%)	2021	Bioorganic & medicinal chemistry, 04-01, Volume: 35	Structure-activity relationship and mechanistic studies for a series of cinnamyl hydroxamate histone deacetylase inhibitors.
AID1819535	Toxicity in C57BL/6J mouse implanted with mouse B16-F10 cells assessed as heart damage at 60 mg/kg, IG administered for 12 days H and E staining based histopathological analysis	2022	Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4	Discovery of DNA-Targeting HDAC Inhibitors with Potent Antitumor Efficacy In Vivo That Trigger Antitumor Immunity.
AID1742742	Genotoxicity in Salmonella typhimurium TA100 by Ames test	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Design and synthesis of novel Flavone-based histone deacetylase inhibitors antagonizing activation of STAT3 in breast cancer.
AID1845307	Inhibition of HDAC1 (unknown origin)	2021	Bioorganic & medicinal chemistry letters, 01-01, Volume: 31	Current status in the discovery of dual BET/HDAC inhibitors.
AID316936	Inhibition of HDAC7	2008	Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6	Histone deacetylase inhibitors: from bench to clinic.
AID1129798	Inhibition of HDAC in human Jurkat cells assessed as increase in H3K9 acetylation by measuring geometric mean fluorescence intensity at 10 uM after 12 hrs by FACS flow cytometric analysis (Rvb = 5.91 no unit)	2014	Bioorganic & medicinal chemistry, Apr-01, Volume: 22, Issue:7	Studies on the antiproliferative effects of tropolone derivatives in Jurkat T-lymphocyte cells.
AID1915566	Cytotoxicity against African green monkey Vero cells	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors.
AID1275246	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	2016	European journal of medicinal chemistry, Feb-15, Volume: 109	Design, synthesis and biological evaluation of N-phenylquinazolin-4-amine hybrids as dual inhibitors of VEGFR-2 and HDAC.
AID1170745	Inhibition of human recombinant HDAC10 using Ac-Arg-His-Lys(Ac)-Lys(Ac)-AMC substrate incubated for 15 to 30 mins	2014	Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22	Methyl effect in azumamides provides insight into histone deacetylase inhibition by macrocycles.
AID1174703	Induction of apoptosis in human U937 cells assessed as apoptotic cells at 1.5 uM after 24 hrs by annexin-V/propidium iodide staining-based flow cytometry	2015	European journal of medicinal chemistry, Jan-07, Volume: 89	Development of 3-hydroxycinnamamide-based HDAC inhibitors with potent in vitro and in vivo anti-tumor activity.
AID1339587	Growth inhibition of human U937 cells after 44 hrs by MTT assay	2017	ACS medicinal chemistry letters, Mar-09, Volume: 8, Issue:3	Structural Requirements of HDAC Inhibitors: SAHA Analogues Modified at the C2 Position Display HDAC6/8 Selectivity.
AID324954	Inhibition of wild type HDAC4 expressed in Escherichia coli at 10 uM	2008	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 18, Issue:6	Probing the elusive catalytic activity of vertebrate class IIa histone deacetylases.
AID1469324	Induction of apoptosis in human MDA-MB-231 cells assessed as late apoptotic cells at 10 uM after 48 hrs by annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 1.53%)	2018	Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7	Discovery of N1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7 H-pyrrolo[2,3- d]pyrimidin-2-yl)amino)phenyl)- N8-hydroxyoctanediamide as a Novel Inhibitor Targeting Cyclin-dependent Kinase 4/9 (CDK4/9) and Histone Deacetlyase1 (HDAC1) against Malignant Cancer
AID1486321	Genotoxicity in Salmonella typhimurium TA97 at 50 times antiproliferative IC50 by Ames test	2017	Bioorganic & medicinal chemistry, 08-01, Volume: 25, Issue:15	Olaparib hydroxamic acid derivatives as dual PARP and HDAC inhibitors for cancer therapy.
AID1511138	Inhibition of HDAC9 (unknown origin) using Ac-LeuGlyLys(tfa)-AMC as substrate preincubated for 5 mins followed by substrate addition and measured after 60 mins by fluorescence based assay	2019	ACS medicinal chemistry letters, Aug-08, Volume: 10, Issue:8	Design, Synthesis, and Biological Evaluation of 2,4-Imidazolinedione Derivatives as HDAC6 Isoform-Selective Inhibitors.
AID1861265	Selectivity index, ratio of IC50 for inhibition of HDAC4 (unknown origin) to IC50 for inhibition of HDAC6 (unknown origin)	2022	Bioorganic & medicinal chemistry letters, 09-01, Volume: 71	Design, synthesis and antitumor activity study of PARP-1/HDAC dual targeting inhibitors.
AID663473	Apparent permeability from basolateral to apical side in human Caco2 cells at 10 uM	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Discovery and extensive in vitro evaluations of NK-HDAC-1: a chiral histone deacetylase inhibitor as a promising lead.
AID1845914	Inhibition of HIV-1 latency in human CD4+ve Th cells infected NL4.3-Luc virus assessed as p24 expression level incubated for 48 hrs by v450 dye based flow cytometry	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	HIV latency reversal agents: A potential path for functional cure?
AID1534443	Cytotoxicity against human A549 cells after 72 hrs by MTT assay	2019	Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2	Quinazolin-2,4-dione-Based Hydroxamic Acids as Selective Histone Deacetylase-6 Inhibitors for Treatment of Non-Small Cell Lung Cancer.
AID1816221	Induction of apoptosis in mouse 4T1 cells assessed as early apoptotic cells at 5 uM measured after 48 hrs by annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 1.12%)
AID274021	AUC after oral dosing at 5 mg kg-1	2007	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2	Identification and optimisation of a series of substituted 5-pyridin-2-yl-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.
AID481574	Cytotoxicity against mouse S180 cells assessed as growth inhibition at 0.1 ug/ml after 24 hrs by MTT assay	2010	Bioorganic & medicinal chemistry letters, May-15, Volume: 20, Issue:10	Synthesis and anticancer evaluation of alpha-lipoic acid derivatives.
AID246120	Effective Concentration of compound to inhibit the growth of human MDA-MB-231 cells	2005	Journal of medicinal chemistry, Feb-24, Volume: 48, Issue:4	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates.
AID1486678	Inhibition of HDAC2 (unknown origin) using Ac-Leu-GlyLys(Ac)-AMC as substrate preincubated for 10 mins followed by substrate addition measured after 30 mins by fluorescence analysis	2017	Bioorganic & medicinal chemistry, 08-01, Volume: 25, Issue:15	Design, synthesis and tumor cell growth inhibitory activity of 3-nitro-2H-cheromene derivatives as histone deacetylaes inhibitors.
AID1434360	Inhibition of HDAC in HEK293 cells assessed as myc-tagged RUNX3 expression by measuring ratio of RUNX3 level to beta-actin level at 1 uM measured after 24 hrs by Western blot analysis relative to control	2017	European journal of medicinal chemistry, Jan-27, Volume: 126	Improving potency and metabolic stability by introducing an alkenyl linker to pyridine-based histone deacetylase inhibitors for orally available RUNX3 modulators.
AID1235108	Inhibition of HDAC1/2 in human HeLa cells using Boc-Lys (acetyl)-AMC as substrate preincubated for 30 mins followed by substrate addition measured after 30 mins by fluorescence assay	2015	Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15	Synthesis and biological evaluation of novel histone deacetylases inhibitors with nitric oxide releasing activity.
AID1622975	Inhibition of recombinant human FLAG/His-tagged HDAC1 expressed in baculovirus expression system using Boc-l-Lys(Ac)-AMC as substrate preincubated up to 3 hrs and measured after 35 mins by fluorescence assay	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.
AID1784980	Antiproliferative activity against human Hep3B cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Design, synthesis and biological evaluation of novel hybrids targeting mTOR and HDACs for potential treatment of hepatocellular carcinoma.
AID1061953	Inhibition of human HDAC3/NCOR2 using RHKK(Ac) as substrate by fluorimetric analysis	2014	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1	Lactam based 7-amino suberoylamide hydroxamic acids as potent HDAC inhibitors.
AID1355705	Antifungal activity against FLC resistant Candida albicans 0304103 after 48 hrs by checkerboard microdilution method	2018	Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14	Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections.
AID1633433	Induction of neurogenesis in human SH-SY5Y cells assessed as upregulation of GAP43 mRNA at 1 uM incubated for 24 hrs by RT-PCR analysis	2019	ACS medicinal chemistry letters, Apr-11, Volume: 10, Issue:4	Discovery of the First-in-Class GSK-3β/HDAC Dual Inhibitor as Disease-Modifying Agent To Combat Alzheimer's Disease.
AID1689776	Antiproliferative activity against human H460 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay	2020	European journal of medicinal chemistry, Mar-01, Volume: 189	Discovery of novel cyclin-dependent kinase (CDK) and histone deacetylase (HDAC) dual inhibitors with potent in vitro and in vivo anticancer activity.
AID695301	Upregulation of Nanog gene expression in C57BL/6 MEF at 100 nM after 24 hrs by quantitative RT-PCR analysis relative to control	2012	Bioorganic & medicinal chemistry, Apr-15, Volume: 20, Issue:8	Development of programmable small DNA-binding molecules with epigenetic activity for induction of core pluripotency genes.
AID1578157	Inhibition of FITC-geldanamycin binding to recombinant human full-length C-terminal His-tagged HSP90alpha expressed in Escherichia coli after 3 hrs by fluorescence polarization assay	2020	European journal of medicinal chemistry, Jan-01, Volume: 185	N-alkyl-hydroxybenzoyl anilide hydroxamates as dual inhibitors of HDAC and HSP90, downregulating IFN-γ induced PD-L1 expression.
AID1812436	Cytotoxicity against human HL-60 cells assessed as inhibition of cell proliferation measured after 72 hrs by ATPlite assay	2021	Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14	Procainamide-SAHA Fused Inhibitors of hHDAC6 Tackle Multidrug-Resistant Malaria Parasites.
AID1816723	Induction of apoptosis in human MGC-803 cells assessed as apoptotic cells at 5 uM incubated for 48 hrs by annexin V-FITC and PI staining based flowcytometry analysis (Rvb =4.3 %)	2021	European journal of medicinal chemistry, Aug-05, Volume: 220	Design, synthesis, and biological evaluation of novel dual inhibitors targeting lysine specific demethylase 1 (LSD1) and histone deacetylases (HDAC) for treatment of gastric cancer.
AID1684875	Antitumor activity against mouse LL/2 cells inoculated in C57BL/6J mouse assessed as reduction of tumor weight at 25 mg/kg, ip administered for 12 days measured at day 14 (Rvb = 0.98 +/- 0.07 g)
AID1485114	Inhibition of SIRT2 in human Hs683 cells assessed as increase of alpha-tubulin acetylation at 2 uM after 8 hrs by Western blotting method relative to control	2017	Journal of medicinal chemistry, 06-08, Volume: 60, Issue:11	Discovery and Characterization of R/S-N-3-Cyanophenyl-N'-(6-tert-butoxycarbonylamino-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-4-yl)urea, a New Histone Deacetylase Class III Inhibitor Exerting Antiproliferative Activity against Cancer Cell Lines.
AID1129799	Inhibition of HDAC in human Jurkat cells assessed as increase in H3K23 acetylation by measuring geometric mean fluorescence intensity at 10 uM after 12 hrs by FACS flow cytometric analysis (Rvb = 20.20 no unit)	2014	Bioorganic & medicinal chemistry, Apr-01, Volume: 22, Issue:7	Studies on the antiproliferative effects of tropolone derivatives in Jurkat T-lymphocyte cells.
AID347872	Growth inhibition of human renal cancer cells at 10 uM relative to control	2008	Journal of medicinal chemistry, Dec-11, Volume: 51, Issue:23	Histone deacetylase inhibitors through click chemistry.
AID366652	Cytotoxicity against HPDE 6c7 cells after 72 hrs by MTT assay	2008	Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15	Use of the nitrile oxide cycloaddition (NOC) reaction for molecular probe generation: a new class of enzyme selective histone deacetylase inhibitors (HDACIs) showing picomolar activity at HDAC6.
AID1367348	Antiproliferative activity against human HCT116 cells after 24 hrs by MTT assay	2017	Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24	Synthesis and biological evaluation of Santacruzamate-A based analogues.
AID1486671	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	2017	Bioorganic & medicinal chemistry, 08-01, Volume: 25, Issue:15	Design, synthesis and tumor cell growth inhibitory activity of 3-nitro-2H-cheromene derivatives as histone deacetylaes inhibitors.
AID395022	Inhibition of recombinant HDAC1 by fluorimetric assay	2009	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 19, Issue:5	N-Hydroxy-1,2-disubstituted-1H-benzimidazol-5-yl acrylamides as novel histone deacetylase inhibitors: design, synthesis, SAR studies, and in vivo antitumor activity.
AID1386686	Inhibition of HDAC in human GM18453 cells harboring NPC1 mutant assessed as increase in total NPC1 protein expression at 5 uM pretreated for 48 hrs followed by endoglycosidase H addition and measured after overnight incubation by Western blot analysis rel	2018	Journal of natural products, 09-28, Volume: 81, Issue:9	GEX1A, a Polyketide from Streptomyces chromofuscus, Corrects the Cellular Defects Associated with Niemann-Pick Type C1 in Human Fibroblasts.
AID1890513	Inhibition of HDAC6 (unknown origin)	2022	Bioorganic & medicinal chemistry letters, 05-15, Volume: 64	Design, synthesis, and biological evaluation of β-carboline 1,3,4-oxadiazole based hybrids as HDAC inhibitors with potential antitumor effects.
AID1441664	Anti-inflammatory activity in LPS-induced C57BL/6 mouse model of acute lung injury assessed as reduction in TNFalpha level pretreated at 25 mg/kg, ip pretreated for 1 hr followed LPS challenge after 24 hrs by ELISA	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
AID1622972	Inhibition of HDAC1 (unknown origin)	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.
AID1667076	Inhibition of HDAC6 in human MDA-MB-231 cells assessed as accumulation of acetylated tubulin at 1.5 uM by western blot analysis	2020	Bioorganic & medicinal chemistry, 03-15, Volume: 28, Issue:6	Pyrimethamine conjugated histone deacetylase inhibitors: Design, synthesis and evidence for triple negative breast cancer selective cytotoxicity.
AID1280274	Selectivity index, ratio of HDAC6 inhibition in human HeLa cells assessed as ratio of acetylated tubulin to GAPDH level at 0.1 uM over class1 HDAC inhibition in human HeLa cells assessed as ratio of acetylated histone H3 to GAPDH level at 0.1 uM	2016	Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4	Synthesis and Biological Investigation of Oxazole Hydroxamates as Highly Selective Histone Deacetylase 6 (HDAC6) Inhibitors.
AID1541445	Inhibition of recombinant human full length C-terminal FLAG-tagged HDAC2 expressed in baculovirus infected Sf9 insect cells using Boc-Lys(epsilon-acetyl)-AMC as substrate incubated for 90 mins by fluorescence assay	2019	Journal of medicinal chemistry, 12-26, Volume: 62, Issue:24	Synthesis of Peptoid-Based Class I-Selective Histone Deacetylase Inhibitors with Chemosensitizing Properties.
AID1784972	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Design, synthesis and biological evaluation of novel hybrids targeting mTOR and HDACs for potential treatment of hepatocellular carcinoma.
AID1433254	Antiproliferative activity against p53 null human U937 cells after 72 hrs by MTT assay	2016	Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17	Synthesis and Antileukemic Activities of Piperlongumine and HDAC Inhibitor Hybrids against Acute Myeloid Leukemia Cells.
AID1572348	Inhibition of HDAC6 in human HL60 cells assessed as acetylated tubulin/GAPDH ratio at 1 uM after 4 hrs by Western blot assay relative to control	2019	Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3	Synthesis and Biological Investigation of Phenothiazine-Based Benzhydroxamic Acids as Selective Histone Deacetylase 6 Inhibitors.
AID1728924	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 5 days by beckman coulter counting method	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Synthesis and anticancer activity evaluation of naphthalene-substituted triazole spirodienones.
AID1326527	Toxicity in nude mouse xenografted with human HCT116 cells assessed as change in body weight at 50 to 100 mg/kg, po qd	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	2-(Phenylsulfonyl)quinoline N-hydroxyacrylamides as potent anticancer agents inhibiting histone deacetylase.
AID1650411	Inhibition of recombinant human HDAC4	2020	Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1	Novel alkoxyamide-based histone deacetylase inhibitors reverse cisplatin resistance in chemoresistant cancer cells.
AID672024	Inhibition of human recombinant HDAC2 using Boc-L-Lys (Ac)-AMC as substrate preincubated with compound for 3 hrs measured after 35 mins by spectrofluorometric analysis	2012	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 22, Issue:15	Design, synthesis, modeling, biological evaluation and photoaffinity labeling studies of novel series of photoreactive benzamide probes for histone deacetylase 2.
AID1403155	Inhibition of HDAC8 (unknown origin)	2018	European journal of medicinal chemistry, Jan-20, Volume: 144	Development of novel β-carboline-based hydroxamate derivatives as HDAC inhibitors with antiproliferative and antimetastatic activities in human cancer cells.
AID1441644	Anti-inflammatory activity in LPS-induced C57BL/6 mouse model of acute lung injury assessed as reduction in protein concentration in BALF at 10 to 50 mg/kg, ip pretreated for 1 hr followed LPS challenge measured after 24 hrs	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
AID1401479	Selectivity ratio of IC50 for HDAC3 in human HeLa-S3 cell lysates to IC50 for recombinant full-length C-terminal His-tagged HDAC8 expressed in baculovirus infected Sf9 insect cell	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
AID1622909	Inhibition of recombinant human GST-fused HDAC1 expressed in HEK293 cells Fluor-de-lys as substrate measured after 60 mins by fluorescence assay	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.
AID1055713	Antiproliferative activity against human NCI-H460 cells after 48 hrs by SRB assay	2013	European journal of medicinal chemistry, , Volume: 70	Novel isatin-based hydroxamic acids as histone deacetylase inhibitors and antitumor agents.
AID1482167	Cytotoxicity against human HL60 cells assessed as growth inhibition at 5 uM after 48 hrs by MTT assay relative to control	2017	Journal of medicinal chemistry, 04-27, Volume: 60, Issue:8	Exploring Derivatives of Quinazoline Alkaloid l-Vasicine as Cap Groups in the Design and Biological Mechanistic Evaluation of Novel Antitumor Histone Deacetylase Inhibitors.
AID1667070	Antiproliferative activity in human MCF7 cells assessed as inhibition of cell viability after 72 hrs by MTS assay	2020	Bioorganic & medicinal chemistry, 03-15, Volume: 28, Issue:6	Pyrimethamine conjugated histone deacetylase inhibitors: Design, synthesis and evidence for triple negative breast cancer selective cytotoxicity.
AID1380944	Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay	2018	Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12	Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously.
AID605533	Antiproliferative activity against human HepG2 cells after 72 hrs by WST-1 assay	2010	Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24	Discovery of 2-(6-{[(6-fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a class I selective orally active histone deacetylase inhibitor.
AID1511968	Inhibition of full length recombinant GST-tagged N-terminal human HDAC6 expressed in baculovirus infected Sf9 insect cells using ZMAL (Z-Lys(Ac)-AMC) as substrate incubated for 90 mins by fluorescence based assay	2019	ACS medicinal chemistry letters, Sep-12, Volume: 10, Issue:9	Fluorinated Analogues of the Histone Deacetylase Inhibitor Vorinostat (Zolinza): Validation of a Chiral Hybrid Bioisostere, BITE.
AID1547265	Inhibition of HDAC9 (unknown origin) using biotinylated histone H3 KAc peptide (1 to 21 residues) as substrate by HTRF assay	2020	Journal of medicinal chemistry, 04-09, Volume: 63, Issue:7	Discovery of Thieno[2,3-
AID90214	Inhibitory activity was tested against histone deacetylase (HDAC).	2003	Bioorganic & medicinal chemistry letters, Jun-02, Volume: 13, Issue:11	Indole amide hydroxamic acids as potent inhibitors of histone deacetylases.
AID1566823	Antiproliferative activity against human JeKo1 cells after 72 hrs by MTT assay	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Discovery of 1,2,4-oxadiazole-Containing hydroxamic acid derivatives as histone deacetylase inhibitors potential application in cancer therapy.
AID1141773	Induction of apoptosis in human HCT116 cells assessed as increase in p53 protein level at 0.1 to 3 uM after 24 hrs by immunoblotting analysis	2014	Journal of medicinal chemistry, May-22, Volume: 57, Issue:10	Azaindolylsulfonamides, with a more selective inhibitory effect on histone deacetylase 6 activity, exhibit antitumor activity in colorectal cancer HCT116 cells.
AID1737138	Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 72 hrs by MTT assay	2020	European journal of medicinal chemistry, Apr-15, Volume: 192	Design, synthesis and biological evaluation of novel indazole-based derivatives as potent HDAC inhibitors via fragment-based virtual screening.
AID241538	Inhibitory concentration against maize histone deacetylase 1-B (class I HDAC)	2005	Journal of medicinal chemistry, May-05, Volume: 48, Issue:9	Class II (IIa)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl)pyrrolyl hydroxyamides.
AID1141772	Cytotoxicity against human HT-29 cells by MTT assay	2014	Journal of medicinal chemistry, May-22, Volume: 57, Issue:10	Azaindolylsulfonamides, with a more selective inhibitory effect on histone deacetylase 6 activity, exhibit antitumor activity in colorectal cancer HCT116 cells.
AID1846130	Inhibition of HDAC1 (unknown origin)	2021	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 38	Current status in the discovery of dual BET/HDAC inhibitors.
AID511065	Inhibition of HDAC3	2010	European journal of medicinal chemistry, Sep, Volume: 45, Issue:9	Design and synthesis of novel isoxazole-based HDAC inhibitors.
AID1339568	Inhibition of HDAC2 in human HeLaS3 cells preincubated for 15 mins followed by HDAC-Glo substrate addition measured after 30 to 45 mins by ELISA	2017	ACS medicinal chemistry letters, Mar-09, Volume: 8, Issue:3	Structural Requirements of HDAC Inhibitors: SAHA Analogues Modified at the C2 Position Display HDAC6/8 Selectivity.
AID632974	Cytotoxicity against human AsPC1 cells	2011	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 21, Issue:24	Benzothiazole-containing hydroxamic acids as histone deacetylase inhibitors and antitumor agents.
AID1845917	Inhibition of HIV-1 latency infected in human ACH-2 cells assessed as fold increase in HIV production by measuring p24 level incubated for 48 hrs in presence of BIX01294 by ELISA	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	HIV latency reversal agents: A potential path for functional cure?
AID1547331	Inhibition of HDAC in human HCT116 cells assessed as activation of IL6-JAK-STAT signaling pathway by measuring increase in IL6 mRNA level at 10 uM after 24 hrs by RT-PCR analysis	2020	Journal of medicinal chemistry, 04-09, Volume: 63, Issue:7	Discovery of Thieno[2,3-
AID607634	Inhibition of HDAC6 in human Hela cells assessed as increase in total lysine acetylation at 0.6 uM after 16 hrs by immunofluorescence microscopy	2011	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 21, Issue:14	A novel HDAC inhibitor with a hydroxy-pyrimidine scaffold.
AID1676593	Binding affinity to Gallium ion assessed as retention ratio by measuring compound detected in elution fraction/total compound detected at 2.55 umol by immobilized metal-ion affinity chromatography	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
AID1821271	Inhibition of HDAC2 (unknown origin) incubated for 30 mins by microplate reader assay	2022	European journal of medicinal chemistry, Feb-05, Volume: 229	Discovery of phthalazino[1,2-b]-quinazolinone derivatives as multi-target HDAC inhibitors for the treatment of hepatocellular carcinoma via activating the p53 signal pathway.
AID1441661	Anti-inflammatory activity in LPS-induced C57BL/6 mouse model of acute lung injury assessed as reduction in TNFalpha mRNA level at 25 mg/kg, ip pretreated for 1 hr followed LPS challenge after 24 hrs by qRT-PCR method	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
AID1653095	Antiproliferative activity against human A549 cells by CCK8 assay	2019	European journal of medicinal chemistry, Mar-01, Volume: 165	Quinolone hybrids and their anti-cancer activities: An overview.
AID1361644	Cell cycle arrest in human A549 cells assessed as accumulation of cells at G1 phase at 5 uM after 48 hrs by flow cytometric analysis (Rvb = 49.01%)	2018	Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16	Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents.
AID1321739	Inhibition of PDE5A in human SH-SY5Y cells assessed as increase in CREB phosphorylation at Ser133 residue at 500 nM after 2 hrs by Western blot analysis relative to control	2016	Journal of medicinal chemistry, 10-13, Volume: 59, Issue:19	Design, Synthesis, and Biological Evaluation of First-in-Class Dual Acting Histone Deacetylases (HDACs) and Phosphodiesterase 5 (PDE5) Inhibitors for the Treatment of Alzheimer's Disease.
AID1578504	Induction of apoptosis in human MV4-11 cells assessed as viable cells at 4 uM incubated for 18 hrs by annexin V FITC and PI based flow cytometry (Rvb = 53.01 to 53.07 %)	2020	ACS medicinal chemistry letters, Jan-09, Volume: 11, Issue:1	Class I/IIb-Selective HDAC Inhibitor Exhibits Oral Bioavailability and Therapeutic Efficacy in Acute Myeloid Leukemia.
AID1709349	Cytotoxicity against human NAMALVA cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	2021	Bioorganic & medicinal chemistry, 04-01, Volume: 35	Structure-activity relationship and mechanistic studies for a series of cinnamyl hydroxamate histone deacetylase inhibitors.
AID1282229	Inhibition of human recombinant HDAC1 using AMC labeled AC-peptide as substrate incubated for 1 hr by fluorescence analysis	2016	Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4	Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
AID1355735	Antitumor activity in human HEL cells xenografted in SCID mouse assessed as mouse survival at 10 mg/kg, ip qd measured after 10 days	2018	Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14	Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections.
AID1406991	Inhibition of class 1 HDAC in human SH-SY5Y cells assessed as levels of histone H3 acetylation at lysine 9/14 at 5 uM after 30 hrs by Western blot analysis relative to control	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Novel spiroindoline HDAC inhibitors: Synthesis, molecular modelling and biological studies.
AID316926	Inhibition of human SW620 cells	2008	Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6	Histone deacetylase inhibitors: from bench to clinic.
AID1293572	Inhibition of human recombinant N-terminal His-tagged HDAC11 (1 to 347 residues) using RHK-K(Ac)-AMC as substrate incubated for 60 mins by fluorescence assay	2016	European journal of medicinal chemistry, Apr-13, Volume: 112	Biphenyl-4-yl-acrylohydroxamic acids: Identification of a novel indolyl-substituted HDAC inhibitor with antitumor activity.
AID492813	Inhibition of HDAC in human NB4 cells assessed as increase in histone H3 acetylation at 5 uM after 24 hrs by Western blot analysis	2010	Journal of medicinal chemistry, Jun-24, Volume: 53, Issue:12	Synthesis and biological characterization of the histone deacetylase inhibitor largazole and C7- modified analogues.
AID496802	Inhibition of human HDAC2	2010	Nature chemical biology, Mar, Volume: 6, Issue:3	Chemical phylogenetics of histone deacetylases.
AID663344	Growth inhibition of human CCRF-CEM cells after 72 hrs by MTS assay	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Discovery and extensive in vitro evaluations of NK-HDAC-1: a chiral histone deacetylase inhibitor as a promising lead.
AID366649	Antiproliferative activity against human Panc04.03 cells after 72 hrs by MTT assay	2008	Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15	Use of the nitrile oxide cycloaddition (NOC) reaction for molecular probe generation: a new class of enzyme selective histone deacetylase inhibitors (HDACIs) showing picomolar activity at HDAC6.
AID1321729	Inhibition of HDAC6 in human SH-SY5Y cells assessed as increase in alpha-tubulin acetylation at Lys 40 after 2 hrs by Western blot analysis	2016	Journal of medicinal chemistry, 10-13, Volume: 59, Issue:19	Design, Synthesis, and Biological Evaluation of First-in-Class Dual Acting Histone Deacetylases (HDACs) and Phosphodiesterase 5 (PDE5) Inhibitors for the Treatment of Alzheimer's Disease.
AID1832693	Inhibition of human C-terminal His-tagged HDAC9 (604 to 1066 residues) expressed in baculovirus infected Sf9 insect cells using Boc-Lys(acetyl)-AMC as fluorogenic substrate measured after 1 hr by flourescence plate reader method	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Cysteine derivatives as acetyl lysine mimics to inhibit zinc-dependent histone deacetylases for treating cancer.
AID1235109	Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	2015	Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15	Synthesis and biological evaluation of novel histone deacetylases inhibitors with nitric oxide releasing activity.
AID1739569	Antiproliferative activity against human HL60 assessed as reduction in cell growth at 20 uM by CellTiter-non radioactive cell proliferation assay	2020	European journal of medicinal chemistry, Aug-15, Volume: 200	Design, synthesis, and biological evaluation of dual targeting inhibitors of histone deacetylase 6/8 and bromodomain BRPF1.
AID1897407	Induction of apoptosis in human SNU-16 cells assessed as dead cells at 1 uM incubated for 72 hrs by annexin-V/FITC propidium iodide staining based flow cytometry analysis (Rvb = 2.65%)
AID404447	Cytotoxicity against human HPDE6c7 cells	2008	Journal of medicinal chemistry, Jun-26, Volume: 51, Issue:12	A series of potent and selective, triazolylphenyl-based histone deacetylases inhibitors with activity against pancreatic cancer cells and Plasmodium falciparum.
AID1129795	Induction of apoptosis in human Jurkat cells assessed as caspase 3/7 activation at 10 uM after 24 hrs by luminescence assay (Rvb = 136,627 +/- 31846.96 no unit)	2014	Bioorganic & medicinal chemistry, Apr-01, Volume: 22, Issue:7	Studies on the antiproliferative effects of tropolone derivatives in Jurkat T-lymphocyte cells.
AID1266840	Activation of p53 in human HCT116 cells assessed as p53 phosphorylation at ser15 residue at 0.1 to 5 uM after 12 hrs by western blot analysis	2015	Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23	Novel β-Carboline/Hydroxamic Acid Hybrids Targeting Both Histone Deacetylase and DNA Display High Anticancer Activity via Regulation of the p53 Signaling Pathway.
AID1727743	Inhibition of HDAC11 (unknown origin) by fluorescence based assay	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	Discovery of selective HDAC/BRD4 dual inhibitors as epigenetic probes.
AID1769651	Inhibition of ALK (unknown origin) preincubated for 10 mins followed by addition of substrate and ATP for 25 mins by caliper EZ reader method	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	Discovery of 2,4-pyrimidinediamine derivatives as potent dual inhibitors of ALK and HDAC.
AID1437243	Cytotoxicity against mouse B16F10 cells assessed as growth inhibition after 72 hrs by MTS assay	2017	Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4	Design, synthesis and evaluation of antiproliferative activity of melanoma-targeted histone deacetylase inhibitors.
AID1515982	Induction of HDAC6 degradation in human MM1S cells assessed as increase in alpha tubulin acetylation at 100 nM measured after 6 hrs by Western blot analysis	2019	Journal of medicinal chemistry, 08-08, Volume: 62, Issue:15	Development of Multifunctional Histone Deacetylase 6 Degraders with Potent Antimyeloma Activity.
AID1065630	Inhibition of HDAC4 in human Jurkat E6.1 cells using Boc-Lys-Ac as substrate incubated for 2 hrs prior to substrate addition measured after 3 hrs by fluorescence assay	2013	Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24	Design, synthesis, and biological evaluation of potent and selective class IIa histone deacetylase (HDAC) inhibitors as a potential therapy for Huntington's disease.
AID1312867	Inhibition of HDAC in human HeLa cell nuclear extract using Ac-Leu-Gly-Lys (Ac)-AMC as substrate after 30 mins by fluorescence assay	2016	Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11	Development of Purine-Based Hydroxamic Acid Derivatives: Potent Histone Deacetylase Inhibitors with Marked in Vitro and in Vivo Antitumor Activities.
AID488275	Inhibition of HDAC3	2010	Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11	On the inhibition of histone deacetylase 8.
AID760501	Cytotoxicity against human NCI60 cells after 48 hrs by SRB assay	2013	ACS medicinal chemistry letters, Aug-08, Volume: 4, Issue:8	Development of a chimeric c-Src kinase and HDAC inhibitor.
AID1597973	Antimigratory activity in human A549 cells at 5 to 10 uM incubated for 12 hrs in presence of mitomycin by inverted microscopic-based wound healing assay	2019	Bioorganic & medicinal chemistry letters, 09-15, Volume: 29, Issue:18	Anti-tumor activity evaluation of novel tubulin and HDAC dual-targeting inhibitors.
AID1394901	Inhibition of HDAC in human HL60 cells assessed as upregulation of acetyl-alpha-tubulin levels at 0.1 to 3 uM after 24 hrs by Western blot analysis	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	1-Aroylindoline-hydroxamic acids as anticancer agents, inhibitors of HSP90 and HDAC.
AID1394888	Inhibition of HDAC in human HeLa nuclear extract using Ac-Lys(Ac)-pNA as substrate measured after 30 mins by fluorometric analysis	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	1-Aroylindoline-hydroxamic acids as anticancer agents, inhibitors of HSP90 and HDAC.
AID1065634	Inhibition of human recombinant full length HDAC3-NCoR2 using Lys_Ac_AMC as substrate after 60 mins by fluorescence assay	2013	Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24	Design, synthesis, and biological evaluation of potent and selective class IIa histone deacetylase (HDAC) inhibitors as a potential therapy for Huntington's disease.
AID1876471	Induction of apoptosis in human HCT-116 cells assessed as early apoptotic cells at 1 uM incubated for 48 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 1.73 %)	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	Design, synthesis, and biological evaluation of indole-based hydroxamic acid derivatives as histone deacetylase inhibitors.
AID1401904	Inhibition of human recombinant HDAC6 using Fluor de Lys-Green as substrate preincubated for 5 mins followed by substrate addition and measured after 1 hr by fluorescence assay	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
AID670970	Inhibition of human recombinant His6-tagged and GST-fuses HDAC1 expressed in insect High5 cells using Ac-Lys-Tyr-Lys(e-acetyl)-AMC as substrate after 24 hrs by fluorescence assay	2012	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14	CCLab--a multi-objective genetic algorithm based combinatorial library design software and an application for histone deacetylase inhibitor design.
AID619054	Competitive inhibition of HDAC9 using KI-104 as substrate by fluorescence assay	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile.
AID1467234	Inhibition of recombinant C-terminal His-tagged HDAC11 (unknown origin) expressed in baculovirus infected Sf9 cells using Ac-Arg-Gly-Lys(Ac)-AMC as substrate pretreated for 3 hrs followed by substrate addition after 30 mins by fluorometric method	2017	Bioorganic & medicinal chemistry letters, 07-01, Volume: 27, Issue:13	Stabilizing HDAC11 with SAHA to assay slow-binding benzamide inhibitors.
AID1869148	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by CCK8 assay
AID695302	Upregulation of Sox2 gene expression in C57BL/6 MEF at 100 nM after 24 hrs by quantitative RT-PCR analysis relative to control	2012	Bioorganic & medicinal chemistry, Apr-15, Volume: 20, Issue:8	Development of programmable small DNA-binding molecules with epigenetic activity for induction of core pluripotency genes.
AID1162485	Growth inhibition of human HCT116 cells after 72 hrs by CellTiter Glo assay	2014	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 24, Issue:19	Design, synthesis and evaluation of novel HDAC inhibitors as potential antitumor agents.
AID1337279	Antiproliferative activity against HEL 92.1.7 cells harboring JAK2 V617F mutant after 36 hrs by PrestoBlue dye based assay	2016	Journal of medicinal chemistry, Sep-22, Volume: 59, Issue:18	Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines.
AID652762	Inhibition of HDAC3-NCoR2 in human HeLa cells nuclear extract using Fluor-de-Lys as substrate after 30 mins by spectrophotometry	2011	ACS medicinal chemistry letters, Jul-21, Volume: 2, Issue:9	Potential Agents for Treating Cystic Fibrosis: Cyclic Tetrapeptides that Restore Trafficking and Activity of ΔF508-CFTR.
AID1403153	Inhibition of HDAC3 (unknown origin)	2018	European journal of medicinal chemistry, Jan-20, Volume: 144	Development of novel β-carboline-based hydroxamate derivatives as HDAC inhibitors with antiproliferative and antimetastatic activities in human cancer cells.
AID1426426	Antiparasitic activity against drug-sensitive Plasmodium falciparum 3D7 infected in erythrocytes assessed as growth inhibition after 48 hrs by SYBR green 1 dye-based flow cytometry	2017	European journal of medicinal chemistry, Feb-15, Volume: 127	Synthesis, biological characterisation and structure activity relationships of aromatic bisamidines active against Plasmodium falciparum.
AID760503	Inhibition of HDAC10 (unknown origin) using fluorogenic peptide from p53 residues (379 to 382) (RHKK(Ac)) as substrate by fluorescence assay	2013	ACS medicinal chemistry letters, Aug-08, Volume: 4, Issue:8	Development of a chimeric c-Src kinase and HDAC inhibitor.
AID1511135	Inhibition of HDAC5 (unknown origin) using Ac-LeuGlyLys(tfa)-AMC as substrate preincubated for 5 mins followed by substrate addition and measured after 60 mins by fluorescence based assay	2019	ACS medicinal chemistry letters, Aug-08, Volume: 10, Issue:8	Design, Synthesis, and Biological Evaluation of 2,4-Imidazolinedione Derivatives as HDAC6 Isoform-Selective Inhibitors.
AID499811	Cytotoxicity against african green monkey Vero cells after 72 hrs by MTS assay	2010	Journal of medicinal chemistry, Aug-26, Volume: 53, Issue:16	Non-peptide macrocyclic histone deacetylase inhibitors derived from tricyclic ketolide skeleton.
AID711156	Inhibition of HDAC4 by fluorometric assay	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	Rapid discovery of highly potent and selective inhibitors of histone deacetylase 8 using click chemistry to generate candidate libraries.
AID1547314	Increase in LIFR expression in tumor tissue of BALB/cAnNCrl mouse xenografted with human HCT116 cells at 30 mg/kg, po administered on day 1 to day 19 measured on day 19 by immunohistochemical analysis	2020	Journal of medicinal chemistry, 04-09, Volume: 63, Issue:7	Discovery of Thieno[2,3-
AID760519	Cytotoxicity against human HMEC after 72 hrs by WST1 assay	2013	ACS medicinal chemistry letters, Aug-08, Volume: 4, Issue:8	Development of a chimeric c-Src kinase and HDAC inhibitor.
AID760373	Cytotoxicity against HDF after 72 hrs by MTS assay	2013	ACS medicinal chemistry letters, Aug-08, Volume: 4, Issue:8	Tropolones as lead-like natural products: the development of potent and selective histone deacetylase inhibitors.
AID1547259	Inhibition of human recombinant His-tagged BRD3 BD2 domain expressed in Escherichia coli BL21(DE3)-R3-pRARE2 cells by AlphaScreen assay	2020	Journal of medicinal chemistry, 04-09, Volume: 63, Issue:7	Discovery of Thieno[2,3-
AID628287	Antiproliferative activity against human HepG2 cells after 48 hrs by XTT assay	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Design, synthesis, docking, and biological evaluation of novel diazide-containing isoxazole- and pyrazole-based histone deacetylase probes.
AID524998	Inhibition of HDAC5 by in vitro deacetylation assay	2010	Nature chemical biology, Jan, Volume: 6, Issue:1	Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.
AID670013	Inhibition of human recombinant HDAC1 using Boc-lys(Ac)-AMC as substrate preincubated for 20 mins with substrate measured after 60 mins by fluorescence analysis	2012	Journal of medicinal chemistry, Feb-23, Volume: 55, Issue:4	Defining the mechanism of action and enzymatic selectivity of psammaplin A against its epigenetic targets.
AID1164798	Intrinsic clearance in human hepatocytes assessed per million cells at 5 uM by LCMS/MS analysis	2014	Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20	ST7612AA1, a thioacetate-ω(γ-lactam carboxamide) derivative selected from a novel generation of oral HDAC inhibitors.
AID1454050	Induction of ATRA-induced human HL60 cell differentiation pretreated for 1 hr followed by ATRA addition measured after 3 days by Wright-Giemsa staining based microscopic analysis	2017	Bioorganic & medicinal chemistry, 07-15, Volume: 25, Issue:14	Synthesis and evaluation of novel dual BRD4/HDAC inhibitors.
AID1598103	Activation of Tat-mediated HIV1 transcription in J-Lat 10.6 cells harboring LTR driven GFP reporter co-expressing CMV driven RFP reporter assessed as LTR-driven gene expression incubated for 48 hr by FACSCalibur flow cytometry	2019	Journal of medicinal chemistry, 05-23, Volume: 62, Issue:10	Identification of 5-Substituted 2-Acylaminothiazoles That Activate Tat-Mediated Transcription in HIV-1 Latency Models.
AID1614130	Inhibition of recombinant full length HDAC6 (unknown origin) using Ac-peptide-AMC as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by fluorescence assay
AID1742703	Induction of apoptosis in human MDA-MB-231 cells assessed as viable cells at 5 uM incubated for 72 hrs by annexinV-FITC and PI staining based flow cytometry analysis (Rvb = 90.3 %)	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Design and synthesis of novel Flavone-based histone deacetylase inhibitors antagonizing activation of STAT3 in breast cancer.
AID1251319	Growth inhibition of human IGROV1/Pt1 cells after 72 hrs	2015	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 25, Issue:20	Investigation on the ZBG-functionality of phenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase inhibitors.
AID1737154	Induction of apoptosis in human HCT-116 cells assessed as necrotic cells at 10 uM after 24 hrs by Annexin V-FITC/PI staining based flow cytometric analysis (Rvb = 0.51%)	2020	European journal of medicinal chemistry, Apr-15, Volume: 192	Design, synthesis and biological evaluation of novel indazole-based derivatives as potent HDAC inhibitors via fragment-based virtual screening.
AID1863173	Inhibition of HDAC3 (unknown origin) using fluorogenic substrate incubated for 30 mins by fluorescence plate reader	2022	European journal of medicinal chemistry, Oct-05, Volume: 240	Design, synthesis, and biological evalution of bifunctional inhibitors against Hsp90-HDAC6 interplay.
AID1396960	Antiproliferative activity against human PC3 cells	2018	Bioorganic & medicinal chemistry letters, 08-15, Volume: 28, Issue:15	Merging of ruxolitinib and vorinostat leads to highly potent inhibitors of JAK2 and histone deacetylase 6 (HDAC6).
AID1819531	Toxicity in C57BL/6J mouse implanted with mouse B16-F10 cells assessed as effect on body weight at 60 mg/kg, IG administered for 12 days	2022	Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4	Discovery of DNA-Targeting HDAC Inhibitors with Potent Antitumor Efficacy In Vivo That Trigger Antitumor Immunity.
AID603542	Inhibition of HDAC in human HeLa cell nuclear extract after 30 mins by fluorescence microplate reader	2011	Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8	Development of tetrahydroisoquinoline-based hydroxamic acid derivatives: potent histone deacetylase inhibitors with marked in vitro and in vivo antitumor activities.
AID434539	Cytotoxicity against human HCT116 cells after 24 hrs by sulforhodamine B assay	2009	Bioorganic & medicinal chemistry letters, May-15, Volume: 19, Issue:10	Exploring bis-(indolyl)methane moiety as an alternative and innovative CAP group in the design of histone deacetylase (HDAC) inhibitors.
AID1598093	Cytotoxicity against human HepG2 cells assessed as reduction in cell growth incubated for 48 hrs by CellTiter-Glo assay	2019	Journal of medicinal chemistry, 05-23, Volume: 62, Issue:10	Identification of 5-Substituted 2-Acylaminothiazoles That Activate Tat-Mediated Transcription in HIV-1 Latency Models.
AID586608	Antimalarial activity against trophozoites stage of Plasmodium falciparum assessed as parasites growth inhibition using giemsa staining after 24 to 56 hrs by microscopic analysis in presence of 10% human serum	2011	Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3	Ex vivo activity of histone deacetylase inhibitors against multidrug-resistant clinical isolates of Plasmodium falciparum and P. vivax.
AID1784187	Inhibition of human recombinant HDAC8 using H2N-Arg-His-Lys(Ac)-Lys(Ac)-AMC as substrate after 90 mins by fluorescence based micro plate assay	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Synthesis, structure-activity relationships, cocrystallization and cellular characterization of novel smHDAC8 inhibitors for the treatment of schistosomiasis.
AID322422	Antitumor activity against human LNCap cells xenografted SCID mouse model at 20 to 10 mg/kg/day, sc relative to control	2008	Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6	Improved synthesis of histone deacetylase inhibitors (HDIs) (MS-275 and CI-994) and inhibitory effects of HDIs alone or in combination with RAMBAs or retinoids on growth of human LNCaP prostate cancer cells and tumor xenografts.
AID1200985	AUC (0 to infinity) in ICR mouse at 50 mg/kg, po	2015	Journal of medicinal chemistry, Mar-26, Volume: 58, Issue:6	Design and synthesis of orally bioavailable aminopyrrolidinone histone deacetylase 6 inhibitors.
AID1890334	Stability in human liver microsomes assessed as half-life and measured by LC-MS/MS analysis	2022	European journal of medicinal chemistry, Apr-05, Volume: 233	Novel biphenyl-based scaffold as potent and selective histone deacetylase 6 (HDAC6) inhibitors: Identification, development and pharmacological evaluation.
AID1126999	Induction of apoptosis in human U937 cells assessed as necrotic cells using annexin-V/propidium iodide staining at 0.5 uM after 24 hrs by flow cytometry analysis (Rvb = 0.06%)	2014	Journal of medicinal chemistry, Apr-24, Volume: 57, Issue:8	Discovery of the first N-hydroxycinnamamide-based histone deacetylase 1/3 dual inhibitors with potent oral antitumor activity.
AID1227046	Drug degradation in human plasma assessed as unidentifiable product formation after 2 hrs by HPLC analysis	2015	Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11	Dual-Mode HDAC Prodrug for Covalent Modification and Subsequent Inhibitor Release.
AID1349721	Cytotoxicity against human A549 cells assessed as inhibition of cell growth after 72 hrs by MTT assay	2018	ACS medicinal chemistry letters, Jan-11, Volume: 9, Issue:1	Dual NAMPT/HDAC Inhibitors as a New Strategy for Multitargeting Antitumor Drug Discovery.
AID1633992	Inhibition of HDAC6 in human HuH7 cells assessed as increase in alpha-tubulin K40 acetylation at varying concentrations incubated for 24 hrs by Western blot analysis	2019	Bioorganic & medicinal chemistry letters, 08-15, Volume: 29, Issue:16	Synthesis of N'-propylhydrazide analogs of hydroxamic inhibitors of histone deacetylases (HDACs) and evaluation of their impact on activities of HDACs and replication of hepatitis C virus (HCV).
AID761580	Antiproliferative activity against human K562 cells after 72 hrs by CellTiter-Glo assay	2013	European journal of medicinal chemistry, Aug, Volume: 66	Design, synthesis and preliminary evaluation of a series of histone deacetylase inhibitors carrying a benzodiazepine ring.
AID1061955	Inhibition of human HDAC1 using RHKK(Ac) as substrate by fluorimetric analysis	2014	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1	Lactam based 7-amino suberoylamide hydroxamic acids as potent HDAC inhibitors.
AID1361638	Inhibition of HDAC in human A549 cells assessed as increase in histone H3 acetylation after 24 hrs by Western blot analysis	2018	Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16	Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents.
AID1487087	Selectivity index, ratio of IC50 for HDAC6 (unknown origin) to IC50 for HDAC3 (unknown origin)	2017	Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15	The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity.
AID1659656	Antiproliferative activity against human A549 cells incubated for 24 hrs by CCK8 assay	2020	Bioorganic & medicinal chemistry letters, 06-01, Volume: 30, Issue:11	Environment-sensitive fluorescent inhibitors of histone deacetylase.
AID1808548	Inhibition of recombinant human full length C-terminal His-tagged HDAC8 expressed in baculovirus infected Sf9 insect cells using fluorometric substrate measured after 60 mins by FRET assay	2021	Journal of medicinal chemistry, 04-08, Volume: 64, Issue:7	Structure-Based Design of a Selective Class I Histone Deacetylase (HDAC) Near-Infrared (NIR) Probe for Epigenetic Regulation Detection in Triple-Negative Breast Cancer (TNBC).
AID1900936	Toxicity in mouse bearing intracranial tumor assessed as last day of survival at 50 mg/kg, ip in presence of clorgyline for 10 days (Rvb=16 days)	2022	Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
AID350725	Growth inhibition of human HBC5 cells after 48 hrs by sulforhodamine B assay	2009	Journal of medicinal chemistry, May-14, Volume: 52, Issue:9	Design, synthesis, and biological activity of boronic acid-based histone deacetylase inhibitors.
AID488355	Agonist activity at VDR in human SCC4 cells assessed as induction of CYP24 gene expression at 1 uM after 5 to 10 mins by RT-PCR analysis	2010	Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11	Vitamin D receptor agonist/histone deacetylase inhibitor molecular hybrids.
AID352522	Antiproliferative activity against human HUPT3 cells by MTT assay	2009	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11	Isoxazole moiety in the linker region of HDAC inhibitors adjacent to the Zn-chelating group: effects on HDAC biology and antiproliferative activity.
AID1886182	Inhibition of HDAC in human HeLa cells using BOC-K(Ac)-AMC as substrate at 1 uM measured after 30 mins by fluorescence based microtiter plate reader assay relative to control	2022	Journal of medicinal chemistry, 08-25, Volume: 65, Issue:16	Discovery of a Novel Vascular Disrupting Agent Inhibiting Tubulin Polymerization and HDACs with Potent Antitumor Effects.
AID1572377	Ratio of inhibition of HDAC6 in human HL60 cells assessed as acetylated tubulin/GAPDH ratio at 10 uM to inhibition of HDAC in human HL60 cells assessed as acetylated H3/GAPDH ratio at 1 uM	2019	Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3	Synthesis and Biological Investigation of Phenothiazine-Based Benzhydroxamic Acids as Selective Histone Deacetylase 6 Inhibitors.
AID1742627	Inhibition of HDAC in human HeLa cell extracts assessed as inhibition of substrate deacetylation using Boc-Lys (q-Ac)-AMC as substrate incubated for 10 mins followed by substrate addition and measured after 30 mins by fluorescence based assay	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Design and synthesis of novel Flavone-based histone deacetylase inhibitors antagonizing activation of STAT3 in breast cancer.
AID1449682	Antiproliferative activity against human K562 cells after 48 hrs by MTT assay	2017	Bioorganic & medicinal chemistry, 05-01, Volume: 25, Issue:9	Development of N-hydroxycinnamamide-based HDAC inhibitors with improved HDAC inhibitory activity and in vitro antitumor activity.
AID1667071	Antiproliferative activity in human MDA-MB-231 cells assessed as inhibition of cell viability after 72 hrs by MTS assay	2020	Bioorganic & medicinal chemistry, 03-15, Volume: 28, Issue:6	Pyrimethamine conjugated histone deacetylase inhibitors: Design, synthesis and evidence for triple negative breast cancer selective cytotoxicity.
AID1578476	Inhibition of recombinant full length human HDAC6 expressed in baculovirus infected Sf9 cells using FAM-RHKK-Ac as substrate incubated for 5 hrs by electrophoretic mobility shift assay	2020	ACS medicinal chemistry letters, Jan-09, Volume: 11, Issue:1	Class I/IIb-Selective HDAC Inhibitor Exhibits Oral Bioavailability and Therapeutic Efficacy in Acute Myeloid Leukemia.
AID1166497	Inhibition of human recombinant full length HDAC3 using (Ac)-Lys-Tyr-Lys(-acetyl)-AMC substrate after 30 mins	2014	Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21	Design, synthesis and biological evaluation of 4-anilinothieno[2,3-d]pyrimidine-based hydroxamic acid derivatives as novel histone deacetylase inhibitors.
AID1401477	Selectivity ratio of IC50 for HDAC1 in human HeLa-S3 cell lysates to IC50 for recombinant full-length C-terminal His-tagged HDAC8 expressed in baculovirus infected Sf9 insect cell	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
AID1865303	Toxicity in BALB/c mouse model allografted with mouse 4T1 cells assessed as effect on kidney at 40 mg/kg, po qd administered for 12 days	2022	Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18	Discovery of Novel Src Homology-2 Domain-Containing Phosphatase 2 and Histone Deacetylase Dual Inhibitors with Potent Antitumor Efficacy and Enhanced Antitumor Immunity.
AID297484	Cytotoxicity against human A2780 cells	2007	Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18	2-aroylindoles and 2-aroylbenzofurans with N-hydroxyacrylamide substructures as a novel series of rationally designed histone deacetylase inhibitors.
AID1676590	Binding affinity to Nickel cation assessed as retention ratio by measuring compound detected in elution fraction/total compound detected at 2.55 umol by immobilized metal-ion affinity chromatography	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
AID1485112	Inhibition of SIRT1 in human Hs683 cells assessed as increase of histone H4 acetylation at 2 uM after 8 hrs by Western blotting method relative to control	2017	Journal of medicinal chemistry, 06-08, Volume: 60, Issue:11	Discovery and Characterization of R/S-N-3-Cyanophenyl-N'-(6-tert-butoxycarbonylamino-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-4-yl)urea, a New Histone Deacetylase Class III Inhibitor Exerting Antiproliferative Activity against Cancer Cell Lines.
AID1441675	Anti-inflammatory activity in BLM-induced C57BL/6 mouse model of acute lung neutrophilic inflammation assessed as MPO activity at 50 mg/kg, ip qd for 7 days post BLM challenge measured on day 7 (Rvb = 0.98 U/g)	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
AID1882457	Inhibition of HDAC2 (unknown origin)	2022	Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4	Chasing a Breath of Fresh Air in Cystic Fibrosis (CF): Therapeutic Potential of Selective HDAC6 Inhibitors to Tackle Multiple Pathways in CF Pathophysiology.
AID90344	Induction of p21 using Histone deacetylase inhibitors	2002	Journal of medicinal chemistry, Feb-14, Volume: 45, Issue:4	Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates.
AID1578495	Induction of apoptosis in human MV4-11 cells assessed as late apoptotic cells at 0.5 uM incubated for 18 hrs by annexin V FITC and PI based flow cytometry (Rvb = 9.2 to 9.63 %)	2020	ACS medicinal chemistry letters, Jan-09, Volume: 11, Issue:1	Class I/IIb-Selective HDAC Inhibitor Exhibits Oral Bioavailability and Therapeutic Efficacy in Acute Myeloid Leukemia.
AID593549	Inhibition of human HDAC4 using ArgHisLysLys(Ac) fluorogenic peptide as a substrate by fluorimetric assay	2011	Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7	Oxime amides as a novel zinc binding group in histone deacetylase inhibitors: synthesis, biological activity, and computational evaluation.
AID1164914	Inhibition of HDAC9 (unknown origin) using fluorogenic peptide as substrate by fluorescence assay	2014	Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19	Identification of a novel aminotetralin class of HDAC6 and HDAC8 selective inhibitors.
AID1887063	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 3 days by methylene blue staining based analysis	2022	Journal of medicinal chemistry, 09-08, Volume: 65, Issue:17	Tunable Cysteine-Targeting Electrophilic Heteroaromatic Warheads Induce Ferroptosis.
AID1722284	Inhibition of HDAC6 in human MDA-MB-231 cells assessed as accumulation of alpha tubulin acetylation at 1.25 to 5 uM incubated for 24 hrs by Western blot analysis	2020	Bioorganic & medicinal chemistry, 09-01, Volume: 28, Issue:17	The design of a novel near-infrared fluorescent HDAC inhibitor and image of tumor cells.
AID1380943	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	2018	Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12	Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously.
AID1848618	Cytotoxicity against human NCI-H23 cells assessed as cell growth inhibition at 10 uM incubated for 24 hrs by MTT assay	2022	Journal of medicinal chemistry, 11-10, Volume: 65, Issue:21	First-in-Class Dual Mechanism Ferroptosis-HDAC Inhibitor Hybrids.
AID438217	Inhibition of HDAC8	2009	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23	Design and synthesis of novel histone deacetylase inhibitor derived from nuclear localization signal peptide.
AID1246523	Therapeutic index, ratio of CC50 for HEK293 cells to IC50 for human K562 cells	2015	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 25, Issue:19	Discovery of 1-hydroxypyridine-2-thiones as selective histone deacetylase inhibitors and their potential application for treating leukemia.
AID1742663	Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Design and synthesis of novel Flavone-based histone deacetylase inhibitors antagonizing activation of STAT3 in breast cancer.
AID1177053	Antiprotozoan activity against Plasmodium falciparum NF54 IEF forms	2015	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 25, Issue:3	Hydroxamic acid based histone deacetylase inhibitors with confirmed activity against the malaria parasite.
AID1541460	Inhibition of class 1 HDAC in human CAL27 cells assessed as potentiation of cisplatin-induced cytotoxicity by measuring fold reduction in cisplatin IC50 at 0.5 uM preincubated for 48 hrs followed by cisplatin addition and measured after 72 hrs by MTT assa	2019	Journal of medicinal chemistry, 12-26, Volume: 62, Issue:24	Synthesis of Peptoid-Based Class I-Selective Histone Deacetylase Inhibitors with Chemosensitizing Properties.
AID1865301	Toxicity in BALB/c mouse model allografted with mouse 4T1 cells assessed as effect on spleen at 40 mg/kg, po qd administered for 12 days	2022	Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18	Discovery of Novel Src Homology-2 Domain-Containing Phosphatase 2 and Histone Deacetylase Dual Inhibitors with Potent Antitumor Efficacy and Enhanced Antitumor Immunity.
AID294382	Inhibition of HDAC by fluorescent assay	2007	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 17, Issue:8	Structural requirements of HDAC inhibitors: SAHA analogs functionalized adjacent to the hydroxamic acid.
AID663470	Half life in mouse liver microsomes	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Discovery and extensive in vitro evaluations of NK-HDAC-1: a chiral histone deacetylase inhibitor as a promising lead.
AID608776	Inhibition of HDAC in human HeLa cells using Ac-Arg-Gly-Lys(Ac)-AMC as fluorescent substrate after 20 mins by fluorescence assay	2011	European journal of medicinal chemistry, Aug, Volume: 46, Issue:8	Structure-based optimization of click-based histone deacetylase inhibitors.
AID1128561	Inhibition of human HDAC-8 using RHK(Ac)K(Ac) as substrate	2014	European journal of medicinal chemistry, Apr-09, Volume: 76	4,5,6,7-Tetrahydro-isoxazolo-[4,5-c]-pyridines as a new class of cytotoxic Hsp90 inhibitors.
AID663352	Growth inhibition of human NCI-H226 cells after 72 hrs by MTS assay	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Discovery and extensive in vitro evaluations of NK-HDAC-1: a chiral histone deacetylase inhibitor as a promising lead.
AID420646	Antitumor activity against human HCT116 cells athymic nude Swiss mouse assessed as tumor volume inhibition at 100 mg/kg, po QD administered 5 days a week for 4 weeks	2009	European journal of medicinal chemistry, May, Volume: 44, Issue:5	Design, synthesis, and evaluation of biphenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors.
AID1740129	Inhibition of recombinant human C-terminal FLAG/His-tagged HDAC1 (1 to 482 residues) expressed in sf9 cells using acetyl-Lys(Ac)-AMC as substrate	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight.
AID1875509	Cytotoxicity against HMEC cells assessed as inhibition of cell growth incubated for 3 days by alamar blue assay	2022	ACS medicinal chemistry letters, Oct-13, Volume: 13, Issue:10	Cancer-Cell-Selective Targeting by Arylcyclopropylamine-Vorinostat Conjugates.
AID274169	Antiproliferative activity against H661 cells	2006	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 16, Issue:20	Synthesis of rigid trichostatin A analogs as HDAC inhibitors.
AID609495	Ratio of IC50 for CYP3A4 to IC50 for human HCT116 cells	2011	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16	The design, synthesis and structure-activity relationships of novel isoindoline-based histone deacetylase inhibitors.
AID1514613	Induction of apoptosis in human HepG2 cells assessed as late apoptotic cells at 5 uM after 48 hrs by annexin V-FITC/propidium iodide staining based assay (Rvb = 1.8 %)	2019	Bioorganic & medicinal chemistry letters, 01-01, Volume: 29, Issue:1	Development of hydroxamate-based histone deacetylase inhibitors containing 1,2,4-oxadiazole moiety core with antitumor activities.
AID1771460	Antiproliferative activity against human HeLa cells assessed as cell growth inhibition after 72 hrs by SRB assay	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Discovery of novel tubulin/HDAC dual-targeting inhibitors with strong antitumor and antiangiogenic potency.
AID1886174	Antiproliferative activity against human K562 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	2022	Journal of medicinal chemistry, 08-25, Volume: 65, Issue:16	Discovery of a Novel Vascular Disrupting Agent Inhibiting Tubulin Polymerization and HDACs with Potent Antitumor Effects.
AID1898909	Antiproliferative activity against human MDA-MB-231 cells incubated for 24 hrs followed by incubating in drug-free medium for 48 hrs and measured by SRB assay	2022	European journal of medicinal chemistry, Jan-15, Volume: 228	Antitumor activity of novel POLA1-HDAC11 dual inhibitors.
AID1742652	Cytotoxicity against human BT-549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Design and synthesis of novel Flavone-based histone deacetylase inhibitors antagonizing activation of STAT3 in breast cancer.
AID1821963	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay
AID1742651	Cytotoxicity against human MDA-MB-468 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Design and synthesis of novel Flavone-based histone deacetylase inhibitors antagonizing activation of STAT3 in breast cancer.
AID1403180	Inhibition of ERK1/2 phosphorylation in human HepG2 cells at 2 uM after 48 hrs by Western blot analysis	2018	European journal of medicinal chemistry, Jan-20, Volume: 144	Development of novel β-carboline-based hydroxamate derivatives as HDAC inhibitors with antiproliferative and antimetastatic activities in human cancer cells.
AID1650409	Inhibition of recombinant human HDAC8	2020	Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1	Novel alkoxyamide-based histone deacetylase inhibitors reverse cisplatin resistance in chemoresistant cancer cells.
AID717658	Inhibition of HDAC6 using Fluor-de-Lys as substrate assessed as remaining activity at 6.25 x 10'-8 M pretreated for 30 mins before substrate addition by fluorescence assay	2012	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23	The structural requirements of histone deacetylase inhibitors: suberoylanilide hydroxamic acid analogs modified at the C6 position.
AID1127319	Antiproliferative activity against human H460 cells assessed as growth inhibition after 72 hrs	2014	European journal of medicinal chemistry, May-22, Volume: 79	Influence of the adamantyl moiety on the activity of biphenylacrylohydroxamic acid-based HDAC inhibitors.
AID1227030	Inhibition of human recombinant HDAC2 using MAZ1600 as fluorogenic substrate measured every 5 mins by optimized homogenous fluorescence based assay	2015	Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11	Dual-Mode HDAC Prodrug for Covalent Modification and Subsequent Inhibitor Release.
AID737917	Inhibition of recombinant HDAC1 (unknown origin) after 10 mins by fluorimetric analysis	2013	Journal of medicinal chemistry, May-09, Volume: 56, Issue:9	Design and synthesis of dual-action inhibitors targeting histone deacetylases and 3-hydroxy-3-methylglutaryl coenzyme A reductase for cancer treatment.
AID1281868	Induction of apoptosis in human RPMI8226 cells assessed as viable cells at 3 uM after 48 hrs by annexin V-FITC/propidium iodide staining-based flow cytometry (Rvb = 87.2%)	2016	European journal of medicinal chemistry, Apr-13, Volume: 112	Design, synthesis and biological evaluation of bisthiazole-based trifluoromethyl ketone derivatives as potent HDAC inhibitors with improved cellular efficacy.
AID1890333	Stability in mouse liver microsomes assessed as clearance and measured by LC-MS/MS analysis	2022	European journal of medicinal chemistry, Apr-05, Volume: 233	Novel biphenyl-based scaffold as potent and selective histone deacetylase 6 (HDAC6) inhibitors: Identification, development and pharmacological evaluation.
AID1623524	Inhibition of HDAC2 (unknown origin) using fluorogenic HDAC substrate-3 by fluorescence assay	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	A novel class of anthraquinone-based HDAC6 inhibitors.
AID618084	Toxicity in athymic nu/nu Harlan mouse xenografted with human HCT116 cells assessed as body weight loss at 300 mg/kg, po QD for 21 days measured on day 19	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile.
AID1281850	Inhibition of full length His6-tagged GST-fused recombinant human HDAC6 expressed in High5 insect cells using Boc-Lys (e-acetyl)-AMC as substrate after 3 hrs by fluorescence assay	2016	European journal of medicinal chemistry, Apr-13, Volume: 112	Design, synthesis and biological evaluation of bisthiazole-based trifluoromethyl ketone derivatives as potent HDAC inhibitors with improved cellular efficacy.
AID1901057	Inhibition of HDAC6 (unknown origin) using trypsin and Ac-peptide as substrates	2022	European journal of medicinal chemistry, Feb-15, Volume: 230	Novel PHD2/HDACs hybrid inhibitors protect against cisplatin-induced acute kidney injury.
AID408881	Inhibition of HDAC2	2008	Journal of medicinal chemistry, Jun-26, Volume: 51, Issue:12	A series of potent and selective, triazolylphenyl-based histone deacetylases inhibitors with activity against pancreatic cancer cells and Plasmodium falciparum.
AID1441655	Anti-inflammatory activity in LPS-induced C57BL/6 mouse model of acute lung injury assessed as reduction in pathological changes at 25 mg/kg, ip pretreated for 1 hr followed LPS challenge measured after 24 hrs by hematoxylin and eosin staining based micro	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
AID1398811	Antagonist activity at ERalpha in human MCF7 cells assessed as down regulation of ESR1 expression at 0.1 to 9 uM after 8 hrs by Western blot analysis	2018	Bioorganic & medicinal chemistry, 08-15, Volume: 26, Issue:15	Incorporation of histone deacetylase inhibitory activity into the core of tamoxifen - A new hybrid design paradigm.
AID1566824	Antiproliferative activity against human Ramos cells after 72 hrs by MTT assay	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Discovery of 1,2,4-oxadiazole-Containing hydroxamic acid derivatives as histone deacetylase inhibitors potential application in cancer therapy.
AID316872	Inhibition of HDAC from human K562 cells	2008	Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6	Histone deacetylase inhibitors: from bench to clinic.
AID476830	Toxicity in FVB mouse assessed as effect on mean cell volume of red cells at 50 mg/kg, po administered 5 times per week for 2 weeks (Rvb = 43.7 +/- 0.4 microm^3)	2010	Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8	Modified cap group suberoylanilide hydroxamic acid histone deacetylase inhibitor derivatives reveal improved selective antileukemic activity.
AID619141	1-Octanol-sodium phosphate buffer distribution coefficient, log D of the compound at pH 7.4	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile.
AID1406983	Inhibition of class 1 HDAC in human NB4 cells assessed as levels of histone H3 acetylation at lysine 9/14 at 5 uM after 30 hrs by Western blot analysis relative to control	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Novel spiroindoline HDAC inhibitors: Synthesis, molecular modelling and biological studies.
AID316901	Inhibition of human MDA-MB-231 cells	2008	Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6	Histone deacetylase inhibitors: from bench to clinic.
AID366642	Inhibition of HDAC3 after 17 hrs	2008	Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15	Use of the nitrile oxide cycloaddition (NOC) reaction for molecular probe generation: a new class of enzyme selective histone deacetylase inhibitors (HDACIs) showing picomolar activity at HDAC6.
AID1476154	Antiproliferative activity against human KMS-12-BM cells after 48 hrs by CellTiter-Glo luminescent assay	2017	Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20	Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat.
AID1485127	Cell cycle arrest in human Hs683 cells assessed as accumulation at G1 phase at 2 uM after 24 to 48 hrs by propidium iodide staining-based flow cytometry	2017	Journal of medicinal chemistry, 06-08, Volume: 60, Issue:11	Discovery and Characterization of R/S-N-3-Cyanophenyl-N'-(6-tert-butoxycarbonylamino-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-4-yl)urea, a New Histone Deacetylase Class III Inhibitor Exerting Antiproliferative Activity against Cancer Cell Lines.
AID1901152	Inhibition of HDAC1 (unknown origin) using FAM-RHKK(Ac)-NH2/FAM-RHKK(trifluoroacetyl)-NH2 as substrate preincubated for 15 mins followed by substrate addition and measured after 3 hrs by microfluidic chip based fluorescence assay	2022	Bioorganic & medicinal chemistry, 02-15, Volume: 56	Synthesis and biological evaluation of aminobenzamides containing purine moiety as class I histone deacetylases inhibitors.
AID1281869	Induction of apoptosis in human RPMI8226 cells assessed as early apoptotic cells at 3 uM after 48 hrs by annexin V-FITC/propidium iodide staining-based flow cytometry (Rvb = 6.3%)	2016	European journal of medicinal chemistry, Apr-13, Volume: 112	Design, synthesis and biological evaluation of bisthiazole-based trifluoromethyl ketone derivatives as potent HDAC inhibitors with improved cellular efficacy.
AID747261	Growth inhibition of human A549 cells by MTT assay	2013	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 23, Issue:11	Design, synthesis, and biological evaluation of novel histone deacetylase 1 inhibitors through click chemistry.
AID1497924	Induction of CRBN ubiquitin ligase-mediated HDAC1 degradation in human MCF7 cells assessed as decrease in HDAC1 levels at 10 uM after 12 hrs by immunoblotting analysis	2018	Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14	Development of the first small molecule histone deacetylase 6 (HDAC6) degraders.
AID1170743	Inhibition of human recombinant HDAC8 using [Ac-Leu-Gly-Lys(Ac)-AMC substrate incubated for 15 to 30 mins	2014	Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22	Methyl effect in azumamides provides insight into histone deacetylase inhibition by macrocycles.
AID1312899	Toxicity in NOD/SCID mouse xenografted with human MV4-11 cells assessed as body weight loss at 50 mg/kg, ip administered every 2 days for 11 days measured on day 17 post last dose	2016	Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11	Development of Purine-Based Hydroxamic Acid Derivatives: Potent Histone Deacetylase Inhibitors with Marked in Vitro and in Vivo Antitumor Activities.
AID1421922	Antimalarial activity against Plasmodium falciparum 3D7 infected in human erythrocytes assessed as reduction in [3H]-hypoxanthine incorporation preincubated for 48 hrs followed by [3H]-hypoxanthine addition measured after 24 hrs by scintillation counting	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	One-pot, multi-component synthesis and structure-activity relationships of peptoid-based histone deacetylase (HDAC) inhibitors targeting malaria parasites.
AID327549	Cytotoxicity against human HCT116 cells assessed as cell viability after 96 hrs by MTS reduction assay	2008	Journal of medicinal chemistry, Apr-24, Volume: 51, Issue:8	Polyaminohydroxamic acids and polyaminobenzamides as isoform selective histone deacetylase inhibitors.
AID1433301	Induction of DNA damage in p53 null human U937 cells assessed as decrease in CHK1 expression level by measuring ratio of CHK1 to beta-actin level at 2 uM after 24 hrs by Western blot analysis relative to control	2016	Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17	Synthesis and Antileukemic Activities of Piperlongumine and HDAC Inhibitor Hybrids against Acute Myeloid Leukemia Cells.
AID1401481	Selectivity ratio of IC50 for recombinant full-length C-terminal His-tagged HDAC8 expressed in baculovirus infected Sf9 insect cell to IC50 for HDAC1 in human HeLa-S3 cell lysates	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
AID1303685	Inhibition of HDAC1 in human Jurkat cells extract after 30 mins by immunoprecipitation assay	2016	Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13	Synergistic potentiation of (-)-lomaiviticin A cytotoxicity by the ATR inhibitor VE-821.
AID1690105	Inhibition of HSP90a (unknown origin)	2020	European journal of medicinal chemistry, Mar-15, Volume: 190	Isoindoline scaffold-based dual inhibitors of HDAC6 and HSP90 suppressing the growth of lung cancer in vitro and in vivo.
AID480067	Inhibition of human recombinant HDAC2 preincubated for 1 hr with substrate by protease coupled end-point assay	2010	Bioorganic & medicinal chemistry letters, May-15, Volume: 20, Issue:10	Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl)benzamides.
AID663378	Growth inhibition of human LOXIMVI cells after 72 hrs by MTS assay	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Discovery and extensive in vitro evaluations of NK-HDAC-1: a chiral histone deacetylase inhibitor as a promising lead.
AID1225977	Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay	2015	ACS medicinal chemistry letters, Mar-12, Volume: 6, Issue:3	Discovery of Novel Multiacting Topoisomerase I/II and Histone Deacetylase Inhibitors.
AID1398803	Cytotoxicity against ER negative human MDA-MB-231 cells treated every 2 days for 4 days measured post last dose by CellTiter-Glo luminescence assay	2018	Bioorganic & medicinal chemistry, 08-15, Volume: 26, Issue:15	Incorporation of histone deacetylase inhibitory activity into the core of tamoxifen - A new hybrid design paradigm.
AID274066	AUC after oral dosing at 5 mg kg-1	2007	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2	Identification and optimisation of a series of substituted 5-(1H-pyrazol-3-yl)-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.
AID304372	Inhibition of human IMPDH 2	2007	Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26	Dual inhibitors of inosine monophosphate dehydrogenase and histone deacetylases for cancer treatment.
AID1819554	Antitumor activity against mouse B16-F10 cells xenografted in C57BL/6J mouse assessed as reduction in tumor heterogeneity at 60 mg/kg, IG administered for 12 days by H and E staining based histopathological analysis	2022	Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4	Discovery of DNA-Targeting HDAC Inhibitors with Potent Antitumor Efficacy In Vivo That Trigger Antitumor Immunity.
AID1462022	Inhibition of HDAC in human HeLa nuclear extract preincubated for 5 mins followed by Boc-Lys (acetyl)-AMC addition measured after 10 mins by fluorescence assay	2017	Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17	Discovery of a tetrahydroisoquinoline-based HDAC inhibitor with improved plasma stability.
AID350722	Ratio of GI50 for human MKN45 cells to IC50 for HDAC in human HeLa cells	2009	Journal of medicinal chemistry, May-14, Volume: 52, Issue:9	Design, synthesis, and biological activity of boronic acid-based histone deacetylase inhibitors.
AID588213	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID725666	Selectivity ratio of IC50 for C-terminal His-tagged and C-terminal FLAG-tagged full length human recombinant HDAC1 to IC50 for C-terminal His-tagged human recombinant HDAC9 (amino acids 604- 1066) by fluorescence analysis	2013	ACS medicinal chemistry letters, Jan-10, Volume: 4, Issue:1	Biological evaluation of new largazole analogues: alteration of macrocyclic scaffold with click chemistry.
AID672027	Inhibition of human recombinant HDAC3 using Boc-L-Lys (Ac)-AMC as substrate preincubated with compound for 3 hrs at 10 uM measured after 35 mins by spectrofluorometric analysis	2012	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 22, Issue:15	Design, synthesis, modeling, biological evaluation and photoaffinity labeling studies of novel series of photoreactive benzamide probes for histone deacetylase 2.
AID1373246	Inhibition of HDAC6 (unknown origin) preincubated for 10 mins followed by Ac-Leu-GlyLys(Ac)-AMC substrate addition measured after 30 mins by fluorescence based assay	2018	Bioorganic & medicinal chemistry, 02-01, Volume: 26, Issue:3	Design, synthesis and evaluate of novel dual FGFR1 and HDAC inhibitors bearing an indazole scaffold.
AID1597939	Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	2019	Bioorganic & medicinal chemistry letters, 09-15, Volume: 29, Issue:18	Anti-tumor activity evaluation of novel tubulin and HDAC dual-targeting inhibitors.
AID1727733	Antiproliferative activity against human MV4-11 cells assessed as cell viability after 72 hrs by CCK8 assay	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	Discovery of selective HDAC/BRD4 dual inhibitors as epigenetic probes.
AID1856996	Antiproliferative activity against human SU-DHL-10 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	2022	Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19	Histone Deacetylase and Enhancer of Zeste Homologue 2 Dual Inhibitors Presenting a Synergistic Effect for the Treatment of Hematological Malignancies.
AID1812469	Antiplasmodial activity against Plasmodium falciparum NF54 late stage IV-V gametocytes assessed as reduction in number of exflagellation centers in at 1 uM treated for 72 hrs	2021	Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14	Procainamide-SAHA Fused Inhibitors of hHDAC6 Tackle Multidrug-Resistant Malaria Parasites.
AID1401542	Antiproliferative activity against human U2932 cells after 72 hrs by MTT assay	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors.
AID1441654	Inhibition of LTB4 biosynthesis in LPS-induced C57BL/6 mouse model of acute lung injury BLAF administered intraperitoneally by ELISA	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
AID1164040	Antiproliferative activity against human K562 cells assessed as growth inhibition after 72 hrs by CCK-8 assay	2014	European journal of medicinal chemistry, Oct-30, Volume: 86	Design, synthesis, and biological evaluation of 1, 3-disubstituted-pyrazole derivatives as new class I and IIb histone deacetylase inhibitors.
AID1126961	Inhibition of HDAC3 (unknown origin) using Boc-Lys(acetyl)-AMC as substrate after 30 mins by fluorescence assay	2014	Journal of medicinal chemistry, Apr-24, Volume: 57, Issue:8	Discovery of the first N-hydroxycinnamamide-based histone deacetylase 1/3 dual inhibitors with potent oral antitumor activity.
AID421214	Inhibition of HDAC6 from human HeLa cells at 5 uM	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Recent advances in the development of polyamine analogues as antitumor agents.
AID586610	Antimalarial activity against Plasmodium vivax assessed as parasites growth inhibition using giemsa staining after 24 to 56 hrs by microscopic analysis in presence of 20% human serum	2011	Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3	Ex vivo activity of histone deacetylase inhibitors against multidrug-resistant clinical isolates of Plasmodium falciparum and P. vivax.
AID297470	Inhibition of HDAC in HeLa cells	2007	Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18	2-aroylindoles and 2-aroylbenzofurans with N-hydroxyacrylamide substructures as a novel series of rationally designed histone deacetylase inhibitors.
AID524993	Inhibition of HDAC7 in human homozygous Fdelta508 primary bronchial epithelial cells assessed as increase in forskolin-stimulated Fdelta508 CFTR channel activity at 10 uM after 24 hrs relative to control	2010	Nature chemical biology, Jan, Volume: 6, Issue:1	Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.
AID1439772	Inhibition of Pseudomonas aeruginosa PA1409 using Boc-Lys(trifluoroacetyl)-AMC as substrate preincubated for 30 mins followed by substrate addition measured after 60 mins by trypsin-based fluorescence assay	2017	Bioorganic & medicinal chemistry letters, 04-01, Volume: 27, Issue:7	Perfluorinated hydroxamic acids are potent and selective inhibitors of HDAC-like enzymes from Pseudomonas aeruginosa.
AID1308511	Inhibition of HDAC (unknown origin)	2016	Bioorganic & medicinal chemistry letters, 06-15, Volume: 26, Issue:12	Targeting epigenetic reader and eraser: Rational design, synthesis and in vitro evaluation of dimethylisoxazoles derivatives as BRD4/HDAC dual inhibitors.
AID352519	Inhibition of human recombinant HDAC2	2009	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11	Isoxazole moiety in the linker region of HDAC inhibitors adjacent to the Zn-chelating group: effects on HDAC biology and antiproliferative activity.
AID1677516	Inhibition of HDAC in human HeLa nuclear extract using Boc-Lys(acetyl)-AMC or Boc-Lys (triflouroacetyl)-AMC as substrate preincubated for 5 mins followed by substrate addition and measured after 30 mins by fluorescence assay	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	HDAC-Bax Multiple Ligands Enhance Bax-Dependent Apoptosis in HeLa Cells.
AID1469495	Antitumor activity against mouse Fluc-labeled 4T1 cells implanted in Balb/c mouse assessed as tumor growth inhibition at 130 mg/kg, po administered daily via gavage for 18 days by bioluminescence assay relative to control	2018	Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7	Discovery of N1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7 H-pyrrolo[2,3- d]pyrimidin-2-yl)amino)phenyl)- N8-hydroxyoctanediamide as a Novel Inhibitor Targeting Cyclin-dependent Kinase 4/9 (CDK4/9) and Histone Deacetlyase1 (HDAC1) against Malignant Cancer
AID1898921	Induction of DNA damage in human NCI-H460 cells at 7.4 uM assessed as increase in p-H2AX levels and measured by Western blot analysis	2022	European journal of medicinal chemistry, Jan-15, Volume: 228	Antitumor activity of novel POLA1-HDAC11 dual inhibitors.
AID1055349	Cytotoxicity against human HDF after 72 hrs by MTS-PMS assay	2013	Journal of natural products, Nov-22, Volume: 76, Issue:11	Santacruzamate A, a potent and selective histone deacetylase inhibitor from the Panamanian marine cyanobacterium cf. Symploca sp.
AID663355	Growth inhibition of human NCI-H460 cells after 72 hrs by MTS assay	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Discovery and extensive in vitro evaluations of NK-HDAC-1: a chiral histone deacetylase inhibitor as a promising lead.
AID1235113	Cytotoxicity against human HeLa cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	2015	Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15	Synthesis and biological evaluation of novel histone deacetylases inhibitors with nitric oxide releasing activity.
AID1399559	Antiproliferative activity against human HCT116 cells after 72 hrs by SRB assay	2018	Bioorganic & medicinal chemistry, 09-01, Volume: 26, Issue:16	A series of camptothecin prodrugs exhibit HDAC inhibition activity.
AID476831	Toxicity in FVB mouse assessed as effect on number of WBC at 50 mg/kg, po administered 5 times per week for 2 weeks measured during test (Rvb = 9.1 +/- 0.2 10^3/mm^3)	2010	Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8	Modified cap group suberoylanilide hydroxamic acid histone deacetylase inhibitor derivatives reveal improved selective antileukemic activity.
AID1688043	Induction of HDAC6 degradation in human HL-60 cells assessed as decrease in HDAC6 level at 2 uM incubated for 12 hrs by Western blot analysis	2020	European journal of medicinal chemistry, Feb-15, Volume: 188	A 18β-glycyrrhetinic acid conjugate with Vorinostat degrades HDAC3 and HDAC6 with improved antitumor effects.
AID1060993	Inhibition of HDAC in human HeLa cell nuclear extract using fluor de Lys as substrate at 1 uM after 15 mins by fluorimetric analysis	2014	Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1	Synthesis and anticancer activities of thieno[3,2-d]pyrimidines as novel HDAC inhibitors.
AID1390011	Inhibition of full length recombinant human C-terminal His-tagged HDAC2 expressed in baculovirus infected sf9 cells using Boc-Lys-(Ac)-AMC as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by fluorescence assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Design, synthesis and biological evaluation of novel hydroxamic acid based histone deacetylase 6 selective inhibitors bearing phenylpyrazol scaffold as surface recognition motif.
AID1622912	Inhibition of HDAC1/HDAC2 in human HeLa nuclear extract	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.
AID1769656	Antiproliferative activity against human NCI-H2228 cells harboring EML4/ALK L1196M mutant assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 assay	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	Discovery of 2,4-pyrimidinediamine derivatives as potent dual inhibitors of ALK and HDAC.
AID352525	Antiproliferative activity against human SU-8686 cells by MTT assay	2009	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11	Isoxazole moiety in the linker region of HDAC inhibitors adjacent to the Zn-chelating group: effects on HDAC biology and antiproliferative activity.
AID1639362	Inhibition of HDAC in human HeLa nuclear extract using Boc-Lys(Ac)-AMC as substrate preincubated for 5 mins followed by substrate addition and measured after 30 mins by fluorescence assay	2019	Bioorganic & medicinal chemistry, 04-15, Volume: 27, Issue:8	Design, synthesis and activity evaluation of indole-based double - Branched HDAC1 inhibitors.
AID1398813	Antagonist activity at ESR1 in human MCF7 cells assessed as suppression of ESR1 mRNA expression at 5 uM after 24 hrs by QIAzol reagent based RT-qPCR analysis	2018	Bioorganic & medicinal chemistry, 08-15, Volume: 26, Issue:15	Incorporation of histone deacetylase inhibitory activity into the core of tamoxifen - A new hybrid design paradigm.
AID1162227	Induction of apoptosis in human HL60 cells assessed as loss of mitochondrial membrane potential in P4 quadrant at 1 uM by Rhodamine123 assay (Rvb = 96.6%)	2014	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 24, Issue:19	Design, synthesis and biological evaluation of β-boswellic acid based HDAC inhibitors as inducers of cancer cell death.
AID1464874	Anti-proliferative activity against human PC3 cells after 48 hrs by MTT assay	2017	Bioorganic & medicinal chemistry letters, 11-01, Volume: 27, Issue:21	Design, synthesis and biological evaluation of novel histone deacetylase inhibitors incorporating 4-aminoquinazolinyl systems as capping groups.
AID1164782	Inhibition of HDAC3 (unknown origin) using fluorogenic tetrapeptide RHKK(Ac) substrate by fluorescence assay	2014	Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20	ST7612AA1, a thioacetate-ω(γ-lactam carboxamide) derivative selected from a novel generation of oral HDAC inhibitors.
AID1336929	Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 72 hrs by MTT assay	2017	Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3	Bifunctional conjugates with potent inhibitory activity towards cyclooxygenase and histone deacetylase.
AID1869150	Cytotoxicity against mouse RAW264.7 cells assessed as cell viability at 10 uM incubated for 48 hrs by CCK8 assay
AID1869151	Cytotoxicity against human L02 cells assessed as cell viability at 10 uM incubated for 48 hrs by CCK8 assay
AID1667079	Inhibition of STAT3 in human MDA-MB-231 cells assessed as upregulation of p-p38 expression after 24 hrs by western blot analysis	2020	Bioorganic & medicinal chemistry, 03-15, Volume: 28, Issue:6	Pyrimethamine conjugated histone deacetylase inhibitors: Design, synthesis and evidence for triple negative breast cancer selective cytotoxicity.
AID1061951	Inhibition of human HDAC10 using RHKK(Ac) as substrate by fluorimetric analysis	2014	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1	Lactam based 7-amino suberoylamide hydroxamic acids as potent HDAC inhibitors.
AID1281853	Antiproliferative activity against human NCI-H929 cells after 72 hrs by CellTiter 96 aqueous non-radioactive cell proliferation assay	2016	European journal of medicinal chemistry, Apr-13, Volume: 112	Design, synthesis and biological evaluation of bisthiazole-based trifluoromethyl ketone derivatives as potent HDAC inhibitors with improved cellular efficacy.
AID1336922	Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 72 hrs by MTT assay	2017	Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3	Bifunctional conjugates with potent inhibitory activity towards cyclooxygenase and histone deacetylase.
AID544095	Cytotoxicity against african green monkey Vero cells by MTT assay	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Antimalarial activity of phenylthiazolyl-bearing hydroxamate-based histone deacetylase inhibitors.
AID1709346	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	2021	Bioorganic & medicinal chemistry, 04-01, Volume: 35	Structure-activity relationship and mechanistic studies for a series of cinnamyl hydroxamate histone deacetylase inhibitors.
AID1421906	Selectivity index, ratio of IC50 for human NFF cells to IC50 for drug-sensitive asexual ring stage Plasmodium falciparum 3D7 infected in human erythrocytes	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	One-pot, multi-component synthesis and structure-activity relationships of peptoid-based histone deacetylase (HDAC) inhibitors targeting malaria parasites.
AID613292	Plasma concentration in dog at 150 mg/kg, po administered as single dose	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Optimization of the in vitro cardiac safety of hydroxamate-based histone deacetylase inhibitors.
AID1177049	Cytotoxicity against human NCI-H460 cells	2015	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 25, Issue:3	Hydroxamic acid based histone deacetylase inhibitors with confirmed activity against the malaria parasite.
AID673993	Inhibition of recombinant HDAC6 using Ac-Lys(Ac)-AMC as substrate after 30 mins by fluorescence analysis	2012	ACS medicinal chemistry letters, Jun-14, Volume: 3, Issue:6	Discovery of HDAC Inhibitors That Lack an Active Site Zn(2+)-Binding Functional Group.
AID1462216	Inhibition of recombinant human HDAC1 at 1 uM after 30 mins by fluorescence assay relative to control	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Structure-based design, synthesis and in vitro antiproliferative effects studies of novel dual BRD4/HDAC inhibitors.
AID1390021	Antiproliferative activity against human MOLT4 cells after 48 hrs by MTT assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Structure optimization and preliminary bioactivity evaluation of N-hydroxybenzamide-based HDAC inhibitors with Y-shaped cap.
AID1454034	Growth inhibition of human HL60 cells after 3 days by counting method	2017	Bioorganic & medicinal chemistry, 07-15, Volume: 25, Issue:14	Synthesis and evaluation of novel dual BRD4/HDAC inhibitors.
AID1821337	Toxicity in mouse xenografted with human HepG2 cells assessed as cellular inflammation in spleen at 12 mg/kg, ip administered every 2 days for 4 weeks by H and E staining based microscopic method	2022	European journal of medicinal chemistry, Feb-05, Volume: 229	Discovery of phthalazino[1,2-b]-quinazolinone derivatives as multi-target HDAC inhibitors for the treatment of hepatocellular carcinoma via activating the p53 signal pathway.
AID1548272	Induction of cell cycle arrest in human RPMI8226 cells assessed as accumulation at S phase at 100 nM incubated for 24 hrs by propidium iodide staining based flow cytometry (Rvb = 27.6%)
AID482951	Antiproliferative activity against human HCT116 cells	2010	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11	Acylurea connected straight chain hydroxamates as novel histone deacetylase inhibitors: Synthesis, SAR, and in vivo antitumor activity.
AID1882462	Inhibition of HDAC6 (unknown origin)	2022	Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4	Chasing a Breath of Fresh Air in Cystic Fibrosis (CF): Therapeutic Potential of Selective HDAC6 Inhibitors to Tackle Multiple Pathways in CF Pathophysiology.
AID1476152	Antiproliferative activity against human Jurkat cells	2017	Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20	Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat.
AID1515884	Induction of apoptosis in human HCT116 cells assessed as necrotic cells at 500 nM after 48 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 5.23%)	2019	Journal of medicinal chemistry, 08-08, Volume: 62, Issue:15	Design, Synthesis, and Biological Evaluation of 4-Methyl Quinazoline Derivatives as Anticancer Agents Simultaneously Targeting Phosphoinositide 3-Kinases and Histone Deacetylases.
AID1394886	Antiproliferative activity against human NCI-H1975 cells after 48 hrs by sulforhodamine B assay	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	1-Aroylindoline-hydroxamic acids as anticancer agents, inhibitors of HSP90 and HDAC.
AID1876342	Inhibition of recombinant full length human HDAC6 expressed in insect Sf9 cells by EMSA analysis	2021	Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12	Development of HDAC Inhibitors Exhibiting Therapeutic Potential in T-Cell Prolymphocytic Leukemia.
AID1321723	Cytotoxicity against human THLE2 cells assessed as reduction in cell viability after 72 hrs by ATP Vialight assay	2016	Journal of medicinal chemistry, 10-13, Volume: 59, Issue:19	Design, Synthesis, and Biological Evaluation of First-in-Class Dual Acting Histone Deacetylases (HDACs) and Phosphodiesterase 5 (PDE5) Inhibitors for the Treatment of Alzheimer's Disease.
AID1697199	Cytotoxicity against human NCI-H23 cells by colorimetric method	2020	Bioorganic & medicinal chemistry letters, 11-15, Volume: 30, Issue:22	Design, synthesis and evaluation of novel indirubin-based N-hydroxybenzamides, N-hydroxypropenamides and N-hydroxyheptanamides as histone deacetylase inhibitors and antitumor agents.
AID1742743	Genotoxicity in Salmonella typhimurium TA1535 by Ames test	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Design and synthesis of novel Flavone-based histone deacetylase inhibitors antagonizing activation of STAT3 in breast cancer.
AID1393286	Inhibition of human recombinant HDAC2 using Ac-Leu-Gly-Lys(Ac)-AMC as substrate preincubated for 30 mins followed by substrate addition and measured after 15 to 30 mins	2018	Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9	Quest for Novel Chemical Entities through Incorporation of Silicon in Drug Scaffolds.
AID1549137	Antifungal activity against azole-resistant Candida albicans 0304103 after 48 hrs by spectrophotometry-based serial microdilution method	2020	Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10	Discovery of Novel Fungal Lanosterol 14α-Demethylase (CYP51)/Histone Deacetylase Dual Inhibitors to Treat Azole-Resistant Candidiasis.
AID328806	Antiproliferative activity against human HCT116 cells by CellTiter-Blue cell viability assay	2008	Journal of medicinal chemistry, Apr-24, Volume: 51, Issue:8	A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo.
AID371221	Inhibition of histone deacetylase in human HeLa cells assessed as induction of histone H3 hyperacetylation	2008	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 18, Issue:24	Alpha-mercaptoketone based histone deacetylase inhibitors.
AID1063036	Inhibition of recombinant HDAC10 (unknown origin) using Fluor-de-Lys-SIRT1 as substrate by fluorescence assay	2014	Journal of natural products, Jan-24, Volume: 77, Issue:1	Protein kinase and HDAC inhibitors from the endophytic fungus Epicoccum nigrum.
AID1865248	Metabolic stability in mouse liver microsome measured at 2 hrs in presence of NADPH	2022	Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18	Discovery of Novel Src Homology-2 Domain-Containing Phosphatase 2 and Histone Deacetylase Dual Inhibitors with Potent Antitumor Efficacy and Enhanced Antitumor Immunity.
AID659636	Antiproliferative activity against human MCF7 cells after 72 hrs by MTS assay	2012	Journal of medicinal chemistry, Feb-23, Volume: 55, Issue:4	Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors.
AID1732190	Cytotoxicity against human HH cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	2021	European journal of medicinal chemistry, Apr-05, Volume: 215	CAP rigidification of MS-275 and chidamide leads to enhanced antiproliferative effects mediated through HDAC1, 2 and tubulin polymerization inhibition.
AID1702050	Antiproliferative activity against human HuH-7 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay	2018	Journal of medicinal chemistry, 02-22, Volume: 61, Issue:4	Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma.
AID1873382	Inhibition of HDAC2 (unknown origin)	2022	Bioorganic & medicinal chemistry letters, 08-15, Volume: 70	Comparison of three zinc binding groups for HDAC inhibitors - A potency, selectivity and enzymatic kinetics study.
AID1476155	Antiproliferative activity against human OPM2 cells after 48 hrs by CellTiter-Glo luminescent assay	2017	Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20	Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat.
AID70687	Percent of murine erythroleukemia cells that became benzidine reactive after administration (2.5 uM)	1995	Journal of medicinal chemistry, Apr-14, Volume: 38, Issue:8	The synthesis of N-hydroxy-N'-phenyloctanediamide and its inhibitory effect on proliferation of AXC rat prostate cancer cells.
AID1390012	Inhibition of full length recombinant human C-terminal His-tagged HDAC3/N-terminal GST-tagged NCOR2 (395 to 489 residues) expressed in baculovirus infected sf9 cells using Boc-Lys-(Ac)-AMC as substrate preincubated for 15 mins followed by substrate additi	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Design, synthesis and biological evaluation of novel hydroxamic acid based histone deacetylase 6 selective inhibitors bearing phenylpyrazol scaffold as surface recognition motif.
AID591328	Inhibition of HDAC in human HeLa cells at 10 uM by fluorescent activity assay	2011	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8	Alkyl piperidine and piperazine hydroxamic acids as HDAC inhibitors.
AID1550100	Inhibition of HDAC2 (unknown origin) using Boc-Lys(acetyl)-AMC as substrate preincubated for 5 mins followed by substrate addition and measured after 30 mins by fluorescence assay	2019	Journal of medicinal chemistry, 04-25, Volume: 62, Issue:8	Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies.
AID1181303	Inhibition of human recombinant HDAC1 using histone H3 substrate pre-incubated at room temperature for 15 mins before substrate addition by fluorimetric assay	2014	Journal of medicinal chemistry, Jul-24, Volume: 57, Issue:14	1,3,4-Oxadiazole-containing histone deacetylase inhibitors: anticancer activities in cancer cells.
AID1702197	Toxicity in Ncr nude mouse xenografted with human HepG2 cells assessed as change in body weight at 60 mg/kg, po QD with 5 days on and 2 days off dosing schedule for 2 weeks cotreated with 75 mg/kg pictilisib and measured at day 12 (Rvb = -0.8%)	2018	Journal of medicinal chemistry, 02-22, Volume: 61, Issue:4	Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma.
AID274014	Percent inhibition of CYP450 1A2 at 1 uM concentration	2007	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2	Identification and optimisation of a series of substituted 5-pyridin-2-yl-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.
AID1605965	Antiproliferative activity against human CCRF-CEM cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	2020	Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8	Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors.
AID1065962	Cytotoxicity against androgen-independent human DU145 cells assessed as growth inhibition after 72 hrs by MTS assay	2013	Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24	Synthesis and structure-activity relationship of 3-hydroxypyridine-2-thione-based histone deacetylase inhibitors.
AID723467	Inhibition of HDAC in cisplatin resistant human KYSE-510 cells after 18 hrs by fluorescence assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID1337287	Antiproliferative activity against human KG1 cells after 48 hrs by CellTiter-Glo assay	2016	Journal of medicinal chemistry, Sep-22, Volume: 59, Issue:18	Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines.
AID1174694	Inhibition of HDAC3 (unknown origin)	2015	European journal of medicinal chemistry, Jan-07, Volume: 89	Development of 3-hydroxycinnamamide-based HDAC inhibitors with potent in vitro and in vivo anti-tumor activity.
AID446346	Volume of distribution at steady state in CD1 mouse at 15 mg/kg, po	2010	Journal of medicinal chemistry, Jan-28, Volume: 53, Issue:2	Synthesis and biological evaluation of N-hydroxyphenylacrylamides and N-hydroxypyridin-2-ylacrylamides as novel histone deacetylase inhibitors.
AID708276	Growth inhibition of human Bel7404 cells incubated for 72 hrs by WST dye reduction assay	2012	Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20	Pharmacokinetic optimization of class-selective histone deacetylase inhibitors and identification of associated candidate predictive biomarkers of hepatocellular carcinoma tumor response.
AID1203891	Inhibition of recombinant HDAC8 (unknown origin) using fluorogenic substrate Boc-Lys (acetyl)-AMC after 20 mins by homogeneous fluorescence release assay	2015	European journal of medicinal chemistry, , Volume: 96	Discovery and preliminary evaluation of 2-aminobenzamide and hydroxamate derivatives containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors.
AID1890516	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	2022	Bioorganic & medicinal chemistry letters, 05-15, Volume: 64	Design, synthesis, and biological evaluation of β-carboline 1,3,4-oxadiazole based hybrids as HDAC inhibitors with potential antitumor effects.
AID1361630	Antiproliferative activity against human MCF7 cells after 72 hrs by CCK8 assay	2018	Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16	Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents.
AID1864224	Inhibition of full length recombinant C-terminal GST-tagged human HDAC1 expressed in baculovirus infected Sf9 insect cells incubated for 50 mins by Glo- luminescence assay	2022	Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18	Discovery of a Novel G-Quadruplex and Histone Deacetylase (HDAC) Dual-Targeting Agent for the Treatment of Triple-Negative Breast Cancer.
AID374812	Antiproliferative activity against human P53-deficient HeLa cells after 72 hrs by celltiter-blue cell viability assay	2009	Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11	Discovery of a potent class I selective ketone histone deacetylase inhibitor with antitumor activity in vivo and optimized pharmacokinetic properties.
AID1614126	Inhibition of recombinant full length HDAC1 (unknown origin) using Ac-peptide-AMC as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by fluorescence assay
AID374820	Inhibition of C-terminal FLAG-tagged HDAC6 expressed in mammalian cells	2009	Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11	Discovery of a potent class I selective ketone histone deacetylase inhibitor with antitumor activity in vivo and optimized pharmacokinetic properties.
AID300833	Growth inhibition of human PC3 cells after 21 hrs by MTT assay	2007	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17	Pomiferin, histone deacetylase inhibitor isolated from the fruits of Maclura pomifera.
AID374826	Antiproliferative activity against human P53 expressing HCT116 cells after 72 hrs by celltiter-blue cell viability assay	2009	Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11	Discovery of a potent class I selective ketone histone deacetylase inhibitor with antitumor activity in vivo and optimized pharmacokinetic properties.
AID1493602	Inhibition of HDAC1/2/3 in human A549 cells assessed as increase in acetylated acetylated histone H4 levels at 500 nM after 3 hrs by Western blot analysis	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Discovery of a fluorescent probe with HDAC6 selective inhibition.
AID1811371	Inhibition of HDAC6 (unknown origin) at 0.1 uM using Ac-peptide as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence assay relative to control	2021	European journal of medicinal chemistry, Dec-15, Volume: 226	Development of novel tetrahydroisoquinoline-hydroxamate conjugates as potent dual SERDs/HDAC inhibitors for the treatment of breast cancer.
AID449262	Antiproliferative activity against human A549 cells after 2 days by MTT assay	2009	European journal of medicinal chemistry, Nov, Volume: 44, Issue:11	Design, synthesis and preliminary biological evaluation of N-hydroxy-4-(3-phenylpropanamido)benzamide (HPPB) derivatives as novel histone deacetylase inhibitors.
AID708271	Growth inhibition of human BGC823 cells incubated for 72 hrs by WST dye reduction assay	2012	Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20	Pharmacokinetic optimization of class-selective histone deacetylase inhibitors and identification of associated candidate predictive biomarkers of hepatocellular carcinoma tumor response.
AID605621	Cell cycle arrest in human HCT116 cells assessed as accumulation at S phase at 300 nM after 15 hrs by propidium iodide staining based flow cytometric analysis	2010	Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24	Discovery of 2-(6-{[(6-fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a class I selective orally active histone deacetylase inhibitor.
AID1727740	Inhibition of HDAC3 (unknown origin) by fluorescence based assay	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	Discovery of selective HDAC/BRD4 dual inhibitors as epigenetic probes.
AID732875	Inhibition of HDAC3 (unknown origin) using Boc-Lys(acetyl)-AMC as substrate preincubated with enzyme for 5 mins prior to substrate addition measured after 30 mins by fluorescence assay	2013	ACS medicinal chemistry letters, Feb-14, Volume: 4, Issue:2	Development of
AID1764280	Inhibition of HDAC in human Cal27CisR cells assessed as potentiation of cisplatin-induced cytotoxicity by measuring cisplatin IC50 at 0.7 uM pretreated for 48 hrs followed by cisplatin addition and measured after 72 hrs by MTT assay relative to cisplatin	2021	European journal of medicinal chemistry, Feb-05, Volume: 211	Synergistic induction of apoptosis in resistant head and neck carcinoma and leukemia by alkoxyamide-based histone deacetylase inhibitors.
AID1845460	Inhibition of HDAC6 (unknown origin)	2021	Journal of medicinal chemistry, 01-14, Volume: 64, Issue:1	Glycogen Synthase Kinase 3β: A New Gold Rush in Anti-Alzheimer's Disease Multitarget Drug Discovery?
AID1855257	Antiproliferative activity against mouse MC38 cells after 48 hrs by CCK-8 assay	2022	European journal of medicinal chemistry, Nov-05, Volume: 241	Discovery of 2,5-diphenyl-1,3,4-thiadiazole derivatives as HDAC inhibitors with DNA binding affinity.
AID1337286	Antiproliferative activity against human OPM2 cells after 48 hrs by CellTiter-Glo assay	2016	Journal of medicinal chemistry, Sep-22, Volume: 59, Issue:18	Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines.
AID1431816	Selectivity ratio of IC50 for human KDAC6 to IC50 for human KDAC3	2017	European journal of medicinal chemistry, Feb-15, Volume: 127	Design and synthesis of benzodiazepine analogs as isoform-selective human lysine deacetylase inhibitors.
AID1765325	Inhibition of human full-length recombinant HDAC2 preincubated for 5 mins followed by HDAC substrate addition and further incubated for 45 mins by fluorescence microplate reader assay	2021	European journal of medicinal chemistry, Oct-15, Volume: 222	A first-in-class anticancer dual HDAC2/FAK inhibitors bearing hydroxamates/benzamides capped by pyridinyl-1,2,4-triazoles.
AID749704	Inhibition of HDAC1 in human HeLa cells using Fluor-de-Lys as substrate after 15 mins by fluorescence assay	2013	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 23, Issue:11	Dual-acting histone deacetylase-topoisomerase I inhibitors.
AID1361628	Inhibition of MDM2 (unknown origin) preincubated for 30 mins by fluorescence polarization assay	2018	Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16	Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents.
AID1785341	Inhibition of recombinant human HDAC11 measured after 30 mins by fluorescence microplate reader assay
AID373080	Inhibition of human recombinant HDAC7	2009	European journal of medicinal chemistry, Mar, Volume: 44, Issue:3	Novel amide derivatives as inhibitors of histone deacetylase: design, synthesis and SAR.
AID304374	Antiproliferative activity against human K562 cells after 72 hrs by MTS assay	2007	Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26	Dual inhibitors of inosine monophosphate dehydrogenase and histone deacetylases for cancer treatment.
AID1537568	Cell cycle arrest in human G55T2 cells assessed as accumulation in G2/M phase at 3 uM incubated for 72 hrs by propidium iodide based flow cytometry (Rvb = 26.8 %)	2019	MedChemComm, Jul-01, Volume: 10, Issue:7	Design, synthesis and biological evaluation of β-peptoid-capped HDAC inhibitors with anti-neuroblastoma and anti-glioblastoma activity.
AID1466055	Inhibition of recombinant human full length HDAC2 using Fluor-de-Lys as substrate after 60 mins by spectrofluorimetric analysis	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	4-Indolyl-N-hydroxyphenylacrylamides as potent HDAC class I and IIB inhibitors in vitro and in vivo.
AID1605975	Antiproliferative activity against human IGROV1 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	2020	Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8	Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors.
AID1653141	Cytotoxicity against human SW620 cells assessed as reduction in cell viability	2019	European journal of medicinal chemistry, Mar-01, Volume: 165	Quinolone hybrids and their anti-cancer activities: An overview.
AID1821350	Toxicity in mouse xenografted with human HepG2 cells assessed as necrosis in kidney at 12 mg/kg, ip administered every 2 days for 4 weeks by H and E staining based microscopic method	2022	European journal of medicinal chemistry, Feb-05, Volume: 229	Discovery of phthalazino[1,2-b]-quinazolinone derivatives as multi-target HDAC inhibitors for the treatment of hepatocellular carcinoma via activating the p53 signal pathway.
AID274030	Permeability (Papp) run from pH 6.5-7.4	2007	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2	Identification and optimisation of a series of substituted 5-pyridin-2-yl-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.
AID327546	Increase in acetylated histone H4 level in human HCT116 cells at 10 uM after 24 hrs relative to control	2008	Journal of medicinal chemistry, Apr-24, Volume: 51, Issue:8	Polyaminohydroxamic acids and polyaminobenzamides as isoform selective histone deacetylase inhibitors.
AID1337306	Inhibition of HDAC1/HDAC2/HDAC3 signalling in HEL 92.1.7 cells harboring JAK2 V617F mutant assessed as increase in acetylated histone-3(Lys9/Lys14) level at 0.1 to 1 uM after 1 hr by immunoblot method	2016	Journal of medicinal chemistry, Sep-22, Volume: 59, Issue:18	Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines.
AID762188	Cytotoxicity against human HCT116 cells assessed as growth inhibition by measuring cellular ATP level after 72 hrs by cell-titer glo assay	2013	Journal of medicinal chemistry, Aug-08, Volume: 56, Issue:15	Discovery of potent, isoform-selective inhibitors of histone deacetylase containing chiral heterocyclic capping groups and a N-(2-aminophenyl)benzamide binding unit.
AID1433252	Antiproliferative activity against human CMK cells after 72 hrs by MTT assay	2016	Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17	Synthesis and Antileukemic Activities of Piperlongumine and HDAC Inhibitor Hybrids against Acute Myeloid Leukemia Cells.
AID1578502	Induction of apoptosis in human MV4-11 cells assessed as viable cells at 2 uM incubated for 18 hrs by annexin V FITC and PI based flow cytometry (Rvb = 53.01 to 53.07 %)	2020	ACS medicinal chemistry letters, Jan-09, Volume: 11, Issue:1	Class I/IIb-Selective HDAC Inhibitor Exhibits Oral Bioavailability and Therapeutic Efficacy in Acute Myeloid Leukemia.
AID258012	Inhibition of human leukemic CEM cell viability	2006	Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2	Aromatic sulfide inhibitors of histone deacetylase based on arylsulfinyl-2,4-hexadienoic acid hydroxyamides.
AID1525777	Inhibition of HADC1 (unknown origin)	2020	Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1	Old but Gold: Tracking the New Guise of Histone Deacetylase 6 (HDAC6) Enzyme as a Biomarker and Therapeutic Target in Rare Diseases.
AID1849158	Inhibition of recombinant human N-terminal GST-tagged HDAC6 (1 to 1215 residues) expressed in Sf9 insect cells using Z-Lys(Ac)-AMC as fluorogenic substrate incubated for 90 mins by microplate reader analysis	2022	Journal of medicinal chemistry, 11-24, Volume: 65, Issue:22	Development of Fluorinated Peptoid-Based Histone Deacetylase (HDAC) Inhibitors for Therapy-Resistant Acute Leukemia.
AID1655892	Inhibition of EZH2 in human U937 cells assessed as H3K27me3 level at 0.5 uM incubated for 96 hrs by Western blot analysis (Rvb = 1 No_unit)	2020	ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5	Design of First-in-Class Dual EZH2/HDAC Inhibitor: Biochemical Activity and Biological Evaluation in Cancer Cells.
AID304375	Differentiation of K562 cells at 0.50 uM after 5 days by MTS assay	2007	Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26	Dual inhibitors of inosine monophosphate dehydrogenase and histone deacetylases for cancer treatment.
AID609726	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	2011	Bioorganic & medicinal chemistry, Aug-01, Volume: 19, Issue:15	Design, synthesis and biological evaluation of tyrosine-based hydroxamic acid analogs as novel histone deacetylases (HDACs) inhibitors.
AID1915597	Inhibition of HDAC11 (unknown origin)	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors.
AID1234902	Antiproliferative activity against human ES2 cells after 48 hrs by MTT assay	2015	Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15	Design, synthesis and preliminary biological evaluation of indoline-2,3-dione derivatives as novel HDAC inhibitors.
AID1436788	Growth inhibition of human NCI-H292 cells after 72 hrs by MTT assay	2017	Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4	Synthesis of Vorinostat and cholesterol conjugate to enhance the cancer cell uptake selectivity.
AID761584	Inhibition of HDAC in human HeLa cell extract using fluor de Lys as substrate after 15 mins by fluorometric analysis	2013	European journal of medicinal chemistry, Aug, Volume: 66	Design, synthesis and preliminary evaluation of a series of histone deacetylase inhibitors carrying a benzodiazepine ring.
AID1897488	Antitumor activity against human SNU-16 cells xenografted in BALB/c nude mouse assessed as reduction in tumor growth at 50 mg/kg/day, ip administered for 18 days and measured every 3 days
AID1542189	Inhibition of HDAC11 (unknown origin)	2019	Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7	Kinase and Histone Deacetylase Hybrid Inhibitors for Cancer Therapy.
AID440466	Metabolic stability in Sprague-Dawley rat plasma at 10 uM by LC-MS/MS analysis	2009	Journal of medicinal chemistry, Nov-12, Volume: 52, Issue:21	Hydroxamates: relationships between structure and plasma stability.
AID1404339	Inhibition of HDAC in human cell lysates using fluoro-substrate peptide/fluoro-deacetylated peptide as substrate incubated for 20 mins measured at 1 to 2 mins interval for 30 to 60 mins by fluorescence assay	2018	ACS medicinal chemistry letters, Feb-08, Volume: 9, Issue:2	Biocompatible Boron-Containing Prodrugs of Belinostat for the Potential Treatment of Solid Tumors.
AID1897370	Inhibition of FGFR2 (unknown origin)
AID243592	Percent inhibition against human histone deacetylase at 100 uM	2005	Journal of medicinal chemistry, Feb-24, Volume: 48, Issue:4	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates.
AID420642	Inhibition of HDAC6 in human IGROV1 cells assessed as alpha-tubulin acetylation at IC80 after 24 hrs by Western blot	2009	European journal of medicinal chemistry, May, Volume: 44, Issue:5	Design, synthesis, and evaluation of biphenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors.
AID1441641	Anti-inflammatory activity in LPS-induced C57BL/6 mouse model of acute lung injury assessed as reduction in lung lesions at 10 to 50 mg/kg, ip pretreated for 1 hr followed LPS challenge measured after 24 hrs by hematoxylin and eosin staining based microsc	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
AID462791	Antiproliferative activity against human SKOV3 cells after 48 hrs by MTT assay	2010	Bioorganic & medicinal chemistry, Mar-01, Volume: 18, Issue:5	Design, synthesis and preliminary activity assay of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives as novel Histone deacetylases (HDACs) inhibitors.
AID1240555	Induction of apoptosis in human MDA-MB-231 cells assessed as early apoptotic cells at 4 uM after 24 hrs using Annexin V-FITC and propidium iodide staining by flow cytometry (Rvb = 2.60%)	2015	Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17	Design, synthesis and biological evaluation of saccharin-based N-hydroxybenzamides as histone deacetylases (HDACs) inhibitors.
AID1518779	Selectivity ratio of IC50 for human HDAC1 to IC50 for human HDAC6	2019	European journal of medicinal chemistry, Dec-15, Volume: 184	Discovery of a potent histone deacetylase (HDAC) 3/6 selective dual inhibitor.
AID1587860	Inhibition of dye-labeled tracer binding to HDAC10 (unknown origin) transfected in human HeLa cells measured after 2 hrs by nano-luciferase reporter gene-based BRET assay	2019	Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9	Selective Inhibition of Histone Deacetylase 10: Hydrogen Bonding to the Gatekeeper Residue is Implicated.
AID1816190	Inhibition of recombinant HDAC7 (unknown origin) using Ac-peptide-AMC as substrate incubated for 240 mins by microplate reader analysis
AID1164194	Inhibition of HDAC in human MCF7 cells assessed as hyperacetylation of p21 at 5 uM after 24 hrs by Western blot analysis relative to control	2014	ACS medicinal chemistry letters, Sep-11, Volume: 5, Issue:9	Novel antiproliferative chimeric compounds with marked histone deacetylase inhibitory activity.
AID1659649	Inhibition of HDAC3 (unknown origin)	2020	Bioorganic & medicinal chemistry letters, 06-01, Volume: 30, Issue:11	Environment-sensitive fluorescent inhibitors of histone deacetylase.
AID670515	Antiproliferative activity against human A431 cells after 48 hrs by MTT assay	2012	Bioorganic & medicinal chemistry, Jul-15, Volume: 20, Issue:14	Synthesis and biological evaluation of N-aryl salicylamides with a hydroxamic acid moiety at 5-position as novel HDAC-EGFR dual inhibitors.
AID1541558	Inhibition of HDAC6 in human Cal27CisR cells assessed as acetylation of alpha-tubulin at 1 uM measured after 24 hrs by immunoblot analysis	2019	Journal of medicinal chemistry, 12-26, Volume: 62, Issue:24	Synthesis of Peptoid-Based Class I-Selective Histone Deacetylase Inhibitors with Chemosensitizing Properties.
AID214058	Compound was tested for anti-proliferative activity in U-937 human leukemia cell line	2004	Bioorganic & medicinal chemistry letters, Jan-19, Volume: 14, Issue:2	Design, synthesis, and activity of HDAC inhibitors with a N-formyl hydroxylamine head group.
AID1441665	Anti-inflammatory activity in LPS-induced C57BL/6 mouse model of acute lung injury assessed as reduction in IL-1beta level pretreated at 25 mg/kg, ip pretreated for 1 hr followed LPS challenge after 24 hrs by ELISA	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
AID1688031	Induction of apoptosis in human HL-60 cells assessed as early apoptotic cells at 0.5 uM measured after 24 hrs by Annexin-V/FITC and propidium iodide staining based flow cytometry (Rvb = 2.46 %)	2020	European journal of medicinal chemistry, Feb-15, Volume: 188	A 18β-glycyrrhetinic acid conjugate with Vorinostat degrades HDAC3 and HDAC6 with improved antitumor effects.
AID462790	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	2010	Bioorganic & medicinal chemistry, Mar-01, Volume: 18, Issue:5	Design, synthesis and preliminary activity assay of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives as novel Histone deacetylases (HDACs) inhibitors.
AID1515887	Induction of cell cycle arrest in human HCT116 cells assessed as accumulation at G2/M phase at 500 nM after 24 hrs by propidium iodide/RNase staining-based FACS analysis	2019	Journal of medicinal chemistry, 08-08, Volume: 62, Issue:15	Design, Synthesis, and Biological Evaluation of 4-Methyl Quinazoline Derivatives as Anticancer Agents Simultaneously Targeting Phosphoinositide 3-Kinases and Histone Deacetylases.
AID90689	Tested for maize Histone deacetylase 2 inhibitory activity	2003	Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23	Discovery of (aryloxopropenyl)pyrrolyl hydroxyamides as selective inhibitors of class IIa histone deacetylase homologue HD1-A.
AID1273867	Antiproliferative activity against human K562 cells assessed as cell viability after 72 hrs by CellTitre-Glo luminescent assay	2016	European journal of medicinal chemistry, Jan-27, Volume: 108	Synthesis, biological characterization and molecular modeling insights of spirochromanes as potent HDAC inhibitors.
AID1876343	Inhibition of recombinant full length human HDAC8 expressed in insect Sf9 cells by EMSA analysis	2021	Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12	Development of HDAC Inhibitors Exhibiting Therapeutic Potential in T-Cell Prolymphocytic Leukemia.
AID1352481	Inhibition of HDAC2 in human HeLa cells after 72 hrs by ELISA	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Spirohydantoins and 1,2,4-triazole-3-carboxamide derivatives as inhibitors of histone deacetylase: Design, synthesis, and biological evaluation.
AID1321698	Selectivity ratio of pLC50 for mouse primary glial cells to pLC50 for human THLE2 cells	2016	Journal of medicinal chemistry, 10-13, Volume: 59, Issue:19	Design, Synthesis, and Biological Evaluation of First-in-Class Dual Acting Histone Deacetylases (HDACs) and Phosphodiesterase 5 (PDE5) Inhibitors for the Treatment of Alzheimer's Disease.
AID1742666	Cytotoxicity against human PANC-1 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Design and synthesis of novel Flavone-based histone deacetylase inhibitors antagonizing activation of STAT3 in breast cancer.
AID465158	Growth inhibition of human Panc 04.03 cells after 72 hrs by MTS assay	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Synthesis and biological evaluation of triazol-4-ylphenyl-bearing histone deacetylase inhibitors as anticancer agents.
AID1260638	Inhibition of human recombinant HDAC2 at 20 uM using Boc-Lys(Ac)-AMC as substrate after 30 to 60 mins by microplate reader assay
AID1689775	Antiproliferative activity against human HCT116 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay	2020	European journal of medicinal chemistry, Mar-01, Volume: 189	Discovery of novel cyclin-dependent kinase (CDK) and histone deacetylase (HDAC) dual inhibitors with potent in vitro and in vivo anticancer activity.
AID288449	Growth inhibition of HCT15 cells by SRB assay	2007	Journal of medicinal chemistry, May-31, Volume: 50, Issue:11	Structure-activity relationship studies of a series of novel delta-lactam-based histone deacetylase inhibitors.
AID619050	Competitive inhibition of HDAC5 using KI-104 as substrate by fluorescence assay	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile.
AID545857	Antimalarial activity against Plasmodium falciparum FCR3 assessed as parasite growth inhibition after 48 hrs by standard growth inhibition assay	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Novel inhibitor of Plasmodium histone deacetylase that cures P. berghei-infected mice.
AID1689771	Antiproliferative activity against human HCT116 cells assessed as inhibition of cell growth at 8 uM measured after 72 hrs by CCK-8 assay relative to control	2020	European journal of medicinal chemistry, Mar-01, Volume: 189	Discovery of novel cyclin-dependent kinase (CDK) and histone deacetylase (HDAC) dual inhibitors with potent in vitro and in vivo anticancer activity.
AID717821	Inhibition of HDAC in human Hela cell lysate using Fluor-de-Lys as substrate assessed as remaining activity at 3.125 x 10'-8 M pretreated for 30 mins before substrate addition by fluorescence assay	2012	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23	The structural requirements of histone deacetylase inhibitors: suberoylanilide hydroxamic acid analogs modified at the C6 position.
AID1739567	Antiproliferative activity against human THP-1 assessed as reduction in cell growth at 4 uM by CellTiter-non radioactive cell proliferation assay	2020	European journal of medicinal chemistry, Aug-15, Volume: 200	Design, synthesis, and biological evaluation of dual targeting inhibitors of histone deacetylase 6/8 and bromodomain BRPF1.
AID1478587	Induction of apoptosis in human K562 cells assessed as late apoptotic cells at 1 uM after 24 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometry (Rvb = 2.83%)	2017	European journal of medicinal chemistry, Jun-16, Volume: 133	Design, synthesis and biological evaluation of quinoline derivatives as HDAC class I inhibitors.
AID1321619	Inhibition of HDAC1/HDAC2 in human HeLa cell nuclear extract preincubated for 20 mins followed by addition of HDAC green as substrate measured after 60 mins by fluorescence analysis	2016	Bioorganic & medicinal chemistry letters, 10-01, Volume: 26, Issue:19	Design, synthesis and in vitro evaluation of amidoximes as histone deacetylase inhibitors for cancer therapy.
AID1467032	Stabilization of human luc fused SMN protein expressed in HEK293 cells at 10 uM after 24 hrs in presence of 10 uM cycloheximide by luciferase reporter gene assay	2017	Journal of medicinal chemistry, 06-08, Volume: 60, Issue:11	Discovery of a Small Molecule Probe That Post-Translationally Stabilizes the Survival Motor Neuron Protein for the Treatment of Spinal Muscular Atrophy.
AID1826633	Synergistic antiproliferative effect on HEL cells assessed as combination index at 0.04 uM in presence of 3-Fluoro-10-hydroxy-14-methyl-8,13,13b,14-tetrahydro-7H-indolo[2',3':3,4]pyrido[2,1-b]quinazolin-5-one	2022	Journal of medicinal chemistry, 03-24, Volume: 65, Issue:6	Evodiamine-Inspired Topoisomerase-Histone Deacetylase Dual Inhibitors: Novel Orally Active Antitumor Agents for Leukemia Therapy.
AID1234903	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	2015	Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15	Design, synthesis and preliminary biological evaluation of indoline-2,3-dione derivatives as novel HDAC inhibitors.
AID1404298	Antiproliferative activity against human HeLa cells after 72 hrs by resazurin dye based fluorescence assay	2018	ACS medicinal chemistry letters, Feb-08, Volume: 9, Issue:2	Biocompatible Boron-Containing Prodrugs of Belinostat for the Potential Treatment of Solid Tumors.
AID1597956	Induction of apoptosis in human A549 cells assessed as necrotic cells at 10 uM incubated for 72 hrs by Annexin V-FITC/propidium iodide-staining based flow cytometric analysis (Rvb = 2.76%)	2019	Bioorganic & medicinal chemistry letters, 09-15, Volume: 29, Issue:18	Anti-tumor activity evaluation of novel tubulin and HDAC dual-targeting inhibitors.
AID1737133	Inhibition of recombinant human C-terminal His/FLAG-tagged HDAC1 (1 to end residues) expressed in sf9 insect cells using Boc-Lys(Ac)-AMC as substrate incubated for 60 mins by fluorescence assay	2020	European journal of medicinal chemistry, Apr-15, Volume: 192	Design, synthesis and biological evaluation of novel indazole-based derivatives as potent HDAC inhibitors via fragment-based virtual screening.
AID672035	Ratio of inhibition of human HDAC3 at 10 uM preincubated for 3 hrs to inhibition of human HDAC3 at 10 uM preincubated for 5 mins	2012	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 22, Issue:15	Design, synthesis, modeling, biological evaluation and photoaffinity labeling studies of novel series of photoreactive benzamide probes for histone deacetylase 2.
AID1890511	Inhibition of HDAC2 (unknown origin)	2022	Bioorganic & medicinal chemistry letters, 05-15, Volume: 64	Design, synthesis, and biological evaluation of β-carboline 1,3,4-oxadiazole based hybrids as HDAC inhibitors with potential antitumor effects.
AID1859936	Antiproliferation activity against human HCT-116 cells assessed as reduction in cell viability at 5 to 50 uM measured after 48 hrs by MTT assay	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Azetidin-2-one-based small molecules as dual hHDAC6/HDAC8 inhibitors: Investigation of their mechanism of action and impact of dual inhibition profile on cell viability.
AID659637	Inhibition of HDAC in human DU145 cells assessed as upregulation of p21waf1 protein expression at 2.5 uM after 24 hrs by Western blot analysis	2012	Journal of medicinal chemistry, Feb-23, Volume: 55, Issue:4	Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors.
AID761579	Antiproliferative activity against human HCT116 cells after 72 hrs by CellTiter-Glo assay	2013	European journal of medicinal chemistry, Aug, Volume: 66	Design, synthesis and preliminary evaluation of a series of histone deacetylase inhibitors carrying a benzodiazepine ring.
AID1548264	Antiproliferative activity against human HET-1A cells incubated for 48 hrs by MTT assay
AID274023	Oral bioavailability after oral dosing at 5 mg kg-1	2007	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2	Identification and optimisation of a series of substituted 5-pyridin-2-yl-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.
AID1689811	Antiproliferative activity against human HCT116 cells assessed as inhibition of cell growth at 2 uM measured after 72 hrs by CCK-8 assay relative to control	2020	European journal of medicinal chemistry, Mar-01, Volume: 189	Discovery of novel cyclin-dependent kinase (CDK) and histone deacetylase (HDAC) dual inhibitors with potent in vitro and in vivo anticancer activity.
AID659492	Inhibition of HDAC1/2 in human HeLa cell nuclear extract using Fluor de Lys as substrate after 15 mins by fluorometric analysis	2012	Journal of medicinal chemistry, Feb-23, Volume: 55, Issue:4	Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors.
AID1784189	Inhibition of recombinant human HDAC1 using ZMAL as substrate incubated for 90 mins by fluorescence based micro plate assay	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Synthesis, structure-activity relationships, cocrystallization and cellular characterization of novel smHDAC8 inhibitors for the treatment of schistosomiasis.
AID1206753	Cell cycle arrest in human HEL cells assessed as accumulation at S phase at 0.5 uM after 48 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 46.88%)	2015	Journal of medicinal chemistry, May-28, Volume: 58, Issue:10	Design, synthesis, and antitumor evaluation of novel histone deacetylase inhibitors equipped with a phenylsulfonylfuroxan module as a nitric oxide donor.
AID473192	Growth inhibition of human MUF cells after 48 hrs by MTT assay	2010	Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5	Biological and biophysical properties of the histone deacetylase inhibitor suberoylanilide hydroxamic acid are affected by the presence of short alkyl groups on the phenyl ring.
AID1266831	Induction of apoptosis in human HCT116 cells at 5 uM after 48 hrs by annexin V-FITC/propidium iodide staining-based flow cytometric analysis	2015	Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23	Novel β-Carboline/Hydroxamic Acid Hybrids Targeting Both Histone Deacetylase and DNA Display High Anticancer Activity via Regulation of the p53 Signaling Pathway.
AID1436789	Growth inhibition of human NCI-H292 cells after 72 hrs in presence of LDL by MTT assay	2017	Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4	Synthesis of Vorinostat and cholesterol conjugate to enhance the cancer cell uptake selectivity.
AID1545989	Antiproliferative activity against human NCI-H23 cells assessed as reduction in cell viability after 48 hrs by MTT assay	2019	European journal of medicinal chemistry, Dec-01, Volume: 183	1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships.
AID1269321	Cytotoxicity against human A2780S/CP5 cells assessed as cell growth at 25 uM measured at 72 hrs by CyQuant proliferation assay relative to control	2016	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2	Bromotyrosine-derived metabolites from an Indonesian marine sponge in the family Aplysinellidae (Order Verongiida).
AID725668	Inhibition of C-terminal His-tagged full length human recombinant HDAC3 co-expressed with NcoR2 in baculovirus expression system using fluorogenic acetylated peptide as substrate preincubated with enzyme for 10 mins prior to substrate addition measured af	2013	ACS medicinal chemistry letters, Jan-10, Volume: 4, Issue:1	Biological evaluation of new largazole analogues: alteration of macrocyclic scaffold with click chemistry.
AID1702056	Inhibition of human full-length recombinant p110alpha/p85alpha co-expressed in baculovirus expression system using PIP2:PS lipid as substrate incubated for 1 hr in presence of ATP by ADP-Glo assay	2018	Journal of medicinal chemistry, 02-22, Volume: 61, Issue:4	Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma.
AID1777024	Inhibition of HDAC in human A549 cells assessed as reduction in fluorescent APS probe fluorescence intensity at 10 uM preincubated with compound for 2 hrs followed by co-incubation with APS probe by intracellular fluorescence competition assay	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Intracellular fluorescence competition assay for inhibitor engagement of histone deacetylase.
AID1550107	Inhibition of HDAC6 in human A549 cells assessed as increase in acetyl alpha tubulin level at 80 to 400 nM after 6 hrs by Western blot analysis	2019	Journal of medicinal chemistry, 04-25, Volume: 62, Issue:8	Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies.
AID1896951	Cytotoxicity against human HUVEC cells assessed as reduction in cell viability by CCK8 assay	2022	Bioorganic & medicinal chemistry, Nov-05, Volume: 75	Novel bioactive hybrid Celecoxib-HDAC Inhibitor, induces apoptosis in human acute lymphoblastic leukemia cells.
AID1239053	Cytotoxicity against human HepG2 cells assessed as cell viability after 72 hrs by CCK8 assay	2015	Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17	Design, synthesis and biological evaluation of isoquinoline-based derivatives as novel histone deacetylase inhibitors.
AID1282244	Inhibition of recombinant HDAC10 (unknown origin) using AMC labeled AC-peptide as substrate incubated for 1 hr by fluorescence analysis	2016	Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4	Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
AID1578888	Inhibition of human HDAC6 using Boc-Lys (Ac)-AMC as substrate incubated for 60 mins by fluorimetric assay	2019	Journal of natural products, 06-28, Volume: 82, Issue:6	Hydroxamic Acid Derivatives of β-Carboline/Hydroxycinnamic Acid Hybrids Inducing Apoptosis and Autophagy through the PI3K/Akt/mTOR Pathways.
AID297480	Cytotoxicity against human MDA-MB-468 cells	2007	Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18	2-aroylindoles and 2-aroylbenzofurans with N-hydroxyacrylamide substructures as a novel series of rationally designed histone deacetylase inhibitors.
AID1403181	Inhibition of HDAC1 in human HepG2 cells assessed as upregulation of acetyl-histone H3 levels at 5 uM after 48 hrs by Western blot analysis	2018	European journal of medicinal chemistry, Jan-20, Volume: 144	Development of novel β-carboline-based hydroxamate derivatives as HDAC inhibitors with antiproliferative and antimetastatic activities in human cancer cells.
AID1622913	Inhibition of HDAC3 (unknown origin)	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.
AID1293567	Inhibition of full length human recombinant N-terminal GST-tagged HDAC6 (1 to 1215 residues) expressed in sf9 cells using RHK-K(Ac)-AMC as substrate incubated for 90 mins by fluorescence assay	2016	European journal of medicinal chemistry, Apr-13, Volume: 112	Biphenyl-4-yl-acrylohydroxamic acids: Identification of a novel indolyl-substituted HDAC inhibitor with antitumor activity.
AID717825	Inhibition of HDAC6 using Fluor-de-Lys as substrate compound pretreated for 30 mins before substrate addition by fluorescence assay	2012	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23	The structural requirements of histone deacetylase inhibitors: suberoylanilide hydroxamic acid analogs modified at the C6 position.
AID1250645	Inhibition of recombinant human HDAC5 after 60 mins by fluorescence assay	2015	Journal of medicinal chemistry, Oct-08, Volume: 58, Issue:19	Discovery of Novel Class I Histone Deacetylase Inhibitors with Promising in Vitro and in Vivo Antitumor Activities.
AID613343	Inhibition of human ERG at 30 uM	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Optimization of the in vitro cardiac safety of hydroxamate-based histone deacetylase inhibitors.
AID316875	Inhibition of HDAC from human HeLa cells	2008	Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6	Histone deacetylase inhibitors: from bench to clinic.
AID1487012	Selectivity index, ratio of IC50 for HDAC2 (unknown origin) to IC50 for HDAC8 (unknown origin)	2017	Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15	The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity.
AID1282294	Toxicity in Balb/c nude mouse xenografted with human HCT116 cells assessed as death at 100 mg/kg, po q2d for 8 days	2016	Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4	Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
AID1403172	Antimetastatic activity in human HepG2 cells assessed as reduction in cell invasion at 1 uM after 48 hrs by crystal violet staining-based transwell invasion assay	2018	European journal of medicinal chemistry, Jan-20, Volume: 144	Development of novel β-carboline-based hydroxamate derivatives as HDAC inhibitors with antiproliferative and antimetastatic activities in human cancer cells.
AID761583	Inhibition of full length His-tagged human recombinant HDAC1 expressed in baculovirus system using fluor de Lys as substrate by fluorometric analysis	2013	European journal of medicinal chemistry, Aug, Volume: 66	Design, synthesis and preliminary evaluation of a series of histone deacetylase inhibitors carrying a benzodiazepine ring.
AID1421917	Gametocytocidal activity against transgenic GFP-fused Plasmodium falciparum NF54 late stage gametocytes after 72 hrs by Mitotracker Red CMH2XRos staining based imaging method	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	One-pot, multi-component synthesis and structure-activity relationships of peptoid-based histone deacetylase (HDAC) inhibitors targeting malaria parasites.
AID663472	Inhibition of human CYP3A4	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Discovery and extensive in vitro evaluations of NK-HDAC-1: a chiral histone deacetylase inhibitor as a promising lead.
AID310187	Antitumor activity against MDA-MB-231 cells xenografted BALB/c nude mouse assessed as body weight at 30 mg/kg, ip for 15 days	2007	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 17, Issue:22	Modification of cap group in delta-lactam-based histone deacetylase (HDAC) inhibitors.
AID1819539	Antitumor immunity against mouse B16-F10 cells implanted in C57BL/6J mouse assessed as increase in proportion of T cells in spleen by flow cytometry analysis	2022	Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4	Discovery of DNA-Targeting HDAC Inhibitors with Potent Antitumor Efficacy In Vivo That Trigger Antitumor Immunity.
AID1431812	Selectivity ratio of IC50 for human KDAC1 to IC50 for human KDAC3	2017	European journal of medicinal chemistry, Feb-15, Volume: 127	Design and synthesis of benzodiazepine analogs as isoform-selective human lysine deacetylase inhibitors.
AID1476159	Antiproliferative activity against human MV4-11 cells after 48 hrs by CellTiter-Glo luminescent assay	2017	Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20	Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat.
AID1547269	Inhibition of HDAC3 (unknown origin) using biotinylated histone H3 KAc peptide (1 to 21 residues) as substrate by HTRF assay	2020	Journal of medicinal chemistry, 04-09, Volume: 63, Issue:7	Discovery of Thieno[2,3-
AID1753841	Selectivity index, ratio of IC50 for inhibition of HDAC2 (unknown origin) to IC50 for inhibition of HDAC6 (unknown origin)	2021	European journal of medicinal chemistry, Jun-05, Volume: 218	Identification of novel 1,3-diaryl-1,2,4-triazole-capped histone deacetylase 6 inhibitors with potential anti-gastric cancer activity.
AID1765330	Selectivity index, ratio of IC50 for human recombinant full length HDAC3 to IC50 for human recombinant full length HDAC2	2021	European journal of medicinal chemistry, Oct-15, Volume: 222	A first-in-class anticancer dual HDAC2/FAK inhibitors bearing hydroxamates/benzamides capped by pyridinyl-1,2,4-triazoles.
AID1702156	Inhibition of human ERG by fluorescence polarization assay	2018	Journal of medicinal chemistry, 02-22, Volume: 61, Issue:4	Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma.
AID1897508	Antiangiogenic activity against BALB/c mouse xenografted with human SNU-16 cells assessed as downregulation of CD31 expression in tumor at 50 mg/kg/day, ip administered for 18 days by immunohistochemical staining based analysis
AID1529550	Cytotoxicity against human PBL cells assessed as cell growth inhibition after 72 hrs by MTS assay	2018	Journal of medicinal chemistry, Aug-09, Volume: 61, Issue:15	Design and Synthesis of Tubulin and Histone Deacetylase Inhibitor Based on iso-Combretastatin A-4.
AID1164041	Antiproliferative activity against human U937 cells assessed as growth inhibition after 72 hrs by CCK-8 assay	2014	European journal of medicinal chemistry, Oct-30, Volume: 86	Design, synthesis, and biological evaluation of 1, 3-disubstituted-pyrazole derivatives as new class I and IIb histone deacetylase inhibitors.
AID675296	Inhibition of HDAC in human HeLa cell extracts using Fluor de Lys as substrate at 0.01 uM by fluorescence assay	2012	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17	Set-up of a new series of HDAC inhibitors: the 5,11-dihydrodibenzo[b,e]azepin-6-ones as privileged structures.
AID1349722	Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth after 72 hrs by MTT assay	2018	ACS medicinal chemistry letters, Jan-11, Volume: 9, Issue:1	Dual NAMPT/HDAC Inhibitors as a New Strategy for Multitargeting Antitumor Drug Discovery.
AID1709360	Induction of apoptosis in human Jurkat cells assessed as late apoptotic cells at IC50 measured after 48 hrs by Annexin V-FITC/7AAD staining based flow cytometry (Rvb = 6.77%)	2021	Bioorganic & medicinal chemistry, 04-01, Volume: 35	Structure-activity relationship and mechanistic studies for a series of cinnamyl hydroxamate histone deacetylase inhibitors.
AID1863433	Inhibition of HDAC1 (unknown origin) by colorimetric method	2022	European journal of medicinal chemistry, Oct-05, Volume: 240	Accommodation of ring C expanded deoxyvasicinone in the HDAC inhibitory pharmacophore culminates into a tractable anti-lung cancer agent and pH-responsive nanocarrier.
AID1699969	Antiproliferative activity against human K562 cells by MTT assay	2020	Bioorganic & medicinal chemistry letters, 12-15, Volume: 30, Issue:24	Discovery of thiosemicarbazone-containing compounds with potent anti-proliferation activity against drug-resistant K562/A02 cells.
AID1623535	Selectivity index, ratio of IC50 for human recombinant HDAC3 to IC50 for human recombinant HDAC6	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	A novel class of anthraquinone-based HDAC6 inhibitors.
AID723479	Inhibition of HDAC in cisplatin resistant human A2780 cells after 18 hrs by fluorescence assay	2013	Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
AID609489	Inhibition of purified recombinant HDAC1	2011	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16	The design, synthesis and structure-activity relationships of novel isoindoline-based histone deacetylase inhibitors.
AID1864677	Inhibition of full length recombinant human HDAC6 in MV4-11 cells assessed as upregulation of acetylated histone H4 at 1 uM measured upto 24 hrs by western blot analysis
AID1449339	Inhibition of HDAC1/HDAC6 in human Cal27CisR cells assessed as potentiation of cisplatin-induced cytotoxicity by measuring fold reduction in cisplatin IC50 at 1 uM preincubated for 48 hrs followed by cisplatin treatment measured after 72 hrs by MTT assay	2017	Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13	Alkoxyurea-Based Histone Deacetylase Inhibitors Increase Cisplatin Potency in Chemoresistant Cancer Cell Lines.
AID1677498	Induction of mitochondrial membrane potential loss in human HeLa cells at 1 to 3 uM after 24 hrs by TMRE staining based fluorescence assay	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	HDAC-Bax Multiple Ligands Enhance Bax-Dependent Apoptosis in HeLa Cells.
AID1709367	Induction of apoptosis in human NAMALVA cells assessed as late apoptotic cells at IC50 measured after 48 hrs by Annexin V-FITC/7AAD staining based flow cytometry (Rvb = 3.52%)	2021	Bioorganic & medicinal chemistry, 04-01, Volume: 35	Structure-activity relationship and mechanistic studies for a series of cinnamyl hydroxamate histone deacetylase inhibitors.
AID1821958	Inhibition of recombinant human HDAC1 expressed in baculovirus expression system using Ac-Leu-Gly-Lys (Ac)-AMC as substrate preincubated for 5 mins followed by substrate addition and measured after 30 mins by fluorescence microtiter plate reader assay
AID1826624	Synergistic antiproliferative effect on HEL cells assessed as fractional inhibitory concentration index at 0.12 uM in presence of 3-Fluoro-10-hydroxy-14-methyl-8,13,13b,14-tetrahydro-7H-indolo[2',3':3,4]pyrido[2,1-b]quinazolin-5-one	2022	Journal of medicinal chemistry, 03-24, Volume: 65, Issue:6	Evodiamine-Inspired Topoisomerase-Histone Deacetylase Dual Inhibitors: Novel Orally Active Antitumor Agents for Leukemia Therapy.
AID274026	Steady state volume of distribution (Vdss) after i.v. dosing at 1 mg kg-1	2007	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2	Identification and optimisation of a series of substituted 5-pyridin-2-yl-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.
AID274097	Effect of compound on Candida albicans sensitivity to Fluconazole: Minimum inhibitory concentration required to inhibit the growth of 50% of isolates after 24h.	2007	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 17, Issue:5	Discovery of uracil-based histone deacetylase inhibitors able to reduce acquired antifungal resistance and trailing growth in Candida albicans.
AID274078	Inhibition of MDA-MB-231 cell proliferation (mean of two experiments)	2007	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2	Identification and optimisation of a series of substituted 5-(1H-pyrazol-3-yl)-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.
AID1890509	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	2022	Bioorganic & medicinal chemistry letters, 05-15, Volume: 64	Design, synthesis, and biological evaluation of β-carboline 1,3,4-oxadiazole based hybrids as HDAC inhibitors with potential antitumor effects.
AID744875	Inhibition of mouse liver HDAC by fluorescence assay	2013	Bioorganic & medicinal chemistry letters, May-01, Volume: 23, Issue:9	Discovery of adamantane based highly potent HDAC inhibitors.
AID1502983	Inhibition of MAOA (unknown origin) using beetle luciferin as substrate by MAO-Glo assay	2017	European journal of medicinal chemistry, Nov-10, Volume: 140	Design and synthesis of tranylcypromine derivatives as novel LSD1/HDACs dual inhibitors for cancer treatment.
AID1547343	Inhibition of HDAC in human HCT116 cells assessed as activation of IL6-JAK-STAT signaling pathway by measuring increase in OSMR expression at 10 uM after 24 hrs by Western blot analysis	2020	Journal of medicinal chemistry, 04-09, Volume: 63, Issue:7	Discovery of Thieno[2,3-
AID1753637	Selectivity index, ratio of IC50 for inhibition of human HDAC1 to IC50 for inhibition of human HDAC6	2021	European journal of medicinal chemistry, Jun-05, Volume: 218	Design, synthesis and biological evaluation of brain penetrant benzazepine-based histone deacetylase 6 inhibitors for alleviating stroke-induced brain infarction.
AID1549165	Inhibition of HDAC6 (unknown origin) after 30 mins by fluorescence based assay	2020	Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10	Discovery of Novel Fungal Lanosterol 14α-Demethylase (CYP51)/Histone Deacetylase Dual Inhibitors to Treat Azole-Resistant Candidiasis.
AID1164910	Inhibition of HDAC5 (unknown origin) using fluorogenic peptide as substrate by fluorescence assay	2014	Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19	Identification of a novel aminotetralin class of HDAC6 and HDAC8 selective inhibitors.
AID1511970	Inhibition of full length recombinant FLAG-tagged C-terminal human HDAC2 expressed in baculovirus infected Sf9 insect cells using ZMAL (Z-Lys(Ac)-AMC) as substrate incubated for 90 mins by fluorescence based assay	2019	ACS medicinal chemistry letters, Sep-12, Volume: 10, Issue:9	Fluorinated Analogues of the Histone Deacetylase Inhibitor Vorinostat (Zolinza): Validation of a Chiral Hybrid Bioisostere, BITE.
AID1810051	Inhibition of HDAC1 (unknown origin) assessed as release of 7-amino-4-methylcoumarin incubated in room temperature for 15 min measured by Spectra max microtitre plate reader
AID663377	Growth inhibition of human U251 cells after 72 hrs by MTS assay	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Discovery and extensive in vitro evaluations of NK-HDAC-1: a chiral histone deacetylase inhibitor as a promising lead.
AID1880243	Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth incubated for 3 days by trypan blue assay	2022	ACS medicinal chemistry letters, May-12, Volume: 13, Issue:5	The
AID1535339	Inhibition of full length recombinant human C-terminal FLAG-tagged HDAC1 expressed in sf9 cells preincubated for 5 mins followed by biotinylated H3K9-Ac substrate addition and measured after 60 mins by HTRF assay	2019	Bioorganic & medicinal chemistry letters, 02-01, Volume: 29, Issue:3	Design, synthesis, and bioactivity evaluation of novel Bcl-2/HDAC dual-target inhibitors for the treatment of multiple myeloma.
AID1758465	Phototoxicity in human HCT-116 cells assessed as reduction in cell viability irradiated 10 j/cm2 for 24 hrs followed by incubated for 24 hrs by CCK8 assay	2021	European journal of medicinal chemistry, May-05, Volume: 217	Novel dual-mode antitumor chlorin-based derivatives as potent photosensitizers and histone deacetylase inhibitors for photodynamic therapy and chemotherapy.
AID1280309	Inhibition of human KDAC8	2016	Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4	Design and Synthesis of Simplified Largazole Analogues as Isoform-Selective Human Lysine Deacetylase Inhibitors.
AID1785345	Inhibition of full length human CDK4 (1 to 303 residues)/N-terminal GST-fusion tagged CyclinD3 (1 to 292 residues) expressed in baculovirus expression system preincubated for 10 mins followed by substrate and ATP addition by mobility shift assay
AID1206763	Inhibition of full length human recombinant HDAC2 expressed in baculovirus infected insect S9 cells using Ac-Leu-GlyLys(Ac)-AMC as substrate after 30 mins by fluorescence assay	2015	Journal of medicinal chemistry, May-28, Volume: 58, Issue:10	Design, synthesis, and antitumor evaluation of novel histone deacetylase inhibitors equipped with a phenylsulfonylfuroxan module as a nitric oxide donor.
AID1622976	Inhibition of recombinant human full-length HDAC2 expressed in baculovirus expression system using Boc-l-Lys(Ac)-AMC as substrate preincubated up to 24 hrs and measured after 60 mins by fluorescence assay	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.
AID1816208	Induction of apoptosis in human MDA-MB-231 cells assessed as necrotic cells at 2.5 uM measured after 48 hrs by annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 5.38%)
AID1476118	Cytotoxicity against TAMH cells assessed as cell viability after 24 hrs by CellTiter-Glo assay	2017	Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20	Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat.
AID1614257	Toxicity against NOD/SCID mouse xenografted with human MM1S cells assessed as mouse survival at 50 mg/kg, po qd administered for 10 days co-treated with 25 mg/kg RAPA
AID1245683	Cytotoxicity against human K562 cells assessed as growth inhibition after 48 hrs by MTT assay	2015	Bioorganic & medicinal chemistry, Oct-01, Volume: 23, Issue:19	Development of N-hydroxybenzamide derivatives with indole-containing cap group as histone deacetylases inhibitors.
AID1225990	Induction of apoptosis in human HCT116 cells assessed as necrotic cells at 5 uM after 48 hrs by annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 5.25%)	2015	ACS medicinal chemistry letters, Mar-12, Volume: 6, Issue:3	Discovery of Novel Multiacting Topoisomerase I/II and Histone Deacetylase Inhibitors.
AID1652191	Inhibition of human recombinant HDAC4 expressed in Escherichia coli BL21(DE3) cells using Boc-Lys(TFA)-AMC as substrate preincubated for 5 followed by substrate addition and measured after 30 mins by fluorescence based assay	2020	ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5	New Dual CK2/HDAC1 Inhibitors with Nanomolar Inhibitory Activity against Both Enzymes.
AID1164037	Antiproliferative activity against human BGC823 cells assessed as growth inhibition after 72 hrs by CCK-8 assay	2014	European journal of medicinal chemistry, Oct-30, Volume: 86	Design, synthesis, and biological evaluation of 1, 3-disubstituted-pyrazole derivatives as new class I and IIb histone deacetylase inhibitors.
AID1676598	Binding affinity to cupric ion assessed as retention ratio by measuring compound detected in elution fraction/total compound detected at 2.55 umol by immobilized metal-ion affinity chromatography	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
AID1503840	Inhibition of recombinant human full length HDAC1 expressed in baculovirus infected Sf9 insect cells using p53 (379 to 382 residues) derived RHKKAc as substrate preincubated for 5 to 10 mins followed by substrate addition measured after 2 hrs by fluoresce	2017	ACS medicinal chemistry letters, Oct-12, Volume: 8, Issue:10	Synthesis and Pharmacological Evaluation of Selective Histone Deacetylase 6 Inhibitors in Melanoma Models.
AID1821262	Toxicity in mouse xenografted with human HepG2 cells assessed as cellular inflammation in liver at 12 mg/kg, ip administered every 2 days for 4 weeks by H and E staining based microscopic method	2022	European journal of medicinal chemistry, Feb-05, Volume: 229	Discovery of phthalazino[1,2-b]-quinazolinone derivatives as multi-target HDAC inhibitors for the treatment of hepatocellular carcinoma via activating the p53 signal pathway.
AID1784977	Antiproliferative activity against human SNU-423 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Design, synthesis and biological evaluation of novel hybrids targeting mTOR and HDACs for potential treatment of hepatocellular carcinoma.
AID1126979	Antiproliferative activity against human KG1 cells after 48 hrs by MTT assay	2014	Journal of medicinal chemistry, Apr-24, Volume: 57, Issue:8	Discovery of the first N-hydroxycinnamamide-based histone deacetylase 1/3 dual inhibitors with potent oral antitumor activity.
AID1873386	Inhibition of HDAC6 (unknown origin)	2022	Bioorganic & medicinal chemistry letters, 08-15, Volume: 70	Comparison of three zinc binding groups for HDAC inhibitors - A potency, selectivity and enzymatic kinetics study.
AID1808545	Inhibition of recombinant human C-terminal FLAG/His-tagged HDAC1 (1 to 482 residues) expressed in Sf9 insect cells using fluorometric substrate measured after 60 mins by FRET assay	2021	Journal of medicinal chemistry, 04-08, Volume: 64, Issue:7	Structure-Based Design of a Selective Class I Histone Deacetylase (HDAC) Near-Infrared (NIR) Probe for Epigenetic Regulation Detection in Triple-Negative Breast Cancer (TNBC).
AID1667072	Cytotoxicity against African Green monkey Vero cells assessed as inhibition of cell viability after 72 hrs by MTS assay	2020	Bioorganic & medicinal chemistry, 03-15, Volume: 28, Issue:6	Pyrimethamine conjugated histone deacetylase inhibitors: Design, synthesis and evidence for triple negative breast cancer selective cytotoxicity.
AID274017	Percent inhibition of CYP450 2C19 at 1 uM concentration	2007	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2	Identification and optimisation of a series of substituted 5-pyridin-2-yl-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.
AID297490	Cytotoxicity against human AsPC1 cells	2007	Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18	2-aroylindoles and 2-aroylbenzofurans with N-hydroxyacrylamide substructures as a novel series of rationally designed histone deacetylase inhibitors.
AID1752941	Cytotoxicity against human HepG2-A16-CD81EGFP cells assessed as inhibition of cell growth incubated for 24 hrs followed by medium transfer and incubation in multimode plate for 48 hrs by CellTiterGlo reagent based luminescence assay
AID1816699	Antiproliferative activity against human MGC-803 cells assessed as reduction in cell viability after 72 hrs by CellTiter-Glo assay	2021	European journal of medicinal chemistry, Aug-05, Volume: 220	Design, synthesis, and biological evaluation of novel dual inhibitors targeting lysine specific demethylase 1 (LSD1) and histone deacetylases (HDAC) for treatment of gastric cancer.
AID1784975	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Design, synthesis and biological evaluation of novel hybrids targeting mTOR and HDACs for potential treatment of hepatocellular carcinoma.
AID593555	Inhibition of human HDAC10 using ArgHisLysLys(Ac) fluorogenic peptide as a substrate by fluorimetric assay	2011	Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7	Oxime amides as a novel zinc binding group in histone deacetylase inhibitors: synthesis, biological activity, and computational evaluation.
AID759304	Inhibition of human recombinant HDAC6 after 30 mins by fluorescence assay	2013	Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14	Histone deacetylase inhibitors equipped with estrogen receptor modulation activity.
AID1647336	Upregulation of acetylated H3K14 protein expression in hippocampus of bilateral common carotid artery occlusion-induced vascular dementia C57BL/6J mouse model at 25 mg/kg, ip measured after 3 months by Western blot analysis	2020	European journal of medicinal chemistry, Feb-01, Volume: 187	Protective effects of 10,11-dihydro-5H-dibenzo[b,f]azepine hydroxamates on vascular cognitive impairment.
AID1515904	Antiproliferative activity against human MCF7 cells after 96 hrs by MTT assay	2019	Journal of medicinal chemistry, 08-08, Volume: 62, Issue:15	Design, Synthesis, and Biological Evaluation of 4-Methyl Quinazoline Derivatives as Anticancer Agents Simultaneously Targeting Phosphoinositide 3-Kinases and Histone Deacetylases.
AID1549136	Antifungal activity against azole-sensitive Candida albicans SC5314 after 48 hrs by spectrophotometry-based serial microdilution method	2020	Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10	Discovery of Novel Fungal Lanosterol 14α-Demethylase (CYP51)/Histone Deacetylase Dual Inhibitors to Treat Azole-Resistant Candidiasis.
AID1266094	Inhibition of HDAC3 (unknown origin) by fluorimetric assay	2016	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1	Cross metathesis with hydroxamate and benzamide BOC-protected alkenes to access HDAC inhibitors and their biological evaluation highlighted intrinsic activity of BOC-protected dihydroxamates.
AID1598094	Cytotoxicity against HEK293 cells assessed as reduction in cell growth incubated for 48 hrs by MTS assay	2019	Journal of medicinal chemistry, 05-23, Volume: 62, Issue:10	Identification of 5-Substituted 2-Acylaminothiazoles That Activate Tat-Mediated Transcription in HIV-1 Latency Models.
AID1250648	Inhibition of recombinant human HDAC6 after 60 mins by fluorescence assay	2015	Journal of medicinal chemistry, Oct-08, Volume: 58, Issue:19	Discovery of Novel Class I Histone Deacetylase Inhibitors with Promising in Vitro and in Vivo Antitumor Activities.
AID1730867	cytotoxicity against human HL-7702 cells assessed as reduction of cell viability incubated for 72 hrs by MTT assay	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Design, synthesis and evaluation of novel ErbB/HDAC multitargeted inhibitors with selectivity in EGFR
AID1421907	Selectivity index, ratio of IC50 for human NFF cells to IC50 for multidrug-resistant asexual ring stage Plasmodium falciparum Dd2 infected in human erythrocytes	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	One-pot, multi-component synthesis and structure-activity relationships of peptoid-based histone deacetylase (HDAC) inhibitors targeting malaria parasites.
AID1514604	Inhibition of HDAC1 in human HepG2 cells assessed as acetylated histone H4 levels at 5 uM by Western blot analysis relative to beta-actin (Rvb = 1 No_unit)	2019	Bioorganic & medicinal chemistry letters, 01-01, Volume: 29, Issue:1	Development of hydroxamate-based histone deacetylase inhibitors containing 1,2,4-oxadiazole moiety core with antitumor activities.
AID1173503	Inhibition of C-terminal 6x-His tagged human HDAC5 (657 to 1123 residues) using fluorogenic acetyl-Lys(trifluoroacetyl)-AMC substrate incubated for 2 hrs by fluorescence assay	2014	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 24, Issue:23	Histone deacetylase inhibitors derived from 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine and related heterocycles selective for the HDAC6 isoform.
AID1386705	Inhibition of HDAC in human GM18453 cells assessed as increase in 250 kDa NPC1 protein expression at 5 uM pretreated for 48 hrs followed by endoglycosidase H addition and measured after overnight incubation by Western blot analysis	2018	Journal of natural products, 09-28, Volume: 81, Issue:9	GEX1A, a Polyketide from Streptomyces chromofuscus, Corrects the Cellular Defects Associated with Niemann-Pick Type C1 in Human Fibroblasts.
AID1394885	Antiproliferative activity against human HL60 cells after 48 hrs by sulforhodamine B assay	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	1-Aroylindoline-hydroxamic acids as anticancer agents, inhibitors of HSP90 and HDAC.
AID1811363	Inhibition of HDAC1 (unknown origin)	2021	European journal of medicinal chemistry, Dec-15, Volume: 226	Development of novel tetrahydroisoquinoline-hydroxamate conjugates as potent dual SERDs/HDAC inhibitors for the treatment of breast cancer.
AID663346	Growth inhibition of human K562 cells after 72 hrs by MTS assay	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Discovery and extensive in vitro evaluations of NK-HDAC-1: a chiral histone deacetylase inhibitor as a promising lead.
AID780588	Inhibition of human recombinant HDAC1 expressed in baculovirus infected insect high5 cells using Ac-Lys-Tyr-Lys (epsilon-acetyl)-AMC as substrate after 3 to 24 hrs by fluorescence assay	2013	Bioorganic & medicinal chemistry, Nov-15, Volume: 21, Issue:22	The discovery and optimization of novel dual inhibitors of topoisomerase II and histone deacetylase.
AID1312891	Toxicity in Balb/c nude mouse xenografted with human HCT116 cells assessed as mortality at 50 mg/kg, ip administered every 2 days for 8 days	2016	Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11	Development of Purine-Based Hydroxamic Acid Derivatives: Potent Histone Deacetylase Inhibitors with Marked in Vitro and in Vivo Antitumor Activities.
AID246067	Effective Concentration of compound to inhibit the growth of human DU-145 cells	2005	Journal of medicinal chemistry, Feb-24, Volume: 48, Issue:4	Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates.
AID1754808	Upregulation of SIRT2 gene expression in human MCF7 cells at 3 uM incubated for 24 hrs by whole transcriptome analysis	2021	Bioorganic & medicinal chemistry, 07-15, Volume: 42	Discovery of novel class of histone deacetylase inhibitors as potential anticancer agents.
AID1762488	Inhibition of HDAC in human HeLa nuclear extracts using Boc-Lys (acetyl)-AMC as substrate preincubated for 5 mins followed by substrate addition and further incubated for 30 mins by fluorescence based assay	2021	European journal of medicinal chemistry, Jul-05, Volume: 219	Synthesis and biological evaluation of phenothiazine derivative-containing hydroxamic acids as potent class II histone deacetylase inhibitors.
AID604138	Inhibition of histone acetyltransferase in human U937 cells assessed as increase of acetylation of histone H3 at K18 at 5 uM after 24 hrs by Western blotting	2011	Bioorganic & medicinal chemistry, Jun-15, Volume: 19, Issue:12	Modulation of the activity of histone acetyltransferases by long chain alkylidenemalonates (LoCAMs).
AID609724	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay	2011	Bioorganic & medicinal chemistry, Aug-01, Volume: 19, Issue:15	Design, synthesis and biological evaluation of tyrosine-based hydroxamic acid analogs as novel histone deacetylases (HDACs) inhibitors.
AID1421920	Antiplasmodial activity against exo-erythrocytic stage of GFP-Luc-fused Plasmodium berghei ANKA infected in human HepG2 cells after 48 hrs by bioluminescence assay	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	One-pot, multi-component synthesis and structure-activity relationships of peptoid-based histone deacetylase (HDAC) inhibitors targeting malaria parasites.
AID1326510	Antiproliferative activity against human HL60 cells after 48 hrs by SRB assay	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	2-(Phenylsulfonyl)quinoline N-hydroxyacrylamides as potent anticancer agents inhibiting histone deacetylase.
AID605532	Antiproliferative activity against human PC3 cells after 72 hrs by WST-1 assay	2010	Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24	Discovery of 2-(6-{[(6-fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a class I selective orally active histone deacetylase inhibitor.
AID344918	Inhibition of 2-oxoglutarate-dependent human JMJD2E preincubated for 30 mins by FDH coupled assay	2008	Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22	Inhibitor scaffolds for 2-oxoglutarate-dependent histone lysine demethylases.
AID1403182	Inhibition of HDAC6 in human HepG2 cells assessed as upregulation of acetyl-alpha-tubulin levels at 5 uM after 48 hrs by Western blot analysis	2018	European journal of medicinal chemistry, Jan-20, Volume: 144	Development of novel β-carboline-based hydroxamate derivatives as HDAC inhibitors with antiproliferative and antimetastatic activities in human cancer cells.
AID241537	Inhibitory concentration against maize histone deacetylase 1-A (class IIa HDAC)	2005	Journal of medicinal chemistry, May-05, Volume: 48, Issue:9	Class II (IIa)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl)pyrrolyl hydroxyamides.
AID481546	Cytotoxicity against human NCI-H460 cells assessed as growth inhibition at 10 ug/ml after 24 hrs by MTT assay	2010	Bioorganic & medicinal chemistry letters, May-15, Volume: 20, Issue:10	Synthesis and anticancer evaluation of alpha-lipoic acid derivatives.
AID1126995	Induction of apoptosis in human U937 cells assessed as necrotic cells using annexin-V/propidium iodide staining at 1 uM after 24 hrs by flow cytometry analysis (Rvb = 0.06%)	2014	Journal of medicinal chemistry, Apr-24, Volume: 57, Issue:8	Discovery of the first N-hydroxycinnamamide-based histone deacetylase 1/3 dual inhibitors with potent oral antitumor activity.
AID1280276	Inhibition of HDAC6 in human HL60 cells assessed as ratio of acetylated tubulin to GAPDH level at 1 uM after 4 hrs by Western blot analysis relative to control	2016	Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4	Synthesis and Biological Investigation of Oxazole Hydroxamates as Highly Selective Histone Deacetylase 6 (HDAC6) Inhibitors.
AID1486669	Antiproliferative activity against human K562 cells after 48 hrs by MTT assay	2017	Bioorganic & medicinal chemistry, 08-01, Volume: 25, Issue:15	Design, synthesis and tumor cell growth inhibitory activity of 3-nitro-2H-cheromene derivatives as histone deacetylaes inhibitors.
AID297483	Cytotoxicity against human SK-OV-3 cells	2007	Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18	2-aroylindoles and 2-aroylbenzofurans with N-hydroxyacrylamide substructures as a novel series of rationally designed histone deacetylase inhibitors.
AID1563942	Inhibition of recombinant HDAC3 (unknown origin) measured after 30 mins by fluorescence assay	2019	European journal of medicinal chemistry, Oct-15, Volume: 180	Design, synthesis, and biological evaluation of a new class of histone acetyltransferase p300 inhibitors.
AID348793	Antiproliferative activity against human HeLa cells after 72 hrs by celltiter-blue viability assay	2008	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20	Optimization of a series of potent and selective ketone histone deacetylase inhibitors.
AID328795	Inhibition of HDAC3	2008	Journal of medicinal chemistry, Apr-24, Volume: 51, Issue:8	A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo.
AID465154	Inhibition of HDAC6 assessed as blockade of decorboxylation of carboxyfluorescein labeled acetylated peptide substrate after 17 hrs	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Synthesis and biological evaluation of triazol-4-ylphenyl-bearing histone deacetylase inhibitors as anticancer agents.
AID1408193	Inhibition of MOF in human HCT116 cells assessed as decrease in H4K16 acetylation level after 24 hrs by Western blot analysis	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Identification of novel inhibitors of histone acetyltransferase hMOF through high throughput screening.
AID1897400	Induction of apoptosis in human SNU-16 cells assessed as live cells at 0.3 uM incubated for 72 hrs by annexin-V/FITC propidium iodide staining based flow cytometry analysis (Rvb = 90.92%)
AID586607	Antimalarial activity against ring stage of Plasmodium vivax assessed as parasites growth inhibition using giemsa staining after 24 to 56 hrs by microscopic analysis in presence of 20% human serum	2011	Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3	Ex vivo activity of histone deacetylase inhibitors against multidrug-resistant clinical isolates of Plasmodium falciparum and P. vivax.
AID1162220	Cell cycle arrest in human HL60 cells assessed as accumulation at G2/M phase at 1 uM by propidium iodide staining-based flow cytometry (Rvb = 21.3%)	2014	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 24, Issue:19	Design, synthesis and biological evaluation of β-boswellic acid based HDAC inhibitors as inducers of cancer cell death.
AID1897371	Inhibition of FGFR3 (unknown origin)
AID1754751	Inhibition of C-terminal FLAG/His-tagged human recombinant HDAC1 (1 to 482 residues) expressed in baculovirus-infected Sf9 cells assessed as reduction in 7-amino-4-methylcoumarin release using fluorogenic HDAC substrate 3 measured every 5 mins by fluoresc	2021	Bioorganic & medicinal chemistry, 07-15, Volume: 42	Discovery of novel class of histone deacetylase inhibitors as potential anticancer agents.
AID1882089	Inhibition of HDAC1 (unknown origin) using fluorimetric substrate incubated for 30 mins by fluorogenic assay	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	Medicinal chemistry updates of novel HDACs inhibitors (2020 to present).
AID1337255	Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay	2016	Journal of medicinal chemistry, Sep-22, Volume: 59, Issue:18	Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines.
AID1514598	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	2019	Bioorganic & medicinal chemistry letters, 01-01, Volume: 29, Issue:1	Development of hydroxamate-based histone deacetylase inhibitors containing 1,2,4-oxadiazole moiety core with antitumor activities.
AID1816187	Inhibition of HDAC3 (unknown origin) incubated for 60 mins using microplate reader analysis
AID1326522	Inhibition of His-tagged full length recombinant human HDAC8 expressed in baculovirus expression system assessed as release of 7-amino-4-methylcoumarin by fluorogenic assay	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	2-(Phenylsulfonyl)quinoline N-hydroxyacrylamides as potent anticancer agents inhibiting histone deacetylase.
AID1129791	Induction of apoptosis in human Jurkat cells assessed as cell death at 10 uM after 24 hrs by annexin V-FITC/propidium iodide staining-based FACS flow cytometric analysis (Rvb = 0.348%)	2014	Bioorganic & medicinal chemistry, Apr-01, Volume: 22, Issue:7	Studies on the antiproliferative effects of tropolone derivatives in Jurkat T-lymphocyte cells.
AID1275593	Inhibition of HDAC in mouse forebrain primary neurons assessed as acetylation of histone H3K9 after 24 hrs by immunofluorescence assay	2016	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4	Dissecting structure-activity-relationships of crebinostat: Brain penetrant HDAC inhibitors for neuroepigenetic regulation.
AID1547247	Antiproliferative activity against human SW620 cells assessed as reduction in cell viability measured after 24 to 48 hrs by MTT assay	2020	Journal of medicinal chemistry, 04-09, Volume: 63, Issue:7	Discovery of Thieno[2,3-
AID1599789	Inhibition of HDAC6 in human A549 cells assessed as upregulation of semaphorin 3F mRNA expression at 2.5 uM after 24 hrs by RT-Sybr green PCR analysis	2019	ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6	Extending Cross Metathesis To Identify Selective HDAC Inhibitors: Synthesis, Biological Activities, and Modeling.
AID1702082	Antiproliferative activity against human SNU-387 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay	2018	Journal of medicinal chemistry, 02-22, Volume: 61, Issue:4	Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma.
AID438219	Inhibition of HDAC6	2009	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23	Design and synthesis of novel histone deacetylase inhibitor derived from nuclear localization signal peptide.
AID1865271	Inhibition of HDAC in human MV4-11 cells assessed as upregulation of acetylated H3 level incubated for 24 hrs by Western blot analysis	2022	Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18	Discovery of Novel Src Homology-2 Domain-Containing Phosphatase 2 and Histone Deacetylase Dual Inhibitors with Potent Antitumor Efficacy and Enhanced Antitumor Immunity.
AID316891	Inhibition of HDAC	2008	Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6	Histone deacetylase inhibitors: from bench to clinic.
AID1129788	Induction of apoptosis in human Jurkat cells assessed as viable cells at 10 uM after 24 hrs by annexin V-FITC/propidium iodide staining-based FACS flow cytometric analysis (Rvb = 99.3%)	2014	Bioorganic & medicinal chemistry, Apr-01, Volume: 22, Issue:7	Studies on the antiproliferative effects of tropolone derivatives in Jurkat T-lymphocyte cells.
AID639364	Clearance in mouse	2011	Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8	Discovery, synthesis, and pharmacological evaluation of spiropiperidine hydroxamic acid based derivatives as structurally novel histone deacetylase (HDAC) inhibitors.
AID1550157	Toxicity in BALB/c nu mouse xenografted with HEL cells assessed as change in body weight at 60 mg/kg/day, ip administered for 16 days and measured every day during compound dosing in presence of ruxolitinib	2019	Journal of medicinal chemistry, 04-25, Volume: 62, Issue:8	Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies.
AID1688037	Induction of apoptosis in human HL-60 cells assessed as necrotic cells at 1 uM measured after 24 hrs by Annexin-V/FITC and propidium iodide staining based flow cytometry (Rvb = 1.01 %)	2020	European journal of medicinal chemistry, Feb-15, Volume: 188	A 18β-glycyrrhetinic acid conjugate with Vorinostat degrades HDAC3 and HDAC6 with improved antitumor effects.
AID1816199	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay
AID546560	Cytotoxicity against human HeLa cells overexpressing HDAC by resazurin dye reduction assay	2010	Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24	Novel chimeric histone deacetylase inhibitors: a series of lapatinib hybrides as potent inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and histone deacetylase activity.
AID1449227	Inhibition of HDAC1/2/3/6 in human Cal27CisR cells assessed as potentiation of cisplatin-induced cytotoxicity by measuring fold reduction in cisplatin IC50 at 1 uM preincubated for 48 hrs followed by cisplatin addition measured after 72 hrs by MTT assay r	2017	Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13	Design, Multicomponent Synthesis, and Anticancer Activity of a Focused Histone Deacetylase (HDAC) Inhibitor Library with Peptoid-Based Cap Groups.
AID1482168	Cytotoxicity against human MOLT4 cells assessed as growth inhibition at 5 uM after 48 hrs by MTT assay relative to control	2017	Journal of medicinal chemistry, 04-27, Volume: 60, Issue:8	Exploring Derivatives of Quinazoline Alkaloid l-Vasicine as Cap Groups in the Design and Biological Mechanistic Evaluation of Novel Antitumor Histone Deacetylase Inhibitors.
AID1215097	Activation of rat PXR expressed in human HepG2 cells after 24 hrs by luciferase reporter gene based luminescent analysis relative to dexamethasone	2011	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1	Identification of clinically used drugs that activate pregnane X receptors.
AID1303630	Potentiation of 0.5 nM (-)-lomaiviticin A-induced cytotoxicity against human K562 cells assessed as combination index at 2.5 uM after 48 hrs by cell titer-glo luminescence assay	2016	Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13	Synergistic potentiation of (-)-lomaiviticin A cytotoxicity by the ATR inhibitor VE-821.
AID1260649	Inhibition of HDAC in human MV411 cells assessed as increase in H3K9 aceylation at 0.1 to 5 uM after 4 hrs by western blot analysis
AID710840	Cytotoxicity against human PC3 cells assessed as growth inhibition by SRB assay	2012	Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23	Property-based optimization of hydroxamate-based γ-lactam HDAC inhibitors to improve their metabolic stability and pharmacokinetic profiles.
AID663351	Growth inhibition of human HOP92 cells after 72 hrs by MTS assay	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Discovery and extensive in vitro evaluations of NK-HDAC-1: a chiral histone deacetylase inhibitor as a promising lead.
AID1900918	Induction of apoptosis in mouse GL26 cells assessed as proteolytic cleavage of PARP1 incubated for 48 hrs by Western blot analysis	2022	Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
AID541649	Inhibition of human HDAC5 by fluorimetric assay	2010	Journal of medicinal chemistry, Dec-09, Volume: 53, Issue:23	Non-natural macrocyclic inhibitors of histone deacetylases: design, synthesis, and activity.
AID1349718	Inhibition of NAMPT (unknown origin) using NAM as substrate incubated for 5 mins followed by substrate addition measured after 15 mins by fluorometric method	2018	ACS medicinal chemistry letters, Jan-11, Volume: 9, Issue:1	Dual NAMPT/HDAC Inhibitors as a New Strategy for Multitargeting Antitumor Drug Discovery.
AID481551	Cytotoxicity against human HO8910 cells assessed as growth inhibition at 1 ug/ml after 24 hrs by MTT assay	2010	Bioorganic & medicinal chemistry letters, May-15, Volume: 20, Issue:10	Synthesis and anticancer evaluation of alpha-lipoic acid derivatives.
AID1864251	Cytotoxicity against human MDA-MB-231 cells harboring wild type BRCA1 and wild BRCA2 assessed as reduction in cell viability	2022	Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18	Discovery of a Novel G-Quadruplex and Histone Deacetylase (HDAC) Dual-Targeting Agent for the Treatment of Triple-Negative Breast Cancer.
AID1164911	Inhibition of HDAC6 (unknown origin) using fluorogenic peptide as substrate by fluorescence assay	2014	Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19	Identification of a novel aminotetralin class of HDAC6 and HDAC8 selective inhibitors.
AID313733	Inhibition of HDAC5	2008	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2	Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2).
AID1754760	Downregulation of HDAC1 gene expression in human MCF7 cells at 3 uM incubated for 24 hrs by whole transcriptome analysis	2021	Bioorganic & medicinal chemistry, 07-15, Volume: 42	Discovery of novel class of histone deacetylase inhibitors as potential anticancer agents.
AID1798524	HDAC Activity Assay from Article 10.1021/jm800079s: \\A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo.\\	2008	Journal of medicinal chemistry, Apr-24, Volume: 51, Issue:8	A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo.
AID1797826	HDAC Enzyme Activity Assay from Article 10.1021/jm0703800: \\The First Biologically Active Synthetic Analogues of FK228, the Depsipeptide Histone Deacetylase Inhibitor.\\	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	The first biologically active synthetic analogues of FK228, the depsipeptide histone deacetylase inhibitor.
AID1802589	HDAC2 Enzyme Assay from Article 10.1016/j.bioorg.2017.02.002: \\Novel N-hydroxybenzamides incorporating 2-oxoindoline with unexpected potent histone deacetylase inhibitory effects and antitumor cytotoxicity.\\	2017	Bioorganic chemistry, 04, Volume: 71	Novel N-hydroxybenzamides incorporating 2-oxoindoline with unexpected potent histone deacetylase inhibitory effects and antitumor cytotoxicity.
AID1798419	HDAC Inhibition Assay from Article 10.1021/jm701606b: \\A series of potent and selective, triazolylphenyl-based histone deacetylases inhibitors with activity against pancreatic cancer cells and Plasmodium falciparum.\\	2008	Journal of medicinal chemistry, Jun-26, Volume: 51, Issue:12	A series of potent and selective, triazolylphenyl-based histone deacetylases inhibitors with activity against pancreatic cancer cells and Plasmodium falciparum.
AID1800141	In vitro HDACs Inhibition Fluorescence Assay from Article 10.1111/cbdd.12144: \\Design and synthesis of a tetrahydroisoquinoline-based hydroxamate derivative (ZYJ-34v), an oral active histone deacetylase inhibitor with potent antitumor activity.\\	2013	Chemical biology & drug design, Aug, Volume: 82, Issue:2	Design and synthesis of a tetrahydroisoquinoline-based hydroxamate derivative (ZYJ-34v), an oral active histone deacetylase inhibitor with potent antitumor activity.
AID1802011	HDAC6 fluorescence anisotropy assay from Article 10.1038/nchembio.2134: \\Histone deacetylase 6 structure and molecular basis of catalysis and inhibition\\	2016	Nature chemical biology, 09, Volume: 12, Issue:9	Histone deacetylase 6 structure and molecular basis of catalysis and inhibition.
AID1802356	Inhibitor Competition Assay from Article 10.1021/acschembio.6b00776: \\LSD1 Substrate Binding and Gene Expression Are Affected by HDAC1-Mediated Deacetylation.\\	2017	ACS chemical biology, 01-20, Volume: 12, Issue:1	LSD1 Substrate Binding and Gene Expression Are Affected by HDAC1-Mediated Deacetylation.
AID1801572	In-vitro HDAC Enzymatic Endpoint Assay from Article 10.1021/acschembio.5b00640: \\An Isochemogenic Set of Inhibitors To Define the Therapeutic Potential of Histone Deacetylases in u00DF-Cell Protection.\\	2016	ACS chemical biology, Feb-19, Volume: 11, Issue:2	An Isochemogenic Set of Inhibitors To Define the Therapeutic Potential of Histone Deacetylases in β-Cell Protection.
AID1802920	HDAC Activity Assay from Article 10.3109/14756360903049034: \\Synthesis of a novel series of benzylether-containing cinnamoyl derivatives as histone deacetylase inhibitors.\\	2010	Journal of enzyme inhibition and medicinal chemistry, Feb, Volume: 25, Issue:1	Synthesis of a novel series of benzylether-containing cinnamoyl derivatives as histone deacetylase inhibitors.
AID1799021	pfHDAC-1 Enzyme Assay from Article 10.1021/jm801654y: \\Identification and characterization of small molecule inhibitors of a class I histone deacetylase from Plasmodium falciparum.\\	2009	Journal of medicinal chemistry, Apr-23, Volume: 52, Issue:8	Identification and characterization of small molecule inhibitors of a class I histone deacetylase from Plasmodium falciparum.
AID1798635	FDH Coupled Inhibition Assay from Article 10.1021/jm800936s: \\Inhibitor Scaffolds for 2-Oxoglutarate-Dependent Histone Lysine Demethylases.\\	2008	Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22	Inhibitor scaffolds for 2-oxoglutarate-dependent histone lysine demethylases.
AID1802398	Enzymatic HDAC Activity Assay from Article 10.1074/jbc.M113.490706: \\Histone deacetylase (HDAC) inhibitor kinetic rate constants correlate with cellular histone acetylation but not transcription and cell viability.\\	2013	The Journal of biological chemistry, Sep-13, Volume: 288, Issue:37	Histone deacetylase (HDAC) inhibitor kinetic rate constants correlate with cellular histone acetylation but not transcription and cell viability.
AID1800408	HDAC8 Inhibition Assay (spectrofluorometric titration) from Article 10.1021/bi400740x: \\Kinetic and thermodynamic rationale for suberoylanilide hydroxamic acid being a preferential human histone deacetylase 8 inhibitor as compared to the structurally simi	2013	Biochemistry, Nov-12, Volume: 52, Issue:45	Kinetic and thermodynamic rationale for suberoylanilide hydroxamic acid being a preferential human histone deacetylase 8 inhibitor as compared to the structurally similar ligand, trichostatin a.
AID1802059	In vitro HDAC8 Assay from Article 10.1111/cbdd.12778: \\Design, synthesis, and biological characterization of tamibarotene analogs as anticancer agents.\\	2016	Chemical biology & drug design, 10, Volume: 88, Issue:4	Design, synthesis, and biological characterization of tamibarotene analogs as anticancer agents.
AID1794865	Enzyme inhibition assay from Article 10.3109/14756366.2013.827678: \\Discovery of a series of hydroximic acid derivatives as potent histone deacetylase inhibitors.\\	2014	Journal of enzyme inhibition and medicinal chemistry, Aug, Volume: 29, Issue:4	Discovery of a series of hydroximic acid derivatives as potent histone deacetylase inhibitors.
AID1798526	HDAC Activity Assay from Article 10.1016/j.bmcl.2008.02.025: \\Probing the elusive catalytic activity of vertebrate class IIa histone deacetylases.\\	2008	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 18, Issue:6	Probing the elusive catalytic activity of vertebrate class IIa histone deacetylases.
AID1802239	In vitro HDACs Inhibition Fluorescence Assay from Article 10.1111/cbdd.12819: \\Design, synthesis, and preliminary bioactivity evaluation of N(1) -hydroxyterephthalamide derivatives with indole cap as novel histone deacetylase inhibitors.\\	2017	Chemical biology & drug design, Jan, Volume: 89, Issue:1	Design, synthesis, and preliminary bioactivity evaluation of N
AID1802399	Proteros Reporter Displacement Assay from Article 10.1074/jbc.M113.490706: \\Histone deacetylase (HDAC) inhibitor kinetic rate constants correlate with cellular histone acetylation but not transcription and cell viability.\\	2013	The Journal of biological chemistry, Sep-13, Volume: 288, Issue:37	Histone deacetylase (HDAC) inhibitor kinetic rate constants correlate with cellular histone acetylation but not transcription and cell viability.
AID1794854	HDAC Activity screening from Article 10.3109/14756366.2013.827675: \\Quinolone-based HDAC inhibitors.\\	2014	Journal of enzyme inhibition and medicinal chemistry, Aug, Volume: 29, Issue:4	Quinolone-based HDAC inhibitors.
AID1798196	Enzyme Inhibition Assay from Article 10.1021/jm7015254: \\Structural Origin of Selectivity in Class II-Selective Histone Deacetylase Inhibitors.\\	2008	Journal of medicinal chemistry, May-22, Volume: 51, Issue:10	Structural origin of selectivity in class II-selective histone deacetylase inhibitors.
AID1800409	HDAC8 Inhibition Assay (kinetic method) from Article 10.1021/bi400740x: \\Kinetic and thermodynamic rationale for suberoylanilide hydroxamic acid being a preferential human histone deacetylase 8 inhibitor as compared to the structurally similar ligand, tri	2013	Biochemistry, Nov-12, Volume: 52, Issue:45	Kinetic and thermodynamic rationale for suberoylanilide hydroxamic acid being a preferential human histone deacetylase 8 inhibitor as compared to the structurally similar ligand, trichostatin a.
AID1798784	HDAC Activity Assay from Article 10.1021/jm801128g: \\Non-peptide macrocyclic histone deacetylase inhibitors.\\	2009	Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2	Non-peptide macrocyclic histone deacetylase inhibitors.
AID1801045	HDAC Enzyme Activity Assay from Article 10.1016/j.bioorg.2015.02.009: \\An efficient synthesis of SK-658 and its analogs as potent histone deacetylase inhibitors.\\	2015	Bioorganic chemistry, Apr, Volume: 59	An efficient synthesis of SK-658 and its analogs as potent histone deacetylase inhibitors.
AID1802060	APN Inhibition Assay from Article 10.1111/cbdd.12778: \\Design, synthesis, and biological characterization of tamibarotene analogs as anticancer agents.\\	2016	Chemical biology & drug design, 10, Volume: 88, Issue:4	Design, synthesis, and biological characterization of tamibarotene analogs as anticancer agents.
AID1347425	Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1508612	NCATS Parallel Artificial Membrane Permeability Assay (PAMPA) Profiling	2017	Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3	Highly predictive and interpretable models for PAMPA permeability.
AID1347424	RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347407	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1508591	NCATS Rat Liver Microsome Stability Profiling	2020	Scientific reports, 11-26, Volume: 10, Issue:1	Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.
AID686947	qHTS for small molecule inhibitors of Yes1 kinase: Primary Screen	2013	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15	Identification of potent Yes1 kinase inhibitors using a library screening approach.
AID1346082	Human histone deacetylase 2 (3.5.1.- Histone deacetylases (HDACs))	2010	Nature chemical biology, Mar, Volume: 6, Issue:3	Chemical phylogenetics of histone deacetylases.
AID1346066	Human histone deacetylase 5 (3.5.1.- Histone deacetylases (HDACs))	2010	Nature chemical biology, Mar, Volume: 6, Issue:3	Chemical phylogenetics of histone deacetylases.
AID1346068	Human histone deacetylase 8 (3.5.1.- Histone deacetylases (HDACs))	2010	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11	Acylurea connected straight chain hydroxamates as novel histone deacetylase inhibitors: Synthesis, SAR, and in vivo antitumor activity.
AID1346080	Human histone deacetylase 11 (3.5.1.- Histone deacetylases (HDACs))	2010	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11	Acylurea connected straight chain hydroxamates as novel histone deacetylase inhibitors: Synthesis, SAR, and in vivo antitumor activity.
AID1346032	Human histone deacetylase 6 (3.5.1.- Histone deacetylases (HDACs))	2010	Nature chemical biology, Mar, Volume: 6, Issue:3	Chemical phylogenetics of histone deacetylases.
AID1346090	Human histone deacetylase 9 (3.5.1.- Histone deacetylases (HDACs))	2010	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11	Acylurea connected straight chain hydroxamates as novel histone deacetylase inhibitors: Synthesis, SAR, and in vivo antitumor activity.
AID1346068	Human histone deacetylase 8 (3.5.1.- Histone deacetylases (HDACs))	2010	Nature chemical biology, Mar, Volume: 6, Issue:3	Chemical phylogenetics of histone deacetylases.
AID1346077	Human histone deacetylase 3 (3.5.1.- Histone deacetylases (HDACs))	2010	Nature chemical biology, Mar, Volume: 6, Issue:3	Chemical phylogenetics of histone deacetylases.
AID1346048	Human histone deacetylase 10 (3.5.1.- Histone deacetylases (HDACs))	2010	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11	Acylurea connected straight chain hydroxamates as novel histone deacetylase inhibitors: Synthesis, SAR, and in vivo antitumor activity.
AID1346134	Human histone deacetylase 1 (3.5.1.- Histone deacetylases (HDACs))	2010	Nature chemical biology, Mar, Volume: 6, Issue:3	Chemical phylogenetics of histone deacetylases.
AID1645848	NCATS Kinetic Aqueous Solubility Profiling	2019	Bioorganic & medicinal chemistry, 07-15, Volume: 27, Issue:14	Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.
AID1347414	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Secondary screen by immunofluorescence	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347415	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: tertiary screen by RT-qPCR	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347412	qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID977610	Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB	2010	Nature chemical biology, Mar, Volume: 6, Issue:3	Chemical phylogenetics of histone deacetylases.
AID977611	Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB	2013	The Journal of biological chemistry, Sep-13, Volume: 288, Issue:37	Histone deacetylase (HDAC) inhibitor kinetic rate constants correlate with cellular histone acetylation but not transcription and cell viability.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	6 (0.24)	18.2507
2000's	480 (19.24)	29.6817
2010's	1591 (63.77)	24.3611
2020's	418 (16.75)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	181 (7.16%)	5.53%
Reviews	139 (5.50%)	6.00%
Case Studies	38 (1.50%)	4.05%
Observational	1 (0.04%)	0.25%
Other	2,170 (85.80%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (272)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Phase I Trial Of Vorinostat In The Treatment Of Advanced Laryngeal, Hypopharyngeal, Nasopharyngeal And Oropharyngeal Squamous Cell Carcinoma Of The Head And Neck. [NCT01064921]	Phase 1	27 participants (Actual)	Interventional	2010-01-19	Completed
Phase I Study of the Combination of Vorinostat and Radiation Therapy for the Treatment of Patients With Brain Metastases [NCT00838929]	Phase 1	17 participants (Actual)	Interventional	2009-03-31	Completed
A Feasibility Study of Vorinostat (SAHA) Combined With Isotretinoin and Chemotherapy in Infants With Embryonal Tumors of the Central Nervous System [NCT00867178]	Phase 1	33 participants (Actual)	Interventional	2009-02-25	Completed
Phase I Study of Vorinostat in Combination With 13-Cis-retinoic Acid in Patients With Refractory/Recurrent Neuroblastoma [NCT01208454]	Phase 1	29 participants (Actual)	Interventional	2010-12-31	Completed
Phase I Study on Suberoylanilide Hydroxyamic Acid (Vorinostat) a Histone Deacetylase Inhibitor, in Palliative Radiotherapy for Advanced Tumors. [NCT00455351]	Phase 1	15 participants (Actual)	Interventional	2007-02-28	Completed
A Phase I Study of Vorinostat and Bortezomib in Children With Refractory of Recurrent Solid Tumors, Including CNS Tumors and Lymphomas [NCT01132911]	Phase 1	5 participants (Anticipated)	Interventional	2010-05-10	Completed
A Phase I Trial of Sirolimus (mTOR Inhibitor) or Vorinostat (HDAC Inhibitor) in Combination With Hydroxychloroquine (Autophagy Inhibitor) in Patients With Advanced Malignancies [NCT01266057]	Phase 1	143 participants (Actual)	Interventional	2011-04-28	Completed
A Phase I/II Trial of Vorinostat and Pegylated Liposomal Doxorubicin in Relapsed or Refractory Lymphomas [NCT00785798]	Phase 1/Phase 2	17 participants (Actual)	Interventional	2009-01-31	Terminated(stopped due to sponsor requested)
The Effect of Vorinostat on ACTH Producing Pituitary Adenomas in Cushing's Disease [NCT04339751]	Phase 2	22 participants (Anticipated)	Interventional	2024-01-03	Recruiting
Phase I Trial of Ixabepilone and Vorinostat in Metastatic Breast Cancer [NCT01084057]	Phase 1	56 participants (Actual)	Interventional	2010-05-17	Completed
Vorinostat With Gemcitabine/Clofarabine/Busulfan for Allogeneic Transplantation for Aggressive Lymphomas [NCT04220008]	Phase 2	30 participants (Anticipated)	Interventional	2023-06-01	Not yet recruiting
A Pilot Study of Peroral Vorinostat (SAHA) in Patients With Refractory Histone Deacetylase-positive Uterine Sarcoma [NCT03509207]	Phase 2	3 participants (Actual)	Interventional	2017-12-14	Terminated(stopped due to The early termination was NOT due to safety reasons, terminated because of the very slow recruitment and problematic access to the study medication in Europe)
A Phase IIb Trial of Vorinostat in Combination With Lenalidomide and Dexamethasone in Multiple Myeloma Patients Refractory to Previous Lenalidomide Containing Regimens [NCT01502085]	Phase 1/Phase 2	25 participants (Actual)	Interventional	2011-12-31	Completed
Pilot Study of the Effect of Vorinostat on Nervous System Hemangioblastomas In Von Hippel-Lindau Disease [NCT02108002]	Phase 1	7 participants (Actual)	Interventional	2014-04-05	Completed
A Randomized Phase II/III Study of Azacitidine in Combination With Lenalidomide (NSC-703813) vs. Azacitidine Alone vs. Azacitidine in Combination With Vorinostat (NSC-701852) for Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leuke [NCT01522976]	Phase 2	282 participants (Actual)	Interventional	2012-03-01	Active, not recruiting
A Phase I Clinical Study of L-001079038 in Patients With Solid Tumors [NCT00127127]	Phase 1	18 participants (Actual)	Interventional	2005-06-10	Completed
A Phase I Study of Pazopanib and Vorinostat in Patients With Advanced Malignancies [NCT01339871]	Phase 1	152 participants (Actual)	Interventional	2011-04-20	Completed
A Pilot Study to Assess the Safety and Effect on HIV Transcription of Vorinostat in Patients Receiving Suppressive Combination Anti-retroviral Therapy [NCT01365065]	Phase 2	20 participants (Actual)	Interventional	2011-05-31	Active, not recruiting
High-Dose Vorinostat With Radiation Therapy in the Treatment of Recurrent Glioma [NCT01378481]	Phase 1	30 participants (Actual)	Interventional	2012-06-30	Terminated
A Phase 2 Clinical Trial Testing the Safety and Efficacy of Voronistat in Pediatric Patients With Drug Resistant Epilepsy [NCT03894826]	Phase 2	12 participants (Anticipated)	Interventional	2018-12-10	Recruiting
SOLAR: A Phase 2, Randomized, Open-label, Parallel-group, Active Comparator, Multi-center Study to Investigate the Efficacy and Safety of Cobomarsen (MRG-106) in Subjects With Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides (MF) Subtype [NCT03713320]	Phase 2	37 participants (Actual)	Interventional	2019-04-02	Terminated(stopped due to The study was terminated early for business reasons, and not due to concerns regarding safety or lack of efficacy.)
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Oral Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) in Patients With Advanced Malignant Pleural Mesothelioma Previously Treated With Systemic Chemotherapy [NCT00128102]	Phase 3	661 participants (Actual)	Interventional	2005-06-30	Completed
Phase I Clinical Trial of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Advanced Multiple Myeloma [NCT00111813]	Phase 1	34 participants (Actual)	Interventional	2005-09-30	Completed
TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II [NCT05848687]	Phase 1/Phase 2	90 participants (Anticipated)	Interventional	2023-11-01	Not yet recruiting
Phase I/II Study of Carboplatin and Etoposide in Combination With Vorinostat for Patients With Extensive Stage Small Cell Lung Cancer [NCT00702962]	Phase 1/Phase 2	8 participants (Actual)	Interventional	2008-09-30	Terminated(stopped due to Poor accrual)
Multicenter Phase I/Ib Trial of Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer [NCT03742245]	Phase 1	28 participants (Anticipated)	Interventional	2019-06-11	Recruiting
Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Myeloma [NCT02114502]	Phase 2	0 participants (Actual)	Interventional	2014-09-30	Withdrawn
A Study Using Molecular Guided Therapy With Induction Chemotherapy Followed by a Randomized Controlled Trial of Standard Immunotherapy With or Without DFMO Followed by DFMO Maintenance for Subjects With Newly Diagnosed High-Risk Neuroblastoma [NCT02559778]	Phase 2	500 participants (Anticipated)	Interventional	2015-09-30	Recruiting
Phase I Study of the HDAC Inhibitor Vorinostat With Chemotherapy and Radiation Therapy for Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC) [NCT01059552]	Phase 1	18 participants (Actual)	Interventional	2009-12-16	Completed
Phase I Clinical Trial of Suberoylanilide Hydroxamic Acid (SAHA) in Combination With Pemetrexed and Cisplatin in Patients With Advanced Cancer [NCT00106626]	Phase 1	52 participants (Actual)	Interventional	2005-08-31	Completed
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) Trial: PRIME [NCT03878524]	Phase 1	2 participants (Actual)	Interventional	2020-04-01	Active, not recruiting
A Phase I Study of the Combination of Lenalidomide With the Histone Deacetylase Inhibitor, Vorinostat in Hodgkin and Non Hodgkin's Lymphoma [NCT01116154]	Phase 1	30 participants (Anticipated)	Interventional	2010-05-31	Terminated(stopped due to Sponsor withdrew support for the study)
Phase I Study of Decitabine, Vorinostat, and Cytarabine in Acute Myeloid Leukemia [NCT01130506]	Phase 1	17 participants (Actual)	Interventional	2010-05-17	Completed
A Phase I Study of Carboplatin + Paclitaxel and MK0683 in Patients With Chemotherapy-naive Non-Small Cell Lung Cancer (NSCLC) [NCT00424775]	Phase 1	3 participants (Actual)	Interventional	2007-01-31	Terminated
A Phase I Clinical Trial of Vorinostat in Combination With Gemcitabine Plus Platinum in Patients With Advanced Non-Small Cell Lung Cancer [NCT00423449]	Phase 1	61 participants (Actual)	Interventional	2007-03-31	Completed
MT2022-06: Phase I Study of FT538 Monotherapy and in Combination With Vorinostat for the Treatment of Persistent Low-Level HIV Viremia [NCT05700630]	Phase 1	34 participants (Anticipated)	Interventional	2024-07-15	Not yet recruiting
Research In Viral Eradication of HIV Reservoirs [NCT02336074]	Phase 2	60 participants (Actual)	Interventional	2015-11-27	Completed
A Phase I/II Trial of Vorinostat (SAHA) (NSC-701852) in Combination With Rituximab-CHOP in Patients With Newly Diagnosed Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL) [NCT00972478]	Phase 1/Phase 2	83 participants (Actual)	Interventional	2010-11-15	Active, not recruiting
Fludarabine/Clofarabine/Busulfan Combined With SAHA in Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation for Acute Leukemia [NCT02083250]	Phase 1	70 participants (Actual)	Interventional	2014-03-06	Completed
A Phase I/II Study of First Line Vorinostat With Pemetrexed-cisplatin, in Patients With Malignant Pleural Mesothelioma [NCT01353482]	Phase 1/Phase 2	0 participants (Actual)	Interventional		Withdrawn(stopped due to UCL CTC were informed by Merck Sharp & Dohme on 22.08.11 that support for the trial had been withdrawn in light of results from another trial with trial drug.)
A Randomized Phase II/III Study of Vorinostat and Local Irradiation OR Temozolomide and Local Irradiation OR Bevacizumab and Local Irradiation Followed by Maintenance Bevacizumab and Temozolomide in Children With Newly Diagnosed High-Grade Gliomas [NCT01236560]	Phase 2/Phase 3	101 participants (Actual)	Interventional	2010-11-15	Active, not recruiting
A Sequential Phase I/Randomized Phase II Trial of Vorinostat and Risk-Adapted Chemotherapy With Rituximab in HIV-Related B-Cell Non-Hodgkin's Lymphoma [NCT01193842]	Phase 1/Phase 2	107 participants (Actual)	Interventional	2010-10-06	Completed
Modulation of Autophagy: A Clinical Study of Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Refractory Metastatic Colorectal Cancer (mCRC) Patients (CTMS# 14-2015) [NCT02316340]	Phase 2	44 participants (Actual)	Interventional	2015-02-11	Completed
Cisplatin and Sodium Thiosulfate Otoprotection With or Without SAHA/Vorinostat Histone Deacetylase Inhibition for Relapsed/Refractory Hepatoblastoma and Other Embryonal Tumors [NCT05756660]	Early Phase 1	33 participants (Anticipated)	Interventional	2023-03-01	Recruiting
Phase I/II Adaptive Randomized Trial of Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma [NCT01266031]	Phase 1/Phase 2	96 participants (Actual)	Interventional	2011-07-12	Completed
A Phase 1 Study of Lenalidomide in Combination With Vorinostat in Pediatric Patients With High Grade or Progressive Central Nervous System Tumors [NCT03050450]	Phase 1	8 participants (Actual)	Interventional	2016-08-10	Terminated(stopped due to Lack of feasibility to accrue patients in allotted time.)
Phase I Study of the Aurora Kinase a Inhibitor MLN8237 in Combination With the Histone Deacetylase Inhibitor Vorinostat in Lymphoid Malignancies [NCT01567709]	Phase 1	34 participants (Actual)	Interventional	2012-04-16	Completed
A Phase I Study of 131I-MIBG With Dinutuximab +/- Vorinostat for Relapsed/Refractory Neuroblastoma [NCT03332667]	Phase 1	45 participants (Actual)	Interventional	2018-09-12	Active, not recruiting
A Phase I/II Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients < 21 Years at Diagnosis With Refractory Solid Tumors [NCT01294670]	Phase 1/Phase 2	27 participants (Actual)	Interventional	2011-02-09	Completed
A Dose-escalating and Phase II Clinical Trial of the Histone Deacetylase (HDAC) Inhibitor Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA, ZolinzaTM) in Combination With Capecitabine (XelodaTM) Using a New Weekly Dose Regimen for Advanced Breast Cancer [NCT00719875]	Phase 1	24 participants (Actual)	Interventional	2008-12-31	Completed
A Randomized Phase II Study of Two Dose-Levels of Vorinostat in Combination With 5-FU and Leucovorin in Patients With Refractory Metastatic Colorectal Cancer [NCT00942266]	Phase 2	58 participants (Actual)	Interventional	2009-07-31	Completed
IGHID 11627 - A Phase I Study to Evaluate the Effects of Vorinostat and HIV-1 Antigen Expanded Specific T Cell Therapy (HXTC) on Persistent HIV-1 Infection in HIV-Infected Individuals Started on Antiretroviral Therapy (The XTRA Study) [NCT03212989]	Phase 1	17 participants (Actual)	Interventional	2017-06-27	Completed
A Phase I/II Study of Vorinostat in Combination With Low Dose Ara-C for Patients With Intermediate-2 or High Risk Myelodysplastic Syndromes [NCT00776503]	Phase 1/Phase 2	52 participants (Actual)	Interventional	2008-05-31	Completed
A Phase 1b Study to Evaluate the Safety and Tolerability of AMG 655 in Combination With Bortezomib or Vorinostat in Subjects With Relapsed or Refractory Lymphoma [NCT00791011]	Phase 1	33 participants (Actual)	Interventional	2008-02-29	Completed
Phase I/II Clinical Trial Evaluating the Use of Vorinostat Combined With Paclitaxel and Radiotherapy in Patients With Inoperable Stage III Non-Small Cell Lung Cancer Unable to Tolerate Cisplatin [NCT00662311]	Phase 1/Phase 2	5 participants (Actual)	Interventional	2008-03-31	Terminated
A Phase I Clinical Trial of Vorinostat in Combination With Vinorelbine in Patients With Advanced Cancer. [NCT00801151]	Phase 1	30 participants (Anticipated)	Interventional	2009-01-31	Terminated
A Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Combination With Isotretinoin (13-cis Retinoic Acid, 13-CRA) in the Treatment of Patients With Advanced Renal Cell Carcinoma [NCT00324740]	Phase 1/Phase 2	14 participants (Actual)	Interventional	2006-03-31	Terminated
Phase II Study of Idarubicin, Cytarabine, and Vorinostat in Patients With High-Risk MDS and AML [NCT00656617]	Phase 2	106 participants (Actual)	Interventional	2008-04-30	Completed
BMS CA180157: A Phase I Combination Study of Dasatinib Plus Vorinostat in Accelerated Phase, Chronic Phase Refractory to Second Line Therapy or Blast Crisis Chronic Myelogenous Leukemia (CML), and in Philadelphia Chromosome Positive Acute Lymphoblastic Le [NCT00816283]	Phase 1	5 participants (Actual)	Interventional	2008-09-30	Completed
HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma [NCT02836548]	Phase 1/Phase 2	22 participants (Anticipated)	Interventional	2016-06-30	Recruiting
Phase II Trial of Velcade Plus Vorinostat in the Treatment of High Risk MDS and Relapsed/Refractory AML [NCT00818649]	Phase 2	16 participants (Actual)	Interventional	2009-01-31	Terminated(stopped due to Met protocol stop rule [i.e., extreme toxicity])
An Open-Label, Proof of Concept Study of Vorinostat for the Treatment of Moderate-to-Severe Crohn's Disease and Maintenance Therapy With Ustekinumab [NCT03167437]	Phase 1/Phase 2	35 participants (Anticipated)	Interventional	2017-10-30	Recruiting
IGHID 11802 - Combination Therapy With the Novel Clearance Modality (VRC07-523LS) and the Latency Reversal Agent (Vorinostat) to Reduce the Frequency of Latent, Resting CD4+ T Cell Infection (The VOR-07 Study) [NCT03803605]	Phase 1	15 participants (Actual)	Interventional	2019-02-12	Completed
A Randomized Study to Compare the Efficacy of Vorinostat/Hydroxychloroquine/Maraviroc (VHM) in Controlling HIV After Treatment Interruption in Subjects Who Initiated ART During Acute HIV Infection [NCT02475915]	Phase 1/Phase 2	15 participants (Actual)	Interventional	2015-01-31	Completed
Epigenetic Reprogramming in Relapse AML: A Phase 1 Study of Decitabine and Vorinostat Followed by Fludarabine, Cytarabine and G-CSF (FLAG) in Children and Young Adults With Relapsed/Refractory AML [NCT03263936]	Phase 1	37 participants (Actual)	Interventional	2017-07-11	Completed
Phase I of Vorinostat-Iressa Combined Therapy on Resistance by BIM Polymorphysim in EGFR Mutant Lung Cancer [NCT02151721]	Phase 1	12 participants (Actual)	Interventional	2014-06-01	Active, not recruiting
A Single Arm Phase I/II Study of MK-3475 Combined With Vorinostat for Recurrent Unresectable and/or Metastatic Squamous Cell Head and Neck Cancer and Recurrent Unresectable and/or Metastatic Salivary Gland Malignancies [NCT02538510]	Phase 1/Phase 2	50 participants (Actual)	Interventional	2015-10-08	Completed
Phase I Trial of Chemoradiation With Capecitabine and Vorinostat in Pancreatic Cancer. [NCT00983268]	Phase 1	21 participants (Actual)	Interventional	2009-10-31	Completed
A Phase I Trial Evaluating the Safety and Efficacy of Vorinostat (Zolinza ®) + RVD (Lenalidomide {Revlimid ®} + Bortezomib {Velcade ®} + Dexamethasone) for Patients With Newly Diagnosed Multiple Myeloma [NCT01038388]	Phase 1	30 participants (Actual)	Interventional	2010-01-15	Completed
Phase I/II Trial of Lenalidomide in Combination With Vorinostat and Dexamethasone as Therapy in Relapsed or Refractory Patients With Peripheral T-Cell Non-Hodgkin's Lymphoma (PTCL) [NCT00972842]	Phase 1/Phase 2	20 participants (Anticipated)	Interventional	2009-09-30	Terminated(stopped due to slow recruitment)
A Phase I Study of Vorinostat and Bortezomib in Children With Refractory or Recurrent Solid Tumors, Including CNS Tumors and Lymphomas [NCT00994500]	Phase 1	20 participants (Actual)	Interventional	2009-08-31	Completed
A Phase I Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (Vorinostat; Zolinza) in Combination With Bexarotene in Patients With Advanced Cutaneous T-Cell Lymphoma [NCT00127101]	Phase 1	23 participants (Actual)	Interventional	2005-09-30	Terminated(stopped due to The study was stopped due to low enrollment.)
A Phase I/II Study of Pembrolizumab and Vorinostat in Patients With Immune Therapy Naïve and Immune Therapy Pretreated Stage IV NSCLC [NCT02638090]	Phase 1/Phase 2	124 participants (Actual)	Interventional	2016-03-22	Active, not recruiting
A Randomized Phase IIa Study of Vorinostat in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome [NCT00486720]	Phase 2	22 participants (Actual)	Interventional	2007-06-30	Terminated
A Phase I Trial of Vorinostat Concurrent With Stereotactic Radiotherapy in Treatment of Brain Metastases From Non-Small Cell Lung Cancer [NCT00946673]	Phase 1	17 participants (Actual)	Interventional	2009-06-30	Completed
A Pilot Study Evaluating Surrogates of Response to Short Term Oral Suberoylanilide Hydroxamic Acid (SAHA) in Women With Newly Diagnosed Breast Cancer [NCT00262834]	Phase 2	54 participants (Actual)	Interventional	2005-10-31	Completed
A Multi-Institutional Double-Blind Phase II Study Evaluating Response and Surrogate Biomarkers to Carboplatin and Nab-Paclitaxel (CP) With or Without Vorinostat as Preoperative Chemotherapy in HER2-negative Primary Operable Breast Cancer [NCT00616967]	Phase 2	68 participants (Actual)	Interventional	2008-05-31	Active, not recruiting
Phase I Clinical and Pharmacological Study of Suberoylanilide Hydroxamic Acid- SAHA (MSK390) in Patients With Advanced Solid Tumors [NCT00005634]	Phase 1	0 participants	Interventional	2000-01-31	Completed
An International, Multicenter, Open-Label Study of Vorinostat (MK0683) in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma [NCT00773838]	Phase 2	143 participants (Actual)	Interventional	2008-12-01	Completed
A Multicenter, Open-Label, Phase I Study of MK-0683 in Combination With Bortezomib in Patients With Relapsed and/or Refractory Multiple Myeloma [NCT00858234]	Phase 1	9 participants (Actual)	Interventional	2009-02-13	Completed
Phase II Study of Vorinostat (SAHA), Cladribine, and Rituximab (SCR) in Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia, and Relapsed B Cell Non-Hodgkin Lymphoma [NCT00764517]	Phase 2	57 participants (Actual)	Interventional	2008-08-31	Completed
Phase I Study of Vorinostat in Combination With Niacinamide, and Etoposide for the Treatment of Patients With Relapsed and Refractory Lymphoid Malignancies [NCT00691210]	Phase 1	40 participants (Actual)	Interventional	2008-06-30	Completed
A Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK0683 in Patients With Advanced Cancer [NCT00750178]	Phase 1	30 participants (Actual)	Interventional	2004-11-01	Completed
Neoadjuvant Androgen Depletion in Combination With Vorinostat Followed by Radical Prostatectomy for Localized Prostate Cancer: Total Androgen-Receptor Gene Expression Targeted Therapy (TARGET) [NCT00589472]	Phase 2	19 participants (Actual)	Interventional	2007-11-30	Completed
A Phase I/II Non-Comparative Study of Paclitaxel Plus Carboplatin in Combination With Vorinostat in Patient With Advanced, Recurrent, Epithelial Ovarian Cancer [NCT00772798]	Phase 2	70 participants (Anticipated)	Interventional	2007-06-30	Recruiting
A Phase II Study to Investigate the Efficacy and Tolerability of Vorinostat in Patients Suffering From Advanced, Metastatic Soft Tissue Sarcoma [NCT00918489]	Phase 2	40 participants (Actual)	Interventional	2010-05-31	Completed
A Phase II Study of Vorinostat (Suberoylanilide Hydroxamic Acid) Plus Rituximab in Indolent Non-Hodgkin's Lymphoma [NCT00720876]	Phase 2	30 participants (Actual)	Interventional	2008-07-23	Completed
Phase I Study of Carboplatin, Paclitaxel, Bevacizumab and Vorinostat for Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) [NCT00702572]	Phase 1	25 participants (Actual)	Interventional	2008-04-30	Terminated(stopped due to Low Enrollment)
A Phase I Study of Suberoylanilide Hydroxamic Acid (SAHA) in Combination With Flavopiridol in Advanced Solid Tumors [NCT00324480]	Phase 1	60 participants (Actual)	Interventional	2006-03-31	Completed
A Phase I/II of Vorinostat Plus CHOP in Untreated T-cell Non-Hodgkin's Lymphoma [NCT00787527]	Phase 1/Phase 2	14 participants (Actual)	Interventional	2008-11-30	Completed
Phase II Trial of Vorinostat Plus Tacrolimus & Mycophenolate to Prevent Graft Versus Host Disease Following Reduced Intensity Conditioning Related Donor Allogeneic Transplant [NCT00810602]	Phase 1/Phase 2	61 participants (Actual)	Interventional	2009-01-31	Completed
A Phase 1/2 Study of Suberoylanilide Hydroxamic Acid (SAHA, Vorinostat) and Local Irradiation, Followed by Maintenance SAHA in Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas (DIPG) [NCT01189266]	Phase 1/Phase 2	79 participants (Actual)	Interventional	2010-08-09	Completed
An International, Multicenter, Randomized, Double-Blind Study of Vorinostat (MK-0683) or Placebo in Combination With Bortezomib in Patients With Multiple Myeloma [NCT00773747]	Phase 3	637 participants (Actual)	Interventional	2008-12-01	Completed
A Phase I Trial of Vorinostat in Combination With Bevacizumab and Irinotecan in Recurrent Glioblastoma [NCT00762255]	Phase 1	19 participants (Actual)	Interventional	2008-09-30	Completed
A Phase II Pharmacodynamic Investigation of the Efficacy of Vorinostat to Induce Fetal Hemoglobin in Adults With Severe Sickle Cell Disease Who Have Not Benefitted From Prior Therapy [NCT01000155]	Phase 2	5 participants (Actual)	Interventional	2009-10-31	Terminated(stopped due to The study terminated early due to slow accrual.)
A Phase I Study of Ridaforolimus and Vorinostat in Patients With Advanced Solid Tumors or Lymphoma (IND 109130) [NCT01169532]	Phase 1	16 participants (Actual)	Interventional	2010-10-31	Completed
Phase I Study of Induction Therapy With VELCADE and Vorinostat in Patients With Surgically Resectable Non-Small Cell Lung Cancer [NCT00731952]	Phase 1	21 participants (Actual)	Interventional	2006-06-30	Completed
Phase II Clinical Evaluation of Vorinostat Combined With Salvage Reinduction Chemotherapy Including Gemtuzumab Ozogamicin, Idarubicin and Cytarabine and Vorinostat Maintenance in Relapse or Refractory Acute Myeloid Leukemia Patients With 50 Years or Older [NCT01039363]	Phase 2	27 participants (Anticipated)	Interventional		Not yet recruiting
IGHID 11424 - A Pilot Trial of the Effect of Vorinostat and AGS-004 on Persistent HIV-1 Infection (The VOR VAX Study) [NCT02707900]	Phase 1	6 participants (Actual)	Interventional	2016-03-31	Terminated(stopped due to Manufacturing of the AGS-004 HIV vaccine by Argos could no longer be provided.)
GCC 0845: Pilot and Phase II- Vorinostat and Lapatinib in Patients With Advanced Solid Tumor Malignancies and Women With Recurrent Local-Regional or Metastatic Breast Cancer to Evaluate Response and Biomarkers of EMT and Breast Cancer Stem Cells [NCT01118975]	Phase 1/Phase 2	12 participants (Actual)	Interventional	2010-03-31	Terminated(stopped due to Lost sponsorship for study drug)
A Phase 1 Dose Escalation Study of Bortezomib (Velcade®), Pegylated Liposomal Doxorubicin (Doxil®), and Vorinostat (Suberoylanilide Hydromaxic Acid, Saha, Zolinzatm) in Patients With Relapse/Refractory Multiple Myeloma [NCT00744354]	Phase 1	32 participants (Actual)	Interventional	2008-10-31	Terminated(stopped due to Drugs unavailable- study terminated 1/2/18)
Phase I/II Trial of Vorinostat and Radiation Therapy in Patients With Locally Advanced Pancreatic Cancer [NCT00831493]	Phase 1/Phase 2	3 participants (Actual)	Interventional	2009-05-31	Terminated(stopped due to Slow Accrual.)
Progression Free Survival (PFS) Comparison Between Suberoylanilide Hydroxamic Acid (SAHA, Vorinostat TM) in Combination With Bortezomib (Velcade TM) and SAHA Alone in Refractory or Recurrent Advanced CTCL. A Randomized Study. [NCT01386398]	Phase 3	0 participants (Actual)	Interventional		Withdrawn(stopped due to Company withdrew interest)
Safety of Vorinostat in Combination With Bortezomib, Doxorubicin and Dexamethasone (VBDD) in Patients With Refractory or Relapsed Multiple Myeloma, A Phase I/II Study, Short Title: VBDD [NCT01394354]	Phase 1/Phase 2	34 participants (Actual)	Interventional	2011-08-31	Completed
Phase I, Open-label, Dose-escalation Study of the Combination of Sorafenib and Vorinostat in Poor-risk Acute Myelogenous Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) [NCT00875745]	Phase 1	15 participants (Actual)	Interventional	2009-04-30	Completed
Phase I/II Study of a Combination of Suberoylanilide Hydroxamic Acid (Vorinostat) Plus Paclitaxel and Bevacizumab in Patients With Advanced Metastatic and/or Local Chest Wall Recurrent Breast Cancer [NCT00368875]	Phase 1/Phase 2	54 participants (Actual)	Interventional	2006-07-31	Completed
A Phase II Study of MK-0683 in Patients With Polycythaemia Vera and Essential Thrombocythaemia. [NCT00866762]	Phase 2	60 participants (Anticipated)	Interventional	2009-02-28	Active, not recruiting
Randomized Phase II Study of Vorinostat or Placebo in Combination With Carboplatin and Paclitaxel for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer [NCT00481078]	Phase 2	94 participants (Actual)	Interventional	2007-05-31	Completed
A Window Trial of Vorinostat in Patients With Ductal Carcinoma in Situ (DCIS) of the Breast [NCT00788112]	Phase 1	17 participants (Actual)	Interventional	2009-07-31	Completed
Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant for Multiple Myeloma [NCT00839956]	Phase 2	31 participants (Actual)	Interventional	2009-02-28	Completed
A Phase 2 Study of Suberoylanilide Hydroxamic Acid (SAHA) in Acute Myeloid Leukemia (AML) [NCT00305773]	Phase 2	37 participants (Actual)	Interventional	2006-01-31	Completed
Phase II Study of Vorinostat (SAHA) in Combination With Bortezomib (PS-341) in Patients With Recurrent Glioblastoma Multiforme [NCT00641706]	Phase 2	44 participants (Actual)	Interventional	2008-07-31	Completed
A Phase I Study of Vorinostat in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma [NCT00642954]	Phase 1	31 participants (Actual)	Interventional	2008-02-13	Completed
A Pilot Clinical Trial to Evaluate the Biological Activity of HDAC (Histone Deacetylase Transferases) Inhibition on ER and PR Expression in Triple Negative Invasive Breast Cancer [NCT01695057]		0 participants (Actual)	Interventional	2012-10-31	Withdrawn(stopped due to Lack of funding)
Phase II Study of Combination Vorinostat and Bortezomib in Patients With Relapsed and/or Refractory Non-Hodgkin Lymphoma [NCT00837174]	Phase 2	0 participants (Actual)	Interventional	2010-06-30	Withdrawn(stopped due to Study never activated/opened as funding source and other support not available.)
Phase II Trial of Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Recurrent Glioblastoma [NCT00238303]	Phase 2	103 participants (Actual)	Interventional	2005-09-30	Completed
A Phase II, Pharmacokinetic and Biologic Correlative Study of Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Advanced Renal Cell Carcinoma (RCC) [NCT00278395]	Phase 2	14 participants (Actual)	Interventional	2005-10-31	Completed
Phase I Study of Vorinostat [Suberoylanilide Hydroxamic Acid (VORINOSTAT)] With Irinotecan, 5-Fluorouracil (5-FU) and Leucovorin (FOLFIRI) for Advanced Upper Gastrointestinal Cancers [NCT00537121]	Phase 1	23 participants (Actual)	Interventional	2006-11-30	Completed
A Phase II Study of Suberoylanilide Hydroxamic Acid (SAHA) in Indolent Non-Hodgkin's Lymphoma [NCT00253630]	Phase 2	37 participants (Actual)	Interventional	2005-09-30	Completed
MK0683 Phase1 Clinical Study - Solid Tumor - [NCT00373490]	Phase 1	16 participants (Actual)	Interventional	2006-07-31	Completed
A Phase I/II Clinical Trial of Oral Vorinostat (MK0683) in Combination With Erlotinib in Patients With Relapsed/Refractory Non-Small-Cell Lung Cancer [NCT00251589]	Phase 1/Phase 2	23 participants (Actual)	Interventional	2006-01-31	Terminated(stopped due to This trial is being closed based on lack of substantive efficacy, slow accrual and overall tolerance in patients treated to date.)
A Phase I Study of SAHA and Temozolomide in Children With Relapsed or Refractory Primary Brain or Spinal Cord Tumors [NCT01076530]	Phase 1	27 participants (Actual)	Interventional	2010-02-28	Completed
A Phase II Trial of Suberoylanilide Hydroxamic Acid (NSC-701852) for Recurrent or Primary Refractory Hodgkin's Lymphoma [NCT00132028]	Phase 2	27 participants (Actual)	Interventional	2005-09-30	Completed
A Phase I/II Study of Vorinostat (Zolinza®) in Combination With Capecitabine (X) and Cisplatin (P) for 1st Line Treatment of Metastatic or Recurrent Gastric Cancer [NCT01045538]	Phase 1/Phase 2	45 participants (Actual)	Interventional	2010-02-28	Completed
A Phase I Study of Sorafenib and Vorinostat in Advanced Hepatocellular Carcinoma [NCT01075113]	Phase 1	16 participants (Actual)	Interventional	2010-08-10	Completed
A Phase 1 Study of SAHA (NSC# 701852) in Pediatric Patients With Recurrent or Refractory Solid Tumors (Including Lymphomas) and Leukemia Followed by a Phase I Study of SAHA in Combination With 13-Cis-Retinoic Acid for Patients With Selected Recurrent/Refr [NCT00217412]	Phase 1	60 participants (Actual)	Interventional	2005-08-31	Completed
A Phase I Trial of Sirolimus or Everolimus or Temsirolimus (mTOR Inhibitor) and Vorinostat (Histone Deacetylase Inhibitor) in Patients With Advanced Cancer [NCT01087554]	Phase 1	249 participants (Anticipated)	Interventional	2010-03-31	Active, not recruiting
A Phase II Study of Suberoylanilide Hydroxamic Acid and Bortezomib in Advanced Soft Tissue Sarcomas [NCT00937495]	Phase 2	16 participants (Actual)	Interventional	2009-06-30	Completed
A Phase I Study of Suberoylanilide Hydroxamic Acid (Vorinostat) (NSC 701852) in Combination With Docetaxel in Patients With Advanced and Relapsed Solid Malignancies [NCT00565227]	Phase 1	12 participants (Actual)	Interventional	2007-04-30	Terminated(stopped due to closed due to toxicity)
A Phase II/III Randomized, Double-Blind Study of Paclitaxel Plus Carboplatin in Combination With Vorinostat or Placebo in Patients With Stage IIIB (With Pleural Effusion) or Stage IV Non-Small-Cell Lung Cancer (NSCLC) [NCT00473889]	Phase 2/Phase 3	253 participants (Actual)	Interventional	2007-05-31	Terminated(stopped due to The study was terminated based on the recommendation by the DSMB following a pre-planned protocol interim analysis because the endpoint was not achieved.)
A Phase I Clinical Trial of Vorinostat in Combination With Decitabine in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome [NCT00479232]	Phase 1	71 participants (Actual)	Interventional	2007-06-30	Completed
A Phase 1 Study of Pembrolizumab Plus Vorinostat for Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, and Hodgkin Lymphoma [NCT03150329]	Phase 1	52 participants (Actual)	Interventional	2017-07-18	Active, not recruiting
Vorinostat and Concomitant Whole Brain Radiation Therapy in Patients With Brain Metastases: A Randomized, Double-blind, Placebo-controlled, Phase II Study [NCT01600742]	Phase 2	4 participants (Actual)	Interventional	2012-08-31	Terminated(stopped due to Sponsor stops to provide the study drug.)
Vorinostat to Augment Response to Lutetium-PSMA-617 in the Treatment of Patients With PSMA-Low Metastatic Castration-Resistant Prostate Cancer [NCT06145633]	Phase 2	15 participants (Anticipated)	Interventional	2024-04-01	Not yet recruiting
Vorinostat (SAHA) and Lenalidomide After Autologous Transplant for Patients With Multiple Myeloma [NCT00729118]	Phase 1	19 participants (Actual)	Interventional	2008-09-26	Completed
Phase I-II Study of Oral Suberoylanilide Hydroxamic Acid (Vorinostat) in Combination With Topotecan in Patients With Chemosensitive Recurrent Small Cell Lung Cancer (SCLC) [NCT00697476]	Phase 1/Phase 2	2 participants (Actual)	Interventional	2009-01-31	Terminated(stopped due to insufficient enrollment)
NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma [NCT00667082]	Phase 1	22 participants (Actual)	Interventional	2008-03-31	Completed
A Phase I Safety and Tolerability Study of Vorinostat in Combination With Sorafenib in Patients With Advanced Solid Tumors, With Exploration of Two Tumor-type Specific Expanded Cohorts at the Recommended Phase 2 Dose [NCT00635791]	Phase 1	36 participants (Actual)	Interventional	2008-03-31	Completed
Phase Ib/II Study of Combination of Vorinostat, Carboplatin and Gemcitabine + Vorinostat Maintenance in Women With Recurrent, Platinum-Sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer [NCT00910000]	Phase 1/Phase 2	15 participants (Actual)	Interventional	2009-06-30	Terminated(stopped due to Terminated due to unacceptable toxicity)
A Continuation Clinical Trial of Oral Vorinostat (MK-0683) in Advanced Cancers [NCT00907738]	Phase 2	27 participants (Actual)	Interventional	2005-08-31	Completed
Bortezomib* and Vorinostat as Maintenance Therapy After Autologous Transplant for Non-Hodgkin Lymphoma Using R-BEAM or BEAM Conditioning Transplant Regimen [NCT00992446]	Phase 2	27 participants (Actual)	Interventional	2010-09-02	Completed
A Phase II Prospective Non-Randomized Clinical Trial of Dose-Adjusted Schedule of Vorinostat in Patients With Primary Cutaneous T-Cell Lymphoma Who Did Not Receive Prior Systemic Therapy or Have Been Treated With Single Agent Targretin [NCT00958074]	Phase 2	11 participants (Actual)	Interventional	2009-07-31	Terminated(stopped due to Terminated due to slow accrual)
Phase 1/2 Study of Vorinostat in Combination With Radiation Therapy and Infusional 5-FU in Patients With Locally Advanced Adenocarcinoma of the Pancreas [NCT00948688]	Phase 1/Phase 2	10 participants (Actual)	Interventional	2009-08-31	Terminated(stopped due to Funding was withdrawn after only 10 participants were enrolled)
A Phase 2 Trial of Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) Who Are Ineligible for Other Leukemia Protocols [NCT00948064]	Phase 2	110 participants (Actual)	Interventional	2009-09-08	Completed
Phase I Trial of Vorinostat (NSC-701852, Suberoylanilide Hydroxamic Acid) and Doxorubicin (NSC-123127, Adriamycin) [NCT00331955]	Phase 1	40 participants (Actual)	Interventional	2006-03-31	Completed
Vorinostat (SAHA) Combined With High-Dose Gemcitabine, Busulfan, and Melphalan With Autologous Hematopoietic Cell Support for Patients With Relapsed or Refractory Lymphoid Malignancies [NCT01421173]	Phase 1	78 participants (Actual)	Interventional	2011-08-31	Completed
Phase I/II Intra-patient Dose Escalation Study of Vorinostat in Children With Relapsed Solid Tumor, Lymphoma or Leukemia [NCT01422499]	Phase 1/Phase 2	50 participants (Actual)	Interventional	2012-03-31	Completed
A Pilot Study of Oral Vorinostat Plus Oral Eltrombopag Support in Patients With Lymphoma (VEIL) [NCT01500538]	Phase 2	1 participants (Actual)	Interventional	2012-10-31	Terminated(stopped due to Poor recruitment rate)
A Phase I/II, Multi-Center, Open Label Study of Vorinostat Plus Melphalan and Prednisone (ZMP) in Advanced, Refractory Multiple Myeloma Patients [NCT00857324]	Phase 1/Phase 2	18 participants (Actual)	Interventional	2009-03-31	Terminated(stopped due to The Phase I of the study was completed, but Phase 2 has not been activated)
A Phase II Study of MK-0683 in Patients With Relapsed / Refractory Follicular Lymphoma (FL), Other Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL) or Mantle Cell Lymphoma (MCL) [NCT00875056]	Phase 2	56 participants (Actual)	Interventional	2009-04-15	Completed
Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma [NCT00731731]	Phase 1/Phase 2	125 participants (Actual)	Interventional	2009-07-10	Completed
Phase I Clinical Study of MK-0683 in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma (CTCL) [NCT00771472]	Phase 1	10 participants (Actual)	Interventional	2008-08-31	Completed
Phase IIb Multicenter Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Advanced Cutaneous T-cell Lymphoma [NCT00091559]	Phase 2	74 participants (Actual)	Interventional	2005-02-03	Completed
A Phase I/II Study of Fludarabine, Cyclophosphamide, Rituximab, and Vorinostat Followed by Rituximab and Vorinostat Maintenance Therapy in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) [NCT00918723]	Phase 1/Phase 2	40 participants (Actual)	Interventional	2009-06-30	Completed
A Phase II Trial of Combination Treatment With Vorinostat, Bortezomib and Dexamethasone in Patients With Relapsed and Relapsed Refractory Multiple Myeloma [NCT01720875]	Phase 2	16 participants (Actual)	Interventional	2013-08-09	Completed
Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors [NCT03382834]	Phase 2	31 participants (Actual)	Interventional	2018-04-26	Active, not recruiting
A Multi-Center, Single-Arm, Phase II Study of Vorinostat (V) in Combination With Pegylated Liposomal Doxorubicin (PLD) and Bortezomib (B) Followed by VB Maintenance in Patients With Relapsed and Relapsed/Refractory Multiple Myeloma [NCT01492881]	Phase 2	0 participants (Actual)	Interventional	2012-04-30	Withdrawn(stopped due to Doxil is currently unavailable)
A Phase I/II Investigation of the Effect of Vorinostat (VOR) on HIV RNA Expression in the Resting CD4+ T Cells of HIV-Infected Patients Receiving Stable Antiretroviral Therapy [NCT01319383]	Phase 1/Phase 2	25 participants (Actual)	Interventional	2011-02-28	Completed
A Pilot Study of Vorinostat to Restore Sensitivity to Aromatase Inhibitor Therapy [NCT01153672]		8 participants (Actual)	Interventional	2010-11-30	Completed
A Phase 1 Study of Paclitaxel and Carboplatin in Solid Tumors (With Focus on Upper Aerodigestive Cancers) in Persons With HIV Infection [NCT01249443]	Phase 1	17 participants (Actual)	Interventional	2013-11-30	Terminated(stopped due to Inadequate accrual rate)
A Phase 2 Study of Suberoylanilide Hydroxamic Acid (SAHA) in Subjects With Locally Advanced, Recurrent or Metastatic Adenoid Cystic Carcinoma (ACC) [NCT01175980]	Phase 2	30 participants (Actual)	Interventional	2010-08-06	Completed
A Multicenter, Open-label, Randomized, Phase I/II Study Evaluating the Safety and Efficacy of Low-dose (12 Gy) Total Skin Electron Beam Therapy (TSEBT) Combined With Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis Fungoides (MF) [NCT01187446]	Phase 1/Phase 2	28 participants (Actual)	Interventional	2010-12-31	Terminated(stopped due to Business decision by funding source)
Phase I / II Adaptive Randomized Trial of Vorinostat, Isotretinoin and Temozolomide in Adults With Recurrent Glioblastoma Multiforme [NCT00555399]	Phase 1/Phase 2	135 participants (Anticipated)	Interventional	2007-11-28	Active, not recruiting
Temozolomide Plus Vorinostat in Patients With Relapse/Refractory Acute Myeloid Leukemia (AML) [NCT01550224]	Phase 2	23 participants (Actual)	Interventional	2013-05-01	Completed
Proof of Concept Study of Vorinostat, A Histone Deacetylase Inhibitor, in Patients With Class 2 High Risk Uveal Melanoma [NCT03022565]	Early Phase 1	0 participants (Actual)	Interventional	2020-01-31	Withdrawn(stopped due to Investigator Decision)
A Phase I Trial of SAHA (NSC 701852) and Decitabine (IND 50733, NSC 127716) in Patients With Relapsed, Refractory or Poor Prognosis Leukemia [NCT00357708]	Phase 1	50 participants (Actual)	Interventional	2006-06-30	Completed
A Phase II Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) [NCT00097929]	Phase 2	18 participants (Actual)	Interventional	2005-05-01	Completed
A Phase 1 Study of Suberoylanilide Hydroxamic Acid (SAHA) in Combination With Gemcitabine in Patients With Epithelial Tumors [NCT00243100]	Phase 1	21 participants (Actual)	Interventional	2005-11-30	Completed
A Phase 1 Study of Vorinostat (Suberoylanilide Hydroxamic Acid; SAHA) in Combination With Decitabine in Patients With Advanced Solid Tumors, Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myel [NCT00275080]	Phase 1	80 participants (Actual)	Interventional	2006-02-28	Completed
A Phase I Study of SAHA in Combination With Bortezomib in Relapsed and Refractory Multiple Myeloma [NCT00310024]	Phase 1	40 participants (Actual)	Interventional	2005-11-30	Completed
An Open Label, Expanded Access Protocol Using 131I-METAIODOBENZYLGUANIDINE (131I-MIBG) Therapy +/- Vorinostat in Patients With Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma [NCT01838187]		0 participants	Expanded Access		No longer available
A Phase 1 Study of Suberoylanilide Hydroxamic Acid (Vorinostat, SAHA) in Combination With Idarubicin in Relapsed or Refractory Leukemia [NCT00331513]	Phase 1	40 participants (Actual)	Interventional	2006-03-31	Completed
Phase II Evaluation of Suberoylanilide Hydroxamic Acid (NSC 701852) in Patients With Advanced Prostate Cancer That Has Progressed on One Prior Chemotherapy [NCT00330161]	Phase 2	29 participants (Actual)	Interventional	2006-03-31	Completed
A Phase I Trial of Pembrolizumab and Vorinostat Combined With Temozolomide and Radiation Therapy for Newly Diagnosed Glioblastoma [NCT03426891]	Phase 1	21 participants (Actual)	Interventional	2018-03-16	Completed
A Phase I Clinical Study of MK0683 in Patients With Malignant Lymphoma [NCT00127140]	Phase 1	10 participants (Actual)	Interventional	2005-06-30	Completed
A Phase I Study of Suberoylanilide Hydroxamic Acid (Vorinostat) in Combination With 5-Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX) in Patients With Colorectal Cancer and Other Solid Tumors [NCT00138177]	Phase 1	54 participants (Actual)	Interventional	2005-07-31	Completed
Phase II Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Advanced Multiple Myeloma [NCT00109109]	Phase 1	60 participants	Interventional	2003-12-01	Terminated
A Phase I Study of Suberoylanilide Hydroxamic Acid (SAHA) in Combination With Capecitabine in Patients With Solid Tumors [NCT00121277]	Phase 1	28 participants (Actual)	Interventional	2005-09-30	Completed
Sequential Phase I/II Trial of Oral Vorinostat in Combination With Erlotinib in Non-small-cell Lung Cancer Patients With Mutations at Epidermal Growth Factor Receptor With Disease Progression After Erlotinib Treatment [NCT00503971]	Phase 1/Phase 2	50 participants (Actual)	Interventional	2007-12-31	Terminated
Phase II Study of Vorinostat (SAHA, Zolinza) and Bortezomib (PS341, Velcade) as Third-Line Treatment in Patients With Advanced Non-Small Cell Lung Cancer [NCT00798720]	Phase 2	18 participants (Actual)	Interventional	2008-12-31	Completed
A Phase II Study To Determine The Safety and Efficacy Of The Combination of Vorinostat and Bortezomib In Patients With Relapsed Or Refractory T-Cell Non-Hodgkin's Lymphoma [NCT00810576]	Phase 2	1 participants (Actual)	Interventional	2009-01-31	Terminated(stopped due to Terminated due to slow accrual.)
Phase I / II Adaptive Randomized Trial of Vorinostat, Erlotinib and Temozolomide in Adults With Recurrent Glioblastoma Multiforme [NCT01110876]	Phase 1/Phase 2	21 participants (Actual)	Interventional	2011-06-30	Terminated(stopped due to Unanticipated Toxicities)
A Therapeutic Trial of Bortezomib (Velcade), Vorinostat (SAHA) and Dexamethasone for Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) [NCT01312818]	Phase 2	2 participants (Actual)	Interventional	2011-06-30	Terminated(stopped due to Slow accrual)
Phase II Randomized Study of Vorinostat or Placebo in Combination With Carboplatin and Paclitaxel for Patients With Advanced Non-small Cell Lung Cancer [NCT01413750]	Phase 1/Phase 2	23 participants (Actual)	Interventional	2010-11-30	Terminated(stopped due to Slow Accrual)
Phase I and Pharmacokinetic Study of Vorinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic Dysfunction [NCT00499811]	Phase 1	15 participants (Actual)	Interventional	2007-06-30	Completed
Safety and Effectiveness of A-dmDT390-bisFv(UCHT1) Fusion Protein (Resimmune®) in Subjects With Mycosis Fungoides: A Phase II Multi-center Randomized Clinical Trial [NCT02943642]	Phase 2	162 participants (Anticipated)	Interventional	2017-01-31	Not yet recruiting
A Phase II Study of Bortezomib and Vorinostat in Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies [NCT02419755]	Phase 2	12 participants (Actual)	Interventional	2015-04-14	Terminated(stopped due to Accrual goals were no longer feasible based on restrictions imposed by the DSMB.)
A Multi-Institutional Phase II Study Evaluating Surrogate Biomarkers of Response to Short Term Oral Vorinostat and Tamoxifen in Women With Newly Diagnosed Breast Cancer [NCT01194427]	Phase 2	2 participants (Actual)	Interventional	2011-03-31	Terminated(stopped due to Difficulty meeting patient accrual goals)
Randomised Comparisons, in Myeloma Patients of All Ages, of Thalidomide, Lenalidomide, Carfilzomib and Bortezomib Induction Combinations, and of Lenalidomide and Combination Lenalidomide Vorinostat as Maintenance (Myeloma XI) [NCT01554852]	Phase 3	4,420 participants (Actual)	Interventional	2010-05-31	Active, not recruiting
A Phase II, Open Label, Two-Arm Study of Therapeutic Iobenguane (131I) as Single Agent or in Combination With Vorinostat for Recurrent or Progressive High- Risk Neuroblastoma Subjects (OPTIMUM TRIAL) [NCT03561259]	Phase 2	60 participants (Anticipated)	Interventional	2019-10-21	Recruiting
A Phase II Clinical Study of Oral Suberoylanilide Hydroxamic Acid in Patients With Relapsed or Refractory Breast, Colorectal, and Non-small Cell Lung Cancer. [NCT00126451]	Phase 2	16 participants (Actual)	Interventional	2004-12-01	Terminated
A Phase II Evaluation of Vorinostat, (SAHA, NCI-Supplied Agent [NSC #701852]) in the Treatment of Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma [NCT00132067]	Phase 2	60 participants (Actual)	Interventional	2005-10-31	Completed
Phase I Clinical Trial of Oral Suberoylanilide Hydroxamic Acid - SAHA (MSK390) in Patients With Advanced Solid Tumors and Hematologic Malignancies [NCT00045006]	Phase 1	0 participants	Interventional	2001-07-31	Completed
Phase II Study of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Recurrent or Metastatic Transitional Cell Carcinoma of the Urothelium [NCT00363883]	Phase 2	14 participants (Actual)	Interventional	2006-06-30	Terminated(stopped due to Trial stopped early for futility)
Phase II Trial of Suberoylanilide Hydroxamic Acid (SAHA, Vorinostat) in Combination With Tamoxifen for Patients With Advanced Breast Cancer Who Have Failed Prior Anti-hormonal Therapy. [NCT00365599]	Phase 2	43 participants (Actual)	Interventional	2006-02-28	Completed
Phase II Trial of Vorinostat (Suberoylanilide Hydroxamic Acid or SAHA; Zolinza™) in Combination With Gemtuzumab Ozogamicin (Mylotarg™) as Induction and Post-Remission Therapy in Older Patients With Previously Untreated Non-M3 Acute Myeloid Leukemia [NCT00673153]	Phase 2	31 participants (Actual)	Interventional	2008-03-31	Terminated
A Multi-Center Phase I/II Trial of Vorinostat in Combination With Cyclophosphamide, Etoposide, Prednisone and Rituximab for Elderly Patients With Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) [NCT00667615]	Phase 1/Phase 2	30 participants (Actual)	Interventional	2008-04-30	Completed
Phase 1/2 Study of Vorinostat Therapy in Niemann-Pick Disease, Type C1 [NCT02124083]	Phase 1/Phase 2	12 participants (Actual)	Interventional	2014-04-25	Completed
Phase I Trial of Carfilzomib (PR-171) in Combination With Vorinostat (SAHA) in Patients With Relapsed/Refractory B-Cell Lymphomas [NCT01276717]	Phase 1	20 participants (Actual)	Interventional	2011-01-31	Completed
A Dose Escalation Study of Vorinostat in Combination With Palliative Radiotherapy for Patients With Non-Small Cell Lung Cancer [NCT00821951]	Phase 1	17 participants (Actual)	Interventional	2009-05-31	Completed
Epigenetic Priming for Immune Therapy in ER-Positive Breast Cancer in Biomarker Select Population [NCT04190056]	Phase 2	1 participants (Actual)	Interventional	2021-03-11	Terminated(stopped due to Change in practice patterns)
Olaparib Combined With High-Dose Chemotherapy for Refractory Lymphomas [NCT03259503]	Phase 1	50 participants (Actual)	Interventional	2019-09-13	Active, not recruiting
Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I [NCT02553460]	Phase 1/Phase 2	50 participants (Actual)	Interventional	2016-01-29	Active, not recruiting
A Phase I Study of Suberoylanilide Hydroxamic Acid (SAHA) in Combination With Bortezomib in Patients With Advanced Malignancies [NCT00227513]	Phase 1	66 participants (Actual)	Interventional	2005-07-31	Completed
Phase I/II Clinical Trial of Vorinostat in Patients With Recurrent and/or Metastatic Breast Cancer [NCT00416130]	Phase 1/Phase 2	49 participants (Anticipated)	Interventional	2007-01-31	Active, not recruiting
Phase I Study Of Suberoylanilide Hydroxamic Acid (SAHA) (NSC 701852) in Combination With Paclitaxel /Carboplatin for Advanced and Refractory Solid Malignancies [NCT00287937]	Phase 1	30 participants (Actual)	Interventional	2005-07-31	Completed
Pilot Study of Curcumin, Vorinostat, and Sorafenib in Patients With Advanced Solid Tumors [NCT01608139]	Phase 1	0 participants (Actual)	Interventional	2012-11-30	Withdrawn
Histone Deacetylase (HDAC) Inhibition Using Vorinostat (SAHA) After Autologous Hematopoietic Stem Cell Transplantation for High Risk Lymphoma [NCT00561418]	Phase 1	23 participants (Actual)	Interventional	2007-11-30	Completed
A Clinical Trial to Validate Molecular Targets of Vorinostat in Patients With Aerodigestive Tract Cancer [NCT00735826]		10 participants (Actual)	Interventional	2009-03-31	Completed
Phase I Trial of Vorinostat (SAHA) in Combination With Alvocidib (Flavopiridol) in Patients With Relapsed, Refractory, or (Selected) Poor Prognosis Acute Leukemia or Refractory Anemia With Excess Blasts-2 [NCT00278330]	Phase 1	24 participants (Actual)	Interventional	2006-01-31	Completed
Phase I/II Clinical Trial With Vorinostat and Infusional 5-FU/LV in Patients With Metastatic Colorectal Cancer Who Failed 5-FU-Based Chemotherapy [NCT00336141]	Phase 1	10 participants (Actual)	Interventional	2006-06-30	Completed
A Phase II, Multi-center, Open-label, Randomized Study of Vorinostat Plus Lenalidomide and Dexamethasone or Lenalidomide Plus Dexamethasone in Multiple Myeloma Patients Who Experience Biochemical Relapse During Lenalidomide Maintenance Therapy [NCT01501370]	Phase 2	0 participants (Actual)	Interventional	2012-01-31	Withdrawn
A Phase 1/2 Study of Vorinostat (Zolinza®) in Combination With Gemtuzumab Ozogamicin (Mylotarg®) and Azacitidine (Vidaza®) in Patients 50 Years of Age and Older With Relapsed/Refractory Non-APL Acute Myeloid Leukemia (AML) [NCT00895934]	Phase 1/Phase 2	52 participants (Actual)	Interventional	2009-05-31	Completed
A Phase I Study of Venetoclax to Augment Epigenetic Modification and Chemotherapy in Pediatric and Young Adult Patients With Relapsed and Refractory Acute Myeloid Leukemia [NCT05317403]	Phase 1	40 participants (Anticipated)	Interventional	2023-03-31	Recruiting
Addition of Suberoylanilide Hydroxamic Acid (Vorinostat) to Azacitidine in Patients With Higher Risk Myelodysplastic Syndromes (MDS): a Phase II add-on Study in Patients With Azacitidine Failure. [NCT01748240]	Phase 2	21 participants (Actual)	Interventional	2013-03-31	Terminated(stopped due to inefficiency)
Phase I Study of Vorinostat (Suberoylanilide Hydroxamic Acid, or SAHA) in Combination With Cytosine Arabinoside (Ara-C) and Etoposide for Patients With Relapsed and/or Refractory Acute Leukemias, Myelodysplasias and Myeloproliferative Disorders [NCT00357305]	Phase 1	25 participants (Actual)	Interventional	2006-05-31	Completed
A Pilot Study of Vorinostat to Restore Sensitivity to Aromatase Inhibitor Therapy Part B [NCT01720602]		15 participants (Actual)	Interventional	2012-11-30	Completed
Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype [NCT01534260]	Phase 1/Phase 2	37 participants (Actual)	Interventional	2012-02-10	Completed
Vorinostat With 131-I MIBG Therapy for Resistant/Relapsed Neuroblastoma: A Phase I Study IND# 105,744 [NCT01019850]	Phase 1	27 participants (Actual)	Interventional	2010-03-31	Completed
A Phase I/II, Open-Label, Non-Randomized, Pilot Study of Weekly Paclitaxel, Every Four-week Carboplatin and Oral Vorinostat for Patients Newly Diagnosed With Stage III/IV Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer [NCT00976183]	Phase 1/Phase 2	18 participants (Actual)	Interventional	2009-10-31	Terminated(stopped due to toxicities)
Open-Label, Multi-Center, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 (Mogamulizumab) Versus Vorinostat in Subjects With Previously Treated Cutaneous T-Cell Lymphoma [NCT01728805]	Phase 3	372 participants (Actual)	Interventional	2012-11-30	Completed
Phase 1b/2 Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma [NCT01879085]	Phase 1/Phase 2	37 participants (Actual)	Interventional	2013-09-24	Completed
A Phase II Study of Vorinostat in Patients With Advanced Melanoma [NCT00121225]	Phase 2	32 participants (Actual)	Interventional	2005-09-30	Completed
A Phase I/II Study of Suberoylanilide Hydroxamic Acid (SAHA) in Combination With Trastuzumab (Herceptin) in Patients With Advanced Metastatic and/or Local Chest Wall Recurrent Her-2 Amplified Breast Cancer [NCT00258349]	Phase 1/Phase 2	16 participants (Actual)	Interventional	2006-08-31	Completed
A Phase II Study of Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Relapsed Non-small Cell Lung Cancer [NCT00138203]	Phase 2	16 participants (Actual)	Interventional	2005-06-30	Completed
Epigenetic Modification for Relapse Prevention: a Dose-finding Study of Vorinostat Used in Combination With Low-dose Azacitidine in Children Undergoing Allogeneic Hematopoietic Cell Transplantation for Myeloid Malignancies [NCT03843528]	Phase 1	15 participants (Anticipated)	Interventional	2019-05-01	Recruiting
A Phase I Study of the mTOR Inhibitor Temsirolimus in Combination With the HDAC Inhibitor Vorinostat in Patients With Metastatic Prostate Cancer [NCT01174199]	Phase 1	13 participants (Actual)	Interventional	2012-02-29	Terminated(stopped due to no value in finding efficacy)
Phase I/II Study of Bevacizumab Plus Daily Temozolomide and Vorinostat for Recurrent Malignant Glioma Patients [NCT00939991]	Phase 1/Phase 2	48 participants (Actual)	Interventional	2009-10-31	Completed
A Therapeutic Trial of Decitabine and Vorinostat in Combination With Chemotherapy (Vincristine, Prednisone, Doxorubicin and PEG-Asparaginase) for Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL) [NCT00882206]	Phase 2	15 participants (Actual)	Interventional	2009-04-30	Terminated(stopped due to Slow accrual)
A Phase II Investigation of Vorinostat in Combination With Intravenous Fludarabine, Mitoxantrone, and Dexamethasone in Patients With Relapsed or Refractory Mantle Cell Lymphoma [NCT01578343]	Phase 2	20 participants (Actual)	Interventional	2012-06-30	Terminated(stopped due to we collected data of a total of 19 patients for an interim analysis. but there are less than 7 responses out of the initial 19 patients.)
Phase II Randomised Trial of 5-azacitidine Versus 5-azacitidine in Combination With Vorinostat in Patients With Acute Myeloid Leukaemia or High Risk Myelodysplastic Syndromes Ineligible for Intensive Chemotherapy [NCT01617226]	Phase 2	260 participants (Actual)	Interventional	2012-09-30	Completed
Phase I/II Study of Suberoylanilide Hydroxamic Acid (SAHA) in Combination With the VEGF Inhibitor Bevacizumab in Patients With Metastatic Renal Cell Carcinoma [NCT00324870]	Phase 1/Phase 2	37 participants (Actual)	Interventional	2006-02-28	Completed
A Randomized, Partially-Blind, Placebo-Controlled, 2-Period Crossover Study to Assess the Effects of a Single Dose of Vorinostat on the QTc Interval in Patients With Advanced Cancer [NCT00632931]	Phase 1	25 participants (Actual)	Interventional	2007-07-31	Completed
A Phase II Study of Vorinostat and Capecitabine in Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN) and Nasopharyngeal Carcinoma (NPC) [NCT01267240]	Phase 2	25 participants (Actual)	Interventional	2010-12-31	Terminated(stopped due to Study treatment did not show clinical activity.)
Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype [NCT02589145]	Phase 1/Phase 2	8 participants (Actual)	Interventional	2016-06-22	Terminated(stopped due to Closed due to very slow accrual)
Reversing Therapy Resistance With Epigenetic-immune Modification: Phase II Trial of Vorinostat, Tamoxifen and Pembrolizumab in Hormone Receptor Expressing Advanced Breast Cancer [NCT02395627]	Phase 2	38 participants (Actual)	Interventional	2015-05-04	Terminated(stopped due to Insufficient efficacy in an unselected patient population)
Azacitidine/Vorinostat/GemBuMel With Autologous Stem-Cell Transplant (SCT) in Patients With Refractory Lymphomas [NCT01983969]	Phase 1/Phase 2	61 participants (Actual)	Interventional	2013-11-07	Completed
A Pilot Trial of Vorinostat Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease Following Unrelated Donor Hematopoietic Stem Cell Transplantation [NCT01789255]	Phase 2	12 participants (Actual)	Interventional	2013-06-30	Completed
A Phase I Study of Suberoylanilide Hydroxamic Acid (SAHA, Vorinostat) With Temsirolimus in Children With Newly Diagnosed or Progressive Diffuse Intrinsic Pontine Glioma (DIPG) [NCT02420613]	Phase 1	18 participants (Anticipated)	Interventional	2015-10-05	Active, not recruiting
A Phase I Study of MLN9708 and Vorinostat to Target Autophagy in Patients With Advanced p53 Mutant Malignancies [NCT02042989]	Phase 1	68 participants (Actual)	Interventional	2014-06-27	Completed
Phase II Study of Histone Deacetylase Inhibitor SAHA (Vorinostat) in Patients With Metastatic Thyroid Carcinoma [NCT00134043]	Phase 2	19 participants (Actual)	Interventional	2005-12-31	Completed
A Phase I Study of Vorinostat in Combination With Vincristine, Irinotecan, and Temozolomide in Children, Adolescents, and Young Adults With Relapsed or Refractory Solid Tumors and CNS Malignancies [NCT04308330]	Phase 1	30 participants (Anticipated)	Interventional	2017-03-17	Recruiting
Epigenetic Reprogramming in Relapse AML: A Phase 1 Study of Decitabine and Vorinostat Followed by Fludarabine, Cytarabine and G-CSF (FLAG) in Children and Young Adults With Relapsed/Refractory AML [NCT02412475]	Phase 1	3 participants (Actual)	Interventional	2015-02-21	Terminated(stopped due to We opened a competing study with the TACL consortium)
A Phase 2 Study of Vorinostat in Combination With Chemoradiation in Patients With Locally Advanced HPV Negative HNSCC [NCT05608369]	Phase 2	64 participants (Anticipated)	Interventional	2023-12-01	Not yet recruiting
Phase I-II Trial of Vorinostat Plus Weekly Paclitaxel (+/- Trastuzumab) Followed by Doxorubicin-cyclophosphamide in Patients With Locally Advanced Breast Cancer [NCT00574587]	Phase 1/Phase 2	55 participants (Actual)	Interventional	2007-12-31	Completed
Phase II Study of Suberoylanilide Hydroxamic Acid (SAHA) (NSC 701852) as Salvage Therapy in Metastatic Breast Cancer [NCT00132002]	Phase 2	14 participants (Actual)	Interventional	2005-06-30	Terminated(stopped due to Early termination for discouraging results)
Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma [NCT03117751]	Phase 2/Phase 3	790 participants (Actual)	Interventional	2017-03-29	Active, not recruiting
Vorinostat and Carboplatin or Vorinostat and Paclitaxel in Patients With Advanced Solid Tumors: A Pharmacokinetic and Pharmacodynamic Study [NCT01281176]	Phase 1	20 participants (Actual)	Interventional	2011-02-09	Active, not recruiting
Phase II Study of Bevacizumab and Vorinostat for Recurrent WHO Grade IV Malignant Glioma Patients [NCT01738646]	Phase 2	48 participants (Actual)	Interventional	2013-01-31	Completed
Phase I/II Study of 5-azacitidine in Combination With Vorinostat in Patients With Relapsed or Refractory DLBCL [NCT01120834]	Phase 1/Phase 2	17 participants (Actual)	Interventional	2010-09-30	Completed
A Phase 1/2 Multi-Center Trial of Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation [NCT03842696]	Phase 1/Phase 2	49 participants (Anticipated)	Interventional	2020-02-04	Recruiting
Combination Latency Reversal With High Dose Disulfiram Plus Vorinostat in HIV-infected Individuals on ART (DIVA): A Single Arm Clinical Trial [NCT03198559]	Phase 1/Phase 2	2 participants (Actual)	Interventional	2017-08-08	Terminated(stopped due to A re-evaluation of research risks to participants were greater than originally anticipated)
Multicenter, Open-label Phase Ib Dose-escalation and Dose-confirmational Study for the Tolerability and Safety of N-hydroxy-N'-Phenyl-octanediamide (Vorinostat) in Patients With Mild Alzheimer's Disease [NCT03056495]	Phase 1	44 participants (Anticipated)	Interventional	2017-09-28	Recruiting
A Phase I/II Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma [NCT01297764]	Phase 1/Phase 2	17 participants (Actual)	Interventional	2011-04-30	Active, not recruiting
Phase II Basket Trial Evaluating the Efficacy of a Combination of Pembrolizumab and Vorinostat in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma [NCT04357873]	Phase 2	112 participants (Actual)	Interventional	2020-10-28	Active, not recruiting
A Phase I/II Study of Vorinostat Plus Rituximab, Ifosphamide, Carboplatin, and Etoposide for Patients With Relapsed or Refractory Lymphoid Malignancies or Untreated T- or Mantle Cell Lymphoma [NCT00601718]	Phase 1/Phase 2	29 participants (Actual)	Interventional	2007-12-31	Completed
Phase II Trial of Bortezomib and Vorinostat in Mantle Cell and Diffuse Large B-Cell Lymphomas [NCT00703664]	Phase 2	65 participants (Actual)	Interventional	2008-07-09	Completed
Using Proton Magnetic Resonance Spectroscopy (MRS) to Predict Response of Vorinostat Treatment in Glioblastoma [NCT01342757]		12 participants (Actual)	Interventional	2010-12-31	Completed
A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy or Idarubicin With High Dose Cytarabine (IA) Versus IA With Vorinostat (NSC-701852) (IA + V) in Younger Patients With Previously Untreated Acute Myeloid Leukemia (AML) [NCT01802333]	Phase 3	754 participants (Actual)	Interventional	2013-02-12	Completed
Decitabine and Vorinostat With CD3/CD19 Depleted Haploidentical Donor Natural Killer (NK) Cells for the Treatment of High Risk Myelodysplastic Syndromes (MDS) [NCT01593670]	Phase 2	9 participants (Actual)	Interventional	2013-03-31	Completed
A Phase 1 Study of Neoadjuvant Chemotherapy, Followed by Concurrent Chemoradiation With Gemcitabine, Sorafenib, and Vorinostat in Pancreatic Cancer [NCT02349867]	Phase 1	23 participants (Actual)	Interventional	2015-01-29	Completed
Compassionate Use of Vorinostat (MK0683) for the Treatment of Patients With Advanced Cutaneous T-Cell Lymphoma [NCT00419367]		0 participants	Expanded Access		No longer available
Pilot Trial of Vorinostat Plus Tacrolimus & Methotrexate to Prevent Graft Versus Host Disease Following Unrelated Donor Allogeneic Transplant [NCT01790568]	Phase 2	26 participants (Actual)	Interventional	2014-12-31	Completed
A Phase 2 Study of Vorinostat (NSC 701852) in Metastatic Uveal Melanoma [NCT01587352]	Phase 2	40 participants (Anticipated)	Interventional	2012-04-20	Active, not recruiting
A Phase I/Ib, Open Label, Dose Finding Study to Evaluate Safety, Pharmacodynamics and Efficacy of Pembrolizumab (MK-3475) in Combination With Vorinostat in Patients With Advanced Renal or Urothelial Cell Carcinoma [NCT02619253]	Phase 1	53 participants (Actual)	Interventional	2016-02-23	Completed
NANT 2011- 01: Randomized Phase II Pick the Winner Study of 131I-MIBG, 131I-MIBG With Vincristine and Irinotecan, or 131I-MIBG With Vorinostat for Resistant/Relapsed Neuroblastoma [NCT02035137]	Phase 2	114 participants (Actual)	Interventional	2014-07-31	Completed
Inhibition of Autophagy in Solid Tumors: A Phase I Pharmacokinetic and Pharmacodynamic Study of Hydroxychloroquine in Combination With the HDAC Inhibitor Vorinostat for the Treatment of Patients With Advanced Solid Tumors With an Expansion Study in Advanc [NCT01023737]	Phase 1	72 participants (Actual)	Interventional	2009-11-30	Completed
A Phase 1/2 Study of Vorinostat [Suberoylanilide Hydroxamic Acid (SAHA)] in Combination With Azacitidine in Patients With the Myelodysplastic Syndrome (MDS) [NCT00392353]	Phase 1/Phase 2	135 participants (Anticipated)	Interventional	2006-11-22	Active, not recruiting
A Phase I Trial of 5Azacitidine and Suberoylanilide Hydroxamic Acid in Patients With Metastatic or Locally Recurrent Nasopharyngeal Carcinoma and Nasal NK-T Cell Lymphoma [NCT00336063]	Phase 1	18 participants (Actual)	Interventional	2006-03-03	Active, not recruiting
A Phase I Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]) in Combination With Temozolomide in Patients With Malignant Gliomas [NCT00268385]	Phase 1	83 participants (Actual)	Interventional	2005-12-16	Active, not recruiting
A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL [NCT01483690]	Phase 1/Phase 2	23 participants (Actual)	Interventional	2011-12-31	Terminated(stopped due to Toxicity)
HDAC Inhibitor Augmentation to Clozapine [NCT03263533]	Early Phase 1	0 participants (Actual)	Interventional	2017-04-30	Withdrawn(stopped due to PIs were unable to recruit any participants)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00106626 (2) [back to overview]	Safety and Tolerability as Measured by the Number of Participants With Disease Progression
NCT00106626 (2) [back to overview]	Maximum Tolerated Dose (MTD) Status as Determined by Number of Participants With Dose Limiting Toxicity (DLT) at Each Dose Level
NCT00111813 (5) [back to overview]	Number of Participants With Dose Modifications of Either Vorinostat or Bortezomib Due to Adverse Experiences (AEs) After Treatment With Study Drug
NCT00111813 (5) [back to overview]	Mean Duration of Treatment With Vorinostat
NCT00111813 (5) [back to overview]	Laboratory AE Summary
NCT00111813 (5) [back to overview]	Clinical AE Summary
NCT00111813 (5) [back to overview]	Mean Time to First AE Resulting in a Dose Modification in Either Vorinostat or Bortezomib
NCT00121225 (5) [back to overview]	Objective Response Rate Assessed by Response Evaluation Criteria for Solid Tumors (RECIST)
NCT00121225 (5) [back to overview]	Comparison of VEGF Serum Levels to Response to Vorinostat
NCT00121225 (5) [back to overview]	Time to Progression Assessed by RECIST
NCT00121225 (5) [back to overview]	Difference in HP1 and MacroH2A Nuclear Foci Expression Between Progressive Minus Stable Disease Outcomes
NCT00121225 (5) [back to overview]	Number of Patients With p53 Allelic Variations (72R or 72P)
NCT00127101 (2) [back to overview]	Number of Participants Who Responded to Treatment
NCT00127101 (2) [back to overview]	Maximum Tolerated Dose (MTD) as Determined by the Number of Participants With Dose Limiting Toxicities
NCT00127127 (15) [back to overview]	Cmax of Vorinostat After 14 Days of Once-Daily or Twice-Daily Administration
NCT00127127 (15) [back to overview]	Cmax of Vorinostat After a Single Oral Dose in a Fed State
NCT00127127 (15) [back to overview]	Maximum Concentration (Cmax) of Vorinostat After a Single Oral Dose in a Fasted State
NCT00127127 (15) [back to overview]	Number of Participants Who Discontinued Study Treatment Due to an Adverse Event
NCT00127127 (15) [back to overview]	Number of Participants Who Experienced One or More Adverse Events
NCT00127127 (15) [back to overview]	Number of Participants With a Dose-Limiting Toxicity (DLT) During Cycle 1
NCT00127127 (15) [back to overview]	t½ of Vorinostat After 14 Days of Once-Daily or Twice-Daily Administration
NCT00127127 (15) [back to overview]	t½ of Vorinostat After a Single Oral Dose in a Fed State
NCT00127127 (15) [back to overview]	Time to Maximum Concentration (Tmax) of Vorinostat After a Single Oral Dose in a Fasted State
NCT00127127 (15) [back to overview]	Tmax of Vorinostat After a Single Oral Dose in a Fed State
NCT00127127 (15) [back to overview]	AUC0-inf of Vorinostat After 14 Days of Once-Daily or Twice-Daily Administration
NCT00127127 (15) [back to overview]	Apparent Terminal Half-Life (t½) of Vorinostat After a Single Oral Dose in a Fasted State
NCT00127127 (15) [back to overview]	Area Under the Plasma Concentration Time Curve From Hour 0 to Infinity (AUC0-inf) of Vorinostat After a Single Oral Dose in a Fasted State
NCT00127127 (15) [back to overview]	Tmax of Vorinostat After 14 Days of Once-Daily or Twice-Daily Administration
NCT00127127 (15) [back to overview]	AUC0-Inf of Vorinostat After a Single Oral Dose in a Fed State
NCT00128102 (10) [back to overview]	Number of Participants Who Experienced Adverse Events (AEs) Characterized as Grade 3 or Grade 4 According to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE)
NCT00128102 (10) [back to overview]	Percentage of Participants With ≥10% Change From Baseline in FVC at Week 12
NCT00128102 (10) [back to overview]	Progression Free Survival (PFS)
NCT00128102 (10) [back to overview]	Number of Participants Who Discontinued Study Treatment Due to an AE
NCT00128102 (10) [back to overview]	Percentage of Participants With ≥50% Change Together With a >10 mm Change From Baseline in the LCSS-Meso Dyspnea Score at Week 12
NCT00128102 (10) [back to overview]	Number of Participants Who Experienced an AE
NCT00128102 (10) [back to overview]	Objective Response Rate (ORR)
NCT00128102 (10) [back to overview]	Overall Survival (OS)
NCT00128102 (10) [back to overview]	Percent Change From Baseline in Forced Vital Capacity (FVC) at Week 12
NCT00128102 (10) [back to overview]	Percent Change From Baseline in Lung Cancer Symptom Scale, Modified for Mesothelioma (LCSS-Meso) Dyspnea Score at Week 12
NCT00132002 (3) [back to overview]	Objective Tumor Response Rate
NCT00132002 (3) [back to overview]	Overall Survival
NCT00132002 (3) [back to overview]	Progression-free Survival
NCT00132028 (3) [back to overview]	Assess Number of Patients Who Achieve Confirmed and Unconfirmed Complete Response (CR) or Partial Response (PR)
NCT00132028 (3) [back to overview]	Progression-Free Survival
NCT00132028 (3) [back to overview]	Overall Survival
NCT00134043 (1) [back to overview]	Objective Response Rate (PR + CR) Using RECIST/WHO Response Criteria
NCT00138203 (4) [back to overview]	Toxicity
NCT00138203 (4) [back to overview]	Response Per RECIST Criteria
NCT00138203 (4) [back to overview]	Overall Survial
NCT00138203 (4) [back to overview]	Time to Progression
NCT00238303 (4) [back to overview]	Survival
NCT00238303 (4) [back to overview]	Time to Progression
NCT00238303 (4) [back to overview]	Confirmed Tumor Response
NCT00238303 (4) [back to overview]	Proportion of Successes (Patients Alive and Progression-free)
NCT00251589 (8) [back to overview]	Stable Disease (SD) as Best Response Based on Response Criteria in Solid Tumors (RECIST)
NCT00251589 (8) [back to overview]	Disease Progression After Week 8 Based on Response Criteria in Solid Tumors (RECIST)
NCT00251589 (8) [back to overview]	Dose Limiting Toxicity (DLT) Occurring in Cycle 1 of the Phase I Portion of the Study
NCT00251589 (8) [back to overview]	Dose Limiting Toxicity Occurring in Cycle 1 of the Phase II Portion of the Study
NCT00251589 (8) [back to overview]	Dose Limiting Toxicity Occurring in Cycles 2 and Beyond of the Phase II Portion of the Study
NCT00251589 (8) [back to overview]	Progression-free Survival
NCT00251589 (8) [back to overview]	Progressive Disease (PD) as Best Response Based on Response Criteria in Solid Tumors (RECIST)
NCT00251589 (8) [back to overview]	Unconfirmed Partial Response (UPR) Based on Response Criteria in Solid Tumors (RECIST)
NCT00253630 (4) [back to overview]	2-Year Overall Survival
NCT00253630 (4) [back to overview]	2-Year Progression Free-Survival
NCT00253630 (4) [back to overview]	Response Rate
NCT00253630 (4) [back to overview]	Number of Participants With Adverse Events
NCT00258349 (3) [back to overview]	Response Rate
NCT00258349 (3) [back to overview]	Time to Progression
NCT00258349 (3) [back to overview]	Overall Survival
NCT00262834 (4) [back to overview]	Change in Tissue Apoptosis After 3 Days of Treatment
NCT00262834 (4) [back to overview]	Change in Tissue Histone Acetylation After 3 Days of Treatment
NCT00262834 (4) [back to overview]	Change in Tissue Proliferation After 3 Days of Treatment
NCT00262834 (4) [back to overview]	Number of Participants With Adverse Events
NCT00278395 (1) [back to overview]	Objective Response
NCT00305773 (4) [back to overview]	Time to Treatment Failure (TTF)
NCT00305773 (4) [back to overview]	Overall Survival (OS)
NCT00305773 (4) [back to overview]	Number of Participants With Severe (Grade 3, 4 or 5) Adverse Events
NCT00305773 (4) [back to overview]	Confirmed Complete Response (CR) Rate
NCT00324740 (2) [back to overview]	Number of Participants With at Least One Dose Limiting Toxicity Associated With Vorinostat Concurrently Administered With Isotretinoin
NCT00324740 (2) [back to overview]	Maximum Tolerated Dose of Vorinostat in Combination With Isotretinoin
NCT00324870 (1) [back to overview]	Progression-free Survival Assessed by Response Evaluation Criteria for Solid Tumors (RECIST) (Phase II)
NCT00330161 (4) [back to overview]	Objective Response Rate
NCT00330161 (4) [back to overview]	Median Survival
NCT00330161 (4) [back to overview]	Progression-free Survival
NCT00330161 (4) [back to overview]	Incidence of Toxicity
NCT00363883 (3) [back to overview]	Objective Tumor Response Rate
NCT00363883 (3) [back to overview]	Progression-free Survial
NCT00363883 (3) [back to overview]	Overall Survival
NCT00365599 (3) [back to overview]	Number of Participants With Objective Response (OR)
NCT00365599 (3) [back to overview]	Number of Participants With Serious Adverse Events (SAEs)
NCT00365599 (3) [back to overview]	Time to Progression (TTP)
NCT00368875 (4) [back to overview]	Overall Survival(OS)
NCT00368875 (4) [back to overview]	Progression-free Survival (PFS),
NCT00368875 (4) [back to overview]	Recommended Phase II Dose as Assessed by NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 (Phase I)
NCT00368875 (4) [back to overview]	Objective Response Rate (CR + PR)
NCT00373490 (7) [back to overview]	Area Under the Curve (AUC(0-infinity) at Day 21 (400 mg)
NCT00373490 (7) [back to overview]	Maximum Concentration (Cmax) at Day 21 (400 mg)
NCT00373490 (7) [back to overview]	Maximum Concentration (Cmax) at Day 1 (600 mg and 400 mg)
NCT00373490 (7) [back to overview]	Area Under the Curve (AUC(0-infinity)) at Day 3 (600 mg)
NCT00373490 (7) [back to overview]	Area Under the Curve (AUC(0-infinity)) at Day 1 (600 mg and 400 mg)
NCT00373490 (7) [back to overview]	Number of Participants With a Dose Limiting Toxicity (DLT)
NCT00373490 (7) [back to overview]	Maximum Concentration (Cmax) at Day 3 (600 mg)
NCT00423449 (4) [back to overview]	Maximum Tolerated Dose of Vorinostat Administered in Combination With Standard Doses of Gemcitabine Plus Either Cisplatin or Carboplatin in Patients With Advanced Stage Non-Small Cell Lung Cancer Who Have Not Received Chemotherapy for Advanced Disease
NCT00423449 (4) [back to overview]	Number of Participants With Dose-limiting Toxicities (DLT) Due to Vorinostat Administered in Combination With Standard Dose of Gemcitabine Plus Either Cisplatin or Carboplatin
NCT00423449 (4) [back to overview]	Number of Participants With Laboratory Adverse Experiences (Safety and Tolerability)
NCT00423449 (4) [back to overview]	Number of Participants With Clinical Adverse Experiences (Safety and Tolerability)
NCT00424775 (5) [back to overview]	Number of Participants With a Dose Limited Toxicity at First Cycle
NCT00424775 (5) [back to overview]	Area Under the Curve (AUC(0-24 hr)) at Day 4
NCT00424775 (5) [back to overview]	Area Under the Curve (AUC(0-24 hr)) at Day 5
NCT00424775 (5) [back to overview]	Maximum Concentration (Cmax) at Day 4
NCT00424775 (5) [back to overview]	Maximum Concentration (Cmax) at Day 5
NCT00473889 (3) [back to overview]	Overall Survival
NCT00473889 (3) [back to overview]	Progression Free Survival
NCT00473889 (3) [back to overview]	Number of Participants Who Had a Disease Response to Treatment
NCT00479232 (3) [back to overview]	Number of Participants Experiencing Dose Limiting Toxicity (DLT) Events
NCT00479232 (3) [back to overview]	Objective Response Rate in Participants Treated With Vorinostat + Decitabine With Intermediate-high Risk Myelodysplastic Syndrome (MDS) or Untreated Acute Myelogenous Leukemia (AML)
NCT00479232 (3) [back to overview]	Objective Response Rate in Participants Treated With Vorinostat + Decitabine With Refractory or Relapse Acute Myelogenous Leukemia (AML)
NCT00481078 (3) [back to overview]	Response Rate
NCT00481078 (3) [back to overview]	Progression-free Survival
NCT00481078 (3) [back to overview]	Overall Survival
NCT00486720 (2) [back to overview]	Number of Responders and Number of Non-responders Defined by International Working Group Response Criteria
NCT00486720 (2) [back to overview]	Safety and Tolerability as Assessed by the Number of Participants With Adverse Events.
NCT00561418 (3) [back to overview]	Duration of Response
NCT00561418 (3) [back to overview]	Clinical Benefit
NCT00561418 (3) [back to overview]	Safety and Tolerability of Vorinostat (SAHA) After Autologous Stem Cell Transplantation
NCT00574587 (2) [back to overview]	Pathological Complete Response (CR) Rate in Patients With Her2/Neu Positive Locally Advanced Breast Cancer.
NCT00574587 (2) [back to overview]	Recommended Phase II Dose of Vorinostat in Combination With Weekly Paclitaxel/Trastuzumab
NCT00589472 (6) [back to overview]	Levels of Testosterone in Blood From Radical Prostatectomy Specimens
NCT00589472 (6) [back to overview]	Levels of PSA in Blood From Radical Prostatectomy Specimens
NCT00589472 (6) [back to overview]	Levels of DHT in Blood From Radical Prostatectomy Specimens
NCT00589472 (6) [back to overview]	Gleason Score
NCT00589472 (6) [back to overview]	Levels of DHEA in Blood From Radical Prostatectomy Specimens
NCT00589472 (6) [back to overview]	Levels of DHEA-S in Blood From Radical Prostatectomy Specimens
NCT00601718 (4) [back to overview]	Efficacy (Response Rate) of Vorinostat Combined With RICE Chemotherapy
NCT00601718 (4) [back to overview]	Ability to Proceed to Peripheral Blood Stem Cell Collection Following Treatment
NCT00601718 (4) [back to overview]	Maximum Tolerated Dose of Vorinostat
NCT00601718 (4) [back to overview]	Safety and Toxicity According to CTCAE v3.0
NCT00616967 (8) [back to overview]	Change in Standard Uptake Value (SULmax) From Baseline to Day 15 on FDG-PET
NCT00616967 (8) [back to overview]	Cumulative Methylation Index (CMI) at Day 15
NCT00616967 (8) [back to overview]	Number of Participants Who Experience Death During Treatment
NCT00616967 (8) [back to overview]	Number of Participants With Clinical Complete Response (cCR)
NCT00616967 (8) [back to overview]	Safety as Measured by Number of Participants Who Experience Adverse Events
NCT00616967 (8) [back to overview]	Change in Cumulative Methylation Index (CMI)
NCT00616967 (8) [back to overview]	Pathological Complete Response (pCR) Rate
NCT00616967 (8) [back to overview]	Absolute Change From Baseline in Ki-67
NCT00632931 (8) [back to overview]	Change From Baseline in QTcF at 1 Hour
NCT00632931 (8) [back to overview]	Change From Baseline in QTcF at 0.5 Hours
NCT00632931 (8) [back to overview]	Change From Baseline in QTcF at 12 Hours
NCT00632931 (8) [back to overview]	Change From Baseline in QTcF at 2 Hours
NCT00632931 (8) [back to overview]	Change From Baseline in QTcF at 3 Hours
NCT00632931 (8) [back to overview]	Change From Baseline in QTcF at 4 Hours
NCT00632931 (8) [back to overview]	Change From Baseline in QTcF at 8 Hours
NCT00632931 (8) [back to overview]	Change From Baseline in QTcF at 24 Hours
NCT00641706 (4) [back to overview]	Overall Survival
NCT00641706 (4) [back to overview]	Proportion of Confirmed Tumor Response Defined as an Objective Status of Confirmed Response (CR), Partial Response (PR), or Regression (REGR) on Two Consecutive Evaluations
NCT00641706 (4) [back to overview]	Time to Progression
NCT00641706 (4) [back to overview]	Progression-free Survival at 6 Months
NCT00642954 (3) [back to overview]	Number of Participants Experiencing Dose-Limiting Toxicities (DLTs)
NCT00642954 (3) [back to overview]	Number of Participants Experiencing Drug-Related Adverse Events (AEs)
NCT00642954 (3) [back to overview]	Number of Participants Experiencing Best Overall Response Determined by Complete Response (CR), Near Complete Response (NCR), Very Good Partial Response (VGPR), Partial Response (PR), Minimal Response (MR), Stable Disease (SD) or Progressive Disease (PD)
NCT00656617 (2) [back to overview]	Progression Free Survival (PFS) at 7 Months
NCT00656617 (2) [back to overview]	Participant Response
NCT00662311 (6) [back to overview]	Radiological Response Rate as Assessed by CT
NCT00662311 (6) [back to overview]	Safety and Toxicity of Vorinostat at the MTD as Assessed by NCI CTCAE Version 3.0
NCT00662311 (6) [back to overview]	Progression-free Survival
NCT00662311 (6) [back to overview]	MTD of Vorinostat When Administered in Combination With Paclitaxel and Radiotherapy Therapy as Assessed by NCI Common Toxicity Criteria for Adverse Events (CTCAE) Version 3.0 (Phase I)
NCT00662311 (6) [back to overview]	Overall Survival
NCT00662311 (6) [back to overview]	Duration of Response
NCT00667615 (2) [back to overview]	Complete Response Rate to Rituximab and a Combination of Vorinostat With Cyclophosphamide, Etoposide, and Prednisone in Elderly Pts With Relapsed Diffuse Large B-cell Lymphoma Who Aren't Candidates for Autologous Stem Cell Transplantation.
NCT00667615 (2) [back to overview]	Maximum Tolerated Dose (MTD) of Vorinostat Given Orally for 10 Days in Combination With Cyclophosphamide, Etoposide, Prednisone and Rituximab for Elderly Patients With Relapsed Diffuse Large B-cell Lymphoma
NCT00673153 (5) [back to overview]	Number of Participants Alive at Day 30 (Poor-risk Group)
NCT00673153 (5) [back to overview]	Relapse-free Survival (Good- and Poor-risk Group)
NCT00673153 (5) [back to overview]	Number of Participants Achieving CR or CRi With Induction Therapy (Good-risk Group)
NCT00673153 (5) [back to overview]	Number of Participants Achieving CR or CRi With Induction Therapy (Poor-risk Group)
NCT00673153 (5) [back to overview]	Number of Participants Alive at Day 30 (Good-risk Group)
NCT00691210 (2) [back to overview]	The Maximum Tolerated Dose (MTD) of Niacinamide in the Combination of Vorinostat and Niacinamide
NCT00691210 (2) [back to overview]	The Greatest Number of Cycles Received in Each Treatment Group
NCT00703664 (5) [back to overview]	Best Response
NCT00703664 (5) [back to overview]	Progression-free Survival (PFS)
NCT00703664 (5) [back to overview]	Duration of Partial Response
NCT00703664 (5) [back to overview]	Duration of Stable Disease
NCT00703664 (5) [back to overview]	Overall Response Rate (ORR)
NCT00720876 (3) [back to overview]	Overall Response Rate (Complete and Partial Response)
NCT00720876 (3) [back to overview]	Progression-free Survival
NCT00720876 (3) [back to overview]	Number of Participants With Grade 3 and 4 Toxicities
NCT00731731 (5) [back to overview]	Maximum Tolerated Dose of Vorinostat, Defined as the Dose at Which Fewer Than One-third of Patients Experience DLTs, Graded According to NCI CTCAE (Common Toxicity Criteria for Adverse Effects) Version 3.0 (Phase I)
NCT00731731 (5) [back to overview]	Time to Tumor Progression (Phase II)
NCT00731731 (5) [back to overview]	Incidence of Adverse Events, as Per NCI CTCAE Version 3.0 (Phase II)
NCT00731731 (5) [back to overview]	Incidence of Adverse Events, Based on CTC (Common Toxicity Criteria) Severity Grade
NCT00731731 (5) [back to overview]	Overall Survival at 15 Months (Phase II)
NCT00735826 (3) [back to overview]	Concentration of Vorinostat in Tumor Tissue
NCT00735826 (3) [back to overview]	Changes in Tumor Markers on Tumors of the Lung, Esophagus, or Head and Neck, After 7 Days of Treatment With Vorinostat
NCT00735826 (3) [back to overview]	Effects of Vorinostat Treatment on Induction of Apoptosis or Necrosis in Treated vs. Untreated Tumors
NCT00764517 (5) [back to overview]	Event-free Survival
NCT00764517 (5) [back to overview]	Objective Response Rate
NCT00764517 (5) [back to overview]	Progression-free Survival
NCT00764517 (5) [back to overview]	Tolerability of Treatment
NCT00764517 (5) [back to overview]	Toxicities as Assessed Using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0
NCT00771472 (6) [back to overview]	Part I: Number of Participants Experiencing Dose Limiting Toxicity (DLT)
NCT00771472 (6) [back to overview]	Part I: Maximum Drug Concentration (Cmax)
NCT00771472 (6) [back to overview]	Part I: The Amount of Time it Takes for the Drug Concentration to Decrease by Half (T1/2)
NCT00771472 (6) [back to overview]	Part I: Total Drug Exposure (Area Under the Concentration Curve, AUC[0-24 Hours])
NCT00771472 (6) [back to overview]	Part I: Time at Which Cmax Occurs (Tmax)
NCT00771472 (6) [back to overview]	Parts I & II: Number of Participants Experiencing Clinical or Laboratory Adverse Experiences (AE)
NCT00773747 (5) [back to overview]	Objective Response Rate
NCT00773747 (5) [back to overview]	Overall Survival
NCT00773747 (5) [back to overview]	Progression-Free Survival (PFS)
NCT00773747 (5) [back to overview]	Time to Progression
NCT00773747 (5) [back to overview]	Number of Participants With Grade 3-5 Clinical or Laboratory Adverse Events (AEs)
NCT00773838 (8) [back to overview]	Overall Survival (OS)
NCT00773838 (8) [back to overview]	Time To Disease Progression (TTP) as Determined by IAC Per EBMT Criteria
NCT00773838 (8) [back to overview]	Objective Response Rate (RR)
NCT00773838 (8) [back to overview]	Number of Participants Who Discontinued Study Treatment Due to an AE
NCT00773838 (8) [back to overview]	Number of Participants Who Experienced an Adverse Event (AE)
NCT00773838 (8) [back to overview]	TTP as Assessed by Investigator Per EBMT Criteria
NCT00773838 (8) [back to overview]	Progression-Free Survival (PFS) as Determined by IAC Per EBMT Criteria
NCT00773838 (8) [back to overview]	PFS as Assessed by Investigator Per EBMT Criteria
NCT00785798 (2) [back to overview]	Number of Subjects With Progressive Disease (PR)
NCT00785798 (2) [back to overview]	Overall Response Rate
NCT00787527 (3) [back to overview]	Number of Participants With Dose Limiting Toxicity for Determination Phase I (Schedule A) MTD of Vorinostat
NCT00787527 (3) [back to overview]	Phase I Maximum Tolerated Dose (MTD) of Vorinostat
NCT00787527 (3) [back to overview]	Phase II MTD of Vorinostat
NCT00798720 (4) [back to overview]	Toxicity
NCT00798720 (4) [back to overview]	Median Overall Survival
NCT00798720 (4) [back to overview]	Three-month Progression-free Survival
NCT00798720 (4) [back to overview]	Response Rate
NCT00810576 (1) [back to overview]	Number of Patients With Response
NCT00810602 (4) [back to overview]	Percent Survival at 2-years
NCT00810602 (4) [back to overview]	100-day Cumulative Incidence of Grade 2-4 Acute Graft Versus Host Disease (GVHD)
NCT00810602 (4) [back to overview]	Number of Serious Adverse Events
NCT00810602 (4) [back to overview]	Percent Cumulative Incidence of Relapse at 2 Years.
NCT00818649 (1) [back to overview]	Number of Patients by Best Clinical Response
NCT00821951 (1) [back to overview]	The Primary Endpoint of the Study is to Establish the Maximum Tolerated Dose of Vorinostat When Given Concurrently With Palliative Radiation.
NCT00831493 (1) [back to overview]	Maximum Tolerated Dose (MTD) of Vorinostat + Chemoradiation
NCT00838929 (1) [back to overview]	Maximum Tolerated Dose (MTD) and Recommended Phase II Dose (RP2D) of Vorinostat and Radiotherapy in Patients With Brain Metastases.
NCT00839956 (4) [back to overview]	Toxicity as Assessed by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v3.0
NCT00839956 (4) [back to overview]	Median Follow-up Survival for All Patients
NCT00839956 (4) [back to overview]	Survival for All Patients
NCT00839956 (4) [back to overview]	Time to Disease Progression in Patients Who Progressed
NCT00858234 (3) [back to overview]	Number of Participants With an Adverse Event (AE)
NCT00858234 (3) [back to overview]	Number of Participants With Dose-Limiting Toxicity (DLT) During Cycle 1
NCT00858234 (3) [back to overview]	Area Under the Plasma Concentration-Time Curve From 0 to 24 Hours Postdose (AUC0-24hr) of Vorinostat Administered With Bortezomib on Days 1 and 11
NCT00875056 (5) [back to overview]	Number of Participants Who Discontinued Study Drug Due to Experiencing an Adverse Event (AE)
NCT00875056 (5) [back to overview]	Number of Participants Who Experienced an Adverse Event (AE)
NCT00875056 (5) [back to overview]	Objective Response Rate (ORR)
NCT00875056 (5) [back to overview]	Time to Response for Relapsed/Refractory FL
NCT00875056 (5) [back to overview]	Time to Treatment Failure for Relapsed/Refractory FL
NCT00882206 (4) [back to overview]	Level of Methylation
NCT00882206 (4) [back to overview]	Response to Treatment
NCT00882206 (4) [back to overview]	Level of Methylation
NCT00882206 (4) [back to overview]	Level of Methylation
NCT00895934 (4) [back to overview]	Number of Participants With Dose-limiting Toxicity (Phase I)
NCT00895934 (4) [back to overview]	Number of Participants With Dose-limiting Toxicity After the Vorinostat Dose
NCT00895934 (4) [back to overview]	Disease Relapse
NCT00895934 (4) [back to overview]	Number of Participants With Complete Remission
NCT00907738 (1) [back to overview]	Percent of Participants With a Serious Drug-related Adverse Event (AE)
NCT00910000 (3) [back to overview]	Vorinostat Maximum Tolerated Dose (MTD) [Phase Ib]
NCT00910000 (3) [back to overview]	Response
NCT00910000 (3) [back to overview]	Dose Limiting Toxicity (DLT) [Phase Ib]
NCT00918723 (4) [back to overview]	Maximum Tolerated Dose (MTD) of Vorinostat That Can be Combined With Fludarabine Phosphate, Cyclophosphamide and Rituximab (FCR) (Phase I)
NCT00918723 (4) [back to overview]	Overall Survival
NCT00918723 (4) [back to overview]	Percentage of Patients With Progression-free Survival at 2 Years
NCT00918723 (4) [back to overview]	To Estimate the Rate of Conversion of Partial Response (PR) to Complete Response (CR) After Fludarabine, Cyclophosphamide and Rituximab (FCR) Plus Vorinostat
NCT00937495 (3) [back to overview]	Overall Survival
NCT00937495 (3) [back to overview]	Progression Free Survival
NCT00937495 (3) [back to overview]	Confirmed Tumor Responses
NCT00939991 (6) [back to overview]	Phase II: Radiographic Response.
NCT00939991 (6) [back to overview]	Phase I: Determination of the Maximum Tolerated Dose (MTD)
NCT00939991 (6) [back to overview]	Phase II: 6-month Progression-free Survival (PFS)
NCT00939991 (6) [back to overview]	Phase II: Median Overall Survival (OS)
NCT00939991 (6) [back to overview]	Phase II: Median Progression-free Survival (PFS)
NCT00939991 (6) [back to overview]	Phase II: Number of Patients With Grade 2 or Greater, Treatment-related Toxicities
NCT00942266 (7) [back to overview]	Overall Survival
NCT00942266 (7) [back to overview]	Response Rate
NCT00942266 (7) [back to overview]	Disease Control Rate (Stable Disease or Objective Response)
NCT00942266 (7) [back to overview]	Fluorouracil Steady-state Pharmacokinetics
NCT00942266 (7) [back to overview]	Vorinostat Pharmacokinetics
NCT00942266 (7) [back to overview]	Median Progression-free Survival
NCT00942266 (7) [back to overview]	Toxicity
NCT00948064 (3) [back to overview]	Survival at Day 60
NCT00948064 (3) [back to overview]	Survival at Day 60
NCT00948064 (3) [back to overview]	Response Rate
NCT00948688 (7) [back to overview]	Progression Free Survival (PFS) at 7 Months From Registration
NCT00948688 (7) [back to overview]	Progression Free Survival
NCT00948688 (7) [back to overview]	Overall Survival
NCT00948688 (7) [back to overview]	Number of Participants Experiencing Unacceptable Toxicity
NCT00948688 (7) [back to overview]	Maximally Tolerated Dose (MTD) of Vorinostat in Combination With Infusional 5-FU and Radiation Therapy.
NCT00948688 (7) [back to overview]	Resectability Rate
NCT00948688 (7) [back to overview]	Response Rate
NCT00958074 (5) [back to overview]	Changes in the Physicians Serial Assessment of Erythroderma Score
NCT00958074 (5) [back to overview]	Objective Response
NCT00958074 (5) [back to overview]	Objective Response Rate of Extracutaneous Manifestations of CTCL (Lymph Node Enlargement, Sezary Cells in Peripheral Blood);
NCT00958074 (5) [back to overview]	Number of Participants With Overall Response as Measured by Sezary Cell Count
NCT00958074 (5) [back to overview]	Occurrences of Dose Adjustment as Measured by Safety/Toxicity
NCT00972478 (5) [back to overview]	Overall Survival (Phase II)
NCT00972478 (5) [back to overview]	Toxicity of Vorinostat-R-CHOP in Patients With Newly Diagnosed DLBCL
NCT00972478 (5) [back to overview]	Safe Dose of Vorinostat to be Used in Combination With R-CHOP Assessed by CTCAE Version 4.0 (Phase I)
NCT00972478 (5) [back to overview]	Response Rate (Complete Response [CR]+Partial Response [PR]) (Phase II)
NCT00972478 (5) [back to overview]	Progression-free Survival (Phase II)
NCT00976183 (2) [back to overview]	Objective Response Rate
NCT00976183 (2) [back to overview]	Number of Participants With Progression Free Survival (PFS) up to 24 Months
NCT00992446 (4) [back to overview]	Toxicity of Vorinostat Bortezomib Maintenance Therapy After Autologous Transplant
NCT00992446 (4) [back to overview]	Median Time to Disease Progression
NCT00992446 (4) [back to overview]	Event-free Survival
NCT00992446 (4) [back to overview]	Overall Survival
NCT01000155 (3) [back to overview]	γ-globin to β-globin Ratio
NCT01000155 (3) [back to overview]	Percent Fetal Hemoglobin (HbF%) Induction Success Rate
NCT01000155 (3) [back to overview]	F-Cell Percentage Level
NCT01110876 (1) [back to overview]	Maximum Tolerated Dose (MTD) of Vorinostat in Combination With Escalating Doses of Erlotinib and Temozolomide
NCT01118975 (2) [back to overview]	Clinical Benefit Rate
NCT01118975 (2) [back to overview]	Dose Limiting Toxicities
NCT01120834 (1) [back to overview]	Overall Response Rate (ORR)
NCT01153672 (5) [back to overview]	Overall Survival
NCT01153672 (5) [back to overview]	Rate of Clinical Benefit According to RECIST
NCT01153672 (5) [back to overview]	Progression-free Survival
NCT01153672 (5) [back to overview]	Percentage of Patients That Experience Adverse Events as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0
NCT01153672 (5) [back to overview]	Duration of Response
NCT01169532 (3) [back to overview]	Maximum Tolerated Dose (MTD)
NCT01169532 (3) [back to overview]	Progression Free Survival
NCT01169532 (3) [back to overview]	Overall Survival
NCT01175980 (11) [back to overview]	Response Duration (RD)
NCT01175980 (11) [back to overview]	Stable Disease Duration (SDD)
NCT01175980 (11) [back to overview]	The Number of Genes Sequenced in the WES Assay as a Measure of the Whole Exome Profile of the Sorted Tumor Population and Matching Germ Line Sample
NCT01175980 (11) [back to overview]	Time to Recurrence (TTR)
NCT01175980 (11) [back to overview]	Unique Probes on the Oligonucleotide CGH Array as a Measure of the Genomic Profile of Each Cell Population.
NCT01175980 (11) [back to overview]	Number of Participants With Grade 3 or Grade 4 Toxicity as Assessed by the Common Terminology Criteria for Adverse Events Version 4.0
NCT01175980 (11) [back to overview]	Progression-free Survival (PFS)
NCT01175980 (11) [back to overview]	Number of Patients With Flow Sort Aneuploid Populations of Tumor Cells From FFPE Tissue
NCT01175980 (11) [back to overview]	Number of Patients With Flow Sort Diploid Populations of Tumor Cells From FFPE Tissue Blocks
NCT01175980 (11) [back to overview]	Number of Patients With Flow Sort Tetraploid Populations of Tumor Cells From FFPE Tissue
NCT01175980 (11) [back to overview]	Overall Survival (OS)
NCT01187446 (4) [back to overview]	Complete Clinical Response (CCR)
NCT01187446 (4) [back to overview]	Duration of Clinical Benefit (Per Protocol Follow-up)
NCT01187446 (4) [back to overview]	Duration of Clinical Benefit (Supplemental Follow-up)
NCT01187446 (4) [back to overview]	Safety and Tolerability as Measured by Severity and Frequency of Adverse Events
NCT01189266 (5) [back to overview]	Overall Survival
NCT01189266 (5) [back to overview]	Incidence of Toxicity During Maintenance Therapy
NCT01189266 (5) [back to overview]	Incidence of Toxicity During Chemoradiation Therapy
NCT01189266 (5) [back to overview]	Maximum Tolerated Dose (MTD) of Vorinostat
NCT01189266 (5) [back to overview]	Event-Free Survival
NCT01193842 (14) [back to overview]	Changes in Epstein-Barr Virus (EBV) Viral Load
NCT01193842 (14) [back to overview]	Changes in Human Herpes Virus (HHV)-8 Viral Load
NCT01193842 (14) [back to overview]	Changes in Human Herpes Virus (HHV)-8 Viral Load
NCT01193842 (14) [back to overview]	Changes in Human Immunodeficiency Virus (HIV) Viral Load
NCT01193842 (14) [back to overview]	Percentage of Participant Experiencing Adverse Events (AEs) for Each Treatment Arm as Assessed by Common Terminology Criteria for Adverse Events Version 4.0 (CTCAE v4.0) (Phase II)
NCT01193842 (14) [back to overview]	Tumor Response (Phase I)
NCT01193842 (14) [back to overview]	Event-free Survival (EFS) (Phase II)
NCT01193842 (14) [back to overview]	Overall Survival (OS) (Phase II)
NCT01193842 (14) [back to overview]	Percentage of Participants With Complete Response (CR) as Assessed by Response Evaluation Criteria in Solid Tumors (Phase II)
NCT01193842 (14) [back to overview]	Recommended Phase II Dose of Vorinostat Determined According to Dose-limiting Toxicities Graded Using Common Terminology Criteria for Adverse Events Version 4.0 (CTCAE v4.0) (Phase I)
NCT01193842 (14) [back to overview]	Change in CD8 Cell Counts (Phase I)
NCT01193842 (14) [back to overview]	Change in Plasma Associated Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) (Phase I)
NCT01193842 (14) [back to overview]	Pharmacokinetic Clearance (Phase I)
NCT01193842 (14) [back to overview]	Changes in Absolute CD4 Cell Counts (Phase I)
NCT01236560 (4) [back to overview]	Cumulative Incidence of Disease Progression in Each Treatment Arm
NCT01236560 (4) [back to overview]	Overall Survival
NCT01236560 (4) [back to overview]	Maximum Tolerated Dose (MTD) of Vorinostat
NCT01236560 (4) [back to overview]	Event-free Survival
NCT01266031 (8) [back to overview]	Time to Progression (TTP)
NCT01266031 (8) [back to overview]	Maximum Tolerated Dose (MTD) of Oral Vorinostat Used With Bevacizumab
NCT01266031 (8) [back to overview]	Number of Participants With Serious and Non-Serious Adverse Events
NCT01266031 (8) [back to overview]	Overall Survival (OS)
NCT01266031 (8) [back to overview]	Mean Symptom Severity Using the MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT) Self Reporting Tool
NCT01266031 (8) [back to overview]	Percentage of Patients Rating Their Symptoms to be 7 or Greater on a 0-10 Scale Using the Mean Severity of the MD Anderson Symptom Inventory-Brain Tumor Module (MDSAI-BT) Self Reporting Tool
NCT01266031 (8) [back to overview]	Mean Symptom Interference at the Time of Clinical Evaluation
NCT01266031 (8) [back to overview]	Progression Free Survival (PFS) at 6 Months
NCT01267240 (3) [back to overview]	Response Rate According to Response Evaluation Criteria in Solid Tumors
NCT01267240 (3) [back to overview]	Progression-free Survival
NCT01267240 (3) [back to overview]	Survival
NCT01312818 (2) [back to overview]	Number of Subjects Who Achieved Complete Remission of Their Disease
NCT01312818 (2) [back to overview]	Number of Subjects Experiencing Drug Related Adverse Events
NCT01319383 (8) [back to overview]	Number of Participants Exhibiting an in Vivo Resting CD4+ T Cell- Associated HIV RNA (RCVL) Increase After Receiving a Single Dose of VOR 400 mg PO
NCT01319383 (8) [back to overview]	Number of Participants Developing Cancer Within 5 Years Following >/= 8 Vorinostat Dose Exposures
NCT01319383 (8) [back to overview]	Number of Participants With Measurable Changes in Plasma HIV-1 RNA
NCT01319383 (8) [back to overview]	Number of Participants With Confirmed Non-hematologic Toxicity >/= Grade 3 and Related to VOR Per Division of AIDS (DAIDS) Grading Table
NCT01319383 (8) [back to overview]	Number of Participants With Confirmed Hematologic Toxicity >/= Grade 2 and Related to VOR Per Division of AIDS (DAIDS) Grading Table
NCT01319383 (8) [back to overview]	Number of Participants With a Significant in Vivo Response in Resting Cell Infection (RCI) and HIV RNA After Paired Doses
NCT01319383 (8) [back to overview]	Number of Participants Exhibiting an in Vivo Resting CD4+ T-cell-associated HIV RNA (Rc-RNA) Increase Following Multiple (n = 10) Interval Doses
NCT01319383 (8) [back to overview]	Number of Participants Exhibiting an in Vivo Resting CD4+ T-cell-associated HIV RNA (Rc-RNA) Increase Following Each of Two Multiple Dose Cycles (11 Doses/Cycle)
NCT01342757 (3) [back to overview]	Mean Change in Metabolite Levels
NCT01342757 (3) [back to overview]	Measurable Change on Magnetic Resonance Spectroscopy Imaging After Vorinostat Administration
NCT01342757 (3) [back to overview]	Proportion of Patients With Magnetic Resonance Spectroscopy (MRS) Response to Initial Vorinostat by MRI and MRS Scans as Determined by Spectroscopic Index
NCT01413750 (3) [back to overview]	Maximum Tolerated Dose (MTD) (Phase I)
NCT01413750 (3) [back to overview]	Progression-free Survival (PFS)
NCT01413750 (3) [back to overview]	Dose Limiting Toxicity (DLT) (Phase I)
NCT01483690 (2) [back to overview]	Number of Participants Who Experienced a Dose Limiting Toxicity (DLT).
NCT01483690 (2) [back to overview]	Disease Response Rate After Treatment.
NCT01502085 (1) [back to overview]	Overall Response Rate (PR or Better) of Vorinostat in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed/Refractory MM Refractory to a Previous Lenalidomide Containing Regimen
NCT01522976 (5) [back to overview]	Response Rate (Phase II)
NCT01522976 (5) [back to overview]	Relapse-free Survival
NCT01522976 (5) [back to overview]	Overall Survival
NCT01522976 (5) [back to overview]	Toxicity Rate
NCT01522976 (5) [back to overview]	Pre-study Cytogenetic Abnormalities
NCT01534260 (4) [back to overview]	Phase II - Treatment-Related Adverse Events Grade 3 or Higher
NCT01534260 (4) [back to overview]	Number of Patients With Dose Limiting Toxicity
NCT01534260 (4) [back to overview]	Phase II - Percentage of Patients With a Partial Response or Greater
NCT01534260 (4) [back to overview]	Phase II - Time to Relapse
NCT01550224 (9) [back to overview]	Complete Remission (CR)
NCT01550224 (9) [back to overview]	Complete Remission With Incomplete Blood Count Recovery (CRp)
NCT01550224 (9) [back to overview]	Cytogenetic Response (CyR)
NCT01550224 (9) [back to overview]	Disease-free Survival (DFS) at 2 Years
NCT01550224 (9) [back to overview]	Morphologic Leukemia-free State (MLFS)
NCT01550224 (9) [back to overview]	Overall Survival (OS) at 2 Years
NCT01550224 (9) [back to overview]	Partial Remission (PR)
NCT01550224 (9) [back to overview]	Relapse-Free Survival (RFS) at 2 Years
NCT01550224 (9) [back to overview]	Treatment Failure (TF)
NCT01593670 (5) [back to overview]	Overall Survival
NCT01593670 (5) [back to overview]	Number of Patients Who Had Natural Killer (NK) Cell Expansion
NCT01593670 (5) [back to overview]	Number of Patients Who Experienced Grade 3 or Higher Non-hematologic Adverse Events
NCT01593670 (5) [back to overview]	Number of Patients Who Became Transfusion Independent
NCT01593670 (5) [back to overview]	The Number of Patients Who Achieved a Clinical Response
NCT01720602 (5) [back to overview]	Duration of Response
NCT01720602 (5) [back to overview]	Response Rate According to RECIST
NCT01720602 (5) [back to overview]	Rate of Clinical Benefit of Patients Receiving Vorinostat/AI Combination Therapy According to RECIST
NCT01720602 (5) [back to overview]	Progression-free Survival (PFS)
NCT01720602 (5) [back to overview]	Overall Survival
NCT01728805 (4) [back to overview]	Quality of Life (QoL) Assessment - Skindex-29 Symptoms Scale Score
NCT01728805 (4) [back to overview]	Progression Free Survival
NCT01728805 (4) [back to overview]	Overall Response Rate
NCT01728805 (4) [back to overview]	Pruritis Evaluation
NCT01738646 (5) [back to overview]	Six-month Progression-free Survival (PFS6)
NCT01738646 (5) [back to overview]	Radiographic Response
NCT01738646 (5) [back to overview]	Percentage of Participants Who Experience Grade 3 or Greater, Treatment Related, Non-hematologic Toxicities.
NCT01738646 (5) [back to overview]	Median Progression-free Survival (PFS)
NCT01738646 (5) [back to overview]	Median Overall Survival (OS)
NCT01748240 (1) [back to overview]	Response Rate
NCT01789255 (7) [back to overview]	The Percentage of Patients Alive at 1 Year
NCT01789255 (7) [back to overview]	The Number of Participants That Experience Grade 2-4 Acute GVHD (Graft Versus Host Disease) by Day 100
NCT01789255 (7) [back to overview]	Mean Percent of Planned Dose Administered
NCT01789255 (7) [back to overview]	Median Plasma Concentration of IL-6 in Patients Treated With Vorinostat and Patients Not Treated With Vorinostat
NCT01789255 (7) [back to overview]	Median Ac-H3 Levels in Patients Treated With Vorinostat and Patients Not Treated With Vorinostat
NCT01789255 (7) [back to overview]	The Percentage of Patients With Relapse at 1 Year
NCT01789255 (7) [back to overview]	The Percentage of Patients Alive Without GVHD or Use of Steroids
NCT01790568 (3) [back to overview]	Non-Relapse Mortality Incidence
NCT01790568 (3) [back to overview]	Percentage of Patients Alive at 1 Year
NCT01790568 (3) [back to overview]	Percentage of Patients That Experience Grade 2-4 GVHD Within 100 Days of Transplant
NCT01802333 (10) [back to overview]	Frequency and Severity of Toxicities
NCT01802333 (10) [back to overview]	Cytogenetic Risk Distribution of Patients on This Study
NCT01802333 (10) [back to overview]	Prevalence of the Mutation NPM1 in Patients on This Study.
NCT01802333 (10) [back to overview]	Rate of Allogeneic HCT
NCT01802333 (10) [back to overview]	Overall Survival (OS)
NCT01802333 (10) [back to overview]	Complete Response (CR) Rate
NCT01802333 (10) [back to overview]	Disease-free Survival (DFS)
NCT01802333 (10) [back to overview]	Disease-free Survival (DFS) Among High Risk Patients
NCT01802333 (10) [back to overview]	EFS of Arm I Compared to Arm II
NCT01802333 (10) [back to overview]	Event-free Survival (EFS)
NCT01879085 (8) [back to overview]	One-year Overall Survival (OS)
NCT01879085 (8) [back to overview]	Objective Response Rate (ORR)
NCT01879085 (8) [back to overview]	Six-month Overall Survival (OS)
NCT01879085 (8) [back to overview]	Progression-free Survival (PFS)
NCT01879085 (8) [back to overview]	Phase I: Recommended Phase II Dose of Vorinostat
NCT01879085 (8) [back to overview]	Overall Survival (OS)
NCT01879085 (8) [back to overview]	One-year Progression-free Survival (PFS)
NCT01879085 (8) [back to overview]	Six-month Progression-free Survival (PFS)
NCT01983969 (2) [back to overview]	Frequency of DLT
NCT01983969 (2) [back to overview]	Participants With Event-free Survival (EFS)
NCT02035137 (2) [back to overview]	Number of Participants With Grade 3 or Greater Non-hematologic Toxicities
NCT02035137 (2) [back to overview]	Objective Tumor Response After One Course of Therapy
NCT02124083 (6) [back to overview]	Biochemical Efficacy as Measured by Serum LGALS3
NCT02124083 (6) [back to overview]	Biochemical Efficacy as Measured by Serum Cathepsin D
NCT02124083 (6) [back to overview]	Biochemical Efficacy as Measured by Serum Cathepsin D
NCT02124083 (6) [back to overview]	Biochemical Efficacy as Measured by Serum LGALS3
NCT02124083 (6) [back to overview]	Number of Participants With Tolerabilty of 200 mg Vorinostat in Niemann-Pick Disease, Type C1
NCT02124083 (6) [back to overview]	Number of Participants With Tolerabilty of 400 mg Vorinostat in Niemann-Pick Disease, Type C1
NCT02336074 (6) [back to overview]	Viral Inhibition
NCT02336074 (6) [back to overview]	CD8+ T-cell Responses
NCT02336074 (6) [back to overview]	Percentage of CD4+ CD154+ IFNγ+ T Cells
NCT02336074 (6) [back to overview]	Total HIV DNA From CD4 T-cells
NCT02336074 (6) [back to overview]	Quantitative Viral Outgrowth
NCT02336074 (6) [back to overview]	Histone H4 Acetylation
NCT02395627 (6) [back to overview]	Number of Participants With Treatment-related Adverse Events (AE)
NCT02395627 (6) [back to overview]	Duration of Response
NCT02395627 (6) [back to overview]	Number of Participants With Tumor Responses Calculated by Immune Related Response-Criteria (irRC)
NCT02395627 (6) [back to overview]	Objective Response Rate (ORR)
NCT02395627 (6) [back to overview]	Overall Survival (OS)
NCT02395627 (6) [back to overview]	Progression Free Survival
NCT02419755 (1) [back to overview]	Number of Relevant Toxicities Related to Therapy
NCT02538510 (3) [back to overview]	Progression Free Survival
NCT02538510 (3) [back to overview]	Incidence of Toxicity Graded According to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0
NCT02538510 (3) [back to overview]	Objective Response Rate
NCT02553460 (1) [back to overview]	Percentage of Treatment-related Mortality (TRM)
NCT03050450 (3) [back to overview]	Total Number of Adverse Events
NCT03050450 (3) [back to overview]	Number Participants With Hematologic and Non-hematologic Toxicities
NCT03050450 (3) [back to overview]	Best Response of Children With Recurrent or Refractory Central Nervous System Tumors
NCT03212989 (2) [back to overview]	Number of Participants w/ at Least One ≥ Grade 3 Adverse Event That is Possibly or Definitely Related to Vorinostat (VOR) or HIV-specific T Cell (HXTC)
NCT03212989 (2) [back to overview]	Number of Participants Demonstrating an HIV-specific Immune Response to the Combination of Vorinostat (VOR) and HIV-specific T Cells (HXTC) Therapy as Well as a Change in the Frequency of Latent HIV Infection
NCT03382834 (4) [back to overview]	Number of Participants With HIV-1 RNA Levels (Measured by Single Copy Assay) Greater or Equal to the Lower Limit of Quantification
NCT03382834 (4) [back to overview]	Proportion of Participants With New Grade 3 or Greater Adverse Events
NCT03382834 (4) [back to overview]	Change From Baseline in Total HIV-1 DNA Levels in CD4+ T Cells
NCT03382834 (4) [back to overview]	Change From Baseline in Cell-associated HIV-1 RNA in CD4+ T Cells
NCT03713320 (14) [back to overview]	Complete Response Rate
NCT03713320 (14) [back to overview]	Duration of Response in Skin
NCT03713320 (14) [back to overview]	Objective Response Rate in the Skin of at Least 28-days Duration (ORR1)
NCT03713320 (14) [back to overview]	Percentage of Subjects Achieving ≥ 50% Improvement in mSWAT at 28 Days
NCT03713320 (14) [back to overview]	Percentage of Subjects Achieving ≥ 50% Improvement in mSWAT at 4 Months
NCT03713320 (14) [back to overview]	Progression-free Survival (PFS)
NCT03713320 (14) [back to overview]	Pruritus Medication Utilization
NCT03713320 (14) [back to overview]	Time to ≥ 50% Improvement in mSWAT
NCT03713320 (14) [back to overview]	Time to Maximal Effect in mSWAT
NCT03713320 (14) [back to overview]	Peak Plasma Concentration (Cmax) of Cobomarsen - First Dose
NCT03713320 (14) [back to overview]	Peak Plasma Concentration (Cmax) of Cobomarsen - Week 5
NCT03713320 (14) [back to overview]	Percentage of Subjects Achieving an Objective Skin Response of at Least 4 Months Duration (ORR4)
NCT03713320 (14) [back to overview]	Area Under the Plasma Concentration vs. Time Curve (AUC) of Cobomarsen - Week 5
NCT03713320 (14) [back to overview]	Time to Progression
NCT03803605 (1) [back to overview]	Percent of Participants With a Grade 3 or Higher Treatment-Related Adverse Event (AE)
NCT04190056 (5) [back to overview]	Percentage of Participants With Tumor Responses
NCT04190056 (5) [back to overview]	Duration of Response (DOR)
NCT04190056 (5) [back to overview]	Median Overall Survival (OS)
NCT04190056 (5) [back to overview]	Median Progression Free Survival (PFS)
NCT04190056 (5) [back to overview]	Overall Response Rate (ORR)

Safety and Tolerability as Measured by the Number of Participants With Disease Progression

Number of participants with disease progression (protocol-mandated reason for discontinuation). Disease progression was determined by the principle investigator. (NCT00106626)
Timeframe: Any time during 8 cycle treatment period through 30 days after.

Intervention	Participants (Number)
Cohort A - Vorinostat BID + Pemetrexed + Cisplatin	4
Cohort B - Vorinostat QD + Pemetrexed + Cisplatin	1
Cohort C - Vorinostat BID + Pemetrexed	9
Cohort D - Vorinostat QD + Pemetrexed	10

Intervention	Participants (Number)
	Number (#) of DLT	# Participants treated at a dose level	# Participants treated at a dose level =MTD	# Participants treated at a dose level >MTD
Dose Level A.1	1	0	6	0
Dose Level A.2	3	0	0	7
Dose Level B.1	0	0	3	0
Dose Level B.2	2	0	0	6
Dose Level C.1	1	7	0	0
Dose Level C.2	0	4	0	0
Dose Level C.3	0	0	3	0
Dose Level D.1	1	0	9	0
Dose Level D.2	2	0	0	7

Intervention	Participants (Number)
	No dose modification	One dose modification	Two or more dose modifications
Vorinostat 200 mg + Bortezomib 0.7 mg/m^2	3	0	0
Vorinostat 200 mg + Bortezomib 0.9 mg/m^2	3	0	0
Vorinostat 300 mg + Bortezomib 1.3 mg/m^2	8	2	0
Vorinostat 400 mg + Bortezomib 0.9 mg/m^2	4	2	0
Vorinostat 400 mg + Bortezomib 1.1 mg/m^2	3	1	2
Vorinostat 400 mg + Bortezomib 1.3 mg/m^2	3	0	3

Intervention	Participants (Number)
	With one or more laboratory AEs	With no laboratory AEs	With drug-related laboratory AEs	With laboratory Serious AEs (SAEs)	With drug-related laboratory SAEs	Who died	Who discontinued due to laboratory AEs	Who discontinued due to drug-related lab AEs	Who discontinued due to laboratory SAEs	Who discontinued due to drug-related lab SAEs
Vorinostat 200 mg + Bortezomib 0.7 mg/m^2	1	2	1	0	0	0	0	0	0	0
Vorinostat 200 mg + Bortezomib 0.9 mg/m^2	1	2	0	0	0	0	0	0	0	0
Vorinostat 300 mg + Bortezomib 1.3 mg/m^2	3	7	2	0	0	0	0	0	0	0
Vorinostat 400 mg + Bortezomib 0.9 mg/m^2	0	6	0	0	0	0	0	0	0	0
Vorinostat 400 mg + Bortezomib 1.1 mg/m^2	2	4	1	0	0	0	0	0	0	0
Vorinostat 400 mg + Bortezomib 1.3 mg/m^2	3	3	3	0	0	0	0	0	0	0

Intervention	Participants (Number)
	With one or more AEs	With no AEs	With drug-related AEs	With Serious AEs (SAEs)	With drug-related SAEs	Who died	Who discontinued due to AEs	Who discontinued due to drug-related AEs	Who discontinued due to SAEs	Who discontinued due to drug-related SAEs
Vorinostat 200 mg + Bortezomib 0.7 mg/m^2	3	0	2	0	0	0	1	0	0	0
Vorinostat 200 mg + Bortezomib 0.9 mg/m^2	3	0	3	1	0	0	2	2	0	0
Vorinostat 300 mg + Bortezomib 1.3 mg/m^2	10	0	10	2	1	0	4	3	1	1
Vorinostat 400 mg + Bortezomib 0.9 mg/m^2	6	0	6	4	4	0	2	2	2	2
Vorinostat 400 mg + Bortezomib 1.1 mg/m^2	6	0	6	4	2	0	1	1	0	0
Vorinostat 400 mg + Bortezomib 1.3 mg/m^2	6	0	6	2	1	0	2	1	1	0

Intervention	Participants (Number)
	Response	No Response
Cohort 1	0	3
Cohort 2	0	5
Cohort 2a	0	3
Cohort 2b	1	2
Cohort 6	2	3
Cohort 7	1	2

Intervention	Participants (Number)
	DLT	No DLT
Cohort 1	0	3
Cohort 2	2	3
Cohort 2a	0	3
Cohort 2b	0	3
Cohort 6	0	5
Cohort 7	1	2

Intervention	μM (Geometric Mean)
Vorinostat 100 mg Twice-daily	0.29
Vorinostat 200 mg Twice-daily	0.84
Vorinostat 400 mg Once-daily	0.86
Vorinostat 500 mg Once-daily	1.09

Intervention	μM (Geometric Mean)
Vorinostat 100 mg FED	0.21
Vorinostat 200 mg FED	0.59
Vorinostat 400 mg FED	0.93
Vorinostat 500 mg FED	1.35

Intervention	μM (Geometric Mean)
Vorinostat 100 mg FASTED	0.49
Vorinostat 200 mg FASTED	0.77
Vorinostat 400 mg FASTED	1.19
Vorinostat 500 mg FASTED	1.06

Intervention	Participants (Count of Participants)
Vorinostat 100 mg	0
Vorinostat 200 mg	1
Vorinostat 400 mg	0
Vorinostat 500 mg	1

Intervention	Hours (Mean)
Vorinostat 100 mg Twice-daily	1.95
Vorinostat 200 mg Twice-daily	1.42
Vorinostat 400 mg Once-daily	1.98
Vorinostat 500 mg Once-daily	1.30

Intervention	Hours (Mean)
Vorinostat 100 mg FED	1.62
Vorinostat 200 mg FED	1.36
Vorinostat 400 mg FED	2.01
Vorinostat 500 mg FED	1.60

Intervention	Hours (Mean)
Vorinostat 100 mg FED	5.66
Vorinostat 200 mg FED	3.00
Vorinostat 400 mg FED	3.53
Vorinostat 500 mg FED	3.17

Intervention	Hours (Mean)
Vorinostat 100 mg FASTED	1.08
Vorinostat 200 mg FASTED	1.83
Vorinostat 400 mg FASTED	1.90
Vorinostat 500 mg FASTED	1.93

Intervention	μM·hours (Geometric Mean)
Vorinostat 100 mg FASTED	1.20
Vorinostat 200 mg FASTED	2.31
Vorinostat 400 mg FASTED	3.96
Vorinostat 500 mg FASTED	3.47

Intervention	Hours (Mean)
Vorinostat 100 mg Twice-daily	4.66
Vorinostat 200 mg Twice-daily	3.30
Vorinostat 400 mg Once-daily	4.34
Vorinostat 500 mg Once-daily	4.61

Intervention	participants (Number)
	Complete Response (CR)	Partial Response (PR)	Unconfirmed Complete Response (UCR)	Unconfirmed Partial Response (UPR)	No Response
SAHA (Vorinostat)	0	1	0	0	24

Intervention	percentage of participants (Number)
	PR (Partial Response)	CR (Complete Response)	Stable disease
DTCs (Well-differentiated Thyroid Carcinomas)	0	0	56
MTC (Medullary Thyroid Cancer)	0	0	0

Intervention	months (Median)
Stratum 1 (Not Undergoing Surgery)	5.7
Stratum 2 (Undergoing Surgery)	10.2
Stratum 3 (Not Undergoing Surgery)	2.2

Intervention	months (Median)
Stratum 1 Patients That Started Treatment	1.9
Stratum 2 (Undergoing Surgery)	3.7
Stratum 3 (Not Undergoing Surgery)	1.4

vorinostat

Description

Cross-References

Synonyms (147)

Research Excerpts

Overview

Effects

Actions

Treatment

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (3)

Drug Classes (2)

Protein Targets (136)

Potency Measurements

Inhibition Measurements

Activation Measurements

Other Measurements

Biological Processes (1116)

Molecular Functions (334)

Ceullar Components (175)

Bioassays (5938)

Research

Studies (2,495)

Market Indicators

Research Demand Index: 53.95

Study Types

Clinical Trials (272)

Trial Overview

Trial Outcomes

Safety and Tolerability as Measured by the Number of Participants With Disease Progression

Maximum Tolerated Dose (MTD) Status as Determined by Number of Participants With Dose Limiting Toxicity (DLT) at Each Dose Level

Number of Participants With Dose Modifications of Either Vorinostat or Bortezomib Due to Adverse Experiences (AEs) After Treatment With Study Drug

Mean Duration of Treatment With Vorinostat

Laboratory AE Summary

Clinical AE Summary

Mean Time to First AE Resulting in a Dose Modification in Either Vorinostat or Bortezomib

Objective Response Rate Assessed by Response Evaluation Criteria for Solid Tumors (RECIST)

Comparison of VEGF Serum Levels to Response to Vorinostat

Time to Progression Assessed by RECIST

Difference in HP1 and MacroH2A Nuclear Foci Expression Between Progressive Minus Stable Disease Outcomes

Number of Patients With p53 Allelic Variations (72R or 72P)

Number of Participants Who Responded to Treatment

Maximum Tolerated Dose (MTD) as Determined by the Number of Participants With Dose Limiting Toxicities

Cmax of Vorinostat After 14 Days of Once-Daily or Twice-Daily Administration

Cmax of Vorinostat After a Single Oral Dose in a Fed State

Maximum Concentration (Cmax) of Vorinostat After a Single Oral Dose in a Fasted State

Number of Participants Who Discontinued Study Treatment Due to an Adverse Event

Number of Participants Who Experienced One or More Adverse Events

Number of Participants With a Dose-Limiting Toxicity (DLT) During Cycle 1

t½ of Vorinostat After 14 Days of Once-Daily or Twice-Daily Administration

t½ of Vorinostat After a Single Oral Dose in a Fed State

Time to Maximum Concentration (Tmax) of Vorinostat After a Single Oral Dose in a Fasted State

Tmax of Vorinostat After a Single Oral Dose in a Fed State

AUC0-inf of Vorinostat After 14 Days of Once-Daily or Twice-Daily Administration

Apparent Terminal Half-Life (t½) of Vorinostat After a Single Oral Dose in a Fasted State

Area Under the Plasma Concentration Time Curve From Hour 0 to Infinity (AUC0-inf) of Vorinostat After a Single Oral Dose in a Fasted State

Tmax of Vorinostat After 14 Days of Once-Daily or Twice-Daily Administration

AUC0-Inf of Vorinostat After a Single Oral Dose in a Fed State

Number of Participants Who Experienced Adverse Events (AEs) Characterized as Grade 3 or Grade 4 According to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE)

Percentage of Participants With ≥10% Change From Baseline in FVC at Week 12

Progression Free Survival (PFS)

Number of Participants Who Discontinued Study Treatment Due to an AE

Percentage of Participants With ≥50% Change Together With a >10 mm Change From Baseline in the LCSS-Meso Dyspnea Score at Week 12

Number of Participants Who Experienced an AE

Objective Response Rate (ORR)

Overall Survival (OS)

Percent Change From Baseline in Forced Vital Capacity (FVC) at Week 12

Percent Change From Baseline in Lung Cancer Symptom Scale, Modified for Mesothelioma (LCSS-Meso) Dyspnea Score at Week 12

Objective Tumor Response Rate

Overall Survival

Progression-free Survival

Assess Number of Patients Who Achieve Confirmed and Unconfirmed Complete Response (CR) or Partial Response (PR)

Progression-Free Survival

Overall Survival

Objective Response Rate (PR + CR) Using RECIST/WHO Response Criteria

Toxicity

Intervention	percentage of participants (Number)
Stratum 1 Patients That Started Treatment	15.2
Stratum 2 (Undergoing Surgery)	26.7
Stratum 3 (Not Undergoing Surgery)	10

Intervention	Participants (Number)
Vorinostat 200 mg b.i.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wk	6
Vorinostat 300 mg q.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wk	1
Vorinostat 300 mg b.i.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wk	1
Vorinostat 400 mg q.d. 21d/4wk + Erlotinib 150 mg q.d. 7d/wk	1

Intervention	Participants (Count of Participants)
	ANC	Anorexia	Fatigue	Hemoglobin	Hypokalemia	Hyponatremia	Hypophosphatemia	Infection -Skin (cellulitis)	INR	Leukocytes (total WBC)	Lymphopenia	Myalgia	Mucositis/stomatitis	Platelets	Thrombosis/thrombus/embolism
Treatment (Vorinostat)	6	1	3	4	1	1	2	1	2	4	5	1	1	10	2

Intervention	participants (Number)
	Best Objective Response Rate (ORR)	Progressive Disease
Vorinostat	4	7

Intervention	days (Median)
Arm A (Once Daily Vorinostat)	42
Arm B (Thrice Daily Vorinostat)	46

Intervention	Participants (Count of Participants)
Dose Level 1: Vorinostat (300mg) and Isotretinoin (0.25 mg/kg)	1
Dose Level 2 Vorinostat (300mg)and Isotretinoin (0.375 mg/kg)	0
Dose Level 2 Vorinostat (300mg)and Isotretinoin (0.5 mg/kg)	0

Intervention	Participants (Number)
Vorinostat 300 7/21+ Gemcitabine 1000 + Cisplatin	0
Vorinostat 300 7/21+ Gemcitabine 1250 + Cisplatin	1
Vorinostat 400 7/21+ Gemcitabine 1250 + Cisplatin	0
Vorinostat 400 10/21+ Gemcitabine 1250 + Cisplatin	0
Vorinostat 400 14/21+ Gemcitabine 1250 + Cisplatin	1

Intervention	Months (Median)
Vorinostat + Paclitaxel + Carboplatin	11.0
Placebo + Paclitaxel + Carboplatin	14.0

Intervention	Participants (Number)
	Responder	Non-Responder
Placebo + Paclitaxel + Carboplatin	36	87
Vorinostat + Paclitaxel + Carboplatin	28	97

Intervention	participants (Number)
Concurrent, Vorinostat 400mg qd x 7d/4wk + Decitabine	0
Concurrent, Vorinostat 400mg qd x 7d/2wk + Decitabine	0
Concurrent, Vorinostat 400mg qd x 14d/4wk + Decitabine (MTD)	0
Sequential, Vorinostat 400mg qd x 7d/4wk + Decitabine	0
Sequential, Vorinostat 400mg qd x 10d/4wk + Decitabine	0
Sequential, Vorinostat 400mg qd x 14d/4wk + Decitabine (MTD)	1